SAMPLE_ID	washed_SMILES	mean_pAC50	Class	PRIMARY_MOA	range_pAC50	count_IDs	SAMPLE_NAME	PUBCHEM_SID	LIBRARY	ASSAY_NAME	CURVE_CLASS2	EFFICACY	SMILES	ALL-SMILES
NCGC00262958-01	Br/C=C\C=1C(=O)NC(=O)N([C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=1		Inactive			1	Bravavir	170466041	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Br/C=C\C=1C(=O)NC(=O)N([C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=1	Br/C=C\C=1C(=O)NC(=O)N([C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=1
NCGC00160445-02	BrC(C(=O)NC(=O)N)C(C)C	5.4499998	Active		0.0	1	Bromisovalum	170465828	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.0369160333	BrC(C(=O)NC(=O)N)C(C)C	BrC(C(=O)NC(=O)N)C(C)C
NCGC00090868-06	BrC(Cl)C(F)(F)F		Inactive	Gaba-a Receptor; Anion Channel Positive Allosteric Modulator&GABA-A receptor; anion channel Positive Allosteric Modulator		1	HALOTHANE	405558947	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.1714020239&0.0	BrC(Cl)C(F)(F)F	BrC(Cl)C(F)(F)F
NCGC00166217-02	BrC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F		Inactive			1	1-Bromoheptadecafluorooctane	170465144	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.531910872&-24.7874873759	BrC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BrC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
NCGC00164057-03	BrC([N+](=O)[O-])(CO)CO		Inactive	Reactive Oxygen Species Biosynthetic Process Activator&reactive oxygen species biosynthetic process Activator		1	2-Bromo-2-nitro-1,3-propanediol	225144251	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	BrC([N+](=O)[O-])(CO)CO	BrC([N+](=O)[O-])(CO)CO
NCGC00346653-06	BrC1=C(N)n2ncc(-c3cn(C)nc3)c2N=C1[C@H]1CNCCC1	4.4499998	Active		0.0	1	SCH 900776	384568884	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-130.2005159236	BrC1=C(N)n2ncc(-c3cn(C)nc3)c2N=C1[C@H]1CNCCC1	BrC1=C(N)n2ncc(-c3cn(C)nc3)c2N=C1[C@H]1CNCCC1
NCGC00346449-02	BrC1=C(NCc2cnccc2)C(OCCCc2ccc(Cl)cc2)=NNC1=O		Inactive	Phosphodiesterase III/Va (PDE) Inhibitor		1	Parogrelil	363677409	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-26.5763116839	BrC1=C(NCc2cnccc2)C(OCCCc2ccc(Cl)cc2)=NNC1=O	BrC1=C(NCc2cnccc2)C(OCCCc2ccc(Cl)cc2)=NNC1=O
NCGC00346500-08	BrC1=Cn2c(/C=N/N(S(=O)(=O)c3c(C)ccc([N+](=O)[O-])c3)C)cnc2C=C1	7.5	Inactive	PI3K Inhibitor	0.0	1	PIK-75	384568805	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-58.293682392	BrC1=Cn2c(/C=N/N(S(=O)(=O)c3c(C)ccc([N+](=O)[O-])c3)C)cnc2C=C1	BrC1=Cn2c(/C=N/N(S(=O)(=O)c3c(C)ccc([N+](=O)[O-])c3)C)cnc2C=C1
NCGC00263165-02	BrC=1C(=O)N(c2c(C)ccc(C(=O)NC)c2)C(C)=CC=1OCc1c(F)cc(F)cc1	4.6500001	Active	p38 MAPK Inhibitor	0.0	1	PH-797804	363677239	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-106.7329181272	BrC=1C(=O)N(c2c(C)ccc(C(=O)NC)c2)C(C)=CC=1OCc1c(F)cc(F)cc1	BrC=1C(=O)N(c2c(C)ccc(C(=O)NC)c2)C(C)=CC=1OCc1c(F)cc(F)cc1
NCGC00273564-01	BrC=1C(=O)N=C(N)NC=1c1ccccc1		Inactive	Toll-like receptor 7 Agonist&Toll-like Receptor 7 Agonist		1	Bropirimine	170465913	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.749309516&-30.0121154455	BrC=1C(=O)N=C(N)NC=1c1ccccc1	BrC=1C(=O)N=C(N)NC=1c1ccccc1
NCGC00090770-09	BrC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	4.8499999	Active	Base Conversion Or Substitution Editing Activator&base conversion or substitution editing Activator	0.0	1	5-Bromo-2'-deoxyuridine	170465870	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.2	-56.9964776664&-49.585255556	BrC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	BrC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00346824-01	BrCC(=O)C(=O)OCC		Inactive	Hexokinase 2 Inhibitor		1	3-Bromopyruvate	174007400	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-31.036014416	BrCC(=O)C(=O)OCC	BrCC(=O)C(=O)OCC
NCGC00510494-01	BrCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1		Inactive	Radiosensitizers		1	RRx-001	384569456	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.61972394	BrCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1	BrCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1
NCGC00095048-06	BrCCC(=O)N1CCN(C(=O)CCBr)CC1	6.0999999	Active	Dna Crosslinking Agent	0.0	1	Pipobroman	170465158	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-42.5173361147	BrCCC(=O)N1CCN(C(=O)CCBr)CC1	BrCCC(=O)N1CCN(C(=O)CCBr)CC1
NCGC00390633-02	BrCCNP(=O)(OCc1n(C)c([N+](=O)[O-])nc1)NCCBr		Inactive	DNA Alkylating Drugs		1	Evofosfamide	384569202	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.0443413679	BrCCNP(=O)(OCc1n(C)c([N+](=O)[O-])nc1)NCCBr	BrCCNP(=O)(OCc1n(C)c([N+](=O)[O-])nc1)NCCBr
NCGC00091099-01	BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr		Inactive	Dna Crosslinking Agent&DNA Crosslinking Agent		1	Dibromomannitol	17389938	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.541881192&0.0	BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr	BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr
NCGC00167564-03	Brc1[nH]c2N(C)C(=O)N(C)C(=O)c2n1	5.3000002	Active		0.0	1	8-Bromotheophylline	170465479	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.8498603232	Brc1[nH]c2N(C)C(=O)N(C)C(=O)c2n1	Brc1[nH]c2N(C)C(=O)N(C)C(=O)c2n1
NCGC00022382-06	Brc1[nH]c2c3c(ccc2)C2=C[C@@H](C(=O)N[C@@]4(C(C)C)C(=O)N5[C@@H](CC(C)C)C(=O)N6[C@H]([C@]5(O)O4)CCC6)CN(C)C2Cc13	4.5749998	Active	Dopamine D3 Receptor Agonist&Dopamine D3 receptor Agonist	0.0	1	NCGC00022382-06&BROMOCRIPTINE	405559134	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-38.9024397799&-105.2418892318	Brc1[nH]c2c3c(ccc2)C2=C[C@@H](C(=O)N[C@@]4(C(C)C)C(=O)N5[C@@H](CC(C)C)C(=O)N6[C@H]([C@]5(O)O4)CCC6)CN(C)C2Cc13	Brc1[nH]c2c3c(ccc2)C2=C[C@@H](C(=O)N[C@@]4(C(C)C)C(=O)N5[C@@H](CC(C)C)C(=O)N6[C@H]([C@]5(O)O4)CCC6)CN(C)C2Cc13
NCGC00159391-03	Brc1c(Br)c(Br)c2C(c3cc(S(=O)(=O)[O-])c(O)cc3)(c3cc(S(=O)(=O)[O-])c(O)cc3)OC(=O)c2c1Br		Inactive	Solute Carrier Organic Anion Transporter Family Member 1b1 Substrate&Solute carrier organic anion transporter family member 1B1 Substrate		1	Sulfobromophthalein	170465816	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.80312702&-20.8315238119	Brc1c(Br)c(Br)c2C(c3cc(S(=O)(=O)[O-])c(O)cc3)(c3cc(S(=O)(=O)[O-])c(O)cc3)OC(=O)c2c1Br.[Na+].[Na+]	Brc1c(Br)c(Br)c2C(c3cc(S(=O)(=O)[O-])c(O)cc3)(c3cc(S(=O)(=O)[O-])c(O)cc3)OC(=O)c2c1Br.[Na+].[Na+]
NCGC00181297-01	Brc1c(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)cc1C		Inactive			1	Mebrofenin	144206328	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.3228144999&-26.9771829479	Brc1c(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)cc1C	Brc1c(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)cc1C
NCGC00343768-05	Brc1c(C)cc(OC[C@H]2OCCNC2)c(NC(=O)Nc2ncc(C)nc2)c1	5.0	Active	Chk1 Inhibitor	0.0	1	Rabusertib	384568714	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-95.7446880758	Brc1c(C)cc(OC[C@H]2OCCNC2)c(NC(=O)Nc2ncc(C)nc2)c1	Brc1c(C)cc(OC[C@H]2OCCNC2)c(NC(=O)Nc2ncc(C)nc2)c1
NCGC00522629-01	Brc1c(C)ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)c1	4.4000001	Active	VEGFR-2 Inhibitor	0.0	1	ACC-789	384569532	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-87.5528976719	Brc1c(C)ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)c1	Brc1c(C)ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)c1
NCGC00181118-01	Brc1c(C)nc(NS(=O)(=O)c2ccc(N)cc2)nc1C		Inactive			1	Sulfabromomethazine	144206282	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&16.891759212	Brc1c(C)nc(NS(=O)(=O)c2ccc(N)cc2)nc1C	Brc1c(C)nc(NS(=O)(=O)c2ccc(N)cc2)nc1C
NCGC00181132-01	Brc1c(Cl)cc2C(=O)N(CC(=O)C[C@H]3[C@H](O)CCCN3)C=Nc2c1	4.4000001	Active		0.0	1	Halofuginone hydrochloride	144206292	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.805668824	Brc1c(Cl)cc2C(=O)N(CC(=O)C[C@H]3[C@H](O)CCCN3)C=Nc2c1.Cl	Brc1c(Cl)cc2C(=O)N(CC(=O)C[C@H]3[C@H](O)CCCN3)C=Nc2c1.Cl
NCGC00402358-02	Brc1c(F)ccc(N/C(=N\O)/c2c(NCCNS(=O)(=O)N)non2)c1		Inactive	IDO Inhibitor		1	Epacadostat	384569216	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.824252808	Brc1c(F)ccc(N/C(=N\O)/c2c(NCCNS(=O)(=O)N)non2)c1	Brc1c(F)ccc(N/C(=N\O)/c2c(NCCNS(=O)(=O)N)non2)c1
NCGC00263232-01	Brc1c(N(C)C)ccc(C2Nc3c(c4c(cc3)cccc4)C3=C2C(=O)CC(C)(C)C3)c1		Inactive	Glutaminase Inhibitor		1	GLS-968	137276076	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1c(N(C)C)ccc(C2Nc3c(c4c(cc3)cccc4)C3=C2C(=O)CC(C)(C)C3)c1	Brc1c(N(C)C)ccc(C2Nc3c(c4c(cc3)cccc4)C3=C2C(=O)CC(C)(C)C3)c1
NCGC00178520-03&NCGC00178520-13	Brc1c(N)c(CN(C)C2CCCCC2)cc(Br)c1	4.8625002	Active	Mucolytic Agent	0.375	2	Bromhexine hydrochloride	170465803&384568357	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4&-1.2	-80.81290406&-55.3403775683&-42.5304362238	Brc1c(N)c(CN(C)C2CCCCC2)cc(Br)c1.Cl	Brc1c(N)c(CN(C)C2CCCCC2)cc(Br)c1.Cl&Brc1c(N)c(CN(C)C2CCCCC2)cc(Br)c1
NCGC00016781-08	Brc1c(N)c(CNC2CCC(O)CC2)cc(Br)c1		Inactive	surfactant homeostasis Modulator&Surfactant Homeostasis Modulator		1	Ambroxol hydrochloride	225144182	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.760438888&-25.672614756	Brc1c(N)c(CNC2CCC(O)CC2)cc(Br)c1	Brc1c(N)c(CNC2CCC(O)CC2)cc(Br)c1
NCGC00346676-04	Brc1c(N2CCN(Cc3noc(C)c3)CC2)c2nc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c2nc1	5.5	Active	Aurora-A/B/C Kinase Inhibitor	0.0	1	CCT-137690	384568902	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.410602706	Brc1c(N2CCN(Cc3noc(C)c3)CC2)c2nc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c2nc1	Brc1c(N2CCN(Cc3noc(C)c3)CC2)c2nc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c2nc1
NCGC00025100-17	Brc1c(NC(=O)/C(/C#N)=C(\O)/C)cc(Br)cc1		Inactive	BTK Inhibitor		1	LFM-A13	384568049	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-10.793226548	Brc1c(NC(=O)/C(/C#N)=C(\O)/C)cc(Br)cc1	Brc1c(NC(=O)/C(/C#N)=C(\O)/C)cc(Br)cc1
NCGC00346690-04	Brc1c(NC(=O)N[C@H]2CN(c3ncc(C(F)(F)F)cc3)CC2)cccc1		Inactive	TRPV1 (Vanilloid VR1 Receptor) Agonist		1	SB-705498	384568912	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-32.2021764639	Brc1c(NC(=O)N[C@H]2CN(c3ncc(C(F)(F)F)cc3)CC2)cccc1	Brc1c(NC(=O)N[C@H]2CN(c3ncc(C(F)(F)F)cc3)CC2)cccc1
NCGC00242491-03	Brc1c(NC(=O)Nc2c3nn[nH]c3c(C#N)cc2)cccc1		Inactive	CXCR2 Antagonist		1	SB-265610	384568497	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1c(NC(=O)Nc2c3nn[nH]c3c(C#N)cc2)cccc1	Brc1c(NC(=O)Nc2c3nn[nH]c3c(C#N)cc2)cccc1
NCGC00532499-01	Brc1c(NC2=NCCN2)c(F)ccc1	4.8499999	Active	Alpha-2B adrenergic receptor Agonist	0.0	1	ROMIFIDINE	405559124	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.513556844	Brc1c(NC2=NCCN2)c(F)ccc1	Brc1c(NC2=NCCN2)c(F)ccc1
NCGC00016069-13	Brc1c(NC2=NCCN2)ccc2nccnc12		Inactive	Alpha-2c Adrenergic Receptor Agonist&Alpha-2C adrenergic receptor Agonist		1	Brimonidine	170464941	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.6722102919&0.0	Brc1c(NC2=NCCN2)ccc2nccnc12	Brc1c(NC2=NCCN2)ccc2nccnc12
NCGC00346687-10	Brc1c(NCCc2[nH]cnc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1	4.0	Inactive	Phosphoinositide Dependent Kinase Inhibitor	0.0	1	BX-912	384568911	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-20.9782288439	Brc1c(NCCc2[nH]cnc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1	Brc1c(NCCc2[nH]cnc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1
NCGC00013895-08	Brc1c(O)c(Br)cc(C(=O)c2c(CC)oc3c2cccc3)c1	5.4499998	Active	Xanthine Dehydrogenase Inhibitor	0.0	1	Benzbromarone	170465792	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-31.7586224617	Brc1c(O)c(Br)cc(C(=O)c2c(CC)oc3c2cccc3)c1	Brc1c(O)c(Br)cc(C(=O)c2c(CC)oc3c2cccc3)c1
NCGC00346942-01	Brc1c(O)c(Br)cc(Nc2ncnc3c2cc(OC)c(OC)c3)c1		Inactive	EGFR Inhibitor		1	WHI-P97	174006541	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-30.118194608	Brc1c(O)c(Br)cc(Nc2ncnc3c2cc(OC)c(OC)c3)c1	Brc1c(O)c(Br)cc(Nc2ncnc3c2cc(OC)c(OC)c3)c1
NCGC00159476-09	Brc1c(O)c(C(=O)Nc2ccc(Br)cc2)cc(Br)c1	4.6999998	Active		0.0	1	Tribromsalan	170465542	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-69.6105690554	Brc1c(O)c(C(=O)Nc2ccc(Br)cc2)cc(Br)c1	Brc1c(O)c(C(=O)Nc2ccc(Br)cc2)cc(Br)c1
NCGC00346684-02	Brc1c(O)c(C(C)(C)C)cc(C=C(C#N)C#N)c1		Inactive	EGFR Inhibitor		1	AG-1024	384568908	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1c(O)c(C(C)(C)C)cc(C=C(C#N)C#N)c1	Brc1c(O)c(C(C)(C)C)cc(C=C(C#N)C#N)c1
NCGC00246387-08	Brc1c(O)c(CN(C)C)c2c(C(=O)OCC)c(CSc3ccccc3)n(C)c2c1	4.5	Active	antiinfluenza drug	0.0	1	Arbidol	384568511	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-77.5544504816	Brc1c(O)c(CN(C)C)c2c(C(=O)OCC)c(CSc3ccccc3)n(C)c2c1	Brc1c(O)c(CN(C)C)c2c(C(=O)OCC)c(CSc3ccccc3)n(C)c2c1
NCGC00538143-01	Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1		Inactive	Surfactant Homeostasis Activator&surfactant homeostasis Activator		1	NCGC00538143-01	405558668	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.584627064&-17.491905132	Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1	Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1
NCGC00351598-04	Brc1c(O)ccc(Nc2ncnc3c2cc(OC)c(OC)c3)c1	4.5	Active	EGFR Inhibitor	0.0	1	WHI-P154	384569016	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-36.094270196	Brc1c(O)ccc(Nc2ncnc3c2cc(OC)c(OC)c3)c1	Brc1c(O)ccc(Nc2ncnc3c2cc(OC)c(OC)c3)c1
NCGC00346680-05	Brc1c(OC2CCN(c3noc(-c4nn(CC(=O)O)nn4)c3)CC2)cc(F)cc1	4.9499998	Inactive	Stearoyl-CoA Desaturase Inhibitor	0.0	1	MK-8245	363677514	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-15.87037568	Brc1c(OC2CCN(c3noc(-c4nn(CC(=O)O)nn4)c3)CC2)cc(F)cc1	Brc1c(OC2CCN(c3noc(-c4nn(CC(=O)O)nn4)c3)CC2)cc(F)cc1
NCGC00189076-01	Brc1c(OCCCOc2c(Br)cc(C(=N)N)cc2)ccc(C(=N)N)c1	4.4749999	Active		0.0	1	Dibromopropamidine dihydrochloride	144207153	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-45.4067326119&-100.4179753269	Brc1c(OCCCOc2c(Br)cc(C(=N)N)cc2)ccc(C(=N)N)c1.Cl.Cl	Brc1c(OCCCOc2c(Br)cc(C(=N)N)cc2)ccc(C(=N)N)c1.Cl.Cl
NCGC00345885-04	Brc1c(Oc2c(C)cc(C#N)cc2C)nc(Nc2ccc(C#N)cc2)nc1N	4.5500002	Active	P-glycoprotein 1 Inhibitor	0.0	1	Etravirine	405558520	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-108.1027605978&-103.3335961619	Brc1c(Oc2c(C)cc(C#N)cc2C)nc(Nc2ccc(C#N)cc2)nc1N	Brc1c(Oc2c(C)cc(C#N)cc2C)nc(Nc2ccc(C#N)cc2)nc1N
NCGC00346707-05	Brc1c2[C@@H](C3CCN(C(=O)CC4CCN(C(=O)N)CC4)CC3)c3ncc(Br)cc3CCc2cc(Cl)c1	5.4499998	Inactive	Farnesyltransferase Inhibitor	0.0	1	Lonafarnib	384568925	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	68.1028895543	Brc1c2[C@@H](C3CCN(C(=O)CC4CCN(C(=O)N)CC4)CC3)c3ncc(Br)cc3CCc2cc(Cl)c1	Brc1c2[C@@H](C3CCN(C(=O)CC4CCN(C(=O)N)CC4)CC3)c3ncc(Br)cc3CCc2cc(Cl)c1
NCGC00344622-15	Brc1c2c(N)ncnc2n([C@H]2[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c1	4.4499998	Active	DOT1L Inhibitor	0.0	1	SGC-0946	384568725	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-107.999940588	Brc1c2c(N)ncnc2n([C@H]2[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c1	Brc1c2c(N)ncnc2n([C@H]2[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c1
NCGC00092381-04	Brc1cc(-c2c3c(N)ncnc3nc(-c3cnc(N4CCOCC4)cc3)c2)ccc1		Inactive	Adenosine Kinase Inhibitor		1	ABT-702	384568109	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1cc(-c2c3c(N)ncnc3nc(-c3cnc(N4CCOCC4)cc3)c2)ccc1	Brc1cc(-c2c3c(N)ncnc3nc(-c3cnc(N4CCOCC4)cc3)c2)ccc1
NCGC00347957-09	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)cnc1		Inactive	L3MBTL3 methyllysine (Kme) reader domain Inhibitor		1	UNC-669	363677733	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)cnc1	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)cnc1
NCGC00389085-04	Brc1cc(CCN(S(=O)(=O)c2c(C)cc(C)cc2C)Cc2ccc(-c3cc(S(=O)(=O)C)ccc3)cc2)ccc1		Inactive	Liver-X-receptor (LXR) inverse Agonist that induces LXR-corepressor interaction		1	SR-9243	384569171	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1cc(CCN(S(=O)(=O)c2c(C)cc(C)cc2C)Cc2ccc(-c3cc(S(=O)(=O)C)ccc3)cc2)ccc1	Brc1cc(CCN(S(=O)(=O)c2c(C)cc(C)cc2C)Cc2ccc(-c3cc(S(=O)(=O)C)ccc3)cc2)ccc1
NCGC00345496-08	Brc1cc(COc2nc(N)nc3nc[nH]c23)sc1		Inactive	MGMT Inhibitor		1	Lomeguatrib	363677349	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1cc(COc2nc(N)nc3nc[nH]c23)sc1	Brc1cc(COc2nc(N)nc3nc[nH]c23)sc1
NCGC00189073-04	Brc1cc(Cl)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1		Inactive	Mek1/2 inibitor		1	Selumetinib	384568456	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	20.35890696	Brc1cc(Cl)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1	Brc1cc(Cl)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1
NCGC00263100-02	Brc1cc(F)c(COc2c(C(=O)N)c(NC(=O)NCCCCN3CCCC3)sn2)c(F)c1	4.4499998	Active	VEGFR-2 Inhibitor	0.0	1	OSI-632	363677201	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-105.7496051827	Brc1cc(F)c(COc2c(C(=O)N)c(NC(=O)NCCCCN3CCCC3)sn2)c(F)c1	Brc1cc(F)c(COc2c(C(=O)N)c(NC(=O)NCCCCN3CCCC3)sn2)c(F)c1
NCGC00345804-10	Brc1cc(F)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1		Inactive	Mek 1/2 Inhibitor		1	ARRY-162	363677367	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.1909896641	Brc1cc(F)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1	Brc1cc(F)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1
NCGC00347936-06	Brc1cc(NC(=O)c2cc(S(=O)(=O)N3CCCCCC3)ccc2)ccc1	4.5	Active	Histone Deacetylase SIRT2 Inhibitor	0.0	1	Ak-7	363677722	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-102.6494544347	Brc1cc(NC(=O)c2cc(S(=O)(=O)N3CCCCCC3)ccc2)ccc1	Brc1cc(NC(=O)c2cc(S(=O)(=O)N3CCCCCC3)ccc2)ccc1
NCGC00386260-02	Brc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1	5.0999999	Active	EGFR Inhibitor	0.0	1	PD-168393	363680172	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.6404457358	Brc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1	Brc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1
NCGC00024956-17	Brc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1		Inactive	EGFR Inhibitor		1	PD-153035	384568037	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.959174532	Brc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1	Brc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1
NCGC00351594-01	Brc1cc2/C(=C/3\C(=O)N(C(C(=O)O)CC(=O)O)C(=S)S\3)/C(=O)Nc2cc1	4.5999999	Active	Bcl-6 Inhibitor	0.0	1	BCL6 Inhibitor	384569013	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-37.7197079928	Brc1cc2/C(=C/3\C(=O)N(C(C(=O)O)CC(=O)O)C(=S)S\3)/C(=O)Nc2cc1	Brc1cc2/C(=C/3\C(=O)N(C(C(=O)O)CC(=O)O)C(=S)S\3)/C(=O)Nc2cc1
NCGC00025207-15	Brc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1		Inactive	Bcl-2 Inhibitor		1	HA-14-1	363676538	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-26.719803908	Brc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1	Brc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1
NCGC00346883-02	Brc1cc2NC(=O)/C(=C/3\C(=N\OC(=O)C)\c4c(N\3)cccc4)/c2cc1		Inactive	GSK-3 Inhibitor		1	6-Bromoindirubin-3'-acetoxime	384568960	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1cc2NC(=O)/C(=C/3\C(=N\OC(=O)C)\c4c(N\3)cccc4)/c2cc1	Brc1cc2NC(=O)/C(=C/3\C(=N\OC(=O)C)\c4c(N\3)cccc4)/c2cc1
NCGC00094112-11	Brc1cc2NC(=O)/C(=C\3/C(=N/O)/c4c(N/3)cccc4)/c2cc1	4.4000001	Active	GSK-3 Inhibitor	0.0	1	BIO	384568126	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-102.5585177324	Brc1cc2NC(=O)/C(=C\3/C(=N/O)/c4c(N/3)cccc4)/c2cc1	Brc1cc2NC(=O)/C(=C\3/C(=N/O)/c4c(N/3)cccc4)/c2cc1
NCGC00348215-03	Brc1cc2c(nc(OC)c([C@H]([C@@](O)(CCN(C)C)c3c4c(ccc3)cccc4)c3ccccc3)c2)cc1	4.4000001	Active	Atp Synthase Subunit C Inhibitor&ATP synthase subunit c Inhibitor	0.0	1	Bedaquiline (TMC-207)	405558612	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-46.2169718519&-40.2901049919	Brc1cc2c(nc(OC)c([C@H]([C@@](O)(CCN(C)C)c3c4c(ccc3)cccc4)c3ccccc3)c2)cc1	Brc1cc2c(nc(OC)c([C@H]([C@@](O)(CCN(C)C)c3c4c(ccc3)cccc4)c3ccccc3)c2)cc1
NCGC00262959-01	Brc1ccc(-c2ccc(C3CC(C=4C(=O)Sc5c(C=4O)cccc5)c4c(cccc4)C3)cc2)cc1	4.7249999	Active		0.0	1	Difethialone	170465892	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.1	-109.5097085775&-110.0175399551	Brc1ccc(-c2ccc(C3CC(C=4C(=O)Sc5c(C=4O)cccc5)c4c(cccc4)C3)cc2)cc1	Brc1ccc(-c2ccc(C3CC(C=4C(=O)Sc5c(C=4O)cccc5)c4c(cccc4)C3)cc2)cc1
NCGC00263127-03	Brc1ccc(-c2ccc(S(=O)(=O)C[C@H](C(=O)O)C(C)C)cc2)cc1		Inactive	MMP13 Inhibitor		1	PD-166793	363677215	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1ccc(-c2ccc(S(=O)(=O)C[C@H](C(=O)O)C(C)C)cc2)cc1	Brc1ccc(-c2ccc(S(=O)(=O)C[C@H](C(=O)O)C(C)C)cc2)cc1
NCGC00387244-01	Brc1ccc(/C=C/C(=O)N2CCN(C(=O)c3ccc(OC)cc3)CC2)cc1		Inactive	G-Protein Coupled Receptor 183 (GPR183; EBI2) Modulators		1	NIBR-189	384569155	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.7118448519	Brc1ccc(/C=C/C(=O)N2CCN(C(=O)c3ccc(OC)cc3)CC2)cc1	Brc1ccc(/C=C/C(=O)N2CCN(C(=O)c3ccc(OC)cc3)CC2)cc1
NCGC00162073-12	Brc1ccc(/C=C/CNCCNS(=O)(=O)c2c3c(cncc3)ccc2)cc1		Inactive	AKT Inhibitor		1	H-89	384568218	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.547345952	Brc1ccc(/C=C/CNCCNS(=O)(=O)c2c3c(cncc3)ccc2)cc1	Brc1ccc(/C=C/CNCCNS(=O)(=O)c2c3c(cncc3)ccc2)cc1
NCGC00263519-01	Brc1ccc(C(=O)c2c(N)c(CC(=O)O)ccc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	NCGC00263519-01&Bromfenac sodium sesquihydrate	170465189	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-12.863115036	Brc1ccc(C(=O)c2c(N)c(CC(=O)[O-])ccc2)cc1.Brc1ccc(C(=O)c2c(N)c(CC(=O)[O-])ccc2)cc1.[Na+].[Na+].O.O.O	Brc1ccc(C(=O)c2c(N)c(CC(=O)[O-])ccc2)cc1.Brc1ccc(C(=O)c2c(N)c(CC(=O)[O-])ccc2)cc1.[Na+].[Na+].O.O.O
NCGC00249891-01	Brc1ccc(C(OCCN(C)C)c2ccccc2)cc1	4.4000001	Inactive	Histamine H1 receptor Antagonist	0.0	1	Bromodiphenhydramine	170465292	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-17.8131459599	Brc1ccc(C(OCCN(C)C)c2ccccc2)cc1	Brc1ccc(C(OCCN(C)C)c2ccccc2)cc1
NCGC00016692-05	Brc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	4.5999999	Active	Dopamine D2 Receptor Antagonist&Dopamine D2 receptor Antagonist	0.0	1	Bromperidol	170465873	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-64.04702412&-70.6275748592	Brc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	Brc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
NCGC00387089-01	Brc1ccc(CN(n2cnnc2)c2ccc(C#N)cc2)cc1		Inactive	Aromatase Inhibitor		1	YM-511	384569152	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.470919752	Brc1ccc(CN(n2cnnc2)c2ccc(C#N)cc2)cc1	Brc1ccc(CN(n2cnnc2)c2ccc(C#N)cc2)cc1
NCGC00347940-04	Brc1ccc(N2C(=O)/C(=C/c3oc(-c4cc5C(=O)NC(=O)c5cc4)cc3)/SC2=N)cc1		Inactive	TRAIL Receptor DR5 Agonist		1	Bioymifi	384568992	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	32.00144006	Brc1ccc(N2C(=O)/C(=C/c3oc(-c4cc5C(=O)NC(=O)c5cc4)cc3)/SC2=N)cc1	Brc1ccc(N2C(=O)/C(=C/c3oc(-c4cc5C(=O)NC(=O)c5cc4)cc3)/SC2=N)cc1
NCGC00346456-05&NCGC00346456-07	Brc1cnc(OCCOc2c(c(NS(=O)(=O)NCCC)ncn2)-c2ccc(Br)cc2)nc1	4.8000002	Active	Endothelin Eta/etb Receptor Antagonist&Endothelin ETA/ETB Receptor Antagonist&Endothelin ETA/ETB Receptor Antagonist	0.5	2	Macitentan	405558977&384568781	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4&-2.4	-51.236499248&-43.9865511544&-67.8040946767	Brc1cnc(OCCOc2c(c(NS(=O)(=O)NCCC)ncn2)-c2ccc(Br)cc2)nc1	Brc1cnc(OCCOc2c(c(NS(=O)(=O)NCCC)ncn2)-c2ccc(Br)cc2)nc1
NCGC00077915-02	Brc1cnc2n3C(=O)/C(=C/c4oc(-c5c(C(=O)O)cccc5)cc4)/Sc3nc2c1		Inactive	Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor		1	ML-119	384568074	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Brc1cnc2n3C(=O)/C(=C/c4oc(-c5c(C(=O)O)cccc5)cc4)/Sc3nc2c1	Brc1cnc2n3C(=O)/C(=C/c4oc(-c5c(C(=O)O)cccc5)cc4)/Sc3nc2c1
NCGC00390657-02	Brc1n(c(SCC(=O)O)nn1)-c1c2c(c(C3CC3)cc1)cccc2	4.4000001	Active	Solute carrier family 22 member 12 Inhibitor	0.0	1	Lesinurad (sodium)	405558615	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-60.7131276359	Brc1n(c(SCC(O[Na])=O)nn1)-c1c2c(c(C3CC3)cc1)cccc2	Brc1n(c(SCC(O[Na])=O)nn1)-c1c2c(c(C3CC3)cc1)cccc2
NCGC00262642-10	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](C)c2ccccc2)ccc1	4.4499998	Active	STAT-3/5 Inhibitor	0.0	1	WP-1066	384568577	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-120.7626503584	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](C)c2ccccc2)ccc1	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](C)c2ccccc2)ccc1
NCGC00263102-06	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](CCC)c2ccccc2)ccc1	5.5	Active	Jak2 Inhibitor	0.0	1	Degrasyn	384568591	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-96.3218132895	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](CCC)c2ccccc2)ccc1	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](CCC)c2ccccc2)ccc1
NCGC00183872-01	Brc1sc2-n3c(C)nnc3CN=C(c3c(Cl)cccc3)c2c1	4.4000001	Active		0.0	1	Brotizolam	144207150	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-79.500771532&-58.035766132	Brc1sc2-n3c(C)nnc3CN=C(c3c(Cl)cccc3)c2c1	Brc1sc2-n3c(C)nnc3CN=C(c3c(Cl)cccc3)c2c1
NCGC00163742-05	C(=C)(C)C1CC=C(C)CC1		Inactive	Response To Oxidative Stress Modulator&response to oxidative stress Modulator		1	d-LIMONENE	405558745	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.7899078959&-25.154241292	C(=C)(C)C1CC=C(C)CC1	C(=C)(C)C1CC=C(C)CC1
NCGC00091056-05	C(=C)c1ccccc1		Inactive			1	Styrene	225144204	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.8271177839	C(=C)c1ccccc1	C(=C)c1ccccc1
NCGC00178575-05	C(=C/C=1N(C)CCCN=1)\c1c(C)ccs1		Inactive	Neuronal Acetylcholine Receptor; Alpha3/beta2 Agonist&Neuronal acetylcholine receptor; alpha3/beta2 Agonist		1	Morantel tartrate	170465696	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.3368674159&-12.5981344399	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.C(=C/C=1N(C)CCCN=1)\c1c(C)ccs1	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.C(=C/C=1N(C)CCCN=1)\c1c(C)ccs1
NCGC00166291-03	C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)(\C=C\C=C(\CCC=C(C)C)/C)/C	5.0500002	Active	response to oxidative stress Modulator	0.0	1	Lycopene	405558667	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-42.393335193	C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)(\C=C\C=C(\CCC=C(C)C)/C)/C	C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)(\C=C\C=C(\CCC=C(C)C)/C)/C
NCGC00096081-04&NCGC00096081-05	C(=C/C=C/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C		Inactive	Vitamin/Supplement&Vitamin/supplement&Vitamin/Supplement		2	beta-Carotene	225144219&384568160	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-13.3221995519&-31.9558863119&-17.902462276	C(=C/C=C/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C	C(=C/C=C/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C
NCGC00181323-02	C(=C/CC/C(=C/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)/C)(\CCC=C(C)C)/C		Inactive	Steroid biosynthesis Modulator&Steroid Biosynthesis Modulator		1	Squalene	225144321	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.378111648&-17.6975724279	C(=C/CC/C(=C/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)/C)(\CCC=C(C)C)/C	C(=C/CC/C(=C/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)/C)(\CCC=C(C)C)/C
NCGC00024714-11	C(=C/CN1CCCC1)(\c1ncccc1)/c1ccc(C)cc1	4.5	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Triprolidine	170464931	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-51.243984992&-60.2979615647	C(=C/CN1CCCC1)(\c1ncccc1)/c1ccc(C)cc1	C(=C/CN1CCCC1)(\c1ncccc1)/c1ccc(C)cc1
NCGC00018187-09	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1	5.9250002	Active	Voltage-gated calcium channel Blocker&Voltage-gated Calcium Channel Blocker	0.0	1	Cinnarizine	170465920	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-1.4	-45.5255894559&-37.7759217336	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
NCGC00160603-02	C(=Cc1ccccc1)c1ccncc1	5.8499999	Inactive		0.0	1	4-Styrylpyridine	144205483	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	1.4	36.5731101984	C(=Cc1ccccc1)c1ccncc1	C(=Cc1ccccc1)c1ccncc1
NCGC00165889-13	C(C)(C)(C)c1[nH]c(c(-c2cc3OCOc3cc2)n1)-c1nc(C)ccc1	5.0	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	SB-505124	384568295	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-92.4567869111	C(C)(C)(C)c1[nH]c(c(-c2cc3OCOc3cc2)n1)-c1nc(C)ccc1	C(C)(C)(C)c1[nH]c(c(-c2cc3OCOc3cc2)n1)-c1nc(C)ccc1
NCGC00186024-12	C(C)(C)(C)c1[nH]c(c(-c2cc3nccnc3cc2)n1)-c1nc(C)ccc1	4.75	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	SB-525334	384568435	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-55.5314536467	C(C)(C)(C)c1[nH]c(c(-c2cc3nccnc3cc2)n1)-c1nc(C)ccc1	C(C)(C)(C)c1[nH]c(c(-c2cc3nccnc3cc2)n1)-c1nc(C)ccc1
NCGC00095836-05	C(C)(C)c1cc-2c(C)ccc-2c(C)cc1	5.8000002	Active	Lipid Oxidation Inhibitor	0.0	1	Guaiazulene	170465862	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.0123266631	C(C)(C)c1cc-2c(C)ccc-2c(C)cc1	C(C)(C)c1cc-2c(C)ccc-2c(C)cc1
NCGC00408838-01	C(C)N1C(C)C(=C2c3c(cccc3)CCc3c2cccc3)CC1	4.9499998	Active	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist	0.0	1	Piroheptine Hydrochloride	405558780	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-78.2879699546&-49.9569832634	C(C)N1C(C)C(=C2c3c(cccc3)CCc3c2cccc3)CC1	C(C)N1C(C)C(=C2c3c(cccc3)CCc3c2cccc3)CC1
NCGC00273481-01	C(C1c2c(Sc3c1cccc3)cccc2)C1CN(C)CCC1	5.0	Active	Muscarinic acetylcholine receptor Antagonist	0.0	1	Metixene hydrochloride	170465287	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-60.312218441	C(C1c2c(Sc3c1cccc3)cccc2)C1CN(C)CCC1.Cl	C(C1c2c(Sc3c1cccc3)cccc2)C1CN(C)CCC1.Cl
NCGC00509991-01	C(CC1CCNCC1)c1c2c(nc(-c3ccccc3)c1)cccc2	4.5	Active	GABA(A) Receptor Agonist	0.0	1	Pipequaline	384569399	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-46.1344736719	C(CC1CCNCC1)c1c2c(nc(-c3ccccc3)c1)cccc2	C(CC1CCNCC1)c1c2c(nc(-c3ccccc3)c1)cccc2
NCGC00018261-06&NCGC00018261-09	C(CC1NCCCC1)(C1CCCCC1)C1CCCCC1	4.75	Active	Mitochondrial Carnitine Palmitoyltransferase-1 Inhbitior&mitochondrial carnitine palmitoyltransferase-1 inhbitior&mitochondrial carnitine palmitoyltransferase-1 inhbitior	0.0	2	Perhexiline	170466435&384568001	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.1&-2.1	-108.8518306068&-98.9988501852&-106.3827306587	O=C(O)/C=C\C(=O)O.C(CC1NCCCC1)(C1CCCCC1)C1CCCCC1	O=C(O)/C=C\C(=O)O.C(CC1NCCCC1)(C1CCCCC1)C1CCCCC1&C(CC1NCCCC1)(C1CCCCC1)C1CCCCC1
NCGC00181040-02	C(CC1NCCCC1)C	5.1999998	Active	Nicotinic Acetylcholine Receptor Alpha1/beta1/gamma/delta Agonist	0.0	1	dl-Coniine	170465693	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.989177264	C(CC1NCCCC1)C	C(CC1NCCCC1)C
NCGC00165976-02	C(CCCC(CCCCC(CCCC(CCCC(C)C)C)C)C)(CCCC(C)C)C	5.5	Active		0.0	1	Squalane	170465658	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.2524332792	C(CCCC(CCCCC(CCCC(CCCC(C)C)C)C)C)(CCCC(C)C)C	C(CCCC(CCCCC(CCCC(CCCC(C)C)C)C)C)(CCCC(C)C)C
NCGC00094207-05	C(CC[N+]1(C)CCCC1)CC[N+]1(C)CCCC1	4.5500002	Active		0.0	1	Pentolinium bitartrate	405559046	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-52.2542064155&-35.9758248439	C(CC[N+]1(C)CCCC1)CC[N+]1(C)CCCC1	C(CC[N+]1(C)CCCC1)CC[N+]1(C)CCCC1
NCGC00159492-03	C(CN1c2c(Sc3c1cccc3)cccc2)CN1CCN(C)CC1	4.5250001	Active	Cytochrome P450 1a2 Inhibitor&Cytochrome P450 1A2 Inhibitor	0.0	1	Perazine	29215457	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.1	-111.8474478254&-87.981378043	C(CN1c2c(Sc3c1cccc3)cccc2)CN1CCN(C)CC1	C(CN1c2c(Sc3c1cccc3)cccc2)CN1CCN(C)CC1
NCGC00188443-01	C(Cc1n2c(nn1)CCCC2)N1CCN(c2c(C)cccc2)CC1		Inactive	Adrenergic Receptor Alpha-1 Antagonist		1	Dapiprazole hydrochloride	144206586	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-13.022037768	C(Cc1n2c(nn1)CCCC2)N1CCN(c2c(C)cccc2)CC1.Cl	C(Cc1n2c(nn1)CCCC2)N1CCN(c2c(C)cccc2)CC1.Cl
NCGC00016421-07	C(N1CCN(C)CC1)(c1ccccc1)c1ccccc1	4.75	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Cyclizine hydrochloride	170465270	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-53.1344746783&-37.4213387337	C(N1CCN(C)CC1)(c1ccccc1)c1ccccc1.Cl.Cl	C(N1CCN(C)CC1)(c1ccccc1)c1ccccc1.Cl.Cl
NCGC00346474-01	C(N1CCNCC1)c1c2c(ccc1)cccc2		Inactive	Bacterial Efflux Pump Inhibitor		1	NMP	174006243	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.806493864	C(N1CCNCC1)c1c2c(ccc1)cccc2	C(N1CCNCC1)c1c2c(ccc1)cccc2
NCGC00165722-03&NCGC00165722-19	C(N1CCNCCCNCCNCCC1)c1ccc(CN2CCNCCCNCCNCCC2)cc1		Inactive	Chemokine Cxcr4 (sdf-1 Receptor) Antagonists&Chemokine CXCR4 (SDF-1 Receptor) Antagonist&Chemokine CXCR4 (SDF-1 Receptor) Antagonist		2	Plerixafor hydrochloride	405558840&384568275	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-20.082578156&-25.3987116639&20.4893690272	C(N1CCNCCCNCCNCCC1)c1ccc(CN2CCNCCCNCCNCCC2)cc1	C(N1CCNCCCNCCNCCC1)c1ccc(CN2CCNCCCNCCNCCC2)cc1
NCGC00183046-03	C(N1c2c(Sc3c1cccc3)cccc2)C1C2CCN(C1)CC2	4.8499999	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Mequitazine	170465794	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-71.9342872134&-83.9618033979	C(N1c2c(Sc3c1cccc3)cccc2)C1C2CCN(C1)CC2	C(N1c2c(Sc3c1cccc3)cccc2)C1C2CCN(C1)CC2
NCGC00014482-03	C(N1c2c(Sc3c1cccc3)cccc2)[C@@H]1CN(C)CC1	4.9250002	Active	ion channel&Ion Channel	0.0	1	Methdilazine hydrochloride	124878446	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.3	-89.8244088556&-76.7308591645	C(N1c2c(Sc3c1cccc3)cccc2)[C@@H]1CN(C)CC1	C(N1c2c(Sc3c1cccc3)cccc2)[C@@H]1CN(C)CC1
NCGC00181356-02	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(C2CCCCC2)OC1		Inactive			1	Oxapium iodide	170465824	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(C2CCCCC2)OC1.[I-]	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(C2CCCCC2)OC1.[I-]
NCGC00182994-01	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(c2ccccc2)OC1		Inactive			1	Anacolin	144206808	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(c2ccccc2)OC1.[I-]	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(c2ccccc2)OC1.[I-]
NCGC00181104-04	C(\C=C\c1[n+](CC)c2c(s1)cccc2)=C/C=C\1/N(CC)c2c(S/1)cccc2	4.9250002	Active		0.0	1	Dithiazanine chloride	124893646	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-82.628189708&-108.8517197324	C(\C=C\c1[n+](CC)c2c(s1)cccc2)=C/C=C\1/N(CC)c2c(S/1)cccc2	C(\C=C\c1[n+](CC)c2c(s1)cccc2)=C/C=C\1/N(CC)c2c(S/1)cccc2
NCGC00183859-01	C(\c1ccccc1)(/c1ccccc1)=C\1/C(C)[N+](CC)(CC)CC/1	4.4499998	Active	Muscarinic acetylcholine receptor Antagonist	0.0	1	Prifinium bromide	144206846	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.829885748	C(\c1ccccc1)(/c1ccccc1)=C\1/C(C)[N+](CC)(CC)CC/1.[Br-]	C(\c1ccccc1)(/c1ccccc1)=C\1/C(C)[N+](CC)(CC)CC/1.[Br-]
NCGC00167984-01	C(\c1sccc1)(/c1sccc1)=C\1/C[N@+]2(C)[C@@H](CC/1)CCCC2	4.8499999	Active		0.0	1	Tiquizium bromide	144206157	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-38.0185920492	C(\c1sccc1)(/c1sccc1)=C\1/C[N@+]2(C)[C@@H](CC/1)CCCC2.[Br-]	C(\c1sccc1)(/c1sccc1)=C\1/C[N@+]2(C)[C@@H](CC/1)CCCC2.[Br-]
NCGC00182057-03	C(c1c(C)c(C)ccc1)c1[nH]cnc1		Inactive	Alpha-2 adrenergic receptor Agonist&Alpha-2 Adrenergic Receptor Agonist		1	Detomidine hydrochloride	170465639	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.9335628399&0.0	C(c1c(C)c(C)ccc1)c1[nH]cnc1.Cl	C(c1c(C)c(C)ccc1)c1[nH]cnc1.Cl
NCGC00095348-11	C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2	4.4000001	Active	Androgen Receptor Antagonist	0.0	1	Diindolylmethane	384568156	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-43.6486901079	C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2	C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2
NCGC00016506-07	C(c1cc2c(cc1)cccc2)C1=NCCN1		Inactive	Alpha-1b Adrenergic Receptor Agonist&Alpha-1b adrenergic receptor Agonist		1	Naphazoline hydrochloride	170464797	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.7332405079&18.620265044	C(c1cc2c(cc1)cccc2)C1=NCCN1.Cl	C(c1cc2c(cc1)cccc2)C1=NCCN1.Cl
NCGC00016283-04	C(c1ccccc1)(c1ccccc1)=C1CC[N+](C)(C)CC1	5.4499998	Active	Antimitotic	0.0	1	Diphemanil methylsulfate	170464876	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-43.1300722426	S(=O)(=O)(OC)[O-].C(c1ccccc1)(c1ccccc1)=C1CC[N+](C)(C)CC1	S(=O)(=O)(OC)[O-].C(c1ccccc1)(c1ccccc1)=C1CC[N+](C)(C)CC1
NCGC00016271-05	C(c1ccccc1)C1=NCCN1	5.1999998	Active	Adrenergic Receptor Alpha-1 Antagonist	0.0	1	Tolazoline hydrochloride	170465219	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-33.373099684	C(c1ccccc1)C1=NCCN1.Cl	C(c1ccccc1)C1=NCCN1.Cl
NCGC00346689-06	C(c1n2N=C(c3cn(C)nc3)C=Cc2nc1)c1cc2c(nccc2)cc1		Inactive	HGFR Inhibitor		1	NVP-BVU-972	363677518	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	C(c1n2N=C(c3cn(C)nc3)C=Cc2nc1)c1cc2c(nccc2)cc1	C(c1n2N=C(c3cn(C)nc3)C=Cc2nc1)c1cc2c(nccc2)cc1
NCGC00085849-02	C(n1c2c(c3c1CCN(C)C3)cccc2)c1ccccc1	4.5500002	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	MEBHYDROLIN	405558588	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-75.4006480474&-113.3322642419	C(n1c2c(c3c1CCN(C)C3)cccc2)c1ccccc1	C(n1c2c(c3c1CCN(C)C3)cccc2)c1ccccc1
NCGC00018254-08	C(n1cncc1)(c1ccc(-c2ccccc2)cc1)c1ccccc1	4.4499998	Active	Cytochrome P450 51 Inhibitor	0.0	1	Bifonazole	170465826	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-80.4844373048&-113.753141836	C(n1cncc1)(c1ccc(-c2ccccc2)cc1)c1ccccc1	C(n1cncc1)(c1ccc(-c2ccccc2)cc1)c1ccccc1
NCGC00016018-11	C1(C2c3c(cccc3)CCC2)=NCCN1	4.4000001	Active	Adrenergic Receptor Alpha Agonist&Adrenergic receptor alpha Agonist	0.0	1	Tetrahydrozoline HCl	405559075	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-36.122364712&-38.556260576	C1(C2c3c(cccc3)CCC2)=NCCN1	C1(C2c3c(cccc3)CCC2)=NCCN1
NCGC00091666-04	CC1(C)OC2(C)CCC1CC2	4.4000001	Active	Tumor Necrosis Factor Production Inhibitor	0.0	1	1,8-Cineol	170465483	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.012965748	CC1(C)OC2(C)CCC1CC2	CC1(C)OC2(C)CCC1CC2
NCGC00346896-03	CC1(N2CCC(n3c([C@H]4CNCCC4)nc4c3cccc4)CC2)CCCCCCC1	5.3000002	Active	ORL1 (OP4, NOP) Agonist	0.0	1	MCOPPB	384568966	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-61.1649534949	CC1(N2CCC(n3c([C@H]4CNCCC4)nc4c3cccc4)CC2)CCCCCCC1	CC1(N2CCC(n3c([C@H]4CNCCC4)nc4c3cccc4)CC2)CCCCCCC1
NCGC00182705-02	CN1CC/C(=C\2/c3ncccc3CCc3c/2cccc3)/CC1	4.4499998	Active	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist	0.0	1	Azatadine	170464865	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-51.3956667479&-41.5157473839	CN1CC/C(=C\2/c3ncccc3CCc3c/2cccc3)/CC1	CN1CC/C(=C\2/c3ncccc3CCc3c/2cccc3)/CC1
NCGC00015656-12	CN1CC2N(c3c(cccc3)Cc3c2cccc3)CC1	4.4000001	Active	5-HT2A Antagonists?&5-ht2a Antagonists?	0.0	1	Mianserin	170465596	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-65.6113916051&-72.909685668	CN1CC2N(c3c(cccc3)Cc3c2cccc3)CC1	CN1CC2N(c3c(cccc3)Cc3c2cccc3)CC1
NCGC00532494-01	CN1CC=2C(c3ccccc3)c3c(cccc3)C=2CC1	5.1750002	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	PHENINDAMINE	405558785	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.4	-41.8391355791&-46.9133561612	CN1CC=2C(c3ccccc3)c3c(cccc3)C=2CC1	CN1CC=2C(c3ccccc3)c3c(cccc3)C=2CC1
NCGC00378937-01	CN1CC=2c3c(cccc3)Cc3c(cccc3)C=2CC1	4.4000001	Active	Serotonin Receptor Signaling Pathway Modulator&serotonin receptor signaling pathway Modulator	0.0	1	Setiptiline	405559104	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-61.745275308&-69.901172436	CN1CC=2c3c(cccc3)Cc3c(cccc3)C=2CC1	CN1CC=2c3c(cccc3)Cc3c(cccc3)C=2CC1
NCGC00096077-06	CN1CCN(C2=Nc3c(Nc4sc(C)cc24)cccc3)CC1	4.8249998	Active	Dopamine D2 Antagonist	0.0	1	Olanzapine	170465009	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-53.6943708235&-31.3314668804	CN1CCN(C2=Nc3c(Nc4sc(C)cc24)cccc3)CC1	CN1CCN(C2=Nc3c(Nc4sc(C)cc24)cccc3)CC1
NCGC00182979-02	CN1CCN(C2=Nc3c(cccc3)Cc3c2cccc3)CC1	4.4000001	Active	Histamine H1 Receptor Inverse Agonist	0.0	1	Perlapine	405558916	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-65.744326912	CN1CCN(C2=Nc3c(cccc3)Cc3c2cccc3)CC1	CN1CCN(C2=Nc3c(cccc3)Cc3c2cccc3)CC1
NCGC00389791-02	CN1CCN(C=2Nc3c(N=C4SC(C)=CC=24)cccc3)CC1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	Olanzapine (LY-170053)	363680854	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.232813244	CN1CCN(C=2Nc3c(N=C4SC(C)=CC=24)cccc3)CC1	CN1CCN(C=2Nc3c(N=C4SC(C)=CC=24)cccc3)CC1
NCGC00094906-06	CN1Cc2c(C(c3ccccc3)OCC1)cccc2		Inactive	Serotonin transporter Inhibitor&Serotonin Transporter Inhibitor		1	Nefopam hydrochloride	170465579	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.000158616&-26.835484528	CN1Cc2c(C(c3ccccc3)OCC1)cccc2.Cl	CN1Cc2c(C(c3ccccc3)OCC1)cccc2.Cl
NCGC00378999-05	CN1Cc2cc(Nc3nc(-c4cc(OCC/C=C/C1)ccc4)ccn3)ccc2	5.5500002	Active	CDK Inhibitor	0.0	1	SB-1317	377020528	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.0073826869	CN1Cc2cc(Nc3nc(-c4cc(OCC/C=C/C1)ccc4)ccn3)ccc2	CN1Cc2cc(Nc3nc(-c4cc(OCC/C=C/C1)ccc4)ccn3)ccc2
NCGC00090693-11	CN1[C@@H](c2cnccc2)CCC1		Inactive	Neuronal Acetylcholine Receptor; Alpha4/beta2 Agonist&Neuronal acetylcholine receptor; alpha4/beta2 Agonist		1	D-Nicotine	170464932	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	CN1[C@@H](c2cnccc2)CCC1	CN1[C@@H](c2cnccc2)CCC1
NCGC00182065-02	CN1[C@@H]2[C@@H]3[C@@](c4c(ccc(C)c4)C2)(CC1)CCCC3	4.5749998	Active		0.0	1	Dimemorfan phosphate	144206689	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-75.9671078879&-64.7662895636	P(=O)(O)(O)O.CN1[C@@H]2[C@@H]3[C@@](c4c(ccc(C)c4)C2)(CC1)CCCC3	P(=O)(O)(O)O.CN1[C@@H]2[C@@H]3[C@@](c4c(ccc(C)c4)C2)(CC1)CCCC3
NCGC00371104-01	C[C@@H]1SC[C@]2(O1)C1CCN(C2)CC1	5.3499999	Active		0.0	1	Cevimeline hydrochloride	405558818	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.6570287849	C[C@@H]1SC[C@]2(O1)C1CCN(C2)CC1	C[C@@H]1SC[C@]2(O1)C1CCN(C2)CC1
NCGC00167540-03	Cc1c2c([nH]c1)cccc2		Inactive	Aryl Hydrocarbon Receptor Partial Agonist&Aryl hydrocarbon receptor Partial Agonist		1	3-Methylindole	170465747	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.4073850039	Cc1c2c([nH]c1)cccc2	Cc1c2c([nH]c1)cccc2
NCGC00510442-01	Cc1cnc(-c2ncc(C)cc2)cc1	5.5	Active	MMP-9 (Gelatinase B) Inhibitor	0.0	1	Abametapir	384569434	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-63.4109139841	Cc1cnc(-c2ncc(C)cc2)cc1	Cc1cnc(-c2ncc(C)cc2)cc1
NCGC00249661-03	Cc1n(c(C)cc1-c1n2c(nn1)CCCCC2)-c1ccc(C)cc1	4.4000001	Active	HPGD Inhibitor	0.0	1	NCGC00249661	384568531	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-93.470918768	Cc1n(c(C)cc1-c1n2c(nn1)CCCCC2)-c1ccc(C)cc1	Cc1n(c(C)cc1-c1n2c(nn1)CCCCC2)-c1ccc(C)cc1
NCGC00242054-15	Cc1nc(-c2c(-c3nc4c(nccc4)cc3)c[nH]n2)ccc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	SJN-2511	384568483	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Cc1nc(-c2c(-c3nc4c(nccc4)cc3)c[nH]n2)ccc1	Cc1nc(-c2c(-c3nc4c(nccc4)cc3)c[nH]n2)ccc1
NCGC00016893-04&NCGC00182084-01	Cl/C(/Cl)=C(/Cl)\c1c(S(=O)(=O)N)cc(S(=O)(=O)N)c(N)c1		Inactive	antiparasitic agent&Anti-parasitic&antiparasitic agent		2	Clorsulon	170466229&124893809	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	16.166663736&-20.919388152&-26.0524457761	Cl/C(/Cl)=C(/Cl)\c1c(S(=O)(=O)N)cc(S(=O)(=O)N)c(N)c1	Cl/C(/Cl)=C(/Cl)\c1c(S(=O)(=O)N)cc(S(=O)(=O)N)c(N)c1
NCGC00090997-11	Cl/C(/Cl)=C\OP(=O)(OC)OC		Inactive	Butyrylcholinesterase Inhibitor		1	Dichlorvos	170466226	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.376627888	Cl/C(/Cl)=C\OP(=O)(OC)OC	Cl/C(/Cl)=C\OP(=O)(OC)OC
NCGC00016511-08	Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1	4.6750002	Active	Estrogen Receptor Modulator&Estrogen receptor Modulator	0.0	1	Chlorotrianisene	170465394	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-32.5950166959&-33.377400248	Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1	Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1
NCGC00164385-06	Cl/C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)/c1ccccc1		Inactive	Selective Estrogen Receptor Modulators (SERM)		1	Clomifene citrate	363676631	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.436118212	Cl/C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)/c1ccccc1	Cl/C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)/c1ccccc1
NCGC00253575-01	Cl/C(=N\OC[C@H](O)CN1CCCCC1)/c1c[n+]([O-])ccc1		Inactive	Heat Shock 70 Kda Protein 1 Activator&Heat shock 70 kDa protein 1 Activator		1	Arimoclomol	170465602	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.6094414439&11.336915012	Cl/C(=N\OC[C@H](O)CN1CCCCC1)/c1c[n+]([O-])ccc1	Cl/C(=N\OC[C@H](O)CN1CCCCC1)/c1c[n+]([O-])ccc1
NCGC00253596-01	Cl/C=C\C(O)(C#C)CC		Inactive	GABA-A receptor; anion channel Positive Allosteric Modulator&Gaba-a Receptor; Anion Channel Positive Allosteric Modulator		1	Ethchlorvynol	170464750	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.648920852&-18.559666304	Cl/C=C\C(O)(C#C)CC	Cl/C=C\C(O)(C#C)CC
NCGC00344521-01	Cl/C=C\[CH-][N+]12CN3CN(C1)CN(C2)C3		Inactive			1	1-(cis-3-Chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride	225144377	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.335032004&18.213319832	Cl/C=C\[CH-][N+]12CN3CN(C1)CN(C2)C3	Cl/C=C\[CH-][N+]12CN3CN(C1)CN(C2)C3
NCGC00386194-01	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OC(=O)CCCCCCCCCCCCCCC)C(SC)O1)C		Inactive	Antibacterial		1	Clindamycin palmitate HCl	405558990	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.942066148&-15.870857196	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OC(=O)CCCCCCCCCCCCCCC)C(SC)O1)C	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OC(=O)CCCCCCCCCCCCCCC)C(SC)O1)C
NCGC00389304-01	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OP(=O)(O)O)C(SC)O1)C	6.5	Active	Bacterial 70s Ribosome Inhibitor	0.0	1	Clindamycin Phosphate	405559083	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-38.2743039238	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OP(=O)(O)O)C(SC)O1)C	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OP(=O)(O)O)C(SC)O1)C
NCGC00091021-01	ClC(Cl)(Cl)C(=O)O		Inactive			1	Trichloroacetic acid	17388684	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-9.5474237359&-34.421775064	ClC(Cl)(Cl)C(=O)O	ClC(Cl)(Cl)C(=O)O
NCGC00159392-05	ClC(Cl)(Cl)C(O)(C)C		Inactive			1	1,1,1-Trichloro-2-methyl-2-propanol	170465458	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.035515536&27.2087950759	ClC(Cl)(Cl)C(O)(C)C	ClC(Cl)(Cl)C(O)(C)C
NCGC00018237-09	ClC(Cl)(Cl)C(P(=O)(OC)OC)O		Inactive	Butyrylcholinesterase Inhibitor		1	Trichlorfon	170465707	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.573040372&-23.852966596	ClC(Cl)(Cl)C(P(=O)(OC)OC)O	ClC(Cl)(Cl)C(P(=O)(OC)OC)O
NCGC00160570-01	ClC(Cl)(Cl)C(P(=O)(OC)OC)OC(=O)CCC	4.1750002	Active		0.0	1	Butonate	144205461	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-31.141837444&-65.7028233551	ClC(Cl)(Cl)C(P(=O)(OC)OC)OC(=O)CCC	ClC(Cl)(Cl)C(P(=O)(OC)OC)OC(=O)CCC
NCGC00091071-08	ClC(Cl)(Cl)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1		Inactive			1	p,p'-DDT	170465529	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.392675928&-10.480247128	ClC(Cl)(Cl)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1	ClC(Cl)(Cl)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1
NCGC00091034-10	ClC(Cl)(Cl)SN1C(=O)C2C(C1=O)CC=CC2	4.6750002	Active		0.0	1	Captan	225144202	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-95.1728175827&-97.4038699028	ClC(Cl)(Cl)SN1C(=O)C2C(C1=O)CC=CC2	ClC(Cl)(Cl)SN1C(=O)C2C(C1=O)CC=CC2
NCGC00162143-03	ClC(Cl)(P(=O)(O)[O-])P(=O)(O)[O-]		Inactive	ADP/ATP translocase 3 Inhibitor&Adp/atp Translocase 3 Inhibitor		1	Clodronate	225144247	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.302974264	ClC(Cl)(P(=O)(O)[O-])P(=O)(O)[O-]	ClC(Cl)(P(=O)(O)[O-])P(=O)(O)[O-]
NCGC00480787-02	ClC(Cl)(P(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3nc(SCCC(F)(F)F)nc(NCCSC)c3nc2)O1)O)(=O)O)P(=O)(O)O		Inactive			1	Cangrelor (AR-C69931)	405559017	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.0670758&0.0	ClC(Cl)(P(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3nc(SCCC(F)(F)F)nc(NCCSC)c3nc2)O1)O)(=O)O)P(=O)(O)O	ClC(Cl)(P(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3nc(SCCC(F)(F)F)nc(NCCSC)c3nc2)O1)O)(=O)O)P(=O)(O)O
NCGC00159390-14	ClC(Cl)=CC1C(C)(C)C1C(=O)OCc1cc(Oc2ccccc2)ccc1	4.4499998	Active	Voltage-sensitive sodium channel Inhibitor	0.0	1	PERMETHRIN	405558899	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-38.9466090283	ClC(Cl)=CC1C(C)(C)C1C(=O)OCc1cc(Oc2ccccc2)ccc1	ClC(Cl)=CC1C(C)(C)C1C(=O)OCc1cc(Oc2ccccc2)ccc1
NCGC00344542-01	ClC(Cl)=C[C@@H]1[C@@H](C(=O)OCc2c(F)c(F)cc(F)c2F)C1(C)C		Inactive	Cytochrome P450 3a2 Activator&Cytochrome P450 3A2 Activator		1	Transfluthrin	225144388	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	ClC(Cl)=C[C@@H]1[C@@H](C(=O)OCc2c(F)c(F)cc(F)c2F)C1(C)C	ClC(Cl)=C[C@@H]1[C@@H](C(=O)OCc2c(F)c(F)cc(F)c2F)C1(C)C
NCGC00016637-10	ClC(Cl)C(=O)N(C)c1ccc(OC(=O)c2occc2)cc1		Inactive			1	Diloxanide furoate	170466783	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.260155972&0.0	ClC(Cl)C(=O)N(C)c1ccc(OC(=O)c2occc2)cc1	ClC(Cl)C(=O)N(C)c1ccc(OC(=O)c2occc2)cc1
NCGC00179366-03	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CF		Inactive			1	Florfenicol	170465648	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.8842849679&-22.272539436	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CF	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CF
NCGC00178319-06	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CO	5.0	Active	Antibiotic	0.0	1	Thiamphenicol	170465845	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.2606301708	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CO	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CO
NCGC00091011-08	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO		Inactive	Antibiotic		1	Chloramphenicol	225144201	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	34.1145895439&0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO
NCGC00094619-06	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCC(=O)[O-]		Inactive	Bacterial 70s Ribosome Inhibitor&Bacterial 70S ribosome Inhibitor		1	Chloramphenicol sodium succinate	170465429	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.4667148607&0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCC(=O)[O-].[Na+]	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCC(=O)[O-].[Na+]
NCGC00348371-01	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCCCCCCCCCCCCCC		Inactive	Antibiotic		1	Chloramphenicol palmitate	405558999	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.01748696&23.8245807407	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCCCCCCCCCCCCCC	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCCCCCCCCCCCCCC
NCGC00168747-01	ClC(Cl)C(F)(F)OC	4.4000001	Active	synaptic transmission Inhibitor	0.0	1	Methoxyflurane	144206179	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.6781562079	ClC(Cl)C(F)(F)OC	ClC(Cl)C(F)(F)OC
NCGC00018302-07&NCGC00018302-12	ClC(Cl)C1NS(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2		Inactive	Solute Carrier Family 12 Member 3 Inhibitor&Diuretic&Diuretic		2	Trichlormethiazide	170464812&384568004	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	ClC(Cl)C1NS(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2	ClC(Cl)C1NS(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2
NCGC00509944-01	ClC(F)(F)Oc1ccc(NC(=O)c2cc(c(N3C[C@H](O)CC3)nc2)-c2[nH]ncc2)cc1	4.6999998	Active	Bcr-Abl Inhibitor	0.0	1	Asciminib	384569392	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-92.802951872	ClC(F)(F)Oc1ccc(NC(=O)c2cc(c(N3C[C@H](O)CC3)nc2)-c2[nH]ncc2)cc1	ClC(F)(F)Oc1ccc(NC(=O)c2cc(c(N3C[C@H](O)CC3)nc2)-c2[nH]ncc2)cc1
NCGC00167422-01	ClC(F)C(F)(F)OC(F)F	4.5250001	Active	Glycine Receptor Positive Allosteric Modulator&Glycine receptor Positive Allosteric Modulator	0.0	1	Enflurane	144205979	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-58.984778524&-48.0176347747	ClC(F)C(F)(F)OC(F)F	ClC(F)C(F)(F)OC(F)F
NCGC00181037-03	ClC(OC(F)F)C(F)(F)F	4.4000001	Active	Glycine receptor Positive Allosteric Modulator	0.0	1	Isoflurane	405558879	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.7813394399	ClC(OC(F)F)C(F)(F)F	ClC(OC(F)F)C(F)(F)F
NCGC00015202-08&NCGC00164447-01	ClC1(Cl)C(c2ccc(OC(C(=O)O)(C)C)cc2)C1		Inactive	Pparalpha Agonist&PPARalpha Agonist&PPARalpha Agonist		2	Ciprofibrate	170466356&26757866	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	ClC1(Cl)C(c2ccc(OC(C(=O)O)(C)C)cc2)C1	ClC1(Cl)C(c2ccc(OC(C(=O)O)(C)C)cc2)C1
NCGC00510749-15	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2CC1	5.5	Active	Bacterial Penicillin-binding Protein Inhibitor	0.0	1	Loracarbef	405558434	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-69.7886554694	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2CC1	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2CC1
NCGC00015260-22	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1		Inactive	Solute Carrier Family 15 Member 2 Inhibitor		1	CEFACLOR	405559149	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
NCGC00092289-01	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O	4.9499998	Active	CDC25 Phosphatase Inhibitor	0.0	1	DA-3003-1	26753179	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-101.6801454897	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O
NCGC00420896-01	ClC1=C/C(=C(/NNC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)\C)/C(=O)C=C1		Inactive	Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitor		1	SP-2509	384569228	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-10.5193590999	ClC1=C/C(=C(/NNC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)\C)/C(=O)C=C1	ClC1=C/C(=C(/NNC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)\C)/C(=O)C=C1
NCGC00241410-02	ClC1=Cn2c(-c3nc(NC4CNC4)ccc3)cnc2C=C1		Inactive	IRAK Inhibitor		1	NCGC00241410	363677139	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.075880932	ClC1=Cn2c(-c3nc(NC4CNC4)ccc3)cnc2C=C1	ClC1=Cn2c(-c3nc(NC4CNC4)ccc3)cnc2C=C1
NCGC00348372-01	ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl	4.4000001	Active	Gaba-a Receptor Binding Agent	0.0	1	LINDANE	405558821	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.49462518	ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl	ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl
NCGC00181011-02	ClC=1C(O)=CC(=O)NC=1		Inactive	Dihydropyrimidine Dehydrogenase Inhibitor		1	Gimeracil	170466048	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	22.282870104&0.0&11.8490777039	ClC=1C(O)=CC(=O)NC=1	ClC=1C(O)=CC(=O)NC=1
NCGC00480898-01	ClC=1C(c2c(F)cc(OCCCNC)cc2F)=C(N[C@H](C(F)(F)F)C)n2ncnc2N=1	4.5500002	Inactive	Microtubule-Stabilizing Agents	0.0	1	Cevipabulin	384569249	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-33.6130685935	ClC=1C(c2c(F)cc(OCCCNC)cc2F)=C(N[C@H](C(F)(F)F)C)n2ncnc2N=1	ClC=1C(c2c(F)cc(OCCCNC)cc2F)=C(N[C@H](C(F)(F)F)C)n2ncnc2N=1
NCGC00022680-05	ClC=1C=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC4)CC3)C=1)CCC(=O)C=2	4.4000001	Active	Androgen Receptor Antagonist	0.0	1	Chlormadinone acetate	170465776	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.8120086519	ClC=1C=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC4)CC3)C=1)CCC(=O)C=2	ClC=1C=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC4)CC3)C=1)CCC(=O)C=2
NCGC00091032-09&NCGC00262575-02	ClC=1C=2[C@](C)([C@@H]3[C@H](C(=O)C=2)C3)[C@@H]2[C@H]([C@H]3[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC3)CC2)C=1	4.6500001	Active	Androgen Receptor Antagonist	0.5	2	Cyproterone acetate	363676548&170465682	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-3.0	-39.815583332&-68.208526704&-94.342088776	ClC=1C=2[C@](C)([C@@H]3[C@H](C(=O)C=2)C3)[C@@H]2[C@H]([C@H]3[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC3)CC2)C=1	ClC=1C=2[C@](C)([C@@H]3[C@H](C(=O)C=2)C3)[C@@H]2[C@H]([C@H]3[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC3)CC2)C=1
NCGC00181041-01	ClC=1SN(C)C(=O)C=1		Inactive	aerobic respiration Inhibitor&Aerobic Respiration Inhibitor		1	5-Chloro-2-methyl-3(2H)-isothiazolone	144206242	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	ClC=1SN(C)C(=O)C=1	ClC=1SN(C)C(=O)C=1
NCGC00343773-03	ClCC(=N)NCCC[C@H](NC(=O)c1cc2c(cc(N(C)C)cc2)cc1)C(=O)NCc1ccccc1		Inactive	Peptidylarginine Deiminase (PAD) Inhibitor		1	YW3-56	384568715	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	29.1884128217	ClCC(=N)NCCC[C@H](NC(=O)c1cc2c(cc(N(C)C)cc2)cc1)C(=O)NCc1ccccc1	ClCC(=N)NCCC[C@H](NC(=O)c1cc2c(cc(N(C)C)cc2)cc1)C(=O)NCc1ccccc1
NCGC00389480-01	ClCC(=O)C1(OC(=O)CC)C2(C)C(C3C(F)(C4(C)C(C(F)C3)=CC(=O)C=C4)C(O)C2)CC1C	5.1999998	Active		0.0	1	NCGC00389480-01	405559014	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.794913348	ClCC(=O)C1(OC(=O)CC)C2(C)C(C3C(F)(C4(C)C(C(F)C3)=CC(=O)C=C4)C(O)C2)CC1C	ClCC(=O)C1(OC(=O)CC)C2(C)C(C3C(F)(C4(C)C(C(F)C3)=CC(=O)C=C4)C(O)C2)CC1C
NCGC00507863-01	ClCC(=O)N1[C@@H](c2ccc(C(=O)OC)cc2)c2[nH]c3c(c2C[C@@H]1C(=O)OC)cccc3	4.5	Active	GPX4 Inhibitor	0.0	1	RSL3	384569338	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-111.2031975534	ClCC(=O)N1[C@@H](c2ccc(C(=O)OC)cc2)c2[nH]c3c(c2C[C@@H]1C(=O)OC)cccc3	ClCC(=O)N1[C@@H](c2ccc(C(=O)OC)cc2)c2[nH]c3c(c2C[C@@H]1C(=O)OC)cccc3
NCGC00384179-01	ClCC(=O)Nc1cc(NC2=NS(=O)(=O)c3c2cccc3)ccc1	4.4499998	Active	p97 ATPase Inhibitor	0.0	1	NMS-859	363679177	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-95.077225698	ClCC(=O)Nc1cc(NC2=NS(=O)(=O)c3c2cccc3)ccc1	ClCC(=O)Nc1cc(NC2=NS(=O)(=O)c3c2cccc3)ccc1
NCGC00347285-06	ClCC(=O)Nc1ccc(-n2c(-c3cc(Cl)c(Cl)cc3)nc(OCCOC)n2)cc1	4.4000001	Active	mucosa associated lymphoid tissue lymphoma translocation 1 (MALT1) Inhibitor	0.0	1	MI-2	363677575	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-111.8274726981	ClCC(=O)Nc1ccc(-n2c(-c3cc(Cl)c(Cl)cc3)nc(OCCOC)n2)cc1	ClCC(=O)Nc1ccc(-n2c(-c3cc(Cl)c(Cl)cc3)nc(OCCOC)n2)cc1
NCGC00094419-03	ClCC(=O)[C@@H](NS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1	4.4000001	Active	Cysteine Protease Inhibitor	0.0	1	TPCK	26753659	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.303984672	ClCC(=O)[C@@H](NS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1	ClCC(=O)[C@@H](NS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1
NCGC00023373-03&NCGC00023373-10	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21		Inactive	Corticosteroid		2	Clobetasol propionate	170465385&384568017	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-13.0847455799	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00022019-03	ClCC(=O)[C@@]1(OC(=O)CCC)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	4.5	Active	corticosteroid	0.0	1	Clobetasone butyrate	170465575	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-101.5860551178	ClCC(=O)[C@@]1(OC(=O)CCC)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	ClCC(=O)[C@@]1(OC(=O)CCC)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00179475-03	ClCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@](F)([C@@H](O)C3)[C@]3(C)C(=CC(=O)CC3)CC4)C[C@H]1OC(C)(C)O2		Inactive			1	Halcinonide	170465389	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	ClCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@](F)([C@@H](O)C3)[C@]3(C)C(=CC(=O)CC3)CC4)C[C@H]1OC(C)(C)O2	ClCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@](F)([C@@H](O)C3)[C@]3(C)C(=CC(=O)CC3)CC4)C[C@H]1OC(C)(C)O2
NCGC00508824-01	ClCC(O)COc1ccc(C(C)(C)c2ccc(OCC(O)CO)cc2)cc1	6.0500002	Inactive	Androgen Receptor Antagonist	0.0	1	Ralaniten (EPI-001)	384569361	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	16.184004124	ClCC(O)COc1ccc(C(C)(C)c2ccc(OCC(O)CO)cc2)cc1	ClCC(O)COc1ccc(C(C)(C)c2ccc(OCC(O)CO)cc2)cc1
NCGC00160530-12&NCGC00160530-13	ClCC/C(=C(/c1ccc(OCCN(C)C)cc1)\c1ccccc1)/c1ccccc1	4.6750002	Active	Selective Estrogen Receptor Modulators (SERM)&Selective Estrogen Receptor Modulators (serm)&Selective Estrogen Receptor Modulators (SERM)	0.25	2	Toremifene citrate	384568200&405558853	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0&-2.1	-95.4270895795&-63.87949096&-93.3491394924	ClCC/C(=C(/c1ccc(OCCN(C)C)cc1)\c1ccccc1)/c1ccccc1	ClCC/C(=C(/c1ccc(OCCN(C)C)cc1)\c1ccccc1)/c1ccccc1
NCGC00167446-02	ClCC1N(C)S(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2		Inactive	Sodium-(potassium)-chloride Cotransporter 2 Inhibitor&Sodium-(potassium)-chloride cotransporter 2 Inhibitor		1	Methyclothiazide	170465243	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.258805188&0.0	ClCC1N(C)S(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2	ClCC1N(C)S(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2
NCGC00522026-01	ClCC1OC1		Inactive			1	NCGC00522026-01&Sevelamer Hydrochloride (Technical Grade)	405558636	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&18.2752840239	ClCC1OC1.NCC=C	ClCC1OC1.NCC=C
NCGC00249908-01	ClCCCNC(Cc1ccccc1)C	4.9749999	Active		0.0	1	Mefenorex	170465601	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-33.306993524&-36.8437750312	ClCCCNC(Cc1ccccc1)C	ClCCCNC(Cc1ccccc1)C
NCGC00164581-02	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)CCCl		Inactive	Estrogen Receptor Beta Modulator&Estrogen receptor beta Modulator		1	Estramustine	170466403	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.323112648&20.237481528	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)CCCl	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)CCCl
NCGC00484900-01	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)(O)O)CC4)CC3)CC2)cc1)CCCl	4.4749999	Active	Dna Alkylating Agent	0.0	1	Estramustine PhosphateNa	405558512	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-76.956086656&-37.512104952	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)(O)O)CC4)CC3)CC2)cc1)CCCl	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)(O)O)CC4)CC3)CC2)cc1)CCCl
NCGC00185756-04	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)([O-])[O-])CC4)CC3)CC2)cc1)CCCl		Inactive	DNA Alkylating Agent		1	Estramustine	384568425	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)([O-])[O-])CC4)CC3)CC2)cc1)CCCl	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)([O-])[O-])CC4)CC3)CC2)cc1)CCCl
NCGC00091835-10&NCGC00091835-15	ClCCN(CCCl)C	4.4000001	Active	DNA Alkylating Agent&Dna Alkylating Agent&DNA Alkylating Agent	0.0	2	Chlormethine	170465017&384568099	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-3.0	-96.27548262&-95.5761427935&-82.045516836	ClCCN(CCCl)C.Cl	ClCCN(CCCl)C.Cl&ClCCN(CCCl)C
NCGC00160575-01	ClCCN(CCCl)C=1C(=O)NC(=O)NC=1		Inactive	Dna Interacts&DNA Interacts		1	Uracil mustard	144205464	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-34.9046862799&-13.640833396	ClCCN(CCCl)C=1C(=O)NC(=O)NC=1	ClCCN(CCCl)C=1C(=O)NC(=O)NC=1
NCGC00015209-11&NCGC00015209-16	ClCCN(CCCl)P1(=O)OCCCN1		Inactive	Bcl2/lgals1 Expression Inhibitor&Bcl-2 Expression Inhibitor&Bcl-2 Expression Inhibitor		2	Cyclophosphamide	170464624&384567825	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&12.3712911879&0.0	ClCCN(CCCl)P1(=O)OCCCN1.O	ClCCN(CCCl)P1(=O)OCCCN1.O&ClCCN(CCCl)P1(=O)OCCCN1
NCGC00181170-02&NCGC00181170-09	ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1	4.42499995	Active	Dna Alkylating Drugs&DNA Alkylating Drugs&DNA Alkylating Drugs	0.04999969999999987	2	Bendamustine	170465340&384568394	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-3.0	-38.2876873159&-90.693602632&-42.382715728	ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1	ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1
NCGC00510486-01	ClCCN(CCCl)c1cc2nc(CCCCCCC(=O)NO)n(C)c2cc1	4.4000001	Active	DNA Alkylating Drugs	0.0	1	Tinostamustine	384569448	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-67.0939958279	ClCCN(CCCl)c1cc2nc(CCCCCCC(=O)NO)n(C)c2cc1	ClCCN(CCCl)c1cc2nc(CCCCCCC(=O)NO)n(C)c2cc1
NCGC00015199-20&NCGC00015199-24	ClCCN(CCCl)c1ccc(CCCC(=O)O)cc1	5.0625	Active	Dna Alkylating Agent&DNA Alkylating Agent&DNA Alkylating Agent	0.9750004000000008	2	Chlorambucil	170464770&384567821	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4&-1.4	-102.2685768298&-79.0316019711&-45.5613714701	ClCCN(CCCl)c1ccc(CCCC(=O)O)cc1	ClCCN(CCCl)c1ccc(CCCC(=O)O)cc1
NCGC00090757-06&NCGC00090757-12	ClCCN(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1	4.72500015	Active	DNA Alkylating Agent	0.6500001000000006	2	Melphalan	170464727&384568082	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-3.0	-85.3106715862&-119.141601391	ClCCN(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1	ClCCN(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1
NCGC00167466-02&NCGC00167466-04	ClCCN(N=O)C(=O)NC1CCCCC1		Inactive	Dna Alkylating Agent&DNA Alkylating Agent&DNA Alkylating Agent		2	Lomustine	170464967&384568316	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	ClCCN(N=O)C(=O)NC1CCCCC1	ClCCN(N=O)C(=O)NC1CCCCC1
NCGC00015755-10	ClCCN(N=O)C(=O)NCc1c(N)nc(C)nc1		Inactive	Dna Crosslinking Agent&DNA Crosslinking Agent		1	Nimustine	170466029	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.3607168159&-16.432447768	ClCCN(N=O)C(=O)NCc1c(N)nc(C)nc1	ClCCN(N=O)C(=O)NCc1c(N)nc(C)nc1
NCGC00179435-05&NCGC00179435-06	ClCCNP1(=O)N(CCCl)CCCO1		Inactive	DNA Alkylating Agent&DNA Alkylating Agent&Dna Alkylating Agent		2	Ifomide	384568373&170464854	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-14.7309314159&0.0&0.0	ClCCNP1(=O)N(CCCl)CCCO1	ClCCNP1(=O)N(CCCl)CCCO1
NCGC00160546-02	ClCCOP(=O)(OCCCl)Oc1cc2OC(=O)C(Cl)=C(C)c2cc1		Inactive	Acetylcholinesterase Inhibitor		1	Haloxon	170466328	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.868941472&12.705464992	ClCCOP(=O)(OCCCl)Oc1cc2OC(=O)C(Cl)=C(C)c2cc1	ClCCOP(=O)(OCCCl)Oc1cc2OC(=O)C(Cl)=C(C)c2cc1
NCGC00344630-02	ClCC[C@@H]1[C@@]2(C)[C@]([C@@H](O)[C@@H]3C=CCCC3)(C(=O)O2)NC1=O	7.8000002	Inactive	Proteasome Inhibitor	0.0	1	Marizomib	384568728	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-43.012025052	ClCC[C@@H]1[C@@]2(C)[C@]([C@@H](O)[C@@H]3C=CCCC3)(C(=O)O2)NC1=O	ClCC[C@@H]1[C@@]2(C)[C@]([C@@H](O)[C@@H]3C=CCCC3)(C(=O)O2)NC1=O
NCGC00249933-01	ClCC[N+]([O-])(CCCl)C	4.4000001	Active		0.0	1	Nitrogen mustard N-oxide	170465894	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.4872427639	ClCC[N+]([O-])(CCCl)C	ClCC[N+]([O-])(CCCl)C
NCGC00384198-02	ClCC[N+]([O-])(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1	4.8499999	Active	HIF-1alpha Inhibitor	0.0	1	PX-478	384569105	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-97.6996090922	ClCC[N+]([O-])(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1	ClCC[N+]([O-])(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1
NCGC00024842-05	ClCCc1c(C)ncs1		Inactive			1	Clomethiazole	170466516	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-9.4327457159&-27.03118752	ClCCc1c(C)ncs1	ClCCc1c(C)ncs1
NCGC00249110-03	ClC[C@@H]1[C@@H](O)[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](Cl)[C@@H](CO)O2)(CCl)O1	5.1500001	Active		0.0	1	Sucralose	170466823	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.5507947	ClC[C@@H]1[C@@H](O)[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](Cl)[C@@H](CO)O2)(CCl)O1	ClC[C@@H]1[C@@H](O)[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](Cl)[C@@H](CO)O2)(CCl)O1
NCGC00164344-04	ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O		Inactive			1	Symclosene	170465634	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.8143016001&-12.6649091999	ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O	ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O
NCGC00167506-04	Cl[C@@H]1[C@H](OC)C[C@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)CC1	4.4499998	Active	Macrolide Antibiotic	0.0	1	Pimecrolimus	405558652	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-78.170588776&-85.9665615312	Cl[C@@H]1[C@H](OC)C[C@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)CC1	Cl[C@@H]1[C@H](OC)C[C@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)CC1
NCGC00179636-04	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)C1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	5.0	Active	Antibacterial	0.0	1	Clindamycin hydrochloride	405558965	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-51.5274386382	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)C1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)C1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C
NCGC00263950-13	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C		Inactive	Bacterial 70S ribosome Inhibitor		1	Clindamycin HCl	384568701	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C
NCGC00185773-02	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](SC)O1)C		Inactive	Antibacterial		1	Clindamycin palmitate	124896661	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](SC)O1)C.Cl	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](SC)O1)C.Cl
NCGC00522015-01	Cl[C@H]([C@@H](NC(=O)[C@H]1NCC[C@@H](CC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	4.4000001	Active	Bacterial 70s Ribosome Inhibitor&Bacterial 70S ribosome Inhibitor	0.0	1	Pirlimycin Hydrochloride	405558973	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-30.108907836&-54.671374024	Cl[C@H]([C@@H](NC(=O)[C@H]1NCC[C@@H](CC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	Cl[C@H]([C@@H](NC(=O)[C@H]1NCC[C@@H](CC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C
NCGC00390090-01	Cl[C@H]1[C@@H]2[C@H]([C@@H](O)C[C@]3(C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@H](C)C[C@@H]23)[C@]2(C)C(=CC(=O)C=C2)C1		Inactive	Glucocorticoid receptor Agonist&Glucocorticoid Receptor Agonist		1	Alclometasone dipropionate	405559007	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Cl[C@H]1[C@@H]2[C@H]([C@@H](O)C[C@]3(C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@H](C)C[C@@H]23)[C@]2(C)C(=CC(=O)C=C2)C1	Cl[C@H]1[C@@H]2[C@H]([C@@H](O)C[C@]3(C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@H](C)C[C@@H]23)[C@]2(C)C(=CC(=O)C=C2)C1
NCGC00179239-05	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]3[C@@H]1C[C@H](F)C=1[C@]2(C)C=CC(=O)C=1	4.4000001	Active		0.0	1	Clocortolone pivalate	405559113	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.391340732	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]3[C@@H]1C[C@H](F)C=1[C@]2(C)C=CC(=O)C=1	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]3[C@@H]1C[C@H](F)C=1[C@]2(C)C=CC(=O)C=1
NCGC00179392-03	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Beclomethasone	170464981	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00178241-04	Cl[Pt]1(Cl)NCCN1		Inactive	DNA Alkylating Agent&Dna Alkylating Agent		1	Dichloro(ethylenediamine)platinum(II)	170466890	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.944400304&0.0	Cl[Pt]1(Cl)NCCN1	Cl[Pt]1(Cl)NCCN1
NCGC00390666-01	Clc1[n+]([O-])c(C)c(Cl)c(C)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)on1	4.6750002	Active	Catechol O-methyltransferase Inhibitor	0.0	1	Opicapone	405559022	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-40.16505524&-98.8724399776	Clc1[n+]([O-])c(C)c(Cl)c(C)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)on1	Clc1[n+]([O-])c(C)c(Cl)c(C)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)on1
NCGC00263210-04	Clc1c(-c2[nH]c3c(n2)cccc3)cc(NC(=O)c2cc(OCC)c(OCC)c(OCC)c2)cc1	4.5999999	Active	Smoothened (Smo) Receptor Antagonist	0.0	1	SANT-2	363677267	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-78.7977220408	Clc1c(-c2[nH]c3c(n2)cccc3)cc(NC(=O)c2cc(OCC)c(OCC)c(OCC)c2)cc1	Clc1c(-c2[nH]c3c(n2)cccc3)cc(NC(=O)c2cc(OCC)c(OCC)c(OCC)c2)cc1
NCGC00250379-21	Clc1c(-c2c(-c3[nH]cc(C)n3)cnc(NCCNc3ncc(C#N)cc3)n2)ccc(Cl)c1	4.4000001	Active	GSK-3 Inhibitor	0.0	1	CT-99021	377020168	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-61.583526328	Clc1c(-c2c(-c3[nH]cc(C)n3)cnc(NCCNc3ncc(C#N)cc3)n2)ccc(Cl)c1	Clc1c(-c2c(-c3[nH]cc(C)n3)cnc(NCCNc3ncc(C#N)cc3)n2)ccc(Cl)c1
NCGC00346677-02	Clc1c(-c2c(-n3cncc3)cnc(NCCNc3nc(N)c([N+](=O)[O-])cc3)n2)ccc(Cl)c1		Inactive	GSK-3 Inhibitor		1	CT-98014	384568903	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-32.1538716999	Clc1c(-c2c(-n3cncc3)cnc(NCCNc3nc(N)c([N+](=O)[O-])cc3)n2)ccc(Cl)c1	Clc1c(-c2c(-n3cncc3)cnc(NCCNc3nc(N)c([N+](=O)[O-])cc3)n2)ccc(Cl)c1
NCGC00178782-04	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)O)C(C)(C)S[C@H]34)c(C)on2)c(Cl)ccc1	5.0	Active	peptidoglycan biosynthetic process Inhibitor	0.0	1	Dicloxacillin sodium salt monohydrate	170465296	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.9969044887	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(Cl)ccc1.[Na+].O	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(Cl)ccc1.[Na+].O
NCGC00178840-05	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)O)C(C)(C)S[C@H]34)c(C)on2)cccc1	4.5999999	Active	Beta-lactam Antibiotic&beta-lactam antibiotic	0.0	1	Cloxacillin sodium	170465404	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-55.5259658829&-24.1532357916	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)cccc1.[Na+]	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)cccc1.[Na+]
NCGC00262578-03	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@H](C(=O)O)C(C)(C)S[C@H]34)c(C)on2)c(F)ccc1		Inactive	Penicillin-binding Protein Inhibitor&Penicillin-binding protein Inhibitor		1	Flucloxacillin sodium	405558889	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.328690496&-27.431251908	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(F)ccc1	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(F)ccc1
NCGC00346696-07	Clc1c(-c2c(C)cc(C)cn2)cc(N2CCN(C(=O)CCS(=O)(=O)C)CC2)nc1		Inactive	Smoothened (Smo) receptor Agonist		1	PF-5274857	384568916	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.3482631359	Clc1c(-c2c(C)cc(C)cn2)cc(N2CCN(C(=O)CCS(=O)(=O)C)CC2)nc1	Clc1c(-c2c(C)cc(C)cn2)cc(N2CCN(C(=O)CCS(=O)(=O)C)CC2)nc1
NCGC00181136-01	Clc1c(-c2c([N+](=O)[O-])c(Cl)ccc2)c[nH]c1	4.4000001	Active	Respiratory Electron Transport Chain Inhibitor&respiratory electron transport chain Inhibitor	0.0	1	Pyrrolnitrin	144206296	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-47.287787208&-46.6357452719	Clc1c(-c2c([N+](=O)[O-])c(Cl)ccc2)c[nH]c1	Clc1c(-c2c([N+](=O)[O-])c(Cl)ccc2)c[nH]c1
NCGC00510167-01	Clc1c(-c2c3c([nH]c2)cccc3)nc(N[C@H]2CN(C(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)CCC2)nc1	5.4499998	Active	CDK12/CDK13	0.0	1	THZ531	384569412	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-59.8132870938	Clc1c(-c2c3c([nH]c2)cccc3)nc(N[C@H]2CN(C(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)CCC2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(N[C@H]2CN(C(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)CCC2)nc1
NCGC00351596-02	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2c(OC)cc(N3CCC(N)CC3)cc2)nc1	4.9000001	Active	ALK Inhibitor	0.0	1	AZD-3463	384569014	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-91.7121785847	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2c(OC)cc(N3CCC(N)CC3)cc2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2c(OC)cc(N3CCC(N)CC3)cc2)nc1
NCGC00389590-05	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)ccc2)nc1	6.0	Active	CDK 7 Inhibitor	0.0	1	THZ1	363680811	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-69.3290023021	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)ccc2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)ccc2)nc1
NCGC00378692-06	Clc1c(-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)cc(NC(C)C)nc1	4.5	Active	ERK1/2 Inhibitor	0.0	1	Ulixertinib	384569063	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-107.1981204929	Clc1c(-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)cc(NC(C)C)nc1	Clc1c(-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)cc(NC(C)C)nc1
NCGC00378840-01	Clc1c(-c2cc(C)c3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc(OC(=O)c2ccccc2)cc1		Inactive	Src Kinase Inhibitor		1	TG-100801	363678229	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.788765164	Clc1c(-c2cc(C)c3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc(OC(=O)c2ccccc2)cc1	Clc1c(-c2cc(C)c3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc(OC(=O)c2ccccc2)cc1
NCGC00386681-01	Clc1c(-c2ccc(Cl)cc2)cc2oc(N3CCC(C(=O)N[C@@H]4C[C@@H](CO)CCC4)CC3)nc2c1		Inactive	Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitor		1	PF-4693627	363680394	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(-c2ccc(Cl)cc2)cc2oc(N3CCC(C(=O)N[C@@H]4C[C@@H](CO)CCC4)CC3)nc2c1	Clc1c(-c2ccc(Cl)cc2)cc2oc(N3CCC(C(=O)N[C@@H]4C[C@@H](CO)CCC4)CC3)nc2c1
NCGC00351601-07	Clc1c(-c2n(-c3ccc(Cl)cc3)c3ncnc(N4CCC(NCC)(C(=O)N)CC4)c3n2)cccc1	4.5500002	Active	Cannabinoid CB1 Antagonist	0.0	1	Otenabant	363677769	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-46.782030334	Clc1c(-c2n(-c3ccc(Cl)cc3)c3ncnc(N4CCC(NCC)(C(=O)N)CC4)c3n2)cccc1	Clc1c(-c2n(-c3ccc(Cl)cc3)c3ncnc(N4CCC(NCC)(C(=O)N)CC4)c3n2)cccc1
NCGC00387870-04	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)NC(CN)Cc2cc(F)c(F)cc2)o1	4.75	Active	Serine/threonine-protein kinase AKT3 Inhibitor	0.0	1	GSK2141795	384569165	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-91.6155734216	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)NC(CN)Cc2cc(F)c(F)cc2)o1	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)NC(CN)Cc2cc(F)c(F)cc2)o1
NCGC00390611-02	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)c(F)cc2)s1	4.9499998	Active		0.0	1	GSK2110183 (hydrochloride)	384569200	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-128.0010192845	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)c(F)cc2)s1	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)c(F)cc2)s1
NCGC00387879-02	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)ccc2)s1	4.5500002	Active	AKT Inhibitor	0.0	1	Afuresertib (GSK2110183)	384569168	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-72.3674992716	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)ccc2)s1	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)ccc2)s1
NCGC00015205-10	Clc1c(-c2nc(C(=O)N(C(CC)C)C)cc3c2cccc3)cccc1		Inactive			1	PK 11195	384567822	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(-c2nc(C(=O)N(C(CC)C)C)cc3c2cccc3)cccc1	Clc1c(-c2nc(C(=O)N(C(CC)C)C)cc3c2cccc3)cccc1
NCGC00481567-03	Clc1c(-c2sc3c(c(C(=O)NC4CC4)ccc3)c2)nc(NCCCN2CCN(C)CC2)nc1	4.4499998	Active	IKK beta Inhibitor	0.0	1	LY-2409881	377020225	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-89.1797434251	Clc1c(-c2sc3c(c(C(=O)NC4CC4)ccc3)c2)nc(NCCCN2CCN(C)CC2)nc1	Clc1c(-c2sc3c(c(C(=O)NC4CC4)ccc3)c2)nc(NCCCN2CCN(C)CC2)nc1
NCGC00263197-03	Clc1c(-n2c(-c3sc(NC(=O)C(C)C)nc3)cc(C(F)F)n2)c(Cl)ccc1	4.4000001	Active	LIMK1/LIMK2 Inhibitor	0.0	1	BMS-5	363677258	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-90.1473682119	Clc1c(-n2c(-c3sc(NC(=O)C(C)C)nc3)cc(C(F)F)n2)c(Cl)ccc1	Clc1c(-n2c(-c3sc(NC(=O)C(C)C)nc3)cc(C(F)F)n2)c(Cl)ccc1
NCGC00390587-01	Clc1c(-n2c(/C=C/c3oc(-c4ccc(C#N)cc4)nn3)nnc2-c2ncc(S(=O)(=O)C)cc2)cccc1		Inactive	Tachykinin NK1 Antagonist		1	G-007-LK	363680917	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.653538452	Clc1c(-n2c(/C=C/c3oc(-c4ccc(C#N)cc4)nn3)nnc2-c2ncc(S(=O)(=O)C)cc2)cccc1	Clc1c(-n2c(/C=C/c3oc(-c4ccc(C#N)cc4)nn3)nnc2-c2ncc(S(=O)(=O)C)cc2)cccc1
NCGC00094574-15	Clc1c(-n2c(N)c([SH0](=O)C(F)(F)F)c(C#N)n2)c(Cl)cc(C(F)(F)F)c1	4.4000001	Active		0.0	1	Fipronil	170465992	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-75.7085686848	Clc1c(-n2c(N)c([SH0](=O)C(F)(F)F)c(C#N)n2)c(Cl)cc(C(F)(F)F)c1	Clc1c(-n2c(N)c([SH0](=O)C(F)(F)F)c(C#N)n2)c(Cl)cc(C(F)(F)F)c1
NCGC00164572-02	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1		Inactive	Cannabinoid CB1 Antagonist&Cannabinoid Receptor 1 Antagonist		1	Rimonabant	170465599	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.235143756&21.2942245801	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1
NCGC00345809-03	Clc1c(-n2nc(C(C)C)c3C(=O)NC(Cc4ccc(OCCO)cc4)=Nc23)c(Cl)ccc1	9.0	Inactive	CDK1/2/3/7/9 Inhibitor	0.0	1	RGB-286147	384568754	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-5.835722364	Clc1c(-n2nc(C(C)C)c3C(=O)NC(Cc4ccc(OCCO)cc4)=Nc23)c(Cl)ccc1	Clc1c(-n2nc(C(C)C)c3C(=O)NC(Cc4ccc(OCCO)cc4)=Nc23)c(Cl)ccc1
NCGC00249921-01	Clc1c(/C(/OCCOc2ccc(Cl)cc2)=C(\C)/n2cncc2)ccc(Cl)c1	4.6999998	Active		0.0	1	Omoconazole	170465847	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.3	-95.7088026268	Clc1c(/C(/OCCOc2ccc(Cl)cc2)=C(\C)/n2cncc2)ccc(Cl)c1	Clc1c(/C(/OCCOc2ccc(Cl)cc2)=C(\C)/n2cncc2)ccc(Cl)c1
NCGC00509938-02	Clc1c(/C(=C(/c2cc3c([nH]nc3)cc2)\c2ccc(/C=C/C(=O)O)cc2)/CC)ccc(F)c1	4.5	Active	Selective Estrogen Receptor Destabilizers (SERD)	0.0	1	Brilanestrant	384569387	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-104.0673701912	Clc1c(/C(=C(/c2cc3c([nH]nc3)cc2)\c2ccc(/C=C/C(=O)O)cc2)/CC)ccc(F)c1	Clc1c(/C(=C(/c2cc3c([nH]nc3)cc2)\c2ccc(/C=C/C(=O)O)cc2)/CC)ccc(F)c1
NCGC00177980-03	Clc1c(/C(=N/OCc2c(Cl)cc(Cl)cc2)/Cn2cncc2)ccc(Cl)c1	4.4250002	Active	Steroid Biosynthesis Inhibitor&Steroid biosynthesis Inhibitor	0.0	1	Oxiconazole nitrate	170465226	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-93.941195416&-123.2411463368	Clc1c(/C(=N/OCc2c(Cl)cc(Cl)cc2)/Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]	Clc1c(/C(=N/OCc2c(Cl)cc(Cl)cc2)/Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]
NCGC00522464-01	Clc1c(/C=C(/C(=O)O)\C)c(Cl)cc(C(=O)Nc2scc(-c3c(OC)c([C@@H](OCCCCCC)C)ccc3)n2)c1	4.8499999	Active	Thrombopoietin Receptor Agonist	0.0	1	Lusutrombopag	405558628	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-51.4213829324	Clc1c(/C=C(/C(=O)O)\C)c(Cl)cc(C(=O)Nc2scc(-c3c(OC)c([C@@H](OCCCCCC)C)ccc3)n2)c1	Clc1c(/C=C(/C(=O)O)\C)c(Cl)cc(C(=O)Nc2scc(-c3c(OC)c([C@@H](OCCCCCC)C)ccc3)n2)c1
NCGC00167739-08	Clc1c(/C=C/c2cc(C(=O)O)ccc2)ccc(OCc2c(C(C)C)onc2-c2c(Cl)cccc2Cl)c1		Inactive	Farnesoid X Receptor Agonist		1	GW-4064X	384568331	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(/C=C/c2cc(C(=O)O)ccc2)ccc(OCc2c(C(C)C)onc2-c2c(Cl)cccc2Cl)c1	Clc1c(/C=C/c2cc(C(=O)O)ccc2)ccc(OCc2c(C(C)C)onc2-c2c(Cl)cccc2Cl)c1
NCGC00024846-08	Clc1c(/C=N/NC(=N)N)c(Cl)ccc1	4.5999999	Active	Adrenergic Receptor Alpha-2 Agonist	0.0	1	Guanabenz	170465364	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-41.5973581216	Clc1c(/C=N/NC(=N)N)c(Cl)ccc1	Clc1c(/C=N/NC(=N)N)c(Cl)ccc1
NCGC00179680-05	Clc1c(/N=C/2\NCCN\2)c(Cl)ccc1	5.4499998	Active	Alpha1-adrenoceptor Agonists	0.0	1	Clonidine	170464900	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-31.233243768	Clc1c(/N=C/2\NCCN\2)c(Cl)ccc1	Clc1c(/N=C/2\NCCN\2)c(Cl)ccc1
NCGC00344510-06	Clc1c(C#N)c(OC[C@H](O)CNC(Cc2cc3c(cc2)cccc3)(C)C)ccc1	4.5	Active	Calcium-Sensing Receptor (CaSR) Antagonist	0.0	1	NPS-2143	384568720	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-103.4584859476	Clc1c(C#N)c(OC[C@H](O)CNC(Cc2cc3c(cc2)cccc3)(C)C)ccc1	Clc1c(C#N)c(OC[C@H](O)CNC(Cc2cc3c(cc2)cccc3)(C)C)ccc1
NCGC00263230-01	Clc1c(C#N)cc2C(O)=C(c3cc(-c4c(OC)cccc4)ccc3)C(=O)Nc2c1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	FASN MRK	137276074	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	10.146529644	Clc1c(C#N)cc2C(O)=C(c3cc(-c4c(OC)cccc4)ccc3)C(=O)Nc2c1	Clc1c(C#N)cc2C(O)=C(c3cc(-c4c(OC)cccc4)ccc3)C(=O)Nc2c1
NCGC00484078-02	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(O)C)c3)C)cc2)c1	4.4000001	Active	Androgen Receptor Antagonist	0.0	1	Darolutamide (ODM-201)	384569270	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.4318201796	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(O)C)c3)C)cc2)c1	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(O)C)c3)C)cc2)c1
NCGC00263084-02	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c(F)ccc(F)c12	5.0	Active	Smoothened (Smo) receptor Agonist	0.0	1	Hh-Ag1.5	174006719	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-94.5720844034	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c(F)ccc(F)c12	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c(F)ccc(F)c12
NCGC00347954-03	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c1cccc2	4.9499998	Active	Hedgehog Agonist	0.0	1	SAG	384568998	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-95.0098062638	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c1cccc2	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c1cccc2
NCGC00094557-06	Clc1c(C(=O)N)ccc([N+](=O)[O-])c1		Inactive			1	2-Chloro-4-nitrobenzamide	170466191	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.921569044&12.2234237721	Clc1c(C(=O)N)ccc([N+](=O)[O-])c1	Clc1c(C(=O)N)ccc([N+](=O)[O-])c1
NCGC00263140-03	Clc1c(C(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)[C@@H](C)C2)cc2c(C(=O)C(=O)N(C)C)cn(C)c2c1		Inactive	p38 MAPK Inhibitor		1	Talmapimod	363677225	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.823033684	Clc1c(C(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)[C@@H](C)C2)cc2c(C(=O)C(=O)N(C)C)cn(C)c2c1	Clc1c(C(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)[C@@H](C)C2)cc2c(C(=O)C(=O)N(C)C)cn(C)c2c1
NCGC00510488-01	Clc1c(C(=O)NC2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)cc2c(NC(=O)C2)c1		Inactive	SMYD3 Inhibitor		1	EPZ-031686	384569450	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.570975012	Clc1c(C(=O)NC2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)cc2c(NC(=O)C2)c1	Clc1c(C(=O)NC2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)cc2c(NC(=O)C2)c1
NCGC00249611-04&NCGC00249611-05	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B(O)O)cc(Cl)cc1	6.72500015	Inactive	Proteasome Inhibitor	0.34999989999999936	2	Ixazomib	405558551&384568528	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-64.151754896&-84.354998764	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B(O)O)cc(Cl)cc1	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B(O)O)cc(Cl)cc1
NCGC00522453-01	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)C(CC(=O)O)(CC(=O)O)O2)cc(Cl)cc1	7.5250001	Inactive	Proteasome Subunit Beta Type-5 Inhibitor&Proteasome subunit beta type-5 Inhibitor	0.0	1	MLN9708	405559125	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-92.471382552&-47.2316374519	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)C(CC(=O)O)(CC(=O)O)O2)cc(Cl)cc1	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)C(CC(=O)O)(CC(=O)O)O2)cc(Cl)cc1
NCGC00249612-02	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)CC(C(=O)O)(CC(=O)O)O2)cc(Cl)cc1	6.5	Inactive	Proteasome Inhibitor	0.0	1	Ixazomib citrate	384568529	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-70.7339800639	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)CC(C(=O)O)(CC(=O)O)O2)cc(Cl)cc1	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)CC(C(=O)O)(CC(=O)O)O2)cc(Cl)cc1
NCGC00379060-01	Clc1c(C(=O)Nc2c(C(=O)NC3CCN(S(=O)(=O)C)CC3)[nH]nc2)c(Cl)ccc1	5.1500001	Inactive	CDK1/2 Inhibitor	0.0	1	NVP-LCQ195	363678333	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	1.95717756	Clc1c(C(=O)Nc2c(C(=O)NC3CCN(S(=O)(=O)C)CC3)[nH]nc2)c(Cl)ccc1	Clc1c(C(=O)Nc2c(C(=O)NC3CCN(S(=O)(=O)C)CC3)[nH]nc2)c(Cl)ccc1
NCGC00345858-03	Clc1c(C(=O)Nc2c(F)ccc(Oc3nc4sc(NC(=O)C5CC5)nc4cc3)c2)cccc1C1(C#N)CC1	4.0	Inactive	VEGFR-2 Inhibitor	0.0	1	Takeda-6d	384568772	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	71.4859293441	Clc1c(C(=O)Nc2c(F)ccc(Oc3nc4sc(NC(=O)C5CC5)nc4cc3)c2)cccc1C1(C#N)CC1	Clc1c(C(=O)Nc2c(F)ccc(Oc3nc4sc(NC(=O)C5CC5)nc4cc3)c2)cccc1C1(C#N)CC1
NCGC00387038-01	Clc1c(C(=O)Nc2cc(NC(=O)C3CC3)ncc2)c(Cl)ccc1	1.85	Inactive	Tyk 2 Inhibitor	0.0	1	GDC-046	363680531	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-13.234738092	Clc1c(C(=O)Nc2cc(NC(=O)C3CC3)ncc2)c(Cl)ccc1	Clc1c(C(=O)Nc2cc(NC(=O)C3CC3)ncc2)c(Cl)ccc1
NCGC00242497-12&NCGC00242497-14	Clc1c(C(=O)Nc2cc(c(Cl)cc2)-c2ncccc2)ccc(S(=O)(=O)C)c1		Inactive	Smoothened Receptor Antagonist&Hedgehog Antagonist&Hedgehog Antagonist		2	Vismodegib	405558608&384568500	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	46.0933953584&-24.20200734&15.686864268	Clc1c(C(=O)Nc2cc(c(Cl)cc2)-c2ncccc2)ccc(S(=O)(=O)C)c1	Clc1c(C(=O)Nc2cc(c(Cl)cc2)-c2ncccc2)ccc(S(=O)(=O)C)c1
NCGC00250384-02	Clc1c(C(=O)Nc2cc3-c4n(-c5ccc(F)cc5)nc(C(=O)N)c4CCc3cc2)cc(N2CCN(C)CC2)nc1	4.4499998	Active	IKK-beta Inhibitor	0.0	1	PHA-408	377020291	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-116.7312256592	Clc1c(C(=O)Nc2cc3-c4n(-c5ccc(F)cc5)nc(C(=O)N)c4CCc3cc2)cc(N2CCN(C)CC2)nc1	Clc1c(C(=O)Nc2cc3-c4n(-c5ccc(F)cc5)nc(C(=O)N)c4CCc3cc2)cc(N2CCN(C)CC2)nc1
NCGC00025220-11	Clc1c(C(=O)O)ccc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)c1		Inactive	CDK1/2/3/4/5 Inhibitor		1	Purvalanol B	384568058	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.283274184	Clc1c(C(=O)O)ccc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)c1	Clc1c(C(=O)O)ccc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)c1
NCGC00183273-04	Clc1c(C(=O)OCCN(CC)CC)ccc(N)c1	5.0	Active	Sodium Channel Alpha Subunits; Brain (types I, Ii, Iii) Inhibitor	0.0	1	Chloroprocaine HCl	405558437	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.312503936	Clc1c(C(=O)OCCN(CC)CC)ccc(N)c1	Clc1c(C(=O)OCCN(CC)CC)ccc(N)c1
NCGC00183104-02	Clc1c(C(=O)c2c(-n3c(CN(CC)CC)ncc3)ccc([N+](=O)[O-])c2)cccc1	4.4499998	Active		0.0	1	Nizofenone	170466022	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-62.3970249723&-43.16346282	Clc1c(C(=O)c2c(-n3c(CN(CC)CC)ncc3)ccc([N+](=O)[O-])c2)cccc1	Clc1c(C(=O)c2c(-n3c(CN(CC)CC)ncc3)ccc([N+](=O)[O-])c2)cccc1
NCGC00263118-02	Clc1c(C(=O)c2c(NC(=O)N)c3c(o2)cc(OS(=O)(=O)C)cc3)ccc(Cl)c1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	Lirimilast	384568602	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(C(=O)c2c(NC(=O)N)c3c(o2)cc(OS(=O)(=O)C)cc3)ccc(Cl)c1	Clc1c(C(=O)c2c(NC(=O)N)c3c(o2)cc(OS(=O)(=O)C)cc3)ccc(Cl)c1
NCGC00168785-03&NCGC00168785-05	Clc1c(C(C#N)c2ccc(Cl)cc2)c(Cl)cc(N2C(=O)NC(=O)C=N2)c1	4.6500001	Active	antiprotozoal agent&Antiprotozoal Agent&antiprotozoal agent	0.5	2	Diclazuril	405559143&384568349	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3&-3.0	-68.0370662359&-115.477034218&-87.2262372359	Clc1c(C(C#N)c2ccc(Cl)cc2)c(Cl)cc(N2C(=O)NC(=O)C=N2)c1	Clc1c(C(C#N)c2ccc(Cl)cc2)c(Cl)cc(N2C(=O)NC(=O)C=N2)c1
NCGC00510266-01	Clc1c(C(F)(F)F)cc(C(Nc2ncnc3c(C(=O)N)cccc23)CN2CCC2)cc1	4.4000001	Active	AKT Inhibitor	0.0	1	M2698	384569423	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-75.0268849664	Clc1c(C(F)(F)F)cc(C(Nc2ncnc3c(C(=O)N)cccc23)CN2CCC2)cc1	Clc1c(C(F)(F)F)cc(C(Nc2ncnc3c(C(=O)N)cccc23)CN2CCC2)cc1
NCGC00263138-10&NCGC00263138-19	Clc1c(C(F)(F)F)cc(NC(=O)Nc2c(F)cc(Oc3cc(C(=O)NC)ncc3)cc2)cc1	4.7750001	Active	VEGFR-2 Inhibitor	0.5500002000000004	2	Regorafenib	384568616&405558722	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-1.3	-112.0457295824&-92.5792915827	Clc1c(C(F)(F)F)cc(NC(=O)Nc2c(F)cc(Oc3cc(C(=O)NC)ncc3)cc2)cc1	Clc1c(C(F)(F)F)cc(NC(=O)Nc2c(F)cc(Oc3cc(C(=O)NC)ncc3)cc2)cc1
NCGC00185743-02	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Cl)cc2)cc1	5.0250001	Active		0.0	1	Cloflucarban	170465550	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-105.2229602013&-90.396809798	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Cl)cc2)cc1	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Cl)cc2)cc1
NCGC00167488-08	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)cc1	4.625	Active	Serine/threonine-protein Kinase B-raf Inhibitor&VEGFR-1/2/3 Inhibitor	0.0	1	Sorafenib	170465175	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-63.8872069299&-105.7059833471	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)cc1.S(=O)(=O)(O)c1ccc(C)cc1	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)cc1.S(=O)(=O)(O)c1ccc(C)cc1
NCGC00247954-03	Clc1c(C(F)(F)F)cccc1C(=O)N[C@H]([C@H]1NCCCC1)c1ccccc1	4.4000001	Active	Glycine Transporter 1 (GlyT-1) Inhibitor	0.0	1	SSR-504734	384568521	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-34.520269324	Clc1c(C(F)(F)F)cccc1C(=O)N[C@H]([C@H]1NCCCC1)c1ccccc1	Clc1c(C(F)(F)F)cccc1C(=O)N[C@H]([C@H]1NCCCC1)c1ccccc1
NCGC00161825-08	Clc1c(C(F)(F)F)cccc1CN(CC(c1ccccc1)c1ccccc1)CCCOc1cc(CC(=O)O)ccc1	4.4000001	Active	ABCA1 Expression Enhancer	0.0	1	GSK-3965	384568215	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-78.850674804	Clc1c(C(F)(F)F)cccc1CN(CC(c1ccccc1)c1ccccc1)CCCOc1cc(CC(=O)O)ccc1	Clc1c(C(F)(F)F)cccc1CN(CC(c1ccccc1)c1ccccc1)CCCOc1cc(CC(=O)O)ccc1
NCGC00421877-04	Clc1c(C(N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1		Inactive			1	AG-120	384569229	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.066191884	Clc1c(C(N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1	Clc1c(C(N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1
NCGC00181096-01	Clc1c(C(O)(CCN(C)C)c2ccccc2)cccc1	4.8499999	Active		0.0	1	Chlophedianol	144206265	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4	-71.462010356&-45.4446474259	Clc1c(C(O)(CCN(C)C)c2ccccc2)cccc1	Clc1c(C(O)(CCN(C)C)c2ccccc2)cccc1
NCGC00016034-05	Clc1c(C(O)CNC(C)(C)C)cccc1		Inactive	Beta-2 Adrenergic Receptor Agonist&Beta-2 adrenergic receptor Agonist		1	Tulobuterol hydrochloride	170465781	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.062385264&0.0	Clc1c(C(O)CNC(C)(C)C)cccc1.Cl	Clc1c(C(O)CNC(C)(C)C)cccc1.Cl
NCGC00167538-02	Clc1c(C(O)CNC(C)C)cccc1		Inactive	Beta-2 Adrenergic Receptor Agonist&Beta-2 adrenergic receptor Agonist		1	Clorprenaline hydrochloride	170466032	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.6318772441&0.0	Clc1c(C(O)CNC(C)C)cccc1.Cl	Clc1c(C(O)CNC(C)C)cccc1.Cl
NCGC00165816-04	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)O)cc3)onc2C)C)cccc1		Inactive	Lysophospholipid edg2 (LPA1)/edg7 (LPA3) Receptor Antagonist		1	KI-16425	384568287	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.2737952319	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)O)cc3)onc2C)C)cccc1	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)O)cc3)onc2C)C)cccc1
NCGC00163778-09	Clc1c(C(OCC=C)Cn2cncc2)ccc(Cl)c1	4.5	Active	O75469|||q9uj26 Rec20 - 20% Relative Effective Concentration; The Concentration Of The Test Compound Showing 20% Of The Agonistic Activity Of 1 _ 10_5 M Rifampicin Via Hpxr&O75469|||Q9UJ26 REC20 - 20% relative effective concentration; the concentration of the test compound showing 20% of the agonistic activity of 1 _ 10_5 M rifampicin via hPXR	0.0	1	Imazalil sulfate	170466809	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-49.5166965959&-57.676588846	Clc1c(C(OCC=C)Cn2cncc2)ccc(Cl)c1.S(=O)(=O)(O)O	Clc1c(C(OCC=C)Cn2cncc2)ccc(Cl)c1.S(=O)(=O)(O)O
NCGC00015233-07	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2c[n+](C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)cc2)ccc(Cl)c1	4.8499999	Active	CaMK-II Inhibitor	0.0	1	Calmidazolium chloride	384567828	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-95.652107975	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2c[n+](C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)cc2)ccc(Cl)c1	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2c[n+](C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)cc2)ccc(Cl)c1
NCGC00018294-13	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2cncc2)ccc(Cl)c1	4.5	Active	Aromatase Inhibitor	0.0	1	Miconazole nitrate	384568002	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-34.6306957	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2cncc2)ccc(Cl)c1	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2cncc2)ccc(Cl)c1
NCGC00179642-03&NCGC00179642-05	Clc1c(C(OCc2c(Cl)cccc2Cl)Cn2cncc2)ccc(Cl)c1	4.4749999	Active	Anti-fungal&Antifungal Agent&Antifungal Agent	0.05000020000000038	2	Isoconazole nitrate	170466012&363676952	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1&-2.3	-86.24283262&-126.9737182629&-116.5380776912	Clc1c(C(OCc2c(Cl)cccc2Cl)Cn2cncc2)ccc(Cl)c1	Clc1c(C(OCc2c(Cl)cccc2Cl)Cn2cncc2)ccc(Cl)c1
NCGC00018258-10&NCGC00018258-12	Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1	4.47500015	Active	Anti-fungal&Antifungal Agent&Antifungal Agent	0.15000010000000064	2	Econazole nitrate	170465422&384568000	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3&-2.3	-57.0934336957&-95.9455931945&-88.191111834	Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]	Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]&Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1
NCGC00253713-01	Clc1c(C(OCc2ccc(Sc3ccccc3)cc2)Cn2cncc2)ccc(Cl)c1	4.4000001	Active	Antifungal Agent	0.0	1	Fenticonazole nitrate	170466486	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-83.6876720718	Clc1c(C(OCc2ccc(Sc3ccccc3)cc2)Cn2cncc2)ccc(Cl)c1	Clc1c(C(OCc2ccc(Sc3ccccc3)cc2)Cn2cncc2)ccc(Cl)c1
NCGC00018250-06	Clc1c(C(SCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1	4.5	Active	Lanosterol 14-alpha demethylase Inhibitor&Lanosterol 14-alpha Demethylase Inhibitor	0.0	1	Sulconazole nitrate	170465344	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-99.0771872655&-103.4148795934	Clc1c(C(SCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]	Clc1c(C(SCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]
NCGC00015251-13	Clc1c(C(n2cncc2)(c2ccccc2)c2ccccc2)cccc1	4.9333334	Active	Lanosterol 14alpha-demethylase Inhibitor&Intermediate Conductance Calcium-activated Potassium Channel Protein 4 Blockers	0.0	1	Clotrimazole	170464807	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4&-2.3	-108.8493247799&-50.4303254517&-90.3842913791	Clc1c(C(n2cncc2)(c2ccccc2)c2ccccc2)cccc1	Clc1c(C(n2cncc2)(c2ccccc2)c2ccccc2)cccc1
NCGC00165909-10	Clc1c(C(n2nccc2)(c2ccccc2)c2ccccc2)cccc1	4.4499998	Active	Intermediate Conductance Channel Blocker	0.0	1	TRAM-34	384568298	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-39.5030857684	Clc1c(C(n2nccc2)(c2ccccc2)c2ccccc2)cccc1	Clc1c(C(n2nccc2)(c2ccccc2)c2ccccc2)cccc1
NCGC00505919-02	Clc1c(C)c(-c2c(-c3oc(F)cc3)sc3ncnc(O[C@H](C(=O)O)Cc4c(OCc5n(CC(F)(F)F)ncc5)cccc4)c23)ccc1OCCN1CCN(C)CC1		Inactive	Mcl-1 Inhibitor		1	S63845	384569318	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(C)c(-c2c(-c3oc(F)cc3)sc3ncnc(O[C@H](C(=O)O)Cc4c(OCc5n(CC(F)(F)F)ncc5)cccc4)c23)ccc1OCCN1CCN(C)CC1	Clc1c(C)c(-c2c(-c3oc(F)cc3)sc3ncnc(O[C@H](C(=O)O)Cc4c(OCc5n(CC(F)(F)F)ncc5)cccc4)c23)ccc1OCCN1CCN(C)CC1
NCGC00384172-01	Clc1c(C)c(F)ccc1C(=O)Nc1c(N2CCN(C)CC2)ccc([N+](=O)[O-])c1		Inactive	Inhibitor of WDR5-MLL interaction. Not the mest WDR5-MLL Inhibitor available but this one offers a different chemotype.		1	WDR5-C47	363679175	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.5349475081	Clc1c(C)c(F)ccc1C(=O)Nc1c(N2CCN(C)CC2)ccc([N+](=O)[O-])c1	Clc1c(C)c(F)ccc1C(=O)Nc1c(N2CCN(C)CC2)ccc([N+](=O)[O-])c1
NCGC00511352-01	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N(CC)CC)n2)ccc1	5.9499998	Active	11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitor	0.0	1	BVT-14225	384569497	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-42.322003224	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N(CC)CC)n2)ccc1	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N(CC)CC)n2)ccc1
NCGC00522639-01	Clc1c(C)c(S(=O)(=O)Nc2scc(CCN3C(=O)COCC3)n2)ccc1		Inactive	11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitor		1	BVT-3498	384569535	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.167701896	Clc1c(C)c(S(=O)(=O)Nc2scc(CCN3C(=O)COCC3)n2)ccc1	Clc1c(C)c(S(=O)(=O)Nc2scc(CCN3C(=O)COCC3)n2)ccc1
NCGC00160431-02	Clc1c(C)cc(Nc2c(C(=O)O)cccc2)cc1	4.4000001	Active		0.0	1	2-[(4-Chloro-3-methylphenyl)amino]benzoic acid	405558671	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.5048884519	Clc1c(C)cc(Nc2c(C(=O)O)cccc2)cc1	Clc1c(C)cc(Nc2c(C(=O)O)cccc2)cc1
NCGC00159384-04	Clc1c(C)cc(O)c(C(C)C)c1		Inactive	Estrogen Receptor Binding Agent&Estrogen receptor Binding Agent		1	6-Chlorothymol	170465546	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.014258276&0.0	Clc1c(C)cc(O)c(C(C)C)c1	Clc1c(C)cc(O)c(C(C)C)c1
NCGC00091338-06	Clc1c(C)cc(O)cc1		Inactive			1	4-Chloro-3-methylphenol	170466134	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(C)cc(O)cc1	Clc1c(C)cc(O)cc1
NCGC00094614-06	Clc1c(C)cc(O)cc1C		Inactive			1	4-Chloro-3,5-dimethylphenol	170465503	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.796462932&0.0	Clc1c(C)cc(O)cc1C	Clc1c(C)cc(O)cc1C
NCGC00489906-01	Clc1c(C)cc(OCCCc2c3c(c(-c4c(C)n(C)nc4C)c(Cl)cc3)n3[C@H](C)CN(c4c5c(n(C)c4)ccc(C(=O)O)c5)C(=O)c23)cc1C	4.5500002	Active	Mcl-1 Inhibitor	0.0	1	VU0661013	384569286	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-126.8452448488	Clc1c(C)cc(OCCCc2c3c(c(-c4c(C)n(C)nc4C)c(Cl)cc3)n3[C@H](C)CN(c4c5c(n(C)c4)ccc(C(=O)O)c5)C(=O)c23)cc1C	Clc1c(C)cc(OCCCc2c3c(c(-c4c(C)n(C)nc4C)c(Cl)cc3)n3[C@H](C)CN(c4c5c(n(C)c4)ccc(C(=O)O)c5)C(=O)c23)cc1C
NCGC00510347-01	Clc1c(C)ccc(NC(=O)NCc2cc3c(C(=O)N(C4C(=O)NC(=O)CC4)C3)cc2)c1	7.5500002	Inactive		0.0	1	CC-885	384569427	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-14.6898732161	Clc1c(C)ccc(NC(=O)NCc2cc3c(C(=O)N(C4C(=O)NC(=O)CC4)C3)cc2)c1	Clc1c(C)ccc(NC(=O)NCc2cc3c(C(=O)N(C4C(=O)NC(=O)CC4)C3)cc2)c1
NCGC00492447-02	Clc1c(C2(C)CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1	4.4000001	Active	KRAS (G12C) Inhibitor	0.0	1	ARS-853	384569288	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-107.6361636192	Clc1c(C2(C)CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1	Clc1c(C2(C)CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1
NCGC00253606-01	Clc1c(C23OCC(C)N2CC(=O)Nc2c3cc(Cl)cc2)cccc1		Inactive			1	Mexazolam	170465840	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.1608060919	Clc1c(C23OCC(C)N2CC(=O)Nc2c3cc(Cl)cc2)cccc1	Clc1c(C23OCC(C)N2CC(=O)Nc2c3cc(Cl)cc2)cccc1
NCGC00249917-01	Clc1c(C23OCCN2CC(=O)Nc2c3cc(Cl)cc2)cccc1	5.4000001	Active	Gaba-a Receptor; Benzodiazepine Site Agonist	0.0	1	Cloxazolam	170465787	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-33.5657832096	Clc1c(C23OCCN2CC(=O)Nc2c3cc(Cl)cc2)cccc1	Clc1c(C23OCCN2CC(=O)Nc2c3cc(Cl)cc2)cccc1
NCGC00183008-01	Clc1c(C2=NC(C)c3n(c(C)nn3)-c3sc(CCc4ccc(CC(C)C)cc4)cc23)cccc1	4.5250001	Active	Interleukin-5 Inhibitor	0.0	1	Israpafant	144206851	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.4	-106.9745215853&-59.395394127	Clc1c(C2=NC(C)c3n(c(C)nn3)-c3sc(CCc4ccc(CC(C)C)cc4)cc23)cccc1	Clc1c(C2=NC(C)c3n(c(C)nn3)-c3sc(CCc4ccc(CC(C)C)cc4)cc23)cccc1
NCGC00390699-04	Clc1c(C2=NC3=C(C)NNC3=Nc3c2cc(F)c(OC)c3)cccc1	5.25	Active	VEGFR-3 Inhibitor	0.0	1	R-1530	377020209	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-39.1652632096	Clc1c(C2=NC3=C(C)NNC3=Nc3c2cc(F)c(OC)c3)cccc1	Clc1c(C2=NC3=C(C)NNC3=Nc3c2cc(F)c(OC)c3)cccc1
NCGC00182031-05	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CC)cc23)cccc1	4.4000001	Active	GABA-A receptor Agonist	0.0	1	Etizolam	405558675	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-52.6001916359	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CC)cc23)cccc1	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CC)cc23)cccc1
NCGC00092377-04	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CCC(=O)N4CCOCC4)cc23)cccc1	5.4000001	Active	Platelet activating factor receptor Inhibitor	0.0	1	Apafant	170466052	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-33.616569352	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CCC(=O)N4CCOCC4)cc23)cccc1	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CCC(=O)N4CCOCC4)cc23)cccc1
NCGC00165957-07	Clc1c(C2C(C(=O)OCC)=C(COCCN)NC(C)=C2C(=O)OC)cccc1	4.9250002	Active		0.0	1	Amlodipine	225144262	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-32.4061308359&-75.9634095988	Clc1c(C2C(C(=O)OCC)=C(COCCN)NC(C)=C2C(=O)OC)cccc1	Clc1c(C2C(C(=O)OCC)=C(COCCN)NC(C)=C2C(=O)OC)cccc1
NCGC00538320-01	Clc1c(C2CCCCC2)cc2c(C(C(=O)O)CC2)c1		Inactive	Prostamide/prostaglandin F synthase Inhibitor&Prostamide/prostaglandin F Synthase Inhibitor		1	NCGC00538320-01	405558505	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.693525352&-29.941066132	Clc1c(C2CCCCC2)cc2c(C(C(=O)O)CC2)c1	Clc1c(C2CCCCC2)cc2c(C(C(=O)O)CC2)c1
NCGC00238624-07	Clc1c(C2NC(Nc3oc4c(n3)cccc4)=NC3=C2C(=O)CCC3)n[nH]c1		Inactive	GALK Inhibitor		1	NCGC00238624	163827054	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.082311516	Clc1c(C2NC(Nc3oc4c(n3)cccc4)=NC3=C2C(=O)CCC3)n[nH]c1	Clc1c(C2NC(Nc3oc4c(n3)cccc4)=NC3=C2C(=O)CCC3)n[nH]c1
NCGC00164544-02	Clc1c(C2S/C(=C(/C#N)\n3cncc3)/SC2)cccc1		Inactive	Lanosterol 14-alpha Demethylase Inhibitor&Lanosterol 14-alpha demethylase Inhibitor		1	Lanoconazole	170465886	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.1057234719&0.0	Clc1c(C2S/C(=C(/C#N)\n3cncc3)/SC2)cccc1	Clc1c(C2S/C(=C(/C#N)\n3cncc3)/SC2)cccc1
NCGC00379255-03	Clc1c(C=2C(=O)N(CC)c3nc(Nc4cc(F)c(N5CCNCC5)cc4)ncc3C=2)ccc(Cl)c1		Inactive	p21-Activated Kinase 1 (PAK1) Inhibitor		1	FRAX-486	384569097	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(C=2C(=O)N(CC)c3nc(Nc4cc(F)c(N5CCNCC5)cc4)ncc3C=2)ccc(Cl)c1	Clc1c(C=2C(=O)N(CC)c3nc(Nc4cc(F)c(N5CCNCC5)cc4)ncc3C=2)ccc(Cl)c1
NCGC00389582-02	Clc1c(C=2C(=O)N(CC)c3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3C=2)ccc(-c2scnc2)c1	5.3499999	Active	p21-Activated Kinase 1/2 (PAK1/2) Inhibitor	0.0	1	FRAX-597	363680807	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-31.0513989639	Clc1c(C=2C(=O)N(CC)c3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3C=2)ccc(-c2scnc2)c1	Clc1c(C=2C(=O)N(CC)c3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3C=2)ccc(-c2scnc2)c1
NCGC00387877-01	Clc1c(C=2Oc3c([C@H]4[C@H](CO)N(C)CC4)c(O)cc(O)c3C(=O)C=2)ccc(C(F)(F)F)c1		Inactive	CDK1/2/4/9 Inhibitor		1	Voruciclib	363680717	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.3722011279	Clc1c(C=2Oc3c([C@H]4[C@H](CO)N(C)CC4)c(O)cc(O)c3C(=O)C=2)ccc(C(F)(F)F)c1	Clc1c(C=2Oc3c([C@H]4[C@H](CO)N(C)CC4)c(O)cc(O)c3C(=O)C=2)ccc(C(F)(F)F)c1
NCGC00389231-01	Clc1c(C=2Oc3c(c(O)cc(O)c3C(=O)C=2)C2C(CO)N(C)CC2)cccc1	5.5500002	Active	CDK1/4/9 Inhibitor	0.0	1	Riviciclib (P276-00)	377020350	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-97.9536144613	Clc1c(C=2Oc3c(c(O)cc(O)c3C(=O)C=2)C2C(CO)N(C)CC2)cccc1	Clc1c(C=2Oc3c(c(O)cc(O)c3C(=O)C=2)C2C(CO)N(C)CC2)cccc1
NCGC00015469-09	Clc1c(CC(=O)NC(=N)N)c(Cl)ccc1		Inactive	Alpha-2a Adrenergic Receptor Agonist&Alpha-2a adrenergic receptor Agonist		1	Guanfacine hydrochloride	170465381	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.72583914&-16.81658262	Clc1c(CC(=O)NC(=N)N)c(Cl)ccc1.Cl	Clc1c(CC(=O)NC(=N)N)c(Cl)ccc1.Cl
NCGC00250388-04	Clc1c(CCC(N)(CO)CO)ccc(Sc2cc(OCc3ccccc3)ccc2)c1	4.5	Active	S1P1/3/4 Agonist	0.0	1	KRP-203	384568541	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-107.3030372441	Clc1c(CCC(N)(CO)CO)ccc(Sc2cc(OCc3ccccc3)ccc2)c1	Clc1c(CCC(N)(CO)CO)ccc(Sc2cc(OCc3ccccc3)ccc2)c1
NCGC00344508-02	Clc1c(CCCN[C@H](C)c2cc(OC)ccc2)cccc1	4.6500001	Active	Calcium-Sensing Receptor (CaSR) Agonist	0.0	1	NPS-R568	384568718	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-95.6050097564	Clc1c(CCCN[C@H](C)c2cc(OC)ccc2)cccc1	Clc1c(CCCN[C@H](C)c2cc(OC)ccc2)cccc1
NCGC00263539-01	Clc1c(CCN2CCN(c3nsc4c3cccc4)CC2)cc2c(NC(=O)C2)c1	4.4499998	Active	5-HT2A Antagonists?	0.0	1	Ziprasidone	170465342	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-74.8795264135	Clc1c(CCN2CCN(c3nsc4c3cccc4)CC2)cc2c(NC(=O)C2)c1	Clc1c(CCN2CCN(c3nsc4c3cccc4)CC2)cc2c(NC(=O)C2)c1
NCGC00182980-01	Clc1c(CN(CC(=O)N2CCOCC2)C)c(NC(=O)c2ccccc2)ccc1		Inactive			1	Fominoben hydrochloride	144206774	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-11.892144424&-26.338841022	Clc1c(CN(CC(=O)N2CCOCC2)C)c(NC(=O)c2ccccc2)ccc1.Cl	Clc1c(CN(CC(=O)N2CCOCC2)C)c(NC(=O)c2ccccc2)ccc1.Cl
NCGC00247668-03	Clc1c(CN2C(=O)/C(=N\OC(=O)C)/c3c2ccc(Cl)c3)cc(Cl)cc1	4.4000001	Active	Reversible, competitive Inhibitor of UCH-L1 deubiquitinase	0.0	1	LDN-57444	384568515	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-113.5890179712	Clc1c(CN2C(=O)/C(=N\OC(=O)C)/c3c2ccc(Cl)c3)cc(Cl)cc1	Clc1c(CN2C(=O)/C(=N\OC(=O)C)/c3c2ccc(Cl)c3)cc(Cl)cc1
NCGC00016872-12&NCGC00016872-19	Clc1c(CN2Cc3c(scc3)CC2)cccc1	4.54999995	Active	P2y12 (p2t) Antagonists&P2Y12 (P2T) Antagonist	0.29999969999999987	2	Ticlopidine hydrochloride	170464698&384567964	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-40.0769776927&-67.777273224	Clc1c(CN2Cc3c(scc3)CC2)cccc1	Clc1c(CN2Cc3c(scc3)CC2)cccc1
NCGC00160424-02	Clc1c(CNC(Cc2ccccc2)C)cccc1		Inactive			1	Clobenzorex hydrochloride	170465619	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.671862164	Clc1c(CNC(Cc2ccccc2)C)cccc1.Cl	Clc1c(CNC(Cc2ccccc2)C)cccc1.Cl
NCGC00181337-03	Clc1c(CO)ccc(Cl)c1	5.5	Active		0.0	1	2,4-Dichlorobenzyl alcohol	170465574	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.9827968312	Clc1c(CO)ccc(Cl)c1	Clc1c(CO)ccc(Cl)c1
NCGC00095125-05	Clc1c(CO)n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCCC)n1	4.8499999	Active	Angiotensin Ii Receptor Antagonist	0.0	1	Losartan	170465135	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-47.4189606047	Clc1c(CO)n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCCC)n1	Clc1c(CO)n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCCC)n1
NCGC00167430-04	Clc1c(COC(Cn2cncc2)c2c(Cl)cc(Cl)cc2)ccs1	4.4166665	Active	Antifungal Agent&Anti-fungal	0.0	1	Tioconazole	170465343	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0&-3.0	-125.5884832436&-116.361653448&-94.662421596	Clc1c(COC(Cn2cncc2)c2c(Cl)cc(Cl)cc2)ccs1	Clc1c(COC(Cn2cncc2)c2c(Cl)cc(Cl)cc2)ccs1
NCGC00506875-01	Clc1c(COCCOCCCCCCNCC(O)c2cc(CO)c(O)cc2)c(Cl)ccc1	4.75	Active	adrenoceptor beta 2, surface Agonist	0.0	1	Vilanterol (GW642444; GW 642444X)	405558572	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-45.6592609252	Clc1c(COCCOCCCCCCNCC(O)c2cc(CO)c(O)cc2)c(Cl)ccc1	Clc1c(COCCOCCCCCCNCC(O)c2cc(CO)c(O)cc2)c(Cl)ccc1
NCGC00346642-04	Clc1c(CS(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5[C@@H](CN6CCCC6)CCC5)c(C)[nH]4)/C(=O)Nc3cc2)c(Cl)ccc1	4.4000001	Active	HGFR Inhibitor	0.0	1	PHA-665752	384568875	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-110.0585135258	Clc1c(CS(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5[C@@H](CN6CCCC6)CCC5)c(C)[nH]4)/C(=O)Nc3cc2)c(Cl)ccc1	Clc1c(CS(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5[C@@H](CN6CCCC6)CCC5)c(C)[nH]4)/C(=O)Nc3cc2)c(Cl)ccc1
NCGC00024567-03	Clc1c(C[N+](CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2c(Cl)cccc2)(CC)CC)cccc1		Inactive	Acetylcholinesterase Inhibitor		1	Ambenonium chloride	170465386	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.9926089519&0.0	Clc1c(C[N+](CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2c(Cl)cccc2)(CC)CC)cccc1.[Cl-].[Cl-]	Clc1c(C[N+](CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2c(Cl)cccc2)(CC)CC)cccc1.[Cl-].[Cl-]
NCGC00389663-01	Clc1c(Cc2ccc(OC3COCC3)cc2)cc(C2C(O)C(O)C(O)C(CO)O2)cc1		Inactive	Sodium/glucose Cotransporter 2 Antagonist&Sodium/glucose cotransporter 2 Antagonist		1	Empagliflozin (BI 10773)	405558611	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.754348616&-23.800029272	Clc1c(Cc2ccc(OC3COCC3)cc2)cc(C2C(O)C(O)C(O)C(CO)O2)cc1	Clc1c(Cc2ccc(OC3COCC3)cc2)cc(C2C(O)C(O)C(O)C(CO)O2)cc1
NCGC00378889-01	Clc1c(Cc2ccc(OCC)cc2)cc([C@]23[C@H](O)[C@@H](O)[C@H](O)[C@](CO)(O2)CO3)cc1		Inactive	Sodium/glucose Cotransporter 2 Inhibitor&Sodium/glucose cotransporter 2 Inhibitor		1	PF-04971729	405558956	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.935626624&-33.0691606119	Clc1c(Cc2ccc(OCC)cc2)cc([C@]23[C@H](O)[C@@H](O)[C@H](O)[C@](CO)(O2)CO3)cc1	Clc1c(Cc2ccc(OCC)cc2)cc([C@]23[C@H](O)[C@@H](O)[C@H](O)[C@](CO)(O2)CO3)cc1
NCGC00016260-13	Clc1c(Cl)c(C(=O)C(=C)CC)ccc1OCC(=O)O	4.75	Active	Sodium/potassium-transporting ATPase subunit alpha-1 Inhibitor	0.0	1	Ethacrynic acid	170465426	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-97.5269395478	Clc1c(Cl)c(C(=O)C(=C)CC)ccc1OCC(=O)O	Clc1c(Cl)c(C(=O)C(=C)CC)ccc1OCC(=O)O
NCGC00346885-02	Clc1c(Cl)cc(Cl)cc1-c1c(N)nc(N2CCN(C)CC2)nc1	4.4499998	Active	Nav1.2 (Brain Type II) Sodium Channel Blocker	0.0	1	Sipatrigine	384568962	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-96.0820830367	Clc1c(Cl)cc(Cl)cc1-c1c(N)nc(N2CCN(C)CC2)nc1	Clc1c(Cl)cc(Cl)cc1-c1c(N)nc(N2CCN(C)CC2)nc1
NCGC00163886-05	Clc1c(Cl)cc(OP(=S)(OC)OC)c(Cl)c1		Inactive	Cholinesterases; Ache & Bche Inhibitor&Cholinesterases; ACHE & BCHE Inhibitor		1	Fenchlorphos	170466415	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.68172734	Clc1c(Cl)cc(OP(=S)(OC)OC)c(Cl)c1	Clc1c(Cl)cc(OP(=S)(OC)OC)c(Cl)c1
NCGC00387310-02	Clc1c(Cl)cc2c(-c3ccncc3)nnc(NC3CCCC3)c2c1		Inactive	Inhibitor of SUV420H1 and SUV420H2		1	A-196	384569158	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.441767028	Clc1c(Cl)cc2c(-c3ccncc3)nnc(NC3CCCC3)c2c1	Clc1c(Cl)cc2c(-c3ccncc3)nnc(NC3CCCC3)c2c1
NCGC00263128-02	Clc1c(Cl)cc2nc(c(NCCCCN(CC)CC)nc2c1)-c1sc(-c2sccc2)cc1	4.4499998	Active	CXCR1/CXCR2 Receptor Antagonist	0.0	1	PD-0220245	384568609	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-65.60383216	Clc1c(Cl)cc2nc(c(NCCCCN(CC)CC)nc2c1)-c1sc(-c2sccc2)cc1	Clc1c(Cl)cc2nc(c(NCCCCN(CC)CC)nc2c1)-c1sc(-c2sccc2)cc1
NCGC00274083-01	Clc1c(Cl)ccc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)c1	4.4000001	Active	Cholecystokinin A Receptor Antagonist&Cholecystokinin A receptor Antagonist	0.0	1	Loxiglumide	170465971	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-34.639468892&-42.213326508	Clc1c(Cl)ccc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)c1	Clc1c(Cl)ccc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)c1
NCGC00024901-04	Clc1c(Cl)ccc(CCN(CCN(C)C)C)c1	4.5	Active	sigma Receptor Antagonist	0.0	1	BD-1047	384568035	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-57.5093964494	Clc1c(Cl)ccc(CCN(CCN(C)C)C)c1	Clc1c(Cl)ccc(CCN(CCN(C)C)C)c1
NCGC00510481-01	Clc1c(Cl)ccc(CN2C(=O)OC3(C2)CCN(C(=O)/C=C/c2ccc(Cl)cc2)CC3)c1		Inactive	EBI2/GPR183 Agonist		1	GSK-682753A	384569444	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(Cl)ccc(CN2C(=O)OC3(C2)CCN(C(=O)/C=C/c2ccc(Cl)cc2)CC3)c1	Clc1c(Cl)ccc(CN2C(=O)OC3(C2)CCN(C(=O)/C=C/c2ccc(Cl)cc2)CC3)c1
NCGC00538147-01	Clc1c(Cl)ccc(CNC(NC(=N)NCCCCCCCC)=N)c1		Inactive			1	NCGC00538147-01	405558439	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(Cl)ccc(CNC(NC(=N)NCCCCCCCC)=N)c1	Clc1c(Cl)ccc(CNC(NC(=N)NCCCCCCCC)=N)c1
NCGC00263143-07	Clc1c(Cl)ccc(CNc2n([C@H]3[C@H](O)[C@H](O)[C@@H](COCc4ccc(C#N)cc4)O3)c3ncnc(N)c3n2)c1	4.4000001	Active	Heat Shock Protein 70 (hsp70) Inhibitor	0.0	1	VER-155008	384568618	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.8323723719	Clc1c(Cl)ccc(CNc2n([C@H]3[C@H](O)[C@H](O)[C@@H](COCc4ccc(C#N)cc4)O3)c3ncnc(N)c3n2)c1	Clc1c(Cl)ccc(CNc2n([C@H]3[C@H](O)[C@H](O)[C@@H](COCc4ccc(C#N)cc4)O3)c3ncnc(N)c3n2)c1
NCGC00163107-07	Clc1c(Cl)ccc(CO/N=C/c2c(-c3ccc(Cl)cc3)nc3SC=Cn23)c1		Inactive	Constitutive androstane receptor Agonist		1	CITCO	384568229	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-10.5568587119	Clc1c(Cl)ccc(CO/N=C/c2c(-c3ccc(Cl)cc3)nc3SC=Cn23)c1	Clc1c(Cl)ccc(CO/N=C/c2c(-c3ccc(Cl)cc3)nc3SC=Cn23)c1
NCGC00164034-05	Clc1c(Cl)ccc(NC(=O)Nc2ccc(Cl)cc2)c1	4.4250002	Active		0.0	1	Triclocarban	170465481	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-123.1413242841&-111.5090406519	Clc1c(Cl)ccc(NC(=O)Nc2ccc(Cl)cc2)c1	Clc1c(Cl)ccc(NC(=O)Nc2ccc(Cl)cc2)c1
NCGC00092386-13&NCGC00092386-26	Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1	4.57500005	Active	Selective Seratonin Reuptake Inhibitor (SSRI)&Sodium-dependent Serotonin Transporter Inhibitor&Selective Seratonin Reuptake Inhibitor (SSRI)	0.04999969999999987	2	Sertraline hydrochloride	170465121&384568111	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3&-2.3	-65.0638783828&-84.0609116505&-110.6646561992	Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1.Cl	Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1.Cl&Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1
NCGC00161408-07	Clc1c(Cl)ccc2NC3=NC(=O)CN3Cc12		Inactive	Phosphodiesterase III (PDE3) Inhibitor		1	Anagrelide	384568206	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(Cl)ccc2NC3=NC(=O)CN3Cc12	Clc1c(Cl)ccc2NC3=NC(=O)CN3Cc12
NCGC00247665-04	Clc1c(Cl)ccc2Nc3n(cc(O)n3)Cc12		Inactive	Phosphodiesterase Iii (pde3) Inhibitor&Phosphodiesterase III (PDE3) inhibitor		1	Anagrelide hydrochloride	170465269	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.7222812479&0.0	Clc1c(Cl)ccc2Nc3n(cc(O)n3)Cc12.Cl	Clc1c(Cl)ccc2Nc3n(cc(O)n3)Cc12.Cl
NCGC00345739-02	Clc1c(Cl)ccc2c(/C(/C#N)=C\N)c(C(=O)OCC)n(C)c12		Inactive	Clk1, Clk4 Inhibitor		1	KH-CB19	174007137	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.1010696079	Clc1c(Cl)ccc2c(/C(/C#N)=C\N)c(C(=O)OCC)n(C)c12	Clc1c(Cl)ccc2c(/C(/C#N)=C\N)c(C(=O)OCC)n(C)c12
NCGC00015605-09&NCGC00015605-13	Clc1c(Cl)cccc1-c1c(N)nc(N)nn1		Inactive	Sodium Channel Blocker&Sodium Channel Inhibitor&Sodium Channel Blocker		2	Lamotrigine	170465024&384567872	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	9.402251676&11.97765302&0.0	Clc1c(Cl)cccc1-c1c(N)nc(N)nn1	Clc1c(Cl)cccc1-c1c(N)nc(N)nn1
NCGC00498442-01	Clc1c(Cl)cccc1-c1c(N)nc(N2CCC(N)(C)CC2)cn1		Inactive	Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor		1	SHP-099	384569303	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(Cl)cccc1-c1c(N)nc(N2CCC(N)(C)CC2)cn1	Clc1c(Cl)cccc1-c1c(N)nc(N2CCC(N)(C)CC2)cn1
NCGC00347909-06	Clc1c(Cl)cccc1-n1c(NCc2c(Oc3ncccc3)cccc2)nnn1	4.4000001	Active	P2X7 Receptor Antagonist	0.0	1	A-839977	363677719	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-109.130942811	Clc1c(Cl)cccc1-n1c(NCc2c(Oc3ncccc3)cccc2)nnn1	Clc1c(Cl)cccc1-n1c(NCc2c(Oc3ncccc3)cccc2)nnn1
NCGC00183830-01	Clc1c(Cl)cccc1C1C(C(=O)OC(C)C)=C(COC(=O)N)NC(C)=C1C(=O)OC		Inactive	Voltage-gated Calcium Channel Blocker&Voltage-gated calcium channel Blocker		1	Lemildipine	144206840	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.1147165159&0.0	Clc1c(Cl)cccc1C1C(C(=O)OC(C)C)=C(COC(=O)N)NC(C)=C1C(=O)OC	Clc1c(Cl)cccc1C1C(C(=O)OC(C)C)=C(COC(=O)N)NC(C)=C1C(=O)OC
NCGC00015455-10	Clc1c(Cl)cccc1C1C(C(=O)OCC)=C(C)NC(C)=C1C(=O)OC	5.1500001	Active	Voltage-gated calcium channel alpha2/delta subunit 1 Inhibitor	0.0	1	Felodipine	170464849	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-31.2545403759	Clc1c(Cl)cccc1C1C(C(=O)OCC)=C(C)NC(C)=C1C(=O)OC	Clc1c(Cl)cccc1C1C(C(=O)OCC)=C(C)NC(C)=C1C(=O)OC
NCGC00262928-01	Clc1c(Cl)cccc1C1C(C(=O)OCOC(=O)CCC)=C(C)NC(C)=C1C(=O)OC		Inactive	Voltage-gated L-type Calcium Channel Blocker&Voltage-gated L-type calcium channel Blocker		1	Clevidipine	170466066	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(Cl)cccc1C1C(C(=O)OCOC(=O)CCC)=C(C)NC(C)=C1C(=O)OC	Clc1c(Cl)cccc1C1C(C(=O)OCOC(=O)CCC)=C(C)NC(C)=C1C(=O)OC
NCGC00379014-01	Clc1c(Cl)cccc1N1CCN(CCC2CCC(NC(=O)N(C)C)CC2)CC1	4.75	Active	Serotonin 1a (5-ht1a) Receptor Partial Agonist	0.0	1	Cariprazine	405558596	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-68.8621799418	Clc1c(Cl)cccc1N1CCN(CCC2CCC(NC(=O)N(C)C)CC2)CC1	Clc1c(Cl)cccc1N1CCN(CCC2CCC(NC(=O)N(C)C)CC2)CC1
NCGC00532501-01	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3N(COC(=O)CCCCCCCCCCC)C(=O)CCc3cc2)CC1		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist&Serotonin 1a (5-ht1a) Receptor Partial Agonist		1	ARIPIPRAZOLE LAUROXIL	405558833	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.247624268&-32.019275404	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3N(COC(=O)CCCCCCCCCCC)C(=O)CCc3cc2)CC1	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3N(COC(=O)CCCCCCCCCCC)C(=O)CCc3cc2)CC1
NCGC00159510-05	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3NC(=O)CCc3cc2)CC1	4.4000001	Active	5-ht1a/2a Antagonist&5-HT1A/2A Antagonist	0.0	1	Aripiprazole	170465392	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-74.1862426917&-101.2519749297	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3NC(=O)CCc3cc2)CC1	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3NC(=O)CCc3cc2)CC1
NCGC00263015-01	Clc1c(Cn2c(C)c(CN(CC(O)COc3ccc(Cl)cc3)C)c(C)n2)cccc1	4.5	Active	TLR4 (LPS) Inhibitor	0.0	1	NCGC00263015	137275919	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-110.8148299692	Clc1c(Cn2c(C)c(CN(CC(O)COc3ccc(Cl)cc3)C)c(C)n2)cccc1	Clc1c(Cn2c(C)c(CN(CC(O)COc3ccc(Cl)cc3)C)c(C)n2)cccc1
NCGC00015609-15	Clc1c(Cn2nc(C(=O)O)c3c2cccc3)ccc(Cl)c1		Inactive	Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor		1	Lonidamine	384567874	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.0657545322	Clc1c(Cn2nc(C(=O)O)c3c2cccc3)ccc(Cl)c1	Clc1c(Cn2nc(C(=O)O)c3c2cccc3)ccc(Cl)c1
NCGC00386362-01	Clc1c(F)c(C(=O)N([C@H](CC#C)C=2N(Nc3ccccc3)C(=O)c3c(N=2)cc(Cl)cc3)CCCN)ccc1	4.9000001	Active	Kinesin-Like Spindle Protein Inhibitor	0.0	1	ARQ-621	363680233	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-119.4180626348	Clc1c(F)c(C(=O)N([C@H](CC#C)C=2N(Nc3ccccc3)C(=O)c3c(N=2)cc(Cl)cc3)CCCN)ccc1	Clc1c(F)c(C(=O)N([C@H](CC#C)C=2N(Nc3ccccc3)C(=O)c3c(N=2)cc(Cl)cc3)CCCN)ccc1
NCGC00346565-07	Clc1c(F)c(Cc2c(OC)cc3N([C@@H](C(C)C)CO)C=C(C(=O)O)C(=O)c3c2)ccc1	4.3499999	Inactive	HIV Integrase Inhibitor	0.0	1	Elvitegravir	384568842	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-42.3171778246	Clc1c(F)c(Cc2c(OC)cc3N([C@@H](C(C)C)CO)C=C(C(=O)O)C(=O)c3c2)ccc1	Clc1c(F)c(Cc2c(OC)cc3N([C@@H](C(C)C)CO)C=C(C(=O)O)C(=O)c3c2)ccc1
NCGC00483922-01	Clc1c(F)c(Nc2ncnc3c2cc(OC(=O)N2[C@H](C)CN(C)CC2)c(OC)c3)ccc1		Inactive	EGFR Inhibitor		1	AZD-3759	363681141	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.349953144	Clc1c(F)c(Nc2ncnc3c2cc(OC(=O)N2[C@H](C)CN(C)CC2)c(OC)c3)ccc1	Clc1c(F)c(Nc2ncnc3c2cc(OC(=O)N2[C@H](C)CN(C)CC2)c(OC)c3)ccc1
NCGC00347284-02&NCGC00390607-01	Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@@H](CN(C)C4)C2)c3)ccc1Cl	4.75	Active	EGFR Inhibitor	0.10000040000000077	2	XL647&Tesevatinib	384568985&363680926	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-93.2267993749&-118.3791445329	Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@@H](CN(C)C4)C2)c3)ccc1Cl	Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@@H](CN(C)C4)C2)c3)ccc1Cl
NCGC00386427-01	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(C(=O)C=C)CC2)c(OC)c3)ccc1Cl	5.75	Active	EGFR Inhibitor	0.0	1	Poziotinib	363680279	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-89.3109618874	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(C(=O)C=C)CC2)c(OC)c3)ccc1Cl	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(C(=O)C=C)CC2)c(OC)c3)ccc1Cl
NCGC00346573-02	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC(=O)NC)CC2)c(OC)c3)ccc1		Inactive	HER2/3 Inhibitor		1	Sapitinib	384568846	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.32562332	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC(=O)NC)CC2)c(OC)c3)ccc1	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC(=O)NC)CC2)c(OC)c3)ccc1
NCGC00346657-02	Clc1c(F)c(OC2CCC(C(=O)O)(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1	5.1999998	Active	Aurora A Inhibitor	0.0	1	MK-5108	384568888	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-94.0761170728	Clc1c(F)c(OC2CCC(C(=O)O)(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1	Clc1c(F)c(OC2CCC(C(=O)O)(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1
NCGC00378611-03	Clc1c(F)c([C@H]2[C@H](C(=O)NC3CCC(O)CC3)N[C@H](CC(C)(C)C)[C@@]32C(=O)Nc2c3ccc(Cl)c2)ccc1	4.5500002	Active	p53-binding protein Mdm-2 Inhibitor	0.0	1	MI-773 (SAR405838)	384569055	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-92.0113773623	Clc1c(F)c([C@H]2[C@H](C(=O)NC3CCC(O)CC3)N[C@H](CC(C)(C)C)[C@@]32C(=O)Nc2c3ccc(Cl)c2)ccc1	Clc1c(F)c([C@H]2[C@H](C(=O)NC3CCC(O)CC3)N[C@H](CC(C)(C)C)[C@@]32C(=O)Nc2c3ccc(Cl)c2)ccc1
NCGC00521942-01	Clc1c(F)c([C@H]2[C@H](C(=O)N[C@H]3CO[C@H](C(=O)N)CC3)NC3([C@]42C(=O)Nc2c4ccc(Cl)c2)CCC(C)(C)CC3)ccn1		Inactive	MDM2 (hdm2) Inhibitor		1	Milademetan	384569507	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.1278978919	Clc1c(F)c([C@H]2[C@H](C(=O)N[C@H]3CO[C@H](C(=O)N)CC3)NC3([C@]42C(=O)Nc2c4ccc(Cl)c2)CCC(C)(C)CC3)ccn1	Clc1c(F)c([C@H]2[C@H](C(=O)N[C@H]3CO[C@H](C(=O)N)CC3)NC3([C@]42C(=O)Nc2c4ccc(Cl)c2)CCC(C)(C)CC3)ccn1
NCGC00511386-01	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)N)cc3)N[C@@H](CC(C)(C)C)[C@]32C(=O)Nc2c3ccc(Cl)c2)ccc1	4.4000001	Active	MDM2 (hdm2) Inhibitor	0.0	1	RO8994	384569501	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.8465741037	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)N)cc3)N[C@@H](CC(C)(C)C)[C@]32C(=O)Nc2c3ccc(Cl)c2)ccc1	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)N)cc3)N[C@@H](CC(C)(C)C)[C@]32C(=O)Nc2c3ccc(Cl)c2)ccc1
NCGC00378976-03	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)O)cc3)N[C@@H](CC(C)(C)C)[C@]2(C#N)c2c(F)cc(Cl)cc2)ccc1		Inactive	MDM2 (hdm2) Inhibitor		1	Idasanutlin	384569081	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)O)cc3)N[C@@H](CC(C)(C)C)[C@]2(C#N)c2c(F)cc(Cl)cc2)ccc1	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)O)cc3)N[C@@H](CC(C)(C)C)[C@]2(C#N)c2c(F)cc(Cl)cc2)ccc1
NCGC00386401-01	Clc1c(F)cc([C@@H](CO)N2C(=O)C=C(c3nc(Nc4n(C)ncc4)ncc3)C=C2)cc1	4.8000002	Active	ERK1 Inhibitor	0.0	1	Ravoxertinib	384569132	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-95.3296679113	Clc1c(F)cc([C@@H](CO)N2C(=O)C=C(c3nc(Nc4n(C)ncc4)ncc3)C=C2)cc1	Clc1c(F)cc([C@@H](CO)N2C(=O)C=C(c3nc(Nc4n(C)ncc4)ncc3)C=C2)cc1
NCGC00273985-04	Clc1c(F)ccc(Nc2c(C#N)cnc3c(Cl)cc(NCc4nnn(C5CCN(CC)CC5)c4)cc23)c1	4.4000001	Active	Tpl-2/Cot (MAP3K8) Kinase Inhibitor	0.0	1	Wyeth Cot Inhibitor 2	363677309	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.2364070495	Clc1c(F)ccc(Nc2c(C#N)cnc3c(Cl)cc(NCc4nnn(C5CCN(CC)CC5)c4)cc23)c1	Clc1c(F)ccc(Nc2c(C#N)cnc3c(Cl)cc(NCc4nnn(C5CCN(CC)CC5)c4)cc23)c1
NCGC00263103-02	Clc1c(F)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1	4.4000001	Active	EGFR Inhibitor	0.0	1	Pelitinib	384568592	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-110.3846734157	Clc1c(F)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1	Clc1c(F)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1
NCGC00387813-02	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(OC2COCC2)c3)c1	5.0	Active	Egfr (her1; Erbb1) Inhibitor&EGFR (HER1; erbB1) inhibitor	0.0	1	NCGC00387813-02&Afatinib (BIBW2992)	405558642	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.1	-62.9786311299&-111.9566217658	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(OC2COCC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(OC2COCC2)c3)c1
NCGC00185000-18	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(O[C@@H]2COCC2)c3)c1	4.6500001	Active	EGFR Inhibitor	0.0	1	Afatinib	384568423	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-65.1988300052	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(O[C@@H]2COCC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(O[C@@H]2COCC2)c3)c1
NCGC00263185-09	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN2CCCCC2)c(OC)c3)c1	4.75	Active	EGFR Inhibitor	0.0	1	Dacomitinib	363677251	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-88.6575511392	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN2CCCCC2)c(OC)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN2CCCCC2)c(OC)c3)c1
NCGC00263195-04	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(C#CC(C)(C)N2CCN(C)CC2)c3)c1	5.4499998	Active	EGFR Inhibitor	0.0	1	AV-412	377020296	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.6791522095	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(C#CC(C)(C)N2CCN(C)CC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(C#CC(C)(C)N2CCN(C)CC2)c3)c1
NCGC00182713-18	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)c1	5.5	Active	EGFR Inhibitor	0.0	1	Canertinib	377020273	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-94.1555243279	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)c1
NCGC00481588-01	Clc1c(N(c2ncc(C(=O)NCCCCCCC(=O)NO)cn2)c2ccccc2)cccc1		Inactive			1	ACY-241	384569257	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(N(c2ncc(C(=O)NCCCCCCC(=O)NO)cn2)c2ccccc2)cccc1	Clc1c(N(c2ncc(C(=O)NCCCCCCC(=O)NO)cn2)c2ccccc2)cccc1
NCGC00181010-02	Clc1c(N)c(C(F)(F)F)cc(C(O)CNC(C)(C)C)c1	5.1500001	Active	Beta-2 adrenergic receptor Agonist	0.0	1	Mabuterol hydrochloride	170465921	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.1053134428	Clc1c(N)c(C(F)(F)F)cc(C(O)CNC(C)(C)C)c1.Cl	Clc1c(N)c(C(F)(F)F)cc(C(O)CNC(C)(C)C)c1.Cl
NCGC00163150-07	Clc1c(N)c(Cl)cc(C(O)CNC(C)(C)C)c1		Inactive	Beta-2 adrenergic receptor Agonist&Beta-2 Adrenergic Receptor Agonist		1	Clenbuterol	170465955	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.699177864&0.0	Clc1c(N)c(Cl)cc(C(O)CNC(C)(C)C)c1	Clc1c(N)c(Cl)cc(C(O)CNC(C)(C)C)c1
NCGC00253867-02&NCGC00253867-11	Clc1c(N)c2c(c(C(=O)NC3CCN(CCCOC)CC3)c1)OCC2		Inactive	5-ht4 Receptor Agonist&5-HT4 Agonist&5-HT4 Agonist		2	Prucalopride	170466188&384568568	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-16.937978012&0.0&0.0	Clc1c(N)c2c(c(C(=O)NC3CCN(CCCOC)CC3)c1)OCC2	Clc1c(N)c2c(c(C(=O)NC3CCN(CCCOC)CC3)c1)OCC2
NCGC00025262-02	Clc1c(N)cc(OC)c(C(=O)NC2C(OC)CN(CCCOc3ccc(F)cc3)CC2)c1	4.5500002	Active		0.0	1	Cisapride	170465200	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-55.427987676&-66.349309652	Clc1c(N)cc(OC)c(C(=O)NC2C(OC)CN(CCCOc3ccc(F)cc3)CC2)c1	Clc1c(N)cc(OC)c(C(=O)NC2C(OC)CN(CCCOc3ccc(F)cc3)CC2)c1
NCGC00016951-05	Clc1c(N)cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)c1	4.4499998	Active	Dopamine D2 Receptor Antagonist&Dopamine D2 receptor Antagonist	0.0	1	Clebopride maleate	170465853	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-58.6596731333&-43.982179536	Clc1c(N)cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)c1.O=C(O)/C=C\C(=O)O	Clc1c(N)cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)c1.O=C(O)/C=C\C(=O)O
NCGC00015643-11	Clc1c(N)cc(OC)c(C(=O)NCCN(CC)CC)c1		Inactive	Muscarinic Acetylcholine Receptor M3 Antagonist&Muscarinic acetylcholine receptor M3 Antagonist		1	Metoclopramide	170464848	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.930231292	Clc1c(N)cc(OC)c(C(=O)NCCN(CC)CC)c1	Clc1c(N)cc(OC)c(C(=O)NCCN(CC)CC)c1
NCGC00183682-14	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@@H]3[C@H](OCC)OC(=O)C3)CCC2)c1		Inactive	Caspase-1 Inhibitor		1	VX-765	384568419	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.3435683997	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@@H]3[C@H](OCC)OC(=O)C3)CCC2)c1	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@@H]3[C@H](OCC)OC(=O)C3)CCC2)c1
NCGC00015147-04	Clc1c(N)nc(N)c(C(=O)/N=C(/NCc2ccccc2)\N)n1	4.4000001	Active	Epithelial Sodium Channels (ENaC) Blocker	0.0	1	Benzamil	124879400	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-115.213202974	Clc1c(N)nc(N)c(C(=O)/N=C(/NCc2ccccc2)\N)n1	Clc1c(N)nc(N)c(C(=O)/N=C(/NCc2ccccc2)\N)n1
NCGC00015089-14&NCGC00015089-17	Clc1c(N)nc(N)c(C(=O)NC(=N)N)n1		Inactive	Epithelial Sodium Channels (ENaC) Blocker&Epithelial Sodium Channels (ENaC) Blocker&Epithelial Sodium Channels (enac) Blocker		2	Amiloride hydrochloride	124879266&170465124	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	11.419379932&0.0&-26.1260266279	Clc1c(N)nc(N)c(C(=O)NC(=N)N)n1	Clc1c(N)nc(N)c(C(=O)NC(=N)N)n1
NCGC00263176-03	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)C(c3ccc(F)cc3)=CNC=2)cc1	4.4000001	Active	VEGFR-2 Inhibitor	0.0	1	BMS-794833	363677245	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.4823355466	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)C(c3ccc(F)cc3)=CNC=2)cc1	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)C(c3ccc(F)cc3)=CNC=2)cc1
NCGC00263157-02	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2OCC)cc1	4.8000002	Active	HGFR Inhibitor	0.0	1	BMS-777607	384568631	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-68.1182131852	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2OCC)cc1	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2OCC)cc1
NCGC00346458-02	Clc1c(N)ncnc1C(=O)N[C@H](C)c1sc(C(=O)Nc2ncc(Cl)c(C(F)(F)F)c2)cn1		Inactive			1	MLN 2480	363677413	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.186954348	Clc1c(N)ncnc1C(=O)N[C@H](C)c1sc(C(=O)Nc2ncc(Cl)c(C(F)(F)F)c2)cn1	Clc1c(N)ncnc1C(=O)N[C@H](C)c1sc(C(=O)Nc2ncc(Cl)c(C(F)(F)F)c2)cn1
NCGC00378460-08	Clc1c(N2C(=O)C3=C(N(C)C(=O)C=C3N2)c2cc(N(C)C)ccc2)cccc1		Inactive	NOX 1/4 Inhibitor		1	GKT-137831	363678082	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(N2C(=O)C3=C(N(C)C(=O)C=C3N2)c2cc(N(C)C)ccc2)cccc1	Clc1c(N2C(=O)C3=C(N(C)C(=O)C=C3N2)c2cc(N(C)C)ccc2)cccc1
NCGC00346963-01	Clc1c(N2C(=O)N(C)c3nc(NCCCCN(CC)CC)ncc3C2)c(Cl)c(OC)cc1OC	5.1999998	Active	CSF1R (c-FMS) Inhibitor	0.0	1	HMSL10083	174006744	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-107.4983666909	Clc1c(N2C(=O)N(C)c3nc(NCCCCN(CC)CC)ncc3C2)c(Cl)c(OC)cc1OC	Clc1c(N2C(=O)N(C)c3nc(NCCCCN(CC)CC)ncc3C2)c(Cl)c(OC)cc1OC
NCGC00510480-01	Clc1c(N2C(=O)N(c3ncc(OC)cc3)c3nc(Nc4c(OC)cc(C5CCN(C)CC5)cc4)ncc3C2)c(C)ccc1	4.4499998	Active	Salt-inducible Kinase (SIK) Inhibitor	0.0	1	YKL-05-099	384569443	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-122.1283114471	Clc1c(N2C(=O)N(c3ncc(OC)cc3)c3nc(Nc4c(OC)cc(C5CCN(C)CC5)cc4)ncc3C2)c(C)ccc1	Clc1c(N2C(=O)N(c3ncc(OC)cc3)c3nc(Nc4c(OC)cc(C5CCN(C)CC5)cc4)ncc3C2)c(C)ccc1
NCGC00390187-02	Clc1c(N2CC(O)C2)c(F)cc2C(=O)C(C(=O)O)=CN(c3c(F)cc(F)c(N)n3)c12	4.4000001	Active	Staphylococcus Aureus Inhibitor	0.0	1	Delafloxacin (meglumine)	405558581	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-68.339420972	Clc1c(N2CC(O)C2)c(F)cc2C(=O)C(C(=O)O)=CN(c3c(F)cc(F)c(N)n3)c12	Clc1c(N2CC(O)C2)c(F)cc2C(=O)C(C(=O)O)=CN(c3c(F)cc(F)c(N)n3)c12
NCGC00489873-03	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2cc3c(n(C)nc3)cc2)cnc1N	4.8499999	Active	CDK 8/19 Inhibitor	0.0	1	CCT-251921	384569285	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-61.0749870887	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2cc3c(n(C)nc3)cc2)cnc1N	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2cc3c(n(C)nc3)cc2)cnc1N
NCGC00509936-02	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2ccc(-c3cn(C)nc3)cc2)cnc1	4.5	Active	CDK 8/19 Inhibitor	0.0	1	CCT-251545	384569385	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-42.5292077389	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2ccc(-c3cn(C)nc3)cc2)cnc1	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2ccc(-c3cn(C)nc3)cc2)cnc1
NCGC00346539-05	Clc1c(N2CCN(CC(=O)Nc3sccn3)CC2)c2nc(-c3ccc(N(C)C)cc3)[nH]c2nc1		Inactive	Aurora Kinase Inhibitor		1	CCT-129202	363677446	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.660402724	Clc1c(N2CCN(CC(=O)Nc3sccn3)CC2)c2nc(-c3ccc(N(C)C)cc3)[nH]c2nc1	Clc1c(N2CCN(CC(=O)Nc3sccn3)CC2)c2nc(-c3ccc(N(C)C)cc3)[nH]c2nc1
NCGC00183844-04	Clc1c(N2C[C@@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN([C@H]3[C@@H](F)C3)c12		Inactive	DNA Topoisomerase IV Inhibitor		1	Sitafloxacin hydrate	384568421	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	27.8919637799	Clc1c(N2C[C@@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN([C@H]3[C@@H](F)C3)c12	Clc1c(N2C[C@@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN([C@H]3[C@@H](F)C3)c12
NCGC00183844-01	Clc1c(N2C[C@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN(C3[C@H](F)C3)c12		Inactive	Bacterial Dna Gyrase Inhibitor&DNA Topoisomerase IV Inhibitor		1	Sitafloxacin hydrate	124894559	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.859695524&-18.4147212319	Clc1c(N2C[C@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN(C3[C@H](F)C3)c12	Clc1c(N2C[C@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN(C3[C@H](F)C3)c12
NCGC00386381-04	Clc1c(N2C[C@H](N)CCCC2)c(F)cc2C(=O)C(C(=O)O)=CN(C3CC3)c12		Inactive	Topoisomerase IV Inhibitor&Topoisomerase Iv Inhibitor		1	Besifloxacin Hydrochloride	405558885	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(N2C[C@H](N)CCCC2)c(F)cc2C(=O)C(C(=O)O)=CN(C3CC3)c12	Clc1c(N2C[C@H](N)CCCC2)c(F)cc2C(=O)C(C(=O)O)=CN(C3CC3)c12
NCGC00346747-02	Clc1c(N2c3c(ccc(C#CC(O)(C)c4sccn4)c3)CC2)nc(N)nc1	4.4000001	Active	NFkappaB-inducing kinase Inhibitor	0.0	1	NCGC00346747	174007018	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-111.7684741765	Clc1c(N2c3c(ccc(C#CC(O)(C)c4sccn4)c3)CC2)nc(N)nc1	Clc1c(N2c3c(ccc(C#CC(O)(C)c4sccn4)c3)CC2)nc(N)nc1
NCGC00015033-03	Clc1c(N=C2NCCN2)c(Cl)cc(N)c1		Inactive	Alpha-2A adrenergic receptor Agonist&Alpha-2a Adrenergic Receptor Agonist		1	p-Aminoclonidine hydrochloride	90341674	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.8173801359&28.4473543879	Clc1c(N=C2NCCN2)c(Cl)cc(N)c1	Clc1c(N=C2NCCN2)c(Cl)cc(N)c1
NCGC00249893-01	Clc1c(NC(=O)C(=O)O)cc(C#N)cc1NC(=O)C(=O)O		Inactive	type I hypersensitivity Inhibitor&Type I Hypersensitivity Inhibitor		1	Lodoxamide	170465346	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(NC(=O)C(=O)O)cc(C#N)cc1NC(=O)C(=O)O	Clc1c(NC(=O)C(=O)O)cc(C#N)cc1NC(=O)C(=O)O
NCGC00182988-01	Clc1c(NC(=O)COC(=O)C)cc(C#N)cc1NC(=O)COC(=O)C	4.5999999	Active		0.0	1	Acreozast	144206850	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.892865392	Clc1c(NC(=O)COC(=O)C)cc(C#N)cc1NC(=O)COC(=O)C	Clc1c(NC(=O)COC(=O)C)cc(C#N)cc1NC(=O)COC(=O)C
NCGC00510235-01	Clc1c(NC(=O)N(C)c2ncnc(Nc3c(NC(=O)C=C)cc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC		Inactive			1	H3B-6527	384569420	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(NC(=O)N(C)c2ncnc(Nc3c(NC(=O)C=C)cc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC	Clc1c(NC(=O)N(C)c2ncnc(Nc3c(NC(=O)C=C)cc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC
NCGC00274030-16	Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC		Inactive	FGFR3 Inhibitor		1	Infigratinib	384568707	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC	Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC
NCGC00522488-01	Clc1c(NC(=O)N2CCN(Cc3cc4OC(F)(F)Oc4cc3)CC2)cncc1	4.4000001	Active	Fatty Acid Amide Hydrolase (FAAH) Inhibitor	0.0	1	JNJ-42165279	384569520	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-46.71231484	Clc1c(NC(=O)N2CCN(Cc3cc4OC(F)(F)Oc4cc3)CC2)cncc1	Clc1c(NC(=O)N2CCN(Cc3cc4OC(F)(F)Oc4cc3)CC2)cncc1
NCGC00345847-02	Clc1c(NC(=O)NCC)ccc(Oc2c(/C=N/OC)c(N)ncn2)c1	4.5	Active	VEGFR-2 Inhibitor	0.0	1	JNJ-38158471	377020179	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-63.0859374786	Clc1c(NC(=O)NCC)ccc(Oc2c(/C=N/OC)c(N)ncn2)c1	Clc1c(NC(=O)NCC)ccc(Oc2c(/C=N/OC)c(N)ncn2)c1
NCGC00346548-07	Clc1c(NC(=O)NCCC)ccc(Oc2ncnc3c2cc(OC)c(OC)c3)c1		Inactive	VEGFR-2 Inhibitor		1	KRN-633	363677450	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.820480948	Clc1c(NC(=O)NCCC)ccc(Oc2ncnc3c2cc(OC)c(OC)c3)c1	Clc1c(NC(=O)NCCC)ccc(Oc2ncnc3c2cc(OC)c(OC)c3)c1
NCGC00249390-02	Clc1c(NC(=O)Nc2noc(C)c2)ccc(Oc2c3c(ncc2)cc(OC)c(OC)c3)c1	4.8499999	Active		0.0	1	Tivozanib (AV-951)	384568525	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-101.8391895045	Clc1c(NC(=O)Nc2noc(C)c2)ccc(Oc2c3c(ncc2)cc(OC)c(OC)c3)c1	Clc1c(NC(=O)Nc2noc(C)c2)ccc(Oc2c3c(ncc2)cc(OC)c(OC)c3)c1
NCGC00250391-05	Clc1c(NC(=O)[C@@](O)(C(F)(F)F)C)ccc(S(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1	4.75	Active	Pyruvate Dehydrogenase Kinase 2 Inhibitor	0.0	1	AZD-7545	384568544	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-82.9626567643	Clc1c(NC(=O)[C@@](O)(C(F)(F)F)C)ccc(S(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1	Clc1c(NC(=O)[C@@](O)(C(F)(F)F)C)ccc(S(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1
NCGC00346525-03	Clc1c(NC(=O)c2ccc(Nc3c(F)cnc(Nc4ccc(CC(=O)N5CCN(CC)CC5)cc4)n3)cc2)cccc1	5.0500002	Active	Aurora A Inhibitor	0.0	1	Aurora A Inhibitor I	384568819	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.756306998	Clc1c(NC(=O)c2ccc(Nc3c(F)cnc(Nc4ccc(CC(=O)N5CCN(CC)CC5)cc4)n3)cc2)cccc1	Clc1c(NC(=O)c2ccc(Nc3c(F)cnc(Nc4ccc(CC(=O)N5CCN(CC)CC5)cc4)n3)cc2)cccc1
NCGC00347944-06	Clc1c(NC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)cc2)nc1		Inactive	LRRK2 Inhibitor		1	Hg-10-102-01	363677725	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(NC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)cc2)nc1	Clc1c(NC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)cc2)nc1
NCGC00015649-08	Clc1c(NC2=NCCN2)c(OC)nc(C)n1		Inactive	Imidazoline I1 Receptor Agonists&Imidazoline I1 Receptor Agonist		1	Moxonidine hydrochloride hydrate	170466534	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&10.2097455119&-21.1381687879	Clc1c(NC2=NCCN2)c(OC)nc(C)n1	Clc1c(NC2=NCCN2)c(OC)nc(C)n1
NCGC00160529-06&NCGC00160529-08	Clc1c(NC2=NCCN2)c2nsnc2cc1		Inactive	alpha2-Adrenoceptor Agonist&Alpha2-adrenoceptor Agonists&alpha2-Adrenoceptor Agonist		2	Tizanidine hydrochloride	170465419&384568199	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-21.957752736&-12.680322596	Clc1c(NC2=NCCN2)c2nsnc2cc1	Clc1c(NC2=NCCN2)c2nsnc2cc1
NCGC00481082-01	Clc1c(NC2=Nn3c(C#N)cnc3C(NC3CC3)=C2)cc(NC(=O)OC)cc1N1CCN(C)CC1	5.4499998	Active	Casein Kinase 2 Inhibitor	0.0	1	BMS-595	363681116	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-78.1318244176	Clc1c(NC2=Nn3c(C#N)cnc3C(NC3CC3)=C2)cc(NC(=O)OC)cc1N1CCN(C)CC1	Clc1c(NC2=Nn3c(C#N)cnc3C(NC3CC3)=C2)cc(NC(=O)OC)cc1N1CCN(C)CC1
NCGC00522603-01	Clc1c(NS(=O)(=O)C2C(C(=O)OCC)=CCCC2)ccc(F)c1	4.4000001	Active		0.0	1	TAK-242	384569531	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-64.289494164	Clc1c(NS(=O)(=O)C2C(C(=O)OCC)=CCCC2)ccc(F)c1	Clc1c(NS(=O)(=O)C2C(C(=O)OCC)=CCCC2)ccc(F)c1
NCGC00253587-01&NCGC00253587-02	Clc1c(NS(=O)(=O)c2c(C(=O)Cc3c(C)cc4OCOc4c3)scc2)onc1C	6.0999999	Inactive	Endothelin ETA Receptor Antagonist&Endothelin-1 Receptor Antagonist&Endothelin ETA Receptor Antagonist	0.0	2	Sitaxentan	170465720&384568564	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	0.0&-15.4201962159&-24.9299427978	Clc1c(NS(=O)(=O)c2c(C(=O)Cc3c(C)cc4OCOc4c3)scc2)onc1C	Clc1c(NS(=O)(=O)c2c(C(=O)Cc3c(C)cc4OCOc4c3)scc2)onc1C
NCGC00482940-01	Clc1c(N[C@H]2[C@H](C(=O)N)[C@@H]3C=C[C@@H]2C3)nc(Nc2c(OC)c3c(cc2)CCC(N2CCOCC2)CC3)nc1		Inactive	ALK Inhibitor		1	CEP28122	377020381	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	54.1464647471	Clc1c(N[C@H]2[C@H](C(=O)N)[C@@H]3C=C[C@@H]2C3)nc(Nc2c(OC)c3c(cc2)CCC(N2CCOCC2)CC3)nc1	Clc1c(N[C@H]2[C@H](C(=O)N)[C@@H]3C=C[C@@H]2C3)nc(Nc2c(OC)c3c(cc2)CCC(N2CCOCC2)CC3)nc1
NCGC00402376-02	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)c3c(cc2)C[C@H](N2CCN(CCO)CC2)CCC3)nc1	4.5500002	Active	ALK Inhibitor	0.0	1	CEP-37440	363681049	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-109.6583549573	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)c3c(cc2)C[C@H](N2CCN(CCO)CC2)CCC3)nc1	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)c3c(cc2)C[C@H](N2CCN(CCO)CC2)CCC3)nc1
NCGC00346931-02	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1	4.8000002	Active	Focal Adhesion Kinase (FAK) Inhibitor	0.0	1	NVP-TAE226	384568967	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-119.4502562866	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1
NCGC00482799-01	Clc1c(Nc2c(C(=O)NOC)cccc2)cc(Nc2n(C(C)C)nc(C)c2)nc1	5.0999999	Inactive	Focal Adhesion Kinase (FAK) Inhibitor	0.0	1	GSK-2256098	384569260	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	2.2	40.4386106	Clc1c(Nc2c(C(=O)NOC)cccc2)cc(Nc2n(C(C)C)nc(C)c2)nc1	Clc1c(Nc2c(C(=O)NOC)cccc2)cc(Nc2n(C(C)C)nc(C)c2)nc1
NCGC00023217-08	Clc1c(Nc2c(C(=O)O)cccc2)c(Cl)ccc1C		Inactive	Cyclooxygenase Inhibitor		1	Meclofenamate sodium	170464886	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.0385738399&0.0	Clc1c(Nc2c(C(=O)[O-])cccc2)c(Cl)ccc1C.[Na+].O	Clc1c(Nc2c(C(=O)[O-])cccc2)c(Cl)ccc1C.[Na+].O
NCGC00181795-02	Clc1c(Nc2c(CC(=O)O)cc(C)cc2)c(F)ccc1		Inactive	Solute Carrier Family 22 Member 8 Inhibitor&Solute carrier family 22 member 8 Inhibitor		1	Lumiracoxib	170465597	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(Nc2c(CC(=O)O)cc(C)cc2)c(F)ccc1	Clc1c(Nc2c(CC(=O)O)cc(C)cc2)c(F)ccc1
NCGC00021125-03&NCGC00021336-14	Clc1c(Nc2c(CC(=O)O)cccc2)c(Cl)ccc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Cyclooxygenase-1/2/3 Inhibitor&Cyclooxygenase-1/2/3 Inhibitor		2	Diclofenac sodium	170464642&384568007	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	16.3337564119&0.0&17.000212956	Clc1c(Nc2c(CC(=O)[O-])cccc2)c(Cl)ccc1.[Na+]	Clc1c(Nc2c(CC(=O)[O-])cccc2)c(Cl)ccc1.[Na+]&Clc1c(Nc2c(CC(=O)[O-])cccc2)c(Cl)ccc1
NCGC00016957-05	Clc1c(Nc2c(CC(=O)OCC(=O)O)cccc2)c(Cl)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Aceclofenac	170465979	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.395839932&11.589427864	Clc1c(Nc2c(CC(=O)OCC(=O)O)cccc2)c(Cl)ccc1	Clc1c(Nc2c(CC(=O)OCC(=O)O)cccc2)c(Cl)ccc1
NCGC00378973-06	Clc1c(Nc2c(NS(=O)(=O)c3cc(NC(=O)C(N)(C)C)ccc3)nc3c(n2)cccc3)cc(OC)cc1		Inactive	PI3Kalpha Inhibitor		1	Pilaralisib	384569080	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.3132781599	Clc1c(Nc2c(NS(=O)(=O)c3cc(NC(=O)C(N)(C)C)ccc3)nc3c(n2)cccc3)cc(OC)cc1	Clc1c(Nc2c(NS(=O)(=O)c3cc(NC(=O)C(N)(C)C)ccc3)nc3c(n2)cccc3)cc(OC)cc1
NCGC00379254-06	Clc1c(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1		Inactive	ALK Inhibitor		1	KRCA-0008	384569096	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.63305404	Clc1c(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1	Clc1c(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1
NCGC00351602-09	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N(C)C)CC3)cc2)nc1	5.0	Active	ALK Inhibitor	0.0	1	AP-26113	363677771	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-65.079685442	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N(C)C)CC3)cc2)nc1	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N(C)C)CC3)cc2)nc1
NCGC00238453-16	Clc1c(Nc2c(S(=O)(=O)C(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1	4.6500001	Active	ALK Inhibitor	0.0	1	TAE-684	384568466	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-105.2335980657	Clc1c(Nc2c(S(=O)(=O)C(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1	Clc1c(Nc2c(S(=O)(=O)C(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1
NCGC00242486-04	Clc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ncc(F)cn2)nc1	4.3000002	Inactive	Jak1/2 Inhibitor	0.0	1	AZD-1480	384568494	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-23.5403385037	Clc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ncc(F)cn2)nc1	Clc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ncc(F)cn2)nc1
NCGC00250381-02	Clc1c(Nc2n[nH]c(OC(C)C)c2)nc(N[C@@H](C)c2ncc(F)cc2)nc1	5.25	Active	Trk Inhibitor	0.0	1	AZ-23	174006473	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-32.95533618	Clc1c(Nc2n[nH]c(OC(C)C)c2)nc(N[C@@H](C)c2ncc(F)cc2)nc1	Clc1c(Nc2n[nH]c(OC(C)C)c2)nc(N[C@@H](C)c2ncc(F)cc2)nc1
NCGC00346697-02	Clc1c(Nc2nc(C(F)(F)F)c(C(=O)NCC3CCOCC3)cn2)ccc(Cl)c1		Inactive	Cannabinoid CB2 Agonist		1	842166X	384568917	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(Nc2nc(C(F)(F)F)c(C(=O)NCC3CCOCC3)cn2)ccc(Cl)c1	Clc1c(Nc2nc(C(F)(F)F)c(C(=O)NCC3CCOCC3)cn2)ccc(Cl)c1
NCGC00387872-01	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)NC(CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1	5.0500002	Active	ERK2 Inhibitor	0.0	1	VS-4718	363680714	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.2597735464	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)NC(CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)NC(CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1
NCGC00242487-08	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1	4.4000001	Active	ERK Inhibitor	0.0	1	NCGC00242487	384568495	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-100.3132707813	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1
NCGC00241099-04	Clc1c(Nc2ncnc3c2c(OC2CCOCC2)cc(OCCN2CCN(C)CC2)c3)c2OCOc2cc1	4.4000001	Active	cSRC Inhibitor	0.0	1	Saracatinib	384568470	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-97.9926207412	Clc1c(Nc2ncnc3c2c(OC2CCOCC2)cc(OCCN2CCN(C)CC2)c3)c2OCOc2cc1	Clc1c(Nc2ncnc3c2c(OC2CCOCC2)cc(OCCN2CCN(C)CC2)c3)c2OCOc2cc1
NCGC00484800-01	Clc1c(Nc2ncnc3c2c2sc(C(OCC)=N)nc2cc3)cc(F)c(F)c1		Inactive	DYRK Inhibitor		1	FX-9847	384569272	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.076337564	Clc1c(Nc2ncnc3c2c2sc(C(OCC)=N)nc2cc3)cc(F)c(F)c1	Clc1c(Nc2ncnc3c2c2sc(C(OCC)=N)nc2cc3)cc(F)c(F)c1
NCGC00370984-01	Clc1c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc(OC)cc1	4.4000001	Active	Src Kinase Inhibitor	0.0	1	M-475271	363677978	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-96.1346513365	Clc1c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc(OC)cc1	Clc1c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc(OC)cc1
NCGC00095166-04	Clc1c(O)c(Cl)c(C)nc1C		Inactive			1	Clopidol	170465668	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.4013492439&0.0	Clc1c(O)c(Cl)c(C)nc1C	Clc1c(O)c(Cl)c(C)nc1C
NCGC00386398-03	Clc1c(O)c(Cl)cc(-c2nc3c(NC4CCC(CN(C)C)CC4)c(C(=O)C)cnc3cc2)c1	7.0	Inactive	MELK Inhibitor	0.0	1	OTS-167	363680254	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-40.512070504	Clc1c(O)c(Cl)cc(-c2nc3c(NC4CCC(CN(C)C)CC4)c(C(=O)C)cnc3cc2)c1	Clc1c(O)c(Cl)cc(-c2nc3c(NC4CCC(CN(C)C)CC4)c(C(=O)C)cnc3cc2)c1
NCGC00015444-07&NCGC00015444-10	Clc1c(O)c(O)cc2C(c3ccc(O)cc3)CNCCc12		Inactive	Dopamine D1 Receptor (DRD1) Agonist&Dopamine D1 Receptor (drd1) Agonist&Dopamine D1 Receptor (DRD1) Agonist		2	Fenoldopam	170465321&384567848	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-16.686272784&-19.1570351481&0.0	Clc1c(O)c(O)cc2C(c3ccc(O)cc3)CNCCc12	Clc1c(O)c(O)cc2C(c3ccc(O)cc3)CNCCc12
NCGC00018163-10	Clc1c(O)c(Sc2c(O)c(Cl)cc(Cl)c2)cc(Cl)c1	4.5500002	Active	Adenylate Cyclase Type 10 Inhibitor&Adenylate cyclase type 10 Inhibitor	0.0	1	Bithionol	170465515	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-114.2779433959&-96.2284778133	Clc1c(O)c(Sc2c(O)c(Cl)cc(Cl)c2)cc(Cl)c1	Clc1c(O)c(Sc2c(O)c(Cl)cc(Cl)c2)cc(Cl)c1
NCGC00095795-06	Clc1c(O)c2nc(C)ccc2c(Cl)c1		Inactive	Botulinum Neurotoxin Type A Inhibitor&Botulinum neurotoxin type A Inhibitor		1	5,7-Dichloro-8-hydroxy-2-methylquinoline	170465701	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(O)c2nc(C)ccc2c(Cl)c1	Clc1c(O)c2nc(C)ccc2c(Cl)c1
NCGC00095264-04	Clc1c(O)c2ncccc2c(Cl)c1	4.5250001	Active	Antibacterial	0.0	1	Chloroxine	170465084	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-100.3933749939&-97.7604214739	Clc1c(O)c2ncccc2c(Cl)c1	Clc1c(O)c2ncccc2c(Cl)c1
NCGC00346304-02	Clc1c(O)cc(-c2c(-c3ccncc3)[nH]c(-c3ccccc3)n2)cc1	4.6500001	Active	Raf kinase C Inhibitor	0.0	1	L-779450	174006393	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-103.5816669966	Clc1c(O)cc(-c2c(-c3ccncc3)[nH]c(-c3ccccc3)n2)cc1	Clc1c(O)cc(-c2c(-c3ccncc3)[nH]c(-c3ccccc3)n2)cc1
NCGC00420878-02	Clc1c(O)cc2Oc3c(O)ccc([C@@H](NC)C(=O)N[C@H]4C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O)c7cc(Cl)c(Oc8c(O[C@H]9[C@H](NC(=O)CCCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O9)c(Oc9ccc(cc9)C4)cc5c8)cc7)C(=O)N[C@H](C(=O)NCCCN(C)C)c4c(c(O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)-c4c(O)ccc6c4)c1c2)c3		Inactive			1	Dalbavancin	405558602	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(O)cc2Oc3c(O)ccc([C@@H](NC)C(=O)N[C@H]4C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O)c7cc(Cl)c(Oc8c(O[C@H]9[C@H](NC(=O)CCCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O9)c(Oc9ccc(cc9)C4)cc5c8)cc7)C(=O)N[C@H](C(=O)NCCCN(C)C)c4c(c(O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)-c4c(O)ccc6c4)c1c2)c3	Clc1c(O)cc2Oc3c(O)ccc([C@@H](NC)C(=O)N[C@H]4C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O)c7cc(Cl)c(Oc8c(O[C@H]9[C@H](NC(=O)CCCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O9)c(Oc9ccc(cc9)C4)cc5c8)cc7)C(=O)N[C@H](C(=O)NCCCN(C)C)c4c(c(O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)-c4c(O)ccc6c4)c1c2)c3
NCGC00015950-05	Clc1c(O)ccc(NC2=C(c3c([N+](=O)[O-])cccc3)C(=O)NC2=O)c1	4.4000001	Active	GSK-3 beta Inhibitor	0.0	1	SB-415286	124881443	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-56.731637764	Clc1c(O)ccc(NC2=C(c3c([N+](=O)[O-])cccc3)C(=O)NC2=O)c1	Clc1c(O)ccc(NC2=C(c3c([N+](=O)[O-])cccc3)C(=O)NC2=O)c1
NCGC00346943-03	Clc1c(OC(C)C)ccc(C(=O)N[C@H](CNC(=O)CN(C)C)Cc2ccc(-c3nc4C([C@@H](O)C)=CC=Cn4c3)cc2)c1	4.3499999	Active	Centromere Associated Protein (CENP) Inhibitor	0.0	1	GSK-923295	384568975	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-58.7199471674	Clc1c(OC(C)C)ccc(C(=O)N[C@H](CNC(=O)CN(C)C)Cc2ccc(-c3nc4C([C@@H](O)C)=CC=Cn4c3)cc2)c1	Clc1c(OC(C)C)ccc(C(=O)N[C@H](CNC(=O)CN(C)C)Cc2ccc(-c3nc4C([C@@H](O)C)=CC=Cn4c3)cc2)c1
NCGC00271513-02	Clc1c(OC(C)C2=NCCN2)c(Cl)ccc1	4.5	Active	Adrenergic Receptor Alpha-2 Agonist&Adrenergic receptor alpha-2 Agonist	0.0	1	Lofexidine	170466275	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-67.351728692&-42.983062244	Clc1c(OC(C)C2=NCCN2)c(Cl)ccc1	Clc1c(OC(C)C2=NCCN2)c(Cl)ccc1
NCGC00095978-06	Clc1c(OC(F)(F)C(F)C(F)(F)F)cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)c1	4.4000001	Active		0.0	1	Lufenuron	170465736	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-59.1543138147&-64.663043316	Clc1c(OC(F)(F)C(F)C(F)(F)F)cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)c1	Clc1c(OC(F)(F)C(F)C(F)(F)F)cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)c1
NCGC00484069-01	Clc1c(OC(F)(F)F)cc2[nH]c(-n3ncc(C(=O)O)c3)nc2c1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	JNJ-42041935	363681161	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(OC(F)(F)F)cc2[nH]c(-n3ncc(C(=O)O)c3)nc2c1	Clc1c(OC(F)(F)F)cc2[nH]c(-n3ncc(C(=O)O)c3)nc2c1
NCGC00263021-04	Clc1c(OC)c(NC(=O)c2c(C)nccc2)c2[nH]c3c(c2c1)ccnc3	4.6500001	Inactive	IKK beta Inhibitor	0.0	1	MLN-120B	363677194	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	24.031116106	Clc1c(OC)c(NC(=O)c2c(C)nccc2)c2[nH]c3c(c2c1)ccnc3	Clc1c(OC)c(NC(=O)c2c(C)nccc2)c2[nH]c3c(c2c1)ccnc3
NCGC00241107-02&NCGC00241107-12	Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1	5.0374999	Active	Bcr-abl Inhibitor&Bcr-Abl Inhibitor&Bcr-Abl Inhibitor	0.9250002000000004	2	Bosutinib	170466788&384568475	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3&-1.1	-117.2371447682&-103.601675612&-98.4431908016	Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1.OC	Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1.OC&Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1
NCGC00167746-09	Clc1c(OC)cc(OC)c(NC(=O)Nc2noc(C)c2)c1		Inactive	Nicotinic alpha7 Positive Allosteric Modulators		1	PNU-120596	384568333	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	27.5173876951	Clc1c(OC)cc(OC)c(NC(=O)Nc2noc(C)c2)c1	Clc1c(OC)cc(OC)c(NC(=O)Nc2noc(C)c2)c1
NCGC00091120-13	Clc1c(OC)cc(OC)c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc12	4.9000001	Active	Tubulin Beta Chain Inhibitor&Tubulin beta chain Inhibitor	0.0	1	Griseofulvin	170465739	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-37.979355432&-55.7440614155	Clc1c(OC)cc(OC)c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc12	Clc1c(OC)cc(OC)c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc12
NCGC00014650-04	Clc1c(OC)cc2cc1N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@@H]1[C@H](C)[C@H]1OC(=O)N[C@@](O)([C@H](OC)/C=C/C=C(\C)/C2)C1	4.3499999	Inactive	Tubulin polymerization Inhibitor	0.0	1	Ansamitocin P3	384567792	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-9.869812584	Clc1c(OC)cc2cc1N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@@H]1[C@H](C)[C@H]1OC(=O)N[C@@](O)([C@H](OC)/C=C/C=C(\C)/C2)C1	Clc1c(OC)cc2cc1N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@@H]1[C@H](C)[C@H]1OC(=O)N[C@@](O)([C@H](OC)/C=C/C=C(\C)/C2)C1
NCGC00386241-01	Clc1c(OC)ccc(CNc2c(C(=O)NCc3ncccn3)cnc(N3[C@H](CO)CCC3)n2)c1	4.4000001	Active	Phosphodiesterase 5a Inhibitor	0.0	1	Avanafil	405558527	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.67440354	Clc1c(OC)ccc(CNc2c(C(=O)NCc3ncccn3)cnc(N3[C@H](CO)CCC3)n2)c1	Clc1c(OC)ccc(CNc2c(C(=O)NCc3ncccn3)cnc(N3[C@H](CO)CCC3)n2)c1
NCGC00378919-01	Clc1c(OCC(=O)Nc2ccc(CC(=O)N3[C@]4(C(=O)N5[C@@H](C(=O)N)CCS[C@@H]5C4)CCC3)cc2)ccc(Cl)c1	4.5999999	Active	Myd88 Dimerization Inhibitor	0.0	1	ST-2825	363678276	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-108.4702291561	Clc1c(OCC(=O)Nc2ccc(CC(=O)N3[C@]4(C(=O)N5[C@@H](C(=O)N)CCS[C@@H]5C4)CCC3)cc2)ccc(Cl)c1	Clc1c(OCC(=O)Nc2ccc(CC(=O)N3[C@]4(C(=O)N5[C@@H](C(=O)N)CCS[C@@H]5C4)CCC3)cc2)ccc(Cl)c1
NCGC00263212-05	Clc1c(OCC(=O)OC)c(OCC)cc(/C=C\2/C(=O)N(c3ccccc3)N=C/2C)c1		Inactive	MDM4 (MDMX) Inhibitor		1	SJ-172550	384568669	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.28201992	Clc1c(OCC(=O)OC)c(OCC)cc(/C=C\2/C(=O)N(c3ccccc3)N=C/2C)c1	Clc1c(OCC(=O)OC)c(OCC)cc(/C=C\2/C(=O)N(c3ccccc3)N=C/2C)c1
NCGC00249915-01	Clc1c(OCC(O)CNC(C)(C)C)cc(C)cc1	4.7249999	Active	Beta-3 Adrenergic Receptor Antagonist&Beta-3 adrenergic receptor Antagonist	0.0	1	Bupranolol	170465802	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-55.8457391817&-44.2933356912	Clc1c(OCC(O)CNC(C)(C)C)cc(C)cc1	Clc1c(OCC(O)CNC(C)(C)C)cc(C)cc1
NCGC00159507-02	Clc1c(OCC=C)ccc(CC(=O)O)c1		Inactive	Cyclooxygenase-2 Inhibitor		1	Alclofenac	144205279	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(OCC=C)ccc(CC(=O)O)c1	Clc1c(OCC=C)ccc(CC(=O)O)c1
NCGC00510750-02	Clc1c(OCc2c3oc(-c4ccccc4)nc3cc(N)c2)c(Cl)cc(C[C@H](N)C(=O)O)c1		Inactive	LAT1 Inhibitor		1	JPH203	384569490	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	27.094894208	Clc1c(OCc2c3oc(-c4ccccc4)nc3cc(N)c2)c(Cl)cc(C[C@H](N)C(=O)O)c1	Clc1c(OCc2c3oc(-c4ccccc4)nc3cc(N)c2)c(Cl)cc(C[C@H](N)C(=O)O)c1
NCGC00167507-13	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(-c2oc(CNCCS(=O)(=O)C)cc2)cc3)c1	4.4000001	Active	EGFR Inhibitor	0.0	1	Lapatinib	384568319	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-71.0945850239	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(-c2oc(CNCCS(=O)(=O)C)cc2)cc3)c1	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(-c2oc(CNCCS(=O)(=O)C)cc2)cc3)c1
NCGC00346478-06	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)c1		Inactive	HER2/4 Inhibitor		1	AST-1306	384568792	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.520686324	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)c1	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)c1
NCGC00370832-01	Clc1c(OCc2ccccc2)ccc(Nc2c(/C=N/OCCN3CCOCC3)c(N)ncn2)c1	4.9000001	Active	EGFR Inhibitor	0.0	1	JNJ-28871063 hydrochloride	377020311	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-92.0496612734	Clc1c(OCc2ccccc2)ccc(Nc2c(/C=N/OCCN3CCOCC3)c(N)ncn2)c1	Clc1c(OCc2ccccc2)ccc(Nc2c(/C=N/OCCN3CCOCC3)c(N)ncn2)c1
NCGC00241101-09&NCGC00241101-10	Clc1c(OCc2ncccc2)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1	5.32500005	Active	EGFR Inhibitor	0.5499996999999999	2	Neratinib	405558751&384568471	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-1.1	-77.4743909971&-88.0708521427	Clc1c(OCc2ncccc2)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1	Clc1c(OCc2ncccc2)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1
NCGC00346724-02	Clc1c(OCc2sccn2)ccc(Nc2ncnc3c2cc(NC=2OC[C@@H](C)N=2)cc3)c1	4.4000001	Active	EGFR Inhibitor	0.0	1	Varlitinib tosylate	363677537	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-92.9646882119	Clc1c(OCc2sccn2)ccc(Nc2ncnc3c2cc(NC=2OC[C@@H](C)N=2)cc3)c1	Clc1c(OCc2sccn2)ccc(Nc2ncnc3c2cc(NC=2OC[C@@H](C)N=2)cc3)c1
NCGC00159417-05	Clc1c(Oc2c(O)cc(Cl)cc2)ccc(Cl)c1	4.8000002	Active	Bacterial Enoyl-[acyl-carrier-protein] Reductase Binding Agent&Bacterial enoyl-[acyl-carrier-protein] reductase Binding Agent	0.0	1	Triclosan	170464936	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.1	-46.089778012&-106.1439455217	Clc1c(Oc2c(O)cc(Cl)cc2)ccc(Cl)c1	Clc1c(Oc2c(O)cc(Cl)cc2)ccc(Cl)c1
NCGC00346699-02	Clc1c(Oc2cc(C(F)(F)F)ccc2)ccc(Nc2ncnc3c2n(CCNC(=O)CC(O)(C)C)cc3)c1	4.5	Active	EGFR Inhibitor	0.0	1	TAK-285	384568919	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-70.0067226002	Clc1c(Oc2cc(C(F)(F)F)ccc2)ccc(Nc2ncnc3c2n(CCNC(=O)CC(O)(C)C)cc3)c1	Clc1c(Oc2cc(C(F)(F)F)ccc2)ccc(Nc2ncnc3c2n(CCNC(=O)CC(O)(C)C)cc3)c1
NCGC00263144-09	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	4.5	Active	EGFR Inhibitor	0.0	1	WZ-4002	384568619	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-116.6594884559	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1
NCGC00346496-05	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1	5.5	Active	EGFR Inhibitor	0.0	1	WZ-3146	384568802	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-89.3528478049	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1
NCGC00386309-03	Clc1c(Oc2cc(NC(=O)CC)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	4.4000001	Active	NUAK kinase Inhibitor	0.0	1	WZ-4003	384569122	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-88.2081396639	Clc1c(Oc2cc(NC(=O)CC)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	Clc1c(Oc2cc(NC(=O)CC)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1
NCGC00181340-02	Clc1c(S(=O)(=O)N)cc(-c2n[nH]nn2)c(NCc2sccc2)c1		Inactive			1	Azosemide	170465933	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.5592670359&0.0	Clc1c(S(=O)(=O)N)cc(-c2n[nH]nn2)c(NCc2sccc2)c1	Clc1c(S(=O)(=O)N)cc(-c2n[nH]nn2)c(NCc2sccc2)c1
NCGC00018172-09&NCGC00018172-18	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C(C)Cc3c2cccc3)cc1		Inactive	Carbonic Anhydrase Type Vii Inhibitor&Carbonic Anhydrase Type VII Inhibitor&Carbonic Anhydrase Type VII Inhibitor		2	Indapamide	170465366&384567994	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C(C)Cc3c2cccc3)cc1	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C(C)Cc3c2cccc3)cc1
NCGC00274275-01	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C[C@@H]3[C@@H](C4C[C@@H]3CC4)C2)cc1		Inactive	Solute Carrier Family 12 Member 2 Inhibitor&Solute carrier family 12 member 2 Inhibitor		1	Tripamide	170466047	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.009242684&-23.5545772079	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C[C@@H]3[C@@H](C4C[C@@H]3CC4)C2)cc1	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C[C@@H]3[C@@H](C4C[C@@H]3CC4)C2)cc1
NCGC00016527-06	Clc1c(S(=O)(=O)N)cc(C(=O)NN2[C@@H](C)CCC[C@H]2C)cc1	4.4000001	Active		0.0	1	Clopamine	405559024	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.0971260879	Clc1c(S(=O)(=O)N)cc(C(=O)NN2[C@@H](C)CCC[C@H]2C)cc1	Clc1c(S(=O)(=O)N)cc(C(=O)NN2[C@@H](C)CCC[C@H]2C)cc1
NCGC00182543-02	Clc1c(S(=O)(=O)N)cc(C(=O)Nc2c(C)cccc2C)c(O)c1		Inactive	Renal Sodium Excretion Activator&renal sodium excretion Activator		1	Xipamide	170466623	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.914473796&0.0	Clc1c(S(=O)(=O)N)cc(C(=O)Nc2c(C)cccc2C)c(O)c1	Clc1c(S(=O)(=O)N)cc(C(=O)Nc2c(C)cccc2C)c(O)c1
NCGC00016241-10	Clc1c(S(=O)(=O)N)cc(C(=O)O)c(NCc2occc2)c1	4.5999999	Active	Loop Diuretics	0.0	1	Furosemide	170464879	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.0990956407	Clc1c(S(=O)(=O)N)cc(C(=O)O)c(NCc2occc2)c1	Clc1c(S(=O)(=O)N)cc(C(=O)O)c(NCc2occc2)c1
NCGC00094616-07	Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1		Inactive	Renal Sodium Excretion Activator&renal sodium excretion Activator		1	Chlorthalidone	170464745	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1	Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1
NCGC00183860-01	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N(CC2(C)OCCC2)C)cc1		Inactive	Carbonic Anhydrase Inhibitor&Carbonic anhydrase Inhibitor		1	Mefruside	144206878	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.615529976&-18.2422554081	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N(CC2(C)OCCC2)C)cc1	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N(CC2(C)OCCC2)C)cc1
NCGC00160444-02	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1		Inactive	Carbonic Anhydrase Inhibitor&Carbonic anhydrase Inhibitor		1	Clofenamide	170466058	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.0307355079&0.0	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1
NCGC00253608-01	Clc1c(S(=O)(=O)N)cc2C(=O)N(C3CCCCC3)Cc2c1	4.4499998	Active		0.0	1	Chlorexolone	170466039	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.8496824032	Clc1c(S(=O)(=O)N)cc2C(=O)N(C3CCCCC3)Cc2c1	Clc1c(S(=O)(=O)N)cc2C(=O)N(C3CCCCC3)Cc2c1
NCGC00093985-11&NCGC00093985-19	Clc1c(S(=O)(=O)N)cc2C(=O)N(c3c(C)cccc3)C(C)Nc2c1	4.5500002	Inactive	Carbonic Anhydrase Type VII Inhibitor&Carbonic Anhydrase 7 Inhibitor&Carbonic Anhydrase Type VII Inhibitor	0.0	2	Metolazone	170464665&384568122	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	-13.2831415199&-35.26034038&-3.0850492159	Clc1c(S(=O)(=O)N)cc2C(=O)N(c3c(C)cccc3)C(C)Nc2c1	Clc1c(S(=O)(=O)N)cc2C(=O)N(c3c(C)cccc3)C(C)Nc2c1
NCGC00179351-03	Clc1c(S(=O)(=O)N)cc2C(=O)NC(CC)Nc2c1	4.9499998	Active	Thiazide-sensitive Sodium-chloride Cotransporter Inhibitor	0.0	1	Quinethazone	170465167	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-38.6072284392	Clc1c(S(=O)(=O)N)cc2C(=O)NC(CC)Nc2c1	Clc1c(S(=O)(=O)N)cc2C(=O)NC(CC)Nc2c1
NCGC00182076-03	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)N(C)C(CSCC(F)(F)F)Nc2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor&Thiazide-sensitive Sodium-chloride Cotransporter Inhibitor		1	Polythiazide	170465068	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.050891484&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)N(C)C(CSCC(F)(F)F)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)N(C)C(CSCC(F)(F)F)Nc2c1
NCGC00015288-09	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(C3C4C=CC(C3)C4)Nc2c1		Inactive	renal sodium ion absorption Inhibitor&Renal Sodium Ion Absorption Inhibitor		1	Cyclothiazide	170465274	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(C3C4C=CC(C3)C4)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(C3C4C=CC(C3)C4)Nc2c1
NCGC00160540-03	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC)Nc2c1		Inactive			1	Ethiazide	170465925	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC)Nc2c1
NCGC00179312-03	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC3CCCC3)Nc2c1		Inactive	Solute Carrier Family 12 Member 3 Inhibitor&Solute carrier family 12 member 3 Inhibitor		1	Cyclopenthiazide	170466046	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	32.9390726356&15.124203556	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC3CCCC3)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC3CCCC3)Nc2c1
NCGC00016347-07	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CSCc3ccccc3)=Nc2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor&Thiazide-sensitive Sodium-chloride Cotransporter Inhibitor		1	Benzthiazide	170465246	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.893745956&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CSCc3ccccc3)=Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CSCc3ccccc3)=Nc2c1
NCGC00014617-01	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(Cc3ccccc3)Nc2c1	4.4000001	Active		0.0	1	Benzylhydrochlorothiazide	144203604	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.401804168	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(Cc3ccccc3)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(Cc3ccccc3)Nc2c1
NCGC00015242-13&NCGC00015242-16	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC=Nc2c1		Inactive	Hypertension treatment&Hypertension Treatment&Hypertension treatment		2	Chlorothiazide	170465303&384567829	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-17.5111253479&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC=Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC=Nc2c1
NCGC00250409-02	Clc1c(S(=O)(=O)N[C@H](C(=O)N2CCN(C(=O)[C@@H](NC(=O)c3sc4c(c3)cccc4)CC(C)C)CC2)CO)ccc(Cl)c1	4.4000001	Active	TRPV4 Agonist	0.0	1	GSK-1016790A	384568557	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-117.1937499899	Clc1c(S(=O)(=O)N[C@H](C(=O)N2CCN(C(=O)[C@@H](NC(=O)c3sc4c(c3)cccc4)CC(C)C)CC2)CO)ccc(Cl)c1	Clc1c(S(=O)(=O)N[C@H](C(=O)N2CCN(C(=O)[C@@H](NC(=O)c3sc4c(c3)cccc4)CC(C)C)CC2)CO)ccc(Cl)c1
NCGC00508855-01	Clc1c(S(=O)(=O)[C@@H]2CNCCC2)c(O)c(NC(=O)Nc2c(C)c(F)ccc2)cc1		Inactive	Chemokine CXCR2 (IL-8 beta Receptor) Antagonist		1	Danirixin	384569363	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(S(=O)(=O)[C@@H]2CNCCC2)c(O)c(NC(=O)Nc2c(C)c(F)ccc2)cc1	Clc1c(S(=O)(=O)[C@@H]2CNCCC2)c(O)c(NC(=O)Nc2c(C)c(F)ccc2)cc1
NCGC00179596-03&NCGC00179596-11	Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1	4.54999995	Active	Antifungal Agent&Anti-fungal&Antifungal Agent	0.29999969999999987	2	Butoconazole nitrate	170464901&384568378	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4&-3.0	-106.5812569348&-35.9377457743&-106.7238954194	Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1.O=[N+](O)[O-]	Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1.O=[N+](O)[O-]&Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1
NCGC00163329-03&NCGC00163329-11	Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1		Inactive	P2y12 (p2t) Antagonists&P2Y12 (P2T) Antagonist&P2Y12 (P2T) Antagonist		2	Clopidogrel bisulfate	170465231&384568233	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&11.987461632	Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1.S(=O)(=O)(O)O	Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1.S(=O)(=O)(O)O&Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1
NCGC00384190-03	Clc1c([C@@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F	4.6750002	Active	Hgfr (met; C-met) Inhibitor&HGFR (MET; c-Met) Inhibitor	0.0	1	(S)-Crizotinib	405558812	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-65.673274218&-88.0207271698	Clc1c([C@@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F	Clc1c([C@@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F
NCGC00509996-01	Clc1c([C@@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Vadadustat	384569403	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.8353223279	Clc1c([C@@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1	Clc1c([C@@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1
NCGC00016912-06	Clc1c([C@@]2(Cn3ncnc3)O[C@H](COc3ccc(N4CCN(C(C)C)CC4)cc3)CO2)ccc(Cl)c1	4.8499999	Active		0.0	1	Terconazole	405558493	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-107.9513348278&-87.7748378528	Clc1c([C@@]2(Cn3ncnc3)O[C@H](COc3ccc(N4CCN(C(C)C)CC4)cc3)CO2)ccc(Cl)c1	Clc1c([C@@]2(Cn3ncnc3)O[C@H](COc3ccc(N4CCN(C(C)C)CC4)cc3)CO2)ccc(Cl)c1
NCGC00476170-03	Clc1c([C@H](N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1	4.4000001	Active	IDH1 Inhibitor	0.0	1	Ivosidenib	384569240	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.4209205479	Clc1c([C@H](N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1	Clc1c([C@H](N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1
NCGC00510267-01	Clc1c([C@H](OC)C2COC2)cc(Cl)c2c1C(=O)N(CC=1C(=O)NC(C)=CC=1OC)CC2		Inactive	EZH2 Inhibitor		1	PF-06821497	384569424	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c([C@H](OC)C2COC2)cc(Cl)c2c1C(=O)N(CC=1C(=O)NC(C)=CC=1OC)CC2	Clc1c([C@H](OC)C2COC2)cc(Cl)c2c1C(=O)N(CC=1C(=O)NC(C)=CC=1OC)CC2
NCGC00250400-05	Clc1c([C@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F	4.9499998	Active	HGFR Inhibitor	0.0	1	Crizotinib	384568549	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-106.2669596715	Clc1c([C@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F	Clc1c([C@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F
NCGC00510479-01	Clc1c([C@H](Oc2c(N)nnc(C(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)c2)C)c(Cl)ccc1F	4.9000001	Active	ALK Inhibitor	0.0	1	Ensartinib	384569442	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-106.6869394979	Clc1c([C@H](Oc2c(N)nnc(C(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)c2)C)c(Cl)ccc1F	Clc1c([C@H](Oc2c(N)nnc(C(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)c2)C)c(Cl)ccc1F
NCGC00346459-07	Clc1c([C@H](Oc2cc3c(/C=C/c4cn(CCO)nc4)n[nH]c3cc2)C)c(Cl)cnc1	5.0500002	Inactive	FGFR Inhibitor	0.0	1	LY-2874455	384568783	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-33.9112716135	Clc1c([C@H](Oc2cc3c(/C=C/c4cn(CCO)nc4)n[nH]c3cc2)C)c(Cl)cnc1	Clc1c([C@H](Oc2cc3c(/C=C/c4cn(CCO)nc4)n[nH]c3cc2)C)c(Cl)cnc1
NCGC00510002-01	Clc1c([C@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1		Inactive	Integrin Receptor Antagonist		1	GLPG0187	384569406	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c([C@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1	Clc1c([C@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1
NCGC00182704-02	Clc1c([C@H]2S/C(=C(\C#N)/n3cncc3)/SC2)ccc(Cl)c1	4.4499998	Active	Lanosterol 14-alpha Demethylase Inhibitor&Lanosterol 14-alpha demethylase Inhibitor	0.0	1	Luliconazole	144206804	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-59.1372949696&-85.1878931028	Clc1c([C@H]2S/C(=C(\C#N)/n3cncc3)/SC2)ccc(Cl)c1	Clc1c([C@H]2S/C(=C(\C#N)/n3cncc3)/SC2)ccc(Cl)c1
NCGC00025000-14	Clc1c([C@]2(Cn3cncc3)O[C@@H](COc3ccc(N4CCN(C(=O)C)CC4)cc3)CO2)ccc(Cl)c1	4.4499998	Active	Aromatase Inhibitor	0.0	1	Ketoconazole	405559066	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-105.9280400807&-111.894058872	Clc1c([C@]2(Cn3cncc3)O[C@@H](COc3ccc(N4CCN(C(=O)C)CC4)cc3)CO2)ccc(Cl)c1	Clc1c([C@]2(Cn3cncc3)O[C@@H](COc3ccc(N4CCN(C(=O)C)CC4)cc3)CO2)ccc(Cl)c1
NCGC00274068-07	Clc1c([C@]2(Cn3ncnc3)O[C@@H](COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(CC)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1		Inactive	cytochrome Inhibitor		1	Itraconazole	363677313	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c([C@]2(Cn3ncnc3)O[C@@H](COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(CC)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1	Clc1c([C@]2(Cn3ncnc3)O[C@@H](COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(CC)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1
NCGC00509912-01	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(N[C@H]3[C@@H](NC(=O)C=C)CCOC3)nc2)cc1	4.75	Active	FGFR4 Inhibitor	0.0	1	BLU-554	384569378	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-51.3717221032	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(N[C@H]3[C@@H](NC(=O)C=C)CCOC3)nc2)cc1	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(N[C@H]3[C@@H](NC(=O)C=C)CCOC3)nc2)cc1
NCGC00480785-05	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(Nc3c(NC(=O)C=C)cccc3C)nc2)cc1	4.0	Inactive	FGFR 4 Inhibitor	0.0	1	BLU-9931	377020469	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-21.187248356	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(Nc3c(NC(=O)C=C)cccc3C)nc2)cc1	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(Nc3c(NC(=O)C=C)cccc3C)nc2)cc1
NCGC00345830-02	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(C(=O)O)ccc3)ncc2C=1		Inactive	cSRC Inhibitor		1	PD-173955 Analogue 1	363677374	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(C(=O)O)ccc3)ncc2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(C(=O)O)ccc3)ncc2C=1
NCGC00345829-03	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(SC)ccc3)ncc2C=1	8.0500002	Inactive	cSRC Inhibitor	0.0	1	PD-173955	377020285	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	21.3199215481	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(SC)ccc3)ncc2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(SC)ccc3)ncc2C=1
NCGC00242490-05	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3ccc(OCCN(CC)CC)cc3)ncc2C=1	5.5	Active	cSRC Inhibitor	0.0	1	PD-166285	384568496	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.6852183083	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3ccc(OCCN(CC)CC)cc3)ncc2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3ccc(OCCN(CC)CC)cc3)ncc2C=1
NCGC00241111-12	Clc1c(c(Cl)ccc1)C=1C(=O)N=CN2N=C(Sc3c(F)cc(F)cc3)C=CC=12	4.4000001	Active	p38 MAPK Inhibitor	0.0	1	VX-745	377020233	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-71.04411534	Clc1c(c(Cl)ccc1)C=1C(=O)N=CN2N=C(Sc3c(F)cc(F)cc3)C=CC=12	Clc1c(c(Cl)ccc1)C=1C(=O)N=CN2N=C(Sc3c(F)cc(F)cc3)C=CC=12
NCGC00531794-01	Clc1c(n(-c2ccc(S(=O)(=O)N)cc2)cn1)-c1cc(F)c(OC)cc1	5.0500002	Active		0.0	1	Cimicoxib	405559129	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-39.9346476626	Clc1c(n(-c2ccc(S(=O)(=O)N)cc2)cn1)-c1cc(F)c(OC)cc1	Clc1c(n(-c2ccc(S(=O)(=O)N)cc2)cn1)-c1cc(F)c(OC)cc1
NCGC00017134-08	Clc1c2C(=C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(=O)N)C(=O)[C@]4(O)C(O)=C3C(=O)c2c(O)cc1	4.5999999	Active		0.0	1	Meclocycline sulfosalicylate	405559138	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-84.8357326782&-49.708203696	Clc1c2C(=C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(=O)N)C(=O)[C@]4(O)C(O)=C3C(=O)c2c(O)cc1.S(=O)(=O)(O)c1cc(C(=O)O)c(O)cc1	Clc1c2C(=C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(=O)N)C(=O)[C@]4(O)C(O)=C3C(=O)c2c(O)cc1.S(=O)(=O)(O)c1cc(C(=O)O)c(O)cc1
NCGC00485481-02	Clc1c2C(=O)N(c3cc(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)ccc3)Cc2ccc1	4.6500001	Active	Bradykinin B1 Receptor Antagonist	0.0	1	ELN-441958	384569275	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-93.8439138051	Clc1c2C(=O)N(c3cc(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)ccc3)Cc2ccc1	Clc1c2C(=O)N(c3cc(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)ccc3)Cc2ccc1
NCGC00387848-03	Clc1c2C(=O)N(c3ccccc3)C(C(Nc3ncnc4nc[nH]c34)C)=Cc2ccc1		Inactive	PI3-kinase p110-gamma subunit Inhibitor		1	IPI-145	363680698	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.8130995188	Clc1c2C(=O)N(c3ccccc3)C(C(Nc3ncnc4nc[nH]c34)C)=Cc2ccc1	Clc1c2C(=O)N(c3ccccc3)C(C(Nc3ncnc4nc[nH]c34)C)=Cc2ccc1
NCGC00351482-09	Clc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)C)=Cc2ccc1	4.3499999	Active	PI3Kd/g Inhibitor	0.0	1	Duvelisib	384569009	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-34.393134548	Clc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)C)=Cc2ccc1	Clc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)C)=Cc2ccc1
NCGC00510263-01	Clc1c2C(=O)N(c3cnccc3)C([C@@H](Nc3c(C#N)c(N)nc(N)n3)C3CC3)=Nc2c(F)cc1	4.4499998	Active	PI3Kdelta Inhibitor	0.0	1	GS-9901	384569421	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-69.2867447704	Clc1c2C(=O)N(c3cnccc3)C([C@@H](Nc3c(C#N)c(N)nc(N)n3)C3CC3)=Nc2c(F)cc1	Clc1c2C(=O)N(c3cnccc3)C([C@@H](Nc3c(C#N)c(N)nc(N)n3)C3CC3)=Nc2c(F)cc1
NCGC00389453-01	Clc1c2C(O)(C)C3C(C(=O)C4(O)C(O)=C(C(=O)N)C(=O)C(N(C)C)C4C3)=C(O)c2c(O)cc1	4.5500002	Active	Translation Inhibitor&translation Inhibitor	0.0	1	Chlortetracycline HCl	405558866	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-43.1745387899&-37.215892352	Clc1c2C(O)(C)C3C(C(=O)C4(O)C(O)=C(C(=O)N)C(=O)C(N(C)C)C4C3)=C(O)c2c(O)cc1	Clc1c2C(O)(C)C3C(C(=O)C4(O)C(O)=C(C(=O)N)C(=O)C(N(C)C)C4C3)=C(O)c2c(O)cc1
NCGC00346886-09	Clc1c2C(O)(CC(=O)c3ccc(OC)cc3)C(=O)Nc2c(Cl)cc1	4.4499998	Active	EWS-FLI1 Inhibitor	0.0	1	YK-4-279	363677551	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-51.068124666	Clc1c2C(O)(CC(=O)c3ccc(OC)cc3)C(=O)Nc2c(Cl)cc1	Clc1c2C(O)(CC(=O)c3ccc(OC)cc3)C(=O)Nc2c(Cl)cc1
NCGC00346701-07&NCGC00346701-09	Clc1c2C(O)=C(C(=O)N(CC)c3ccccc3)C(=O)N(C)c2ccc1	5.5999999	Inactive	Brain-derived Neurotrophic Factor Activator&Immunomodulators&Immunomodulators	0.0	2	Laquinimod	405558743&384568921	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	0.0&-25.3304502599&37.4922438763	Clc1c2C(O)=C(C(=O)N(CC)c3ccccc3)C(=O)N(C)c2ccc1	Clc1c2C(O)=C(C(=O)N(CC)c3ccccc3)C(=O)N(C)c2ccc1
NCGC00346519-04	Clc1c2Oc3c(O[C@H]4[C@H](NC(=O)CCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc(cc5)C[C@@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O[C@H]7[C@H](NC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O7)c(c1)cc2)C(=O)N[C@@H](C(=O)O)c1c(c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)c1)-c1c(O)ccc6c1)c(c3)c4)c1cc(O)cc(Oc2c(O)ccc([C@@H](N)C(=O)N5)c2)c1		Inactive	glycopeptide antibiotic		1	Teicoplanin	384568816	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.6948587479	Clc1c2Oc3c(O[C@H]4[C@H](NC(=O)CCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc(cc5)C[C@@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O[C@H]7[C@H](NC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O7)c(c1)cc2)C(=O)N[C@@H](C(=O)O)c1c(c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)c1)-c1c(O)ccc6c1)c(c3)c4)c1cc(O)cc(Oc2c(O)ccc([C@@H](N)C(=O)N5)c2)c1	Clc1c2Oc3c(O[C@H]4[C@H](NC(=O)CCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc(cc5)C[C@@H]5C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O[C@H]7[C@H](NC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O7)c(c1)cc2)C(=O)N[C@@H](C(=O)O)c1c(c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)c1)-c1c(O)ccc6c1)c(c3)c4)c1cc(O)cc(Oc2c(O)ccc([C@@H](N)C(=O)N5)c2)c1
NCGC00162383-04&NCGC00162383-05	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5		Inactive	glycopeptide antibiotic&Bacterial Penicillin Binding Protein Inhibitor&glycopeptide antibiotic		2	Vancomycin hydrochloride	405558582&384568223	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	19.5172759561&26.507818088&7.8509728039	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5
NCGC00162149-07	Clc1c2[C@@H](O)[C@@H]3C(C(=O)c2c(O)cc1)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]1C3		Inactive	Bacterial 70s Ribosome Inhibitor&Bacterial 70S ribosome Inhibitor		1	Demeclocycline hydrochloride	170465205	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1c2[C@@H](O)[C@@H]3C(C(=O)c2c(O)cc1)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]1C3.Cl	Clc1c2[C@@H](O)[C@@H]3C(C(=O)c2c(O)cc1)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]1C3.Cl
NCGC00370731-05	Clc1c2[nH]c(-c3nc(C4CCC(C(=O)O)CC4)n4c3C(N)=NC=C4)cc2ccc1		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	OXA-01	384569035	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.8093276559	Clc1c2[nH]c(-c3nc(C4CCC(C(=O)O)CC4)n4c3C(N)=NC=C4)cc2ccc1	Clc1c2[nH]c(-c3nc(C4CCC(C(=O)O)CC4)n4c3C(N)=NC=C4)cc2ccc1
NCGC00390744-01	Clc1c2[nH]cc(C[C@H]3C(=O)N(C)C(=O)N3)c2ccc1		Inactive	RIP1 Kinase Inhibitor		1	Necrostatin 2	363680980	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c2[nH]cc(C[C@H]3C(=O)N(C)C(=O)N3)c2ccc1	Clc1c2[nH]cc(C[C@H]3C(=O)N(C)C(=O)N3)c2ccc1
NCGC00507893-01	Clc1c2c(c(NC(=N)N)nc1)cc(S(=O)(=O)NC(C(=O)O)(C)C)cc2		Inactive	Urokinase (u-PA) Inhibitor		1	UK-371804	384569356	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.706296288	Clc1c2c(c(NC(=N)N)nc1)cc(S(=O)(=O)NC(C(=O)O)(C)C)cc2	Clc1c2c(c(NC(=N)N)nc1)cc(S(=O)(=O)NC(C(=O)O)(C)C)cc2
NCGC00390261-01	Clc1c2c(c(NS(=O)(=O)c3ccc(S(=O)(=O)N)cc3)ccc2)[nH]c1		Inactive	Carbonic Anhydrase Type I/II/IV/VB/IX Inhibitor		1	Indisulam (E7070)	384569182	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1c2c(c(NS(=O)(=O)c3ccc(S(=O)(=O)N)cc3)ccc2)[nH]c1	Clc1c2c(c(NS(=O)(=O)c3ccc(S(=O)(=O)N)cc3)ccc2)[nH]c1
NCGC00095303-04	Clc1c2c(c(O)cc1)nccc2	5.0500002	Active	Mycobacterium tuberculosis Inhibitor&Mycobacterium Tuberculosis Inhibitor	0.0	1	Cloxyquin	170465523	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-1.4	-91.0572950816&-32.9086128779	Clc1c2c(c(O)cc1)nccc2	Clc1c2c(c(O)cc1)nccc2
NCGC00509999-02	Clc1c2nc(c([C@@H](Nc3ncnc4c3nccc4)C(F)(F)F)cc2ccc1)-c1c[n+]([O-])ccc1	5.5	Active	PI3K delta Inhibitor	0.0	1	Seletalisib	384569405	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-51.2878265348	Clc1c2nc(c([C@@H](Nc3ncnc4c3nccc4)C(F)(F)F)cc2ccc1)-c1c[n+]([O-])ccc1	Clc1c2nc(c([C@@H](Nc3ncnc4c3nccc4)C(F)(F)F)cc2ccc1)-c1c[n+]([O-])ccc1
NCGC00510444-01	Clc1cc(-c2c(N)nc3nc(N)nc(N)c3n2)ccc1		Inactive	CK1 Inhibitor		1	Epiblastin A	384569436	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(-c2c(N)nc3nc(N)nc(N)c3n2)ccc1	Clc1cc(-c2c(N)nc3nc(N)nc(N)c3n2)ccc1
NCGC00345018-01	Clc1cc(-c2c(OC)ccc(Cc3ccc(NC(=O)N)cc3)c2)ccc1	4.4000001	Active	Phosphodiesterase IIII D (PDE4D) Inhibitor	0.0	1	D-159687	174006279	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-58.1425923379	Clc1cc(-c2c(OC)ccc(Cc3ccc(NC(=O)N)cc3)c2)ccc1	Clc1cc(-c2c(OC)ccc(Cc3ccc(NC(=O)N)cc3)c2)ccc1
NCGC00510490-01	Clc1cc(-c2cc(C(=O)NCc3nc(OC)c(OC)cc3)c(-c3ncccc3)nc2)cnc1	4.8499999	Active	Orexin OX-2 Receptor Antagonist	0.0	1	MK-1064	384569452	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-36.8121681239	Clc1cc(-c2cc(C(=O)NCc3nc(OC)c(OC)cc3)c(-c3ncccc3)nc2)cnc1	Clc1cc(-c2cc(C(=O)NCc3nc(OC)c(OC)cc3)c(-c3ncccc3)nc2)cnc1
NCGC00509994-02	Clc1cc(-c2cc(O)c(C(=O)NCC(=O)O)nc2)ccc1		Inactive			1	Vadadustat	384569401	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(-c2cc(O)c(C(=O)NCC(=O)O)nc2)ccc1	Clc1cc(-c2cc(O)c(C(=O)NCC(=O)O)nc2)ccc1
NCGC00350511-01	Clc1cc(-c2ccc(-c3oc(CCCc4nc5ncccc5cc4)nn3)cc2)ccc1		Inactive	GPR91 Inhibitor		1	PRP003-073	384569004	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(-c2ccc(-c3oc(CCCc4nc5ncccc5cc4)nn3)cc2)ccc1	Clc1cc(-c2ccc(-c3oc(CCCc4nc5ncccc5cc4)nn3)cc2)ccc1
NCGC00165898-11	Clc1cc(-c2nc(Nc3ccncc3)c3nccnc3n2)c(F)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	SD-208	384568296	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.598161824	Clc1cc(-c2nc(Nc3ccncc3)c3nccnc3n2)c(F)cc1	Clc1cc(-c2nc(Nc3ccncc3)c3nccnc3n2)c(F)cc1
NCGC00390241-07&NCGC00390241-09	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)OCC)cc3)c2)C(F)(F)F)cc1	4.4000001	Active	5-HT Release Inhibitor	0.0	2	LX1606 (Hippurate)&Telotristat Etiprate (LX 1606 Hippurate)	405559103&384569180	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-99.4057494427&-43.0282613199	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)OCC)cc3)c2)C(F)(F)F)cc1	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)OCC)cc3)c2)C(F)(F)F)cc1
NCGC00384181-05	Clc1cc(/C(=N/NC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)/C)c(O)cc1	4.4000001	Active		0.0	1	SP2509	384569103	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-113.2499538901	Clc1cc(/C(=N/NC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)/C)c(O)cc1	Clc1cc(/C(=N/NC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)/C)c(O)cc1
NCGC00386882-01	Clc1cc(/C=C/C(=O)NCC(=O)N(C)C2CCS(=O)(=O)CC2)ccc1		Inactive	In vivo Inhibitor of KLF5 and EGR1 expression		1	ML264	384569147	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	27.5323016319	Clc1cc(/C=C/C(=O)NCC(=O)N(C)C2CCS(=O)(=O)CC2)ccc1	Clc1cc(/C=C/C(=O)NCC(=O)N(C)C2CCS(=O)(=O)CC2)ccc1
NCGC00015122-11&NCGC00015122-14	Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1		Inactive	Dopamine Transporter (DAT) Inhibitor&Sodium-dependent Dopamine Transporter Inhibitor&Dopamine Transporter (DAT) Inhibitor		2	Bupropion hydrochloride	170464747&363676440	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-30.9352204519&-14.332838416	Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1.Cl	Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1.Cl&Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1
NCGC00024563-11	Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(C)c2c1		Inactive	5-HT3 Receptor Antagonist		1	Azasetron hydrochloride	384568029	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.628353408	Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(C)c2c1	Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(C)c2c1
NCGC00015467-20	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1		Inactive	Sulfonylurea Receptor 2 Modulator&Sulfonylurea receptor 2 Modulator		1	Glybenclamide	170464964	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.5767061456&-22.693540312	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1
NCGC00486932-01	Clc1cc(C(=O)O)c(NC(=O)COCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1		Inactive	PAI Inhibitor		1	TM-5275	384569281	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(C(=O)O)c(NC(=O)COCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1	Clc1cc(C(=O)O)c(NC(=O)COCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
NCGC00249937-01	Clc1cc(C(=O)OC)c(NS(=O)(=O)C(F)(F)F)cc1		Inactive			1	Amidoflumet	170465981	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.73045876&0.0	Clc1cc(C(=O)OC)c(NS(=O)(=O)C(F)(F)F)cc1	Clc1cc(C(=O)OC)c(NS(=O)(=O)C(F)(F)F)cc1
NCGC00181034-04	Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1		Inactive	Cytochrome P450 CYP17A1 Inhibitor		1	Liarozole	384568388	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1	Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1
NCGC00087387-05	Clc1cc(C)c(OCCCC(=O)NO)cc1		Inactive	HDAC Inhibitor		1	Droxinostat	384568077	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	32.6221498479	Clc1cc(C)c(OCCCC(=O)NO)cc1	Clc1cc(C)c(OCCCC(=O)NO)cc1
NCGC00508901-01	Clc1cc(CN(C(=O)[C@]2(C)N(C(=O)c3c4c(sc3)cccc4)CC2)CCCC(=O)O)ccc1		Inactive	Free Fatty Acid Receptor 2 (FFAR2; GPR43) Antagonist		1	GLPG-0974	384569372	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.92931212	Clc1cc(CN(C(=O)[C@]2(C)N(C(=O)c3c4c(sc3)cccc4)CC2)CCCC(=O)O)ccc1	Clc1cc(CN(C(=O)[C@]2(C)N(C(=O)c3c4c(sc3)cccc4)CC2)CCCC(=O)O)ccc1
NCGC00381477-05	Clc1cc(CN2[C@H](C(F)(F)F)CCN3C(=O)C=C(N4[C@H](C)COCC4)N=C23)cnc1	4.4000001	Active	VPS34 Inhibitor	0.0	1	SAR-405	384569098	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-35.743038796	Clc1cc(CN2[C@H](C(F)(F)F)CCN3C(=O)C=C(N4[C@H](C)COCC4)N=C23)cnc1	Clc1cc(CN2[C@H](C(F)(F)F)CCN3C(=O)C=C(N4[C@H](C)COCC4)N=C23)cnc1
NCGC00091325-09	Clc1cc(Cc2c(O)ccc(Cl)c2)c(O)cc1	4.6750002	Active	Indoleamine 2,3-dioxygenase Inhibitor	0.0	1	Dichlorophen	170465475	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-99.5766642713&-104.4390184648	Clc1cc(Cc2c(O)ccc(Cl)c2)c(O)cc1	Clc1cc(Cc2c(O)ccc(Cl)c2)c(O)cc1
NCGC00091532-06	Clc1cc(Cc2ccccc2)c(O)cc1		Inactive			1	Clorophene	170465725	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.102958468&-29.82337406	Clc1cc(Cc2ccccc2)c(O)cc1	Clc1cc(Cc2ccccc2)c(O)cc1
NCGC00390731-01	Clc1cc(Cl)cc(-c2oc3c(n2)ccc(C(=O)O)c3)c1	4.4000001	Active	Transthyretin Modulator	0.0	1	Tafamidis	405558810	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-106.5534988134	Clc1cc(Cl)cc(-c2oc3c(n2)ccc(C(=O)O)c3)c1	Clc1cc(Cl)cc(-c2oc3c(n2)ccc(C(=O)O)c3)c1
NCGC00509862-02	Clc1cc(Cl)cc(C2(C(F)(F)F)ON=C(c3cc(C)c(C(=O)NCC(=O)NCC(F)(F)F)cc3)C2)c1	4.4000001	Active		0.0	1	Fluralaner	405558651	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-49.382456052&-91.0236171959	Clc1cc(Cl)cc(C2(C(F)(F)F)ON=C(c3cc(C)c(C(=O)NCC(=O)NCC(F)(F)F)cc3)C2)c1	Clc1cc(Cl)cc(C2(C(F)(F)F)ON=C(c3cc(C)c(C(=O)NCC(=O)NCC(F)(F)F)cc3)C2)c1
NCGC00263194-02	Clc1cc(Cl)cc(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)c1	5.4499998	Active	GSK-3 Inhibitor	0.0	1	SB-216763	384568658	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-34.67749672	Clc1cc(Cl)cc(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)c1	Clc1cc(Cl)cc(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)c1
NCGC00241342-03	Clc1cc(Cl)cc(CNc2c(-c3cc4OCOc4cc3)cncn2)c1	5.4499998	Active	Clk Inhibitor	0.0	1	KUC107550N	377020353	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-49.0291738128	Clc1cc(Cl)cc(CNc2c(-c3cc4OCOc4cc3)cncn2)c1	Clc1cc(Cl)cc(CNc2c(-c3cc4OCOc4cc3)cncn2)c1
NCGC00346939-07	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3cc4OC(=O)Nc4cc3)CC2)c1		Inactive	Phosphodiesterase II (ENPP2; Autotaxin) Inhibitor		1	PF-8380	384568973	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3cc4OC(=O)Nc4cc3)CC2)c1	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3cc4OC(=O)Nc4cc3)CC2)c1
NCGC00521067-01	Clc1cc(Cl)cc(N2C(=O)N(C)[C@]3([C@H](c4ccc(C#N)cc4)CN(Cc4scc(C(=O)O)c4)C3)C2=O)c1	4.4000001	Active	ICAM-1 Inhibitor	0.0	1	BMS-587101	384569504	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-60.6254599079	Clc1cc(Cl)cc(N2C(=O)N(C)[C@]3([C@H](c4ccc(C#N)cc4)CN(Cc4scc(C(=O)O)c4)C3)C2=O)c1	Clc1cc(Cl)cc(N2C(=O)N(C)[C@]3([C@H](c4ccc(C#N)cc4)CN(Cc4scc(C(=O)O)c4)C3)C2=O)c1
NCGC00420895-01	Clc1cc(Cl)cc(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)c1	4.4000001	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	PU-WS-13	384569227	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-44.1954035159	Clc1cc(Cl)cc(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)c1	Clc1cc(Cl)cc(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)c1
NCGC00345461-06	Clc1cc(F)c(Cc2c(C)nc3C(CN4CCOCC4)=CC(Nc4[nH]nc(C)c4)=Nn23)cc1	4.9000001	Active	Jak2 Inhibitor	0.0	1	Gandotinib	384568735	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-65.8148533551	Clc1cc(F)c(Cc2c(C)nc3C(CN4CCOCC4)=CC(Nc4[nH]nc(C)c4)=Nn23)cc1	Clc1cc(F)c(Cc2c(C)nc3C(CN4CCOCC4)=CC(Nc4[nH]nc(C)c4)=Nn23)cc1
NCGC00165902-08	Clc1cc(N(S(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5CCN(C)CC5)c(C)[nH]4)/C(=O)Nc3cc2)C)ccc1	4.9000001	Active	HGFR Inhibitor	0.0	1	SU-MI-2	384568297	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-91.3236744544	Clc1cc(N(S(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5CCN(C)CC5)c(C)[nH]4)/C(=O)Nc3cc2)C)ccc1	Clc1cc(N(S(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5CCN(C)CC5)c(C)[nH]4)/C(=O)Nc3cc2)C)ccc1
NCGC00508850-01	Clc1cc(N2C(=O)CN(Cc3n(Cc4ccc(C#N)cc4)cnc3)CC2)ccc1		Inactive	Farnesyltransferase Inhibitor		1	L-778123	384569362	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(N2C(=O)CN(Cc3n(Cc4ccc(C#N)cc4)cnc3)CC2)ccc1	Clc1cc(N2C(=O)CN(Cc3n(Cc4ccc(C#N)cc4)cnc3)CC2)ccc1
NCGC00346805-02	Clc1cc(N2CCN(C(=O)c3n(-c4ccccc4)nc(C)c3)CC2)ccc1	5.5500002	Active	Tubulin polymerization Inhibitor	0.0	1	XRP-44X	363677543	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-66.7005853024	Clc1cc(N2CCN(C(=O)c3n(-c4ccccc4)nc(C)c3)CC2)ccc1	Clc1cc(N2CCN(C(=O)c3n(-c4ccccc4)nc(C)c3)CC2)ccc1
NCGC00165846-04	Clc1cc(N2CCN(CCCN3C(=O)N(CCOc4ccccc4)C(CC)=N3)CC2)ccc1	4.4250002	Active	Serotonin Transporter Antagonist&Serotonin transporter Antagonist	0.0	1	Nefazodone hydrochloride	170465078	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-101.433720416&-123.5665920464	Clc1cc(N2CCN(CCCN3C(=O)N(CCOc4ccccc4)C(CC)=N3)CC2)ccc1.Cl	Clc1cc(N2CCN(CCCN3C(=O)N(CCOc4ccccc4)C(CC)=N3)CC2)ccc1.Cl
NCGC00016035-13	Clc1cc(N2CCN(CCCN3C(=O)N4C(=N3)C=CC=C4)CC2)ccc1		Inactive	alpha2-Adrenoceptor Antagonists&Alpha2-adrenoceptor Antagonists		1	Trazodone hydrochloride	170465234	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.013182576&-21.177668396	Clc1cc(N2CCN(CCCN3C(=O)N4C(=N3)C=CC=C4)CC2)ccc1.Cl	Clc1cc(N2CCN(CCCN3C(=O)N4C(=N3)C=CC=C4)CC2)ccc1.Cl
NCGC00092384-05	Clc1cc(NC(=O)NC=2N(C)CC(=O)N=2)ccc1		Inactive	mgluR5 Antagonist		1	Fenobam	384568110	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(NC(=O)NC=2N(C)CC(=O)N=2)ccc1	Clc1cc(NC(=O)NC=2N(C)CC(=O)N=2)ccc1
NCGC00165873-03	Clc1cc(NC(=O)c2cnccc2)c2[nH]c3c(c2c1)ccnc3		Inactive	IKK beta Inhibitor		1	PS-1145	384568293	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.554347168	Clc1cc(NC(=O)c2cnccc2)c2[nH]c3c(c2c1)ccnc3	Clc1cc(NC(=O)c2cnccc2)c2[nH]c3c(c2c1)ccnc3
NCGC00387841-01	Clc1cc(NCc2sc(C(=O)NC(C(=O)NC3CC3)CC3CCCC3)cc2)c(C)nc1	4.4000001	Active	Protein phosphatase 1D (PP-2Cdelta; WIP1) Allosteric Inhibitor	0.0	1	GSK-2830371	363680692	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-104.9008845043	Clc1cc(NCc2sc(C(=O)NC(C(=O)NC3CC3)CC3CCCC3)cc2)c(C)nc1	Clc1cc(NCc2sc(C(=O)NC(C(=O)NC3CC3)CC3CCCC3)cc2)c(C)nc1
NCGC00378599-01	Clc1cc(NS(=O)(=O)C)c(F)c(-c2c(-c3nc(NC[C@@H](NC(=O)OC)C)ncc3)cn(C(C)C)n2)c1	4.4000001	Active	Raf Kinase Inhibitor B (V600E Mutant)	0.0	1	Encorafenib	384569054	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-89.142384732	Clc1cc(NS(=O)(=O)C)c(F)c(-c2c(-c3nc(NC[C@@H](NC(=O)OC)C)ncc3)cn(C(C)C)n2)c1	Clc1cc(NS(=O)(=O)C)c(F)c(-c2c(-c3nc(NC[C@@H](NC(=O)OC)C)ncc3)cn(C(C)C)n2)c1
NCGC00181760-01	Clc1cc(Nc2c(C(=O)O)cccc2)c(C(=O)O)cc1	4.8499999	Active	Response To Oxidative Stress Modulator&response to oxidative stress Modulator	0.0	1	Lobenzarit sodium	144206494	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-51.5383715863&-38.7514973531	Clc1cc(Nc2c(C(=O)[O-])cccc2)c(C(=O)[O-])cc1.[Na+].[Na+]	Clc1cc(Nc2c(C(=O)[O-])cccc2)c(C(=O)[O-])cc1.[Na+].[Na+]
NCGC00346940-03	Clc1cc(Nc2nc(-c3cc(NCCCO)ncc3)ccn2)ccc1	9.0	Inactive	CDK1/2 Inhibitor	0.0	1	CGP-60474	384568974	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-18.099289736	Clc1cc(Nc2nc(-c3cc(NCCCO)ncc3)ccn2)ccc1	Clc1cc(Nc2nc(-c3cc(NCCCO)ncc3)ccn2)ccc1
NCGC00025219-10	Clc1cc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)ccc1	5.0999999	Active	CDK1/2/3/4/5 Inhibitor	0.0	1	Purvalanol A	377020478	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-95.9355846318	Clc1cc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)ccc1	Clc1cc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)ccc1
NCGC00016017-20	Clc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1		Inactive	EGFR Inhibitor		1	AG-1478	363676471	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	42.893472444	Clc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1	Clc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1
NCGC00249416-01	Clc1cc(OCC(O)CNC(CNc2ccc(C=3C(C)CC(=O)NN=3)cc2)(C)C)c(C#N)cc1	4.4000001	Active	Adrenergic Receptor Beta Antagonist	0.0	1	Oberadilol	144206753	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-69.4718023119	Clc1cc(OCC(O)CNC(CNc2ccc(C=3C(C)CC(=O)NN=3)cc2)(C)C)c(C#N)cc1	Clc1cc(OCC(O)CNC(CNc2ccc(C=3C(C)CC(=O)NN=3)cc2)(C)C)c(C#N)cc1
NCGC00181914-01	Clc1cc(OCC=C)c(C(=O)NCCN(CC)CC)cc1	4.4000001	Active		0.0	1	Alloclamide	144206889	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-44.22121967&-33.673032136	Clc1cc(OCC=C)c(C(=O)NCCN(CC)CC)cc1	Clc1cc(OCC=C)c(C(=O)NCCN(CC)CC)cc1
NCGC00165774-05	Clc1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]2O)ccc1	4.4000001	Active		0.0	1	Cloprostenol (sodium salt)	405558813	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.772398184	Clc1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)[O-])[C@@H](O)C[C@H]2O)ccc1	Clc1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)[O-])[C@@H](O)C[C@H]2O)ccc1
NCGC00370925-02	Clc1cc(OCc2nn(C3CCOCC3)c3ncnc(N)c23)ccc1		Inactive	Casein Kinase 1 Inhibitor		1	PF-4800567	363677938	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.58511784	Clc1cc(OCc2nn(C3CCOCC3)c3ncnc(N)c23)ccc1	Clc1cc(OCc2nn(C3CCOCC3)c3ncnc(N)c23)ccc1
NCGC00387801-02	Clc1cc([C@@H]2[C@H](N([C@@H](C(C)C)CS(=O)(=O)C(C)C)C(=O)[C@](CC(=O)O)(C)C2)c2ccc(Cl)cc2)ccc1		Inactive	MDM2 (hdm2) Inhibitor		1	AMG-232	384569162	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.5630876161	Clc1cc([C@@H]2[C@H](N([C@@H](C(C)C)CS(=O)(=O)C(C)C)C(=O)[C@](CC(=O)O)(C)C2)c2ccc(Cl)cc2)ccc1	Clc1cc([C@@H]2[C@H](N([C@@H](C(C)C)CS(=O)(=O)C(C)C)C(=O)[C@](CC(=O)O)(C)C2)c2ccc(Cl)cc2)ccc1
NCGC00346460-05	Clc1cc([C@H](O)CNC2=C(c3[nH]c4c(c(C)cc(N5CCOCC5)c4)n3)C(=O)NC=C2)ccc1		Inactive	IGF-1R Inhibitor		1	BMS-536924	363677414	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	30.000890689	Clc1cc([C@H](O)CNC2=C(c3[nH]c4c(c(C)cc(N5CCOCC5)c4)n3)C(=O)NC=C2)ccc1	Clc1cc([C@H](O)CNC2=C(c3[nH]c4c(c(C)cc(N5CCOCC5)c4)n3)C(=O)NC=C2)ccc1
NCGC00521070-01	Clc1cc(c(OC)cc1)C=1N(CC(=O)N)C(=S)NC(=O)C=1		Inactive	myeloperoxidase Inhibitor		1	PF-06282999	384569505	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc(c(OC)cc1)C=1N(CC(=O)N)C(=S)NC(=O)C=1	Clc1cc(c(OC)cc1)C=1N(CC(=O)N)C(=S)NC(=O)C=1
NCGC00013683-06	Clc1cc2/C(=C/CCN(C)C)/c3c(Sc2cc1)cccc3	5.0	Active	Serotonin (5-ht) Receptor Antagonist	0.0	1	Chlorprothixene	170465069	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-94.879020781	Clc1cc2/C(=C/CCN(C)C)/c3c(Sc2cc1)cccc3	Clc1cc2/C(=C/CCN(C)C)/c3c(Sc2cc1)cccc3
NCGC00179306-04	Clc1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3	4.5500002	Active	Serotonin 2 (5-ht2) Receptor Antagonist&Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Zuclopenthixol (-)-10-Camphorsulfonic Acid Salt	405558792	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-105.1640447861&-112.9237355081	Clc1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3	Clc1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3
NCGC00522029-01	Clc1cc2/C(=C\CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3		Inactive			1	Zuclopenthixol Decanoate	405558666	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&19.2281413159	Clc1cc2/C(=C\CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3	Clc1cc2/C(=C\CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3
NCGC00346935-09	Clc1cc2/C(=C\c3oc(-c4cc(C(=O)N5CCN(C)CCC5)ccc4)cc3)/C(=O)Nc2cc1	6.0	Active	Pim 1/2/3 Kinase Inhibitor	0.0	1	CX-6258	384568970	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-64.6086912343	Clc1cc2/C(=C\c3oc(-c4cc(C(=O)N5CCN(C)CCC5)ccc4)cc3)/C(=O)Nc2cc1	Clc1cc2/C(=C\c3oc(-c4cc(C(=O)N5CCN(C)CCC5)ccc4)cc3)/C(=O)Nc2cc1
NCGC00021145-11	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Oc2cc1)cccc3	4.6750002	Active	Muscarinic Acetylcholine Receptor M1 Antagonist&Muscarinic acetylcholine receptor M1 Antagonist	0.0	1	Loxapine succinate	170465094	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-68.3840544043&-50.6003645125	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Oc2cc1)cccc3.O=C(O)CCC(=O)O	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Oc2cc1)cccc3.O=C(O)CCC(=O)O
NCGC00160387-04	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Sc2cc1)cccc3	6.1500001	Active	Gaba-a Receptor; Benzodiazepine Site Antagonist	0.0	1	Clothiapine	170465938	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-41.7142709439	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Sc2cc1)cccc3	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Sc2cc1)cccc3
NCGC00015004-13	Clc1cc2C(N3CCNCC3)=Nc3c(Oc2cc1)cccc3		Inactive	5-ht2a Antagonists?&5-HT2A Antagonists?		1	Amoxapine	170465376	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-11.331297456&0.0	Clc1cc2C(N3CCNCC3)=Nc3c(Oc2cc1)cccc3	Clc1cc2C(N3CCNCC3)=Nc3c(Oc2cc1)cccc3
NCGC00486944-01	Clc1cc2C(N[C@@H]3CN(C(=O)NC(C)C)CC3)=Nc3c(N(CC(F)F)c2cc1)ccc(F)c3	5.8499999	Active	p21-Activated Kinase 1 (PAK1) Inhibitor	0.0	1	NVS-PAK1-1	363681470	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-39.8848410743	Clc1cc2C(N[C@@H]3CN(C(=O)NC(C)C)CC3)=Nc3c(N(CC(F)F)c2cc1)ccc(F)c3	Clc1cc2C(N[C@@H]3CN(C(=O)NC(C)C)CC3)=Nc3c(N(CC(F)F)c2cc1)ccc(F)c3
NCGC00346626-05	Clc1cc2C(N[C@H]3C4CCN(C3)CC4)=C(c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1	9.0	Inactive	Chk1 Inhibitor	0.0	1	CHIR-124	384568866	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-19.998786032	Clc1cc2C(N[C@H]3C4CCN(C3)CC4)=C(c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1	Clc1cc2C(N[C@H]3C4CCN(C3)CC4)=C(c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1
NCGC00182081-04	Clc1cc2C(OCCN(C)C)=Cc3c(Sc2cc1)cccc3	4.5999999	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Zotepine	170465934	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-85.991484346&-73.2485882559	Clc1cc2C(OCCN(C)C)=Cc3c(Sc2cc1)cccc3	Clc1cc2C(OCCN(C)C)=Cc3c(Sc2cc1)cccc3
NCGC00346488-03	Clc1cc2C(c3c(F)cccc3F)=NCc3c(nc(Nc4ccc(C(=O)O)cc4)nc3)-c2cc1	5.9499998	Active	Aurora-A Inhibitor	0.0	1	MLN-8054	384568797	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-81.3605823724	Clc1cc2C(c3c(F)cccc3F)=NCc3c(nc(Nc4ccc(C(=O)O)cc4)nc3)-c2cc1	Clc1cc2C(c3c(F)cccc3F)=NCc3c(nc(Nc4ccc(C(=O)O)cc4)nc3)-c2cc1
NCGC00263271-04	Clc1cc2C(c3c(F)cccc3OC)=NCc3c(nc(Nc4cc(OC)c(C(=O)O)cc4)nc3)-c2cc1	4.0500002	Inactive	Aurora-A Inhibitor	0.0	1	Alisertib	384568683	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-20.377536368	Clc1cc2C(c3c(F)cccc3OC)=NCc3c(nc(Nc4cc(OC)c(C(=O)O)cc4)nc3)-c2cc1	Clc1cc2C(c3c(F)cccc3OC)=NCc3c(nc(Nc4cc(OC)c(C(=O)O)cc4)nc3)-c2cc1
NCGC00183004-01	Clc1cc2N(C(=O)c3c(C)cccc3)CC/C(=N\OS(=O)(=O)[O-])/c2cc1		Inactive	renal sodium ion transport Inhibitor&Renal Sodium Ion Transport Inhibitor		1	Alilusem potassium	144206835	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1cc2N(C(=O)c3c(C)cccc3)CC/C(=N\OS(=O)(=O)[O-])/c2cc1.[K+]	Clc1cc2N(C(=O)c3c(C)cccc3)CC/C(=N\OS(=O)(=O)[O-])/c2cc1.[K+]
NCGC00182978-01	Clc1cc2N(CC(=O)N3CCN(CCO)CC3)C(=O)Sc2cc1	4.4000001	Active		0.0	1	Tiaramide hydrochloride	144206772	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.8121093159	Clc1cc2N(CC(=O)N3CCN(CCO)CC3)C(=O)Sc2cc1.Cl	Clc1cc2N(CC(=O)N3CCN(CCO)CC3)C(=O)Sc2cc1.Cl
NCGC00015273-19	Clc1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	4.7249999	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Chlorpromazine	170465371	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-101.3858686372&-70.7907751952	Clc1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	Clc1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3
NCGC00015264-13&NCGC00015264-24	Clc1cc2N(CCCN(C)C)c3c(cccc3)CCc2cc1	4.5625	Active	Serotonin Transporter (sert) Inhibitor&Serotonin Transporter (SERT) Inhibitor&Serotonin Transporter (SERT) Inhibitor	0.024999599999999234	2	Clomipramine hydrochloride	170464702&384567835	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4&-2.1	-98.1980831657&-82.1544222492&-95.4291483392	Clc1cc2N(CCCN(C)C)c3c(cccc3)CCc2cc1	Clc1cc2N(CCCN(C)C)c3c(cccc3)CCc2cc1
NCGC00253595-01	Clc1cc2N(CCCN3CCC(C(=O)N)(N4CCCCC4)CC3)c3c(cccc3)CCc2cc1	4.6999998	Active	Serotonin 2a (5-HT2a) receptor Antagonist&Serotonin 2a (5-ht2a) Receptor Antagonist	0.0	1	Clocapramine	170465785	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-101.1036946419&-100.8296909568	Clc1cc2N(CCCN3CCC(C(=O)N)(N4CCCCC4)CC3)c3c(cccc3)CCc2cc1	Clc1cc2N(CCCN3CCC(C(=O)N)(N4CCCCC4)CC3)c3c(cccc3)CCc2cc1
NCGC00183853-01	Clc1cc2N(CCCN3CCC4(C(=O)NC5N4CCCC5)CC3)c3c(cccc3)CCc2cc1	4.6500001	Active	Dopamine D4 Receptor Antagonist&Dopamine D4 receptor Antagonist	0.0	1	Mosapramine	144206880	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-91.0442858705&-78.7317715287	Clc1cc2N(CCCN3CCC4(C(=O)NC5N4CCCC5)CC3)c3c(cccc3)CCc2cc1	Clc1cc2N(CCCN3CCC4(C(=O)NC5N4CCCC5)CC3)c3c(cccc3)CCc2cc1
NCGC00014648-04	Clc1cc2N(CCCN3CCC4(SCC(=O)N4)CC3)c3c(Sc2cc1)cccc3	4.5250001	Active	Adrenergic Receptor Antagonist&Adrenergic receptor Antagonist	0.0	1	Spiclomazine hydrochloride	405558575	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-109.2112341872&-93.371115924	Clc1cc2N(CCCN3CCC4(SCC(=O)N4)CC3)c3c(Sc2cc1)cccc3	Clc1cc2N(CCCN3CCC4(SCC(=O)N4)CC3)c3c(Sc2cc1)cccc3
NCGC00015856-10	Clc1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	4.6750002	Active	Dopamine D2 Antagonist	0.0	1	Prochlorperazine dimaleate	170464761	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.1	-72.2638420039&-95.8824662518	Clc1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O	Clc1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O
NCGC00015826-13	Clc1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	4.7249999	Active	Muscarinic Acetylcholine Receptor M1 Antagonist&Muscarinic acetylcholine receptor M1 Antagonist	0.0	1	Perphenazine	170464834	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.4	-93.0172738796&-75.1586997415	Clc1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	Clc1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00015254-20&NCGC00015254-30	Clc1cc2N=C(N3CCN(C)CC3)c3c(Nc2cc1)cccc3	4.9250002	Active	Serotonin 2a (5-ht2a) Receptor Antagonist&Dopamine D4 Antagonist&Dopamine D4 Antagonist	0.25	2	Clozapine	170464853&384567833	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4&-1.4	-79.4740418306&-54.2516393444&-62.9114406922	Clc1cc2N=C(N3CCN(C)CC3)c3c(Nc2cc1)cccc3	Clc1cc2N=C(N3CCN(C)CC3)c3c(Nc2cc1)cccc3
NCGC00263174-02	Clc1cc2N=C([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)N(Cc3ccccc3)C(=O)c2cc1	9.0	Inactive	Kinesin-Like Spindle Protein Inhibitor	0.0	1	Ispinesib	384568644	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-22.6352901481	Clc1cc2N=C([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)N(Cc3ccccc3)C(=O)c2cc1	Clc1cc2N=C([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)N(Cc3ccccc3)C(=O)c2cc1
NCGC00014670-17&NCGC00014670-26	Clc1cc2NC(=O)N(C3CCN(CCCN4C(=O)Nc5c4cccc5)CC3)c2cc1	4.67499995	Active	Dopamine Receptor Antagonist	0.5499996999999999	2	Domperidone	170465594&384567793	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-59.4962467587&-36.7360383	Clc1cc2NC(=O)N(C3CCN(CCCN4C(=O)Nc5c4cccc5)CC3)c2cc1	Clc1cc2NC(=O)N(C3CCN(CCCN4C(=O)Nc5c4cccc5)CC3)c2cc1
NCGC00015238-13	Clc1cc2NC(=O)Oc2cc1		Inactive	Intermediate conductance calcium-activated potassium channel protein 4 Activator&Intermediate Conductance Calcium-activated Potassium Channel Protein 4 Activator		1	Chlorzoxazone	170464957	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-26.18476406	Clc1cc2NC(=O)Oc2cc1	Clc1cc2NC(=O)Oc2cc1
NCGC00246187-03	Clc1cc2NC=3C(=C(N=C4C=C(CN5CCCC5)C(=O)C(CN5CCCC5)=C4)c2cc1)NC(OC)=CC=3	4.4000001	Active		0.0	1	PYRONARIDINE TETRAPHOSPHATE	384568510	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-110.2349191936	Clc1cc2NC=3C(=C(N=C4C=C(CN5CCCC5)C(=O)C(CN5CCCC5)=C4)c2cc1)NC(OC)=CC=3	Clc1cc2NC=3C(=C(N=C4C=C(CN5CCCC5)C(=O)C(CN5CCCC5)=C4)c2cc1)NC(OC)=CC=3
NCGC00346571-07	Clc1cc2OC([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)=C(Cc3ccccc3)C(=O)c2cc1	4.3000002	Inactive	Kinesin-Like Spindle Protein Inhibitor	0.0	1	SB-743921	384568845	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-40.7879687124	Clc1cc2OC([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)=C(Cc3ccccc3)C(=O)c2cc1	Clc1cc2OC([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)=C(Cc3ccccc3)C(=O)c2cc1
NCGC00347937-02	Clc1cc2OCC(c3ccc(C)cc3)=Nc2cc1	4.4499998	Active	RARalpha Antagonist	0.0	1	AR-7	384568989	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-60.3396847808	Clc1cc2OCC(c3ccc(C)cc3)=Nc2cc1	Clc1cc2OCC(c3ccc(C)cc3)=Nc2cc1
NCGC00022882-03	Clc1cc2S(=O)(=O)NC(C)=Nc2cc1		Inactive	Sulfonylurea Receptor 1, Kir6.2 Opener&Sulfonylurea receptor 1, Kir6.2 Opener		1	Diazoxide	170465328	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.652287276&0.0	Clc1cc2S(=O)(=O)NC(C)=Nc2cc1	Clc1cc2S(=O)(=O)NC(C)=Nc2cc1
NCGC00188689-09	Clc1cc2[C@@H]3[C@@H](c4c(Oc2cc1)cccc4)CN(C)C3	4.6500001	Active	Dopamine D1/D2 Antagonist	0.0	1	Asenapine maleate	384568450	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-82.59733699	Clc1cc2[C@@H]3[C@@H](c4c(Oc2cc1)cccc4)CN(C)C3	Clc1cc2[C@@H]3[C@@H](c4c(Oc2cc1)cccc4)CN(C)C3
NCGC00263540-04	Clc1cc2[C@H]3[C@H](c4c(Oc2cc1)cccc4)CN(C)C3		Inactive	Dopamine D1/d2 Antagonist&Dopamine D1/D2 Antagonist		1	Asenapine	405558453	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1cc2[C@H]3[C@H](c4c(Oc2cc1)cccc4)CN(C)C3	Clc1cc2[C@H]3[C@H](c4c(Oc2cc1)cccc4)CN(C)C3
NCGC00159337-04&NCGC00271713-05	Clc1cc2[C@](C(F)(F)F)(C#CC3CC3)OC(=O)Nc2cc1	4.48333335	Active	Reverse Transcriptase Inhibitor	0.06666710000000009	2	Efavirenz	170464810&363677307	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4&-3.0&-3.0	-79.006227036&-85.654637786&-100.9730493891&-61.9022183039	Clc1cc2[C@](C(F)(F)F)(C#CC3CC3)OC(=O)Nc2cc1	Clc1cc2[C@](C(F)(F)F)(C#CC3CC3)OC(=O)Nc2cc1
NCGC00015619-13	Clc1cc2c(/C(=C/3\CCN(C(=O)OCC)CC\3)/c3ncccc3CC2)cc1	4.4000001	Active	Histamine H1 Receptor Antagonists	0.0	1	Loratadine	170464867	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-105.3888692454	Clc1cc2c(/C(=C/3\CCN(C(=O)OCC)CC\3)/c3ncccc3CC2)cc1	Clc1cc2c(/C(=C/3\CCN(C(=O)OCC)CC\3)/c3ncccc3CC2)cc1
NCGC00159325-05	Clc1cc2c(/C(=C/3\CCNCC\3)/c3ncccc3CC2)cc1	4.5500002	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Desloratadine	170464781	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-93.7108550372&-62.9568801199	Clc1cc2c(/C(=C/3\CCNCC\3)/c3ncccc3CC2)cc1	Clc1cc2c(/C(=C/3\CCNCC\3)/c3ncccc3CC2)cc1
NCGC00386213-04	Clc1cc2c(C(=C3CCN(Cc4cc(C)cnc4)CC3)c3ncccc3CC2)cc1	4.6500001	Active	Platelet Activating Factor Receptor Antagonist&Platelet activating factor receptor Antagonist	0.0	1	Rupatadine (Fumarate)	405558713	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-72.0452155415&-81.9503998048	Clc1cc2c(C(=C3CCN(Cc4cc(C)cnc4)CC3)c3ncccc3CC2)cc1	Clc1cc2c(C(=C3CCN(Cc4cc(C)cnc4)CC3)c3ncccc3CC2)cc1
NCGC00181782-03	Clc1cc2c(C3CCN(CCN4C(=O)NCC4)CC3)cn(-c3ccc(F)cc3)c2cc1	4.6999998	Active	Serotonin 2c (5-ht2c) Receptor Antagonist&Serotonin 2c (5-HT2c) receptor Antagonist	0.0	1	Sertindole	170465613	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-97.3374330572&-109.022865076	Clc1cc2c(C3CCN(CCN4C(=O)NCC4)CC3)cn(-c3ccc(F)cc3)c2cc1	Clc1cc2c(C3CCN(CCN4C(=O)NCC4)CC3)cn(-c3ccc(F)cc3)c2cc1
NCGC00250389-02	Clc1cc2c(CCOc3ccc(C(=O)O)cc3)c(C)n(C(c3ccccc3)c3ccccc3)c2cc1		Inactive	Phospholipase C Inhibitor		1	CDIBA	384568542	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.1357259356	Clc1cc2c(CCOc3ccc(C(=O)O)cc3)c(C)n(C(c3ccccc3)c3ccccc3)c2cc1	Clc1cc2c(CCOc3ccc(C(=O)O)cc3)c(C)n(C(c3ccccc3)c3ccccc3)c2cc1
NCGC00378691-02	Clc1cc2c(O[C@H]3CN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)[C@H](C(=O)N[C@@]4(C(=O)NS(=O)(=O)C5CC5)[C@H](C=C)C4)C3)ncc(OC)c2cc1	4.4499998	Active	Solute carrier organic anion transporter family member 2B1 Inhibitor	0.0	1	Asunaprevir (BMS-650032)	405558863	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.3	-111.7637658289	Clc1cc2c(O[C@H]3CN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)[C@H](C(=O)N[C@@]4(C(=O)NS(=O)(=O)C5CC5)[C@H](C=C)C4)C3)ncc(OC)c2cc1	Clc1cc2c(O[C@H]3CN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)[C@H](C(=O)N[C@@]4(C(=O)NS(=O)(=O)C5CC5)[C@H](C=C)C4)C3)ncc(OC)c2cc1
NCGC00346646-02	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(C)C)Cc3ccccc3)c2)cc1		Inactive	Glycogen Phosphorylase a Inhibitor		1	CP-91149	363677494	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(C)C)Cc3ccccc3)c2)cc1	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(C)C)Cc3ccccc3)c2)cc1
NCGC00242458-15	Clc1cc2c([nH]c3C(C(=O)N)CCCc23)cc1		Inactive	Histone Deacetylase SIRT1 Inhibitor		1	Selisistat	384568488	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc2c([nH]c3C(C(=O)N)CCCc23)cc1	Clc1cc2c([nH]c3C(C(=O)N)CCCc23)cc1
NCGC00094937-04	Clc1cc2c([nH]c3c2ccc(C(C(=O)O)C)c3)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Carprofen	170464799	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.7290892439&0.0	Clc1cc2c([nH]c3c2ccc(C(C(=O)O)C)c3)cc1	Clc1cc2c([nH]c3c2ccc(C(C(=O)O)C)c3)cc1
NCGC00378617-04	Clc1cc2c(oc3C(=O)NC([C@H]4NCCC4)=Nc23)cc1	5.1500001	Active	Serine/threonine-protein kinase PIM1  Inhibitor	0.0	1	XL 413 hydrochloride	384569057	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.6383549606	Clc1cc2c(oc3C(=O)NC([C@H]4NCCC4)=Nc23)cc1	Clc1cc2c(oc3C(=O)NC([C@H]4NCCC4)=Nc23)cc1
NCGC00164568-04	Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC(=O)O)CC4)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1		Inactive	Cysteinyl leukotriene receptor 1 Antagonist&Cysteinyl Leukotriene Receptor 1 Antagonist		1	Montelukast sodium	170465230	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.667529136&0.0	Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC(=O)[O-])CC4)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1.[Na+]	Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC(=O)[O-])CC4)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1.[Na+]
NCGC00015874-05	Clc1cc2nc3c(c(NC(CCCN(CC)CC)C)c2cc1)cc(OC)cc3	4.4000001	Active	Secretory Phospholipase A2 (sPLA2) Inhibitor	0.0	1	Quinacrine	170466085	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-95.710816512	Clc1cc2nc3c(c(NC(CCCN(CC)CC)C)c2cc1)cc(OC)cc3.Cl.Cl.O.O	Clc1cc2nc3c(c(NC(CCCN(CC)CC)C)c2cc1)cc(OC)cc3.Cl.Cl.O.O
NCGC00242503-02	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)NC4(C(=O)O)C5CC6CC4CC(C5)C6)n3)c2cc1		Inactive	Carboxypeptidase A Inhibitor		1	Meclinertant	384568503	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	10.14881896	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)NC4(C(=O)O)C5CC6CC4CC(C5)C6)n3)c2cc1	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)NC4(C(=O)O)C5CC6CC4CC(C5)C6)n3)c2cc1
NCGC00344515-02	Clc1cc2nccc(N3CCN(CCCN4CCN(c5c6c(ncc5)cc(Cl)cc6)CC4)CC3)c2cc1		Inactive	antimalarial agents		1	Piperaquine	174006179	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	27.3550618699	Clc1cc2nccc(N3CCN(CCCN4CCN(c5c6c(ncc5)cc(Cl)cc6)CC4)CC3)c2cc1	Clc1cc2nccc(N3CCN(CCCN4CCN(c5c6c(ncc5)cc(Cl)cc6)CC4)CC3)c2cc1
NCGC00015256-12&NCGC00015256-17	Clc1cc2nccc(NC(CCCN(CC)CC)C)c2cc1	5.0	Active	antimalarial agents	0.5	2	Chloroquine	170464753&363676447	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-52.2180972802&-48.4614348264	Clc1cc2nccc(NC(CCCN(CC)CC)C)c2cc1.P(=O)(O)(O)O.P(=O)(O)(O)O	Clc1cc2nccc(NC(CCCN(CC)CC)C)c2cc1.P(=O)(O)(O)O.P(=O)(O)(O)O&Clc1cc2nccc(NC(CCCN(CC)CC)C)c2cc1
NCGC00094881-07	Clc1cc2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2cc1	5.3499999	Active		0.0	1	Glafenine hydrochloride	170465943	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-45.5031497434	Clc1cc2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2cc1.Cl	Clc1cc2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2cc1.Cl
NCGC00017063-07	Clc1cc2nccc(Nc3cc(CN(CC)CC)c(O)cc3)c2cc1	5.0	Active	Antimalarial; Histamine N-methyl Transferase Inhibitor	0.0	1	Amodiaquin dihydrochloride dihydrate	405558845	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-97.6747550526	Clc1cc2nccc(Nc3cc(CN(CC)CC)c(O)cc3)c2cc1	Clc1cc2nccc(Nc3cc(CN(CC)CC)c(O)cc3)c2cc1
NCGC00347949-11	Clc1cc2sc(NC(=O)CCc3cc(OC)c(OC)cc3)nc2cc1		Inactive	Wnt Signaling Inhibitor		1	KY-02111	363677729	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cc2sc(NC(=O)CCc3cc(OC)c(OC)cc3)nc2cc1	Clc1cc2sc(NC(=O)CCc3cc(OC)c(OC)cc3)nc2cc1
NCGC00250374-02	Clc1ccc(-c2c(CC(=O)O)n3c(c2-c2ccccc2)CC(C)(C)C3)cc1		Inactive	5-Lipoxygenase Inhibitor		1	Licofelone	363677173	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.432085816	Clc1ccc(-c2c(CC(=O)O)n3c(c2-c2ccccc2)CC(C)(C)C3)cc1	Clc1ccc(-c2c(CC(=O)O)n3c(c2-c2ccccc2)CC(C)(C)C3)cc1
NCGC00183868-02	Clc1ccc(-c2c(CC(=O)O)sc(-c3ccccc3)n2)cc1	4.4000001	Active		0.0	1	Fentiazac	170466003	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.641876356	Clc1ccc(-c2c(CC(=O)O)sc(-c3ccccc3)n2)cc1	Clc1ccc(-c2c(CC(=O)O)sc(-c3ccccc3)n2)cc1
NCGC00253562-10	Clc1ccc(-c2c(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(N[C@@H](CSc6ccccc6)CCN(C)C)cc5)cc4)CC3)cccc2)cc1		Inactive	Bcl-xL Inhibitor		1	ABT-737	384568563	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.431372068	Clc1ccc(-c2c(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(N[C@@H](CSc6ccccc6)CCN(C)C)cc5)cc4)CC3)cccc2)cc1	Clc1ccc(-c2c(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(N[C@@H](CSc6ccccc6)CCN(C)C)cc5)cc4)CC3)cccc2)cc1
NCGC00016256-17&NCGC00016256-20	Clc1ccc(-c2c(N)nc(N)nc2CC)cc1	4.4499998	Active	Dihydrofolate Reductase (dhfr) Inhibitor&Dihydrofolate Reductase (DHFR) Inhibitor&Dihydrofolate Reductase (DHFR) Inhibitor	0.0	2	Pyrimethamine	170464930&384567926	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3&-3.0	-45.1059876642&-97.6972950104&-96.1119469588	Clc1ccc(-c2c(N)nc(N)nc2CC)cc1	Clc1ccc(-c2c(N)nc(N)nc2CC)cc1
NCGC00345832-03	Clc1ccc(-c2c(c(C3CCN(C(=O)CO)CC3)n[nH]2)-c2ncncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SD-06	384568759	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(-c2c(c(C3CCN(C(=O)CO)CC3)n[nH]2)-c2ncncc2)cc1	Clc1ccc(-c2c(c(C3CCN(C(=O)CO)CC3)n[nH]2)-c2ncncc2)cc1
NCGC00253573-01	Clc1ccc(-c2n(-c3ccc(OC)cc3)nc(CCC(=O)N(O)C)c2)cc1	4.6500001	Active	platelet aggregation Inhibitor	0.0	1	Tepoxalin	170466265	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-77.3709123576	Clc1ccc(-c2n(-c3ccc(OC)cc3)nc(CCC(=O)N(O)C)c2)cc1	Clc1ccc(-c2n(-c3ccc(OC)cc3)nc(CCC(=O)N(O)C)c2)cc1
NCGC00092309-06	Clc1ccc(-c2nc(Nc3ccc(O)cc3)sc2)cc1	4.5500002	Active	Sphingosine Kinase Inhibitor	0.0	1	SKI-II	363676558	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-93.742473121	Clc1ccc(-c2nc(Nc3ccc(O)cc3)sc2)cc1	Clc1ccc(-c2nc(Nc3ccc(O)cc3)sc2)cc1
NCGC00346700-13	Clc1ccc(-c2oc(C(=O)Nc3cc(OC)cc(OC)c3)cc2)cc1		Inactive	Nav1.8 (SNS/PN3) Sodium Channel Blocker		1	A-803467	384568920	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.446498716	Clc1ccc(-c2oc(C(=O)Nc3cc(OC)cc(OC)c3)cc2)cc1	Clc1ccc(-c2oc(C(=O)Nc3cc(OC)cc(OC)c3)cc2)cc1
NCGC00510190-02	Clc1ccc(-c2oc(C)c(COc3cc(CN(C(=O)OC)CC(=O)O)ccc3)n2)cc1	4.4000001	Active	PPARalpha Agonist	0.0	1	BMS-687453	384569413	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-69.178994256	Clc1ccc(-c2oc(C)c(COc3cc(CN(C(=O)OC)CC(=O)O)ccc3)n2)cc1	Clc1ccc(-c2oc(C)c(COc3cc(CN(C(=O)OC)CC(=O)O)ccc3)n2)cc1
NCGC00242499-02	Clc1ccc(-c2onc3c2cc(-c2nc(N)ncc2)cc3)cc1	4.4499998	Active	Pim-1 Kinase Inhibitor	0.0	1	Pim 1 Inhibitor 2	384568502	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-82.9479995759	Clc1ccc(-c2onc3c2cc(-c2nc(N)ncc2)cc3)cc1	Clc1ccc(-c2onc3c2cc(-c2nc(N)ncc2)cc3)cc1
NCGC00162399-13	Clc1ccc(/C=C/CN(Cc2c(N(S(=O)(=O)c3ccc(OC)cc3)CCO)cccc2)C)cc1	4.75	Active	CaMKII inhibitor	0.0	1	KN-93	384568224	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-102.8357577403	Clc1ccc(/C=C/CN(Cc2c(N(S(=O)(=O)c3ccc(OC)cc3)CCO)cccc2)C)cc1	Clc1ccc(/C=C/CN(Cc2c(N(S(=O)(=O)c3ccc(OC)cc3)CCO)cccc2)C)cc1
NCGC00181026-02	Clc1ccc(/C=N/NC(N/N=C\c2ccc(Cl)cc2)=N)cc1	5.0	Inactive	Eimeria tenella Inhibitor	0.0	1	Robenidine	170465629	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	60.8310014611	Clc1ccc(/C=N/NC(N/N=C\c2ccc(Cl)cc2)=N)cc1	Clc1ccc(/C=N/NC(N/N=C\c2ccc(Cl)cc2)=N)cc1
NCGC00166397-04	Clc1ccc(C(=O)CN(CCCN2c3c(cccc3)CCc3c2cccc3)C)cc1		Inactive	Norepinephrine Uptake Inhibitor&norepinephrine uptake Inhibitor		1	Lofepramine hydrochloride	170465926	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.547490908	Clc1ccc(C(=O)CN(CCCN2c3c(cccc3)CCc3c2cccc3)C)cc1.Cl	Clc1ccc(C(=O)CN(CCCN2c3c(cccc3)CCc3c2cccc3)C)cc1.Cl
NCGC00027930-07	Clc1ccc(C(=O)NCCN2CCOCC2)cc1		Inactive	Monoamine Oxidase A Inhibitor&Monoamine oxidase A Inhibitor		1	Moclobemide	170465663	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.927906764&-23.77972174	Clc1ccc(C(=O)NCCN2CCOCC2)cc1	Clc1ccc(C(=O)NCCN2CCOCC2)cc1
NCGC00263111-11	Clc1ccc(C(=O)NCCS(=O)(=O)c2ncc(C(F)(F)F)cc2)cc1	4.8000002	Active	PPARdelta Antagonist	0.0	1	GSK-3787	384568597	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-45.6029762143	Clc1ccc(C(=O)NCCS(=O)(=O)c2ncc(C(F)(F)F)cc2)cc1	Clc1ccc(C(=O)NCCS(=O)(=O)c2ncc(C(F)(F)F)cc2)cc1
NCGC00016850-15	Clc1ccc(C(=O)NCCc2ccc(OC(C(=O)O)(C)C)cc2)cc1		Inactive	Peroxisome Proliferator-activated Receptor Gamma Agonist&Peroxisome proliferator-activated receptor gamma Agonist		1	Bezafibrate	170465743	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.657145332&0.0	Clc1ccc(C(=O)NCCc2ccc(OC(C(=O)O)(C)C)cc2)cc1	Clc1ccc(C(=O)NCCc2ccc(OC(C(=O)O)(C)C)cc2)cc1
NCGC00092364-11	Clc1ccc(C(=O)N[C@@H]2C3CCN(C2)CC3)cc1		Inactive	Nicotinic alpha7 Agonist		1	PNU-282987	384568107	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(C(=O)N[C@@H]2C3CCN(C2)CC3)cc1	Clc1ccc(C(=O)N[C@@H]2C3CCN(C2)CC3)cc1
NCGC00344507-02	Clc1ccc(C(=O)N[C@@H]2[C@@H](NC(C)c3c4c(ccc3)cccc4)CCCC2)cc1	4.5500002	Active	Calcium-Sensing Receptor (CaSR) Agonist	0.0	1	Calhex-231	174006263	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-89.2856307028	Clc1ccc(C(=O)N[C@@H]2[C@@H](NC(C)c3c4c(ccc3)cccc4)CCCC2)cc1	Clc1ccc(C(=O)N[C@@H]2[C@@H](NC(C)c3c4c(ccc3)cccc4)CCCC2)cc1
NCGC00015562-25&NCGC00015562-39	Clc1ccc(C(=O)n2c(C)c(CC(=O)O)c3c2ccc(OC)c3)cc1	4.92499995	Active	Non-steroidal Antiinflammatory&Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitor	0.9500003000000001	2	Indomethacin	170464705&384567865	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-31.689556056&-61.8419326856	Clc1ccc(C(=O)n2c(C)c(CC(=O)O)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)O)c3c2ccc(OC)c3)cc1
NCGC00253581-01	Clc1ccc(C(=O)n2c(C)c(CC(=O)OC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)c3c2ccc(OC)c3)cc1	6.0999999	Active		0.0	1	Indomethacin farnesil	170466014	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-36.7115774982	Clc1ccc(C(=O)n2c(C)c(CC(=O)OC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)OC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)c3c2ccc(OC)c3)cc1
NCGC00016868-12	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCC(=O)O)c3c2ccc(OC)c3)cc1		Inactive	Cyclooxygenase-1/2/3 Inhibitor		1	Acemetacin	170466043	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.228143128&0.0	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCC(=O)O)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCC(=O)O)c3c2ccc(OC)c3)cc1
NCGC00183024-01	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCCN3CCN(CCCOC(=O)CCC(NC(=O)c4ccccc4)C(=O)N(CCC)CCC)CC3)c3c2ccc(OC)c3)cc1	4.4749999	Active	Cyclooxygenase-2 Inhibitor	0.0	1	Proglumetacin	144206876	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-76.777362664&-97.8740357408	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCCN3CCN(CCCOC(=O)CCC(NC(=O)c4ccccc4)C(=O)N(CCC)CCC)CC3)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCCN3CCN(CCCOC(=O)CCC(NC(=O)c4ccccc4)C(=O)N(CCC)CCC)CC3)c3c2ccc(OC)c3)cc1
NCGC00015156-15	Clc1ccc(C(CN)CC(=O)O)cc1		Inactive	GABA-B receptor Agonist&Gaba-b Receptor Agonist		1	Baclofen	170465099	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.939629852&-22.314292152	Clc1ccc(C(CN)CC(=O)O)cc1	Clc1ccc(C(CN)CC(=O)O)cc1
NCGC00179384-10	Clc1ccc(C(N2CCN(C)CC2)c2ccccc2)cc1	5.0	Active	Hepatitis C virus Inhibitor	0.0	1	Chlorcyclizine	405558456	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-78.7934249359	Clc1ccc(C(N2CCN(C)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(C)CC2)c2ccccc2)cc1
NCGC00018271-07	Clc1ccc(C(N2CCN(C)CCC2)c2ccccc2)cc1	4.9499998	Active		0.0	1	Homochlorcyclizine	170465786	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-73.5013703511&-92.0238097364	Clc1ccc(C(N2CCN(C)CCC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(C)CCC2)c2ccccc2)cc1
NCGC00167781-12	Clc1ccc(C(N2CCN(CCOCC(=O)O)CC2)c2ccccc2)cc1		Inactive	Histamine H1 Receptor Antagonists		1	CETIRIZINE HYDROCHLORIDE	405558424	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.726679164	Clc1ccc(C(N2CCN(CCOCC(=O)O)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(CCOCC(=O)O)CC2)c2ccccc2)cc1
NCGC00021152-06	Clc1ccc(C(N2CCN(CCOCCO)CC2)c2ccccc2)cc1	4.5749998	Active	antiparasitic agent&Monoamine Oxidase B Inhibitor	0.0	1	Hydroxyzine	170464958	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-32.836592008&-66.5573636246	Clc1ccc(C(N2CCN(CCOCCO)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(CCOCCO)CC2)c2ccccc2)cc1
NCGC00018296-07&NCGC00018296-15	Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1	4.8499999	Active	Constitutive Androstane Receptor Agonist	0.6999997999999996	2	Meclizine hydrochloride	170464899&384568003	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-33.4095531&-95.7967460123	Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1.Cl.Cl	Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1.Cl.Cl&Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1
NCGC00386387-01	Clc1ccc(C(N2CCN(Cc3ccc(C(C)(C)C)cc3)CC2)c2ccccc2)cc1	4.4000001	Active	Histamine H1 receptor Antagonist	0.0	1	Buclizine HCl	405558507	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-80.0562022008	Clc1ccc(C(N2CCN(Cc3ccc(C(C)(C)C)cc3)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(Cc3ccc(C(C)(C)C)cc3)CC2)c2ccccc2)cc1
NCGC00178069-05	Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1	5.1999998	Active		0.0	1	Cloperastine hydrochloride	170465832	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-63.777835794&-69.275898788	Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1.Cl	Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1.Cl
NCGC00092357-04	Clc1ccc(C2(C(N(C)C)CC(C)C)CCC2)cc1		Inactive	5-HT Reuptake Inhibitor		1	Sibutramine hydrochloride	174007250	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(C2(C(N(C)C)CC(C)C)CCC2)cc1	Clc1ccc(C2(C(N(C)C)CC(C)C)CCC2)cc1
NCGC00015608-11&NCGC00015608-22	Clc1ccc(C2(O)CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)cc1	4.625	Active	Mu-opioid Antagonists&mu-Opioid Antagonist&mu-Opioid Antagonist	0.25	2	Loperamide hydrochloride	170464852&384567873	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3&-2.3	-99.3520760079&-88.4713060335&-117.7690241368	Clc1ccc(C2(O)CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)cc1	Clc1ccc(C2(O)CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)cc1
NCGC00015500-19	Clc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	4.4000001	Active	Dopamine D2 Antagonist	0.0	1	Haloperidol	170464841	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-51.881964096&-51.903497676	Clc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	Clc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
NCGC00508704-02	Clc1ccc(C2(OC(=O)CCCCCCCCC)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	5.0500002	Active	Dopamine D4 receptor Inverse Agonist	0.0	1	HALOPERIDOL DECANOATE	405558790	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-50.3483757165	Clc1ccc(C2(OC(=O)CCCCCCCCC)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	Clc1ccc(C2(OC(=O)CCCCCCCCC)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
NCGC00346549-08	Clc1ccc(C2(c3ccc(-c4c[nH]nc4)cc3)CCNCC2)cc1	4.4499998	Active	AKT Inhibitor	0.0	1	AT-7867	384568834	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-53.1450224488	Clc1ccc(C2(c3ccc(-c4c[nH]nc4)cc3)CCNCC2)cc1	Clc1ccc(C2(c3ccc(-c4c[nH]nc4)cc3)CCNCC2)cc1
NCGC00346441-01	Clc1ccc(C23CC4(C(=O)NCc5ccncc5)C[C@H](C2)C[C@@H](C4)C3)cc1	4.4499998	Active	Sphingosine Kinase 1 (SphK1) Inhibitor	0.0	1	ABC-294640	174006706	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-87.4896083556	Clc1ccc(C23CC4(C(=O)NCc5ccncc5)C[C@H](C2)C[C@@H](C4)C3)cc1	Clc1ccc(C23CC4(C(=O)NCc5ccncc5)C[C@H](C2)C[C@@H](C4)C3)cc1
NCGC00188344-07	Clc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc(S(=O)(=O)C(F)(F)F)c(N[C@@H](CSc6ccccc6)CCN6CCOCC6)cc5)cc4)CC3)CC(C)(C)CC2)cc1		Inactive	Bcl-xL Inhibitor		1	Navitoclax (ABT-263)	384568447	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc(S(=O)(=O)C(F)(F)F)c(N[C@@H](CSc6ccccc6)CCN6CCOCC6)cc5)cc4)CC3)CC(C)(C)CC2)cc1	Clc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc(S(=O)(=O)C(F)(F)F)c(N[C@@H](CSc6ccccc6)CCN6CCOCC6)cc5)cc4)CC3)CC(C)(C)CC2)cc1
NCGC00420887-01	Clc1ccc(C2=NC(CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	IL-6 Production Inhibitor		1	CPI-203	384569226	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.452827176	Clc1ccc(C2=NC(CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=NC(CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00387876-01	Clc1ccc(C2=NC(CC(=O)Nc3ccc(O)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	4.5	Inactive	Brd2 Inhibitor	0.0	1	Birabresib	384569166	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	64.1521675412	Clc1ccc(C2=NC(CC(=O)Nc3ccc(O)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=NC(CC(=O)Nc3ccc(O)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00356071-11	Clc1ccc(C2=N[C@@H](CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Bromodomain-containing protein 4 Inhibitor		1	CPI-203	384569026	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(C2=N[C@@H](CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00483135-03	Clc1ccc(C2=N[C@@H](CC(=O)N)c3onc(C)c3-c3c2cccc3)cc1	4.9499998	Active	Bromodomain-containing protein 4 Inhibitor	0.0	1	CPI-0610	384569263	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-89.7057582596	Clc1ccc(C2=N[C@@H](CC(=O)N)c3onc(C)c3-c3c2cccc3)cc1	Clc1ccc(C2=N[C@@H](CC(=O)N)c3onc(C)c3-c3c2cccc3)cc1
NCGC00263621-12	Clc1ccc(C2=N[C@@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1	4.8000002	Active	Brd4 Inhibitor	0.0	1	I-BET762	384568695	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-47.3187424561	Clc1ccc(C2=N[C@@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1	Clc1ccc(C2=N[C@@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1
NCGC00483927-02	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(OCCOCCOCCOCCNc4c5C(=O)N(C(=O)c5ccc4)C4C(=O)NC(=O)CC4)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	4.4499998	Active	Brd4 Inhibitor	0.0	1	ARV-825	384569267	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-49.3250930338	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(OCCOCCOCCOCCNc4c5C(=O)N(C(=O)c5ccc4)C4C(=O)NC(=O)CC4)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(OCCOCCOCCOCCNc4c5C(=O)N(C(=O)c5ccc4)C4C(=O)NC(=O)CC4)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00250412-08	Clc1ccc(C2=N[C@@H](CC(=O)OC(C)(C)C)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Brd4 Inhibitor		1	JQ1	384568560	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.9743397839	Clc1ccc(C2=N[C@@H](CC(=O)OC(C)(C)C)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)OC(C)(C)C)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00345173-01	Clc1ccc(C2=N[C@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1		Inactive	Brd4 Inhibitor		1	GSK-525768	174006338	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.4023983272	Clc1ccc(C2=N[C@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1	Clc1ccc(C2=N[C@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1
NCGC00015191-13&NCGC00015191-21	Clc1ccc(C2S(=O)(=O)CCC(=O)N2C)cc1		Inactive	Gamma-aminobutyric Acid Receptor Modulator&GABA Modulators&GABA Modulators		2	Chlormezanone	170465161&384567820	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&10.3956991999	Clc1ccc(C2S(=O)(=O)CCC(=O)N2C)cc1	Clc1ccc(C2S(=O)(=O)CCC(=O)N2C)cc1
NCGC00159437-03	Clc1ccc(CC(O)(C(CN(C)C)C)C)cc1		Inactive	Herg Inhibitor&HERG Inhibitor		1	Clobutinol hydrochloride	170466051	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.8380280439&-13.1966107639	Clc1ccc(CC(O)(C(CN(C)C)C)C)cc1.Cl	Clc1ccc(CC(O)(C(CN(C)C)C)C)cc1.Cl
NCGC00346621-05	Clc1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1	4.4499998	Active	AKT Inhibitor	0.0	1	CCT-128930	363677482	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-47.3204701395	Clc1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1	Clc1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1
NCGC00177979-05	Clc1ccc(CC2=NN(C(=O)c3c2cccc3)C2CCN(C)CCC2)cc1	4.625	Active	Histamine H1 Receptor Antagonists	0.0	1	Azelastine hydrochloride	170465172	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-95.86779206&-85.6915457507	Clc1ccc(CC2=NN(C(=O)c3c2cccc3)C2CCN(C)CCC2)cc1.Cl	Clc1ccc(CC2=NN(C(=O)c3c2cccc3)C2CCN(C)CCC2)cc1.Cl
NCGC00370823-03	Clc1ccc(CCCOCCCN2CCCCC2)cc1	5.0999999	Active	Histamine H3 receptor Inverse Agonist	0.0	1	Pitolisant (hydrochloride)	405558641	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-74.7002682801	Clc1ccc(CCCOCCCN2CCCCC2)cc1	Clc1ccc(CCCOCCCN2CCCCC2)cc1
NCGC00242476-03	Clc1ccc(CN(CC(=O)OC(C)(C)C)Cc2sc([N+](=O)[O-])cc2)cc1	5.1999998	Active	Rev-erb alpha Agonist	0.0	1	GSK-4112	384568489	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-43.2067018271	Clc1ccc(CN(CC(=O)OC(C)(C)C)Cc2sc([N+](=O)[O-])cc2)cc1	Clc1ccc(CN(CC(=O)OC(C)(C)C)Cc2sc([N+](=O)[O-])cc2)cc1
NCGC00347956-02	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)NCCCCC)CC2)cc1		Inactive	Rev-erb alpha Agonist		1	SR-9011	384569000	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-26.282042556	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)NCCCCC)CC2)cc1	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)NCCCCC)CC2)cc1
NCGC00345084-02	Clc1ccc(CNC(=O)C[C@H]2C(=O)NC[C@@H](c3ccccc3)OC(=O)CC/C=C\C2)cc1		Active	Hedgehog Antagonist		1	Robotnikinin	384568732	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	0.0	Clc1ccc(CNC(=O)C[C@H]2C(=O)NC[C@@H](c3ccccc3)OC(=O)CC/C=C\C2)cc1	Clc1ccc(CNC(=O)C[C@H]2C(=O)NC[C@@H](c3ccccc3)OC(=O)CC/C=C\C2)cc1
NCGC00346882-02	Clc1ccc(COc2c(C(=O)N[C@@H](C)c3ccccc3)scc2)cc1	4.4000001	Active	SH2 containing inositol phosphatase (SHIP) Inhibitor	0.0	1	AS-1949490	384568959	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-106.9235257828	Clc1ccc(COc2c(C(=O)N[C@@H](C)c3ccccc3)scc2)cc1	Clc1ccc(COc2c(C(=O)N[C@@H](C)c3ccccc3)scc2)cc1
NCGC00481544-01	Clc1ccc(C[C@@H](/N=C(\O)/[C@H](/N=C(\O)/C)Cc2cc3c(cc2)cccc3)/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](C(=O)N2[C@H](/C(/O)=N/[C@@H](C(O)=N)C)CCC2)CCCNC(=N)N)CC(C)C)CCCNC(O)=N)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1	5.4499998	Active	Gonadotropin-releasing Hormone Receptor Antagonist	0.0	1	Cetrorelix	405558930	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.096670384	Clc1ccc(C[C@@H](/N=C(\O)/[C@H](/N=C(\O)/C)Cc2cc3c(cc2)cccc3)/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](C(=O)N2[C@H](/C(/O)=N/[C@@H](C(O)=N)C)CCC2)CCCNC(=N)N)CC(C)C)CCCNC(O)=N)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1	Clc1ccc(C[C@@H](/N=C(\O)/[C@H](/N=C(\O)/C)Cc2cc3c(cc2)cccc3)/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](C(=O)N2[C@H](/C(/O)=N/[C@@H](C(O)=N)C)CCC2)CCCNC(=N)N)CC(C)C)CCCNC(O)=N)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1
NCGC00162249-09	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(C(C)C)c3)cc1		Inactive	5-lipoxygenase-activating (FLAP) Inhibitor		1	MK-886	384568221	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	24.683161876	Clc1ccc(Cn2c(CC(C(=O)[O-])(C)C)c(SC(C)(C)C)c3c2ccc(C(C)C)c3)cc1	Clc1ccc(Cn2c(CC(C(=O)[O-])(C)C)c(SC(C)(C)C)c3c2ccc(C(C)C)c3)cc1
NCGC00379068-03	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(OCc2nc4c(cc2)cccc4)c3)cc1		Inactive	5-lipoxygenase activating protein Inhibitor		1	MK591	384569092	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(OCc2nc4c(cc2)cccc4)c3)cc1	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(OCc2nc4c(cc2)cccc4)c3)cc1
NCGC00015243-10&NCGC00015243-14	Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1	4.58749985	Active	Histamine H1 Receptor Antagonist	0.27500010000000064	2	Clemizole hydrochloride	170465924&384567830	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0&-2.3	-54.9924615307&-86.991867184&-117.8637404452	Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1.Cl	Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1.Cl&Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1
NCGC00345790-03	Clc1ccc(Cn2c3c(S(=O)(=O)C)cc(F)cc3c3c2[C@@H](CC(=O)O)CC3)cc1		Inactive	prostaglandin D2 DP1 Inhibitor		1	Laropiprant	384568743	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.0956618	Clc1ccc(Cn2c3c(S(=O)(=O)C)cc(F)cc3c3c2[C@@H](CC(=O)O)CC3)cc1	Clc1ccc(Cn2c3c(S(=O)(=O)C)cc(F)cc3c3c2[C@@H](CC(=O)O)CC3)cc1
NCGC00160428-03	Clc1ccc(Cn2c3c(c(C(=O)C(=O)Nc4ccncc4)c2)cccc3)cc1	9.0	Inactive	Tubulin polymerization Inhibitor	0.0	1	Indibulin	384568195	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-17.9316136279	Clc1ccc(Cn2c3c(c(C(=O)C(=O)Nc4ccncc4)c2)cccc3)cc1	Clc1ccc(Cn2c3c(c(C(=O)C(=O)Nc4ccncc4)c2)cccc3)cc1
NCGC00371144-02	Clc1ccc(N2C(=O)N=C(N3CCOCC3)C2)cc1	4.5	Active		0.0	1	AWD 131-138	405558706	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-65.271414018	Clc1ccc(N2C(=O)N=C(N3CCOCC3)C2)cc1	Clc1ccc(N2C(=O)N=C(N3CCOCC3)C2)cc1
NCGC00346884-02	Clc1ccc(NC(=O)N(O)C2N(c3ccc(Cl)cc3)C(=O)N(CC(=O)N/N=C/C=C/c3oc([N+](=O)[O-])cc3)C2(C)C)cc1	4.75	Active	Inhibitor of endoplasmic reticulum associated protein degradation	0.0	1	Eeyarestatin I	384568961	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-104.1925096248	Clc1ccc(NC(=O)N(O)C2N(c3ccc(Cl)cc3)C(=O)N(CC(=O)N/N=C/C=C/c3oc([N+](=O)[O-])cc3)C2(C)C)cc1	Clc1ccc(NC(=O)N(O)C2N(c3ccc(Cl)cc3)C(=O)N(CC(=O)N/N=C/C=C/c3oc([N+](=O)[O-])cc3)C2(C)C)cc1
NCGC00510233-01	Clc1ccc(NC(=O)[C@H](C)C2CCC(c3c4c(ncc3)ccc(F)c4)CC2)cc1	4.4000001	Active	IDO Inhibitor	0.0	1	BMS-986205	384569418	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-88.8284422211	Clc1ccc(NC(=O)[C@H](C)C2CCC(c3c4c(ncc3)ccc(F)c4)CC2)cc1	Clc1ccc(NC(=O)[C@H](C)C2CCC(c3c4c(ncc3)ccc(F)c4)CC2)cc1
NCGC00016528-05	Clc1ccc(NC(NC(=N)NC(C)C)=N)cc1	4.4000001	Active	Dhfr Inhibitor	0.0	1	Proguanil hydrochloride	170464800	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-71.4615163279	Clc1ccc(NC(NC(=N)NC(C)C)=N)cc1.Cl	Clc1ccc(NC(NC(=N)NC(C)C)=N)cc1.Cl
NCGC00016246-09&NCGC00016246-10	Clc1ccc(NC(NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)=N)cc1	4.5875001	Active	N-acetyltransferase Eis (mycobacterium Tuberculosis) Inhibitor&N-Acetyltransferase Eis (Mycobacterium tuberculosis) Inhibitor&N-Acetyltransferase Eis (Mycobacterium tuberculosis) Inhibitor	0.3249997999999996	2	Chlorhexidine	170464748&384567925	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-2.1	-38.5442841399&-107.500006008&-99.2435085172	Clc1ccc(NC(NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)=N)cc1	Clc1ccc(NC(NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)=N)cc1
NCGC00016600-08	Clc1ccc(NC=2/C(=N/C(C)C)/C=C3N(c4ccc(Cl)cc4)c4c(N=C3C=2)cccc4)cc1	4.4000001	Active	Dna Binding Agent	0.0	1	Clofazimine	387065713	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-36.376055874	Clc1ccc(NC=2/C(=N/C(C)C)/C=C3N(c4ccc(Cl)cc4)c4c(N=C3C=2)cccc4)cc1	Clc1ccc(NC=2/C(=N/C(C)C)/C=C3N(c4ccc(Cl)cc4)c4c(N=C3C=2)cccc4)cc1
NCGC00356069-03	Clc1ccc(N[C@H]2c3c(N(C(=O)C)[C@@H](C)C2)ccc(-c2ccc(C(=O)O)cc2)c3)cc1	4.5500002	Active	Bromodomain-containing protein 4 Inhibitor	0.0	1	GSK1324726A (I-BET726)	384569025	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-31.4153182568	Clc1ccc(N[C@H]2c3c(N(C(=O)C)[C@@H](C)C2)ccc(-c2ccc(C(=O)O)cc2)c3)cc1	Clc1ccc(N[C@H]2c3c(N(C(=O)C)[C@@H](C)C2)ccc(-c2ccc(C(=O)O)cc2)c3)cc1
NCGC00181350-14	Clc1ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)cc1		Inactive	VEGFR-2 Inhibitor		1	Vatalanib	384568397	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	28.760043892	Clc1ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)cc1	Clc1ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)cc1
NCGC00249392-05	Clc1ccc(Nc2nnc(OCc3cc(C(=O)NC)ncc3)c3occc23)cc1		Inactive	VEGFR-2,3 Inhibitor		1	Telatinib	377020517	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(Nc2nnc(OCc3cc(C(=O)NC)ncc3)c3occc23)cc1	Clc1ccc(Nc2nnc(OCc3cc(C(=O)NC)ncc3)c3occc23)cc1
NCGC00090814-07	Clc1ccc(O)cc1		Inactive	Macrophage Activation Involved In Immune Response Inhibitor&macrophage activation involved in immune response Inhibitor		1	4-Chlorophenol	170465673	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.14446222&0.0	Clc1ccc(O)cc1	Clc1ccc(O)cc1
NCGC00166153-02	Clc1ccc(OC(C(=O)C(C)(C)C)n2cncc2)cc1	4.6999998	Active		0.0	1	Climbazole	170465557	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-83.7130655284	Clc1ccc(OC(C(=O)C(C)(C)C)n2cncc2)cc1	Clc1ccc(OC(C(=O)C(C)(C)C)n2cncc2)cc1
NCGC00015257-14&NCGC00015257-18	Clc1ccc(OC(C(=O)OCC)(C)C)cc1	4.0	Inactive	PPARalpha Agonist&Pparalpha Agonist&PPARalpha Agonist	0.0	2	Clofibrate	170465329&384567834	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	9.83489854&20.918907612&59.345488444	Clc1ccc(OC(C(=O)OCC)(C)C)cc1	Clc1ccc(OC(C(=O)OCC)(C)C)cc1
NCGC00249923-01	Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1		Inactive	Triglyceride Biosynthesis Inhibitor		1	Cholesolvin	170466018	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1	Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1
NCGC00015279-08	Clc1ccc(OCC(=O)OCCN(C)C)cc1		Inactive			1	Meclofenoxate hydrochloride	170465815	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.3272521881&12.2651643359	Clc1ccc(OCC(=O)OCCN(C)C)cc1.Cl	Clc1ccc(OCC(=O)OCCN(C)C)cc1.Cl
NCGC00160584-01	Clc1ccc(OCC(O)CO)cc1		Inactive			1	Chlorphenesin	144207103	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.0591069639&-31.59188356	Clc1ccc(OCC(O)CO)cc1	Clc1ccc(OCC(O)CO)cc1
NCGC00179607-03	Clc1ccc(OCC(O)COC(=O)N)cc1		Inactive			1	Chlorphensin carbamate	225144309	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&27.9152360519	Clc1ccc(OCC(O)COC(=O)N)cc1	Clc1ccc(OCC(O)COC(=O)N)cc1
NCGC00345782-02	Clc1ccc(OCCCCCCN/C(=N\C#N)/Nc2ccncc2)cc1	2.8499999	Inactive	IKK beta Inhibitor	0.0	1	GMX-1778	384568738	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-16.926667876	Clc1ccc(OCCCCCCN/C(=N\C#N)/Nc2ccncc2)cc1	Clc1ccc(OCCCCCCN/C(=N\C#N)/Nc2ccncc2)cc1
NCGC00378789-02	Clc1ccc(OCCCCCC[C@@]2(C(=O)OCC)OC2)cc1	4.4000001	Active	CPT-1 Inhibitor	0.0	1	Etomoxir	384569068	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-100.666011276	Clc1ccc(OCCCCCC[C@@]2(C(=O)OCC)OC2)cc1	Clc1ccc(OCCCCCC[C@@]2(C(=O)OCC)OC2)cc1
NCGC00499786-01	Clc1ccc(Oc2c(F)cc(S(=O)(=O)N3C(C(=O)NO)CN(C(=O)OCCOC)CC3)cc2F)cc1	4.8000002	Active	ADAM10 Inhibitor	0.0	1	XL-784	384569310	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-99.3412190379	Clc1ccc(Oc2c(F)cc(S(=O)(=O)N3C(C(=O)NO)CN(C(=O)OCCOC)CC3)cc2F)cc1	Clc1ccc(Oc2c(F)cc(S(=O)(=O)N3C(C(=O)NO)CN(C(=O)OCCOC)CC3)cc2F)cc1
NCGC00165768-05	Clc1ccc(Oc2ccc(-c3[nH]c4c(n3)cc(C(=O)N)cc4)cc2)cc1	4.4000001	Active	Chk2 Inhibitor	0.0	1	BML-277	363676640	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-87.4200411119	Clc1ccc(Oc2ccc(-c3[nH]c4c(n3)cc(C(=O)N)cc4)cc2)cc1	Clc1ccc(Oc2ccc(-c3[nH]c4c(n3)cc(C(=O)N)cc4)cc2)cc1
NCGC00378723-01	Clc1ccc(Oc2ccc(S(=O)(=O)CC3(C(=O)NO)CCOCC3)cc2)cc1	4.4000001	Active	MMP-12 (Macrophage Elastase) Inhibitor	0.0	1	CTS-1027	384569065	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.537810344	Clc1ccc(Oc2ccc(S(=O)(=O)CC3(C(=O)NO)CCOCC3)cc2)cc1	Clc1ccc(Oc2ccc(S(=O)(=O)CC3(C(=O)NO)CCOCC3)cc2)cc1
NCGC00263184-06	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(CCC(=O)O)CC2)cc1		Inactive	g-Secretase Inhibitor		1	MK-0752	384568652	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(CCC(=O)O)CC2)cc1	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(CCC(=O)O)CC2)cc1
NCGC00346504-07	Clc1ccc(S(=O)(=O)N([C@@H](C(=O)N)CCC(F)(F)F)Cc2c(F)cc(-c3nocn3)cc2)cc1		Inactive	g-Secretase Inhibitor		1	Avagacestat	384568808	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	39.0750513199	Clc1ccc(S(=O)(=O)N([C@@H](C(=O)N)CCC(F)(F)F)Cc2c(F)cc(-c3nocn3)cc2)cc1	Clc1ccc(S(=O)(=O)N([C@@H](C(=O)N)CCC(F)(F)F)Cc2c(F)cc(-c3nocn3)cc2)cc1
NCGC00346875-02	Clc1ccc(S(=O)(=O)N([C@H](C)c2c(CCCC(=O)O)cc(F)cc2)c2c(F)ccc(F)c2)cc1	4.6500001	Active	g-Secretase Inhibitor	0.0	1	BMS-299897	384568953	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-54.0621949272	Clc1ccc(S(=O)(=O)N([C@H](C)c2c(CCCC(=O)O)cc(F)cc2)c2c(F)ccc(F)c2)cc1	Clc1ccc(S(=O)(=O)N([C@H](C)c2c(CCCC(=O)O)cc(F)cc2)c2c(F)ccc(F)c2)cc1
NCGC00015216-17	Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1		Inactive	Sulfonylurea receptor 1, Kir6.2 Inhibitor&Sulfonylurea Receptor 1, Kir6.2 Inhibitor		1	Chlorpropamide	170464898	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.531550016&0.0	Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1	Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1
NCGC00182989-01	Clc1ccc(S(=O)(=O)NC(=O)NN2CCCC2)cc1		Inactive			1	Glyclopyramide	144206854	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Clc1ccc(S(=O)(=O)NC(=O)NN2CCCC2)cc1	Clc1ccc(S(=O)(=O)NC(=O)NN2CCCC2)cc1
NCGC00182026-02	Clc1ccc(SC(P(=O)(O)[O-])P(=O)(O)[O-])cc1	6.6081004	Active	Osteoclasts Inhibitor	0.0	1	Tiludronate disodium salt hydrate	225144329	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.000112472	Clc1ccc(SC(P(=O)(O)[O-])P(=O)(O)[O-])cc1	Clc1ccc(SC(P(=O)(O)[O-])P(=O)(O)[O-])cc1
NCGC00263124-09	Clc1ccc([C@@H]2N(C(=O)N3CC(=O)NCC3)C(c3c(OC(C)C)cc(OC)cc3)=N[C@@H]2c2ccc(Cl)cc2)cc1	4.4000001	Active	HDM2/HDMX Inhibitor	0.0	1	Nutlin-3	384568607	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-114.8972119308	Clc1ccc([C@@H]2N(C(=O)N3CC(=O)NCC3)C(c3c(OC(C)C)cc(OC)cc3)=N[C@@H]2c2ccc(Cl)cc2)cc1	Clc1ccc([C@@H]2N(C(=O)N3CC(=O)NCC3)C(c3c(OC(C)C)cc(OC)cc3)=N[C@@H]2c2ccc(Cl)cc2)cc1
NCGC00390552-02	Clc1ccc([C@@H]2N(c3ccc(N(CC4CCC(N5CC(=O)N(C)CC5)CC4)C)cc3)C(=O)Cc3c2cc(OC(C)C)c(OC)c3)cc1	4.5	Active	MDM2 (hdm2) Inhibitor	0.0	1	CGM-097	384569191	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.5365536844	Clc1ccc([C@@H]2N(c3ccc(N(CC4CCC(N5CC(=O)N(C)CC5)CC4)C)cc3)C(=O)Cc3c2cc(OC(C)C)c(OC)c3)cc1	Clc1ccc([C@@H]2N(c3ccc(N(CC4CCC(N5CC(=O)N(C)CC5)CC4)C)cc3)C(=O)Cc3c2cc(OC(C)C)c(OC)c3)cc1
NCGC00016710-05	Clc1ccc([C@@](OCC[C@@H]2N(C)CCC2)(C)c2ccccc2)cc1	5.0	Active	Histamine H1 Receptor Antagonists	0.0	1	Clemastine fumarate	170465318	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-86.1767671104	Clc1ccc([C@@](OCC[C@@H]2N(C)CCC2)(C)c2ccccc2)cc1.O=C(O)/C=C/C(=O)O	Clc1ccc([C@@](OCC[C@@H]2N(C)CCC2)(C)c2ccccc2)cc1.O=C(O)/C=C/C(=O)O
NCGC00378588-02	Clc1ccc([C@@]2(C)N(C(=O)N3CCN(CC(=O)N4CCOCC4)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=N[C@@]2(C)c2ccc(Cl)cc2)cc1	4.5999999	Active	p53-MDM2 interaction Inhibitor	0.0	1	NCGC00378588	363678105	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-62.3392841732	Clc1ccc([C@@]2(C)N(C(=O)N3CCN(CC(=O)N4CCOCC4)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=N[C@@]2(C)c2ccc(Cl)cc2)cc1	Clc1ccc([C@@]2(C)N(C(=O)N3CCN(CC(=O)N4CCOCC4)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=N[C@@]2(C)c2ccc(Cl)cc2)cc1
NCGC00015227-08	Clc1ccc([C@H](CCN(C)C)c2ncccc2)cc1	4.6500001	Active	Histamine H1 Receptor Antagonists; Snri	0.0	1	Dexchlorpheniramine hydrochloride	170466889	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-56.6678892905	Clc1ccc([C@H](CCN(C)C)c2ncccc2)cc1.Cl	Clc1ccc([C@H](CCN(C)C)c2ncccc2)cc1.Cl
NCGC00386356-02	Clc1ccc([C@H](OC2CCN(CCCC(=O)O)CC2)c2ncccc2)cc1		Inactive	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist		1	Bepotastine (Beslilate)	405558923	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.168699212&12.430520068	Clc1ccc([C@H](OC2CCN(CCCC(=O)O)CC2)c2ncccc2)cc1	Clc1ccc([C@H](OC2CCN(CCCC(=O)O)CC2)c2ncccc2)cc1
NCGC00510162-01	Clc1ccc([C@H]2N(C(=O)c3cnc4[nH]nc(C)c4c3)CCC2)cc1		Inactive	CDK8 Inhibitor		1	MSC2530818	384569411	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	24.194861604	Clc1ccc([C@H]2N(C(=O)c3cnc4[nH]nc(C)c4c3)CCC2)cc1	Clc1ccc([C@H]2N(C(=O)c3cnc4[nH]nc(C)c4c3)CCC2)cc1
NCGC00386423-05	Clc1ccc([C@](O)(CN)c2ccc(-c3c[nH]nc3)cc2)cc1	4.4000001	Active	AKT Inhibitor	0.0	1	AT-13148	384569136	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-102.008113939	Clc1ccc([C@](O)(CN)c2ccc(-c3c[nH]nc3)cc2)cc1	Clc1ccc([C@](O)(CN)c2ccc(-c3c[nH]nc3)cc2)cc1
NCGC00167737-02	Clc1cnc(C(=O)NCCN)cc1		Inactive	Monoamine Oxidase B Inhibitor&Monoamine oxidase B Inhibitor		1	Lazabemide hydrochloride	170466038	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.424617548&-13.3973650239	Clc1cnc(C(=O)NCCN)cc1.Cl	Clc1cnc(C(=O)NCCN)cc1.Cl
NCGC00506868-01	Clc1cnc(CC(=O)Nc2cc(C(=O)c3c4c(n(C(CO)(C)C)c3)nc(N)nc4)cnc2)cc1		Inactive	Trk A/B/C Inhibitor		1	PF-06273340	384569320	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cnc(CC(=O)Nc2cc(C(=O)c3c4c(n(C(CO)(C)C)c3)nc(N)nc4)cnc2)cc1	Clc1cnc(CC(=O)Nc2cc(C(=O)c3c4c(n(C(CO)(C)C)c3)nc(N)nc4)cnc2)cc1
NCGC00510689-01	Clc1cnc(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccc(OC)cc3)cc2)cc1	4.6999998	Active	homology-dependent DNA repair Inhibitor	0.0	1	YU-238259	384569479	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-79.3934018644	Clc1cnc(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccc(OC)cc3)cc2)cc1	Clc1cnc(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccc(OC)cc3)cc2)cc1
NCGC00159515-03	Clc1cnc(N2[C@@H](OC(=O)N3CCN(C)CC3)c3nccnc3C2=O)cc1		Inactive	Gabaa Receptor Modulator&GABAA Receptor Modulator		1	Eszopiclone	170465445	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-34.731320648&-22.04721328	Clc1cnc(N2[C@@H](OC(=O)N3CCN(C)CC3)c3nccnc3C2=O)cc1	Clc1cnc(N2[C@@H](OC(=O)N3CCN(C)CC3)c3nccnc3C2=O)cc1
NCGC00378907-01	Clc1cnc(NC(=O)C(=O)N[C@@H]2[C@H](NC(=O)c3sc4c(n3)CCN(C)C4)C[C@@H](C(=O)N(C)C)CC2)cc1		Inactive	Coagulation Factor X Inhibitor		1	Edoxaban tosylate monohydrate	405559062	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.4114918519&-19.539788012	Clc1cnc(NC(=O)C(=O)N[C@@H]2[C@H](NC(=O)c3sc4c(n3)CCN(C)C4)C[C@@H](C(=O)N(C)C)CC2)cc1	Clc1cnc(NC(=O)C(=O)N[C@@H]2[C@H](NC(=O)c3sc4c(n3)CCN(C)C4)C[C@@H](C(=O)N(C)C)CC2)cc1
NCGC00371122-04	Clc1cnc(NC(=O)c2c(NC(=O)c3ccc(C(N(C)C)=N)cc3)ccc(OC)c2)cc1	4.5500002	Active	Coagulation factor X Inhibitor	0.0	1	Betrixaban	405558517	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-53.2992159347	Clc1cnc(NC(=O)c2c(NC(=O)c3ccc(C(N(C)C)=N)cc3)ccc(OC)c2)cc1	Clc1cnc(NC(=O)c2c(NC(=O)c3ccc(C(N(C)C)=N)cc3)ccc(OC)c2)cc1
NCGC00187911-06	Clc1cnc2[nH]cc(C(=O)c3c(F)c(NS(=O)(=O)CCC)ccc3F)c2c1	4.4499998	Active	Raf kinase B Inhibitor	0.0	1	PLX-4720	363677115	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-76.613360919	Clc1cnc2[nH]cc(C(=O)c3c(F)c(NS(=O)(=O)CCC)ccc3F)c2c1	Clc1cnc2[nH]cc(C(=O)c3c(F)c(NS(=O)(=O)CCC)ccc3F)c2c1
NCGC00480774-04	Clc1cnc2[nH]cc(Cc3cnc(NCc4cnc(C(F)(F)F)cc4)cc3)c2c1		Inactive	CSF1R (c-FMS) Inhibitor		1	Pexidartinib	384569242	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1cnc2[nH]cc(Cc3cnc(NCc4cnc(C(F)(F)F)cc4)cc3)c2c1	Clc1cnc2[nH]cc(Cc3cnc(NCc4cnc(C(F)(F)F)cc4)cc3)c2c1
NCGC00386367-02	Clc1n([C@@H]2[C@@H](F)CN(C3COC3)CC2)ncc1Nc1nc(NC)c(C(F)(F)F)cn1		Inactive	LRRK2 Inhibitor		1	GNE-9605	363680236	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1n([C@@H]2[C@@H](F)CN(C3COC3)CC2)ncc1Nc1nc(NC)c(C(F)(F)F)cn1	Clc1n([C@@H]2[C@@H](F)CN(C3COC3)CC2)ncc1Nc1nc(NC)c(C(F)(F)F)cn1
NCGC00096095-02	Clc1n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)c2ncnc(N)c2n1	4.4000001	Active	Telomerase Inhibitor	0.0	1	8-Cl-Ado	26753806	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-84.8246903199	Clc1n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)c2ncnc(N)c2n1	Clc1n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)c2ncnc(N)c2n1
NCGC00509935-01	Clc1nc(-c2nc(N[C@@H](C(F)(F)F)C)nc(N[C@H](C(F)(F)F)C)n2)ccc1		Inactive	Mutant IDH1 Inhibitor		1	AG-881	384569384	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.535153652	Clc1nc(-c2nc(N[C@@H](C(F)(F)F)C)nc(N[C@H](C(F)(F)F)C)n2)ccc1	Clc1nc(-c2nc(N[C@@H](C(F)(F)F)C)nc(N[C@H](C(F)(F)F)C)n2)ccc1
NCGC00480817-01	Clc1nc(C(=O)NCC(=O)O)c(O)c2c1cccc2		Inactive	alpha-Ketoglutarate-Dependent Dioxygenase FTO Inhibitor		1	FG-2216	384569247	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Clc1nc(C(=O)NCC(=O)O)c(O)c2c1cccc2	Clc1nc(C(=O)NCC(=O)O)c(O)c2c1cccc2
NCGC00018167-05	Clc1nc(N)c2ncn(C3OC(CO)C(O)C3)c2n1	4.9749999	Active	Adenosine Deaminase Inhibitor	0.0	1	Cladribine	405558565	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.3	-70.2501039854&-91.8253607892	Clc1nc(N)c2ncn(C3OC(CO)C(O)C3)c2n1	Clc1nc(N)c2ncn(C3OC(CO)C(O)C3)c2n1
NCGC00022567-15	Clc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)C3)c2n1	4.5500002	Active	Adenosine Deaminase Inhibitor	0.0	1	Cladribine	384568011	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-49.5823667747	Clc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)C3)c2n1	Clc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)C3)c2n1
NCGC00164553-02&NCGC00164553-07	Clc1nc(N)c2ncn([C@H]3[C@@H](F)[C@H](O)[C@@H](CO)O3)c2n1	4.7125001	Active	Dna Polymerase Alpha Catalytic Subunit Inhibitor&DNA Polymerase Inhibitor&DNA Polymerase Inhibitor	0.125	2	Clofarabine	170465145&384568252	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.3&-2.1	-105.7114861707&-92.9555518147&-103.2682091546	Clc1nc(N)c2ncn([C@H]3[C@@H](F)[C@H](O)[C@@H](CO)O3)c2n1	Clc1nc(N)c2ncn([C@H]3[C@@H](F)[C@H](O)[C@@H](CO)O3)c2n1
NCGC00247877-09	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cnc12	5.3000002	Inactive	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	CNF-2024	384568518	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-28.4839800073	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cnc12	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cnc12
NCGC00163736-04	Clc1ncc(CN2/C(=N/[N+](=O)[O-])/NCC2)cc1		Inactive			1	Imidacloprid	170465741	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.390992156&0.0	Clc1ncc(CN2/C(=N/[N+](=O)[O-])/NCC2)cc1	Clc1ncc(CN2/C(=N/[N+](=O)[O-])/NCC2)cc1
NCGC00345842-03	Clc1nccc(C2=NC(c3c(F)cc(Cl)cc3)C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)N2)c1	4.4000001	Active	ROCK Inhibitor	0.0	1	GSK-25	384568764	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-69.8951293799	Clc1nccc(C2=NC(c3c(F)cc(Cl)cc3)C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)N2)c1	Clc1nccc(C2=NC(c3c(F)cc(Cl)cc3)C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)N2)c1
NCGC00016323-09	Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1		Inactive	Salmonella Inhibitor		1	Sulfachloropyridazine	170466574	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.802308464&0.0	Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1	Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1
NCGC00262945-01	Clc1sc(C(=O)NCC2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1	4.4000001	Active	Coagulation Factor Xa Inhibitor	0.0	1	Rivaroxaban	170466121	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.255827184	Clc1sc(C(=O)NCC2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1	Clc1sc(C(=O)NCC2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1
NCGC00262945-03	Clc1sc(C(=O)NC[C@@H]2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1	6.0500002	Inactive		0.0	1	Rivaroxaban	363677193	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	17.443736652	Clc1sc(C(=O)NC[C@@H]2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1	Clc1sc(C(=O)NC[C@@H]2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1
NCGC00249417-03	Clc1sc(S(=O)(=O)Nc2c(C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc(Cl)cc2)cc1	4.4000001	Active	Soluble Guanylate Cyclase (sGC) Activator	0.0	1	Ataciguat	384568527	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-56.27414958	Clc1sc(S(=O)(=O)Nc2c(C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc(Cl)cc2)cc1	Clc1sc(S(=O)(=O)Nc2c(C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc(Cl)cc2)cc1
NCGC00485024-02	Cn1ncc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)c1		Inactive	LRRK2 Inhibitor		1	PF-06454589	384569274	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Cn1ncc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)c1	Cn1ncc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)c1
NCGC00481319-01	FC(CN1[C@H](c2c(F)cc(/C=C/C(=O)O)cc2F)c2[nH]c3c(c2C[C@H]1C)cccc3)(C)C	4.9000001	Active	Selective Estrogen Receptor Destabilizers (SERD)	0.0	1	AZD-9496 maleate	384569254	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-92.9632552623	FC(CN1[C@H](c2c(F)cc(/C=C/C(=O)O)cc2F)c2[nH]c3c(c2C[C@H]1C)cccc3)(C)C	FC(CN1[C@H](c2c(F)cc(/C=C/C(=O)O)cc2F)c2[nH]c3c(c2C[C@H]1C)cccc3)(C)C
NCGC00390577-02	FC(F)(C(=O)N[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2)C	6.0	Active	Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activator	0.0	1	Omaveloxolone	384569196	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-71.9402948632	FC(F)(C(=O)N[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2)C	FC(F)(C(=O)N[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2)C
NCGC00346580-02	FC(F)(C)[C@H]1CN2C[C@H](C1)C[C@](C(=O)OC)(c1c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c1)c1[nH]c3c(c1C2)cccc3	6.5500002	Inactive	Tubulin polymerization Inhibitor	0.0	1	Vinflunine	363677462	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-20.479495409	FC(F)(C)[C@H]1CN2C[C@H](C1)C[C@](C(=O)OC)(c1c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c1)c1[nH]c3c(c1C2)cccc3	FC(F)(C)[C@H]1CN2C[C@H](C1)C[C@](C(=O)OC)(c1c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c1)c1[nH]c3c(c1C2)cccc3
NCGC00389309-01	FC(F)(CCCC)C1(O)OC2C(C(CCCCCCC(=O)O)C(=O)C2)CC1	6.5	Active	Chloride Channel Protein 2 Activator	0.0	1	Lubiprostone	405559047	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-33.380997252	FC(F)(CCCC)C1(O)OC2C(C(CCCCCCC(=O)O)C(=O)C2)CC1	FC(F)(CCCC)C1(O)OC2C(C(CCCCCCC(=O)O)C(=O)C2)CC1
NCGC00183105-01	FC(F)(CCCC)[C@]1(O)O[C@H]2[C@@H]([C@@H](CCCCCCC(=O)O)C(=O)C2)CC1		Inactive	ClC-2 Channel Activator		1	Lubiprostone	124894305	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(CCCC)[C@]1(O)O[C@H]2[C@@H]([C@@H](CCCCCCC(=O)O)C(=O)C2)CC1	FC(F)(CCCC)[C@]1(O)O[C@H]2[C@@H]([C@@H](CCCCCCC(=O)O)C(=O)C2)CC1
NCGC00389618-01	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3C(C(=O)N)CCC3)s2)c1		Inactive	PI3K alpha Inhibitor		1	BYL-719	363680823	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.7574749361	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3C(C(=O)N)CCC3)s2)c1	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3C(C(=O)N)CCC3)s2)c1
NCGC00346717-02	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3[C@H](C(=O)N)CCC3)s2)c1		Inactive	PI3K alpha Inhibitor		1	Alpelisib	384568930	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.718851576	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3[C@H](C(=O)N)CCC3)s2)c1	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3[C@H](C(=O)N)CCC3)s2)c1
NCGC00386234-03	FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1		Inactive	EGFR Inhibitor		1	CEP-32496	363680161	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1	FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1
NCGC00166122-01	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	4.6999998	Active		0.0	1	Perflexane	144205881	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-26.7944338012	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
NCGC00167420-01	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	4.4000001	Active		0.0	1	Perflenapent	144205977	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-50.0370412359&-103.5153244556	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
NCGC00263162-08	FC(F)(F)C(F)(F)CNC(=O)C(C(=O)N[C@@H]1C(=O)Nc2c(-c3c1cccc3)cccc2)(C)C		Inactive	g-Secretase Inhibitor		1	RO-4929097	384568633	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.34646064	FC(F)(F)C(F)(F)CNC(=O)C(C(=O)N[C@@H]1C(=O)Nc2c(-c3c1cccc3)cccc2)(C)C	FC(F)(F)C(F)(F)CNC(=O)C(C(=O)N[C@@H]1C(=O)Nc2c(-c3c1cccc3)cccc2)(C)C
NCGC00496795-01	FC(F)(F)C(N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C		Inactive			1	WO2016044770	384569291	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	33.5089368319	FC(F)(F)C(N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C	FC(F)(F)C(N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C
NCGC00378920-01	FC(F)(F)C(O)(C(F)(F)F)CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	4.4000001	Active		0.0	1	Falecalcitriol	405558573	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-74.9786454759	FC(F)(F)C(O)(C(F)(F)F)CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	FC(F)(F)C(O)(C(F)(F)F)CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1
NCGC00379220-07	FC(F)(F)C(O)(C(F)(F)F)c1cc(F)c(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)cc1		Inactive	ROR-gamma Inverse Agonist		1	SR-2211	384569095	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)C(O)(C(F)(F)F)c1cc(F)c(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)cc1	FC(F)(F)C(O)(C(F)(F)F)c1cc(F)c(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)cc1
NCGC00167421-02	FC(F)(F)C(OCF)C(F)(F)F	4.4000001	Active	Gaba-b Receptor Modulator	0.0	1	Sevoflurane	225144283	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.6342685359	FC(F)(F)C(OCF)C(F)(F)F	FC(F)(F)C(OCF)C(F)(F)F
NCGC00482953-01	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1		Inactive	Tryptophan Hydroxylase 2 (TPH2) Inhibitor		1	LP-533401	384569262	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1
NCGC00480794-01	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1		Inactive	Tryptophan Hydroxylase 2 (TPH2) Inhibitor		1	LP-533401	384569246	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1
NCGC00371263-02	FC(F)(F)C=1C(C(=O)Nc2c(N3CCN(C)CC3)ccc(-c3cc(CN4CCOCC4)ccc3)c2)=CNC(=O)C=1	4.5999999	Active	Inhibitor of WDR5-MLL interaction.	0.0	1	OICR-9429	363678072	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.9106277944	FC(F)(F)C=1C(C(=O)Nc2c(N3CCN(C)CC3)ccc(-c3cc(CN4CCOCC4)ccc3)c2)=CNC(=O)C=1	FC(F)(F)C=1C(C(=O)Nc2c(N3CCN(C)CC3)ccc(-c3cc(CN4CCOCC4)ccc3)c2)=CNC(=O)C=1
NCGC00345841-02	FC(F)(F)C=1C=C(NC(C)C)n2nc(NC(=O)c3cnccc3)nc2C=1		Inactive	ASK1 Inhibitor		1	S-99	363677384	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.4250303999	FC(F)(F)C=1C=C(NC(C)C)n2nc(NC(=O)c3cnccc3)nc2C=1	FC(F)(F)C=1C=C(NC(C)C)n2nc(NC(=O)c3cnccc3)nc2C=1
NCGC00507841-02	FC(F)(F)CCC(=O)N[C@H](C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2c1cccc2)C		Inactive	Notch Signaling Inhibitor		1	Crenigacestat	384569323	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)CCC(=O)N[C@H](C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2c1cccc2)C	FC(F)(F)CCC(=O)N[C@H](C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2c1cccc2)C
NCGC00507871-01	FC(F)(F)CCNC=1c2n(c(-c3cc(C)c(C(=O)NC4CC4)cc3)cn2)N=C(Oc2c(F)c(F)c(OC)cc2)C=1		Inactive	MPS1 Inhibitor		1	BAY-1217389	384569344	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.01145432	FC(F)(F)CCNC=1c2n(c(-c3cc(C)c(C(=O)NC4CC4)cc3)cn2)N=C(Oc2c(F)c(F)c(OC)cc2)C=1	FC(F)(F)CCNC=1c2n(c(-c3cc(C)c(C(=O)NC4CC4)cc3)cn2)N=C(Oc2c(F)c(F)c(OC)cc2)C=1
NCGC00510498-01	FC(F)(F)CC[C@H](Oc1cc(C)c(c(C)c1)-c1ccc(C(C)(C)C)cc1)c1ccc(C(=O)NCCC(=O)O)cc1		Inactive	Glucagon Receptor (GCGR) Antagonist		1	Adomeglivant	384569460	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)CC[C@H](Oc1cc(C)c(c(C)c1)-c1ccc(C(C)(C)C)cc1)c1ccc(C(=O)NCCC(=O)O)cc1	FC(F)(F)CC[C@H](Oc1cc(C)c(c(C)c1)-c1ccc(C(C)(C)C)cc1)c1ccc(C(=O)NCCC(=O)O)cc1
NCGC00390592-01	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CC1CC1)C(=O)N[C@@H]1C(=O)Nc2c(F)cccc2C(c2ccccc2)=N1		Inactive	Notch Signaling Inhibitor		1	BMS-983970	363680919	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CC1CC1)C(=O)N[C@@H]1C(=O)Nc2c(F)cccc2C(c2ccccc2)=N1	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CC1CC1)C(=O)N[C@@H]1C(=O)Nc2c(F)cccc2C(c2ccccc2)=N1
NCGC00475729-01	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2		Inactive	Notch Signaling Inhibitor		1	BMS-906024	384569232	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2
NCGC00507883-01	FC(F)(F)CN1CCC([C@@H](C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1		Inactive	EZH2 Inhibitor		1	CPI-1205	384569348	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	30.34618884	FC(F)(F)CN1CCC([C@@H](C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1	FC(F)(F)CN1CCC([C@@H](C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1
NCGC00386364-01	FC(F)(F)CNC(=O)C1(CCCCN2CCC(NC(=O)c3c(-c4ccc(C(F)(F)F)cc4)cccc3)CC2)c2c(-c3c1cccc3)cccc2	4.4250002	Active	Microsomal triglyceride transfer protein large subunit Inhibitor&Microsomal Triglyceride Transfer Protein Large Subunit Inhibitor	0.0	1	Lomitapide	405558897	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-111.6570842215&-117.790676496	FC(F)(F)CNC(=O)C1(CCCCN2CCC(NC(=O)c3c(-c4ccc(C(F)(F)F)cc4)cccc3)CC2)c2c(-c3c1cccc3)cccc2	FC(F)(F)CNC(=O)C1(CCCCN2CCC(NC(=O)c3c(-c4ccc(C(F)(F)F)cc4)cccc3)CC2)c2c(-c3c1cccc3)cccc2
NCGC00402345-02	FC(F)(F)CNC(=O)[C@](Nc1nc(-c2c3c([nH]c2)nccc3)ncc1)(CC)C	4.5999999	Inactive	Jak2/3 Inhibitor	0.0	1	Decernotinib	363681031	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	18.037368744	FC(F)(F)CNC(=O)[C@](Nc1nc(-c2c3c([nH]c2)nccc3)ncc1)(CC)C	FC(F)(F)CNC(=O)[C@](Nc1nc(-c2c3c([nH]c2)nccc3)ncc1)(CC)C
NCGC00475741-01	FC(F)(F)COc1c(C(=O)NC2CCN(C(=O)CO)CC2)n(C)c2c1C(=O)N(CC(=O)c1ccccc1)C(CC)=C2		Inactive	Hedgehog Antagonist		1	TAK-441	384569236	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.90240036	FC(F)(F)COc1c(C(=O)NC2CCN(C(=O)CO)CC2)n(C)c2c1C(=O)N(CC(=O)c1ccccc1)C(CC)=C2	FC(F)(F)COc1c(C(=O)NC2CCN(C(=O)CO)CC2)n(C)c2c1C(=O)N(CC(=O)c1ccccc1)C(CC)=C2
NCGC00015443-17&NCGC00015443-22	FC(F)(F)COc1c(C(=O)NCC2NCCCC2)cc(OCC(F)(F)F)cc1		Inactive	Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blocker&Sodium Channel Protein Type 5 Subunit Alpha Blocker&Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blocker		2	Flecainide acetate	170464874&384567847	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-10.00178394&-20.76577034&19.068618272	FC(F)(F)COc1c(C(=O)NCC2NCCCC2)cc(OCC(F)(F)F)cc1	FC(F)(F)COc1c(C(=O)NCC2NCCCC2)cc(OCC(F)(F)F)cc1
NCGC00345882-03	FC(F)(F)COc1c(OCCN[C@@H](Cc2cc(C(=O)N)c3N(CCCO)CCc3c2)C)cccc1	4.4000001	Active	Alpha1-adrenoceptor Antagonists&alpha1-Adrenoceptor Antagonists	0.0	1	Silodosin	405558750	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-47.6828633839&-43.178900704	FC(F)(F)COc1c(OCCN[C@@H](Cc2cc(C(=O)N)c3N(CCCO)CCc3c2)C)cccc1	FC(F)(F)COc1c(OCCN[C@@H](Cc2cc(C(=O)N)c3N(CCCO)CCc3c2)C)cccc1
NCGC00507854-01	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(C)c5c(n(Cc6c[nH]nc6)c(C#N)c5)cc4)CC3)c2c1	5.0500002	Active	Histone methyl transferase Inhibitor	0.0	1	MI-503	384569332	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-83.0522766356	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(C)c5c(n(Cc6c[nH]nc6)c(C#N)c5)cc4)CC3)c2c1	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(C)c5c(n(Cc6c[nH]nc6)c(C#N)c5)cc4)CC3)c2c1
NCGC00510519-01	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(O)cc5n(Cc6c[nH]nc6)c(C#N)cc5c4)CC3)c2c1	4.75	Active	In vivo active Menin-MLL Inhibitor	0.0	1	MI-538	384569472	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-109.1575499483	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(O)cc5n(Cc6c[nH]nc6)c(C#N)cc5c4)CC3)c2c1	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(O)cc5n(Cc6c[nH]nc6)c(C#N)cc5c4)CC3)c2c1
NCGC00263223-02	FC(F)(F)Cn1c2nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(CCN(C)C)C)cc4)cc3)nc(N3CCOCC3)c2cc1	9.0	Inactive	PI3Kalpha Inhibitor	0.0	1	CAY-10626	384568677	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-18.179380236	FC(F)(F)Cn1c2nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(CCN(C)C)C)cc4)cc3)nc(N3CCOCC3)c2cc1	FC(F)(F)Cn1c2nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(CCN(C)C)C)cc4)cc3)nc(N3CCOCC3)c2cc1
NCGC00386361-02	FC(F)(F)Oc1c(Nc2nc3-c4n(CCO)nc(C(=O)N)c4CCc3cn2)cc(N2CCN(C)CC2)cc1	6.0500002	Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor	0.0	1	NMS-P937	384569128	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	24.5571831161	FC(F)(F)Oc1c(Nc2nc3-c4n(CCO)nc(C(=O)N)c4CCc3cn2)cc(N2CCN(C)CC2)cc1	FC(F)(F)Oc1c(Nc2nc3-c4n(CCO)nc(C(=O)N)c4CCc3cn2)cc(N2CCN(C)CC2)cc1
NCGC00263186-04	FC(F)(F)Oc1cc(-c2n3N=C(NCC4CCN(C)CC4)C=Cc3nc2)ccc1	4.5999999	Active	Pim-1/Flt3 Inhibitor	0.0	1	SGI-1776	384568653	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-112.5962669371	FC(F)(F)Oc1cc(-c2n3N=C(NCC4CCN(C)CC4)C=Cc3nc2)ccc1	FC(F)(F)Oc1cc(-c2n3N=C(NCC4CCN(C)CC4)C=Cc3nc2)ccc1
NCGC00402372-02	FC(F)(F)Oc1cc(-c2ncc(C[C@@H](NC(=O)c3sc(C)c(CCC)c3)C(=O)N[C@H]3CNCC3)cc2)ccc1	4.5	Active	Kinesin-Like Spindle Protein Inhibitor	0.0	1	AZ-82	384569218	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-122.5141468544	FC(F)(F)Oc1cc(-c2ncc(C[C@@H](NC(=O)c3sc(C)c(CCC)c3)C(=O)N[C@H]3CNCC3)cc2)ccc1	FC(F)(F)Oc1cc(-c2ncc(C[C@@H](NC(=O)c3sc(C)c(CCC)c3)C(=O)N[C@H]3CNCC3)cc2)ccc1
NCGC00356145-10	FC(F)(F)Oc1cc(CC(=O)Nc2nnc(CCCCc3sc(NC(=O)Cc4ncccc4)nn3)cc2)ccc1	4.4000001	Active	Glutaminase Inhibitor	0.0	1	CB-839	384569029	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-49.5912701359	FC(F)(F)Oc1cc(CC(=O)Nc2nnc(CCCCc3sc(NC(=O)Cc4ncccc4)nn3)cc2)ccc1	FC(F)(F)Oc1cc(CC(=O)Nc2nnc(CCCCc3sc(NC(=O)Cc4ncccc4)nn3)cc2)ccc1
NCGC00015882-15	FC(F)(F)Oc1cc2sc(N)nc2cc1		Inactive	Glutamate Release Inhibitor		1	Riluzole	170464928	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(F)Oc1cc2sc(N)nc2cc1	FC(F)(F)Oc1cc2sc(N)nc2cc1
NCGC00250382-06	FC(F)(F)Oc1ccc(-c2c(C)c(C(=O)Nc3cnc(N4C[C@@H](C)O[C@@H](C)C4)cc3)ccc2)cc1		Inactive	Smo Receptor Antagonist		1	Sonidegib	384568538	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)Oc1ccc(-c2c(C)c(C(=O)Nc3cnc(N4C[C@@H](C)O[C@@H](C)C4)cc3)ccc2)cc1	FC(F)(F)Oc1ccc(-c2c(C)c(C(=O)Nc3cnc(N4C[C@@H](C)O[C@@H](C)C4)cc3)ccc2)cc1
NCGC00263142-04	FC(F)(F)Oc1ccc(-c2cc3c(C(=O)C(=O)O)cn(Cc4ccccc4)c3cc2)cc1		Inactive	PAI Inhibitor		1	Tiplasinin	363677226	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)Oc1ccc(-c2cc3c(C(=O)C(=O)O)cn(Cc4ccccc4)c3cc2)cc1	FC(F)(F)Oc1ccc(-c2cc3c(C(=O)C(=O)O)cn(Cc4ccccc4)c3cc2)cc1
NCGC00507887-01	FC(F)(F)Oc1ccc(C(=O)NCCC(=O)N[C@H]2c3c(cccc3)CCC2)cc1		Inactive	DHODH Inhibitor		1	ML-390	384569351	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.674430624	FC(F)(F)Oc1ccc(C(=O)NCCC(=O)N[C@H]2c3c(cccc3)CCC2)cc1	FC(F)(F)Oc1ccc(C(=O)NCCC(=O)N[C@H]2c3c(cccc3)CCC2)cc1
NCGC00346682-08	FC(F)(F)Oc1ccc(CO[C@@H]2COc3n(cc([N+](=O)[O-])n3)C2)cc1		Inactive	Nitric Oxide (NO) Donors		1	PA-824	384568906	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.7112004839	FC(F)(F)Oc1ccc(CO[C@@H]2COc3n(cc([N+](=O)[O-])n3)C2)cc1	FC(F)(F)Oc1ccc(CO[C@@H]2COc3n(cc([N+](=O)[O-])n3)C2)cc1
NCGC00263159-10	FC(F)(F)Oc1ccc(NC(=O)c2c(NCc3c4c(ncc3)cccc4)ccs2)cc1		Inactive	PDGFR beta Inhibitor		1	OSI-930	363677236	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.589412172	FC(F)(F)Oc1ccc(NC(=O)c2c(NCc3c4c(ncc3)cccc4)ccs2)cc1	FC(F)(F)Oc1ccc(NC(=O)c2c(NCc3c4c(ncc3)cccc4)ccs2)cc1
NCGC00488771-02	FC(F)(F)Oc1ccc(Nc2n([C@@H]3C[C@H](C)CC(C)(C)C3)c3c(n2)cc(CCC(=O)O)cc3)cc1		Inactive	IDH1 Inhibitor		1	BAY-1436032	384569284	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.6708996359	FC(F)(F)Oc1ccc(Nc2n([C@@H]3C[C@H](C)CC(C)(C)C3)c3c(n2)cc(CCC(=O)O)cc3)cc1	FC(F)(F)Oc1ccc(Nc2n([C@@H]3C[C@H](C)CC(C)(C)C3)c3c(n2)cc(CCC(=O)O)cc3)cc1
NCGC00346808-03	FC(F)(F)Oc1ccc(Nc2ncnc(-c3cc(C(=O)N)ccc3)c2)cc1	4.4000001	Active	Bcr-Abl Inhibitor	0.0	1	GNF-2	384568942	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-101.8958280444	FC(F)(F)Oc1ccc(Nc2ncnc(-c3cc(C(=O)N)ccc3)c2)cc1	FC(F)(F)Oc1ccc(Nc2ncnc(-c3cc(C(=O)N)ccc3)c2)cc1
NCGC00390365-01	FC(F)(F)Oc1ccc(OC2CCN(c3ccc(OCC4(C)Oc5n(cc([N+](=O)[O-])n5)C4)cc3)CC2)cc1	4.4000001	Active		0.0	1	Delamanid	405558727	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.966296312	FC(F)(F)Oc1ccc(OC2CCN(c3ccc(OCC4(C)Oc5n(cc([N+](=O)[O-])n5)C4)cc3)CC2)cc1	FC(F)(F)Oc1ccc(OC2CCN(c3ccc(OCC4(C)Oc5n(cc([N+](=O)[O-])n5)C4)cc3)CC2)cc1
NCGC00505117-01&NCGC00505118-01	FC(F)(F)[C@@H](N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C		Inactive	CBP/p300 Inhibitor		2	NCGC00505117&NCGC00505118	384569316&384569317	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.4943652961&0.0	FC(F)(F)[C@@H](N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C	FC(F)(F)[C@@H](N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C
NCGC00346577-02	FC(F)(F)c1[nH]c(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)[nH]c4cc3)c2)nc1	4.5	Active	Raf kinase B/C Inhibitor	0.0	1	RAF-265 derivative	363677460	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-79.4904454104	FC(F)(F)c1[nH]c(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)[nH]c4cc3)c2)nc1	FC(F)(F)c1[nH]c(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)[nH]c4cc3)c2)nc1
NCGC00496841-01	FC(F)(F)c1c(-c2n(C)c(C34CCC(c5nc(C6CC(F)(F)C6)on5)(CC3)CC4)nn2)cccc1		Inactive	Smo Inhibitor		1	MK-4101	384569295	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.327563124	FC(F)(F)c1c(-c2n(C)c(C34CCC(c5nc(C6CC(F)(F)C6)on5)(CC3)CC4)nn2)cccc1	FC(F)(F)c1c(-c2n(C)c(C34CCC(c5nc(C6CC(F)(F)C6)on5)(CC3)CC4)nn2)cccc1
NCGC00510232-02	FC(F)(F)c1c(-c2nc(C(=O)Nc3c(N4CCC(N)(C)CC4)cccn3)c(N)nc2)nccc1	4.8499999	Active	PKC-alpha, PKC-theta Inhibitor	0.0	1	LXS-196	384569417	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-91.286513099	FC(F)(F)c1c(-c2nc(C(=O)Nc3c(N4CCC(N)(C)CC4)cccn3)c(N)nc2)nccc1	FC(F)(F)c1c(-c2nc(C(=O)Nc3c(N4CCC(N)(C)CC4)cccn3)c(N)nc2)nccc1
NCGC00510199-01	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc(N)c1	5.1999998	Active	PI3K Inhibitor	0.0	1	Bimiralisib	384569414	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-92.0084349824	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc(N)c1	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc(N)c1
NCGC00390655-01	FC(F)(F)c1c(-c2nc(Nc3ccc(C(F)(F)F)cc3)sc2)n2c(n1)C=CC=C2	6.0500002	Active	Polycomb Complex Protein BMI-1 Inhibitor	0.0	1	PTC-691	363680957	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-39.5359349141	FC(F)(F)c1c(-c2nc(Nc3ccc(C(F)(F)F)cc3)sc2)n2c(n1)C=CC=C2	FC(F)(F)c1c(-c2nc(Nc3ccc(C(F)(F)F)cc3)sc2)n2c(n1)C=CC=C2
NCGC00346499-02	FC(F)(F)c1c(C#N)ccc(NC(=O)[C@@](O)(COc2ccc(C#N)cc2)C)c1		Inactive	Selective Androgen Receptor Modulators (SARM)		1	Ostarine	384568804	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.9320429839	FC(F)(F)c1c(C#N)ccc(NC(=O)[C@@](O)(COc2ccc(C#N)cc2)C)c1	FC(F)(F)c1c(C#N)ccc(NC(=O)[C@@](O)(COc2ccc(C#N)cc2)C)c1
NCGC00263170-02	FC(F)(F)c1c(C(=O)N(C)C2CCN(c3nnc(-c4n(C)ncc4)c4c3cccc4)CC2)ccc(F)c1	4.4000001	Active	Smoothened (Smo) Receptor Antagonist	0.0	1	Taladegib	384568640	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-60.526679384	FC(F)(F)c1c(C(=O)N(C)C2CCN(c3nnc(-c4n(C)ncc4)c4c3cccc4)CC2)ccc(F)c1	FC(F)(F)c1c(C(=O)N(C)C2CCN(c3nnc(-c4n(C)ncc4)c4c3cccc4)CC2)ccc(F)c1
NCGC00345796-09	FC(F)(F)c1c(C)c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc23)ccc1		Inactive	PI3Kbeta Inhibitor		1	GSK-2636771	384568746	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1c(C)c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc23)ccc1	FC(F)(F)c1c(C)c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc23)ccc1
NCGC00180889-03	FC(F)(F)c1c(C)c(Nc2c(C(=O)O)cccn2)ccc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor&Prostaglandin G/h Synthase 2 Inhibitor		1	Flunixin meglumine	170466598	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	FC(F)(F)c1c(C)c(Nc2c(C(=O)O)cccn2)ccc1.O[C@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO	FC(F)(F)c1c(C)c(Nc2c(C(=O)O)cccn2)ccc1.O[C@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO
NCGC00509987-01	FC(F)(F)c1c(C)ccc(NC(=O)[C@@H]2[C@@H](N(C(=O)c3c(F)cccc3C)CCC2)c2ccc(NC3CCCC3)cc2)c1		Inactive	C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist		1	Avacopan	384569396	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-34.15924306	FC(F)(F)c1c(C)ccc(NC(=O)[C@@H]2[C@@H](N(C(=O)c3c(F)cccc3C)CCC2)c2ccc(NC3CCCC3)cc2)c1	FC(F)(F)c1c(C)ccc(NC(=O)[C@@H]2[C@@H](N(C(=O)c3c(F)cccc3C)CCC2)c2ccc(NC3CCCC3)cc2)c1
NCGC00522578-01	FC(F)(F)c1c(C2CCCC2)ccc(COc2cc3c([nH]c4[C@@H](CC(=O)O)CCc34)cc2)c1	3.0	Inactive	Lysophospholipid edg8 (S1P5) Receptor Agonist	0.0	1	Etrasimod	384569527	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	70.24195352	FC(F)(F)c1c(C2CCCC2)ccc(COc2cc3c([nH]c4[C@@H](CC(=O)O)CCc34)cc2)c1	FC(F)(F)c1c(C2CCCC2)ccc(COc2cc3c([nH]c4[C@@H](CC(=O)O)CCc34)cc2)c1
NCGC00347938-05	FC(F)(F)c1c(C2CCCCC2)ccc(CO/N=C(\C)/c2cc(CC)c(CN3CC(C(=O)O)C3)cc2)c1		Inactive	Lysophospholipid edg8 (S1P5) Receptor Ligands; Lysophospholipid edg1 (S1P1) Receptor Agonist		1	BAF-312	384568990	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1c(C2CCCCC2)ccc(CO/N=C(\C)/c2cc(CC)c(CN3CC(C(=O)O)C3)cc2)c1	FC(F)(F)c1c(C2CCCCC2)ccc(CO/N=C(\C)/c2cc(CC)c(CN3CC(C(=O)O)C3)cc2)c1
NCGC00522303-02&NCGC00522303-03	FC(F)(F)c1c(CN2C(=O)N(C[C@H](NCCCC(=O)O)c3ccccc3)C(=O)C(c3c(F)c(OC)ccc3)=C2C)c(F)ccc1		Inactive	GnRH (LHRH) Receptor Antagonist		2	Elagolix	384569515&384569516	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.274780488&-34.221409732	FC(F)(F)c1c(CN2C(=O)N(C[C@H](NCCCC(=O)O)c3ccccc3)C(=O)C(c3c(F)c(OC)ccc3)=C2C)c(F)ccc1	FC(F)(F)c1c(CN2C(=O)N(C[C@H](NCCCC(=O)O)c3ccccc3)C(=O)C(c3c(F)c(OC)ccc3)=C2C)c(F)ccc1
NCGC00378614-02	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)c1	4.75	Active	Bcr-Abl Inhibitor	0.0	1	Flumatinib mesylate	384569056	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-103.1276800336	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)c1
NCGC00347958-03	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1	6.0	Active	beta Cell Proliferation Inducer	0.0	1	WS-3	384569001	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-55.0433888036	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1
NCGC00351607-02	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3cnc4[nH]ncc4c3)c(C)cc2)c1	4.9000001	Active	Bcr-Abl Inhibitor	0.0	1	GZD-824	384569021	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-97.6307935268	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3cnc4[nH]ncc4c3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3cnc4[nH]ncc4c3)c(C)cc2)c1
NCGC00263152-12	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(C)cc2)c1	5.25	Active	FGFR Inhibitor&Proto-oncogene Tyrosine-protein Kinase Receptor Ret Inhibitor	0.0	1	Ponatinib	405558658	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-1.1	-97.046627353&-88.764643048	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(C)cc2)c1
NCGC00354729-02	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC)c3)cc2)c1	5.5	Active	Flt3 Inhibitor	0.0	1	AST-487	384569023	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-97.3123431807	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC)c3)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC)c3)cc2)c1
NCGC00390570-02	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(/C=C/c3c(OC)c4c([nH]cc4)nc3)c(C)cc2)c1	5.0	Active	Raf kinase B Inhibitor	0.0	1	HG-6-64-1	384569194	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.1973791601	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(/C=C/c3c(OC)c4c([nH]cc4)nc3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(/C=C/c3c(OC)c4c([nH]cc4)nc3)c(C)cc2)c1
NCGC00390558-02	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(NC(=O)c3cc(-c4sccc4)cnc3)c(C)cc2)c1	5.5	Active	RET Inhibitor	0.0	1	ALW-II-41-27	384569192	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-97.5359470812	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(NC(=O)c3cc(-c4sccc4)cnc3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(NC(=O)c3cc(-c4sccc4)cnc3)c(C)cc2)c1
NCGC00386698-03	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cncnc4)ccn3)c(C)cc2)c1		Inactive	Tyrosine-protein kinase Lyn  Inhibitor		1	Bafetinib (INNO-406)	363680403	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.4470613	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cncnc4)ccn3)c(C)cc2)c1	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cncnc4)ccn3)c(C)cc2)c1
NCGC00346514-04	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3ncc(-c4cncnc4)cn3)c(C)cc2)c1	4.4499998	Active	Bcr-Abl Inhibitor	0.0	1	Bafetinib	384568814	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-119.3490849405	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3ncc(-c4cncnc4)cn3)c(C)cc2)c1	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3ncc(-c4cncnc4)cn3)c(C)cc2)c1
NCGC00386723-01	FC(F)(F)c1c(CNC(=O)[C@H]2C[C@@H](Nc3nc(NC)nc(C)n3)CCC2)ccc(C#N)c1		Inactive	Soluble Epoxide Hydrolase Inhibitor		1	GSK-2256294A	363680418	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1c(CNC(=O)[C@H]2C[C@@H](Nc3nc(NC)nc(C)n3)CCC2)ccc(C#N)c1	FC(F)(F)c1c(CNC(=O)[C@H]2C[C@@H](Nc3nc(NC)nc(C)n3)CCC2)ccc(C#N)c1
NCGC00415059-02	FC(F)(F)c1c(Cc2c(C(=O)N3OC[C@](O)(C)C3)c3C(=O)N(C)C(=O)N(C(C)C)c3s2)c(C)[nH]n1		Inactive	MCT2 Inhibitor		1	AZD-3965	384569222	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.3350846241	FC(F)(F)c1c(Cc2c(C(=O)N3OC[C@](O)(C)C3)c3C(=O)N(C)C(=O)N(C(C)C)c3s2)c(C)[nH]n1	FC(F)(F)c1c(Cc2c(C(=O)N3OC[C@](O)(C)C3)c3C(=O)N(C)C(=O)N(C(C)C)c3s2)c(C)[nH]n1
NCGC00511388-01	FC(F)(F)c1c(F)c(C(=O)N2CCC(N3CC(CC#N)(n4ncc(-c5ncnc6[nH]ccc56)c4)C3)CC2)ccn1		Inactive	Jak1 Inhibitor		1	Itacitinib	384569502	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.0617668799	FC(F)(F)c1c(F)c(C(=O)N2CCC(N3CC(CC#N)(n4ncc(-c5ncnc6[nH]ccc56)c4)C3)CC2)ccn1	FC(F)(F)c1c(F)c(C(=O)N2CCC(N3CC(CC#N)(n4ncc(-c5ncnc6[nH]ccc56)c4)C3)CC2)ccn1
NCGC00386428-07	FC(F)(F)c1c(F)ccc(-c2nc(n(C)c2)C2CCN(c3ncnc4[nH]ncc34)CC2)c1		Inactive	Ribosomal Protein S6 Kinase beta (p70S6K) Inhibitor		1	LY-2584702	384569138	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1c(F)ccc(-c2nc(n(C)c2)C2CCN(c3ncnc4[nH]ncc34)CC2)c1	FC(F)(F)c1c(F)ccc(-c2nc(n(C)c2)C2CCN(c3ncnc4[nH]ncc34)CC2)c1
NCGC00350264-01	FC(F)(F)c1c(F)ccc(-c2noc(CNC(=O)CCCc3nc4ncccc4cc3)c2)c1		Inactive	GPR91 Inhibitor		1	PRP003-062	384569003	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.053291868	FC(F)(F)c1c(F)ccc(-c2noc(CNC(=O)CCCc3nc4ncccc4cc3)c2)c1	FC(F)(F)c1c(F)ccc(-c2noc(CNC(=O)CCCc3nc4ncccc4cc3)c2)c1
NCGC00378793-02	FC(F)(F)c1c(F)ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)c1		Inactive	Chemokine CXCR3 Receptor Antagonist		1	NBI-74330	384569069	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.16480944	FC(F)(F)c1c(F)ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)c1	FC(F)(F)c1c(F)ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)c1
NCGC00189393-09	FC(F)(F)c1c(F)ccc(NC(=O)Nc2sc(-c3ccncc3)nn2)c1	5.5	Inactive	BLM Inhibitor	0.0	1	NCGC00189393	363677130	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	65.3982537596	FC(F)(F)c1c(F)ccc(NC(=O)Nc2sc(-c3ccncc3)nn2)c1	FC(F)(F)c1c(F)ccc(NC(=O)Nc2sc(-c3ccncc3)nn2)c1
NCGC00263215-04	FC(F)(F)c1c(N2CCN(C(=O)CC)CC2)ccc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc4c(c3)cccc4)c2)c1	9.0	Inactive	mTOR Inhibitor	0.0	1	Torin-1	384568670	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-41.815637267	FC(F)(F)c1c(N2CCN(C(=O)CC)CC2)ccc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc4c(c3)cccc4)c2)c1	FC(F)(F)c1c(N2CCN(C(=O)CC)CC2)ccc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc4c(c3)cccc4)c2)c1
NCGC00389726-01	FC(F)(F)c1c(NC(=O)C2C3(C)C(C4C(C5(C)C=CC(=O)NC5CC4)CC3)CC2)cc(C(F)(F)F)cc1		Inactive	Steroid 5alpha-reductase Inhibitor&Steroid 5alpha-Reductase Inhibitors		1	NCGC00389726-01&Dutasteride	405558728	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.6347313879&0.0	FC(F)(F)c1c(NC(=O)C2C3(C)C(C4C(C5(C)C=CC(=O)NC5CC4)CC3)CC2)cc(C(F)(F)F)cc1	FC(F)(F)c1c(NC(=O)C2C3(C)C(C4C(C5(C)C=CC(=O)NC5CC4)CC3)CC2)cc(C(F)(F)F)cc1
NCGC00164571-04	FC(F)(F)c1c(NC(=O)[C@@H]2[C@]3(C)[C@H]([C@H]4C([C@]5(C)[C@H](NC(=O)C=C5)CC4)CC3)CC2)cc(C(F)(F)F)cc1		Inactive	Steroid 5alpha-Reductase Inhibitors		1	Dutasteride	384568256	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.68318484	FC(F)(F)c1c(NC(=O)[C@@H]2[C@]3(C)[C@H]([C@H]4C([C@]5(C)[C@H](NC(=O)C=C5)CC4)CC3)CC2)cc(C(F)(F)F)cc1	FC(F)(F)c1c(NC(=O)[C@@H]2[C@]3(C)[C@H]([C@H]4C([C@]5(C)[C@H](NC(=O)C=C5)CC4)CC3)CC2)cc(C(F)(F)F)cc1
NCGC00488701-03	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C#N)cc2)n1	4.5500002	Inactive	Solute Carrier Family 2, Facilitated Glucose Transporter Member 1 (GLUT-1; SLC2A1) Inhibitor	0.0	1	BAY-876	384569283	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-22.9483753584	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C#N)cc2)n1	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C#N)cc2)n1
NCGC00510779-01	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C(C)(C)C)cc2)n1	4.0	Inactive	Orally bioavailable GLUT1 Inhibitor for oncology	0.0	1	BAY-876	384569491	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-14.933082616	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C(C)(C)C)cc2)n1	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C(C)(C)C)cc2)n1
NCGC00346652-08	FC(F)(F)c1c(NC2CCC2)nc(Nc2cc3[C@@H]4N(C(=O)CNC(=O)C)[C@H](c3cc2)CC4)nc1	5.5	Active	Aurora Kinase Inhibitor	0.0	1	PF-03814735	384568883	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-69.9876563358	FC(F)(F)c1c(NC2CCC2)nc(Nc2cc3[C@@H]4N(C(=O)CNC(=O)C)[C@H](c3cc2)CC4)nc1	FC(F)(F)c1c(NC2CCC2)nc(Nc2cc3[C@@H]4N(C(=O)CNC(=O)C)[C@H](c3cc2)CC4)nc1
NCGC00386293-01	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1	6.0	Active	EGFR (Thr790Met Mutant) Inhibitor	0.0	1	Rociletinib	384569121	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-68.6312403453	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1
NCGC00386271-02	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(NC3CN(CCF)C3)cc2)nc1	4.75	Active	EGFR Inhibitor	0.0	1	CNX-2006	384569119	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.2072649234	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(NC3CN(CCF)C3)cc2)nc1	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(NC3CN(CCF)C3)cc2)nc1
NCGC00510495-01	FC(F)(F)c1c(OCCCCCCC)ccc(CCC(N)(CO)CO)c1	4.4000001	Active	Lysophospholipid edg1 (S1P1) Receptor Ligands	0.0	1	Amiselimod hydrochloride	384569457	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-107.2849525427	FC(F)(F)c1c(OCCCCCCC)ccc(CCC(N)(CO)CO)c1	FC(F)(F)c1c(OCCCCCCC)ccc(CCC(N)(CO)CO)c1
NCGC00263112-02	FC(F)(F)c1c([C@H](Oc2c(C(=O)N)sc(-n3c4c(nc3)ccc(CN3CCN(C)CC3)c4)c2)C)cccc1	9.0	Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor	0.0	1	GSK-461364A	384568598	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-15.242824772	FC(F)(F)c1c([C@H](Oc2c(C(=O)N)sc(-n3c4c(nc3)ccc(CN3CCN(C)CC3)c4)c2)C)cccc1	FC(F)(F)c1c([C@H](Oc2c(C(=O)N)sc(-n3c4c(nc3)ccc(CN3CCN(C)CC3)c4)c2)C)cccc1
NCGC00015452-20&NCGC00015452-23	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(C)C)c1	4.51250005	Active	Androgen Receptor Antagonist	0.22499990000000025	2	Flutamide	170464921&384567851	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0&-3.0	-89.6065866195&-69.511891176&-46.5490706811	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(C)C)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(C)C)c1
NCGC00091014-06	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(O)(C)C)c1	4.4000001	Active	Androgen Receptor Antagonist	0.0	1	Hydroxyflutamide	174007324	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-42.4827651959	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(O)(C)C)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(O)(C)C)c1
NCGC00263150-04	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)[C@@](O)(COc2ccc(NC(=O)C)cc2)C)c1		Inactive	Selective Androgen Receptor Modulators (SARM)		1	Andarine	363677230	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)[C@@](O)(COc2ccc(NC(=O)C)cc2)C)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)[C@@](O)(COc2ccc(NC(=O)C)cc2)C)c1
NCGC00249912-01	FC(F)(F)c1c2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2ccc1	4.6999998	Active	Prostaglandin G/h Synthase 2 Inhibitor	0.0	1	Floctafenine	170465681	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-48.9170426276	FC(F)(F)c1c2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2ccc1	FC(F)(F)c1c2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2ccc1
NCGC00511354-01	FC(F)(F)c1cc(-c2n3N=C(NC4CCC(C(O)(C)C)CC4)C=Cc3nc2)ccc1		Inactive	Pim-1/3 kinase Inhibitor		1	TP-3654	384569498	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	8.8757971359	FC(F)(F)c1cc(-c2n3N=C(NC4CCC(C(O)(C)C)CC4)C=Cc3nc2)ccc1	FC(F)(F)c1cc(-c2n3N=C(NC4CCC(C(O)(C)C)CC4)C=Cc3nc2)ccc1
NCGC00345836-13	FC(F)(F)c1cc(/C=C\2/C(=O)NC(=O)S/2)ccc1	4.4000001	Active	Pim-1 Kinase Inhibitor	0.0	1	SMI-4a	384568760	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-35.611201312	FC(F)(F)c1cc(/C=C\2/C(=O)NC(=O)S/2)ccc1	FC(F)(F)c1cc(/C=C\2/C(=O)NC(=O)S/2)ccc1
NCGC00480775-01	FC(F)(F)c1cc(C(=O)NCC(=O)N2C[C@@H](NC3CCC(O)(c4ncc(-c5ncccn5)cc4)CC3)CC2)ccc1		Inactive	Chemokine CCR2 (MCP-1 Receptor) Antagonist		1	INCB8761 (PF-4136309)	384569243	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-36.134389328	FC(F)(F)c1cc(C(=O)NCC(=O)N2C[C@@H](NC3CCC(O)(c4ncc(-c5ncccn5)cc4)CC3)CC2)ccc1	FC(F)(F)c1cc(C(=O)NCC(=O)N2C[C@@H](NC3CCC(O)(c4ncc(-c5ncccn5)cc4)CC3)CC2)ccc1
NCGC00476210-01	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5cnc(C)cc5)ncc4C3)c(C)cc2)ccc1	5.4000001	Active	Bcr-Abl Inhibitor	0.0	1	GNF-7	377020190	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-90.3823330478	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5cnc(C)cc5)ncc4C3)c(C)cc2)ccc1	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5cnc(C)cc5)ncc4C3)c(C)cc2)ccc1
NCGC00167403-06	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5n(C)nc(C)c5)ncc4C3)c(C)cc2)ccc1	5.1500001	Active	Dual RASGAP/Erk Inhibitor	0.0	1	Pluripotin	384568310	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-106.9071694653	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5n(C)nc(C)c5)ncc4C3)c(C)cc2)ccc1	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5n(C)nc(C)c5)ncc4C3)c(C)cc2)ccc1
NCGC00511383-01	FC(F)(F)c1cc(C(=O)Nc2cc(c(C)nc2)-c2cc(N3CCOCC3)c(OC3CCOCC3)nc2)ccc1	4.4000001	Active	Raf A/B/C kinase Inhibitor	0.0	1	RAF-709	384569500	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-57.6280569852	FC(F)(F)c1cc(C(=O)Nc2cc(c(C)nc2)-c2cc(N3CCOCC3)c(OC3CCOCC3)nc2)ccc1	FC(F)(F)c1cc(C(=O)Nc2cc(c(C)nc2)-c2cc(N3CCOCC3)c(OC3CCOCC3)nc2)ccc1
NCGC00508985-02	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C(/C(=O)N)\c3cncnc3)cn2)c1	5.9000001	Active	Exportin-1 Antagonist	0.0	1	Eltanexor	384569373	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-93.9878394904	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C(/C(=O)N)\c3cncnc3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C(/C(=O)N)\c3cncnc3)cn2)c1
NCGC00386310-03	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3nccnc3)cn2)c1	5.5500002	Active	Exportin-1 Antagonist	0.0	1	Selinexor	363680201	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.1843352533	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3nccnc3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3nccnc3)cn2)c1
NCGC00390569-01	FC(F)(F)c1cc(C(F)(F)F)cc(C(C(=O)N(C)c2c(-c3c(C)cccc3)cc(N3CCN(C)CC3)nc2)(C)C)c1	4.4000001	Active		0.0	1	Netupitant	363680908	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.0429437919	FC(F)(F)c1cc(C(F)(F)F)cc(C(C(=O)N(C)c2c(-c3c(C)cccc3)cc(N3CCN(C)CC3)nc2)(C)C)c1	FC(F)(F)c1cc(C(F)(F)F)cc(C(C(=O)N(C)c2c(-c3c(C)cccc3)cc(N3CCN(C)CC3)nc2)(C)C)c1
NCGC00346703-08	FC(F)(F)c1cc(C(F)(F)F)cc(CN(C(=O)OC)[C@@H]2c3c(N(C(=O)OCC)[C@H](CC)C2)ccc(C(F)(F)F)c3)c1		Inactive	Cholesteryl Ester Transfer Protein (CETP) Inhibitor		1	Torcetrapib	384568922	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(CN(C(=O)OC)[C@@H]2c3c(N(C(=O)OCC)[C@H](CC)C2)ccc(C(F)(F)F)c3)c1	FC(F)(F)c1cc(C(F)(F)F)cc(CN(C(=O)OC)[C@@H]2c3c(N(C(=O)OCC)[C@H](CC)C2)ccc(C(F)(F)F)c3)c1
NCGC00386231-04	FC(F)(F)c1cc(C(F)(F)F)cc(CN([C@@H]2c3c(N(CC4CCC(C(=O)O)CC4)CCC2)c(C)cc(C)c3)c2nn(C)nn2)c1		Inactive	Cholesteryl Ester Transfer Protein (CETP) Inhibitor		1	Evacetrapib (LY2484595)	384569117	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-33.124669228	FC(F)(F)c1cc(C(F)(F)F)cc(CN([C@@H]2c3c(N(CC4CCC(C(=O)O)CC4)CCC2)c(C)cc(C)c3)c2nn(C)nn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(CN([C@@H]2c3c(N(CC4CCC(C(=O)O)CC4)CCC2)c(C)cc(C)c3)c2nn(C)nn2)c1
NCGC00346671-06	FC(F)(F)c1cc(C(F)(F)F)cc([C@@H]2[C@H](C)N(Cc3c(-c4c(OC)cc(F)c(C(C)C)c4)ccc(C(F)(F)F)c3)C(=O)O2)c1		Inactive	Cholesteryl Ester Transfer Protein (CETP) Inhibitor		1	Anacetrapib	384568897	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc([C@@H]2[C@H](C)N(Cc3c(-c4c(OC)cc(F)c(C(C)C)c4)ccc(C(F)(F)F)c3)C(=O)O2)c1	FC(F)(F)c1cc(C(F)(F)F)cc([C@@H]2[C@H](C)N(Cc3c(-c4c(OC)cc(F)c(C(C)C)c4)ccc(C(F)(F)F)c3)C(=O)O2)c1
NCGC00167574-03	FC(F)(F)c1cc(C2=CCN(CCc3cc4c(cc3)cccc4)CC2)ccc1	4.4000001	Active	Serotonin 1a (5-HT1a) receptor Agonist	0.0	1	Xaliproden hydrochloride	170465603	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.4924717199	FC(F)(F)c1cc(C2=CCN(CCc3cc4c(cc3)cccc4)CC2)ccc1.Cl	FC(F)(F)c1cc(C2=CCN(CCc3cc4c(cc3)cccc4)CC2)ccc1.Cl
NCGC00263019-01	FC(F)(F)c1cc(C2CCN(C(=O)[C@@]([C@H](c3c(OC)cccc3)c3c4c(ccc3)cccc4)(C#N)C)CC2)ccc1		Inactive	NF-kappaB Activation Inhibitor		1	WAY-204688	137275923	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1cc(C2CCN(C(=O)[C@@]([C@H](c3c(OC)cccc3)c3c4c(ccc3)cccc4)(C#N)C)CC2)ccc1	FC(F)(F)c1cc(C2CCN(C(=O)[C@@]([C@H](c3c(OC)cccc3)c3c4c(ccc3)cccc4)(C#N)C)CC2)ccc1
NCGC00346070-02	FC(F)(F)c1cc(CC(=O)N2c3c(cc(-c4c5c(N)ncnc5n(C)c4)cc3)CC2)ccc1		Inactive	PERK Inhibitor		1	GSK-2606414	384568773	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.1981483519	FC(F)(F)c1cc(CC(=O)N2c3c(cc(-c4c5c(N)ncnc5n(C)c4)cc3)CC2)ccc1	FC(F)(F)c1cc(CC(=O)N2c3c(cc(-c4c5c(N)ncnc5n(C)c4)cc3)CC2)ccc1
NCGC00181002-04&NCGC00181002-10	FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1	4.47500015	Active	Calcium-sensing Receptor (casr) Agonist&Calcium-Sensing Receptor (CaSR) Agonist&Calcium-Sensing Receptor (CaSR) Agonist	0.15000010000000064	2	Cinacalcet hydrochloride	170465336&384568386	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1&-3.0	-86.809725352&-105.2180118147&-106.7469166452	FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1.Cl	FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1.Cl&FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1
NCGC00345800-03	FC(F)(F)c1cc(Cn2ncc(-c3[nH]c4C(=O)N(CCC)C(=O)N(CC)c4n3)c2)ccc1		Inactive	Adenosine A2B Antagonist		1	CVT-6883	384568749	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.002546204	FC(F)(F)c1cc(Cn2ncc(-c3[nH]c4C(=O)N(CCC)C(=O)N(CC)c4n3)c2)ccc1	FC(F)(F)c1cc(Cn2ncc(-c3[nH]c4C(=O)N(CCC)C(=O)N(CC)c4n3)c2)ccc1
NCGC00263216-02	FC(F)(F)c1cc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc(N)cc3)c2)ccc1	6.0	Active	mTOR Inhibitor	0.0	1	Torin-2	174006464	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-62.9930651157	FC(F)(F)c1cc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc(N)cc3)c2)ccc1	FC(F)(F)c1cc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc(N)cc3)c2)ccc1
NCGC00386567-02	FC(F)(F)c1cc(N2CCN(CCN3C(=O)Nc4c3cccc4)CC2)ccc1	4.4250002	Active	Serotonin 2a (5-ht2a) Receptor Antagonist&Serotonin 2a (5-HT2a) receptor Antagonist	0.0	1	FLIBANSERIN	405558804	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-69.1882382559&-73.357564396	FC(F)(F)c1cc(N2CCN(CCN3C(=O)Nc4c3cccc4)CC2)ccc1	FC(F)(F)c1cc(N2CCN(CCN3C(=O)Nc4c3cccc4)CC2)ccc1
NCGC00378936-02	FC(F)(F)c1cc(N2[C@@H](CC(=O)O)c3c(c(F)ccc3)N=C2N2CCN(c3cc(OC)ccc3)CC2)c(OC)cc1		Inactive	Tripartite Terminase Subunit Ul28 Homolog Inhibitor&Tripartite terminase subunit UL28 homolog Inhibitor		1	Letermovir	405559086	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.535163548&-22.9218804679	FC(F)(F)c1cc(N2[C@@H](CC(=O)O)c3c(c(F)ccc3)N=C2N2CCN(c3cc(OC)ccc3)CC2)c(OC)cc1	FC(F)(F)c1cc(N2[C@@H](CC(=O)O)c3c(c(F)ccc3)N=C2N2CCN(c3cc(OC)ccc3)CC2)c(OC)cc1
NCGC00499575-01	FC(F)(F)c1cc(N2[C@H]3CN(c4ncc(C(=O)NO)cn4)[C@@H](C2)C3)ncc1		Inactive	HDAC Inhibitor		1	HDACi-02	384569307	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1cc(N2[C@H]3CN(c4ncc(C(=O)NO)cn4)[C@@H](C2)C3)ncc1	FC(F)(F)c1cc(N2[C@H]3CN(c4ncc(C(=O)NO)cn4)[C@@H](C2)C3)ncc1
NCGC00481611-02	FC(F)(F)c1cc(NC(=O)Nc2c(F)cc(-c3c(COC)c(CN4CCOCC4)n4N=CN=C(N)c34)cc2)c(F)cc1	5.0999999	Active	FGFR Inhibitor	0.0	1	ACTB-1003	377020235	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-79.606594671	FC(F)(F)c1cc(NC(=O)Nc2c(F)cc(-c3c(COC)c(CN4CCOCC4)n4N=CN=C(N)c34)cc2)c(F)cc1	FC(F)(F)c1cc(NC(=O)Nc2c(F)cc(-c3c(COC)c(CN4CCOCC4)n4N=CN=C(N)c34)cc2)c(F)cc1
NCGC00346936-13	FC(F)(F)c1cc(NC(=O)Nc2cc(Nc3cc4NC(=O)/C(=C\c5[nH]ccc5)/c4cc3)c(C)cc2)c(F)cc1	4.4000001	Active	Trk A/B/C Inhibitor	0.0	1	GNF-5837	384568971	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-73.279774252	FC(F)(F)c1cc(NC(=O)Nc2cc(Nc3cc4NC(=O)/C(=C\c5[nH]ccc5)/c4cc3)c(C)cc2)c(F)cc1	FC(F)(F)c1cc(NC(=O)Nc2cc(Nc3cc4NC(=O)/C(=C\c5[nH]ccc5)/c4cc3)c(C)cc2)c(F)cc1
NCGC00242057-03	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3c(-c4ccc(OC)cc4)oc4ncnc(N)c34)cc2)c(F)cc1		Inactive	Tie-2 kinase Inhibitor		1	GW-768505A	384568485	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3c(-c4ccc(OC)cc4)oc4ncnc(N)c34)cc2)c(F)cc1	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3c(-c4ccc(OC)cc4)oc4ncnc(N)c34)cc2)c(F)cc1
NCGC00263214-02	FC(F)(F)c1cc(NC(=O)c2c(C)n(CCCN3CCOCC3)c(-c3ccccc3)c2)ccc1	4.5	Active	TRPV4 Antagonist	0.0	1	HC-067047	363677270	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-33.4848560185	FC(F)(F)c1cc(NC(=O)c2c(C)n(CCCN3CCOCC3)c(-c3ccccc3)c2)ccc1	FC(F)(F)c1cc(NC(=O)c2c(C)n(CCCN3CCOCC3)c(-c3ccccc3)c2)ccc1
NCGC00507846-01	FC(F)(F)c1cc(NC(=O)c2c3c(cc(Oc4ncnc(CO)c4)cc3)ccc2)ccc1	4.5	Active	VEGFR-2 Inhibitor	0.0	1	BFH-772	384569327	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-33.4619654679	FC(F)(F)c1cc(NC(=O)c2c3c(cc(Oc4ncnc(CO)c4)cc3)ccc2)ccc1	FC(F)(F)c1cc(NC(=O)c2c3c(cc(Oc4ncnc(CO)c4)cc3)ccc2)ccc1
NCGC00347217-03	FC(F)(F)c1cc(NC(=O)c2cc(C#CC3=Cn4nccc4N=C3)c(CC)cc2)cc(CN2CCN(C)CC2)c1	4.6500001	Active	DDR1 Inhibitor	0.0	1	PRP003-013	377020175	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-110.2643282854	FC(F)(F)c1cc(NC(=O)c2cc(C#CC3=Cn4nccc4N=C3)c(CC)cc2)cc(CN2CCN(C)CC2)c1	FC(F)(F)c1cc(NC(=O)c2cc(C#CC3=Cn4nccc4N=C3)c(CC)cc2)cc(CN2CCN(C)CC2)c1
NCGC00183285-06&NCGC00183285-15	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)ccn3)c(C)cc2)cc(-n2cc(C)nc2)c1	5.04999995	Active	Bcr-Abl Inhibitor&Bcr-abl Kinase Inhibitor	0.7999996999999999	2	Nilotinib	384568418&405558616	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.2	-34.9067032093&-60.7171310095	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)ccn3)c(C)cc2)cc(-n2cc(C)nc2)c1	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)ccn3)c(C)cc2)cc(-n2cc(C)nc2)c1
NCGC00249391-11	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)nc4n(C)ncc34)c(C)cc2)ccc1	5.5500002	Active	Raf kinase B/C Inhibitor	0.0	1	NVP-BHG712	384568526	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-65.6070692717	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)nc4n(C)ncc34)c(C)cc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)nc4n(C)ncc34)c(C)cc2)ccc1
NCGC00263199-04	FC(F)(F)c1cc(NC(=O)c2cc(Oc3c(-c4nc(NC)ncc4)cccn3)c(C)cc2)ccc1	4.5999999	Active	Tie-2 kinase Inhibitor	0.0	1	AMG-Tie2-1	384568659	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-35.3271287417	FC(F)(F)c1cc(NC(=O)c2cc(Oc3c(-c4nc(NC)ncc4)cccn3)c(C)cc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(Oc3c(-c4nc(NC)ncc4)cccn3)c(C)cc2)ccc1
NCGC00263206-04	FC(F)(F)c1cc(NC(=O)c2cc(c(C)cc2)-c2cc3c(nc(NCCN4CCOCC4)nc3)cc2)ccc1	4.5	Active	Lck Kinase Inhibitor	0.0	1	AMG-47a	384568665	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-93.8721784751	FC(F)(F)c1cc(NC(=O)c2cc(c(C)cc2)-c2cc3c(nc(NCCN4CCOCC4)nc3)cc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(c(C)cc2)-c2cc3c(nc(NCCN4CCOCC4)nc3)cc2)ccc1
NCGC00016490-12	FC(F)(F)c1cc(Nc2c(C(=O)O)cccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Flufenamic acid	170465857	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	FC(F)(F)c1cc(Nc2c(C(=O)O)cccc2)ccc1	FC(F)(F)c1cc(Nc2c(C(=O)O)cccc2)ccc1
NCGC00346741-02	FC(F)(F)c1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]2O)ccc1	4.8499999	Active	Prostanoid TP Agonist	0.0	1	Travoprost	405558495	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-103.6740791851	FC(F)(F)c1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]2O)ccc1	FC(F)(F)c1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]2O)ccc1
NCGC00480777-01	FC(F)(F)c1cc([C@H](OC[C@]2(c3ccccc3)NC[C@]3(NC(=O)CC3)CC2)C)cc(C(F)(F)F)c1	4.4499998	Active	Tachykinin NK1 Antagonist	0.0	1	Rolapitant	384569244	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-104.9417123008	FC(F)(F)c1cc([C@H](OC[C@]2(c3ccccc3)NC[C@]3(NC(=O)CC3)CC2)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](OC[C@]2(c3ccccc3)NC[C@]3(NC(=O)CC3)CC2)C)cc(C(F)(F)F)c1
NCGC00181785-01&NCGC00344566-01	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)N=N3)CCO2)C2CCC(F)CC2)C)cc(C(F)(F)F)c1	4.4375	Active	Tachykinin NK1 Antagonist&Neurokinin 1 Receptor Antagonist&Tachykinin NK1 Antagonist	0.0749998000000005	2	Aprepitant&NCGC00344566-01&Aprepitant	50126334&170464796	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-3.0	-105.1882732518&-39.420574384&-99.7300471772	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)N=N3)CCO2)C2CCC(F)CC2)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)N=N3)CCO2)C2CCC(F)CC2)C)cc(C(F)(F)F)c1
NCGC00346489-03	FC(F)(F)c1cc([N+](=O)[O-])c2SC(N3CCC4(OC(C)CO4)CC3)=NC(=O)c2c1	4.3499999	Active	tuberculosis pathway Inhibitor	0.0	1	BTZ-10526043	363677423	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-33.3616419631	FC(F)(F)c1cc([N+](=O)[O-])c2SC(N3CCC4(OC(C)CO4)CC3)=NC(=O)c2c1	FC(F)(F)c1cc([N+](=O)[O-])c2SC(N3CCC4(OC(C)CO4)CC3)=NC(=O)c2c1
NCGC00532514-01	FC(F)(F)c1cc2/C(=C/CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3	4.75	Active	Serotonin 2 (5-ht2) Receptor Antagonist&Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	FLUPENTIXOL DECANOATE	405558676	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-55.5908229258&-46.781753136	FC(F)(F)c1cc2/C(=C/CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2/C(=C/CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3
NCGC00181168-01	FC(F)(F)c1cc2N(CC(CN(C)C)C)c3c(Sc2cc1)cccc3	4.6750002	Active		0.0	1	Trifluomeprazine 2-butenedioate	144206322	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-109.5622819506&-89.4459468418	FC(F)(F)c1cc2N(CC(CN(C)C)C)c3c(Sc2cc1)cccc3.O=C(O)C=CC(=O)O	FC(F)(F)c1cc2N(CC(CN(C)C)C)c3c(Sc2cc1)cccc3.O=C(O)C=CC(=O)O
NCGC00016012-12	FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	4.4250002	Active	Muscarinic acetylcholine receptor M2 Antagonist&Muscarinic Acetylcholine Receptor M2 Antagonist	0.0	1	Triflupromazine hydrochloride	170465325	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-124.4900460073&-96.990925356	FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl	FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl
NCGC00013226-25&NCGC00186653-01	FC(F)(F)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	4.625	Active	CaMK-II Inhibitor&Dopamine Receptor D2 Antagonist&Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers	0.050000199999999495	2	Trifluoperazine hydrochloride&NCGC00186653-01&Fluoperazine dihydrochloride	384567788&170465265	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0&-2.2	-63.2317678252&-113.8471785171&-58.3114453256	FC(F)(F)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3&FC(F)(F)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3.Cl.Cl
NCGC00386699-01	FC(F)(F)c1cc2N(CCCN3CCN(CCOC(=O)CCCCCCCCC)CC3)c3c(Sc2cc1)cccc3	4.6999998	Active		0.0	1	Fluphenazine decanoate dihydrochloride	405558673	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-91.7135496044&-57.8637982252	FC(F)(F)c1cc2N(CCCN3CCN(CCOC(=O)CCCCCCCCC)CC3)c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2N(CCCN3CCN(CCOC(=O)CCCCCCCCC)CC3)c3c(Sc2cc1)cccc3
NCGC00522550-01	FC(F)(F)c1cc2[C@H]3O[C@@H](CNC(=O)NCCN(C)C)CC[C@H]3[C@H](c3ccccc3)Nc2cc1	4.5999999	Active	Kinesin-like Spindle Protein KIF11 (KSP; Eg5) Inhibitor	0.0	1	EMD-534085	384569525	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-66.639820682	FC(F)(F)c1cc2[C@H]3O[C@@H](CNC(=O)NCCN(C)C)CC[C@H]3[C@H](c3ccccc3)Nc2cc1	FC(F)(F)c1cc2[C@H]3O[C@@H](CNC(=O)NCCN(C)C)CC[C@H]3[C@H](c3ccccc3)Nc2cc1
NCGC00522492-01	FC(F)(F)c1cc2nc(/C=C/C(=O)c3ccncc3)ccc2cc1		Inactive	PFKFB3 Inhibitor		1	PFK-158	384569521	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.911544828	FC(F)(F)c1cc2nc(/C=C/C(=O)c3ccncc3)ccc2cc1	FC(F)(F)c1cc2nc(/C=C/C(=O)c3ccncc3)ccc2cc1
NCGC00263134-08	FC(F)(F)c1cc2nc(CN3CCN(c4c(CC)cncn4)CC3)[nH]c2cc1	4.5500002	Active	p70 ribosomal S6 kinase (S6K1) Inhibitor	0.0	1	PF-4708671	363677221	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-84.204757782	FC(F)(F)c1cc2nc(CN3CCN(c4c(CC)cncn4)CC3)[nH]c2cc1	FC(F)(F)c1cc2nc(CN3CCN(c4c(CC)cncn4)CC3)[nH]c2cc1
NCGC00386720-01	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(cc3)CN(Cc3[nH]ncn3)CC4)cccc2)cc1	4.4000001	Inactive	ApoB Secretion Inhibitor	0.0	1	CP-346086	363680415	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	32.2966179339	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(cc3)CN(Cc3[nH]ncn3)CC4)cccc2)cc1	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(cc3)CN(Cc3[nH]ncn3)CC4)cccc2)cc1
NCGC00538141-01	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(n(C)c(C(=O)N[C@@H](C(=O)N(Cc5ccccc5)C)c5ccccc5)c4)cc3)cccc2)cc1		Inactive	Microsomal Triglyceride Transfer Protein Inhibitor&Microsomal triglyceride transfer protein Inhibitor		1	NCGC00538141-01	405558747	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-8.840398024&-29.589342316	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(n(C)c(C(=O)N[C@@H](C(=O)N(Cc5ccccc5)C)c5ccccc5)c4)cc3)cccc2)cc1	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(n(C)c(C(=O)N[C@@H](C(=O)N(Cc5ccccc5)C)c5ccccc5)c4)cc3)cccc2)cc1
NCGC00386948-01	FC(F)(F)c1ccc(-c2cc(COc3ccc([C@@H](C#CC)CC(=O)O)cc3)ccc2)cc1	4.4000001	Active	Free Fatty Acid Receptor 1 (FFAR1; GPR40) Agonist	0.0	1	AMG-837	363680520	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-50.6139528759	FC(F)(F)c1ccc(-c2cc(COc3ccc([C@@H](C#CC)CC(=O)O)cc3)ccc2)cc1	FC(F)(F)c1ccc(-c2cc(COc3ccc([C@@H](C#CC)CC(=O)O)cc3)ccc2)cc1
NCGC00522470-01	FC(F)(F)c1ccc(-c2ccc(-c3n(-c4ccc(N5CCNCC5)cc4)nc(CCC(=O)NC)c3)cc2)cc1	4.5500002	Inactive	ILK Inhibitor	0.0	1	OSU-T315	384569519	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-3.330612856	FC(F)(F)c1ccc(-c2ccc(-c3n(-c4ccc(N5CCNCC5)cc4)nc(CCC(=O)NC)c3)cc2)cc1	FC(F)(F)c1ccc(-c2ccc(-c3n(-c4ccc(N5CCNCC5)cc4)nc(CCC(=O)NC)c3)cc2)cc1
NCGC00250397-04	FC(F)(F)c1ccc(-c2nc(O)c3c(n2)CCSC3)cc1	5.0	Active	TNKS1/TNKS2 Inhibitor	0.0	1	NVP-XAV-939	384568546	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-44.7147467995	FC(F)(F)c1ccc(-c2nc(O)c3c(n2)CCSC3)cc1	FC(F)(F)c1ccc(-c2nc(O)c3c(n2)CCSC3)cc1
NCGC00018193-11	FC(F)(F)c1ccc(/C(=N/OCCN)/CCCCOC)cc1	4.4499998	Active	5-ht Reuptake Inhibitor	0.0	1	Fluvoxamine	170464809	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-81.7915794984	FC(F)(F)c1ccc(/C(=N/OCCN)/CCCCOC)cc1	FC(F)(F)c1ccc(/C(=N/OCCN)/CCCCOC)cc1
NCGC00346582-03	FC(F)(F)c1ccc(/C=C/c2occ(COc3ccc(CCCCn4nncc4)cc3)n2)cc1	6.5	Inactive	HER2 Inhibitor	0.0	1	Mubritinib	384568851	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-87.413337004	FC(F)(F)c1ccc(/C=C/c2occ(COc3ccc(CCCCn4nncc4)cc3)n2)cc1	FC(F)(F)c1ccc(/C=C/c2occ(COc3ccc(CCCCn4nncc4)cc3)n2)cc1
NCGC00165799-03	FC(F)(F)c1ccc(C(=O)/C=C(\N[C@H](CNC(=O)CC)Cc2ccc(OCCc3c(C)oc(-c4ccccc4)n3)cc2)/C)cc1		Inactive	PPARalpha Antagonist		1	GW-6471	384568284	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.762559544	FC(F)(F)c1ccc(C(=O)/C=C(\N[C@H](CNC(=O)CC)Cc2ccc(OCCc3c(C)oc(-c4ccccc4)n3)cc2)/C)cc1	FC(F)(F)c1ccc(C(=O)/C=C(\N[C@H](CNC(=O)CC)Cc2ccc(OCCc3c(C)oc(-c4ccccc4)n3)cc2)/C)cc1
NCGC00183000-01	FC(F)(F)c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1		Inactive	Sodium channel alpha subunit Binding Agent&Sodium Channel Alpha Subunit Binding Agent		1	Lanperisone hydrochloride	144206892	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-12.8335217479	FC(F)(F)c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1	FC(F)(F)c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1
NCGC00025099-02	FC(F)(F)c1ccc(C(OCCN2CC(C(=O)O)=CCC2)c2ccc(C(F)(F)F)cc2)cc1		Inactive	GAT-1 Inhibitor		1	CI-966	384568048	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.309400064	FC(F)(F)c1ccc(C(OCCN2CC(C(=O)O)=CCC2)c2ccc(C(F)(F)F)cc2)cc1	FC(F)(F)c1ccc(C(OCCN2CC(C(=O)O)=CCC2)c2ccc(C(F)(F)F)cc2)cc1
NCGC00481596-01	FC(F)(F)c1ccc(C/N=C\2/NC=C(Cc3c4c([nH]c3)nccc4)C=C/2)cc1	4.6999998	Active	cKit Inhibitor	0.0	1	PLX-647	377020230	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-107.6990305407	FC(F)(F)c1ccc(C/N=C\2/NC=C(Cc3c4c([nH]c3)nccc4)C=C/2)cc1	FC(F)(F)c1ccc(C/N=C\2/NC=C(Cc3c4c([nH]c3)nccc4)C=C/2)cc1
NCGC00378431-08	FC(F)(F)c1ccc(C2C(C#N)=C(N)Oc3n(C)nc(C)c23)cc1		Inactive	Ral GTPase Inhibitor		1	BQU-57	363678080	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.033829016	FC(F)(F)c1ccc(C2C(C#N)=C(N)Oc3n(C)nc(C)c23)cc1	FC(F)(F)c1ccc(C2C(C#N)=C(N)Oc3n(C)nc(C)c23)cc1
NCGC00346096-02	FC(F)(F)c1ccc(C2C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)NC(=O)C2)cc1		Inactive	ROCK 1, ROCK 2 Inhibitor		1	GSK-429286A	174006479	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.727155076	FC(F)(F)c1ccc(C2C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)NC(=O)C2)cc1	FC(F)(F)c1ccc(C2C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)NC(=O)C2)cc1
NCGC00263123-02	FC(F)(F)c1ccc(CNC(=O)c2c(OC)ccc(CC3C(=O)NC(=O)S3)c2)cc1		Inactive	PPARalpha/gamma Agonist		1	MK-767	384568606	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-8.6415049239	FC(F)(F)c1ccc(CNC(=O)c2c(OC)ccc(CC3C(=O)NC(=O)S3)c2)cc1	FC(F)(F)c1ccc(CNC(=O)c2c(OC)ccc(CC3C(=O)NC(=O)S3)c2)cc1
NCGC00379032-06	FC(F)(F)c1ccc(N(C(=O)C=2C(=O)N(C)c3c(c(OC)ccc3)C=2O)C)cc1		Inactive	S100A9 Inhibitor		1	Tasquinimod	384569088	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	28.8208999752	FC(F)(F)c1ccc(N(C(=O)C=2C(=O)N(C)c3c(c(OC)ccc3)C=2O)C)cc1	FC(F)(F)c1ccc(N(C(=O)C=2C(=O)N(C)c3c(c(OC)ccc3)C=2O)C)cc1
NCGC00263218-08	FC(F)(F)c1ccc(NC(=O)/C(/C#N)=C(\O)/C)cc1	4.4000001	Active	DHODH Inhibitor	0.0	1	Teriflunomide	384568672	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-50.8886059759	FC(F)(F)c1ccc(NC(=O)/C(/C#N)=C(\O)/C)cc1	FC(F)(F)c1ccc(NC(=O)/C(/C#N)=C(\O)/C)cc1
NCGC00015610-17&NCGC00015610-29	FC(F)(F)c1ccc(NC(=O)c2c(C)onc2)cc1		Inactive	DHODH Inhibitor&Jak Inhibitor&DHODH Inhibitor		2	Leflunomide	170464823&384567875	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-18.483748648	FC(F)(F)c1ccc(NC(=O)c2c(C)onc2)cc1	FC(F)(F)c1ccc(NC(=O)c2c(C)onc2)cc1
NCGC00015428-15	FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1	4.5500002	Active	Serotonin transporter Inhibitor&Serotonin Transporter Inhibitor	0.0	1	(+/-) -Fluoxetine	170465374	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-75.2540076352&-47.969661565	FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1	FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1
NCGC00182549-04	FC(F)(F)c1ccc([C@H](COC)N2[C@@H](C)CN(C3(C)CCN(C(=O)c4c(C)ncnc4C)CC3)CC2)cc1		Inactive	Chemokine CCR5 Antagonist		1	Vicriviroc (SCH-417690)	384568410	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.205608564	FC(F)(F)c1ccc([C@H](COC)N2[C@@H](C)CN(C3(C)CCN(C(=O)c4c(C)ncnc4C)CC3)CC2)cc1	FC(F)(F)c1ccc([C@H](COC)N2[C@@H](C)CN(C3(C)CCN(C(=O)c4c(C)ncnc4C)CC3)CC2)cc1
NCGC00378983-02	FC(F)(F)c1cnc(Oc2cc(C=C3CCN(C(=O)Nc4nnccc4)CC3)ccc2)cc1	4.6999998	Active	Fatty Acid Amide Hydrolase (FAAH) Inhibitor	0.0	1	PF-04457845	384569083	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-100.3869701923	FC(F)(F)c1cnc(Oc2cc(C=C3CCN(C(=O)Nc4nnccc4)CC3)ccc2)cc1	FC(F)(F)c1cnc(Oc2cc(C=C3CCN(C(=O)Nc4nnccc4)CC3)ccc2)cc1
NCGC00263131-05	FC(F)(F)c1cnc(Oc2cc(CC3CCN(C(=O)Nc4cnccc4)CC3)ccc2)cc1	4.9499998	Active	Fatty Acid Amide Hydrolase (FAAH) Inhibitor	0.0	1	PF-3845	384568611	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.159753418	FC(F)(F)c1cnc(Oc2cc(CC3CCN(C(=O)Nc4cnccc4)CC3)ccc2)cc1	FC(F)(F)c1cnc(Oc2cc(CC3CCN(C(=O)Nc4cnccc4)CC3)ccc2)cc1
NCGC00378765-02	FC(F)(F)c1cnc2c(c1)CN(C(=O)[C@]1(C(C)C)C[C@H](N[C@@H]3[C@H](OC)COCC3)CC1)CC2		Inactive	Chemokine CCR2 (MCP-1 Receptor) Antagonist		1	MK-0812	363678186	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1cnc2c(c1)CN(C(=O)[C@]1(C(C)C)C[C@H](N[C@@H]3[C@H](OC)COCC3)CC1)CC2	FC(F)(F)c1cnc2c(c1)CN(C(=O)[C@]1(C(C)C)C[C@H](N[C@@H]3[C@H](OC)COCC3)CC1)CC2
NCGC00386284-05	FC(F)(F)c1n2N=C(N3CCC(c4ccc(OCCN5CCN(C(=O)C)CC5)cc4)CC3)CCc2nn1	4.5	Inactive	Drugs Acting on Androgen Receptor	0.0	1	AZD-3514	363680185	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	36.995603392	FC(F)(F)c1n2N=C(N3CCC(c4ccc(OCCN5CCN(C(=O)C)CC5)cc4)CC3)CCc2nn1	FC(F)(F)c1n2N=C(N3CCC(c4ccc(OCCN5CCN(C(=O)C)CC5)cc4)CC3)CCc2nn1
NCGC00178734-06&NCGC00178734-10	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1c(F)cc(F)c(F)c1)CC2	5.04999995	Active	Dipeptidyl Peptidase Iv (cd26; Dpp-iv; Dp-iv) Inhibitor&DPP-IV Inhibitor	0.7999996999999999	2	Sitagliptin	405558639&384568363	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.2	-41.0599715372&-39.4690885043	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1c(F)cc(F)c(F)c1)CC2	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1c(F)cc(F)c(F)c1)CC2
NCGC00250407-05	FC(F)(F)c1nc(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)n(C)c4cc3)c2)[nH]c1		Inactive	Raf kinase B/C Inhibitor		1	CHIR-265	384568555	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-24.101684296	FC(F)(F)c1nc(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)n(C)c4cc3)c2)[nH]c1	FC(F)(F)c1nc(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)n(C)c4cc3)c2)[nH]c1
NCGC00094994-10	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c(C(O)C2NCCCC2)c1	4.8499999	Active		0.0	1	MEFLOQUINE	384568139	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-95.3395382392	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c(C(O)C2NCCCC2)c1	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c(C(O)C2NCCCC2)c1
NCGC00161831-04	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c([C@H](O)[C@@H]2NCCCC2)c1	4.5500002	Active	antimalarial agents; Inhibtion of heme crystallization	0.0	1	Mefloquine hydrochloride	170465100	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-104.9182505262	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c([C@H](O)[C@@H]2NCCCC2)c1.Cl	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c([C@H](O)[C@@H]2NCCCC2)c1.Cl
NCGC00378933-01	FC(F)(F)c1ncc(Nc2cnc(-c3ccc(C4CCC(CC(=O)O)CC4)cc3)cc2)cc1		Inactive	Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitor		1	Pradigastat	363678285	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.0493121119	FC(F)(F)c1ncc(Nc2cnc(-c3ccc(C4CCC(CC(=O)O)CC4)cc3)cc2)cc1	FC(F)(F)c1ncc(Nc2cnc(-c3ccc(C4CCC(CC(=O)O)CC4)cc3)cc2)cc1
NCGC00346633-02	FC(F)(F)c1nn(-c2cc(NC3CCC(O)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2	6.8499999	Inactive	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	SNX-2112	384568869	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-67.3833345961	FC(F)(F)c1nn(-c2cc(NC3CCC(O)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2	FC(F)(F)c1nn(-c2cc(NC3CCC(O)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2
NCGC00346640-05	FC(F)(F)c1nn(-c2cc(NC3CCC(OC(=O)CN)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2	4.3499999	Inactive	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	SNX-5422	384568874	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-7.9536436679	FC(F)(F)c1nn(-c2cc(NC3CCC(OC(=O)CN)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2	FC(F)(F)c1nn(-c2cc(NC3CCC(OC(=O)CN)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2
NCGC00507884-01	FC(F)(F)c1oc(-c2cnc(N3CCC(n4c(C(=O)NC(C)(C)C)cnc4)CC3)cc2)nn1	4.4000001	Active	WNK kinase Inhibitor	0.0	1	WNK-463	384569349	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-30.525751016	FC(F)(F)c1oc(-c2cnc(N3CCC(n4c(C(=O)NC(C)(C)C)cnc4)CC3)cc2)nn1	FC(F)(F)c1oc(-c2cnc(N3CCC(n4c(C(=O)NC(C)(C)C)cnc4)CC3)cc2)nn1
NCGC00386712-01	FC(F)(F)c1onc(-c2cc(C(=O)NCC(C)(C)c3nc(-c4ccccc4)oc3)ccc2)n1		Inactive	HDAC Inhibitor		1	TMP-195	363680410	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	FC(F)(F)c1onc(-c2cc(C(=O)NCC(C)(C)c3nc(-c4ccccc4)oc3)ccc2)n1	FC(F)(F)c1onc(-c2cc(C(=O)NCC(C)(C)c3nc(-c4ccccc4)oc3)ccc2)n1
NCGC00165952-05	FC(F)(F)c1sc(NC(=O)/C(/C#N)=C/c2cc(OC)c(OCc3c(C(F)(F)F)cc(C(F)(F)F)cc3)cc2)nn1		Inactive	Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonist		1	XCT-790	384568300	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.4026195479	FC(F)(F)c1sc(NC(=O)/C(/C#N)=C/c2cc(OC)c(OCc3c(C(F)(F)F)cc(C(F)(F)F)cc3)cc2)nn1	FC(F)(F)c1sc(NC(=O)/C(/C#N)=C/c2cc(OC)c(OCc3c(C(F)(F)F)cc(C(F)(F)F)cc3)cc2)nn1
NCGC00263189-06	FC(F)(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1		Inactive	HGFR Inhibitor		1	JNJ-38877605	363677254	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	11.541813328	FC(F)(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1	FC(F)(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1
NCGC00015316-05&NCGC00015316-08	FC(F)C(N)(C(=O)O)CCCN		Inactive	Ornithine Decarboxylase Inhibitor&Ornithine Decarboxylase Inhibitors&Ornithine Decarboxylase Inhibitor		2	Eflornithine Hydrochloride	170465007&384567837	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)C(N)(C(=O)O)CCCN.Cl	FC(F)C(N)(C(=O)O)CCCN.Cl&FC(F)C(N)(C(=O)O)CCCN
NCGC00181770-02	FC(F)Oc1c(-c2cc3c([C@@H](C)NC3)cc2)ccc2C(=O)C(C(=O)O)=CN(C3CC3)c12		Inactive	Topoisomerase Iv Inhibitor&Topoisomerase IV Inhibitor		1	Garenoxacin mesylate hydrate	170465937	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.7505219871&22.559893196	S(=O)(=O)(O)C.FC(F)Oc1c(-c2cc3c([C@@H](C)NC3)cc2)ccc2C(=O)C(C(=O)O)=CN(C3CC3)c12.O	S(=O)(=O)(O)C.FC(F)Oc1c(-c2cc3c([C@@H](C)NC3)cc2)ccc2C(=O)C(C(=O)O)=CN(C3CC3)c12.O
NCGC00390672-01	FC(F)Oc1c(OC(F)F)cc2c(c1)cc([C@@](O)(C(C)C)c1nn[nH]c1)cc2	4.4000001	Active	Cytochrome P450 CYP17A1 Inhibitor	0.0	1	Seviteronel	363680966	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.1166170114	FC(F)Oc1c(OC(F)F)cc2c(c1)cc([C@@](O)(C(C)C)c1nn[nH]c1)cc2	FC(F)Oc1c(OC(F)F)cc2c(c1)cc([C@@](O)(C(C)C)c1nn[nH]c1)cc2
NCGC00249759-02	FC(F)Oc1cc(-c2c3ncccc3cc(COc3ccc(CCC(O)(C)C)cc3)c2)ccc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	NCGC00249759	174006307	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.380238264	FC(F)Oc1cc(-c2c3ncccc3cc(COc3ccc(CCC(O)(C)C)cc3)c2)ccc1	FC(F)Oc1cc(-c2c3ncccc3cc(COc3ccc(CCC(O)(C)C)cc3)c2)ccc1
NCGC00389624-01	FC1(F)CCC(C(=O)NC(CCN2C3CC(n4c(C(C)C)nnc4C)CC2CC3)c2ccccc2)CC1		Inactive	Chemokine CCR5 Antagonist;Signal Transduction Modulators;HIV Attachment Inhibitor;Reverse Transcriptase Inhibitor		1	Celsentri (Maraviroc)	363680825	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	33.1237295701	FC1(F)CCC(C(=O)NC(CCN2C3CC(n4c(C(C)C)nnc4C)CC2CC3)c2ccccc2)CC1	FC1(F)CCC(C(=O)NC(CCN2C3CC(n4c(C(C)C)nnc4C)CC2CC3)c2ccccc2)CC1
NCGC00186009-04	FC1(F)Oc2c(O1)ccc(/C=C\1/C(=O)NC(=O)S/1)c2	4.4000001	Active	PI3K gamma Inhibitor	0.0	1	AS-604850	363677107	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-64.2088210839	FC1(F)Oc2c(O1)ccc(/C=C\1/C(=O)NC(=O)S/1)c2	FC1(F)Oc2c(O1)ccc(/C=C\1/C(=O)NC(=O)S/1)c2
NCGC00378563-01	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C(CCC)CCC)C=C1	4.5	Active	Ribonucleotide reductase Inhibitor	0.0	1	LY-2334737	363678091	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-109.9143821576	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C(CCC)CCC)C=C1	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C(CCC)CCC)C=C1
NCGC00274062-01	FC1(F)[C@H]2[C@@H]1c1c(C(N3CCN(C[C@@H](O)COc4c5c(nccc5)ccc4)CC3)c3c2cccc3)cccc1	4.5166669	Active	P-Glycoprotein (MDR-1) Inhibitor&P-glycoprotein (mdr-1) Inhibitor	0.0	1	Zosuquidar trihydrochloride	174006281	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0&-2.1	-100.1337235787&-66.4349344119&-115.7226480408	FC1(F)[C@H]2[C@@H]1c1c(C(N3CCN(C[C@@H](O)COc4c5c(nccc5)ccc4)CC3)c3c2cccc3)cccc1.Cl.Cl.Cl	FC1(F)[C@H]2[C@@H]1c1c(C(N3CCN(C[C@@H](O)COc4c5c(nccc5)ccc4)CC3)c3c2cccc3)cccc1.Cl.Cl.Cl
NCGC00378990-02	FC1(F)c2c(-c3c1cc(-c1cc4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@H]6C[C@@H]5CC6)nc4cc1)cc3)ccc(-c1[nH]c([C@H]3N(C(=O)[C@@H](NC(=O)OC)C(C)C)CC4(C3)CC4)nc1)c2	5.25	Active	Nonstructural protein 5A Inhibitor	0.0	1	Ledipasvir (GS 5885)	405559115	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-64.6252188179	FC1(F)c2c(-c3c1cc(-c1cc4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@H]6C[C@@H]5CC6)nc4cc1)cc3)ccc(-c1[nH]c([C@H]3N(C(=O)[C@@H](NC(=O)OC)C(C)C)CC4(C3)CC4)nc1)c2	FC1(F)c2c(-c3c1cc(-c1cc4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@H]6C[C@@H]5CC6)nc4cc1)cc3)ccc(-c1[nH]c([C@H]3N(C(=O)[C@@H](NC(=O)OC)C(C)C)CC4(C3)CC4)nc1)c2
NCGC00159360-03	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C(OC(=O)CC)(C(=O)COC(=O)CC)C(C)C1)CC2O	4.0	Inactive	Glucocorticoid steroid	0.0	1	Betamethasone dipropionate	384568172	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	58.4496194978	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C(OC(=O)CC)(C(=O)COC(=O)CC)C(C)C1)CC2O	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C(OC(=O)CC)(C(=O)COC(=O)CC)C(C)C1)CC2O
NCGC00183865-01	FC12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1	4.4499998	Active		0.0	1	Flugestone	144206781	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.4490664632	FC12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1	FC12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1
NCGC00253576-01	FC12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	5.5	Inactive		0.0	1	Amelometasone	170465753	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	57.6407825053	FC12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	FC12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00095165-07&NCGC00095165-08	FC=1C(=O)NC(=O)N(C(=O)NCCCCCC)C=1	5.2125001	Active	Acid Ceramidase Inhibitor&Pyrimidine Antagonist&Pyrimidine Antagonist	0.4250002000000004	2	Carmofur	170465833&384568154	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.3&-1.3	-85.8204095152&-36.2763489284&-79.7946559783	FC=1C(=O)NC(=O)N(C(=O)NCCCCCC)C=1	FC=1C(=O)NC(=O)N(C(=O)NCCCCCC)C=1
NCGC00159418-05&NCGC00159418-07	FC=1C(=O)NC(=O)N(C2OCCC2)C=1		Inactive	Pyrimidine Antagonist		2	Tegafur	170465809&384568175	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	8.6165859519&17.9008312688&0.0	FC=1C(=O)NC(=O)N(C2OCCC2)C=1	FC=1C(=O)NC(=O)N(C2OCCC2)C=1
NCGC00015442-15&NCGC00015442-19	FC=1C(=O)NC(=O)NC=1	4.89999985	Active	Pyrimidine Antagonist	0.09999989999999936	2	Fluorouracil	170464762&384567846	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.1	-68.1183952024&-89.6435300152	FC=1C(=O)NC(=O)NC=1	FC=1C(=O)NC(=O)NC=1
NCGC00346830-03	FC=1C(N)=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	5.5	Inactive	DNA Methyltransferase (DNMT) Inhibitor	0.0	1	NSC-48006	384568946	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	90.7373529034	FC=1C(N)=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	FC=1C(N)=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00164564-06	FC=1C(N)=NC(=O)N([C@H]2O[C@@H](CO)SC2)C=1		Inactive	Reverse Transcriptase Inhibitor		1	Emtricitabine	405558951	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-19.156936632	FC=1C(N)=NC(=O)N([C@H]2O[C@@H](CO)SC2)C=1	FC=1C(N)=NC(=O)N([C@H]2O[C@@H](CO)SC2)C=1
NCGC00016599-04&NCGC00016599-10	FC=1C(N)=NC(=O)NC=1		Inactive	Pyrimidine Antagonist		2	Flucytosine	170465407&384567951	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-20.908552452&26.9472441564&-15.79817616	FC=1C(N)=NC(=O)NC=1	FC=1C(N)=NC(=O)NC=1
NCGC00164569-02&NCGC00164569-08	FC=1C(NC(=O)OCCCCC)=NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1		Inactive	Pyrimidine Antagonist		2	Capecitabine	170464779&384568255	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	FC=1C(NC(=O)OCCCCC)=NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1	FC=1C(NC(=O)OCCCCC)=NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1
NCGC00485875-01	FC=1[C@@H](N2C(=O)N=C(N)C=C2)[C@H](O)[C@H](O)C=1CO	4.6500001	Inactive	CDK Inhibitor	0.0	1	Fluorocyclopentenylcytosine	363681386	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-19.575520792	FC=1[C@@H](N2C(=O)N=C(N)C=C2)[C@H](O)[C@H](O)C=1CO	FC=1[C@@H](N2C(=O)N=C(N)C=C2)[C@H](O)[C@H](O)C=1CO
NCGC00483923-01	FC=1c2n(c([C@@H](C)N3C(=O)c4c(ncc(OCCOC)c4)C=C3)nn2)C=C(c2cn(C)nc2)C=1	4.4000001	Active	HGFR Inhibitor	0.0	1	AMG-337	363681142	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-51.9410310519	FC=1c2n(c([C@@H](C)N3C(=O)c4c(ncc(OCCOC)c4)C=C3)nn2)C=C(c2cn(C)nc2)C=1	FC=1c2n(c([C@@H](C)N3C(=O)c4c(ncc(OCCOC)c4)C=C3)nn2)C=C(c2cn(C)nc2)C=1
NCGC00263239-03	FCC(=O)c1n(CCCNCCOC)c2ncnc(N)c2c1-c1ccc(C)cc1		Inactive	RSK Inhibitor		1	FMK	384568682	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.597188108	FCC(=O)c1n(CCCNCCOC)c2ncnc(N)c2c1-c1ccc(C)cc1	FCC(=O)c1n(CCCNCCOC)c2ncnc(N)c2c1-c1ccc(C)cc1
NCGC00167443-02	FCC=1N(c2c(C)cccc2)C(=O)c2c(N=1)ccc(N)c2	5.25	Active		0.0	1	Afloqualone	405558862	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.00307926	FCC=1N(c2c(C)cccc2)C(=O)c2c(N=1)ccc(N)c2	FCC=1N(c2c(C)cccc2)C(=O)c2c(N=1)ccc(N)c2
NCGC00167558-02	FCCN1c2c(F)c(N3CCN(C)CC3)c(F)cc2C(=O)C(C(=O)O)=C1	6.1500001	Active	Quinoline Antibiotic	0.0	1	Fleroxacin	170466056	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-37.2117920345	FCCN1c2c(F)c(N3CCN(C)CC3)c(F)cc2C(=O)C(C(=O)O)=C1	FCCN1c2c(F)c(N3CCN(C)CC3)c(F)cc2C(=O)C(C(=O)O)=C1
NCGC00182548-02	FCC[N+]1(C)[C@H]2CC(OC(=O)C(O)(c3ccccc3)c3ccccc3)C[C@@H]1CC2	4.9250002	Active	Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonist	0.0	1	Flutropium bromide	170465904	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-49.2016732099&-50.1065509231	FCC[N+]1(C)[C@H]2CC(OC(=O)C(O)(c3ccccc3)c3ccccc3)C[C@@H]1CC2.[Br-].[Br-]	FCC[N+]1(C)[C@H]2CC(OC(=O)C(O)(c3ccccc3)c3ccccc3)C[C@@H]1CC2.[Br-].[Br-]
NCGC00263574-01	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@H](C(=O)COC(=O)CCCC)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Annexin A1 Activator		1	Diflucortolone valerate	170465700	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@H](C(=O)COC(=O)CCCC)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@H](C(=O)COC(=O)CCCC)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00021761-05	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid receptor Agonist		1	Flumethasone	170465750	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00022408-04	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive			1	Flumethasone pivalate	405559110	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00507799-01	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive			1	Flumethasone acetate	405558593	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00022003-06	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)C)(C(=O)COC(=O)C)[C@@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive			1	Diflorasone diacetate	170465294	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)C)(C(=O)COC(=O)C)[C@@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)C)(C(=O)COC(=O)C)[C@@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00386547-01	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)C)CC[C@H]4C3C1)C=CC(=O)C=2		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid receptor Agonist		1	Difluprednate	405558562	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-10.5646504479	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)C)CC[C@H]4C3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)C)CC[C@H]4C3C1)C=CC(=O)C=2
NCGC00021301-06&NCGC00021301-09	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid		2	Fluocinolone acetonide	170464630&384568006	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-14.252924668	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00022398-05&NCGC00022398-13	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)COC(=O)C)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid steroid&Glucocorticoid Receptor Agonist&Glucocorticoid steroid		2	Fluocinonide	170464717&384568010	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)COC(=O)C)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)COC(=O)C)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00159474-03	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid receptor Agonist		1	Fluprednisolone	170465086	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00185748-01	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid Receptor Interacts&Glucocorticoid receptor Interacts		1	Paramethasone acetate	144206683	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-10.261543768	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00179492-03&NCGC00179492-08	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid Receptor Agonist&Corticosteroid		2	Flunisolide&FLUNISOLIDE	170465331&384568374	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&15.5&31.711330808	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00023234-05	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)CCC(=O)C=2		Inactive			1	Flurandrenolide	170465298	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)CCC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)CCC(=O)C=2
NCGC00509941-01	F[C@@H]1[C@@H](NC(=O)C=C)CN(c2nc(Nc3c(OC)nn(C)c3)c3ncn(C)c3n2)C1	5.9499998	Active	EGFR (Thr790Met Mutant) Inhibitor	0.0	1	PF-06747775	384569389	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-65.5080053497	F[C@@H]1[C@@H](NC(=O)C=C)CN(c2nc(Nc3c(OC)nn(C)c3)c3ncn(C)c3n2)C1	F[C@@H]1[C@@H](NC(=O)C=C)CN(c2nc(Nc3c(OC)nn(C)c3)c3ncn(C)c3n2)C1
NCGC00510500-01	F[C@H]1[C@@H](CC)[C@@H](COc2nccc3c2cc(OC)c(C(=O)N)c3)NC1=O	4.75	Active	Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Inhibitor	0.0	1	PF-06650833	384569461	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-78.3065278956	F[C@H]1[C@@H](CC)[C@@H](COc2nccc3c2cc(OC)c(C(=O)N)c3)NC1=O	F[C@H]1[C@@H](CC)[C@@H](COc2nccc3c2cc(OC)c(C(=O)N)c3)NC1=O
NCGC00522572-01	F[C@H]1[C@H](N)CCN(c2n(C)ncc2NC(=O)c2c(N)sc(-c3c(F)cccc3F)n2)CC1	4.4000001	Active	Pim-1/2/3 Kinase Inhibitor	0.0	1	GDC-0339	384569526	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-81.621958824	F[C@H]1[C@H](N)CCN(c2n(C)ncc2NC(=O)c2c(N)sc(-c3c(F)cccc3F)n2)CC1	F[C@H]1[C@H](N)CCN(c2n(C)ncc2NC(=O)c2c(N)sc(-c3c(F)cccc3F)n2)CC1
NCGC00345781-01	F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1		Inactive	DNA-Intercalating Drugs		1	NSC-678515	174006953	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.8600061159	F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1	F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1
NCGC00023648-04	F[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid receptor Agonist&Glucocorticoid Receptor Agonist		1	Desoximetasone	170464795	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00021575-05	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid receptor Agonist		1	Fluorometholone	170464629	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1
NCGC00274078-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1		Inactive	Mineralocorticoid Receptor Agonist		1	Fludrocortisone	170464959	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&23.972348192	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1
NCGC00093684-06	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)CC3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	BETAMETHASONE	384568117	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)CC3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)CC3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00091019-19&NCGC00091019-23	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Antiinflammatory agent&Antiinflammatory; Glucocorticoid Receptor Antagonist&Antiinflammatory agent		2	Dexamethasone	384568091&405559016	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00178404-03	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](O)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Triamcinolone	170465188	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](O)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](O)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00182066-02	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)C(=C)CC3C1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Fluprednidene acetate	144206681	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.8655793239	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)C(=C)CC3C1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)C(=C)CC3C1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00179685-03	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Isoflupredone acetate	170465628	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00022662-05	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Mineralocorticoid Receptor Agonist&Mineralocorticoid receptor Agonist		1	Dexamethasone acetate	170466872	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00159320-04	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](OC(=O)C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Triamcinolone diacetate	170464837	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.9445017919&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](OC(=O)C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](OC(=O)C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00522021-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid receptor Agonist		1	Dexamethasone 21-Palmitate	405558516	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-25.105111896	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00249903-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)c4ccncc4)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Dexamethasone isonicotinate	170466851	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)c4ccncc4)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)c4ccncc4)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00373228-02	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)C)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1	4.4000001	Active		0.0	1	Fluorometholone Acetate	363678077	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.0949863879	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)C)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)C)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1
NCGC00159443-05	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid		1	BETAMETHASONE 17,21-DIPROPIONATE	405558654	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00183597-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Betamethasone butyrate propionate	144206581	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00274064-02	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid steroid		1	Betamethasone valerate	384568710	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00274064-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid		1	Betamethasone valerate	174007479	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00183040-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)c4ccccc4)(C(=O)CO)[C@@H](C)C[C@H]3[C@H]1CCC=1[C@]2(C)C=CC(=O)C=1	4.4000001	Active		0.0	1	NCGC00183040-01	124894246	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-75.383354752	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)c4ccccc4)(C(=O)CO)[C@@H](C)C[C@H]3[C@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)c4ccccc4)(C(=O)CO)[C@@H](C)C[C@H]3[C@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00023193-06&NCGC00023193-11	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)CO)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid		2	Triamcinolone acetonide	170464660&384568016	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)CO)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)CO)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00021193-03	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)C)OC5(O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1)CCCC5		Inactive			1	AMCINONIDE	405559147	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)C)OC5(O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1)CCCC5	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)C)OC5(O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1)CCCC5
NCGC00182544-01	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)CC(C)(C)C)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Triamcinolone hexacetonide	144206532	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.56824138&14.7536038	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)CC(C)(C)C)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)CC(C)(C)C)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00387273-01	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cccc1		Inactive	p38 MAPK Inhibitor		1	TA02	363680607	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	32.6202096249	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cccc1	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cccc1
NCGC00346576-01	Fc1c(-c2[nH]c3c(C(=O)N)cccc3n2)ccc([C@@H]2NCCC2)c1	4.5	Active	PARP Inhibitor	0.0	1	A-966492	174006329	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-118.4501359724	Fc1c(-c2[nH]c3c(C(=O)N)cccc3n2)ccc([C@@H]2NCCC2)c1	Fc1c(-c2[nH]c3c(C(=O)N)cccc3n2)ccc([C@@H]2NCCC2)c1
NCGC00475739-01	Fc1c(-c2c(C#N)c(N3CCOCC3)sc2-c2[nH]cnn2)ccc(C#N)c1	4.8000002	Active	PI3Kalpha Inhibitor	0.0	1	PF-4989216	384569235	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-103.5551710479	Fc1c(-c2c(C#N)c(N3CCOCC3)sc2-c2[nH]cnn2)ccc(C#N)c1	Fc1c(-c2c(C#N)c(N3CCOCC3)sc2-c2[nH]cnn2)ccc(C#N)c1
NCGC00249684-04	Fc1c(-c2c(C(=O)N)ccc(N(C(=O)N)c3c(F)cccc3F)n2)ccc(F)c1		Inactive	p38 MAPK Inhibitor		1	VX-702	384568532	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-24.0089083279	Fc1c(-c2c(C(=O)N)ccc(N(C(=O)N)c3c(F)cccc3F)n2)ccc(F)c1	Fc1c(-c2c(C(=O)N)ccc(N(C(=O)N)c3c(F)cccc3F)n2)ccc(F)c1
NCGC00510688-01	Fc1c(-c2c(F)ccc(C(=O)Nc3c([C@H]4C[C@@H](N)C[C@@H](C)C4)ccnc3)n2)c(F)ccc1	4.4000001	Active	Pim-1 Kinase Inhibitor	0.0	1	LGH-447	384569478	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-103.0759071654	Fc1c(-c2c(F)ccc(C(=O)Nc3c([C@H]4C[C@@H](N)C[C@@H](C)C4)ccnc3)n2)c(F)ccc1	Fc1c(-c2c(F)ccc(C(=O)Nc3c([C@H]4C[C@@H](N)C[C@@H](C)C4)ccnc3)n2)c(F)ccc1
NCGC00016765-09	Fc1c(-c2cc(C(=O)O)c(O)cc2)ccc(F)c1		Inactive	Cyclooxygenase-2 Inhibitor		1	Diflunisal	170464956	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.1949507239	Fc1c(-c2cc(C(=O)O)c(O)cc2)ccc(F)c1	Fc1c(-c2cc(C(=O)O)c(O)cc2)ccc(F)c1
NCGC00351599-02&NCGC00351599-03	Fc1c(-c2cc(F)c3nc(C)n(C(C)C)c3c2)nc(Nc2ncc(CN3CCN(CC)CC3)cc2)nc1	5.0999999	Active	CDK4/6 Inhibitor	0.19999979999999962	2	Abemaciclib	405558877&384569017	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-1.3	-77.1897073616&-110.3487725424	Fc1c(-c2cc(F)c3nc(C)n(C(C)C)c3c2)nc(Nc2ncc(CN3CCN(CC)CC3)cc2)nc1	Fc1c(-c2cc(F)c3nc(C)n(C(C)C)c3c2)nc(Nc2ncc(CN3CCN(CC)CC3)cc2)nc1
NCGC00480786-02	Fc1c(-c2ccc(-c3c(C)c(C(=O)O)c4c(n3)ccc(F)c4)cc2)cccc1	6.5	Inactive	DHODH Inhibitor	0.0	1	Brequinar	384569245	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-88.7515434	Fc1c(-c2ccc(-c3c(C)c(C(=O)O)c4c(n3)ccc(F)c4)cc2)cccc1	Fc1c(-c2ccc(-c3c(C)c(C(=O)O)c4c(n3)ccc(F)c4)cc2)cccc1
NCGC00018157-13&NCGC00018157-21	Fc1c(-c2ccccc2)ccc(C(C(=O)O)C)c1		Inactive	Cyclooxygenase Inhibitor&non-steroidal antiinflammatory&non-steroidal antiinflammatory		2	Flurbiprofen	405559106&384567993	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-30.919310608&0.0&18.182697412	Fc1c(-c2ccccc2)ccc(C(C(=O)O)C)c1	Fc1c(-c2ccccc2)ccc(C(C(=O)O)C)c1
NCGC00182710-02	Fc1c(-c2ccccc2)ccc(C(C(=O)OC(OC(=O)C)C)C)c1	5.25	Active		0.0	1	Flurbiprofen axetil	144206486	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.6620557532	Fc1c(-c2ccccc2)ccc(C(C(=O)OC(OC(=O)C)C)C)c1	Fc1c(-c2ccccc2)ccc(C(C(=O)OC(OC(=O)C)C)C)c1
NCGC00387472-01	Fc1c(-c2cn(CCO)nc2)cc(-c2c(-c3nc(C)ccc3)n[nH]c2)cc1	4.5	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	R-268712	363680628	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-62.4427115296	Fc1c(-c2cn(CCO)nc2)cc(-c2c(-c3nc(C)ccc3)n[nH]c2)cc1	Fc1c(-c2cn(CCO)nc2)cc(-c2c(-c3nc(C)ccc3)n[nH]c2)cc1
NCGC00378911-02	Fc1c(-c2cnc(-c3nn(C)nn3)cc2)ccc(N2C(=O)O[C@H](CO)C2)c1		Inactive	Bacterial 70S ribosome Inhibitor&Bacterial 70s Ribosome Inhibitor		1	(S)-Tedizolid	405558814	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-17.8166685839	Fc1c(-c2cnc(-c3nn(C)nn3)cc2)ccc(N2C(=O)O[C@H](CO)C2)c1	Fc1c(-c2cnc(-c3nn(C)nn3)cc2)ccc(N2C(=O)O[C@H](CO)C2)c1
NCGC00346719-03	Fc1c(-c2cncnc2)cc(c(F)c1)[C@@]1(C)N=C(N)SCC1		Inactive	beta-Secretase Inhibitor		1	LY-2811376	384568932	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.9842267878	Fc1c(-c2cncnc2)cc(c(F)c1)[C@@]1(C)N=C(N)SCC1	Fc1c(-c2cncnc2)cc(c(F)c1)[C@@]1(C)N=C(N)SCC1
NCGC00386429-04	Fc1c(-c2nc(N3CCOCC3)c3sc(CN4CCN(CC5CC5)CC4)cc3n2)c2c([nH]cc2)cc1	4.5	Active	PI3K alpha Inhibitor	0.0	1	PI-3065	384569139	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-117.0472784762	Fc1c(-c2nc(N3CCOCC3)c3sc(CN4CCN(CC5CC5)CC4)cc3n2)c2c([nH]cc2)cc1	Fc1c(-c2nc(N3CCOCC3)c3sc(CN4CCN(CC5CC5)CC4)cc3n2)c2c([nH]cc2)cc1
NCGC00499577-01	Fc1c(-c2ncnc3[nH]cc(C(=O)OCC)c23)cc(NC(=O)C=C)cc1		Inactive	Jak3		1	JAK3i	384569309	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(-c2ncnc3[nH]cc(C(=O)OCC)c23)cc(NC(=O)C=C)cc1	Fc1c(-c2ncnc3[nH]cc(C(=O)OCC)c23)cc(NC(=O)C=C)cc1
NCGC00168759-05&NCGC00168759-10	Fc1c(-c2onc(-c3cc(C(=O)O)ccc3)n2)cccc1	4.0	Inactive	Cftr-g542x Nonsense Allele Inhibitor&CFTR-G542X nonsense allele Inhibitor&CFTR-G542X nonsense allele Inhibitor	0.0	2	PTC-124	170466862&363676681	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	0.0&0.0&35.805180728	Fc1c(-c2onc(-c3cc(C(=O)O)ccc3)n2)cccc1	Fc1c(-c2onc(-c3cc(C(=O)O)ccc3)n2)cccc1
NCGC00509989-01	Fc1c(-n2nc(NC(=O)C3CCC4(OC(=O)c5c4cncc5)CC3)cc2)cccc1		Inactive	Neuropeptide Y5 (NPY Y5) Receptor Antagonist		1	MK-0557	384569397	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	5.5327699119	Fc1c(-n2nc(NC(=O)C3CCC4(OC(=O)c5c4cncc5)CC3)cc2)cccc1	Fc1c(-n2nc(NC(=O)C3CCC4(OC(=O)c5c4cncc5)CC3)cc2)cccc1
NCGC00381558-06	Fc1c(C(=O)N2CCC(OC)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	4.6500001	Active	PARP Inhibitor	0.0	1	AZD-2461	363679154	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-95.9477208281	Fc1c(C(=O)N2CCC(OC)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	Fc1c(C(=O)N2CCC(OC)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1
NCGC00238451-09&NCGC00238451-11	Fc1c(C(=O)N2CCN(C(=O)C3CC3)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	4.57500005	Active	PARP Inhibitor&PARP Inhibitor&Poly [adp-ribose] Polymerase 1 Inhibitor	0.15000009999999975	2	Olaparib	363677132&405559119	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4&-2.4	-68.9688026367&-73.7552564704&-66.9663598576	Fc1c(C(=O)N2CCN(C(=O)C3CC3)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	Fc1c(C(=O)N2CCN(C(=O)C3CC3)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1
NCGC00346647-03	Fc1c(C(=O)NC)c(Nc2nc(Nc3c(OC)cc4c(N(C(=O)CN(C)C)CC4)c3)nc3[nH]ccc23)ccc1	4.6999998	Active	IGF-1R Inhibitor	0.0	1	GSK-1838705A	384568878	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-69.1544605371	Fc1c(C(=O)NC)c(Nc2nc(Nc3c(OC)cc4c(N(C(=O)CN(C)C)CC4)c3)nc3[nH]ccc23)ccc1	Fc1c(C(=O)NC)c(Nc2nc(Nc3c(OC)cc4c(N(C(=O)CN(C)C)CC4)c3)nc3[nH]ccc23)ccc1
NCGC00346702-05	Fc1c(C(=O)NC)ccc(C2=Nn3c(Cc4cc5c(nccc5)cc4)cnc3N=C2)c1	4.4000001	Active	HGFR Inhibitor	0.0	1	Capmatinib	363677527	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.61580314	Fc1c(C(=O)NC)ccc(C2=Nn3c(Cc4cc5c(nccc5)cc4)cnc3N=C2)c1	Fc1c(C(=O)NC)ccc(C2=Nn3c(Cc4cc5c(nccc5)cc4)cnc3N=C2)c1
NCGC00387488-03	Fc1c(C(=O)NC2CCN(C)CC2)cc(OC)c(Nc2nc3N(C4CCCC4)CC(F)(F)C(=O)N(C)c3cn2)c1	5.0	Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor	0.0	1	TAK-960	363680640	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-23.7423723451	Fc1c(C(=O)NC2CCN(C)CC2)cc(OC)c(Nc2nc3N(C4CCCC4)CC(F)(F)C(=O)N(C)c3cn2)c1	Fc1c(C(=O)NC2CCN(C)CC2)cc(OC)c(Nc2nc3N(C4CCCC4)CC(F)(F)C(=O)N(C)c3cn2)c1
NCGC00479176-02	Fc1c(C(=O)Nc2nc(-c3n(C(C)C)cnn3)ccc2)cc(-n2cc(C3CC3)nc2)c(C)c1	5.0500002	Active	ASK1 Inhibitor	0.0	1	Selonsertib	363681104	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-93.7764621792	Fc1c(C(=O)Nc2nc(-c3n(C(C)C)cnn3)ccc2)cc(-n2cc(C3CC3)nc2)c(C)c1	Fc1c(C(=O)Nc2nc(-c3n(C(C)C)cnn3)ccc2)cc(-n2cc(C3CC3)nc2)c(C)c1
NCGC00242477-02	Fc1c(C(=O)O)ccc(-c2sc(C)c(OCCOCCCC)n2)c1	5.4499998	Inactive	RARbeta2 Agonist	0.0	1	AC-261066	384568490	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	82.4705358235	Fc1c(C(=O)O)ccc(-c2sc(C)c(OCCOCCCC)n2)c1	Fc1c(C(=O)O)ccc(-c2sc(C)c(OCCOCCCC)n2)c1
NCGC00346693-02	Fc1c(C(=O)c2c(OCCCC)c3c([nH]nc3)nc2)c(F)cc(C)c1	5.9499998	Active	CDK1/2 Inhibitor	0.0	1	BMS-265246	384568915	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-97.1633009879	Fc1c(C(=O)c2c(OCCCC)c3c([nH]nc3)nc2)c(F)cc(C)c1	Fc1c(C(=O)c2c(OCCCC)c3c([nH]nc3)nc2)c(F)cc(C)c1
NCGC00244250-02	Fc1c(C(=O)n2c(N)nc(Nc3ccc(N(C)C)cc3)n2)c(F)ccc1	4.9000001	Active	Tyk 2 Inhibitor	0.0	1	NCGC00244250	174006689	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-97.2627701227	Fc1c(C(=O)n2c(N)nc(Nc3ccc(N(C)C)cc3)n2)c(F)ccc1	Fc1c(C(=O)n2c(N)nc(Nc3ccc(N(C)C)cc3)n2)c(F)ccc1
NCGC00188690-02&NCGC00188690-09	Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1		Inactive	P2y12 (p2t) Antagonists&P2Y12 (P2T) Antagonist&P2Y12 (P2T) Antagonist		2	Prasugrel	174006898&384568451	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-11.193948556&0.0	Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1.Cl	Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1.Cl&Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1
NCGC00095089-10&NCGC00095089-21	Fc1c(C(O)(Cn2ncnc2)Cn2ncnc2)ccc(F)c1		Inactive	Antifungal Agent&Fungal Lanosterol 14-alpha Demethylase Inhibitor&Antifungal Agent		2	Fluconazole	170464782&384568143	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	16.659353404&0.0&15.59240844	Fc1c(C(O)(Cn2ncnc2)Cn2ncnc2)ccc(F)c1	Fc1c(C(O)(Cn2ncnc2)Cn2ncnc2)ccc(F)c1
NCGC00386332-03	Fc1c(C)c(-c2ncc(C(=O)NCC(C)(C)C)cc2)cc(C(=O)NC2CC2)c1		Inactive	MAP kinase p38 beta Inhibitor		1	Losmapimod	363680217	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.250461008	Fc1c(C)c(-c2ncc(C(=O)NCC(C)(C)C)cc2)cc(C(=O)NC2CC2)c1	Fc1c(C)c(-c2ncc(C(=O)NCC(C)(C)C)cc2)cc(C(=O)NC2CC2)c1
NCGC00387189-01	Fc1c(C)c(C2=C(F)c3n(c(C(C)(C)C)nn3)C=C2F)cc(C(=O)NC2CC2)c1		Inactive	p38 MAPK Inhibitor		1	AL-8697	363680564	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.82849932	Fc1c(C)c(C2=C(F)c3n(c(C(C)(C)C)nn3)C=C2F)cc(C(=O)NC2CC2)c1	Fc1c(C)c(C2=C(F)c3n(c(C(C)(C)C)nn3)C=C2F)cc(C(=O)NC2CC2)c1
NCGC00167527-03	Fc1c(C)c2C(=O)C(C(=O)O)=CN(C3CC3)c2cc1N1CC(C)NCC1		Inactive	Topoisomerase IV Inhibitor&Topoisomerase Iv Inhibitor		1	Grepafloxacin hydrochloride	170466148	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.280697056&0.0	Fc1c(C)c2C(=O)C(C(=O)O)=CN(C3CC3)c2cc1N1CC(C)NCC1.Cl	Fc1c(C)c2C(=O)C(C(=O)O)=CN(C3CC3)c2cc1N1CC(C)NCC1.Cl
NCGC00249910-01	Fc1c(C)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1		Inactive	Bacterial DNA gyrase Inhibitor&Bacterial Dna Gyrase Inhibitor		1	Ibafloxacine	170466478	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.562376948&-24.497954464	Fc1c(C)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1	Fc1c(C)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1
NCGC00510463-03	Fc1c(C)cc(N2C(=O)C=Cc3c2c2c([nH]cc2)nc3)cc1	4.4000001	Active	STK16 kinase Inhibitor	0.0	1	STK16-IN-1	384569437	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-67.46239524	Fc1c(C)cc(N2C(=O)C=Cc3c2c2c([nH]cc2)nc3)cc1	Fc1c(C)cc(N2C(=O)C=Cc3c2c2c([nH]cc2)nc3)cc1
NCGC00167534-02	Fc1c(C2(N)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	Topoisomerase Iv Inhibitor&Topoisomerase IV Inhibitor		1	Pazufloxacin	170465985	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Fc1c(C2(N)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(C2(N)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00522014-01	Fc1c(C2=NCC(=O)N(C)c3n(C)nc(C)c23)cccc1	4.7750001	Active		0.0	1	Zolazepam Hydrochloride	405558721	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-23.455877911&-92.6139167061	Fc1c(C2=NCC(=O)N(C)c3n(C)nc(C)c23)cccc1	Fc1c(C2=NCC(=O)N(C)c3n(C)nc(C)c23)cccc1
NCGC00183009-01	Fc1c(C2=N[C@H](NC(=O)c3[nH]c4c(c3)cccc4)C(=O)N3c4c2cccc4CC3)cccc1		Inactive	Cholecystokinin A receptor Antagonist&Cholecystokinin A Receptor Antagonist		1	Pranazepide	144206813	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.821977308&0.0	Fc1c(C2=N[C@H](NC(=O)c3[nH]c4c(c3)cccc4)C(=O)N3c4c2cccc4CC3)cccc1	Fc1c(C2=N[C@H](NC(=O)c3[nH]c4c(c3)cccc4)C(=O)N3c4c2cccc4CC3)cccc1
NCGC00381751-04	Fc1c(C=2S[C@](CCCN)(N(C(=O)N(OC)C)N=2)c2ccccc2)cc(F)cc1	6.0500002	Inactive	Kinesin-Like Spindle Protein Inhibitor	0.0	1	Filanesib	363679167	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	25.9009058319	Fc1c(C=2S[C@](CCCN)(N(C(=O)N(OC)C)N=2)c2ccccc2)cc(F)cc1	Fc1c(C=2S[C@](CCCN)(N(C(=O)N(OC)C)N=2)c2ccccc2)cc(F)cc1
NCGC00263130-02	Fc1c(CN2C(=O)N(CCCC)c3[nH]c(Cc4ccc(NC(=O)C)cc4)nc3C2=O)cccc1		Inactive	cPEPCK Inhibitor		1	cPEPCK Inhibitor	363677217	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(CN2C(=O)N(CCCC)c3[nH]c(Cc4ccc(NC(=O)C)cc4)nc3C2=O)cccc1	Fc1c(CN2C(=O)N(CCCC)c3[nH]c(Cc4ccc(NC(=O)C)cc4)nc3C2=O)cccc1
NCGC00509985-02	Fc1c(CN2C(=O)N(c3ccccc3)C(=O)c3c(CN(Cc4ccccc4)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1	5.1999998	Active	GnRH (LHRH) Receptor Antagonist	0.0	1	Sufugolix	384569395	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-67.1707351098	Fc1c(CN2C(=O)N(c3ccccc3)C(=O)c3c(CN(Cc4ccccc4)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1	Fc1c(CN2C(=O)N(c3ccccc3)C(=O)c3c(CN(Cc4ccccc4)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1
NCGC00522107-03	Fc1c(CN2C(=O)N(c3nnc(OC)cc3)C(=O)c3c(CN(C)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1		Inactive	GnRH (LHRH) Receptor Antagonist		1	Relugolix	384569513	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.99584216	Fc1c(CN2C(=O)N(c3nnc(OC)cc3)C(=O)c3c(CN(C)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1	Fc1c(CN2C(=O)N(c3nnc(OC)cc3)C(=O)c3c(CN(C)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1
NCGC00263202-06	Fc1c(CN2CCOCC2)c(F)cc(-c2c3nc(-c4cn(C5CCNCC5)nc4)cnc3ccc2)c1	4.9000001	Active	Jak2 Inhibitor	0.0	1	NVP-BSK805	384568661	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-100.5336370561	Fc1c(CN2CCOCC2)c(F)cc(-c2c3nc(-c4cn(C5CCNCC5)nc4)cnc3ccc2)c1	Fc1c(CN2CCOCC2)c(F)cc(-c2c3nc(-c4cn(C5CCNCC5)nc4)cnc3ccc2)c1
NCGC00346629-02	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@H](C)CCO[C@H]4CN3C=2)ccc(F)c1	4.2750001	Inactive	HIV Integrase Inhibitors&Hiv Integrase Inhibitors	0.0	1	Dolutegravir (GSK1349572)	405558481	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-16.8606187882&-22.4830713281	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@H](C)CCO[C@H]4CN3C=2)ccc(F)c1	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@H](C)CCO[C@H]4CN3C=2)ccc(F)c1
NCGC00378606-02	Fc1c(Cc2sc3c(c2)cccc3)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	Sodium/glucose cotransporter 2 Inhibitor&Sodium/glucose Cotransporter 2 Inhibitor		1	Ipragliflozin	405558762	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.1956247999&29.2391352999	Fc1c(Cc2sc3c(c2)cccc3)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	Fc1c(Cc2sc3c(c2)cccc3)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00379065-03&NCGC00379065-05	Fc1c(Cn2nc(-c3nc(N)c(N(C(=O)OC)C)c(N)n3)c3c2nccc3)cccc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator&Soluble Guanylate Cyclase (sgc) Activator&Soluble Guanylate Cyclase (sGC) Activator		2	Riociguat	363678334&405558591	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&14.0664837839&0.0	Fc1c(Cn2nc(-c3nc(N)c(N(C(=O)OC)C)c(N)n3)c3c2nccc3)cccc1	Fc1c(Cn2nc(-c3nc(N)c(N(C(=O)OC)C)c(N)n3)c3c2nccc3)cccc1
NCGC00263227-02	Fc1c(Cn2nc(-c3nc(N)c(N4CCOCC4)c(N)n3)c3c2nccc3)cccc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator		1	BAY-41-8543	384568679	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(Cn2nc(-c3nc(N)c(N4CCOCC4)c(N)n3)c3c2nccc3)cccc1	Fc1c(Cn2nc(-c3nc(N)c(N4CCOCC4)c(N)n3)c3c2nccc3)cccc1
NCGC00165883-04	Fc1c(Cn2nnc(C(=O)N)c2)c(F)ccc1		Inactive	Sodium Channel Protein Type Ix Alpha Subunit Modulator&Sodium channel protein type IX alpha subunit Modulator		1	Rufinamide	170465202	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	31.509104672&0.0	Fc1c(Cn2nnc(C(=O)N)c2)c(F)ccc1	Fc1c(Cn2nnc(C(=O)N)c2)c(F)ccc1
NCGC00319021-01	Fc1c(F)c(COC)c(F)c(F)c1COC(=O)C1C(C)(C)C1/C=C/C		Inactive	DNA synthesis involved in DNA replication Activator&Dna Synthesis Involved In Dna Replication Activator		1	NCGC00319021-01	225144375	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.1055514799&29.1584364719	Fc1c(F)c(COC)c(F)c(F)c1COC(=O)C1C(C)(C)C1/C=C/C	Fc1c(F)c(COC)c(F)c(F)c1COC(=O)C1C(C)(C)C1/C=C/C
NCGC00263105-06	Fc1c(F)ccc(C(=O)N2C=C(C(=O)OC(C)C)c3[nH]c4c(c3C(C)(C)C2)cccc4)c1		Inactive	Farnesoid X Receptor Agonist		1	Turofexorate isopropyl	363677205	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.283969012	Fc1c(F)ccc(C(=O)N2C=C(C(=O)OC(C)C)c3[nH]c4c(c3C(C)(C)C2)cccc4)c1	Fc1c(F)ccc(C(=O)N2C=C(C(=O)OC(C)C)c3[nH]c4c(c3C(C)(C)C2)cccc4)c1
NCGC00346947-02	Fc1c(F)ccc(CN2C(=O)C(C(=O)N[C@@H](COc3cc4NC(=O)Nc4cc3)c3ccccc3)=CC=C2)c1	4.4499998	Active	Phosphoinositide Dependent Kinase Inhibitor	0.0	1	PDPK1 Inhibitor	363677565	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-41.8227315362	Fc1c(F)ccc(CN2C(=O)C(C(=O)N[C@@H](COc3cc4NC(=O)Nc4cc3)c3ccccc3)=CC=C2)c1	Fc1c(F)ccc(CN2C(=O)C(C(=O)N[C@@H](COc3cc4NC(=O)Nc4cc3)c3ccccc3)=CC=C2)c1
NCGC00346721-04	Fc1c(F)ccc(NCC(=O)Nc2c(C)ccc(CN3CCNCC3)c2)c1		Inactive	P2X7 Receptor Antagonist		1	GW-791343	363677536	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(F)ccc(NCC(=O)Nc2c(C)ccc(CN3CCNCC3)c2)c1	Fc1c(F)ccc(NCC(=O)Nc2c(C)ccc(CN3CCNCC3)c2)c1
NCGC00510078-03	Fc1c(F)ccc2nc(CNc3nc(N4CCOCC4)nc4n(-c5cc(F)ccc5)cnc34)[nH]c12		Inactive	CDK6 Inhibitor		1	SR-3029	384569408	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.6323952426	Fc1c(F)ccc2nc(CNc3nc(N4CCOCC4)nc4n(-c5cc(F)ccc5)cnc34)[nH]c12	Fc1c(F)ccc2nc(CNc3nc(N4CCOCC4)nc4n(-c5cc(F)ccc5)cnc34)[nH]c12
NCGC00481604-01	Fc1c(N/C(/O)=N/CCC(C)(C)C)cc(c(C)c1)-c1c(C)nc2N/C(=N/C)/N=Cc2c1	4.4499998	Active	Raf Kinase Inhibitor	0.0	1	LY-3009120	377020508	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-73.1992381203	Fc1c(N/C(/O)=N/CCC(C)(C)C)cc(c(C)c1)-c1c(C)nc2N/C(=N/C)/N=Cc2c1	Fc1c(N/C(/O)=N/CCC(C)(C)C)cc(c(C)c1)-c1c(C)nc2N/C(=N/C)/N=Cc2c1
NCGC00178711-03	Fc1c(N2C/C(=N\OC)/C(CN)C2)nc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Topoisomerase Iv Subunit A Inhibitor&Topoisomerase IV subunit A  Inhibitor		1	Gemifloxacin mesylate	170465333	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.659076032	S(=O)(=O)(O)C.Fc1c(N2C/C(=N\OC)/C(CN)C2)nc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	S(=O)(=O)(O)C.Fc1c(N2C/C(=N\OC)/C(CN)C2)nc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00015603-08&NCGC00015603-14	Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12	4.4000001	Inactive	Quinoline Antibiotic	0.0	2	Lomefloxacin hydrochloride	170465262&384567871	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&4.0	39.7334028607&29.083069052	Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12.Cl	Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12.Cl&Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12
NCGC00068236-07&NCGC00068236-11	Fc1c(N2CC(C)NCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	DNA Topoisomerase IV Inhibitor&Bacterial Dna Gyrase Inhibitor&DNA Topoisomerase IV Inhibitor		2	Gatifloxacin	170465592&384568072	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-24.7162802544&0.0	Fc1c(N2CC(C)NCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CC(C)NCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00167532-02&NCGC00167532-05	Fc1c(N2CC(NC)CCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		2	Balofloxacin	170465911&384568327	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-31.6937453559&-28.518866908&-11.77636962	Fc1c(N2CC(NC)CCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CC(NC)CCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00164620-02	Fc1c(N2CCC(O)CC2)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1		Inactive	Dna Gyrase Inhibitor&DNA gyrase Inhibitor		1	Nadifloxacin	170465882	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.998244&0.0	Fc1c(N2CCC(O)CC2)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1	Fc1c(N2CCC(O)CC2)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1
NCGC00015772-20	Fc1c(N2CCN(C)CC2)c2OCC(C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	Antibiotic		1	Ofloxacin	384567889	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(N2CCN(C)CC2)c2OCC(C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(N2CCN(C)CC2)c2OCC(C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00166310-02	Fc1c(N2CCN(C)CC2)c2OCN(C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	Antibiotic		1	Marbofloxacin	170465732	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.46718776&-26.6723607519	Fc1c(N2CCN(C)CC2)c2OCN(C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(N2CCN(C)CC2)c2OCN(C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00177986-12	Fc1c(N2CCN(C)CC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		1	Pefloxacin	384568351	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(N2CCN(C)CC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCN(C)CC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1
NCGC00166308-02	Fc1c(N2CCN(C)CC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1	5.0500002	Active	Bacterial Dna Gyrase Inhibitor	0.0	1	Difloxacin hydrochloride	170465623	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-48.009824712	Fc1c(N2CCN(C)CC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1.Cl	Fc1c(N2CCN(C)CC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1.Cl
NCGC00510234-01	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3c([nH]cc3)n2)c1	4.9000001	Active	EGFR Inhibitor	0.0	1	Avitinib	384569419	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-116.9595277	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3c([nH]cc3)n2)c1	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3c([nH]cc3)n2)c1
NCGC00018143-05	Fc1c(N2CCN(CC)CC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Topoisomerase IV Inhibitor&Topoisomerase Iv Inhibitor		1	Enrofloxacin	170465572	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Fc1c(N2CCN(CC)CC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCN(CC)CC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00164615-02&NCGC00164615-05	Fc1c(N2CCN(CC3=C(C)OC(=O)O3)CC2)cc2N3C(C)SC3=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		2	Prulifloxacin	170465849&384568265	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-20.774264772&0.0	Fc1c(N2CCN(CC3=C(C)OC(=O)O3)CC2)cc2N3C(C)SC3=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCN(CC3=C(C)OC(=O)O3)CC2)cc2N3C(C)SC3=C(C(=O)O)C(=O)c2c1
NCGC00016959-06&NCGC00016959-17	Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Bacterial Dna Gyrase Inhibitor&DNA Topoisomerase IV Inhibitor&DNA Topoisomerase IV Inhibitor		2	Ciprofloxacin	170464757&384567969	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-21.902165484&14.4224492479&0.0	Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1.Cl	Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1.Cl&Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00016916-11&NCGC00016916-15	Fc1c(N2CCNCC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1		Inactive	Dna Topoisomerase Iv Inhibitors&DNA Topoisomerase IV Inhibitor&DNA Topoisomerase IV Inhibitor		2	Norfloxacin	170464769&384567967	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-24.5670010559&0.0&-16.920034556	Fc1c(N2CCNCC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCNCC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1
NCGC00016927-11	Fc1c(N2CCNCC2)nc2N(CC)C=C(C(=O)O)C(=O)c2c1		Inactive	Quinoline Antibiotic		1	Enoxacin	170465263	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.7715491999&-25.607910992	Fc1c(N2CCNCC2)nc2N(CC)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCNCC2)nc2N(CC)C=C(C(=O)O)C(=O)c2c1
NCGC00160518-03	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1F	5.4000001	Active	Dna Gyrase Binding Agent	0.0	1	Orbifloxacin	170465644	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-35.0831245304	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1F	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1F
NCGC00166294-03&NCGC00166294-08	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1N		Inactive	DNA Topoisomerase IV Inhibitor&Bacterial Dna Gyrase Inhibitor&DNA Topoisomerase IV Inhibitor		2	Sparfloxacin	170465370&384568305	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-9.490327788&0.0&0.0	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1N	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1N
NCGC00510315-02	Fc1c(N2C[C@@H]3OCCN[C@H]3C2)c(C#N)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	5.0500002	Active		0.0	1	Finafloxacin	405558895	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-47.336775736	Fc1c(N2C[C@@H]3OCCN[C@H]3C2)c(C#N)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2C[C@@H]3OCCN[C@H]3C2)c(C#N)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00164548-02	Fc1c(N2[C@@H]3CN(C)[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Bacterial Dna Gyrase Inhibitor&Bacterial DNA gyrase Inhibitor		1	Danofloxacin	170466637	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.5823264881&-32.9634761239	Fc1c(N2[C@@H]3CN(C)[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2[C@@H]3CN(C)[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00167536-03	Fc1c(N2c3nc(N4CC(N)CC4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	4.4000001	Active	Topoisomerase Iv Inhibitor	0.0	1	Tosufloxacin toluenesulfonic acid	170466053	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-56.197044784	S(=O)(=O)(O)c1ccc(C)cc1.Fc1c(N2c3nc(N4CC(N)CC4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	S(=O)(=O)(O)c1ccc(C)cc1.Fc1c(N2c3nc(N4CC(N)CC4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1
NCGC00263538-01	Fc1c(N2c3nc(N4C[C@H]5C(N)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	4.4000001	Active	Streptococcus Pneumoniae Inhibitor	0.0	1	Trovafloxacin mesylate	170465074	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-93.715552768	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(N)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(N)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1
NCGC00261969-01	Fc1c(N2c3nc(N4C[C@H]5C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)(C)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1		Inactive			1	Alatrofloxacin mesylate	170465095	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.8378545319&0.0	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)(C)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)(C)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1
NCGC00386210-03	Fc1c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)ccc(Oc2cc(NC(=O)N3CCC(N4CCN(C)CC4)CC3)ncc2)c1	4.4499998	Active	VEGFR-2 Inhibitor	0.0	1	Golvatinib	384569115	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-106.6161302108	Fc1c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)ccc(Oc2cc(NC(=O)N3CCC(N4CCN(C)CC4)CC3)ncc2)c1	Fc1c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)ccc(Oc2cc(NC(=O)N3CCC(N4CCN(C)CC4)CC3)ncc2)c1
NCGC00167768-11	Fc1c(NC(=O)Nc2c(F)cc(Oc3c4c(ncc3)cc(OC)c(OC)c4)cc2)ccc(F)c1	5.6500001	Active	VEGFR-2 Inhibitor	0.0	1	KI-8751	377020487	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-58.559519742	Fc1c(NC(=O)Nc2c(F)cc(Oc3c4c(ncc3)cc(OC)c(OC)c4)cc2)ccc(F)c1	Fc1c(NC(=O)Nc2c(F)cc(Oc3c4c(ncc3)cc(OC)c(OC)c4)cc2)ccc(F)c1
NCGC00250403-11	Fc1c(NC(=O)Nc2ccc(-c3c4c(N)n[nH]c4ccc3)cc2)cc(C)cc1	4.4000001	Active	VEGFR-2 Inhibitor	0.0	1	Linifanib	377020321	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-58.6737335959	Fc1c(NC(=O)Nc2ccc(-c3c4c(N)n[nH]c4ccc3)cc2)cc(C)cc1	Fc1c(NC(=O)Nc2ccc(-c3c4c(N)n[nH]c4ccc3)cc2)cc(C)cc1
NCGC00346618-07	Fc1c(NC(=O)Nc2cnc(C)cc2)cccc1CN1CCN(C(=O)OC)CC1	4.4000001	Active	Cardiac Myosin Activator	0.0	1	Omecamtiv mecarbil	363677479	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-60.6409581519	Fc1c(NC(=O)Nc2cnc(C)cc2)cccc1CN1CCN(C(=O)OC)CC1	Fc1c(NC(=O)Nc2cnc(C)cc2)cccc1CN1CCN(C(=O)OC)CC1
NCGC00263172-10	Fc1c(NC(=O)Nc2n(-c3cc4c(nccc4)cc3)nc(C(C)(C)C)c2)ccc(Oc2cc(C(=O)NC)ncc2)c1	4.4000001	Active	Bcr-Abl Inhibitor	0.0	1	DCC-2036	384568642	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-93.630847084	Fc1c(NC(=O)Nc2n(-c3cc4c(nccc4)cc3)nc(C(C)(C)C)c2)ccc(Oc2cc(C(=O)NC)ncc2)c1	Fc1c(NC(=O)Nc2n(-c3cc4c(nccc4)cc3)nc(C(C)(C)C)c2)ccc(Oc2cc(C(=O)NC)ncc2)c1
NCGC00346706-07	Fc1c(NC(=O)c2ccc(OCCCC)cc2)ccc(F)c1		Inactive	mgluR5 allosteric modulator		1	VU0357121	363677528	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(NC(=O)c2ccc(OCCCC)cc2)ccc(F)c1	Fc1c(NC(=O)c2ccc(OCCCC)cc2)ccc(F)c1
NCGC00387023-02	Fc1c(NC(=O)c2n(C)nc(C)c2)cc(Nc2cc3n[nH]c(/C=C/c4ncccc4)c3cc2)cc1	4.4000001	Active	VEGFR-2 Inhibitor	0.0	1	AG-13958	384569148	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-109.1534782196	Fc1c(NC(=O)c2n(C)nc(C)c2)cc(Nc2cc3n[nH]c(/C=C/c4ncccc4)c3cc2)cc1	Fc1c(NC(=O)c2n(C)nc(C)c2)cc(Nc2cc3n[nH]c(/C=C/c4ncccc4)c3cc2)cc1
NCGC00345844-02	Fc1c(NC(CO)(C)C)nc(Nc2cc(NC(=O)NC(C)(C)C)ccc2)nc1	4.75	Active	Tyk 2 Inhibitor	0.0	1	Bayer-18	363677387	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-92.8885948412	Fc1c(NC(CO)(C)C)nc(Nc2cc(NC(=O)NC(C)(C)C)ccc2)nc1	Fc1c(NC(CO)(C)C)nc(Nc2cc(NC(=O)NC(C)(C)C)ccc2)nc1
NCGC00510464-01	Fc1c(NC2=NC(C3CC3)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCOCC2)c1	4.4000001	Inactive	BRK/PTK6 Inhibitor	0.0	1	P21d hydrochloride	384569438	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	41.7232462531	Fc1c(NC2=NC(C3CC3)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCOCC2)c1	Fc1c(NC2=NC(C3CC3)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCOCC2)c1
NCGC00386413-01	Fc1c(NCc2[nH]c(c(C3=Cn4ncnc4C=C3)n2)-c2nc(C)ccc2)cccc1		Inactive	ALK5 Inhibitor		1	Vactosertib	363680266	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.1736929263	Fc1c(NCc2[nH]c(c(C3=Cn4ncnc4C=C3)n2)-c2nc(C)ccc2)cccc1	Fc1c(NCc2[nH]c(c(C3=Cn4ncnc4C=C3)n2)-c2nc(C)ccc2)cccc1
NCGC00510693-01	Fc1c(N[C@H]2[C@@H](N)CCCC2)nc(-c2cn(C)nc2)c2C(=O)NCc12		Inactive	Syk Kinase Inhibitor		1	TAK-659	384569483	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(N[C@H]2[C@@H](N)CCCC2)nc(-c2cn(C)nc2)c2C(=O)NCc12	Fc1c(N[C@H]2[C@@H](N)CCCC2)nc(-c2cn(C)nc2)c2C(=O)NCc12
NCGC00532515-01	Fc1c(Nc2c(CC(=O)O)cc(CC)cc2)c(F)c(F)cc1F	4.4000001	Active	Cyclooxygenase-2 Inhibitor	0.0	1	ROBENACOXIB	405558760	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.231690412	Fc1c(Nc2c(CC(=O)O)cc(CC)cc2)c(F)c(F)cc1F	Fc1c(Nc2c(CC(=O)O)cc(CC)cc2)c(F)c(F)cc1F
NCGC00386306-06	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(OCCOC)cc2)nc1	5.4499998	Active	BTK Inhibitor	0.0	1	Spebrutinib (AVL-292)	363680199	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-74.6321160508	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(OCCOC)cc2)nc1	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(OCCOC)cc2)nc1
NCGC00386312-01	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)nc1	4.6500001	Active	BTK Inhibitor	0.0	1	CNX-774	384569123	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-117.9811602934	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)nc1	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)nc1
NCGC00510526-01	Fc1c(Nc2n(C)c3c(c(C)c(Oc4cc(NC(=O)C)ncc4)cc3)n2)ccc(F)c1	4.4000001	Active	Jak2 Inhibitor	0.0	1	CHZ868	384569473	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-115.7974911779	Fc1c(Nc2n(C)c3c(c(C)c(Oc4cc(NC(=O)C)ncc4)cc3)n2)ccc(F)c1	Fc1c(Nc2n(C)c3c(c(C)c(Oc4cc(NC(=O)C)ncc4)cc3)n2)ccc(F)c1
NCGC00346960-01	Fc1c(Nc2n([C@H]3COCC3)c3nc(NC4CCC(O)CC4)ncc3n2)c(F)cc(F)c1		Inactive	JNK Inhibitor		1	HMSL10058	174006727	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(Nc2n([C@H]3COCC3)c3nc(NC4CCC(O)CC4)ncc3n2)c(F)cc(F)c1	Fc1c(Nc2n([C@H]3COCC3)c3nc(NC4CCC(O)CC4)ncc3n2)c(F)cc(F)c1
NCGC00346581-05	Fc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ccc(F)cc2)c(C#N)c1	4.4000001	Active	Jak2/3 Inhibitor	0.0	1	AZ-960	384568850	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-83.6995363004	Fc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ccc(F)cc2)c(C#N)c1	Fc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ccc(F)cc2)c(C#N)c1
NCGC00182051-05	Fc1c(Nc2nc3NC(=O)C(C)(C)Oc3cc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1		Inactive	Syk Kinase Inhibitor		1	R-406	384568406	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(Nc2nc3NC(=O)C(C)(C)Oc3cc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1	Fc1c(Nc2nc3NC(=O)C(C)(C)Oc3cc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1
NCGC00263086-08	Fc1c(O)c(F)cc(Nc2nc3N(CCC(C)C)C(C)C(=N)N(C)c3cn2)c1	4.5	Active	RSK Inhibitor	0.0	1	BI-D1870	363677195	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-59.3647657723	Fc1c(O)c(F)cc(Nc2nc3N(CCC(C)C)C(C)C(=N)N(C)c3cn2)c1	Fc1c(O)c(F)cc(Nc2nc3N(CCC(C)C)C(C)C(=N)N(C)c3cn2)c1
NCGC00370919-02	Fc1c(O)ccc(-c2oc3c(C=C)cc(O)cc3n2)c1		Inactive	Selective Estrogen Receptor beta Agonist		1	Prinaberel	363677934	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(O)ccc(-c2oc3c(C=C)cc(O)cc3n2)c1	Fc1c(O)ccc(-c2oc3c(C=C)cc(O)cc3n2)c1
NCGC00509910-02	Fc1c(OC(C)C)ccc(-c2nn([C@@H](C)C3=C(c4cc(F)ccc4)C(=O)c4c(O3)ccc(F)c4)c3ncnc(N)c23)c1		Inactive	Casein Kinase 1 Inhibitor		1	Umbralisib	384569377	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.546542088	Fc1c(OC(C)C)ccc(-c2nn([C@@H](C)C3=C(c4cc(F)ccc4)C(=O)c4c(O3)ccc(F)c4)c3ncnc(N)c23)c1	Fc1c(OC(C)C)ccc(-c2nn([C@@H](C)C3=C(c4cc(F)ccc4)C(=O)c4c(O3)ccc(F)c4)c3ncnc(N)c23)c1
NCGC00389340-01	Fc1c(OC2=NC=Nn3c2c(C)c(OCC(OC(=O)C(N)C)C)c3)ccc2[nH]c(C)cc12	4.9499998	Active	FGFR 1/3 Inhibitor	0.0	1	Brivanib	363680772	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.2307711762	Fc1c(OC2=NC=Nn3c2c(C)c(OCC(OC(=O)C(N)C)C)c3)ccc2[nH]c(C)cc12	Fc1c(OC2=NC=Nn3c2c(C)c(OCC(OC(=O)C(N)C)C)c3)ccc2[nH]c(C)cc12
NCGC00263160-06	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](O)C)c3)ccc2[nH]c(C)cc12	4.3499999	Active	VEGFR-2,3/FGFR1,2,3 Inhibitor	0.0	1	Brivanib	384568632	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-48.1732511337	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](O)C)c3)ccc2[nH]c(C)cc12	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](O)C)c3)ccc2[nH]c(C)cc12
NCGC00262195-03	Fc1c(OC=2C(=O)N(C)c3nc(NC4CCOCC4)ncc3C=2)ccc(F)c1		Inactive	p38 MAPK Inhibitor		1	R-1487	377020177	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(OC=2C(=O)N(C)c3nc(NC4CCOCC4)ncc3C=2)ccc(F)c1	Fc1c(OC=2C(=O)N(C)c3nc(NC4CCOCC4)ncc3C=2)ccc(F)c1
NCGC00346477-02	Fc1c(OCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(=O)Nc2c(C(C)(C)C)cccc2)C)CC(=O)O)c(F)c(F)cc1F	6.0500002	Inactive	Caspase Inhibitor	0.0	1	Emricasan	384568791	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-42.9521812178	Fc1c(OCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(=O)Nc2c(C(C)(C)C)cccc2)C)CC(=O)O)c(F)c(F)cc1F	Fc1c(OCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(=O)Nc2c(C(C)(C)C)cccc2)C)CC(=O)O)c(F)c(F)cc1F
NCGC00346938-02	Fc1c(OCC)c(OCC)cc2c1C(=N)N(CC(=O)c1cc(C(C)(C)C)c(OC)c(N3CCOCC3)c1)C2	4.4499998	Active	Thrombin Inhibitor	0.0	1	E5555	384568972	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-121.2254710215	Fc1c(OCC)c(OCC)cc2c1C(=N)N(CC(=O)c1cc(C(C)(C)C)c(OC)c(N3CCOCC3)c1)C2	Fc1c(OCC)c(OCC)cc2c1C(=N)N(CC(=O)c1cc(C(C)(C)C)c(OC)c(N3CCOCC3)c1)C2
NCGC00348110-01	Fc1c(OCCN2CCCC2)ccc(Nc2nc3n(CCC(OC)(C)C)nc(Nc4c(C)cccc4C)c3cn2)c1	4.9499998	Active	ACK1 Inhibitor	0.0	1	PRP003-032	384569002	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.1547699131	Fc1c(OCCN2CCCC2)ccc(Nc2nc3n(CCC(OC)(C)C)nc(Nc4c(C)cccc4C)c3cn2)c1	Fc1c(OCCN2CCCC2)ccc(Nc2nc3n(CCC(OC)(C)C)nc(Nc4c(C)cccc4C)c3cn2)c1
NCGC00378921-05	Fc1c(Oc2c(-c3c[nH]nc3)cc3n(C)ncc3c2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(C)=CC=2)c1	4.75	Active	MET Inhibitor	0.0	1	Merestinib	384569075	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-79.4257502767	Fc1c(Oc2c(-c3c[nH]nc3)cc3n(C)ncc3c2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(C)=CC=2)c1	Fc1c(Oc2c(-c3c[nH]nc3)cc3n(C)ncc3c2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(C)=CC=2)c1
NCGC00481564-01	Fc1c(Oc2c3c(-c4ccccc4)c[nH]c3ncc2)ccc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccc(F)cc2)c1	4.8499999	Active	HGFR Inhibitor	0.0	1	NPS-1034	377020339	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-65.1353413156	Fc1c(Oc2c3c(-c4ccccc4)c[nH]c3ncc2)ccc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccc(F)cc2)c1	Fc1c(Oc2c3c(-c4ccccc4)c[nH]c3ncc2)ccc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccc(F)cc2)c1
NCGC00345824-02	Fc1c(Oc2c3c([nH]cc3)ncc2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2)c1		Inactive	HGFR Inhibitor		1	BMS-2	363677371	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-26.758310048	Fc1c(Oc2c3c([nH]cc3)ncc2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2)c1	Fc1c(Oc2c3c([nH]cc3)ncc2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2)c1
NCGC00509945-01	Fc1c(Oc2c3c(ncc2)cc(OC)c(OC)c3)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(=O)N(C(C)C)C=2)c1		Inactive	TYRO3 Inhibitor		1	CEP-40783	384569393	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c(Oc2c3c(ncc2)cc(OC)c(OC)c3)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(=O)N(C(C)C)C=2)c1	Fc1c(Oc2c3c(ncc2)cc(OC)c(OC)c3)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(=O)N(C(C)C)C=2)c1
NCGC00345848-02	Fc1c(Oc2c3c(ncc2)cc(OC)cc3)ccc(NC(=O)C=2C(=O)N(N(CC(O)(C)C)C=2C)c2ccccc2)c1		Inactive	HGFR Inhibitor		1	AMG-1	363677390	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.9111380559	Fc1c(Oc2c3c(ncc2)cc(OC)cc3)ccc(NC(=O)C=2C(=O)N(N(CC(O)(C)C)C=2C)c2ccccc2)c1	Fc1c(Oc2c3c(ncc2)cc(OC)cc3)ccc(NC(=O)C=2C(=O)N(N(CC(O)(C)C)C=2C)c2ccccc2)c1
NCGC00510492-02	Fc1c(Oc2c3c(ncc2)cc(OCC2(N)CC2)c(OC)c3)ccc2[nH]c(C)cc12	4.9499998	Active	VEGFR-3 Inhibitor	0.0	1	Anlotinib	384569454	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-103.3869510344	Fc1c(Oc2c3c(ncc2)cc(OCC2(N)CC2)c(OC)c3)ccc2[nH]c(C)cc12	Fc1c(Oc2c3c(ncc2)cc(OCC2(N)CC2)c(OC)c3)ccc2[nH]c(C)cc12
NCGC00263201-04	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(C=2C(=O)N(C)C(Nc3ccc(F)cc3)=NC=2)c1	4.9499998	Active	HGFR Inhibitor	0.0	1	AMG-51	384568660	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.9082788453	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(C=2C(=O)N(C)C(Nc3ccc(F)cc3)=NC=2)c1	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(C=2C(=O)N(C)C(Nc3ccc(F)cc3)=NC=2)c1
NCGC00263104-06	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	5.0500002	Active	VEGFR-2 Inhibitor	0.0	1	Foretinib	384568593	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-55.1605674311	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1
NCGC00483926-01	Fc1c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1		Inactive	VEGFR-1/2/3 Inhibitor		1	Sitravatinib	363681145	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.101821952	Fc1c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	Fc1c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1
NCGC00378974-02	Fc1c(Oc2cc(-c3cn(C)nc3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccccc3)CC2)c1	4.6999998	Active	PDGFR alpha Inhibitor	0.0	1	DCC-2618	377020266	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-94.9106024959	Fc1c(Oc2cc(-c3cn(C)nc3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccccc3)CC2)c1	Fc1c(Oc2cc(-c3cn(C)nc3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccccc3)CC2)c1
NCGC00480913-01	Fc1c(Oc2cc(NC(=O)C3CC3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	6.0999999	Inactive	HGFR Inhibitor	0.0	1	Altiratinib	384569250	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-26.7989607175	Fc1c(Oc2cc(NC(=O)C3CC3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	Fc1c(Oc2cc(NC(=O)C3CC3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1
NCGC00485430-01	Fc1c(Oc2ccc(-c3c(C(=O)N)c(N)n([C@H]4CN(C#N)CCC4)n3)cc2)ccc(F)c1	4.4000001	Active	BTK Inhibitor	0.0	1	PF-06250112	363681335	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-40.279555156	Fc1c(Oc2ccc(-c3c(C(=O)N)c(N)n([C@H]4CN(C#N)CCC4)n3)cc2)ccc(F)c1	Fc1c(Oc2ccc(-c3c(C(=O)N)c(N)n([C@H]4CN(C#N)CCC4)n3)cc2)ccc(F)c1
NCGC00263097-03	Fc1c(Oc2ncnc3c2cc(OC)c(OCCCN2CCCC2)c3)ccc2[nH]c(C)cc12	4.75	Active	VEGFR-1/2/3 Inhibitor	0.0	1	Cediranib	384568588	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-92.9621854381	Fc1c(Oc2ncnc3c2cc(OC)c(OCCCN2CCCC2)c3)ccc2[nH]c(C)cc12	Fc1c(Oc2ncnc3c2cc(OC)c(OCCCN2CCCC2)c3)ccc2[nH]c(C)cc12
NCGC00507859-01	Fc1c([C@@H]2N(C3=Nc4c(NC(=O)N5C[C@@H](O)CC5)cnn4C=C3)CCC2)cc(F)cc1		Inactive	TRK B Inhibitor		1	Larotrectinib	384569335	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c([C@@H]2N(C3=Nc4c(NC(=O)N5C[C@@H](O)CC5)cnn4C=C3)CCC2)cc(F)cc1	Fc1c([C@@H]2N(C3=Nc4c(NC(=O)N5C[C@@H](O)CC5)cnn4C=C3)CCC2)cc(F)cc1
NCGC00507866-01	Fc1c([C@@]2(C)NC(=N)N(C)S(=O)(=O)C2)cc(NC(=O)c2ncc(F)cc2)cc1		Inactive	beta-Secretase Inhibitor		1	MK-8931	384569341	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c([C@@]2(C)NC(=N)N(C)S(=O)(=O)C2)cc(NC(=O)c2ncc(F)cc2)cc1	Fc1c([C@@]2(C)NC(=N)N(C)S(=O)(=O)C2)cc(NC(=O)c2ncc(F)cc2)cc1
NCGC00346506-05	Fc1c([C@@]23N=C(N)SC[C@@H]2COC3)cc(NC(=O)c2ncc(F)cc2)cc1		Inactive	beta-Secretase 1/2 (BACE1/2) Inhibitor		1	LY-2886721	384568809	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.977465608	Fc1c([C@@]23N=C(N)SC[C@@H]2COC3)cc(NC(=O)c2ncc(F)cc2)cc1	Fc1c([C@@]23N=C(N)SC[C@@H]2COC3)cc(NC(=O)c2ncc(F)cc2)cc1
NCGC00509932-01	Fc1c([C@H]2c3c(-c4nc(Nc5cc(CCNCCOC)ccc5)ncc4C2)cccc3)cccc1	4.4000001	Active	FGFR Inhibitor	0.0	1	Derazantinib	384569382	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-72.425175268	Fc1c([C@H]2c3c(-c4nc(Nc5cc(CCNCCOC)ccc5)ncc4C2)cccc3)cccc1	Fc1c([C@H]2c3c(-c4nc(Nc5cc(CCNCCOC)ccc5)ncc4C2)cccc3)cccc1
NCGC00390702-02	Fc1c([C@](O)([C@@H](C)N2CCC(=C)CC2)Cn2ncnc2)ccc(F)c1	4.4000001	Active	Lanosterol 14-alpha demethylase Inhibitor	0.0	1	Efinaconazole	405558761	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.223324068	Fc1c([C@](O)([C@@H](C)N2CCC(=C)CC2)Cn2ncnc2)ccc(F)c1	Fc1c([C@](O)([C@@H](C)N2CCC(=C)CC2)Cn2ncnc2)ccc(F)c1
NCGC00164622-02&NCGC00164622-16	Fc1c([C@](O)([C@@H](C)c2c(F)cncn2)Cn2ncnc2)ccc(F)c1		Inactive	Lanosterol 14alpha-demethylase Inhibitors&Lanosterol 14alpha-demethylase Inhibitor&Lanosterol 14alpha-demethylase Inhibitor		2	Voriconazole	170464890&384568268	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.939412168&-27.0076918159&-27.812598172	Fc1c([C@](O)([C@@H](C)c2c(F)cncn2)Cn2ncnc2)ccc(F)c1	Fc1c([C@](O)([C@@H](C)c2c(F)cncn2)Cn2ncnc2)ccc(F)c1
NCGC00532509-01	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2nc[n+](C(OC(=O)N(C)c3c(COC(=O)CNC)cccn3)C)c2)cc(F)cc1	4.6999998	Active	Lanosterol 14-alpha demethylase Inhibitor	0.0	1	ISAVUCONAZONIUM SULFATE	405558653	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-41.4438013889	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2nc[n+](C(OC(=O)N(C)c3c(COC(=O)CNC)cccn3)C)c2)cc(F)cc1	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2nc[n+](C(OC(=O)N(C)c3c(COC(=O)CNC)cccn3)C)c2)cc(F)cc1
NCGC00390646-02	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2ncnc2)cc(F)cc1	4.4499998	Active		0.0	1	Isavuconazole	405558433	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-87.81574398&-116.6533413606	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2ncnc2)cc(F)cc1	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2ncnc2)cc(F)cc1
NCGC00498439-01	Fc1c([C@]2(C)NC(=O)c3c2ccc(-c2c[nH]nc2)c3)ncnc1	5.5	Active	CDK 7 Inhibitor	0.0	1	LY-3177833	384569302	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-97.8625849957	Fc1c([C@]2(C)NC(=O)c3c2ccc(-c2c[nH]nc2)c3)ncnc1	Fc1c([C@]2(C)NC(=O)c3c2ccc(-c2c[nH]nc2)c3)ncnc1
NCGC00185736-03&NCGC00274060-01	Fc1c([C@]2(Cn3ncnc3)OCC(COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1	4.95000005	Active	Lanosterol 14alpha-demethylase Inhibitor&Lanosterol 14alpha-demethylase Inhibitors	0.20000030000000013	2	Posaconazole	384568424&170464963	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-74.3056426412&-81.8973630751	Fc1c([C@]2(Cn3ncnc3)OCC(COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1	Fc1c([C@]2(Cn3ncnc3)OCC(COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1
NCGC00249685-09	Fc1c2C(N)=C(c3[nH]c4c(n3)cc(N3CCN(C)CC3)cc4)C(=O)Nc2ccc1	4.9000001	Active	FGFR Inhibitor	0.0	1	Dovitinib	384568533	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-93.7572847017	Fc1c2C(N)=C(c3[nH]c4c(n3)cc(N3CCN(C)CC3)cc4)C(=O)Nc2ccc1	Fc1c2C(N)=C(c3[nH]c4c(n3)cc(N3CCN(C)CC3)cc4)C(=O)Nc2ccc1
NCGC00510487-01	Fc1c2[C@H](C[C@@H](O)C3CCC(O)CC3)n3c(-c2ccc1)cnc3		Inactive	IDO Inhibitor		1	Navoximod	384569449	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1c2[C@H](C[C@@H](O)C3CCC(O)CC3)n3c(-c2ccc1)cnc3	Fc1c2[C@H](C[C@@H](O)C3CCC(O)CC3)n3c(-c2ccc1)cnc3
NCGC00378713-03	Fc1c2c(cc(F)c1)CC[C@H](N[C@H](C(=O)Nc1ncn(C(CNCC(C)(C)C)(C)C)c1)CCC)C2	4.5	Active	g-Secretase Inhibitor	0.0	1	Nirogacestat	384569064	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-102.7506897908	Fc1c2c(cc(F)c1)CC[C@H](N[C@H](C(=O)Nc1ncn(C(CNCC(C)(C)C)(C)C)c1)CCC)C2	Fc1c2c(cc(F)c1)CC[C@H](N[C@H](C(=O)Nc1ncn(C(CNCC(C)(C)C)(C)C)c1)CCC)C2
NCGC00025330-09	Fc1c2nc(C)cc(NC(=O)Nc3ccc(N(C)C)cc3)c2cc(F)c1		Inactive	Orexin OX-1 Antagonist		1	SB-408124	384568068	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.1483417239	Fc1c2nc(C)cc(NC(=O)Nc3ccc(N(C)C)cc3)c2cc(F)c1	Fc1c2nc(C)cc(NC(=O)Nc3ccc(N(C)C)cc3)c2cc(F)c1
NCGC00263108-02	Fc1cc(-c2cnc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@H]4[C@H]3CC[C@@H](NC(=O)OCC)C4)cc2)ccc1	4.5500002	Active	PAR1 Antagonist	0.0	1	Vorapaxar	384568595	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-74.302039958	Fc1cc(-c2cnc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@H]4[C@H]3CC[C@@H](NC(=O)OCC)C4)cc2)ccc1	Fc1cc(-c2cnc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@H]4[C@H]3CC[C@@H](NC(=O)OCC)C4)cc2)ccc1
NCGC00482976-01	Fc1cc(-c2cnc(/C=C/[C@H]3[C@H]4[C@@H](C[C@H](NC(=O)OCC)CC4)C[C@H]4C(=O)O[C@H](C)C34)cc2)ccc1	4.6750002	Active	Proteinase-activated Receptor 1 Antagonist&Proteinase-activated receptor 1 Antagonist	0.0	1	Vorapaxar Sulfate	405558904	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-59.129021586&-85.314506259	Fc1cc(-c2cnc(/C=C/[C@H]3[C@H]4[C@@H](C[C@H](NC(=O)OCC)CC4)C[C@H]4C(=O)O[C@H](C)C34)cc2)ccc1	Fc1cc(-c2cnc(/C=C/[C@H]3[C@H]4[C@@H](C[C@H](NC(=O)OCC)CC4)C[C@H]4C(=O)O[C@H](C)C34)cc2)ccc1
NCGC00522520-01	Fc1cc(-c2nc3c(N)ncc(C(=O)NC4CN(C(=O)C5CC5)C4)c3cc2)ccc1	5.9499998	Active	MAP4K4 Inhibitor	0.0	1	GNE-495	384569524	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-59.8379652495	Fc1cc(-c2nc3c(N)ncc(C(=O)NC4CN(C(=O)C5CC5)C4)c3cc2)ccc1	Fc1cc(-c2nc3c(N)ncc(C(=O)NC4CN(C(=O)C5CC5)C4)c3cc2)ccc1
NCGC00346534-03	Fc1cc(C(=O)/C=C/c2cn(C)c(/C=C/C(=O)NO)c2)ccc1	4.4499998	Active	HDAC Inhibitor	0.0	1	MC-1568	384568824	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-34.079967592	Fc1cc(C(=O)/C=C/c2cn(C)c(/C=C/C(=O)NO)c2)ccc1	Fc1cc(C(=O)/C=C/c2cn(C)c(/C=C/C(=O)NO)c2)ccc1
NCGC00509914-01	Fc1cc(C(=O)N)c2C(=O)N(C3CCN(C4CCC(F)(F)CC4)CC3)Cc2c1		Inactive	PARP Inhibitor		1	NMS-P118	384569380	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.308982132	Fc1cc(C(=O)N)c2C(=O)N(C3CCN(C4CCC(F)(F)CC4)CC3)Cc2c1	Fc1cc(C(=O)N)c2C(=O)N(C3CCN(C4CCC(F)(F)CC4)CC3)Cc2c1
NCGC00507873-02	Fc1cc(C(C(=O)Nc2sccn2)N2C(=O)c3c(cccc3)C2)c(O)cc1		Inactive	Allosteric EGFR Inhibitor (L858R/T790M-specific)		1	EAI045	384569345	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.8879796399	Fc1cc(C(C(=O)Nc2sccn2)N2C(=O)c3c(cccc3)C2)c(O)cc1	Fc1cc(C(C(=O)Nc2sccn2)N2C(=O)c3c(cccc3)C2)c(O)cc1
NCGC00481573-01	Fc1cc(C/N=C(\O)/Nc2n(-c3ccc(C)cc3)nc(C(C)(C)C)c2)c(Oc2cc3c(n(CCO)nc3)cc2)cc1	4.5	Active	p38 MAPK Inhibitor	0.0	1	Pexmetinib	377020380	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-116.5075087185	Fc1cc(C/N=C(\O)/Nc2n(-c3ccc(C)cc3)nc(C(C)(C)C)c2)c(Oc2cc3c(n(CCO)nc3)cc2)cc1	Fc1cc(C/N=C(\O)/Nc2n(-c3ccc(C)cc3)nc(C(C)(C)C)c2)c(Oc2cc3c(n(CCO)nc3)cc2)cc1
NCGC00531749-01	Fc1cc(C2(Nc3ncc(C(=O)NO)cn3)CCCCC2)ccc1	4.5500002	Active	HDAC Inhibitor	0.0	1	ACY-775	384569536	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-102.2539161524	Fc1cc(C2(Nc3ncc(C(=O)NO)cn3)CCCCC2)ccc1	Fc1cc(C2(Nc3ncc(C(=O)NO)cn3)CCCCC2)ccc1
NCGC00509995-02	Fc1cc(C2=C([C@@H](Nc3ncnc4nc[nH]c34)CC)Oc3c(C2=O)cccc3)ccc1		Inactive	PI3Kdelta/gamma Inhibitor		1	Tenalisib	384569402	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc(C2=C([C@@H](Nc3ncnc4nc[nH]c34)CC)Oc3c(C2=O)cccc3)ccc1	Fc1cc(C2=C([C@@H](Nc3ncnc4nc[nH]c34)CC)Oc3c(C2=O)cccc3)ccc1
NCGC00378845-01	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2C[C@H](N)CCC2)c(C#N)cc1		Inactive			1	Trelagliptin succinate	405558763	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.474391328&-29.419373848	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2C[C@H](N)CCC2)c(C#N)cc1	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2C[C@H](N)CCC2)c(C#N)cc1
NCGC00346529-03	Fc1cc(COc2ccc(CN[C@H](C(=O)N)C)cc2)ccc1		Inactive	Sodium Channel Inhibitor&Sodium channel inhibitor		1	Safinamide	405558801	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Fc1cc(COc2ccc(CN[C@H](C(=O)N)C)cc2)ccc1	Fc1cc(COc2ccc(CN[C@H](C(=O)N)C)cc2)ccc1
NCGC00389718-01	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OCC2NCCOC2)c4)c3)ccc1	4.4000001	Active	EGFR Inhibitor	0.0	1	BMS-599626	384569179	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-66.5377714999	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OCC2NCCOC2)c4)c3)ccc1	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OCC2NCCOC2)c4)c3)ccc1
NCGC00346483-02	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OC[C@H]2NCCOC2)c4)c3)ccc1	4.4499998	Active	EGFR Inhibitor	0.0	1	AC-480	384568793	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-54.6767044418	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OC[C@H]2NCCOC2)c4)c3)ccc1	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OC[C@H]2NCCOC2)c4)c3)ccc1
NCGC00263188-03	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1		Inactive	g-Secretase Inhibitor		1	YO-01027	363677253	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	9.7506462639	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1
NCGC00167803-13	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H](C(=O)OC(C)(C)C)c2ccccc2)C)c1		Inactive	g-Secretase Inhibitor		1	GSI-IX	384568339	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	44.0150690758	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H](C(=O)OC(C)(C)C)c2ccccc2)C)c1	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H](C(=O)OC(C)(C)C)c2ccccc2)C)c1
NCGC00484067-03	Fc1cc(F)cc(Cc2cc3c(NC(=O)c4c(NC5CCOCC5)cc(N5CCN(C)CC5)cc4)n[nH]c3cc2)c1	4.5500002	Active	TrkA/B/C,ROS1,ALK Inhibitor	0.0	1	Entrectinib	363681159	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-122.4386322252	Fc1cc(F)cc(Cc2cc3c(NC(=O)c4c(NC5CCOCC5)cc(N5CCN(C)CC5)cc4)n[nH]c3cc2)c1	Fc1cc(F)cc(Cc2cc3c(NC(=O)c4c(NC5CCOCC5)cc(N5CCN(C)CC5)cc4)n[nH]c3cc2)c1
NCGC00475728-01	Fc1cc(F)cc(N[C@H](C)c2c3OC(N4CCOCC4)=CC(=O)c3cc(C(=O)N(C)C)c2)c1	4.4000001	Active		0.0	1	AZD-8186	384569231	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-54.4666029559	Fc1cc(F)cc(N[C@H](C)c2c3OC(N4CCOCC4)=CC(=O)c3cc(C(=O)N(C)C)c2)c1	Fc1cc(F)cc(N[C@H](C)c2c3OC(N4CCOCC4)=CC(=O)c3cc(C(=O)N(C)C)c2)c1
NCGC00390695-02	Fc1cc(F)cc([C@H](O)C(=O)NNC(=O)c2c(CC)c(C)c(O)cc2)c1		Inactive	SGK1 Inhibitor		1	EMD-638683	377020505	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.8644899561	Fc1cc(F)cc([C@H](O)C(=O)NNC(=O)c2c(CC)c(C)c(O)cc2)c1	Fc1cc(F)cc([C@H](O)C(=O)NNC(=O)c2c(CC)c(C)c(O)cc2)c1
NCGC00346841-07	Fc1cc(F)cc([C@H](O)C(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1	4.4000001	Active	g-Secretase Inhibitor	0.0	1	LY-411575	384568950	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-89.027181316	Fc1cc(F)cc([C@H](O)C(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1	Fc1cc(F)cc([C@H](O)C(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1
NCGC00346546-04	Fc1cc(F)cc([C@H]2N(CC(=O)Nc3cc4c(cc3)C[C@@]3(C(=O)Nc5ncccc35)C4)C(=O)C3(NC2)CCCC3)c1		Inactive	Calcitonin Gene-Related Peptides (CGRP) Antagonist		1	MK-3207	384568832	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.265363528	Fc1cc(F)cc([C@H]2N(CC(=O)Nc3cc4c(cc3)C[C@@]3(C(=O)Nc5ncccc35)C4)C(=O)C3(NC2)CCCC3)c1	Fc1cc(F)cc([C@H]2N(CC(=O)Nc3cc4c(cc3)C[C@@]3(C(=O)Nc5ncccc35)C4)C(=O)C3(NC2)CCCC3)c1
NCGC00347946-02	Fc1cc(N(C(=O)CNc2ccc(C#N)cc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1		Inactive	IDH1 Inhibitor		1	IDH-C227	363677726	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc(N(C(=O)CNc2ccc(C#N)cc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1	Fc1cc(N(C(=O)CNc2ccc(C#N)cc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1
NCGC00347934-09	Fc1cc(N(C(=O)Cn2c(C)ncc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1		Inactive	Mutant IDH1 Inhibitor		1	AGI-5198	363677720	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc(N(C(=O)Cn2c(C)ncc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1	Fc1cc(N(C(=O)Cn2c(C)ncc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1
NCGC00263089-07	Fc1cc(NC(=O)Cc2[nH]nc(Nc3ncnc4c3ccc(OCCCN(CCO)CC)c4)c2)ccc1	4.5500002	Inactive	Aurora-B/C Inhibitor	0.0	1	Barasertib	363677197	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	11.346580744	Fc1cc(NC(=O)Cc2[nH]nc(Nc3ncnc4c3ccc(OCCCN(CCO)CC)c4)c2)ccc1	Fc1cc(NC(=O)Cc2[nH]nc(Nc3ncnc4c3ccc(OCCCN(CCO)CC)c4)c2)ccc1
NCGC00263598-06	Fc1cc(NC(=O)c2ccc(CNC(=O)/C=C/c3cnccc3)cc2)c(N)cc1	4.4000001	Active	Histone deacetylase 8 Inhibitor	0.0	1	Chidamide	384568691	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-115.2206528054	Fc1cc(NC(=O)c2ccc(CNC(=O)/C=C/c3cnccc3)cc2)c(N)cc1	Fc1cc(NC(=O)c2ccc(CNC(=O)/C=C/c3cnccc3)cc2)c(N)cc1
NCGC00185997-11	Fc1cc(O)c(-c2oc(/C=C\3/C(=O)NC(=O)S/3)cc2)cc1		Inactive	PI3K gamma Inhibitor		1	AS-252424	384568433	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc(O)c(-c2oc(/C=C\3/C(=O)NC(=O)S/3)cc2)cc1	Fc1cc(O)c(-c2oc(/C=C\3/C(=O)NC(=O)S/3)cc2)cc1
NCGC00488783-01	Fc1cc([C@@]2(COc3c(C)nc(C)nc3)[C@H](C(=O)Nc3ncc(F)cc3)C2)ccc1		Inactive	Orexin OX-1/2 Antagonist		1	Lemborexant	363681476	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc([C@@]2(COc3c(C)nc(C)nc3)[C@H](C(=O)Nc3ncc(F)cc3)C2)ccc1	Fc1cc([C@@]2(COc3c(C)nc(C)nc3)[C@H](C(=O)Nc3ncc(F)cc3)C2)ccc1
NCGC00485046-01	Fc1cc([C@H](Oc2c(N)ncc(-c3c(C)nc([C@](O)(CO)C)s3)c2)C)c(-n2nccn2)cc1	4.6500001	Active	ALK Inhibitor	0.0	1	PF-06439015	363681205	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-98.5575008196	Fc1cc([C@H](Oc2c(N)ncc(-c3c(C)nc([C@](O)(CO)C)s3)c2)C)c(-n2nccn2)cc1	Fc1cc([C@H](Oc2c(N)ncc(-c3c(C)nc([C@](O)(CO)C)s3)c2)C)c(-n2nccn2)cc1
NCGC00389197-01	Fc1cc(c(C2NC(=O)c3c(C)nc(N)nc3C2)cc1)-c1nc(OC)ccc1	3.8499999	Inactive	Heat Shock Protein 90 (Hsp90) Inhibitor	0.0	1	HSP-990	363680736	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-23.518545032	Fc1cc(c(C2NC(=O)c3c(C)nc(N)nc3C2)cc1)-c1nc(OC)ccc1	Fc1cc(c(C2NC(=O)c3c(C)nc(N)nc3C2)cc1)-c1nc(OC)ccc1
NCGC00164631-05	Fc1cc2/C(=C/C3=C(C)C(C(=O)NCCN(CC)CC)C(C)=N3)/C(=O)Nc2cc1	4.8000002	Active	Vegfr-1/2/3 Inhibitor&VEGFR-1/2/3 Inhibitor	0.0	1	Sunitinib malate	170465289	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-72.6454496927&-117.918376664	Fc1cc2/C(=C/C3=C(C)C(C(=O)NCCN(CC)CC)C(C)=N3)/C(=O)Nc2cc1.O=C(O)C(O)CC(=O)O	Fc1cc2/C(=C/C3=C(C)C(C(=O)NCCN(CC)CC)C(C)=N3)/C(=O)Nc2cc1.O=C(O)C(O)CC(=O)O
NCGC00164631-19	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1	4.4499998	Active	VEGFR-1/2/3 Inhibitor	0.0	1	Sunitinib malate	384568270	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-104.2281970255	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1
NCGC00379021-02	Fc1cc2/C(=C/c3c(C)c(C(=O)NC[C@H](O)CN4CCOCC4)c(C)[nH]3)/C(=O)Nc2cc1	4.4000001	Active	VEGFR-2 Inhibitor	0.0	1	SU-014813	384569086	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-64.515380548	Fc1cc2/C(=C/c3c(C)c(C(=O)NC[C@H](O)CN4CCOCC4)c(C)[nH]3)/C(=O)Nc2cc1	Fc1cc2/C(=C/c3c(C)c(C(=O)NC[C@H](O)CN4CCOCC4)c(C)[nH]3)/C(=O)Nc2cc1
NCGC00015439-11&NCGC00015439-20	Fc1cc2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2cc1		Inactive	GABA(A) BZ Site Receptor Antagonist&Gaba(a) Bz Site Receptor Antagonists&GABA(A) BZ Site Receptor Antagonist		2	Flumazenil	170464960&384567845	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-12.810504656&24.1558487639&0.0	Fc1cc2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2cc1	Fc1cc2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2cc1
NCGC00408915-01	Fc1cc2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4nc[nH]c34)C)=Nc2cc1	4.4000001	Inactive	PI3Kdelta Inhibitor	0.0	1	Acalisib	363681083	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-27.5957092733	Fc1cc2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4nc[nH]c34)C)=Nc2cc1	Fc1cc2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4nc[nH]c34)C)=Nc2cc1
NCGC00351600-04	Fc1cc2C(=O)NN=C3[C@@H]([C@@H](c4ccc(F)cc4)Nc(c23)c1)c1n(C)ncn1	5.3499999	Active	PARP Inhibitor	0.0	1	BMN-673	384569018	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-92.1397783933	Fc1cc2C(=O)NN=C3[C@@H]([C@@H](c4ccc(F)cc4)Nc(c23)c1)c1n(C)ncn1	Fc1cc2C(=O)NN=C3[C@@H]([C@@H](c4ccc(F)cc4)Nc(c23)c1)c1n(C)ncn1
NCGC00482791-01	Fc1cc2C(C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3		Inactive	ALK Inhibitor		1	Lorlatinib	377020401	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.74674396	Fc1cc2C(C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3	Fc1cc2C(C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3
NCGC00510692-02	Fc1cc2[C@@H](C)NC3=Nc4n(ncc4C(=O)NC[C@H](C)Oc2cc1)C=C3	4.8000002	Active	ALK Inhibitor	0.0	1	TPX-0005	384569482	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-47.0341994823	Fc1cc2[C@@H](C)NC3=Nc4n(ncc4C(=O)NC[C@H](C)Oc2cc1)C=C3	Fc1cc2[C@@H](C)NC3=Nc4n(ncc4C(=O)NC[C@H](C)Oc2cc1)C=C3
NCGC00386417-06	Fc1cc2[C@@H](C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3		Inactive	ROS1/ALK Inhibitor		1	Lorlatinib	384569134	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.208871432	Fc1cc2[C@@H](C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3	Fc1cc2[C@@H](C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3
NCGC00167477-01	Fc1cc2[C@]3(C(=O)NC(=O)N3)C[C@@H](C(=O)N)Oc2cc1	4.4000001	Active	Aldose Reductase Inhibitor	0.0	1	Fidarestat	144206034	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-69.1610201199	Fc1cc2[C@]3(C(=O)NC(=O)N3)C[C@@H](C(=O)N)Oc2cc1	Fc1cc2[C@]3(C(=O)NC(=O)N3)C[C@@H](C(=O)N)Oc2cc1
NCGC00346475-02	Fc1cc2[nH]c(-c3c(C[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C4)c4c([nH]3)cc(F)cc4)c(C[C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C3)c2cc1	4.4499998	Active	IAP Inhibitor	0.0	1	Birinapant	384568790	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-63.14792367	Fc1cc2[nH]c(-c3c(C[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C4)c4c([nH]3)cc(F)cc4)c(C[C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C3)c2cc1	Fc1cc2[nH]c(-c3c(C[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C4)c4c([nH]3)cc(F)cc4)c(C[C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C3)c2cc1
NCGC00510231-01	Fc1cc2[nH]c3[C@]4(C)N(CC5=NNC(=O)c(c2c35)c1)CCC4		Inactive	PARP inhibitor		1	GDC-0077	384569416	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc2[nH]c3[C@]4(C)N(CC5=NNC(=O)c(c2c35)c1)CCC4	Fc1cc2[nH]c3[C@]4(C)N(CC5=NNC(=O)c(c2c35)c1)CCC4
NCGC00264110-02	Fc1cc2c(B(O)OC2)cc1		Inactive			1	AN-2690	405558827	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.2092486719&-30.69932742	Fc1cc2c(B(O)OC2)cc1	Fc1cc2c(B(O)OC2)cc1
NCGC00378942-03	Fc1cc2c(C3=C(c4n5c(nc4)C=CC=C5)C(=O)NC3=O)cn3c2c(c1)CN(C(=O)N1CCCCC1)CC3	5.75	Active	GSK-3 beta Inhibitor	0.0	1	LY-2090314	384569077	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-99.0829579874	Fc1cc2c(C3=C(c4n5c(nc4)C=CC=C5)C(=O)NC3=O)cn3c2c(c1)CN(C(=O)N1CCCCC1)CC3	Fc1cc2c(C3=C(c4n5c(nc4)C=CC=C5)C(=O)NC3=O)cn3c2c(c1)CN(C(=O)N1CCCCC1)CC3
NCGC00509942-01	Fc1cc2c(C3C(=O)NC(=O)C3)c[nH]c2cc1		Inactive	IDO Inhibitor		1	EOS-200271	384569390	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.7806888639	Fc1cc2c(C3C(=O)NC(=O)C3)c[nH]c2cc1	Fc1cc2c(C3C(=O)NC(=O)C3)c[nH]c2cc1
NCGC00263579-01	Fc1cc2c(O[C@H]([C@@H](O)CNC[C@H](O)[C@@H]3Oc4c(cc(F)cc4)CC3)CC2)cc1	4.8000002	Active	beta1-Adrenoceptor Antagonists&Beta1-adrenoceptor Antagonists	0.0	1	rac Nebivolol hydrochloride	170465208	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.4	-107.1736200355&-72.6104755755	Fc1cc2c(O[C@H]([C@@H](O)CNC[C@H](O)[C@@H]3Oc4c(cc(F)cc4)CC3)CC2)cc1.Cl	Fc1cc2c(O[C@H]([C@@H](O)CNC[C@H](O)[C@@H]3Oc4c(cc(F)cc4)CC3)CC2)cc1.Cl
NCGC00378895-01	Fc1cc2c([nH]c3C4(OCCc23)CCC(N(C)C)(c2ccccc2)CC4)cc1	6.0500002	Active	Nociceptin Receptor (OPRL1; KOR3; ORL1) Agonist	0.0	1	Cebranopadol	363678262	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-65.1918867864	Fc1cc2c([nH]c3C4(OCCc23)CCC(N(C)C)(c2ccccc2)CC4)cc1	Fc1cc2c([nH]c3C4(OCCc23)CCC(N(C)C)(c2ccccc2)CC4)cc1
NCGC00484061-01	Fc1cc2c(c(C)[nH]c2cc1)-c1[nH]c2c(n1)c1c(nccc1)c1ncccc21	6.0	Inactive	Phase I enhancer of KLF4 expression, apoptosis inducer, angiogensis Inhibitor, cell cycle Inhibitor.	0.0	1	APTO-253	363681154	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-96.8884763884	Fc1cc2c(c(C)[nH]c2cc1)-c1[nH]c2c(n1)c1c(nccc1)c1ncccc21	Fc1cc2c(c(C)[nH]c2cc1)-c1[nH]c2c(n1)c1c(nccc1)c1ncccc21
NCGC00345828-07	Fc1cc2c(c3[nH]c(C(C)(C)C)nc3c3c2C(=O)NC=C3)cc1	5.9000001	Active	Jak Inhibitor	0.0	1	Pyridone 6	377020265	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-43.0477240713	Fc1cc2c(c3[nH]c(C(C)(C)C)nc3c3c2C(=O)NC=C3)cc1	Fc1cc2c(c3[nH]c(C(C)(C)C)nc3c3c2C(=O)NC=C3)cc1
NCGC00379246-01	Fc1cc2nc(-c3cc(C)c(NC(=O)[C@@H](N)CCCCN)cc3)sc2cc1	4.5500002	Active	Aryl Hydrocarbon Receptor (AhR) Agonist	0.0	1	Phortress (NSC-710305)	363678445	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-118.058490963	Fc1cc2nc(-c3cc(C)c(NC(=O)[C@@H](N)CCCCN)cc3)sc2cc1	Fc1cc2nc(-c3cc(C)c(NC(=O)[C@@H](N)CCCCN)cc3)sc2cc1
NCGC00498438-01	Fc1cc2nc(NC(=O)N3CCN(c4cc(OC)cc(OC)c4)CC3)c(OC)nc2cc1	4.4000001	Active	p68 RNA Helicase Inhibitor	0.0	1	RX-5902 (SUPINOXIN)	384569301	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.985819412	Fc1cc2nc(NC(=O)N3CCN(c4cc(OC)cc(OC)c4)CC3)c(OC)nc2cc1	Fc1cc2nc(NC(=O)N3CCN(c4cc(OC)cc(OC)c4)CC3)c(OC)nc2cc1
NCGC00481653-02	Fc1cc2nc(c([C@@H](Nc3ncnc4[nH]cnc34)C)cc2cc1)-c1ncccc1		Inactive	PI3Kdelta Inhibitor		1	AMG-319	363681127	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1cc2nc(c([C@@H](Nc3ncnc4[nH]cnc34)C)cc2cc1)-c1ncccc1	Fc1cc2nc(c([C@@H](Nc3ncnc4[nH]cnc34)C)cc2cc1)-c1ncccc1
NCGC00015883-11	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(=NC=4C)CCCC5)CC3)c2cc1	4.4000001	Active	Dopamine D2 Antagonist	0.0	1	Risperidone	170464925	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-24.3607257432	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(=NC=4C)CCCC5)CC3)c2cc1	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(=NC=4C)CCCC5)CC3)c2cc1
NCGC00522023-01	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(C(OC(=O)CCCCCCCCCCCCCCC)CCC5)=NC=4C)CC3)c2cc1	5.0500002	Active		0.0	1	Paliperidone Palmitate	405558884	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-38.0560770113	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(C(OC(=O)CCCCCCCCCCCCCCC)CCC5)=NC=4C)CC3)c2cc1	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(C(OC(=O)CCCCCCCCCCCCCCC)CCC5)=NC=4C)CC3)c2cc1
NCGC00186014-02	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C([C@H](O)CCC5)=NC=4C)CC3)c2cc1	5.1500001	Active	Serotonin 2a (5-ht2a) Receptor Antagonist&Serotonin 2a (5-HT2a) receptor Antagonist	0.0	1	Paliperidone	170464996	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-38.95580049&-34.2426330828	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C([C@H](O)CCC5)=NC=4C)CC3)c2cc1	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C([C@H](O)CCC5)=NC=4C)CC3)c2cc1
NCGC00188864-02	Fc1cc2onc(C3CCN(CCCOc4c(OC)cc(C(=O)C)cc4)CC3)c2cc1	4.5749998	Active	Dopamine D2 Antagonist	0.0	1	Iloperidone	170465198	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.3	-100.4147321121&-117.7747509891	Fc1cc2onc(C3CCN(CCCOc4c(OC)cc(C(=O)C)cc4)CC3)c2cc1	Fc1cc2onc(C3CCN(CCCOc4c(OC)cc(C(=O)C)cc4)CC3)c2cc1
NCGC00093828-12	Fc1ccc(-c2c(-c3ccncc3)[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1	4.4499998	Active	p38 MAPK Inhibitor	0.0	1	PD-169316	384568119	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-104.9966127287	Fc1ccc(-c2c(-c3ccncc3)[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1	Fc1ccc(-c2c(-c3ccncc3)[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1
NCGC00015962-25	Fc1ccc(-c2c(-c3ccncc3)nc(-c3ccc(O)cc3)[nH]2)cc1	5.0500002	Active	SAPK1 (JNK) Inhibitor	0.0	1	SB-202190	384567911	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-82.3354509508	Fc1ccc(-c2c(-c3ccncc3)nc(-c3ccc(O)cc3)[nH]2)cc1	Fc1ccc(-c2c(-c3ccncc3)nc(-c3ccc(O)cc3)[nH]2)cc1
NCGC00346537-04	Fc1ccc(-c2c(-c3nc4n(CC(C)(C)C)c(N)nc4cc3)[nH]c(C(C)(C)C)n2)cc1	4.4000001	Active	p38 MAPK Inhibitor	0.0	1	LY-2228820	384568826	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-72.51960152	Fc1ccc(-c2c(-c3nc4n(CC(C)(C)C)c(N)nc4cc3)[nH]c(C(C)(C)C)n2)cc1	Fc1ccc(-c2c(-c3nc4n(CC(C)(C)C)c(N)nc4cc3)[nH]c(C(C)(C)C)n2)cc1
NCGC00381753-02	Fc1ccc(-c2c(/C=C/C(O)CC(O)CC(=O)O)c(C3CC3)nc3c2cccc3)cc1	9.25	Inactive	Hmg-coa Reductase Inhibitor	0.0	1	NCGC00381753-02	405558648	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-43.5357075521	Fc1ccc(-c2c(/C=C/C(O)CC(O)CC(=O)[O-])c(C3CC3)nc3c2cccc3)cc1	Fc1ccc(-c2c(/C=C/C(O)CC(O)CC(=O)[O-])c(C3CC3)nc3c2cccc3)cc1
NCGC00164625-04	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(C(C)C)nc(C(C)C)c2COC)cc1	4.0	Inactive	Hmg-coa Reductase Inhibitor	0.0	1	Cerivastatin sodium	170465109	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	87.949410848	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)nc(C(C)C)c2COC)cc1.[Na+]	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)nc(C(C)C)c2COC)cc1.[Na+]
NCGC00164566-07	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(C3CC3)nc3c2cccc3)cc1		Inactive	HMG-CoA Reductase Inhibitor		1	Pitavastatin calcium	384568254	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C3CC3)nc3c2cccc3)cc1	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C3CC3)nc3c2cccc3)cc1
NCGC00164604-06	Fc1ccc(-c2c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)n(C(C)C)c3c2cccc3)cc1		Inactive	HMG-CoA Reductase Inhibitor		1	Fluvastatin	384568263	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.159095316	Fc1ccc(-c2c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)n(C(C)C)c3c2cccc3)cc1	Fc1ccc(-c2c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)n(C(C)C)c3c2cccc3)cc1
NCGC00402250-03	Fc1ccc(-c2c(C3=NN(c4c(C)cccc4)C(=O)C=C3)c3n(n2)C[C@H](CO)CN3)cc1		Inactive	p38 MAPK Inhibitor		1	AS-1940477	363680999	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	29.5262269559	Fc1ccc(-c2c(C3=NN(c4c(C)cccc4)C(=O)C=C3)c3n(n2)C[C@H](CO)CN3)cc1	Fc1ccc(-c2c(C3=NN(c4c(C)cccc4)C(=O)C=C3)c3n(n2)C[C@H](CO)CN3)cc1
NCGC00494684-01	Fc1ccc(-c2c(COc3ncc(C(=O)N4CCS(=O)(=O)CC4)cc3)c(C)on2)cc1		Inactive	GABA(A) Receptor Subunit alpha-5 (GABRA5) Inverse Agonist		1	Basmisanil	384569290	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-38.95533182	Fc1ccc(-c2c(COc3ncc(C(=O)N4CCS(=O)(=O)CC4)cc3)c(C)on2)cc1	Fc1ccc(-c2c(COc3ncc(C(=O)N4CCS(=O)(=O)CC4)cc3)c(C)on2)cc1
NCGC00025329-02	Fc1ccc(-c2c(n(C3CCC(O)CC3)cn2)-c2nc(OC)ncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SB-239063	174007082	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.9243056919	Fc1ccc(-c2c(n(C3CCC(O)CC3)cn2)-c2nc(OC)ncc2)cc1	Fc1ccc(-c2c(n(C3CCC(O)CC3)cn2)-c2nc(OC)ncc2)cc1
NCGC00370842-02	Fc1ccc(-c2c(n(C3CCCCC3)cn2)-c2nc(N)ncc2)cc1		Inactive	Casein Kinase 1 Inhibitor		1	PF-670462	384569037	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.0538979679	Fc1ccc(-c2c(n(C3CCCCC3)cn2)-c2nc(N)ncc2)cc1	Fc1ccc(-c2c(n(C3CCCCC3)cn2)-c2nc(N)ncc2)cc1
NCGC00522007-01	Fc1ccc(-c2c(n(C3CCN(Cc4nocc4)CC3)cn2)-c2nc(N)ncc2)cc1	4.5	Active	Casein Kinase 1 delta/epsilon Inhibitor	0.0	1	PF-5006739	384569509	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-35.30460176	Fc1ccc(-c2c(n(C3CCN(Cc4nocc4)CC3)cn2)-c2nc(N)ncc2)cc1	Fc1ccc(-c2c(n(C3CCN(Cc4nocc4)CC3)cn2)-c2nc(N)ncc2)cc1
NCGC00345831-03	Fc1ccc(-c2c(n(C3CCNCC3)cn2)-c2nc(OC)ncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SB-242235	363677375	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	11.636094248	Fc1ccc(-c2c(n(C3CCNCC3)cn2)-c2nc(OC)ncc2)cc1	Fc1ccc(-c2c(n(C3CCNCC3)cn2)-c2nc(OC)ncc2)cc1
NCGC00241112-04	Fc1ccc(-c2c(n(CCCc3ccccc3)c(C#CCCO)n2)-c2ccncc2)cc1	4.5500002	Active	p38 MAPK Inhibitor	0.0	1	RWJ-67657	384568477	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-67.7998956276	Fc1ccc(-c2c(n(CCCc3ccccc3)c(C#CCCO)n2)-c2ccncc2)cc1	Fc1ccc(-c2c(n(CCCc3ccccc3)c(C#CCCO)n2)-c2ccncc2)cc1
NCGC00183858-01	Fc1ccc(-c2c3c(nc(N4CCN(CC)CC4)c2)CCCCCC3)cc1		Inactive	Serotonin 2a (5-ht2a) Receptor Antagonist&Serotonin 2a (5-HT2a) receptor Antagonist		1	Blonanserin	144206818	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Fc1ccc(-c2c3c(nc(N4CCN(CC)CC4)c2)CCCCCC3)cc1	Fc1ccc(-c2c3c(nc(N4CCN(CC)CC4)c2)CCCCCC3)cc1
NCGC00484085-01	Fc1ccc(-c2c3oc(CNC(=O)/C=C/c4cnc(N)cc4)cc3cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)c2)cc1	6.0999999	Inactive	PAK4/NAMPT	0.0	1	KPT-9274	363681176	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-37.986679534	Fc1ccc(-c2c3oc(CNC(=O)/C=C/c4cnc(N)cc4)cc3cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)c2)cc1	Fc1ccc(-c2c3oc(CNC(=O)/C=C/c4cnc(N)cc4)cc3cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)c2)cc1
NCGC00159458-05&NCGC00159458-11	Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)O)c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1	5.0500002	Active	Hmg-coa Reductase Inhibitor&HMG-CoA Reductase Inhibitor	0.5	2	Atorvastatin calcium	170465113&384568180	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-3.0	-85.9099290788&-50.1380833088	Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.[Ca+2]	Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.[Ca+2]&Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)O)c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1
NCGC00386692-01	Fc1ccc(-c2nn(CC3CCC(N)CC3)c3nc(NCCCC)ncc23)cc1	5.0	Active	Mer Receptor Inhibitor	0.0	1	UNC-569	363680398	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-88.9065478844	Fc1ccc(-c2nn(CC3CCC(N)CC3)c3nc(NCCCC)ncc23)cc1	Fc1ccc(-c2nn(CC3CCC(N)CC3)c3nc(NCCCC)ncc23)cc1
NCGC00346625-03	Fc1ccc(-c2oc(/C=C/3\C(=O)NC(=O)S\3)cc2)cc1		Inactive	PI3K gamma Inhibitor		1	CAY10505	384568865	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1ccc(-c2oc(/C=C/3\C(=O)NC(=O)S\3)cc2)cc1	Fc1ccc(-c2oc(/C=C/3\C(=O)NC(=O)S\3)cc2)cc1
NCGC00346691-02&NCGC00346691-07	Fc1ccc(-c2sc(Cc3c(C)ccc([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c3)cc2)cc1	4.57500005	Active	Sglt-2 Inhibitor&SGLT-2 Inhibitor&SGLT-2 Inhibitor	0.34999990000000025	2	Canagliflozin	405558992&384568913	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-2.1	-39.649883716&-65.3566611216&-105.506197772	Fc1ccc(-c2sc(Cc3c(C)ccc([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c3)cc2)cc1	Fc1ccc(-c2sc(Cc3c(C)ccc([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c3)cc2)cc1
NCGC00167773-13	Fc1ccc(-c2sc(NC(=O)N)c(C(=O)N)c2)cc1		Inactive	IKK beta Inhibitor		1	TPCA-1	384568335	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.5646633239	Fc1ccc(-c2sc(NC(=O)N)c(C(=O)N)c2)cc1	Fc1ccc(-c2sc(NC(=O)N)c(C(=O)N)c2)cc1
NCGC00509993-01	Fc1ccc(-c2scc(C(NC(=O)O[C@H]3C4CCN(C3)CC4)(C)C)n2)cc1	4.4000001	Active	Ceramide Glucosyltransferase Inhibitor	0.0	1	Ibiglustat	384569400	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-38.4960321848	Fc1ccc(-c2scc(C(NC(=O)O[C@H]3C4CCN(C3)CC4)(C)C)n2)cc1	Fc1ccc(-c2scc(C(NC(=O)O[C@H]3C4CCN(C3)CC4)(C)C)n2)cc1
NCGC00021146-09	Fc1ccc(C(=O)C2CCN(CCN3C(=O)Nc4c(C3=O)cccc4)CC2)cc1	4.9499998	Active	5-ht2a Antagonists?	0.0	1	Ketanserin	170466645	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-35.813902516	Fc1ccc(C(=O)C2CCN(CCN3C(=O)Nc4c(C3=O)cccc4)CC2)cc1	Fc1ccc(C(=O)C2CCN(CCN3C(=O)Nc4c(C3=O)cccc4)CC2)cc1
NCGC00016504-09	Fc1ccc(C(=O)CCCN2CC=C(N3C(=O)Nc4c3cccc4)CC2)cc1	4.4000001	Active	Herg Inhibitor	0.0	1	Droperidol	170464722	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-44.600714346	Fc1ccc(C(=O)CCCN2CC=C(N3C(=O)Nc4c3cccc4)CC2)cc1	Fc1ccc(C(=O)CCCN2CC=C(N3C(=O)Nc4c3cccc4)CC2)cc1
NCGC00165864-04	Fc1ccc(C(=O)CCCN2CCC(C(=O)N)(N3CCCCC3)CC2)cc1		Inactive	Serotonin 2c (5-ht2c) Receptor Antagonist&Serotonin 2c (5-HT2c) receptor Antagonist		1	Pipamperone dihydrochloride	170465949	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.950375064	Fc1ccc(C(=O)CCCN2CCC(C(=O)N)(N3CCCCC3)CC2)cc1.Cl.Cl	Fc1ccc(C(=O)CCCN2CCC(C(=O)N)(N3CCCCC3)CC2)cc1.Cl.Cl
NCGC00160383-02	Fc1ccc(C(=O)CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)cc1	4.75	Active	Serotonin 2 (5-ht2) Receptor Antagonist&Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Lenperone Hydrochloride	405558683	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.4	-56.9593055852&-38.1957150071	Fc1ccc(C(=O)CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)cc1
NCGC00167744-02	Fc1ccc(C(=O)CCCN2CCC(C)CC2)cc1		Inactive			1	Methylperone	170466288	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	27.876592412&-21.024832632	Fc1ccc(C(=O)CCCN2CCC(C)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC(C)CC2)cc1
NCGC00016602-04	Fc1ccc(C(=O)CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1	6.1999998	Active	Dopamine D2 Receptor Antagonist	0.0	1	Benperidol	170466409	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-36.6671018599	Fc1ccc(C(=O)CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1
NCGC00188430-01	Fc1ccc(C(=O)CCCN2CCC(O)(c3ccc(C)cc3)CC2)cc1	4.6500001	Active	Serotonin 2a (5-HT2a) receptor Inverse Agonist&Serotonin 2a (5-ht2a) Receptor Inverse Agonist	0.0	1	Moperone	144207164	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-64.621632156&-65.8066471787	S(=O)(=O)(O)O.Fc1ccc(C(=O)CCCN2CCC(O)(c3ccc(C)cc3)CC2)cc1	S(=O)(=O)(O)O.Fc1ccc(C(=O)CCCN2CCC(O)(c3ccc(C)cc3)CC2)cc1
NCGC00015964-17	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CNC3=O)CC2)cc1		Inactive	Dopamine D4 Receptor Antagonist&Dopamine D4 receptor Antagonist		1	Spiperone	170465856	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.499389012	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CNC3=O)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CNC3=O)CC2)cc1
NCGC00016590-06	Fc1ccc(C(=O)CCCN2CCN(c3ncccc3)CC2)cc1		Inactive			1	Azaperone	170465697	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.24251578&-27.766655632	Fc1ccc(C(=O)CCCN2CCN(c3ncccc3)CC2)cc1	Fc1ccc(C(=O)CCCN2CCN(c3ncccc3)CC2)cc1
NCGC00371019-02	Fc1ccc(C(=O)N2CC(C(=O)O)(COc3cc4c(cc(OC)cc4)cc3)C2)cc1		Inactive	Prostaglandin EP2 receptor Antagonist		1	PF-04418948	363677996	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.5897417279	Fc1ccc(C(=O)N2CC(C(=O)O)(COc3cc4c(cc(OC)cc4)cc3)C2)cc1	Fc1ccc(C(=O)N2CC(C(=O)O)(COc3cc4c(cc(OC)cc4)cc3)C2)cc1
NCGC00346722-06	Fc1ccc(C(=O)N2C[C@@H](c3onc(-c4ccc(F)cc4)n3)CCC2)cc1	4.4000001	Active	mgluR5 Antagonist	0.0	1	ADX-47273	384568933	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-81.2158543919	Fc1ccc(C(=O)N2C[C@@H](c3onc(-c4ccc(F)cc4)n3)CCC2)cc1	Fc1ccc(C(=O)N2C[C@@H](c3onc(-c4ccc(F)cc4)n3)CCC2)cc1
NCGC00510695-01	Fc1ccc(C(=O)Nc2n(C3CCC(C(=O)NC(C)C)CC3)c3c(n2)ccc(CN2CCC(C(O)(C)C)CC2)c3)cc1		Inactive	ALK Inhibitor		1	Belizatinib	384569484	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.16849808	Fc1ccc(C(=O)Nc2n(C3CCC(C(=O)NC(C)C)CC3)c3c(n2)ccc(CN2CCC(C(O)(C)C)CC2)c3)cc1	Fc1ccc(C(=O)Nc2n(C3CCC(C(=O)NC(C)C)CC3)c3c(n2)ccc(CN2CCC(C(O)(C)C)CC2)c3)cc1
NCGC00246966-11	Fc1ccc(C(=O)c2cc3nc(NC(=O)OC)[nH]c3cc2)cc1	5.9000001	Active	antiparasitic agent	0.0	1	Flubendazole	384568513	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-64.7999909513	Fc1ccc(C(=O)c2cc3nc(NC(=O)OC)[nH]c3cc2)cc1	Fc1ccc(C(=O)c2cc3nc(NC(=O)OC)[nH]c3cc2)cc1
NCGC00378579-06	Fc1ccc(C(=O)c2nc([C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)C4CCCCC4)CCC3)sc2)cc1		Inactive	IAP Inhibitor		1	LCL-161	384569051	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1ccc(C(=O)c2nc([C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)C4CCCCC4)CCC3)sc2)cc1	Fc1ccc(C(=O)c2nc([C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)C4CCCCC4)CCC3)sc2)cc1
NCGC00015802-18	Fc1ccc(C(CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)c2ccc(F)cc2)cc1	4.6750002	Active	Herg Inhibitor&HERG Inhibitor	0.0	1	Pimozide	170464864	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-80.6967454638&-101.8828476385	Fc1ccc(C(CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)c2ccc(F)cc2)cc1
NCGC00018102-12	Fc1ccc(C(N2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1	4.4000001	Active	Calcium Channel Blocker	0.0	1	Flunarizine	170466037	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-68.843042712&-93.1849619239	Fc1ccc(C(N2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(N2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
NCGC00384249-01	Fc1ccc(C(N2CCN(Cc3c(C)nc(C)c(C)n3)CC2)c2ccc(F)cc2)cc1	4.6500001	Active	NOX Inhibitor	0.0	1	CXC-195	384569108	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-48.6207727524	Fc1ccc(C(N2CCN(Cc3c(C)nc(C)c(C)n3)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(N2CCN(Cc3c(C)nc(C)c(C)n3)CC2)c2ccc(F)cc2)cc1
NCGC00164543-02	Fc1ccc(C(N2CCN(Cc3c(OC)c(OC)c(OC)cc3)CC2)c2ccc(F)cc2)cc1	4.4250002	Active	Ca Channel Blocker - Benzhydryl Class&Ca channel blocker - benzhydryl class	0.0	1	Lomerizine dihydrochloride	170466010	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-55.369137924&-122.1995615206	Fc1ccc(C(N2CCN(Cc3c(OC)c(OC)c(OC)cc3)CC2)c2ccc(F)cc2)cc1.Cl.Cl	Fc1ccc(C(N2CCN(Cc3c(OC)c(OC)c(OC)cc3)CC2)c2ccc(F)cc2)cc1.Cl.Cl
NCGC00015300-11	Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1	4.75	Active	Dopamine Reuptake Inhibitor	0.0	1	Vanoxeamine	384567836	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-79.138776967	Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
NCGC00179240-04	Fc1ccc(C2(C#N)CCC(N3C[C@@H](C)[C@@](C(=O)O)(c4ccccc4)CC3)CC2)cc1	4.4000001	Active	Neurotensin Receptor Type 2 Inverse Agonist	0.0	1	Levocabastine hydrochloride	170465061	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.898755792	Fc1ccc(C2(C#N)CCC(N3C[C@@H](C)[C@@](C(=O)O)(c4ccccc4)CC3)CC2)cc1.Cl	Fc1ccc(C2(C#N)CCC(N3C[C@@H](C)[C@@](C(=O)O)(c4ccccc4)CC3)CC2)cc1.Cl
NCGC00015267-11	Fc1ccc(C2(CCCN(C)C)OCc3c2ccc(C#N)c3)cc1	4.9499998	Active	5-HT Reuptake Inhibitor&5-ht Reuptake Inhibitor	0.0	1	Citalopram hydrobromide	405558908	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-39.3209008148&-43.4273841998	Fc1ccc(C2(CCCN(C)C)OCc3c2ccc(C#N)c3)cc1	Fc1ccc(C2(CCCN(C)C)OCc3c2ccc(C#N)c3)cc1
NCGC00510356-01	Fc1ccc(C2=C(CN3CCCC3)COc3c2cc(OC)cc3)cc1	4.75	Active	T Cell Receptor (TCR)/Cytoplasmic Protein NCK1 Interaction Inhibitor	0.0	1	AX-024	384569431	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-62.7035327603	Fc1ccc(C2=C(CN3CCCC3)COc3c2cc(OC)cc3)cc1	Fc1ccc(C2=C(CN3CCCC3)COc3c2cc(OC)cc3)cc1
NCGC00387775-03	Fc1ccc(CCOc2ccc(CCCc3oc(C(=O)O)cc3)cc2)cc1	4.5	Active	AMPK Activator	0.0	1	D-942	363680662	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-79.2129755983	Fc1ccc(CCOc2ccc(CCCc3oc(C(=O)O)cc3)cc2)cc1	Fc1ccc(CCOc2ccc(CCCc3oc(C(=O)O)cc3)cc2)cc1
NCGC00390656-02	Fc1ccc(CN(C(=O)NCc2ccc(OCC(C)C)cc2)C2CCN(C)CC2)cc1	4.4499998	Active		0.0	1	Pimavanserin	405558435	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-118.7128497599&-90.7746927507	Fc1ccc(CN(C(=O)NCc2ccc(OCC(C)C)cc2)C2CCN(C)CC2)cc1	Fc1ccc(CN(C(=O)NCc2ccc(OCC(C)C)cc2)C2CCN(C)CC2)cc1
NCGC00387145-01	Fc1ccc(CN2C(=O)/C(=C/c3ccc(OCc4cc(B(O)O)ccc4)cc3)/SC2=O)cc1		Inactive	ENPP2 (Autotaxin) Inhibitor		1	HA-130	384569153	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.581059972	Fc1ccc(CN2C(=O)/C(=C/c3ccc(OCc4cc(B(O)O)ccc4)cc3)/SC2=O)cc1	Fc1ccc(CN2C(=O)/C(=C/c3ccc(OCc4cc(B(O)O)ccc4)cc3)/SC2=O)cc1
NCGC00346739-06	Fc1ccc(CNc2cc(N)c(NC(=O)OCC)cc2)cc1		Inactive	Voltage-Gated K(V) 7 (KCNQ) Channel Activator		1	Retigabine	363677539	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.411645836	Fc1ccc(CNc2cc(N)c(NC(=O)OCC)cc2)cc1	Fc1ccc(CNc2cc(N)c(NC(=O)OCC)cc2)cc1
NCGC00015451-11	Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1		Inactive	Voltage-Gated K(V) 7 (KCNQ) Channel Activator		1	Flupirtine maleate	384567850	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.979537192	Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1	Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1
NCGC00346443-01	Fc1ccc(C[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@H]2C(=O)NCC2)CC(=O)[C@@H](NC(=O)c2noc(C)c2)C(C)C)cc1	4.75	Active	HRV 3C Protease Inhibitor	0.0	1	Rupintrivir	174007383	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-32.6134849393	Fc1ccc(C[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@H]2C(=O)NCC2)CC(=O)[C@@H](NC(=O)c2noc(C)c2)C(C)C)cc1	Fc1ccc(C[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@H]2C(=O)NCC2)CC(=O)[C@@H](NC(=O)c2noc(C)c2)C(C)C)cc1
NCGC00420704-02	Fc1ccc(Cc2cnc3C(C)(C)CN(C(=O)CN4[C@@H](CN5[C@H](C)COCC5)CN[C@H](C)C4)c3c2)cc1	4.4000001	Active	IAP Inhibitor	0.0	1	AT-IAP	384569224	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.502804276	Fc1ccc(Cc2cnc3C(C)(C)CN(C(=O)CN4[C@@H](CN5[C@H](C)COCC5)CN[C@H](C)C4)c3c2)cc1	Fc1ccc(Cc2cnc3C(C)(C)CN(C(=O)CN4[C@@H](CN5[C@H](C)COCC5)CN[C@H](C)C4)c3c2)cc1
NCGC00344565-01	Fc1ccc(Cn2c(N3CCC(N(C)C4=NC=CC(=O)N4)CC3)nc3c2cccc3)cc1	5.0999999	Active	Histamine H1 Receptor Antagonists	0.0	1	Mizolastine	170465604	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-57.1035635119	Fc1ccc(Cn2c(N3CCC(N(C)C4=NC=CC(=O)N4)CC3)nc3c2cccc3)cc1	Fc1ccc(Cn2c(N3CCC(N(C)C4=NC=CC(=O)N4)CC3)nc3c2cccc3)cc1
NCGC00016913-14	Fc1ccc(Cn2c(NC3CCN(CCc4ccc(OC)cc4)CC3)nc3c2cccc3)cc1	5.0	Active	Histamine H1 receptor Antagonist	0.0	1	Astemizole	170465888	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-83.5242019468	Fc1ccc(Cn2c(NC3CCN(CCc4ccc(OC)cc4)CC3)nc3c2cccc3)cc1	Fc1ccc(Cn2c(NC3CCN(CCc4ccc(OC)cc4)CC3)nc3c2cccc3)cc1
NCGC00480972-03	Fc1ccc(Cn2nc(C(=O)Nc3cc(C)c(OC)c(C)c3)c3c2[C@](C(=O)N)(C)CN(C(=O)c2[nH]ccc2)C3)cc1		Inactive	IDH1 Inhibitor		1	GSK-864	363681115	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Fc1ccc(Cn2nc(C(=O)Nc3cc(C)c(OC)c(C)c3)c3c2[C@](C(=O)N)(C)CN(C(=O)c2[nH]ccc2)C3)cc1	Fc1ccc(Cn2nc(C(=O)Nc3cc(C)c(OC)c(C)c3)c3c2[C@](C(=O)N)(C)CN(C(=O)c2[nH]ccc2)C3)cc1
NCGC00183837-01	Fc1ccc(N2CCN(CCCC(=O)NC3c4c(SCc5c3cccc5)cccc4)CC2)cc1	4.5	Active	Calcium Channel Blocker	0.0	1	Monatepil	124894552	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-57.930081336&-81.4891430948	Fc1ccc(N2CCN(CCCC(=O)NC3c4c(SCc5c3cccc5)cccc4)CC2)cc1	Fc1ccc(N2CCN(CCCC(=O)NC3c4c(SCc5c3cccc5)cccc4)CC2)cc1
NCGC00263164-07&NCGC00263164-17	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c(ncc4)cc(OC)c(OC)c5)cc3)CC2)cc1	5.1875	Active	VEGFR-2 Inhibitor&Proto-oncogene Tyrosine-protein Kinase Receptor Ret Inhibitor&VEGFR-2 Inhibitor	0.625	2	Cabozantinib	384568635&405558578	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.3&-2.3	-79.5934586051&-85.7785587814&-98.5475485417	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c(ncc4)cc(OC)c(OC)c5)cc3)CC2)cc1	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c(ncc4)cc(OC)c(OC)c5)cc3)CC2)cc1
NCGC00025355-12	Fc1ccc([C@H]2[C@H](COc3cc4OCOc4cc3)CNCC2)cc1	4.4000001	Active	5-ht Reuptake Inhibitor	0.0	1	Paroxetine	170465075	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-66.2373987159	Fc1ccc([C@H]2[C@H](COc3cc4OCOc4cc3)CNCC2)cc1	Fc1ccc([C@H]2[C@H](COc3cc4OCOc4cc3)CNCC2)cc1
NCGC00373041-02&NCGC00373041-03	Fc1nc(C(=O)N)c(O)nc1		Inactive	RNA-dependant RNA polymeriase&Influenza A Virus H3n2 Inhibitor&RNA-dependant RNA polymeriase		2	Favipiravir	384569046&405558604	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-11.770212696&-13.13806274&-34.923846656	Fc1nc(C(=O)N)c(O)nc1	Fc1nc(C(=O)N)c(O)nc1
NCGC00181336-01&NCGC00182047-03	Fc1nc(N)c2ncn([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)c2n1		Inactive	Purine-Nucleoside Phosphorylase Inhibitor&Purine Antagonist		2	2-Fluoroadenosine&Fludarabine phosphate	144206348&170464764	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0		Fc1nc(N)c2ncn([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)c2n1	Fc1nc(N)c2ncn([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)c2n1
NCGC00346453-03	Fc1ncc(NC(=O)[C@@]2(C)N(C=3N=C(Nc4n[nH]c(C5CC5)c4)c4n(N=3)ccc4)CCC2)cc1	5.8499999	Active	IGF-1R Inhibitor	0.0	1	BMS-754807	363677410	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-71.4477948774	Fc1ncc(NC(=O)[C@@]2(C)N(C=3N=C(Nc4n[nH]c(C5CC5)c4)c4n(N=3)ccc4)CCC2)cc1	Fc1ncc(NC(=O)[C@@]2(C)N(C=3N=C(Nc4n[nH]c(C5CC5)c4)c4n(N=3)ccc4)CCC2)cc1
NCGC00522465-01	Fc1nccc(-c2c(C)cc(CC(=O)Nc3ncc(N4CCN(C(=O)C)CC4)cc3)cn2)c1		Inactive	Wnt Signaling Inhibitor		1	GNF-6231	384569518	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.67171736	Fc1nccc(-c2c(C)cc(CC(=O)Nc3ncc(N4CCN(C(=O)C)CC4)cc3)cn2)c1	Fc1nccc(-c2c(C)cc(CC(=O)Nc3ncc(N4CCN(C(=O)C)CC4)cc3)cn2)c1
NCGC00370783-06	Fc1nccc(-c2cc(C(=O)Nc3cnccc3)c(OCc3ccccc3)cc2)c1	5.4499998	Inactive	LRRK2 Inhibitor	0.0	1	GSK-2578215A	363677854	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	62.5768241664	Fc1nccc(-c2cc(C(=O)Nc3cnccc3)c(OCc3ccccc3)cc2)c1	Fc1nccc(-c2cc(C(=O)Nc3cnccc3)c(OCc3ccccc3)cc2)c1
NCGC00475723-01	Fc1nccc2c1n(C1CCCC1)c1nc(Nc3ncc(N4CCC(N(CCO)C)CC4)cc3)ncc21		Inactive	CDK4 Inhibitor		1	AM-5992	377020299	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.188398084	Fc1nccc2c1n(C1CCCC1)c1nc(Nc3ncc(N4CCC(N(CCO)C)CC4)cc3)ncc21	Fc1nccc2c1n(C1CCCC1)c1nc(Nc3ncc(N4CCC(N(CCO)C)CC4)cc3)ncc21
NCGC00183856-01	IC#CCCCCCCCCC(=O)Oc1ccccc1		Inactive			1	Phenyl 11-iodo-10-undecynoate	144206805	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	IC#CCCCCCCCCC(=O)Oc1ccccc1	IC#CCCCCCCCCC(=O)Oc1ccccc1
NCGC00181134-04	IC#CCOc1c(Cl)cc(Cl)c(Cl)c1	4.4250002	Active		0.0	1	Haloprogin	405558522	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-102.3885469899&-101.1224954707	IC#CCOc1c(Cl)cc(Cl)c(Cl)c1	IC#CCOc1c(Cl)cc(Cl)c(Cl)c1
NCGC00159397-03	IC=1C(=O)N(N(C)C=1C)c1ccccc1		Inactive			1	Iodoantipyrine	170465556	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	IC=1C(=O)N(N(C)C=1C)c1ccccc1	IC=1C(=O)N(N(C)C=1C)c1ccccc1
NCGC00179673-03&NCGC00179673-09	IC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	4.82500005	Active	Anti-Herpes Simplex Virus Drug	0.04999969999999987	2	Idoxuridine	170465014&384568382	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-50.2507327228&-79.3773528011	IC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	IC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00159504-04	IOc1c(C(C)C)cc(c(C)c1)-c1c(C)cc(OI)c(C(C)C)c1		Inactive			1	Thymol iodide	170465466	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&20.7627041919	IOc1c(C(C)C)cc(c(C)c1)-c1c(C)cc(OI)c(C(C)C)c1	IOc1c(C(C)C)cc(c(C)c1)-c1c(C)cc(OI)c(C(C)C)c1
NCGC00181092-01	Ic1c(/N=C/N(C)C)c(I)cc(I)c1CCC(=O)O		Inactive			1	Ipodate sodium	144206261	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.076863324&15.6108021119	Ic1c(/N=C/N(C)C)c(I)cc(I)c1CCC(=O)[O-].[Na+]	Ic1c(/N=C/N(C)C)c(I)cc(I)c1CCC(=O)[O-].[Na+]
NCGC00160456-03	Ic1c(C(=O)NCC(=O)O)cccc1		Inactive	Renal Filtration Interacts&renal filtration Interacts		1	2-Iodohippuric acid	170465302	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.72396864&0.0	Ic1c(C(=O)NCC(=O)O)cccc1	Ic1c(C(=O)NCC(=O)O)cccc1
NCGC00016886-04	Ic1c(N(C(=O)C)C)c(I)c(C(=O)NC)c(I)c1C(=O)NCC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I	4.8499999	Active	Thrombin Inhibitor	0.0	1	Ioxaglic Acid	405558537	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.9617408	Ic1c(N(C(=O)C)C)c(I)c(C(=O)NC)c(I)c1C(=O)NCC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I	Ic1c(N(C(=O)C)C)c(I)c(C(=O)NC)c(I)c1C(=O)NCC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I
NCGC00179520-04	Ic1c(N(C(=O)C)C)c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2O)c(I)c1NC(=O)C	4.8249998	Active		0.0	1	Metrizamide	405559101	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-54.700951812&-31.0615111458	Ic1c(N(C(=O)C)C)c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2O)c(I)c1NC(=O)C	Ic1c(N(C(=O)C)C)c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2O)c(I)c1NC(=O)C
NCGC00181093-01	Ic1c(N(C(=O)C)C)c(I)c(C(=O)O)c(I)c1NC(=O)C		Inactive			1	Metrizoate sodium	144206262	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.898450552&-32.317325456	Ic1c(N(C(=O)C)C)c(I)c(C(=O)[O-])c(I)c1NC(=O)C.[Na+]	Ic1c(N(C(=O)C)C)c(I)c(C(=O)[O-])c(I)c1NC(=O)C.[Na+]
NCGC00179430-04	Ic1c(N(C(=O)C)CC(C(=O)O)C)c(I)cc(I)c1N	5.25	Active		0.0	1	Iocetamic acid	405559045	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-3.0	-37.2692924077&-35.8545437792	Ic1c(N(C(=O)C)CC(C(=O)O)C)c(I)cc(I)c1N	Ic1c(N(C(=O)C)CC(C(=O)O)C)c(I)cc(I)c1N
NCGC00179408-03	Ic1c(N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c2I)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Iodixanol	170464924	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.2061172079&-17.330714204	Ic1c(N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c2I)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c2I)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00166000-04	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	4.9000001	Active		0.0	1	Iohexol	170464962	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-35.1078601199	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00182070-03	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCCO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Ioxilan	170465160	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	27.755378424&18.4359509719	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCCO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCCO)c(I)c1C(=O)NCC(O)CO
NCGC00183283-01	Ic1c(N(C(=O)CO)C)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Iomeprol	144207160	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.6372930239	Ic1c(N(C(=O)CO)C)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)CO)C)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00179364-03	Ic1c(N(C(=O)CO)CCO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	5.0749998	Active		0.0	1	Ioversol	170464725	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-36.1812472056&-34.3157158127	Ic1c(N(C(=O)CO)CCO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)CO)CCO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00274272-01	Ic1c(N)c(I)cc(I)c1C(=O)N(CCC(=O)O)c1ccccc1	4.4000001	Active		0.0	1	Iobenzamic acid	170465948	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.3794244399	Ic1c(N)c(I)cc(I)c1C(=O)N(CCC(=O)O)c1ccccc1	Ic1c(N)c(I)cc(I)c1C(=O)N(CCC(=O)O)c1ccccc1
NCGC00095082-06	Ic1c(N)c(I)cc(I)c1CC(C(=O)O)CC		Inactive			1	Iopanoic acid	170465056	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Ic1c(N)c(I)cc(I)c1CC(C(=O)O)CC	Ic1c(N)c(I)cc(I)c1CC(C(=O)O)CC
NCGC00532516-01	Ic1c(NC(=O)C(CO)CO)c(I)c(C(=O)N(CC(O)CO)C)c(I)c1C(=O)N(CC(O)CO)C	4.4000001	Active		0.0	1	IOBITRIDOL	405559008	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.0576098479	Ic1c(NC(=O)C(CO)CO)c(I)c(C(=O)N(CC(O)CO)C)c(I)c1C(=O)N(CC(O)CO)C	Ic1c(NC(=O)C(CO)CO)c(I)c(C(=O)N(CC(O)CO)C)c(I)c1C(=O)N(CC(O)CO)C
NCGC00253600-01	Ic1c(NC(=O)C)c(I)c(C(=O)NC)c(I)c1C(=O)O		Inactive			1	Iothalamate sodium	170465058	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.497357904	Ic1c(NC(=O)C)c(I)c(C(=O)NC)c(I)c1C(=O)[O-].[Na+]	Ic1c(NC(=O)C)c(I)c(C(=O)NC)c(I)c1C(=O)[O-].[Na+]
NCGC00021123-03	Ic1c(NC(=O)C)c(I)c(C(=O)O)c(I)c1NC(=O)C		Inactive			1	Diatrizoic acid dihydrate	170464638	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.9843321919&0.0	Ic1c(NC(=O)C)c(I)c(C(=O)O)c(I)c1NC(=O)C.O.O	Ic1c(NC(=O)C)c(I)c(C(=O)O)c(I)c1NC(=O)C.O.O
NCGC00094851-05	Ic1c(NC(=O)C)c(I)c(CNC(=O)C)c(I)c1C(=O)O		Inactive			1	Iodamide	170465213	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Ic1c(NC(=O)C)c(I)c(CNC(=O)C)c(I)c1C(=O)O	Ic1c(NC(=O)C)c(I)c(CNC(=O)C)c(I)c1C(=O)O
NCGC00095105-05	Ic1c(NC(=O)C)c(I)cc(I)c1C(=O)O		Inactive	Solute Carrier Organic Anion Transporter Family Member 1b1 Activator&Solute carrier organic anion transporter family member 1B1 Activator		1	Acetrizoic acid	170465154	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.1229937&10.401513624	Ic1c(NC(=O)C)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)C)c(I)cc(I)c1C(=O)O
NCGC00181094-01	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(C(=O)O)CC	5.5	Active		0.0	1	Sodium tyropanoate	144206263	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.400019775	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(C(=O)[O-])CC.[Na+]	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(C(=O)[O-])CC.[Na+]
NCGC00249936-01	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NC)c2I)c(I)c(C(=O)NC)c(I)c1C(=O)O		Inactive			1	Iocarmic acid	170465965	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NC)c2I)c(I)c(C(=O)NC)c(I)c1C(=O)O	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NC)c2I)c(I)c(C(=O)NC)c(I)c1C(=O)O
NCGC00016523-05	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	5.25	Active	Complement factor B Inhibitor	0.0	1	Iodipamide	170464888	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.912291442	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O
NCGC00262940-01	Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O		Inactive			1	Iodoxamic Acid	170465432	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O
NCGC00179367-03	Ic1c(NC(=O)COC)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)N(CC(O)CO)C		Inactive			1	Iopromide	170465023	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.190019676&-14.8194372599	Ic1c(NC(=O)COC)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)N(CC(O)CO)C	Ic1c(NC(=O)COC)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)N(CC(O)CO)C
NCGC00183025-01	Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O		Inactive			1	Biliscopin	144206809	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.25204328&12.8999973799	Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O
NCGC00016892-04	Ic1c(NC(=O)[C@@H](O)C)c(I)c(C(=O)NC(CO)CO)c(I)c1C(=O)NC(CO)CO	4.4000001	Active		0.0	1	Iopamidol	170464646	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.502807176	Ic1c(NC(=O)[C@@H](O)C)c(I)c(C(=O)NC(CO)CO)c(I)c1C(=O)NC(CO)CO	Ic1c(NC(=O)[C@@H](O)C)c(I)c(C(=O)NC(CO)CO)c(I)c1C(=O)NC(CO)CO
NCGC00250386-10	Ic1c(NCCCNC(=O)c2sccc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1		Inactive	IKK-epsilon Inhibitor		1	BX-795	384568539	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Ic1c(NCCCNC(=O)c2sccc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1	Ic1c(NCCCNC(=O)c2sccc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1
NCGC00166312-02	Ic1c(O)c(C(=O)Nc2c(C)cc(C(C#N)c3ccc(Cl)cc3)c(Cl)c2)cc(I)c1	4.6750002	Active		0.0	1	Closantel	170466628	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-88.5562736792&-91.743699839	Ic1c(O)c(C(=O)Nc2c(C)cc(C(C#N)c3ccc(Cl)cc3)c(Cl)c2)cc(I)c1	Ic1c(O)c(C(=O)Nc2c(C)cc(C(C#N)c3ccc(Cl)cc3)c(Cl)c2)cc(I)c1
NCGC00160408-06	Ic1c(O)c(I)cc(C(=O)c2c(CC)oc3c2cccc3)c1	4.4000001	Active		0.0	1	Benziodarone	405558418	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.2373796148	Ic1c(O)c(I)cc(C(=O)c2c(CC)oc3c2cccc3)c1	Ic1c(O)c(I)cc(C(=O)c2c(CC)oc3c2cccc3)c1
NCGC00166241-02	Ic1c(O)c(I)cc([N+](=O)[O-])c1	4.6999998	Active		0.0	1	2,6-DIIODO-4-NITROPHENOL	225144276	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-52.8144280315	Ic1c(O)c(I)cc([N+](=O)[O-])c1	Ic1c(O)c(I)cc([N+](=O)[O-])c1
NCGC00166249-03	Ic1c(O)c(I)cc2C3(OC(=O)c4c3cccc4)c3c(c(I)c(O)c(I)c3)Oc12	4.4000001	Active		0.0	1	Erythrosin B	170465719	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.862516377	Ic1c(O)c(I)cc2C3(OC(=O)c4c3cccc4)c3c(c(I)c(O)c(I)c3)Oc12	Ic1c(O)c(I)cc2C3(OC(=O)c4c3cccc4)c3c(c(I)c(O)c(I)c3)Oc12
NCGC00016391-13	Ic1c(O)c2ncccc2c(Cl)c1	4.4000001	Active		0.0	1	Clioquinol	170465019	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-104.6414578015	Ic1c(O)c2ncccc2c(Cl)c1	Ic1c(O)c2ncccc2c(Cl)c1
NCGC00018098-07	Ic1c(O)c2ncccc2c(I)c1	4.5250001	Active		0.0	1	Iodoquinol	170465640	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-113.7269834733&-62.4949098125	Ic1c(O)c2ncccc2c(I)c1	Ic1c(O)c2ncccc2c(I)c1
NCGC00347903-02	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(NC(CO)CO)nc2)c1		Inactive	P2X3/P2X2 Receptor Antagonist		1	Ro-51	384568987	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(NC(CO)CO)nc2)c1	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(NC(CO)CO)nc2)c1
NCGC00015096-17&NCGC00015096-27	Ic1c(OCCN(CC)CC)c(I)cc(C(=O)c2c(CCCC)oc3c2cccc3)c1	4.67499995	Active	Muscarinic M3 Receptor Ligands&Muscarinic M3 Receptor Ligand&Muscarinic M3 Receptor Ligands	0.45000030000000013	2	Amiodarone hydrochloride	170464920&384567808	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4&-2.4	-66.6461178175&-94.7478881596&-80.5049896608	Ic1c(OCCN(CC)CC)c(I)cc(C(=O)c2c(CCCC)oc3c2cccc3)c1	Ic1c(OCCN(CC)CC)c(I)cc(C(=O)c2c(CCCC)oc3c2cccc3)c1
NCGC00094852-04	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(CC(N)C(=O)O)c1	4.6999998	Active	synthetic hormone	0.0	1	L-Thyroxine	405558662	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.9605270786	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(CC(N)C(=O)O)c1	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(CC(N)C(=O)O)c1
NCGC00164336-05	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(C[C@H](N)C(=O)O)c1		Inactive	synthetic hormone		1	L-Thyroxine	174006930	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.591223452	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(C[C@H](N)C(=O)O)c1	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(C[C@H](N)C(=O)O)c1
NCGC00013556-15	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(C[C@H](N)C(=O)O)c1		Inactive	Thyroid Hormone Receptor Beta-1 Agonist&Thyroid hormone receptor beta-1 Agonist		1	Liothyronine Sodium	405559084	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(C[C@H](N)C(=O)O)c1	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(C[C@H](N)C(=O)O)c1
NCGC00263096-16	Ic1c([N+](=O)[O-])cc(C(=O)N)cc1		Inactive	PARP Inhibitor		1	Iniparib	384568587	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Ic1c([N+](=O)[O-])cc(C(=O)N)cc1	Ic1c([N+](=O)[O-])cc(C(=O)N)cc1
NCGC00159508-04&NCGC00159508-05	Ic1c([O-])c(I)cc2C(c3c(Cl)c(Cl)c(Cl)c(Cl)c3C(=O)[O-])=C3C(=C(I)C(=O)C(I)=C3)Oc12	4.5999999	Active	Free Radical Stimulator	0.19999979999999962	2	Rose Bengal disodium	225144230&174006187	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.3	-50.1544067996&-100.1647890846	Ic1c([O-])c(I)cc2C(c3c(Cl)c(Cl)c(Cl)c(Cl)c3C(=O)[O-])=C3C(=C(I)C(=O)C(I)=C3)Oc12	Ic1c([O-])c(I)cc2C(c3c(Cl)c(Cl)c(Cl)c(Cl)c3C(=O)[O-])=C3C(=C(I)C(=O)C(I)=C3)Oc12
NCGC00181912-01	Ic1c2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2ccc1	4.8499999	Active	Gabaergic Synapse Modulator	0.0	1	Iomazenil	144206800	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-44.5225746128	Ic1c2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2ccc1	Ic1c2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2ccc1
NCGC00015554-13	Ic1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1		Inactive	MLCK Inhibitor		1	ML-7	384567863	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-31.459337932	Ic1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1	Ic1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1
NCGC00167793-02	Ic1cc(C)c(Nc2c(F)c(F)c(F)cc2C(=O)NOCC2CC2)cc1	4.9000001	Active	ERK1/2 Inhibitor	0.0	1	PD-198306	377020440	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-99.5141757809	Ic1cc(C)c(Nc2c(F)c(F)c(F)cc2C(=O)NOCC2CC2)cc1	Ic1cc(C)c(Nc2c(F)c(F)c(F)cc2C(=O)NOCC2CC2)cc1
NCGC00015572-06	Ic1cc(CNC(=N)N)ccc1	4.5749998	Active		0.0	1	MIBG	405558858	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-41.154372828&-38.973378868	Ic1cc(CNC(=N)N)ccc1	Ic1cc(CNC(=N)N)ccc1
NCGC00025001-03	Ic1cc(CNc2nc(Cl)nc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)ccc1		Inactive	Adenosine A3 Agonist		1	Namodenoson	384568042	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.2315828999	Ic1cc(CNc2nc(Cl)nc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)ccc1	Ic1cc(CNc2nc(Cl)nc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)ccc1
NCGC00189074-12	Ic1cc(Cl)c(Nc2c(F)c(F)ccc2C(=O)NOCC2CC2)cc1	4.5	Active	MEK Inhibitor	0.0	1	PD-184352	384568457	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-106.0479299989	Ic1cc(Cl)c(Nc2c(F)c(F)ccc2C(=O)NOCC2CC2)cc1	Ic1cc(Cl)c(Nc2c(F)c(F)ccc2C(=O)NOCC2CC2)cc1
NCGC00351593-05	Ic1cc(F)c(NC2=C(C(=O)NOCCO)C=Cc3n2cnc3)cc1		Inactive	MEK Inhibitor		1	GDC-0623	377020510	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.965540908	Ic1cc(F)c(NC2=C(C(=O)NOCCO)C=Cc3n2cnc3)cc1	Ic1cc(F)c(NC2=C(C(=O)NOCCO)C=Cc3n2cnc3)cc1
NCGC00263187-07	Ic1cc(F)c(NC2=C(F)C(=O)N(C)C=3N=CN(C[C@@H](O)CO)C(=O)C2=3)cc1	4.4499998	Active	MEK Inhibitor	0.0	1	TAK-733	384568654	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-73.43584496	Ic1cc(F)c(NC2=C(F)C(=O)N(C)C=3N=CN(C[C@@H](O)CO)C(=O)C2=3)cc1	Ic1cc(F)c(NC2=C(F)C(=O)N(C)C=3N=CN(C[C@@H](O)CO)C(=O)C2=3)cc1
NCGC00263180-08	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C(=O)C=23)C2CC2)cc1	4.5	Active	Mek 1/2 Inhibitor	0.0	1	Trametinib	384568648	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-41.1567634868	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C(=O)C=23)C2CC2)cc1	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C(=O)C=23)C2CC2)cc1
NCGC00346567-12	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=CC=2C(=O)NOCCO)cc1		Inactive	MEK Inhibitor		1	AZD-8330	377020162	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.8766660119	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=CC=2C(=O)NOCCO)cc1	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=CC=2C(=O)NOCCO)cc1
NCGC00346530-09	Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1		Inactive	Mek 1/2 Inhibitor		1	Pimasertib	384568822	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1	Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1
NCGC00346552-08	Ic1cc(F)c(Nc2c(F)c(F)c(Br)cc2C(=O)NOCC(O)CO)cc1		Inactive	Mek 1/2 Inhibitor		1	PD-318088	384568837	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.858478736	Ic1cc(F)c(Nc2c(F)c(F)c(Br)cc2C(=O)NOCC(O)CO)cc1	Ic1cc(F)c(Nc2c(F)c(F)c(Br)cc2C(=O)NOCC(O)CO)cc1
NCGC00378595-03	Ic1cc(F)c(Nc2c(F)c(F)c(CN3C(=O)CCCO3)cc2C(=O)NOCCO)cc1	4.9000001	Active	MEK Inhibitor	0.0	1	RO-4987655	377020160	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-48.0615223648	Ic1cc(F)c(Nc2c(F)c(F)c(CN3C(=O)CCCO3)cc2C(=O)NOCCO)cc1	Ic1cc(F)c(Nc2c(F)c(F)c(CN3C(=O)CCCO3)cc2C(=O)NOCCO)cc1
NCGC00188380-05	Ic1cc(F)c(Nc2c(F)c(F)cc(OC)c2NS(=O)(=O)C2(C[C@H](O)CO)CC2)cc1	4.5999999	Active	Mek 1/2 Inhibitor	0.0	1	Refametinib	384568448	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-116.144223894	Ic1cc(F)c(Nc2c(F)c(F)cc(OC)c2NS(=O)(=O)C2(C[C@H](O)CO)CC2)cc1	Ic1cc(F)c(Nc2c(F)c(F)cc(OC)c2NS(=O)(=O)C2(C[C@H](O)CO)CC2)cc1
NCGC00346455-02&NCGC00346455-05	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)([C@H]3NCCCC3)C2)cc1	4.75	Active	Mek Inhibitor	0.3000001999999995	2	Cobimetinib	384568780&405558491	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4&-2.3	-102.6067498423&-61.8122259479&-111.0352852664	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)([C@H]3NCCCC3)C2)cc1	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)([C@H]3NCCCC3)C2)cc1
NCGC00189075-02	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)NOCC(O)CO)cc1		Inactive	MEK Inhibitor		1	PD-0325901	363677126	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.3400716839	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)NOCC(O)CO)cc1	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)NOCC(O)CO)cc1
NCGC00015478-17	Ic1cc2/C(=C/c3cc(Br)c(O)c(Br)c3)/C(=O)Nc2cc1		Inactive	Raf Kinase C Inhibitor		1	GW-5074	384567854	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.707886616	Ic1cc2/C(=C/c3cc(Br)c(O)c(Br)c3)/C(=O)Nc2cc1	Ic1cc2/C(=C/c3cc(Br)c(O)c(Br)c3)/C(=O)Nc2cc1
NCGC00025012-06	Ic1cc2n(CCN3CCOCC3)c(C)c(C(=O)c3ccc(OC)cc3)c2cc1	5.9499998	Inactive	cannabinoid CB2 Antagonist	0.0	1	AM-630	384568043	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	50.6370398871	Ic1cc2n(CCN3CCOCC3)c(C)c(C(=O)c3ccc(OC)cc3)c2cc1	Ic1cc2n(CCN3CCOCC3)c(C)c(C(=O)c3ccc(OC)cc3)c2cc1
NCGC00346821-04	Ic1ccc(/C=C(\S)/C(=O)O)cc1	4.4000001	Active	Calpain Inhibitor	0.0	1	PD-150606	384568943	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-48.0463205119	Ic1ccc(/C=C(\S)/C(=O)O)cc1	Ic1ccc(/C=C(\S)/C(=O)O)cc1
NCGC00094048-01	Ic1ccc(CC(NC(C)C)C)cc1	4.8249998	Active		0.0	1	Iofetamine hydrochloride	144204790	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-47.1028748303&-62.279129696	Ic1ccc(CC(NC(C)C)C)cc1.Cl	Ic1ccc(CC(NC(C)C)C)cc1.Cl
NCGC00319175-03	N#C/C=C/c1cc(C)c(Nc2nc(Nc3ccc(C#N)cc3)ncc2)c(C)c1	4.5250001	Active		0.0	1	Rilpivirine	405558769	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-115.4636885703&-117.655318524	N#C/C=C/c1cc(C)c(Nc2nc(Nc3ccc(C#N)cc3)ncc2)c(C)c1	N#C/C=C/c1cc(C)c(Nc2nc(Nc3ccc(C#N)cc3)ncc2)c(C)c1
NCGC00015787-09	N#C/N=C(/NC(C(C)(C)C)C)\Nc1ccncc1	4.4499998	Active	Sulfonylurea Receptor 2, Kir6.2 Opener	0.0	1	PINACIDIL	405558656	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-82.1854770816	N#C/N=C(/NC(C(C)(C)C)C)\Nc1ccncc1	N#C/N=C(/NC(C(C)(C)C)C)\Nc1ccncc1
NCGC00253611-01	N#CC(C(C)C)(CC(N(C)C)C)c1ccccc1		Inactive			1	Isoaminile	170465846	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	37.823267732&11.608773384	N#CC(C(C)C)(CC(N(C)C)C)c1ccccc1	N#CC(C(C)C)(CC(N(C)C)C)c1ccccc1
NCGC00346953-01	N#CC(c1sc2c(n1)cccc2)c1nc(NCCc2cnccc2)ncc1		Inactive	JNK Inhibitor		1	JNK Inhibitor V	174006712	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	N#CC(c1sc2c(n1)cccc2)c1nc(NCCc2cnccc2)ncc1	N#CC(c1sc2c(n1)cccc2)c1nc(NCCc2cnccc2)ncc1
NCGC00244253-18	N#CC[C@@H](n1ncc(-c2ncnc3[nH]ccc23)c1)C1CCCC1	4.3499999	Active	Jak1/2 Inhibitor	0.0	1	Ruxolitinib	384568508	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-43.7976914	N#CC[C@@H](n1ncc(-c2ncnc3[nH]ccc23)c1)C1CCCC1	N#CC[C@@H](n1ncc(-c2ncnc3[nH]ccc23)c1)C1CCCC1
NCGC00390733-04	N#Cc1cc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)ccc1		Inactive	LRRK2 Inhibitor		1	PF-06447475	384569210	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	N#Cc1cc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)ccc1	N#Cc1cc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)ccc1
NCGC00016973-06&NCGC00016973-08	N#Cc1ccc(C(n2ncnc2)c2ccc(C#N)cc2)cc1		Inactive	Aromatase Inhibitor		2	Letrozole	225144183&384567970	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-13.5708976879	N#Cc1ccc(C(n2ncnc2)c2ccc(C#N)cc2)cc1	N#Cc1ccc(C(n2ncnc2)c2ccc(C#N)cc2)cc1
NCGC00390223-01	N#Cc1ccc(C2n3c(cnc3)CCC2)cc1		Inactive	Aromatase Inhibitor		1	Fadrozole	363680864	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	24.514189784	N#Cc1ccc(C2n3c(cnc3)CCC2)cc1	N#Cc1ccc(C2n3c(cnc3)CCC2)cc1
NCGC00378610-02	N#Cc1nccc(-c2nc(-c3ccncc3)[nH]n2)c1	5.1500001	Active	Xanthine dehydrogenase Inhibitor	0.0	1	Topiroxostat	405558772	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.1893608316	N#Cc1nccc(-c2nc(-c3ccncc3)[nH]n2)c1	N#Cc1nccc(-c2nc(-c3ccncc3)[nH]n2)c1
NCGC00094572-12	N(/C=N/c1c(C)cc(C)cc1)(/C=N/c1c(C)cc(C)cc1)C		Inactive			1	Amitraz	170465703	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.0399777359&-12.455963412	N(/C=N/c1c(C)cc(C)cc1)(/C=N/c1c(C)cc(C)cc1)C	N(/C=N/c1c(C)cc(C)cc1)(/C=N/c1c(C)cc(C)cc1)C
NCGC00183050-01	N(=C(/NCc1ccccc1)\NC)\C		Inactive	adrenergic receptor signaling pathway involved in heart process Inhibitor&Adrenergic Receptor Signaling Pathway Involved In Heart Process Inhibitor		1	Bethanidine sulfate (2:1)	144206760	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	28.662376724&0.0	S(=O)(=O)(O)O.N(=C(/NCc1ccccc1)\NC)\C.N(=C(/NCc1ccccc1)\NC)\C	S(=O)(=O)(O)O.N(=C(/NCc1ccccc1)\NC)\C.N(=C(/NCc1ccccc1)\NC)\C
NCGC00018130-09	N(=N/c1ccccc1)\c1c(N)nc(N)cc1		Inactive			1	Phenazopyridine hydrochloride	170465267	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	N(=N/c1ccccc1)\c1c(N)nc(N)cc1.Cl	N(=N/c1ccccc1)\c1c(N)nc(N)cc1.Cl
NCGC00016564-06&NCGC00016564-17	N(C(=N)NC(=N)N)(C)C		Inactive	Amp-activated Protein Kinase (ampk) Activator&AMPK Activator&AMPK Activator		2	Metformin	170464804&384567949	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-9.64198222&-19.6391098959&0.0	N(C(=N)NC(=N)N)(C)C.Cl	N(C(=N)NC(=N)N)(C)C.Cl&N(C(=N)NC(=N)N)(C)C
NCGC00183030-02	N(C(C)(C)C)C(CC(c1ccccc1)c1ccccc1)C	4.8000002	Active	Herg Inhibitor&HERG Inhibitor	0.0	1	Terodiline hydrochloride	405558600	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-53.2324853658&-68.7077244156	N(C(C)(C)C)C(CC(c1ccccc1)c1ccccc1)C	N(C(C)(C)C)C(CC(c1ccccc1)c1ccccc1)C
NCGC00091070-02	N(C(C)C)C(C)C	5.9000001	Active	Pyruvate Dehydrogenase Kinase Isoform 4 Inhibitor	0.0	1	Diisopropylamine	170466002	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-53.2032457779	N(C(C)C)C(C)C	N(C(C)C)C(C)C
NCGC00347951-03	N(C(C)c1cc2OCCOc2cc1)[C@@H]1[C@@H](c2ccccc2)C1		Inactive	Lysine Specific Demethylase 1 (LSD1) Inhibitor		1	LSD1-C76	384568996	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	N(C(C)c1cc2OCCOc2cc1)[C@@H]1[C@@H](c2ccccc2)C1	N(C(C)c1cc2OCCOc2cc1)[C@@H]1[C@@H](c2ccccc2)C1
NCGC00015884-15	N(C(C1CC1)C1CC1)C=1OCCN=1		Inactive	Imidazoline I1 Receptor Agonist		1	Rilmenidine	384567900	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	N(C(C1CC1)C1CC1)C=1OCCN=1	N(C(C1CC1)C1CC1)C=1OCCN=1
NCGC00510944-01	N(C(CC1CCCC1)C)C		Inactive			1	Cyclopentamine hydrochloride	405558489	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.37670232&-19.6298730399	N(C(CC1CCCC1)C)C	N(C(CC1CCCC1)C)C
NCGC00182042-04	N(C(CC1CCCCC1)C)C	4.25	Active	Trace Amine-associated Receptor 1 Agonist	0.0	1	Propylhexedrine (hydrochloride)	405558687	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.0522409756	N(C(CC1CCCCC1)C)C	N(C(CC1CCCCC1)C)C
NCGC00160594-03	N(C(CCCC(C)C)C)C(C)C		Inactive	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist		1	IPROHEPTINE	405558890	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.863772092&-23.156858708	N(C(CCCC(C)C)C)C(C)C	N(C(CCCC(C)C)C)C(C)C
NCGC00015817-14	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	4.6500001	Active		0.0	1	Promethazine	170465107	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-85.4412584408&-76.9621881504	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(C)C
NCGC00178860-06	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(CC)CC	4.7750001	Active	Butyrylcholinesterase Inhibitor	0.0	1	Ethopropazine hydrochloride	170465065	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-65.2231805547&-43.4713637875	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(CC)CC.Cl	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(CC)CC.Cl
NCGC00181101-01	N(C(CN1c2ncccc2Sc2c1cccc2)C)(C)C	4.9250002	Active	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist	0.0	1	Isothipendyl hydrochloride	144206270	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-75.0024631006&-81.7019683738	N(C(CN1c2ncccc2Sc2c1cccc2)C)(C)C.Cl	N(C(CN1c2ncccc2Sc2c1cccc2)C)(C)C.Cl
NCGC00016570-06	N(C(Cc1ccccc1)(C)C)C		Inactive			1	Mephentermine hemisulfate	170465271	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.51750426&24.221200192	S(=O)(=O)(O)O.N(C(Cc1ccccc1)(C)C)C.N(C(Cc1ccccc1)(C)C)C	S(=O)(=O)(O)O.N(C(Cc1ccccc1)(C)C)C.N(C(Cc1ccccc1)(C)C)C
NCGC00378621-01	N(C)(C)C1=N[C@H](C)N=C(N)N1		Inactive	AMPK Activator		1	Imeglimin	384569058	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.1679774359	N(C)(C)C1=N[C@H](C)N=C(N)N1	N(C)(C)C1=N[C@H](C)N=C(N)N1
NCGC00014352-10	N(C)(C)c1c(CN2C(N(Cc3c(N(C)C)cccc3)CCC2)c2ccncc2)cccc1	4.4499998	Active	Hedgehog pathway Inhibitor	0.0	1	GANT-61	384567791	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-81.4818474748	N(C)(C)c1c(CN2C(N(Cc3c(N(C)C)cccc3)CCC2)c2ccncc2)cccc1	N(C)(C)c1c(CN2C(N(Cc3c(N(C)C)cccc3)CCC2)c2ccncc2)cccc1
NCGC00167496-03	N(C)(C)c1cc2[s+]c3c(nc2cc1)ccc(N(C)C)c3	5.1500001	Active	antimalarial agents	0.0	1	Methylene blue	170465461	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.1	-97.6705551138	N(C)(C)c1cc2[s+]c3c(nc2cc1)ccc(N(C)C)c3.[Cl-]	N(C)(C)c1cc2[s+]c3c(nc2cc1)ccc(N(C)C)c3.[Cl-]
NCGC00015100-15&NCGC00015100-16	N(C)(C)c1nc(N(C)C)nc(N(C)C)n1		Inactive	Antineoplastic Agent&DNA Alkylating Drugs&DNA Alkylating Drugs		2	Altretamine	170464714&384567809	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-23.881614272&16.431424884&-23.693347736	N(C)(C)c1nc(N(C)C)nc(N(C)C)n1	N(C)(C)c1nc(N(C)C)nc(N(C)C)n1
NCGC00015703-06	N(C)C1(C)C(C)(C)C2CC1CC2		Inactive	Neuronal Acetylcholine Receptor; Alpha4/beta2 Antagonist&Neuronal acetylcholine receptor; alpha4/beta2 Antagonist		1	Mecamylamine	170465225	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	N(C)C1(C)C(C)(C)C2CC1CC2	N(C)C1(C)C(C)(C)C2CC1CC2
NCGC00159346-04	N(C/C=C/C#CC(C)(C)C)(Cc1c2c(ccc1)cccc2)C	4.4000001	Active	Fungal Squalene Monooxygenase Inhibitor	0.0	1	Terbinafine	170465174	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-67.885703364	N(C/C=C/C#CC(C)(C)C)(Cc1c2c(ccc1)cccc2)C	N(C/C=C/C#CC(C)(C)C)(Cc1c2c(ccc1)cccc2)C
NCGC00179332-03	N(C/C=C/c1ccccc1)(Cc1c2c(ccc1)cccc2)C	4.9749999	Active	Squalene monooxygenase Inhibitor&Squalene Monooxygenase Inhibitor	0.0	1	Naftifine hydrochloride	170464903	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-77.0097462785&-81.0159577532	N(C/C=C/c1ccccc1)(Cc1c2c(ccc1)cccc2)C.Cl	N(C/C=C/c1ccccc1)(Cc1c2c(ccc1)cccc2)C.Cl
NCGC00090955-06	N(C1CCCCC1)C1CCCCC1		Inactive	Spermidine Biosynthetic Process Inhibitor&spermidine biosynthetic process Inhibitor		1	Dicyclohexylamine	170466864	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	N(C1CCCCC1)C1CCCCC1	N(C1CCCCC1)C1CCCCC1
NCGC00346431-02	N(CC#C)(CC=1c2c(Oc3c(cccc3)C=1)cccc2)C		Inactive	Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitor		1	Omigapil	384568774	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.654094308	N(CC#C)(CC=1c2c(Oc3c(cccc3)C=1)cccc2)C	N(CC#C)(CC=1c2c(Oc3c(cccc3)C=1)cccc2)C
NCGC00015841-11	N(CC#C)(Cc1ccccc1)C		Inactive	Monoamine oxidase B Inhibitor&Monoamine Oxidase B Inhibitor		1	Pargyline hydrochloride	170465066	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-11.651041112	N(CC#C)(Cc1ccccc1)C.Cl	N(CC#C)(Cc1ccccc1)C.Cl
NCGC00168774-02&NCGC00168774-04	N(CC#C)[C@H]1c2c(cccc2)CC1		Inactive	MAO-B Inhibitor&Monoamine Oxidase B Inhibitor&MAO-B Inhibitor		2	Rasagiline mesylate	170465410&384568347	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-11.5040637759	S(=O)(=O)(O)C.N(CC#C)[C@H]1c2c(cccc2)CC1	S(=O)(=O)(O)C.N(CC#C)[C@H]1c2c(cccc2)CC1&N(CC#C)[C@H]1c2c(cccc2)CC1
NCGC00016013-06	N(CC(CN1c2c(cccc2)CCc2c1cccc2)C)(C)C	4.6750002	Active	Serotonin 2 (5-ht2) Receptor Antagonist&Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Trimipramine maleate	170465260	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-72.2974967981&-74.780643078	O=C(O)/C=C\C(=O)O.N(CC(CN1c2c(cccc2)CCc2c1cccc2)C)(C)C	O=C(O)/C=C\C(=O)O.N(CC(CN1c2c(cccc2)CCc2c1cccc2)C)(C)C
NCGC00345822-02	N(CC(CNC=1C(C2CCC2)=Cc2n(c(-c3ccccc3)nn2)N=1)(C)C)(C)C		Inactive	AKT Inhibitor		1	Akt-I-1	363677369	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	N(CC(CNC=1C(C2CCC2)=Cc2n(c(-c3ccccc3)nn2)N=1)(C)C)(C)C	N(CC(CNC=1C(C2CCC2)=Cc2n(c(-c3ccccc3)nn2)N=1)(C)C)(C)C
NCGC00016715-04	N(CC)(CC)C=1n2ncnc2N=C(C)C=1	4.4000001	Active	C-c Motif Chemokine 2 Inhibitor	0.0	1	Trapidil	170465770	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.4827417055	N(CC)(CC)C=1n2ncnc2N=C(C)C=1	N(CC)(CC)C=1n2ncnc2N=C(C)C=1
NCGC00024929-02	N(CC)(c1nc(C)[n+](C)c(NC)c1)c1ccccc1		Inactive	HCN [I(h)] Blocker		1	ICI-D7288	384568036	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	N(CC)(c1nc(C)[n+](C)c(NC)c1)c1ccccc1	N(CC)(c1nc(C)[n+](C)c(NC)c1)c1ccccc1
NCGC00181088-01	N(CC/C=C/1\c2c(C(C)(C)c3c\1cccc3)cccc2)(C)C	4.875	Active		0.0	1	Melitracen hydrochloride	144206258	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-93.2433195788&-74.4715309818	N(CC/C=C/1\c2c(C(C)(C)c3c\1cccc3)cccc2)(C)C.Cl	N(CC/C=C/1\c2c(C(C)(C)c3c\1cccc3)cccc2)(C)C.Cl
NCGC00013841-09	N(CC/C=C/1\c2c(cccc2)C=Cc2c\1cccc2)(C)C	4.875	Active	5-ht2a Receptor Ligands&5-HT2A Receptor Ligands	0.0	1	Cyclobenzaprine hydrochloride	170464953	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.2	-96.6249723468&-79.672892274	N(CC/C=C/1\c2c(cccc2)C=Cc2c\1cccc2)(C)C.Cl	N(CC/C=C/1\c2c(cccc2)C=Cc2c\1cccc2)(C)C.Cl
NCGC00015095-15	N(CC/C=C/1\c2c(cccc2)CCc2c\1cccc2)(C)C	4.5749998	Active	Sodium-dependent Serotonin Transporter Inhibitor&Sodium-dependent serotonin transporter Inhibitor	0.0	1	Amitriptyline hydrochloride	170464758	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-101.370485163&-83.6049328867	N(CC/C=C/1\c2c(cccc2)CCc2c\1cccc2)(C)C.Cl	N(CC/C=C/1\c2c(cccc2)CCc2c\1cccc2)(C)C.Cl
NCGC00024623-04	N(CC/C=C\1/c2c(OCc3c/1cccc3)cccc2)(C)C	4.6999998	Active	Unknown&unknown	0.0	1	NCGC00024623-04&Doxepin hydrochloride	170465413	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-85.6865886188&-60.1365966387	N(CC/C=C\1/c2c(OCc3c/1cccc3)cccc2)(C)C.Cl	N(CC/C=C\1/c2c(OCc3c/1cccc3)cccc2)(C)C.Cl
NCGC00016549-05	N(CC/C=C\1/c2c(SCc3c/1cccc3)cccc2)(C)C	4.6999998	Active	Serotonin Transporter Inhibitor&Serotonin transporter Inhibitor	0.0	1	Dosulepin hydrochloride	405558989	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.1	-104.8129528322&-91.1173142467	N(CC/C=C\1/c2c(SCc3c/1cccc3)cccc2)(C)C	N(CC/C=C\1/c2c(SCc3c/1cccc3)cccc2)(C)C
NCGC00167441-02&NCGC00167441-07	N(CCC)[C@@H]1Cc2sc(N)nc2CC1		Inactive	Dopamine D3 Antagonist&Dopamine Receptor D3 Agonist&Dopamine D3 Antagonist		2	Pramipexole hydrochloride	170465264&384568313	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	23.821894576&-13.712566652&-12.6887822839	N(CCC)[C@@H]1Cc2sc(N)nc2CC1	N(CCC)[C@@H]1Cc2sc(N)nc2CC1
NCGC00025158-02	N(CCC1=C([C@H](C)c2ncccc2)c2c(cccc2)C1)(C)C	4.4000001	Active	Histamine H1 Receptor Antagonist	0.0	1	(S)-(+)-Dimethindene maleate	170465880	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-82.0403068744	O=C(O)/C=C\C(=O)O.N(CCC1=C([C@H](C)c2ncccc2)c2c(cccc2)C1)(C)C	O=C(O)/C=C\C(=O)O.N(CCC1=C([C@H](C)c2ncccc2)c2c(cccc2)C1)(C)C
NCGC00013841-13	N(CCC=C1c2c(cccc2)C=Cc2c1cccc2)(C)C	4.5500002	Active	5-HT2A Receptor Ligands	0.0	1	Cyclobenzaprine hydrochloride	384567790	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-104.1022384824	N(CCC=C1c2c(cccc2)C=Cc2c1cccc2)(C)C	N(CCC=C1c2c(cccc2)C=Cc2c1cccc2)(C)C
NCGC00014483-16	N(CCC=C1c2c(cccc2)CCc2c1cccc2)C	4.7249999	Active	Norepinephrine Transporter Inhibitor&Norepinephrine transporter Inhibitor	0.0	1	Pamelor	405559064	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-95.6044803624&-76.05683361	N(CCC=C1c2c(cccc2)CCc2c1cccc2)C	N(CCC=C1c2c(cccc2)CCc2c1cccc2)C
NCGC00092318-12	N(CCCC(Nc1nc(Nc2cc3c(N)cc(C)nc3cc2)cc(C)n1)C)(CC)CC		Inactive	Rac1-GEF Inhibitor		1	NSC-23766	384568105	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.090716792	N(CCCC(Nc1nc(Nc2cc3c(N)cc(C)nc3cc2)cc(C)n1)C)(CC)CC	N(CCCC(Nc1nc(Nc2cc3c(N)cc(C)nc3cc2)cc(C)n1)C)(CC)CC
NCGC00015708-19	N(CCCC12c3c(cccc3)C(c3c1cccc3)CC2)C	4.5500002	Active	Noradrenaline Reuptake Inhibitor	0.0	1	Maprotiline hydrochloride	363676460	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-102.3900100207	N(CCCC12c3c(cccc3)C(c3c1cccc3)CC2)C	N(CCCC12c3c(cccc3)C(c3c1cccc3)CC2)C
NCGC00015851-10	N(CCCC1c2c(cccc2)C=Cc2c1cccc2)C	4.5250001	Active	Norepinephrine transporter Inhibitor&Norepinephrine Transporter Inhibitor	0.0	1	Protriptyline hydrochloride	170465077	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-76.7300796678&-90.3718813484	N(CCCC1c2c(cccc2)C=Cc2c1cccc2)C.Cl	N(CCCC1c2c(cccc2)C=Cc2c1cccc2)C.Cl
NCGC00346553-10	N(CCCCCCN)C1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1	4.6500001	Active	CDK 7 Inhibitor	0.0	1	BS-181	384568838	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-106.442568338	N(CCCCCCN)C1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1	N(CCCCCCN)C1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1
NCGC00167576-02	N(CCCN(c1ccccc1)C1Cc2c(cccc2)C1)(CC)CC	4.625	Active	Calmodulin Inhibitor	0.0	1	Aprindine hydrochloride	170465842	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.3	-100.7001867376&-113.0991770431	N(CCCN(c1ccccc1)C1Cc2c(cccc2)C1)(CC)CC.Cl	N(CCCN(c1ccccc1)C1Cc2c(cccc2)C1)(CC)CC.Cl
NCGC00015937-04	N(CCCN)CCCCN	4.4000001	Active	NOS Inhibitor	0.0	1	Spermidine	124881420	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-41.351514656	N(CCCN)CCCCN	N(CCCN)CCCCN
NCGC00015829-12	N(CCCN1c2c(Sc3c1cccc3)cccc2)(C)C	4.6999998	Active	Serotonin 2a (5-ht2a) Receptor Antagonist&Serotonin 2a (5-HT2a) receptor Antagonist	0.0	1	Promazine hydrochloride	170464766	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.2	-102.0737276324&-77.8057837576	N(CCCN1c2c(Sc3c1cccc3)cccc2)(C)C.Cl	N(CCCN1c2c(Sc3c1cccc3)cccc2)(C)C.Cl
NCGC00015563-13	N(CCCN1c2c(cccc2)CCc2c1cccc2)(C)C	4.5749998	Active	Serum Paraoxonase/arylesterase 1 Inhibitor&Serum paraoxonase/arylesterase 1 Inhibitor	0.0	1	Imipramine	170464777	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-98.9784765812&-72.3298672916	N(CCCN1c2c(cccc2)CCc2c1cccc2)(C)C	N(CCCN1c2c(cccc2)CCc2c1cccc2)(C)C
NCGC00015340-14	N(CCCN1c2c(cccc2)CCc2c1cccc2)C	4.4749999	Active	Serotonin Transporter Inhibitor&Serotonin transporter Inhibitor	0.0	1	Desipramine hydrochloride	170465424	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-80.33774544&-78.819263226	N(CCCN1c2c(cccc2)CCc2c1cccc2)C.Cl	N(CCCN1c2c(cccc2)CCc2c1cccc2)C.Cl
NCGC00021122-08	N(CCCc1ccccc1)(CCCc1ccccc1)CC	5.0500002	Active		0.0	1	Alverine citrate	170466248	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-54.2090369924	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCCc1ccccc1)(CCCc1ccccc1)CC	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCCc1ccccc1)(CCCc1ccccc1)CC
NCGC00018125-05	N(CCN(Cc1ccccc1)c1ncccc1)(C)C	4.6750002	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Tripelennamine citrate	170465118	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-53.6569900263&-33.197548148	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCN(Cc1ccccc1)c1ncccc1)(C)C	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCN(Cc1ccccc1)c1ncccc1)(C)C
NCGC00253602-01	N(CCN(Cc1cscc1)c1ncccc1)(C)C		Inactive			1	Thenyldiamine	170465520	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.5682634&0.0	N(CCN(Cc1cscc1)c1ncccc1)(C)C	N(CCN(Cc1cscc1)c1ncccc1)(C)C
NCGC00015704-09	N(CCN(Cc1sccc1)c1ncccc1)(C)C		Inactive			1	Methapyrilene hydrochloride	170465531	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.27020054&-35.366192884	N(CCN(Cc1sccc1)c1ncccc1)(C)C.Cl	N(CCN(Cc1sccc1)c1ncccc1)(C)C.Cl
NCGC00091695-03	N(CCNCCN)CCN		Inactive	Copper Chelating Agent		1	Triethylenetetramine	170465257	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.6519378639&0.0	N(CCNCCN)CCN	N(CCNCCN)CCN
NCGC00090964-04	N(CCNCCN)CCNCCN		Inactive	Oxidative Stress Inhibitor		1	Tetraethylenepentamine	170464940	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&21.9309944359	N(CCNCCN)CCNCCN	N(CCNCCN)CCNCCN
NCGC00166222-04	N(CCNCc1ccccc1)Cc1ccccc1	4.4000001	Active	F-box Only Protein 3 Inhibitor	0.0	1	N,N'-Dibenzylethane-1,2-diamine dihydrochloride	170465030	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.9677566079	N(CCNCc1ccccc1)Cc1ccccc1.Cl.Cl	N(CCNCc1ccccc1)Cc1ccccc1.Cl.Cl
NCGC00095899-09	N(CCc1c2c([nH]c1)ccc(Cn1ncnc1)c2)(C)C	4.5999999	Active	5-HT1B Agonist	0.0	1	Rizatriptan Benzoate	405558730	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.17238354	N(CCc1c2c([nH]c1)ccc(Cn1ncnc1)c2)(C)C	N(CCc1c2c([nH]c1)ccc(Cn1ncnc1)c2)(C)C
NCGC00263171-03	N(CCc1c2c([nH]c1)cccc2)c1ccc(Nc2ccncc2)cc1	5.0500002	Active	MDM2 (hdm2) Inhibitor	0.0	1	Serdemetan	384568641	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-98.1515435164	N(CCc1c2c([nH]c1)cccc2)c1ccc(Nc2ccncc2)cc1	N(CCc1c2c([nH]c1)cccc2)c1ccc(Nc2ccncc2)cc1
NCGC00246113-02	N(CCc1ccccc1)Cc1ccccc1	4.7750001	Active		0.0	1	NCGC00246113-02	405558428	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.2	-79.936543888&-45.4099098415	N(CCc1ccccc1)Cc1ccccc1	N(CCc1ccccc1)Cc1ccccc1
NCGC00093362-05	N(CCc1ncccc1)C		Inactive	Histamine H3 receptor Antagonist&Histamine H3 Receptor Antagonist		1	Betahistine mesylate	170465694	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.291259628&0.0	S(=O)(=O)(O)C.N(CCc1ncccc1)C	S(=O)(=O)(O)C.N(CCc1ncccc1)C
NCGC00182981-01	N(CCc1onc(C(CC)c2ccccc2)n1)(CC)CC	4.6999998	Active		0.0	1	Proxazole citrate	144206776	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.8056899532	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCc1onc(C(CC)c2ccccc2)n1)(CC)CC	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCc1onc(C(CC)c2ccccc2)n1)(CC)CC
NCGC00178737-05	N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	4.8249998	Active	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist	0.0	1	Trimeprazine tartrate	170465278	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-76.6347329092&-77.0281926037	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C
NCGC00347279-01	N(C[C@H]1OCCC1)c1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1	5.1999998	Inactive	ACK1 Inhibitor	0.0	1	AIM-100	174006684	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	2.729123096	N(C[C@H]1OCCC1)c1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1	N(C[C@H]1OCCC1)c1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1
NCGC00159511-04	N(Cc1c2c(ccc1)cccc2)(Cc1ccc(C(C)(C)C)cc1)C		Inactive	Trichophyton Mentagrophytes Inhibitor&Trichophyton mentagrophytes Inhibitor		1	Butenafine	170465093	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	N(Cc1c2c(ccc1)cccc2)(Cc1ccc(C(C)(C)C)cc1)C	N(Cc1c2c(ccc1)cccc2)(Cc1ccc(C(C)(C)C)cc1)C
NCGC00273984-04	N(Cc1c2n(CC)c(-c3c(N)non3)nc2cnc1)C1CCNCC1	4.3499999	Active	MSK1/2 Inhibitor	0.0	1	SB-747651-A	384568706	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-43.952249684	N(Cc1c2n(CC)c(-c3c(N)non3)nc2cnc1)C1CCNCC1	N(Cc1c2n(CC)c(-c3c(N)non3)nc2cnc1)C1CCNCC1
NCGC00379161-04	N(Cc1ccc(-c2ccccc2)cc1)c1c(-c2ccccc2)nnc(-c2ncccc2)n1	5.6999998	Active	HIF-1alpha Activator	0.0	1	ML-228	363678392	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-98.907750946	N(Cc1ccc(-c2ccccc2)cc1)c1c(-c2ccccc2)nnc(-c2ncccc2)n1	N(Cc1ccc(-c2ccccc2)cc1)c1c(-c2ccccc2)nnc(-c2ncccc2)n1
NCGC00262306-10	N(Cc1ccc(-n2nncc2)cc1)c1c(C)cnc(-c2c(C(C)C)cccc2)n1	4.4000001	Active	USP1/UAF1 Inhibitor	0.0	1	ML323	384568572	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-66.322650356	N(Cc1ccc(-n2nncc2)cc1)c1c(C)cnc(-c2c(C(C)C)cccc2)n1	N(Cc1ccc(-n2nncc2)cc1)c1c(C)cnc(-c2c(C(C)C)cccc2)n1
NCGC00090991-02	N(Cc1ccccc1)(C)C	5.0	Active		0.0	1	N,N-Dimethylbenzylamine	144207006	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-32.285006652	N(Cc1ccccc1)(C)C	N(Cc1ccccc1)(C)C
NCGC00016613-10	N(Cc1ccccc1)(CC1=NCCN1)c1ccccc1		Inactive	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist		1	Antazoline hydrochloride	170464765	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.1822374079&0.0	N(Cc1ccccc1)(CC1=NCCN1)c1ccccc1.Cl	N(Cc1ccccc1)(CC1=NCCN1)c1ccccc1.Cl
NCGC00347065-03	N(Cc1ccccc1)c1nc(N2c3c(OCC2)cccc3)nc2c1CCCC2	4.4000001	Active	p97 ATPase Inhibitor	0.0	1	KUC107887N	363677570	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-71.5530468399	N(Cc1ccccc1)c1nc(N2c3c(OCC2)cccc3)nc2c1CCCC2	N(Cc1ccccc1)c1nc(N2c3c(OCC2)cccc3)nc2c1CCCC2
NCGC00347066-11	N(Cc1ccccc1)c1nc(NCc2ccccc2)c2c(n1)cccc2	4.6500001	Active	p97 ATPase Inhibitor	0.0	1	KUC105555N	384568981	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-106.0991789553	N(Cc1ccccc1)c1nc(NCc2ccccc2)c2c(n1)cccc2	N(Cc1ccccc1)c1nc(NCc2ccccc2)c2c(n1)cccc2
NCGC00345082-02	N(Cc1nc(-c2ccccc2)sc1)c1nc(NCC(C)C)ccn1	4.9499998	Active	lineage-specific differentiation enhancer	0.0	1	KHS-101	363677344	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-101.02011905	N(Cc1nc(-c2ccccc2)sc1)c1nc(NCC(C)C)ccn1	N(Cc1nc(-c2ccccc2)sc1)c1nc(NCC(C)C)ccn1
NCGC00371045-07	N(Cc1ncccc1)Cc1ccc(CN2CCNCCCNCCNCCC2)cc1		Inactive	Chemokine CXCR4 (SDF-1 Receptor) Antagonist		1	AMD-3465	384569040	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.8662282999	N(Cc1ncccc1)Cc1ccc(CN2CCNCCCNCCNCCC2)cc1	N(Cc1ncccc1)Cc1ccc(CN2CCNCCCNCCNCCC2)cc1
NCGC00016488-15	N(Cc1occc1)c1ncnc2nc[nH]c12		Inactive	plant hormone		1	Kinetin	384567945	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.9816629639	N(Cc1occc1)c1ncnc2nc[nH]c12	N(Cc1occc1)c1ncnc2nc[nH]c12
NCGC00378978-02	N(Cc1onc(C(C)C)c1)c1nc(Nc2n[nH]c(C3CC3)c2)cc(N2CCN(C)CC2)n1	5.5999999	Active	IGF-1R Inhibitor	0.0	1	XL-228	384569082	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-70.8898791365	N(Cc1onc(C(C)C)c1)c1nc(Nc2n[nH]c(C3CC3)c2)cc(N2CCN(C)CC2)n1	N(Cc1onc(C(C)C)c1)c1nc(Nc2n[nH]c(C3CC3)c2)cc(N2CCN(C)CC2)n1
NCGC00015082-09	N(N)C(=N)N		Inactive			1	AMINOGUANIDINE HYDROCHLORIDE	170466652	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	20.9604741	S(=O)(=O)(O)O.N(N)C(=N)N.N(N)C(=N)N	S(=O)(=O)(O)O.N(N)C(=N)N.N(N)C(=N)N
NCGC00015830-08	N(N)CCc1ccccc1		Inactive	MAO Inhibitor&Mao Inhibitor		1	Phenelzine	170465229	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(O)O.N(N)CCc1ccccc1	S(=O)(=O)(O)O.N(N)CCc1ccccc1
NCGC00015501-05&NCGC00015501-09	N(N)c1nncc2c1cccc2	4.75	Inactive	Smooth Muscle Relaxant	0.0	2	Apresoline	90341825&170464806	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&3.0	59.1817767603&90.388356122	N(N)c1nncc2c1cccc2	N(N)c1nncc2c1cccc2&N(N)c1nncc2c1cccc2.Cl
NCGC00024994-06&NCGC00024994-12	N([C@@H](Cc1ccccc1)C)(CC#C)C		Inactive	MAO-B Inhibitor&Mao-b Inhibitor&MAO-B Inhibitor		2	Selegiline hydrochloride	170464993&384568038	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-13.184980816&-16.30025302	N([C@@H](Cc1ccccc1)C)(CC#C)C.Cl	N([C@@H](Cc1ccccc1)C)(CC#C)C.Cl&N([C@@H](Cc1ccccc1)C)(CC#C)C
NCGC00344505-01	N([C@H](C)c1c2c(ccc1)cccc2)Cc1[nH]c2c(c1)cccc2	4.75	Active	Calcium-Sensing Receptor (CaSR) Agonist	0.0	1	Calindol	174006301	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-106.0697538702	N([C@H](C)c1c2c(ccc1)cccc2)Cc1[nH]c2c(c1)cccc2	N([C@H](C)c1c2c(ccc1)cccc2)Cc1[nH]c2c(c1)cccc2
NCGC00263149-06	N([C@H](C)c1ccccc1)c1ncnc2[nH]c(-c3ccc(CN4CCN(CC)CC4)cc3)cc12	4.4000001	Active	EGFR Inhibitor	0.0	1	AEE-788	384568624	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-112.9595622356	N([C@H](C)c1ccccc1)c1ncnc2[nH]c(-c3ccc(CN4CCN(CC)CC4)cc3)cc12	N([C@H](C)c1ccccc1)c1ncnc2[nH]c(-c3ccc(CN4CCN(CC)CC4)cc3)cc12
NCGC00262376-01	N([C@H]1CNCC1)c1nc(-c2n3c(nc2)C=CC(c2c[nH]nc2)=C3)ccc1	4.4000001	Active	Flt3/IRAK Inhibitor	0.0	1	NCGC00262376	174006421	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-108.3460311117	N([C@H]1CNCC1)c1nc(-c2n3c(nc2)C=CC(c2c[nH]nc2)=C3)ccc1	N([C@H]1CNCC1)c1nc(-c2n3c(nc2)C=CC(c2c[nH]nc2)=C3)ccc1
NCGC00480828-04	N([C@H]1[C@H](c2ccccc2)C1)C1CCC(N)CC1	5.5500002	Inactive	Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitor	0.0	1	ORY-1001	363681111	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	63.3479331189	N([C@H]1[C@H](c2ccccc2)C1)C1CCC(N)CC1	N([C@H]1[C@H](c2ccccc2)C1)C1CCC(N)CC1
NCGC00510111-01	N(\Nc1nnc2c([nH]c3c(C)cccc23)n1)=C(\C)/c1ncccc1		Inactive	Autophagy Inducer		1	VLX-600	384569409	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.574400844	N(\Nc1nnc2c([nH]c3c(C)cccc23)n1)=C(\C)/c1ncccc1	N(\Nc1nnc2c([nH]c3c(C)cccc23)n1)=C(\C)/c1ncccc1
NCGC00522030-01	N(\Nc1nncc2c1cccc2)=C(\C=C(C)C)/C		Inactive	Adrenergic Receptor Signaling Pathway Modulator&adrenergic receptor signaling pathway Modulator		1	Budralazine	405558679	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&12.342368464	N(\Nc1nncc2c1cccc2)=C(\C=C(C)C)/C	N(\Nc1nncc2c1cccc2)=C(\C=C(C)C)/C
NCGC00379217-03	N(c1[nH]nc(C2CC2)c1)c1nc(Nc2cc3[nH]cnc3cc2)ncc1	4.5	Inactive	IRE1 Inhibitor	0.0	1	APY29	363678425	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	26.3144195481	N(c1[nH]nc(C2CC2)c1)c1nc(Nc2cc3[nH]cnc3cc2)ncc1	N(c1[nH]nc(C2CC2)c1)c1nc(Nc2cc3[nH]cnc3cc2)ncc1
NCGC00016098-11	N(c1c(C)cccc1C)C=1SCCCN=1	6.0999999	Active	Sigma Opioid Receptor Antagonist	0.0	1	Xylazine	170466147	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-44.0064139488	N(c1c(C)cccc1C)C=1SCCCN=1	N(c1c(C)cccc1C)C=1SCCCN=1
NCGC00378596-08	N(c1ccc(N2CCOCC2)cc1)C1=NC(c2cc3[nH]ncc3cc2)=Cn2c1ncc2		Inactive	Syk Kinase Inhibitor		1	Entospletinib	384569053	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-31.90628764	N(c1ccc(N2CCOCC2)cc1)C1=NC(c2cc3[nH]ncc3cc2)=Cn2c1ncc2	N(c1ccc(N2CCOCC2)cc1)C1=NC(c2cc3[nH]ncc3cc2)=Cn2c1ncc2
NCGC00390634-03	N(c1nc(-c2cc3c(C(C)C)n(C)nc3cc2)ccn1)C1CCC(NC2CCOCC2)CC1	6.0500002	Active	CDK 7/8/9 Inhibitor	0.0	1	LY-2857785	384569203	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-72.7191469125	N(c1nc(-c2cc3c(C(C)C)n(C)nc3cc2)ccn1)C1CCC(NC2CCOCC2)CC1	N(c1nc(-c2cc3c(C(C)C)n(C)nc3cc2)ccn1)C1CCC(NC2CCOCC2)CC1
NCGC00263178-03	N(c1nc(/C=C/c2ccccc2)nc(N2CCN(C)CC2)c1)c1n[nH]c(C)c1	4.9499998	Active	Aurora-A Inhibitor	0.0	1	ENMD-981693	384568647	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-126.2513905899	N(c1nc(/C=C/c2ccccc2)nc(N2CCN(C)CC2)c1)c1n[nH]c(C)c1	N(c1nc(/C=C/c2ccccc2)nc(N2CCN(C)CC2)c1)c1n[nH]c(C)c1
NCGC00025225-03	N(c1nc(N)c2c(n1)ccc1n(Cc3ccc(C(C)C)cc3)ccc21)C1CC1	6.0	Inactive	PAR1 Antagonist	0.0	1	SCH-79797	384568059	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-36.9303215502	N(c1nc(N)c2c(n1)ccc1n(Cc3ccc(C(C)C)cc3)ccc21)C1CC1	N(c1nc(N)c2c(n1)ccc1n(Cc3ccc(C(C)C)cc3)ccc21)C1CC1
NCGC00386327-03	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1c(C)cc(N2CCOCC2)cc1	4.75	Active	MPS1 Inhibitor	0.0	1	MPI-0479605	363680213	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-69.5301460144	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1c(C)cc(N2CCOCC2)cc1	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1c(C)cc(N2CCOCC2)cc1
NCGC00165880-14	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1ccc(N2CCOCC2)cc1	4.4000001	Active	Adenosine A3 Antagonist	0.0	1	Reversine	377020303	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-41.7257266359	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1ccc(N2CCOCC2)cc1	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1ccc(N2CCOCC2)cc1
NCGC00386224-06	N(c1ncnc2c1cc1OCCOCCOCCOc1c2)c1cc(C#C)ccc1		Inactive	EGFR Inhibitor		1	Icotinib hydrochloride	377020161	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.0368728439	N(c1ncnc2c1cc1OCCOCCOCCOc1c2)c1cc(C#C)ccc1	N(c1ncnc2c1cc1OCCOCCOCCOc1c2)c1cc(C#C)ccc1
NCGC00386665-06	N(c1nn(c(N)n1)-c1nnc2-c3c(cccc3)CCCc2c1)c1cc2c(cc1)CC[C@H](N1CCCC1)CC2	4.9000001	Active	AXL Kinase Inhibitor	0.0	1	Bemcentinib	384569144	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-100.1203276553	N(c1nn(c(N)n1)-c1nnc2-c3c(cccc3)CCCc2c1)c1cc2c(cc1)CC[C@H](N1CCCC1)CC2	N(c1nn(c(N)n1)-c1nnc2-c3c(cccc3)CCCc2c1)c1cc2c(cc1)CC[C@H](N1CCCC1)CC2
NCGC00378894-01	N(c1sc2c(n1)cccc2)c1ccc(C(C(CC)CC)n2ncnc2)cc1	4.4000001	Active	Cytochrome P450 26A1 Inhibitor	0.0	1	Talarozole (R enantiomer)	363678261	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-112.7946237733	N(c1sc2c(n1)cccc2)c1ccc(C(C(CC)CC)n2ncnc2)cc1	N(c1sc2c(n1)cccc2)c1ccc(C(C(CC)CC)n2ncnc2)cc1
NCGC00344081-06	N(c1scc(-c2ccncc2)n1)c1cc(C)ccc1	5.0	Active	Renal cell growth inhibition	0.0	1	STF-62247	384568717	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-98.4418996383	N(c1scc(-c2ccncc2)n1)c1cc(C)ccc1	N(c1scc(-c2ccncc2)n1)c1cc(C)ccc1
NCGC00386324-08	N1(c2ccc(C3=Cn4ncc(-c5c6c(nccc6)ccc5)c4N=C3)cc2)CCNCC1		Inactive	ALK2 Inhibitor		1	LDN-212854	363680210	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.746030588	N1(c2ccc(C3=Cn4ncc(-c5c6c(nccc6)ccc5)c4N=C3)cc2)CCNCC1	N1(c2ccc(C3=Cn4ncc(-c5c6c(nccc6)ccc5)c4N=C3)cc2)CCNCC1
NCGC00094719-08	N12CN3CN(CN(C1)C3)C2		Inactive			1	Methenamine	170465468	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	27.5862079519&0.0	N12CN3CN(CN(C1)C3)C2	N12CN3CN(CN(C1)C3)C2
NCGC00181124-02	N12[C@@H]([C@@H]3CN4[C@H]([C@H](C1)C3)CCCC4)CCCC2	4.8499999	Active	Sodium Ion Transport Inhibitor	0.0	1	Sparteine	170465740	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.625018528	N12[C@@H]([C@@H]3CN4[C@H]([C@H](C1)C3)CCCC4)CCCC2	N12[C@@H]([C@@H]3CN4[C@H]([C@H](C1)C3)CCCC4)CCCC2
NCGC00094762-08	N1CCNCC1		Inactive			1	Piperazine	405558781	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&27.100438076	N1CCNCC1	N1CCNCC1
NCGC00164533-02	N=C(NC(=N)N)NCCCC	5.2750001	Inactive	Amp-activated Protein Kinase, Ampk Activator&AMP-activated protein kinase, AMPK Activator	0.0	1	Buformin	170465982	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	9.028531608&56.1924003642	N=C(NC(=N)N)NCCCC	N=C(NC(=N)N)NCCCC
NCGC00016543-13	N=C(NC(=N)N)NCCc1ccccc1		Inactive	antidiabetic drug		1	Phenformin hydrochloride	384567948	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.5462450039	N=C(NC(=N)N)NCCc1ccccc1	N=C(NC(=N)N)NCCc1ccccc1
NCGC00179419-05	N=C(NCC1OC2(OC1)CCCCC2)N	5.4000001	Active	Norepinephrine Transporter Partial Agonist&Norepinephrine transporter Partial Agonist	0.0	1	Guanadrel sulfate	405558962	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-39.2898816248&-32.65406822	N=C(NCC1OC2(OC1)CCCCC2)N	N=C(NCC1OC2(OC1)CCCCC2)N
NCGC00016272-05	N=C(NCCN1CCCCCCC1)N		Inactive			1	Guanethidine sulfate	170464954	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.S(=O)(=O)(O)O.N=C(NCCN1CCCCCCC1)N	S(=O)(=O)(O)O.S(=O)(=O)(O)O.N=C(NCCN1CCCCCCC1)N
NCGC00090698-06	N=C(Nc1ccccc1)Nc1ccccc1		Inactive			1	1,3-Diphenylguanidine	170465656	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.1465765801&11.884979828	N=C(Nc1ccccc1)Nc1ccccc1	N=C(Nc1ccccc1)Nc1ccccc1
NCGC00345823-02	NC(C)(C)c1ccc(-c2c(-c3ccccc3)nc3c(n2)cccc3)cc1		Inactive	AKT Inhibitor		1	Akt-I-1,2	363677370	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.1926732599	NC(C)(C)c1ccc(-c2c(-c3ccccc3)nc3c(n2)cccc3)cc1	NC(C)(C)c1ccc(-c2c(-c3ccccc3)nc3c(n2)cccc3)cc1
NCGC00262942-01	NC/C(=C(/c1ccccc1)\c1ccccc1)/CC		Inactive			1	Etifelmine hydrochloride	170465899	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.3099644	NC/C(=C(/c1ccccc1)\c1ccccc1)/CC.Cl	NC/C(=C(/c1ccccc1)\c1ccccc1)/CC.Cl
NCGC00094819-07	NC1(C)CN(CC(CCCC)CC)CN(CC(CCCC)CC)C1	5.1999998	Active		0.0	1	Hexetidine	170465729	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.1349652271	NC1(C)CN(CC(CCCC)CC)CN(CC(CCCC)CC)C1	NC1(C)CN(CC(CCCC)CC)CN(CC(CCCC)CC)C1
NCGC00015705-07&NCGC00015705-13	NC12CC3(C)CC(C)(C1)CC(C2)C3		Inactive	Nmda Antagonist&NMDA Antagonist&NMDA Antagonist		2	Memantine hydrochloride	170464999&384567883	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-25.362786012&-13.8900983319&-30.524495288	NC12CC3(C)CC(C)(C1)CC(C2)C3	NC12CC3(C)CC(C)(C1)CC(C2)C3
NCGC00165791-04	NC=1N2c3c(cccc3)Cc3c(cccc3)C2CN=1	4.5999999	Active	Histamine H1 receptor Antagonist	0.0	1	Epinastine hydrochloride	170465284	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.3629797892	NC=1N2c3c(cccc3)Cc3c(cccc3)C2CN=1.Cl	NC=1N2c3c(cccc3)Cc3c(cccc3)C2CN=1.Cl
NCGC00386713-03	NCC1CCN(c2nc(-c3cc4c(cc3)cccc4)ccn2)CC1	4.75	Active	Wnt Signaling Inhibitor	0.0	1	WAY-262611	363680411	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-89.7265504075	NCC1CCN(c2nc(-c3cc4c(cc3)cccc4)ccn2)CC1	NCC1CCN(c2nc(-c3cc4c(cc3)cccc4)ccn2)CC1
NCGC00015513-11	NCCc1[nH]cnc1		Inactive	Histamine Receptor Agonist		1	Histamine dihydrochloride	170465001	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.8890933999&0.0	NCCc1[nH]cnc1	NCCc1[nH]cnc1
NCGC00015513-20	NCCc1nc[nH]c1		Inactive	Histamine Receptor Agonist		1	Histamine dihydrochloride	384567859	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	11.45038506	NCCc1nc[nH]c1	NCCc1nc[nH]c1
NCGC00015848-05&NCGC00015848-09	N[C@H]1[C@H](c2ccccc2)C1		Inactive	MAO-A/B Inhibitor&Mao-a/b Inhibitor		2	Tranylcypromine&Tranylcypromine hydrochloride	384567898&405558823	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-31.1459329519&-14.676332568&0.0	N[C@H]1[C@H](c2ccccc2)C1	N[C@H]1[C@H](c2ccccc2)C1
NCGC00016016-18	Nc1c(-c2ccccc2)nc2c(N)nc(N)nc2n1		Inactive	Heart Phosphodiesterase Inhibitor&Heart phosphodiesterase Inhibitor		1	Triamterene	170464706	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.93433758&0.0	Nc1c(-c2ccccc2)nc2c(N)nc(N)nc2n1	Nc1c(-c2ccccc2)nc2c(N)nc(N)nc2n1
NCGC00507881-01	Nc1c(-c2n(-c3ccc(C4(N)CCC4)cc3)c3nc(-c4ccccc4)ccc3n2)cccn1	4.8000002	Active	AKT Inhibitor	0.0	1	Miransertib	384569347	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-112.022239784	Nc1c(-c2n(-c3ccc(C4(N)CCC4)cc3)c3nc(-c4ccccc4)ccc3n2)cccn1	Nc1c(-c2n(-c3ccc(C4(N)CCC4)cc3)c3nc(-c4ccccc4)ccc3n2)cccn1
NCGC00263460-01	Nc1c(C[n+]2c(C)cccc2)cnc(CCC)n1		Inactive	Eimeria Tenella Inhibitor&Eimeria tenella Inhibitor		1	NCGC00263460-01&Amprolium hydrochloride	170465675	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Nc1c(C[n+]2c(C)cccc2)cnc(CCC)n1.Cl.[Cl-]	Nc1c(C[n+]2c(C)cccc2)cnc(CCC)n1.Cl.[Cl-]
NCGC00015339-07	Nc1c2c([n+](CCCCCCCCCC[n+]3c(C)cc(N)c4c3cccc4)c(C)c1)cccc2	5.5500002	Active	Protein kinase C beta Inhibitor	0.0	1	Dequalinium dichloride	225144172	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-44.7031891159	Nc1c2c([n+](CCCCCCCCCC[n+]3c(C)cc(N)c4c3cccc4)c(C)c1)cccc2	Nc1c2c([n+](CCCCCCCCCC[n+]3c(C)cc(N)c4c3cccc4)c(C)c1)cccc2
NCGC00094857-05	Nc1c2c(nc3c1cccc3)cccc2	4.5250001	Active		0.0	1	9-Aminoacridine, monohydrochloride, monohydrate	170465046	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-110.0824983013&-98.4164164853	Nc1c2c(nc3c1cccc3)cccc2.Cl.O	Nc1c2c(nc3c1cccc3)cccc2.Cl.O
NCGC00178831-03	Nc1cc2[n+](C)c3c(cc2cc1)ccc(N)c3	5.0999999	Active	Hypoxia-inducible factor 1 alpha Interacts	0.0	1	Acriflavine hydrochloride	170465670	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.1	-91.7641747694	Nc1cc2[n+](C)c3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3.[Cl-]	Nc1cc2[n+](C)c3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3.[Cl-]
NCGC00166245-04	Nc1cc2nc3c(cc2cc1)ccc(N)c3	5.0999999	Active	RNA Binding Agent	0.0	1	Proflavin hemisulfate	170466523	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.1	-93.3421210889	S(=O)(=O)(O)O.Nc1cc2nc3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3	S(=O)(=O)(O)O.Nc1cc2nc3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3
NCGC00091297-05	Nc1ccccc1	5.4000001	Active		0.0	1	Anilinium nitrate	170465650	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.863243028	O=[N+](O)[O-].[NH3+]c1ccccc1	O=[N+](O)[O-].[NH3+]c1ccccc1
NCGC00015009-23	Nc1ccncc1		Inactive	Voltage-gated Potassium Channel Subunit Kv1.3 Blocker&Voltage-gated potassium channel subunit Kv1.3 Blocker		1	4-Aminopyridine	405559072	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-33.867725016	Nc1ccncc1	Nc1ccncc1
NCGC00183912-09	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4c3C=CC=C4)cc12		Inactive	ERK1/2 Inhibitor		1	FR-180204	363677100	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.2487858599	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4c3C=CC=C4)cc12	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4c3C=CC=C4)cc12
NCGC00070736-03&NCGC00070736-17	Nc1nc2c(c3n(CC(C)C)cnc13)cccc2		Inactive	Tlr 7 Receptor Antagonist&TLR 7 Receptor Antagonist&TLR 7 Receptor Antagonist		2	Imiquimod	170464691&384568073	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.073852044&-13.864003172&6.4053336719	Nc1nc2c(c3n(CC(C)C)cnc13)cccc2	Nc1nc2c(c3n(CC(C)C)cnc13)cccc2
NCGC00507864-01	Nc1ncc(-c2nc(N3CCOCC3)c3nc4C(C)(C)OCCn4c3n2)cn1	4.5999999	Active	PI3K Inhibitor	0.0	1	GDC-0084	384569339	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-46.867583438	Nc1ncc(-c2nc(N3CCOCC3)c3nc4C(C)(C)OCCn4c3n2)cn1	Nc1ncc(-c2nc(N3CCOCC3)c3nc4C(C)(C)OCCn4c3n2)cn1
NCGC00386370-01	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)c(C)nc23)cn1	6.0	Active	PI3K/mTOR Inhibitor	0.0	1	VS-5584	384569129	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-48.0344108509	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)c(C)nc23)cn1	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)c(C)nc23)cn1
NCGC00345447-10	Nc1ncn(C)c-2ncnc1-2		Inactive	PI3K Inhibitor		1	3-Methyladenine	384568734	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.030840416	Nc1ncn(C)c-2ncnc1-2	Nc1ncn(C)c-2ncnc1-2
NCGC00346839-01	Nc1ncnc2c1cccc2		Inactive	EGFR Inhibitor		1	4-Quinazolinamine	174006584	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Nc1ncnc2c1cccc2	Nc1ncnc2c1cccc2
NCGC00094856-05	Nc1ncnc2nc[nH]c12		Inactive	Xanthine Dehydrogenase Inhibitor&Xanthine dehydrogenase Inhibitor		1	Adenine	170465950	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Nc1ncnc2nc[nH]c12	Nc1ncnc2nc[nH]c12
NCGC00346654-11	Nc1oc2c(n1)cc(-c1nn(C(C)C)c3ncnc(N)c13)cc2	5.5	Inactive	mTORC1/2 Inhibitor	0.0	1	INK-128	384568885	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	18.6994820549	Nc1oc2c(n1)cc(-c1nn(C(C)C)c3ncnc(N)c13)cc2	Nc1oc2c(n1)cc(-c1nn(C(C)C)c3ncnc(N)c13)cc2
NCGC00163160-04	Nc1sc2c(n1)CCN(CC=C)CC2	6.1500001	Active	Dopamine D4 Receptor Agonist	0.0	1	Talipexole	170466015	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-33.5824067671	Nc1sc2c(n1)CCN(CC=C)CC2	Nc1sc2c(n1)CCN(CC=C)CC2
NCGC00179584-05	O(/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)/c1nc(N)sc1)C(C(=O)O)(C)C	4.6999998	Active	Penicillin-binding protein 4 Inhibitor	0.0	1	Ceftazidime	405558776	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.1806363503	O(/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)/c1nc(N)sc1)C(C(=O)O)(C)C	O(/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)/c1nc(N)sc1)C(C(=O)O)(C)C
NCGC00402337-02	O(/N=C(\N)/c1cnccc1)CC(O)CN1CCCCC1		Inactive	Insulin Sensitizers		1	BGP-15	384569215	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	36.2733448575	O(/N=C(\N)/c1cnccc1)CC(O)CN1CCCCC1	O(/N=C(\N)/c1cnccc1)CC(O)CN1CCCCC1
NCGC00163732-03	O(/N=C/1\[C@H](C)[C@@H](/C(=C/C(C)C)/C)O[C@]2(O[C@H]3C[C@H](OC(=O)[C@H]4[C@@]/5(O)[C@@H]([C@H](O)C(C)=C4)OC\C\5=C/C=C/[C@H](C)C/C(/C)=C/C3)C2)C\1)C	4.875	Active		0.0	1	Moxidectin	405558680	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-31.162586016&-66.6212253304	O(/N=C/1\[C@H](C)[C@@H](/C(=C/C(C)C)/C)O[C@]2(O[C@H]3C[C@H](OC(=O)[C@H]4[C@@]/5(O)[C@@H]([C@H](O)C(C)=C4)OC\C\5=C/C=C/[C@H](C)C/C(/C)=C/C3)C2)C\1)C	O(/N=C/1\[C@H](C)[C@@H](/C(=C/C(C)C)/C)O[C@]2(O[C@H]3C[C@H](OC(=O)[C@H]4[C@@]/5(O)[C@@H]([C@H](O)C(C)=C4)OC\C\5=C/C=C/[C@H](C)C/C(/C)=C/C3)C2)C\1)C
NCGC00253588-01	O(/N=C/c1c2c(nc3c1CN1C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C31)cccc2)C(C)(C)C	4.4000001	Inactive		0.0	1	Gimatecan	170465615	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	2.1149092479	O(/N=C/c1c2c(nc3c1CN1C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C31)cccc2)C(C)(C)C	O(/N=C/c1c2c(nc3c1CN1C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C31)cccc2)C(C)(C)C
NCGC00178510-09	O(/N=C\1/[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](O)(C)C[C@H]/1C)COCCOC		Inactive	Macrolide Antibiotic&Bacterial 70S ribosome Inhibitor		1	Roxithromycin	405558438	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.9188756239&18.6167725399	O(/N=C\1/[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](O)(C)C[C@H]/1C)COCCOC	O(/N=C\1/[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](O)(C)C[C@H]/1C)COCCOC
NCGC00249905-01	O(C(C#C)(CC)C)C(=O)c1c(C(=O)O)cccc1	6.1500001	Active		0.0	1	Phthalofyne	170466477	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.0127578295	O(C(C#C)(CC)C)C(=O)c1c(C(=O)O)cccc1	O(C(C#C)(CC)C)C(=O)c1c(C(=O)O)cccc1
NCGC00178377-07	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1	5.0500002	Active	Nitric oxide synthase, inducible Inhibitor	0.0	1	Amygdalin	384568355	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-57.5413795196	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1
NCGC00021147-11	O(C(C)(c1ncccc1)c1ccccc1)CCN(C)C	5.3499999	Active	Histamine H1 Receptor Antagonist	0.0	1	Doxylamine succinate	170465171	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-40.9754420308	O=C(O)CCC(=O)O.O(C(C)(c1ncccc1)c1ccccc1)CCN(C)C	O=C(O)CCC(=O)O.O(C(C)(c1ncccc1)c1ccccc1)CCN(C)C
NCGC00024868-09	O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1		Inactive	Beta1-adrenoceptor Antagonists&beta1-Adrenoceptor Antagonists		1	Bisoprolol fumarate	170464815	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.848505624&-15.589343672	O=C(O)/C=C/C(=O)O.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1	O=C(O)/C=C/C(=O)O.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1
NCGC00507847-01	O(C(C)C)c1c(C#N)cc(-c2onc(-c3c4c([C@@H](NCCO)CC4)ccc3)n2)cc1		Inactive	Lysophospholipid edg8 (S1P5) Receptor Agonist		1	Ozanimod	384569328	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.927318648	O(C(C)C)c1c(C#N)cc(-c2onc(-c3c4c([C@@H](NCCO)CC4)ccc3)n2)cc1	O(C(C)C)c1c(C#N)cc(-c2onc(-c3c4c([C@@H](NCCO)CC4)ccc3)n2)cc1
NCGC00018139-05&NCGC00018139-07	O(C(C)C)c1cc2OC=C(c3ccccc3)C(=O)c2cc1		Inactive	Treatment of Osteoporosis&Treatment Of Osteoporosis&Treatment of Osteoporosis		2	Ipriflavone	170465997&170466811	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O(C(C)C)c1cc2OC=C(c3ccccc3)C(=O)c2cc1	O(C(C)C)c1cc2OC=C(c3ccccc3)C(=O)c2cc1
NCGC00015471-08&NCGC00015471-09	O(C(CO)CO)Cn1c2N=C(N)NC(=O)c2nc1		Inactive	DNA Polymerase Inhibitor&Dna Polymerase Inhibitors&DNA Polymerase Inhibitor		2	Ganciclovir	170464961&384567853	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	23.1912574361&-31.615304332&24.956858704	O(C(CO)CO)Cn1c2N=C(N)NC(=O)c2nc1	O(C(CO)CO)Cn1c2N=C(N)NC(=O)c2nc1
NCGC00179274-03	O(C(COCc1ccccc1)[C@@H]1[C@H](OCc2ccccc2)[C@@H](O)[C@H](OCC)O1)Cc1ccccc1	4.5	Active		0.0	1	Tribenoside	170465999	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-91.3873350159	O(C(COCc1ccccc1)[C@@H]1[C@H](OCc2ccccc2)[C@@H](O)[C@H](OCC)O1)Cc1ccccc1	O(C(COCc1ccccc1)[C@@H]1[C@H](OCc2ccccc2)[C@@H](O)[C@H](OCC)O1)Cc1ccccc1
NCGC00164462-01	O(C(COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1	5.8499999	Active	Juvenile Hormone Metabolic Process Modulator	0.0	1	Pyriproxyfen	26757881	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-37.3469159611	O(C(COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1	O(C(COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1
NCGC00015771-13	O(C(c1c(C)cccc1)c1ccccc1)CCN(C)C	4.875	Active	Muscarinic Antagonists	0.0	1	Orphenadrine dihydrogen citrate	170464910	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.2&-2.4	-42.4533756759&-50.2279213575	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(C(c1c(C)cccc1)c1ccccc1)CCN(C)C	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(C(c1c(C)cccc1)c1ccccc1)CCN(C)C
NCGC00016395-06	O(C(c1ccccc1)c1ccccc1)C1CCN(C)CC1	4.4749999	Active	Histamine H1 Receptor Agonist&Histamine H1 receptor Agonist	0.0	1	Diphenylpyraline hydrochloride	170464816	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-59.325420736&-55.2992349372	O(C(c1ccccc1)c1ccccc1)C1CCN(C)CC1.Cl	O(C(c1ccccc1)c1ccccc1)C1CCN(C)CC1.Cl
NCGC00013495-15	O(C(c1ccccc1)c1ccccc1)C1C[C@@H]2N(C)[C@H](C1)CC2	4.8499999	Active	Dopamine Transporter Inhibitor&Dopamine transporter Inhibitor	0.0	1	Benztropine mesylate	405558618	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-66.1711575776&-86.095206664	O(C(c1ccccc1)c1ccccc1)C1C[C@@H]2N(C)[C@H](C1)CC2	O(C(c1ccccc1)c1ccccc1)C1C[C@@H]2N(C)[C@H](C1)CC2
NCGC00181913-02	O(C(c1ccccc1)c1ccccc1)CCN(C(C(O)c1ccccc1)C)C	4.5999999	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Difeterol	144206884	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-85.912793084&-84.9534924463	O(C(c1ccccc1)c1ccccc1)CCN(C(C(O)c1ccccc1)C)C	O(C(c1ccccc1)c1ccccc1)CCN(C(C(O)c1ccccc1)C)C
NCGC00015335-11	O(C(c1ccccc1)c1ccccc1)CCN(C)C		Inactive	Histamine H1 Receptor Antagonist		1	Diphenhydramine hydrochloride	124879863	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.664021856	O(C(c1ccccc1)c1ccccc1)CCN(C)C	O(C(c1ccccc1)c1ccccc1)CCN(C)C
NCGC00522025-01	O(C)C1(O[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H]6S[C@@H]6C5)CC4)CC3)CC2)CCCC1		Inactive	Estrogen receptor Antagonist&Estrogen Receptor Antagonist		1	Mepitiostane (Contains ~15% 3a,4a-Epithio isomer)	405558928	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)C1(O[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H]6S[C@@H]6C5)CC4)CC3)CC2)CCCC1	O(C)C1(O[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H]6S[C@@H]6C5)CC4)CC3)CC2)CCCC1
NCGC00507869-01	O(C)C1CCC2([C@@]3(N=C(N)C(C)=N3)c3c(ccc(-c4cc(C#CC)cnc4)c3)C2)CC1		Inactive	beta-Secretase Inhibitor		1	LY-3314814	384569343	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)C1CCC2([C@@]3(N=C(N)C(C)=N3)c3c(ccc(-c4cc(C#CC)cnc4)c3)C2)CC1	O(C)C1CCC2([C@@]3(N=C(N)C(C)=N3)c3c(ccc(-c4cc(C#CC)cnc4)c3)C2)CC1
NCGC00181009-02	O(C)C1C[N+](C)(C)C/C(=C(/c2sccc2)\c2sccc2)/C1		Inactive	Muscarinic Acetylcholine Receptor M5 Antagonist&Muscarinic acetylcholine receptor M5 Antagonist		1	Timepidium bromide	170465823	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.6802086919	O(C)C1C[N+](C)(C)C/C(=C(/c2sccc2)\c2sccc2)/C1.[Br-]	O(C)C1C[N+](C)(C)C/C(=C(/c2sccc2)\c2sccc2)/C1.[Br-]
NCGC00263166-10	O(C)C=1/C(=C\c2c(C)cc(C)[nH]2)/N=C(c2[nH]c3c(c2)cccc3)C=1	5.0500002	Active	Bcl-xL Inhibitor	0.0	1	Obatoclax	384568636	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-79.4688945609	O(C)C=1/C(=C\c2c(C)cc(C)[nH]2)/N=C(c2[nH]c3c(c2)cccc3)C=1	O(C)C=1/C(=C\c2c(C)cc(C)[nH]2)/N=C(c2[nH]c3c(c2)cccc3)C=1
NCGC00159429-03	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)=C(C)C(=O)C=1OC		Inactive	Mitochondrial Electron Transport&mitochondrial electron transport		1	Coenzyme Q10	225144226	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.2559924479&-27.903089712	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)=C(C)C(=O)C=1OC	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)=C(C)C(=O)C=1OC
NCGC00095322-05	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(\CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)/C)\C)\C)\C)=C(C)C(=O)C=1OC	4.4499998	Inactive	mitochondrial electron transport	0.0	1	Coenzyme Q10	384568155	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	86.5160863047	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(\CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)/C)\C)\C)\C)=C(C)C(=O)C=1OC	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(\CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)/C)\C)\C)\C)=C(C)C(=O)C=1OC
NCGC00160514-02&NCGC00160514-14	O(C)C=1C(=O)C(CCCCCCCCCCO)=C(C)C(=O)C=1OC	4.5	Active	Free Radical Scavenger	0.1999998000000005	2	Idebenone	170465611&384568196	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4&-3.0	-84.0543108719&-53.0143325002&-80.101212376	O(C)C=1C(=O)C(CCCCCCCCCCO)=C(C)C(=O)C=1OC	O(C)C=1C(=O)C(CCCCCCCCCCO)=C(C)C(=O)C=1OC
NCGC00094047-10	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@@H](CC)C)[C@@H](C)CC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	4.6750002	Active	Glutamate-gated Chloride Channel Activator	0.0	1	Ivermectin	405558905	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-44.0329422634&-40.858124328	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@@H](CC)C)[C@@H](C)CC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@@H](CC)C)[C@@H](C)CC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00168290-05	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@H](CC)C)[C@@H](C)C=C5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	5.0	Active		0.0	1	Avermectin B1a	405558426	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-94.839132201	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@H](CC)C)[C@@H](C)C=C5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@H](CC)C)[C@@H](C)C=C5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00164591-04&NCGC00164591-10	O(C)[C@@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2		Inactive	Antimalarial Agents&antimalarial agents&antimalarial agents		2	Artemether	225144260&384568261	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	24.711287776&31.383458056&-17.289944188	O(C)[C@@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2	O(C)[C@@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2
NCGC00162400-09	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)NCc4c3c3c1cccc3)cccc2	8.9499998	Inactive	CDK1/2 Inhibitor	0.0	1	Staurosporine	363676610	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-60.9041684561	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)NCc4c3c3c1cccc3)cccc2	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)NCc4c3c3c1cccc3)cccc2
NCGC00021305-08&NCGC00021305-19	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C[C@H]2C[C@@H](OC)[C@H](O)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2	4.52499985	Active	mTOR Inhibitor	0.34999989999999936	2	Sirolimus	124886756&405558660	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-34.055357852&-110.8132320922	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C[C@H]2C[C@@H](OC)[C@H](O)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C[C@H]2C[C@@H](OC)[C@H](O)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2
NCGC00261966-01	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@@]4(O)[C@H](C(=O)O[C@@H]5C[C@@]6(O[C@@H]([C@@H](C)CC6)C6CCCCC6)O[C@@H](C5)C/C=C/2\C)C=C(C)C[C@H]4OC/3)C1	4.4000001	Active		0.0	1	NCGC00261966-01	405558496	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.1396892479	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@@]4(O)[C@H](C(=O)O[C@@H]5C[C@@]6(O[C@@H]([C@@H](C)CC6)C6CCCCC6)O[C@@H](C5)C/C=C/2\C)C=C(C)C[C@H]4OC/3)C1	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@@]4(O)[C@H](C(=O)O[C@@H]5C[C@@]6(O[C@@H]([C@@H](C)CC6)C6CCCCC6)O[C@@H](C5)C/C=C/2\C)C=C(C)C[C@H]4OC/3)C1
NCGC00263875-02	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](/C(=N\O)/C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)CC5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1		Inactive			1	SELAMECTIN	405558820	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.145151284&17.8341454519	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](/C(=N\O)/C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)CC5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](/C(=N\O)/C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)CC5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00389554-01	O(C)[C@@H]1[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](C(O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)C=C5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	4.6999998	Active	chloride transmembrane transport Activator&Chloride Transmembrane Transport Activator	0.0	1	DORAMECTIN	405558736	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-82.1955107074&-46.426134349	O(C)[C@@H]1[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](C(O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)C=C5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](C(O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)C=C5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00389499-01	O(C)[C@@]1(C)[C@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C(=O)[C@@H](C)C(=O)OC(CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@H]2[C@H](C)C(=O)[C@H](C)C1	4.7750001	Active	Ketolide Antibiotic&Ketolide antibiotic	0.0	1	TELITHROMYCIN	405558900	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-49.9586521632&-69.46525351	O(C)[C@@]1(C)[C@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C(=O)[C@@H](C)C(=O)OC(CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@H]2[C@H](C)C(=O)[C@H](C)C1	O(C)[C@@]1(C)[C@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C(=O)[C@@H](C)C(=O)OC(CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@H]2[C@H](C)C(=O)[C@H](C)C1
NCGC00510028-01	O(C)c1[n+](-c2ccccc2)ncc(N)c1	4.8249998	Active	Amine Oxidase [flavin-containing] B Inhibitor&Amine oxidase [flavin-containing] B Inhibitor	0.0	1	Amezinium methylsulfate	405559018	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-58.0430660176&-40.7749806824	O(C)c1[n+](-c2ccccc2)ncc(N)c1	O(C)c1[n+](-c2ccccc2)ncc(N)c1
NCGC00344588-08	O(C)c1c(-c2c(C)onc2C)cc2ncc3NC(=O)N([C@H](C)c4ncccc4)c3c2c1		Inactive	Brd4 Inhibitor		1	I-BET151	363677337	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.0330081319	O(C)c1c(-c2c(C)onc2C)cc2ncc3NC(=O)N([C@H](C)c4ncccc4)c3c2c1	O(C)c1c(-c2c(C)onc2C)cc2ncc3NC(=O)N([C@H](C)c4ncccc4)c3c2c1
NCGC00015692-08	O(C)c1c(C(O)C(N)C)cc(OC)cc1	5.1500001	Active		0.0	1	Methoxamine hydrochloride	225144174	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-31.089003484	O(C)c1c(C(O)C(N)C)cc(OC)cc1	O(C)c1c(C(O)C(N)C)cc(OC)cc1
NCGC00159469-04	O(C)c1c(CC(NC)C)cccc1		Inactive	Adrenergic receptor beta Agonist&Adrenergic Receptor Beta Agonist		1	Methoxyphenamine	170465530	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.053332312&-15.661937916	O(C)c1c(CC(NC)C)cccc1	O(C)c1c(CC(NC)C)cccc1
NCGC00496840-01	O(C)c1c(CN(C)C)c(OC)cc(C=2c3c(C(=O)N(C)C=2)cncc3)c1		Inactive	Brd7 Inhibitor		1	BI-7273	384569294	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1c(CN(C)C)c(OC)cc(C=2c3c(C(=O)N(C)C=2)cncc3)c1	O(C)c1c(CN(C)C)c(OC)cc(C=2c3c(C(=O)N(C)C=2)cncc3)c1
NCGC00181097-01	O(C)c1c(CN(C)C)c2OC(c3ccccc3)=C(C)C(=O)c2cc1	5.0250001	Active		0.0	1	Dimefline hydrochloride	144206266	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-39.89871466&-38.9835164103	O(C)c1c(CN(C)C)c2OC(c3ccccc3)=C(C)C(=O)c2cc1.Cl	O(C)c1c(CN(C)C)c2OC(c3ccccc3)=C(C)C(=O)c2cc1.Cl
NCGC00481108-02	O(C)c1c(CN(C)C)cc(OC)c(C=2c3c(C(=O)N(C)C=2)cncc3)c1		Inactive	Brd9 Inhibitor		1	BI-9564	384569253	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.147768644	O(C)c1c(CN(C)C)cc(OC)c(C=2c3c(C(=O)N(C)C=2)cncc3)c1	O(C)c1c(CN(C)C)cc(OC)c(C=2c3c(C(=O)N(C)C=2)cncc3)c1
NCGC00390625-02	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cc(C(C)(C)C)cc1	4.875	Active	Substance-P receptor Antagonist&Substance-p Receptor Antagonist	0.0	1	Maropitant	405558794	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-1.4	-50.9133828532&-50.925929864	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cc(C(C)(C)C)cc1	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cc(C(C)(C)C)cc1
NCGC00015790-18	O(C)c1c(N)c(C=2Oc3c(C(=O)C=2)cccc3)ccc1		Inactive	Mek 2 inibitor		1	PD-098059	384567891	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1c(N)c(C=2Oc3c(C(=O)C=2)cccc3)ccc1	O(C)c1c(N)c(C=2Oc3c(C(=O)C=2)cccc3)ccc1
NCGC00016066-14	O(C)c1c(N2CCN(CCCNC=3N(C)C(=O)N(C)C(=O)C=3)CC2)cccc1		Inactive	Adrenergic receptor alpha-1 Antagonist&Adrenergic Receptor Alpha-1 Antagonist		1	Urapidil hydrochloride	170466013	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.722030388&-29.806376	O(C)c1c(N2CCN(CCCNC=3N(C)C(=O)N(C)C(=O)C=3)CC2)cccc1.Cl	O(C)c1c(N2CCN(CCCNC=3N(C)C(=O)N(C)C(=O)C=3)CC2)cccc1.Cl
NCGC00389251-02	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cncc4)ccn2)ccc(N2CCN(C)CC2)c1	4.8000002	Active	DYRK1B Inhibitor	0.0	1	AZ-191	384569172	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-103.8173303654	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cncc4)ccn2)ccc(N2CCN(C)CC2)c1	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cncc4)ccn2)ccc(N2CCN(C)CC2)c1
NCGC00263090-09	O(C)c1c(Nc2nc3N(C(=O)N(C)c3cn2)C2CCCC2)ccc(OC2CCN(C)CC2)c1	4.5500002	Active	MPS1 Inhibitor	0.0	1	AZ-3146	384568583	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-89.9868863035	O(C)c1c(Nc2nc3N(C(=O)N(C)c3cn2)C2CCCC2)ccc(OC2CCN(C)CC2)c1	O(C)c1c(Nc2nc3N(C(=O)N(C)c3cn2)C2CCCC2)ccc(OC2CCN(C)CC2)c1
NCGC00522579-01	O(C)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCN(C)CC2)c1	4.4000001	Active	ERK5 Inhibitor	0.0	1	XMD17-109 (ERK5-IN-1)	384569528	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.318874552	O(C)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCN(C)CC2)c1	O(C)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCN(C)CC2)c1
NCGC00507875-01	O(C)c1c(Nc2nc3N(C)c4c(C(=O)Nc3cn2)cccc4)ccc(N2CCN(C)CC2)c1	4.4000001	Active	TNK2 Inhibitor	0.0	1	XMD8-87	384569346	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-89.1700173999	O(C)c1c(Nc2nc3N(C)c4c(C(=O)Nc3cn2)cccc4)ccc(N2CCN(C)CC2)c1	O(C)c1c(Nc2nc3N(C)c4c(C(=O)Nc3cn2)cccc4)ccc(N2CCN(C)CC2)c1
NCGC00161927-04	O(C)c1c(O)c(OC)cc([C@@H]2c3c([C@@H](O)C4C2C(=O)OC4)cc2OCOc2c3)c1	6.0999999	Active	Antimitotic Agent	0.0	1	DMEP	384568217	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-72.1041190608	O(C)c1c(O)c(OC)cc([C@@H]2c3c([C@@H](O)C4C2C(=O)OC4)cc2OCOc2c3)c1	O(C)c1c(O)c(OC)cc([C@@H]2c3c([C@@H](O)C4C2C(=O)OC4)cc2OCOc2c3)c1
NCGC00178065-03	O(C)c1c(O)c(OC)cc([C@H]2[C@H]3C(=O)OCC3C(O[C@H]3[C@H](O)[C@@H](O)C4O[C@H](c5sccc5)OC[C@H]4O3)c3c2cc2OCOc2c3)c1	9.0	Inactive	DNA Topoisomerase II Inhibitors	0.0	1	TENIPOSIDE	405559077	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-21.9468868599	O(C)c1c(O)c(OC)cc([C@H]2[C@H]3C(=O)OCC3C(O[C@H]3[C@H](O)[C@@H](O)C4O[C@H](c5sccc5)OC[C@H]4O3)c3c2cc2OCOc2c3)c1	O(C)c1c(O)c(OC)cc([C@H]2[C@H]3C(=O)OCC3C(O[C@H]3[C@H](O)[C@@H](O)C4O[C@H](c5sccc5)OC[C@H]4O3)c3c2cc2OCOc2c3)c1
NCGC00178480-03	O(C)c1c(O)c2Oc3ccc(cc3)C[C@@H]3N(C)CCc4c3cc(c(OC)c4)Oc3c(O)ccc(c3)C[C@H]3[N+](C)(C)CCc(c23)c1		Inactive	Small Conductance Calcium-activated Potassium Channel Protein 2 Blocker&Small conductance calcium-activated potassium channel protein 2 Blocker		1	(+)-Tubocurarine chloride hydrochloride	170464882	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.684163912	O(C)c1c(O)c2Oc3ccc(cc3)C[C@@H]3N(C)CCc4c3cc(c(OC)c4)Oc3c(O)ccc(c3)C[C@H]3[N+](C)(C)CCc(c23)c1.Cl.[Cl-]	O(C)c1c(O)c2Oc3ccc(cc3)C[C@@H]3N(C)CCc4c3cc(c(OC)c4)Oc3c(O)ccc(c3)C[C@H]3[N+](C)(C)CCc(c23)c1.Cl.[Cl-]
NCGC00388392-01	O(C)c1c(O)c2[C@H]3O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]3OC(=O)c2cc1O	5.0500002	Active	Protein Tyrosine Phosphatase (ptp) Inhibitors	0.0	1	NCGC00388392-01	405559126	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.1809140348	O(C)c1c(O)c2[C@H]3O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]3OC(=O)c2cc1O	O(C)c1c(O)c2[C@H]3O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]3OC(=O)c2cc1O
NCGC00161641-05	O(C)c1c(O)c2c(cc1)C[C@@H]1N(C)CC[C@]32[C@@H]1C=C(OC)C(=O)C3		Inactive	Antiinflammatory opioid		1	Sinomenine	363676605	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.395398632	O(C)c1c(O)c2c(cc1)C[C@@H]1N(C)CC[C@]32[C@@H]1C=C(OC)C(=O)C3	O(C)c1c(O)c2c(cc1)C[C@@H]1N(C)CC[C@]32[C@@H]1C=C(OC)C(=O)C3
NCGC00163540-01	O(C)c1c(O)cc(C=2Oc3c(c(O)cc(O)c3)C(=O)C=2)cc1		Inactive	Lipid Lowering Agents		1	Hesperetin	26756923	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	35.3348124641	O(C)c1c(O)cc(C=2Oc3c(c(O)cc(O)c3)C(=O)C=2)cc1	O(C)c1c(O)cc(C=2Oc3c(c(O)cc(O)c3)C(=O)C=2)cc1
NCGC00094082-08	O(C)c1c(O)cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)c1		Inactive	Hypoxia Inducible Factor 1-alpha Inhibitor		1	2-Methoxyestradiol (2-MeOE2)	384568123	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.5062875959	O(C)c1c(O)cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)c1	O(C)c1c(O)cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)c1
NCGC00091470-05	O(C)c1c(O)ccc(C=CC)c1		Inactive	Tyrosyl-dna Phosphodiesterase 2 Inhibitor&Tyrosyl-DNA phosphodiesterase 2 Inhibitor		1	Isoeugenol	170465654	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1c(O)ccc(C=CC)c1	O(C)c1c(O)ccc(C=CC)c1
NCGC00091449-10	O(C)c1c(O)ccc(CC=C)c1		Inactive	reactive oxygen species biosynthetic process Modulator&Reactive Oxygen Species Biosynthetic Process Modulator		1	Eugenol	170465464	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.23157914&-19.345330704	O(C)c1c(O)ccc(CC=C)c1	O(C)c1c(O)ccc(CC=C)c1
NCGC00346838-01	O(C)c1c(O)ccc(C[C@H]([C@H](CO)Cc2cc(OC)c(O)cc2)CO)c1		Inactive	phenylpropanoid		1	Secoisolariciresinol	174007232	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1c(O)ccc(C[C@H]([C@H](CO)Cc2cc(OC)c(O)cc2)CO)c1	O(C)c1c(O)ccc(C[C@H]([C@H](CO)Cc2cc(OC)c(O)cc2)CO)c1
NCGC00091057-08	O(C)c1c(O)ccc([C@@H]2[C@@H](CO)Oc3c(O2)cc([C@@H]2[C@@H](O)C(=O)c4c(O)cc(O)cc4O2)cc3)c1		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Silybin	384568092	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.957234728	O(C)c1c(O)ccc([C@@H]2[C@@H](CO)Oc3c(O2)cc([C@@H]2[C@@H](O)C(=O)c4c(O)cc(O)cc4O2)cc3)c1	O(C)c1c(O)ccc([C@@H]2[C@@H](CO)Oc3c(O2)cc([C@@H]2[C@@H](O)C(=O)c4c(O)cc(O)cc4O2)cc3)c1
NCGC00090827-07	O(C)c1c(O)cccc1		Inactive	Intestine Smooth Muscle Contraction Inhibitor&intestine smooth muscle contraction Inhibitor		1	Guaiacol	225144199	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1c(O)cccc1	O(C)c1c(O)cccc1
NCGC00016697-04	O(C)c1c(OC)c(CN2CCNCC2)ccc1OC		Inactive	Trifunctional Enzyme Subunit Beta, Mitochondrial Inhibitor&Trifunctional enzyme subunit beta, mitochondrial Inhibitor		1	Trimetazidine dihydrochloride	170465797	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1c(OC)c(CN2CCNCC2)ccc1OC.Cl.Cl	O(C)c1c(OC)c(CN2CCNCC2)ccc1OC.Cl.Cl
NCGC00347676-02	O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@H](C)[C@](O)(C)Cc2cc1OC	4.4000001	Active	MAPK signaling pathway Modulator	0.0	1	Schisandrol B	405558731	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-61.1748159	O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@H](C)[C@](O)(C)Cc2cc1OC	O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@H](C)[C@](O)(C)Cc2cc1OC
NCGC00166035-05	O(C)c1c(OC)c2c(cc1OC)CC[C@H](NC)C=1C2=CC=C(OC)C(=O)C=1	9.0	Inactive	Tubulin polymerization Inhibitor	0.0	1	Demecolcine	384568302	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-2.835329792	O(C)c1c(OC)c2c(cc1OC)CC[C@H](NC)C=1C2=CC=C(OC)C(=O)C=1	O(C)c1c(OC)c2c(cc1OC)CC[C@H](NC)C=1C2=CC=C(OC)C(=O)C=1
NCGC00390660-02	O(C)c1c(OC)cc(-c2c(C)ncc(-c3ccc(N4CCNCC4)cc3)c2)cc1OC	4.4000001	Active	ALK2 Inhibitor	0.0	1	LDN-214117	363680961	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-49.4933293916	O(C)c1c(OC)cc(-c2c(C)ncc(-c3ccc(N4CCNCC4)cc3)c2)cc1OC	O(C)c1c(OC)cc(-c2c(C)ncc(-c3ccc(N4CCNCC4)cc3)c2)cc1OC
NCGC00263098-05	O(C)c1c(OC)cc(/C=C\c2cc(O)c(OC)cc2)cc1OC	5.9499998	Inactive	Tubulin polymerization Inhibitor	0.0	1	Combretastatin A-4	384568589	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	18.731032752	O(C)c1c(OC)cc(/C=C\c2cc(O)c(OC)cc2)cc1OC	O(C)c1c(OC)cc(/C=C\c2cc(O)c(OC)cc2)cc1OC
NCGC00015686-11	O(C)c1c(OC)cc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)cc1OC	4.5250001	Active	Voltage-gated L-type calcium channel Blocker&Voltage-gated L-type Calcium Channel Blocker	0.0	1	Gallopamil hydrochloride	170465991	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-41.121141032&-74.7260489044	O(C)c1c(OC)cc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)cc1OC.Cl	O(C)c1c(OC)cc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)cc1OC.Cl
NCGC00167523-03	O(C)c1c(OC)cc(C)c(Cc2c(N)nc(N)nc2)c1	5.8000002	Active	Folate Biosynthesis Inhibitor	0.0	1	Ormetoprim	170465718	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-37.0625516511	O(C)c1c(OC)cc(C)c(Cc2c(N)nc(N)nc2)c1	O(C)c1c(OC)cc(C)c(Cc2c(N)nc(N)nc2)c1
NCGC00182977-01	O(C)c1c(OC)cc(C[C@@H]2NCCc3c2cc(O)c(O)c3)cc1OC	5.25	Active	Beta-3 Adrenergic Receptor Agonist	0.0	1	Trimethoquinol	144206771	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-57.0425772927	O(C)c1c(OC)cc(C[C@@H]2NCCc3c2cc(O)c(O)c3)cc1OC.Cl	O(C)c1c(OC)cc(C[C@@H]2NCCc3c2cc(O)c(O)c3)cc1OC.Cl
NCGC00016055-16	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1OC		Inactive	Bacterial Dihydrofolate Reductase Inhibitor&Bacterial dihydrofolate reductase Inhibitor		1	Trimethoprim	170464633	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.052128528	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1OC	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1OC
NCGC00161419-06	O(C)c1c(OC)cc(NCc2c(C)c3c(N)nc(N)nc3cc2)cc1OC	4.8000002	Active	Dihydrofolate Reductase (DHFR) Inhibitor	0.0	1	Trimetrexate	384568209	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-80.5363262404	O(C)c1c(OC)cc(NCc2c(C)c3c(N)nc(N)nc3cc2)cc1OC	O(C)c1c(OC)cc(NCc2c(C)c3c(N)nc(N)nc3cc2)cc1OC
NCGC00022001-19	O(C)c1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC	9.0	Inactive	Antimitotic Agent	0.0	1	Podofilox	384568009	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-7.5206312681	O(C)c1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC	O(C)c1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC
NCGC00379089-04	O(C)c1c(OC)cc-2c(C(=O)N(CCNC)c3c4c(ncc-23)cc2OCOc2c4)c1	5.6999998	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	Genz-644282	384569094	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-3.2170900279	O(C)c1c(OC)cc-2c(C(=O)N(CCNC)c3c4c(ncc-23)cc2OCOc2c4)c1	O(C)c1c(OC)cc-2c(C(=O)N(CCNC)c3c4c(ncc-23)cc2OCOc2c4)c1
NCGC00025288-07	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(OC(C)(C)C=C1)cc4	6.5500002	Inactive	PI3K Inhibitor	0.0	1	Deguelin	384568065	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-74.5588458876	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(OC(C)(C)C=C1)cc4	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(OC(C)(C)C=C1)cc4
NCGC00183866-01	O(C)c1c(OC)cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2c1	4.5999999	Active	Adenylate Cyclase Inhibitor	0.0	1	Oxypertine hydrochloride	144206763	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-55.7008425123	O(C)c1c(OC)cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2c1.Cl	O(C)c1c(OC)cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2c1.Cl
NCGC00167537-02	O(C)c1c(OC)cc2c(C(=O)C(CC3CCN(Cc4ccccc4)CC3)C2)c1	4.4000001	Active	Acetylcholinesterase Inhibitor	0.0	1	Donepezil hydrochloride	170464858	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-75.6921059159	O(C)c1c(OC)cc2c(C(=O)C(CC3CCN(Cc4ccccc4)CC3)C2)c1.Cl	O(C)c1c(OC)cc2c(C(=O)C(CC3CCN(Cc4ccccc4)CC3)C2)c1.Cl
NCGC00505021-01	O(C)c1c(OC)cc2c(C(=O)N(CCCN3CCOCC3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	4.4499998	Active	DNA Topoisomerase I Inhibitor	0.0	1	Indotecan hydrochloride (LMP-400)	384569315	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-50.6814714262	O(C)c1c(OC)cc2c(C(=O)N(CCCN3CCOCC3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	O(C)c1c(OC)cc2c(C(=O)N(CCCN3CCOCC3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1
NCGC00505019-01	O(C)c1c(OC)cc2c(C(=O)N(CCCNCCO)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	4.6500001	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	LMP-744	384569313	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-7.370816624	O(C)c1c(OC)cc2c(C(=O)N(CCCNCCO)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	O(C)c1c(OC)cc2c(C(=O)N(CCCNCCO)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1
NCGC00505020-01	O(C)c1c(OC)cc2c(C(=O)N(CCCn3cncc3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	4.0	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	Indimitecan hydrochloride (LMP-776)	384569314	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-18.223543848	O(C)c1c(OC)cc2c(C(=O)N(CCCn3cncc3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	O(C)c1c(OC)cc2c(C(=O)N(CCCn3cncc3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1
NCGC00178891-03	O(C)c1c(OC)cc2c(C(C[C@@H]3[C@@H](CC)CN4C(c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1	5.5	Active	Antiprotozoal Agent&antiprotozoal agent	0.0	1	NCGC00178891-03&EMETINE DIHYDROCHLORIDE	404904688	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.1&-1.1	-98.8377840961&-98.967990591	O(C)c1c(OC)cc2c(C(C[C@@H]3[C@@H](CC)CN4C(c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1	O(C)c1c(OC)cc2c(C(C[C@@H]3[C@@H](CC)CN4C(c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1
NCGC00263445-02	O(C)c1c(OC)cc2c(N3C(=O)C[C@@H]4OCC=C5[C@H]6[C@@H]4[C@H]3[C@]32[C@@H](N(C5)CC3)C6)c1		Inactive	Vascular endothelial growth factor receptor 2 Inhibitor&Vascular Endothelial Growth Factor Receptor 2 Inhibitor		1	Brucine-N-oxide	405558773	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.7230399839&14.2860446479	O(C)c1c(OC)cc2c(N3C(=O)C[C@@H]4OCC=C5[C@H]6[C@@H]4[C@H]3[C@]32[C@@H](N(C5)CC3)C6)c1	O(C)c1c(OC)cc2c(N3C(=O)C[C@@H]4OCC=C5[C@H]6[C@@H]4[C@H]3[C@]32[C@@H](N(C5)CC3)C6)c1
NCGC00024379-18	O(C)c1c(OC)cc2c([C@@H](C[C@@H]3[C@@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1	5.9000001	Active	antiprotozoal agent	0.0	1	Emetine	384568026	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-89.6136500575	O(C)c1c(OC)cc2c([C@@H](C[C@@H]3[C@@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1	O(C)c1c(OC)cc2c([C@@H](C[C@@H]3[C@@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1
NCGC00092321-03	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC(C)C)C(=O)C3)CC2)c1	4.6750002	Active	Synaptic Vesicular Amine Transporter Inhibitor&Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor	0.0	1	Tetrabenazine Mesylate	405558756	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-67.2475667716&-33.095820004	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC(C)C)C(=O)C3)CC2)c1	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC(C)C)C(=O)C3)CC2)c1
NCGC00160421-03&NCGC00160421-04	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(=O)C1)CC2		Inactive	Synaptic Vesicular Amine Transporter Inhibitor&Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor&Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor		2	Tetrabenazine	170464675&384568194	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-21.370647492&-18.901997408&14.195953628	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(=O)C1)CC2	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(=O)C1)CC2
NCGC00263444-01	O(C)c1c(OC)cc2c3[C@H]([N+](C)(C)CC2)Cc2cc(c(OC)cc2)Oc2c(OC)cc4c([C@@H]([N+](C)(C)CC4)Cc4ccc(Oc13)cc4)c2		Inactive			1	Metocurine iodide	170465111	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1c(OC)cc2c3[C@H]([N+](C)(C)CC2)Cc2cc(c(OC)cc2)Oc2c(OC)cc4c([C@@H]([N+](C)(C)CC4)Cc4ccc(Oc13)cc4)c2.[I-].[I-]	O(C)c1c(OC)cc2c3[C@H]([N+](C)(C)CC2)Cc2cc(c(OC)cc2)Oc2c(OC)cc4c([C@@H]([N+](C)(C)CC4)Cc4ccc(Oc13)cc4)c2.[I-].[I-]
NCGC00263017-01	O(C)c1c(OC)cc2nc(-c3ccc(N4CCN(C)CC4)cc3)nc(NCCN3CCOCC3)c2c1		Inactive	TLR 7, 8 and 9 Antagonist		1	CPG-52364	137275921	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.986053472	O(C)c1c(OC)cc2nc(-c3ccc(N4CCN(C)CC4)cc3)nc(NCCN3CCOCC3)c2c1	O(C)c1c(OC)cc2nc(-c3ccc(N4CCN(C)CC4)cc3)nc(NCCN3CCOCC3)c2c1
NCGC00185850-16	O(C)c1c(OC)cc2nc(N3CCN(C)CCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1	5.5	Active	EHMT2 Inhibitor	0.0	1	BIX-01294	384568428	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.3494877465	O(C)c1c(OC)cc2nc(N3CCN(C)CCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1	O(C)c1c(OC)cc2nc(N3CCN(C)CCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1
NCGC00263099-07	O(C)c1c(OC)cc2ncnc(-n3c(N)nc(-c4ncccc4)n3)c2c1		Inactive	ATM Kinase Inhibitor		1	CP-466722	384568590	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.0707975039	O(C)c1c(OC)cc2ncnc(-n3c(N)nc(-c4ncccc4)n3)c2c1	O(C)c1c(OC)cc2ncnc(-n3c(N)nc(-c4ncccc4)n3)c2c1
NCGC00480876-01	O(C)c1c(OC)ccc(-c2c(C)nn3C(NCCN4CCOCC4)=CC(C)=Nc23)c1		Inactive	PI4Kbeta Inhibitor		1	T-00127-HEV1	363681112	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1c(OC)ccc(-c2c(C)nn3C(NCCN4CCOCC4)=CC(C)=Nc23)c1	O(C)c1c(OC)ccc(-c2c(C)nn3C(NCCN4CCOCC4)=CC(C)=Nc23)c1
NCGC00016083-23&NCGC00344584-01	O(C)c1c(OC)ccc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1	4.5625	Active	Dopamine D2 Receptor (DRD2) Antagonist&Dopamine Receptor D2 Antagonist&Calcium Channel Blocker	0.3249998000000005	2	Verapamil	384567918&170464904	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4&-2.2	-62.436268486&-47.9178512188&-38.8392752063	O(C)c1c(OC)ccc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1	O(C)c1c(OC)ccc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1
NCGC00165912-03	O(C)c1c(OC)ccc(C2=NN=C(C)C(CC)c3c2cc(OC)c(OC)c3)c1		Inactive			1	Tofisopam	405558838	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.380873736&0.0	O(C)c1c(OC)ccc(C2=NN=C(C)C(CC)c3c2cc(OC)c(OC)c3)c1	O(C)c1c(OC)ccc(C2=NN=C(C)C(CC)c3c2cc(OC)c(OC)c3)c1
NCGC00263226-01	O(C)c1c(OC)ccc(CC2=NN3C([C@H]([C@H](O)C)CCCc4ccccc4)=NC(C)C3C(=O)N2)c1		Inactive	Phosphodiesterase II (PDE2A) Inhibitor		1	BAY-60-7550	137276070	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1c(OC)ccc(CC2=NN3C([C@H]([C@H](O)C)CCCc4ccccc4)=NC(C)C3C(=O)N2)c1	O(C)c1c(OC)ccc(CC2=NN3C([C@H]([C@H](O)C)CCCc4ccccc4)=NC(C)C3C(=O)N2)c1
NCGC00263126-04	O(C)c1c(OC)ccc(CCN2CCN(CCCc3ccccc3)CC2)c1	4.4000001	Active	sigma1 Receptor Agonist	0.0	1	Cutamesine hydrochloride	363677214	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-43.299267452	O(C)c1c(OC)ccc(CCN2CCN(CCCc3ccccc3)CC2)c1	O(C)c1c(OC)ccc(CCN2CCN(CCCc3ccccc3)CC2)c1
NCGC00015810-12	O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1	4.9250002	Active	Phosphodiesterase X (PDE10) Inhibitor&Phosphodiesterase 10a Inhibitor	0.0	1	Papaverine hydrochloride	170465687	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-90.1784290714&-92.341026511	O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1.Cl	O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1.Cl
NCGC00023230-10	O(C)c1c(OC)ccc2[C@@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12		Inactive	Tubulin Polymerization Inhibitors&Tubulin polymerization inhibitors		1	Noscapine	170465539	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.206271992&-13.4894877519	O(C)c1c(OC)ccc2[C@@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12	O(C)c1c(OC)ccc2[C@@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12
NCGC00016388-04	O(C)c1c(OC)ccc2[C@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12	4.4499998	Active	Tubulin Polymerization Inhibitor	0.0	1	Noscapine	384567936	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-60.0727154648	O(C)c1c(OC)ccc2[C@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12	O(C)c1c(OC)ccc2[C@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12
NCGC00017326-05	O(C)c1c(OC)ccc2[C@H]([C@H]3N(C)CCc4c3cc3OCOc3c4)OC(=O)c12		Inactive	Gaba-a Receptor; Anion Channel Antagonist&GABA-A receptor; anion channel Antagonist		1	(1S,9R)-beta-Hydrastine	170465706	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.738378584&0.0	O(C)c1c(OC)ccc2[C@H]([C@H]3N(C)CCc4c3cc3OCOc3c4)OC(=O)c12	O(C)c1c(OC)ccc2[C@H]([C@H]3N(C)CCc4c3cc3OCOc3c4)OC(=O)c12
NCGC00015225-08	O(C)c1c(OC)ccc2c1c[n+](C)c1c3c(cc4OCOc4c3)ccc21	5.0	Inactive	PKC Inhibitor	0.0	1	Chelerythrine chloride	384567826	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-25.9397414282	O(C)c1c(OC)ccc2c1c[n+](C)c1c3c(cc4OCOc4c3)ccc21	O(C)c1c(OC)ccc2c1c[n+](C)c1c3c(cc4OCOc4c3)ccc21
NCGC00016526-16	O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2	4.4000001	Active	Protein Tyrosine Phosphatase (PTP) Inhibitor	0.0	1	Berberine	384567947	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-108.3296738013	O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2	O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2
NCGC00015898-15&NCGC00015898-28	O(C)c1c(OC2CCCC2)cc(C2CC(=O)NC2)cc1		Inactive	Phosphodiesterase 4 Inhibitor&Phosphodiesterase IIII (PDE4) Inhibitor&Phosphodiesterase IIII (PDE4) Inhibitor		2	Rolipram	170465962&384567905	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	24.284055636&9.236511868&-13.6583247759	O(C)c1c(OC2CCCC2)cc(C2CC(=O)NC2)cc1	O(C)c1c(OC2CCCC2)cc(C2CC(=O)NC2)cc1
NCGC00016899-11	O(C)c1c(OC2CCCC2)cc([C@H]2CC(=O)NC2)cc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	S-(+)-Rolipram	384567966	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1c(OC2CCCC2)cc([C@H]2CC(=O)NC2)cc1	O(C)c1c(OC2CCCC2)cc([C@H]2CC(=O)NC2)cc1
NCGC00168459-04	O(C)c1c(O[C@H]2COCC2)cc(C2=Nn3c(-c4c(OC)ccc(OC)c4)nnc3C=C2)cc1	5.75	Active	Phosphodiesterase IIII (PDE4) Inhibitor	0.0	1	NCGC00168459-01	174006302	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-43.2662462	O(C)c1c(O[C@H]2COCC2)cc(C2=Nn3c(-c4c(OC)ccc(OC)c4)nnc3C=C2)cc1	O(C)c1c(O[C@H]2COCC2)cc(C2=Nn3c(-c4c(OC)ccc(OC)c4)nnc3C=C2)cc1
NCGC00016666-06	O(C)c1c2OCOc2cc2c1CN(C)CC2		Inactive	Cytochrome P450 3A4 Inhibitor&Cytochrome P450 3a4 Inhibitor		1	Hydrocotarnine hydrobromide	170465806	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.113059492&18.505578464	O(C)c1c2OCOc2cc2c1CN(C)CC2.Br	O(C)c1c2OCOc2cc2c1CN(C)CC2.Br
NCGC00017256-17	O(C)c1c2O[C@@H]3[C@]4(c2c(cc1)CN(C)CC4)C=C[C@H](O)C3		Inactive	Acetylcholinesterase Inhibitors		1	Galanthamine	405558901	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1c2O[C@@H]3[C@]4(c2c(cc1)CN(C)CC4)C=C[C@H](O)C3	O(C)c1c2O[C@@H]3[C@]4(c2c(cc1)CN(C)CC4)C=C[C@H](O)C3
NCGC00161621-03	O(C)c1c2Oc3c4OCOc4cc4c3[C@@H](N(C)CC4)Cc3ccc(Oc4c(OC)ccc(c4)C[C@H]4N(C)CCc(c4c2)c1)cc3	5.5250001	Active		0.0	1	Cepharanthine	170465994	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-1.3	-115.5832560827&-91.4586432797	O(C)c1c2Oc3c4OCOc4cc4c3[C@@H](N(C)CC4)Cc3ccc(Oc4c(OC)ccc(c4)C[C@H]4N(C)CCc(c4c2)c1)cc3	O(C)c1c2Oc3c4OCOc4cc4c3[C@@H](N(C)CC4)Cc3ccc(Oc4c(OC)ccc(c4)C[C@H]4N(C)CCc(c4c2)c1)cc3
NCGC00522011-01	O(C)c1c2[C@@H](C)C=C3C4(N(CC)C(=O)N3Cc2cc(OC)c1)CCN(Cc1cc(C)cc(C)c1)CC4	4.4000001	Active	Potent EP4 Receptor Antagonist	0.0	1	ER 819762	384569511	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-70.7780480389	O(C)c1c2[C@@H](C)C=C3C4(N(CC)C(=O)N3Cc2cc(OC)c1)CCN(Cc1cc(C)cc(C)c1)CC4	O(C)c1c2[C@@H](C)C=C3C4(N(CC)C(=O)N3Cc2cc(OC)c1)CCN(Cc1cc(C)cc(C)c1)CC4
NCGC00165875-04	O(C)c1c2c(C(CCCN3CCN(C4CCCCC4)CC3)CCC2)ccc1	4.4000001	Active	sigma1/2 Receptor Agonist	0.0	1	PB-28	384568294	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-51.2241452112	O(C)c1c2c(C(CCCN3CCN(C4CCCCC4)CC3)CCC2)ccc1	O(C)c1c2c(C(CCCN3CCN(C4CCCCC4)CC3)CCC2)ccc1
NCGC00347064-04	O(C)c1c2nc(-n3c(N)nc4c3cccc4)nc(NCc3ccccc3)c2ccc1	4.75	Active	p97 ATPase Inhibitor	0.0	1	KUC107871N	363677569	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-58.4083207597	O(C)c1c2nc(-n3c(N)nc4c3cccc4)nc(NCc3ccccc3)c2ccc1	O(C)c1c2nc(-n3c(N)nc4c3cccc4)nc(NCc3ccccc3)c2ccc1
NCGC00016418-15&NCGC00016418-23	O(C)c1c2occc2cc2c1OC(=O)C=C2		Inactive	Cytochrome P450 Cyp1a2 Inhibitor&Cytochrome P450 CYP1A2 Inhibitor&Cytochrome P450 CYP1A2 Inhibitor		2	Methoxsalen	170465041&384567939	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	23.740313888&0.0&0.0	O(C)c1c2occc2cc2c1OC(=O)C=C2	O(C)c1c2occc2cc2c1OC(=O)C=C2
NCGC00510503-01	O(C)c1cc(N(CC)Cc2ccc(CCNCC)cc2)c([C@H]2Cc3c(cc(O)cc3)CC2)cc1	4.5	Active	Selective Estrogen Receptor Modulators (SERM)	0.0	1	Elacestrant	384569464	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-126.9947428451	O(C)c1cc(N(CC)Cc2ccc(CCNCC)cc2)c([C@H]2Cc3c(cc(O)cc3)CC2)cc1	O(C)c1cc(N(CC)Cc2ccc(CCNCC)cc2)c([C@H]2Cc3c(cc(O)cc3)CC2)cc1
NCGC00178754-06	O(C)c1cc(NC(CCCN)C)c2ncccc2c1	6.1500001	Active	Antimalarial	0.0	1	Primaquine diphosphate	174006623	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-37.0324757403	P(=O)(O)(O)O.P(=O)(O)(O)O.O(C)c1cc(NC(CCCN)C)c2ncccc2c1	P(=O)(O)(O)O.P(=O)(O)(O)O.O(C)c1cc(NC(CCCN)C)c2ncccc2c1
NCGC00378630-01	O(C)c1cc(NC2=NC=Nn3c2c(CN2C[C@@H](O)[C@H](N)CC2)cc3)ccc1		Inactive	VEGFR-3 Inhibitor		1	BMS-690514	363678131	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1cc(NC2=NC=Nn3c2c(CN2C[C@@H](O)[C@H](N)CC2)cc3)ccc1	O(C)c1cc(NC2=NC=Nn3c2c(CN2C[C@@H](O)[C@H](N)CC2)cc3)ccc1
NCGC00183677-03	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@@H](O)CC3OC3c2c1	4.4499998	Active	Mek 1/2 Inhibitor	0.0	1	Hypothemycin	174006434	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-122.3255368782	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@@H](O)CC3OC3c2c1	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@@H](O)CC3OC3c2c1
NCGC00475735-01	O(C)c1cc(OC)cc(N(CCNC(C)C)c2cc3nc(-c4cn(C)nc4)cnc3cc2)c1	4.5500002	Active	FGFR 1/2/3/4 Inhibitor	0.0	1	Erdafitinib	377020396	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-107.6155511065	O(C)c1cc(OC)cc(N(CCNC(C)C)c2cc3nc(-c4cn(C)nc4)cnc3cc2)c1	O(C)c1cc(OC)cc(N(CCNC(C)C)c2cc3nc(-c4cn(C)nc4)cnc3cc2)c1
NCGC00095239-05	O(C)c1cc(OC)cc(OC)c1		Inactive			1	1,3,5-Trimethoxybenzene	170465963	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.939448456&11.0592620199	O(C)c1cc(OC)cc(OC)c1	O(C)c1cc(OC)cc(OC)c1
NCGC00179370-05	O(C)c1cc2N(C[C@@H](CN(C)C)C)c3c(Sc2cc1)cccc3	4.8249998	Active	Serotonin 2 (5-HT2) receptor Antagonist&Serotonin 2 (5-ht2) Receptor Antagonist	0.0	1	Methotrimeprazine maleat salt	405559100	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.3	-90.527448255&-105.0098482381	O(C)c1cc2N(C[C@@H](CN(C)C)C)c3c(Sc2cc1)cccc3	O(C)c1cc2N(C[C@@H](CN(C)C)C)c3c(Sc2cc1)cccc3
NCGC00487085-02	O(C)c1cc2[C@@]3([C@H](c4cc5[nH]nc(/C=C/c6ccc(CN7C[C@@H](C)O[C@@H](C)C7)cc6)c5cc4)C3)C(=O)Nc2cc1	5.0500002	Active	Polo-like Kinase-4 (Plk-4) Inhibitor	0.0	1	CFI-400945	384569282	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-48.1146502626	O(C)c1cc2[C@@]3([C@H](c4cc5[nH]nc(/C=C/c6ccc(CN7C[C@@H](C)O[C@@H](C)C7)cc6)c5cc4)C3)C(=O)Nc2cc1	O(C)c1cc2[C@@]3([C@H](c4cc5[nH]nc(/C=C/c6ccc(CN7C[C@@H](C)O[C@@H](C)C7)cc6)c5cc4)C3)C(=O)Nc2cc1
NCGC00095192-05	O(C)c1cc2c(/C=N/NC(=N)NCCCCC)c[nH]c2cc1	4.6500001	Active	5-HT4 Partial Agonist	0.0	1	Tegaserod maleate	170466887	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-114.5530776472	O(C)c1cc2c(/C=N/NC(=N)NCCCCC)c[nH]c2cc1	O(C)c1cc2c(/C=N/NC(=N)NCCCCC)c[nH]c2cc1
NCGC00015871-04	O(C)c1cc2c(C(O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1	4.5500002	Active	antimalarial agents; Cytochrome P450 CYP2D6 Inhibitor	0.0	1	Quinidine	124881279	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-63.8679436984	O(C)c1cc2c(C(O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1	O(C)c1cc2c(C(O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1
NCGC00163505-09	O(C)c1cc2c(C3=C(c4c5c([nH]c4)cccc5)C(=O)NC3=O)cn(CCCN(C)C)c2cc1	4.5	Active	PKC Inhibitor	0.0	1	Go-6983	384568244	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-111.9741898124	O(C)c1cc2c(C3=C(c4c5c([nH]c4)cccc5)C(=O)NC3=O)cn(CCCN(C)C)c2cc1	O(C)c1cc2c(C3=C(c4c5c([nH]c4)cccc5)C(=O)NC3=O)cn(CCCN(C)C)c2cc1
NCGC00166281-02	O(C)c1cc2c([C@@H](O)[C@H]3N4C[C@H](C=C)[C@H](C3)CC4)ccnc2cc1		Inactive			1	NCGC00166281-02	124893255	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	32.8682962422	O(C)c1cc2c([C@@H](O)[C@H]3N4C[C@H](C=C)[C@H](C3)CC4)ccnc2cc1	O(C)c1cc2c([C@@H](O)[C@H]3N4C[C@H](C=C)[C@H](C3)CC4)ccnc2cc1
NCGC00025091-11	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](NCCCCCCN5C(=O)C=CC5=O)CC4)CC3)CC2)cc1		Inactive	Phospholipase C Inhibitor		1	U-73122	384568047	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](NCCCCCCN5C(=O)C=CC5=O)CC4)CC3)CC2)cc1	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](NCCCCCCN5C(=O)C=CC5=O)CC4)CC3)CC2)cc1
NCGC00093347-05&NCGC00093347-12	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1		Inactive	Estrogen Receptor Alpha Agonist&Estrogen Receptor (ER) Agonist&Estrogen Receptor (ER) Agonist		2	Mestranol	170465357&384568112	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-18.3588866839&0.0&0.0	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1
NCGC00091231-04	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1	5.0749998	Active	Antimalarial Agents; Cytochrome P450 Cyp2d6 Inhibitors	0.0	1	Quinidine hydrochloride monohydrate	170465031	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4	-37.6383470549&-41.722818738	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1
NCGC00180461-02	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](CC)[C@H](C3)CC4)ccnc2cc1	4.4499998	Active	Sodium Channel Alpha Subunit Inhibitor&Sodium channel alpha subunit Inhibitor	0.0	1	Hydroquinidine HCl	405558746	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-59.412818588&-58.1806597843	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](CC)[C@H](C3)CC4)ccnc2cc1	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](CC)[C@H](C3)CC4)ccnc2cc1
NCGC00274063-05	O(C)c1ccc(-c2[nH]c3c(n2)cc(C=2C(C)CC(=O)NN=2)cc3)cc1	4.4000001	Active	Phosphodiesterase III (PDE3) Inhibitor	0.0	1	Pimobendan	363677311	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-51.3247678119	O(C)c1ccc(-c2[nH]c3c(n2)cc(C=2C(C)CC(=O)NN=2)cc3)cc1	O(C)c1ccc(-c2[nH]c3c(n2)cc(C=2C(C)CC(=O)NN=2)cc3)cc1
NCGC00274063-01	O(C)c1ccc(-c2[nH]c3c(n2)ccc(C=2C(C)CC(=O)NN=2)c3)cc1		Inactive	Phosphodiesterase Iii (pde3) Inhibitor&Phosphodiesterase III (PDE3) Inhibitor		1	Pimobendan	174007050	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.1599585399&-27.480870268	O(C)c1ccc(-c2[nH]c3c(n2)ccc(C=2C(C)CC(=O)NN=2)c3)cc1.Cl	O(C)c1ccc(-c2[nH]c3c(n2)ccc(C=2C(C)CC(=O)NN=2)c3)cc1.Cl
NCGC00263231-01	O(C)c1ccc(-c2c(C)[nH]nc2-c2c(O)cc(O)cc2)cc1	4.5	Inactive	Pyruvate Dehydrogenase Kinase 2 Inhibitor	0.0	1	PDHK RIKEN	137276075	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	45.564113256	O(C)c1ccc(-c2c(C)[nH]nc2-c2c(O)cc(O)cc2)cc1	O(C)c1ccc(-c2c(C)[nH]nc2-c2c(O)cc(O)cc2)cc1
NCGC00390402-02	O(C)c1ccc(-c2nc3c(c(C(O)C4NCCCC4)c2)cccc3)cc1	4.9000001	Active	P-Glycoprotein (MDR-1) Inhibitor	0.0	1	NSC-23925	363680887	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-102.0793467887	O(C)c1ccc(-c2nc3c(c(C(O)C4NCCCC4)c2)cccc3)cc1	O(C)c1ccc(-c2nc3c(c(C(O)C4NCCCC4)c2)cccc3)cc1
NCGC00095109-08	O(C)c1ccc(C(CN(C)C)C2(O)CCCCC2)cc1		Inactive	5-ht Reuptake Inhibitor&5-HT Reuptake Inhibitor		1	Venlafaxine	170465123	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.627410964&0.0	O(C)c1ccc(C(CN(C)C)C2(O)CCCCC2)cc1	O(C)c1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
NCGC00345813-03	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)c(CC=C(C)C)c3O2)cc1		Inactive	flavone		1	Icaritin	384568757	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.33207	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)c(CC=C(C)C)c3O2)cc1	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)c(CC=C(C)C)c3O2)cc1
NCGC00346592-02	O(C)c1ccc(C2=C(OC3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(OC4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(CC=C(C)C)c3O2)cc1		Inactive	Phosphodiesterase V (PDE5) Inhibitor		1	Icariin	384568852	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.229613396	O(C)c1ccc(C2=C(OC3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(OC4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(CC=C(C)C)c3O2)cc1	O(C)c1ccc(C2=C(OC3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(OC4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(CC=C(C)C)c3O2)cc1
NCGC00379236-08	O(C)c1ccc(C2=Cn3ncc(-c4c5c(nccc5)ccc4)c3N=C2)cc1		Inactive	ALK1/2 Inhibitor		1	ML-347	363678438	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1ccc(C2=Cn3ncc(-c4c5c(nccc5)ccc4)c3N=C2)cc1	O(C)c1ccc(C2=Cn3ncc(-c4c5c(nccc5)ccc4)c3N=C2)cc1
NCGC00094969-05	O(C)c1ccc(C2C(=O)c3c(C2=O)cccc3)cc1		Inactive	Vitamin K-dependent Gamma-carboxylase Inhibitor&Vitamin K-dependent gamma-carboxylase Inhibitor		1	Anisindione	170465379	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.4259587279&0.0	O(C)c1ccc(C2C(=O)c3c(C2=O)cccc3)cc1	O(C)c1ccc(C2C(=O)c3c(C2=O)cccc3)cc1
NCGC00017369-07	O(C)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1	4.4000001	Active	flavanoid	0.0	1	Biochanin A	124883152	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-102.6984140657	O(C)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1	O(C)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1
NCGC00091493-09	O(C)c1ccc(C=CC)cc1		Inactive	Tnf Signaling Pathway Inhibitor&TNF signaling pathway Inhibitor		1	Anethole	170465678	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1ccc(C=CC)cc1	O(C)c1ccc(C=CC)cc1
NCGC00522533-01	O(C)c1ccc(CC(NC[C@H](O)c2c3OCC(=O)Nc3cc(O)c2)(C)C)cc1		Inactive	Beta-2 Adrenergic Receptor Agonist&Beta-2 adrenergic receptor Agonist		1	Olodaterol	405558846	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(C)c1ccc(CC(NC[C@H](O)c2c3OCC(=O)Nc3cc(O)c2)(C)C)cc1	O(C)c1ccc(CC(NC[C@H](O)c2c3OCC(=O)Nc3cc(O)c2)(C)C)cc1
NCGC00186046-02	O(C)c1ccc(CC=2C(=O)N(CCN(CC)CC)c3c(N=2)cccc3)cc1		Inactive	AMPA Antagonist		1	Caroverine	174006990	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-33.3346153039	O(C)c1ccc(CC=2C(=O)N(CCN(CC)CC)c3c(N=2)cccc3)cc1	O(C)c1ccc(CC=2C(=O)N(CCN(CC)CC)c3c(N=2)cccc3)cc1
NCGC00015822-15	O(C)c1ccc(CN(CCN(C)C)c2ncccc2)cc1		Inactive	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist		1	Pyrilamine	170464656	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&21.6954465084	O(C)c1ccc(CN(CCN(C)C)c2ncccc2)cc1	O(C)c1ccc(CN(CCN(C)C)c2ncccc2)cc1
NCGC00178145-03	O(C)c1ccc(CN(CCN(C)C)c2ncccn2)cc1		Inactive			1	Thonzylamine hydrochloride	170465519	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.7673566081&9.222738492	O(C)c1ccc(CN(CCN(C)C)c2ncccn2)cc1.Cl	O(C)c1ccc(CN(CCN(C)C)c2ncccn2)cc1.Cl
NCGC00016507-05	O(C)c1ccc(CN(CC[N+](CCCCCCCCCCCCCCCC)(C)C)c2ncccn2)cc1	4.5250001	Active	Osteoclast Development Inhibitor&osteoclast development Inhibitor	0.0	1	Thonzonium bromide	170465335	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-93.1803134043&-112.0318456876	O(C)c1ccc(CN(CC[N+](CCCCCCCCCCCCCCCC)(C)C)c2ncccn2)cc1.[Br-]	O(C)c1ccc(CN(CC[N+](CCCCCCCCCCCCCCCC)(C)C)c2ncccn2)cc1.[Br-]
NCGC00379012-01	O(C)c1ccc(CNc2nc(N(CCO)CCO)nc3n(C(C)C)cnc23)cc1	4.5	Active	CDK1/2 Inhibitor	0.0	1	CVT-313	363678315	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-112.757250966	O(C)c1ccc(CNc2nc(N(CCO)CCO)nc3n(C(C)C)cnc23)cc1	O(C)c1ccc(CNc2nc(N(CCO)CCO)nc3n(C(C)C)cnc23)cc1
NCGC00387248-01	O(C)c1ccc(N(C)c2nc(C)nc3c2cccc3)cc1	4.0	Inactive	Tubulin polymerization Inhibitor	0.0	1	Azixa	363680593	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-18.3076872279	O(C)c1ccc(N(C)c2nc(C)nc3c2cccc3)cc1	O(C)c1ccc(N(C)c2nc(C)nc3c2cccc3)cc1
NCGC00165770-04	O(C)c1ccc(Nc2nc(NCCO)ccn2)cc1		Inactive	Cardiomyocytes differentiation initiator		1	Cardiogenol	384568280	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1ccc(Nc2nc(NCCO)ccn2)cc1	O(C)c1ccc(Nc2nc(NCCO)ccn2)cc1
NCGC00091390-04	O(C)c1ccc(O)cc1	4.6500001	Active	Tyrosinase Substrate	0.0	1	4-Methoxyphenol	170464687	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.4542449715	O(C)c1ccc(O)cc1	O(C)c1ccc(O)cc1
NCGC00016737-04	O(C)c1n(-c2nc(OC)cc(C)n2)nc(C)c1	5.0500002	Active		0.0	1	Epirizole	170465827	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-37.9688298113	O(C)c1n(-c2nc(OC)cc(C)n2)nc(C)c1	O(C)c1n(-c2nc(OC)cc(C)n2)nc(C)c1
NCGC00181098-02	O(C)c1nc(N)nc2n(C3C(O)C(O)C(CO)O3)cnc12		Inactive	Purine Antagonist		1	Nelarabine	384568389	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C)c1nc(N)nc2n(C3C(O)C(O)C(CO)O3)cnc12	O(C)c1nc(N)nc2n(C3C(O)C(O)C(CO)O3)cnc12
NCGC00274059-01	O(C)c1nc(N)nc2n([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)cnc12	4.4000001	Active	Purine Antagonist	0.0	1	Nelarabine	170464759	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.9791141759	O(C)c1nc(N)nc2n([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)cnc12	O(C)c1nc(N)nc2n([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00183845-01	O(C/C=C\CNC=1C(=O)C(=O)C=1N)c1nccc(CN2CCCCC2)c1	4.7249999	Active	Histamine H2 receptor Binding Agent&Histamine H2 Receptor Binding Agent	0.0	1	Pibutidine	144206830	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-30.4776788281&-52.3864764814	O(C/C=C\CNC=1C(=O)C(=O)C=1N)c1nccc(CN2CCCCC2)c1	O(C/C=C\CNC=1C(=O)C(=O)C=1N)c1nccc(CN2CCCCC2)c1
NCGC00015155-11&NCGC00015155-14	O(CC(C)C)CC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	4.86249995	Active	Ca Channel Blocker&Calcium Channel Blocker&Calcium Channel Blocker	0.025000099999999748	2	Bepridil	170465240&384567817	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.1&-2.1	-56.4520189947&-87.8219309766&-85.2492667803	O(CC(C)C)CC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	O(CC(C)C)CC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
NCGC00261970-01	O(CC(CCCC)CC)c1cc(O)c(-c2nc(-c3c(O)cc(OCC(CCCC)CC)cc3)nc(-c3ccc(OC)cc3)n2)cc1	5.4000001	Active		0.0	1	BEMOTRIZINOL	225144355	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-56.86440288	O(CC(CCCC)CC)c1cc(O)c(-c2nc(-c3c(O)cc(OCC(CCCC)CC)cc3)nc(-c3ccc(OC)cc3)n2)cc1	O(CC(CCCC)CC)c1cc(O)c(-c2nc(-c3c(O)cc(OCC(CCCC)CC)cc3)nc(-c3ccc(OC)cc3)n2)cc1
NCGC00015659-14	O(CC(N)C)c1c(C)cccc1C		Inactive			1	Mexiletene hydrochloride	170464740	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.705484164&13.4815935238	O(CC(N)C)c1c(C)cccc1C.Cl	O(CC(N)C)c1c(C)cccc1C.Cl
NCGC00018295-05	O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1		Inactive			1	Isoxsuprine hydrochloride	170465968	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1.Cl	O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1.Cl
NCGC00164375-03	O(CC(O)C)c1ccccc1		Inactive			1	1-Phenoxy-2-propanol	170465645	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-32.5790298359	O(CC(O)C)c1ccccc1	O(CC(O)C)c1ccccc1
NCGC00538146-01	O(CC(O)CNC(C)(C)C)C=1c2c(C(=O)N(C)C=1)cccc2		Inactive	Adrenergic receptor beta Blocker&Adrenergic Receptor Beta Blocker		1	NCGC00538146-01	405558755	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.655886336&0.0	O(CC(O)CNC(C)(C)C)C=1c2c(C(=O)N(C)C=1)cccc2	O(CC(O)CNC(C)(C)C)C=1c2c(C(=O)N(C)C=1)cccc2
NCGC00532503-01	O(CC(O)CNC(C)(C)C)c1c(C#N)cccc1		Inactive	Beta-2 adrenergic receptor Antagonist&Beta-2 Adrenergic Receptor Antagonist		1	BUNITROLOL	405558869	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.58430412	O(CC(O)CNC(C)(C)C)c1c(C#N)cccc1	O(CC(O)CNC(C)(C)C)c1c(C#N)cccc1
NCGC00179359-04	O(CC(O)CNC(C)(C)C)c1c(C2CCCC2)cccc1	5.0	Active		0.0	1	Penbutolol sulfate	405559025	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-70.4827218429	O(CC(O)CNC(C)(C)C)c1c(C2CCCC2)cccc1	O(CC(O)CNC(C)(C)C)c1c(C2CCCC2)cccc1
NCGC00261968-01	O(CC(O)CNC(C)(C)C)c1c(OCC2OCCC2)cccc1		Inactive	Adrenergic Receptor Beta Antagonist&Adrenergic receptor beta Antagonist		1	Bufetolol	170465825	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.9259725119&24.0087014679	O(CC(O)CNC(C)(C)C)c1c(OCC2OCCC2)cccc1	O(CC(O)CNC(C)(C)C)c1c(OCC2OCCC2)cccc1
NCGC00179541-03	O(CC(O)CNC(C)(C)C)c1c2c(NC(=O)CC2)ccc1		Inactive	Adrenergic Receptor Beta Partial Agonist&Adrenergic receptor beta Partial Agonist		1	Carteolol hydrochloride	170465122	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(CC(O)CNC(C)(C)C)c1c2c(NC(=O)CC2)ccc1.Cl	O(CC(O)CNC(C)(C)C)c1c2c(NC(=O)CC2)ccc1.Cl
NCGC00021623-05	O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C[C@@H](O)[C@@H](O)C2		Inactive	Beta-2 Adrenergic Receptor Antagonist&Beta-2 adrenergic receptor Antagonist		1	Nadolol	170464945	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.9057846199&18.418202816	O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C[C@@H](O)[C@@H](O)C2	O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C[C@@H](O)[C@@H](O)C2
NCGC00015099-11	O(CC(O)CNC(C)C)c1c(CC=C)cccc1	4.5	Active	Beta-adrenergic Receptor Antagonist	0.0	1	Alprenolol	170465812	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.9334927947	O(CC(O)CNC(C)C)c1c(CC=C)cccc1	O(CC(O)CNC(C)C)c1c(CC=C)cccc1
NCGC00179342-03	O(CC(O)CNC(C)C)c1c(OCC=C)cccc1	5.1500001	Active	Adrenergic receptor beta Antagonist	0.0	1	Oxprenolol hydrochloride	170464995	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-55.5528155819	O(CC(O)CNC(C)C)c1c(OCC=C)cccc1.Cl	O(CC(O)CNC(C)C)c1c(OCC=C)cccc1.Cl
NCGC00015786-16	O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1	5.0500002	Active	Serotonin 1a (5-HT1a) receptor Antagonist	0.0	1	Pindolol	170464892	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.169814538	O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1	O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1
NCGC00182040-01	O(CC(O)CNCCc1cc(OC)c(OC)cc1)c1cc(C)ccc1	4.9499998	Active	Adrenergic receptor beta Antagonist	0.0	1	Bevantolol hydrochloride	144206530	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-39.028132924	O(CC(O)CNCCc1cc(OC)c(OC)cc1)c1cc(C)ccc1.Cl	O(CC(O)CNCCc1cc(OC)c(OC)cc1)c1cc(C)ccc1.Cl
NCGC00183846-01	O(CC(O)CNCc1cc(OC)c(OC)cc1)c1cc2c(NC(=O)C=C2)cc1	4.5500002	Active	Phosphodiesterase 3 Inhibitor	0.0	1	Toborinone	144206841	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-66.5459329708&-39.4720574912	O(CC(O)CNCc1cc(OC)c(OC)cc1)c1cc2c(NC(=O)C=C2)cc1	O(CC(O)CNCc1cc(OC)c(OC)cc1)c1cc2c(NC(=O)C=C2)cc1
NCGC00095748-04	O(CC(O)CO)CCCCCCCCCCCCCCCCCC	6.1500001	Active		0.0	1	3-(Octadecyloxy)-1,2-propanediol	170465730	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-38.6803686149	O(CC(O)CO)CCCCCCCCCCCCCCCCCC	O(CC(O)CO)CCCCCCCCCCCCCCCCCC
NCGC00094908-06	O(CC(O)CO)c1c(C)cccc1		Inactive	Glutamate Nmda Receptor Antagonist&Glutamate NMDA receptor Antagonist		1	Mephenesin	170466586	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.169690396&10.23251012	O(CC(O)CO)c1c(C)cccc1	O(CC(O)CO)c1c(C)cccc1
NCGC00094689-06	O(CC(O)CO)c1c(OC)cccc1		Inactive			1	Guaifenesin	170464855	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	43.8191370144&-21.334056972	O(CC(O)CO)c1c(OC)cccc1	O(CC(O)CO)c1c(OC)cccc1
NCGC00387826-01	O(CC(n1c(-c2ccccc2)nc2c1cccc2)C1CCNCC1)c1ccc(-c2n(Cc3ccccc3)c3c(n2)cccc3)cc1	5.0	Active	Prenyl-Binding Protein (PrBP)/delta Inhibitor	0.0	1	Deltarasin	363680682	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-90.2079203296	O(CC(n1c(-c2ccccc2)nc2c1cccc2)C1CCNCC1)c1ccc(-c2n(Cc3ccccc3)c3c(n2)cccc3)cc1	O(CC(n1c(-c2ccccc2)nc2c1cccc2)C1CCNCC1)c1ccc(-c2n(Cc3ccccc3)c3c(n2)cccc3)cc1
NCGC00249932-01	O(CC)C=1C(=O)N(C)N=CC=1N1CCOCC1		Inactive			1	Emorfazone	170465843	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.658956216&26.542518148	O(CC)C=1C(=O)N(C)N=CC=1N1CCOCC1	O(CC)C=1C(=O)N(C)N=CC=1N1CCOCC1
NCGC00370784-05	O(CC)Cc1n(CC(O)(C)C)c2c(c(N)nc3c2cccc3)n1		Inactive	Toll-Like Receptor 7 (TLR7) Agonist		1	Resiquimod	363677855	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-30.484123136	O(CC)Cc1n(CC(O)(C)C)c2c(c(N)nc3c2cccc3)n1	O(CC)Cc1n(CC(O)(C)C)c2c(c(N)nc3c2cccc3)n1
NCGC00347939-08	O(CC)c1c(N/N=C\2/C(=O)N(c3scc(-c4ccccc4)n3)N=C/2C)cccc1		Inactive	BAX Activator		1	BAM-7	384568991	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(CC)c1c(N/N=C\2/C(=O)N(c3scc(-c4ccccc4)n3)N=C/2C)cccc1	O(CC)c1c(N/N=C\2/C(=O)N(c3scc(-c4ccccc4)n3)N=C/2C)cccc1
NCGC00250385-11	O(CC)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCC(O)CC2)c1	4.4000001	Active	ERK5/BMK1 Inhibitor	0.0	1	XMD8-92	377020424	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-102.96571817	O(CC)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCC(O)CC2)c1	O(CC)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCC(O)CC2)c1
NCGC00016557-06	O(CC)c1c(OCC)ccc(Cc2nccc3c2cc(OCC)c(OCC)c3)c1	5.0500002	Active	Voltage-gated L-type calcium channel Blocker	0.0	1	Ethaverine hydrochloride	170466346	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.3	-63.6576533468	O(CC)c1c(OCC)ccc(Cc2nccc3c2cc(OCC)c(OCC)c3)c1.Cl	O(CC)c1c(OCC)ccc(Cc2nccc3c2cc(OCC)c(OCC)c3)c1.Cl
NCGC00168251-01	O(CC)c1c2O[C@H]3[C@@H](O)C=C[C@H]4[C@@H]5N(C)CC[C@]34c2c(cc1)C5	4.7249999	Active	Opioid Receptors; Mu/kappa/delta Agonist&Opioid receptors; mu/kappa/delta Agonist	0.0	1	Ethylmorphine	144206163	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-46.960826908&-31.829933224	O(CC)c1c2O[C@H]3[C@@H](O)C=C[C@H]4[C@@H]5N(C)CC[C@]34c2c(cc1)C5	O(CC)c1c2O[C@H]3[C@@H](O)C=C[C@H]4[C@@H]5N(C)CC[C@]34c2c(cc1)C5
NCGC00016348-15	O(CC)c1cc2C(C)=CC(C)(C)Nc2cc1	4.4499998	Active	Heat shock protein HSP 90-beta Inhibitor	0.0	1	Ethoxyquin	405559074	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-66.1891704066	O(CC)c1cc2C(C)=CC(C)(C)Nc2cc1	O(CC)c1cc2C(C)=CC(C)(C)Nc2cc1
NCGC00096056-02	O(CC)c1cc2c(N)c3c(nc2cc1)cc(N)cc3	4.8249998	Active		0.0	1	Ethacridine lactate hydrate	170465798	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-32.1207833947&-96.2939867318	O=C(O)C(O)C.O(CC)c1cc2c(N)c3c(nc2cc1)cc(N)cc3.O	O=C(O)C(O)C.O(CC)c1cc2c(N)c3c(nc2cc1)cc(N)cc3.O
NCGC00181080-01	O(CC)c1ccc(/N=C(/Nc2ccc(OCC)cc2)\C)cc1	4.875	Active	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Inhibitor&Calcium/calmodulin-dependent 3',5'-cyclic Nucleotide Phosphodiesterase 1a Inhibitor	0.0	1	Phenacaine hydrochloride	144206789	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-36.6532885819&-66.3055542532	O(CC)c1ccc(/N=C(/Nc2ccc(OCC)cc2)\C)cc1.Cl	O(CC)c1ccc(/N=C(/Nc2ccc(OCC)cc2)\C)cc1.Cl
NCGC00263211-04	O(CC)c1ccc(Nc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1	4.75	Active	Alcohol dehydrogenase 7 Inhibitor	0.0	1	JK-184	384568668	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-107.0656175341	O(CC)c1ccc(Nc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1	O(CC)c1ccc(Nc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1
NCGC00346658-03	O(CC1(C)COC1)c1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1	5.0	Active	PDGFR beta Inhibitor	0.0	1	Crenolanib	384568889	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.6921073221	O(CC1(C)COC1)c1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1	O(CC1(C)COC1)c1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1
NCGC00161599-09&NCGC00161599-13	O(CC1(C)Oc2c(C)c(C)c(O)c(C)c2CC1)c1ccc(CC2C(=O)NC(=O)S2)cc1	4.53750015	Active	Peroxisome Proliferator-activated Receptor Gamma Agonist&CCL2 Expression Inhibitor&CCL2 Expression Inhibitor	0.27500010000000064	2	Troglitazone	170465091&384568210	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3&-3.0	-75.5171089736&-86.1737958192&-64.884597544	O(CC1(C)Oc2c(C)c(C)c(O)c(C)c2CC1)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(CC1(C)Oc2c(C)c(C)c(O)c(C)c2CC1)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00346881-02	O(CC1(CO)C(=O)C2CCN1CC2)C		Inactive	p53-dependent reactivation of massive apoptosis		1	APR-246	384568958	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.29753884	O(CC1(CO)C(=O)C2CCN1CC2)C	O(CC1(CO)C(=O)C2CCN1CC2)C
NCGC00390649-02	O(CC1CC1)c1c(c(O)ccc1)-c1nc2NC(=O)OCc2c([C@H]2CNCCC2)c1	4.9000001	Inactive	Inhibitor of nuclear factor kappa B kinase beta subunit Inhibitor	0.0	1	Bay-65-1942 hydrochloride	384569206	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-11.362612456	O(CC1CC1)c1c(c(O)ccc1)-c1nc2NC(=O)OCc2c([C@H]2CNCCC2)c1	O(CC1CC1)c1c(c(O)ccc1)-c1nc2NC(=O)OCc2c([C@H]2CNCCC2)c1
NCGC00345793-01	O(CC1CCN(C)CC1)c1cnc(-c2cc(CN3C(=O)C=CC(c4cc(C#N)ccc4)=N3)ccc2)nc1	4.4000001	Active	HGFR Inhibitor	0.0	1	EMD-1214063	174006592	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-48.616560068	O(CC1CCN(C)CC1)c1cnc(-c2cc(CN3C(=O)C=CC(c4cc(C#N)ccc4)=N3)ccc2)nc1	O(CC1CCN(C)CC1)c1cnc(-c2cc(CN3C(=O)C=CC(c4cc(C#N)ccc4)=N3)ccc2)nc1
NCGC00095116-05	O(CC1OC(=O)NC1)c1cc(C)cc(C)c1		Inactive			1	Metaxalone	170465241	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.05552484&-15.942079612	O(CC1OC(=O)NC1)c1cc(C)cc(C)c1	O(CC1OC(=O)NC1)c1cc(C)cc(C)c1
NCGC00483117-01	O(CCC)c1ccc(CCc2n(CCN3CCOCC3)c3c(n2)cc(-c2c(C)onc2C)cc3)cc1	4.4499998	Active	CBP/p300 Inhibitor	0.0	1	PF-CBP1	363681136	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.9714709907	O(CCC)c1ccc(CCc2n(CCN3CCOCC3)c3c(n2)cc(-c2c(C)onc2C)cc3)cc1	O(CCC)c1ccc(CCc2n(CCN3CCOCC3)c3c(n2)cc(-c2c(C)onc2C)cc3)cc1
NCGC00482383-01	O(CCC1CCOCC1)C1CC(Oc2ccc(-c3c(CN(CCNC)C)c[nH]n3)cc2)C1	4.6500001	Active	PRMT6 Inhibitor	0.0	1	EPZ-020411	363681128	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-31.1150545519	O(CCC1CCOCC1)C1CC(Oc2ccc(-c3c(CN(CCNC)C)c[nH]n3)cc2)C1	O(CCC1CCOCC1)C1CC(Oc2ccc(-c3c(CN(CCNC)C)c[nH]n3)cc2)C1
NCGC00016529-07	O(CCCC)c1ccc(OCCCN2CCOCC2)cc1		Inactive	Sodium channel alpha subunit Antagonist&Sodium Channel Alpha Subunit Antagonist		1	Pramoxine hydrochloride	170465004	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.657239&16.01041692	O(CCCC)c1ccc(OCCCN2CCOCC2)cc1.Cl	O(CCCC)c1ccc(OCCCN2CCOCC2)cc1.Cl
NCGC00390283-03	O(CCCC)c1nc(N)c2NC(=O)CN(Cc3cc(CN4CCCC4)ccc3)c2n1		Inactive	Toll-Like Receptor 7 (TLR7) Agonist		1	Vesatolimod	363680873	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.3259318001	O(CCCC)c1nc(N)c2NC(=O)CN(Cc3cc(CN4CCCC4)ccc3)c2n1	O(CCCC)c1nc(N)c2NC(=O)CN(Cc3cc(CN4CCCC4)ccc3)c2n1
NCGC00183007-01	O(CCCCC)c1c(OCC)cc(C2C(=O)NC(=O)S2)cc1		Inactive	Aldose Reductase Inhibitor&Aldose reductase Inhibitor		1	Risarestat	144206824	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.389919348&16.1786479639	O(CCCCC)c1c(OCC)cc(C2C(=O)NC(=O)S2)cc1	O(CCCCC)c1c(OCC)cc(C2C(=O)NC(=O)S2)cc1
NCGC00181091-01	O(CCCCCC)c1c2c(c(C(N(CCCC)CCCC)=N)cc1)cccc2	4.9000001	Active		0.0	1	Bunamidine hydrochloride	144206260	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-109.503624384&-95.9279735723	O(CCCCCC)c1c2c(c(C(N(CCCC)CCCC)=N)cc1)cccc2.Cl	O(CCCCCC)c1c2c(c(C(N(CCCC)CCCC)=N)cc1)cccc2.Cl
NCGC00408859-01	O(CCCCCCCCCCCCCCCC)C=1OC(=O)c2c(N=1)ccc(C)c2		Inactive	Pancreatic Lipase Inhibitor&Pancreatic lipase Inhibitor		1	Cetilistat	405559027	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.40363886	O(CCCCCCCCCCCCCCCC)C=1OC(=O)c2c(N=1)ccc(C)c2	O(CCCCCCCCCCCCCCCC)C=1OC(=O)c2c(N=1)ccc(C)c2
NCGC00015938-05	O(CCCCCCNCC(O)c1cc(CO)c(O)cc1)CCCCc1ccccc1	4.4499998	Active	Beta-2 adrenergic receptor Agonist	0.0	1	Salmeterol xinafoate	170465397	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.15406272	O=C(O)c1c(O)c2c(cc1)cccc2.O(CCCCCCNCC(O)c1cc(CO)c(O)cc1)CCCCc1ccccc1	O=C(O)c1c(O)c2c(cc1)cccc2.O(CCCCCCNCC(O)c1cc(CO)c(O)cc1)CCCCc1ccccc1
NCGC00179034-07&NCGC00179034-15	O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1	4.60000015	Active	PRL Phosphatase Inhibitor&Prl Phosphatase Inhibitors&PRL Phosphatase Inhibitor	0.40000010000000064	2	Pentamidine isethionate	170464786&384568368	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-2.1	-68.9819289799&-49.220363787&-90.0097032338	S(=O)(=O)(O)CCO.S(=O)(=O)(O)CCO.O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1	S(=O)(=O)(O)CCO.S(=O)(=O)(O)CCO.O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1&O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1
NCGC00378574-01	O(CCCCN1CCN(c2c3c(scc3)ccc2)CC1)c1cc2NC(=O)C=Cc2cc1	4.4250002	Active	Dopamine D3 receptor Partial Agonist&Dopamine D3 Receptor Partial Agonist	0.0	1	Brexpiprazole	405558789	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-116.647115848&-50.3992699516	O(CCCCN1CCN(c2c3c(scc3)ccc2)CC1)c1cc2NC(=O)C=Cc2cc1	O(CCCCN1CCN(c2c3c(scc3)ccc2)CC1)c1cc2NC(=O)C=Cc2cc1
NCGC00024778-02	O(CCCCNC)c1c(Cc2ccccc2)cccc1	4.4000001	Active	Monoamine Oxidase B Inhibitor&Monoamine oxidase B Inhibitor	0.0	1	Bifemelane	170465900	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-82.3178538532&-70.5198146199	O(CCCCNC)c1c(Cc2ccccc2)cccc1	O(CCCCNC)c1c(Cc2ccccc2)cccc1
NCGC00015207-12&NCGC00015207-24	O(CCCCc1n(C2CCCCC2)nnn1)c1cc2c(NC(=O)CC2)cc1	4.75	Active	Phosphodiesterase Iii (pde3) Inhibitor&Phosphodiesterase III (PDE3) Inhibitor&Phosphodiesterase III (PDE3) Inhibitor	0.6000004000000008	2	Cilostazol	170465347&384567823	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-1.3	-57.7862787799&-62.868130476&-96.7386857713	O(CCCCc1n(C2CCCCC2)nnn1)c1cc2c(NC(=O)CC2)cc1	O(CCCCc1n(C2CCCCC2)nnn1)c1cc2c(NC(=O)CC2)cc1
NCGC00249914-01	O(CCCN(C)C)C1(Cc2ccccc2)CCCCCC1	4.4499998	Active		0.0	1	Bencyclane	170465760	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.5714426025	O(CCCN(C)C)C1(Cc2ccccc2)CCCCCC1	O(CCCN(C)C)C1(Cc2ccccc2)CCCCCC1
NCGC00185956-04	O(CCCN(C)C)c1c(OC)cc2c(NC3CCN(C)CC3)nc(N3CCN(C)CCC3)nc2c1		Inactive	EHMT2 Inhibitor		1	UNC-0224	384568430	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	8.142981788	O(CCCN(C)C)c1c(OC)cc2c(NC3CCN(C)CC3)nc(N3CCN(C)CCC3)nc2c1	O(CCCN(C)C)c1c(OC)cc2c(NC3CCN(C)CC3)nc(N3CCN(C)CCC3)nc2c1
NCGC00498437-01	O(CCCN(C)C)c1ncc(-c2cc3c(ncc4N(C)C(=O)N(C5CCOCC5)c34)cc2)cc1	5.0	Active	ATM Kinase Inhibitor	0.0	1	AZD-0156	384569300	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-65.4339358901	O(CCCN(C)C)c1ncc(-c2cc3c(ncc4N(C)C(=O)N(C5CCOCC5)c34)cc2)cc1	O(CCCN(C)C)c1ncc(-c2cc3c(ncc4N(C)C(=O)N(C5CCOCC5)c34)cc2)cc1
NCGC00016397-04	O(CCCN(C)C)c1nn(Cc2ccccc2)c2c1cccc2	4.75	Active	Prostaglandin Production Involved In Inflammatory Response Inhibitor&prostaglandin production involved in inflammatory response Inhibitor	0.0	1	Benzydamine hydrochloride	170465576	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-90.6029905277&-74.0205474184	O(CCCN(C)C)c1nn(Cc2ccccc2)c2c1cccc2.Cl	O(CCCN(C)C)c1nn(Cc2ccccc2)c2c1cccc2.Cl
NCGC00390643-01	O(CCCN)c1c(c(OC)ccc1)-c1[nH]nc(Nc2ncc(C#N)nc2)c1		Inactive	Chk1 Inhibitor		1	Prexasertib	384569204	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.5830769999	O(CCCN)c1c(c(OC)ccc1)-c1[nH]nc(Nc2ncc(C#N)nc2)c1	O(CCCN)c1c(c(OC)ccc1)-c1[nH]nc(Nc2ncc(C#N)nc2)c1
NCGC00351478-06	O(CCCN1CCCC1)c1c(OC)cc2C3(C(N)=Nc2c1)CCC3		Inactive	G9a/EHMT2; decrease H3K9me2		1	A-366	384569007	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	33.148969484	O(CCCN1CCCC1)c1c(OC)cc2C3(C(N)=Nc2c1)CCC3	O(CCCN1CCCC1)c1c(OC)cc2C3(C(N)=Nc2c1)CCC3
NCGC00189220-12	O(CCCN1CCCC1)c1c(OC)cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2c1	5.0500002	Active	EHMT2 Inhibitor	0.0	1	UNC-0638	384568460	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-98.5915270711	O(CCCN1CCCC1)c1c(OC)cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2c1	O(CCCN1CCCC1)c1c(OC)cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2c1
NCGC00189144-02	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	4.9499998	Active	EHMT2 Inhibitor	0.0	1	UNC-0646	384568459	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-106.4416108764	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1
NCGC00189130-07	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	5.5	Active	EHMT2 Inhibitor	0.0	1	UNC-0631	384568458	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-94.1533968687	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1
NCGC00378832-01	O(CCCO)[C@H]1[C@H](O)C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(O)(C)C)C)CC3)CCC\2)/C[C@H]1O		Inactive			1	Eldecalcitol	405558953	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.002877188	O(CCCO)[C@H]1[C@H](O)C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(O)(C)C)C)CC3)CCC\2)/C[C@H]1O	O(CCCO)[C@H]1[C@H](O)C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(O)(C)C)C)CC3)CCC\2)/C[C@H]1O
NCGC00522455-01	O(CCCOc1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3)c1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3	5.3499999	Inactive	DNA-Intercalating Drugs	0.0	1	SJG-136	384569517	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	85.7577992392	O(CCCOc1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3)c1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3	O(CCCOc1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3)c1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3
NCGC00183108-01	O(CCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1	4.9499998	Active		0.0	1	Propamidine	144206602	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.3	-84.4616028315	O(CCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1	O(CCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1
NCGC00021141-05	O(CCN(C)C)c1c(Cc2ccccc2)cccc1	4.7249999	Active	Histamine H1 Receptor Blocker&Histamine H1 receptor Blocker	0.0	1	Phenyltoloxamine citrate	170465477	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-55.5946434583&-59.4037937175	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(CCN(C)C)c1c(Cc2ccccc2)cccc1	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(CCN(C)C)c1c(Cc2ccccc2)cccc1
NCGC00242249-05	O(CCN(C)C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(/C(=N/O)/CC3)cc2)cc1	4.9000001	Active	Raf kinase B Inhibitor	0.0	1	SB-590885	384568487	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-102.3711649463	O(CCN(C)C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(/C(=N/O)/CC3)cc2)cc1	O(CCN(C)C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(/C(=N/O)/CC3)cc2)cc1
NCGC00024928-14&NCGC00024928-23	O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1	4.83749985	Active	Selective Estrogen Receptor Modulators (SERM)&Selective Estrogen Receptor Modulators (serm)&Selective Estrogen Receptor Modulators (SERM)	0.5250001000000006	2	Tamoxifen	124886964&170465425	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4&-3.0	-77.8028817247&-53.9252501296&-101.9825701289	O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1	O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1&O=C(O)C(O)(CC(=O)O)CC(=O)O.O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1
NCGC00016618-04	O(CCN(C)C)c1nc(CCCC)cc2c1cccc2	4.7249999	Active	Neuronal Acetylcholine Receptor; Alpha4/beta4 Inhibitor&Neuronal acetylcholine receptor; alpha4/beta4 Inhibitor	0.0	1	Dimethisoquin hydrochloride	170465516	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-87.542221124&-82.2891319928	O(CCN(C)C)c1nc(CCCC)cc2c1cccc2.Cl	O(CCN(C)C)c1nc(CCCC)cc2c1cccc2.Cl
NCGC00095124-08&NCGC00095124-31	O(CCN(C)c1ncccc1)c1ccc(CC2C(=O)NC(=O)S2)cc1		Inactive	PPARgamma Agonist&Peroxisome Proliferator-activated Receptor Gamma Agonist&PPARgamma Agonist		2	Rosiglitazone	170465417&384568147	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-14.140777568&29.4370320719	O(CCN(C)c1ncccc1)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(CCN(C)c1ncccc1)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00160485-01	O(CCN(CC)CC)c1cc2sc(N(C)C)nc2cc1	4.8000002	Active		0.0	1	Diamthazole	144205400	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.9906168279	O(CCN(CC)CC)c1cc2sc(N(C)C)nc2cc1	O(CCN(CC)CC)c1cc2sc(N(C)C)nc2cc1
NCGC00024762-06	O(CCN(CC)CC)c1ccc(Cc2ccccc2)cc1	4.5999999	Active	Estrogen Receptor Antagonist	0.0	1	Tesmilifene hydrochloride	384568034	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-87.8895677711	O(CCN(CC)CC)c1ccc(Cc2ccccc2)cc1	O(CCN(CC)CC)c1ccc(Cc2ccccc2)cc1
NCGC00181100-01	O(CCN1CCCC1)c1ccc([C@H]2[C@H](c3ccccc3)C(C)(C)Oc3c2ccc(OC)c3)cc1	4.8000002	Active	Estrogen receptor Partial Agonist	0.0	1	Ormeloxifene	144206269	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-86.2565025576	O(CCN1CCCC1)c1ccc([C@H]2[C@H](c3ccccc3)C(C)(C)Oc3c2ccc(OC)c3)cc1	O(CCN1CCCC1)c1ccc([C@H]2[C@H](c3ccccc3)C(C)(C)Oc3c2ccc(OC)c3)cc1
NCGC00345826-04	O(CCN1CCCCC1)c1cc(-c2n[nH]c3c2cc(-c2n[nH]cn2)cc3)ccc1	4.4000001	Active	JNK Inhibitor	0.0	1	CC-401	363677373	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-82.6304255199	O(CCN1CCCCC1)c1cc(-c2n[nH]c3c2cc(-c2n[nH]cn2)cc3)ccc1	O(CCN1CCCCC1)c1cc(-c2n[nH]c3c2cc(-c2n[nH]cn2)cc3)ccc1
NCGC00165869-22	O(CCN1CCCCC1)c1ccc(C2=Cn3ncc(-c4ccncc4)c3N=C2)cc1	4.9499998	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	Dorsomorphin	384568292	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-100.2755635511	O(CCN1CCCCC1)c1ccc(C2=Cn3ncc(-c4ccncc4)c3N=C2)cc1	O(CCN1CCCCC1)c1ccc(C2=Cn3ncc(-c4ccncc4)c3N=C2)cc1
NCGC00182995-01	O(CCN1CCCCC1)c1ccc(NC2N(CC)C(=O)c3c2cccc3)cc1	4.4000001	Active		0.0	1	Etomidoline	144206828	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.0826092839	O(CCN1CCCCC1)c1ccc(NC2N(CC)C(=O)c3c2cccc3)cc1	O(CCN1CCCCC1)c1ccc(NC2N(CC)C(=O)c3c2cccc3)cc1
NCGC00510909-01	O(CCN1CCCCC1)c1ccc([C@H]2C(c3ccc(O)cc3)=C(C)c3c(O2)cc(O)cc3)cc1		Inactive	Selective Estrogen Receptor Modulators (SERM)		1	Acolbifene	384569493	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.896736616	O(CCN1CCCCC1)c1ccc([C@H]2C(c3ccc(O)cc3)=C(C)c3c(O2)cc(O)cc3)cc1	O(CCN1CCCCC1)c1ccc([C@H]2C(c3ccc(O)cc3)=C(C)c3c(O2)cc(O)cc3)cc1
NCGC00182055-03&NCGC00182055-09	O(CCN1CCCCCC1)c1ccc(Cn2c(c(C)c3c2ccc(O)c3)-c2ccc(O)cc2)cc1	4.5875001	Active	Selective Estrogen Receptor Modulators (serm)&Selective Estrogen Receptor Modulators (SERM)&Selective Estrogen Receptor Modulators (SERM)	0.17500020000000038	2	Bazedoxifene	170466793&384568408	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3&-2.4	-87.750716016&-79.4147319121&-85.315966901	O=C(O)C.O(CCN1CCCCCC1)c1ccc(Cn2c(c(C)c3c2ccc(O)c3)-c2ccc(O)cc2)cc1	O=C(O)C.O(CCN1CCCCCC1)c1ccc(Cn2c(c(C)c3c2ccc(O)c3)-c2ccc(O)cc2)cc1&O(CCN1CCCCCC1)c1ccc(Cn2c(c(C)c3c2ccc(O)c3)-c2ccc(O)cc2)cc1
NCGC00242598-10	O(CCN1CCOCC1)c1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	LY-2109761	377020452	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	24.984787928	O(CCN1CCOCC1)c1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1	O(CCN1CCOCC1)c1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1
NCGC00508900-01	O(CCN1CCOCC1)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	VU-0364849	384569371	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(CCN1CCOCC1)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1	O(CCN1CCOCC1)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1
NCGC00510269-04	O(CCN1[C@H](C)C(=O)N(C)CC1)c1ccc(C2CCN(C3=Nn4c(OC)nnc4C=C3)CC2)cc1		Inactive	Brd4 Inhibitor		1	AZD-5153 6-Hydroxy-2-naphthoic acid	384569426	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(CCN1[C@H](C)C(=O)N(C)CC1)c1ccc(C2CCN(C3=Nn4c(OC)nnc4C=C3)CC2)cc1	O(CCN1[C@H](C)C(=O)N(C)CC1)c1ccc(C2CCN(C3=Nn4c(OC)nnc4C=C3)CC2)cc1
NCGC00346806-06	O(CCNC)c1ccc(/C(=C(\CC)/c2ccccc2)/c2ccc(O)cc2)cc1	4.4000001	Inactive	PKC Inhibitor	0.0	1	Endoxifen	384568940	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	14.62801248	O(CCNC)c1ccc(/C(=C(\CC)/c2ccccc2)/c2ccc(O)cc2)cc1	O(CCNC)c1ccc(/C(=C(\CC)/c2ccccc2)/c2ccc(O)cc2)cc1
NCGC00167832-06	O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1	4.75	Active	Beta1-adrenoceptor Antagonists&beta1-Adrenoceptor Antagonists	0.0	1	Carvedilol tartrate	170465440	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.2	-106.0565778261&-78.8050518187	O=C(O)C(O)C(O)C(=O)O.O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1	O=C(O)C(O)C(O)C(=O)O.O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1
NCGC00274074-01	O(CCO)CCCCCCCCCCCC		Inactive			1	2-(Dodecyloxy)ethanol	170466587	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-11.971616476&19.758484604	O(CCO)CCCCCCCCCCCC	O(CCO)CCCCCCCCCCCC
NCGC00095911-06	O(CCO)CCN1CCN(C2=Nc3c(Sc4c2cccc4)cccc3)CC1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist&Serotonin 2a (5-ht2a) Receptor Antagonist		1	Quetiapine	170465146	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(CCO)CCN1CCN(C2=Nc3c(Sc4c2cccc4)cccc3)CC1	O(CCO)CCN1CCN(C2=Nc3c(Sc4c2cccc4)cccc3)CC1
NCGC00384193-03	O(CCO)CCNc1c2c(C)n[nH]c2nc2c1cc(OC)cc2	4.4000001	Active	MTH1 Inhibitor	0.0	1	SCH-51344	384569104	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-47.1284957679	O(CCO)CCNc1c2c(C)n[nH]c2nc2c1cc(OC)cc2	O(CCO)CCNc1c2c(C)n[nH]c2nc2c1cc(OC)cc2
NCGC00015061-13&NCGC00015061-27	O(CCO)Cn1c2N=C(N)NC(=O)c2nc1		Inactive	Dna Polymerase Inhibitors&DNA Polymerase Inhibitor&DNA Polymerase Inhibitor		2	Aciclovir	170464640&384567804	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O(CCO)Cn1c2N=C(N)NC(=O)c2nc1	O(CCO)Cn1c2N=C(N)NC(=O)c2nc1
NCGC00356073-13	O(CCO)c1c(C)cc(C2=Nc3c(c(OC)cc(OC)c3)C(=O)N2)cc1C		Inactive	Brd4 Inhibitor		1	RVX-208	384569027	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(CCO)c1c(C)cc(C2=Nc3c(c(OC)cc(OC)c3)C(=O)N2)cc1C	O(CCO)c1c(C)cc(C2=Nc3c(c(OC)cc(OC)c3)C(=O)N2)cc1C
NCGC00090731-08	O(CCO)c1ccccc1	4.3499999	Active	Vanilloid receptor Agonist	0.0	1	2-Phenoxyethanol	170465671	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-37.8451473601	O(CCO)c1ccccc1	O(CCO)c1ccccc1
NCGC00389470-01	O(CCOC)CC1OC2C(O)(C)C(CC)OC(=O)C(C)C(OC3OC(C)C(O)C(OC)(C)C3)C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(O)(C)CC(C)C(C2C)N1	4.5	Active	Bacterial 70s Ribosome Inhibitor&Bacterial 70S ribosome Inhibitor	0.0	1	Dirithromycin	405558768	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-69.8316423879&-84.8569187503	O(CCOC)CC1OC2C(O)(C)C(CC)OC(=O)C(C)C(OC3OC(C)C(O)C(OC)(C)C3)C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(O)(C)CC(C)C(C2C)N1	O(CCOC)CC1OC2C(O)(C)C(CC)OC(=O)C(C)C(OC3OC(C)C(O)C(OC)(C)C3)C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(O)(C)CC(C)C(C2C)N1
NCGC00090874-06	O(CCOCCCC)CCOCc1c(CCC)cc2OCOc2c1		Inactive			1	Piperonyl butoxide	170464741	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.288405	O(CCOCCCC)CCOCc1c(CCC)cc2OCOc2c1	O(CCOCCCC)CCOCc1c(CCC)cc2OCOc2c1
NCGC00163798-06	O(CCOCCO)CCO		Inactive			1	Triethylene glycol	405559002	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O(CCOCCO)CCO	O(CCOCCO)CCO
NCGC00166290-03	O(CCOCCOCCOCCOCCO)CCOCCOCCOCCOCCCCCCCCCCCC	4.8249998	Active		0.0	1	Polyoxyethylene (9) lauryl ether	170466791	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-106.17617037&-106.4445901739	O(CCOCCOCCOCCOCCO)CCOCCOCCOCCOCCCCCCCCCCCC	O(CCOCCOCCOCCOCCO)CCOCCOCCOCCOCCCCCCCCCCCC
NCGC00509863-01	O(CCOCCOCCOCCO[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1)CCOCCOCCOC		Inactive	Mu-type Opioid Receptor Antagonist&Mu-type opioid receptor Antagonist		1	Naloxegol (oxalate)	405558803	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-26.8448553239	O(CCOCCOCCOCCO[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1)CCOCCOCCOC	O(CCOCCOCCOCCO[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1)CCOCCOCCOC
NCGC00346578-08	O(CCOc1c(OCCO)cc2c(Nc3cc(C#C)ccc3)ncnc2c1)C	4.5	Active	EGFR Inhibitor	0.0	1	OSI-420	384568849	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-65.0071460997	O(CCOc1c(OCCO)cc2c(Nc3cc(C#C)ccc3)ncnc2c1)C	O(CCOc1c(OCCO)cc2c(Nc3cc(C#C)ccc3)ncnc2c1)C
NCGC00164574-06&NCGC00164574-14	O(CCOc1c(OCCOC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1)C	4.85000015	Active	EGFR Inhibitor&Egfr (her1; Erbb1) Inhibitor&EGFR Inhibitor	0.09999989999999936	2	Erlotinib	170465434&363676637	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4&-2.4	-38.835268&-70.7696528359&-39.4777792004	O(CCOc1c(OCCOC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1)C	O(CCOc1c(OCCOC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1)C
NCGC00346718-02	O(CCOc1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1)C	4.9000001	Active	PDGFR beta Inhibitor	0.0	1	CP-673451	384568931	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-100.1988919913	O(CCOc1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1)C	O(CCOc1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1)C
NCGC00016373-08	O(CCOc1ccc(C(CC(C)(C)C)(C)C)cc1)CC[N+](Cc1ccccc1)(C)C	4.6500001	Active		0.0	1	Benzethonium chloride	170465473	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-109.8111590732&-60.3661136108	O(CCOc1ccc(C(CC(C)(C)C)(C)C)cc1)CC[N+](Cc1ccccc1)(C)C.[Cl-]	O(CCOc1ccc(C(CC(C)(C)C)(C)C)cc1)CC[N+](Cc1ccccc1)(C)C.[Cl-]
NCGC00378857-02	O(CCOc1ccc(N2CCN(CCn3ncc4-c5n(C(N)=Nc34)nc(-c3occc3)n5)CC2)cc1)C		Inactive	Adenosine A2A Antagonist		1	Preladenant	363678239	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.383764692	O(CCOc1ccc(N2CCN(CCn3ncc4-c5n(C(N)=Nc34)nc(-c3occc3)n5)CC2)cc1)C	O(CCOc1ccc(N2CCN(CCn3ncc4-c5n(C(N)=Nc34)nc(-c3occc3)n5)CC2)cc1)C
NCGC00253658-01	O(CC[C@H](N(C)C)c1ccccc1)c1c2c(ccc1)cccc2	5.0	Active	Serotonin Transporter (SERT) Inhibitor	0.0	1	Dapoxetine	170466555	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-71.862632644	O(CC[C@H](N(C)C)c1ccccc1)c1c2c(ccc1)cccc2	O(CC[C@H](N(C)C)c1ccccc1)c1c2c(ccc1)cccc2
NCGC00015482-07&NCGC00015482-15	O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC		Inactive	Muscarinic M2 Antagonists&Muscarinic M2 Antagonist&Muscarinic M2 Antagonist		2	Gallamine triethiodide	170465398&384567857	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]	O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]&O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC
NCGC00091010-03	O(CC[N+](CCCCCCCCCCCC)(C)C)c1ccccc1	4.4749999	Active	Herg Inhibitor&HERG Inhibitor	0.0	1	Domiphen bromide	170465494	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-106.83885004&-122.2204278022	O(CC[N+](CCCCCCCCCCCC)(C)C)c1ccccc1.[Br-]	O(CC[N+](CCCCCCCCCCCC)(C)C)c1ccccc1.[Br-]
NCGC00181794-01	O(CC[N+](Cc1sccc1)(C)C)c1ccccc1		Inactive	Acetylcholine Metabolic Process Modulator&acetylcholine metabolic process Modulator		1	Dimethyl(2-phenoxyethyl)-2-thenylammonium iodide	144207154	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-28.600934956	O(CC[N+](Cc1sccc1)(C)C)c1ccccc1.[I-]	O(CC[N+](Cc1sccc1)(C)C)c1ccccc1.[I-]
NCGC00531790-01	O(CCc1c(C)oc(-c2ccccc2)n1)c1ccc(CC2C(=O)ONC2=O)cc1	5.6500001	Active	Peroxisome Proliferator-activated Receptor Gamma Agonist	0.0	1	JTT-501	405558852	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-35.038170688	O(CCc1c(C)oc(-c2ccccc2)n1)c1ccc(CC2C(=O)ONC2=O)cc1	O(CCc1c(C)oc(-c2ccccc2)n1)c1ccc(CC2C(=O)ONC2=O)cc1
NCGC00185775-01	O(CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	5.0	Active	beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors	0.0	1	Salidroside	144207114	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.91668736	O(CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00021148-08	O(CCc1ccc(OCC(O)CNC(C)C)cc1)C		Inactive			1	Metoprolol tartrate	170464652	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-13.155022344	O=C(O)[C@H](O)[C@@H](O)C(=O)O.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C	O=C(O)[C@H](O)[C@@H](O)C(=O)O.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C
NCGC00015159-13&NCGC00015159-22	O(CCc1ccc(OCC(O)CNC(C)C)cc1)CC1CC1		Inactive	Beta1-adrenoceptor Antagonists		2	Betaxolol HCl&Betaxolol	405558860&384567818	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	11.177417968&0.0&-18.045769856	O(CCc1ccc(OCC(O)CNC(C)C)cc1)CC1CC1	O(CCc1ccc(OCC(O)CNC(C)C)cc1)CC1CC1
NCGC00163128-17	O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1	4.4000001	Active	PPARgamma Agonist	0.0	1	Pioglitazone hydrochloride	384568232	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-48.5648636919	O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00263093-04	O(CCc1ncccc1)c1nc(N/N=C/c2cc(C)ccc2)cc(N2CCOCC2)n1	7.0	Inactive	PIKFyve Inhibitor	0.0	1	Apilimod	384568585	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-75.870860304	O(CCc1ncccc1)c1nc(N/N=C/c2cc(C)ccc2)cc(N2CCOCC2)n1	O(CCc1ncccc1)c1nc(N/N=C/c2cc(C)ccc2)cc(N2CCOCC2)n1
NCGC00242514-13	O(CCn1c(C)[n+](Cc2nccnc2)c2C(=O)c3c(C(=O)c12)cccc3)C	9.0	Inactive	Survivin Inhibitor	0.0	1	Sepantronium bromide	384568506	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-19.8776163321	O(CCn1c(C)[n+](Cc2nccnc2)c2C(=O)c3c(C(=O)c12)cccc3)C	O(CCn1c(C)[n+](Cc2nccnc2)c2C(=O)c3c(C(=O)c12)cccc3)C
NCGC00181341-02	O(CCn1c(N2CCN(C)CCC2)nc2c1cccc2)CC	4.6500001	Active	Histamine H1 Receptor Antagonist	0.0	1	Emedastine difumarate	170465197	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.2838819523	O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O(CCn1c(N2CCN(C)CCC2)nc2c1cccc2)CC	O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O(CCn1c(N2CCN(C)CCC2)nc2c1cccc2)CC
NCGC00347278-03	O(C[C@@H](N)Cc1c2c([nH]c1)cccc2)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1	9.0	Inactive	AKT Inhibitor	0.0	1	A-443654	384568984	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-22.215049588	O(C[C@@H](N)Cc1c2c([nH]c1)cccc2)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1	O(C[C@@H](N)Cc1c2c([nH]c1)cccc2)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1
NCGC00263147-03	O(C[C@@H](N)Cc1ccccc1)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1	5.1500001	Active	AKT Inhibitor	0.0	1	A-674563	384568622	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-97.4184530746	O(C[C@@H](N)Cc1ccccc1)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1	O(C[C@@H](N)Cc1ccccc1)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1
NCGC00016798-11	O(C[C@@H](O)CNC(C)(C)C)c1c(N2CCOCC2)nsn1		Inactive	Beta-2 Adrenergic Receptor Antagonist&Beta-2 adrenergic receptor Antagonist		1	(S)-Timolol	170465062	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.497247452&0.0	O(C[C@@H](O)CNC(C)(C)C)c1c(N2CCOCC2)nsn1	O(C[C@@H](O)CNC(C)(C)C)c1c(N2CCOCC2)nsn1
NCGC00016801-05	O(C[C@@H](O)CNC(C)(C)C)c1c2c(C(=O)CCC2)ccc1	4.4000001	Active	Beta-2 Adrenergic Receptor Antagonist	0.0	1	Levobunolol hydrochloride	170464743	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.3089516052	O(C[C@@H](O)CNC(C)(C)C)c1c2c(C(=O)CCC2)ccc1.Cl	O(C[C@@H](O)CNC(C)(C)C)c1c2c(C(=O)CCC2)ccc1.Cl
NCGC00160628-03	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	Aldose Reductase Inhibitor&Aldose reductase Inhibitor		1	Rutin trihydrate	170465691	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.441545416&19.34232968	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00344564-05	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	Aryl Hydrocarbon Receptor (AhR) Agonist		1	Diosmin	384568723	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00179501-03&NCGC00179501-09	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	Free Radical Scavenger		2	Aurantiamarin (Methyl Hesperidin)	225144305&384568375	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00532495-01	O(C[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](CO)[C@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	4.4499998	Active		0.0	1	Sizofilan	405558842	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.184242156	O(C[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](CO)[C@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](CO)[C@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00348375-01	O(C[C@@H]\1[C@@H](CC)OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H](C)O2)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(/C)=C/1)[C@H]1[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O1	4.8000002	Active	Bacterial 70s Ribosome Binding Agent&Bacterial 70S ribosome Binding Agent	0.0	1	TILMICOSIN	405558560	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-42.5085019015&-40.3926615799	O(C[C@@H]\1[C@@H](CC)OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H](C)O2)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(/C)=C/1)[C@H]1[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O1	O(C[C@@H]\1[C@@H](CC)OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H](C)O2)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(/C)=C/1)[C@H]1[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O1
NCGC00015798-11	O(C[C@H](O)CNC(C)C)c1c2c(ccc1)cccc2	5.3499999	Active	Adrenergic Receptor Beta Antagonist	0.0	1	Dexpropranolol	170464682	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-49.0662819739	O(C[C@H](O)CNC(C)C)c1c2c(ccc1)cccc2	O(C[C@H](O)CNC(C)C)c1c2c(ccc1)cccc2
NCGC00509990-02	O(Cc1ccc(CN2CCOCC2)cc1)c1c2c(C(=O)N([C@@H]3C(=O)NC(=O)CC3)C2)ccc1		Inactive	IL-2 Production Enhancers		1	Iberdomide	384569398	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.3255821081	O(Cc1ccc(CN2CCOCC2)cc1)c1c2c(C(=O)N([C@@H]3C(=O)NC(=O)CC3)C2)ccc1	O(Cc1ccc(CN2CCOCC2)cc1)c1c2c(C(=O)N([C@@H]3C(=O)NC(=O)CC3)C2)ccc1
NCGC00345850-02	O(Cc1ccc(CN2CCOCC2)cc1)c1nc(/C(/C#N)=C\2/Sc3c(N/2)cccc3)ccn1	3.95	Inactive	JNK Inhibitor	0.0	1	AS-602801	384568765	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-11.915686612	O(Cc1ccc(CN2CCOCC2)cc1)c1nc(/C(/C#N)=C\2/Sc3c(N/2)cccc3)ccn1	O(Cc1ccc(CN2CCOCC2)cc1)c1nc(/C(/C#N)=C\2/Sc3c(N/2)cccc3)ccn1
NCGC00242051-10	O(Cc1ccc(OC)cc1)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1	4.5500002	Inactive	CSF1R (c-FMS) Inhibitor	0.0	1	GW-2580	384568482	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-17.534802	O(Cc1ccc(OC)cc1)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1	O(Cc1ccc(OC)cc1)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1
NCGC00263125-03	O(Cc1ccc(OC)cc1)c1c(OC)cc-2c(OC(=O)c3c-2ccc(C(O)C)c3)c1		Inactive	mTORC1/2 Inhibitor		1	SG-00529	384568608	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.7240735799	O(Cc1ccc(OC)cc1)c1c(OC)cc-2c(OC(=O)c3c-2ccc(C(O)C)c3)c1	O(Cc1ccc(OC)cc1)c1c(OC)cc-2c(OC(=O)c3c-2ccc(C(O)C)c3)c1
NCGC00346461-02	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCC4)C3)c2)ccc1	4.4000001	Active		0.0	1	NVP-AEW541	384568784	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-43.929995636	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCC4)C3)c2)ccc1	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCC4)C3)c2)ccc1
NCGC00386129-03	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCCC4)C3)c2)ccc1	4.8499999	Active	IGF-1R Inhibitor	0.0	1	ADW-742	363680114	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-101.088321655	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCCC4)C3)c2)ccc1	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCCC4)C3)c2)ccc1
NCGC00015144-05	O(Cc1ccccc1)c1nc(N)nc2[nH]cnc12		Inactive	MGMT Inhibitor		1	O6-Benzylguanine	384567813	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(Cc1ccccc1)c1nc(N)nc2[nH]cnc12	O(Cc1ccccc1)c1nc(N)nc2[nH]cnc12
NCGC00378991-02	O(Cc1n(C)c2c(n1)ccc(Oc1cc(C)c(N)c(C)c1)c2)c1ccc(CC2C(=O)NC(=O)S2)cc1		Inactive	PAPRgamma Agonist		1	Efatutazone	384569084	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(Cc1n(C)c2c(n1)ccc(Oc1cc(C)c(N)c(C)c1)c2)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(Cc1n(C)c2c(n1)ccc(Oc1cc(C)c(N)c(C)c1)c2)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00346507-07	O(Cc1n2N=C(c3ccccc3)C=Cc2nn1)c1c2c(ncc1)cc(OC)cc2		Inactive	HGFR Inhibitor		1	AMG-208	363677433	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.858200136	O(Cc1n2N=C(c3ccccc3)C=Cc2nn1)c1c2c(ncc1)cc(OC)cc2	O(Cc1n2N=C(c3ccccc3)C=Cc2nn1)c1c2c(ncc1)cc(OC)cc2
NCGC00522052-01	O(Cc1nc(Cn2nnc3c(-c4oc(C)cc4)nc(N)nc23)ccc1)[C@@H]1COCC1		Inactive	Adenosine A2A Antagonist		1	CPI-444	384569512	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(Cc1nc(Cn2nnc3c(-c4oc(C)cc4)nc(N)nc23)ccc1)[C@@H]1COCC1	O(Cc1nc(Cn2nnc3c(-c4oc(C)cc4)nc(N)nc23)ccc1)[C@@H]1COCC1
NCGC00346630-05	O(Cc1nc2c(cc1)cccc2)c1ccc(-c2c(-c3ccncc3)cn(C)n2)cc1	4.4000001	Active	Phosphodiesterase PDE10A Inhibitor	0.0	1	MP-10	363677485	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-57.382156308	O(Cc1nc2c(cc1)cccc2)c1ccc(-c2c(-c3ccncc3)cn(C)n2)cc1	O(Cc1nc2c(cc1)cccc2)c1ccc(-c2c(-c3ccncc3)cn(C)n2)cc1
NCGC00159380-05	O(OC(=O)c1ccccc1)C(=O)c1ccccc1	4.5999999	Active		0.0	1	Benzoyl peroxide	170464986	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-52.6429466738	O(OC(=O)c1ccccc1)C(=O)c1ccccc1	O(OC(=O)c1ccccc1)C(=O)c1ccccc1
NCGC00379076-01	O([C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(C)C		Inactive	Vitamin D Receptor Agonist&Vitamin D receptor Agonist		1	Maxacalcitol-D6	405558501	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.7944988999&0.0	O([C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(C)C	O([C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(C)C
NCGC00345803-02	O([C@@H](CC#N)CC)C(=O)N[C@@H](C)c1cc(NC(=O)Nc2cc(OC)c(-c3ocnc3)cc2)ccc1	9.0	Inactive		0.0	1	AVN944	384568751	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-22.225735304	O([C@@H](CC#N)CC)C(=O)N[C@@H](C)c1cc(NC(=O)Nc2cc(OC)c(-c3ocnc3)cc2)ccc1	O([C@@H](CC#N)CC)C(=O)N[C@@H](C)c1cc(NC(=O)Nc2cc(OC)c(-c3ocnc3)cc2)ccc1
NCGC00165856-03	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)C(NC=O)CC(C)C		Inactive	Pancreatic Lipase Inhibitor&Fatty acid synthase inhibitor		1	Orlistat	170464663	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-28.6342318279	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)C(NC=O)CC(C)C	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)C(NC=O)CC(C)C
NCGC00164559-03	O([C@@H](CCNC)c1sccc1)c1c2c(ccc1)cccc2	4.625	Active	Serotonin Transporter (sert) Inhibitor&Serotonin Transporter (SERT) Inhibitor	0.0	1	Duloxetine hydrochloride	170465319	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-113.4960795968&-109.6677369719	O([C@@H](CCNC)c1sccc1)c1c2c(ccc1)cccc2.Cl	O([C@@H](CCNC)c1sccc1)c1c2c(ccc1)cccc2.Cl
NCGC00508876-01	O([C@@H](CN(C)C)C)c1c(C#N)ncc(Nc2ncc(c(OC)c2)-c2cn(C)nc2)n1	5.0500002	Active	Chk1 Inhibitor	0.0	1	CCT-244747	384569369	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-41.5670352578	O([C@@H](CN(C)C)C)c1c(C#N)ncc(Nc2ncc(c(OC)c2)-c2cn(C)nc2)n1	O([C@@H](CN(C)C)C)c1c(C#N)ncc(Nc2ncc(c(OC)c2)-c2cn(C)nc2)n1
NCGC00263541-01	O([C@@H]([C@@H]1OCCNC1)c1ccccc1)c1c(OCC)cccc1	4.4000001	Active		0.0	1	Reboxetine mesylate	170465620	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.4236995519	S(=O)(=O)(O)C.O([C@@H]([C@@H]1OCCNC1)c1ccccc1)c1c(OCC)cccc1	S(=O)(=O)(O)C.O([C@@H]([C@@H]1OCCNC1)c1ccccc1)c1c(OCC)cccc1
NCGC00263893-02	O([C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1		Inactive	Maltase-glucoamylase Inhibitor		1	Lactitol	170465917	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.603519232&0.0	O([C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1	O([C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1
NCGC00351592-01	O([C@@H]([C@H](O)c1cc(OC)c(OC)cc1)C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c(O[C@@H]([C@H](O)c4cc(OC)c(OC)cc4)C)cc3)O2)cc1	4.5	Inactive	HIF-1alpha Inhibitor	0.0	1	Manassantin A	384569012	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	24.151911176	O([C@@H]([C@H](O)c1cc(OC)c(OC)cc1)C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c(O[C@@H]([C@H](O)c4cc(OC)c(OC)cc4)C)cc3)O2)cc1	O([C@@H]([C@H](O)c1cc(OC)c(OC)cc1)C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c(O[C@@H]([C@H](O)c4cc(OC)c(OC)cc4)C)cc3)O2)cc1
NCGC00167967-05	O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	5.0999999	Active	Ketolide antibiotic	0.0	1	Telithromycin	384568342	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-36.8497194299	O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00094652-06	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1	6.5	Inactive		0.0	1	DIGITOXIN	405559111	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-36.557354564	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1
NCGC00090797-12&NCGC00090797-28	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1	9.25	Inactive	Steroid	0.5	2	Digoxin	405558822&384568087	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-5.5741690439&-79.6996542481	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1
NCGC00159441-03	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@@H]4C[C@@H]5[C@@](C)([C@@H]6[C@H]([C@]7(O)[C@](C)([C@H](O)C6)[C@@H](C6=CC(=O)OC6)CC7)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	5.6999998	Active	Sodium/potassium-transporting ATPase Inhibitor&Sodium/potassium-transporting Atpase Inhibitor	0.0	1	Deslanoside	170465236	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-1.2	-99.2631727073&-74.1886979425	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@@H]4C[C@@H]5[C@@](C)([C@@H]6[C@H]([C@]7(O)[C@](C)([C@H](O)C6)[C@@H](C6=CC(=O)OC6)CC7)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@@H]4C[C@@H]5[C@@](C)([C@@H]6[C@H]([C@]7(O)[C@](C)([C@H](O)C6)[C@@H](C6=CC(=O)OC6)CC7)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00179619-17	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive	Bacterial 70S ribosome Binding Agent		1	Erythromycin	384568380	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00178054-06	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive	Macrolide Antibiotic		1	Clarithromycin	405558922	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.042894208&13.9322643359	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00090753-06&NCGC00090753-20	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	4.75	Active	50S Ribosomal Protein Inhibitor	0.3000001999999995	2	Azithromycin	405558826&384568081	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.2	-73.60322018&-69.0189256752	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00179611-05	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]1NC(=N)N)[C@H]1[C@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@](O)(CO)[C@H](C)O1	4.875	Active	Large-conductance Mechanosensitive Channel Modulator&Large-conductance mechanosensitive channel Modulator	0.0	1	DIHYDROSTREPTOMYCIN [5mM]	405558590	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.2	-40.4877024791&-30.9143258279	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]1NC(=N)N)[C@H]1[C@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@](O)(CO)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]1NC(=N)N)[C@H]1[C@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@](O)(CO)[C@H](C)O1
NCGC00389765-01	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)CC[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1		Inactive			1	DIBEKACIN	405558422	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.173446172&0.0	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)CC[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)CC[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1
NCGC00178852-04&NCGC00178852-05	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1		Inactive	30S Ribosomal Protein Inhibitor&30s Ribosomal Protein Inhibitors&30S Ribosomal Protein Inhibitor		2	Tobramycin	384568365&225144300	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-10.7124169599&0.0&-16.617628312	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1
NCGC00346600-02	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	4.9000001	Active	peroxiredoxins (PRDX) 1/6	0.0	1	Dioscin	384568854	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-86.9846133606	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00179493-03	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@H]7N([C@H]6C5)C[C@@H](C)CC7)CC4)CC=3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	4.8000002	Active	Cholinesterase Inhibitor	0.0	1	Solanine alpha	405559114	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-83.6266695511&-92.6291017	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@H]7N([C@H]6C5)C[C@@H](C)CC7)CC4)CC=3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@H]7N([C@H]6C5)C[C@@H](C)CC7)CC4)CC=3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00164248-05	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1	4.9499998	Active	Starch and sucrose metabolism Substrate	0.0	1	Sucrose	405559043	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-34.7577946292	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00263944-01	O([C@@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1		Inactive	30S Ribosomal Protein Inhibitor		1	Kanamycin	174006252	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.223047012	O([C@@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1	O([C@@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1
NCGC00263824-02	O([C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H]([C@H](NC)C)O1		Inactive	Antibiotic		1	GENTAMICIN SULFATE	225144365	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O([C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H]([C@H](NC)C)O1	O([C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H]([C@H](NC)C)O1
NCGC00522632-01	O([C@H](C)[C@@H]1C(=O)C[C@H]2C(=C)[C@H](OC(=O)/C=C(/CC)\C)C[C@@H](C(C)C)[C@H]12)C(=O)C		Inactive	Platelet-Activating Factor Receptor (PAFR) Antagonist		1	Tussilagone	384569533	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.8015302	O([C@H](C)[C@@H]1C(=O)C[C@H]2C(=C)[C@H](OC(=O)/C=C(/CC)\C)C[C@@H](C(C)C)[C@H]12)C(=O)C	O([C@H](C)[C@@H]1C(=O)C[C@H]2C(=C)[C@H](OC(=O)/C=C(/CC)\C)C[C@@H](C(C)C)[C@H]12)C(=O)C
NCGC00510489-01	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)onc1C	4.4499998	Active	Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Antagonist	0.0	1	BMS-986020	384569451	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-112.1454778326	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)onc1C	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)onc1C
NCGC00025345-02	O([C@H](CCNC)c1ccccc1)c1c(C)cccc1		Inactive	Serotonin transporter Inhibitor&Serotonin Transporter Inhibitor		1	Atomoxetine hydrochloride	170465067	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.041412156&-14.05944704	O([C@H](CCNC)c1ccccc1)c1c(C)cccc1.Cl	O([C@H](CCNC)c1ccccc1)c1c(C)cccc1.Cl
NCGC00178255-02	O([C@H]([C@@H]1N2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)ccc(OC)c2)C(=O)OCC	4.6750002	Active	Ferriprotoporphyrin Ix Antagonist&Ferriprotoporphyrin IX Antagonist	0.0	1	QUININE ETHYL CARBONATE	405558844	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-51.184279518&-52.3818717095	O([C@H]([C@@H]1N2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)ccc(OC)c2)C(=O)OCC	O([C@H]([C@@H]1N2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)ccc(OC)c2)C(=O)OCC
NCGC00181300-01	O([C@H]([C@H](OC(=O)CCC)COC(=O)CCC)[C@@H](OC(=O)CCC)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)C(=O)CCC	5.3499999	Active	Platelet Aggregation Inhibitor	0.0	1	Riboflavin tetrabutyrate	144206329	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-41.7902553632	O([C@H]([C@H](OC(=O)CCC)COC(=O)CCC)[C@@H](OC(=O)CCC)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)C(=O)CCC	O([C@H]([C@H](OC(=O)CCC)COC(=O)CCC)[C@@H](OC(=O)CCC)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)C(=O)CCC
NCGC00263839-02	O([C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1		Inactive	Staphylococcus Aureus Inhibitor&Staphylococcus aureus Inhibitor		1	Pentisomicin	170465779	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.203704448&18.4457605279	O([C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1	O([C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1
NCGC00483049-02	O([C@H]1[C@@](O)(C)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)C1C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	4.9499998	Active		0.0	1	Gamithromycin	405558723	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-81.7279121148&-81.8777397028	O([C@H]1[C@@](O)(C)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)C1C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@H]1[C@@](O)(C)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)C1C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00188433-02	O([C@H]1[C@H](O)[C@@H](NC)C[C@@H](N)[C@@H]1O)[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC3([C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O[C@H]12	4.75	Active	Ribosome-associated ATPase Inhibitor	0.0	1	Hygromycin B	405558855	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-106.9601560729	O([C@H]1[C@H](O)[C@@H](NC)C[C@@H](N)[C@@H]1O)[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC3([C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O[C@H]12	O([C@H]1[C@H](O)[C@@H](NC)C[C@@H](N)[C@@H]1O)[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC3([C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O[C@H]12
NCGC00160515-01	O([C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1		Inactive	alpha-Glucosidase Inhibitor		1	Acarbose	29216197	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.6384082919	O([C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1
NCGC00179504-05	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](C)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2	6.5	Inactive	DNA Topoisomerase II Inhibitor	0.0	1	Etoposide	225144306	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-68.7745305453	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](C)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](C)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2
NCGC00346563-03	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](c3sccc3)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2	6.0500002	Inactive	DNA Topoisomerase II Inhibitor	0.0	1	Teniposide	384568841	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-14.1437756	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](c3sccc3)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](c3sccc3)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2
NCGC00346608-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@@]4(C)O[C@@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1		Inactive	treatment of degenerative bone diseases		1	Astragaloside A	384568856	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@@]4(C)O[C@@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@@]4(C)O[C@@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1
NCGC00389762-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	4.4000001	Active		0.0	1	D-(+)-MALTOSE	405558630	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.51146662	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00160515-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1	5.1999998	Active	Alpha-glucosidase Inhibitors	0.0	1	Acarbose	170464784	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.9826754163	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1
NCGC00142605-05	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CO)cccc1		Inactive	Antiinflammatory agent		1	Salicin	384568166	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.299135528	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CO)cccc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CO)cccc1
NCGC00094874-05	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc2OC(=O)C=Cc2c1		Inactive	tumor necrosis factor production Inhibitor&Tumor Necrosis Factor Production Inhibitor		1	Esculin hydrate	225144214	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&26.5245141304	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc2OC(=O)C=Cc2c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc2OC(=O)C=Cc2c1
NCGC00246971-04	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(/C=C/c2ccc(O)cc2)c1		Inactive	V/ICAM1 Expression Inhibitor		1	Polydatin	363677157	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.93204236	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(/C=C/c2ccc(O)cc2)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(/C=C/c2ccc(O)cc2)c1
NCGC00163532-06	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC=C(c3ccc(O)cc3)C(=O)c2cc1		Inactive	Alcohol Dehydrogenase Inhibitor		1	Daidzin	384568245	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.8992418039	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC=C(c3ccc(O)cc3)C(=O)c2cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC=C(c3ccc(O)cc3)C(=O)c2cc1
NCGC00166076-07	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1	5.4499998	Active	Free Radical Scavenger	0.0	1	Arbutin	170465722	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-33.6967345119	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1
NCGC00179506-05	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1	5.4000001	Active	30s Ribosomal Protein Inhibitors	0.0	1	Kanamycin (sulfate)	405558981	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.12188052	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1
NCGC00183277-01	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H](CNC)O1		Inactive			1	Micronomicin sulfate	144206497	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.233328816	S(=O)(=O)(O)O.O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H](CNC)O1	S(=O)(=O)(O)O.O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H](CNC)O1
NCGC00142624-05&NCGC00142624-06	O([C@H]1[C@H](O)[C@@](O)(CO)O[C@@H]1CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1		Inactive	Synthetic sugar&Bacterial Growth Inducer&Synthetic sugar		2	Lactulose	170464861&384568168	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-12.1299084959&0.0&0.0	O([C@H]1[C@H](O)[C@@](O)(CO)O[C@@H]1CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@](O)(CO)O[C@@H]1CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1
NCGC00015769-14&NCGC00015769-32	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21	9.0	Inactive	Sodium/potassium-transporting ATPase subunit alpha-3 Inhibitor	0.0	2	Strophantine octahydrate&Ouabain octahydrate	384567888&405559108	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-21.1771530441&-4.983476776	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21
NCGC00179612-03	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1		Inactive	30s Ribosomal Protein Inhibitors&30S Ribosomal Protein Inhibitors		1	Neomycin sulfate	225144310	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.0923120321&-24.512242332	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1
NCGC00166210-02	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1		Inactive	Bacterial 70S ribosome Inhibitor&Bacterial 70s Ribosome Inhibitor		1	PAROMOMYCIN SULFATE	405559135	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	5.673742228&-11.779624504	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1
NCGC00178417-03	O([C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(O)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1		Inactive	Protein Disulfide-isomerase Inhibitor&Protein disulfide-isomerase Inhibitor		1	Ribostamycin sulfate	170465814	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.O([C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(O)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1	S(=O)(=O)(O)O.O([C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(O)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1
NCGC00482518-02	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1		Inactive	apoptotic process Inhibitor		1	Ginsenoside Rb1	384569259	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1
NCGC00263094-05	O(c1c(-c2nc(N)ncc2)cccn1)c1ccc(Nc2nnc(-c3scc(C)c3)c3c2cccc3)cc1	4.8000002	Active	Aurora-A/B/C Kinase Inhibitor	0.0	1	AMG-900	384568586	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-53.7893656625	O(c1c(-c2nc(N)ncc2)cccn1)c1ccc(Nc2nnc(-c3scc(C)c3)c3c2cccc3)cc1	O(c1c(-c2nc(N)ncc2)cccn1)c1ccc(Nc2nnc(-c3scc(C)c3)c3c2cccc3)cc1
NCGC00482879-02	O(c1c(C)cc(Nc2ncnc3c2cc(NC=2OCC(C)(C)N=2)cc3)cc1)C1=Cc2n(ncn2)C=C1	4.4000001	Active	HER2 Inhibitor	0.0	1	Tucatinib	377020215	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-101.001932857	O(c1c(C)cc(Nc2ncnc3c2cc(NC=2OCC(C)(C)N=2)cc3)cc1)C1=Cc2n(ncn2)C=C1	O(c1c(C)cc(Nc2ncnc3c2cc(NC=2OCC(C)(C)N=2)cc3)cc1)C1=Cc2n(ncn2)C=C1
NCGC00507888-01	O(c1c2nc(Nc3cc4[nH]cnc4cc3)ncc2ccc1)C1CCC(O)CC1	6.0500002	Active	TRAF2 and NCK-Interacting Protein Kinase (TNIK) Inhibitor;Wnt Signaling Inhibitor	0.0	1	NCB-1026	384569352	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-47.6679770078	O(c1c2nc(Nc3cc4[nH]cnc4cc3)ncc2ccc1)C1CCC(O)CC1	O(c1c2nc(Nc3cc4[nH]cnc4cc3)ncc2ccc1)C1CCC(O)CC1
NCGC00370768-04	O(c1cc(C)ccc1)C=1C=NC(=O)NC=1		Inactive	Lyn Kinase Activator		1	Tolimidone	363677843	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(c1cc(C)ccc1)C=1C=NC(=O)NC=1	O(c1cc(C)ccc1)C=1C=NC(=O)NC=1
NCGC00345792-02	O(c1cc2c(B(O)OC2)cc1)c1ccc(C#N)cc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	AN-2728	363677355	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O(c1cc2c(B(O)OC2)cc1)c1ccc(C#N)cc1	O(c1cc2c(B(O)OC2)cc1)c1ccc(C#N)cc1
NCGC00166146-02	O(c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1)C1CCCC1		Inactive	Estrogen Receptor Agonist&Estrogen receptor Agonist		1	Quinestrol	170465054	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.305713558&19.854139172	O(c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1)C1CCCC1	O(c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1)C1CCCC1
NCGC00370980-01	O(c1ccc(-c2c3c(N)ncnc3n(C3CCC(N4CCN(C)CC4)CC3)c2)cc1)c1ccccc1	4.75	Active	HCK Kinase Inhibitor	0.0	1	A-419259	384569038	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-102.9514615179	O(c1ccc(-c2c3c(N)ncnc3n(C3CCC(N4CCN(C)CC4)CC3)c2)cc1)c1ccccc1	O(c1ccc(-c2c3c(N)ncnc3n(C3CCC(N4CCN(C)CC4)CC3)c2)cc1)c1ccccc1
NCGC00344053-04	O(c1nc(Nc2ccc(N3CCOCC3)cc2)c2ncn(C3CCCCC3)c2n1)c1c2c(ccc1)cccc2		Inactive	lineage-specific differentiation enhancer		1	Purmorphamine	384568716	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.287939492	O(c1nc(Nc2ccc(N3CCOCC3)cc2)c2ncn(C3CCCCC3)c2n1)c1c2c(ccc1)cccc2	O(c1nc(Nc2ccc(N3CCOCC3)cc2)c2ncn(C3CCCCC3)c2n1)c1c2c(ccc1)cccc2
NCGC00346638-03	O(c1ncnc2[nH]c(-c3cc(N)ccc3)cc12)c1cc(O)ccc1		Inactive	GSK-3 beta Inhibitor		1	TWS-119	384568872	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.0699729959	O(c1ncnc2[nH]c(-c3cc(N)ccc3)cc12)c1cc(O)ccc1	O(c1ncnc2[nH]c(-c3cc(N)ccc3)cc12)c1cc(O)ccc1
NCGC00481574-01	O/C(=N\Cc1c(O)nc(C)cc1C)/c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	4.4000001	Active	EZH2 Inhibitor	0.0	1	GSK-503	384569256	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-53.742774524	O/C(=N\Cc1c(O)nc(C)cc1C)/c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	O/C(=N\Cc1c(O)nc(C)cc1C)/c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1
NCGC00319018-01	O/N=C(/[C@H](NCC(CN[C@@H](/C(=N/O)/C)C)(C)C)C)\C		Inactive			1	Exametazime	170465570	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O/N=C(/[C@H](NCC(CN[C@@H](/C(=N/O)/C)C)(C)C)C)\C	O/N=C(/[C@H](NCC(CN[C@@H](/C(=N/O)/C)C)(C)C)C)\C
NCGC00178286-05	O/N=C/c1[n+](C)cccc1		Inactive	Butyrylcholinesterase Activator		1	Pralidoxime chloride	170465059	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-19.645732304	O/N=C/c1[n+](C)cccc1.[Cl-]	O/N=C/c1[n+](C)cccc1.[Cl-]
NCGC00485891-01	O/N=C\1/C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC/1		Inactive	Progesterone receptor Agonist&Progesterone Receptor Agonist		1	Norgestimate metabolite Norelgestromin	363681397	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.4979119399&0.0	O/N=C\1/C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC/1	O/N=C\1/C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC/1
NCGC00263179-09	O/N=C\1/c2c(cc(-c3c(-c4ccncc4)nn(CCO)c3)cc2)CC/1		Inactive	Raf kinase B Inhibitor		1	AR-00341677	377020324	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O/N=C\1/c2c(cc(-c3c(-c4ccncc4)nn(CCO)c3)cc2)CC/1	O/N=C\1/c2c(cc(-c3c(-c4ccncc4)nn(CCO)c3)cc2)CC/1
NCGC00522633-01	O=C(/C=C/C=1[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CC=1)C	4.5999999	Active	NF-kappaB Activation Inhibitor	0.0	1	Xanthatin	384569534	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-108.8751077818	O=C(/C=C/C=1[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CC=1)C	O=C(/C=C/C=1[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CC=1)C
NCGC00249895-01	O=C(/C=C/C=C/1\C(C)(C)C2CC\1CC2)C		Inactive			1	Bornelone	170465560	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.3826310559&-13.798347256	O=C(/C=C/C=C/1\C(C)(C)C2CC\1CC2)C	O=C(/C=C/C=C/1\C(C)(C)C2CC\1CC2)C
NCGC00253590-01	O=C(/C=C/C=C/C(=C/C(O)CCCC)/C)N1C(=O)CCC1		Inactive			1	Variotin	170465957	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.667310192&-10.3415320159	O=C(/C=C/C=C/C(=C/C(O)CCCC)/C)N1C(=O)CCC1	O=C(/C=C/C=C/C(=C/C(O)CCCC)/C)N1C(=O)CCC1
NCGC00094872-13	O=C(/C=C/C=C/c1cc2OCOc2cc1)N1CCCCC1		Inactive	MAO-A/B Inhibitor		1	Piperine	384568138	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.63363396	O=C(/C=C/C=C/c1cc2OCOc2cc1)N1CCCCC1	O=C(/C=C/C=C/c1cc2OCOc2cc1)N1CCCCC1
NCGC00371001-05	O=C(/C=C/N1[C@H]2CN(c3ncccc3)[C@@H](C1)C2)c1c(O)cccc1	4.6500001	Active	SMARCA2 Inhibitor	0.0	1	PFI-3	384569039	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-58.5237593611	O=C(/C=C/N1[C@H]2CN(c3ncccc3)[C@@H](C1)C2)c1c(O)cccc1	O=C(/C=C/N1[C@H]2CN(c3ncccc3)[C@@H](C1)C2)c1c(O)cccc1
NCGC00017159-23	O=C(/C=C/c1cc(OC)c(O)cc1)CC(=O)/C=C/c1cc(OC)c(O)cc1	4.6500001	Active	NF-kappaB Activation Inhibitor	0.0	1	Curcumin	384567975	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-94.1024338679	O=C(/C=C/c1cc(OC)c(O)cc1)CC(=O)/C=C/c1cc(OC)c(O)cc1	O=C(/C=C/c1cc(OC)c(O)cc1)CC(=O)/C=C/c1cc(OC)c(O)cc1
NCGC00090504-14	O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O)cc1	4.4000001	Active	Histone Deacetylase/SIRT1 Activator	0.0	1	Isoliquiritigenin	384568078	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-114.5127303763	O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O)cc1	O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O)cc1
NCGC00025228-15	O=C(/C=C/c1ccccc1)c1c(O)c(Cc2c(O)c(C(=O)C)c(O)c(C)c2O)c(O)c2c1OC(C)(C)C=C2	5.5500002	Active		0.0	1	Rottlerin	384568060	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-41.5438936876	O=C(/C=C/c1ccccc1)c1c(O)c(Cc2c(O)c(C(=O)C)c(O)c(C)c2O)c(O)c2c1OC(C)(C)C=C2	O=C(/C=C/c1ccccc1)c1c(O)c(Cc2c(O)c(C(=O)C)c(O)c(C)c2O)c(O)c2c1OC(C)(C)C=C2
NCGC00032387-14	O=C(/C=C\1/N(CC)c2c(S/1)ccc(OC)c2)C		Inactive	Clk1, Clk4 Inhibitor		1	TG-003	384568071	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.9497239759	O=C(/C=C\1/N(CC)c2c(S/1)ccc(OC)c2)C	O=C(/C=C\1/N(CC)c2c(S/1)ccc(OC)c2)C
NCGC00378736-01	O=C(/C=C\c1cc(OC)c(OC)c(OC)c1)N1CCN(CC(=O)N2CCCC2)CC1	4.4000001	Active	Voltage-gated Calcium Channel Blocker	0.0	1	Cinepazide Maleate	405558463	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-53.96608209	O=C(/C=C\c1cc(OC)c(OC)c(OC)c1)N1CCN(CC(=O)N2CCCC2)CC1	O=C(/C=C\c1cc(OC)c(OC)c(OC)c1)N1CCN(CC(=O)N2CCCC2)CC1
NCGC00507865-01	O=C(C#CC)N1C[C@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CC1	4.75	Inactive	BTK Inhibitor	0.0	1	ONO-4059 (GS-4059)	384569340	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-62.1973081029	O=C(C#CC)N1C[C@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CC1	O=C(C#CC)N1C[C@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CC1
NCGC00479074-01	O=C(C#CC)N1[C@H](c2n3c(c(-c4ccc(C(=O)Nc5ncccc5)cc4)n2)C(N)=NC=C3)CCC1	4.75	Active	BTK Inhibitor	0.0	1	Acalabrutinib	363681103	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-36.669522112	O=C(C#CC)N1[C@H](c2n3c(c(-c4ccc(C(=O)Nc5ncccc5)cc4)n2)C(N)=NC=C3)CCC1	O=C(C#CC)N1[C@H](c2n3c(c(-c4ccc(C(=O)Nc5ncccc5)cc4)n2)C(N)=NC=C3)CCC1
NCGC00346623-04	O=C(C(=O)c1c-2c(OC)cc[nH]c-2nc1)N1[C@H](C)CN(C(=O)c2ccccc2)CC1		Inactive	HIV Attachment Inhibitor		1	BMS-378806	384568863	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(C(=O)c1c-2c(OC)cc[nH]c-2nc1)N1[C@H](C)CN(C(=O)c2ccccc2)CC1	O=C(C(=O)c1c-2c(OC)cc[nH]c-2nc1)N1[C@H](C)CN(C(=O)c2ccccc2)CC1
NCGC00496921-02	O=C(C(C)(C)C)N1[C@H](c2ccccc2)CC=N1		Inactive	RIP1 kinase Inhibitor		1	GSK-963	384569298	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(C(C)(C)C)N1[C@H](c2ccccc2)CC=N1	O=C(C(C)(C)C)N1[C@H](c2ccccc2)CC=N1
NCGC00016242-05	O=C(C(C)(C)c1cnccc1)c1cnccc1		Inactive	Cytochrome P450 11b1 Inhibitor&Cytochrome P450 11B1 Inhibitor		1	Metyrapone	170465268	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.126558256&-18.2576220279	O=C(C(C)(C)c1cnccc1)c1cnccc1	O=C(C(C)(C)c1cnccc1)c1cnccc1
NCGC00015542-07	O=C(C(C)C)c1c(C(C)C)nn2c1C=CC=C2		Inactive	Phosphodiesterase 4a Inhibitor&Phosphodiesterase 4A Inhibitor		1	Ibudilast	170466049	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(C(C)C)c1c(C(C)C)nn2c1C=CC=C2	O=C(C(C)C)c1c(C(C)C)nn2c1C=CC=C2
NCGC00249911-01	O=C(C(CCN(C)C)(c1ccccc1)c1ccccc1)CC	4.4499998	Inactive	Mu-type opioid receptor Agonist	0.0	1	Normethadone	170465674	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	74.6782339817	O=C(C(CCN(C)C)(c1ccccc1)c1ccccc1)CC	O=C(C(CCN(C)C)(c1ccccc1)c1ccccc1)CC
NCGC00178060-03	O=C(C(CN1CCCCC1)C)c1ccc(C)cc1	5.125	Active	Voltage-gated calcium channel Inhibitor&Voltage-gated Calcium Channel Inhibitor	0.0	1	Tolperisone hydrochloride	170465769	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4	-43.4461190268&-33.6997150886	O=C(C(CN1CCCCC1)C)c1ccc(C)cc1.Cl	O=C(C(CN1CCCCC1)C)c1ccc(C)cc1.Cl
NCGC00167973-02	O=C(C(CN1CCCCC1)C)c1ccc(CC)cc1	5.8000002	Active	skeletal muscle contraction Inhibitor	0.0	1	Eperisone hydrochloride	170465796	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-59.20454745	O=C(C(CN1CCCCC1)C)c1ccc(CC)cc1.Cl	O=C(C(CN1CCCCC1)C)c1ccc(CC)cc1.Cl
NCGC00167445-02	O=C(C(CN1CCN(CC(OCC)c2ccccc2)CC1)C)c1ccccc1	5.25	Active	Neurokinin 1 receptor Antagonist&Neurokinin 1 Receptor Antagonist	0.0	1	Eprazinone dihydrochloride	170465851	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-45.8578423495&-32.2694954679	O=C(C(CN1CCN(CC(OCC)c2ccccc2)CC1)C)c1ccccc1.Cl.Cl	O=C(C(CN1CCN(CC(OCC)c2ccccc2)CC1)C)c1ccccc1.Cl.Cl
NCGC00166322-02	O=C(C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)N1C(C(=O)N)CCC1		Inactive	Thyrotropin-releasing hormone receptor Agonist&Thyrotropin-releasing Hormone Receptor Agonist		1	PROTIRELIN	405558504	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-31.45368628	O=C(C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)N1C(C(=O)N)CCC1	O=C(C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)N1C(C(=O)N)CCC1
NCGC00091396-05	O=C(C(O)c1ccccc1)c1ccccc1		Inactive			1	Benzoin	170465507	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.613715708&15.46995424	O=C(C(O)c1ccccc1)c1ccccc1	O=C(C(O)c1ccccc1)c1ccccc1
NCGC00378575-03	O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2c3c(nccc3)ccc2)CC1	4.4000001	Active	MRP-1 Inhibitor	0.0	1	Dofequidar	384569050	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-65.442951284	O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2c3c(nccc3)ccc2)CC1	O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2c3c(nccc3)ccc2)CC1
NCGC00015785-10	O=C(C)C1C2(C)C(C3C(C4(C)C(=CC(=O)CC4)CC3)CC2)CC1	4.4000001	Active	Progestogen hormone	0.0	1	Progesterone	384567890	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-69.005241552	O=C(C)C1C2(C)C(C3C(C4(C)C(=CC(=O)CC4)CC3)CC2)CC1	O=C(C)C1C2(C)C(C3C(C4(C)C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00263129-08&NCGC00263129-31	O=C(C)C=1C(=O)N(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2C=1C	4.42499995	Active	CDK4/6 Inhibitor&Cdk4, 6 Inhibitor&CDK4/6 Inhibitor	0.04999969999999987	2	Palbociclib	405558929&384568610	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3&-3.0	-85.3640805704&-84.5759198195&-96.4696167839	O=C(C)C=1C(=O)N(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2C=1C	O=C(C)C=1C(=O)N(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2C=1C
NCGC00510264-02	O=C(C)N1CCC(Nc2ncnc(C(=O)NC[C@H](O)CN3Cc4c(cccc4)CC3)c2)CC1		Inactive	PRMT5 Inhibitor		1	GSK-3326595	384569422	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(C)N1CCC(Nc2ncnc(C(=O)NC[C@H](O)CN3Cc4c(cccc4)CC3)c2)CC1	O=C(C)N1CCC(Nc2ncnc(C(=O)NC[C@H](O)CN3Cc4c(cccc4)CC3)c2)CC1
NCGC00346955-02	O=C(C)N1CCN(C2CCC(n3nc(-c4cc(OC)c(NC(=O)c5n(C)c6c(c5)cccc6)cc4)c4c(N)ncnc34)CC2)CC1	4.9000001	Active	Lck Kinase Inhibitor	0.0	1	A-770041	384568976	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-48.46214061	O=C(C)N1CCN(C2CCC(n3nc(-c4cc(OC)c(NC(=O)c5n(C)c6c(c5)cccc6)cc4)c4c(N)ncnc34)CC2)CC1	O=C(C)N1CCN(C2CCC(n3nc(-c4cc(OC)c(NC(=O)c5n(C)c6c(c5)cccc6)cc4)c4c(N)ncnc34)CC2)CC1
NCGC00387224-01	O=C(C)N1[C@H](C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2		Inactive	Kainate Receptor Antagonist		1	Ampanel	363680579	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	28.994949044	O=C(C)N1[C@H](C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2	O=C(C)N1[C@H](C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2
NCGC00022185-14	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1	4.4000001	Active	Progestogen Hormone&Progestogen hormone	0.0	1	Progesterone	405559122	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-67.522382756&-85.801909772	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00163125-06&NCGC00163125-13	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1		Inactive	Steroid		2	Pregnenolone	170465558&384568230	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&22.463261036&0.0	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1
NCGC00179460-03	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)CC2)CC1	4.4000001	Active	Glucocorticoid Receptor Agonist	0.0	1	Medrysone	170465194	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-70.235844348	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)CC2)CC1
NCGC00179445-03	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1	6.1500001	Active	Signaling/transport	0.0	1	Dydrogesterone	170465104	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-34.9741423394	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1
NCGC00390270-02	O=C(C)[C@@]1(N)C[C@H](O[C@@H]2OC[C@@H](O)[C@@H](O)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4		Inactive	DNA Topoisomerase II Inhibitor		1	Amrubicin	384569184	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(C)[C@@]1(N)C[C@H](O[C@@H]2OC[C@@H](O)[C@@H](O)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4	O=C(C)[C@@]1(N)C[C@H](O[C@@H]2OC[C@@H](O)[C@@H](O)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4
NCGC00510144-01	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1		Inactive			1	Gestonorone	405558510	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-33.5557916119&-22.968164412	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00023064-05	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1	4.4000001	Active		0.0	1	Medroxyprogesterone	170466063	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.499884548	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1
NCGC00016634-04	O=C(C)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	4.4749999	Active		0.0	1	Acetopromazine maleate	170465731	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-81.959670566&-81.0294331561	O=C(O)/C=C\C(=O)O.O=C(C)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	O=C(O)/C=C\C(=O)O.O=C(C)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3
NCGC00016642-04	O=C(C)c1cc2N(CCCN3CCC(CCO)CC3)c3c(Sc2cc1)cccc3	4.8499999	Active		0.0	1	Piperacetazine	170465363	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-71.4809911068&-108.1357578399	O=C(C)c1cc2N(CCCN3CCC(CCO)CC3)c3c(Sc2cc1)cccc3	O=C(C)c1cc2N(CCCN3CCC(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00181120-02	O=C(C)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	5.4000001	Active	Sigma Opioid Receptor Antagonist	0.0	1	Acetophenazine Maleate	405558986	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-62.6608830904	O=C(C)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	O=C(C)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00390475-03	O=C(C)c1oc2C(=O)c3c(C(=O)c2c1)cccc3	4.4000001	Active	STAT-3 Inhibitor	0.0	1	Napabucasin	384569185	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-82.4589736439	O=C(C)c1oc2C(=O)c3c(C(=O)c2c1)cccc3	O=C(C)c1oc2C(=O)c3c(C(=O)c2c1)cccc3
NCGC00522022-01	O=C(C)c1oc2c(OCC(O)CNC(C)C)cccc2c1	4.5	Active	Adrenergic receptor beta Antagonist	0.0	1	Befunolol	405558805	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.9524768403	O=C(C)c1oc2c(OCC(O)CNC(C)C)cccc2c1	O=C(C)c1oc2c(OCC(O)CNC(C)C)cccc2c1
NCGC00387861-02	O=C(C=C)N1CC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	4.625	Active	Btk/lck/lyn Inhibitor&Btk/Lck/Lyn inhibitor	0.0	1	NCGC00387861-02&PCI-32765 (Ibrutinib)	405559011	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-79.5853432088&-83.682048756	O=C(C=C)N1CC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	O=C(C=C)N1CC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1
NCGC00510501-01	O=C(C=C)N1CCC(C2n3nc(c(C(=O)N)c3NCC2)-c2ccc(Oc3ccccc3)cc2)CC1	4.4000001	Active	BTK Inhibitor	0.0	1	BGB-3111	384569462	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-44.121150532	O=C(C=C)N1CCC(C2n3nc(c(C(=O)N)c3NCC2)-c2ccc(Oc3ccccc3)cc2)CC1	O=C(C=C)N1CCC(C2n3nc(c(C(=O)N)c3NCC2)-c2ccc(Oc3ccccc3)cc2)CC1
NCGC00510507-01	O=C(C=C)N1CCC(CNc2c(c(N)ncn2)-c2ccc(Oc3ccccc3)cc2)CC1		Inactive	BTK Inhibitor		1	Evobrutinib	384569468	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.029402768	O=C(C=C)N1CCC(CNc2c(c(N)ncn2)-c2ccc(Oc3ccccc3)cc2)CC1	O=C(C=C)N1CCC(CNc2c(c(N)ncn2)-c2ccc(Oc3ccccc3)cc2)CC1
NCGC00480771-01	O=C(C=C)N1C[C@@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	4.4000001	Active	BTK Inhibitor	0.0	1	ONO-4059 analog	384569241	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-50.205141664	O=C(C=C)N1C[C@@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	O=C(C=C)N1C[C@@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1
NCGC00507838-01	O=C(C=C)N1C[C@H](Oc2c(CC)nc(C(=O)N)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)n2)CC1	5.5	Active	EGFR (Thr790Met Mutant) Inhibitor	0.0	1	Naquotinib mesylate	384569321	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-96.2789354338	O=C(C=C)N1C[C@H](Oc2c(CC)nc(C(=O)N)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)n2)CC1	O=C(C=C)N1C[C@H](Oc2c(CC)nc(C(=O)N)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)n2)CC1
NCGC00187912-13	O=C(C=C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1		Inactive	BTK Inhibitor		1	Ibrutinib (PCI-32765)	384568446	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(C=C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	O=C(C=C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1
NCGC00501213-01	O=C(C=C)N1[C@@H](C)CC[C@@H](Nc2ncnc3[nH]ccc23)C1		Inactive	Jak3		1	PF-06651600	384569312	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(C=C)N1[C@@H](C)CC[C@@H](Nc2ncnc3[nH]ccc23)C1	O=C(C=C)N1[C@@H](C)CC[C@@H](Nc2ncnc3[nH]ccc23)C1
NCGC00229511-10&NCGC00229511-21	O=C(CC#N)N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1	4.4000001	Active	Tyrosine-protein Kinase Jak3 Inhibitor&Jak1/2/3 Inhibitor	0.0	2	Tofacitinib	405558458&384568461	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-31.941521788&-63.675270556	O=C(CC#N)N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1	O=C(CC#N)N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1
NCGC00095112-05&NCGC00095112-07	O=C(CC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OC)cc1		Inactive	UVA ray absorber&Free Radical Scavenger&UVA ray absorber		2	Avobenzone	170464749&384568146	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-27.42556432&0.0&0.0	O=C(CC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OC)cc1	O=C(CC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OC)cc1
NCGC00094810-08	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1O)cccc2)C		Inactive	Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitor		1	Warfarin sodium	384568136	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1O)cccc2)C	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1O)cccc2)C
NCGC00094810-04	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1[O-])cccc2)C		Inactive	Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitor&Vitamin K Epoxide Reductase (vker, Vkor) Inhibitor		1	Warfarin sodium	170464790	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.695497696&-24.8681197879	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1[O-])cccc2)C.[K+]	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1[O-])cccc2)C.[K+]
NCGC00510508-01	O=C(CC)N1Cc2c(c(C(=O)N[C@@H]3CN(C)CCC3)cc(-c3cc(OC)cc(OC)c3)c2)OCC1		Inactive	CBP/p300 Inhibitor		1	TPOP-146	384569469	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-30.273375152	O=C(CC)N1Cc2c(c(C(=O)N[C@@H]3CN(C)CCC3)cc(-c3cc(OC)cc(OC)c3)c2)OCC1	O=C(CC)N1Cc2c(c(C(=O)N[C@@H]3CN(C)CCC3)cc(-c3cc(OC)cc(OC)c3)c2)OCC1
NCGC00094817-05	O=C(CC)c1c(O)cc(O)cc1O		Inactive	Catechol O-methyltransferase Inhibitor		1	Flopropione	170465817	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.427495876&0.0	O=C(CC)c1c(O)cc(O)cc1O	O=C(CC)c1c(O)cc(O)cc1O
NCGC00015838-06	O=C(CC)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	4.4499998	Active	Trypanothione reductase Inhibitor&Trypanothione Reductase Inhibitor	0.0	1	Propionylpromazine hydrochloride	170466841	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-96.2202656207&-106.2158408279	O=C(CC)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl	O=C(CC)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl
NCGC00018097-06	O=C(CC)c1ccc(O)cc1		Inactive	Succinate Semialdehyde Dehydrogenase Inhibitor&Succinate semialdehyde dehydrogenase Inhibitor		1	Paroxypropione	170465896	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.177728072&0.0	O=C(CC)c1ccc(O)cc1	O=C(CC)c1ccc(O)cc1
NCGC00508867-01	O=C(CC1=NC(=O)C=C(N2CCOCC2)N1)N1C(C)Cc2c1cccc2		Inactive	PI3Kbeta Inhibitor		1	SAR-260301	384569367	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.4358125519	O=C(CC1=NC(=O)C=C(N2CCOCC2)N1)N1C(C)Cc2c1cccc2	O=C(CC1=NC(=O)C=C(N2CCOCC2)N1)N1C(C)Cc2c1cccc2
NCGC00015606-06	O=C(CC1N(C)C(CC(O)c2ccccc2)CCC1)c1ccccc1	5.75	Active	Synaptic vesicular amine transporter Inhibitor	0.0	1	LOBELINE HYDROCHLORIDE	405558910	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-69.1414377603	O=C(CC1N(C)C(CC(O)c2ccccc2)CCC1)c1ccccc1	O=C(CC1N(C)C(CC(O)c2ccccc2)CCC1)c1ccccc1
NCGC00510940-01	O=C(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)C		Inactive	Cyclooxygenase Inhibitor		1	Kebuzone	405558634	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.190358072&-23.062037112	O=C(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)C	O=C(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)C
NCGC00182034-01	O=C(CCC=C(CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)C)C		Inactive	Heat Shock 70 Kda Protein 1 Modulator&Heat shock 70 kDa protein 1 Modulator		1	Teprenone	144206513	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.987179636&-26.6389295159	O=C(CCC=C(CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)C)C	O=C(CCC=C(CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)C)C
NCGC00015801-12	O=C(CCCCN1C(=O)N(C)c2ncn(C)c2C1=O)C	4.5	Active	3',5'-cyclic Phosphodiesterase Inhibitor	0.0	1	Pentoxifylline	170465384	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-38.6759463164	O=C(CCCCN1C(=O)N(C)c2ncn(C)c2C1=O)C	O=C(CCCCN1C(=O)N(C)c2ncn(C)c2C1=O)C
NCGC00015861-09	O=C(CCCCN1C(=O)N(C)c2ncn(CCC)c2C1=O)C		Inactive	Adenosine Receptor Modulator&Adenosine receptor Modulator		1	Propentofylline	170465624	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.30092324&0.0	O=C(CCCCN1C(=O)N(C)c2ncn(CCC)c2C1=O)C	O=C(CCCCN1C(=O)N(C)c2ncn(CCC)c2C1=O)C
NCGC00164603-04	O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccc(C(C)(C)C)cc1	4.625	Active	Histamine H1 Receptor Antagonist&Histamine H1 receptor Antagonist	0.0	1	Ebastine	170465995	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-112.2257967421&-53.6248213006	O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccc(C(C)(C)C)cc1	O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccc(C(C)(C)C)cc1
NCGC00016831-09	O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC		Inactive	vasodilator		1	Buflomedil hydrochloride	384567962	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.4596257159	O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC	O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC
NCGC00016107-09	O=C(CCN(C(C)C)Cc1ccccc1)c1cc2c(cc1)cccc2	4.6999998	Active	Jak1/3 Inhibitor	0.0	1	ZM-39923	363676477	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-36.5249064307	O=C(CCN(C(C)C)Cc1ccccc1)c1cc2c(cc1)cccc2	O=C(CCN(C(C)C)Cc1ccccc1)c1cc2c(cc1)cccc2
NCGC00016498-08	O=C(CCN1CCCCC1)c1ccc(OCCCC)cc1	4.875	Active	Sodium channel protein type II alpha subunit Inhibitor&Sodium Channel Protein Type Ii Alpha Subunit Inhibitor	0.0	1	Dyclonine hydrochloride	170464776	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-3.0	-41.7943427255&-61.6813619919	O=C(CCN1CCCCC1)c1ccc(OCCCC)cc1.Cl	O=C(CCN1CCCCC1)c1ccc(OCCCC)cc1.Cl
NCGC00182060-03	O=C(CCN[C@H]([C@H](O)c1ccccc1)C)c1cc(OC)ccc1	4.9000001	Active	Adrenergic Receptor Beta Partial Agonist&Adrenergic receptor beta Partial Agonist	0.0	1	l-Oxyfedrine hydrochloride	170465929	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-44.0270046467&-52.3144863256	O=C(CCN[C@H]([C@H](O)c1ccccc1)C)c1cc(OC)ccc1.Cl	O=C(CCN[C@H]([C@H](O)c1ccccc1)C)c1cc(OC)ccc1.Cl
NCGC00484075-02	O=C(CCO)N1CCC(c2nn(CC)c(-c3nc(c(N)nc3)-c3oc(C(C)(C)C)nn3)n2)CC1	5.3000002	Active	PI3Ka/d Inhibitor	0.0	1	AZD-8835	384569269	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-54.8363521112	O=C(CCO)N1CCC(c2nn(CC)c(-c3nc(c(N)nc3)-c3oc(C(C)(C)C)nn3)n2)CC1	O=C(CCO)N1CCC(c2nn(CC)c(-c3nc(c(N)nc3)-c3oc(C(C)(C)C)nn3)n2)CC1
NCGC00016853-06	O=C(CCc1cc2c(cc(OC)cc2)cc1)C		Inactive	Cyclooxygenase-2 Inhibitor		1	Nabumetone	170464970	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(CCc1cc2c(cc(OC)cc2)cc1)C	O=C(CCc1cc2c(cc(OC)cc2)cc1)C
NCGC00015840-09	O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O		Inactive	VCAM1 Expression Inhibitor		1	Phloretin	174006856	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.8922055599	O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O	O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O
NCGC00142423-05&NCGC00142423-06	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O		Inactive	SGLT-1/2 Inhibitor&Sglt-1/2 Inhibitor&SGLT-1/2 Inhibitor		2	Phlorizin	384568163&405558498	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	5.3775875479&0.0&-19.988658064	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O
NCGC00015819-15&NCGC00015819-17	O=C(CCc1ccccc1)c1c(OCC(O)CNCCC)cccc1	4.5	Active	Potassium Channel Subfamily K Member 3 (TASK-1; KCNK3) Blocker&Anti-arrythmia Drug&Potassium Channel Subfamily K Member 3 (TASK-1; KCNK3) Blocker	0.10000040000000077	2	Propafenone hydrochloride	170464755&384567894	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0&-2.2	-78.8985955068&-58.603527844&-65.5786998463	O=C(CCc1ccccc1)c1c(OCC(O)CNCCC)cccc1	O=C(CCc1ccccc1)c1c(OCC(O)CNCCC)cccc1
NCGC00160484-02	O=C(CCc1ccccc1)c1c(OCCN(CC)CC)cccc1	4.5999999	Active	Vascular Smooth Muscle Contraction Inhibitor&vascular smooth muscle contraction Inhibitor	0.0	1	Etafenone	170466000	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-75.08245246&-44.7803358848	O=C(CCc1ccccc1)c1c(OCCN(CC)CC)cccc1	O=C(CCc1ccccc1)c1c(OCCN(CC)CC)cccc1
NCGC00345853-03	O=C(CN(C)C)N1CCC(c2cc(c(NC(=O)c3[nH]cc(C#N)n3)cc2)C2=CCCCC2)CC1	4.5	Active	CSF1R (c-FMS) Inhibitor	0.0	1	JNJ-28312141	384568768	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-78.3617218584	O=C(CN(C)C)N1CCC(c2cc(c(NC(=O)c3[nH]cc(C#N)n3)cc2)C2=CCCCC2)CC1	O=C(CN(C)C)N1CCC(c2cc(c(NC(=O)c3[nH]cc(C#N)n3)cc2)C2=CCCCC2)CC1
NCGC00015836-12	O=C(CN1CCN(C)CC1)N1c2ncccc2NC(=O)c2c1cccc2		Inactive	Muscarinic Acetylcholine Receptor M1 Antagonist&Muscarinic acetylcholine receptor M1 Antagonist		1	Pirenzepine	170465793	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.316756388&-14.7126707159	O=C(CN1CCN(C)CC1)N1c2ncccc2NC(=O)c2c1cccc2	O=C(CN1CCN(C)CC1)N1c2ncccc2NC(=O)c2c1cccc2
NCGC00350780-09	O=C(CN1C[C@H](C(=O)Nc2cc3c(-c4ccncc4)n[nH]c3cc2)CC1)N1CCN(c2ccc(-c3ncccn3)cc2)CC1	4.4000001	Active	ERK1/2 Inhibitor	0.0	1	SCH-772984	384569005	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-55.9375046072	O=C(CN1C[C@H](C(=O)Nc2cc3c(-c4ccncc4)n[nH]c3cc2)CC1)N1CCN(c2ccc(-c3ncccn3)cc2)CC1	O=C(CN1C[C@H](C(=O)Nc2cc3c(-c4ccncc4)n[nH]c3cc2)CC1)N1CCN(c2ccc(-c3ncccn3)cc2)CC1
NCGC00386200-02	O=C(CNC12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)CCC1		Inactive	Dipeptidyl Peptidase Iv Inhibitor&Dipeptidyl peptidase IV Inhibitor		1	Vildagliptin	405558787	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.9014044199&0.0	O=C(CNC12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)CCC1	O=C(CNC12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)CCC1
NCGC00510354-01	O=C(CNCC(CC)C)N1C(c2nc(C)ccc2)c2c(scc2)CC1	4.5	Active	Protein-Cysteine N-Palmitoyltransferase HHAT Inhibitor	0.0	1	RUSKI-201	384569429	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-48.4362429102	O=C(CNCC(CC)C)N1C(c2nc(C)ccc2)c2c(scc2)CC1	O=C(CNCC(CC)C)N1C(c2nc(C)ccc2)c2c(scc2)CC1
NCGC00384220-02	O=C(CO)N1Cc2c(nc(Nc3nc4n(C5CCC(C)CC5)c5c(c4cn3)ccnc5)cc2)CC1		Inactive	CDK4/6 Inhibitor		1	AMG-925 (FLX925)	384569107	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(CO)N1Cc2c(nc(Nc3nc4n(C5CCC(C)CC5)c5c(c4cn3)ccnc5)cc2)CC1	O=C(CO)N1Cc2c(nc(Nc3nc4n(C5CCC(C)CC5)c5c(c4cn3)ccnc5)cc2)CC1
NCGC00024415-57	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	9.0	Inactive	DNA Topoisomerase II Inhibitor	0.0	1	Doxorubicin	384568027	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	37.18502192	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1
NCGC00182851-02&NCGC00182851-05	O=C(CO)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid		2	Meprednisone	170465165&384568411	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-13.6741096799	O=C(CO)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	O=C(CO)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00242505-01	O=C(CO)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3		Inactive	Glucocorticoid Receptor (GR) Agonist		1	Deacetyl cortivazol	137275859	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(CO)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3	O=C(CO)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3
NCGC00090766-07&NCGC00090766-15	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)C(=O)C2)CC1		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid		2	Prednisone	170464847&384568085	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-26.88340302&-11.689091452	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)C(=O)C2)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)C(=O)C2)CC1
NCGC00179649-06&NCGC00179649-13	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1	5.5	Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid	0.0	2	Prednisolone	170464732&384568381	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	0.0&0.0&95.0774525409	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1
NCGC00022848-17&NCGC00022848-25	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1		Inactive	immunosuppressant&Glucocorticoid Receptor Agonist&immunosuppressant		2	Hydrocortisone	170464635&384568014	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1
NCGC00022735-06&NCGC00022735-16	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1		Inactive	Glucocorticoid Receptor Antagonist&Glucocorticoid steroid&Glucocorticoid steroid		2	Methylprednisolone	170465051&384568013	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1
NCGC00161834-01	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC1OC(CCC)O2	4.4000001	Active	Glucocorticoid steroid	0.0	1	Budesonide	26755470	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-54.335443412	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC1OC(CCC)O2	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC1OC(CCC)O2
NCGC00274065-01&NCGC00274065-06	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)(C)O2		Inactive	Corticosteroid		2	Desonide	174007408&384568711	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&11.177612296&0.0	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)(C)O2	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)(C)O2
NCGC00021318-08	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(CCC)O2		Inactive	Glucocorticoid Receptor Antagonist&Glucocorticoid steroid		1	Budesonide	405558701	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-26.0772814839	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(CCC)O2	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(CCC)O2
NCGC00249927-01	O=C(COc1c(OC)cc(CCC)cc1)N1CCN(C(=O)COc2c(OC)cc(CCC)cc2)CC1		Inactive			1	Simetride	170466023	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(COc1c(OC)cc(CCC)cc1)N1CCN(C(=O)COc2c(OC)cc(CCC)cc2)CC1	O=C(COc1c(OC)cc(CCC)cc1)N1CCN(C(=O)COc2c(OC)cc(CCC)cc2)CC1
NCGC00378744-02	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2C(c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC		Inactive	Serotonin 2b (5-HT2b) receptor Agonist		1	Cabergoline	384569067	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.807606344	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2C(c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2C(c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC
NCGC00344544-01	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC	4.7750001	Active	Serotonin 2b (5-ht2b) Receptor Agonist&Serotonin 2b (5-HT2b) receptor Agonist	0.0	1	Cabergoline	170464667	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-97.9259701699&-69.1154434747	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC
NCGC00016382-07	O=C(N(C(Cc1ccccc1)(C)C)C)CN(CC(=O)N(C(Cc1ccccc1)(C)C)C)CCO	4.4250002	Active		0.0	1	Oxethazaine	170465643	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-70.0015181884&-95.609117712	O=C(N(C(Cc1ccccc1)(C)C)C)CN(CC(=O)N(C(Cc1ccccc1)(C)C)C)CCO	O=C(N(C(Cc1ccccc1)(C)C)C)CN(CC(=O)N(C(Cc1ccccc1)(C)C)C)CCO
NCGC00249935-01	O=C(N(C)C)CN(C(=O)C)c1ccccc1		Inactive			1	Phenylacetylglycine dimethylamide	170465887	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&12.7963692399	O=C(N(C)C)CN(C(=O)C)c1ccccc1	O=C(N(C)C)CN(C(=O)C)c1ccccc1
NCGC00346648-05	O=C(N(C)C)Nc1ccc(-c2c(-c3c4c([nH]c(-c5cc(CN(C)C)ccc5)c4)ncc3)cn(CC)n2)cc1	4.6999998	Active	Aurora-B/C Inhibitor	0.0	1	GSK-1070916A	384568879	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-48.3233715321	O=C(N(C)C)Nc1ccc(-c2c(-c3c4c([nH]c(-c5cc(CN(C)C)ccc5)c4)ncc3)cn(CC)n2)cc1	O=C(N(C)C)Nc1ccc(-c2c(-c3c4c([nH]c(-c5cc(CN(C)C)ccc5)c4)ncc3)cn(CC)n2)cc1
NCGC00346544-09	O=C(N(C)C)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	4.4000001	Active	Mek 5 Inhibitor	0.0	1	BIX-02189	384568830	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-66.763214668	O=C(N(C)C)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	O=C(N(C)C)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1
NCGC00510683-01	O=C(N(C)C)c1ncc(Oc2c3c(oc(C)c3)cc(C(=O)Nc3ncc(C)nc3)c2)cn1		Inactive	Glucokinase Activator		1	PF-04937319	384569477	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N(C)C)c1ncc(Oc2c3c(oc(C)c3)cc(C(=O)Nc3ncc(C)nc3)c2)cn1	O=C(N(C)C)c1ncc(Oc2c3c(oc(C)c3)cc(C(=O)Nc3ncc(C)nc3)c2)cn1
NCGC00345083-01	O=C(N(C)C1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5C(=O)NC(=O)c5c4c4c3cccc4)cccc2)C1)c1ccccc1	4.0500002	Inactive	lineage-specific differentiation enhancer	0.0	1	Stauprimide	174007178	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	54.7599948241	O=C(N(C)C1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5C(=O)NC(=O)c5c4c4c3cccc4)cccc2)C1)c1ccccc1	O=C(N(C)C1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5C(=O)NC(=O)c5c4c4c3cccc4)cccc2)C1)c1ccccc1
NCGC00185750-01	O=C(N(C)[C@@H]1[C@@H](OC)[C@@H](O)[C@H](N)[C@@H](O[C@@H]2[C@H](N)CC[C@@H]([C@@H](N)C)O2)[C@@H]1O)CN	4.4000001	Active	Bacterial 70s Ribosome Binding Agent	0.0	1	Astromicin	144206938	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-58.181269784	O=C(N(C)[C@@H]1[C@@H](OC)[C@@H](O)[C@H](N)[C@@H](O[C@@H]2[C@H](N)CC[C@@H]([C@@H](N)C)O2)[C@@H]1O)CN	O=C(N(C)[C@@H]1[C@@H](OC)[C@@H](O)[C@H](N)[C@@H](O[C@@H]2[C@H](N)CC[C@@H]([C@@H](N)C)O2)[C@@H]1O)CN
NCGC00241102-08	O=C(N(C)[C@H]1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5c(C(=O)NC5)c4c4c3cccc4)cccc2)C1)c1ccccc1	4.8000002	Active	PKC/flt3 Inhibitor	0.0	1	Midostaurin	384568472	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-45.3795540608	O=C(N(C)[C@H]1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5c(C(=O)NC5)c4c4c3cccc4)cccc2)C1)c1ccccc1	O=C(N(C)[C@H]1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5c(C(=O)NC5)c4c4c3cccc4)cccc2)C1)c1ccccc1
NCGC00390266-01	O=C(N(C)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1)/C=C/c1cocc1		Inactive	Kappa opioid receptor Agonist		1	Nalfurafine hydrochloride	405558567	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.529127752&16.4067096079	O=C(N(C)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1)/C=C/c1cocc1	O=C(N(C)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1)/C=C/c1cocc1
NCGC00025172-03	O=C(N(C)c1ccccc1)C=1C(=O)N(C)c2c(C=1O)cccc2	6.0500002	Inactive	Immunostimulant	0.0	1	Roquinimex	384568053	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-57.1901906041	O=C(N(C)c1ccccc1)C=1C(=O)N(C)c2c(C=1O)cccc2	O=C(N(C)c1ccccc1)C=1C(=O)N(C)c2c(C=1O)cccc2
NCGC00345798-03	O=C(N(C1CC1)C1CC1)c1n(CC)c2nc(Nc3nn(C)c(C)c3)c3ncn(C)c3c2c1		Inactive	Jak2 Inhibitor		1	BMS-911543	384568747	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.9602395159	O=C(N(C1CC1)C1CC1)c1n(CC)c2nc(Nc3nn(C)c(C)c3)c3ncn(C)c3c2c1	O=C(N(C1CC1)C1CC1)c1n(CC)c2nc(Nc3nn(C)c(C)c3)c3ncn(C)c3c2c1
NCGC00178778-07	O=C(N(CC)CC)N1CCN(C)CC1		Inactive			1	DIETHYLCARBAMAZINE CITRATE	405559090	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.228659296&24.434708468	O=C(N(CC)CC)N1CCN(C)CC1	O=C(N(CC)CC)N1CCN(C)CC1
NCGC00179663-03	O=C(N(CC)CC)N[C@@H]1C=C2[C@@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive	Dopamine D5 Receptor Agonist&Dopamine D5 receptor Agonist		1	(-)-(5S,8R)-Lisuride	170465966	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N(CC)CC)N[C@@H]1C=C2[C@@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N(CC)CC)N[C@@H]1C=C2[C@@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00094476-03	O=C(N(CC)CC)N[C@@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	4.6750002	Active	Serotonin 1a (5-HT1a) receptor Antagonist&Serotonin 1a (5-ht1a) Receptor Antagonist	0.0	1	Terguride	144204835	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-60.1029711351&-48.6009123519	O=C(N(CC)CC)N[C@@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	O=C(N(CC)CC)N[C@@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1
NCGC00344562-01	O=C(N(CC)CC)Nc1cc(C(=O)C)c(OCC(O)CNC(C)(C)C)cc1	5.1500001	Active	Beta-2 Adrenergic Receptor Partial Agonist	0.0	1	Celiprolol hydrochloride	170465958	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-60.3144153953	O=C(N(CC)CC)Nc1cc(C(=O)C)c(OCC(O)CNC(C)(C)C)cc1.Cl	O=C(N(CC)CC)Nc1cc(C(=O)C)c(OCC(O)CNC(C)(C)C)cc1.Cl
NCGC00165825-02	O=C(N(CC)CC)[C@]1([C@@H](CN)C1)c1ccccc1	4.5250001	Active	Serotonin transporter Inhibitor&Serotonin Transporter Inhibitor	0.0	1	Milnacipran hydrochloride	225144261	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-49.9036955104&-45.804195075	O=C(N(CC)CC)[C@]1([C@@H](CN)C1)c1ccccc1	O=C(N(CC)CC)[C@]1([C@@H](CN)C1)c1ccccc1
NCGC00091219-08	O=C(N(CC)CC)c1cc(C)ccc1		Inactive			1	DEET	170466080	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-34.5727718659&-26.8167868119	O=C(N(CC)CC)c1cc(C)ccc1	O=C(N(CC)CC)c1cc(C)ccc1
NCGC00346641-07	O=C(N(CC)CC)c1ccc(C=2c3c(O)cccc3OC3(C=2)CCNCC3)cc1		Inactive	delta-Opioid Agonist		1	ADL-5859	363677491	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.4415346	O=C(N(CC)CC)c1ccc(C=2c3c(O)cccc3OC3(C=2)CCNCC3)cc1	O=C(N(CC)CC)c1ccc(C=2c3c(O)cccc3OC3(C=2)CCNCC3)cc1
NCGC00016065-11	O=C(N(CC)Cc1ccncc1)C(CO)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor M3 Antagonist&Muscarinic acetylcholine receptor M3 Antagonist		1	Tropicamide	170464754	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.584377392	O=C(N(CC)Cc1ccncc1)C(CO)c1ccccc1	O=C(N(CC)Cc1ccncc1)C(CO)c1ccccc1
NCGC00094571-10	O=C(N(CC)c1c(C)cccc1)/C=C/C		Inactive	antipruritic		1	Crotamiton	384568131	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.250627016	O=C(N(CC)c1c(C)cccc1)/C=C/C	O=C(N(CC)c1c(C)cccc1)/C=C/C
NCGC00094571-08	O=C(N(CC)c1c(C)cccc1)C=CC	5.5	Active	Antipruritic	0.0	1	Crotamiton	170464851	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-45.0639151719	O=C(N(CC)c1c(C)cccc1)C=CC	O=C(N(CC)c1c(C)cccc1)C=CC
NCGC00510699-01	O=C(N(CC)c1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	GSK9311	384569485	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.341891568	O=C(N(CC)c1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(N(CC)c1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00390606-01	O=C(N(CC1=NC2=C(C(=O)N1)COCC2)CC1CC1)CN1CCC(C(=O)c2ccc(OC)cc2)CC1	5.5500002	Inactive	Tachykinin NK2 Antagonist	0.0	1	TNKS-656	363680925	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	59.2347864663	O=C(N(CC1=NC2=C(C(=O)N1)COCC2)CC1CC1)CN1CCC(C(=O)c2ccc(OC)cc2)CC1	O=C(N(CC1=NC2=C(C(=O)N1)COCC2)CC1CC1)CN1CCC(C(=O)c2ccc(OC)cc2)CC1
NCGC00015623-10&NCGC00015623-11	O=C(N(CCC)CCC)C(NC(=O)c1ccccc1)CCC(=O)O		Inactive	Cholecystokinin B receptor Antagonist&Cholecystokinin B Receptor Antagonist&Cholecystokinin B receptor Antagonist		2	Proglumide	170465774&384567877	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&13.4949638&8.1064242439	O=C(N(CCC)CCC)C(NC(=O)c1ccccc1)CCC(=O)O	O=C(N(CCC)CCC)C(NC(=O)c1ccccc1)CCC(=O)O
NCGC00378853-02	O=C(N(CCCC)CCCC)CN1[C@H]([C@H](C(=O)O)[C@@H](c2cc3OCOc3cc2)C1)c1ccc(OC)cc1	5.75	Inactive	Endothelin ETA Receptor Antagonist	0.0	1	Atrasentan	384569071	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	53.7853393561	O=C(N(CCCC)CCCC)CN1[C@H]([C@H](C(=O)O)[C@@H](c2cc3OCOc3cc2)C1)c1ccc(OC)cc1	O=C(N(CCCC)CCCC)CN1[C@H]([C@H](C(=O)O)[C@@H](c2cc3OCOc3cc2)C1)c1ccc(OC)cc1
NCGC00263016-01	O=C(N(CCCCC)CCC12CC3CC(C1)CC(C2)C3)NCCCc1ccncc1		Inactive	TRPV4 Antagonist		1	DE-096	137275920	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	29.1607061816	O=C(N(CCCCC)CCC12CC3CC(C1)CC(C2)C3)NCCCc1ccncc1	O=C(N(CCCCC)CCC12CC3CC(C1)CC(C2)C3)NCCCc1ccncc1
NCGC00183832-01	O=C(N(CCCc1cnccc1)c1c(C)cccc1C)C(N)C	4.5	Active	Thromboxane A2 Receptor Inhibitor	0.0	1	Ro 22-9194	144206801	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-84.6990461868	O=C(N(CCCc1cnccc1)c1c(C)cccc1C)C(N)C.Cl.Cl	O=C(N(CCCc1cnccc1)c1c(C)cccc1C)C(N)C.Cl.Cl
NCGC00249916-01	O=C(N(CCN(C(=O)N1CCOCC1)CCCC)CCCC)N1CCOCC1		Inactive	Skeletal Muscle Contraction Activator&skeletal muscle contraction Activator		1	Dimorpholamine	170465773	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.421875216&0.0	O=C(N(CCN(C(=O)N1CCOCC1)CCCC)CCCC)N1CCOCC1	O=C(N(CCN(C(=O)N1CCOCC1)CCCC)CCCC)N1CCOCC1
NCGC00371443-05	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)OCC)c1		Inactive	KDM5A/KDM5B Inhibitor		1	KDM5-C70	384569043	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.622818004	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)OCC)c1	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)OCC)c1
NCGC00346889-03	O=C(N(CCO)C)C=1C=C(N[C@H]2c3c(C)cccc3OCC2)c2n(cc(C)n2)C=1		Inactive	H+/K+-ATPase Inhibitor		1	PF-03716556	363677553	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N(CCO)C)C=1C=C(N[C@H]2c3c(C)cccc3OCC2)c2n(cc(C)n2)C=1	O=C(N(CCO)C)C=1C=C(N[C@H]2c3c(C)cccc3OCC2)c2n(cc(C)n2)C=1
NCGC00346685-03	O=C(N(CCOC)CCOC)Cc1c(C(=O)c2cc(OC)c(OCCN3CCOCC3)cc2)c(O)cc(O)c1CC		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	KW-2478	384568909	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N(CCOC)CCOC)Cc1c(C(=O)c2cc(OC)c(OCCN3CCOCC3)cc2)c(O)cc(O)c1CC	O=C(N(CCOC)CCOC)Cc1c(C(=O)c2cc(OC)c(OCCN3CCOCC3)cc2)c(O)cc(O)c1CC
NCGC00178802-06&NCGC00178802-11	O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C	4.57500005	Active	Iron Chelating Agent	0.34999990000000025	2	Deferoxamine mesylate	170464752&384568364	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-109.9113497992&-106.6026228244	S(=O)(=O)(O)C.O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C	S(=O)(=O)(O)C.O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C&O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
NCGC00485958-01	O=C(N([C@@H](C)c1[nH]c(-c2ccccc2)cn1)Cc1cc(C(=O)O)c(OC)cc1)[C@@H](N)Cc1c(C)cc(C(=O)N)cc1C		Inactive			1	Eluxadoline	363681443	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.452773116&-35.8025371159	O=C(N([C@@H](C)c1[nH]c(-c2ccccc2)cn1)Cc1cc(C(=O)O)c(OC)cc1)[C@@H](N)Cc1c(C)cc(C(=O)N)cc1C	O=C(N([C@@H](C)c1[nH]c(-c2ccccc2)cn1)Cc1cc(C(=O)O)c(OC)cc1)[C@@H](N)Cc1c(C)cc(C(=O)N)cc1C
NCGC00509861-02	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)NCCc2ccccc2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C	5.2750001	Active	microtubule polymerization Inhibitor&Microtubule Polymerization Inhibitor	0.0	1	Auristatin PE	405559023	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-69.3676549544&-49.9451453345	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)NCCc2ccccc2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)NCCc2ccccc2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C
NCGC00378623-01	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C	6.8000002	Inactive	Tubulin polymerization Inhibitor	0.0	1	Dolastatin 10	384569059	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-71.413309852	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C
NCGC00346491-08	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)O)ccc2	6.0500002	Inactive	Secretory Phospholipase A2 (sPLA2) Inhibitor	0.0	1	Varespladib	363677425	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	19.791819056	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)O)ccc2	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)O)ccc2
NCGC00387039-04	O=C(N)C(C)(C)n1ncc(-c2cc3OCCn4c(nc(-c5n(C(C)C)nc(C)n5)c4)-c3cc2)c1	4.5500002	Active	PI3Kalpha Inhibitor	0.0	1	Taselisib (GDC-0032)	384569150	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-88.6700933676	O=C(N)C(C)(C)n1ncc(-c2cc3OCCn4c(nc(-c5n(C(C)C)nc(C)n5)c4)-c3cc2)c1	O=C(N)C(C)(C)n1ncc(-c2cc3OCCn4c(nc(-c5n(C(C)C)nc(C)n5)c4)-c3cc2)c1
NCGC00263910-02	O=C(N)C(CC(N(C)C)C)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Aminopentamide sulfate	170466283	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.1449985919&-19.9623509559	S(=O)(=O)(O)O.O=C(N)C(CC(N(C)C)C)(c1ccccc1)c1ccccc1	S(=O)(=O)(O)O.O=C(N)C(CC(N(C)C)C)(c1ccccc1)c1ccccc1
NCGC00186028-02	O=C(N)C(CC)N1C(=O)CCC1		Inactive	N-Type Calcium Channel (Ca(v) 2.2) Blocker&N-type Calcium Channel (ca(v) 2.2) Blockers		1	Levetiracetam	170464988	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.926960464&0.0	O=C(N)C(CC)N1C(=O)CCC1	O=C(N)C(CC)N1C(=O)CCC1
NCGC00015358-18	O=C(N)C(CCN(C(C)C)C(C)C)(c1ncccc1)c1ccccc1	5.0250001	Active	Na Channel Blocker&Na channel blocker	0.0	1	Disopyramide	174006632	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-35.6310688679&-35.6160818357	O=C(N)C(CCN(C(C)C)C(C)C)(c1ncccc1)c1ccccc1	O=C(N)C(CCN(C(C)C)C(C)C)(c1ncccc1)c1ccccc1
NCGC00016308-06	O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonist		1	Isopropamide	170465291	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.86875804&0.0	O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1	O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1
NCGC00183110-02	O=C(N)C(CCn1c(C)ncc1)(c1ccccc1)c1ccccc1	4.4000001	Active	Potassium Ion Transport Inhibitor	0.0	1	Imidafenacin	405558861	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.5500768039	O=C(N)C(CCn1c(C)ncc1)(c1ccccc1)c1ccccc1	O=C(N)C(CCn1c(C)ncc1)(c1ccccc1)c1ccccc1
NCGC00263922-02	O=C(N)C([C@H]1CN(CCc2cc3c(OCC3)cc2)CC1)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor M3 Antagonist&Muscarinic acetylcholine receptor M3 Antagonist		1	Darifenacin hydrobromide	170465079	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N)C([C@H]1CN(CCc2cc3c(OCC3)cc2)CC1)(c1ccccc1)c1ccccc1.Br	O=C(N)C([C@H]1CN(CCc2cc3c(OCC3)cc2)CC1)(c1ccccc1)c1ccccc1.Br
NCGC00249887-01	O=C(N)C1(CCCNC(C)C)c2c(-c3c1cccc3)cccc2		Inactive	Sodium Channel Alpha Subunit Blocker&Sodium channel alpha subunit Blocker		1	Indecainide	170465192	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N)C1(CCCNC(C)C)c2c(-c3c1cccc3)cccc2	O=C(N)C1(CCCNC(C)C)c2c(-c3c1cccc3)cccc2
NCGC00522040-01	O=C(N)C1(N2CCCCC2)CCN(CCCN2c3c(cccc3)CCc3c2cccc3)CC1	4.75	Active		0.0	1	Carpipramine Dihydrochloride	405558850	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-79.7542998404&-97.6602336814	O=C(N)C1(N2CCCCC2)CCN(CCCN2c3c(cccc3)CCc3c2cccc3)CC1	O=C(N)C1(N2CCCCC2)CCN(CCCN2c3c(cccc3)CCc3c2cccc3)CC1
NCGC00389413-02	O=C(N)C1=C(O)C2(O)C(=O)C3=C(O)c4c(O)cccc4C(C)C3C(O)C2C(N(C)C)C1=O		Inactive	MMP Inhibitor		1	Doxycycline	384569175	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.1395656	O=C(N)C1=C(O)C2(O)C(=O)C3=C(O)c4c(O)cccc4C(C)C3C(O)C2C(N(C)C)C1=O	O=C(N)C1=C(O)C2(O)C(=O)C3=C(O)c4c(O)cccc4C(C)C3C(O)C2C(N(C)C)C1=O
NCGC00510443-01	O=C(N)C1=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4C[C@H]3C[C@H]2CC1=O	4.75	Active	MMP-9 (Gelatinase B) Inhibitor	0.0	1	Incyclinide	384569435	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-90.8670086532	O=C(N)C1=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4C[C@H]3C[C@H]2CC1=O	O=C(N)C1=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4C[C@H]3C[C@H]2CC1=O
NCGC00509934-01	O=C(N)C1=Nn2c(c(-c3ccc(C4(N)CCC4)cc3)nc2C=C1)-c1ccccc1	4.5999999	Active	AKT Inhibitor	0.0	1	BAY-1125976	384569383	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-85.9440799943	O=C(N)C1=Nn2c(c(-c3ccc(C4(N)CCC4)cc3)nc2C=C1)-c1ccccc1	O=C(N)C1=Nn2c(c(-c3ccc(C4(N)CCC4)cc3)nc2C=C1)-c1ccccc1
NCGC00179358-04	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O	4.9749999	Active	Tetracycline Antibiotic	0.0	1	Methacycline hydrochloride	170465224	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-52.2459863196&-49.0237113802	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl
NCGC00161602-06	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O	4.7249999	Active	Matrix Metalloproteinase (MMP) Inhibitor&Matrix Metalloproteinase Inhibitor	0.0	1	Doxycycline	170465097	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-50.2390531295&-48.2157684468	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl
NCGC00017323-08&NCGC00017323-11	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O		Inactive	30s Ribosomal Protein Inhibitors&30S Ribosomal Protein Inhibitor&30S Ribosomal Protein Inhibitor		2	Tetracycline hydrochloride	170464838&384567983	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	19.174168616&0.0&0.0	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O.Cl&O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O
NCGC00091268-11&NCGC00091268-12	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O		Inactive	Tetracycline Antibiotic		2	Oxytetracycline	174007181&225144208	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	11.3444667319&-22.391193&17.15837026	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O
NCGC00016645-03	O=C(N)C=1C(=O)[C@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O		Inactive	Tetracycline Antibiotic		1	Methacycline hydrochloride	124882458	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.928743868	O=C(N)C=1C(=O)[C@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O	O=C(N)C=1C(=O)[C@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O
NCGC00166104-04	O=C(N)CCCCC1SSCC1		Inactive	Apoptotic Process Inhibitor&apoptotic process Inhibitor		1	alpha-Lipoic acid amide	170465868	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.4526140039&0.0	O=C(N)CCCCC1SSCC1	O=C(N)CCCCC1SSCC1
NCGC00346732-02	O=C(N)CC[C@H]1[C@@](CC(=O)N)(C)[C@@]2(C)[NH+]3[Co+]456(O)[NH+]7c8c(N([C@@H]9[C@H](O)[C@@H]([C@@H](CO)O9)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@]9(C)[C@@H](CC(=O)N)[C@H]2N4C9=C(C)[C-]2[C@@H](CCC(=O)N)C(C)(C)C([NH+]52)=C[C-]2[C@@H](CCC(=O)N)[C@@](CC(=O)N)(C)C(=C(C)[C-]13)[NH+]62)[CH-]7)cc(C)c(C)c8		Inactive	Vitamin		1	Hydroxocobalamin	384568936	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.826288268	O=C(N)CC[C@H]1[C@@](CC(=O)N)(C)[C@@]2(C)[NH+]3[Co+]456(O)[NH+]7c8c(N([C@@H]9[C@H](O)[C@@H]([C@@H](CO)O9)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@]9(C)[C@@H](CC(=O)N)[C@H]2N4C9=C(C)[C-]2[C@@H](CCC(=O)N)C(C)(C)C([NH+]52)=C[C-]2[C@@H](CCC(=O)N)[C@@](CC(=O)N)(C)C(=C(C)[C-]13)[NH+]62)[CH-]7)cc(C)c(C)c8	O=C(N)CC[C@H]1[C@@](CC(=O)N)(C)[C@@]2(C)[NH+]3[Co+]456(O)[NH+]7c8c(N([C@@H]9[C@H](O)[C@@H]([C@@H](CO)O9)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@]9(C)[C@@H](CC(=O)N)[C@H]2N4C9=C(C)[C-]2[C@@H](CCC(=O)N)C(C)(C)C([NH+]52)=C[C-]2[C@@H](CCC(=O)N)[C@@](CC(=O)N)(C)C(=C(C)[C-]13)[NH+]62)[CH-]7)cc(C)c(C)c8
NCGC00015821-10	O=C(N)CN1C(=O)CCC1	4.4000001	Active	Glutamate Receptor Ionotropic, Ampa 3 Positive Allosteric Modulator	0.0	1	Piracetam	170465901	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.9678471968	O=C(N)CN1C(=O)CCC1	O=C(N)CN1C(=O)CCC1
NCGC00185741-02	O=C(N)Cc1c(N)c(C(=O)c2ccccc2)ccc1	4.4499998	Active	Cyclooxygenase-2 Inhibitor	0.0	1	Nepafenac	170465203	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.8991483644	O=C(N)Cc1c(N)c(C(=O)c2ccccc2)ccc1	O=C(N)Cc1c(N)c(C(=O)c2ccccc2)ccc1
NCGC00015007-14	O=C(N)Cc1ccc(OC[C@H](O)CNC(C)C)cc1	6.1500001	Active	Beta-2 Adrenergic Receptor Antagonist	0.0	1	R-(+)-Atenolol	170464744	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-39.5516286478	O=C(N)Cc1ccc(OC[C@H](O)CNC(C)C)cc1	O=C(N)Cc1ccc(OC[C@H](O)CNC(C)C)cc1
NCGC00065934-05	O=C(N)N1c2c(C(=O)Cc3c1cccc3)cccc2	4.4000001	Active	Sodium Channel Inhibitor	0.0	1	Oxcarbazepine	170464811	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-66.1653928235	O=C(N)N1c2c(C(=O)Cc3c1cccc3)cccc2	O=C(N)N1c2c(C(=O)Cc3c1cccc3)cccc2
NCGC00015234-19	O=C(N)N1c2c(cccc2)C=Cc2c1cccc2	5.1500001	Active	Sodium channel protein type 5 subunit alpha Blocker	0.0	1	Carbamazepine	170464712	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.7449690471	O=C(N)N1c2c(cccc2)C=Cc2c1cccc2	O=C(N)N1c2c(cccc2)C=Cc2c1cccc2
NCGC00250393-01	O=C(N)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c3c([nH]c2)cccc3)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CC(=O)[C@H](N)Cc2ccccc2)CSSC1)C(O)C	4.4000001	Active	Somatostatin srif2B (sst4) Agonist	0.0	1	CAP-232	137275895	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-116.7389991753	O=C(N)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c3c([nH]c2)cccc3)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CC(=O)[C@H](N)Cc2ccccc2)CSSC1)C(O)C	O=C(N)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c3c([nH]c2)cccc3)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CC(=O)[C@H](N)Cc2ccccc2)CSSC1)C(O)C
NCGC00510690-01	O=C(N)[C@@H](Oc1cc2OCCn3c(nc(-c4n(C(C)C)ncn4)c3)-c2cc1)C	4.5500002	Active	PI3K alpha Inhibitor	0.0	1	GDC-0326	384569480	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-64.9372399944	O=C(N)[C@@H](Oc1cc2OCCn3c(nc(-c4n(C(C)C)ncn4)c3)-c2cc1)C	O=C(N)[C@@H](Oc1cc2OCCn3c(nc(-c4n(C(C)C)ncn4)c3)-c2cc1)C
NCGC00160614-01	O=C(N)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1	4.1999998	Active		0.0	1	Glucuronamide	144205490	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-45.0385156596	O=C(N)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1	O=C(N)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1
NCGC00186028-04	O=C(N)[C@H](CC)N1C(=O)CCC1		Inactive	N-Type Calcium Channel (Ca(v) 2.2) Blocker		1	Levetiracetam	384568436	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N)[C@H](CC)N1C(=O)CCC1	O=C(N)[C@H](CC)N1C(=O)CCC1
NCGC00390779-02	O=C(N)[C@H](CC)N1C(=O)C[C@@H](CCC)C1		Inactive	Synaptic Vesicle Glycoprotein 2a Modulator&Synaptic vesicle glycoprotein 2A Modulator		1	Brivaracetam	405558777	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.959876736&-24.056912448	O=C(N)[C@H](CC)N1C(=O)C[C@@H](CCC)C1	O=C(N)[C@H](CC)N1C(=O)C[C@@H](CCC)C1
NCGC00163492-01	O=C(N)[C@H]1[C@@H](C(=O)CC/C=C/C/C=C/C)O1	4.9000001	Active	Fatty Acid Synthase (FAS) Inhibitor	0.0	1	Cerulenin	26756878	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-53.0110104876	O=C(N)[C@H]1[C@@H](C(=O)CC/C=C/C/C=C/C)O1	O=C(N)[C@H]1[C@@H](C(=O)CC/C=C/C/C=C/C)O1
NCGC00165736-04&NCGC00165736-13	O=C(N)c1c(N)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1		Inactive	Amp-activated Protein Kinase (ampk) Activator&AMPK Activator&AMPK Activator		2	Acadesine	170465608&384568276	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-17.560817392&0.0&-19.229167776	O=C(N)c1c(N)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1	O=C(N)c1c(N)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1
NCGC00501212-01	O=C(N)c1c(NC2[C@@H]3CC4(O)CC2CC(C4)C3)c2c([nH]cc2)nc1	4.5500002	Active	Jak3	0.0	1	Peficitinib	384569311	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-106.7711937961	O=C(N)c1c(NC2[C@@H]3CC4(O)CC2CC(C4)C3)c2c([nH]cc2)nc1	O=C(N)c1c(NC2[C@@H]3CC4(O)CC2CC(C4)C3)c2c([nH]cc2)nc1
NCGC00346945-06	O=C(N)c1c(NC=2n3c(ncc3)C=C(c3cc(OC)c(OC)cc3)N=2)nccc1	4.8499999	Active	Syk Kinase Inhibitor	0.0	1	BAY61-3606	363677563	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-30.4224910655	O=C(N)c1c(NC=2n3c(ncc3)C=C(c3cc(OC)c(OC)cc3)N=2)nccc1	O=C(N)c1c(NC=2n3c(ncc3)C=C(c3cc(OC)c(OC)cc3)N=2)nccc1
NCGC00351606-08	O=C(N)c1c(Nc2cc(-n3nccn3)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	4.4000001	Active	Syk Kinase Inhibitor	0.0	1	PRT-062607	384569020	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-90.834090468	O=C(N)c1c(Nc2cc(-n3nccn3)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	O=C(N)c1c(Nc2cc(-n3nccn3)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1
NCGC00253909-02	O=C(N)c1c(Nc2cc(C)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	4.4000001	Active	Syk Kinase Inhibitor	0.0	1	PRT-060318	137275916	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-108.7548193968	O=C(N)c1c(Nc2cc(C)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	O=C(N)c1c(Nc2cc(C)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1
NCGC00481652-04	O=C(N)c1c(Nc2cc(OC)c(N3CCC(N4CCN(C)CC4)CC3)cc2)nc(NC2CCOCC2)c(CC)n1	5.0	Active		0.0	1	Gilteritinib	384569258	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-97.1973574374	O=C(N)c1c(Nc2cc(OC)c(N3CCC(N4CCN(C)CC4)CC3)cc2)nc(NC2CCOCC2)c(CC)n1	O=C(N)c1c(Nc2cc(OC)c(N3CCC(N4CCN(C)CC4)CC3)cc2)nc(NC2CCOCC2)c(CC)n1
NCGC00507850-01	O=C(N)c1c(Nc2nc(C)c(C)cc2)cc(N[C@H]2[C@@H](N)CCCC2)nn1		Inactive	Syk Kinase Inhibitor		1	RO-9021	384569330	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N)c1c(Nc2nc(C)c(C)cc2)cc(N[C@H]2[C@@H](N)CCCC2)nn1	O=C(N)c1c(Nc2nc(C)c(C)cc2)cc(N[C@H]2[C@@H](N)CCCC2)nn1
NCGC00378943-01	O=C(N)c1c(Nc2nc(Nc3cc(O)ccc3)ncc2)cccc1	5.0500002	Active	SAPK1 (JNK) Inhibitor	0.0	1	DB-07268	363678291	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-56.905802894	O=C(N)c1c(Nc2nc(Nc3cc(O)ccc3)ncc2)cccc1	O=C(N)c1c(Nc2nc(Nc3cc(O)ccc3)ncc2)cccc1
NCGC00015595-14	O=C(N)c1c(O)ccc(C(O)CNC(CCc2ccccc2)C)c1		Inactive	Adrenergic receptor Antagonist&Adrenergic Receptor Antagonist		1	Labetalol HCl	405558617	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.1927616119&-28.5741646475	O=C(N)c1c(O)ccc(C(O)CNC(CCc2ccccc2)C)c1	O=C(N)c1c(O)ccc(C(O)CNC(CCc2ccccc2)C)c1
NCGC00091414-07	O=C(N)c1c(O)cccc1		Inactive			1	Salicylamide	170465496	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.842617568&-12.932916096	O=C(N)c1c(O)cccc1	O=C(N)c1c(O)cccc1
NCGC00094087-05&NCGC00094087-07&NCGC00094087-08	O=C(N)c1c(O)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1		Inactive	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor&Inosine 5'-monophosphate Dehydrogenase (impdh) Inhibitors&Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor		3	Mizoribine	170466027&384568124&384568125	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0&4.0	-15.3509715719&0.0&21.232494136&0.0	O=C(N)c1c(O)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1	O=C(N)c1c(O)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1
NCGC00091616-03	O=C(N)c1c(OCC)cccc1	4.4000001	Active		0.0	1	2-Ethoxybenzamide	170465775	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-55.5416045	O=C(N)c1c(OCC)cccc1	O=C(N)c1c(OCC)cccc1
NCGC00095049-04	O=C(N)c1c(OCCCCCC)cccc1	4.4000001	Active		0.0	1	Exalamide	170465990	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.032615356	O=C(N)c1c(OCCCCCC)cccc1	O=C(N)c1c(OCCCCCC)cccc1
NCGC00250404-06	O=C(N)c1c2nc([C@]3(C)NCCC3)[nH]c2ccc1		Inactive	PARP Inhibitor		1	Veliparib	384568552	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	40.1832217328	O=C(N)c1c2nc([C@]3(C)NCCC3)[nH]c2ccc1	O=C(N)c1c2nc([C@]3(C)NCCC3)[nH]c2ccc1
NCGC00378571-03	O=C(N)c1c2nn(-c3ccc(C4CNCCC4)cc3)cc2ccc1	4.75	Active	Parp-1/parp-2 Inhibitor&PARP-1/PARP-2 Inhibitor	0.0	1	NCGC00378571-03&MK-4827	405559085	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-122.2782009206&-97.0508250126	O=C(N)c1c2nn(-c3ccc(C4CNCCC4)cc3)cc2ccc1	O=C(N)c1c2nn(-c3ccc(C4CNCCC4)cc3)cc2ccc1
NCGC00346435-07	O=C(N)c1c2nn(-c3ccc([C@H]4CNCCC4)cc3)cc2ccc1	5.0500002	Active	PARP Inhibitor	0.0	1	Niraparib	384568775	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-67.4985161858	O=C(N)c1c2nn(-c3ccc([C@H]4CNCCC4)cc3)cc2ccc1	O=C(N)c1c2nn(-c3ccc([C@H]4CNCCC4)cc3)cc2ccc1
NCGC00475742-01	O=C(N)c1cc(CC)c(-n2nc(C(C)C)c3c(-n4cc(-c5cn(C)nc5)nc4)ccnc23)cc1	5.5999999	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	TAS-116	363681099	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.9294818828	O=C(N)c1cc(CC)c(-n2nc(C(C)C)c3c(-n4cc(-c5cn(C)nc5)nc4)ccnc23)cc1	O=C(N)c1cc(CC)c(-n2nc(C(C)C)c3c(-n4cc(-c5cn(C)nc5)nc4)ccnc23)cc1
NCGC00015034-15	O=C(N)c1cc(N)ccc1		Inactive	PARP Inhibitor		1	INO-1001	384567798	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N)c1cc(N)ccc1	O=C(N)c1cc(N)ccc1
NCGC00345856-01	O=C(N)c1cc(c(-c2ccc(C3(N)CCC3)cc2)nc1)-c1ccccc1	4.4000001	Active	AKT Inhibitor	0.0	1	AZD-26	174006466	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.432889656	O=C(N)c1cc(c(-c2ccc(C3(N)CCC3)cc2)nc1)-c1ccccc1	O=C(N)c1cc(c(-c2ccc(C3(N)CCC3)cc2)nc1)-c1ccccc1
NCGC00378801-04	O=C(N)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	4.4000001	Active	Mitogen-activated protein kinase 7 Inhibitor	0.0	1	BIX02188	384569070	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-87.0287434479	O=C(N)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	O=C(N)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1
NCGC00384167-11	O=C(N)c1cc2c(-c3c(-c4nc(C)ccc4)nn4c3CCC4)ccnc2cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	Galunisertib	384569102	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N)c1cc2c(-c3c(-c4nc(C)ccc4)nn4c3CCC4)ccnc2cc1	O=C(N)c1cc2c(-c3c(-c4nc(C)ccc4)nn4c3CCC4)ccnc2cc1
NCGC00408835-01	O=C(N)c1cc2c([nH]c3c2C[C@H](NC)CC3)cc1		Inactive	Serotonin 1d (5-ht1d) Receptor Agonist&Serotonin 1d (5-HT1d) receptor Agonist		1	Frovatriptan succinate	405558720	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.03683784&19.6699421079	O=C(N)c1cc2c([nH]c3c2C[C@H](NC)CC3)cc1	O=C(N)c1cc2c([nH]c3c2C[C@H](NC)CC3)cc1
NCGC00162142-06	O=C(N)c1cc2c([nH]cc2)cc1		Inactive	p38 MAPK Inhibitor		1	SD-169	384568219	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	39.0679602551	O=C(N)c1cc2c([nH]cc2)cc1	O=C(N)c1cc2c([nH]cc2)cc1
NCGC00242498-14	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCCOc4cc3)n2)-c2ncccc2)cc1	4.6999998	Active	Casein Kinase 1 Inhibitor	0.0	1	D-4476	384568501	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-49.0479641441	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCCOc4cc3)n2)-c2ncccc2)cc1	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCCOc4cc3)n2)-c2ncccc2)cc1
NCGC00025230-21	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCOc4cc3)n2)-c2ncccc2)cc1	4.4000001	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	SB-431542	377020509	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-59.1605076759	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCOc4cc3)n2)-c2ncccc2)cc1	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCOc4cc3)n2)-c2ncccc2)cc1
NCGC00093354-13	O=C(N)c1cnccc1		Inactive	Vitamin		1	Niacinamide	384568113	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.794828948	O=C(N)c1cnccc1	O=C(N)c1cnccc1
NCGC00015833-15&NCGC00015833-18	O=C(N)c1nccnc1		Inactive	Fatty Acid Synthase Inhibitor&Fatty Acid Synthase (FAS) Inhibitor&Fatty Acid Synthase (FAS) Inhibitor		2	Pyrazinamide	170464703&384567896	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-22.648718844&0.0&-33.629097048	O=C(N)c1nccnc1	O=C(N)c1nccnc1
NCGC00167429-04&NCGC00167429-10	O=C(N)c1ncn2C(=O)N(C)N=Nc12		Inactive	Dna Alkylating Drugs&DNA Topoisomerase II Inhibitor&DNA Topoisomerase II Inhibitor		2	Temozolomide	170464968&384568311	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-26.0009013999&-14.5831936801&-18.754636024	O=C(N)c1ncn2C(=O)N(C)N=Nc12	O=C(N)c1ncn2C(=O)N(C)N=Nc12
NCGC00346555-05&NCGC00346555-08	O=C(N)c1nn(-c2ccc(OC)cc2)c2C(=O)N(c3ccc(N4C(=O)CCCC4)cc3)CCc12	4.70000005	Active	Coagulation Factor Xa Inhibitor	0.5999999000000003	2	Apixaban	405558566&363677453	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-38.0416769&-45.1868639455	O=C(N)c1nn(-c2ccc(OC)cc2)c2C(=O)N(c3ccc(N4C(=O)CCCC4)cc3)CCc12	O=C(N)c1nn(-c2ccc(OC)cc2)c2C(=O)N(c3ccc(N4C(=O)CCCC4)cc3)CCc12
NCGC00371130-03	O=C(N)c1oc2c(c1)cc(N1CCN(CCCCc3c4c([nH]c3)ccc(C#N)c4)CC1)cc2	4.7249999	Active	Sodium-dependent Serotonin Transporter Inhibitor&Sodium-dependent serotonin transporter Inhibitor	0.0	1	Vilazodone Hydrochloride	405558674	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-93.1303469349&-63.9171974552	O=C(N)c1oc2c(c1)cc(N1CCN(CCCCc3c4c([nH]c3)ccc(C#N)c4)CC1)cc2	O=C(N)c1oc2c(c1)cc(N1CCN(CCCCc3c4c([nH]c3)ccc(C#N)c4)CC1)cc2
NCGC00179246-05	O=C(N/C=C\1/C(=O)N[C@@H]([C@@H]2NC(N)=N[C@@H](O)C2)C(=O)NC[C@H](NC(=O)C[C@@H](N)CCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N/1)N		Inactive	70s Ribosome Inhibitor		1	VIOMYCIN SULFATE	405558719	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.431402868	O=C(N/C=C\1/C(=O)N[C@@H]([C@@H]2NC(N)=N[C@@H](O)C2)C(=O)NC[C@H](NC(=O)C[C@@H](N)CCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N/1)N	O=C(N/C=C\1/C(=O)N[C@@H]([C@@H]2NC(N)=N[C@@H](O)C2)C(=O)NC[C@H](NC(=O)C[C@@H](N)CCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N/1)N
NCGC00167473-02	O=C(N/C=C\1/C(=O)N[C@@H]([C@H]2N=C(N)NCC2)C(=O)NC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CNC(=O)C[C@@H](N)CCCN)C(=O)N/1)N		Inactive			1	Capreomycin IB	174006669	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-12.4761346359	O=C(N/C=C\1/C(=O)N[C@@H]([C@H]2N=C(N)NCC2)C(=O)NC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CNC(=O)C[C@@H](N)CCCN)C(=O)N/1)N	O=C(N/C=C\1/C(=O)N[C@@H]([C@H]2N=C(N)NCC2)C(=O)NC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CNC(=O)C[C@@H](N)CCCN)C(=O)N/1)N
NCGC00167785-11	O=C(N/N=C/c1c(O)c(CC=C)ccc1)CN1CCN(Cc2ccccc2)CC1	4.5	Active	Procaspase 3 Activator	0.0	1	PAC-1	384568336	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-121.0213203317	O=C(N/N=C/c1c(O)c(CC=C)ccc1)CN1CCN(Cc2ccccc2)CC1	O=C(N/N=C/c1c(O)c(CC=C)ccc1)CN1CCN(Cc2ccccc2)CC1
NCGC00346879-04	O=C(N/N=C/c1oc(C)cc1)c1c(Oc2ccccc2)cccc1		Inactive	Wnt Signaling Inhibitor		1	PNU-74654	384568957	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N/N=C/c1oc(C)cc1)c1c(Oc2ccccc2)cccc1	O=C(N/N=C/c1oc(C)cc1)c1c(Oc2ccccc2)cccc1
NCGC00344541-01	O=C(N/N=C\1/C(=O)C=C2N(C)CC(O)C2=C/1)N		Inactive			1	Adrenochrome semicarbazone	225144387	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.6965229079&14.47807656	O=C(N/N=C\1/C(=O)C=C2N(C)CC(O)C2=C/1)N	O=C(N/N=C\1/C(=O)C=C2N(C)CC(O)C2=C/1)N
NCGC00015116-13&NCGC00015116-20	O=C(N1C(=O)CCC1)c1ccc(OC)cc1		Inactive	Ampa Receptor Modulator&AMPA receptor modulator&AMPA receptor modulator		2	Aniracetam	170465854&384567811	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-33.629762644&15.39568328&-14.847723932	O=C(N1C(=O)CCC1)c1ccc(OC)cc1	O=C(N1C(=O)CCC1)c1ccc(OC)cc1
NCGC00015818-14&NCGC00015818-25	O=C(N1CC(=O)N2C(c3c(cccc3)CC2)C1)C1CCCCC1		Inactive	Antiparasitic Agent&antiparasitic agent&antiparasitic agent		2	Praziquantel	170464906&384567893	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.8156974519&-17.998932092&17.933578004	O=C(N1CC(=O)N2C(c3c(cccc3)CC2)C1)C1CCCCC1	O=C(N1CC(=O)N2C(c3c(cccc3)CC2)C1)C1CCCCC1
NCGC00249902-01	O=C(N1CC(=O)N2C(c3c(cccc3)CCC2)C1)C1CCCCC1	5.75	Active	Calcium Ion Homeostasis Inhibitor	0.0	1	Epsiprantel	170465737	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.9748295491	O=C(N1CC(=O)N2C(c3c(cccc3)CCC2)C1)C1CCCCC1	O=C(N1CC(=O)N2C(c3c(cccc3)CCC2)C1)C1CCCCC1
NCGC00484062-02	O=C(N1CC(C)(C)C1)c1ccc(C=2n3nc(NC(=O)C4CC4)nc3C=CC=2)cc1	4.9000001	Inactive	Jak1 Inhibitor	0.0	1	Solcitinib	384569268	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-9.6376185519	O=C(N1CC(C)(C)C1)c1ccc(C=2n3nc(NC(=O)C4CC4)nc3C=CC=2)cc1	O=C(N1CC(C)(C)C1)c1ccc(C=2n3nc(NC(=O)C4CC4)nc3C=CC=2)cc1
NCGC00510705-01	O=C(N1CCC(CC(O)(C)C)CC1)c1[nH]c2c(c1)cc(OC)cc2		Inactive	AKR1C3 Inhibitor		1	ASP-9521	384569488	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N1CCC(CC(O)(C)C)CC1)c1[nH]c2c(c1)cc(OC)cc2	O=C(N1CCC(CC(O)(C)C)CC1)c1[nH]c2c(c1)cc(OC)cc2
NCGC00344623-17	O=C(N1CCC(N2CCCC2)CC1)c1c(Nc2ccccc2)cc(C(=O)N2CCC(N3CCCC3)CC2)cc1		Inactive	L3MBTL3 methyllysine (Kme) reader domain Inhibitor		1	UNC-1215	384568726	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.547365856	O=C(N1CCC(N2CCCC2)CC1)c1c(Nc2ccccc2)cc(C(=O)N2CCC(N3CCCC3)CC2)cc1	O=C(N1CCC(N2CCCC2)CC1)c1c(Nc2ccccc2)cc(C(=O)N2CCC(N3CCCC3)CC2)cc1
NCGC00167767-12	O=C(N1CCC(N2CCCC2)CC1)c1ccc(Nc2nc(-c3sc4c(c3)cccc4)ccn2)cc1	4.9499998	Active	IKK beta Inhibitor	0.0	1	IKK-16	377020288	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.1188526346	O=C(N1CCC(N2CCCC2)CC1)c1ccc(Nc2nc(-c3sc4c(c3)cccc4)ccn2)cc1	O=C(N1CCC(N2CCCC2)CC1)c1ccc(Nc2nc(-c3sc4c(c3)cccc4)ccn2)cc1
NCGC00346807-05	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OC)c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)cc1	4.5	Active	LRRK2 Inhibitor	0.0	1	LRRK2-IN-1	384568941	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-112.3681840776	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OC)c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)cc1	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OC)c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)cc1
NCGC00378965-05	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OCC)c(Nc2nc3N(C4CCCC4)c4c(C(=O)N(C)c3cn2)cccc4)cc1	4.5999999	Active	ERK5 Inhibitor	0.0	1	XMD17-109	384569078	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-81.6437194849	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OCC)c(Nc2nc3N(C4CCCC4)c4c(C(=O)N(C)c3cn2)cccc4)cc1	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OCC)c(Nc2nc3N(C4CCCC4)c4c(C(=O)N(C)c3cn2)cccc4)cc1
NCGC00421916-03	O=C(N1CCC2(CC(=O)c3n(C(C)C)ncc3C2)CC1)c1cc2nc(C)[nH]c2cc1	4.8499999	Active	Acetyl-CoA Carboxylase Inhibitor	0.0	1	PF-05175157	384569230	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-91.6675200917	O=C(N1CCC2(CC(=O)c3n(C(C)C)ncc3C2)CC1)c1cc2nc(C)[nH]c2cc1	O=C(N1CCC2(CC(=O)c3n(C(C)C)ncc3C2)CC1)c1cc2nc(C)[nH]c2cc1
NCGC00475743-01	O=C(N1CCCC1)c1ccc(-c2cc3N=C(N)CC(C(=O)N(CCC)CCC)=Cc3cc2)cc1	4.4000001	Active	Toll-Like Receptor 8 (TLR8) Agonist	0.0	1	Motolimod	384569237	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-71.3439812759	O=C(N1CCCC1)c1ccc(-c2cc3N=C(N)CC(C(=O)N(CCC)CCC)=Cc3cc2)cc1	O=C(N1CCCC1)c1ccc(-c2cc3N=C(N)CC(C(=O)N(CCC)CCC)=Cc3cc2)cc1
NCGC00182992-01	O=C(N1CCCCC1)[C@@H]1NC(=O)CC1		Inactive	Gaba-b Receptor Antagonist&GABA-B receptor Antagonist		1	Fasoracetam	144206891	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N1CCCCC1)[C@@H]1NC(=O)CC1	O=C(N1CCCCC1)[C@@H]1NC(=O)CC1
NCGC00262228-03	O=C(N1CCCCC1)c1cc2ncn(-c3ccc(OC)cc3)c2cc1		Inactive	HPGD Inhibitor		1	NCGC00262228	384568571	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	20.377569824	O=C(N1CCCCC1)c1cc2ncn(-c3ccc(OC)cc3)c2cc1	O=C(N1CCCCC1)c1cc2ncn(-c3ccc(OC)cc3)c2cc1
NCGC00522584-01	O=C(N1CCN(C)CC1)c1sc(-c2cc3c(c(C=O)c(O)cc3)cc2)cc1		Inactive	IRE1 Inhibitor		1	MKC-3946	384569530	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N1CCN(C)CC1)c1sc(-c2cc3c(c(C=O)c(O)cc3)cc2)cc1	O=C(N1CCN(C)CC1)c1sc(-c2cc3c(c(C=O)c(O)cc3)cc2)cc1
NCGC00508883-01	O=C(N1CCN(c2c(C#N)cccn2)CC1)c1cc(CC2=NNC(=O)c3c2cccc3)ccc1	8.5500002	Inactive	PARP Inhibitor	0.0	1	AZ-9482	384569370	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-64.2008259601	O=C(N1CCN(c2c(C#N)cccn2)CC1)c1cc(CC2=NNC(=O)c3c2cccc3)ccc1	O=C(N1CCN(c2c(C#N)cccn2)CC1)c1cc(CC2=NNC(=O)c3c2cccc3)ccc1
NCGC00510509-01&NCGC00510509-02	O=C(N1CCN(c2cc3c(NC(=O)CC3)cc2)CC1)c1cc(OC)c(OC)cc1		Inactive	p97 ATPase Inhibitor&P97 Atpase Inhibitor&p97 ATPase Inhibitor		2	Vesnarinone	384569470&405558927	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-20.666140364	O=C(N1CCN(c2cc3c(NC(=O)CC3)cc2)CC1)c1cc(OC)c(OC)cc1	O=C(N1CCN(c2cc3c(NC(=O)CC3)cc2)CC1)c1cc(OC)c(OC)cc1
NCGC00016026-10	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1OCCC1		Inactive	Alpha1-adrenoceptor Antagonists		1	Terazosin hydrochloride	170465073	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1OCCC1.Cl	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1OCCC1.Cl
NCGC00018158-09	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2	4.5500002	Active	Alpha1-adrenoceptor Antagonists&alpha1-Adrenoceptor Antagonists	0.0	1	Doxazosin mesylate	170465395	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-31.694475944&-57.1670153368	S(=O)(=O)(O)C.O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2	S(=O)(=O)(O)C.O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2
NCGC00346569-03	O=C(N1CCNCC1)c1ccc(/C=C/c2n[nH]c3c2cccc3)cc1		Inactive	Bcr-Abl Inhibitor		1	KW-2449	384568844	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N1CCNCC1)c1ccc(/C=C/c2n[nH]c3c2cccc3)cc1	O=C(N1CCNCC1)c1ccc(/C=C/c2n[nH]c3c2cccc3)cc1
NCGC00509943-03	O=C(N1CCOCC1)c1n2c(nc1)C=CC(c1cc3nc(N)oc3cc1)=C2		Inactive	PI3K alpha Inhibitor		1	Serabelisib	384569391	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N1CCOCC1)c1n2c(nc1)C=CC(c1cc3nc(N)oc3cc1)=C2	O=C(N1CCOCC1)c1n2c(nc1)C=CC(c1cc3nc(N)oc3cc1)=C2
NCGC00378896-03	O=C(N1CSCC1)[C@H]1NC[C@@H](N2CCN(c3n(-c4ccccc4)nc(C)c3)CC2)C1		Inactive	Dipeptidyl Peptidase Iv Inhibitor&Dipeptidyl peptidase IV Inhibitor		1	Teneligliptin	405558594	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.753416684&0.0	O=C(N1CSCC1)[C@H]1NC[C@@H](N2CCN(c3n(-c4ccccc4)nc(C)c3)CC2)C1	O=C(N1CSCC1)[C@H]1NC[C@@H](N2CCN(c3n(-c4ccccc4)nc(C)c3)CC2)C1
NCGC00263281-01	O=C(N1C[C@H](Cn2c(-c3ccc(-c4cc5c(occ5)cc4)cc3)nc3c2ccnc3)CC1)C1CC1	4.5	Active	Fatty Acid Synthase (FAS) Inhibitor	0.0	1	GSK-1995010	137276089	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-83.5808971531	O=C(N1C[C@H](Cn2c(-c3ccc(-c4cc5c(occ5)cc4)cc3)nc3c2ccnc3)CC1)C1CC1	O=C(N1C[C@H](Cn2c(-c3ccc(-c4cc5c(occ5)cc4)cc3)nc3c2ccnc3)CC1)C1CC1
NCGC00386721-01	O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1)N1CCCC1		Inactive	FGFR 1 Inhibitor		1	PF-956980	363680416	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1)N1CCCC1	O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1)N1CCCC1
NCGC00480912-02	O=C(N1C[C@H](N)[C@H](O)CC1)c1cc(OC)c2n(C)c(-c3n(CC4CC4)c4c(c3)cccc4)nc2c1	4.5500002	Active	PADI4 Inhibitor (Protein-arginine deiminase type-4)	0.0	1	GSK-484	363681114	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-79.0873069408	O=C(N1C[C@H](N)[C@H](O)CC1)c1cc(OC)c2n(C)c(-c3n(CC4CC4)c4c(c3)cccc4)nc2c1	O=C(N1C[C@H](N)[C@H](O)CC1)c1cc(OC)c2n(C)c(-c3n(CC4CC4)c4c(c3)cccc4)nc2c1
NCGC00345024-01	O=C(N1Cc2c3n(cc(C4=C(c5n6c(nc5)C=CC=C6)C(=O)NC4=O)c3ccc2)CC1)N1CCOCC1	5.9499998	Active	GSK-3 Inhibitor	0.0	1	GSK3 Inhibitor	174007010	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.6344161025	O=C(N1Cc2c3n(cc(C4=C(c5n6c(nc5)C=CC=C6)C(=O)NC4=O)c3ccc2)CC1)N1CCOCC1	O=C(N1Cc2c3n(cc(C4=C(c5n6c(nc5)C=CC=C6)C(=O)NC4=O)c3ccc2)CC1)N1CCOCC1
NCGC00250392-01	O=C(N1OC[C@@H](O)C1)c1c(Cc2c(C)[nH]nc2C)sc2N(CC(C)C)C(=O)N(C)C(=O)c12	5.5	Inactive	MCT1 Inhibitor	0.0	1	AR-C155858	137275894	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-43.8590464283	O=C(N1OC[C@@H](O)C1)c1c(Cc2c(C)[nH]nc2C)sc2N(CC(C)C)C(=O)N(C)C(=O)c12	O=C(N1OC[C@@H](O)C1)c1c(Cc2c(C)[nH]nc2C)sc2N(CC(C)C)C(=O)N(C)C(=O)c12
NCGC00510200-01	O=C(NC(=N)Nc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)c(C)cc1)c1cc(OC)c(OC)c(OC)c1	4.9499998	Active	Hedgehog Antagonist	0.0	1	MRT-83	384569415	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-111.5777133519	O=C(NC(=N)Nc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)c(C)cc1)c1cc(OC)c(OC)c(OC)c1	O=C(NC(=N)Nc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)c(C)cc1)c1cc(OC)c(OC)c(OC)c1
NCGC00180997-01	O=C(NC(=O)C(CC)c1ccccc1)N		Inactive			1	Ethylphenylacetylurea	144206203	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.004998192	O=C(NC(=O)C(CC)c1ccccc1)N	O=C(NC(=O)C(CC)c1ccccc1)N
NCGC00182986-01	O=C(NC(=O)C(CC)c1ccccc1)NC(=O)C		Inactive			1	Acetylpheneturide	144206817	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.196535228&0.0	O=C(NC(=O)C(CC)c1ccccc1)NC(=O)C	O=C(NC(=O)C(CC)c1ccccc1)NC(=O)C
NCGC00094754-05	O=C(NC(=O)Cc1ccccc1)N		Inactive	Sodium channel alpha subunit Blocker&Sodium Channel Alpha Subunit Blocker		1	Phenacemide	170465322	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.1865149	O=C(NC(=O)Cc1ccccc1)N	O=C(NC(=O)Cc1ccccc1)N
NCGC00262569-03	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=N[C@H]3c4nc(sc4)[C@@H]4[C@@H](C)OC(=O)c5nc6[C@@H](O)[C@H](N[C@@H](C(CC)C)C(=O)N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N[C@]3(c3scc(C(=O)N[C@@H]([C@H](O)C)C(=O)N/C(=C/C)/C=7SC[C@H](C(=O)N[C@@H]([C@@](O)([C@H](O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c([C@@H](O)C)c5)sc1)=C	5.0500002	Active	Toll-like receptor 9 Inhibitor	0.0	1	Thiostrepton	405558975	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.3	-64.9277216054	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=N[C@H]3c4nc(sc4)[C@@H]4[C@@H](C)OC(=O)c5nc6[C@@H](O)[C@H](N[C@@H](C(CC)C)C(=O)N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N[C@]3(c3scc(C(=O)N[C@@H]([C@H](O)C)C(=O)N/C(=C/C)/C=7SC[C@H](C(=O)N[C@@H]([C@@](O)([C@H](O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c([C@@H](O)C)c5)sc1)=C	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=N[C@H]3c4nc(sc4)[C@@H]4[C@@H](C)OC(=O)c5nc6[C@@H](O)[C@H](N[C@@H](C(CC)C)C(=O)N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N[C@]3(c3scc(C(=O)N[C@@H]([C@H](O)C)C(=O)N/C(=C/C)/C=7SC[C@H](C(=O)N[C@@H]([C@@](O)([C@H](O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c([C@@H](O)C)c5)sc1)=C
NCGC00178768-03	O=C(NC(C(=O)NC1C(=O)NC(CCN)C(=O)NC(Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)CCN)C(NC(=O)C(NC(=O)CCCCC(CC)C)CCN)C(O)C		Inactive	Peptide Antibiotic		1	POLYMYXIN B SULFATE	405558758	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.63101124&-17.103954732	O=C(NC(C(=O)NC1C(=O)NC(CCN)C(=O)NC(Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)CCN)C(NC(=O)C(NC(=O)CCCCC(CC)C)CCN)C(O)C	O=C(NC(C(=O)NC1C(=O)NC(CCN)C(=O)NC(Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)CCN)C(NC(=O)C(NC(=O)CCCCC(CC)C)CCN)C(O)C
NCGC00389662-01	O=C(NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NCC(=O)N)CCC1)CCCN=C(N)N)CC(C)C)Cc1ccc(O)cc1)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	4.4000001	Active	Putative Gonadotropin-releasing Hormone Ii Receptor Agonist	0.0	1	Luteinizing hormone releasing hormone human acetate salt (LHRH)	405558523	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.768971908	O=C(NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NCC(=O)N)CCC1)CCCN=C(N)N)CC(C)C)Cc1ccc(O)cc1)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	O=C(NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NCC(=O)N)CCC1)CCCN=C(N)N)CC(C)C)Cc1ccc(O)cc1)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO
NCGC00165863-16	O=C(NC(C)(C)C)Nc1c(-c2cc(OC)cc(OC)c2)cc2c(n1)nc(NCCCCN(CC)CC)nc2	4.75	Active	FGFR 1/3 Inhibitor	0.0	1	PD-173074	384568291	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.4639342152	O=C(NC(C)(C)C)Nc1c(-c2cc(OC)cc(OC)c2)cc2c(n1)nc(NCCCCN(CC)CC)nc2	O=C(NC(C)(C)C)Nc1c(-c2cc(OC)cc(OC)c2)cc2c(n1)nc(NCCCCN(CC)CC)nc2
NCGC00182849-01	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C=C(C(=O)O)CC4)=CC3)CC2)CC1	4.4000001	Active	3-oxo-5-alpha-steroid 4-dehydrogenase 2 Inhibitor	0.0	1	Epristeride	144206545	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.533597248	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C=C(C(=O)O)CC4)=CC3)CC2)CC1	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C=C(C(=O)O)CC4)=CC3)CC2)CC1
NCGC00093560-05&NCGC00093560-13	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)C=C4)CC3)CC2)CC1		Inactive	Androgen Receptor Antagonist		2	Finasteride	170464818&384568115	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-20.85624972&16.463986096&0.0	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)C=C4)CC3)CC2)CC1	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)C=C4)CC3)CC2)CC1
NCGC00378903-01	O=C(NC(C)C)COc1cc(-c2nc(Nc3cc4c([nH]nc4)cc3)c3c(n2)cccc3)ccc1		Inactive	ROCK 2 Inhibitor		1	KD-025	363678268	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	30.0034223731	O=C(NC(C)C)COc1cc(-c2nc(Nc3cc4c([nH]nc4)cc3)c3c(n2)cccc3)ccc1	O=C(NC(C)C)COc1cc(-c2nc(Nc3cc4c([nH]nc4)cc3)c3c(n2)cccc3)ccc1
NCGC00016438-04&NCGC00016438-06	O=C(NC(C)C)c1ccc(CNNC)cc1		Inactive	DNA Alkylating Drugs&Dna Alkylating Drugs&DNA Alkylating Drugs		2	Procarbazine hydrochloride	170465402&384567940	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	15.9744201319&20.6211086239&0.0	O=C(NC(C)C)c1ccc(CNNC)cc1.Cl	O=C(NC(C)C)c1ccc(CNNC)cc1.Cl&O=C(NC(C)C)c1ccc(CNNC)cc1
NCGC00263235-01	O=C(NC(C)c1ccc(Oc2ccc(OC(C)C)cc2)cc1)C		Inactive	Acetyl-CoA Carboxylase Inhibitor		1	ACC1 BMS	137276079	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.237258736	O=C(NC(C)c1ccc(Oc2ccc(OC(C)C)cc2)cc1)C	O=C(NC(C)c1ccc(Oc2ccc(OC(C)C)cc2)cc1)C
NCGC00182997-01	O=C(NC(C)c1ccccc1)CCCCCCC/C=C\C/C=C\CCCCC	4.6500001	Active	Acyl coenzyme A:cholesterol acyltransferase Inhibitor	0.0	1	Melinamide	144206837	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-56.426360176	O=C(NC(C)c1ccccc1)CCCCCCC/C=C\C/C=C\CCCCC	O=C(NC(C)c1ccccc1)CCCCCCC/C=C\C/C=C\CCCCC
NCGC00263193-02	O=C(NC(C)c1sccn1)Nc1c(OC)cc(Oc2c3c(ncc2)cc(OC)c(OC)c3)cc1	4.5500002	Active	CSF1R (c-FMS) Inhibitor	0.0	1	KI-20227	384568657	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-65.5537752936	O=C(NC(C)c1sccn1)Nc1c(OC)cc(Oc2c3c(ncc2)cc(OC)c(OC)c3)cc1	O=C(NC(C)c1sccn1)Nc1c(OC)cc(Oc2c3c(ncc2)cc(OC)c(OC)c3)cc1
NCGC00388389-01	O=C(NC(C=O)C(O)C(O)[C@H](O)CO)C		Inactive			1	N-acetyl-D-Glucosamine	405558640	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	5.78712044&0.0	O=C(NC(C=O)C(O)C(O)[C@H](O)CO)C	O=C(NC(C=O)C(O)C(O)[C@H](O)CO)C
NCGC00347908-01	O=C(NC(N/C(=N/C#N)/Nc1c2c(ccc1)cccc2)C(C)(C)C)Cc1cc(OC)c(OC)cc1	4.9000001	Active	P2X7 Receptor Antagonist	0.0	1	A-740003	174006396	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-53.7158178774	O=C(NC(N/C(=N/C#N)/Nc1c2c(ccc1)cccc2)C(C)(C)C)Cc1cc(OC)c(OC)cc1	O=C(NC(N/C(=N/C#N)/Nc1c2c(ccc1)cccc2)C(C)(C)C)Cc1cc(OC)c(OC)cc1
NCGC00094763-03	O=C(NC([C@H](O)C)C(=O)N[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCN)C(=O)N[C@H](CCN)C(=O)NC([C@H](O)C)C(=O)NCC1)CCN)[C@@H](NC(=O)CCCCC(CC)C)CCN		Inactive	Peptide Antibiotic		1	Polymyxin B sulphate	174006989	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NC([C@H](O)C)C(=O)N[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCN)C(=O)N[C@H](CCN)C(=O)NC([C@H](O)C)C(=O)NCC1)CCN)[C@@H](NC(=O)CCCCC(CC)C)CCN	O=C(NC([C@H](O)C)C(=O)N[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCN)C(=O)N[C@H](CCN)C(=O)NC([C@H](O)C)C(=O)NCC1)CCN)[C@@H](NC(=O)CCCCC(CC)C)CCN
NCGC00389228-01	O=C(NC)C1=C(N)N(CC)c2nc(C#CC(O)(COC)C)ccc2C1=O		Inactive	VEGFR-3 Inhibitor		1	SAR-131675	363680747	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NC)C1=C(N)N(CC)c2nc(C#CC(O)(COC)C)ccc2C1=O	O=C(NC)C1=C(N)N(CC)c2nc(C#CC(O)(COC)C)ccc2C1=O
NCGC00346635-10	O=C(NC)Nc1ccc(-c2nc(N3CC4OC(C3)CC4)c3c(n(C4CCC5(OCCO5)CC4)nc3)n2)cc1	5.25	Inactive	mTORC1/2 Inhibitor	0.0	1	WYE-125132	377020163	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	7.2952855441	O=C(NC)Nc1ccc(-c2nc(N3CC4OC(C3)CC4)c3c(n(C4CCC5(OCCO5)CC4)nc3)n2)cc1	O=C(NC)Nc1ccc(-c2nc(N3CC4OC(C3)CC4)c3c(n(C4CCC5(OCCO5)CC4)nc3)n2)cc1
NCGC00163450-06	O=C(NC)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1c2c([nH]c1)cccc2	5.4499998	Active	MMP Inhibitor	0.0	1	Ilomastat (GM6001, Galardin)	384568240	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-43.3356569215	O=C(NC)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1c2c([nH]c1)cccc2	O=C(NC)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1c2c([nH]c1)cccc2
NCGC00481603-01	O=C(NC)c1c(C)oc2c1ccc(Oc1ncnc3c1cc(OC)c(OC)c3)c2		Inactive	VEGFR-1/2/3 Inhibitor		1	Fruquintinib	377020212	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NC)c1c(C)oc2c1ccc(Oc1ncnc3c1cc(OC)c(OC)c3)c2	O=C(NC)c1c(C)oc2c1ccc(Oc1ncnc3c1cc(OC)c(OC)c3)c2
NCGC00532324-01	O=C(NC)c1c2c(c([C@@H](CNc3ncnc(-c4cnc(C)nc4)c3)C)ccc2)ncc1		Inactive	DNA-PK Inhibitor		1	VX-984	384569538	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.3643488679	O=C(NC)c1c2c(c([C@@H](CNc3ncnc(-c4cnc(C)nc4)c3)C)ccc2)ncc1	O=C(NC)c1c2c(c([C@@H](CNc3ncnc(-c4cnc(C)nc4)c3)C)ccc2)ncc1
NCGC00378878-02	O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC3(N)CC3)c(OC)c4)cc2)ccc1	4.5	Inactive	CSF1R (c-FMS) Inhibitor	0.0	1	Lucitanib	363678252	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-27.3044944415	O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC3(N)CC3)c(OC)c4)cc2)ccc1	O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC3(N)CC3)c(OC)c4)cc2)ccc1
NCGC00346543-05	O=C(NC)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	4.4000001	Active	MEK Inhibitor	0.0	1	NCGC00346543	384568829	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-35.16186	O=C(NC)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	O=C(NC)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1
NCGC00346631-02	O=C(NC)c1cc2c(cc(C3(O)c4n(cnc4)CC3)cc2)cc1		Inactive	Androgen Biosynthesis Inhibitor		1	Orteronel	363677486	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.846250268	O=C(NC)c1cc2c(cc(C3(O)c4n(cnc4)CC3)cc2)cc1	O=C(NC)c1cc2c(cc(C3(O)c4n(cnc4)CC3)cc2)cc1
NCGC00249892-01	O=C(NC)c1cn(-c2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)c3n2)nc1		Inactive	Adenosine A2a Receptor Agonist&Adenosine A2a receptor Agonist		1	Lexiscan	170465244	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.554912536&0.0	O=C(NC)c1cn(-c2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)c3n2)nc1	O=C(NC)c1cn(-c2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)c3n2)nc1
NCGC00386432-02	O=C(NC)c1nccc(Oc2cc3sc(N[C@H]4[C@H](O)CCCC4)nc3cc2)c1	4.4000001	Active	CSF1R (c-FMS) Inhibitor	0.0	1	BLZ-945	363680284	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-81.905835212	O=C(NC)c1nccc(Oc2cc3sc(N[C@H]4[C@H](O)CCCC4)nc3cc2)c1	O=C(NC)c1nccc(Oc2cc3sc(N[C@H]4[C@H](O)CCCC4)nc3cc2)c1
NCGC00263101-07	O=C(NC/C=C/c1cc2c(Nc3cc(C)c(Oc4cnc(C)cc4)cc3)ncnc2cc1)COC	4.4000001	Active	HER2 Inhibitor	0.0	1	CP-724714	363677202	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-47.3237004134	O=C(NC/C=C/c1cc2c(Nc3cc(C)c(Oc4cnc(C)cc4)cc3)ncnc2cc1)COC	O=C(NC/C=C/c1cc2c(Nc3cc(C)c(Oc4cnc(C)cc4)cc3)ncnc2cc1)COC
NCGC00371151-06	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(N2CCN(CCC)CC2)cc1	6.0	Active	Cruzipain (Trypanosoma cruzi) Inhibitor	0.0	1	Balicatib	363678065	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-45.8608793342	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(N2CCN(CCC)CC2)cc1	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(N2CCN(CCC)CC2)cc1
NCGC00167515-03	O=C(NC1=NC(=O)N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1)CCCCCCCCCCCCCCCCCCCCC	4.0500002	Inactive	cell growth Inhibitor	0.0	1	Enocitabine	405558460	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	83.9578355321	O=C(NC1=NC(=O)N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1)CCCCCCCCCCCCCCCCCCCCC	O=C(NC1=NC(=O)N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1)CCCCCCCCCCCCCCCCCCCCC
NCGC00238454-10	O=C(NC1=Nc2c(OC)c(OC)ccc2C=2N1CCN=2)c1cnccc1		Inactive	PI3K Inhibitor		1	PIK-90	377020194	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NC1=Nc2c(OC)c(OC)ccc2C=2N1CCN=2)c1cnccc1	O=C(NC1=Nc2c(OC)c(OC)ccc2C=2N1CCN=2)c1cnccc1
NCGC00389455-01	O=C(NC1C(=O)N2C(C(=O)O)C(C)(C)SC12)Cc1ccccc1	4.4000001	Active	Bacterial Penicillin-binding Protein Inhibitor	0.0	1	Penicillin G Sodium	405558782	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-54.2481164079	O=C(NC1C(=O)N2C(C(=O)[O-])C(C)(C)SC12)Cc1ccccc1	O=C(NC1C(=O)N2C(C(=O)[O-])C(C)(C)SC12)Cc1ccccc1
NCGC00094956-04	O=C(NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)Cc1sccc1		Inactive	Solute Carrier Family 22 Member 7 Inhibitor&Solute carrier family 22 member 7 Inhibitor		1	Cephaloridine	124891818	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.850224996&0.0	O=C(NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)Cc1sccc1	O=C(NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)Cc1sccc1
NCGC00094854-07	O=C(NC1C(=O)NC(=O)N1)N		Inactive	Allantoinase Substrate		1	Allantoin	170465460	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(NC1C(=O)NC(=O)N1)N	O=C(NC1C(=O)NC(=O)N1)N
NCGC00025059-08	O=C(NC1C(=O)NC(C(C)C)C(=O)N2C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC1C)CCC2)c1c2N=C3C(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1	8.5	Inactive	DNA-Directed RNA Polymerase Inhibitor	0.0	1	Actinomycin D	384568044	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-53.2947106399	O=C(NC1C(=O)NC(C(C)C)C(=O)N2C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC1C)CCC2)c1c2N=C3C(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1	O=C(NC1C(=O)NC(C(C)C)C(=O)N2C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC1C)CCC2)c1c2N=C3C(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1
NCGC00379082-01	O=C(NC1C(=O)NC(C(O)C)C(=O)N2C(C(=O)NC(C(O)C(O)c3ccc(O)cc3)C(=O)NC(C(O)C)C(=O)N3C(C(=O)NC(O)C(O)C1)C(O)C(C)C3)CC(O)C2)c1ccc(-c2ccc(-c3ccc(OCCCCC)cc3)cc2)cc1	5.0	Active		0.0	1	Anidulafungin	405558984	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-109.4556073796&-109.5376474155	O=C(NC1C(=O)NC(C(O)C)C(=O)N2C(C(=O)NC(C(O)C(O)c3ccc(O)cc3)C(=O)NC(C(O)C)C(=O)N3C(C(=O)NC(O)C(O)C1)C(O)C(C)C3)CC(O)C2)c1ccc(-c2ccc(-c3ccc(OCCCCC)cc3)cc2)cc1	O=C(NC1C(=O)NC(C(O)C)C(=O)N2C(C(=O)NC(C(O)C(O)c3ccc(O)cc3)C(=O)NC(C(O)C)C(=O)N3C(C(=O)NC(O)C(O)C1)C(O)C(C)C3)CC(O)C2)c1ccc(-c2ccc(-c3ccc(OCCCCC)cc3)cc2)cc1
NCGC00379009-01	O=C(NC1C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c3c([nH]c2)cccc3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(C(O)C)CO)CSSC1)C(N)Cc1ccccc1		Inactive	Growth Hormone Release Inhibitor&Growth Hormone Release Inhibitors		1	Octreotide acetate	405558482	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.1709868&-15.777346488	O=C(NC1C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c3c([nH]c2)cccc3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(C(O)C)CO)CSSC1)C(N)Cc1ccccc1	O=C(NC1C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c3c([nH]c2)cccc3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(C(O)C)CO)CSSC1)C(N)Cc1ccccc1
NCGC00386357-01	O=C(NC1C(=O)N[C@@H]([C@H](O)C)C(=O)N2[C@H](C(=O)N[C@@H]([C@H](O)[C@@H](O)c3ccc(O)cc3)C(=O)N[C@@H]([C@H](O)CCN)C(=O)N3[C@@H]([C@@H](O)CC3)C(=O)N[C@H](NCCN)[C@H](O)C1)C[C@@H](O)C2)CCCCCCCC[C@@H](C[C@@H](CC)C)C		Inactive	1,3-beta-glucan Synthase Inhibitor&1,3-beta-glucan synthase Inhibitor		1	NCGC00386357-01&Caspofungin Acetate	405558793	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.826437212&17.87507272	O=C(NC1C(=O)N[C@@H]([C@H](O)C)C(=O)N2[C@H](C(=O)N[C@@H]([C@H](O)[C@@H](O)c3ccc(O)cc3)C(=O)N[C@@H]([C@H](O)CCN)C(=O)N3[C@@H]([C@@H](O)CC3)C(=O)N[C@H](NCCN)[C@H](O)C1)C[C@@H](O)C2)CCCCCCCC[C@@H](C[C@@H](CC)C)C	O=C(NC1C(=O)N[C@@H]([C@H](O)C)C(=O)N2[C@H](C(=O)N[C@@H]([C@H](O)[C@@H](O)c3ccc(O)cc3)C(=O)N[C@@H]([C@H](O)CCN)C(=O)N3[C@@H]([C@@H](O)CC3)C(=O)N[C@H](NCCN)[C@H](O)C1)C[C@@H](O)C2)CCCCCCCC[C@@H](C[C@@H](CC)C)C
NCGC00510518-01	O=C(NC1CC1)c1c(C)cc(-c2c3n(C(NCC4CC(O)(C)C4)=CC(Oc4cnccc4)=N3)nc2)cc1		Inactive	MPS1 Inhibitor		1	CFI-402257	384569471	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.058823124	O=C(NC1CC1)c1c(C)cc(-c2c3n(C(NCC4CC(O)(C)C4)=CC(Oc4cnccc4)=N3)nc2)cc1	O=C(NC1CC1)c1c(C)cc(-c2c3n(C(NCC4CC(O)(C)C4)=CC(Oc4cnccc4)=N3)nc2)cc1
NCGC00346966-01	O=C(NC1CC1)c1cc(-c2cc3[nH]nc(NC(=O)C4CC4)c3cc2)ccc1	5.0999999	Active	Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)	0.0	1	HMSL10088	174006754	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-50.3111229443	O=C(NC1CC1)c1cc(-c2cc3[nH]nc(NC(=O)C4CC4)c3cc2)ccc1	O=C(NC1CC1)c1cc(-c2cc3[nH]nc(NC(=O)C4CC4)c3cc2)ccc1
NCGC00386261-01	O=C(NC1CC2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	6.0	Active	Heat Shock Protein 90 (Hsp90) Inhibitor	0.0	1	XL-888	363680173	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-69.2077762636	O=C(NC1CC2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	O=C(NC1CC2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1
NCGC00263087-10	O=C(NC1CCC(N2CCN(CC3CC3)CC2)CC1)c1cc(OC)c(Nc2nc3N(C(C)C)[C@H](CC)C(=O)N(C)c3cn2)cc1	5.5500002	Active	Polo-like Kinase-1 (Plk-1) Inhibitor	0.0	1	Volasertib	384568581	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-84.7352218852	O=C(NC1CCC(N2CCN(CC3CC3)CC2)CC1)c1cc(OC)c(Nc2nc3N(C(C)C)[C@H](CC)C(=O)N(C)c3cn2)cc1	O=C(NC1CCC(N2CCN(CC3CC3)CC2)CC1)c1cc(OC)c(Nc2nc3N(C(C)C)[C@H](CC)C(=O)N(C)c3cn2)cc1
NCGC00346836-09	O=C(NC1CCCCC1)[C@@H]1CN([C@H](C)CC1)c1nc(NC)nc(-c2cc3[nH]nc(N)c3cc2)c1	4.4000001	Active	Phosphoinositide Dependent Kinase Inhibitor	0.0	1	GSK-2334470	384568948	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-65.570540968	O=C(NC1CCCCC1)[C@@H]1CN([C@H](C)CC1)c1nc(NC)nc(-c2cc3[nH]nc(N)c3cc2)c1	O=C(NC1CCCCC1)[C@@H]1CN([C@H](C)CC1)c1nc(NC)nc(-c2cc3[nH]nc(N)c3cc2)c1
NCGC00346965-01	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N(C4CCCC4)CCC(=O)N(C(C)C)c3cn2)cc1	4.5	Active	FLT4	0.0	1	HMSL10087	174006428	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-120.9236376863	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N(C4CCCC4)CCC(=O)N(C(C)C)c3cn2)cc1	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N(C4CCCC4)CCC(=O)N(C(C)C)c3cn2)cc1
NCGC00253438-12	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N([C@H](CC)C(=O)N(C)c3cn2)C2CCCC2)cc1	9.0	Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor	0.0	1	BI-2536	384568561	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-34.0700892215	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N([C@H](CC)C(=O)N(C)c3cn2)C2CCCC2)cc1	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N([C@H](CC)C(=O)N(C)c3cn2)C2CCCC2)cc1
NCGC00165810-02	O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1	4.4000001	Active	Alpha-1d Adrenergic Receptor Antagonist	0.0	1	Indoramin hydrochloride	170466233	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-27.602710064	O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1.Cl	O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1.Cl
NCGC00346679-10	O=C(NC1CCOCC1)c1ccc(-c2nccc(-c3c(-c4ncccc4)n[nH]c3)c2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	GW-788388	363677513	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NC1CCOCC1)c1ccc(-c2nccc(-c3c(-c4ncccc4)n[nH]c3)c2)cc1	O=C(NC1CCOCC1)c1ccc(-c2nccc(-c3c(-c4ncccc4)n[nH]c3)c2)cc1
NCGC00183029-02	O=C(NC1CNCCC1)c1cc(OC)c(OC)c(OC)c1		Inactive	Reactive Oxygen Species Biosynthetic Process Inhibitor&reactive oxygen species biosynthetic process Inhibitor		1	Troxipide	170465889	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-9.9952290759&0.0	O=C(NC1CNCCC1)c1cc(OC)c(OC)c(OC)c1	O=C(NC1CNCCC1)c1cc(OC)c(OC)c(OC)c1
NCGC00183011-01	O=C(NC1C[C@@H]2N(C)[C@H](C1)CC2)N1C(=O)Nc2c1cccc2		Inactive	Serotonin 3 (5-ht3) Receptor Antagonist&Serotonin 3 (5-HT3) receptor Antagonist		1	Itasetron	144206831	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.2037143039&13.729721004	O=C(NC1C[C@@H]2N(C)[C@H](C1)CC2)N1C(=O)Nc2c1cccc2	O=C(NC1C[C@@H]2N(C)[C@H](C1)CC2)N1C(=O)Nc2c1cccc2
NCGC00408801-01	O=C(NC1C[C@H]2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	5.9499998	Active	Heat Shock Protein 90 (Hsp90) Inhibitor	0.0	1	XL-888	363681051	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-40.4086925946	O=C(NC1C[C@H]2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	O=C(NC1C[C@H]2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1
NCGC00016605-08	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)c1cnccc1		Inactive			1	Nifenazone	170466050	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.9297056319&0.0	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)c1cnccc1	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)c1cnccc1
NCGC00244257-02	O=C(NCC#N)c1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2)cc1	5.0	Active	Jak1/2 Inhibitor	0.0	1	Momelotinib	384568509	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.9652475883	O=C(NCC#N)c1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2)cc1	O=C(NCC#N)c1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2)cc1
NCGC00387803-01	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(Cc3ccc(OCC)cc3)NC(=O)CCSSC2)CCC1)CCCN		Inactive	Oxytocin Receptor Antagonist&Oxytocin receptor Antagonist		1	Atosiban	405558677	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	42.377049312&-27.4996885365	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(Cc3ccc(OCC)cc3)NC(=O)CCSSC2)CCC1)CCCN	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(Cc3ccc(OCC)cc3)NC(=O)CCSSC2)CCC1)CCCN
NCGC00379053-02	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(Cc3ccccc3)NC(=O)C(Cc3ccc(O)cc3)NC(=O)CCSSC2)CCC1)CCCNC(=N)N		Inactive	Vasopressin receptor Agonist&Vasopressin Receptor Agonist		1	Desmopressin (Acetate)	405558564	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.445412892&0.0	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(Cc3ccccc3)NC(=O)C(Cc3ccc(O)cc3)NC(=O)CCSSC2)CCC1)CCCNC(=N)N	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(Cc3ccccc3)NC(=O)C(Cc3ccc(O)cc3)NC(=O)CCSSC2)CCC1)CCCNC(=N)N
NCGC00390811-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CC(C)C	4.4000001	Active	Oxytocin Receptor Agonist	0.0	1	Oxytocin	405558950	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.617025084	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CC(C)C	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CC(C)C
NCGC00181743-02	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN		Inactive	Vasopressin Receptor Agonist&Vasopressin receptor Agonist		1	Lypressin	144206977	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.426723732&-25.650588084	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN
NCGC00509864-02	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCN	4.5	Active		0.0	1	ORNIPRESSIN	405558494	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.704892916	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCN
NCGC00185754-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC2)CCC1)CCCCN	4.6999998	Active	Vasopressin V1a Receptor Partial Agonist	0.0	1	Terlipressin	144206925	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-35.7799185105&-38.247145196	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC2)CCC1)CCCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC2)CCC1)CCCCN
NCGC00182033-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN		Inactive	Vasopressin V1a Receptor Agonist&Vasopressin V1a receptor Agonist		1	Felypressin	144206485	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.920580544&17.2934148921	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN
NCGC00183107-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)N(C)C(=O)CCCSC2)CCC1)CC(C)C		Inactive			1	NCGC00183107-01	124894307	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-33.917916608&-9.2934207641	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)N(C)C(=O)CCCSC2)CCC1)CC(C)C	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)N(C)C(=O)CCCSC2)CCC1)CC(C)C
NCGC00384204-04	O=C(NCC(=O)N1CCCC1)Nc1cc2c(cncc2)cc1		Inactive	PRMT3 Inhibitor		1	SGC-707	363679195	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.778092876	O=C(NCC(=O)N1CCCC1)Nc1cc2c(cncc2)cc1	O=C(NCC(=O)N1CCCC1)Nc1cc2c(cncc2)cc1
NCGC00378640-02&NCGC00378640-03	O=C(NCC(=O)O)[C@H](CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)Cc1ccccc1		Inactive	mu-Opioid Antagonist&Mu-type Opioid Receptor Antagonist&mu-Opioid Antagonist		2	Alvimopan	363678135&405558558	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-24.287553812	O=C(NCC(=O)O)[C@H](CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)Cc1ccccc1	O=C(NCC(=O)O)[C@H](CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)Cc1ccccc1
NCGC00186464-03&NCGC00186464-04	O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1		Inactive	Renin Inhibitor		2	Aliskiren hemifumarate	170465199&384568441	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	20.566115388&-16.924701136&0.0	O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1.Cl	O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1.Cl&O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1
NCGC00511392-01	O=C(NCC(C)(C)n1nc(-c2ccc(C)cc2)c2c(N)ncnc12)c1ccncc1	4.75	Active	RIP2 kinase Inhibitor	0.0	1	WEHI-345	384569503	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-60.5083211228	O=C(NCC(C)(C)n1nc(-c2ccc(C)cc2)c2c(N)ncnc12)c1ccncc1	O=C(NCC(C)(C)n1nc(-c2ccc(C)cc2)c2c(N)ncnc12)c1ccncc1
NCGC00178238-05	O=C(NCC(O)c1c(OC)ccc(OC)c1)CN	5.5	Active	Alpha-1b Adrenergic Receptor Agonist	0.0	1	Midodrine hydrochloride	170464672	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-43.8568781168	O=C(NCC(O)c1c(OC)ccc(OC)c1)CN.Cl	O=C(NCC(O)c1c(OC)ccc(OC)c1)CN.Cl
NCGC00481575-01	O=C(NCC)C#Cc1cc2NC(=O)/C(=C(\Nc3ccc(CN(C)C)cc3)/c3ccccc3)/c2cc1	4.75	Active	Aurora Kinase Inhibitor	0.0	1	BI-847325	363681124	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-61.2314865182	O=C(NCC)C#Cc1cc2NC(=O)/C(=C(\Nc3ccc(CN(C)C)cc3)/c3ccccc3)/c2cc1	O=C(NCC)C#Cc1cc2NC(=O)/C(=C(\Nc3ccc(CN(C)C)cc3)/c3ccccc3)/c2cc1
NCGC00346520-02	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(O)CCc2ccccc2)[C@@H](O)C[C@@H]1O		Inactive	prostaglandin		1	Bimatoprost	363677439	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-24.1658478759	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(O)CCc2ccccc2)[C@@H](O)C[C@@H]1O	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(O)CCc2ccccc2)[C@@H](O)C[C@@H]1O
NCGC00181745-03	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O		Inactive	prostaglandin&Prostaglandin		1	Bimatoprost	405558553	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.1266611&0.0	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
NCGC00346574-04	O=C(NCC)Nc1c(OC)cc(-c2nc(N[C@@H](CCC)c3cnccc3)c(C)cn2)cc1	9.0	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Lexibulin hydrochloride	384568847	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-14.9928328041	O=C(NCC)Nc1c(OC)cc(-c2nc(N[C@@H](CCC)c3cnccc3)c(C)cn2)cc1	O=C(NCC)Nc1c(OC)cc(-c2nc(N[C@@H](CCC)c3cnccc3)c(C)cn2)cc1
NCGC00346465-06	O=C(NCC)Nc1ccc(-c2nc(N3[C@@H](C)COCC3)c3c(n2)CN(C2COC2)CC3)cc1	5.0	Active	Pim-3 Kinase Inhibitor, mTOR	0.0	1	GDC-0349	384568786	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-68.3942340936	O=C(NCC)Nc1ccc(-c2nc(N3[C@@H](C)COCC3)c3c(n2)CN(C2COC2)CC3)cc1	O=C(NCC)Nc1ccc(-c2nc(N3[C@@H](C)COCC3)c3c(n2)CN(C2COC2)CC3)cc1
NCGC00372509-03	O=C(NCC)Nc1sc(-c2nc(-c3nccnc3)nc(-c3c(C)cc(OC)cc3C)c2)cn1		Inactive	LIMK1/LIMK2 Inhibitor		1	BMS-4	363678075	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NCC)Nc1sc(-c2nc(-c3nccnc3)nc(-c3c(C)cc(OC)cc3C)c2)cn1	O=C(NCC)Nc1sc(-c2nc(-c3nccnc3)nc(-c3c(C)cc(OC)cc3C)c2)cn1
NCGC00247878-08	O=C(NCC)c1c(c(-c2c(O)cc(O)c(C(C)C)c2)on1)-c1ccc(CN2CCOCC2)cc1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	NVP-AUY922	384568519	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	44.067432606	O=C(NCC)c1c(c(-c2c(O)cc(O)c(C(C)C)c2)on1)-c1ccc(CN2CCOCC2)cc1	O=C(NCC)c1c(c(-c2c(O)cc(O)c(C(C)C)c2)on1)-c1ccc(CN2CCOCC2)cc1
NCGC00384304-02	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCC(N(CCOC)C)CC2)cc(C#CCN2CCOCC2)c1		Inactive	Histone-lysine N-methyltransferase EZH2 Inhibitor		1	EPZ011989	384569110	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCC(N(CCOC)C)CC2)cc(C#CCN2CCOCC2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCC(N(CCOC)C)CC2)cc(C#CCN2CCOCC2)c1
NCGC00381562-02	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCOCC2)cc(-c2ccc(CN3CCOCC3)cc2)c1		Inactive	EZH2 Inhibitor		1	Tazemetostat	384569100	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.355211228	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCOCC2)cc(-c2ccc(CN3CCOCC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCOCC2)cc(-c2ccc(CN3CCOCC3)cc2)c1
NCGC00480919-01	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	4.9499998	Inactive		0.0	1	GSK-503?EZH2 inhibitor	384569251	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	57.7491877958	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1
NCGC00347286-15	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn([C@H](CC)C)c2cc(-c2cnc(N3CCNCC3)cc2)c1	4.4499998	Active	EZH2 Inhibitor	0.0	1	GSK-126	384568986	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-60.7951399559	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn([C@H](CC)C)c2cc(-c2cnc(N3CCNCC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn([C@H](CC)C)c2cc(-c2cnc(N3CCNCC3)cc2)c1
NCGC00351604-03	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(n(C3CCCC3)nc2)cc(-c2ccc(CN3CCOCC3)cc2)c1	4.4000001	Active	EZH2 Inhibitor	0.0	1	EPZ-005687	384569019	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-36.181050024	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(n(C3CCCC3)nc2)cc(-c2ccc(CN3CCOCC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(n(C3CCCC3)nc2)cc(-c2ccc(CN3CCOCC3)cc2)c1
NCGC00351480-16	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cc(N3CCN(C)CC3)ncc2)c1	4.4000001	Active	EZH2 Inhibitor	0.0	1	GSK-343	384569008	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-95.3877866199	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cc(N3CCN(C)CC3)ncc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cc(N3CCN(C)CC3)ncc2)c1
NCGC00351477-05	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cnc(N3CCN(C(C)C)CC3)cc2)c1	4.9000001	Active	EZH1 Inhibitor	0.0	1	UNC-1999	384569006	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-91.26228454	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cnc(N3CCN(C(C)C)CC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cnc(N3CCN(C(C)C)CC3)cc2)c1
NCGC00390645-03	O=C(NCC=1C(=O)NC(C)=CC=1OC)c1c(C)n([C@H](C)C2CCOCC2)c2c1cccc2	4.4000001	Active	EZH2 Inhibitor	0.0	1	CPI-360	384569205	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-45.168213116	O=C(NCC=1C(=O)NC(C)=CC=1OC)c1c(C)n([C@H](C)C2CCOCC2)c2c1cccc2	O=C(NCC=1C(=O)NC(C)=CC=1OC)c1c(C)n([C@H](C)C2CCOCC2)c2c1cccc2
NCGC00167328-03	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)OCC)O1)CC(C)C	5.75	Active	Calpain Inhibitor	0.0	1	Aloxistatin	363676654	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-82.5001574127	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)OCC)O1)CC(C)C	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)OCC)O1)CC(C)C
NCGC00507842-01	O=C(NCCC)c1c(C)c2C(Nc3c(C)ccc(C(=O)NC4CC4)c3)=NC=Nn2c1		Inactive	p38 MAPK Inhibitor		1	BMS-582949	384569324	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-32.923479736	O=C(NCCC)c1c(C)c2C(Nc3c(C)ccc(C(=O)NC4CC4)c3)=NC=Nn2c1	O=C(NCCC)c1c(C)c2C(Nc3c(C)ccc(C(=O)NC4CC4)c3)=NC=Nn2c1
NCGC00167476-02	O=C(NCCCC(=O)O)C(O)C(CO)(C)C	5.0	Active		0.0	1	Calcium hopantenate	50112729	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-54.8730803586	O=C(NCCCC(=O)[O-])C(O)C(CO)(C)C	O=C(NCCCC(=O)[O-])C(O)C(CO)(C)C
NCGC00182868-16	O=C(NCCCCC1CCN(C(=O)c2ccccc2)CC1)/C=C/c1cnccc1	4.5	Inactive	NAMPT Inhibitor	0.0	1	Daporinad	384568412	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-1.8374284561	O=C(NCCCCC1CCN(C(=O)c2ccccc2)CC1)/C=C/c1cnccc1	O=C(NCCCCC1CCN(C(=O)c2ccccc2)CC1)/C=C/c1cnccc1
NCGC00167801-02	O=C(NCCCCN1CCOCC1)c1oc2c(c1)cccc2	5.4499998	Inactive	MMP13 Inhibitor	0.0	1	CL-82198	384568338	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	89.7049782067	O=C(NCCCCN1CCOCC1)c1oc2c(c1)cccc2	O=C(NCCCCN1CCOCC1)c1oc2c(c1)cccc2
NCGC00183869-01	O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N	4.5	Active	Heat Shock Protein Hsp90 Binding Agent&Heat shock protein HSP90 Binding Agent	0.0	1	Gusperimus trihydrochloride	144206777	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-48.2844748456&-49.4129882296	O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N.Cl.Cl.Cl	O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N.Cl.Cl.Cl
NCGC00356803-11	O=C(NCCCN(C(C)C)C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1)Nc1ccc(C(C)(C)C)cc1		Inactive	DOT1L Inhibitor		1	EPZ004777	384569032	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.64231652	O=C(NCCCN(C(C)C)C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1)Nc1ccc(C(C)(C)C)cc1	O=C(NCCCN(C(C)C)C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1)Nc1ccc(C(C)(C)C)cc1
NCGC00183808-01	O=C(NCCCN(C)C)c1ccc(-c2cc(O)c3ncccc3c2)cc1	4.4000001	Active	JMJ Inhibitor	0.0	1	ML324	85736407	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-115.2235559498	O=C(NCCCN(C)C)c1ccc(-c2cc(O)c3ncccc3c2)cc1	O=C(NCCCN(C)C)c1ccc(-c2cc(O)c3ncccc3c2)cc1
NCGC00095152-09	O=C(NCCCN(C)c1nc(N)c2c(n1)cc(OC)c(OC)c2)C1OCCC1	4.4000001	Active	Alpha1-adrenoceptor Antagonists&alpha1-Adrenoceptor Antagonists	0.0	1	Alfuzosin hydrochloride	170465022	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-68.3852089799&-64.916964276	O=C(NCCCN(C)c1nc(N)c2c(n1)cc(OC)c(OC)c2)C1OCCC1.Cl	O=C(NCCCN(C)c1nc(N)c2c(n1)cc(OC)c(OC)c2)C1OCCC1.Cl
NCGC00356417-05	O=C(NCCCN1CCCC1)c1cc(C#N)cc(-c2c(N3CCN(CCn4c5c(c(C)c4)cccc5)CC3)cccc2)c1	4.75	Active	SMYD2 Inhibitor	0.0	1	LLY-507	384569030	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-107.798355806	O=C(NCCCN1CCCC1)c1cc(C#N)cc(-c2c(N3CCN(CCn4c5c(c(C)c4)cccc5)CC3)cccc2)c1	O=C(NCCCN1CCCC1)c1cc(C#N)cc(-c2c(N3CCN(CCn4c5c(c(C)c4)cccc5)CC3)cccc2)c1
NCGC00522516-01	O=C(NCCCN=[N+]=[N-])CCCOc1c(C(C)(C)C)cc(-c2[nH]c3c(n2)ccc(N2CCN(C)CC2)c3)cc1C(C)(C)C	5.4499998	Active	microRNA-96 Inhibitor	0.0	1	MIR96-IN-1	384569523	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-82.9336622151	O=C(NCCCN=[N+]=[N-])CCCOc1c(C(C)(C)C)cc(-c2[nH]c3c(n2)ccc(N2CCN(C)CC2)c3)cc1C(C)(C)C	O=C(NCCCN=[N+]=[N-])CCCOc1c(C(C)(C)C)cc(-c2[nH]c3c(n2)ccc(N2CCN(C)CC2)c3)cc1C(C)(C)C
NCGC00386818-01	O=C(NCCCNC(=O)c1noc(-c2ccccc2)c1)c1c(O)nccc1		Inactive	CDH1 Expression Enhancers		1	ML327	363680447	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NCCCNC(=O)c1noc(-c2ccccc2)c1)c1c(O)nccc1	O=C(NCCCNC(=O)c1noc(-c2ccccc2)c1)c1c(O)nccc1
NCGC00378780-02	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc(CN3CCOCC3)ccc2)n1)C1CCC1		Inactive	ULK1 Inhibitor		1	MRT-67307	363678194	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc(CN3CCOCC3)ccc2)n1)C1CCC1	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc(CN3CCOCC3)ccc2)n1)C1CCC1
NCGC00486904-01	O=C(NCCCNc1c(C2CC2)cnc(Nc2ccc(N3CCOCC3)cc2)n1)C1CCC1	4.8000002	Active	IKK-epsilon Inhibitor	0.0	1	MRT-68601 hydrochloride	377020217	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.8489305801	O=C(NCCCNc1c(C2CC2)cnc(Nc2ccc(N3CCOCC3)cc2)n1)C1CCC1	O=C(NCCCNc1c(C2CC2)cnc(Nc2ccc(N3CCOCC3)cc2)n1)C1CCC1
NCGC00186658-01	O=C(NCCCO)[C@H](O)C(CO)(C)C		Inactive			1	Dexpanthenol	170464647	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.281856632	O=C(NCCCO)[C@H](O)C(CO)(C)C	O=C(NCCCO)[C@H](O)C(CO)(C)C
NCGC00167499-02	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)COC(=O)C	6.1500001	Active		0.0	1	Roxatidine acetate hydrochloride	170465941	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.2339057919	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)COC(=O)C.Cl	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)COC(=O)C.Cl
NCGC00182982-01	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)NCC		Inactive	Histamine H2 Receptor Antagonist&Histamine H2 receptor Antagonist		1	Dalcotidine	144206834	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)NCC	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)NCC
NCGC00386757-02	O=C(NCCN(C)C)COc1c2cccc1Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)C2		Inactive	Allosteric Inhibitor of galectin-1		1	OTX-008	384569145	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NCCN(C)C)COc1c2cccc1Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)C2	O=C(NCCN(C)C)COc1c2cccc1Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)C2
NCGC00510483-02	O=C(NCCN(CC)CC)c1c(C)c(/C=C\2/C(=O)Nc3c/2cc(-c2nc(-c4ccccc4)sc2)cc3)[nH]c1C	4.6500001	Active	PDGFR alpha Inhibitor	0.0	1	Amcasertib	384569446	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-111.0721319944	O=C(NCCN(CC)CC)c1c(C)c(/C=C\2/C(=O)Nc3c/2cc(-c2nc(-c4ccccc4)sc2)cc3)[nH]c1C	O=C(NCCN(CC)CC)c1c(C)c(/C=C\2/C(=O)Nc3c/2cc(-c2nc(-c4ccccc4)sc2)cc3)[nH]c1C
NCGC00016338-10	O=C(NCCN(CC)CC)c1c2c(nc(OCCCC)c1)cccc2	4.8499999	Active	Sodium Channel Protein Type X Alpha Subunit Blocker&Sodium channel protein type X alpha subunit Blocker	0.0	1	Dibucaine	170464829	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-71.5584716844&-81.7653769369	O=C(NCCN(CC)CC)c1c2c(nc(OCCCC)c1)cccc2	O=C(NCCN(CC)CC)c1c2c(nc(OCCCC)c1)cccc2
NCGC00015859-14	O=C(NCCN(CC)CC)c1ccc(N)cc1		Inactive	Sodium channel alpha subunit Blocker&Sodium Channel Alpha Subunit Blocker		1	Procainamide	170464952	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(NCCN(CC)CC)c1ccc(N)cc1	O=C(NCCN(CC)CC)c1ccc(N)cc1
NCGC00482810-01	O=C(NCCNCc1c(OC)nc(OCc2c(C)c(-c3ccccc3)ccc2)cc1)C	4.9499998	Active	Inhibitor of PD-l/PD-Ll	0.0	1	BMS-202	384569261	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-98.5035234807	O=C(NCCNCc1c(OC)nc(OCc2c(C)c(-c3ccccc3)ccc2)cc1)C	O=C(NCCNCc1c(OC)nc(OCc2c(C)c(-c3ccccc3)ccc2)cc1)C
NCGC00346486-03	O=C(NCCOc1ccc(C(=O)NO)cc1)c1c(CN(C)C)c2c(o1)cccc2		Inactive	HDAC Inhibitor		1	Abexinostat	384568795	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NCCOc1ccc(C(=O)NO)cc1)c1c(CN(C)C)c2c(o1)cccc2	O=C(NCCOc1ccc(C(=O)NO)cc1)c1c(CN(C)C)c2c(o1)cccc2
NCGC00015680-18&NCGC00015680-33	O=C(NCCc1c2c([nH]c1)ccc(OC)c2)C		Inactive	Free Radical Scavengers; Nos2 Expression Inhibitors; Th Expression Enhancers&NOS2 Expression Inhibitor&NOS2 Expression Inhibitor		2	Melatonin	170465589&384567881	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NCCc1c2c([nH]c1)ccc(OC)c2)C	O=C(NCCc1c2c([nH]c1)ccc(OC)c2)C
NCGC00253646-01&NCGC00253646-08	O=C(NCCc1c2c(ccc(OC)c2)ccc1)C	4.4499998	Inactive	5-ht2c Antagonist&5-HT2C Antagonist&5-HT2C Antagonist	0.0	2	Agomelatine	174006904&384568565	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	0.0&0.0&78.5707130985	O=C(NCCc1c2c(ccc(OC)c2)ccc1)C	O=C(NCCc1c2c(ccc(OC)c2)ccc1)C
NCGC00263906-02	O=C(NCN1CCCC1)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)C3C[C@H]2[C@H](N(C)C)C=1O		Inactive			1	Rolitetracycline	170465919	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.8408645159&0.0	O=C(NCN1CCCC1)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)C3C[C@H]2[C@H](N(C)C)C=1O	O=C(NCN1CCCC1)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)C3C[C@H]2[C@H](N(C)C)C=1O
NCGC00179313-05	O=C(NCNC(=O)NC1N(CO)C(=O)NC1=O)NC1N(CO)C(=O)NC1=O		Inactive	T-lymphocyte Activation Antigen Cd86 Activator&T-lymphocyte activation antigen CD86 Activator		1	Imidazolidinyl urea	405559029	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.2493697839&0.0	O=C(NCNC(=O)NC1N(CO)C(=O)NC1=O)NC1N(CO)C(=O)NC1=O	O=C(NCNC(=O)NC1N(CO)C(=O)NC1=O)NC1N(CO)C(=O)NC1=O
NCGC00483168-02	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1cc(NC2CCC2)ncc1		Inactive	PRMT5 Inhibitor		1	EPZ-015866	384569264	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	8.2619950479	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1cc(NC2CCC2)ncc1	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1cc(NC2CCC2)ncc1
NCGC00386436-01	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1ncnc(NC2COC2)c1		Inactive	PRMT5 Inhibitor		1	EPZ-015666	384569141	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.7198302639	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1ncnc(NC2COC2)c1	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1ncnc(NC2COC2)c1
NCGC00522560-01	O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC		Inactive	Melatonin Receptor Type 1b Agonist&Melatonin receptor type 1B Agonist		1	Tasimelteon	405558964	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.6548020119&-15.7225652481	O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC	O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC
NCGC00510160-03	O=C(NCc1cc(C)c(Oc2cc(C)cc(C)c2)cc1)[C@@H](N)C	4.4000001	Active	CoActivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitor	0.0	1	SGC-2085	384569410	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-36.751552372	O=C(NCc1cc(C)c(Oc2cc(C)cc(C)c2)cc1)[C@@H](N)C	O=C(NCc1cc(C)c(Oc2cc(C)cc(C)c2)cc1)[C@@H](N)C
NCGC00371153-09	O=C(NCc1cc(O)ccc1)Nc1scc(-c2ccncc2)n1	4.4000001	Active	ROCK1/ROCK2 Inhibitor	0.0	1	RKI-1447	363678067	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-72.533754808	O=C(NCc1cc(O)ccc1)Nc1scc(-c2ccncc2)n1	O=C(NCc1cc(O)ccc1)Nc1scc(-c2ccncc2)n1
NCGC00016089-06	O=C(NCc1cc(OC)c(O)cc1)CCCCCCCC		Inactive	Vanilloid receptor Agonist&Vanilloid Receptor Agonist		1	Nonivamide	170466476	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.522160396&0.0	O=C(NCc1cc(OC)c(O)cc1)CCCCCCCC	O=C(NCc1cc(OC)c(O)cc1)CCCCCCCC
NCGC00016509-06	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1		Inactive	Dopamine D2 Receptor Antagonist&Dopamine D2 receptor Antagonist		1	Trimethobenzamide hydrochloride	170465132	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.6958001119&17.8935886119	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1.Cl	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1.Cl
NCGC00167529-02	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)cc1	4.4000001	Active	Acetylcholinesterase Inhibitor	0.0	1	Itopride hydrochloride	170465974	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.877400832	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)cc1.Cl	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)cc1.Cl
NCGC00016014-09	O=C(NCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1	4.5500002	Active	STAT-3 Inhibitor	0.0	1	Tyrphostin B42	124881627	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-54.1039428576	O=C(NCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1	O=C(NCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1
NCGC00346644-04	O=C(NCc1ccccc1)Cc1ncc(-c2ccc(OCCN3CCOCC3)cc2)cc1	9.0	Inactive	Src Kinase Inhibitor	0.0	1	KX-01	384568876	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-7.264735376	O=C(NCc1ccccc1)Cc1ncc(-c2ccc(OCCN3CCOCC3)cc2)cc1	O=C(NCc1ccccc1)Cc1ncc(-c2ccc(OCCN3CCOCC3)cc2)cc1
NCGC00263116-09	O=C(NCc1ccccc1)N1[C@@H]2N([C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3c4c(ccc3)cccc4)C2)C(=O)CC1	9.0	Inactive	Wnt Signaling Inhibitor	0.0	1	ICG-001	384568600	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-11.422348344	O=C(NCc1ccccc1)N1[C@@H]2N([C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3c4c(ccc3)cccc4)C2)C(=O)CC1	O=C(NCc1ccccc1)N1[C@@H]2N([C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3c4c(ccc3)cccc4)C2)C(=O)CC1
NCGC00345807-02	O=C(NCc1ccccc1)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCc2ccc(O)cc2)O1)Cc1ccccc1	6.4499998	Active	Cathepsin L Inhibitor	0.0	1	CAA-0225	384568753	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-95.6319446458	O=C(NCc1ccccc1)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCc2ccc(O)cc2)O1)Cc1ccccc1	O=C(NCc1ccccc1)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCc2ccc(O)cc2)O1)Cc1ccccc1
NCGC00253740-06	O=C(NCc1ccccc1)[C@H](NC(=O)C)COC		Inactive	NMDA Glycine-Site Antagonist		1	Lacosamide	384568567	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.200145452	O=C(NCc1ccccc1)[C@H](NC(=O)C)COC	O=C(NCc1ccccc1)[C@H](NC(=O)C)COC
NCGC00187983-01	O=C(NCc1ccccc1)c1nc(Nc2ncncc2)sc1	4.6500001	Active	ROCK Inhibitor	0.0	1	Thiazovivin	174006432	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-39.1935004656	O=C(NCc1ccccc1)c1nc(Nc2ncncc2)sc1	O=C(NCc1ccccc1)c1nc(Nc2ncncc2)sc1
NCGC00346627-08	O=C(NCc1ncc(C)nc1)C=1C(=O)c2c(nc(N3CCN(C)CCC3)cc2)N2c3c(SC=12)cccc3	5.5	Active	RNA Polymerase Inhibitor	0.0	1	CX-5461	363677484	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-83.1425565356	O=C(NCc1ncc(C)nc1)C=1C(=O)c2c(nc(N3CCN(C)CCC3)cc2)N2c3c(SC=12)cccc3	O=C(NCc1ncc(C)nc1)C=1C(=O)c2c(nc(N3CCN(C)CCC3)cc2)N2c3c(SC=12)cccc3
NCGC00016244-15&NCGC00016244-21	O=C(NN)c1ccncc1		Inactive	Cell Wall Biosynthesis Inhibitors&Cytochrome P450 CYP1A2 Inhibitor&Cytochrome P450 CYP1A2 Inhibitor		2	Isoniazid	170466877&384567924	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	14.9832507519&0.0&0.0	O=C(NN)c1ccncc1	O=C(NN)c1ccncc1
NCGC00390582-04	O=C(NN1CCOCC1)Nc1c2C(=O)c3c(-c4ccc(CN5CCN(CCOC)CC5)cc4)n[nH]c3-c2ccc1	4.0	Inactive	CDK/Cyclin Complex Inhibitor	0.0	1	RGB-286638	384569197	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-21.238127612	O=C(NN1CCOCC1)Nc1c2C(=O)c3c(-c4ccc(CN5CCN(CCOC)CC5)cc4)n[nH]c3-c2ccc1	O=C(NN1CCOCC1)Nc1c2C(=O)c3c(-c4ccc(CN5CCN(CCOC)CC5)cc4)n[nH]c3-c2ccc1
NCGC00390804-01	O=C(NNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CC2)Cc2[nH]cnc2)Cc2c3c([nH]c2)cccc3)CO)Cc2ccc(O)cc2)COC(C)(C)C)CC(C)C)CCCNC(=N)N)CCC1)N		Inactive	Lncap Inhibitor&LNCaP Inhibitor		1	Goserelin (acetate)	405558960	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	6.15554026&-14.1514037999	O=C(NNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CC2)Cc2[nH]cnc2)Cc2c3c([nH]c2)cccc3)CO)Cc2ccc(O)cc2)COC(C)(C)C)CC(C)C)CCCNC(=N)N)CCC1)N	O=C(NNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CC2)Cc2[nH]cnc2)Cc2c3c([nH]c2)cccc3)CO)Cc2ccc(O)cc2)COC(C)(C)C)CC(C)C)CCCNC(=N)N)CCC1)N
NCGC00015163-09	O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO		Inactive	DOPA decarboxylase Inhibitor&Dopa Decarboxylase Inhibitor		1	Benserazide	170465804	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO.Cl	O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO.Cl
NCGC00016267-06	O=C(NNCc1ccccc1)c1noc(C)c1	4.1999998	Active	Monoamine Oxidase Inhibitor	0.0	1	Isocarboxazid	405558734	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.6865424172	O=C(NNCc1ccccc1)c1noc(C)c1	O=C(NNCc1ccccc1)c1noc(C)c1
NCGC00371137-09	O=C(NNc1ccccc1)c1ccncc1		Inactive	SCD1 Inhibitor		1	PluriSln 1	384569042	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.2733938919	O=C(NNc1ccccc1)c1ccncc1	O=C(NNc1ccccc1)c1ccncc1
NCGC00263136-07	O=C(NO)/C=C/c1cc2nc(CCCC)n(CCN(CC)CC)c2cc1		Inactive	HDAC Inhibitor		1	Pracinostat	384568614	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)/C=C/c1cc2nc(CCCC)n(CCN(CC)CC)c2cc1	O=C(NO)/C=C/c1cc2nc(CCCC)n(CCN(CC)CC)c2cc1
NCGC00532294-01	O=C(NO)/C=C/c1ccc(CN(CC23CC4CC(C2)CC(C3)C4)C)cc1	5.3000002	Active	HDAC Inhibitor	0.0	1	Martinostat	384569537	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-100.8604927003	O=C(NO)/C=C/c1ccc(CN(CC23CC4CC(C2)CC(C3)C4)C)cc1	O=C(NO)/C=C/c1ccc(CN(CC23CC4CC(C2)CC(C3)C4)C)cc1
NCGC00345539-10	O=C(NO)/C=C/c1ccc(CN(CCO)CCc2c3c([nH]c2)cccc3)cc1		Inactive	HDAC Inhibitor		1	Dacinostat	384568737	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)/C=C/c1ccc(CN(CCO)CCc2c3c([nH]c2)cccc3)cc1	O=C(NO)/C=C/c1ccc(CN(CCO)CCc2c3c([nH]c2)cccc3)cc1
NCGC00510505-01	O=C(NO)CCCCCCC(=O)N/N=C/c1ccc(N(c2ccccc2)c2ccccc2)cc1	5.5	Active	HDAC Inhibitor	0.0	1	WT-161	384569466	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-100.5318432462	O=C(NO)CCCCCCC(=O)N/N=C/c1ccc(N(c2ccccc2)c2ccccc2)cc1	O=C(NO)CCCCCCC(=O)N/N=C/c1ccc(N(c2ccccc2)c2ccccc2)cc1
NCGC00346891-02	O=C(NO)CCCCCCC(=O)Nc1cnccc1		Inactive	HDAC Inhibitor		1	Pyroxamide	384568964	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)CCCCCCC(=O)Nc1cnccc1	O=C(NO)CCCCCCC(=O)Nc1cnccc1
NCGC00181165-01	O=C(NO)CCCCCCCCC	4.5250001	Active		0.0	1	Sodium decanehydroxamate	144206782	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-57.0136360969&-36.9567772439	O=C(N[O-])CCCCCCCCC.[Na+]	O=C(N[O-])CCCCCCCCC.[Na+]
NCGC00263617-13	O=C(NO)CCCCCCNC(=O)c1ccc(N(C)C)cc1		Inactive	HDAC Inhibitor		1	M-344	384568694	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)CCCCCCNC(=O)c1ccc(N(C)C)cc1	O=C(NO)CCCCCCNC(=O)c1ccc(N(C)C)cc1
NCGC00345802-09	O=C(NO)CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1		Inactive	HDAC Inhibitor		1	ACY-1215	384568750	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1	O=C(NO)CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1
NCGC00263177-04	O=C(NO)CCCCCCOc1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1		Inactive	EGFR Inhibitor		1	CUDC-101	384568646	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)CCCCCCOc1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1	O=C(NO)CCCCCCOc1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1
NCGC00346888-03	O=C(NO)C[C@@H](CCCC1CCCCC1)c1onc(C(=O)N)n1		Inactive	Procollagen C-Endopeptidase Inhibitor		1	UK-383367	363677552	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.8543092119	O=C(NO)C[C@@H](CCCC1CCCCC1)c1onc(C(=O)N)n1	O=C(NO)C[C@@H](CCCC1CCCCC1)c1onc(C(=O)N)n1
NCGC00016611-10&NCGC00016611-11	O=C(NO)Cc1ccc(OCCCC)cc1		Inactive	non-steroidal antiinflammatory&Non-steroidal Antiinflammatory&non-steroidal antiinflammatory		2	Bufexamac	170465813&384567953	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-20.480740492&-16.662717336&-17.1455167159	O=C(NO)Cc1ccc(OCCCC)cc1	O=C(NO)Cc1ccc(OCCCC)cc1
NCGC00015520-11&NCGC00015520-13	O=C(NO)N		Inactive	Ribonucleoside-diphosphate Reductase Inhibitor&Ribonucleoside-Diphosphate Reductase Inhibitor&Ribonucleoside-Diphosphate Reductase Inhibitor		2	Hydroxyurea	170465025&384567861	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-13.787177692&0.0&-13.998698016	O=C(NO)N	O=C(NO)N
NCGC00371093-04	O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C	4.3499999	Active	Matrix Metalloproteinase Inhibitor	0.0	1	Marimastat	384569041	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-39.886833416	O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C	O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
NCGC00378675-01	O=C(NO)[C@H](C[C@H](NC(=O)c1ccc(Oc2ccccc2)cc1)COCOCC)C		Inactive	Matrix Metalloproteinase (MMP) Inhibitor		1	ONO-4817	384569062	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-24.6998048	O=C(NO)[C@H](C[C@H](NC(=O)c1ccc(Oc2ccccc2)cc1)COCOCC)C	O=C(NO)[C@H](C[C@H](NC(=O)c1ccc(Oc2ccccc2)cc1)COCOCC)C
NCGC00345492-06	O=C(NO)c1cc2n(Cc3ccc(OC)cc3)ccc2cc1	4.4000001	Active	HDAC Inhibitor	0.0	1	PCI-34051	384568736	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-31.706695608	O=C(NO)c1cc2n(Cc3ccc(OC)cc3)ccc2cc1	O=C(NO)c1cc2n(Cc3ccc(OC)cc3)ccc2cc1
NCGC00499576-01	O=C(NO)c1ccc(C2=Nc3c(Oc4c2cccc4)cccc3)cc1	4.4000001	Active	HDAC Inhibitor	0.0	1	HDACi-01	384569308	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-114.4647757126	O=C(NO)c1ccc(C2=Nc3c(Oc4c2cccc4)cccc3)cc1	O=C(NO)c1ccc(C2=Nc3c(Oc4c2cccc4)cccc3)cc1
NCGC00263606-06	O=C(NO)c1ccc(Cn2c3c(c4c2CCN(C)C4)cccc3)cc1		Inactive	HDAC Inhibitor		1	Tubastatin A	384568693	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.6349691599	O=C(NO)c1ccc(Cn2c3c(c4c2CCN(C)C4)cccc3)cc1	O=C(NO)c1ccc(Cn2c3c(c4c2CCN(C)C4)cccc3)cc1
NCGC00345786-03	O=C(NO)c1ccc(Cn2c3c(c4c2CN(C)CC4)cccc3)cc1	4.4499998	Active	HDAC Inhibitor	0.0	1	Compound 7	384568741	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-81.1354182759	O=C(NO)c1ccc(Cn2c3c(c4c2CN(C)CC4)cccc3)cc1	O=C(NO)c1ccc(Cn2c3c(c4c2CN(C)CC4)cccc3)cc1
NCGC00346692-03	O=C(NO)c1cnc(N(Cc2sc3c(N4CCOCC4)nc(-c4cnc(OC)cc4)nc3c2)C)nc1		Inactive	PI3K Inhibitor		1	CUDC-907	384568914	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)c1cnc(N(Cc2sc3c(N4CCOCC4)nc(-c4cnc(OC)cc4)nc3c2)C)nc1	O=C(NO)c1cnc(N(Cc2sc3c(N4CCOCC4)nc(-c4cnc(OC)cc4)nc3c2)C)nc1
NCGC00346487-03	O=C(NO)c1cnc(N2CCC(CNCc3c4c(n(C)c3)cccc4)CC2)nc1		Inactive	HDAC Inhibitor		1	Quisinostat	384568796	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)c1cnc(N2CCC(CNCc3c4c(n(C)c3)cccc4)CC2)nc1	O=C(NO)c1cnc(N2CCC(CNCc3c4c(n(C)c3)cccc4)CC2)nc1
NCGC00511370-01	O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1		Inactive	HDAC Inhibitor		1	ACY-738	384569499	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1	O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1
NCGC00378854-02	O=C(N[C@@H](C(=O)N1C[C@](C(=O)N(N(C)C)C)(Cc2ccccc2)CCC1)Cc1c2c([nH]c1)cccc2)C(N)(C)C	4.6500001	Active	GHS Receptor Agonist	0.0	1	Anamorelin	384569072	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-34.8099467639	O=C(N[C@@H](C(=O)N1C[C@](C(=O)N(N(C)C)C)(Cc2ccccc2)CCC1)Cc1c2c([nH]c1)cccc2)C(N)(C)C	O=C(N[C@@H](C(=O)N1C[C@](C(=O)N(N(C)C)C)(Cc2ccccc2)CCC1)Cc1c2c([nH]c1)cccc2)C(N)(C)C
NCGC00181352-01	O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(O)cc1)[C@H](N)CC(=O)NC		Inactive			1	Aspoxicillin	144206363	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.73519474&27.310867948	O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(O)cc1)[C@H](N)CC(=O)NC	O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(O)cc1)[C@H](N)CC(=O)NC
NCGC00346433-07	O=C(N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N)C		Inactive	Neuraminidase (sialidase) Inhibitors&Influenza Infection Inhibitor		1	Peramivir	405558732	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-9.397464416	O=C(N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N)C	O=C(N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N)C
NCGC00509939-01	O=C(N[C@@H](C)C=1N(c2ccccc2)C(=O)c2c(C#Cc3cn(C)nc3)cccc2C=1)c1c(N)nn2c1N=CC=C2	5.4000001	Active	PI3Kgamma Inhibitor	0.0	1	IPI-549	384569388	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-30.079073324	O=C(N[C@@H](C)C=1N(c2ccccc2)C(=O)c2c(C#Cc3cn(C)nc3)cccc2C=1)c1c(N)nn2c1N=CC=C2	O=C(N[C@@H](C)C=1N(c2ccccc2)C(=O)c2c(C#Cc3cn(C)nc3)cccc2C=1)c1c(N)nn2c1N=CC=C2
NCGC00510708-01	O=C(N[C@@H](C)c1ccc(-c2nc(CCC3CCCC3)on2)cc1)[C@@H]1[C@@H](O)CCN1	4.0	Inactive	Sphingosine Kinase 1 (SphK1) Inhibitor	0.0	1	NCGC00510708	384569489	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-12.144937604	O=C(N[C@@H](C)c1ccc(-c2nc(CCC3CCCC3)on2)cc1)[C@@H]1[C@@H](O)CCN1	O=C(N[C@@H](C)c1ccc(-c2nc(CCC3CCCC3)on2)cc1)[C@@H]1[C@@H](O)CCN1
NCGC00345816-01	O=C(N[C@@H](C)c1ccccc1)[C@@H](NC(=O)[C@@H](CC(=O)O)CC(C)C)Cc1c2c([nH]c1)cccc2		Inactive	MMP Inhibitor		1	GM-1489	174007112	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.61190948	O=C(N[C@@H](C)c1ccccc1)[C@@H](NC(=O)[C@@H](CC(=O)O)CC(C)C)Cc1c2c([nH]c1)cccc2	O=C(N[C@@H](C)c1ccccc1)[C@@H](NC(=O)[C@@H](CC(=O)O)CC(C)C)Cc1c2c([nH]c1)cccc2
NCGC00346469-03	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nc(-c2ccccc2)ccc1)[C@H](O)C	9.0	Inactive	Proteasome Inhibitor	0.0	1	Delanzomib	384568788	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-7.8997094279	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nc(-c2ccccc2)ccc1)[C@H](O)C	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nc(-c2ccccc2)ccc1)[C@H](O)C
NCGC00263107-03	O=C(N[C@@H]([C@@H](CC)C)C(=O)N1CCC2(c3c(cccc3)CC2)CC1)[C@@H](NC(=O)c1oncc1)CC1CCCCC1		Inactive	PAR2 Antagonist		1	GB-83	384568594	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@@H]([C@@H](CC)C)C(=O)N1CCC2(c3c(cccc3)CC2)CC1)[C@@H](NC(=O)c1oncc1)CC1CCCCC1	O=C(N[C@@H]([C@@H](CC)C)C(=O)N1CCC2(c3c(cccc3)CC2)CC1)[C@@H](NC(=O)c1oncc1)CC1CCCCC1
NCGC00509905-01	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCC	4.4000001	Active	Ceramide Glucosyltransferase Antagonist&Ceramide glucosyltransferase Antagonist	0.0	1	Eliglustat (Tartrate)	405558462	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-97.4750487439&-83.6932967399	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCC	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCC
NCGC00510527-02	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1[nH]nc(Cc2ccccc2)n1		Inactive	RIP1 kinase Inhibitor		1	GSK-2982772	384569474	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1[nH]nc(Cc2ccccc2)n1	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1[nH]nc(Cc2ccccc2)n1
NCGC00499427-02	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1noc(Cc2ccccc2)c1	5.0500002	Active	RIP1 kinase Inhibitor	0.0	1	GSK-481	384569306	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-82.252640336	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1noc(Cc2ccccc2)c1	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1noc(Cc2ccccc2)c1
NCGC00159513-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C/C)CS[C@H]12)[C@H](N)c1ccc(O)cc1		Inactive	Cephalosporin Antibiotic&Cephalosporin antibiotic		1	Cefprozil	225144231	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.6980124551&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C/C)CS[C@H]12)[C@H](N)c1ccc(O)cc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C/C)CS[C@H]12)[C@H](N)c1ccc(O)cc1
NCGC00263951-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@@H]12)[C@H](N)C1=CCC=CC1	4.4000001	Active	Cephalosporin Antibiotic	0.0	1	CEPHRADINE	405558705	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.357617148	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@@H]12)[C@H](N)C1=CCC=CC1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@@H]12)[C@H](N)C1=CCC=CC1
NCGC00179556-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccc(O)cc1	4.5	Active	Solute carrier family 15 member 2 Substrate	0.0	1	Cefadroxil	170464658	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-46.1192753849	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccc(O)cc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccc(O)cc1
NCGC00159522-05	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccccc1		Inactive	Cephalosporin Antibiotic&Cephalosporin antibiotic		1	Cephalexin	170464982	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.087173636&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccccc1
NCGC00178499-08	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\O)/c1nc(N)sc1	4.4000001	Active	Cephalosporin Antibiotic&Cephalosporin antibiotic	0.0	1	Cefdinir	405559056	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-73.9906193759&-37.402970432	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\O)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\O)/c1nc(N)sc1
NCGC00179521-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\OCC(=O)O)/c1nc(N)sc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Cefixime	405559067	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\OCC(=O)O)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\OCC(=O)O)/c1nc(N)sc1
NCGC00379079-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(CN3N(CCO)C(=N)C=C3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive	Antibiotic		1	Cefoselis (sulfate)	405558638	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.7782864599&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(CN3N(CCO)C(=N)C=C3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(CN3N(CCO)C(=N)C=C3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00093358-08	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Cefotaxime sodium salt	405558920	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.6506860487&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00510891-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)CC#N		Inactive			1	Cefacetrile	405558954	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.7653457599	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)CC#N	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)CC#N
NCGC00023699-09	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)Cc1sccc1	4.5999999	Inactive	Solute Carrier Family 22 Member 7 Inhibitor	0.0	1	Cephalothin	170465101	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	13.0483048559	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)Cc1sccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)Cc1sccc1
NCGC00521078-02	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)[C@H](N)c1ccccc1	5.3499999	Active	Bacterial Penicillin-binding Protein Inhibitor	0.0	1	Cephaloglycin	405558643	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.5989271912	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)[C@H](N)c1ccccc1
NCGC00532497-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive			1	CEFPODOXIME	405559088	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.823308884&-19.264750384	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00183016-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3nc(C)nn3)CS[C@H]12)/C(=N/OC)/c1nc(N)sc1		Inactive			1	Cefteram	144206853	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.227078684&-20.183670224	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3nc(C)nn3)CS[C@H]12)/C(=N/OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3nc(C)nn3)CS[C@H]12)/C(=N/OC)/c1nc(N)sc1
NCGC00185745-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(OC)CS[C@H]12)[C@H](N)C1=CCC=CC1	4.75	Active		0.0	1	Cefroxadine	144206693	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-52.3928920176	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(OC)CS[C@H]12)[C@H](N)C1=CCC=CC1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(OC)CS[C@H]12)[C@H](N)C1=CCC=CC1
NCGC00178501-04	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=C\CC(=O)O)/c1nc(N)sc1		Inactive	Peptidoglycan Synthase Ftsi Inhibitor&Peptidoglycan synthase FtsI Inhibitor		1	CEFTIBUTEN	405558519	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.634726539&-19.353171632	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=C\CC(=O)O)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=C\CC(=O)O)/c1nc(N)sc1
NCGC00167460-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=N/OC)/c1nc(N)sc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor		1	CeftizoximNa	405558486	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.51579146&-24.077107604	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=CCS[C@H]12)/C(=N/OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=CCS[C@H]12)/C(=N/OC)/c1nc(N)sc1
NCGC00178554-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)NCC1)c1ccccc1	4.9000001	Active	Bacterial penicillin-binding protein Inhibitor	0.0	1	AZLOCILLIN SODIUM	405558664	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-45.8693206492	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)NCC1)c1ccccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)NCC1)c1ccccc1
NCGC00017147-02	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	CEFEPIME HYDROCHLORIDE	405559036	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0		O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00181750-01	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3c4n(N=CC=C4)cc3)CS[C@H]12)/C(=N/OC)/c1nc(N)sn1	5.0500002	Active	Bacterial Penicillin-binding Protein Binding Agent	0.0	1	Cefozopran hydrochloride	144206474	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-47.9186036188	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3c4n(N=CC=C4)cc3)CS[C@H]12)/C(=N/OC)/c1nc(N)sn1.Cl	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3c4n(N=CC=C4)cc3)CS[C@H]12)/C(=N/OC)/c1nc(N)sn1.Cl
NCGC00179310-03	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)Cc1sccc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Cefalonium	170466431	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.012052268&13.7138301319	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)Cc1sccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)Cc1sccc1
NCGC00016797-11&NCGC00016797-15	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]12)[C@@H](N)c1ccc(O)cc1		Inactive	Beta-lactam Antibiotic&beta-lactam antibiotic&beta-lactam antibiotic		2	Amoxicillin sodium	405558548&384567960	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-23.000431204&0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]12)[C@@H](N)c1ccc(O)cc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]12)[C@@H](N)c1ccc(O)cc1
NCGC00179009-06	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)C		Inactive	Bacterial penicillin-binding protein Inhibitor&Bacterial Penicillin-binding Protein Inhibitor		1	Phenethicillin potassium salt	405558484	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.6897279839&-28.385583216	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)C(Oc1ccccc1)C	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)C(Oc1ccccc1)C
NCGC00160673-01	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)CC		Inactive			1	Propicillin	144205529	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-10.10357502&-8.326717336	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)CC	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)CC
NCGC00164005-06	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)COc1ccccc1		Inactive			1	PENICILLIN V POTASSIUM	405558690	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.123147116&0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)COc1ccccc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)COc1ccccc1
NCGC00023282-21	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	4.5999999	Active		0.0	1	AMPICILLIN SODIUM	405558724	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-35.8915845919&-38.2618731384	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1
NCGC00253577-01	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCC3=C(C)OC(=O)O3)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1		Inactive			1	Lenampicillin hydrochloride	170465777	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-20.6196816119	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCC3=C(C)OC(=O)O3)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1.Cl	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCC3=C(C)OC(=O)O3)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1.Cl
NCGC00179290-03	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1		Inactive			1	Pivampicillin	170466065	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.432108104	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1
NCGC00188437-01	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)[C@H]3C(C)(C)S(=O)(=O)[C@H]4N3C(=O)C4)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	5.3000002	Active	Staphylococcus Aureus Inhibitor	0.0	1	Sultamicillin tosylate	144206543	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.5986462053	S(=O)(=O)(O)c1ccc(C)cc1.O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)[C@H]3C(C)(C)S(=O)(=O)[C@H]4N3C(=O)C4)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	S(=O)(=O)(O)c1ccc(C)cc1.O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)[C@H]3C(C)(C)S(=O)(=O)[C@H]4N3C(=O)C4)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1
NCGC00346675-02	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)NC(c3ccccc3)c3ccccc3)CC[C@@H]2CCN(C(=O)CC(C)C)C1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	AT-406	384568901	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)NC(c3ccccc3)c3ccccc3)CC[C@@H]2CCN(C(=O)CC(C)C)C1)[C@@H](NC)C	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)NC(c3ccccc3)c3ccccc3)CC[C@@H]2CCN(C(=O)CC(C)C)C1)[C@@H](NC)C
NCGC00263236-02	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](c3nnn(CCCCc4ccc(CCCCn5nnc([C@@H](NC(=O)[C@H]6N7C(=O)[C@@H](NC(=O)[C@@H](NC)C)CCCC[C@H]7CC6)c6ccccc6)c5)cc4)c3)c3ccccc3)CC[C@@H]2CCCC1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	SM-164	384568680	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.9038590319	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](c3nnn(CCCCc4ccc(CCCCn5nnc([C@@H](NC(=O)[C@H]6N7C(=O)[C@@H](NC(=O)[C@@H](NC)C)CCCC[C@H]7CC6)c6ccccc6)c5)cc4)c3)c3ccccc3)CC[C@@H]2CCCC1)[C@@H](NC)C	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](c3nnn(CCCCc4ccc(CCCCn5nnc([C@@H](NC(=O)[C@H]6N7C(=O)[C@@H](NC(=O)[C@@H](NC)C)CCCC[C@H]7CC6)c6ccccc6)c5)cc4)c3)c3ccccc3)CC[C@@H]2CCCC1)[C@@H](NC)C
NCGC00263949-02	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)C(=O)N(CC)CC1)c1ccccc1		Inactive	Penicillin-binding protein 2B Binding Agent&Penicillin-binding Protein 2b Binding Agent		1	Piperacillin sodium salt	170465380	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.069552444&0.0	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)C(=O)N(CC)CC1)c1ccccc1.[Na+]	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)C(=O)N(CC)CC1)c1ccccc1.[Na+]
NCGC00390548-02	O=C(N[C@@H]1C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N)CSSC1)C		Inactive	N-Cadherin Antagonist		1	Exherin	384569190	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@@H]1C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N)CSSC1)C	O=C(N[C@@H]1C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N)CSSC1)C
NCGC00181796-03	O=C(N[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](N)Cc1ccccc1		Inactive	Growth Hormone Release Inhibitor		1	Octreotide	384568403	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.0653098079	O=C(N[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](N)Cc1ccccc1	O=C(N[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](N)Cc1ccccc1
NCGC00263228-01	O=C(N[C@@H]1C[C@@H](C(=O)N(C)c2ccc(-c3oc4c(n3)cccc4)cc2)CC1)CC	4.4000001	Active	Fatty Acid Synthase (FAS) Inhibitor	0.0	1	FASN BI	137276072	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-49.7042282007	O=C(N[C@@H]1C[C@@H](C(=O)N(C)c2ccc(-c3oc4c(n3)cccc4)cc2)CC1)CC	O=C(N[C@@H]1C[C@@H](C(=O)N(C)c2ccc(-c3oc4c(n3)cccc4)cc2)CC1)CC
NCGC00159460-04	O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1		Inactive	Hiv Protease Inhibitors&HIV Protease Inhibitors		1	Indinavir sulfate	170465228	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	7.249619176&0.0	S(=O)(=O)(O)O.O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1	S(=O)(=O)(O)O.O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1
NCGC00384474-01	O=C(N[C@@H]1[C@H](OCC)OC(=O)C1)[C@H]1N2C(=O)[C@@H](NC(=O)c3nccc4c3cccc4)CCC(=O)N2CCC1		Inactive	Caspase-1 Inhibitor		1	Pralnacasan	384569111	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@@H]1[C@H](OCC)OC(=O)C1)[C@H]1N2C(=O)[C@@H](NC(=O)c3nccc4c3cccc4)CCC(=O)N2CCC1	O=C(N[C@@H]1[C@H](OCC)OC(=O)C1)[C@H]1N2C(=O)[C@@H](NC(=O)c3nccc4c3cccc4)CCC(=O)N2CCC1
NCGC00017074-02	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	4.4000001	Active	Adrenergic receptor alpha Blocker	0.0	1	Hydergine	144206902	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-62.3564270241	S(=O)(=O)(O)C.O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	S(=O)(=O)(O)C.O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1
NCGC00183332-01	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	4.9499998	Active	D(1A) dopamine receptor Partial Agonist	0.0	1	Dihydroergocriptine	144206629	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-63.4324758722	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1
NCGC00356592-02	O=C(N[C@@]1(C)C(=O)N2[C@@H](Cc3ccccc3)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive			1	Ergotamine tartrate	405559037	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-24.183361836	O=C(N[C@@]1(C)C(=O)N2[C@@H](Cc3ccccc3)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N[C@@]1(C)C(=O)N2[C@@H](Cc3ccccc3)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00507840-01	O=C(N[C@H](C(=O)N)CCCCN)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)Cc1c2c([nH]c1)cccc2)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)C(c1ccccc1)c1ccccc1	4.5	Active	Microenvironment modifier	0.0	1	LTX-315	384569322	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-102.4318935839	O=C(N[C@H](C(=O)N)CCCCN)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)Cc1c2c([nH]c1)cccc2)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)C(c1ccccc1)c1ccccc1	O=C(N[C@H](C(=O)N)CCCCN)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)Cc1c2c([nH]c1)cccc2)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)C(c1ccccc1)c1ccccc1
NCGC00482904-01	O=C(N[C@H](C(=O)N1C[C@]2(Cc3ccccc3)C(=O)N(C)N=C2CC1)COCc1ccccc1)C(N)(C)C	4.4000001	Active	Ghrelin Receptor Agonist&Ghrelin receptor Agonist	0.0	1	Capromorelin	405558917	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-59.285770524&-41.542930488	O=C(N[C@H](C(=O)N1C[C@]2(Cc3ccccc3)C(=O)N(C)N=C2CC1)COCc1ccccc1)C(N)(C)C	O=C(N[C@H](C(=O)N1C[C@]2(Cc3ccccc3)C(=O)N(C)N=C2CC1)COCc1ccccc1)C(N)(C)C
NCGC00390575-03	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nc(-c3occn3)s2)CCC1)C1CCCCC1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	CUDC-427	384569195	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nc(-c3occn3)s2)CCC1)C1CCCCC1)[C@@H](NC)C	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nc(-c3occn3)s2)CCC1)C1CCCCC1)[C@@H](NC)C
NCGC00386277-03	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nns2)CCC1)C1CCCCC1)[C@@H](NC)C	4.4000001	Active	IAP Inhibitor	0.0	1	GDC-0152	384569120	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-60.37502504	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nns2)CCC1)C1CCCCC1)[C@@H](NC)C	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nns2)CCC1)C1CCCCC1)[C@@H](NC)C
NCGC00167301-02	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC(=O)N)CCC1)CCCNC(=N)N)CC(C)C)Cc1c2c([nH]c1)cccc2)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	5.25	Active	Gonadotropin-releasing hormone receptor Agonist	0.0	1	Triptorelin	405558815	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.0069736656	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC(=O)N)CCC1)CCCNC(=N)N)CC(C)C)Cc1c2c([nH]c1)cccc2)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC(=O)N)CCC1)CCCNC(=N)N)CC(C)C)Cc1c2c([nH]c1)cccc2)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO
NCGC00346556-03	O=C(N[C@H](C(=O)N[C@@H]1C(=O)N(C)CCc2c1cccc2)C)[C@@H](O)C(C)C		Inactive	g-Secretase Inhibitor		1	Semagacestat	384568839	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@H](C(=O)N[C@@H]1C(=O)N(C)CCc2c1cccc2)C)[C@@H](O)C(C)C	O=C(N[C@H](C(=O)N[C@@H]1C(=O)N(C)CCc2c1cccc2)C)[C@@H](O)C(C)C
NCGC00263280-01	O=C(N[C@H](C(=O)N[C@@]1(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CCC(=O)N)(C)CCC/C=C\CCCCCC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCNC(=O)C)CCC(=O)N)CO)CCC(=O)N)CCC(=O)N)[C@@H](O)C	4.4499998	Active	HDM2/HDMX Inhibitor	0.0	1	Ac-SAH-p53-8	137276088	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-74.7765747679	O=C(N[C@H](C(=O)N[C@@]1(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CCC(=O)N)(C)CCC/C=C\CCCCCC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCNC(=O)C)CCC(=O)N)CO)CCC(=O)N)CCC(=O)N)[C@@H](O)C	O=C(N[C@H](C(=O)N[C@@]1(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CCC(=O)N)(C)CCC/C=C\CCCCCC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCNC(=O)C)CCC(=O)N)CO)CCC(=O)N)CCC(=O)N)[C@@H](O)C
NCGC00249613-10&NCGC00249613-11	O=C(N[C@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)CC(C)C	9.0	Inactive	Proteasome Inhibitor	0.0	2	Carfilzomib	384568530&405558759	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-1.764971328&-16.0473989322	O=C(N[C@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)CC(C)C	O=C(N[C@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)CC(C)C
NCGC00161670-08	O=C(N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)O)CC(C)C)C)CC(C)C)C(C)C)[C@@H](NC(=O)CC(C)C)C(C)C		Inactive	Aspartyl Protease Inhibitor		1	Pepstatin	384568214	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.933071528	O=C(N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)O)CC(C)C)C)CC(C)C)C(C)C)[C@@H](NC(=O)CC(C)C)C(C)C	O=C(N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)O)CC(C)C)C)CC(C)C)C(C)C)[C@@H](NC(=O)CC(C)C)C(C)C
NCGC00346517-07&NCGC00346517-10	O=C(N[C@H](C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2c(N)cccc2)NC(=O)[C@H]([C@H](CC(=O)O)C)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)CC(=O)O)[C@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC)Cc1c2c([nH]c1)cccc2)CC(=O)N		Inactive	Drugs Acting On Potassium Channels&Lipopeptide Antibiotic&Lipopeptide Antibiotic		2	Daptomycin	405558903&384568815	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	13.109170648&-25.854173896&0.0	O=C(N[C@H](C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2c(N)cccc2)NC(=O)[C@H]([C@H](CC(=O)O)C)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)CC(=O)O)[C@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC)Cc1c2c([nH]c1)cccc2)CC(=O)N	O=C(N[C@H](C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2c(N)cccc2)NC(=O)[C@H]([C@H](CC(=O)O)C)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)CC(=O)O)[C@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC)Cc1c2c([nH]c1)cccc2)CC(=O)N
NCGC00345799-06	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)c1sc(C)nc1)COC)COC	9.0	Inactive	Proteasome Inhibitor	0.0	1	Oprozomib	384568748	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-2.7091350599	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)c1sc(C)nc1)COC)COC	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)c1sc(C)nc1)COC)COC
NCGC00345784-11	O=C(N[C@H](CN(C)C)c1ccccc1)N1C(C)(C)c2[nH]nc(Nc3nc(C)nc4c3scc4)c2C1	5.6500001	Active	p21-Activated Kinase 4 (PAK4) Inhibitor	0.0	1	PF-3758309	384568740	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-99.3374132722	O=C(N[C@H](CN(C)C)c1ccccc1)N1C(C)(C)c2[nH]nc(Nc3nc(C)nc4c3scc4)c2C1	O=C(N[C@H](CN(C)C)c1ccccc1)N1C(C)(C)c2[nH]nc(Nc3nc(C)nc4c3scc4)c2C1
NCGC00017253-03	O=C(N[C@H](CO)C)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	5.0500002	Active	Serotonin (5-HT) receptor Partial Agonist	0.0	1	Ergobasine	124882896	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-42.123906124	O=C(N[C@H](CO)C)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N[C@H](CO)C)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00017258-08	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive	Serotonin 2b (5-ht2b) Receptor Partial Agonist&Serotonin 2b (5-HT2b) receptor Partial Agonist		1	Methergine	170465383	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.260898932&0.0	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00024027-09	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c(n(C)c1)cccc23		Inactive	Serotonin 7 (5-ht7) Receptor Antagonist&Serotonin 7 (5-HT7) receptor Antagonist		1	Methysergide	170464684	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c(n(C)c1)cccc23	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c(n(C)c1)cccc23
NCGC00164576-04	O=C(N[C@H](C[C@H](O)[C@@H](NC(=O)COc1c(C)cccc1C)Cc1ccccc1)Cc1ccccc1)[C@H](C(C)C)N1C(=O)NCCC1	4.4000001	Active	HIV Protease Inhibitors	0.0	1	Lopinavir	170464773	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-79.4970662519	O=C(N[C@H](C[C@H](O)[C@@H](NC(=O)COc1c(C)cccc1C)Cc1ccccc1)Cc1ccccc1)[C@H](C(C)C)N1C(=O)NCCC1	O=C(N[C@H](C[C@H](O)[C@@H](NC(=O)COc1c(C)cccc1C)Cc1ccccc1)Cc1ccccc1)[C@H](C(C)C)N1C(=O)NCCC1
NCGC00091469-04	O=C(N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)[C@@H](NC(=O)c1nc2c(cc1)cccc2)CC(=O)N	4.6999998	Active	protease inhibitor	0.0	1	Saquinavir	225144210	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-85.3597496796	O=C(N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)[C@@H](NC(=O)c1nc2c(cc1)cccc2)CC(=O)N	O=C(N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)[C@@H](NC(=O)c1nc2c(cc1)cccc2)CC(=O)N
NCGC00485486-02	O=C(N[C@H]1C(=O)N(CC(=O)C(C)(C)C)c2c(N(C3CCCCC3)C1)cccc2)Nc1cc(C(=O)O)ccc1		Inactive	CCK2 (CCKB/Gastrin) Receptor Antagonist		1	Nastorazepide	384569277	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@H]1C(=O)N(CC(=O)C(C)(C)C)c2c(N(C3CCCCC3)C1)cccc2)Nc1cc(C(=O)O)ccc1	O=C(N[C@H]1C(=O)N(CC(=O)C(C)(C)C)c2c(N(C3CCCCC3)C1)cccc2)Nc1cc(C(=O)O)ccc1
NCGC00378600-02	O=C(N[C@H]1C[C@@H](N(C)CC1)c1[nH]c2c(n1)cccc2)Nc1ccc(C#N)cc1	5.4000001	Inactive	Hedgehog Antagonist	0.0	1	Glasdegib	363678116	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	87.1747895924	O=C(N[C@H]1C[C@@H](N(C)CC1)c1[nH]c2c(n1)cccc2)Nc1ccc(C#N)cc1	O=C(N[C@H]1C[C@@H](N(C)CC1)c1[nH]c2c(n1)cccc2)Nc1ccc(C#N)cc1
NCGC00271789-02	O=C(N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2N(C(=O)[C@@H](C(C)C)NC1=O)CCC2)c1c2N=C3C(C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]5N(C(=O)[C@@H](C(C)C)NC4=O)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1	9.0	Inactive	DNA-Directed RNA Polymerase Inhibitor	0.0	1	Actinomycin D	170464668	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-10.966215676	O=C(N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2N(C(=O)[C@@H](C(C)C)NC1=O)CCC2)c1c2N=C3C(C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]5N(C(=O)[C@@H](C(C)C)NC4=O)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1	O=C(N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2N(C(=O)[C@@H](C(C)C)NC1=O)CCC2)c1c2N=C3C(C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]5N(C(=O)[C@@H](C(C)C)NC4=O)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1
NCGC00475765-01	O=C(N[C@H]1[C@H](C)N(C(=O)C)c2c(N(Cc3c(C)ccc4c3cccc4)C1=O)ccc(C#N)c2)[C@@H](NC)C		Inactive	IAP Inhibitor		1	Compound 36	384569238	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(N[C@H]1[C@H](C)N(C(=O)C)c2c(N(Cc3c(C)ccc4c3cccc4)C1=O)ccc(C#N)c2)[C@@H](NC)C	O=C(N[C@H]1[C@H](C)N(C(=O)C)c2c(N(Cc3c(C)ccc4c3cccc4)C1=O)ccc(C#N)c2)[C@@H](NC)C
NCGC00390238-01	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](OC2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CN	4.8499999	Active	30S Ribosomal Protein Inhibitors&30s Ribosomal Protein Inhibitors	0.0	1	Isepamicin	405558465	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-40.2850004268&-46.3575748377	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](OC2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CN	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](OC2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CN
NCGC00164587-01	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)C(O)CN		Inactive	30S Ribosomal Protein Inhibitors		1	Isepamicin sulfate	144205766	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.113563748	S(=O)(=O)(O)O.O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)C(O)CN	S(=O)(=O)(O)O.O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)C(O)CN
NCGC00164561-02	O=C(N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N)C		Inactive	Neuraminidase (sialidase) Inhibitors&Neuraminidase (Sialidase) Inhibitors		1	Zanamivir	170464662	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.3135748879&17.17588394	O=C(N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N)C	O=C(N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N)C
NCGC00346493-03	O=C(Nc1c(-c2[nH]c3c(n2)cc(CN2CCOCC2)cc3)n[nH]c1)NC1CC1	9.0	Inactive	Aurora-A/B Inhibitor	0.0	1	AT-9283	384568800	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-31.6463743207	O=C(Nc1c(-c2[nH]c3c(n2)cc(CN2CCOCC2)cc3)n[nH]c1)NC1CC1	O=C(Nc1c(-c2[nH]c3c(n2)cc(CN2CCOCC2)cc3)n[nH]c1)NC1CC1
NCGC00379071-02	O=C(Nc1c(-c2nc3SC=C(CN4CCOCC4)n3c2)cccc1)c1c(C)nc(-c2cnccc2)s1		Inactive	SIRT1 Activator		1	SRT-2104	384569093	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1c(-c2nc3SC=C(CN4CCOCC4)n3c2)cccc1)c1c(C)nc(-c2cnccc2)s1	O=C(Nc1c(-c2nc3SC=C(CN4CCOCC4)n3c2)cccc1)c1c(C)nc(-c2cnccc2)s1
NCGC00508871-01	O=C(Nc1c(-c2nn(-c3ccc(CCN4Cc5c(cc(OC)c(OC)c5)CC4)cc3)nn2)cc(OC)c(OC)c1)C=1Oc2c(C(=O)C=1)cccc2		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	HM-30181	384569368	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	7.6781452759	O=C(Nc1c(-c2nn(-c3ccc(CCN4Cc5c(cc(OC)c(OC)c5)CC4)cc3)nn2)cc(OC)c(OC)c1)C=1Oc2c(C(=O)C=1)cccc2	O=C(Nc1c(-c2nn(-c3ccc(CCN4Cc5c(cc(OC)c(OC)c5)CC4)cc3)nn2)cc(OC)c(OC)c1)C=1Oc2c(C(=O)C=1)cccc2
NCGC00483118-01	O=C(Nc1c(-c2sc3ncc(CN4CCCC4)cc3n2)cccc1)c1c(CCCOC)sc(-c2ccccc2)n1		Inactive	SIRT1 Activator		1	SRT-3025	363681137	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1c(-c2sc3ncc(CN4CCCC4)cc3n2)cccc1)c1c(CCCOC)sc(-c2ccccc2)n1	O=C(Nc1c(-c2sc3ncc(CN4CCCC4)cc3n2)cccc1)c1c(CCCOC)sc(-c2ccccc2)n1
NCGC00242227-11	O=C(Nc1c(C#N)c2c(s1)CCCC2)c1c2c(ccc1)cccc2	6.0999999	Inactive	JNK 2/3 Inhibitor	0.0	1	TCS-JNK-5a	377020378	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-11.753349364	O=C(Nc1c(C#N)c2c(s1)CCCC2)c1c2c(ccc1)cccc2	O=C(Nc1c(C#N)c2c(s1)CCCC2)c1c2c(ccc1)cccc2
NCGC00481403-01	O=C(Nc1c(C(=O)N)cc(-c2c(O[C@@H]3CNCC3)cc(-c3c(C)onc3C)cc2)s1)N	4.3499999	Active	IKK beta Inhibitor	0.0	1	AZD-3264	377020458	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-34.0547034333	O=C(Nc1c(C(=O)N)cc(-c2c(O[C@@H]3CNCC3)cc(-c3c(C)onc3C)cc2)s1)N	O=C(Nc1c(C(=O)N)cc(-c2c(O[C@@H]3CNCC3)cc(-c3c(C)onc3C)cc2)s1)N
NCGC00274038-02	O=C(Nc1c(C(=O)N)sc(-c2ccc(CN3CCOCC3)cc2)c1)N		Inactive	TGF-bR1 (ALK5) Inhibitor		1	AZ-TAK1 Inhibitor	384568708	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	48.2964792636	O=C(Nc1c(C(=O)N)sc(-c2ccc(CN3CCOCC3)cc2)c1)N	O=C(Nc1c(C(=O)N)sc(-c2ccc(CN3CCOCC3)cc2)c1)N
NCGC00263196-01	O=C(Nc1c(C(=O)O)cc(C(C)(C)C)s1)Nc1cc2c([nH]nc2)cc1		Inactive	p70 ribosomal S6 kinase (S6K1) Inhibitor		1	S6K-18	137276040	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.80584584	O=C(Nc1c(C(=O)O)cc(C(C)(C)C)s1)Nc1cc2c([nH]nc2)cc1	O=C(Nc1c(C(=O)O)cc(C(C)(C)C)s1)Nc1cc2c([nH]nc2)cc1
NCGC00242492-04	O=C(Nc1c(C(=O)O)cccc1)/C=C(\C)/c1cc2c(cc1)cccc2	4.4000001	Active	Telomerase Inhibitor	0.0	1	BIBR-1532	384568498	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-79.4198724359	O=C(Nc1c(C(=O)O)cccc1)/C=C(\C)/c1cc2c(cc1)cccc2	O=C(Nc1c(C(=O)O)cccc1)/C=C(\C)/c1cc2c(cc1)cccc2
NCGC00249930-01	O=C(Nc1c(C(=O)OC)cccc1C)CN(CC)CC	4.8000002	Active		0.0	1	Tolycaine	170465945	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-49.1697948959	O=C(Nc1c(C(=O)OC)cccc1C)CN(CC)CC	O=C(Nc1c(C(=O)OC)cccc1C)CN(CC)CC
NCGC00179248-03	O=C(Nc1c(C(=O)OC)scc1C)C(NCCC)C	5.4000001	Active	Sodium Channel Alpha Subunit Blocker	0.0	1	Articaine hydrochloride	170464825	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.7071544748	O=C(Nc1c(C(=O)OC)scc1C)C(NCCC)C.Cl	O=C(Nc1c(C(=O)OC)scc1C)C(NCCC)C.Cl
NCGC00346602-01	O=C(Nc1c(C(=O)O[C@]23[C@@H]4[C@]5([C@@H](OC)CC2)[C@H](N(CC)C3)[C@@H]([C@]2(O)[C@@]3(O)[C@@H](OC)[C@@H]([C@@H](OC)C2)C[C@@H]53)C4)cccc1)C		Inactive	Antiinflammatory alkaloid		1	Lappaconitine	174006325	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	8.2091641039	O=C(Nc1c(C(=O)O[C@]23[C@@H]4[C@]5([C@@H](OC)CC2)[C@H](N(CC)C3)[C@@H]([C@]2(O)[C@@]3(O)[C@@H](OC)[C@@H]([C@@H](OC)C2)C[C@@H]53)C4)cccc1)C	O=C(Nc1c(C(=O)O[C@]23[C@@H]4[C@]5([C@@H](OC)CC2)[C@H](N(CC)C3)[C@@H]([C@]2(O)[C@@]3(O)[C@@H](OC)[C@@H]([C@@H](OC)C2)C[C@@H]53)C4)cccc1)C
NCGC00242480-02&NCGC00242480-03	O=C(Nc1c(C(C)(C)C)cc(C(C)(C)C)c(O)c1)C=1C(=O)c2c(NC=1)cccc2	4.42499995	Active	CFTR Channel Activator&Cftr Channel Activator&CFTR Channel Activator	0.04999969999999987	2	Ivacaftor	384568492&405559089	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-3.0	-113.9360360548&-74.6886002319&-120.3568838022	O=C(Nc1c(C(C)(C)C)cc(C(C)(C)C)c(O)c1)C=1C(=O)c2c(NC=1)cccc2	O=C(Nc1c(C(C)(C)C)cc(C(C)(C)C)c(O)c1)C=1C(=O)c2c(NC=1)cccc2
NCGC00345857-05	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C(=O)N4CCOCC4)cc3)C(=O)N(C)C=2)ccc1)c1ccc(C(C)(C)C)cc1		Inactive	BTK Inhibitor		1	CGI-1746	384568771	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C(=O)N4CCOCC4)cc3)C(=O)N(C)C=2)ccc1)c1ccc(C(C)(C)C)cc1	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C(=O)N4CCOCC4)cc3)C(=O)N(C)C=2)ccc1)c1ccc(C(C)(C)C)cc1
NCGC00390563-02	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C4N(C)CCN(C)C4=O)cc3)C(=O)N(C)C=2)ccc1)c1sc2c(c1)CCCC2		Inactive	BTK Inhibitor		1	GDC-0834 racemate	384569193	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C4N(C)CCN(C)C4=O)cc3)C(=O)N(C)C=2)ccc1)c1sc2c(c1)CCCC2	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C4N(C)CCN(C)C4=O)cc3)C(=O)N(C)C=2)ccc1)c1sc2c(c1)CCCC2
NCGC00386301-06	O=C(Nc1c(C)ccc(CNC)c1)c1ccc(Nc2nc(-c3ccccc3)c3c(n2)cccc3)cc1	4.8499999	Active	Smo Inhibitor	0.0	1	BMS-833923	363680195	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-70.4678166387	O=C(Nc1c(C)ccc(CNC)c1)c1ccc(Nc2nc(-c3ccccc3)c3c(n2)cccc3)cc1	O=C(Nc1c(C)ccc(CNC)c1)c1ccc(Nc2nc(-c3ccccc3)c3c(n2)cccc3)cc1
NCGC00485933-01	O=C(Nc1c(C)ccc(OC2=Nn3c(nc(NC(=O)C4CC4)c3)C=C2)c1)c1n(C)nc(C)c1	4.5	Active	PDGFR Inhibitor	0.0	1	TAK-593	363681426	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-60.308782586	O=C(Nc1c(C)ccc(OC2=Nn3c(nc(NC(=O)C4CC4)c3)C=C2)c1)c1n(C)nc(C)c1	O=C(Nc1c(C)ccc(OC2=Nn3c(nc(NC(=O)C4CC4)c3)C=C2)c1)c1n(C)nc(C)c1
NCGC00015860-06	O=C(Nc1c(C)cccc1)C(NCCC)C		Inactive	reactive oxygen species biosynthetic process Inhibitor&Reactive Oxygen Species Biosynthetic Process Inhibitor		1	Prilocaine hydrochloride	170464697	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(Nc1c(C)cccc1)C(NCCC)C.Cl	O=C(Nc1c(C)cccc1)C(NCCC)C.Cl
NCGC00183654-01	O=C(Nc1c(C)cccc1C)C(N(CCC)CC)CC		Inactive	Sodium Channel Protein Type Ii Alpha Subunit Blocker&Sodium channel protein type II alpha subunit Blocker		1	Etidocaine	144206521	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.2344415239&-22.7617528799	O=C(Nc1c(C)cccc1C)C(N(CCC)CC)CC	O=C(Nc1c(C)cccc1C)C(N(CCC)CC)CC
NCGC00162129-06	O=C(Nc1c(C)cccc1C)C(N)C		Inactive	Sodium Channel Alpha Subunit Inhibitor&Sodium channel alpha subunit Inhibitor		1	Tocainide hydrochloride	170465114	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.0376998081&9.460465656	O=C(Nc1c(C)cccc1C)C(N)C.Cl	O=C(Nc1c(C)cccc1C)C(N)C.Cl
NCGC00018284-06	O=C(Nc1c(C)cccc1C)C1N(C)CCCC1		Inactive	Sodium channel protein type X alpha subunit Inhibitor&Sodium Channel Protein Type X Alpha Subunit Inhibitor		1	MEPIVACAINE HYDROCHLORIDE	405559140	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.378886392&-19.980043008	O=C(Nc1c(C)cccc1C)C1N(C)CCCC1	O=C(Nc1c(C)cccc1C)C1N(C)CCCC1
NCGC00167454-02	O=C(Nc1c(C)cccc1C)CC12N(CCC1)CCC2		Inactive	Sodium Channel Alpha Subunit Blocker&Sodium channel alpha subunit Blocker		1	Pilsicainide	170465988	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.07286788&-12.194761212	O=C(Nc1c(C)cccc1C)CC12N(CCC1)CCC2	O=C(Nc1c(C)cccc1C)CC12N(CCC1)CCC2
NCGC00015611-18	O=C(Nc1c(C)cccc1C)CN(CC)CC		Inactive	Sodium Channel Protein Type Ix Alpha Subunit Blocker&Sodium channel protein type IX alpha subunit Blocker		1	Lidocaine	170464729	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(Nc1c(C)cccc1C)CN(CC)CC	O=C(Nc1c(C)cccc1C)CN(CC)CC
NCGC00186006-10	O=C(Nc1c(C)cccc1C)CN1C(=O)CCC1		Inactive	GABAergic Transmission Enhancer		1	Nefiracetam	384568434	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.4079797439	O=C(Nc1c(C)cccc1C)CN1C(=O)CCC1	O=C(Nc1c(C)cccc1C)CN1C(=O)CCC1
NCGC00017043-03&NCGC00091886-04	O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1	4.7125001	Active	Taste receptor type 2 member 8 Agonist&Taste Receptor Type 2 Member 8 Agonist&Glycolysis / Gluconeogenesis Inhibitor	0.625	2	Denatonium benzoate	405558882&170464678	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.2&-3.0	-40.906980512&-36.1708766999&-39.19583042	O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1	O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1&O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1.O=C([O-])c1ccccc1
NCGC00164597-02	O=C(Nc1c(C)cccc1C)[C@H]1N(CCC)CCCC1		Inactive	Voltage-gated Potassium Channel Subunit Kv1.5 Inhibitor&Voltage-gated potassium channel subunit Kv1.5 Inhibitor		1	Ropivacaine hydrochloride	170465120	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.425709108&-44.657400624	O=C(Nc1c(C)cccc1C)[C@H]1N(CCC)CCCC1.Cl	O=C(Nc1c(C)cccc1C)[C@H]1N(CCC)CCCC1.Cl
NCGC00178579-04	O=C(Nc1c(C)cccc1C)[C@H]1N(CCCC)CCCC1	4.4499998	Active	Sodium Channel Protein Type Iv Alpha Subunit Blocker&Sodium channel protein type IV alpha subunit Blocker	0.0	1	Levobupivacaine hydrochloride	170465452	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-58.46104668&-58.9578058341	O=C(Nc1c(C)cccc1C)[C@H]1N(CCCC)CCCC1.Cl	O=C(Nc1c(C)cccc1C)[C@H]1N(CCCC)CCCC1.Cl
NCGC00346526-03	O=C(Nc1c(CC)cccc1CC)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1	5.9000001	Active	Aurora-A/B/c Inhibitor	0.0	1	PHA-680632	384568820	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-32.5729282576	O=C(Nc1c(CC)cccc1CC)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1	O=C(Nc1c(CC)cccc1CC)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1
NCGC00185765-02	O=C(Nc1c(CCC2N(C)CCCC2)cccc1)c1ccc(OC)cc1	5.0500002	Inactive	Sodium Channel Protein Type V Alpha Subunit Inhibitor	0.0	1	Encainide hydrochloride	405558508	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	45.9730537344	O=C(Nc1c(CCC2N(C)CCCC2)cccc1)c1ccc(OC)cc1	O=C(Nc1c(CCC2N(C)CCCC2)cccc1)c1ccc(OC)cc1
NCGC00378622-03&NCGC00378622-10	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)c1)C=C	5.375	Active	Epidermal Growth Factor Receptor (thr790met Mutant) Inhibitor&EGFR (Thr790Met Mutant) Inhibitor&EGFR (Thr790Met Mutant) Inhibitor	0.25	2	Osimertinib mesylate	405558589&363678127	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-2.1&-1.2	-82.6483608569&-97.6362786016&-73.5640185006	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)c1)C=C	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)c1)C=C
NCGC00263182-04	O=C(Nc1c(N)cccc1)c1ccc(CNc2nc(-c3cnccc3)ccn2)cc1		Inactive	HDAC Inhibitor		1	Mocetinostat	384568650	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1c(N)cccc1)c1ccc(CNc2nc(-c3cnccc3)ccn2)cc1	O=C(Nc1c(N)cccc1)c1ccc(CNc2nc(-c3cnccc3)ccn2)cc1
NCGC00348107-03	O=C(Nc1c(N2CCC(C)CC2)cc(N2CCN(C)CC2)cc1)c1[nH]cc(C#N)c1		Inactive	CSF1R (c-FMS) Inhibitor		1	c-FMS Inhibitor	363677735	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.812951348	O=C(Nc1c(N2CCC(C)CC2)cc(N2CCN(C)CC2)cc1)c1[nH]cc(C#N)c1	O=C(Nc1c(N2CCC(C)CC2)cc(N2CCN(C)CC2)cc1)c1[nH]cc(C#N)c1
NCGC00476204-01	O=C(Nc1c(N2CCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	PFI-4	363681102	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.444879148	O=C(Nc1c(N2CCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(Nc1c(N2CCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00107508-04	O=C(Nc1c(N2CCCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	GSK-5959	384568161	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.370901056	O=C(Nc1c(N2CCCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(Nc1c(N2CCCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00509915-01	O=C(Nc1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	GSK-6853	384569381	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.887603824	O=C(Nc1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(Nc1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00183095-07	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C	5.0999999	Active	glycylcycline antibiotics	0.0	1	Tigecycline	384568415	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-34.7861878376	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C
NCGC00183095-01	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C		Inactive	Glycylcycline Antibiotics&glycylcycline antibiotics		1	Tigecycline	124894296	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.608263812&-25.5341919039	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C
NCGC00346937-01	O=C(Nc1c(OC)ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c1)[C@H](N)CO	4.0	Inactive	Tubulin polymerization Inhibitor	0.0	1	Ombrabulin	174007341	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	70.3961674801	O=C(Nc1c(OC)ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c1)[C@H](N)CO	O=C(Nc1c(OC)ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c1)[C@H](N)CO
NCGC00345833-01	O=C(Nc1c(OCCN(C)C)cc(-c2c[nH]nc2)cc1)C1Oc2c(OC1)cccc2		Inactive	ROCK II Inhibitor		1	SR-3677	174006422	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.057815992	O=C(Nc1c(OCCN(C)C)cc(-c2c[nH]nc2)cc1)C1Oc2c(OC1)cccc2	O=C(Nc1c(OCCN(C)C)cc(-c2c[nH]nc2)cc1)C1Oc2c(OC1)cccc2
NCGC00346944-02	O=C(Nc1c2c([nH]cc2)ncc1)c1ccc([C@H](N)C)cc1	4.5999999	Inactive	ROCK Inhibitor	0.0	1	Y-39983	363677562	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-28.7614486805	O=C(Nc1c2c([nH]cc2)ncc1)c1ccc([C@H](N)C)cc1	O=C(Nc1c2c([nH]cc2)ncc1)c1ccc([C@H](N)C)cc1
NCGC00250387-06	O=C(Nc1c2c(c(-c3c4OC(N5CCOCC5)=CC(=O)c4ccc3)cc1)sc1c2cccc1)CN1CCN(CC)CC1	5.25	Active	DNA-PK Inhibitor	0.0	1	KU-0060648	384568540	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.1783566489	O=C(Nc1c2c(c(-c3c4OC(N5CCOCC5)=CC(=O)c4ccc3)cc1)sc1c2cccc1)CN1CCN(CC)CC1	O=C(Nc1c2c(c(-c3c4OC(N5CCOCC5)=CC(=O)c4ccc3)cc1)sc1c2cccc1)CN1CCN(CC)CC1
NCGC00347905-02	O=C(Nc1c2c(nc(NCCNCCO)cc2)ccc1)CC12CC3CC(C1)CC(C2)C3	4.4000001	Active	P2X7 Receptor Antagonist	0.0	1	AZ-10606120	363677717	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-49.6842654559	O=C(Nc1c2c(nc(NCCNCCO)cc2)ccc1)CC12CC3CC(C1)CC(C2)C3	O=C(Nc1c2c(nc(NCCNCCO)cc2)ccc1)CC12CC3CC(C1)CC(C2)C3
NCGC00346683-02	O=C(Nc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1)c1cnc(N)cc1	6.0500002	Active	PIKfyve Inhibitor	0.0	1	YM-201636	384568907	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.2801496156	O=C(Nc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1)c1cnc(N)cc1	O=C(Nc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1)c1cnc(N)cc1
NCGC00018215-06	O=C(Nc1cc(C(=O)C)c(OCC(O)CNC(C)C)cc1)CCC	5.0500002	Active	Beta-1 Adrenergic Receptor Antagonist	0.0	1	Acebutolol hydrochloride	170465309	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.765744964	O=C(Nc1cc(C(=O)C)c(OCC(O)CNC(C)C)cc1)CCC.Cl	O=C(Nc1cc(C(=O)C)c(OCC(O)CNC(C)C)cc1)CCC.Cl
NCGC00174046-02	O=C(Nc1cc(C2=NCCN2)ccc1)Nc1cc(C2=NCCN2)ccc1		Inactive	Adenosine deaminase Inhibitor&Adenosine Deaminase Inhibitor		1	Imidocarb dipropionate	170466330	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.3742466679&14.783758188	O=C(Nc1cc(C2=NCCN2)ccc1)Nc1cc(C2=NCCN2)ccc1.O=C(O)CC.O=C(O)CC	O=C(Nc1cc(C2=NCCN2)ccc1)Nc1cc(C2=NCCN2)ccc1.O=C(O)CC.O=C(O)CC
NCGC00249904-01	O=C(Nc1cc(C2N=C3SCCN3C2)ccc1)C(C)C		Inactive	Nicotinic Acetylcholine Receptor Alpha Subunit Agonist&Nicotinic acetylcholine receptor alpha subunit Agonist		1	Butamisole	170466389	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(Nc1cc(C2N=C3SCCN3C2)ccc1)C(C)C	O=C(Nc1cc(C2N=C3SCCN3C2)ccc1)C(C)C
NCGC00274171-10	O=C(Nc1cc(C=2SC=3N(C(=O)C=C(N4CCNCC4)N=3)N=2)cnc1)CN		Inactive	Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonist		1	RUC-4	384568713	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.440395648	O=C(Nc1cc(C=2SC=3N(C(=O)C=C(N4CCNCC4)N=3)N=2)cnc1)CN	O=C(Nc1cc(C=2SC=3N(C(=O)C=C(N4CCNCC4)N=3)N=2)cnc1)CN
NCGC00025109-13	O=C(Nc1cc(NC(=O)c2ccc(O)cc2)c(C)cc1)c1cc(N(C)C)ccc1		Inactive	Raf Kinase Inhibitor		1	ZM-336372	384568051	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1cc(NC(=O)c2ccc(O)cc2)c(C)cc1)c1cc(N(C)C)ccc1	O=C(Nc1cc(NC(=O)c2ccc(O)cc2)c(C)cc1)c1cc(N(C)C)ccc1
NCGC00250380-10	O=C(Nc1cc(Nc2cc3C(=O)N(C)C=Nc3cc2)c(C)cc1)c1cc(C(C#N)(C)C)ccc1	4.4499998	Active	Raf kinase B/C Inhibitor	0.0	1	AZ-628	377020384	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-35.710424205	O=C(Nc1cc(Nc2cc3C(=O)N(C)C=Nc3cc2)c(C)cc1)c1cc(C(C#N)(C)C)ccc1	O=C(Nc1cc(Nc2cc3C(=O)N(C)C=Nc3cc2)c(C)cc1)c1cc(C(C#N)(C)C)ccc1
NCGC00159456-11&NCGC00159456-30	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1	4.5749998	Active	Bcr-abl Inhibitor&Bcr-Abl Inhibitor&Bcr-Abl Inhibitor	0.25	2	Imatinib	170465393&384568179	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.4&-2.1	-93.5988474862&-81.524471128&-113.1468334698	S(=O)(=O)(O)C.O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1	S(=O)(=O)(O)C.O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1&O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1
NCGC00485941-02	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCNCC2)cc1		Inactive	LRRK2 Inhibitor		1	CGP-74588 (N-Desmethyl imatinib)	384569278	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-31.031722108	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCNCC2)cc1	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCNCC2)cc1
NCGC00241103-06&NCGC00241103-11	O=C(Nc1cc(Nc2scc(-c3cnccc3)n2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1	4.52499985	Active	Fgfr 3 Inhibitor&FGFR 3 Inhibitor&FGFR 3 Inhibitor	0.15000010000000064	2	Masitinib	405558715&384568473	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0&-3.0	-92.6564132484&-89.5357581145&-112.4467136454	O=C(Nc1cc(Nc2scc(-c3cnccc3)n2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1	O=C(Nc1cc(Nc2scc(-c3cnccc3)n2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1
NCGC00160624-04	O=C(Nc1cc(OCC)c(C(=O)OC)cc1)C		Inactive	Folic Acid Biosynthetic Process Modulator&folic acid biosynthetic process Modulator		1	Ethopabate	170466827	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.4451731679&-10.714931628	O=C(Nc1cc(OCC)c(C(=O)OC)cc1)C	O=C(Nc1cc(OCC)c(C(=O)OC)cc1)C
NCGC00498432-01	O=C(Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3c2scc3)ccc1)C=C	5.0999999	Active	Jak3 Inhibitor	0.0	1	Olmutinib	384569299	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-75.7971926134	O=C(Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3c2scc3)ccc1)C=C	O=C(Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3c2scc3)ccc1)C=C
NCGC00263205-02	O=C(Nc1cc2NCC(C)(C)c2cc1)c1c(NCc2ccncc2)nccc1		Inactive	VEGFR-1,2,3 Inhibitor		1	Motesanib	384568664	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	20.8860016479	O=C(Nc1cc2NCC(C)(C)c2cc1)c1c(NCc2ccncc2)nccc1	O=C(Nc1cc2NCC(C)(C)c2cc1)c1c(NCc2ccncc2)nccc1
NCGC00263132-03	O=C(Nc1cc2[nH]c(-c3cn(C)nc3)c3c2c(C(=O)NN=C3)c1)[C@H](N)C1CCCCC1	5.0500002	Active	Chk1 Inhibitor	0.0	1	PF-477736	384568612	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.1746780151	O=C(Nc1cc2[nH]c(-c3cn(C)nc3)c3c2c(C(=O)NN=C3)c1)[C@H](N)C1CCCCC1	O=C(Nc1cc2[nH]c(-c3cn(C)nc3)c3c2c(C(=O)NN=C3)c1)[C@H](N)C1CCCCC1
NCGC00161418-13	O=C(Nc1cc2c(N)cc(C)nc2cc1)c1c(COc2ccc(CC)cc2)cccc1	5.0	Active	ORL1 (OP4, NOP) Antagonist	0.0	1	JTC-801	384568208	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.9486629052	O=C(Nc1cc2c(N)cc(C)nc2cc1)c1c(COc2ccc(CC)cc2)cccc1	O=C(Nc1cc2c(N)cc(C)nc2cc1)c1c(COc2ccc(CC)cc2)cccc1
NCGC00229735-09	O=C(Nc1cc2c(Sc3c(C=4OC(N5CCOCC5)=CC(=O)C=4)cccc3C2)cc1)CN1C[C@@H](C)O[C@@H](C)C1	4.5500002	Active	ATM Kinase Inhibitor	0.0	1	KU-60019	384568464	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-102.582188107	O=C(Nc1cc2c(Sc3c(C=4OC(N5CCOCC5)=CC(=O)C=4)cccc3C2)cc1)CN1C[C@@H](C)O[C@@H](C)C1	O=C(Nc1cc2c(Sc3c(C=4OC(N5CCOCC5)=CC(=O)C=4)cccc3C2)cc1)CN1C[C@@H](C)O[C@@H](C)C1
NCGC00507845-01	O=C(Nc1cc2c(cncc2)cc1)[C@H](CN)c1ccc(COC(=O)c2c(C)cc(C)cc2)cc1	5.0333333	Active	Rock Inhibitor&ROCK Inhibitor	0.0	1	Netarsudil	384569326	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0&-2.3	-78.5323579702&-83.009697892&-62.547426805	O=C(Nc1cc2c(cncc2)cc1)[C@H](CN)c1ccc(COC(=O)c2c(C)cc(C)cc2)cc1	O=C(Nc1cc2c(cncc2)cc1)[C@H](CN)c1ccc(COC(=O)c2c(C)cc(C)cc2)cc1
NCGC00390715-04	O=C(Nc1cc2c3c(C(=O)N(CCN(C)C)C(=O)c3ccc2)c1)N	5.1500001	Active	Chemokine Receptor Antagonist	0.0	1	UNBS-5162	384569208	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-96.9658813934	O=C(Nc1cc2c3c(C(=O)N(CCN(C)C)C(=O)c3ccc2)c1)N	O=C(Nc1cc2c3c(C(=O)N(CCN(C)C)C(=O)c3ccc2)c1)N
NCGC00346522-06	O=C(Nc1ccc(-c2ccc(C(=O)[C@H]3[C@H](C(=O)O)CCC3)cc2)cc1)Nc1ccccc1		Inactive	Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitor		1	A-922500	384568817	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	49.0199581081	O=C(Nc1ccc(-c2ccc(C(=O)[C@H]3[C@H](C(=O)O)CCC3)cc2)cc1)Nc1ccccc1	O=C(Nc1ccc(-c2ccc(C(=O)[C@H]3[C@H](C(=O)O)CCC3)cc2)cc1)Nc1ccccc1
NCGC00389508-01	O=C(Nc1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2)cc1)C1NCCC1		Inactive	Jak2 Inhibitor		1	XL-019	384569176	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.1684088879	O=C(Nc1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2)cc1)C1NCCC1	O=C(Nc1ccc(-c2nc(Nc3ccc(N4CCOCC4)cc3)ncc2)cc1)C1NCCC1
NCGC00346649-04	O=C(Nc1ccc(C(=O)N2CCN(C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(CC)c3n2)cc1	9.0	Inactive	PI3K Inhibitor	0.0	1	PKI-402	384568880	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-26.182671421	O=C(Nc1ccc(C(=O)N2CCN(C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(CC)c3n2)cc1	O=C(Nc1ccc(C(=O)N2CCN(C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(CC)c3n2)cc1
NCGC00345881-04&NCGC00345881-05	O=C(Nc1ccc(C(=O)N2c3c(-c4[nH]c(C)nc4CC2)cccc3)cc1)c1c(-c2ccccc2)cccc1	4.47500015	Active	Vasopressin V2 Receptor Antagonist&Vasopressin (AVP) V1a/V2 Antagonist&Vasopressin (AVP) V1a/V2 Antagonist	0.15000010000000064	2	Conivaptan hydrochloride	405559087&363677399	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4&-3.0	-44.8226207959&-89.750244982&-89.660477976	O=C(Nc1ccc(C(=O)N2c3c(-c4[nH]c(C)nc4CC2)cccc3)cc1)c1c(-c2ccccc2)cccc1	O=C(Nc1ccc(C(=O)N2c3c(-c4[nH]c(C)nc4CC2)cccc3)cc1)c1c(-c2ccccc2)cccc1
NCGC00241114-02	O=C(Nc1ccc(C(=O)NC(C)(C)C)cc1)C		Inactive	p38 MAPK Inhibitor		1	CPI-1189	384568479	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	42.6716251574	O=C(Nc1ccc(C(=O)NC(C)(C)C)cc1)C	O=C(Nc1ccc(C(=O)NC(C)(C)C)cc1)C
NCGC00263153-07	O=C(Nc1ccc(C(=O)NO)cc1)[C@@H](C(C)C)c1ccccc1	4.0	Inactive	HDAC Inhibitor	0.0	1	AR-42	384568627	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-23.5557515921	O=C(Nc1ccc(C(=O)NO)cc1)[C@@H](C(C)C)c1ccccc1	O=C(Nc1ccc(C(=O)NO)cc1)[C@@H](C(C)C)c1ccccc1
NCGC00263639-13	O=C(Nc1ccc(C(=O)Nc2c(N)cccc2)cc1)C		Inactive	HDAC Inhibitor		1	Tacedinaline	384568696	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1ccc(C(=O)Nc2c(N)cccc2)cc1)C	O=C(Nc1ccc(C(=O)Nc2c(N)cccc2)cc1)C
NCGC00090820-03	O=C(Nc1ccc(C(=O)O)cc1)C		Inactive	Immune Response Modulator&immune response Modulator		1	4-Acetamidobenzoic acid	170466207	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.177117616&29.642579796	O=C(Nc1ccc(C(=O)O)cc1)C	O=C(Nc1ccc(C(=O)O)cc1)C
NCGC00164607-01	O=C(Nc1ccc(C(=O)O)cc1)[C@@H](NC(=O)c1ccccc1)Cc1ccc(O)cc1		Inactive			1	Bentiromide sodium	144205782	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.6434599479&-13.17564524	O=C(Nc1ccc(C(=O)[O-])cc1)[C@@H](NC(=O)c1ccccc1)Cc1ccc(O)cc1.[Na+]	O=C(Nc1ccc(C(=O)[O-])cc1)[C@@H](NC(=O)c1ccccc1)Cc1ccc(O)cc1.[Na+]
NCGC00181909-01	O=C(Nc1ccc(C(=O)OCC)cc1)CN1CCCCC1		Inactive			1	Sulcaine	144206885	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	34.6306774789&0.0	O=C(Nc1ccc(C(=O)OCC)cc1)CN1CCCCC1	O=C(Nc1ccc(C(=O)OCC)cc1)CN1CCCCC1
NCGC00263225-01	O=C(Nc1ccc(C)cc1)N[C@@]1(CC(=O)Nc2ccc(C)cc2)C(=O)N(CC(OCC)OCC)c2c1cccc2	4.5	Active	gastrin/CCKB receptor Antagonist	0.0	1	AG-041R	137276069	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-120.9155152651	O=C(Nc1ccc(C)cc1)N[C@@]1(CC(=O)Nc2ccc(C)cc2)C(=O)N(CC(OCC)OCC)c2c1cccc2	O=C(Nc1ccc(C)cc1)N[C@@]1(CC(=O)Nc2ccc(C)cc2)C(=O)N(CC(OCC)OCC)c2c1cccc2
NCGC00249393-08	O=C(Nc1ccc(C2(C#N)CCCC2)cc1)c1c(NCc2ccncc2)nccc1		Inactive	VEGFR-2 Inhibitor		1	Apatinib	377020310	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1ccc(C2(C#N)CCCC2)cc1)c1c(NCc2ccncc2)nccc1	O=C(Nc1ccc(C2(C#N)CCCC2)cc1)c1c(NCc2ccncc2)nccc1
NCGC00165782-07	O=C(Nc1ccc(C2=NCCN2)cc1)/C=C/c1ccc(/C=C/C(=O)Nc2ccc(C3=NCCN3)cc2)cc1		Inactive	Neutral Sphingomyelinase (N-SMase) Inhibitor		1	GW-4869	384568282	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-30.666749244	O=C(Nc1ccc(C2=NCCN2)cc1)/C=C/c1ccc(/C=C/C(=O)Nc2ccc(C3=NCCN3)cc2)cc1	O=C(Nc1ccc(C2=NCCN2)cc1)/C=C/c1ccc(/C=C/C(=O)Nc2ccc(C3=NCCN3)cc2)cc1
NCGC00346448-03	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c(NC(=O)c2cnc3c(c2)cccc3)cc(OC)c(OC)c1	4.5500002	Active	P-Glycoprotein (MDR-1) Inhibitor	0.0	1	Tariquidar	384568779	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-43.6836508396	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c(NC(=O)c2cnc3c(c2)cccc3)cc(OC)c(OC)c1	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c(NC(=O)c2cnc3c(c2)cccc3)cc(OC)c(OC)c1
NCGC00263219-03	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c2Nc3c(OC)cccc3C(=O)c2ccc1		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Elacridar	384568673	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.742991312	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c2Nc3c(OC)cccc3C(=O)c2ccc1	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c2Nc3c(OC)cccc3C(=O)c2ccc1
NCGC00386239-01	O=C(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)Cc1nc(N)sc1		Inactive	Beta-3 Adrenergic Receptor Agonist&Beta-3 adrenergic receptor Agonist		1	Mirabegron	405558549	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.200221268&-28.56735328	O=C(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)Cc1nc(N)sc1	O=C(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)Cc1nc(N)sc1
NCGC00159574-16	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OCCCN2CCOCC2)c3)cc1)c1ccccc1	5.0999999	Active	Aurora-A/B Inhibitor	0.0	1	ZM-447439	384568190	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-101.5324172317	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OCCCN2CCOCC2)c3)cc1)c1ccccc1	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OCCCN2CCOCC2)c3)cc1)c1ccccc1
NCGC00090752-04	O=C(Nc1ccc(O)cc1)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	4.3499999	Active	RARbeta/gamma Agonist	0.0	1	Fenretinide	26752780	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-72.5239488122	O=C(Nc1ccc(O)cc1)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	O=C(Nc1ccc(O)cc1)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00160580-02	O=C(Nc1ccc(O)cc1)c1c(O)cccc1	4.5500002	Active	Ribonucleoside-diphosphate Reductase M2 Chain Inhibitor&Ribonucleoside-diphosphate reductase M2 chain Inhibitor	0.0	1	2-Hydroxy-N-(4-hydroxyphenyl)-benzamide	405558623	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-77.8589292768&-57.15259234	O=C(Nc1ccc(O)cc1)c1c(O)cccc1	O=C(Nc1ccc(O)cc1)c1c(O)cccc1
NCGC00241097-06	O=C(Nc1ccc(OC(C)C)cc1)N1CCN(c2ncnc3c2cc(OC)c(OCCCN2CCCCC2)c3)CC1	4.4499998	Active	KIT Inhibitor	0.0	1	Tandutinib	384568469	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-95.473602867	O=C(Nc1ccc(OC(C)C)cc1)N1CCN(c2ncnc3c2cc(OC)c(OCCCN2CCCCC2)c3)CC1	O=C(Nc1ccc(OC(C)C)cc1)N1CCN(c2ncnc3c2cc(OC)c(OCCCN2CCCCC2)c3)CC1
NCGC00016281-11	O=C(Nc1ccc(OCC)cc1)C		Inactive	Prostaglandin G/H synthase 1 Inhibitor&Prostaglandin G/h Synthase 1 Inhibitor		1	Phenacetin	170465554	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-14.173740428	O=C(Nc1ccc(OCC)cc1)C	O=C(Nc1ccc(OCC)cc1)C
NCGC00166139-03	O=C(Nc1ccc(OCC)cc1)CC(O)C		Inactive			1	3-Hydroxy-4-butyrophenetidide	170465885	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.099833544&-25.5553775239	O=C(Nc1ccc(OCC)cc1)CC(O)C	O=C(Nc1ccc(OCC)cc1)CC(O)C
NCGC00091326-06	O=C(Nc1ccccc1)C		Inactive			1	Acetanilide	170465493	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.671222048&44.9255425994	O=C(Nc1ccccc1)C	O=C(Nc1ccccc1)C
NCGC00092276-11	O=C(Nc1ccncc1)C1CCC([C@H](N)C)CC1	5.3000002	Active		0.0	1	NCGC00092276-11	384568101	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-31.9574468252	O=C(Nc1ccncc1)C1CCC([C@H](N)C)CC1	O=C(Nc1ccncc1)C1CCC([C@H](N)C)CC1
NCGC00015917-09	O=C(Nc1cnccc1)N1c2c(cc3n(C)ccc3c2)CC1		Inactive	5-HT2B Receptor Antagonist		1	SB-206553	384567906	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.426594712	O=C(Nc1cnccc1)N1c2c(cc3n(C)ccc3c2)CC1	O=C(Nc1cnccc1)N1c2c(cc3n(C)ccc3c2)CC1
NCGC00241104-09	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1c2c(c(OCCN3CCOCC3)cc1)cccc2		Inactive	p38 MAPK Inhibitor		1	Doramapimod	384568474	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.0663892279	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1c2c(c(OCCN3CCOCC3)cc1)cccc2	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1c2c(c(OCCN3CCOCC3)cc1)cccc2
NCGC00379091-01	O=C(Nc1n(CCCN(C)C)c2c(n1)cccc2)c1cc2n3[C@H](C)CCNC(=O)c3cc2cc1	4.4000001	Active	p70 ribosomal S6 kinase (S6K1) Inhibitor	0.0	1	BIX-02565	363678347	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-70.291585536	O=C(Nc1n(CCCN(C)C)c2c(n1)cccc2)c1cc2n3[C@H](C)CCNC(=O)c3cc2cc1	O=C(Nc1n(CCCN(C)C)c2c(n1)cccc2)c1cc2n3[C@H](C)CCNC(=O)c3cc2cc1
NCGC00346713-05	O=C(Nc1n[nH]c(CCc2cc(OC)cc(OC)c2)c1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1	4.8499999	Active	FGFR 3 Inhibitor	0.0	1	AZD-4547	363677532	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-100.4824074587	O=C(Nc1n[nH]c(CCc2cc(OC)cc(OC)c2)c1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1	O=C(Nc1n[nH]c(CCc2cc(OC)cc(OC)c2)c1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1
NCGC00357427-09	O=C(Nc1nc2c(c(OCCN)c1)cccc2)c1nc(C(=O)Nc2nc3c(c(OCCN)c2)cccc3)cc(OCCN)c1	4.4000001	Active	G-quadraplex binding ligand	0.0	1	Pyridostatin	384569034	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-74.1086658599	O=C(Nc1nc2c(c(OCCN)c1)cccc2)c1nc(C(=O)Nc2nc3c(c(OCCN)c2)cccc3)cc(OCCN)c1	O=C(Nc1nc2c(c(OCCN)c1)cccc2)c1nc(C(=O)Nc2nc3c(c(OCCN)c2)cccc3)cc(OCCN)c1
NCGC00509947-01	O=C(Nc1ncc(C#N)c(NCCOC)c1)N1c2nc(C=O)c(CN3C(=O)CN(C)CC3)cc2CCC1		Inactive	FGFR4 Inhibitor		1	NVP-FGF-401	384569394	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1ncc(C#N)c(NCCOC)c1)N1c2nc(C=O)c(CN3C(=O)CN(C)CC3)cc2CCC1	O=C(Nc1ncc(C#N)c(NCCOC)c1)N1c2nc(C=O)c(CN3C(=O)CN(C)CC3)cc2CCC1
NCGC00346670-03	O=C(Nc1ncc(Oc2c3c(ncc2)cc(OC)cc3)cc1)C=1C(=O)N(N(CC(O)(C)C)C=1C)c1ccccc1	4.4000001	Active	HGFR Inhibitor	0.0	1	AMG-458	384568896	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-89.9478233559	O=C(Nc1ncc(Oc2c3c(ncc2)cc(OC)cc3)cc1)C=1C(=O)N(N(CC(O)(C)C)C=1C)c1ccccc1	O=C(Nc1ncc(Oc2c3c(ncc2)cc(OC)cc3)cc1)C=1C(=O)N(N(CC(O)(C)C)C=1C)c1ccccc1
NCGC00345834-05	O=C(Nc1nccc(-c2c(-c3cc(C)ccc3)nc(CC)s2)c1)c1ccccc1	4.5999999	Active	p38 MAPK Inhibitor	0.0	1	TAK-715	363677378	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-92.0765053323	O=C(Nc1nccc(-c2c(-c3cc(C)ccc3)nc(CC)s2)c1)c1ccccc1	O=C(Nc1nccc(-c2c(-c3cc(C)ccc3)nc(CC)s2)c1)c1ccccc1
NCGC00015823-17&NCGC00015823-23	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2	4.0	Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Cyclooxygenase Inhibitor&Cyclooxygenase Inhibitor	0.0	2	Piroxicam	170464817&384567895	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	48.584284467&-17.652961564&53.798015748	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2
NCGC00345855-06	O=C(Nc1nn2C(c3ccc(CN4CCS(=O)(=O)CC4)cc3)=CC=Cc2n1)C1CC1	4.4000001	Active	Jak1/2 Inhibitor	0.0	1	Filgotinib	384568770	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-55.718240832	O=C(Nc1nn2C(c3ccc(CN4CCS(=O)(=O)CC4)cc3)=CC=Cc2n1)C1CC1	O=C(Nc1nn2C(c3ccc(CN4CCS(=O)(=O)CC4)cc3)=CC=Cc2n1)C1CC1
NCGC00242493-09	O=C(Nc1noc(C(C)(C)C)c1)Nc1ccc(-c2nc3Sc4c(-n3c2)ccc(OCCN2CCOCC2)c4)cc1	4.5	Active	Flt3 Inhibitor	0.0	1	Quizartinib	384568499	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-51.8780854834	O=C(Nc1noc(C(C)(C)C)c1)Nc1ccc(-c2nc3Sc4c(-n3c2)ccc(OCCN2CCOCC2)c4)cc1	O=C(Nc1noc(C(C)(C)C)c1)Nc1ccc(-c2nc3Sc4c(-n3c2)ccc(OCCN2CCOCC2)c4)cc1
NCGC00345805-01	O=C(Nc1oc(-c2occc2)nn1)c1c2c(nc(-c3ccccc3)c1)cccc2	4.5	Active	STAT-3 Inhibitor	0.0	1	STX-0119	174006676	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-96.3997511984	O=C(Nc1oc(-c2occc2)nn1)c1c2c(nc(-c3ccccc3)c1)cccc2	O=C(Nc1oc(-c2occc2)nn1)c1c2c(nc(-c3ccccc3)c1)cccc2
NCGC00247866-05	O=C(Nc1sc(-c2ccncc2)nn1)Nc1cc(C#N)c(-c2c[nH]nc2)cc1		Inactive	BLM Inhibitor		1	NCGC00247866	384568517	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1sc(-c2ccncc2)nn1)Nc1cc(C#N)c(-c2c[nH]nc2)cc1	O=C(Nc1sc(-c2ccncc2)nn1)Nc1cc(C#N)c(-c2c[nH]nc2)cc1
NCGC00263191-02	O=C(Nc1sc(C(C)C)cn1)[C@@H](C)c1ccc(NC(=O)C)cc1	5.4499998	Active	CDK2 Inhibitor	0.0	1	PHA-690509	363677255	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-79.3848282328	O=C(Nc1sc(C(C)C)cn1)[C@@H](C)c1ccc(NC(=O)C)cc1	O=C(Nc1sc(C(C)C)cn1)[C@@H](C)c1ccc(NC(=O)C)cc1
NCGC00263878-01	O=C(Nc1sc(C)cn1)C1N(C)S(=O)(=O)c2c(C1=O)cccc2		Inactive	Cyclooxygenase-1/2 Inhibitor		1	MELOXICAM SODIUM	384568698	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1[O-])cccc2	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1[O-])cccc2
NCGC00018248-18&NCGC00159516-02	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2		Inactive	Cyclooxygenase-1/2 Inhibitor		2	Meloxicam	384567999&144205287	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.971735184&-30.722449496	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2
NCGC00346624-10	O=C(Nc1sc(c(C)n1)-c1nc(C(C)(C)C)sc1)N1[C@H](C(=O)N)CCC1		Inactive	PI3Kalpha Inhibitor		1	A-66	384568864	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	34.1592456163	O=C(Nc1sc(c(C)n1)-c1nc(C(C)(C)C)sc1)N1[C@H](C(=O)N)CCC1	O=C(Nc1sc(c(C)n1)-c1nc(C(C)(C)C)sc1)N1[C@H](C(=O)N)CCC1
NCGC00263217-05	O=C(Nc1sc2c(n1)ccc(NC(=O)C1C3CC4CC1CC(C3)C4)c2)c1ccccc1	5.5999999	Active	Ceramide kinase Inhibitor	0.0	1	NVP-231	384568671	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-78.1077908389	O=C(Nc1sc2c(n1)ccc(NC(=O)C1C3CC4CC1CC(C3)C4)c2)c1ccccc1	O=C(Nc1sc2c(n1)ccc(NC(=O)C1C3CC4CC1CC(C3)C4)c2)c1ccccc1
NCGC00506872-01	O=C(Nc1scc(C(=O)NCCN(C(C)C)C(C)C)n1)c1c(O)cc(OC)c(OC)c1		Inactive	Acetylcholinesterase Inhibitor		1	Acotiamide hydrochlorid	405558502	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-8.3673061801&0.0	O=C(Nc1scc(C(=O)NCCN(C(C)C)C(C)C)n1)c1c(O)cc(OC)c(OC)c1	O=C(Nc1scc(C(=O)NCCN(C(C)C)C(C)C)n1)c1c(O)cc(OC)c(OC)c1
NCGC00017030-10	O=C(O)/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)CC2(C)[C@]3(C)[C@@H]([C@H](O)C[C@@H]/12)[C@]1(C)[C@H]([C@H](C)[C@H](O)CC1)CC3		Inactive			1	Fusidic Acid (sodium salt)	405558530	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.879963548&-18.703943712	O=C([O-])/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)CC2(C)[C@]3(C)[C@@H]([C@H](O)C[C@@H]/12)[C@]1(C)[C@H]([C@H](C)[C@H](O)CC1)CC3	O=C([O-])/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)CC2(C)[C@]3(C)[C@@H]([C@H](O)C[C@@H]/12)[C@]1(C)[C@H]([C@H](C)[C@H](O)CC1)CC3
NCGC00013082-04	O=C(O)/C(=C/C(=O)O)/CC(=O)O		Inactive	Cytoplasmic Aconitate Hydratase Substrate&Cytoplasmic aconitate hydratase Substrate		1	trans-Aconitic acid	170466847	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.4532093938&12.220652028	O=C(O)/C(=C/C(=O)O)/CC(=O)O	O=C(O)/C(=C/C(=O)O)/CC(=O)O
NCGC00164557-11	O=C(O)/C(=C/c1n(Cc2ccc(C(=O)O)cc2)c(CCCC)nc1)/Cc1sccc1	4.75	Active	Angiotensin At1 Antagonist&urate transport Inhibitor	0.0	1	Eprosartan mesylate	405558474	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-51.634631096&-37.307023168	O=C(O)/C(=C/c1n(Cc2ccc(C(=O)O)cc2)c(CCCC)nc1)/Cc1sccc1	O=C(O)/C(=C/c1n(Cc2ccc(C(=O)O)cc2)c(CCCC)nc1)/Cc1sccc1
NCGC00249913-01	O=C(O)/C(=N\NC(=O)c1ccncc1)/C		Inactive	Isocitrate Lyase Inhibitor&Isocitrate lyase Inhibitor		1	Isoniazid pyruvate	170465758	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.8163664239&24.64363592	O=C(O)/C(=N\NC(=O)c1ccncc1)/C	O=C(O)/C(=N\NC(=O)c1ccncc1)/C
NCGC00017280-37	O=C(O)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	Retinoid RORbeta Ligand		1	Tretinoin	384567982	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	O=C(O)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00163127-04&NCGC00163127-08	O=C(O)/C=C(/C=C/C=C(/C=C/c1c(C)c(C)c(OC)cc1C)\C)\C		Inactive	Retinoid&retinoid&retinoid		2	Acitretin	225144249&384568231	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-33.182771626&0.0&0.0	O=C(O)/C=C(/C=C/C=C(/C=C/c1c(C)c(C)c(OC)cc1C)\C)\C	O=C(O)/C=C(/C=C/C=C(/C=C/c1c(C)c(C)c(OC)cc1C)\C)\C
NCGC00386776-01	O=C(O)/C=C(/C=C/[C@H]1[C@@](C)(c2cc3C(C)(C)CCC(C)(C)c3cc2)C1)\C		Inactive	RXR Agonist		1	AGN-194204	384569146	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.57269674	O=C(O)/C=C(/C=C/[C@H]1[C@@](C)(c2cc3C(C)(C)CCC(C)(C)c3cc2)C1)\C	O=C(O)/C=C(/C=C/[C@H]1[C@@](C)(c2cc3C(C)(C)CCC(C)(C)c3cc2)C1)\C
NCGC00094358-05&NCGC00094358-38	O=C(O)/C=C(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C		Inactive	Retinoid Rar Agonists? Retinoid Rorbeta Ligand&Retinoid RAR Agonist&Retinoid RAR Agonist		2	Isotretinoin	26753641&384568128	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	23.192366508&0.0&35.0077585079	O=C(O)/C=C(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C	O=C(O)/C=C(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C
NCGC00091737-05	O=C(O)/C=C/C=C/C		Inactive			1	Sorbic acid	405559109	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)/C=C/C=C/C	O=C(O)/C=C/C=C/C
NCGC00253601-01	O=C(O)/C=C/CCCCCCCC		Inactive			1	Calcium undecylenate	170465553	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C([O-])/C=C/CCCCCCCC.O=C([O-])/C=C/CCCCCCCC.[Ca+2]	O=C([O-])/C=C/CCCCCCCC.O=C([O-])/C=C/CCCCCCCC.[Ca+2]
NCGC00344134-02	O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@H](CCCC)C)[C@H](O)CC1=O		Inactive			1	Limaprost	405559048	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.697026608&-26.473844848	O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@H](CCCC)C)[C@H](O)CC1=O	O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@H](CCCC)C)[C@H](O)CC1=O
NCGC00025195-06&NCGC00025195-09	O=C(O)/C=C/c1ccc(Cn2cncc2)cc1		Inactive	Thromboxane Synthase Inhibitor		2	Ozagrel hydrochloride	170466054&384568055	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	29.473623212&0.0&0.0	O=C(O)/C=C/c1ccc(Cn2cncc2)cc1.Cl	O=C(O)/C=C/c1ccc(Cn2cncc2)cc1.Cl&O=C(O)/C=C/c1ccc(Cn2cncc2)cc1
NCGC00159448-05	O=C(O)/C=C/c1ccc(OC)cc1		Inactive			1	4-Methoxycinnamic acid	225144227	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.863942796&-24.336097516	O=C(O)/C=C/c1ccc(OC)cc1	O=C(O)/C=C/c1ccc(OC)cc1
NCGC00165979-06	O=C(O)/C=C/c1ccccc1	4.1500001	Active		0.0	1	CINNAMIC ACID	405558448	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-60.8068792759	O=C(O)/C=C/c1ccccc1	O=C(O)/C=C/c1ccccc1
NCGC00182053-03	O=C(O)/C=C/c1nc(/C(=C/CN2CCCC2)/c2ccc(C)cc2)ccc1	4.4000001	Active	Histamine H1 receptor Antagonist&Histamine H1 Receptor Antagonist	0.0	1	Acrivastine	405558933	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-47.3273086217&-30.2251137959	O=C(O)/C=C/c1nc(/C(=C/CN2CCCC2)/c2ccc(C)cc2)ccc1	O=C(O)/C=C/c1nc(/C(=C/CN2CCCC2)/c2ccc(C)cc2)ccc1
NCGC00090970-03	O=C(O)/C=C\C(=O)O		Inactive	Nadp-dependent Malic Enzyme, Mitochondrial Inhibitor&NADP-dependent malic enzyme, mitochondrial Inhibitor		1	Maleic acid	170465983	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.0028192439&-25.208980752	O=C(O)/C=C\C(=O)O	O=C(O)/C=C\C(=O)O
NCGC00188429-03	O=C(O)C(=O)Nc1cc(-c2[nH]nnn2)ccc1		Inactive	Mediator Release Inhibitor		1	Acitazanolast	384568449	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C(=O)Nc1cc(-c2[nH]nnn2)ccc1	O=C(O)C(=O)Nc1cc(-c2[nH]nnn2)ccc1
NCGC00188429-02	O=C(O)C(=O)Nc1cc(-c2n[nH]nn2)ccc1		Inactive	Mediator Release Inhibitor		1	Acitazanolast	170466060	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-25.632767992	O=C(O)C(=O)Nc1cc(-c2n[nH]nn2)ccc1	O=C(O)C(=O)Nc1cc(-c2n[nH]nn2)ccc1
NCGC00249898-01	O=C(O)C(=O)c1cc(C)c(C)cc1		Inactive			1	Sodium 3, 4-dimethylphenyl-glyoxylate	170465549	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.04463608&-8.217812448	O=C([O-])C(=O)c1cc(C)c(C)cc1.[Na+]	O=C([O-])C(=O)c1cc(C)c(C)cc1.[Na+]
NCGC00022579-05	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Carbenicillin disodium	170465106	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.851448512&0.0	O=C([O-])C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]	O=C([O-])C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]
NCGC00388518-02	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1cscc1	4.4000001	Active		0.0	1	Ticarcillin sodium	405559121	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.926757304	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1cscc1	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1cscc1
NCGC00015453-08	O=C(O)C(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	5.1999998	Active	Histamine H1 Receptor Antagonist	0.0	1	Fexofenadine hydrochloride	170464669	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.399283216	O=C(O)C(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl	O=C(O)C(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl
NCGC00262907-01	O=C(O)C(C)(C)c1ccc(CCN2CCC(c3n(CCOCC)c4c(n3)cccc4)CC2)cc1	4.5250001	Active		0.0	1	Bilastine	170466329	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-55.692946484&-50.861017654	O=C(O)C(C)(C)c1ccc(CCN2CCC(c3n(CCOCC)c4c(n3)cccc4)CC2)cc1	O=C(O)C(C)(C)c1ccc(CCN2CCC(c3n(CCOCC)c4c(n3)cccc4)CC2)cc1
NCGC00183658-01	O=C(O)C(C)c1c2c(c(C3CCCCC3)cc1)cccc2		Inactive	Prostaglandin G/H synthase 2 Inhibitor&Prostaglandin G/h Synthase 2 Inhibitor		1	Quadrisol	144207184	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.982081492&28.2521698079	O=C(O)C(C)c1c2c(c(C3CCCCC3)cc1)cccc2	O=C(O)C(C)c1c2c(c(C3CCCCC3)cc1)cccc2
NCGC00167980-02	O=C(O)C(C)c1cc2c(Oc3ncccc3C2)cc1		Inactive	Prostaglandin Biosynthetic Process Inhibitor&prostaglandin biosynthetic process Inhibitor		1	Pranoprofen	170465811	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.3648540119&-14.362799992	O=C(O)C(C)c1cc2c(Oc3ncccc3C2)cc1	O=C(O)C(C)c1cc2c(Oc3ncccc3C2)cc1
NCGC00183878-01&NCGC00263585-01	O=C(O)C(C)c1cc2c(Sc3c(C(=O)C2)cccc3)cc1		Inactive	Cyclooxygenase Inhibitor		2	Zaltoprofen	124894594&170465838	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-17.283037068	O=C(O)C(C)c1cc2c(Sc3c(C(=O)C2)cccc3)cc1	O=C(O)C(C)c1cc2c(Sc3c(C(=O)C2)cccc3)cc1
NCGC00183010-01	O=C(O)C(C)c1ccc(/C=C\2/C(=O)CCCC/2)cc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Prostaglandin G/H synthase 2 Inhibitor		1	Pelubiprofen	144206823	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)C(C)c1ccc(/C=C\2/C(=O)CCCC/2)cc1	O=C(O)C(C)c1ccc(/C=C\2/C(=O)CCCC/2)cc1
NCGC00094916-06	O=C(O)C(C)c1ccc(C(=O)c2sccc2)cc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Prostaglandin G/H synthase 2 Inhibitor		1	Suprofen	170465412	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)C(C)c1ccc(C(=O)c2sccc2)cc1	O=C(O)C(C)c1ccc(C(=O)c2sccc2)cc1
NCGC00015529-15&NCGC00015529-22	O=C(O)C(C)c1ccc(CC(C)C)cc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Cyclooxygenase-1/2 Inhibitor&Cyclooxygenase-1/2 Inhibitor		2	Ibuprofen lysine	170464979&384567862	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	15.113722348&0.0&0.0	O=C(O)C(C)c1ccc(CC(C)C)cc1	O=C(O)C(C)c1ccc(CC(C)C)cc1
NCGC00263577-01	O=C(O)C(C)c1ccc(CC2C(=O)CCC2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	NCGC00263577-01&Loxoprofen	170465808	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)C(C)c1ccc(CC2C(=O)CCC2)cc1	O=C(O)C(C)c1ccc(CC2C(=O)CCC2)cc1
NCGC00522017-01	O=C(O)C(C)c1ccc(NCC(=C)C)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	rac Alminoprofen	405558807	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.3573652919	O=C(O)C(C)c1ccc(NCC(=C)C)cc1	O=C(O)C(C)c1ccc(NCC(=C)C)cc1
NCGC00179573-03	O=C(O)C(C)c1sc(C(=O)c2ccccc2)cc1		Inactive	Cyclooxygenase Inhibitor		1	Tiaprofenic acid	170465577	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)C(C)c1sc(C(=O)c2ccccc2)cc1	O=C(O)C(C)c1sc(C(=O)c2ccccc2)cc1
NCGC00095055-12	O=C(O)C(CC)C1OC(C(C(O)C(C(=O)C(CC)C2C(C)CC(C)C3(O[C@]4(C(O)C=C3)O[C@@](C)(C3OC(C)[C@](O)(CC)CC3)CC4)O2)C)C)C(C)CC1	4.5	Active	Anticoccidial/Antibacterial	0.0	1	Salinomycin	384568142	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-64.3421689088	O=C([O-])C(CC)C1OC(C(C(O)C(C(=O)C(CC)C2C(C)CC(C)C3(O[C@]4(C(O)C=C3)O[C@@](C)(C3OC(C)[C@](O)(CC)CC3)CC4)O2)C)C)C(C)CC1	O=C([O-])C(CC)C1OC(C(C(O)C(C(=O)C(CC)C2C(C)CC(C)C3(O[C@]4(C(O)C=C3)O[C@@](C)(C3OC(C)[C@](O)(CC)CC3)CC4)O2)C)C)C(C)CC1
NCGC00162288-07&NCGC00162288-12	O=C(O)C(CCC)CCC		Inactive	Gsk-3 Inhibitor&GSK-3 Inhibitor&GSK-3 Inhibitor		2	NCGC00162288-07&Valproic acid sodium salt&Valproic acid sodium salt	170465446&384568222	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-18.3544273759&9.4151528839&17.5158581879	O=C(O)C(CCC)CCC	O=C(O)C(CCC)CCC&O=C([O-])C(CCC)CCC
NCGC00016794-13&NCGC00016794-14	O=C(O)C(CCCOc1c(C)ccc(C)c1)(C)C		Inactive	Pparalpha Agonist&PPARalpha Agonist&PPARalpha Agonist		2	Gemfibrozil	170464998&174007259	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&11.5355857399	O=C(O)C(CCCOc1c(C)ccc(C)c1)(C)C	O=C(O)C(CCCOc1c(C)ccc(C)c1)(C)C
NCGC00420882-01	O=C(O)C(N)(CC1c2c(Oc3c1cccc3)cccc2)C1C(C(=O)O)C1		Inactive	mgluR3 Receptor Antagonist;Signal Transduction Modulators;mgluR2 Receptor Antagonist		1	LY-341495	384569225	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C(N)(CC1c2c(Oc3c1cccc3)cccc2)C1C(C(=O)O)C1	O=C(O)C(N)(CC1c2c(Oc3c1cccc3)cccc2)C1C(C(=O)O)C1
NCGC00274084-01	O=C(O)C(N)C(CC)C		Inactive			1	DL-Isoleucine	170465505	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&9.220961608	O=C(O)C(N)C(CC)C	O=C(O)C(N)C(CC)C
NCGC00183365-02	O=C(O)C(N)CCCN	5.4000001	Active	G-protein coupled receptor family C group 6 member A Agonist	0.0	1	ORNITHINE HYDROCHLORIDE	405558661	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-42.0509268492	O=C(O)C(N)CCCN	O=C(O)C(N)CCCN
NCGC00344533-01	O=C(O)C(NC(=O)C)CCC(=O)N		Inactive			1	Nalpha-Acetyl-L-glutamine	170465810	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	33.6938181359&17.660238208	O=C(O)C(NC(=O)C)CCC(=O)N	O=C(O)C(NC(=O)C)CCC(=O)N
NCGC00389655-01	O=C(O)C(NC(=O)C1N(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)O)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(CC)C)Cc2[nH]cnc2)CCC1)Cc1ccccc1	4.6999998	Active		0.0	1	Angiotensin II	405558595	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-29.5593783204	O=C(O)C(NC(=O)C1N(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)O)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(CC)C)Cc2[nH]cnc2)CCC1)Cc1ccccc1	O=C(O)C(NC(=O)C1N(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)O)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(CC)C)Cc2[nH]cnc2)CCC1)Cc1ccccc1
NCGC00015038-11	O=C(O)C(NC(=O)c1ccc(NCc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O		Inactive	Dihydrofolate Reductase (DHFR) Inhibitor		1	Aminopterin	384567800	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.681816544	O=C(O)C(NC(=O)c1ccc(NCc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O	O=C(O)C(NC(=O)c1ccc(NCc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O
NCGC00179305-04	O=C(O)C(NCNC(=O)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O)CCCCN		Inactive			1	Lymecycline	405558898	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.4937949199&-15.4872742601	O=C(O)C(NCNC(=O)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O)CCCCN	O=C(O)C(NCNC(=O)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O)CCCCN
NCGC00015185-06	O=C(O)C(NN)(Cc1cc(O)c(O)cc1)C		Inactive	Aromatic-L-amino-acid decarboxylase Inhibitor		1	Carbidopa	384567819	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.0768374119	O=C(O)C(NN)(Cc1cc(O)c(O)cc1)C	O=C(O)C(NN)(Cc1cc(O)c(O)cc1)C
NCGC00167547-02	O=C(O)C(O)(C(C(=O)O)CCCCCCCCCCCCCCCC)CC(=O)O	4.5500002	Active		0.0	1	Agaric acid	170465652	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-45.716145088&-71.7580663687	O=C(O)C(O)(C(C(=O)O)CCCCCCCCCCCCCCCC)CC(=O)O	O=C(O)C(O)(C(C(=O)O)CCCCCCCCCCCCCCCC)CC(=O)O
NCGC00164253-04	O=C(O)C(O)(CC(=O)O)CC(=O)O	4.8499999	Active		0.0	1	LITHIUM CITRATE	405558476	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-76.0245927664	O=C([O-])C(O)(CC(=O)[O-])CC(=O)[O-]	O=C([O-])C(O)(CC(=O)[O-])CC(=O)[O-]
NCGC00347131-03	O=C(O)C(O)C(O)C(=O)O	5.4000001	Active		0.0	1	D(-)-Tartaric acid	405558948	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-45.7217763368	O=C(O)C(O)C(O)C(=O)O	O=C(O)C(O)C(O)C(=O)O
NCGC00043225-04	O=C(O)C(O)CC(=O)O		Inactive			1	Disodium 2-hydroxybutanedioate	170465632	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-30.0656319359	O=C([O-])C(O)CC(=O)[O-].[Na+].[Na+]	O=C([O-])C(O)CC(=O)[O-].[Na+].[Na+]
NCGC00346605-03	O=C(O)C(O)Cc1cc(O)c(O)cc1		Inactive	Pregnane X Receptor (PXR) Regulator		1	Sodium Danshensu	384568855	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.146644924	O=C([O-])C(O)Cc1cc(O)c(O)cc1	O=C([O-])C(O)Cc1cc(O)c(O)cc1
NCGC00264001-02	O=C(O)C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO	4.4250002	Active		0.0	1	CALCIUM GLUCEPTATE	405558708	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-51.9421297119&-39.7603616432	O=C([O-])C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO	O=C([O-])C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO
NCGC00346710-03	O=C(O)C(OCc1nn(Cc2ccccc2)c2c1cccc2)(C)C		Inactive	non-steroidal antiinflammatory		1	Bindarit	363677530	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C(OCc1nn(Cc2ccccc2)c2c1cccc2)(C)C	O=C(O)C(OCc1nn(Cc2ccccc2)c2c1cccc2)(C)C
NCGC00167453-02&NCGC00167453-04	O=C(O)C(Oc1ccc(C2(c3ccc(OC(C(=O)O)(CC)C)cc3)CCCCC2)cc1)(CC)C		Inactive	treatment of lipoprotein diseases&Treatment Of Lipoprotein Diseases&treatment of lipoprotein diseases		2	Clinofibrate	174007296&384568314	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)C(Oc1ccc(C2(c3ccc(OC(C(=O)O)(CC)C)cc3)CCCCC2)cc1)(CC)C	O=C(O)C(Oc1ccc(C2(c3ccc(OC(C(=O)O)(CC)C)cc3)CCCCC2)cc1)(CC)C
NCGC00390260-01	O=C(O)C(Oc1ccc(CC(=O)Nc2cc(C)cc(C)c2)cc1)(C)C		Inactive	Chemosensitizer		1	Efaproxiral	363680869	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C(Oc1ccc(CC(=O)Nc2cc(C)cc(C)c2)cc1)(C)C	O=C(O)C(Oc1ccc(CC(=O)Nc2cc(C)cc(C)c2)cc1)(C)C
NCGC00346598-02	O=C(O)C1=CC(O)C(O)[C@H](O)C1		Inactive	plant biochemical intermediate		1	Shikimic acid	384568853	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.79348064	O=C(O)C1=CC(O)C(O)[C@H](O)C1	O=C(O)C1=CC(O)C(O)[C@H](O)C1
NCGC00263566-03	O=C(O)C1=NC(=O)NC(=O)N1		Inactive	Orotate phosphoribosyltransferase Inhibitor		1	Oteracil potassium	174006211	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-24.0837000279	O=C([O-])C1=NC(=O)NC(=O)N1	O=C([O-])C1=NC(=O)NC(=O)N1
NCGC00165772-06	O=C(O)C1C(=C)C(=O)OC1CCCCCCCC	4.4000001	Active	Fatty Acid Synthase (FAS) Inhibitor	0.0	1	C75	384568281	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-36.4403889959	O=C(O)C1C(=C)C(=O)OC1CCCCCCCC	O=C(O)C1C(=C)C(=O)OC1CCCCCCCC
NCGC00263831-02	O=C(O)C1C(O)C[C@]2(O)OC1CC(OC1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C2		Inactive	Antifungal Agent&Anti-fungal		1	NYSTATIN	405558644	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	22.469193084&-27.9097200243	O=C(O)C1C(O)C[C@]2(O)OC1CC(OC1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C2	O=C(O)C1C(O)C[C@]2(O)OC1CC(OC1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C2
NCGC00016569-09&NCGC00016569-10	O=C(O)C1CCC(CN)CC1		Inactive	Tissue-type Plasminogen Activator Inhibitor (tpa) Inhibitor		2	TRANEXAMIC ACID&Tranexamic Acid	225144181&384567950	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-26.2321794479&14.8446112319&0.0	O=C(O)C1CCC(CN)CC1	O=C(O)C1CCC(CN)CC1
NCGC00386179-04	O=C(O)C1CCC(c2n3N=CN=C(N)c3c(-c3[nH]c4c(OC)cccc4c3)n2)CC1	5.1999998	Active	mTORC1/2 Inhibitor	0.0	1	OSI-027	363680137	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-43.6903715051	O=C(O)C1CCC(c2n3N=CN=C(N)c3c(-c3[nH]c4c(OC)cccc4c3)n2)CC1	O=C(O)C1CCC(c2n3N=CN=C(N)c3c(-c3[nH]c4c(OC)cccc4c3)n2)CC1
NCGC00015977-06	O=C(O)C1CN(CCC=C(c2ccccc2)c2ccccc2)CCC1		Inactive	GAT-1 Inhibitor		1	SKF-89976A	384567912	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C1CN(CCC=C(c2ccccc2)c2ccccc2)CCC1	O=C(O)C1CN(CCC=C(c2ccccc2)c2ccccc2)CCC1
NCGC00263467-03	O=C(O)C1NC(=O)CC1		Inactive			1	2-Pyrrolidone-5-carboxylic acid	225144361	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.6075085799&-23.013821228	O=C(O)C1NC(=O)CC1	O=C(O)C1NC(=O)CC1
NCGC00532517-01	O=C(O)C=1C(=O)c2c(N(C3CC3)C=1)c(C)c(-c1cc(C)c(NC)nc1)cc2	4.9499998	Active	Topoisomerase Iv Inhibitor	0.0	1	OZENOXACIN	405558514	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-58.0474648704	O=C(O)C=1C(=O)c2c(N(C3CC3)C=1)c(C)c(-c1cc(C)c(NC)nc1)cc2	O=C(O)C=1C(=O)c2c(N(C3CC3)C=1)c(C)c(-c1cc(C)c(NC)nc1)cc2
NCGC00018181-12	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(C)cc2		Inactive	Quinoline Antibiotic		1	Nalidixic acid	170465215	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	6.524193356&0.0	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(C)cc2	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(C)cc2
NCGC00016743-08	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCCC1)nc2		Inactive			1	Piromidic acid	170466042	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.860986744&40.4150446436	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCCC1)nc2	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCCC1)nc2
NCGC00016866-11	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCNCC1)nc2	5.1999998	Active		0.0	1	Pipemidic acid	170465767	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.8493015527	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCNCC1)nc2	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCNCC1)nc2
NCGC00015277-17	O=C(O)C=1C(=O)c2c(N(CC)N=1)cc1OCOc1c2		Inactive	Topoisomerase Iv Inhibitor&Topoisomerase IV Inhibitor		1	Cinoxacin	170465414	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)C=1C(=O)c2c(N(CC)N=1)cc1OCOc1c2	O=C(O)C=1C(=O)c2c(N(CC)N=1)cc1OCOc1c2
NCGC00182073-03	O=C(O)C=1N(CC)c2c(CCC)c3OC(C(=O)O)=CC(=O)c3cc2C(=O)C=1		Inactive	Mast Cell Degranulation Inhibitor&mast cell degranulation Inhibitor		1	Nedocromil	170464978	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.986416784&-21.27974148	O=C(O)C=1N(CC)c2c(CCC)c3OC(C(=O)O)=CC(=O)c3cc2C(=O)C=1	O=C(O)C=1N(CC)c2c(CCC)c3OC(C(=O)O)=CC(=O)c3cc2C(=O)C=1
NCGC00188943-09	O=C(O)C=1NC(=O)NC(=O)C=1		Inactive	metabolite		1	Orotic acid	384568454	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.3632167359	O=C(O)C=1NC(=O)NC(=O)C=1	O=C(O)C=1NC(=O)NC(=O)C=1
NCGC00022858-08&NCGC00022858-10	O=C(O)C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)O)Oc4ccc3)ccc2)C(=O)C=1		Inactive	Mediator Release Inhibitor		2	Sodium cromoglycate	170464887&384568015	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&10.967472208	O=C([O-])C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)[O-])Oc4ccc3)ccc2)C(=O)C=1.[Na+].[Na+]	O=C([O-])C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)[O-])Oc4ccc3)ccc2)C(=O)C=1.[Na+].[Na+]&O=C([O-])C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)[O-])Oc4ccc3)ccc2)C(=O)C=1
NCGC00346663-04	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2		Inactive	radioprotectant		1	Geniposidic acid	384568893	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2
NCGC00016786-15	O=C(O)CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C	5.8499999	Active	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor	0.0	1	Mycophenolic acid	170465182	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.3	-45.4135107451	O=C(O)CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C	O=C(O)CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C
NCGC00161345-07	O=C(O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC		Inactive	Voltage-gated L-type Calcium Channel Modulator&Voltage-gated L-type calcium channel Modulator		1	DOCONEXENT	405558420	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.9732139799&21.5095015639	O=C(O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC	O=C(O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
NCGC00025325-03	O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCc1ccc(-c2ccccc2)cc1	4.4250002	Active	Thromboxane A2 Receptor Antagonist&Prostanoid TP Antagonist	0.0	1	Vapiprost hydrochloride	174006925	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-56.8851537668&-81.1938706799	O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCc1ccc(-c2ccccc2)cc1	O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCc1ccc(-c2ccccc2)cc1
NCGC00015399-16	O=C(O)CC1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Cyclooxygenase-2 Inhibitor		1	Etodolac	170464915	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.7282128679&0.0	O=C(O)CC1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12	O=C(O)CC1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12
NCGC00356837-03	O=C(O)CC1CCC(c2ccc(N3C(=O)c4c(N)ncnc4OCC3)cc2)CC1		Inactive	Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitor		1	PF-04620110	384569033	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CC1CCC(c2ccc(N3C(=O)c4c(N)ncnc4OCC3)cc2)CC1	O=C(O)CC1CCC(c2ccc(N3C(=O)c4c(N)ncnc4OCC3)cc2)CC1
NCGC00249052-02	O=C(O)CCC(=O)C		Inactive			1	Calcium levulinate	170465651	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&16.533291796	O=C([O-])CCC(=O)C.O=C([O-])CCC(=O)C.[Ca+2].O.O	O=C([O-])CCC(=O)C.O=C([O-])CCC(=O)C.[Ca+2].O.O
NCGC00178086-03	O=C(O)CCC(=O)CN		Inactive	Dna Inhibitor&DNA Inhibitor		1	Aminolevulinic acid hydrochloride	170464700	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.0320478319&-23.7621154599	O=C(O)CCC(=O)CN.Cl	O=C(O)CCC(=O)CN.Cl
NCGC00091281-10	O=C(O)CCC(=O)NN(C)C		Inactive	KDM2/7 Histone Demethylases Inhibitor		1	Daminozide	384568095	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-24.6779279679	O=C(O)CCC(=O)NN(C)C	O=C(O)CCC(=O)NN(C)C
NCGC00159372-04	O=C(O)CCC(=O)O		Inactive			1	Butanedioic acid	170465738	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.5598331528&12.246921548	O=C(O)CCC(=O)O	O=C(O)CCC(=O)O
NCGC00167448-02	O=C(O)CCC(=O)c1c(OCC)cc(OCC)c(OCC)c1	4.4000001	Active	Catechol O-methyltransferase Inhibitor	0.0	1	Trepibutone	170465772	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.9218069799	O=C(O)CCC(=O)c1c(OCC)cc(OCC)c(OCC)c1	O=C(O)CCC(=O)c1c(OCC)cc(OCC)c(OCC)c1
NCGC00016834-07	O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Prostaglandin G/H synthase 2 Inhibitor		1	Fenbufen	170465799	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.5621215696&14.232030756	O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1	O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1
NCGC00016087-11	O=C(O)CCC(N)C=C		Inactive	Gamma-amino-n-butyrate Transaminase Inhibitor&Gamma-amino-N-butyrate transaminase Inhibitor		1	Vigabatrin	225144175	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.7802560006&19.637269852	O=C(O)CCC(N)C=C	O=C(O)CCC(N)C=C
NCGC00167427-02	O=C(O)CCC/C=C/1\O[C@@H]2[C@@H]([C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C2)C\1	4.5500002	Active	Prostanoid Ip Receptor Agonist	0.0	1	Epoprostenol sodium	124893308	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.3370184399	O=C([O-])CCC/C=C/1\O[C@@H]2[C@@H]([C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C2)C\1	O=C([O-])CCC/C=C/1\O[C@@H]2[C@@H]([C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C2)C\1
NCGC00344182-03	O=C(O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O		Inactive	Prostanoid FP receptor Agonist&Prostanoid Fp Receptor Agonist		1	5-trans Prostaglandin F2?	405558427	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-10.784458152&-27.6764672708	O=C(O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O	O=C(O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O
NCGC00181784-01	O=C(O)CCC/C=C\1/C[C@@H]2C(/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C[C@@H]2C/1	4.9000001	Active	Prostanoid IP receptor Agonist&Prostanoid Ip Receptor Agonist	0.0	1	Iloprost	144207135	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-32.501186604&-48.7022098899	O=C(O)CCC/C=C\1/C[C@@H]2C(/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C[C@@H]2C/1	O=C(O)CCC/C=C\1/C[C@@H]2C(/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C[C@@H]2C/1
NCGC00161344-07	O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC		Inactive	Lipoprotein Oxidation Inhibitor&lipoprotein oxidation Inhibitor		1	Eicosapentaenoic Acid	405558471	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.47426294&-27.2763202479	O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC	O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
NCGC00161290-05	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(CCCC)(C)C)[C@H](O)CC1=O	4.0	Inactive	prostaglandin	0.0	1	16,16-dimethyl PGE2	174006821	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	60.1719385039	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(CCCC)(C)C)[C@H](O)CC1=O	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(CCCC)(C)C)[C@H](O)CC1=O
NCGC00092361-06	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O		Inactive	prostaglandin&Prostaglandin		1	Prostaglandin E2	174006772	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O
NCGC00185003-01	O=C(O)CCC1=C(C)C=2N=C1C=C1C(CCC(=O)O)=C(C)C(=N1)C=[cH0]1c(C=C)c(C)[cH0]([nH]1)=Cc1c(C=C)c(C)c([nH]1)C=2	4.4499998	Active		0.0	1	NCGC00185003-01	124896579	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.4421729879	O=C([O-])CCC1=C(C)C=2N=C1C=C1C(CCC(=O)[O-])=C(C)C(=N1)C=[cH0]1c(C=C)c(C)[cH0]([nH]1)=Cc1c(C=C)c(C)c([nH]1)C=2	O=C([O-])CCC1=C(C)C=2N=C1C=C1C(CCC(=O)[O-])=C(C)C(=N1)C=[cH0]1c(C=C)c(C)[cH0]([nH]1)=Cc1c(C=C)c(C)c([nH]1)C=2
NCGC00183281-03	O=C(O)CCCC		Inactive			1	Valeric acid	405558533	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-19.4757659599	O=C(O)CCCC	O=C(O)CCCC
NCGC00160469-01	O=C(O)CCCC/C=C\C/C=C\C/C=C\CCCCC		Inactive	Prostanoid Metabolic Process Interacts&prostanoid metabolic process Interacts		1	Gamolenic acid	144205388	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.119066312	O=C(O)CCCC/C=C\C/C=C\C/C=C\CCCCC	O=C(O)CCCC/C=C\C/C=C\C/C=C\CCCCC
NCGC00091345-04	O=C(O)CCCCC(=O)O		Inactive			1	Hexanedioic acid	170465352	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&10.4341988199	O=C(O)CCCCC(=O)O	O=C(O)CCCCC(=O)O
NCGC00016032-11	O=C(O)CCCCC1SSCC1		Inactive			1	alpha-Lipoic acid	170465713	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.7492324718	O=C(O)CCCCC1SSCC1	O=C(O)CCCCC1SSCC1
NCGC00345022-04	O=C(O)CCCCCC(=O)NN=C1CCCC1		Inactive	lineage-specific differentiation enhancer		1	IDE-2	384568730	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.8181727679	O=C(O)CCCCCC(=O)NN=C1CCCC1	O=C(O)CCCCCC(=O)NN=C1CCCC1
NCGC00090957-05	O=C(O)CCCCCCC		Inactive	Solute Carrier Family 22 Member 8 Substrate&Solute carrier family 22 member 8 Substrate		1	Octanoic acid	405558921	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.5248117039&0.0	O=C(O)CCCCCCC	O=C(O)CCCCCCC
NCGC00344326-02	O=C(O)CCCCCCC/C=C/C/C=C/CCCCC	4.4000001	Active	Streptococcus Mutans Inhibitor	0.0	1	9(E),12(E)-Octadecadienoic acid	405558983	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-53.6497814639	O=C(O)CCCCCCC/C=C/C/C=C/CCCCC	O=C(O)CCCCCCC/C=C/C/C=C/CCCCC
NCGC00344330-02	O=C(O)CCCCCCC/C=C/CCCCCCCC	4.4250002	Active	Siha Inhibitor&SiHa Inhibitor	0.0	1	Elaidic Acid	405558971	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-42.8218151759&-37.598865312	O=C(O)CCCCCCC/C=C/CCCCCCCC	O=C(O)CCCCCCC/C=C/CCCCCCCC
NCGC00091058-11	O=C(O)CCCCCCC/C=C\C/C=C\C/C=C\CC		Inactive	Fatty Acid Desaturase 2 Substrate&Fatty acid desaturase 2 Substrate		1	Linolenic acid	225144205	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.1378261839&9.583030376	O=C(O)CCCCCCC/C=C\C/C=C\C/C=C\CC	O=C(O)CCCCCCC/C=C\C/C=C\C/C=C\CC
NCGC00161336-01	O=C(O)CCCCCCC/C=C\C[C@H](O)CCCCCC	4.6500001	Active	Prostanoid Ep3 Receptor Binding Agent	0.0	1	Potassium ricinoleate	26754911	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.5754004839	O=C(O)CCCCCCC/C=C\C[C@H](O)CCCCCC	O=C(O)CCCCCCC/C=C\C[C@H](O)CCCCCC
NCGC00476141-01	O=C(O)CCCCCCC1[C@@H](/C=C/C(O)CCCCC)[C@@H](O)CC1=O	6.1500001	Active	Prostaglandin	0.0	1	11?-Prostaglandin E1	405558649	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-38.2769581119	O=C(O)CCCCCCC1[C@@H](/C=C/C(O)CCCCC)[C@@H](O)CC1=O	O=C(O)CCCCCCC1[C@@H](/C=C/C(O)CCCCC)[C@@H](O)CC1=O
NCGC00014993-12	O=C(O)CCCCCCCC(=O)O		Inactive	reactive oxygen species biosynthetic process Inhibitor&Reactive Oxygen Species Biosynthetic Process Inhibitor		1	Nonanedioic acid	170465358	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)CCCCCCCC(=O)O	O=C(O)CCCCCCCC(=O)O
NCGC00091320-05	O=C(O)CCCCCCCCC		Inactive	Peroxisome Proliferator-activated Receptor Gamma Modulator&Peroxisome proliferator-activated receptor gamma Modulator		1	Decanoic acid	225144209	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.9508102679&0.0	O=C(O)CCCCCCCCC	O=C(O)CCCCCCCCC
NCGC00159425-09	O=C(O)CCCCCCCCC=C		Inactive	Fatty Acid Biosynthesis Inhibitor		1	ZINC UNDECYLENATE	405559144	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&19.019126228	O=C(O)CCCCCCCCC=C	O=C(O)CCCCCCCCC=C
NCGC00091596-05	O=C(O)CCCCCCCCCCCCCCCCC		Inactive			1	Octadecanoic acid	170465630	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&20.837115016	O=C(O)CCCCCCCCCCCCCCCCC	O=C(O)CCCCCCCCCCCCCCCCC
NCGC00025234-17	O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O		Inactive	prostaglandin		1	Alprostadil	384568061	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O	O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O
NCGC00015092-10&NCGC00015092-11	O=C(O)CCCCCN		Inactive	PAI Inhibitor&Pai Inhibitor&PAI Inhibitor		2	Aminocaproic acid	170465057&384567807	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	15.656544928&0.0&-35.569353224	O=C(O)CCCCCN	O=C(O)CCCCCN
NCGC00378941-04	O=C(O)CCCCN(CCc1c(OCc2ccc(CCc3ccccc3)cc2)cccc1)Cc1ccc(C(=O)O)cc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator		1	Cinaciguat	384569076	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CCCCN(CCc1c(OCc2ccc(CCc3ccccc3)cc2)cccc1)Cc1ccc(C(=O)O)cc1	O=C(O)CCCCN(CCc1c(OCc2ccc(CCc3ccccc3)cc2)cccc1)Cc1ccc(C(=O)O)cc1
NCGC00346835-01	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12		Inactive	NOS-2 Inhibitor		1	2-Iminobiotin	174007481	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.641203988	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12
NCGC00179580-04	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12		Inactive			1	Biotin	170464763	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.163927816&0.0	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12
NCGC00015043-10	O=C(O)CCCN		Inactive	GABA-A receptor; anion channel Activator&Gaba-a Receptor; Anion Channel Activator		1	GABA	225144171	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.252920304&0.0	O=C(O)CCCN	O=C(O)CCCN
NCGC00183097-01	O=C(O)CCCc1c2O[C@@H]3[C@@H]([C@@H](/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C3)c2ccc1	4.4000001	Active	Thyroid Hormone Receptor Antagonist	0.0	1	Beraprost sodium	144206467	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.520723284	O=C([O-])CCCc1c2O[C@@H]3[C@@H]([C@@H](/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C3)c2ccc1.[Na+]	O=C([O-])CCCc1c2O[C@@H]3[C@@H]([C@@H](/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C3)c2ccc1.[Na+]
NCGC00164296-05	O=C(O)CCCc1c2c([nH]c1)cccc2		Inactive	plant hormone		1	3-indolebutyric acid	363676628	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CCCc1c2c([nH]c1)cccc2	O=C(O)CCCc1c2c([nH]c1)cccc2
NCGC00018113-07	O=C(O)CCCc1ccccc1		Inactive	Glutamine Binding Agent		1	Sodium 4-phenylbutyrate	170465108	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.46321488&0.0	O=C([O-])CCCc1ccccc1.[Na+]	O=C([O-])CCCc1ccccc1.[Na+]
NCGC00346575-02	O=C(O)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1		Inactive	Thrombin Inhibitor		1	Dabigatran	384568848	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1	O=C(O)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1
NCGC00164634-02&NCGC00164634-07	O=C(O)CCNC(=O)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1		Inactive	Agents For Ibs And Constipation&agents for IBS and constipation&agents for IBS and constipation		2	Balsalazide disodium	170465305&384568272	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&18.3911965239	O=C(O)CCNC(=O)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1	O=C(O)CCNC(=O)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1
NCGC00018241-07	O=C(O)CCNC(=O)c1ccccc1		Inactive	Solute Carrier Family 22 Member 8 Inhibitor&Solute carrier family 22 member 8 Inhibitor		1	Betamipron	170466040	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)CCNC(=O)c1ccccc1	O=C(O)CCNC(=O)c1ccccc1
NCGC00351549-05	O=C(O)CCNc1nc(-c2cnccc2)nc(N2CCc3c(cccc3)CC2)c1		Inactive	Inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A		1	GSK-J2	384569011	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.5644531	O=C(O)CCNc1nc(-c2cnccc2)nc(N2CCc3c(cccc3)CC2)c1	O=C(O)CCNc1nc(-c2cnccc2)nc(N2CCc3c(cccc3)CC2)c1
NCGC00347943-09	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1	4.5	Active	H3K27 Histone Demethylases UTX and JMJD3 Inhibitor	0.0	1	GSK-J1	363677724	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-89.5332874877	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1
NCGC00024025-05	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)C(=O)C[C@@H]3[C@]4(C)[C@H](CC(=O)[C@H]3[C@@H]2CC1)CC(=O)CC4		Inactive	bile acid secretion Inhibitor&Bile Acid Secretion Inhibitor		1	Dehydrocholic acid	170465502	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.322817548&-17.683267908	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)C(=O)C[C@@H]3[C@]4(C)[C@H](CC(=O)[C@H]3[C@@H]2CC1)CC(=O)CC4	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)C(=O)C[C@@H]3[C@]4(C)[C@H](CC(=O)[C@H]3[C@@H]2CC1)CC(=O)CC4
NCGC00091038-04	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@@H](C[C@H](O)CC4)CC[C@H]3[C@@H]2CC1		Inactive			1	Sodium deoxycholate monohydrate	225144203	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-33.0381143177&0.0	O=C([O-])CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@@H](C[C@H](O)CC4)CC[C@H]3[C@@H]2CC1	O=C([O-])CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@@H](C[C@H](O)CC4)CC[C@H]3[C@@H]2CC1
NCGC00142384-03	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@H](C[C@@H](O)[C@H]3[C@@H]2CC1)C[C@H](O)CC4		Inactive	Bile Acid Receptor Fxr Agonist&Bile acid receptor FXR Agonist		1	Cholic Acid	405559065	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-33.411905612&0.0	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@H](C[C@@H](O)[C@H]3[C@@H]2CC1)C[C@H](O)CC4	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@H](C[C@@H](O)[C@H]3[C@@H]2CC1)C[C@H](O)CC4
NCGC00264052-02	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)C(C3C([C@]4(C)[C@H]([C@@H](O)C3)C[C@H](O)CC4)CC2)CC1		Inactive	Glucocorticoid steroid		1	Hyodeoxycholic acid	384568702	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.5005375439	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)C(C3C([C@]4(C)[C@H]([C@@H](O)C3)C[C@H](O)CC4)CC2)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)C(C3C([C@]4(C)[C@H]([C@@H](O)C3)C[C@H](O)CC4)CC2)CC1
NCGC00179363-03&NCGC00179363-05	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1		Inactive	Farnesoid X Receptor Agonist; Steroid&Steroid&Steroid		2	Ursodiol	225144303&384568372	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-23.2999051159	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1
NCGC00142400-07	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1		Inactive	Farnesoid X Receptor Agonist		1	Chenodeoxycholic acid	384568162	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.2998183719	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1
NCGC00480885-01	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)[C@H](CC)[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1		Inactive	Bile Acid Receptor Fxr Agonist&Bile acid receptor FXR Agonist		1	INT-747 (Obeticholic acid)	405558423	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-10.988412896&-9.921477736	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)[C@H](CC)[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)[C@H](CC)[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1
NCGC00179626-05	O=C(O)CC[C@@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1	4.8499999	Active	Mineralocorticoid Receptor Antagonist	0.0	1	NCGC00179626-05	405558909	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-36.9021443288&-40.5718190008	O=C([O-])CC[C@@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1	O=C([O-])CC[C@@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1
NCGC00346878-04	O=C(O)CCc1c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]cc1C		Inactive	FGFR 1/3 Inhibitor		1	SU-5402	384568956	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	28.2880754239	O=C(O)CCc1c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]cc1C	O=C(O)CCc1c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]cc1C
NCGC00241113-04	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]c1C	4.4000001	Active	VEGFR-2 Inhibitor	0.0	1	Orantinib	384568478	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-89.8705339679	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]c1C	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]c1C
NCGC00024976-06	O=C(O)CCc1ccc(CCNc2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O4)c3n2)cc1		Inactive	Adenosine A2A Agonist		1	CGS-21680	363676534	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CCc1ccc(CCNc2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O4)c3n2)cc1	O=C(O)CCc1ccc(CCNc2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O4)c3n2)cc1
NCGC00167811-13	O=C(O)CCc1ccc(NCc2cc(Oc3ccccc3)ccc2)cc1		Inactive	Free Fatty Acid Receptor 1 Agonist		1	GW-9508	363676671	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CCc1ccc(NCc2cc(Oc3ccccc3)ccc2)cc1	O=C(O)CCc1ccc(NCc2cc(Oc3ccccc3)ccc2)cc1
NCGC00164584-03	O=C(O)CCc1ccc(OC(=O)C2CCC(CN)CC2)cc1		Inactive	Prostaglandin Synthesis And Regulation Modulator&Prostaglandin Synthesis and Regulation Modulator		1	Cetraxate hydrochloride	170465783	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.6083362596&-25.90122524	O=C(O)CCc1ccc(OC(=O)C2CCC(CN)CC2)cc1.Cl	O=C(O)CCc1ccc(OC(=O)C2CCC(CN)CC2)cc1.Cl
NCGC00014711-14	O=C(O)CCc1oc(c(-c2ccccc2)n1)-c1ccccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Oxaprozin	170464987	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.34794652&0.0	O=C(O)CCc1oc(c(-c2ccccc2)n1)-c1ccccc1	O=C(O)CCc1oc(c(-c2ccccc2)n1)-c1ccccc1
NCGC00532505-01	O=C(O)CN(C)C	4.4000001	Active	Glutamate [NMDA] receptor Agonist	0.0	1	N,N-DIMETHYLGLYCINE HYDROCHLORIDE	405558468	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.4069217399	O=C(O)CN(C)C	O=C(O)CN(C)C
NCGC00016902-04	O=C(O)CN(CC(=O)O)CC(=O)Nc1c(CC)cccc1CC		Inactive			1	Etifenin	170466635	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.345474788&0.0	O=C(O)CN(CC(=O)O)CC(=O)Nc1c(CC)cccc1CC	O=C(O)CN(CC(=O)O)CC(=O)Nc1c(CC)cccc1CC
NCGC00015360-08	O=C(O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O	4.6999998	Active	Radioactive Metals Chelating Agent	0.0	1	Pentetic acid	170465150	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.7616724472	O=C(O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O	O=C(O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O
NCGC00181349-02	O=C(O)CN(CC(=O)O)c1c(C#N)c(CC(=O)O)c(C(=O)O)s1		Inactive	Calcium-sensing Receptor Agonist		1	Ranelic acid distrontium salt&Strontium Ranelate	225144325	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-21.0138997599&0.0&20.861593596	O=C([O-])CN(CC(=O)[O-])c1c(C#N)c(CC(=O)[O-])c(C(=O)[O-])s1.[Sr+2].[Sr+2].O.O.O.O.O.O.O	O=C([O-])CN(CC(=O)[O-])c1c(C#N)c(CC(=O)[O-])c(C(=O)[O-])s1.[Sr+2].[Sr+2].O.O.O.O.O.O.O
NCGC00370805-01	O=C(O)CN(CCOc1c(C(C)(C)C)cc(-c2cc3OCOc3cc2)cc1)C		Inactive	GlyT-1 Inhibitor		1	LY-2365109 hydrochloride	384569036	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.616105512	O=C(O)CN(CCOc1c(C(C)(C)C)cc(-c2cc3OCOc3cc2)cc1)C	O=C(O)CN(CCOc1c(C(C)(C)C)cc(-c2cc3OCOc3cc2)cc1)C
NCGC00263114-01	O=C(O)CN(C[C@H]1[C@@H](c2ccccc2)c2c(cc(OC)cc2)CC1)C		Inactive	Glycine Transporter 1 (GlyT-1) Inhibitor		1	SCH-900435	137275958	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CN(C[C@H]1[C@@H](c2ccccc2)c2c(cc(OC)cc2)CC1)C	O=C(O)CN(C[C@H]1[C@@H](c2ccccc2)c2c(cc(OC)cc2)CC1)C
NCGC00166207-01	O=C(O)CN1c2c(C(=O)c3c1cccc3)cccc2	4.4000001	Active	Interferon Inducers	0.0	1	Cridanimod	144205901	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-46.59541498	O=C(O)CN1c2c(C(=O)c3c1cccc3)cccc2	O=C(O)CN1c2c(C(=O)c3c1cccc3)cccc2
NCGC00496910-01	O=C(O)CNC(=O)C1C(=O)N(C(=O)N(C1=O)C1CCCCC1)C1CCCCC1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Daprodustat	384569297	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CNC(=O)C1C(=O)N(C(=O)N(C1=O)C1CCCCC1)C1CCCCC1	O=C(O)CNC(=O)C1C(=O)N(C(=O)N(C1=O)C1CCCCC1)C1CCCCC1
NCGC00344625-13	O=C(O)CNC(=O)C=1C(=O)N(Cc2ccccc2)c2c(C=1O)cccc2		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	IOX2	363677341	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CNC(=O)C=1C(=O)N(Cc2ccccc2)c2c(C=1O)cccc2	O=C(O)CNC(=O)C=1C(=O)N(Cc2ccccc2)c2c(C=1O)cccc2
NCGC00346527-03	O=C(O)CNC(=O)c1c(O)c2c(c(C)n1)cc(Oc1ccccc1)cc2		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Roxadustat	384568821	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)CNC(=O)c1c(O)c2c(c(C)n1)cc(Oc1ccccc1)cc2	O=C(O)CNC(=O)c1c(O)c2c(c(C)n1)cc(Oc1ccccc1)cc2
NCGC00016279-05	O=C(O)CNC(=O)c1ccc(N)cc1		Inactive			1	Aminohippuric acid	170465155	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.335379032&18.686981796	O=C(O)CNC(=O)c1ccc(N)cc1	O=C(O)CNC(=O)c1ccc(N)cc1
NCGC00159486-06	O=C(O)CNC(=O)c1ccccc1		Inactive	Solute Carrier Family 22 Member 8 Inhibitor&Solute carrier family 22 member 8 Inhibitor		1	Hippuric acid	170464791	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-29.77006136	O=C(O)CNC(=O)c1ccccc1	O=C(O)CNC(=O)c1ccccc1
NCGC00274269-01	O=C(O)CNCCNCCNCCCCCCCCCCCC	4.9000001	Active		0.0	1	NCGC00274269-01	225144370	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-66.7629708629	O=C(O)CNCCNCCNCCCCCCCCCCCC	O=C(O)CNCCNCCNCCCCCCCCCCCC
NCGC00159481-03	O=C(O)COc1c(C(=O)/C=C/c2ccc(OC/C=C(\C)/C)cc2)ccc(OC/C=C(\C)/C)c1	4.5	Active	Prostaglandin Synthesis and Regulation Modulator	0.0	1	Sofalcone	170466017	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-78.6761690712	O=C(O)COc1c(C(=O)/C=C/c2ccc(OC/C=C(\C)/C)cc2)ccc(OC/C=C(\C)/C)c1	O=C(O)COc1c(C(=O)/C=C/c2ccc(OC/C=C(\C)/C)cc2)ccc(OC/C=C(\C)/C)c1
NCGC00319020-01	O=C(O)COc1c2c(ccc1)C[C@H]1[C@H](CC[C@H](O)CCCCC)[C@@H](O)C[C@H]1C2	4.4000001	Active	Prostanoid Ip Receptor Agonist	0.0	1	NCGC00319020-01	225144374	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.40590878	O=C(O)COc1c2c(ccc1)C[C@H]1[C@H](CC[C@H](O)CCCCC)[C@@H](O)C[C@H]1C2	O=C(O)COc1c2c(ccc1)C[C@H]1[C@H](CC[C@H](O)CCCCC)[C@@H](O)C[C@H]1C2
NCGC00015599-10	O=C(O)COc1ccc(OCCCOc2c(CCC)c(O)c(C(=O)C)cc2)cc1		Inactive	PPARdelta Agonist		1	L-165041	384567870	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.187045332	O=C(O)COc1ccc(OCCCOc2c(CCC)c(O)c(C(=O)C)cc2)cc1	O=C(O)COc1ccc(OCCCOc2c(CCC)c(O)c(C(=O)C)cc2)cc1
NCGC00091151-04	O=C(O)COc1ccccc1		Inactive	cell proliferation Activator&Cell Proliferation Activator		1	Phenoxyacetic acid	170465537	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-10.8588831839	O=C(O)COc1ccccc1	O=C(O)COc1ccccc1
NCGC00263571-01	O=C(O)COc1nn(Cc2ccccc2)c2c1cccc2		Inactive	Xanthine Dehydrogenase/oxidase Inhibitor&Xanthine dehydrogenase/oxidase Inhibitor		1	Bendazac sodium	170465952	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.521068332&-22.010902676	O=C([O-])COc1nn(Cc2ccccc2)c2c1cccc2.[Na+]	O=C([O-])COc1nn(Cc2ccccc2)c2c1cccc2.[Na+]
NCGC00346738-05	O=C(O)C[C@@H](CN)CC(C)C		Inactive	L-type Ca2+ channel Blocker		1	Pregabalin	384568938	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C[C@@H](CN)CC(C)C	O=C(O)C[C@@H](CN)CC(C)C
NCGC00507844-01	O=C(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N1)CCC2		Inactive	Endothelin ETA Receptor Antagonist		1	BQ-123	384569325	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N1)CCC2	O=C(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N1)CCC2
NCGC00024504-09	O=C(O)C[C@@H]1[C@@H](C(=O)O)NC[C@@H]1C(=C)C		Inactive	Glutamate Receptor Ionotropic Kainate 5 Agonist&Glutamate receptor ionotropic kainate 5 Agonist		1	Kainic acid	170465818	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)C[C@@H]1[C@@H](C(=O)O)NC[C@@H]1C(=C)C	O=C(O)C[C@@H]1[C@@H](C(=O)O)NC[C@@H]1C(=C)C
NCGC00386139-01	O=C(O)C[C@@]1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12		Inactive	Cyclooxygenase-2 Inhibitor		1	R-Etodolac	363680117	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C[C@@]1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12	O=C(O)C[C@@]1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12
NCGC00483929-01	O=C(O)C[C@H](c1cc(OC)c2n(C)nnc2c1)c1cc(CN2S(=O)(=O)c3c(O[C@H](C)C2)cccc3)c(C)cc1		Inactive	NRF2:KEAP1 Inhibitor		1	KI-696	363681148	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	24.99273542	O=C(O)C[C@H](c1cc(OC)c2n(C)nnc2c1)c1cc(CN2S(=O)(=O)c3c(O[C@H](C)C2)cccc3)c(C)cc1	O=C(O)C[C@H](c1cc(OC)c2n(C)nnc2c1)c1cc(CN2S(=O)(=O)c3c(O[C@H](C)C2)cccc3)c(C)cc1
NCGC00167505-03	O=C(O)C[C@H]1C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N1)CCC2	5.0500002	Active	Integrin alpha-IIb/beta-3 Inhibitor	0.0	1	Eptifibatide	405558574	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-60.5534257138	O=C(O)C[C@H]1C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N1)CCC2	O=C(O)C[C@H]1C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N1)CCC2
NCGC00390264-01	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N1		Inactive	Integrin alphavbeta3 (Vitronectin) Antagonist		1	Cilengitide	384569183	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N1	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N1
NCGC00386242-02	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N1	4.5749998	Active	Integrin Alpha-v/beta-5 Antagonist&Integrin alpha-V/beta-5 Antagonist	0.0	1	Cilengitide	405558444	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-72.146963697&-68.6329581804	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N1	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N1
NCGC00510003-01	O=C(O)C[C@H]1OB(O)[C@@H](NC(=O)Cc2sccc2)CC1	4.5749998	Active		0.0	1	Vaborbactam	405559093	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-70.988605052&-34.6538189917	O=C(O)C[C@H]1OB(O)[C@@H](NC(=O)Cc2sccc2)CC1	O=C(O)C[C@H]1OB(O)[C@@H](NC(=O)Cc2sccc2)CC1
NCGC00184993-03	O=C(O)Cc1c(N)c(C(=O)c2ccccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Amfenac Sodium	225144335	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.955596836&0.0	O=C([O-])Cc1c(N)c(C(=O)c2ccccc2)ccc1	O=C([O-])Cc1c(N)c(C(=O)c2ccccc2)ccc1
NCGC00167563-01	O=C(O)Cc1c(c(-c2ccc(OC)cc2)no1)-c1ccc(OC)cc1	4.4000001	Active	Cyclooxygenase-1 Inhibitor	0.0	1	Mofezolac	144206111	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.5608947239	O=C(O)Cc1c(c(-c2ccc(OC)cc2)no1)-c1ccc(OC)cc1	O=C(O)Cc1c(c(-c2ccc(OC)cc2)no1)-c1ccc(OC)cc1
NCGC00165783-03	O=C(O)Cc1c2Oc3c(C)c(C)ccc3C(=O)c2ccc1		Inactive	Interferon Inducer		1	Vadimezan	384568283	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.332330668	O=C(O)Cc1c2Oc3c(C)c(C)ccc3C(=O)c2ccc1	O=C(O)Cc1c2Oc3c(C)c(C)ccc3C(=O)c2ccc1
NCGC00090987-05	O=C(O)Cc1c2c(ccc1)cccc2		Inactive	Fusarium Oxysporum Inhibitor&Fusarium oxysporum Inhibitor		1	1-Naphthaleneacetic acid	170466030	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-34.167103796&0.0	O=C(O)Cc1c2c(ccc1)cccc2	O=C(O)Cc1c2c(ccc1)cccc2
NCGC00183833-01	O=C(O)Cc1cc(-c2c(O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)ccc(CCCCCCc3cc(c(O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)-c3cc(CC(=O)O)ccc3)c2)ccc1		Inactive	Selectin E Inhibitor		1	Bimosiamose	144206811	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.96042734&-17.410713676	O=C(O)Cc1cc(-c2c(O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)ccc(CCCCCCc3cc(c(O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)-c3cc(CC(=O)O)ccc3)c2)ccc1	O=C(O)Cc1cc(-c2c(O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)ccc(CCCCCCc3cc(c(O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)-c3cc(CC(=O)O)ccc3)c2)ccc1
NCGC00263532-01&NCGC00263532-10	O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1		Inactive	Mediator Release Inhibitor		2	Olopatadine hydrochloride	170465181&384568685	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	12.4187194159&19.483165832&0.0	O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1.Cl	O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1.Cl&O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1
NCGC00160451-02	O=C(O)Cc1ccc(CC(C)C)cc1	4.6500001	Active		0.0	1	Ibufenac	170465922	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-32.29385936	O=C(O)Cc1ccc(CC(C)C)cc1	O=C(O)Cc1ccc(CC(C)C)cc1
NCGC00160450-03	O=C(O)Cc1ccc(NC(=O)C)cc1		Inactive			1	4-Acetylaminophenylacetic acid	170465954	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.2572054199&-11.932929284	O=C(O)Cc1ccc(NC(=O)C)cc1	O=C(O)Cc1ccc(NC(=O)C)cc1
NCGC00159477-05	O=C(O)Cc1ccccc1		Inactive			1	Phenylacetic acid	170465102	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	31.846485824&0.0	O=C(O)Cc1ccccc1	O=C(O)Cc1ccccc1
NCGC00178815-03	O=C(O)Cc1n(C)c(C(=O)c2ccc(C)cc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Tolmetin sodium dihydrate	170465216	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.96970078&0.0	O=C([O-])Cc1n(C)c(C(=O)c2ccc(C)cc2)cc1.[Na+].O.O	O=C([O-])Cc1n(C)c(C(=O)c2ccc(C)cc2)cc1.[Na+].O.O
NCGC00094887-05	O=C(O)[C@@H](C)c1cc(Oc2ccccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Fenoprofen calcium salt dihydrate	170465299	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.300345684&0.0	O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.[Ca+2].O.O	O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.[Ca+2].O.O
NCGC00016759-04&NCGC00016759-08	O=C(O)[C@@H](C)c1cc2c(cc(OC)cc2)cc1		Inactive	Udp-glucuronosyltransferase 1-1 Substrate&Cyclooxygenase-1/2 Inhibitor&Cyclooxygenase-1/2 Inhibitor		2	Naproxen sodium	170465301&384567957	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	19.999043156&-22.87610988&-20.779356788	O=C([O-])[C@@H](C)c1cc2c(cc(OC)cc2)cc1.[Na+]	O=C([O-])[C@@H](C)c1cc2c(cc(OC)cc2)cc1.[Na+]&O=C(O)[C@@H](C)c1cc2c(cc(OC)cc2)cc1
NCGC00183861-01	O=C(O)[C@@H](CCCCCC)CCC		Inactive	S100 Beta Biosynthetic Process Inhibitor&S100 beta biosynthetic process Inhibitor		1	(2R)-2-Propyloctanoic acid	144206875	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-13.1067929559	O=C(O)[C@@H](CCCCCC)CCC	O=C(O)[C@@H](CCCCCC)CCC
NCGC00178027-08	O=C(O)[C@@H](N(C(=O)CCCC)Cc1ccc(-c2c(-c3n[nH]nn3)cccc2)cc1)C(C)C	5.0250001	Active	Neprilysin Inhibitor	0.0	1	VALSARTAN	405559028	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-40.7329931643&-37.6796610452	O=C(O)[C@@H](N(C(=O)CCCC)Cc1ccc(-c2c(-c3n[nH]nn3)cccc2)cc1)C(C)C	O=C(O)[C@@H](N(C(=O)CCCC)Cc1ccc(-c2c(-c3n[nH]nn3)cccc2)cc1)C(C)C
NCGC00344520-01	O=C(O)[C@@H](N)C(C)C		Inactive	Tryptophan Transport Inhibitor&tryptophan transport Inhibitor		1	L-Valine	225144376	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-9.9661724119&-18.897378344	O=C(O)[C@@H](N)C(C)C	O=C(O)[C@@H](N)C(C)C
NCGC00024499-06	O=C(O)[C@@H](N)CC(=O)O		Inactive	Isoaspartyl peptidase/L-asparaginase Interacts&Isoaspartyl Peptidase/l-asparaginase Interacts		1	D-Aspartic acid	225144192	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.307334872&-21.6232563119	O=C(O)[C@@H](N)CC(=O)O	O=C(O)[C@@H](N)CC(=O)O
NCGC00166296-02	O=C(O)[C@@H](N)CCCCN		Inactive	Serotonin 4 (5-ht4) Receptor Antagonist&Serotonin 4 (5-HT4) receptor Antagonist		1	L-(+)-Lysine monohydrochloride	225144279	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	28.18140116&0.0	O=C(O)[C@@H](N)CCCCN	O=C(O)[C@@H](N)CCCCN
NCGC00024715-05	O=C(O)[C@@H](N)CCCNC(=N)N		Inactive			1	L-Arginine	170465748	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.6462457079&-14.4045464959	O=C(O)[C@@H](N)CCCNC(=N)N	O=C(O)[C@@H](N)CCCNC(=N)N
NCGC00091062-09	O=C(O)[C@@H](N)Cc1c2c([nH]c1)ccc(O)c2		Inactive	Serotonin modulator		1	5-Hydroxytryptophan	170466308	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@@H](N)Cc1c2c([nH]c1)ccc(O)c2	O=C(O)[C@@H](N)Cc1c2c([nH]c1)ccc(O)c2
NCGC00016270-09&NCGC00016270-13	O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1	5.5	Inactive	Dopamine Precursor&Dopamine Precursors&Dopamine Precursors	0.0	2	Levodopa	225144176&384567928	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	27.1382953559&0.0&44.7414193343	O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1	O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1
NCGC00344531-01	O=C(O)[C@@H](N)[C@@H](O)c1cc(O)c(O)cc1	4.4000001	Active	Adrenergic receptor Agonist	0.0	1	Droxidopa	170465890	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.473952784	O=C(O)[C@@H](N)[C@@H](O)c1cc(O)c(O)cc1	O=C(O)[C@@H](N)[C@@H](O)c1cc(O)c(O)cc1
NCGC00164520-02	O=C(O)[C@@H](N)[C@H](O)C		Inactive			1	L-Threonine	170465476	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	8.9673685999&0.0	O=C(O)[C@@H](N)[C@H](O)C	O=C(O)[C@@H](N)[C@H](O)C
NCGC00159393-03	O=C(O)[C@@H](NC(=O)C)Cc1ccc(O)cc1	4.5	Active		0.0	1	N-Acetyl-L-tyrosine	170465742	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.3303113188	O=C(O)[C@@H](NC(=O)C)Cc1ccc(O)cc1	O=C(O)[C@@H](NC(=O)C)Cc1ccc(O)cc1
NCGC00507698-01	O=C(O)[C@@H](NC(=O)CC1=C2[C@@H](CCC(=O)O)[C@H](C)C(=N2)C=[cH0]2c(C)c(C=C)[cH0]([nH]2)=Cc2c(C)c(CC)c([nH]2)C=C2C(C)=C(C(=O)O)C1=N2)CC(=O)O	4.4000001	Active		0.0	1	Talaporfin sodium	405558614	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-52.79272138&-51.1027255604	O=C(O)[C@@H](NC(=O)CC1=C2[C@@H](CCC(=O)O)[C@H](C)C(=N2)C=[cH0]2c(C)c(C=C)[cH0]([nH]2)=Cc2c(C)c(CC)c([nH]2)C=C2C(C)=C(C(=O)O)C1=N2)CC(=O)O	O=C(O)[C@@H](NC(=O)CC1=C2[C@@H](CCC(=O)O)[C@H](C)C(=N2)C=[cH0]2c(C)c(C=C)[cH0]([nH]2)=Cc2c(C)c(CC)c([nH]2)C=C2C(C)=C(C(=O)O)C1=N2)CC(=O)O
NCGC00521952-01	O=C(O)[C@@H](NC(=O)CC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(=O)C)C)C)C(=O)N)CCCCNC(=O)CCCCCCCCCCCCCCCCC	4.5749998	Active	Tnf-alpha Activator&TNF-alpha Activator	0.0	1	ROMURTIDE	405558571	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-36.9087140376&-39.07400704	O=C(O)[C@@H](NC(=O)CC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(=O)C)C)C)C(=O)N)CCCCNC(=O)CCCCCCCCCCCCCCCCC	O=C(O)[C@@H](NC(=O)CC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(=O)C)C)C)C(=O)N)CCCCNC(=O)CCCCCCCCCCCCCCCCC
NCGC00499351-01	O=C(O)[C@@H](NC(=O)N1[C@@H](Cc2ccccc2)C(=O)N(Cc2c(C)nc[nH]2)CC1)CC(C)C		Inactive	Geranyl Geranyl Transferase Inhibitor		1	GGTI-2418	384569305	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@@H](NC(=O)N1[C@@H](Cc2ccccc2)C(=O)N(Cc2c(C)nc[nH]2)CC1)CC(C)C	O=C(O)[C@@H](NC(=O)N1[C@@H](Cc2ccccc2)C(=O)N(Cc2c(C)nc[nH]2)CC1)CC(C)C
NCGC00522278-02	O=C(O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)Cc1c2c([nH]c1)cccc2		Inactive	VEGF Inhibitor		1	Oglufanide	384569514	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)Cc1c2c([nH]c1)cccc2	O=C(O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)Cc1c2c([nH]c1)cccc2
NCGC00485994-01	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H]3N(C(=O)[C@@H](N)Cc4ccccc4)CCC3)CCCNC(=N)N)CCC2)CC(=O)N)CC(=O)O)Cc2ccccc2)CCC(=O)O)CCC(=O)O)[C@H](CC)C)CCC1)CCC(=O)O)CCC(=O)O)Cc1ccc(O)cc1)CC(C)C		Inactive			1	Bivalirudin (Trifluoroacetate)	405558931	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.0985337399&-41.2953039359	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H]3N(C(=O)[C@@H](N)Cc4ccccc4)CCC3)CCCNC(=N)N)CCC2)CC(=O)N)CC(=O)O)Cc2ccccc2)CCC(=O)O)CCC(=O)O)[C@H](CC)C)CCC1)CCC(=O)O)CCC(=O)O)Cc1ccc(O)cc1)CC(C)C	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H]3N(C(=O)[C@@H](N)Cc4ccccc4)CCC3)CCCNC(=N)N)CCC2)CC(=O)N)CC(=O)O)Cc2ccccc2)CCC(=O)O)CCC(=O)O)[C@H](CC)C)CCC1)CCC(=O)O)CCC(=O)O)Cc1ccc(O)cc1)CC(C)C
NCGC00346895-01	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](O)[C@H](N)CC(C)C)C(C)C)C(C)C)CC(=O)O		Inactive	cytosolic leucine aminopeptidase Inhibitor		1	Amastatin	174007115	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.3581725279	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](O)[C@H](N)CC(C)C)C(C)C)C(C)C)CC(=O)O	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](O)[C@H](N)CC(C)C)C(C)C)C(C)C)CC(=O)O
NCGC00390805-02	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=N)N)CCCNC(=N)N)CCC4)C[C@H](O)C3)Cc3sccc3)CO)Cc3c(cccc3)C2)[C@@H]2[C@H](C1)CCCC2)CCCNC(=N)N		Inactive	Bradykinin B2 Receptor Antagonist&Bradykinin B2 receptor Antagonist		1	Icatibant	405558587	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=N)N)CCCNC(=N)N)CCC4)C[C@H](O)C3)Cc3sccc3)CO)Cc3c(cccc3)C2)[C@@H]2[C@H](C1)CCCC2)CCCNC(=N)N	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=N)N)CCCNC(=N)N)CCC4)C[C@H](O)C3)Cc3sccc3)CO)Cc3c(cccc3)C2)[C@@H]2[C@H](C1)CCCC2)CCCNC(=N)N
NCGC00389841-01	O=C(O)[C@@H](NC(=O)[C@H]1NC(=O)CNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]2NC(=O)[C@H](C)NC(=O)[C@H]3N(C(=O)[C@H](CC(=O)N)NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC4)CSSC2)CSSC1)CCC3)Cc1ccc(O)cc1	4.6999998	Active	Heat-stable Enterotoxin Receptor Agonist	0.0	1	LINACLOTIDE (1 mg/ml)	405558997	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.7758017039	O=C(O)[C@@H](NC(=O)[C@H]1NC(=O)CNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]2NC(=O)[C@H](C)NC(=O)[C@H]3N(C(=O)[C@H](CC(=O)N)NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC4)CSSC2)CSSC1)CCC3)Cc1ccc(O)cc1	O=C(O)[C@@H](NC(=O)[C@H]1NC(=O)CNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]2NC(=O)[C@H](C)NC(=O)[C@H]3N(C(=O)[C@H](CC(=O)N)NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC4)CSSC2)CSSC1)CCC3)Cc1ccc(O)cc1
NCGC00166414-05&NCGC00166414-11	O=C(O)[C@@H](NC(=O)c1ccc(CCc2c3C(=O)N=C(N)Nc3[nH]c2)cc1)CCC(=O)O	5.54999995	Active	Thymidylate synthase Inhibitor	0.20000030000000013	2	Pemetrexed&Pemetrexed Disodium heptahydrate	384568308&405558550	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-1.4	-89.750747984&-73.855323508	O=C(O)[C@@H](NC(=O)c1ccc(CCc2c3C(=O)N=C(N)Nc3[nH]c2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(CCc2c3C(=O)N=C(N)Nc3[nH]c2)cc1)CCC(=O)O
NCGC00510946-01	O=C(O)[C@@H](NC(=O)c1ccc(N2CN3C=4C(=O)N=C(N)NC=4NCC3C2)cc1)CCC(=O)O	4.8499999	Inactive	Antimetabolite	0.0	1	Modufolin	384569495	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	30.4447230384	O=C(O)[C@@H](NC(=O)c1ccc(N2CN3C=4C(=O)N=C(N)NC=4NCC3C2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(N2CN3C=4C(=O)N=C(N)NC=4NCC3C2)cc1)CCC(=O)O
NCGC00178756-05	O=C(O)[C@@H](NC(=O)c1ccc(NCC2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)O	6.8581004	Active	Antineoplastic Enhancing Agents	0.0	1	LEUCOVORIN CALCIUM	225144299	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-39.3113053053	O=C([O-])[C@@H](NC(=O)c1ccc(NCC2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]	O=C([O-])[C@@H](NC(=O)c1ccc(NCC2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]
NCGC00378841-01	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@@H]2N(C)C=3C(=O)NC(N)=NC=3NC2)cc1)CCC(=O)O	6.0	Active		0.0	1	Levomefolate calcium	405558655	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-42.4019621328&-57.8837305719	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@@H]2N(C)C=3C(=O)NC(N)=NC=3NC2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@@H]2N(C)C=3C(=O)NC(N)=NC=3NC2)cc1)CCC(=O)O
NCGC00185071-01	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@H]2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)O		Inactive	Antineoplastic Enhancing Agents		1	Calcium folinate	124896608	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C([O-])[C@@H](NC(=O)c1ccc(NC[C@H]2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]	O=C([O-])[C@@H](NC(=O)c1ccc(NC[C@H]2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]
NCGC00016265-08	O=C(O)[C@@H](NC(=O)c1ccc(NCc2nc3C(=O)N=C(N)Nc3nc2)cc1)CCC(=O)O		Inactive	folic acid-containing compound metabolic process Substrate&Folic Acid-containing Compound Metabolic Process Substrate		1	Folic acid	170464833	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.512791104&32.57473656	O=C(O)[C@@H](NC(=O)c1ccc(NCc2nc3C(=O)N=C(N)Nc3nc2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(NCc2nc3C(=O)N=C(N)Nc3nc2)cc1)CCC(=O)O
NCGC00229704-02	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)N=C(C)Nc3cc2)C)cc1)CCC(=O)O	4.9499998	Active	thymidylate synthase Inhibitor	0.0	1	Raltitrexed	384568463	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-67.1819081772	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)N=C(C)Nc3cc2)C)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)N=C(C)Nc3cc2)C)cc1)CCC(=O)O
NCGC00229704-01	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)NC(C)=Nc3cc2)C)cc1)CCC(=O)O	5.3000002	Active	Thymidylate Synthase Inhibitor&thymidylate synthase Inhibitor	0.0	1	Raltitrexed	124939249	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-1.3	-32.3980411438&-37.6350917792	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)NC(C)=Nc3cc2)C)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)NC(C)=Nc3cc2)C)cc1)CCC(=O)O
NCGC00179623-04	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1	4.9499998	Active	Angiotensin-converting Enzyme Inhibitor	0.0	1	Lisinopril dihydrate	170464907	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-45.7606107879	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1.O.O	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1.O.O
NCGC00160662-02&NCGC00346730-07	O=C(O)[C@@H](Oc1nc(C)cc(C)n1)C(OC)(c1ccccc1)c1ccccc1	5.3000002	Inactive	Endothelin Eta Receptor Antagonist&Endothelin ETA Receptor Antagonist&Endothelin ETA Receptor Antagonist	0.0	2	Ambrisentan	170465143&384568935	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	0.0&0.0&57.1386876966	O=C(O)[C@@H](Oc1nc(C)cc(C)n1)C(OC)(c1ccccc1)c1ccccc1	O=C(O)[C@@H](Oc1nc(C)cc(C)n1)C(OC)(c1ccccc1)c1ccccc1
NCGC00250411-03	O=C(O)[C@@H](c1ccc(OCc2nc3c(cc2)cccc3)cc1)C1CCCC1		Inactive	5-lipoxygenase-activating (FLAP) Inhibitor		1	Veliflapon	384568559	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-26.732502468	O=C(O)[C@@H](c1ccc(OCc2nc3c(cc2)cccc3)cc1)C1CCCC1	O=C(O)[C@@H](c1ccc(OCc2nc3c(cc2)cccc3)cc1)C1CCCC1
NCGC00090808-04&NCGC00090808-05	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C2		Inactive	Macrolide Antibiotic		2	Amphotericin B	405558702&384568088	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	15.33665264&0.0&0.0	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C2	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C2
NCGC00183039-03	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C2	6.0999999	Inactive	Antifungal Agent	0.0	1	Nystatin	384568414	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-20.2847098941	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C2	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C2
NCGC00496851-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1	4.9000001	Active		0.0	1	NCGC00496851-01	405559033	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4	-64.4258832212&-35.92299146	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1
NCGC00408796-01	O=C(O)[C@@H]1[C@H](C(=O)N2CCN(C)CC2)[C@H]2O[C@@H]1CC2		Inactive	Protein Phosphatase 2A (PP-2A) Inhibitor		1	EMPM	384569220	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@@H]1[C@H](C(=O)N2CCN(C)CC2)[C@H]2O[C@@H]1CC2	O=C(O)[C@@H]1[C@H](C(=O)N2CCN(C)CC2)[C@H]2O[C@@H]1CC2
NCGC00016686-07	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)/C=C\C=C/C=C\C=C/C[C@H](C)OC(=O)/C=C\[C@H]1O[C@@H]1C[C@H](O)C2		Inactive	Antifungal Agent		1	Natamycin	363676490	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.814759372	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)/C=C\C=C/C=C\C=C/C[C@H](C)OC(=O)/C=C\[C@H]1O[C@@H]1C[C@H](O)C2	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)/C=C\C=C/C=C\C=C/C[C@H](C)OC(=O)/C=C\[C@H]1O[C@@H]1C[C@H](O)C2
NCGC00016686-13	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)C=CC=CC=CC=CC[C@H](C)OC(=O)C=C[C@H]1O[C@@H]1C[C@H](O)C2		Inactive	Anti-fungal		1	Pimaricin	405558570	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	30.9456733128&11.959525652	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)C=CC=CC=CC=CC[C@H](C)OC(=O)C=C[C@H]1O[C@@H]1C[C@H](O)C2	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)C=CC=CC=CC=CC[C@H](C)OC(=O)C=C[C@H]1O[C@@H]1C[C@H](O)C2
NCGC00024667-14&NCGC00024667-19	O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C		Inactive	Aromatic-l-amino-acid Decarboxylase Inhibitor&DOPA decarboxylase Inhibitor		2	Methyldopa	170464643&384568031	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	14.3432982639&0.0&0.0	O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O.O.O	O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O.O.O&O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C
NCGC00015701-06	O=C(O)[C@@](N)(Cc1ccc(O)cc1)C		Inactive	Tyrosine 3-hydroxylase Inhibitor		1	Metyrosine	170465112	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.2255736119	O=C(O)[C@@](N)(Cc1ccc(O)cc1)C	O=C(O)[C@@](N)(Cc1ccc(O)cc1)C
NCGC00024596-08	O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C		Inactive	decarboxylase inhibitor&Aromatic-l-amino-acid Decarboxylase Inhibitor		1	Carbidopa	225144194	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C	O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C
NCGC00178913-11	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1	4.8499999	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	Tripterin	384568367	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-100.9094493682	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1
NCGC00017223-05	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2		Inactive	STAT-3 Inhibitor		1	Ursolic acid	384567976	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2
NCGC00346584-02	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	Nitric Oxide Production Inhibitor		1	Asiatic acid	363677465	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00163409-07	O=C(O)[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2		Inactive	Caspase 3/8 Activator		1	Betulinic acid	384568234	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.460872948	O=C(O)[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2	O=C(O)[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2
NCGC00346524-02	O=C(O)[C@H](C[C@H](C(=O)/C(=C/[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@]3([C@H](C)[C@@H](OC4O[C@H](C)[C@@H](OC)CC4)C1)[C@@H](C)C[C@H]([C@@H]1[C@@H](C)C[C@@H](C)[C@](O)(CO)O1)O3)CC2)/C)C)C	5.9499998	Active	Polyether Antibiotic	0.0	1	Nanchangmycin	384568818	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-79.3913486146	O=C([O-])[C@H](C[C@H](C(=O)/C(=C/[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@]3([C@H](C)[C@@H](OC4O[C@H](C)[C@@H](OC)CC4)C1)[C@@H](C)C[C@H]([C@@H]1[C@@H](C)C[C@@H](C)[C@](O)(CO)O1)O3)CC2)/C)C)C	O=C([O-])[C@H](C[C@H](C(=O)/C(=C/[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@]3([C@H](C)[C@@H](OC4O[C@H](C)[C@@H](OC)CC4)C1)[C@@H](C)C[C@H]([C@@H]1[C@@H](C)C[C@@H](C)[C@](O)(CO)O1)O3)CC2)/C)C)C
NCGC00014891-14	O=C(O)[C@H](Cc1c2c([nH]c1)cccc2)N1C(=O)c2c(C1=O)cccc2	4.4499998	Active	DNA Methyltransferase (DNMT) Inhibitor	0.0	1	RG-108	384567795	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-39.6592784636	O=C(O)[C@H](Cc1c2c([nH]c1)cccc2)N1C(=O)c2c(C1=O)cccc2	O=C(O)[C@H](Cc1c2c([nH]c1)cccc2)N1C(=O)c2c(C1=O)cccc2
NCGC00024494-02	O=C(O)[C@H](N)C	4.4000001	Active	Alanine Aminotransferase 1 Substrate	0.0	1	D-Alanine	170465038	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.438126612	O=C(O)[C@H](N)C	O=C(O)[C@H](N)C
NCGC00013565-03	O=C(O)[C@H](N)CC(C)C		Inactive	Mammalian target of Rapamycin (mTORC1) Activator&Mammalian Target Of Rapamycin (mtorc1) Activator		1	D-Leucine	170465492	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.87348106&-26.765108616	O=C(O)[C@H](N)CC(C)C	O=C(O)[C@H](N)CC(C)C
NCGC00093936-08	O=C(O)[C@H](N)CCC(=O)N		Inactive	Protein-glutamine Gamma-glutamyltransferase Substrate&Protein-glutamine gamma-glutamyltransferase Substrate		1	D-Glutamine	170465304	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O)[C@H](N)CCC(=O)N	O=C(O)[C@H](N)CCC(=O)N
NCGC00024501-04	O=C(O)[C@H](N)CCC(=O)O		Inactive	Metabotropic Glutamate Receptor 1 Agonist&Metabotropic glutamate receptor 1 Agonist		1	D-Glutamic acid	225144193	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.382265552&0.0	O=C(O)[C@H](N)CCC(=O)O	O=C(O)[C@H](N)CCC(=O)O
NCGC00094363-07	O=C(O)[C@H](N)CO		Inactive	Serine Palmitoyltransferase 1 Substrate&Serine palmitoyltransferase 1 Substrate		1	D-SERINE	405558559	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.4966282361&-19.690430812	O=C(O)[C@H](N)CO	O=C(O)[C@H](N)CO
NCGC00094437-05	O=C(O)[C@H](N)Cc1c2c([nH]c1)cccc2		Inactive	Tryptophan Metabolism Substrate&Tryptophan metabolism Substrate		1	d-Tryptophan	170465485	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.147706772&13.497446788	O=C(O)[C@H](N)Cc1c2c([nH]c1)cccc2	O=C(O)[C@H](N)Cc1c2c([nH]c1)cccc2
NCGC00346842-04	O=C(O)[C@H](N)Cc1c2c(n(C)c1)cccc2		Inactive	IDO Inhibitor		1	Indoximod	384568951	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-10.3196405079	O=C(O)[C@H](N)Cc1c2c(n(C)c1)cccc2	O=C(O)[C@H](N)Cc1c2c(n(C)c1)cccc2
NCGC00163338-03	O=C(O)[C@H](N)Cc1ccccc1		Inactive			1	D-Phenylalanine	405558712	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.8325457719&-10.863020816	O=C(O)[C@H](N)Cc1ccccc1	O=C(O)[C@H](N)Cc1ccccc1
NCGC00142611-02	O=C(O)[C@H](N)Cc1nc[nH]c1	5.0500002	Active	Histidine Decarboxylase Substrate&Histidine decarboxylase Substrate	0.0	1	D-HISTIDINE	26754413	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-53.9203040784&-32.4279822435	O=C(O)[C@H](N)Cc1nc[nH]c1	O=C(O)[C@H](N)Cc1nc[nH]c1
NCGC00164593-02	O=C(O)[C@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1		Inactive			1	Enalapril acid	170464938	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.539199924&0.0	O=C(O)[C@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1	O=C(O)[C@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1
NCGC00344532-01	O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O		Inactive			1	Mucic acid	170464883	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.289695788&-26.5535340439	O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O	O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O
NCGC00164076-03	O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO		Inactive			1	SODIUM GLUCONATE	405559091	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.055183084	O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
NCGC00179532-03	O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO	4.4000001	Active	Matrix Metalloproteinase (MMP) Inhibitor	0.0	1	Lactobionic acid	170466730	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-37.357633832	O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO	O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO
NCGC00166022-02	O=C(O)[C@H](O)c1ccccc1	4.75	Active		0.0	1	D-(-)-Mandelic acid	170465573	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.60390282	O=C(O)[C@H](O)c1ccccc1	O=C(O)[C@H](O)c1ccccc1
NCGC00510484-01	O=C(O)[C@H](Oc1cc(CN(CCCOc2ccc(OC)cc2)c2oc3c(n2)cccc3)ccc1)CC		Inactive	PPARalpha Agonist		1	Pemafibrate	384569447	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.340372152	O=C(O)[C@H](Oc1cc(CN(CCCOc2ccc(OC)cc2)c2oc3c(n2)cccc3)ccc1)CC	O=C(O)[C@H](Oc1cc(CN(CCCOc2ccc(OC)cc2)c2oc3c(n2)cccc3)ccc1)CC
NCGC00179454-04	O=C(O)[C@H]([C@H](OC)[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@](CC)([C@H]3[C@@H](C)C[C@H]([C@@H]4[C@@H](C)C[C@@H](C)[C@](O)(CO)O4)O3)CC1)CC2)C	4.75	Active	Polyether Antibiotic	0.0	1	Monensin sodium salt	174007192	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-58.6132625174	O=C([O-])[C@H]([C@H](OC)[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@](CC)([C@H]3[C@@H](C)C[C@H]([C@@H]4[C@@H](C)C[C@@H](C)[C@](O)(CO)O4)O3)CC1)CC2)C	O=C([O-])[C@H]([C@H](OC)[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@](CC)([C@H]3[C@@H](C)C[C@H]([C@@H]4[C@@H](C)C[C@@H](C)[C@](O)(CO)O4)O3)CC1)CC2)C
NCGC00180892-03	O=C(O)[C@H]1/C(=C/CO)/O[C@H]2N1C(=O)C2		Inactive	Beta-lactamase Tem Inhibitor		1	CLAVULANATE LITHIUM	225144312	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&15.09520814	O=C([O-])[C@H]1/C(=C/CO)/O[C@H]2N1C(=O)C2	O=C([O-])[C@H]1/C(=C/CO)/O[C@H]2N1C(=O)C2
NCGC00159336-03	O=C(O)[C@H]1C(C)(C)S(=O)(=O)[C@H]2N1C(=O)C2		Inactive	Beta-lactamase Tem Inhibitor&beta-Lactamase Inhibitor		1	Sulbactam	170465248	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.1657700027&-25.7711167919	O=C(O)[C@H]1C(C)(C)S(=O)(=O)[C@H]2N1C(=O)C2	O=C(O)[C@H]1C(C)(C)S(=O)(=O)[C@H]2N1C(=O)C2
NCGC00263825-02	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N12		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	HETACILLIN POTASSIUM	405558828	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-33.397007216&-24.217054428	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N12	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N12
NCGC00164583-02	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12		Inactive			1	Amdinocillin	170465354	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.2364532703&-25.88129906	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12
NCGC00263560-01	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](N)C(=O)N12		Inactive			1	6-Aminopenicillanic acid	225144362	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.655258436	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](N)C(=O)N12	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](N)C(=O)N12
NCGC00022787-04	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(C)onc3-c3ccccc3)C(=O)N12		Inactive	Beta-lactam Antibiotic&beta-lactam antibiotic		1	Oxacillin sodium	405558799	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-26.8381234519	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(C)onc3-c3ccccc3)C(=O)N12	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(C)onc3-c3ccccc3)C(=O)N12
NCGC00178877-03	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OC)cccc3OC)C(=O)N12		Inactive	Peptidoglycan Biosynthetic Process Inhibitor&peptidoglycan biosynthetic process Inhibitor		1	Methicillin sodium hydrate	170465152	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.3951950639&-18.426062624	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OC)cccc3OC)C(=O)N12.[Na+].O	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OC)cccc3OC)C(=O)N12.[Na+].O
NCGC00273482-01	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OCC)ccc4c3cccc4)C(=O)N12		Inactive			1	Nafcillin sodium monohydrate	170465253	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.2364681599&0.0	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OCC)ccc4c3cccc4)C(=O)N12.[Na+].O	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OCC)ccc4c3cccc4)C(=O)N12.[Na+].O
NCGC00346594-02	O=C(O)[C@H]1C2[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC2)CC(C)(C)C1		Inactive	Secretory Phospholipase A2 (sPLA2) Inhibitor		1	Oleanolic acid	363677469	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@H]1C2[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC2)CC(C)(C)C1	O=C(O)[C@H]1C2[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC2)CC(C)(C)C1
NCGC00164626-02	O=C(O)[C@H]1CN(CC/C=C(\c2c(C)ccs2)/c2c(C)ccs2)CCC1	5.125	Active	Gat-1 Inhibitor&GAT-1 Inhibitor	0.0	1	Tiagabine hydrochloride	170465153	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-37.554565921&-40.5151459864	O=C(O)[C@H]1CN(CC/C=C(\c2c(C)ccs2)/c2c(C)ccs2)CCC1.Cl	O=C(O)[C@H]1CN(CC/C=C(\c2c(C)ccs2)/c2c(C)ccs2)CCC1.Cl
NCGC00164626-07	O=C(O)[C@H]1CN(CCC=C(c2c(C)ccs2)c2c(C)ccs2)CCC1		Inactive	GAT-1 Inhibitor		1	Tiagabine hydrochloride	384568269	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.9874286879	O=C(O)[C@H]1CN(CCC=C(c2c(C)ccs2)c2c(C)ccs2)CCC1	O=C(O)[C@H]1CN(CCC=C(c2c(C)ccs2)c2c(C)ccs2)CCC1
NCGC00507856-01	O=C(O)[C@H]1N(Cc2c(OC)cc(OCc3c(C)c(-c4ccccc4)ccc3)cc2OC)CCCC1	5.3000002	Inactive	PD-1 /PD-L1 interaction Inhibitor	0.0	1	PD-1/PD-L1 Inhibitor 1	384569334	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	87.8091696919	O=C(O)[C@H]1N(Cc2c(OC)cc(OCc3c(C)c(-c4ccccc4)ccc3)cc2OC)CCCC1	O=C(O)[C@H]1N(Cc2c(OC)cc(OCc3c(C)c(-c4ccccc4)ccc3)cc2OC)CCCC1
NCGC00014017-03	O=C(O)[C@H]1NCCC1		Inactive			1	L-Proline	225144170	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.3833585839	O=C(O)[C@H]1NCCC1	O=C(O)[C@H]1NCCC1
NCGC00168248-02	O=C(O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2		Inactive			1	Benzoylecgonine	144206406	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.660004456&-28.5190712199	O=C(O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2	O=C(O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2
NCGC00346612-06	O=C(O)[C@H]1[C@@H]2S(=O)(=O)C[C@@](N)(C(=O)O)[C@H]12		Inactive	mgluR2/3 Agonist		1	LY-2140023	384568858	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@H]1[C@@H]2S(=O)(=O)C[C@@](N)(C(=O)O)[C@H]12	O=C(O)[C@H]1[C@@H]2S(=O)(=O)C[C@@](N)(C(=O)O)[C@H]12
NCGC00159340-05	O=C(O)[C@H]1[C@@](Cn2nncc2)(C)S(=O)(=O)[C@H]2N1C(=O)C2		Inactive	Bacterial Beta-lactamase Tem Inhibitor&Bacterial beta-lactamase TEM Inhibitor		1	Tazobactam sodium	170465148	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-17.45559472	O=C([O-])[C@H]1[C@@](Cn2nncc2)(C)S(=O)(=O)[C@H]2N1C(=O)C2.[Na+]	O=C([O-])[C@H]1[C@@](Cn2nncc2)(C)S(=O)(=O)[C@H]2N1C(=O)C2.[Na+]
NCGC00185990-04	O=C(O)[C@H]1c2n(c(C(=O)c3ccccc3)cc2)CC1	4.4000001	Active	Non-steroidal Antiinflammatory	0.0	1	Ketorolac	170464659	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.045504012	O=C(O)[C@H]1c2n(c(C(=O)c3ccccc3)cc2)CC1.OCC(N)(CO)CO	O=C(O)[C@H]1c2n(c(C(=O)c3ccccc3)cc2)CC1.OCC(N)(CO)CO
NCGC00178566-03	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)C(C(=O)C=C23)[C@]2(C)C(C(C)(C)[C@@H](O)CC2)CC4)CC1		Inactive	15-hydroxyprostaglandin dehydrogenase inhibitor&15-hydroxyprostaglandin Dehydrogenase Inhibitor		1	ENOXOLONE&NCGC00178566-03	405559050	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.7931592439&-21.8917254881	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)C(C(=O)C=C23)[C@]2(C)C(C(C)(C)[C@@H](O)CC2)CC4)CC1	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)C(C(=O)C=C23)[C@]2(C)C(C(C)(C)[C@@H](O)CC2)CC4)CC1
NCGC00017244-10	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@H](C(=O)C=C23)[C@]2(C)[C@H](C(C)(C)[C@@H](O)CC2)CC4)CC1		Inactive	15-hydroxyprostaglandin dehydrogenase Inhibitor		1	Enoxolone	384567978	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@H](C(=O)C=C23)[C@]2(C)[C@H](C(C)(C)[C@@H](O)CC2)CC4)CC1	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@H](C(=O)C=C23)[C@]2(C)[C@H](C(C)(C)[C@@H](O)CC2)CC4)CC1
NCGC00390255-01	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	Glycogen Phosphorylase Inhibitor		1	Maslinic acid	384569181	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00095150-08&NCGC00095150-16	O=C(O)c1c(-c2ccc(Cn3c(CCC)nc4c(C)cc(-c5n(C)c6c(n5)cccc6)cc34)cc2)cccc1		Inactive	Angiotensin At1 Receptor Antagonist&Angiotensin AT1 Antagonist&Angiotensin AT1 Antagonist		2	Telmisartan	170464873&384568151	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-20.777089944&12.924532776	O=C(O)c1c(-c2ccc(Cn3c(CCC)nc4c(C)cc(-c5n(C)c6c(n5)cccc6)cc34)cc2)cccc1	O=C(O)c1c(-c2ccc(Cn3c(CCC)nc4c(C)cc(-c5n(C)c6c(n5)cccc6)cc34)cc2)cccc1
NCGC00263694-01	O=C(O)c1c(C(=O)Nc2ccc(-c3ccccc3)cc2)cccc1		Inactive	chondrocyte differentiation initiator		1	Kartogenin	174007246	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)c1c(C(=O)Nc2ccc(-c3ccccc3)cc2)cccc1	O=C(O)c1c(C(=O)Nc2ccc(-c3ccccc3)cc2)cccc1
NCGC00091015-01	O=C(O)c1c(C(c2ccc(O)cc2)c2ccc(O)cc2)cccc1		Inactive			1	Phenolphthalin	17389504	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.22450288&-15.6907256159	O=C(O)c1c(C(c2ccc(O)cc2)c2ccc(O)cc2)cccc1	O=C(O)c1c(C(c2ccc(O)cc2)c2ccc(O)cc2)cccc1
NCGC00247988-03	O=C(O)c1c(C)c2C(=O)c3c(O)c([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)c(O)c3C(=O)c2cc1O	5.2249999	Active	Solute Carrier Organic Anion Transporter Family Member 1b1 Inhibitor&Solute carrier organic anion transporter family member 1B1 Inhibitor	0.0	1	Cochineal	170466801	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-54.3676142919&-55.0152075003	O=C(O)c1c(C)c2C(=O)c3c(O)c([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)c(O)c3C(=O)c2cc1O	O=C(O)c1c(C)c2C(=O)c3c(O)c([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)c(O)c3C(=O)c2cc1O
NCGC00182059-03&NCGC00182059-11	O=C(O)c1c(C)nc(-c2cc(C#N)c(OCC(C)C)cc2)s1		Inactive	Xanthine Dehydrogenase Inhibitor&Xanthine Oxidase Inhibitor&Xanthine Oxidase Inhibitor		2	Febuxostat	170465220&384568409	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&10.150640528	O=C(O)c1c(C)nc(-c2cc(C#N)c(OCC(C)C)cc2)s1	O=C(O)c1c(C)nc(-c2cc(C#N)c(OCC(C)C)cc2)s1
NCGC00250410-11	O=C(O)c1c(C2CCCC2)cc(-c2c3c([nH]c2)ncc(-c2ccccc2)c3)cc1	5.5500002	Active	SGK1 Inhibitor	0.0	1	GSK-650394	384568558	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-89.5802695324	O=C(O)c1c(C2CCCC2)cc(-c2c3c([nH]c2)ncc(-c2ccccc2)c3)cc1	O=C(O)c1c(C2CCCC2)cc(-c2c3c([nH]c2)ncc(-c2ccccc2)c3)cc1
NCGC00379003-05	O=C(O)c1c(CCCOc2ccc(CN)cc2)sc(-c2cc3/C(=N/Nc4sc5c(n4)cccc5)/CCCc3cc2)n1		Inactive	Bcl-xl Inhibitor		1	WEHI-539	384569085	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)c1c(CCCOc2ccc(CN)cc2)sc(-c2cc3/C(=N/Nc4sc5c(n4)cccc5)/CCCc3cc2)n1	O=C(O)c1c(CCCOc2ccc(CN)cc2)sc(-c2cc3/C(=N/Nc4sc5c(n4)cccc5)/CCCc3cc2)n1
NCGC00346532-01	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(O)CC2)cc(C#CC(C)(C)C)s1	4.4000001	Active		0.0	1	VX-222	174007365	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-50.2664593279	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(O)CC2)cc(C#CC(C)(C)C)s1	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(O)CC2)cc(C#CC(C)(C)C)s1
NCGC00346467-01	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(OC)CC2)cc(C2=CCCCC2)s1		Inactive			1	VCH-916 	174007403	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C([O-])c1c(N(C(=O)C2CCC(C)CC2)C2CCC(OC)CC2)cc(C2=CCCCC2)s1	O=C([O-])c1c(N(C(=O)C2CCC(C)CC2)C2CCC(OC)CC2)cc(C2=CCCCC2)s1
NCGC00167472-03&NCGC00167472-10	O=C(O)c1c(N)nc2Oc3c(C(=O)c2c1)cc(C(C)C)cc3		Inactive	Mediator Release Inhibitor		2	Amlexanox	170465365&384568317	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&22.684766204&0.0	O=C(O)c1c(N)nc2Oc3c(C(=O)c2c1)cc(C(C)C)cc3	O=C(O)c1c(N)nc2Oc3c(C(=O)c2c1)cc(C(C)C)cc3
NCGC00263154-08	O=C(O)c1c(N[C@H](C)C=2C3=NC(N4CCOCC4)=CC(=O)N3C=C(C)C=2)cccc1	4.9000001	Active	PI3Kb/d Inhibitor	0.0	1	AZD-6482	384568628	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-37.769242524	O=C(O)c1c(N[C@H](C)C=2C3=NC(N4CCOCC4)=CC(=O)N3C=C(C)C=2)cccc1	O=C(O)c1c(N[C@H](C)C=2C3=NC(N4CCOCC4)=CC(=O)N3C=C(C)C=2)cccc1
NCGC00016278-10	O=C(O)c1c(Nc2c(C)c(C)ccc2)cccc1	5.8000002	Active	Cyclooxygenase-2 Inhibitor	0.0	1	Mefenamic acid	170464813	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-36.4469180573	O=C(O)c1c(Nc2c(C)c(C)ccc2)cccc1	O=C(O)c1c(Nc2c(C)c(C)ccc2)cccc1
NCGC00181008-02	O=C(O)c1c(O)ccc(/N=N/c2cc(C(=O)O)c(O)cc2)c1		Inactive	Cyclooxygenase Inhibitor		1	Olsalazine sodium	225144315	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.75281976&-26.6202087949	O=C([O-])c1c(O)ccc(/N=N/c2cc(C(=O)[O-])c(O)cc2)c1	O=C([O-])c1c(O)ccc(/N=N/c2cc(C(=O)[O-])c(O)cc2)c1
NCGC00016344-07	O=C(O)c1c(O)ccc(N)c1	4.5	Active	Reactive Oxygen Species Biosynthetic Process Inhibitor	0.0	1	5-Aminosalicylic acid	170464840	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-32.15201748	O=C(O)c1c(O)ccc(N)c1	O=C(O)c1c(O)ccc(N)c1
NCGC00263121-03	O=C(O)c1c(O)cccc1CCc1ccc(CCCCCCC)cc1		Inactive	Histone acetyltransferase Inhibitor		1	MG-149	384568605	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-31.82085878	O=C(O)c1c(O)cccc1CCc1ccc(CCCCCCC)cc1	O=C(O)c1c(O)cccc1CCc1ccc(CCCCCCC)cc1
NCGC00241036-03	O=C(O)c1c2c(c(O)cc1)ncc(N1CCOCC1)c2	4.5500002	Active	JMJ Inhibitor	0.0	1	NCGC00241036	384568468	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-110.0733570047	O=C(O)c1c2c(c(O)cc1)ncc(N1CCOCC1)c2	O=C(O)c1c2c(c(O)cc1)ncc(N1CCOCC1)c2
NCGC00183784-18	O=C(O)c1c2c(c(O)cc1)nccc2	4.4000001	Active	Lysine-Specific Demethylase 4A (KDM4A; JMJD2A) Inhibitor	0.0	1	IOX-1	384568420	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-65.667835116	O=C(O)c1c2c(c(O)cc1)nccc2	O=C(O)c1c2c(c(O)cc1)nccc2
NCGC00386206-03	O=C(O)c1c2n(Cc3ccc(-c4c(C5=NC(=O)ON5)cccc4)cc3)c(OCC)nc2ccc1	4.4000001	Active	Type-1 Angiotensin Ii Receptor Antagonist	0.0	1	Azilsartan (TAK-536)	405558540	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.108320224	O=C(O)c1c2n(Cc3ccc(-c4c(C5=NC(=O)ON5)cccc4)cc3)c(OCC)nc2ccc1	O=C(O)c1c2n(Cc3ccc(-c4c(C5=NC(=O)ON5)cccc4)cc3)c(OCC)nc2ccc1
NCGC00274067-01&NCGC00274067-09	O=C(O)c1cc(-c2c(O)c(N/N=C\3/C(=O)N(c4cc(C)c(C)cc4)N=C/3C)ccc2)ccc1	4.42499995	Active	Thrombopoietin Receptor (TpoR) Agonist	0.15000009999999975	2	Eltrombopag olamine	174006931&384568712	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-110.5867871739&-32.7525260839	O=C(O)c1cc(-c2c(O)c(N/N=C\3/C(=O)N(c4cc(C)c(C)cc4)N=C/3C)ccc2)ccc1	O=C(O)c1cc(-c2c(O)c(N/N=C\3/C(=O)N(c4cc(C)c(C)cc4)N=C/3C)ccc2)ccc1
NCGC00091125-07	O=C(O)c1cc(O)c(O)c(O)c1		Inactive	intrinsic apoptotic signaling pathway in response to oxidative stress Inhibitor&Intrinsic Apoptotic Signaling Pathway In Response To Oxidative Stress Inhibitor		1	Gallic acid	170465633	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-17.339868484	O=C(O)c1cc(O)c(O)c(O)c1	O=C(O)c1cc(O)c(O)c(O)c1
NCGC00018199-09	O=C(O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	4.4000001	Active	component of rhubarb	0.0	1	Rhein	384567996	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-109.5718557808	O=C(O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	O=C(O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1
NCGC00385183-01	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cccc34)c2c1	5.0749998	Active	Potassium-transporting ATPase Inhibitor&Potassium-transporting Atpase Inhibitor	0.0	1	NCGC00385183-01	405559009	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-54.6080659543&-87.8933335497	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cccc34)c2c1	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cccc34)c2c1
NCGC00166280-02	O=C(O)c1cc(O)c2O[Bi](O)Oc2c1		Inactive			1	Bismuth(III) gallate basic hydrate	225144278	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.471521784&-29.641817988	O=C(O)c1cc(O)c2O[Bi](O)Oc2c1	O=C(O)c1cc(O)c2O[Bi](O)Oc2c1
NCGC00181754-07&NCGC00263572-01	O=C(O)c1ccc(-n2c(-c3c(O)cccc3)nc(-c3c(O)cccc3)n2)cc1	4.47500015	Active	Iron Chelator&Iron Chelating Agent	0.15000010000000064	2	Deferasirox	384568398&170464723	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-109.5664448885&-100.3201509037	O=C(O)c1ccc(-n2c(-c3c(O)cccc3)nc(-c3c(O)cccc3)n2)cc1	O=C(O)c1ccc(-n2c(-c3c(O)cccc3)nc(-c3c(O)cccc3)n2)cc1
NCGC00181111-02&NCGC00181111-05	O=C(O)c1ccc(C(=O)Nc2cc3C(C)(C)CCC(C)(C)c3cc2)cc1	4.5250001	Active	Retinoid Rar Agonists?&Retinoid RAR Agonist&Retinoid RAR Agonist	0.25	2	Tamibarotene	170465883&384568390	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2&-3.0	-51.211389544&-57.1045546968&-66.785013964	O=C(O)c1ccc(C(=O)Nc2cc3C(C)(C)CCC(C)(C)c3cc2)cc1	O=C(O)c1ccc(C(=O)Nc2cc3C(C)(C)CCC(C)(C)c3cc2)cc1
NCGC00166226-02	O=C(O)c1ccc(CCC)cc1	4.4499998	Active		0.0	1	4-Propylbenzoic acid	225144274	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.447029916	O=C(O)c1ccc(CCC)cc1	O=C(O)c1ccc(CCC)cc1
NCGC00387878-04	O=C(O)c1ccc(CN2CCC(CN[C@H]3[C@H](c4ccccc4)C3)CC2)cc1		Inactive	Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitor		1	GSK-2879552	384569167	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)c1ccc(CN2CCC(CN[C@H]3[C@H](c4ccccc4)C3)CC2)cc1	O=C(O)c1ccc(CN2CCC(CN[C@H]3[C@H](c4ccccc4)C3)CC2)cc1
NCGC00091051-04	O=C(O)c1ccc(N)cc1		Inactive	Carbonic anhydrase II Inhibitor&Carbonic Anhydrase Ii Inhibitor		1	4-Aminobenzoic acid	170466660	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.478014296&-15.587646348	O=C(O)c1ccc(N)cc1	O=C(O)c1ccc(N)cc1
NCGC00166266-03	O=C(O)c1ccc(OCCCOc2ccc(C(=O)O)cc2)cc1		Inactive			1	1,3-Bis(4-carboxyphenoxy)propane	170466646	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&23.700099156	O=C(O)c1ccc(OCCCOc2ccc(C(=O)O)cc2)cc1	O=C(O)c1ccc(OCCCOc2ccc(C(=O)O)cc2)cc1
NCGC00263135-02	O=C(O)c1cn(-c2cc(C#N)c(OCC(C)(C)C)cc2)nc1	4.0500002	Inactive	Xanthine Oxidase Inhibitor	0.0	1	Piraxostat	384568613	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	85.975512033	O=C(O)c1cn(-c2cc(C#N)c(OCC(C)(C)C)cc2)nc1	O=C(O)c1cn(-c2cc(C#N)c(OCC(C)(C)C)cc2)nc1
NCGC00242489-02	O=C(O)c1cnc(C2(c3c(C)cc4C(C)(C)CCC(C)(C)c4c3)CC2)cc1		Inactive	RXR Agonist		1	LG-100268	363677145	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O)c1cnc(C2(c3c(C)cc4C(C)(C)CCC(C)(C)c4c3)CC2)cc1	O=C(O)c1cnc(C2(c3c(C)cc4C(C)(C)CCC(C)(C)c4c3)CC2)cc1
NCGC00016268-08&NCGC00016268-21	O=C(O)c1cnccc1		Inactive	Vitamin&Nicotinic acid&Nicotinic acid		2	Niacin	170465044&384567927	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-11.028849532&33.138411912	O=C(O)c1cnccc1	O=C(O)c1cnccc1
NCGC00188943-03	O=C(O)c1nc(O)nc(O)c1		Inactive	Dihydroorotate Dehydrogenase Product&metabolite		1	Orotic acid	170465761	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.096106316	O=C(O)c1nc(O)nc(O)c1	O=C(O)c1nc(O)nc(O)c1
NCGC00166236-02	O=C(O)c1nc(O)nc(O)n1	7.0081005	Active	Orotate Phosphoribosyltransferase Inhibitor	0.0	1	Oteracil potassium	405559107	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-30.903158372	O=C([O-])c1nc(O)nc(O)n1	O=C([O-])c1nc(O)nc(O)n1
NCGC00167452-03	O=C(O)c1nc2C(=O)C=C3Oc4c(N=C3c2c(O)c1)cccc4	4.9000001	Active	Maintenance Of Lens Transparency Activator	0.0	1	Pirenoxine Sodium	225144286	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.0721433602	O=C([O-])c1nc2C(=O)C=C3Oc4c(N=C3c2c(O)c1)cccc4	O=C([O-])c1nc2C(=O)C=C3Oc4c(N=C3c2c(O)c1)cccc4
NCGC00160519-13	O=C(O)c1ncc(C)[n+]([O-])c1		Inactive	Niacin deravitive		1	Acipimox	384568197	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.728831812	O=C(O)c1ncc(C)[n+]([O-])c1	O=C(O)c1ncc(C)[n+]([O-])c1
NCGC00165993-02	O=C(O)c1ncccc1		Inactive			1	Picolinic acid	170466822	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.790042356&15.111348112	O=C(O)c1ncccc1	O=C(O)c1ncccc1
NCGC00263529-01	O=C(OC(C)(C)C)/C=C/c1c(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OCC)cccc1	4.5999999	Active	Ca channel blocker - DHP class	0.0	1	Lacidipine	170465580	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-87.2449890156	O=C(OC(C)(C)C)/C=C/c1c(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OCC)cccc1	O=C(OC(C)(C)C)/C=C/c1c(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OCC)cccc1
NCGC00347910-01	O=C(OC(C)(C)C)NCCCCCCNc1nc(NCCO)nc2n(C(C)C)cnc12	4.5500002	Active	CaMK-II Inhibitor	0.0	1	CK-59	174006383	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-77.9588603644	O=C(OC(C)(C)C)NCCCCCCNc1nc(NCCO)nc2n(C(C)C)cnc12	O=C(OC(C)(C)C)NCCCCCCNc1nc(NCCO)nc2n(C(C)C)cnc12
NCGC00181306-04	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1	9.0	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Docetaxel	170464919	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-16.1682288079	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1
NCGC00346704-07	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](OC)C(=O)[C@]3(C)[C@@H](OC)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1	9.0	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Cabazitaxel	384568923	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-46.7718488775	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](OC)C(=O)[C@]3(C)[C@@H](OC)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](OC)C(=O)[C@]3(C)[C@@H](OC)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1
NCGC00250390-10	O=C(OC(C)(C)C)Nc1ccc(-c2onc(C(=O)NCCCCCCC(=O)NO)c2)cc1		Inactive	HDAC Inhibitor		1	ISOX	384568543	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OC(C)(C)C)Nc1ccc(-c2onc(C(=O)NCCCCCCC(=O)NO)c2)cc1	O=C(OC(C)(C)C)Nc1ccc(-c2onc(C(=O)NCCCCCCC(=O)NO)c2)cc1
NCGC00025341-06	O=C(OC(C)C)C1=C(C)NC(C)=C(C(=O)OC)C1c1c2nonc2ccc1	5.4499998	Active	Voltage-gated L-type Calcium Channel Blocker	0.0	1	Isradipine	170465070	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-31.6289569766	O=C(OC(C)C)C1=C(C)NC(C)=C(C(=O)OC)C1c1c2nonc2ccc1	O=C(OC(C)C)C1=C(C)NC(C)=C(C(=O)OC)C1c1c2nonc2ccc1
NCGC00183877-01	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(=O)CCCCCCC)[C@H](O)C[C@@H]1O	4.5	Active	Prostanoid Fp Receptor Agonist&Prostanoid FP receptor Agonist	0.0	1	Unoprostone isopropyl ester	144207178	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.1	-31.1066713799&-106.5547932967	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(=O)CCCCCCC)[C@H](O)C[C@@H]1O	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(=O)CCCCCCC)[C@H](O)C[C@@H]1O
NCGC00246969-06	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O	5.1500001	Active	Prostanoid FP receptor Agonist	0.0	1	Latanoprost	405558599	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.4199934191	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
NCGC00164071-03	O=C(OC(C)C)CCCCCCCCCCCCC		Inactive			1	Isopropyl tetradecanoic acid	170465683	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.59782036&0.0	O=C(OC(C)C)CCCCCCCCCCCCC	O=C(OC(C)C)CCCCCCCCCCCCC
NCGC00164128-02	O=C(OC(C)C)CCCCCCCCCCCCCCC		Inactive	N-acylsphingosine-amidohydrolase Inhibitor		1	Hexadecanoic acid, 1-methylethyl ester	170465544	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.329630324&0.0	O=C(OC(C)C)CCCCCCCCCCCCCCC	O=C(OC(C)C)CCCCCCCCCCCCCCC
NCGC00262943-01	O=C(OC(C)c1ccc(C)cc1)C1(C)C(C)(C)C(C(=O)O)CC1		Inactive			1	Tocanfil	170466061	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-11.8512585639	O=C(OC(C)c1ccc(C)cc1)C1(C)C(C)(C)C(C(=O)O)CC1.OCCNCCO	O=C(OC(C)c1ccc(C)cc1)C1(C)C(C)(C)C(C(=O)O)CC1.OCCNCCO
NCGC00261973-01	O=C(OC(CC(=O)NCC(CCCC)CC)C)CCC(=O)O	5.6500001	Active		0.0	1	Butoctamide semisuccinate	170466034	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-45.6630164356	O=C(OC(CC(=O)NCC(CCCC)CC)C)CCC(=O)O	O=C(OC(CC(=O)NCC(CCCC)CC)C)CCC(=O)O
NCGC00095128-04	O=C(OC(CCCCCCCCCCC)CC1C(CCCCCC)C(=O)O1)C(NC=O)CC(C)C		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	Orlistat	124891847	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	4.93284712	O=C(OC(CCCCCCCCCCC)CC1C(CCCCCC)C(=O)O1)C(NC=O)CC(C)C	O=C(OC(CCCCCCCCCCC)CC1C(CCCCCC)C(=O)O1)C(NC=O)CC(C)C
NCGC00179382-03	O=C(OC(CNC1CCCCC1)C)c1ccccc1		Inactive	Sodium channel alpha subunit Blocker&Sodium Channel Alpha Subunit Blocker		1	Hexylcaine hydrochloride	170465088	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	8.310299948&0.0	O=C(OC(CNC1CCCCC1)C)c1ccccc1.Cl	O=C(OC(CNC1CCCCC1)C)c1ccccc1.Cl
NCGC00091612-09	O=C(OC(COC(=O)C)COC(=O)C)C		Inactive			1	Triacetin	170465543	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.047295088&0.0	O=C(OC(COC(=O)C)COC(=O)C)C	O=C(OC(COC(=O)C)COC(=O)C)C
NCGC00091285-03	O=C(OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)CCCCCCC		Inactive			1	Tricaprylin	170465841	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&29.9189530872	O=C(OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)CCCCCCC	O=C(OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)CCCCCCC
NCGC00166142-04	O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1	4.7750001	Active	Sodium Ion Transmembrane Transport Inhibitor&sodium ion transmembrane transport Inhibitor	0.0	1	Diperodon hydrochloride	170465536	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-64.0092110029&-73.9748696856	O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1.Cl	O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1.Cl
NCGC00167489-03	O=C(OC(COc1c(CCc2cc(OC)ccc2)cccc1)CN(C)C)CCC(=O)O	4.5250001	Active	5HT(2A) and 5HT(2B) inhibitor&5ht(2a) And 5ht(2b) Inhibitor	0.0	1	Sarpogrelate hydrochloride	174006666	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-66.3104671163&-51.958271444	O=C(OC(COc1c(CCc2cc(OC)ccc2)cccc1)CN(C)C)CCC(=O)O.Cl	O=C(OC(COc1c(CCc2cc(OC)ccc2)cccc1)CN(C)C)CCC(=O)O.Cl
NCGC00262961-01	O=C(OC(COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)[C@@H](N)CCCCN	4.4000001	Active	Mast Cell Activation Inhibitor	0.0	1	Cromoglicate lisetil	170465975	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-58.487644276	O=C(OC(COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)[C@@H](N)CCCCN	O=C(OC(COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)[C@@H](N)CCCCN
NCGC00015045-09	O=C(OC(C[N+](C)(C)C)C)C		Inactive	Muscarinic Acetylcholine Receptor M2 Binding Agent&Muscarinic acetylcholine receptor M2 Binding Agent		1	Methacholine chloride	170464971	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC(C[N+](C)(C)C)C)C.[Cl-]	O=C(OC(C[N+](C)(C)C)C)C.[Cl-]
NCGC00015245-10&NCGC00015245-12	O=C(OC(C[N+](C)(C)C)C)N		Inactive	Muscarinic Acetylcholine Receptor M2 Agonist&Muscarinic receptor Agonist&Muscarinic receptor Agonist		2	Bethanechol chloride	170464912&384567831	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	6.7972296839&0.0&0.0	O=C(OC(C[N+](C)(C)C)C)N.[Cl-]	O=C(OC(C[N+](C)(C)C)C)N.[Cl-]&O=C(OC(C[N+](C)(C)C)C)N
NCGC00532500-01	O=C(OC(OC(=O)C(C)C)C)NCC1(CC(=O)O)CCCCC1	4.4250002	Active		0.0	1	GABAPENTIN ENACARBIL	405559030	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-41.821251068&-42.9970132908	O=C(OC(OC(=O)C(C)C)C)NCC1(CC(=O)O)CCCCC1	O=C(OC(OC(=O)C(C)C)C)NCC1(CC(=O)O)CCCCC1
NCGC00164598-03	O=C(OC(OC(=O)C1=C(COC)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C)OC(C)C	5.0500002	Active		0.0	1	CEFPODOXIME PROXETIL	405558543	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-40.0385039854	O=C(OC(OC(=O)C1=C(COC)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C)OC(C)C	O=C(OC(OC(=O)C1=C(COC)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C)OC(C)C
NCGC00179582-03	O=C(OC(OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N12)C)OCC		Inactive			1	Bacampicillin hydrochloride	170465170	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.011529036&-28.5993690419	O=C(OC(OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N12)C)OCC.Cl	O=C(OC(OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N12)C)OCC.Cl
NCGC00095123-10	O=C(OC(OC(=O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1)C)OC1CCCCC1	4.4000001	Active		0.0	1	Candesartan cilexetil (Atacand)	405558788	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-74.720431124&-111.6587913832	O=C(OC(OC(=O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1)C)OC1CCCCC1	O=C(OC(OC(=O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1)C)OC1CCCCC1
NCGC00164605-02	O=C(OC(OC1=C(C(=O)Nc2ncccc2)N(C)S(=O)(=O)c2c1cccc2)C)OCC	5.5	Active	Cyclooxygenase Inhibitor	0.0	1	Ampiroxicam	170466020	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-67.648144276	O=C(OC(OC1=C(C(=O)Nc2ncccc2)N(C)S(=O)(=O)c2c1cccc2)C)OCC	O=C(OC(OC1=C(C(=O)Nc2ncccc2)N(C)S(=O)(=O)c2c1cccc2)C)OCC
NCGC00531792-01	O=C(OC)/C(=C/[C@H]1[C@H](C(=O)O[C@H]2C(C)=C(C/C=C/C=C)C(=O)C2)C1(C)C)/C	4.4000001	Active	Plasmodium falciparum Inhibitor	0.0	1	PYRETHRIN II	405559034	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-41.0711286739	O=C(OC)/C(=C/[C@H]1[C@H](C(=O)O[C@H]2C(C)=C(C/C=C/C=C)C(=O)C2)C1(C)C)/C	O=C(OC)/C(=C/[C@H]1[C@H](C(=O)O[C@H]2C(C)=C(C/C=C/C=C)C(=O)C2)C1(C)C)/C
NCGC00346639-03	O=C(OC)/C=C/C(=O)OC		Inactive	NFkappaB-inducing kinase Inhibitor		1	Dimethyl fumarate	384568873	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.7848404879	O=C(OC)/C=C/C(=O)OC	O=C(OC)/C=C/C(=O)OC
NCGC00248247-02	O=C(OC)/C=C\C(=O)OC		Inactive	Nfkappab-inducing Kinase Inhibitor&NFkappaB-inducing kinase Inhibitor		1	Dimethyl maleate	170466784	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.581825524&-25.2914432479	O=C(OC)/C=C\C(=O)OC	O=C(OC)/C=C\C(=O)OC
NCGC00248587-03	O=C(OC)C(c1ccccc1)C1NCCCC1	5.3499999	Active		0.0	1	METHYLPHENIDATE HYDROCHLORIDE	405558857	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-43.7118417907	O=C(OC)C(c1ccccc1)C1NCCCC1	O=C(OC)C(c1ccccc1)C1NCCCC1
NCGC00181762-01	O=C(OC)C=1C(=O)c2c(NC=1)cc(OCc1ccccc1)c(CCCC)c2	4.4000001	Active	Eimeria tenella Inhibitor	0.0	1	Nequinate	144206498	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-53.158010464	O=C(OC)C=1C(=O)c2c(NC=1)cc(OCc1ccccc1)c(CCCC)c2	O=C(OC)C=1C(=O)c2c(NC=1)cc(OCc1ccccc1)c(CCCC)c2
NCGC00018251-05	O=C(OC)CCC(=O)CN		Inactive	Porphyrin And Chlorophyll Metabolism Modulator&Porphyrin and chlorophyll metabolism Modulator		1	Methyl delta-aminolevulinate hydrochloride	225144187	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC)CCC(=O)CN	O=C(OC)CCC(=O)CN
NCGC00162445-05	O=C(OC)CCCCCC[C@@H]1[C@@H](/C=C/CC(O)(CCCC)C)[C@H](O)CC1=O	6.1500001	Active	Prostanoid Ep3 Receptor Agonist	0.0	1	Misoprostol	225144248	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-37.9398072064	O=C(OC)CCCCCC[C@@H]1[C@@H](/C=C/CC(O)(CCCC)C)[C@H](O)CC1=O	O=C(OC)CCCCCC[C@@H]1[C@@H](/C=C/CC(O)(CCCC)C)[C@H](O)CC1=O
NCGC00181355-02	O=C(OC)CCC[N+](C)(C)C		Inactive	Muscarinic Acetylcholine Receptor Agonist&Muscarinic acetylcholine receptor Agonist		1	Carpronium chloride	225144327	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	29.5949747399&-17.012924308	O=C(OC)CCC[N+](C)(C)C	O=C(OC)CCC[N+](C)(C)C
NCGC00344558-01	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2	4.4749999	Active	Photosensitizer&photosensitizer	0.0	1	NCGC00344558-01&Verteporfin	225144392	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-116.344025112&-127.1307926799	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2
NCGC00346712-05	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2		Inactive	photosensitizer		1	Verteporfin	384568927	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2
NCGC00185766-04	O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1	5.1999998	Active	Sodium Ion Transport Inhibitor	0.0	1	Esmolol hydrochloride	170465277	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.6967368091	O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl	O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl
NCGC00095156-06	O=C(OC)N/N=C/C=1N([O-])c2c([N+](=O)C=1)cccc2		Inactive			1	Carbadox	170466261	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.5854861654&0.0	O=C(OC)N/N=C/c1[n+]([O-])c2c([n+]([O-])c1)cccc2	O=C(OC)N/N=C/c1[n+]([O-])c2c([n+]([O-])c1)cccc2
NCGC00498399-01	O=C(OC)N1[C@H](C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)CC2(C1)CC2		Inactive	ADAM10 Inhibitor		1	Aderbasib	363681480	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.29436692	O=C(OC)N1[C@H](C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)CC2(C1)CC2	O=C(OC)N1[C@H](C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)CC2(C1)CC2
NCGC00522503-01	O=C(OC)N[C@H](C(=O)N1[C@@H](C)CC[C@H]1c1[nH]c2c(n1)ccc1c2cc2OCc3c(-c2c1)ccc(-c1[nH]c([C@H]2N(C(=O)[C@H](NC(=O)OC)c4ccccc4)C[C@@H](COC)C2)nc1)c3)C(C)C	4.8499999	Active	Nonstructural protein 5A Inhibitor	0.0	1	Velpatasvir	405558874	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-87.12628458	O=C(OC)N[C@H](C(=O)N1[C@@H](C)CC[C@H]1c1[nH]c2c(n1)ccc1c2cc2OCc3c(-c2c1)ccc(-c1[nH]c([C@H]2N(C(=O)[C@H](NC(=O)OC)c4ccccc4)C[C@@H](COC)C2)nc1)c3)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@@H](C)CC[C@H]1c1[nH]c2c(n1)ccc1c2cc2OCc3c(-c2c1)ccc(-c1[nH]c([C@H]2N(C(=O)[C@H](NC(=O)OC)c4ccccc4)C[C@@H](COC)C2)nc1)c3)C(C)C
NCGC00510316-02	O=C(OC)N[C@H](C(=O)N1[C@H](C(=O)Nc2ccc([C@H]3N([C@H](c4ccc(NC(=O)[C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)cc4)CC3)c3ccc(C(C)(C)C)cc3)cc2)CCC1)C(C)C		Inactive			1	Ombitasvir	405559012	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-25.4689106079	O=C(OC)N[C@H](C(=O)N1[C@H](C(=O)Nc2ccc([C@H]3N([C@H](c4ccc(NC(=O)[C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)cc4)CC3)c3ccc(C(C)(C)C)cc3)cc2)CCC1)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@H](C(=O)Nc2ccc([C@H]3N([C@H](c4ccc(NC(=O)[C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)cc4)CC3)c3ccc(C(C)(C)C)cc3)cc2)CCC1)C(C)C
NCGC00510317-02	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3cc4c(n5[C@H](c6ccccc6)Oc6c(-c5c4)ccc(-c4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)nc4)c6)cc3)cn2)CCC1)C(C)C	5.25	Active	Nonstructural protein 5A Inhibitor	0.0	1	Elbasvir	405558499	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.745083042	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3cc4c(n5[C@H](c6ccccc6)Oc6c(-c5c4)ccc(-c4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)nc4)c6)cc3)cn2)CCC1)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3cc4c(n5[C@H](c6ccccc6)Oc6c(-c5c4)ccc(-c4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)nc4)c6)cc3)cn2)CCC1)C(C)C
NCGC00346533-09&NCGC00346533-13	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3ccc(-c4ccc(-c5[nH]c([C@H]6N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC6)nc5)cc4)cc3)cn2)CCC1)C(C)C	4.4000001	Active	HCV NS5A Inhibitor&Viral Non-structural Protein 5a (ns5a) (hcv) Inhibitor&HCV NS5A Inhibitor	0.0	2	Daclatasvir dihydrochloride	405558621&384568823	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-3.0	-104.0815948096&-84.861194524&-117.6423544116	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3ccc(-c4ccc(-c5[nH]c([C@H]6N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC6)nc5)cc4)cc3)cn2)CCC1)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3ccc(-c4ccc(-c5[nH]c([C@H]6N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC6)nc5)cc4)cc3)cn2)CCC1)C(C)C
NCGC00016806-13&NCGC00016806-17	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1ccccc1)cc2	5.8499999	Inactive	Tubulin depolymerization Inhibitor	0.0	2	Mebendazole	170464914&384567961	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&4.0	-16.219180216	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1ccccc1)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1ccccc1)cc2
NCGC00015647-31	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1sccc1)cc2	9.0	Inactive	Tubulin Polymerization Inhibitor	0.0	1	Nocodazole	384567878	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	57.7532600057	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1sccc1)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1sccc1)cc2
NCGC00016706-10	O=C(OC)Nc1[nH]c2c(n1)cc(CCCC)cc2	6.0999999	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Parbendazole	384567956	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	5.290010196	O=C(OC)Nc1[nH]c2c(n1)cc(CCCC)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(CCCC)cc2
NCGC00018238-11	O=C(OC)Nc1[nH]c2c(n1)cc(OCCC)cc2	6.0500002	Active	DNA Polymerase Inhibitor	0.0	1	Oxibendazole	384567998	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-46.1023955609	O=C(OC)Nc1[nH]c2c(n1)cc(OCCC)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(OCCC)cc2
NCGC00346636-03	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(Cc5cnccc5)CC4)nc3)n2)cc1	5.1999998	Active	mTOR Inhibitor	0.0	1	WYE-687	363677489	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-102.3506781967	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(Cc5cnccc5)CC4)nc3)n2)cc1	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(Cc5cnccc5)CC4)nc3)n2)cc1
NCGC00160481-02	O=C(OC)Nc1sc2c(n1)ccc(OCCC)c2	4.7249999	Active	Microtubule Polymerization Inhibitor&microtubule polymerization Inhibitor	0.0	1	Tioxidazole	124892286	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.2	-43.421682612&-33.5315855919	O=C(OC)Nc1sc2c(n1)ccc(OCCC)c2	O=C(OC)Nc1sc2c(n1)ccc(OCCC)c2
NCGC00091104-10	O=C(OC)[C@@H](NC(=O)[C@@H](N)CC(=O)O)Cc1ccccc1		Inactive	Synthetic sugar substitute		1	Aspartame	384568093	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OC)[C@@H](NC(=O)[C@@H](N)CC(=O)O)Cc1ccccc1	O=C(OC)[C@@H](NC(=O)[C@@H](N)CC(=O)O)Cc1ccccc1
NCGC00507885-01	O=C(OC)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(C(C)(C)C)cc1)Cc1ccccc1)C)CC(C)C)CCCCN(CC)CC)CO		Inactive	Peptidic Inhibitor of CDYL/CBX4/CBX7		1	UNC-3866	384569350	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	15.3546665239	O=C(OC)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(C(C)(C)C)cc1)Cc1ccccc1)C)CC(C)C)CCCCN(CC)CC)CO	O=C(OC)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(C(C)(C)C)cc1)Cc1ccccc1)C)CC(C)C)CCCCN(CC)CC)CO
NCGC00091250-12	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3		Inactive	Synaptic Vesicular Amine Transporter Inhibitor&Alkaloid anitpsychotic		1	Reserpine	170465405	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.0920320199&-27.636961328	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3
NCGC00168786-02	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3	4.4000001	Active	Synaptic vesicular amine transporter Inhibitor	0.0	1	Deserpidine	144206653	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-70.2047500079	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3
NCGC00179273-03	O=C(OC)[C@@]1(C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21		Inactive	Glucocorticoid receptor Agonist&Glucocorticoid Receptor Agonist		1	Rimexolone	170464695	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC)[C@@]1(C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	O=C(OC)[C@@]1(C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00185772-01	O=C(OC)[C@@]1(c2c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c2)c2[nH]c3c(c2CC[N@@]2C[C@](O)(CC)C[C@H](C1)C2)cccc3	5.5500002	Active	Tubulin polymerization inhibitor	0.0	1	Vindesine sulfate salt	124896659	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-42.4361146336	S(=O)(=O)(O)O.O=C(OC)[C@@]1(c2c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c2)c2[nH]c3c(c2CC[N@@]2C[C@](O)(CC)C[C@H](C1)C2)cccc3	S(=O)(=O)(O)O.O=C(OC)[C@@]1(c2c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c2)c2[nH]c3c(c2CC[N@@]2C[C@](O)(CC)C[C@H](C1)C2)cccc3
NCGC00025018-10&NCGC00025018-11	O=C(OC)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c3c([nH]c12)cccc3		Inactive	Alpha2-adrenoceptor Antagonist&alpha2-Adrenoceptor Antagonist&alpha2-Adrenoceptor Antagonist		2	Yohimbine	170465467&363676536	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-22.760298364&0.0&-10.74587518	O=C(OC)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c3c([nH]c12)cccc3	O=C(OC)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c3c([nH]c12)cccc3
NCGC00379062-01	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@@H](O)CO)O2)c1		Inactive			1	Episilvestrol	384569090	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	11.834086648	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@@H](O)CO)O2)c1	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@@H](O)CO)O2)c1
NCGC00159467-03	O=C(OC)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2		Inactive	Serotonin Transporter Inhibitor&Serotonin transporter Inhibitor		1	(-)-Cocaine hydrochloride	144206436	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.163662476	O=C(OC)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2.Cl	O=C(OC)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2.Cl
NCGC00167503-02	O=C(OC)[C@H]1[C@@](O)(CC)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)C(=O)CC4)[C@@H](O)C3)[C@@H](N(C)C)C2)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc12	4.5999999	Active	Dna Topoisomerase Ii Inhibitor&DNA Topoisomerase II Inhibitor	0.0	1	Aclarubicin	174007366	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0&-3.0	-49.59986038&-83.2628313519&-71.8669472	O=C(OC)[C@H]1[C@@](O)(CC)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)C(=O)CC4)[C@@H](O)C3)[C@@H](N(C)C)C2)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc12	O=C(OC)[C@H]1[C@@](O)(CC)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)C(=O)CC4)[C@@H](O)C3)[C@@H](N(C)C)C2)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc12
NCGC00159559-03&NCGC00159559-10	O=C(OC)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)C[C@H]3O[C@@]23[C@]2(C)C(=CC(=O)CC2)C1		Inactive	Mineralocorticoid Receptor (mr) Antagonist&Mineralocorticoid Receptor (MR) Antagonist&Mineralocorticoid Receptor (MR) Antagonist		2	Eplerenone	170465283&384568188	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-25.505739884&0.0&-20.3033460759	O=C(OC)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)C[C@H]3O[C@@]23[C@]2(C)C(=CC(=O)CC2)C1	O=C(OC)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)C[C@H]3O[C@@]23[C@]2(C)C(=CC(=O)CC2)C1
NCGC00091106-05	O=C(OC)c1c(O)cccc1		Inactive			1	Methyl salicylate	225144206	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.121642136&0.0	O=C(OC)c1c(O)cccc1	O=C(OC)c1c(O)cccc1
NCGC00159376-04	O=C(OC)c1ccc(O)cc1	5.1500001	Active	Canonical Glycolysis Inhibitor	0.0	1	Methylparaben	170465480	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.6404987647	O=C(OC)c1ccc(O)cc1	O=C(OC)c1ccc(O)cc1
NCGC00159479-05	O=C(OC)c1cnccc1		Inactive			1	Methyl nicotinate	170465506	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.6331850959&21.798392096	O=C(OC)c1cnccc1	O=C(OC)c1cnccc1
NCGC00073457-04	O=C(OC)c1n(C(C)c2ccccc2)cnc1		Inactive	Cytochrome P450 2a5 Inhibitor&Cytochrome P450 2A5 Inhibitor		1	Metomidate hydrochloride	170466159	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC)c1n(C(C)c2ccccc2)cnc1.Cl	O=C(OC)c1n(C(C)c2ccccc2)cnc1.Cl
NCGC00095056-04	O=C(OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)CCCCCCCCCCCCCCC		Inactive			1	Retinyl palmitate	225144218	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.3276317879&0.0	O=C(OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)CCCCCCCCCCCCCCC	O=C(OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)CCCCCCCCCCCCCCC
NCGC00274274-01	O=C(OC1C(C(=O)N(CC)CC)CN2C(c3c(cc(OC)c(OC)c3)CC2)C1)C		Inactive	Dopamine D2 Receptor Modulator&Dopamine D2 receptor Modulator		1	Benzquinamide	170465138	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC1C(C(=O)N(CC)CC)CN2C(c3c(cc(OC)c(OC)c3)CC2)C1)C	O=C(OC1C(C(=O)N(CC)CC)CN2C(c3c(cc(OC)c(OC)c3)CC2)C1)C
NCGC00159361-06	O=C(OC1C(C(C)C)CCC(C)C1)c1c(N)cccc1		Inactive			1	Menthyl Anthranilate	405559000	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.226788652&0.0	O=C(OC1C(C(C)C)CCC(C)C1)c1c(N)cccc1	O=C(OC1C(C(C)C)CCC(C)C1)c1c(N)cccc1
NCGC00181042-02	O=C(OC1C(C(C)C)CCC(C)C1)c1c(O)cccc1	4.9499998	Active		0.0	1	Menthyl salicylate	225144318	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-35.8235992495	O=C(OC1C(C(C)C)CCC(C)C1)c1c(O)cccc1	O=C(OC1C(C(C)C)CCC(C)C1)c1c(O)cccc1
NCGC00163953-03	O=C(OC1C(C)=C(CC=C)C(=O)C1)C1C(C)(C)C1/C=C(\C)/C	4.1750002	Active	Testis-specific Androgen-binding Protein Binding Agent&Testis-specific androgen-binding protein Binding Agent	0.0	1	Allethrin	144214035	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-105.371264527&-97.9174676619	O=C(OC1C(C)=C(CC=C)C(=O)C1)C1C(C)(C)C1/C=C(\C)/C	O=C(OC1C(C)=C(CC=C)C(=O)C1)C1C(C)(C)C1/C=C(\C)/C
NCGC00346893-01	O=C(OC1C(OC(=O)C)C(C)OC(OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)C1O)C		Inactive	RSK Inhibitor		1	SL-0101-1	174007040	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OC1C(OC(=O)C)C(C)OC(OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)C1O)C	O=C(OC1C(OC(=O)C)C(C)OC(OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)C1O)C
NCGC00532507-01	O=C(OC1C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C1OC(=O)c1cnccc1)c1cnccc1		Inactive			1	INOSITOL NIACINATE	405558892	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.9003631&-28.2552929119	O=C(OC1C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C1OC(=O)c1cnccc1)c1cnccc1	O=C(OC1C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C1OC(=O)c1cnccc1)c1cnccc1
NCGC00015888-06	O=C(OC1C(OC)C(C(=O)OC)C2C(C1)CN1C(c3[nH]c4c(c3CC1)ccc(OC)c4)C2)c1cc(OC)c(OC)c(OC)c1	4.4000001	Active	Alkaloid antipsychotic	0.0	1	Reserpine	384567902	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-35.522310496	O=C(OC1C(OC)C(C(=O)OC)C2C(C1)CN1C(c3[nH]c4c(c3CC1)ccc(OC)c4)C2)c1cc(OC)c(OC)c(OC)c1	O=C(OC1C(OC)C(C(=O)OC)C2C(C1)CN1C(c3[nH]c4c(c3CC1)ccc(OC)c4)C2)c1cc(OC)c(OC)c(OC)c1
NCGC00159354-06	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C		Inactive			1	BORNYL ACETATE	405559120	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.5949399839	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C
NCGC00346874-02	O=C(OC1C2CC3CC1CC(C2)C3)N[C@@](C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1)(Cc1c2c([nH]c1)cccc2)C		Inactive	CCK2 (CCKB/Gastrin) Antagonist		1	PD-134308	384568952	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OC1C2CC3CC1CC(C2)C3)N[C@@](C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1)(Cc1c2c([nH]c1)cccc2)C	O=C(OC1C2CC3CC1CC(C2)C3)N[C@@](C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1)(Cc1c2c([nH]c1)cccc2)C
NCGC00018171-06	O=C(OC1C2CC[N+](C)(C1)CC2)C(O)(c1ccccc1)c1ccccc1		Inactive			1	Clidinium bromide	170464768	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.401151612&0.0	O=C(OC1C2CC[N+](C)(C1)CC2)C(O)(c1ccccc1)c1ccccc1.[Br-]	O=C(OC1C2CC[N+](C)(C1)CC2)C(O)(c1ccccc1)c1ccccc1.[Br-]
NCGC00091888-09	O=C(OC1CC(C)(C)CC(C)C1)c1c(O)cccc1		Inactive			1	3,3,5-Trimethylcyclohexyl salicylate	170465478	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.7807991639	O=C(OC1CC(C)(C)CC(C)C1)c1c(O)cccc1	O=C(OC1CC(C)(C)CC(C)C1)c1c(O)cccc1
NCGC00015026-16	O=C(OC1CC2N(C)C(C1)CC2)C(CO)c1ccccc1		Inactive			1	Atropine (sulfate monohydrate)	384567797	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.9258585481	O=C(OC1CC2N(C)C(C1)CC2)C(CO)c1ccccc1	O=C(OC1CC2N(C)C(C1)CC2)C(CO)c1ccccc1
NCGC00261971-01	O=C(OC1CC2N(C)C(C1)CCC2(C)C)C(O)(c1sccc1)c1sccc1	5.1750002	Active		0.0	1	Mazaticol	170466055	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-67.3502769291&-35.3487474656	O=C(OC1CC2N(C)C(C1)CCC2(C)C)C(O)(c1sccc1)c1sccc1	O=C(OC1CC2N(C)C(C1)CCC2(C)C)C(O)(c1sccc1)c1sccc1
NCGC00522037-01	O=C(OC1CC2[N+](CC)(C)C([C@@H]3O[C@H]23)C1)[C@H](CO)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Oxitropium Bromide	405558419	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.046978912&-23.6145106996	O=C(OC1CC2[N+](CC)(C)C([C@@H]3O[C@H]23)C1)[C@H](CO)c1ccccc1	O=C(OC1CC2[N+](CC)(C)C([C@@H]3O[C@H]23)C1)[C@H](CO)c1ccccc1
NCGC00522020-01	O=C(OC1CC2[N+](Cc3ccc(OCCCC)cc3)(C)C(C1)CC2)[C@H](CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonist		1	Butropium Bromide	405558868	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.0407484&0.0	O=C(OC1CC2[N+](Cc3ccc(OCCCC)cc3)(C)C(C1)CC2)[C@H](CO)c1ccccc1	O=C(OC1CC2[N+](Cc3ccc(OCCCC)cc3)(C)C(C1)CC2)[C@H](CO)c1ccccc1
NCGC00389390-01	O=C(OC1CC=2C(C)(C3C(C4C(C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1)C		Inactive	Cytochrome P450 17A1 Inhibitor&Cytochrome P450 17a1 Inhibitor		1	Abiraterone acetate	405558467	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.008770488&-14.097107428	O=C(OC1CC=2C(C)(C3C(C4C(C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1)C	O=C(OC1CC=2C(C)(C3C(C4C(C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1)C
NCGC00263175-02	O=C(OC1CCCC1)[C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)c1ccccc1	4.5999999	Active	Aminopeptidase N Inhibitor	0.0	1	Tosedostat	384568645	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-81.045154163	O=C(OC1CCCC1)[C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)c1ccccc1	O=C(OC1CCCC1)[C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)c1ccccc1
NCGC00181103-02	O=C(OC1CCN(C)CC1)C(OCCC)(c1ccccc1)c1ccccc1	4.625	Active	Muscarinic Acetylcholine Receptor Blocker&Muscarinic acetylcholine receptor Blocker	0.0	1	Propiverine hydrochloride	170466036	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-78.480868456&-49.723468813	O=C(OC1CCN(C)CC1)C(OCCC)(c1ccccc1)c1ccccc1.Cl	O=C(OC1CCN(C)CC1)C(OCCC)(c1ccccc1)c1ccccc1.Cl
NCGC00178395-04	O=C(OC1CN(CC)CCC1)C(c1ccccc1)c1ccccc1		Inactive			1	Piperidolate hydrochloride	170465927	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-25.708978068	O=C(OC1CN(CC)CCC1)C(c1ccccc1)c1ccccc1.Cl	O=C(OC1CN(CC)CCC1)C(c1ccccc1)c1ccccc1.Cl
NCGC00178783-03	O=C(OC1C[C@@H]2N(C)C(C1)CC2)[C@H](CO)c1ccccc1	4.4000001	Active	M1 Muscarinic Acetylcholine Receptor Antagonists	0.0	1	HYOSCYAMINE	405558529	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-52.808053916	O=C(OC1C[C@@H]2N(C)C(C1)CC2)[C@H](CO)c1ccccc1	O=C(OC1C[C@@H]2N(C)C(C1)CC2)[C@H](CO)c1ccccc1
NCGC00024357-07	O=C(OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1		Inactive	Muscarinic Antagonists		1	Scopolamine hydrobromide	170464830	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1.Br	O=C(OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1.Br
NCGC00179630-03	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C(O)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Homatropine hydrobromide	170465642	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C(O)c1ccccc1.Br	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C(O)c1ccccc1.Br
NCGC00161414-03	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)c1c2c([nH]c1)cccc2	4.4000001	Active	5-ht3 Antagonists	0.0	1	Tropisetron	170466432	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-67.2614243079	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)c1c2c([nH]c1)cccc2	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)c1c2c([nH]c1)cccc2
NCGC00181048-02	O=C(OC1C[C@@H]2N3[C@H](C1)CC(C(=O)C3)C2)c1c2c([nH]c1)cccc2	5.0	Active	Serotonin 3a (5-HT3a) receptor Antagonist	0.0	1	Dolasetron mesylate hydrate	225144319	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-32.3437458891	O=C(OC1C[C@@H]2N3[C@H](C1)CC(C(=O)C3)C2)c1c2c([nH]c1)cccc2	O=C(OC1C[C@@H]2N3[C@H](C1)CC(C(=O)C3)C2)c1c2c([nH]c1)cccc2
NCGC00022819-04	O=C(OC1C[C@@H]2[N+](C(C)C)(C)[C@H](C1)CC2)C(CO)c1ccccc1		Inactive	Muscarinic Antagonists		1	Ipratropium bromide	405559003	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.7200921879&-25.495976752	O=C(OC1C[C@@H]2[N+](C(C)C)(C)[C@H](C1)CC2)C(CO)c1ccccc1	O=C(OC1C[C@@H]2[N+](C(C)C)(C)[C@H](C1)CC2)C(CO)c1ccccc1
NCGC00379039-02	O=C(OC1C[C@@H]2[N+](C)(C)[C@@H]([C@H]3O[C@H]23)C1)C(O)(c1sccc1)c1sccc1	4.9000001	Active	Muscarinic M3 Antagonists	0.0	1	Tiotropium (Bromide)	405559060	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-44.5349877719	O=C(OC1C[C@@H]2[N+](C)(C)[C@@H]([C@H]3O[C@H]23)C1)C(O)(c1sccc1)c1sccc1	O=C(OC1C[C@@H]2[N+](C)(C)[C@@H]([C@H]3O[C@H]23)C1)C(O)(c1sccc1)c1sccc1
NCGC00021394-04	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CCC)CCC	4.6500001	Active	Muscarinic acetylcholine receptor M3 Antagonist&Muscarinic Acetylcholine Receptor M3 Antagonist	0.0	1	Anisotropine methylbromide	144207024	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-46.9673947684&-61.037139364	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CCC)CCC.[Br-]	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CCC)CCC.[Br-]
NCGC00015080-08	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CO)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Methylatropine nitrate	170465893	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.79746968&-21.8100555921	O=[N+]([O-])[O-].O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CO)c1ccccc1	O=[N+]([O-])[O-].O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CO)c1ccccc1
NCGC00186628-01&NCGC00186628-02	O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist&Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonists		2	Butylscopolamine bromide	124897815&170465685	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-14.363574284&0.0&12.5700041479	O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1	O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1&O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1.[Br-]
NCGC00484907-01	O=C(OC1C[C@@H]2[N+]([O-])(C)[C@H]([C@@H]3O[C@H]23)C1)C(CO)c1ccccc1	5.0500002	Active	Acetylcholinesterase Inhibitor	0.0	1	(-)-Scopolamine N-oxide	405559073	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-33.8432423	O=C(OC1C[C@@H]2[N+]([O-])(C)[C@H]([C@@H]3O[C@H]23)C1)C(CO)c1ccccc1	O=C(OC1C[C@@H]2[N+]([O-])(C)[C@H]([C@@H]3O[C@H]23)C1)C(CO)c1ccccc1
NCGC00167438-02	O=C(OC1C[C@@H]2[N+]3([C@H](C1)CC2)CCCC3)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Antagonists		1	Trospium chloride	174006890	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.969171604&0.0	O=C(OC1C[C@@H]2[N+]3([C@H](C1)CC2)CCCC3)C(O)(c1ccccc1)c1ccccc1.[Cl-]	O=C(OC1C[C@@H]2[N+]3([C@H](C1)CC2)CCCC3)C(O)(c1ccccc1)c1ccccc1.[Cl-]
NCGC00178803-03	O=C(OC1C[C@H]2[N+](C)(C)C(C1)CC2)C(O)c1ccccc1	4.4000001	Active		0.0	1	HOMATROPINE METHYLBROMIDE	405558716	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.791457644	O=C(OC1C[C@H]2[N+](C)(C)C(C1)CC2)C(O)c1ccccc1	O=C(OC1C[C@H]2[N+](C)(C)C(C1)CC2)C(O)c1ccccc1
NCGC00179456-04	O=C(OC1C[N+](C)(C)CC1)C(O)(c1ccccc1)C1CCCC1		Inactive			1	Glycopyrrolate bromide	170465427	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.1773190999&0.0	O=C(OC1C[N+](C)(C)CC1)C(O)(c1ccccc1)C1CCCC1.[Br-]	O=C(OC1C[N+](C)(C)CC1)C(O)(c1ccccc1)C1CCCC1.[Br-]
NCGC00178896-05	O=C(OC1C[N+](C)(C)CCC1)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor M3 Antagonist&Muscarinic acetylcholine receptor M3 Antagonist		1	Mepenzolate bromide	170465214	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.1559314079&-26.73196808	O=C(OC1C[N+](C)(C)CCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]	O=C(OC1C[N+](C)(C)CCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]
NCGC00094932-04	O=C(OC1[C@H](O[C@@H]2C(O)C(O)C(O)C(CO)O2)[C@@H](C)O[C@@H](O[C@H]2C(C)O[C@@H](O[C@H]3C(C)O[C@H](OC4CC5[C@](C)(C6C([C@@]7(O)[C@@](C)(C(O)C6)C(C6=CC(=O)OC6)CC7)CC5)CC4)CC3O)CC2O)C1)C	6.5	Inactive		0.0	1	NCGC00094932-04	405558692	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-42.579238816	O=C(OC1[C@H](O[C@@H]2C(O)C(O)C(O)C(CO)O2)[C@@H](C)O[C@@H](O[C@H]2C(C)O[C@@H](O[C@H]3C(C)O[C@H](OC4CC5[C@](C)(C6C([C@@]7(O)[C@@](C)(C(O)C6)C(C6=CC(=O)OC6)CC7)CC5)CC4)CC3O)CC2O)C1)C	O=C(OC1[C@H](O[C@@H]2C(O)C(O)C(O)C(CO)O2)[C@@H](C)O[C@@H](O[C@H]2C(C)O[C@@H](O[C@H]3C(C)O[C@H](OC4CC5[C@](C)(C6C([C@@]7(O)[C@@](C)(C(O)C6)C(C6=CC(=O)OC6)CC7)CC5)CC4)CC3O)CC2O)C1)C
NCGC00159403-03	O=C(OC1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC	4.4000001	Active		0.0	1	Nandrolone decanoate	26754490	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-58.6490351999	O=C(OC1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC	O=C(OC1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC
NCGC00015767-10	O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C1CCCCC1	4.6500001	Active	Muscarinic Antagonists	0.0	1	Oxybutynin chloride	405559139	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-59.2634387795	O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C1CCCCC1	O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C1CCCCC1
NCGC00181915-01	O=C(OCC(=O)N(C)C)C(C)c1cc2c(Oc3nc(C)ccc3C2)cc1		Inactive			1	Mepranoprofen arbamel	144206887	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.0&-22.76553508	O=C(OCC(=O)N(C)C)C(C)c1cc2c(Oc3nc(C)ccc3C2)cc1	O=C(OCC(=O)N(C)C)C(C)c1cc2c(Oc3nc(C)ccc3C2)cc1
NCGC00167526-02&NCGC00167526-06	O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1		Inactive	Serine Protease Inhibitor&Trypsin Inhibitor&Serine Protease Inhibitor		2	Camostat	170465784&384568326	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&27.364337772&0.0	S(=O)(=O)(O)C.O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1	S(=O)(=O)(O)C.O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1&O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1
NCGC00022043-06	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C	4.75	Active	Mineralocorticoid Receptor Agonist&Mineralocorticoid receptor Agonist	0.0	1	Deoxycorticosterone acetate	170465334	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-38.0392910452&-49.37463983	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C
NCGC00160511-01	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C(C)(C)C		Inactive			1	Desoxycorticosterone Pivalate	29216193	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.634214244	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C(C)(C)C	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C(C)(C)C
NCGC00242504-01	O=C(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3)C		Inactive	Glucocorticoid Receptor (GR) Agonist		1	Cortivazol	137275858	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3)C	O=C(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3)C
NCGC00263897-02	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCC(=O)O		Inactive			1	PREDNISOLONE HEMISUCCINATE	405559061	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&16.6804432839	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCC(=O)O	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCC(=O)O
NCGC00021277-04	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C		Inactive			1	Hydrocortisone acetate	170466796	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.31197636&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C
NCGC00021191-09&NCGC00021191-15	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C	4.4000001	Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid	0.0	2	Cortisone acetate	170464685&384568005	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	17.23518396&10.782616816&46.9449081235	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C
NCGC00261967-01	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C	4.4000001	Active	Glucocorticoid and meneralocorticoid receptor agonists/antagonists Agonist	0.0	1	Prednisolone farnesylate	170466045	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-64.952991324	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C
NCGC00021925-03&NCGC00021925-05	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)C		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid steroid&Glucocorticoid steroid		2	Prednisolone acetate	170464632&363676517	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)C
NCGC00249886-01	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CC(C)(C)C		Inactive			1	Prednisolone tebutate	170465430	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.817259444&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CC(C)(C)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CC(C)(C)C
NCGC00022248-04	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC(=O)O		Inactive			1	Hydrocortisone 21-hemisuccinate sodium salt	170465053	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC(=O)[O-].[Na+]	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC(=O)[O-].[Na+]
NCGC00249883-01	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CN(CC)CC		Inactive	Glucocorticoid Receptor Agonist&Glucocorticoid receptor Agonist		1	Hydrocortamate	170465314	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CN(CC)CC	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CN(CC)CC
NCGC00159503-02	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)C		Inactive			1	Methylprednisolone acetate	144205275	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-22.970702892	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)C
NCGC00185763-03	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CCC(=O)O		Inactive			1	6?-Methylprednisolone 21-hemisuccinate	405558627	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-22.2942752879	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CCC(=O)O	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CCC(=O)O
NCGC00263521-01&NCGC00263521-07	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)=N2)C		Inactive	Corticosteroid		2	Deflazacort	170466610&384568684	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&23.190142576&0.0	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)=N2)C	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)=N2)C
NCGC00386545-01	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C1CCCCC1)O2)C(C)C	4.5500002	Active	Glucocorticoid receptor Agonist	0.0	1	Ciclesonide	405558718	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-60.213780678	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C1CCCCC1)O2)C(C)C	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C1CCCCC1)O2)C(C)C
NCGC00167972-02	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1O[C@@H](C1CCCCC1)O2)C(C)C		Inactive	Glucocorticoid receptor Agonist		1	Ciclesonide	384568343	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.983076084	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1O[C@@H](C1CCCCC1)O2)C(C)C	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1O[C@@H](C1CCCCC1)O2)C(C)C
NCGC00249890-01	O=C(OCC(C(CC)C)(COC(=O)N)C)N		Inactive			1	Mebutamate	170465233	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.949914808&22.67934772	O=C(OCC(C(CC)C)(COC(=O)N)C)N	O=C(OCC(C(CC)C)(COC(=O)N)C)N
NCGC00015954-04	O=C(OCC(C)C)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	4.9000001	Active	Dna Topoisomerase Ii Inhibitor	0.0	1	Sobuzoxane	90341303	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-37.9164975275	O=C(OCC(C)C)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	O=C(OCC(C)C)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O
NCGC00160682-02	O=C(OCC(C)C)c1ccc(N)cc1		Inactive			1	Isocaine	170466550	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC(C)C)c1ccc(N)cc1	O=C(OCC(C)C)c1ccc(N)cc1
NCGC00160623-04	O=C(OCC(CCCC)CC)C=Cc1ccc(OC)cc1		Inactive			1	Octinoxate	170464894	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.735860088&0.0	O=C(OCC(CCCC)CC)C=Cc1ccc(OC)cc1	O=C(OCC(CCCC)CC)C=Cc1ccc(OC)cc1
NCGC00159324-04	O=C(OCC(CCCC)CC)c1c(O)cccc1		Inactive			1	2-Ethylhexyl salicylate	170465498	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.371622856&-17.3364972961	O=C(OCC(CCCC)CC)c1c(O)cccc1	O=C(OCC(CCCC)CC)c1c(O)cccc1
NCGC00090764-04	O=C(OCC(CCCC)CC)c1ccc(N(C)C)cc1		Inactive			1	2-Ethylhexyl 4-(dimethylamino)benzoate	170465499	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&11.9084377239	O=C(OCC(CCCC)CC)c1ccc(N(C)C)cc1	O=C(OCC(CCCC)CC)c1ccc(N(C)C)cc1
NCGC00183599-01	O=C(OCC(CCCC)CC)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)n2)cc1		Inactive			1	NCGC00183599-01	124894454	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.706337404&-32.12730714	O=C(OCC(CCCC)CC)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)n2)cc1	O=C(OCC(CCCC)CC)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)n2)cc1
NCGC00095133-06&NCGC00095133-09	O=C(OCC(COC(=O)C)CCn1c2nc(N)ncc2nc1)C		Inactive	Viral Dna Polymerase Inhibitor&antiviral&antiviral		2	Famciclovir	170464774&384568149	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.0076495159&0.0&0.0	O=C(OCC(COC(=O)C)CCn1c2nc(N)ncc2nc1)C	O=C(OCC(COC(=O)C)CCn1c2nc(N)ncc2nc1)C
NCGC00015429-14&NCGC00015429-18	O=C(OCC(COC(=O)N)c1ccccc1)N		Inactive	Gabaa Receptor Modulator&GABA(A) Receptor Modulators&GABA(A) Receptor Modulators		2	Felbamate	170465178&384567842	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCC(COC(=O)N)c1ccccc1)N	O=C(OCC(COC(=O)N)c1ccccc1)N
NCGC00538142-01	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)CCCCCC)c1cnccc1	4.4000001	Active	Vasoconstriction Inhibitor	0.0	1	NCGC00538142-01	405558454	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.018185972	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)CCCCCC)c1cnccc1	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)CCCCCC)c1cnccc1
NCGC00185747-02	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)COC(=O)c1cnccc1)c1cnccc1		Inactive	Hydroxycarboxylic Acid Receptor 2 Agonist&Hydroxycarboxylic acid receptor 2 Agonist		1	Niceritrol	170465789	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.5587484075&-26.823268964	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)COC(=O)c1cnccc1)c1cnccc1	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)COC(=O)c1cnccc1)c1cnccc1
NCGC00018269-05	O=C(OCC(N(C)C)(CC)c1ccccc1)c1cc(OC)c(OC)c(OC)c1	5.0500002	Active		0.0	1	Trimebutine maleate	170465734	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-69.2694871257&-34.739797936	O=C(O)/C=C\C(=O)O.O=C(OCC(N(C)C)(CC)c1ccccc1)c1cc(OC)c(OC)c(OC)c1	O=C(O)/C=C\C(=O)O.O=C(OCC(N(C)C)(CC)c1ccccc1)c1cc(OC)c(OC)c(OC)c1
NCGC00016551-04	O=C(OCC(NCCC)(C)C)c1ccccc1		Inactive	Sodium channel alpha subunits; brain (Types I, II, III) Inhibitor&Sodium Channel Alpha Subunits; Brain (types I, Ii, Iii) Inhibitor		1	Meprylcaine hydrochloride	170466009	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.813089828&-22.437233444	O=C(OCC(NCCC)(C)C)c1ccccc1.Cl	O=C(OCC(NCCC)(C)C)c1ccccc1.Cl
NCGC00159505-03	O=C(OCC(O)C)CCCCCCCCCCCCCCCCC		Inactive			1	Octadecanoic acid, monoester with 1,2-propanediol	29215477	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.205489256	O=C(OCC(O)C)CCCCCCCCCCCCCCCCC	O=C(OCC(O)C)CCCCCCCCCCCCCCCCC
NCGC00161605-02	O=C(OCC(O)C1C(O)=C(O)C(=O)O1)CCCCCCCCCCCCCCC	4.75	Active		0.0	1	L-Ascorbyl 6-palmitate	405558500	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-47.2017198159&-33.9672169065	O=C(OCC(O)C1C(O)=C(O)C(=O)O1)CCCCCCCCCCCCCCC	O=C(OCC(O)C1C(O)=C(O)C(=O)O1)CCCCCCCCCCCCCCC
NCGC00166144-03	O=C(OCC(O)CO)CCCCCCC		Inactive			1	2,3-Dihydroxypropyl octanoate	170465212	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.6707797479&-12.0016992399	O=C(OCC(O)CO)CCCCCCC	O=C(OCC(O)CO)CCCCCCC
NCGC00164528-04	O=C(OCC(O)CO)CCCCCCCCCCC		Inactive	Toxic Shock Syndrome Toxin-1 Inhibitor&Toxic shock syndrome toxin-1 Inhibitor		1	GLYCERYL LAURATE	225144258	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.211975568&0.0	O=C(OCC(O)CO)CCCCCCCCCCC	O=C(OCC(O)CO)CCCCCCCCCCC
NCGC00164529-04	O=C(OCC(O)CO)CCCCCCCCCCCCCCCCC		Inactive	Phospholipase A2 Group Iia Inhibitor&Phospholipase A2 group IIA Inhibitor		1	1-Stearoyl-rac-glycerol	170465522	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.261709236&0.0	O=C(OCC(O)CO)CCCCCCCCCCCCCCCCC	O=C(OCC(O)CO)CCCCCCCCCCCCCCCCC
NCGC00249900-01	O=C(OCC(O)CO)c1c(N)cccc1		Inactive			1	Glyceryl 1-(2-aminobenzoate)	170465551	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&24.3693856408	O=C(OCC(O)CO)c1c(N)cccc1	O=C(OCC(O)CO)c1c(N)cccc1
NCGC00018257-08	O=C(OCC(O)COc1c(OC)cccc1)N		Inactive	Muscle Relaxant&Muscle relaxant		1	Methocarbamol	170464808	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.093881908&0.0	O=C(OCC(O)COc1c(OC)cccc1)N	O=C(OCC(O)COc1c(OC)cccc1)N
NCGC00389459-01	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)C(N)C(C)C		Inactive	DNA Polymerase Inhibitor		1	Cymeval	377020277	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	27.2552874744	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)C(N)C(C)C	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)C(N)C(C)C
NCGC00387997-02	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)[C@@H](N)C(C)C	5.1500001	Active	Viral Dna Polymerase Inhibitor	0.0	1	ValganciclovirHCl	405558800	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-3.0	-35.237542348&-33.2703034548	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)[C@@H](N)C(C)C	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)[C@@H](N)C(C)C
NCGC00167500-02	O=C(OCC)/C=C(/C=C/C=C(/C=Cc1c(C)c(C)c(OC)cc1C)\C)\C		Inactive	Retinoic Acid Receptor Alpha Agonist&Retinoic acid receptor alpha Agonist		1	Etretinate	170465372	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.86703184&-19.836338052	O=C(OCC)/C=C(/C=C/C=C(/C=Cc1c(C)c(C)c(OC)cc1C)\C)\C	O=C(OCC)/C=C(/C=C/C=C(/C=Cc1c(C)c(C)c(OC)cc1C)\C)\C
NCGC00248275-02	O=C(OCC)/C=C(/C=C/C[C@H](CCCC(C)C)C)\C	4.4000001	Active		0.0	1	S-Hydroprene	225144342	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.9019262679	O=C(OCC)/C=C(/C=C/C[C@H](CCCC(C)C)C)\C	O=C(OCC)/C=C(/C=C/C[C@H](CCCC(C)C)C)\C
NCGC00249928-01	O=C(OCC)/C=C\C=C/C=C\C=C/C=C\CCCCCCCCC		Inactive			1	Eicosapentaenoic acid ethyl ester	170466007	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.1517252759&0.0	O=C(OCC)/C=C\C=C/C=C\C=C/C=C\CCCCCCCCC	O=C(OCC)/C=C\C=C/C=C\C=C/C=C\CCCCCCCCC
NCGC00081778-05	O=C(OCC)C(Oc1c2c(C(=O)N(CC(=O)Nc3cc4OCCOc4cc3)C=C2)ccc1)C		Inactive	SF1 (NR5A1) Receptor Antagonist		1	SID-7969543	384568076	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OCC)C(Oc1c2c(C(=O)N(CC(=O)Nc3cc4OCCOc4cc3)C=C2)ccc1)C	O=C(OCC)C(Oc1c2c(C(=O)N(CC(=O)Nc3cc4OCCOc4cc3)C=C2)ccc1)C
NCGC00183870-01	O=C(OCC)C1(c2ccccc2)CCN(C)CCC1	4.4000001	Active	Opioid Receptors; Mu/kappa/delta Modulator	0.0	1	Ethoheptazine hydrochloride	144206778	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.611926384	O=C(OCC)C1(c2ccccc2)CCN(C)CCC1.Cl	O=C(OCC)C1(c2ccccc2)CCN(C)CCC1.Cl
NCGC00253613-01	O=C(OCC)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1	4.9499998	Active		0.0	1	Anileridine	170465266	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-60.3027889195	O=C(OCC)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1	O=C(OCC)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1
NCGC00347947-04	O=C(OCC)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1	4.4499998	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	ITD-1	384568994	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-95.0872661553	O=C(OCC)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1	O=C(OCC)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1
NCGC00024631-03	O=C(OCC)C1=C(O)C(=O)N(Cc2ccccc2)C1		Inactive	Aldose Reductase Inhibitor		1	EBPC	384568030	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OCC)C1=C(O)C(=O)N(Cc2ccccc2)C1	O=C(OCC)C1=C(O)C(=O)N(Cc2ccccc2)C1
NCGC00018204-13	O=C(OCC)C=1n2c3c(c4c2[C@@H]2[C@](CC)(C=1)CCCN2CC4)cccc3	5.0	Active	Na channel blocker, also PDE1, IKK inhibitor	0.0	1	Vinpocetine	170465859	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-27.013925473	O=C(OCC)C=1n2c3c(c4c2[C@@H]2[C@](CC)(C=1)CCCN2CC4)cccc3	O=C(OCC)C=1n2c3c(c4c2[C@@H]2[C@](CC)(C=1)CCCN2CC4)cccc3
NCGC00021382-07	O=C(OCC)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C		Inactive	Bacterial 70s Ribosome Binding Agent&Bacterial 70S ribosome Binding Agent		1	ERYTHROMYCIN ETHYLSUCCINATE	405558563	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C	O=C(OCC)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C
NCGC00181039-02	O=C(OCC)CCCCCCC/C=C\C/C=C\CCCCC	4.4000001	Active	regulation of prostaglandin secretion Inhibitor	0.0	1	Ethyl linoleate	170466006	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.996551116	O=C(OCC)CCCCCCC/C=C\C/C=C\CCCCC	O=C(OCC)CCCCCCC/C=C\C/C=C\CCCCC
NCGC00344626-12	O=C(OCC)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1	4.0999999	Inactive	Lysine-Specific Demethylase 6A (UTX) Inhibitor	0.0	1	GSK-J4	384568727	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	75.0015590761	O=C(OCC)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1	O=C(OCC)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1
NCGC00345818-01	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)N(C)c2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1		Inactive	Thrombin Inhibitor		1	Ximelagatran	174006826	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.673407624	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)N(C)c2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)N(C)c2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1
NCGC00183598-02	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)NCc2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1		Inactive	Thrombin Inhibitor		1	Ximelagatran	405559049	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.9231088159&-17.9954274319	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)NCc2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)NCc2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1
NCGC00182973-01	O=C(OCC)COc1cc2OC(=O)C(CCN(CC)CC)=C(C)c2cc1	4.4000001	Active	Platelet Aggregation (Plug Formation) Inhibitor	0.0	1	Chromonar hydrochloride	144206761	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.2455371159	O=C(OCC)COc1cc2OC(=O)C(CCN(CC)CC)=C(C)c2cc1.Cl	O=C(OCC)COc1cc2OC(=O)C(CCN(CC)CC)=C(C)c2cc1.Cl
NCGC00182622-03	O=C(OCC)COc1cc2OC(c3ccccc3)=CC(=O)c2cc1	4.9499998	Active		0.0	1	EFLOXATE	405558472	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-55.9445422964	O=C(OCC)COc1cc2OC(c3ccccc3)=CC(=O)c2cc1	O=C(OCC)COc1cc2OC(c3ccccc3)=CC(=O)c2cc1
NCGC00160454-01	O=C(OCC)Cc1ccc(-c2ccccc2)cc1	4.1500001	Active		0.0	1	Felbinac ethyl	144205377	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-67.2862041515	O=C(OCC)Cc1ccc(-c2ccccc2)cc1	O=C(OCC)Cc1ccc(-c2ccccc2)cc1
NCGC00182996-01	O=C(OCC)Cn1c(-c2sc(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)ccc1	4.625	Active	Platelet Aggregation Inhibitor&platelet aggregation Inhibitor	0.0	1	Pamicogrel	144206832	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-70.1139563327&-31.4555818519	O=C(OCC)Cn1c(-c2sc(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)ccc1	O=C(OCC)Cn1c(-c2sc(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)ccc1
NCGC00182063-03	O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1	4.4000001	Active		0.0	1	Cadralazine	170466021	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.103254296	O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1	O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1
NCGC00016640-06	O=C(OCC)NNc1nncc2c1cccc2		Inactive	Histone Acetylation Inhibitor&histone acetylation Inhibitor		1	Todralazine hydrochloride	170465782	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.8319035549&0.0	O=C(OCC)NNc1nncc2c1cccc2.Cl	O=C(OCC)NNc1nncc2c1cccc2.Cl
NCGC00016809-07	O=C(OCC)Nc1cc2N(C(=O)CCN3CCOCC3)c3c(Sc2cc1)cccc3		Inactive	class 1c antiarrhythmic, Na(v)1.5 channel blocker&Class 1c Antiarrhythmic, Na(v)1.5 Channel Blocker		1	Moricizine hydrochloride	174006664	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.318346404&-26.484235196	O=C(OCC)Nc1cc2N(C(=O)CCN3CCOCC3)c3c(Sc2cc1)cccc3.Cl	O=C(OCC)Nc1cc2N(C(=O)CCN3CCOCC3)c3c(Sc2cc1)cccc3.Cl
NCGC00179357-05	O=C(OCC)O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1		Inactive	Glucocorticoid Receptor Agonist		1	PREDNICARBATE	405558774	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.1184927639	O=C(OCC)O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1	O=C(OCC)O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1
NCGC00179590-04	O=C(OCC)Oc1c(OC)cc(C(=O)O[C@H]2[C@H](OC)[C@@H](C(=O)OC)[C@@H]3[C@H](C2)CN2[C@@H](c4[nH]c5c(c4CC2)ccc(OC)c5)C3)cc1OC	4.5749998	Active		0.0	1	Syrosingopine	405558663	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-94.4320327892&-98.5331465808	O=C(OCC)Oc1c(OC)cc(C(=O)O[C@H]2[C@H](OC)[C@@H](C(=O)OC)[C@@H]3[C@H](C2)CN2[C@@H](c4[nH]c5c(c4CC2)ccc(OC)c5)C3)cc1OC	O=C(OCC)Oc1c(OC)cc(C(=O)O[C@H]2[C@H](OC)[C@@H](C(=O)OC)[C@@H]3[C@H](C2)CN2[C@@H](c4[nH]c5c(c4CC2)ccc(OC)c5)C3)cc1OC
NCGC00387800-02	O=C(OCC)[C@@H](C[C@H](NC(=O)CCC(=O)O)Cc1ccc(-c2ccccc2)cc1)C	4.4000001	Active		0.0	1	AHU-377	405558830	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.380511428	O=C(OCC)[C@@H](C[C@H](NC(=O)CCC(=O)O)Cc1ccc(-c2ccccc2)cc1)C	O=C(OCC)[C@@H](C[C@H](NC(=O)CCC(=O)O)Cc1ccc(-c2ccccc2)cc1)C
NCGC00178557-02	O=C(OCC)[C@@H](N[C@@H](C(=O)N1[C@H](C(=O)O)CC2C1CCCC2)C)CCc1ccccc1		Inactive			1	NCGC00178557-02&TRANDOLAPRIL	405558872	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.05728606&-33.2847167119	O=C(OCC)[C@@H](N[C@@H](C(=O)N1[C@H](C(=O)O)CC2C1CCCC2)C)CCc1ccccc1	O=C(OCC)[C@@H](N[C@@H](C(=O)N1[C@H](C(=O)O)CC2C1CCCC2)C)CCc1ccccc1
NCGC00181345-01&NCGC00263583-01	O=C(OCC)[C@@H](N[C@@H]1C(=O)N(CC(=O)O)C[C@@H](c2sccc2)SC1)CCc1ccccc1		Inactive	Angiotensin-I Converting Enzyme Inhibitor&Angiotensin-i Converting Enzyme Inhibitor&Angiotensin-I Converting Enzyme Inhibitor		2	Temocapril hydrochloride	50125938&170465944	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-26.958376952	O=C(OCC)[C@@H](N[C@@H]1C(=O)N(CC(=O)O)C[C@@H](c2sccc2)SC1)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@@H]1C(=O)N(CC(=O)O)C[C@@H](c2sccc2)SC1)CCc1ccccc1.Cl
NCGC00182039-02	O=C(OCC)[C@@H](N[C@@H]1C(=O)N2[C@H](C(=O)O)CCCN2CCC1)CCc1ccccc1		Inactive	Angiotensin-converting Enzyme Inhibitor&Angiotensin-converting enzyme Inhibitor		1	Cilazapril	225144330	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.237466556&-32.993681708	O=C(OCC)[C@@H](N[C@@H]1C(=O)N2[C@H](C(=O)O)CCCN2CCC1)CCc1ccccc1	O=C(OCC)[C@@H](N[C@@H]1C(=O)N2[C@H](C(=O)O)CCCN2CCC1)CCc1ccccc1
NCGC00181755-01	O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C1Cc2c(cccc2)C1)C)CCc1ccccc1	4.6750002	Active		0.0	1	Delapril hydrochloride	144206480	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-57.2011285352&-46.071693836	O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C1Cc2c(cccc2)C1)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C1Cc2c(cccc2)C1)C)CCc1ccccc1.Cl
NCGC00021569-09&NCGC00021569-20	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1		Inactive	Angiotensin-i Converting Enzyme Inhibitor&Angiotensin-I Converting Enzyme Inhibitor&Angiotensin-I Converting Enzyme Inhibitor		2	Enalapril maleate	170464969&384568008	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	33.2683953279&-24.33179394&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1
NCGC00181342-02	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CN(C)C1=O)C)CCc1ccccc1	5.4499998	Active		0.0	1	Imidapril hydrochloride	170466024	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.787773836	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CN(C)C1=O)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CN(C)C1=O)C)CCc1ccccc1.Cl
NCGC00178127-02&NCGC00178127-11	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCC2)C)CCc1ccccc1		Inactive	Angiotensin-I Converting Enzyme Inhibitor&Angiotensin-i Converting Enzyme Inhibitor&Angiotensin-I Converting Enzyme Inhibitor		2	Ramipril	170464731&384568353	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&38.8986607595&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCC2)C)CCc1ccccc1	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCC2)C)CCc1ccccc1
NCGC00159509-02&NCGC00274070-01	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC		Inactive	Angiotensin-I Converting Enzyme Inhibitor&Angiotensin-I Converting Enzyme Inhibitor&Angiotensin-i Converting Enzyme Inhibitor		2	Perindopril	29215484&170464836	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	6.2141339959&-15.372806012&24.706722304	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC
NCGC00263546-01	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1	4.4000001	Active	Angiotensin-converting Enzyme Inhibitor	0.0	1	Moexipril hydrochloride	170465131	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.224062552	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1.Cl
NCGC00167962-06	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cccc2)C1)C)CCc1ccccc1		Inactive	Angiotensin-converting enzyme Inhibitor&Angiotensin-converting Enzyme Inhibitor		1	Quinapril hydrochloride	170465312	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.0767226484	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cccc2)C1)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cccc2)C1)C)CCc1ccccc1.Cl
NCGC00015661-12	O=C(OCC)[N-]c1on[n+](N2CCOCC2)c1		Inactive			1	Molsidomine	170465872	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.5900999737&0.0	O=C(OCC)[N-]c1on[n+](N2CCOCC2)c1	O=C(OCC)[N-]c1on[n+](N2CCOCC2)c1
NCGC00090974-06	O=C(OCC)c1c(C(=O)OCC)cccc1		Inactive	Androgen receptor Antagonist&Androgen Receptor Antagonist		1	Diethyl phthalate	225144200	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.280248676&0.0	O=C(OCC)c1c(C(=O)OCC)cccc1	O=C(OCC)c1c(C(=O)OCC)cccc1
NCGC00160670-08	O=C(OCC)c1c(C)n(C)c2c1cc(O)cc2		Inactive	antiinfluenza drug		1	Mecarbinate	384568202	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.38829266	O=C(OCC)c1c(C)n(C)c2c1cc(O)cc2	O=C(OCC)c1c(C)n(C)c2c1cc(O)cc2
NCGC00159451-06	O=C(OCC)c1c(N)sc2c1CCN(Cc1ccccc1)C2		Inactive	Lipid Oxidation Inhibitor&lipid oxidation Inhibitor		1	Tinoridine	170465864	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.66141552&0.0	O=C(OCC)c1c(N)sc2c1CCN(Cc1ccccc1)C2	O=C(OCC)c1c(N)sc2c1CCN(Cc1ccccc1)C2
NCGC00181109-03	O=C(OCC)c1c(O)c2c(nc1)cc(OCC)c(OCCCCCCCCCC)c2	6.4499998	Active	Antiprotozoal Agent	0.0	1	Decoquinate	170466244	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.8478031135	O=C(OCC)c1c(O)c2c(nc1)cc(OCC)c(OCCCCCCCCCC)c2	O=C(OCC)c1c(O)c2c(nc1)cc(OCC)c(OCCCCCCCCCC)c2
NCGC00181161-03	O=C(OCC)c1c(O)cccc1	5.3000002	Active		0.0	1	Ethyl salicylate	170466844	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.0692304643	O=C(OCC)c1c(O)cccc1	O=C(OCC)c1c(O)cccc1
NCGC00166020-03	O=C(OCC)c1cc(N)ccc1		Inactive	Sodium channel alpha subunit Blocker&Sodium Channel Alpha Subunit Blocker		1	Ethyl 3-aminobenzoate methanesulfonic acid salt	170465717	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-55.9212203279&0.0	S(=O)(=O)(O)C.O=C(OCC)c1cc(N)ccc1	S(=O)(=O)(O)C.O=C(OCC)c1cc(N)ccc1
NCGC00016352-07	O=C(OCC)c1ccc(N)cc1		Inactive	Sodium Channel Protein Type 10 Subunit Alpha Blocker&Sodium channel protein type 10 subunit alpha Blocker		1	Benzocaine	170465463	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC)c1ccc(N)cc1	O=C(OCC)c1ccc(N)cc1
NCGC00160654-06	O=C(OCC)c1ccc(O)cc1		Inactive			1	Ethylparaben	170465715	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC)c1ccc(O)cc1	O=C(OCC)c1ccc(O)cc1
NCGC00183836-01	O=C(OCC)c1ccc(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)cc1		Inactive	Maltase-glucoamylase Inhibitor		1	Emiglitate	144206827	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	5.613253284&0.0	O=C(OCC)c1ccc(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)cc1	O=C(OCC)c1ccc(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)cc1
NCGC00167525-02&NCGC00167525-11	O=C(OCC)c1cnc(C#Cc2cc3C(C)(C)CCSc3cc2)cc1		Inactive	Retinoid Rar Agonists?&Retinoid RAR Agonist&Retinoid RAR Agonist		2	Tazarotene	170464671&384568325	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCC)c1cnc(C#Cc2cc3C(C)(C)CCSc3cc2)cc1	O=C(OCC)c1cnc(C#Cc2cc3C(C)(C)CCSc3cc2)cc1
NCGC00025176-02	O=C(OCC)c1n(C(C)c2ccccc2)cnc1		Inactive	Gabaa Receptor Modulator&GABAA Receptor Modulator		1	Etomidate	170465117	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.0330674879&0.0	O=C(OCC)c1n(C(C)c2ccccc2)cnc1	O=C(OCC)c1n(C(C)c2ccccc2)cnc1
NCGC00016799-08	O=C(OCC1(CCCC)C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)CCC(=O)O		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Prostaglandin G/H synthase 2 Inhibitor		1	Suxibuzone	170465972	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.13497572&-18.67080182	O=C(OCC1(CCCC)C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)CCC(=O)O	O=C(OCC1(CCCC)C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)CCC(=O)O
NCGC00182074-03	O=C(OCC1(COC(=O)c2cnccc2)C(O)C(COC(=O)c2cnccc2)(COC(=O)c2cnccc2)CCC1)c1cnccc1	4.5500002	Active	Cholesterol Biosynthesis Modulator	0.0	1	Nicomolol	170465790	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.3007258159	O=C(OCC1(COC(=O)c2cnccc2)C(O)C(COC(=O)c2cnccc2)(COC(=O)c2cnccc2)CCC1)c1cnccc1	O=C(OCC1(COC(=O)c2cnccc2)C(O)C(COC(=O)c2cnccc2)(COC(=O)c2cnccc2)CCC1)c1cnccc1
NCGC00093351-06	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)Cc3sccc3)[C@H]2SC1)N		Inactive	Penicillin-binding Protein 2b Inhibitor&Penicillin-binding protein 2B Inhibitor		1	Cefoxitin	170465105	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.653401008&15.4672132	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)Cc3sccc3)[C@H]2SC1)N	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)Cc3sccc3)[C@H]2SC1)N
NCGC00185751-06	O=C(OCC1=C(C(=O)OC(OC(=O)C)C)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3occc3)[C@H]2SC1)N	4.4499998	Active		0.0	1	Cefuroxime Axetil	405558449	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-65.1072719252	O=C(OCC1=C(C(=O)OC(OC(=O)C)C)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3occc3)[C@H]2SC1)N	O=C(OCC1=C(C(=O)OC(OC(=O)C)C)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3occc3)[C@H]2SC1)N
NCGC00183096-01	O=C(OCC1=C(C(=O)OCOC(=O)C(C)(C)C)N2C(=O)[C@@H](NC(=O)/C(=C\CC)/c3nc(N)sc3)[C@H]2SC1)N		Inactive	Penicillin-binding Protein Inhibitor&Penicillin-binding protein Inhibitor		1	Cefcapene pivoxil hydrochloride	144206464	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.2742321919&-19.2903782719	O=C(OCC1=C(C(=O)OCOC(=O)C(C)(C)C)N2C(=O)[C@@H](NC(=O)/C(=C\CC)/c3nc(N)sc3)[C@H]2SC1)N.Cl	O=C(OCC1=C(C(=O)OCOC(=O)C(C)(C)C)N2C(=O)[C@@H](NC(=O)/C(=C\CC)/c3nc(N)sc3)[C@H]2SC1)N.Cl
NCGC00390559-05	O=C(OCC1=C(C)OC(=O)O1)c1c2n(Cc3ccc(-c4c(C5=NOC(=O)N5)cccc4)cc3)c(OCC)nc2ccc1		Inactive	Type-1 Angiotensin Ii Receptor Antagonist&Type-1 angiotensin II receptor Antagonist		1	Azilsartan Medoxomil	405558503	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.831086504&-21.712242392	O=C(OCC1=C(C)OC(=O)O1)c1c2n(Cc3ccc(-c4c(C5=NC(=O)O[N-]5)cccc4)cc3)c(OCC)nc2ccc1	O=C(OCC1=C(C)OC(=O)O1)c1c2n(Cc3ccc(-c4c(C5=NC(=O)O[N-]5)cccc4)cc3)c(OCC)nc2ccc1
NCGC00095136-09	O=C(OCC1=C(C)OC(=O)O1)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C		Inactive			1	Olmesartan medoxomil	405558542	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-32.3451784719	O=C(OCC1=C(C)OC(=O)O1)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C	O=C(OCC1=C(C)OC(=O)O1)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C
NCGC00246835-02	O=C(OCC1C2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)CC1N(C)C21)N	4.4000001	Active	DNA-Damaging Drugs	0.0	1	Porfiromycin	384568512	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-106.3480234001	O=C(OCC1C2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)CC1N(C)C21)N	O=C(OCC1C2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)CC1N(C)C21)N
NCGC00167423-01	O=C(OCC1[N+](C)(C)CCCC1)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Bevonium metilsulfate	144205980	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.020911164&-8.5877547399	S(=O)(=O)(OC)[O-].O=C(OCC1[N+](C)(C)CCCC1)C(O)(c1ccccc1)c1ccccc1	S(=O)(=O)(OC)[O-].O=C(OCC1[N+](C)(C)CCCC1)C(O)(c1ccccc1)c1ccccc1
NCGC00018210-05	O=C(OCC=1N(C)CCCN=1)C(O)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic Acetylcholine Receptor M4 Binding Agent&Muscarinic acetylcholine receptor M4 Binding Agent		1	Oxyphencyclimine hydrochloride	170465276	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.1091720879&14.644658852	O=C(OCC=1N(C)CCCN=1)C(O)(c1ccccc1)C1CCCCC1.Cl	O=C(OCC=1N(C)CCCN=1)C(O)(c1ccccc1)C1CCCCC1.Cl
NCGC00159435-03	O=C(OCCC(C)C)/C=C/c1ccc(OC)cc1	5.0999999	Active		0.0	1	Amiloxate	29215377	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.815887652	O=C(OCCC(C)C)/C=C/c1ccc(OC)cc1	O=C(OCCC(C)C)/C=C/c1ccc(OC)cc1
NCGC00164526-02	O=C(OCCC(C)C)C(NCCN(CC)CC)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Camylofin	170465936	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.466723532	O=C(OCCC(C)C)C(NCCN(CC)CC)c1ccccc1	O=C(OCCC(C)C)C(NCCN(CC)CC)c1ccccc1
NCGC00090965-07	O=C(OCCC)c1ccc(O)cc1	5.75	Active		0.0	1	Propyl-4-hydroxybenzoate	405559148	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.20058568	O=C(OCCC)c1ccc(O)cc1	O=C(OCCC)c1ccc(O)cc1
NCGC00159383-04	O=C(OCCC)c1ccccc1	6.1500001	Active		0.0	1	Propyl benzoate	170465563	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-41.7208908448	O=C(OCCC)c1ccccc1	O=C(OCCC)c1ccccc1
NCGC00183655-01	O=C(OCCCC)C(=O)Nc1cc(-c2n[nH]nn2)ccc1	5.0500002	Active	histamine secretion by mast cell Inhibitor	0.0	1	Tazanolast	144206520	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-55.7994170864	O=C(OCCCC)C(=O)Nc1cc(-c2n[nH]nn2)ccc1	O=C(OCCCC)C(=O)Nc1cc(-c2n[nH]nn2)ccc1
NCGC00016353-08	O=C(OCCCC)c1ccc(N)cc1		Inactive			1	Butyl 4-aminobenzoate	170465735	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	22.648702192&0.0	O=C(OCCCC)c1ccc(N)cc1	O=C(OCCCC)c1ccc(N)cc1
NCGC00016354-11	O=C(OCCCC)c1ccc(O)cc1		Inactive			1	Butylparaben	170465688	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCCCC)c1ccc(O)cc1	O=C(OCCCC)c1ccc(O)cc1
NCGC00164554-06	O=C(OCCCCCCCCC(=O)O)/C=C(/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@H]2[C@H]([C@H]([C@@H](O)C)C)O2)CO1)\C		Inactive			1	Mupirocin	405558980	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-28.638685496	O=C(OCCCCCCCCC(=O)O)/C=C(/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@H]2[C@H]([C@H]([C@@H](O)C)C)O2)CO1)\C	O=C(OCCCCCCCCC(=O)O)/C=C(/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@H]2[C@H]([C@H]([C@@H](O)C)C)O2)CO1)\C
NCGC00262598-02&NCGC00262598-03	O=C(OCCCCCOC(=O)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1		Inactive	Neuromuscular Blocker		2	Atracurium besylate	225144360&384568573	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-30.88925778&0.0	O=C(OCCCCCOC(=O)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1	O=C(OCCCCCOC(=O)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1
NCGC00018277-06	O=C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)c1cc(OC)c(OC)cc1	4.9000001	Active		0.0	1	Mebeverine hydrochloride	170466168	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.2	-68.1396644447&-73.7484661955	O=C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)c1cc(OC)c(OC)cc1.Cl	O=C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)c1cc(OC)c(OC)cc1.Cl
NCGC00016411-10	O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc1		Inactive			1	Butacaine	170465459	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.265103372&-13.368938788	O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc1	O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc1
NCGC00253585-01	O=C(OCCCN1C(C)CCCC1)c1ccc(OC2CCCCC2)cc1	4.6750002	Active		0.0	1	Cyclomethycaine	170465528	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-66.0158726352&-89.8225118873	O=C(OCCCN1C(C)CCCC1)c1ccc(OC2CCCCC2)cc1	O=C(OCCCN1C(C)CCCC1)c1ccc(OC2CCCCC2)cc1
NCGC00167552-01	O=C(OCCCN1C(C)CCCC1)c1ccccc1	4.4000001	Active	Nicotinic Acetylcholine Receptor Blocker&Nicotinic acetylcholine receptor  Blocker	0.0	1	Piperocaine hydrochloride	144206100	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-37.602499348&-54.2682479224	O=C(OCCCN1C(C)CCCC1)c1ccccc1.Cl	O=C(OCCCN1C(C)CCCC1)c1ccccc1.Cl
NCGC00016747-07	O=C(OCCCN1CCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CCC1)c1cc(OC)c(OC)c(OC)c1	4.6750002	Active	Equilibrative Nucleoside Transporter 2 Inhibitor&Equilibrative nucleoside transporter 2 Inhibitor	0.0	1	Dilazep	170465831	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-72.1722873375&-36.103810528	O=C(OCCCN1CCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CCC1)c1cc(OC)c(OC)c(OC)c1	O=C(OCCCN1CCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CCC1)c1cc(OC)c(OC)c(OC)c1
NCGC00167469-02	O=C(OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1)CC/C=C/CCC(=O)OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1		Inactive	Muscle-type Nicotinic Acetylcholine Receptor Antagonist		1	NCGC00167469-02	405558707	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.3313253159&0.0	O=C(OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1)CC/C=C/CCC(=O)OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1	O=C(OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1)CC/C=C/CCC(=O)OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1
NCGC00164589-02	O=C(OCCCc1ccccc1)N		Inactive			1	Phenprobamate	170465902	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.802163852&0.0	O=C(OCCCc1ccccc1)N	O=C(OCCCc1ccccc1)N
NCGC00018213-06	O=C(OCCN(C)C)C(c1ccccc1)C1(O)CCCC1		Inactive	Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonist		1	Cyclopentolate hydrochloride	170464720	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.459028376	O=C(OCCN(C)C)C(c1ccccc1)C1(O)CCCC1.Cl	O=C(OCCN(C)C)C(c1ccccc1)C1(O)CCCC1.Cl
NCGC00016049-07	O=C(OCCN(C)C)c1ccc(NCCCC)cc1	4.4000001	Active	Sodium Channel Alpha Subunit Blocker	0.0	1	Tetracaine hydrochloride	170465190	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-52.0526246916	O=C(OCCN(C)C)c1ccc(NCCCC)cc1.Cl	O=C(OCCN(C)C)c1ccc(NCCCC)cc1.Cl
NCGC00178213-05	O=C(OCCN(CC)CC)C(Cc1c2c(ccc1)cccc2)CC1OCCC1	4.5749998	Active	Serotonin 2 (5-ht2) Receptor Antagonist&Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Nafronyl oxalate	170465616	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-86.4094310108&-70.062749044	O=C(O)C(=O)O.O=C(OCCN(CC)CC)C(Cc1c2c(ccc1)cccc2)CC1OCCC1	O=C(O)C(=O)O.O=C(OCCN(CC)CC)C(Cc1c2c(ccc1)cccc2)CC1OCCC1
NCGC00181082-01	O=C(OCCN(CC)CC)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M4 Antagonist&Muscarinic Acetylcholine Receptor M4 Antagonist		1	Benzactyzine methobromide	144206254	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.876778548	BrC.O=C(OCCN(CC)CC)C(O)(c1ccccc1)c1ccccc1	BrC.O=C(OCCN(CC)CC)C(O)(c1ccccc1)c1ccccc1
NCGC00015368-11	O=C(OCCN(CC)CC)C1(C2CCCCC2)CCCCC1	4.8499999	Active	Muscarinic Acetylcholine Receptor M3 Antagonist&Muscarinic acetylcholine receptor M3 Antagonist	0.0	1	Dicyclomine	170464896	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.4	-40.0774257392&-45.310135904	O=C(OCCN(CC)CC)C1(C2CCCCC2)CCCCC1	O=C(OCCN(CC)CC)C1(C2CCCCC2)CCCCC1
NCGC00167426-03	O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1	4.5999999	Active		0.0	1	Caramiphen edisylate	170465518	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-44.965552789&-74.3997371079	S(=O)(=O)(O)CCS(=O)(=O)O.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1	S(=O)(=O)(O)CCS(=O)(=O)O.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1
NCGC00016505-06	O=C(OCCN(CC)CC)c1c(OCCC)cc(N)cc1	4.4000001	Active		0.0	1	PROPOXYCAINE HYDROCHLORIDE	405558691	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-65.412612832	O=C(OCCN(CC)CC)c1c(OCCC)cc(N)cc1	O=C(OCCN(CC)CC)c1c(OCCC)cc(N)cc1
NCGC00016991-05&NCGC00016991-07	O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1		Inactive	Sodium Channel Inhibitor		2	Proparacaine	170465400&384567972	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-22.7898296959&0.0&-18.3773021721	O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1.Cl	O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1.Cl&O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1
NCGC00016667-04	O=C(OCCN(CC)CC)c1cc(OCCCC)c(N)cc1	4.8499999	Active	Sodium channel alpha subunit Blocker	0.0	1	Benoxinate hydrochloride	170464771	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.0523127411	O=C(OCCN(CC)CC)c1cc(OCCCC)c(N)cc1.Cl	O=C(OCCN(CC)CC)c1cc(OCCCC)c(N)cc1.Cl
NCGC00183003-01	O=C(OCCN(CC)CC)c1ccc(NCCCC)cc1	4.875	Active		0.0	1	Depolipon	144206803	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-58.4058380284&-48.56506425	O=C(OCC[NH+](CC)CC)c1ccc(NCCCC)cc1.[Cl-]	O=C(OCC[NH+](CC)CC)c1ccc(NCCCC)cc1.[Cl-]
NCGC00159450-04	O=C(OCCN(CC)CC)c1ccc(OCC)cc1	4.4000001	Active		0.0	1	Parethoxycaine	170465538	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.886434208	O=C(OCCN(CC)CC)c1ccc(OCC)cc1	O=C(OCCN(CC)CC)c1ccc(OCC)cc1
NCGC00167584-01	O=C(OCCN(CC)CC)c1cnccc1		Inactive	Cell Growth Inhibitor&cell growth Inhibitor		1	Nicametate citrate	144206129	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.7030964559&-24.4783512485	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C(OCCN(CC)CC)c1cnccc1	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C(OCCN(CC)CC)c1cnccc1
NCGC00538148-01	O=C(OCCN(CCO)CCO)c1c(O)cccc1	5.1999998	Active		0.0	1	NCGC00538148-01	405558798	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-37.6077400999	O=C(OCCN(CCO)CCO)c1c(O)cccc1	O=C(OCCN(CCO)CCO)c1c(O)cccc1
NCGC00249909-01	O=C(OCCN1C(C)C(c2ccccc2)OCC1)C(CC)c1ccccc1		Inactive	Monoamine Transporters; Norepinephrine & Dopamine Agonist&Monoamine transporters; Norepinephrine & dopamine Agonist		1	Fenbutrazate	170465618	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.436337364&-11.3274484719	O=C(OCCN1C(C)C(c2ccccc2)OCC1)C(CC)c1ccccc1	O=C(OCCN1C(C)C(c2ccccc2)OCC1)C(CC)c1ccccc1
NCGC00181083-01	O=C(OCCN1CCCCC1)C(O)(c1ccccc1)c1ccccc1		Inactive			1	Piperilate hydrochloride	144206255	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.093680168	O=C(OCCN1CCCCC1)C(O)(c1ccccc1)c1ccccc1.Cl	O=C(OCCN1CCCCC1)C(O)(c1ccccc1)c1ccccc1.Cl
NCGC00016636-05	O=C(OCCN1CCCCC1)c1c2OC(c3ccccc3)=C(C)C(=O)c2ccc1	4.9000001	Active	Muscarinic Acetylcholine Receptors; M1 & M2 Antagonist	0.0	1	Flavoxate hydrochloride	170466285	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.6998869583	O=C(OCCN1CCCCC1)c1c2OC(c3ccccc3)=C(C)C(=O)c2ccc1.Cl	O=C(OCCN1CCCCC1)c1c2OC(c3ccccc3)=C(C)C(=O)c2ccc1.Cl
NCGC00183103-01	O=C(OCCO)CCC(=O)Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C	4.5500002	Active		0.0	1	Tocophersolan	144206517	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-112.2674209133	O=C(OCCO)CCC(=O)Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C	O=C(OCCO)CCC(=O)Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C
NCGC00188435-01	O=C(OCCO)CCCCCCCCCCCCCCCCC	4.4499998	Active		0.0	1	2-Hydroxyethyl octadecanoate	144206587	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.8975723379	O=C(OCCO)CCCCCCCCCCCCCCCCC	O=C(OCCO)CCCCCCCCCCCCCCCCC
NCGC00159379-04	O=C(OCCO)c1c(O)cccc1		Inactive			1	BETA-HYDROXYETHYL SALICYLATE	225144223	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	5.4456261759&-13.201453236	O=C(OCCO)c1c(O)cccc1	O=C(OCCO)c1c(O)cccc1
NCGC00346826-01	O=C(OCCOC)C1=C(C)NC2=C(C(=O)CC(c3c(OC)cccc3)C2)C1c1cc(O)ccc1	5.9000001	Active	Smoothened (Smo) Receptor Antagonist	0.0	1	HPI-1	174006691	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-72.507160302	O=C(OCCOC)C1=C(C)NC2=C(C(=O)CC(c3c(OC)cccc3)C2)C1c1cc(O)ccc1	O=C(OCCOC)C1=C(C)NC2=C(C(=O)CC(c3c(OC)cccc3)C2)C1c1cc(O)ccc1
NCGC00249899-01	O=C(OCCOCC)C=Cc1ccc(OC)cc1	6.1500001	Active		0.0	1	Cinoxate	170465555	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-36.287145035	O=C(OCCOCC)C=Cc1ccc(OC)cc1	O=C(OCCOCC)C=Cc1ccc(OC)cc1
NCGC00249906-01	O=C(OCCOCCCC)c1cnccc1		Inactive	positive regulation of vasodilation Activator&Positive Regulation Of Vasodilation Activator		1	Nicoboxil	170465989	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	7.411985456&9.805807236	O=C(OCCOCCCC)c1cnccc1	O=C(OCCOCCCC)c1cnccc1
NCGC00389219-01	O=C(OCCOCCN(CC)CC)C(CC)(CC)c1ccccc1	4.8499999	Active		0.0	1	Oxeladin Citrate	405558942	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-71.183273096&-60.4974474122	O=C(OCCOCCN(CC)CC)C(CC)(CC)c1ccccc1	O=C(OCCOCCN(CC)CC)C(CC)(CC)c1ccccc1
NCGC00024595-08	O=C(OCCOCCN(CC)CC)C1(c2ccccc2)CCCC1	4.7750001	Active	Sigma-1 receptor Agonist&Sigma-1 Receptor Agonist	0.0	1	Carbetapentane	170465562	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-55.9311636728&-31.341916592	O=C(OCCOCCN(CC)CC)C1(c2ccccc2)CCCC1	O=C(OCCOCCN(CC)CC)C1(c2ccccc2)CCCC1
NCGC00016362-05	O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1	4.3499999	Inactive	Slowly Adapting Pulmonary Stretch Receptor Inhibitor	0.0	1	Benzonatate	170465391	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-25.241231585	O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1	O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1
NCGC00015854-10	O=C(OCC[N+](C(C)C)(C(C)C)C)C1c2c(Oc3c1cccc3)cccc2		Inactive	Muscarinic Acetylcholine Receptor M4 Antagonist&Muscarinic acetylcholine receptor M4 Antagonist		1	Propantheline bromide	170464881	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-37.2843849239&10.798065324	O=C(OCC[N+](C(C)C)(C(C)C)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]	O=C(OCC[N+](C(C)C)(C(C)C)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]
NCGC00018123-07	O=C(OCC[N+](C)(C)C)C		Inactive	Acetylcholinesterase Substrate		1	Acetylcholine chloride	170464783	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.1572909121&-24.8848605799	O=C(OCC[N+](C)(C)C)C.[Cl-]	O=C(OCC[N+](C)(C)C)C.[Cl-]
NCGC00015971-05	O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C		Inactive	Muscle-type Nicotinic Acetylcholine Receptor Agonist&Muscle-type nicotinic acetylcholine receptor Agonist		1	Succinylcholine chloride	170464625	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.8546701135&0.0	O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]	O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]
NCGC00015237-07	O=C(OCC[N+](C)(C)C)N		Inactive	Acetylcholinesterase Substrate		1	Carbachol	170464972	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.470122076&37.3671755796	O=C(OCC[N+](C)(C)C)N.[Cl-]	O=C(OCC[N+](C)(C)C)N.[Cl-]
NCGC00185757-01	O=C(OCC[N+](CC)(CC)C)C(C(CC)C)c1ccccc1	4.6999998	Active	Muscarinic acetylcholine receptor M3 Antagonist&Muscarinic Acetylcholine Receptor M3 Antagonist	0.0	1	Diethylmethyl(2-3-methyl-2-phenylvaleryloxy)-ethyl)ammonium bromide	144207102	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-39.2200261795&-31.1441638999	O=C(OCC[N+](CC)(CC)C)C(C(CC)C)c1ccccc1.[Br-]	O=C(OCC[N+](CC)(CC)C)C(C(CC)C)c1ccccc1.[Br-]
NCGC00018256-06	O=C(OCC[N+](CC)(CC)C)C(O)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonist		1	Oxyphenonium bromide	170465282	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC[N+](CC)(CC)C)C(O)(c1ccccc1)C1CCCCC1.[Br-]	O=C(OCC[N+](CC)(CC)C)C(O)(c1ccccc1)C1CCCCC1.[Br-]
NCGC00016239-04	O=C(OCC[N+](CC)(CC)C)C1c2c(Oc3c1cccc3)cccc2		Inactive	Histamine H2 Receptor Antagonist&Histamine H2 receptor Antagonist		1	Methantheline bromide	170465350	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCC[N+](CC)(CC)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]	O=C(OCC[N+](CC)(CC)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]
NCGC00183852-01	O=C(OCC[N+](CC)(CC)CC)C(C1CCCC1)C1CCCC1		Inactive	Muscarinic acetylcholine receptor Antagonist&Muscarinic Acetylcholine Receptor Antagonist		1	Diponium bromide	144206825	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&39.23998766	O=C(OCC[N+](CC)(CC)CC)C(C1CCCC1)C1CCCC1.[Br-]	O=C(OCC[N+](CC)(CC)CC)C(C1CCCC1)C1CCCC1.[Br-]
NCGC00167509-02	O=C(OCC[N+]1(CC)CCCCC1)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist		1	Pipethanate ethylbromide	170465967	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-29.268469832	O=C(OCC[N+]1(CC)CCCCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]	O=C(OCC[N+]1(CC)CCCCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]
NCGC00181788-01	O=C(OCOC(=O)C1=C(C)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C	4.4000001	Active		0.0	1	Cefetamet pivoxil HCl	144206472	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-56.3959123439	O=C(OCOC(=O)C1=C(C)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C.Cl	O=C(OCOC(=O)C1=C(C)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C.Cl
NCGC00179344-04	O=C(OCOC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12)C(C)(C)C	4.6500001	Active		0.0	1	Pivmecillinam	405558689	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-53.0839843671&-71.35593522	O=C(OCOC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12)C(C)(C)C	O=C(OCOC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12)C(C)(C)C
NCGC00181308-01	O=C(OC[C@@H](O)[C@@H]1[C@H](O)[C@@H](O)CO1)CCCCCCCCCCCCCCC	5.0	Active		0.0	1	Sorbitan monohexadecanoate	144206336	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.9221494577	O=C(OC[C@@H](O)[C@@H]1[C@H](O)[C@@H](O)CO1)CCCCCCCCCCCCCCC	O=C(OC[C@@H](O)[C@@H]1[C@H](O)[C@@H](O)CO1)CCCCCCCCCCCCCCC
NCGC00179867-02	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1	4.4499998	Active		0.0	1	NCGC00179867-02	405559098	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-96.4272237783	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1
NCGC00160615-03	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@@H](O[C@@]2(COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O2)O1)C		Inactive			1	Sucrose octaacetate	170465525	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.693578132&-16.095566796	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@@H](O[C@@]2(COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O2)O1)C	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@@H](O[C@@]2(COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O2)O1)C
NCGC00186054-01	O=C(OC[C@@H]1[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)O1)c1cc(OC(=O)c2cc(O)c(O)c(O)c2)c(O)c(O)c1	4.4000001	Active	Beta-secretase 1 Inhibitor	0.0	1	Tannic acid	124896727	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-66.196599376&-112.9929090456	O=C(OC[C@@H]1[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)O1)c1cc(OC(=O)c2cc(O)c(O)c(O)c2)c(O)c(O)c1	O=C(OC[C@@H]1[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)O1)c1cc(OC(=O)c2cc(O)c(O)c(O)c2)c(O)c(O)c1
NCGC00181140-02	O=C(OC[C@H](OC)C=1C(=O)C(N2CC2)=C(C)C(=O)C=1N1CC1)N	4.4000001	Active	Cell Growth Inhibitor	0.0	1	Carboquone	124893654	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-61.6035756039	O=C(OC[C@H](OC)C=1C(=O)C(N2CC2)=C(C)C(=O)C=1N1CC1)N	O=C(OC[C@H](OC)C=1C(=O)C(N2CC2)=C(C)C(=O)C=1N1CC1)N
NCGC00183020-01	O=C(OC[C@H](OC)COC(=O)N1CCC(OC(=O)NCCCCCCCCCCCCCCCCCC)CC1)N(C(=O)c1c(OC)cccc1)Cc1[n+](CC)cccc1	5.0	Active	Platelet activating factor receptor Antagonist	0.0	1	Minopafant	144206826	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-98.5402813789	O=C(OC[C@H](OC)COC(=O)N1CCC(OC(=O)NCCCCCCCCCCCCCCCCCC)CC1)N(C(=O)c1c(OC)cccc1)Cc1[n+](CC)cccc1.[Cl-]	O=C(OC[C@H](OC)COC(=O)N1CCC(OC(=O)NCCCCCCCCCCCCCCCCCC)CC1)N(C(=O)c1c(OC)cccc1)Cc1[n+](CC)cccc1.[Cl-]
NCGC00182709-03	O=C(OC[C@H]1OC(C)(C)OC1)CCc1ccc(OC[C@@H](O)CNCCNC(=O)N2CCOCC2)cc1		Inactive	Beta-1 adrenergic receptor Antagonist&Beta-1 Adrenergic Receptor Antagonist		1	Landiolol hydrochloride	170465910	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OC[C@H]1OC(C)(C)OC1)CCc1ccc(OC[C@@H](O)CNCCNC(=O)N2CCOCC2)cc1.Cl	O=C(OC[C@H]1OC(C)(C)OC1)CCc1ccc(OC[C@@H](O)CNCCNC(=O)N2CCOCC2)cc1.Cl
NCGC00174736-02	O=C(OC[C@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)NC(=O)C=C2)O1)C		Inactive	Pyrimidine Antagonist		1	Uridine triacetate	174006168	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-29.3094183351&0.0	O=C(OC[C@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)NC(=O)C=C2)O1)C	O=C(OC[C@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)NC(=O)C=C2)O1)C
NCGC00262957-01	O=C(OCc1cc(OC(=O)[C@H]2C(C)(C)S[C@@H]3[C@H](NC(=O)Cc4ccccc4)C(=O)N23)ccc1)C(C)C	5.5500002	Active		0.0	1	Tobicillin	170466044	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-39.4040477445	O=C(OCc1cc(OC(=O)[C@H]2C(C)(C)S[C@@H]3[C@H](NC(=O)Cc4ccccc4)C(=O)N23)ccc1)C(C)C	O=C(OCc1cc(OC(=O)[C@H]2C(C)(C)S[C@@H]3[C@H](NC(=O)Cc4ccccc4)C(=O)N23)ccc1)C(C)C
NCGC00094561-06	O=C(OCc1cc(Oc2ccccc2)ccc1)C1C(C)(C)C1/C=C(\C)/C		Inactive			1	Phenothrin	170465585	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(OCc1cc(Oc2ccccc2)ccc1)C1C(C)(C)C1/C=C(\C)/C	O=C(OCc1cc(Oc2ccccc2)ccc1)C1C(C)(C)C1/C=C(\C)/C
NCGC00346743-03	O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc1ccc(C(=O)NO)cc1	4.4000001	Active	HDAC Inhibitor	0.0	1	Givinostat hydrochloride	384568939	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-49.24084656	O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc1ccc(C(=O)NO)cc1	O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc1ccc(C(=O)NO)cc1
NCGC00485261-01	O=C(OCc1ccc(CNCCCCN(O)C(=O)/C=C/C(=O)OC)cc1)Nc1c2c(ccc1)cccc2		Inactive	Lysine-specific demethylase 4E Inhibitor		1	Methylstat	363681270	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.3118047759	O=C(OCc1ccc(CNCCCCN(O)C(=O)/C=C/C(=O)OC)cc1)Nc1c2c(ccc1)cccc2	O=C(OCc1ccc(CNCCCCN(O)C(=O)/C=C/C(=O)OC)cc1)Nc1c2c(ccc1)cccc2
NCGC00166124-03	O=C(OCc1ccccc1)C=Cc1ccccc1	5.3000002	Active		0.0	1	Benzyl cinnamate	170465584	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.7555633547	O=C(OCc1ccccc1)C=Cc1ccccc1	O=C(OCc1ccccc1)C=Cc1ccccc1
NCGC00345806-02	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)C=O)CC(C)C)Cc1ccccc1	4.8499999	Active	Cathepsin S Inhibitor	0.0	1	Cathepsin S Inhibitor	384568752	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-85.5488097738	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)C=O)CC(C)C)Cc1ccccc1	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)C=O)CC(C)C)Cc1ccccc1
NCGC00161679-02	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CC(C)C)CC(C)C)CC(C)C	6.0999999	Inactive	Proteasome Inhibitor	0.0	1	MG-132	26755342	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-32.9339814392	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CC(C)C)CC(C)C)CC(C)C	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CC(C)C)CC(C)C)CC(C)C
NCGC00163432-03	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C	5.5500002	Inactive	Proteasome Inhibitor	0.0	1	Calpeptin	384568239	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-66.7809904025	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C
NCGC00164155-02	O=C(OCc1ccccc1)c1ccc(O)cc1	5.5999999	Active	Estrogen Receptor Alpha Agonist	0.0	1	Benzylparaben	170465711	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-41.8162687395	O=C(OCc1ccccc1)c1ccc(O)cc1	O=C(OCc1ccccc1)c1ccc(O)cc1
NCGC00094981-07	O=C(OCc1ccccc1)c1ccccc1	6.1999998	Active		0.0	1	Benzyl benzoate	170465382	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-31.9442218719	O=C(OCc1ccccc1)c1ccccc1	O=C(OCc1ccccc1)c1ccccc1
NCGC00166105-04	O=C(OCc1ccccc1)c1cnccc1		Inactive			1	BENZYL NICOTINATE	225144269	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.221970684&0.0	O=C(OCc1ccccc1)c1cnccc1	O=C(OCc1ccccc1)c1cnccc1
NCGC00165833-10	O=C(OCc1cnccc1)NCc1ccc(C(=O)Nc2c(N)cccc2)cc1		Inactive	HDAC Inhibitor		1	Entinostat	384568288	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(OCc1cnccc1)NCc1ccc(C(=O)Nc2c(N)cccc2)cc1	O=C(OCc1cnccc1)NCc1ccc(C(=O)Nc2c(N)cccc2)cc1
NCGC00074022-02	O=C(OCc1nc(COC(=O)NC)ccc1)NC		Inactive	Bradykinin B2 Receptor Antagonist&Bradykinin B2 receptor Antagonist		1	Pyricarbate	144204540	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.145093512&0.0	O=C(OCc1nc(COC(=O)NC)ccc1)NC	O=C(OCc1nc(COC(=O)NC)ccc1)NC
NCGC00249924-01	O=C(OCc1ncccc1)C(C)c1ccc(CC(C)C)cc1		Inactive			1	Ibuprofen piconol	170465895	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.2554903839&0.0	O=C(OCc1ncccc1)C(C)c1ccc(CC(C)C)cc1	O=C(OCc1ncccc1)C(C)c1ccc(CC(C)C)cc1
NCGC00386235-04	O=C(OCc1scnc1)N[C@H](CC[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)CCN1CCOCC1)Cc1ccccc1)Cc1ccccc1	4.9000001	Active	Cytochrome P450 3A Inhibitor	0.0	1	Cobicistat	405558682	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.3	-76.7759509857	O=C(OCc1scnc1)N[C@H](CC[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)CCN1CCOCC1)Cc1ccccc1)Cc1ccccc1	O=C(OCc1scnc1)N[C@H](CC[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)CCN1CCOCC1)Cc1ccccc1)Cc1ccccc1
NCGC00159462-04	O=C(OCc1scnc1)N[C@H]([C@@H](O)C[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)C(C)C)Cc1ccccc1)Cc1ccccc1	4.5	Active	HIV Protease Inhibitors	0.0	1	Ritonavir	170464891	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-70.1202554939	O=C(OCc1scnc1)N[C@H]([C@@H](O)C[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)C(C)C)Cc1ccccc1)Cc1ccccc1	O=C(OCc1scnc1)N[C@H]([C@@H](O)C[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)C(C)C)Cc1ccccc1)Cc1ccccc1
NCGC00242478-04	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(NCCN(C)C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	5.4000001	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	Alvespimycin hydrochloride	384568491	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-110.4922864202	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(NCCN(C)C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(NCCN(C)C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N
NCGC00162413-14	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(OC)C(=O)C=2)C[C@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Geldanamycin	384568226	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.158245184	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(OC)C(=O)C=2)C[C@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(OC)C(=O)C=2)C[C@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N
NCGC00346438-03	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)Nc2c(O)c(c(NCC=C)c(O)c2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	5.5	Inactive	Heat shock protein HSP90 Inhibitor	0.0	1	Retaspimycin (Hydrochloride)	405558694	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-8.1796547199	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)Nc2c(O)c(c(NCC=C)c(O)c2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)Nc2c(O)c(c(NCC=C)c(O)c2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N
NCGC00179431-03	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3C(=O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@H]4C[C@](C(=O)O)(C)CC2)CC1)CCC(=O)O		Inactive	Gap Junction Assembly Inhibitor&gap junction assembly Inhibitor		1	Carbenoxolone sodium	170465951	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3C(=O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@H]4C[C@](C(=O)[O-])(C)CC2)CC1)CCC(=O)[O-].[Na+].[Na+]	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3C(=O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@H]4C[C@](C(=O)[O-])(C)CC2)CC1)CCC(=O)[O-].[Na+].[Na+]
NCGC00181756-01	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@@H]([C@@H](CC/C=C(\C)/C)C)CC5)CC4)CC2)C3)CC1)/C=C/c1cc(OC)c(O)cc1		Inactive	Lipid Oxidation Inhibitor&lipid oxidation Inhibitor		1	gamma-Oryzanol	144206489	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.2345849079&-15.0216725039	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@@H]([C@@H](CC/C=C(\C)/C)C)CC5)CC4)CC2)C3)CC1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@@H]([C@@H](CC/C=C(\C)/C)C)CC5)CC4)CC2)C3)CC1)/C=C/c1cc(OC)c(O)cc1
NCGC00522039-01	O=C(O[C@@H]1C(C)=C(C/C=C\C=C)C(=O)C1)[C@H]1[C@H](C=C(C)C)C1(C)C	5.5500002	Active	Trypanosoma brucei rhodesiense Inhibitor	0.0	1	Pyrethrin 1	405558749	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-34.8616632982	O=C(O[C@@H]1C(C)=C(C/C=C\C=C)C(=O)C1)[C@H]1[C@H](C=C(C)C)C1(C)C	O=C(O[C@@H]1C(C)=C(C/C=C\C=C)C(=O)C1)[C@H]1[C@H](C=C(C)C)C1(C)C
NCGC00024995-15&NCGC00024995-43	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)(C3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1	9.0	Inactive	Tubulin depolymerization Inhibitor&Tubulin Depolymerization Inhibitor	0.0	2	Paclitaxel	384568039&405558867	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&5.0	-33.7135304281	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)(C3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)(C3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1
NCGC00346661-05	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C/C)/C)c1ccccc1	9.0	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Cephalomannine	384568892	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-8.1811033281	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C/C)/C)c1ccccc1	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C/C)/C)c1ccccc1
NCGC00025155-01	O=C(O[C@@H]1C(OC)=CC23N(CCc4c([C@H]12)cc1OCOc1c4)CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C	5.3000002	Active	Alkaloid	0.0	1	Omacetaxine mepesuccinate	11114076	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-32.48737438	O=C(O[C@@H]1C(OC)=CC23N(CCc4c([C@H]12)cc1OCOc1c4)CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C	O=C(O[C@@H]1C(OC)=CC23N(CCc4c([C@H]12)cc1OCOc1c4)CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C
NCGC00025155-07	O=C(O[C@@H]1C(OC)=C[C@]23N(CCc4c([C@H]12)cc1OCOc1c4)CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C	5.5250001	Active	Alkaloid	0.0	1	Omacetaxine mepesuccinate	405558996	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-1.1	-63.6751797704&-99.7863526147	O=C(O[C@@H]1C(OC)=C[C@]23N(CCc4c([C@H]12)cc1OCOc1c4)CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C	O=C(O[C@@H]1C(OC)=C[C@]23N(CCc4c([C@H]12)cc1OCOc1c4)CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C
NCGC00253579-01	O=C(O[C@@H]1C2(C)C(C3C(C4C(=C[C@@H](OC(=O)CC)CC4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Agonist		1	Bolandiol dipropionate	170465909	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-11.184945104&0.0	O=C(O[C@@H]1C2(C)C(C3C(C4C(=C[C@@H](OC(=O)CC)CC4)CC3)CC2)CC1)CC	O=C(O[C@@H]1C2(C)C(C3C(C4C(=C[C@@H](OC(=O)CC)CC4)CC3)CC2)CC1)CC
NCGC00168778-06	O=C(O[C@@H]1C2CCN(C1)CC2)N1[C@@H](c2ccccc2)c2c(cccc2)CC1	4.7249999	Active	Muscarinic acetylcholine receptor M5 Antagonist&Muscarinic Acetylcholine Receptor M5 Antagonist	0.0	1	Solifenacin (hydrochloride)	405558475	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-57.3924338568&-71.1819337755	O=C(O[C@@H]1C2CCN(C1)CC2)N1[C@@H](c2ccccc2)c2c(cccc2)CC1	O=C(O[C@@H]1C2CCN(C1)CC2)N1[C@@H](c2ccccc2)c2c(cccc2)CC1
NCGC00386257-02	O=C(O[C@@H]1C2CC[N+](CCCOc3ccccc3)(C1)CC2)C(O)(c1sccc1)c1sccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist&Muscarinic Acetylcholine Receptor M3 Antagonist		1	Aclidinium (Bromide)	405559015	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.8219410839&0.0	O=C(O[C@@H]1C2CC[N+](CCCOc3ccccc3)(C1)CC2)C(O)(c1sccc1)c1sccc1	O=C(O[C@@H]1C2CC[N+](CCCOc3ccccc3)(C1)CC2)C(O)(c1sccc1)c1sccc1
NCGC00387792-03	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CC=C)CC=C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)(C(=O)CC2)C1)C		Inactive			1	PX-866	384569161	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.710258144	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CC=C)CC=C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)(C(=O)CC2)C1)C	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CC=C)CC=C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)(C(=O)CC2)C1)C
NCGC00166138-04	O=C(O[C@@H]1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](OC(=O)C)(C#C)CC4)CC3)CC2)CC1)C	4.4000001	Active	Progesterone Receptor Agonist&Progesterone receptor Agonist	0.0	1	Ethynodiol diacetate	170464933	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-88.869777168&-94.2746424799	O=C(O[C@@H]1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](OC(=O)C)(C#C)CC4)CC3)CC2)CC1)C	O=C(O[C@@H]1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](OC(=O)C)(C#C)CC4)CC3)CC2)CC1)C
NCGC00166271-02	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)C		Inactive			1	Pregnenolone acetate	405558657	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.582428816&45.3180915712	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)C	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)C
NCGC00507775-01	O=C(O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(=O)C)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@@]1(OC(=O)C)C)CC	4.4000001	Active	Ribosome Inhibitor	0.0	1	Midecamycin Acetate	405558744	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.275740012	O=C(O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(=O)C)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@@]1(OC(=O)C)C)CC	O=C(O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(=O)C)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@@]1(OC(=O)C)C)CC
NCGC00017338-03	O=C(O[C@@H]1[C@@H](CCCCCC)C(=O)O[C@H](C)[C@H](NC(=O)c2c(O)c(NC=O)ccc2)C(=O)O[C@H]1C)CC(C)C	9.0	Inactive	Antifungal Agent	0.0	1	Antimycin A	124883057	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-12.9817578519	O=C(O[C@@H]1[C@@H](CCCCCC)C(=O)O[C@H](C)[C@H](NC(=O)c2c(O)c(NC=O)ccc2)C(=O)O[C@H]1C)CC(C)C	O=C(O[C@@H]1[C@@H](CCCCCC)C(=O)O[C@H](C)[C@H](NC(=O)c2c(O)c(NC=O)ccc2)C(=O)O[C@H]1C)CC(C)C
NCGC00016060-14	O=C(O[C@@H]1[C@@H](OC(=O)CCCCCCC)[C@@H]2[C@](OC(=O)C)(C)C[C@H](OC(=O)CCC)[C@]3(O)[C@@](O)(C)C(=O)O[C@H]3C2=C1C)/C(=C\C)/C	4.6500001	Active	SERCA inhibitor	0.0	1	Thapsigargin	384567917	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-110.6480518724	O=C(O[C@@H]1[C@@H](OC(=O)CCCCCCC)[C@@H]2[C@](OC(=O)C)(C)C[C@H](OC(=O)CCC)[C@]3(O)[C@@](O)(C)C(=O)O[C@H]3C2=C1C)/C(=C\C)/C	O=C(O[C@@H]1[C@@H](OC(=O)CCCCCCC)[C@@H]2[C@](OC(=O)C)(C)C[C@H](OC(=O)CCC)[C@]3(O)[C@@](O)(C)C(=O)O[C@H]3C2=C1C)/C(=C\C)/C
NCGC00025202-12	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=CCC1)[C@H](CC)C	5.3000002	Inactive	HMG-CoA Reductase Inhibitor	0.0	1	Mevastatin	384568056	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	59.4553946373	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=CCC1)[C@H](CC)C	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=CCC1)[C@H](CC)C
NCGC00347303-01	O=C(O[C@@H]1[C@@]2(C(C)C)O[C@](C)([C@H](OC(=O)CO)C2)[C@H]2[C@H]1[C@H](C)CC2)/C=C/c1ccccc1	3.55	Inactive	PKC Activator	0.0	1	Englerin A	174006484	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	82.8886149481	O=C(O[C@@H]1[C@@]2(C(C)C)O[C@](C)([C@H](OC(=O)CO)C2)[C@H]2[C@H]1[C@H](C)CC2)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@]2(C(C)C)O[C@](C)([C@H](OC(=O)CO)C2)[C@H]2[C@H]1[C@H](C)CC2)/C=C/c1ccccc1
NCGC00345812-02&NCGC00345812-03	O=C(O[C@@H]1[C@@]2(O)[C@H](O)C(CO)=CC3C(=O)C2([C@H](C)C[C@H]2C(C)(C)[C@@H]32)C=C1C)/C(=C\C)/C	4.75	Inactive	Pkc Activator&PKC Activator	0.0	2	Ingenol mebutate	405558836&384568756	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&4.0	-3.7138796401&0.0	O=C(O[C@@H]1[C@@]2(O)[C@H](O)C(CO)=CC3C(=O)C2([C@H](C)C[C@H]2C(C)(C)[C@@H]32)C=C1C)/C(=C\C)/C	O=C(O[C@@H]1[C@@]2(O)[C@H](O)C(CO)=CC3C(=O)C2([C@H](C)C[C@H]2C(C)(C)[C@@H]32)C=C1C)/C(=C\C)/C
NCGC00016981-05	O=C(O[C@@H]1[C@H](C)[C@H](C)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](OC(=O)C)[C@H](OC)C2)[C@H](C)[C@H](O[C@H]2[C@H](OC(=O)C)[C@H](N(C)C)C[C@H](C)O2)[C@H](C)C[C@]2(C(=O)[C@@H]1C)OC2)C	4.4000001	Active	70s Ribosome Inhibitor	0.0	1	Troleandomycin	405558894	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-64.001560692	O=C(O[C@@H]1[C@H](C)[C@H](C)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](OC(=O)C)[C@H](OC)C2)[C@H](C)[C@H](O[C@H]2[C@H](OC(=O)C)[C@H](N(C)C)C[C@H](C)O2)[C@H](C)C[C@]2(C(=O)[C@@H]1C)OC2)C	O=C(O[C@@H]1[C@H](C)[C@H](C)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](OC(=O)C)[C@H](OC)C2)[C@H](C)[C@H](O[C@H]2[C@H](OC(=O)C)[C@H](N(C)C)C[C@H](C)O2)[C@H](C)C[C@]2(C(=O)[C@@H]1C)OC2)C
NCGC00263874-02	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](C)[C@H](C)[C@H](CC)OC2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCCNC(=N)N)n3)n2)C(O)C)C)C)c2nc[nH]c2)O[C@H](CO)[C@H]1O)N	7.0	Inactive		0.0	1	BLEOMYCIN (bleomycin B2 shown)	405559102	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-60.3399930641	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](C)[C@H](C)[C@H](CC)OC2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCCNC(=N)N)n3)n2)C(O)C)C)C)c2nc[nH]c2)O[C@H](CO)[C@H]1O)N	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](C)[C@H](C)[C@H](CC)OC2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCCNC(=N)N)n3)n2)C(O)C)C)C)c2nc[nH]c2)O[C@H](CO)[C@H]1O)N
NCGC00182036-01	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCN[C@@H](C)c4ccccc4)n3)n2)C(O)C)C)C)c2[nH]cnc2)O[C@H](CO)[C@H]1O)N	6.8499999	Inactive		0.0	1	Peplomycin sulfate	144206501	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-90.6055504454	S(=O)(=O)(O)O.O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCN[C@@H](C)c4ccccc4)n3)n2)C(O)C)C)C)c2[nH]cnc2)O[C@H](CO)[C@H]1O)N	S(=O)(=O)(O)O.O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCN[C@@H](C)c4ccccc4)n3)n2)C(O)C)C)C)c2[nH]cnc2)O[C@H](CO)[C@H]1O)N
NCGC00167439-03	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C		Inactive	Progesterone Receptor Binding Agent&Progesterone receptor Binding Agent		1	Trenbolone (acetate)	405558864	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.4397304359&-29.375043096	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C
NCGC00181156-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=C(O)C(=O)CC4)CC3)CC2)CC1)CCC1CCCC1	5.5	Active	Androgen Receptor Agonist	0.0	1	Oxabolone cipioncate	144206313	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-48.9462959002	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=C(O)C(=O)CC4)CC3)CC2)CC1)CCC1CCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=C(O)C(=O)CC4)CC3)CC2)CC1)CCC1CCCC1
NCGC00249920-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCCC1	5.4499998	Active	Androgen Receptor Agonist	0.0	1	Nandrolone cyclohexylpropionate	170465905	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-41.5812597775	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCCC1
NCGC00159356-02&NCGC00274069-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1		Inactive	Steroid hormone&Steroid Hormone&Steroid hormone		2	Nandrolone phenylpropionate&Nandrolone phenpropionate	29215274&170465193	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-16.1517699&-15.360778044&14.560325144	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1
NCGC00249919-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1occc1		Inactive			1	Nandrolone furylpropionate	170465918	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.6437037559&0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1occc1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1occc1
NCGC00484057-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)C	5.0500002	Active		0.0	1	Methenolone (acetate)	363681150	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-48.4051027307	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)C
NCGC00167979-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)CCCCCC	4.4000001	Active		0.0	1	Methenolone enanthate	144206153	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-49.251522212	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)CCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)CCCCCC
NCGC00378669-02	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)CC2)CC1)CCCCCCCCC=C	4.4499998	Active		0.0	1	Boldenone Undecylenate	405558970	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.619611164	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)CC2)CC1)CCCCCCCCC=C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)CC2)CC1)CCCCCCCCC=C
NCGC00179602-03	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Agonist		1	Testosterone propionate	170464835	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-11.0002039438&22.7869607399	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC
NCGC00181019-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC(C)C		Inactive			1	Testosterone isocaproate	144206222	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.639806708&-10.594791672	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC(C)C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC(C)C
NCGC00346736-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCC1		Inactive	Androgen Receptor Activator		1	Testosterone cypionate	174007287	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-9.163158724	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCC1
NCGC00160513-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC		Inactive	Androgen Receptor Agonist		1	Testosterone decanoate	144205416	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.888652232	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC
NCGC00484056-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCCC	5.0	Active		0.0	1	Testosterone (undecanoate)	405558851	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-46.4291965841	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCCC
NCGC00160504-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1		Inactive			1	Testosterone 17-phenylpropionate	144206667	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.626834672&0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1
NCGC00507798-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC(=O)[C@H](C)C4)CC3)CC2)CC1)CC	4.4000001	Active	Androgen Receptor Agonist	0.0	1	Drostanolone propionate	405559055	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.424100044	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC(=O)[C@H](C)C4)CC3)CC2)CC1)CC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC(=O)[C@H](C)C4)CC3)CC2)CC1)CC
NCGC00166134-02	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCC1CCCC1		Inactive	Androgen Receptor Antagonist		1	Estradiol cypionate	170464789	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.6150324999	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCC1CCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCC1CCCC1
NCGC00018166-02	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCC	4.5	Inactive		0.0	1	Estradiol valerate	405558513	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-27.137237264	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCC
NCGC00188442-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCCCC	4.4000001	Active		0.0	1	Estradiol enanthate	144206583	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-31.959675184&-92.0276459279	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCCCC
NCGC00344540-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(OC(=O)CC)cc4)CC3)CC2)CC1)CC	5.0	Active		0.0	1	17-BETA-ESTRADIOL 3,17-DIPROPIONATE	225144386	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-46.0287786714	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(OC(=O)CC)cc4)CC3)CC2)CC1)CC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(OC(=O)CC)cc4)CC3)CC2)CC1)CC
NCGC00165752-04	O=C(O[C@@H]1c2c(N(C(=O)N)c3c(cccc3)C1)cccc2)C	4.4000001	Active	Sodium Channel Alpha Subunit Antagonist	0.0	1	Eslicarbazepine (acetate)	405558796	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.54385282	O=C(O[C@@H]1c2c(N(C(=O)N)c3c(cccc3)C1)cccc2)C	O=C(O[C@@H]1c2c(N(C(=O)N)c3c(cccc3)C1)cccc2)C
NCGC00163424-11	O=C(O[C@@H]\1[C@@H](OC)/C=C\C=C(/C)\C(=O)NC=2C(=O)C(=C(NCC=C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C/1\C)N	4.8499999	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	Tanespimycin	384568237	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-112.0251077928	O=C(O[C@@H]\1[C@@H](OC)/C=C\C=C(/C)\C(=O)NC=2C(=O)C(=C(NCC=C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C/1\C)N	O=C(O[C@@H]\1[C@@H](OC)/C=C\C=C(/C)\C(=O)NC=2C(=O)C(=C(NCC=C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C/1\C)N
NCGC00017048-03	O=C(O[C@@]([C@H](CN(C)C)C)(Cc1ccccc1)c1ccccc1)CC	4.4749999	Active	Kappa Opioid Receptor Antagonist	0.0	1	Levopropoxyphene napsylate	405558477	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-63.243061398&-72.319604864	S(=O)(=O)(O)c1cc2c(cc1)cccc2.O=C(O[C@@]([C@H](CN(C)C)C)(Cc1ccccc1)c1ccccc1)CC	S(=O)(=O)(O)c1cc2c(cc1)cccc2.O=C(O[C@@]([C@H](CN(C)C)C)(Cc1ccccc1)c1ccccc1)CC
NCGC00179247-04	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C	4.5500002	Active	Androgen Receptor Antagonist	0.0	1	Nomegestrol acetate	405558605	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-53.1854565144	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C
NCGC00024196-05&NCGC00024196-12	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C		Inactive	Progesterone Receptor Agonist&Progesterone Receptor Antagonist&Progesterone Receptor Antagonist		2	Megestrol acetate	170465406&384568021	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.432115908&0.0&0.0	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C
NCGC00262960-01	O=C(O[C@@]1(C(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	4.4000001	Active	Glucocorticoid Receptor Agonist	0.0	1	Resocortol butyrate	170466824	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-56.7870301079	O=C(O[C@@]1(C(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	O=C(O[C@@]1(C(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC
NCGC00346468-03	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Antagonist		1	17 alpha-propionate	384568787	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC
NCGC00274077-01	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC		Inactive			1	Hydrocortisone 17-butyrate	170465456	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.103993056&-18.834909628	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC
NCGC00024016-03	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCCC		Inactive			1	Hydrocortisone valerate	170464775	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCCC	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCCC
NCGC00532510-01	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCCC		Inactive			1	PREDNISOLONE VALERATE ACETATE	405558610	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&20.516100576	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCCC	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCCC
NCGC00532512-01	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CC		Inactive			1	HYDROCORTISONE ACEPONATE	405558972	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-21.675091056	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CC	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CC
NCGC00510142-01	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CC		Inactive			1	Methylprednisolone aceponate	405558524	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.2920671&0.0	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CC	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CC
NCGC00183276-01	O=C(O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC		Inactive			1	Hydrocortisone buteprate	144206491	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.142439108&0.0	O=C(O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	O=C(O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC
NCGC00378324-03	O=C(O[C@H]1C(=O)O[C@H]2[C@@]34[C@@H]1[C@@](C(=O)OC)([C@@H](O)[C@H](O)[C@@H]3[C@]1(C)[C@H](C(C)=C(O)C(=O)C1)C2)OC4)/C=C(/C(C)C)\C	1.45	Inactive	MYC Expression Inhibitor;Apoptosis Inducers	0.0	1	Bruceantin	384569047	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	25.403255664	O=C(O[C@H]1C(=O)O[C@H]2[C@@]34[C@@H]1[C@@](C(=O)OC)([C@@H](O)[C@H](O)[C@@H]3[C@]1(C)[C@H](C(C)=C(O)C(=O)C1)C2)OC4)/C=C(/C(C)C)\C	O=C(O[C@H]1C(=O)O[C@H]2[C@@]34[C@@H]1[C@@](C(=O)OC)([C@@H](O)[C@H](O)[C@@H]3[C@]1(C)[C@H](C(C)=C(O)C(=O)C1)C2)OC4)/C=C(/C(C)C)\C
NCGC00183831-01	O=C(O[C@H]1C(=O)O[C@H]2[C@H](OC(=O)C)C(=O)O[C@@H]12)C		Inactive			1	Aceglatone	144206883	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.33298628&14.8511644519	O=C(O[C@H]1C(=O)O[C@H]2[C@H](OC(=O)C)C(=O)O[C@@H]12)C	O=C(O[C@H]1C(=O)O[C@H]2[C@H](OC(=O)C)C(=O)O[C@@H]12)C
NCGC00178357-03	O=C(O[C@H]1C(n2c3ncnc(NC(=O)CCC)c3nc2)O[C@H]2[C@H]1OP(=O)(O)OC2)CCC	4.4000001	Active		0.0	1	BUCLADESINE	405558832	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-68.655931092	O=C(O[C@H]1C(n2c3ncnc(NC(=O)CCC)c3nc2)O[C@H]2[C@H]1OP(=O)(O)OC2)CCC	O=C(O[C@H]1C(n2c3ncnc(NC(=O)CCC)c3nc2)O[C@H]2[C@H]1OP(=O)(O)OC2)CCC
NCGC00016094-10	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2C2[C@@](C)(C(=O)CC2)C1)oc4)C		Inactive	PI3K Inhibitor		1	17_-hydroxy Wortmannin	384567920	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	8.981330456	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2C2[C@@](C)(C(=O)CC2)C1)oc4)C	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2C2[C@@](C)(C(=O)CC2)C1)oc4)C
NCGC00345783-02	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2[C@H]2[C@@](C)([C@@H](O)CC2)C1)oc4)C	4.4000001	Active	PI3K Inhibitor	0.0	1	17-hydroxy Wortmannin	384568739	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-54.6404791119	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2[C@H]2[C@@](C)([C@@H](O)CC2)C1)oc4)C	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2[C@H]2[C@@](C)([C@@H](O)CC2)C1)oc4)C
NCGC00182606-01	O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)\C)/C)/C)=C(C)C1)CCCCCCCCCCCCCCC	4.75	Active		0.0	1	Physalien	144206657	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.4	-62.830998364&-42.9501336039	O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)\C)/C)/C)=C(C)C1)CCCCCCCCCCCCCCC	O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)\C)/C)/C)=C(C)C1)CCCCCCCCCCCCCCC
NCGC00378682-03	O=C(O[C@H]1CN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@H](c3ccccc3)NC(=O)[C@@H]2C1)NCCN	4.9000001	Active	Somatostatin receptor 5 Agonist	0.0	1	Pasireotide (ditrifluoroacetate)	405558784	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-49.336269808	O=C(O[C@H]1CN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@H](c3ccccc3)NC(=O)[C@@H]2C1)NCCN	O=C(O[C@H]1CN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@H](c3ccccc3)NC(=O)[C@@H]2C1)NCCN
NCGC00182708-01	O=C(O[C@H]1[C@@H](N2CC[N+](C)(C)CC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CC[N+](C)(C)CC4)C3)CC[C@@H]21)C	4.6999998	Active	Muscle-type Nicotinic Acetylcholine Receptor Antagonist&Muscle-type nicotinic acetylcholine receptor Antagonist	0.0	1	Pipecuronium bromide	144206565	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-78.6352874535&-32.4665977279	O=C(O[C@H]1[C@@H](N2CC[N+](C)(C)CC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CC[N+](C)(C)CC4)C3)CC[C@@H]21)C.[Br-].[Br-]	O=C(O[C@H]1[C@@H](N2CC[N+](C)(C)CC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CC[N+](C)(C)CC4)C3)CC[C@@H]21)C.[Br-].[Br-]
NCGC00178810-03	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(C/C=C(\C)/C)c(O)cc4)C(=O)c3cc2)OC(C)(C)[C@@H]1OC)N		Inactive	Hsp90 Inhibitor&Heat Shock Protein 90 (hsp90) Inhibitor		1	Novobiocin sodium	170465360	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.16678298&0.0	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(C/C=C(\C)/C)c(O)cc4)=C([O-])c3cc2)OC(C)(C)[C@@H]1OC)N.[Na+]	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(C/C=C(\C)/C)c(O)cc4)=C([O-])c3cc2)OC(C)(C)[C@@H]1OC)N.[Na+]
NCGC00161630-03	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(CC=C(C)C)c(O)cc4)C(=O)c3cc2)OC(C)(C)[C@@H]1OC)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Novobiocin sodium	384568212	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(CC=C(C)C)c([O-])cc4)=C(O)c3cc2)OC(C)(C)[C@@H]1OC)N	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(CC=C(C)C)c([O-])cc4)=C(O)c3cc2)OC(C)(C)[C@@H]1OC)N
NCGC00163699-07	O=C(O[C@H]1[C@@H](OC)[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)[C@]2(OC2)CC1)/C=C/C=C/C=C/C=C/C(=O)O	4.6999998	Active	Methionine Aminopeptidase 2 Inhibitor	0.0	1	Fumagillin	405559052	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-41.098746864&-50.8105567476	O=C(O[C@H]1[C@@H](OC)[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)[C@]2(OC2)CC1)/C=C/C=C/C=C/C=C/C(=O)O	O=C(O[C@H]1[C@@H](OC)[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)[C@]2(OC2)CC1)/C=C/C=C/C=C/C=C/C(=O)O
NCGC00167467-03	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)C		Inactive	Neuronal Acetylcholine Receptor Subunit Alpha-2 Antagonist&Steroid non-depolarizing neuromuscular Blocker		1	Vecuronium bromide	170465295	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-22.450279152&-24.223407996&0.0	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)C.[Br-]	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)C.[Br-]
NCGC00023037-06&NCGC00023037-08	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H]([N+]4(C)CCCCC4)C3)CC[C@@H]21)C		Inactive	Steroid non-depolarizing Blocker&Steroid Non-depolarizing Blocker&Steroid non-depolarizing Blocker		2	Pancuronium bromide	124886818&225144191	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-11.0548577519&-16.23254876&0.0	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H]([N+]4(C)CCCCC4)C3)CC[C@@H]21)C	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H]([N+]4(C)CCCCC4)C3)CC[C@@H]21)C
NCGC00167433-05&NCGC00167433-06	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](O)[C@@H](N4CCOCC4)C3)CC[C@@H]21)C		Inactive	Neuronal Acetylcholine Receptor Subunit Alpha-1 Antagonist&Steroid non-depolarizing neuromuscular Blocker&Steroid non-depolarizing neuromuscular Blocker		2	Rocuronium bromide	405558883&384568312	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-32.542262724&-29.200874792&-16.131353112	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](O)[C@@H](N4CCOCC4)C3)CC[C@@H]21)C	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](O)[C@@H](N4CCOCC4)C3)CC[C@@H]21)C
NCGC00183839-01	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)CC		Inactive	Muscarinic acetylcholine receptor M5 Negative Allosteric Modulator&Muscarinic Acetylcholine Receptor M5 Negative Allosteric Modulator		1	Rapacuronium bromide	144206855	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)CC.[Br-]	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)CC.[Br-]
NCGC00262543-01	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC	4.4000001	Active	Ribosome Inhibitor	0.0	1	Midecamycin	405558985	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.265143032	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC
NCGC00510884-01	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](C)[C@H](OC(=O)C)CC(=O)O[C@H](CC)[C@@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC(C)C	4.5500002	Active	Bacterial 70S ribosome Inhibitor	0.0	1	Tylvalosin	405558459	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.2978891823	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](C)[C@H](OC(=O)C)CC(=O)O[C@H](CC)[C@@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC(C)C	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](C)[C@H](OC(=O)C)CC(=O)O[C@H](CC)[C@@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC(C)C
NCGC00022678-08	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C		Inactive	DNA-Directed RNA Polymerase Inhibitor		1	Rifampicin	384568012	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00167431-03	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N\N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	4.4000001	Active	DNA-Directed RNA Polymerase Inhibitor	0.0	1	Rifapentine	124893311	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-32.045290184	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N\N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N\N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00271415-05	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C/[C@H](OC)[C@H]1C)C	4.4000001	Active	Pregnane X Receptor (PXR) Agonist	0.0	1	Rifaximin	384568704	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-106.7671478539	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C/[C@H](OC)[C@H]1C)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C/[C@H](OC)[C@H]1C)C
NCGC00386298-01	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)Nc2c(/C=N/N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C		Inactive	DNA-Directed RNA Polymerase Inhibitor&Dna-directed Rna Polymerase Inhibitor		1	Rifapentine	405559051	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.346370812&20.31978912	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)Nc2c(/C=N/N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)Nc2c(/C=N/N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00387269-01	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(\C)/C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C\[C@H](OC)[C@H]1C)C		Inactive	Pregnane X Receptor (PXR) Agonist&Dna-directed Rna Polymerase Subunit Beta Inhibitor		1	Rifaximin	405558998	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.41046364&-22.2539649	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(\C)/C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C\[C@H](OC)[C@H]1C)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(\C)/C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C\[C@H](OC)[C@H]1C)C
NCGC00179536-02	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)C=CC=C(C)C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)OC=C[C@H](OC)[C@H]1C)c2O)C	4.4000001	Active	DNA-Directed RNA Polymerase Inhibitor	0.0	1	Rifampicin	170464760	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.991122872	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)C=CC=C(C)C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)OC=C[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)C=CC=C(C)C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)OC=C[C@H](OC)[C@H]1C)c2O)C
NCGC00522306-02	O=C(O[C@H]1[C@H](CC(C)C)CN2[C@@H](c3c(cc(OC)c(OC)c3)CC2)C1)[C@@H](N)C(C)C	4.75	Active		0.0	1	Valbenazine	405558870	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-70.1746524921&-47.5138340667	O=C(O[C@H]1[C@H](CC(C)C)CN2[C@@H](c3c(cc(OC)c(OC)c3)CC2)C1)[C@@H](N)C(C)C	O=C(O[C@H]1[C@H](CC(C)C)CN2[C@@H](c3c(cc(OC)c(OC)c3)CC2)C1)[C@@H](N)C(C)C
NCGC00160471-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)\C)\C)/C)/C		Inactive	Tyrosinase Inhibitor		1	Crocin?	405558579	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.0946178761&15.301170468	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)\C)\C)/C)/C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)\C)\C)/C)/C
NCGC00249922-01	O=C(O[C@H]1[C@H](OC(=O)C)CC2C1(C)CCC1c3c(cc(OC(=O)c4ccccc4)cc3)CCC21)C		Inactive			1	Estriol benzoate diacetate	170465998	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.744165592&0.0	O=C(O[C@H]1[C@H](OC(=O)C)CC2C1(C)CCC1c3c(cc(OC(=O)c4ccccc4)cc3)CCC21)C	O=C(O[C@H]1[C@H](OC(=O)C)CC2C1(C)CCC1c3c(cc(OC(=O)c4ccccc4)cc3)CCC21)C
NCGC00249918-01	O=C(O[C@H]1[C@H](OC(=O)CC)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(OC(=O)CC)c2)CC		Inactive			1	Estriol tripropionate	170465876	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.1389719474&0.0	O=C(O[C@H]1[C@H](OC(=O)CC)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(OC(=O)CC)c2)CC	O=C(O[C@H]1[C@H](OC(=O)CC)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(OC(=O)CC)c2)CC
NCGC00253604-01	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(O)cc1	4.6500001	Active	smooth muscle contraction Inhibitor&Smooth Muscle Contraction Inhibitor	0.0	1	Rescimetol	170465875	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-84.1411439013&-96.856116384	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(O)cc1
NCGC00179585-04	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1	5.4000001	Active	Serotonergic Synapse Inhibitor	0.0	1	Rescinnamin	363676949	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.568573036	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1
NCGC00185767-01	O=C(O[C@H]1[C@H](OC)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](N(C)C)CC2)C=CC=CC[C@@H](C)OC(=O)C1)C	4.6999998	Active	Bacterial 70s Ribosome Binding Agent&Bacterial 70S ribosome Binding Agent	0.0	1	Spiramycin II	144207139	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-80.3100753516&-65.9480698672	O=C(O[C@H]1[C@H](OC)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](N(C)C)CC2)C=CC=CC[C@@H](C)OC(=O)C1)C	O=C(O[C@H]1[C@H](OC)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](N(C)C)CC2)C=CC=CC[C@@H](C)OC(=O)C1)C
NCGC00179619-06	O=C(O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C)CC	4.5999999	Active	NF-kappaB Activation Inhibitor&Nf-kappab Activation Inhibitor	0.0	1	Erythromycin propionate	170465433	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-43.9838305768&-51.527994376	O=C(O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C)CC	O=C(O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C)CC
NCGC00344583-01	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CC[N@]4C[C@](O)(CC)C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	9.0	Inactive	Tubulin Inhibitor	0.0	1	Vinblastine sulfate	170464976	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-20.968764964	S(=O)(=O)(O)O.O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CC[N@]4C[C@](O)(CC)C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	S(=O)(=O)(O)O.O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CC[N@]4C[C@](O)(CC)C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00263568-01	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4C[N@]4CC(CC)=C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	9.0	Inactive	Tubulin polymerization inhibitor	0.0	1	Vinorelbine tartrate	170465330	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-14.3464878	O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O.O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4C[N@]4CC(CC)=C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O.O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4C[N@]4CC(CC)=C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00163700-12&NCGC00163700-14	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C=O)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	9.0	Inactive	Tubulin polymerization Inhibitor	0.0	2	Vincristine sulfate	404904683&384568248	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-39.8611984469&-18.979667532	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C=O)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C=O)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00183366-07	O=C(O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)C	4.4000001	Active	Progesterone Receptor Agonist	0.0	1	NORETHINDRONE ACETATE	405558906	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-51.063557632&-50.56808708	O=C(O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)C	O=C(O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)C
NCGC00344561-01	O=C(O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@@H]([C@@H]4C(=C/C(=N/O)/CC4)CC3)CC2)CC1)C		Inactive	Progesterone Receptor Agonist&Progesterone receptor Agonist		1	Norgestimate	170464733	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0		O=C(O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@@H]([C@@H]4C(=C/C(=N/O)/CC4)CC3)CC2)CC1)C	O=C(O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@@H]([C@@H]4C(=C/C(=N/O)/CC4)CC3)CC2)CC1)C
NCGC00166298-02	O=C(O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=CC(=O)CC3)C	4.4000001	Active		0.0	1	Melengestrol acetate	170465702	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.754407224	O=C(O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=CC(=O)CC3)C	O=C(O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=CC(=O)CC3)C
NCGC00017360-04	O=C(O[C@]12[C@@H](O)[C@H](OC)[C@]3(O)[C@H](OC(=O)c4ccccc4)C1C([C@]14[C@@H](OC)C[C@@H](O)[C@]5(COC)C1[C@@H](OC)C2[C@H]4N(CC)C5)C3)C	4.4000001	Active		0.0	1	Aconitine	405558809	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-53.0649028168&-28.897712664	O=C(O[C@]12[C@@H](O)[C@H](OC)[C@]3(O)[C@H](OC(=O)c4ccccc4)C1C([C@]14[C@@H](OC)C[C@@H](O)[C@]5(COC)C1[C@@H](OC)C2[C@H]4N(CC)C5)C3)C	O=C(O[C@]12[C@@H](O)[C@H](OC)[C@]3(O)[C@H](OC(=O)c4ccccc4)C1C([C@]14[C@@H](OC)C[C@@H](O)[C@]5(COC)C1[C@@H](OC)C2[C@H]4N(CC)C5)C3)C
NCGC00346660-03	O=C(O[C@]12[C@H]3[C@H](OC(=O)c4ccccc4)[C@@]4(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]1OC2)=C(C)[C@@H](O)C4)C	4.5	Active	antineoplastic intermediate	0.0	1	10-Deacetylbaccatin	384568891	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-56.2508850304	O=C(O[C@]12[C@H]3[C@H](OC(=O)c4ccccc4)[C@@]4(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]1OC2)=C(C)[C@@H](O)C4)C	O=C(O[C@]12[C@H]3[C@H](OC(=O)c4ccccc4)[C@@]4(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]1OC2)=C(C)[C@@H](O)C4)C
NCGC00096014-03	O=C(Oc1c(C(=O)O)cccc1)c1c(O)cccc1		Inactive	Prostaglandin Biosynthetic Process Inhibitor&prostaglandin biosynthetic process Inhibitor		1	Salsalate	170465545	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.159459992	O=C(Oc1c(C(=O)O)cccc1)c1c(O)cccc1	O=C(Oc1c(C(=O)O)cccc1)c1c(O)cccc1
NCGC00167468-02	O=C(Oc1c(C(=O)Oc2ccc(NC(=O)C)cc2)cccc1)C		Inactive	Prostaglandin Biosynthetic Process Inhibitor&prostaglandin biosynthetic process Inhibitor		1	Benorylate	170466237	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.300755844&-12.936796712	O=C(Oc1c(C(=O)Oc2ccc(NC(=O)C)cc2)cccc1)C	O=C(Oc1c(C(=O)Oc2ccc(NC(=O)C)cc2)cccc1)C
NCGC00159498-03	O=C(Oc1c(C)c(C)c(OCC(O)CNC(C)C)cc1C)C	4.3249998	Active	Beta-2 adrenergic receptor Antagonist&Beta-2 Adrenergic Receptor Antagonist	0.0	1	Metipranolol	29215466	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-43.9184513935&-39.6584487332	O=C(Oc1c(C)c(C)c(OCC(O)CNC(C)C)cc1C)C	O=C(Oc1c(C)c(C)c(OCC(O)CNC(C)C)cc1C)C
NCGC00181354-02	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	Retinoic Acid Receptor Gamma Agonist&Retinoic acid receptor gamma Agonist		1	Tocoretinate	225144326	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00095255-08	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)C		Inactive			1	dl-alpha-Tocopheryl acetate	170465444	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&18.523634232	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)C	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)C
NCGC00167561-03	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)CCC(=O)O	4.6500001	Active		0.0	1	D-alpha-Tocopherol succinate	225144294	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-44.8855991759&-39.9210364096	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)CCC(=O)O	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)CCC(=O)O
NCGC00164499-03	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)c1cnccc1		Inactive	Platelet Aggregation Inhibitor&platelet aggregation Inhibitor		1	DL-alpha Tocopheryl nicotinate	170465780	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.5490962039	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)c1cnccc1	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)c1cnccc1
NCGC00160567-01	O=C(Oc1c(C)cc(OC(=O)C)c2c1cccc2)C	4.3499999	Active		0.0	1	Acetomenaphthone	144205458	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-101.6236389895&-101.9023376342	O=C(Oc1c(C)cc(OC(=O)C)c2c1cccc2)C	O=C(Oc1c(C)cc(OC(=O)C)c2c1cccc2)C
NCGC00015678-10	O=C(Oc1c(C)cc(OCCN(C)C)c(C(C)C)c1)C	4.6500001	Active	Adrenergic Receptor Alpha-1 Antagonist	0.0	1	Moxisylyte hydrochloride	170465759	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.659416368	O=C(Oc1c(C)cc(OCCN(C)C)c(C(C)C)c1)C.Cl	O=C(Oc1c(C)cc(OCCN(C)C)c(C(C)C)c1)C.Cl
NCGC00346959-11	O=C(Oc1c(C)cccc1C)N(c1c(OC)cc(OC)cc1)c1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1		Inactive	Lck Kinase Inhibitor		1	HMSL10038	384568977	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(Oc1c(C)cccc1C)N(c1c(OC)cc(OC)cc1)c1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1	O=C(Oc1c(C)cccc1C)N(c1c(OC)cc(OC)cc1)c1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1
NCGC00179499-05	O=C(Oc1c(OC(=O)C(C)(C)C)ccc(C(O)CNC)c1)C(C)(C)C	4.5999999	Inactive	Beta-2 Adrenergic Receptor Agonist	0.0	1	Dipivefrin hydrochloride	405559013	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-10.9006793119	O=C(Oc1c(OC(=O)C(C)(C)C)ccc(C(O)CNC)c1)C(C)(C)C	O=C(Oc1c(OC(=O)C(C)(C)C)ccc(C(O)CNC)c1)C(C)(C)C
NCGC00253593-01	O=C(Oc1c(OC(=O)c2ccc(C)cc2)ccc(C(O)CNC(C)(C)C)c1)c1ccc(C)cc1	4.75	Active	Beta-2 adrenergic receptor Agonist	0.0	1	Bitolterol	170465239	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-66.658190073	O=C(Oc1c(OC(=O)c2ccc(C)cc2)ccc(C(O)CNC(C)(C)C)c1)c1ccc(C)cc1	O=C(Oc1c(OC(=O)c2ccc(C)cc2)ccc(C(O)CNC(C)(C)C)c1)c1ccc(C)cc1
NCGC00164512-02	O=C(Oc1c(OC)cccc1)Oc1c(OC)cccc1	4.5	Active		0.0	1	Guaiacol carbonate	170465684	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-36.887661164	O=C(Oc1c(OC)cccc1)Oc1c(OC)cccc1	O=C(Oc1c(OC)cccc1)Oc1c(OC)cccc1
NCGC00346540-03	O=C(Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(CO)cc1)C(C)C	4.625	Active	Muscarinic Antagonists	0.0	1	FESOTERODINE FUMARATE	405558955	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-108.2766179016&-100.2482485119	O=C(Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(CO)cc1)C(C)C	O=C(Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(CO)cc1)C(C)C
NCGC00090680-06	O=C(Oc1c2c(ccc1)cccc2)NC		Inactive	Acetylcholinesterase Inhibitor		1	Carbaryl	170465695	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.544356264	O=C(Oc1c2c(ccc1)cccc2)NC	O=C(Oc1c2c(ccc1)cccc2)NC
NCGC00015862-07	O=C(Oc1c[n+](C)ccc1)N(C)C	5.8499999	Active	Acetylcholinesterase Inhibitor	0.0	1	Pyridostigmine bromide	170464878	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-39.4720240592	O=C(Oc1c[n+](C)ccc1)N(C)C.[Br-]	O=C(Oc1c[n+](C)ccc1)N(C)C.[Br-]
NCGC00510033-02	O=C(Oc1c[n+](C)ccc1)N(CCCCCCN(C(=O)Oc1c[n+](C)ccc1)C)C		Inactive	Acetylcholinesterase Inhibitor		1	Distigmine Bromide	405558528	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.734422728&-20.2216578	O=C(Oc1c[n+](C)ccc1)N(CCCCCCN(C(=O)Oc1c[n+](C)ccc1)C)C	O=C(Oc1c[n+](C)ccc1)N(CCCCCCN(C(=O)Oc1c[n+](C)ccc1)C)C
NCGC00165915-05	O=C(Oc1cc(-c2cc(C(=O)N)ccc2)ccc1)NC1CCCCC1	4.9000001	Active	Fatty Acid Amide Hydrolase (FAAH) Inhibitor	0.0	1	KDS-4103	384568299	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-35.067752232	O=C(Oc1cc(-c2cc(C(=O)N)ccc2)ccc1)NC1CCCCC1	O=C(Oc1cc(-c2cc(C(=O)N)ccc2)ccc1)NC1CCCCC1
NCGC00159365-04	O=C(Oc1cc(C)ccc1)C		Inactive			1	m-Cresyl acetate	170466849	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	35.5712740718&0.0	O=C(Oc1cc(C)ccc1)C	O=C(Oc1cc(C)ccc1)C
NCGC00484080-01&NCGC00484080-02	O=C(Oc1cc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)ccc1)N(C)C	4.5500002	Inactive	LIMK1/LIMK2 Inhibitor	0.0	2	LX-7101	363681171&384569271	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&5.0	0.0&-21.9534381162	O=C(Oc1cc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)ccc1)N(C)C	O=C(Oc1cc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)ccc1)N(C)C
NCGC00095054-05	O=C(Oc1cc(O)ccc1)C		Inactive			1	Resorcinol monoacetate	170465513	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	26.787655184&-14.0066818159	O=C(Oc1cc(O)ccc1)C	O=C(Oc1cc(O)ccc1)C
NCGC00179546-05	O=C(Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1)N(C)C		Inactive	Butyrylcholinesterase Inhibitor		1	Bambuterol hydrochloride	170466370	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1)N(C)C.Cl	O=C(Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1)N(C)C.Cl
NCGC00167531-02	O=C(Oc1cc([C@@H](N(C)C)C)ccc1)N(CC)C		Inactive	Acetylcholinesterase Inhibitors		1	Rivastigmine tartrate	170464721	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.5136104559&0.0	O=C(Oc1cc([C@@H](N(C)C)C)ccc1)N(CC)C.O=C(O)[C@@H](O)[C@H](O)C(=O)O	O=C(Oc1cc([C@@H](N(C)C)C)ccc1)N(CC)C.O=C(O)[C@@H](O)[C@H](O)C(=O)O
NCGC00015730-11	O=C(Oc1cc([N+](C)(C)C)ccc1)N(C)C		Inactive	Acetylcholinesterase Inhibitor		1	Neostigmine bromide	170465765	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.1492209039&-17.0821699399	O=C(Oc1cc([N+](C)(C)C)ccc1)N(C)C.[Br-]	O=C(Oc1cc([N+](C)(C)C)ccc1)N(C)C.[Br-]
NCGC00179526-05	O=C(Oc1cc([N+](C)(C)C)ccc1)N(CCCCCCCCCCN(C(=O)Oc1cc([N+](C)(C)C)ccc1)C)C	5.0	Active	Acetylcholinesterase Inhibitor	0.0	1	Demecarium bromide	405558429	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-58.7029234161	O=C(Oc1cc([N+](C)(C)C)ccc1)N(CCCCCCCCCCN(C(=O)Oc1cc([N+](C)(C)C)ccc1)C)C	O=C(Oc1cc([N+](C)(C)C)ccc1)N(CCCCCCCCCCN(C(=O)Oc1cc([N+](C)(C)C)ccc1)C)C
NCGC00093889-12	O=C(Oc1cc2[C@@]3(C)[C@@H](N(C)c2cc1)N(C)CC3)NC		Inactive			1	Physostigmine	170465757	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.309444324	O=C(Oc1cc2[C@@]3(C)[C@@H](N(C)c2cc1)N(C)CC3)NC	O=C(Oc1cc2[C@@]3(C)[C@@H](N(C)c2cc1)N(C)CC3)NC
NCGC00178697-07	O=C(Oc1cc2c(CC)c3c(nc2cc1)C=1N(C(=O)C2=C([C@@](O)(CC)C(=O)OC2)C=1)C3)N1CCC(N2CCCCC2)CC1	9.0	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	Irinotecan	384568360	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	7.8015613479	O=C(Oc1cc2c(CC)c3c(nc2cc1)C=1N(C(=O)C2=C([C@@](O)(CC)C(=O)OC2)C=1)C3)N1CCC(N2CCCCC2)CC1	O=C(Oc1cc2c(CC)c3c(nc2cc1)C=1N(C(=O)C2=C([C@@](O)(CC)C(=O)OC2)C=1)C3)N1CCC(N2CCCCC2)CC1
NCGC00249885-01	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)C		Inactive			1	Estradiol acetate	170465258	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.4113036199	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)C	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)C
NCGC00021274-04	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)c1ccccc1		Inactive			1	ESTRADIOL BENZOATE	405559069	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.7778863761&-12.0265014119	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)c1ccccc1	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)c1ccccc1
NCGC00160398-05&NCGC00160398-09	O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1		Inactive	Tryptase Inhibitor		2	Nafamostat mesilate	170465855&384568193	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	17.5476937039&0.0&0.0	S(=O)(=O)(O)C.O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1	S(=O)(=O)(O)C.O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1&O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1
NCGC00181917-01	O=C(Oc1cc2c(cc1)CCC2)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor&Bacterial Penicillin-binding Protein Inhibitor		1	Carbenicillin indanyl	144206652	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-32.7167121279	O=C(Oc1cc2c(cc1)CCC2)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1	O=C(Oc1cc2c(cc1)CCC2)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1
NCGC00165767-04	O=C(Oc1ccc(C(c2ccc(OC(=O)C)cc2)=C2CCCCC2)cc1)C	5.1999998	Active	Estrogen receptor beta Antagonist	0.0	1	Cyclofenil	170465970	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.9996353927	O=C(Oc1ccc(C(c2ccc(OC(=O)C)cc2)=C2CCCCC2)cc1)C	O=C(Oc1ccc(C(c2ccc(OC(=O)C)cc2)=C2CCCCC2)cc1)C
NCGC00182998-01	O=C(Oc1ccc(C2(c3ccc(OC(=O)C)cc3)C(=O)Nc3c(O2)cccc3)cc1)C	4.6750002	Active		0.0	1	Bisoxatin acetate	144206872	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-95.0373988548&-82.7035278079	O=C(Oc1ccc(C2(c3ccc(OC(=O)C)cc3)C(=O)Nc3c(O2)cccc3)cc1)C	O=C(Oc1ccc(C2(c3ccc(OC(=O)C)cc3)C(=O)Nc3c(O2)cccc3)cc1)C
NCGC00095933-04	O=C(Oc1ccccc1)c1c(O)cc(N)cc1		Inactive			1	Phenyl 4-aminosalicylate	170465273	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C(Oc1ccccc1)c1c(O)cc(N)cc1	O=C(Oc1ccccc1)c1c(O)cc(N)cc1
NCGC00090887-04	O=C(Oc1ccccc1)c1c(O)cccc1		Inactive	Estrogen Receptor Alpha Agonist&Estrogen receptor alpha Agonist		1	Phenyl salicylate	170465501	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.275952144&18.724898952	O=C(Oc1ccccc1)c1c(O)cccc1	O=C(Oc1ccccc1)c1c(O)cccc1
NCGC00346894-04	O=C([C@@H](C/C=C/C)C)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O		Inactive	P-Glycoprotein (MDR-1; ABCB1) Inhibitor		1	Valspodar	384568965	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.2617574199	O=C([C@@H](C/C=C/C)C)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O	O=C([C@@H](C/C=C/C)C)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O
NCGC00242597-01&NCGC00242597-02	O=C([C@@H](N)C12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)C[C@H]2[C@@H]1C2		Inactive	Dipeptidyl Peptidase Iv (cd26; Dpp-iv; Dp-iv) Inhibitor&DPP-IV Inhibitor&DPP-IV Inhibitor		2	Saxagliptin	124950715&363677150	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-26.2976677479&0.0&-16.095229316	O=C([C@@H](N)C12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)C[C@H]2[C@@H]1C2	O=C([C@@H](N)C12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)C[C@H]2[C@@H]1C2
NCGC00181033-02	O=C([C@@H](NC(=O)[C@@H]1NC(=O)N(C)C(=O)C1)Cc1[nH]cnc1)N1[C@H](C(=O)N)CCC1	5.5500002	Inactive	Thyrotropin-Releasing Hormone (TRH) Analogs	0.0	1	Taltirelin	174006814	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	79.1467772341	O=C([C@@H](NC(=O)[C@@H]1NC(=O)N(C)C(=O)C1)Cc1[nH]cnc1)N1[C@H](C(=O)N)CCC1	O=C([C@@H](NC(=O)[C@@H]1NC(=O)N(C)C(=O)C1)Cc1[nH]cnc1)N1[C@H](C(=O)N)CCC1
NCGC00163431-06	O=C([C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCC)O1)C(CC)C)N1[C@H](C(=O)OC)CCC1	4.5	Active	Cathepsin B Inhibitor	0.0	1	CA-074 Me	384568238	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-99.5348927856	O=C([C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCC)O1)C(CC)C)N1[C@H](C(=O)OC)CCC1	O=C([C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCC)O1)C(CC)C)N1[C@H](C(=O)OC)CCC1
NCGC00381723-02	O=C([C@@H](NC(=O)[C@H]1NC(=O)N(C)C(=O)C1)Cc1nc[nH]c1)N1[C@H](C(=O)N)CCC1	4.4000001	Active	Thyrotropin Releasing Hormone Receptor Modulator	0.0	1	Taltirelin	405558765	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.019696724	O=C([C@@H](NC(=O)[C@H]1NC(=O)N(C)C(=O)C1)Cc1nc[nH]c1)N1[C@H](C(=O)N)CCC1	O=C([C@@H](NC(=O)[C@H]1NC(=O)N(C)C(=O)C1)Cc1nc[nH]c1)N1[C@H](C(=O)N)CCC1
NCGC00387037-01	O=C([C@@H](O)C)N1CCC(N2C(=O)N(C)c3c2c2nc(-c4cnc(C)cc4)ccc2nc3)CC1	5.9499998	Inactive	mTOR Inhibitor	0.0	1	PF-04979064	363680530	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-22.084695192	O=C([C@@H](O)C)N1CCC(N2C(=O)N(C)c3c2c2nc(-c4cnc(C)cc4)ccc2nc3)CC1	O=C([C@@H](O)C)N1CCC(N2C(=O)N(C)c3c2c2nc(-c4cnc(C)cc4)ccc2nc3)CC1
NCGC00263109-15	O=C([C@@H](O)C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1	4.4000001	Active	mTOR Inhibitor	0.0	1	GDC-0980	384568596	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-63.2158933799	O=C([C@@H](O)C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1	O=C([C@@H](O)C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1
NCGC00186637-01	O=C([C@@H](O)[C@@H](O)C)[C@H](OC)[C@H]1[C@H](OC2O[C@H](C)[C@@H](O)[C@H](OC3O[C@@H](C)[C@H](O)[C@@H](OC4O[C@@H](C)[C@H](OC(=O)C)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(OC4O[C@@H](C)[C@@H](OC(=O)C)[C@@H](OC5O[C@@H](C)[C@@H](OC)[C@@H](O)C5)C4)cc3cc2C1	6.9000001	Inactive		0.0	1	Chromomycin A<SUB>3</SUB> from Streptomyces griseus	124897824	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-97.3697939078	O=C([C@@H](O)[C@@H](O)C)[C@H](OC)[C@H]1[C@H](OC2O[C@H](C)[C@@H](O)[C@H](OC3O[C@@H](C)[C@H](O)[C@@H](OC4O[C@@H](C)[C@H](OC(=O)C)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(OC4O[C@@H](C)[C@@H](OC(=O)C)[C@@H](OC5O[C@@H](C)[C@@H](OC)[C@@H](O)C5)C4)cc3cc2C1	O=C([C@@H](O)[C@@H](O)C)[C@H](OC)[C@H]1[C@H](OC2O[C@H](C)[C@@H](O)[C@H](OC3O[C@@H](C)[C@H](O)[C@@H](OC4O[C@@H](C)[C@H](OC(=O)C)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(OC4O[C@@H](C)[C@@H](OC(=O)C)[C@@H](OC5O[C@@H](C)[C@@H](OC)[C@@H](O)C5)C4)cc3cc2C1
NCGC00181319-01	O=C([C@@H](O)[C@H](O)C)[C@@H](OC)C1[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(O[C@@H]4O[C@H](C)[C@H](O)[C@H](O[C@@H]5O[C@H](C)[C@@H](O)[C@H](O)C5)C4)cc3cc2C1	4.0	Inactive	DNA Antagonist	0.0	1	Plicamycin	144206340	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-15.90094888	O=C([C@@H](O)[C@H](O)C)[C@@H](OC)C1[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(O[C@@H]4O[C@H](C)[C@H](O)[C@H](O[C@@H]5O[C@H](C)[C@@H](O)[C@H](O)C5)C4)cc3cc2C1	O=C([C@@H](O)[C@H](O)C)[C@@H](OC)C1[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(O[C@@H]4O[C@H](C)[C@H](O)[C@H](O[C@@H]5O[C@H](C)[C@@H](O)[C@H](O)C5)C4)cc3cc2C1
NCGC00344523-01	O=C([C@@H](O)[C@H](O)[C@@H](O)CO)CO		Inactive			1	L-(-)-Sorbose	170465548	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.15401206&0.0	O=C([C@@H](O)[C@H](O)[C@@H](O)CO)CO	O=C([C@@H](O)[C@H](O)[C@@H](O)CO)CO
NCGC00179767-02	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](C)([C@H]3[C@@](C)(C(=O)C2)[C@H]2C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=CC3)CC1O)/C=C/C(OC(=O)C)(C)C	4.9000001	Active	lipid metabolic process Modulator	0.0	1	NCGC00179767-02	363676967	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.8794991799	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](C)([C@H]3[C@@](C)(C(=O)C2)[C@H]2C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=CC3)CC1O)/C=C/C(OC(=O)C)(C)C	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](C)([C@H]3[C@@](C)(C(=O)C2)[C@H]2C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=CC3)CC1O)/C=C/C(OC(=O)C)(C)C
NCGC00263203-06	O=C([C@H](OC)c1ccccc1)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1	5.1500001	Inactive	Aurora-A/B/C Kinase Inhibitor	0.0	1	Danusertib	384568662	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-62.8832953187	O=C([C@H](OC)c1ccccc1)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1	O=C([C@H](OC)c1ccccc1)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1
NCGC00162440-05	O=C([C@H]([C@H](O)[C@H](C/C(=C/C(=O)O)/C)C)C)[C@@H](/C=C(/C=C/C[C@H](/C=C(\C=C\[C@H]1[C@@H](C)C=CC(=O)O1)/CC)C)\C)C	3.45	Inactive	Nuclear export Inhibitor	0.0	1	Leptomycin B	384568227	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-23.144373944	O=C([C@H]([C@H](O)[C@H](C/C(=C/C(=O)O)/C)C)C)[C@@H](/C=C(/C=C/C[C@H](/C=C(\C=C\[C@H]1[C@@H](C)C=CC(=O)O1)/CC)C)\C)C	O=C([C@H]([C@H](O)[C@H](C/C(=C/C(=O)O)/C)C)C)[C@@H](/C=C(/C=C/C[C@H](/C=C(\C=C\[C@H]1[C@@H](C)C=CC(=O)O1)/CC)C)\C)C
NCGC00167437-02	O=C([C@H]1Cc2nc[nH]c2CC1)c1c2c(n(C)c1)cccc2	4.6750002	Active	Serotonin 3a (5-ht3a) Receptor Antagonist&Serotonin 3a (5-HT3a) receptor Antagonist	0.0	1	Ramosetron hydrochloride	170465928	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-80.034736628&-31.531189024	O=C([C@H]1Cc2nc[nH]c2CC1)c1c2c(n(C)c1)cccc2.Cl	O=C([C@H]1Cc2nc[nH]c2CC1)c1c2c(n(C)c1)cccc2.Cl
NCGC00178874-03	O=C([O-])CC(O)C[N+](C)(C)C	4.7750001	Active	Mitochondrial carnitine/acylcarnitine carrier protein Substrate&Mitochondrial Carnitine/acylcarnitine Carrier Protein Substrate	0.0	1	DL-Carnitine HCl	405558577	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.4	-37.231050012&-66.29037656	O=C(O)CC(O)C[N+](C)(C)C	O=C(O)CC(O)C[N+](C)(C)C
NCGC00015150-04&NCGC00015150-07	O=C([O-])C[N+](C)(C)C		Inactive	Nitric Oxide Donor&Nitric Oxide (NO) Donors&Nitric Oxide (NO) Donors		2	Betaine	174007375&384567816	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	11.519373452&0.0&-20.795952576	O=C(O)C[N+](C)(C)C.[Cl-]	O=C(O)C[N+](C)(C)C.[Cl-]&O=C(O)C[N+](C)(C)C
NCGC00263233-01	O=C(c1[nH]c2c(c3c(cc2)cccc3)c1)c1ccc(N)cc1	5.3499999	Active	Inducible phosphofructokinase-2 Inhibitor	0.0	1	IPFK2	137276077	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-72.702885238	O=C(c1[nH]c2c(c3c(cc2)cccc3)c1)c1ccc(N)cc1	O=C(c1[nH]c2c(c3c(cc2)cccc3)c1)c1ccc(N)cc1
NCGC00015889-11&NCGC00015889-21	O=C(c1c(-c2ccc(O)cc2)sc2c1ccc(O)c2)c1ccc(OCCN2CCCCC2)cc1	4.5250001	Active	Selective Estrogen Receptor Modulators (serm)&Selective Estrogen Receptor Modulators (SERM)&Selective Estrogen Receptor Modulators (SERM)	0.05000020000000038	2	Raloxifene hydrochloride	170465341&384567903	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0&-2.1	-107.3097997959&-104.180668992&-107.2801769098	O=C(c1c(-c2ccc(O)cc2)sc2c1ccc(O)c2)c1ccc(OCCN2CCCCC2)cc1.Cl	O=C(c1c(-c2ccc(O)cc2)sc2c1ccc(O)c2)c1ccc(OCCN2CCCCC2)cc1.Cl&O=C(c1c(-c2ccc(O)cc2)sc2c1ccc(O)c2)c1ccc(OCCN2CCCCC2)cc1
NCGC00160396-04	O=C(c1c(C)n(CCN2CCOCC2)c2c1cccc2)c1ccc(OC)cc1	4.5	Active	COX Inhibitor and cannabinoid (CB) agonist	0.0	1	Pravadoline	170466117	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-92.6111132677	O=C(c1c(C)n(CCN2CCOCC2)c2c1cccc2)c1ccc(OC)cc1	O=C(c1c(C)n(CCN2CCOCC2)c2c1cccc2)c1ccc(OC)cc1
NCGC00480730-01	O=C(c1c(N)c(c(C)cc1)-c1cc2c(nc(C)cc2)cc1)C=1C(=O)N(N(C)C=1c1ccccc1)c1ccccc1	4.4000001	Active	PERK Inhibitor	0.0	1	AMG PERK 44	377020519	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-72.4651561871	O=C(c1c(N)c(c(C)cc1)-c1cc2c(nc(C)cc2)cc1)C=1C(=O)N(N(C)C=1c1ccccc1)c1ccccc1	O=C(c1c(N)c(c(C)cc1)-c1cc2c(nc(C)cc2)cc1)C=1C(=O)N(N(C)C=1c1ccccc1)c1ccccc1
NCGC00386433-04	O=C(c1c(N)n(-c2cc3[nH]c(C)nc3cc2)nc1)c1[nH]c2c(c1)cccc2	4.9499998	Active	FGFR 1/2/3 Inhibitor	0.0	1	CH-5183284	384569140	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-68.1407748645	O=C(c1c(N)n(-c2cc3[nH]c(C)nc3cc2)nc1)c1[nH]c2c(c1)cccc2	O=C(c1c(N)n(-c2cc3[nH]c(C)nc3cc2)nc1)c1[nH]c2c(c1)cccc2
NCGC00016393-07	O=C(c1c(O)cc(OC)cc1)c1c(O)cccc1	5.8000002	Active		0.0	1	2,2'-Dihydroxy-4-methoxybenzophenone	170465540	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-38.0970794279	O=C(c1c(O)cc(OC)cc1)c1c(O)cccc1	O=C(c1c(O)cc(OC)cc1)c1c(O)cccc1
NCGC00016394-10	O=C(c1c(O)cc(OC)cc1)c1ccccc1		Inactive			1	2-Hydroxy-4-methoxybenzophenone	170465010	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&27.321601712	O=C(c1c(O)cc(OC)cc1)c1ccccc1	O=C(c1c(O)cc(OC)cc1)c1ccccc1
NCGC00092375-02	O=C(c1cc2c(nc3OCCCc3c2)cc1)C1CCC(OC)CC1		Inactive	mgluR1 Antagonist		1	JNJ-16259685	174006314	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C(c1cc2c(nc3OCCCc3c2)cc1)C1CCC(OC)CC1	O=C(c1cc2c(nc3OCCCc3c2)cc1)C1CCC(OC)CC1
NCGC00090787-08	O=C(c1ccccc1)c1ccccc1		Inactive			1	Benzophenone	170465649	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	26.4761017159&0.0	O=C(c1ccccc1)c1ccccc1	O=C(c1ccccc1)c1ccccc1
NCGC00185990-14	O=C(c1n2c(C(C(=O)O)CC2)cc1)c1ccccc1		Inactive	non-steroidal antiinflammatory		1	Ketorolac	384568431	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	16.85457536	O=C(c1n2c(C(C(=O)O)CC2)cc1)c1ccccc1	O=C(c1n2c(C(C(=O)O)CC2)cc1)c1ccccc1
NCGC00499248-01	O=C(c1nc2c(-c3ccc(-c4cn(C)nc4)cc3)cnc(N)c2cc1)C1CC(OC)C1	5.0500002	Active	CDK 8/19 Inhibitor	0.0	1	CDK8i-51	384569304	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-90.910020556	O=C(c1nc2c(-c3ccc(-c4cn(C)nc4)cc3)cnc(N)c2cc1)C1CC(OC)C1	O=C(c1nc2c(-c3ccc(-c4cn(C)nc4)cc3)cnc(N)c2cc1)C1CC(OC)C1
NCGC00511348-01	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1C(CC)CCCC1	5.0	Active	ABHD11 Inhibitor	0.0	1	ML226	384569496	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-80.1881635473	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1C(CC)CCCC1	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1C(CC)CCCC1
NCGC00091512-04	O=C/C=C/c1ccccc1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist&Peroxisome Proliferator-activated Receptor Gamma Agonist		1	(2E)-3-Phenylprop-2-enal	144204695	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.148883876&-17.201291072	O=C/C=C/c1ccccc1	O=C/C=C/c1ccccc1
NCGC00179302-06	O=C1/C(=C/2\C(=O)c3c(N\2)cccc3)/c2c(N1)cccc2		Inactive	CDK1/2/4/5 Inhibitor		1	Indirubin	384568370	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1/C(=C/2\C(=O)c3c(N\2)cccc3)/c2c(N1)cccc2	O=C1/C(=C/2\C(=O)c3c(N\2)cccc3)/c2c(N1)cccc2
NCGC00095597-05	O=C1/C(=C/CC2C(=C)CCC3[C@@](CO)(C)C(O)CC[C@]23C)/C(O)CO1	4.4000001	Active	TNF-alpha Production Inhibitor	0.0	1	Andrographolide	384568158	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-86.5398819279	O=C1/C(=C/CC2C(=C)CCC3[C@@](CO)(C)C(O)CC[C@]23C)/C(O)CO1	O=C1/C(=C/CC2C(=C)CCC3[C@@](CO)(C)C(O)CC[C@]23C)/C(O)CO1
NCGC00179817-06	O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/[C@H](O)CO1	4.5999999	Active	TNF-alpha Production Inhibitor	0.0	1	Andrographolide	384568383	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-109.0681497053	O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/[C@H](O)CO1	O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/[C@H](O)CO1
NCGC00263169-06	O=C1/C(=C/c2c(C(C)(C)C)[nH]cn2)/NC(=O)/C(=C/c2ccccc2)/N1	4.3499999	Inactive	Tubulin polymerization Inhibitor	0.0	1	Plinabulin	384568639	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-39.343446457	O=C1/C(=C/c2c(C(C)(C)C)[nH]cn2)/NC(=O)/C(=C/c2ccccc2)/N1	O=C1/C(=C/c2c(C(C)(C)C)[nH]cn2)/NC(=O)/C(=C/c2ccccc2)/N1
NCGC00387042-02	O=C1/C(=C/c2c(N3CC(N)CCC3)c(-c3ccccc3)ccc2)/SC(=O)N1		Inactive	Pim-1/2/3 kinase Inhibitor		1	AZD-1208	384569151	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-8.808434988	O=C1/C(=C/c2c(N3CC(N)CCC3)c(-c3ccccc3)ccc2)/SC(=O)N1	O=C1/C(=C/c2c(N3CC(N)CCC3)c(-c3ccccc3)ccc2)/SC(=O)N1
NCGC00186030-12	O=C1/C(=C/c2cc3nccnc3cc2)/SC(=O)N1		Inactive	PI3K gamma Inhibitor		1	AS-605240	384568437	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1/C(=C/c2cc3nccnc3cc2)/SC(=O)N1	O=C1/C(=C/c2cc3nccnc3cc2)/SC(=O)N1
NCGC00163355-05	O=C1/C(=C\2/C(=O)c3c(N/2)cccc3)/Nc2c1cccc2		Inactive			1	Indigo	170465746	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1/C(=C\2/C(=O)c3c(N/2)cccc3)/Nc2c1cccc2	O=C1/C(=C\2/C(=O)c3c(N/2)cccc3)/Nc2c1cccc2
NCGC00094381-09	O=C1/C(=C\c2c(C)cc(C)[nH]2)/c2c(N1)cccc2		Inactive	Flt3 Inhibitor		1	Semaxanib	384568130	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1/C(=C\c2c(C)cc(C)[nH]2)/c2c(N1)cccc2	O=C1/C(=C\c2c(C)cc(C)[nH]2)/c2c(N1)cccc2
NCGC00242501-03	O=C1/C(=C\c2c(C)n(c(C)c2)-c2ccccc2)/Sc2n1c1c(n2)cccc1	5.9499998	Inactive	Triple Functional Domain Protein (TRIO) Inhibitor	0.0	1	ITX3	377020171	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-19.8957630839	O=C1/C(=C\c2c(C)n(c(C)c2)-c2ccccc2)/Sc2n1c1c(n2)cccc1	O=C1/C(=C\c2c(C)n(c(C)c2)-c2ccccc2)/Sc2n1c1c(n2)cccc1
NCGC00161398-06	O=C1/C(=C\c2c3c(n(C)c2)cccc3)/c2ncccc2N1	6.0999999	Inactive	Trk A Inhibitor	0.0	1	GW-441756	384568205	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-9.76829794	O=C1/C(=C\c2c3c(n(C)c2)cccc3)/c2ncccc2N1	O=C1/C(=C\c2c3c(n(C)c2)cccc3)/c2ncccc2N1
NCGC00167419-03	O=C1/C(=C\c2ccc(C)cc2)/C2C(C)(C)C1(C)CC2		Inactive			1	ENZACAMENE	405559131	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1/C(=C\c2ccc(C)cc2)/C2C(C)(C)C1(C)CC2	O=C1/C(=C\c2ccc(C)cc2)/C2C(C)(C)C1(C)CC2
NCGC00532513-01	O=C1/C(=N\NC(=N)N)/C=C2C(O)CN(C)C2=C1	5.6999998	Active		0.0	1	ADRENOCHROME MONOAMINOGUANIDINE MESILATE ANHYDROUS	405558436	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-32.5952876	O=C1/C(=N\NC(=N)N)/C=C2C(O)CN(C)C2=C1	O=C1/C(=N\NC(=N)N)/C=C2C(O)CN(C)C2=C1
NCGC00167740-02	O=C1C(=C)C2C(O1)/C=C(/C)\CC/C=C(/C)\CC2	4.9499998	Active	Telomerase Inhibitor	0.0	1	Costunolide	384568332	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-50.1048252536	O=C1C(=C)C2C(O1)/C=C(/C)\CC/C=C(/C)\CC2	O=C1C(=C)C2C(O1)/C=C(/C)\CC/C=C(/C)\CC2
NCGC00346595-02	O=C1C(=C)[C@H]2[C@@H](O)[C@]31[C@@]1(O)[C@@H](O)[C@@H]4C(C)(C)CC[C@H](O)[C@]4(C3CC2)CO1	4.9000001	Active	Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activator	0.0	1	Oridonin	363677470	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-117.77147752	O=C1C(=C)[C@H]2[C@@H](O)[C@]31[C@@]1(O)[C@@H](O)[C@@H]4C(C)(C)CC[C@H](O)[C@]4(C3CC2)CO1	O=C1C(=C)[C@H]2[C@@H](O)[C@]31[C@@]1(O)[C@@H](O)[C@@H]4C(C)(C)CC[C@H](O)[C@]4(C3CC2)CO1
NCGC00163415-04&NCGC00163415-09	O=C1C(=C)[C@H]2[C@H](O1)[C@@H]1[C@](C)(O1)CC/C=C(\C)/CC2	4.48749995	Active	Nf-kappab Activation Modulator&NF-kappaB Activation Modulator&NF-kappaB Activation Modulator	0.07500030000000013	2	NCGC00163415-04&Parthenolide&Parthenolide	405559133&384568236	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1&-2.3	-118.52303472&-110.7739902677&-105.9502659803	O=C1C(=C)[C@H]2[C@H](O1)[C@@H]1[C@](C)(O1)CC/C=C(\C)/CC2	O=C1C(=C)[C@H]2[C@H](O1)[C@@H]1[C@](C)(O1)CC/C=C(\C)/CC2
NCGC00390770-02	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC[C@@]31[C@@](C)(O3)CC2	4.5	Active	Farnesyltransferase Inhibitor	0.0	1	Arglabin	384569212	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-50.4127246816	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC[C@@]31[C@@](C)(O3)CC2	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC[C@@]31[C@@](C)(O3)CC2
NCGC00015598-16	O=C1C(=O)C2=C(OC(C)(C)CC2)c2c1cccc2	4.4000001	Active	Tryptophan 2,3-Dioxygenase (TDO) Inhibitor	0.0	1	beta-Lapachone	384567869	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-91.608001684	O=C1C(=O)C2=C(OC(C)(C)CC2)c2c1cccc2	O=C1C(=O)C2=C(OC(C)(C)CC2)c2c1cccc2
NCGC00163650-04	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(C(C)(C)CCC1)cc2		Inactive	STAT-3 Inhibitor		1	Cryptotanshinone	384568247	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(C(C)(C)CCC1)cc2	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(C(C)(C)CCC1)cc2
NCGC00095709-08	O=C1C(=O)c2c(-c3occ(C)c13)ccc1C(C)(C)CCCc21		Inactive	TNF-alpha Production Inhibitor		1	Tanshinone IIA	363676577	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.527078576	O=C1C(=O)c2c(-c3occ(C)c13)ccc1C(C)(C)CCCc21	O=C1C(=O)c2c(-c3occ(C)c13)ccc1C(C)(C)CCCc21
NCGC00250373-04	O=C1C(C#N)=C(O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1		Inactive	AMPK Activator		1	A-769662	384568535	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	9.912571792	O=C1C(C#N)=C(O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1	O=C1C(C#N)=C(O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1
NCGC00162385-04	O=C1C(C#N)=CC(=C(C)N1)C1=Cn2c(ncc2)C=C1		Inactive	Phosphodiesterase 3 Inhibitor&Phosphodiesterase III (PDE3) Inhibitor		1	Olprinone	170465898	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-11.780459416&0.0&0.0	O=C1C(C#N)=CC(=C(C)N1)C1=Cn2c(ncc2)C=C1.Cl	O=C1C(C#N)=CC(=C(C)N1)C1=Cn2c(ncc2)C=C1.Cl
NCGC00015675-11&NCGC00015675-22	O=C1C(C#N)=CC(c2ccncc2)=C(C)N1		Inactive	Phosphodiesterase Iii (pde3) Inhibitor&Phosphodiesterase III (PDE3) Inhibitor&Phosphodiesterase III (PDE3) Inhibitor		2	Milrinone	170465221&384567880	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&10.1581840479&0.0	O=C1C(C#N)=CC(c2ccncc2)=C(C)N1	O=C1C(C#N)=CC(c2ccncc2)=C(C)N1
NCGC00486892-01	O=C1C(C(C)C)=C(c2ccccc2)Nc2c(C#N)cnn12		Inactive	Lysine-Specific Demethylase 5B (KDM5B; JARID1B) Inhibitor		1	CPI-455	384569280	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(C(C)C)=C(c2ccccc2)Nc2c(C#N)cnn12	O=C1C(C(C)C)=C(c2ccccc2)Nc2c(C#N)cnn12
NCGC00253567-01	O=C1C(C(CC)C)(CC=C)C(=O)NC(=O)N1		Inactive	Gaba-a Receptor; Anion Channel Positive Allosteric Modulator&GABA-A receptor; anion channel Positive Allosteric Modulator		1	Talbutal	170465408	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.0827908159&-20.9743419639	O=C1C(C(CC)C)(CC=C)C(=O)NC(=O)N1	O=C1C(C(CC)C)(CC=C)C(=O)NC(=O)N1
NCGC00390775-03	O=C1C(C)=C2C(O1)=C[C@]1(C)[C@H](C(=C)CCC1)C2		Inactive	TNF-alpha Production Inhibitor		1	Atractylenolide I	384569213	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.745856208	O=C1C(C)=C2C(O1)=C[C@]1(C)[C@H](C(=C)CCC1)C2	O=C1C(C)=C2C(O1)=C[C@]1(C)[C@H](C(=C)CCC1)C2
NCGC00181325-03	O=C1C(C/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)=C(C)C(=O)c2c1cccc2	4.4000001	Active	bone resorption Inhibitor	0.0	1	Menaquinone	405558876	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.034607156	O=C1C(C/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)=C(C)C(=O)c2c1cccc2	O=C1C(C/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)=C(C)C(=O)c2c1cccc2
NCGC00159423-03	O=C1C(C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)\C)=C(C)C(=O)c2c1cccc2		Inactive	Vitamin K Epoxide Reductase Complex Subunit 1 Substrate&Vitamin K epoxide reductase complex subunit 1 Substrate		1	Phytonadione	170464798	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.589406844&0.0	O=C1C(C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)\C)=C(C)C(=O)c2c1cccc2	O=C1C(C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)\C)=C(C)C(=O)c2c1cccc2
NCGC00015418-09&NCGC00015418-11	O=C1C(CC)(C)CC(=O)N1		Inactive	Voltage-dependent T-type Calcium Channel Subunit Alpha-1g Inhibitor&T-Type Calcium Channel Blocker&T-Type Calcium Channel Blocker		2	Ethosuximide	170464802&384567840	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(CC)(C)CC(=O)N1	O=C1C(CC)(C)CC(=O)N1
NCGC00015110-09&NCGC00015110-20	O=C1C(CC)(c2ccc(N)cc2)CCC(=O)N1		Inactive	Aromatase Inhibitor		2	Aminoglutethimide	170465259&384567810	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-9.071854828	O=C1C(CC)(c2ccc(N)cc2)CCC(=O)N1	O=C1C(CC)(c2ccc(N)cc2)CCC(=O)N1
NCGC00015834-19&NCGC00015834-27	O=C1C(CC)(c2ccccc2)C(=O)NCN1		Inactive	Anticonvulsant Agent&Anticonvulsant agent&Anticonvulsant agent		2	Primidone	170464846&384567897	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	8.88573288&20.985075088&-22.9288947759	O=C1C(CC)(c2ccccc2)C(=O)NCN1	O=C1C(CC)(c2ccccc2)C(=O)NCN1
NCGC00016296-07	O=C1C(CC=2C(=O)Oc3c(C=2O)cccc3)=C(O)c2c(O1)cccc2		Inactive	Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor&Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		1	Dicumarol	170465275	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-17.969631632	O=C1C(CC=2C(=O)Oc3c(C=2O)cccc3)=C(O)c2c(O1)cccc2	O=C1C(CC=2C(=O)Oc3c(C=2O)cccc3)=C(O)c2c(O1)cccc2
NCGC00179297-04	O=C1C(CCC)C(=O)N2N1C(N(C)C)=Nc1c2cc(C)cc1		Inactive	Interleukin-1 Alpha Production Inhibitor&interleukin-1 alpha production Inhibitor		1	Azapropazone	405558878	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.3592942879&0.0	O=C1C(CCC)C(=O)N2N1C(N(C)C)=Nc1c2cc(C)cc1	O=C1C(CCC)C(=O)N2N1C(N(C)C)=Nc1c2cc(C)cc1
NCGC00017248-18	O=C1C(CCCCCCCCCCC)=C(O)C(=O)C=C1O		Inactive	IAP Inhibitor		1	Embelin	384567980	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(CCCCCCCCCCC)=C(O)C(=O)C=C1O	O=C1C(CCCCCCCCCCC)=C(O)C(=O)C=C1O
NCGC00162218-05	O=C1C(CN2CCOCC2)CCc2[nH]c(C)c(CC)c12		Inactive	Serotonin 7 (5-HT7) receptor Antagonist&Serotonin 7 (5-ht7) Receptor Antagonist		1	Molindone hydrochloride	170465047	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.757043568&0.0	O=C1C(CN2CCOCC2)CCc2[nH]c(C)c(CC)c12.Cl	O=C1C(CN2CCOCC2)CCc2[nH]c(C)c(CC)c12.Cl
NCGC00179341-04	O=C1C(Cn2c(C)ncc2)CCc2n(C)c3c(c12)cccc3	4.4000001	Active	5-ht3 Antagonists	0.0	1	Ondansetron	170464701	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-63.837223516	O=C1C(Cn2c(C)ncc2)CCc2n(C)c3c(c12)cccc3	O=C1C(Cn2c(C)ncc2)CCc2n(C)c3c(c12)cccc3
NCGC00016896-06	O=C1C(N)=CC(c2ccncc2)=CN1		Inactive	Platelet Aggregation Inhibitor&platelet aggregation Inhibitor		1	Amrinone	170465367	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1C(N)=CC(c2ccncc2)=CN1	O=C1C(N)=CC(c2ccncc2)=CN1
NCGC00015989-17&NCGC00015989-22	O=C1C(N2C(=O)c3c(C2=O)cccc3)CCC(=O)N1		Inactive	Tnf-alpha Inhibitor&TNF-alpha Production Inhibitor&TNF-alpha Production Inhibitor		2	Thalidomide	170465323&384567913	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(N2C(=O)c3c(C2=O)cccc3)CCC(=O)N1	O=C1C(N2C(=O)c3c(C2=O)cccc3)CCC(=O)N1
NCGC00167491-04	O=C1C(N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1		Inactive	Protein Cereblon Inhibitor&TNF-alpha Production Inhibitor		1	Lenalidomide	170465201	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.5419404279&-14.8139835239	O=C1C(N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1	O=C1C(N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1
NCGC00509909-01	O=C1C(N2C(C)=Nc3c(c(N)ccc3)C2=O)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		1	Avadomide	384569376	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.6891535721	O=C1C(N2C(C)=Nc3c(c(N)ccc3)C2=O)CCC(=O)N1	O=C1C(N2C(C)=Nc3c(c(N)ccc3)C2=O)CCC(=O)N1
NCGC00510878-01	O=C1C(N2CC2)=CC(=O)c2n(C)c(/C=C/CO)c(CO)c12		Inactive	DNA Alkylating Drugs		1	Apaziquone	384569492	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-10.1323356359	O=C1C(N2CC2)=CC(=O)c2n(C)c(/C=C/CO)c(CO)c12	O=C1C(N2CC2)=CC(=O)c2n(C)c(/C=C/CO)c(CO)c12
NCGC00179264-03	O=C1C(NCC)(c2sccc2)CCCC1	5.0500002	Active	Glutamate [NMDA] receptor subunit epsilon 2 Antagonist	0.0	1	Tiletamine Hydrochloride	405558786	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-30.157605724	O=C1C(NCC)(c2sccc2)CCCC1	O=C1C(NCC)(c2sccc2)CCCC1
NCGC00492296-02	O=C1C(Nc2ncnc(N)c2)=CC(C)=C2C(=O)NC3(N12)CCCCC3		Inactive	MNK1/2 Inhibitor		1	eFT508	384569287	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(Nc2ncnc(N)c2)=CC(C)=C2C(=O)NC3(N12)CCCCC3	O=C1C(Nc2ncnc(N)c2)=CC(C)=C2C(=O)NC3(N12)CCCCC3
NCGC00090548-04	O=C1C(O)=C(C)N(C)C=C1	4.4499998	Active	Iron Chelating Agent	0.0	1	Deferiprone	405558541	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.176760448	O=C1C(O)=C(C)N(C)C=C1	O=C1C(O)=C(C)N(C)C=C1
NCGC00091517-06	O=C1C(O)=C(O)[C@@H]([C@@H](O)CO)O1	5.75	Active		0.0	1	L-Ascorbic acid	170464728	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.2806427768	O=C1C(O)=C(O)[C@@H]([C@@H](O)CO)O1	O=C1C(O)=C(O)[C@@H]([C@@H](O)CO)O1
NCGC00015672-15	O=C1C(O)=C(c2c(O)cc(O)cc2)Oc2c1c(O)cc(O)c2		Inactive	Cytochrome P450 CYP1A2 Inhibitor		1	Morin hydrate	384567879	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(O)=C(c2c(O)cc(O)cc2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2c(O)cc(O)cc2)Oc2c1c(O)cc(O)c2
NCGC00015697-01	O=C1C(O)=C(c2cc(O)c(O)c(O)c2)Oc2c1c(O)cc(O)c2		Inactive	Cytochrome P450 CYP1A2 Inhibitor		1	Myricetin	11111487	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(O)=C(c2cc(O)c(O)c(O)c2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2cc(O)c(O)c(O)c2)Oc2c1c(O)cc(O)c2
NCGC00015870-26&NCGC00015870-27	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2		Inactive	Flavone&Catechol-o-methyltransferase Inhibitor&Flavone		2	Quercetin	384567899&170466817	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-13.688782596&-35.660072924&0.0	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2&O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2.O.O
NCGC00017344-11	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1ccc(O)c2	4.4000001	Active	Histone Deacetylase/SIRT1 Activator	0.0	1	Fisetin	384567986	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-85.601670968	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1ccc(O)c2	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1ccc(O)c2
NCGC00016480-20	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1c(O)cc(O)c2		Inactive	flavanoid		1	Kaempferol	384567944	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1c(O)cc(O)c2
NCGC00164380-01	O=C1C(O)=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2)CC1		Inactive	Aromatase Inhibitor		1	Formestane	26757799	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(O)=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2)CC1	O=C1C(O)=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2)CC1
NCGC00017325-06	O=C1C(O)=COC(CO)=C1		Inactive	Tyrosinase Inhibitor		1	Kojic acid	170466814	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	5.2514952479&0.0	O=C1C(O)=COC(CO)=C1	O=C1C(O)=COC(CO)=C1
NCGC00163489-03	O=C1C([C@H](O)CC=C(C)C)=CC(=O)c2c(O)ccc(O)c12		Inactive	Drugs Acting on Chemokine Receptors		1	Shikonin	384568243	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C([C@H](O)CC=C(C)C)=CC(=O)c2c(O)ccc(O)c12	O=C1C([C@H](O)CC=C(C)C)=CC(=O)c2c(O)ccc(O)c12
NCGC00181135-02	O=C1C([C@H](O)CCCCC)[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=C[C@@H](O)C(C)O1		Inactive			1	Pentamycin	144206785	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.44539252&-24.024037492	O=C1C([C@H](O)CCCCC)[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=C[C@@H](O)C(C)O1	O=C1C([C@H](O)CCCCC)[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=C[C@@H](O)C(C)O1
NCGC00167434-02	O=C1C(c2[nH]nnn2)=CN=C2C(C)=CC=CN12		Inactive			1	Pemirolast potassium	170465431	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-36.7627705879&0.0	O=C1C(c2nnn[n-]2)=CN=C2C(C)=CC=CN12.[K+]	O=C1C(c2nnn[n-]2)=CN=C2C(C)=CC=CN12.[K+]
NCGC00262009-03	O=C1C(c2c3c([nH]c2)cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1	4.4000001	Active	CDK4 Inhibitor	0.0	1	Bisindolylmaleimide	377020269	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-87.074806536	O=C1C(c2c3c([nH]c2)cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1	O=C1C(c2c3c([nH]c2)cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1
NCGC00238452-03&NCGC00238452-05	O=C1C(c2c3c(n(C)c2)cccc3)=C(c2c3c(n(C4CCN(Cc5ncccc5)CC4)c2)cccc3)C(=O)N1	5.60000015	Active	PKCa, PKCb, PKCg inhbitor	0.09999989999999936	2	Enzastaurin	170465609&384568465	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4	-53.8346754532&-35.8068620496	O=C1C(c2c3c(n(C)c2)cccc3)=C(c2c3c(n(C4CCN(Cc5ncccc5)CC4)c2)cccc3)C(=O)N1	O=C1C(c2c3c(n(C)c2)cccc3)=C(c2c3c(n(C4CCN(Cc5ncccc5)CC4)c2)cccc3)C(=O)N1
NCGC00262061-03	O=C1C(c2c3c(n4c2CC(CN)CC4)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1		Inactive	PKC Inhibitor		1	Ro-31-8425	384568570	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.838753844	O=C1C(c2c3c(n4c2CC(CN)CC4)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1	O=C1C(c2c3c(n4c2CC(CN)CC4)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1
NCGC00096060-07	O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c(O)ccc12	4.5	Inactive		0.0	1	Puerarin	384568159	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	48.1677080369	O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c(O)ccc12	O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c(O)ccc12
NCGC00015365-22	O=C1C(c2ccc(O)cc2)=COc2c1ccc(O)c2		Inactive	Estrogen Receptor (ER) beta Agonist		1	Daidzein	384567838	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C(c2ccc(O)cc2)=COc2c1ccc(O)c2	O=C1C(c2ccc(O)cc2)=COc2c1ccc(O)c2
NCGC00021139-11	O=C1C(c2ccccc2)(c2ccccc2)NC(=O)N1		Inactive			1	5,5-Diphenylhydantoin	170464785	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1C(c2ccccc2)(c2ccccc2)NC(=O)N1	O=C1C(c2ccccc2)(c2ccccc2)NC(=O)N1
NCGC00016329-07	O=C1C(c2ccccc2)C(=O)c2c1cccc2		Inactive	Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor&Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		1	Phenindione	170465130	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.07482536&-13.44579114	O=C1C(c2ccccc2)C(=O)c2c1cccc2	O=C1C(c2ccccc2)C(=O)c2c1cccc2
NCGC00238621-08	O=C1C(c2nc(N3CCN(C)CC3)nc3c2cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1	4.5500002	Active	Protein kinase C theta Inhibitor	0.0	1	Sotrastaurin	384568467	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-66.4449398876	O=C1C(c2nc(N3CCN(C)CC3)nc3c2cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1	O=C1C(c2nc(N3CCN(C)CC3)nc3c2cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1
NCGC00263858-10	O=C1C2(C(=O)O[Pt]O1)CCC2		Inactive	DNA Alkylating Agent		1	Carboplatin	384568697	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.739576196	O=C1C2(C(=O)O[Pt]O1)CCC2	O=C1C2(C(=O)O[Pt]O1)CCC2
NCGC00263190-11	O=C1C=C(N2CCOCC2)OC(c2c3Sc4c(Sc3ccc2)cccc4)=C1	4.5	Active	ATM Kinase Inhibitor	0.0	1	KU-0064	384568655	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-56.1435127301	O=C1C=C(N2CCOCC2)OC(c2c3Sc4c(Sc3ccc2)cccc4)=C1	O=C1C=C(N2CCOCC2)OC(c2c3Sc4c(Sc3ccc2)cccc4)=C1
NCGC00025179-12&NCGC00025179-20	O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@]4(C)[C@](O)(C#CC)CC[C@H]4[C@@H]3CC2)CC1	4.6500001	Active	Progesterone Receptor Antagonist	0.5	2	Mifepristone	170465151&384568054	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-38.5976639336&-41.7920088559	O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@]4(C)[C@](O)(C#CC)CC[C@H]4[C@@H]3CC2)CC1	O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@]4(C)[C@](O)(C#CC)CC[C@H]4[C@@H]3CC2)CC1
NCGC00166309-02	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC=C)CC4)C=C3)CC2)CC1	4.4499998	Active		0.0	1	Altrenogest	170465646	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-88.84703074&-60.0568482409	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC=C)CC4)C=C3)CC2)CC1	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC=C)CC4)C=C3)CC2)CC1
NCGC00167457-02	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)C=C3)CC2)CC1	4.5749998	Active	Progesterone receptor Agonist&Progesterone Receptor Agonist	0.0	1	Gestrinone	170466364	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-46.0929420476&-52.753657	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)C=C3)CC2)CC1	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)C=C3)CC2)CC1
NCGC00095023-08	O=C1C=C2C(C)(C3C(C4C(C)(C(O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Ethisterone	384568141	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C=C2C(C)(C3C(C4C(C)(C(O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2C(C)(C3C(C4C(C)(C(O)(C#C)CC4)CC3)CC2)CC1
NCGC00344378-02	O=C1C=C2C([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progestogen Hormone&Progestogen hormone		1	Norgestrel	405558518	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.412923688&-22.4233407279	O=C1C=C2C([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2C([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00274271-01	O=C1C=C2[C@@H](C)C[C@H]3[C@H]4[C@@](C)([C@](O)(C#CC)CC4)CC[C@@H]3[C@@]2(C)CC1	4.625	Active		0.0	1	Dimethisteron	170465914	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-3.0	-78.9084619571&-97.8189903453	O=C1C=C2[C@@H](C)C[C@H]3[C@H]4[C@@](C)([C@](O)(C#CC)CC4)CC[C@@H]3[C@@]2(C)CC1	O=C1C=C2[C@@H](C)C[C@H]3[C@H]4[C@@](C)([C@](O)(C#CC)CC4)CC[C@@H]3[C@@]2(C)CC1
NCGC00253603-01	O=C1C=C2[C@@H]([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C)CC2)CC3)CC1	4.5	Active	Progesterone Receptor Agonist&Progesterone receptor Agonist	0.0	1	Mibolerone	170466095	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-73.6583799839&-53.1272713363	O=C1C=C2[C@@H]([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C)CC2)CC3)CC1	O=C1C=C2[C@@H]([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C)CC2)CC3)CC1
NCGC00183854-01	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)[C@@H](CC)C4)CC3)CC2)CC1	4.4000001	Active		0.0	1	Oxendolone	144206842	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.1419305279	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)[C@@H](CC)C4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)[C@@H](CC)C4)CC3)CC2)CC1
NCGC00179669-04	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive			1	Norethindrone	170464683	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&20.269064196	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00263565-01&NCGC00263565-06	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)C=C4)CC3)CC2)CC1	4.70000005	Active	Progestogen Hormone&Progestogen hormone	0.5999999000000003	2	Gestodene	170466131&384568689	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-81.707762224&-46.5556190732	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)C=C4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)C=C4)CC3)CC2)CC1
NCGC00159349-15	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Levonorgestrel	384568171	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00168777-04	O=C1C=C2[C@@H]([C@H]3C(=C)C[C@]4(CC)[C@](O)(C#C)CC[C@H]4[C@@H]3CC2)CC1	4.4000001	Active	contraceptive&Contraceptive	0.0	1	Etonogestrel	405558738	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-68.5727095199&-47.934112344	O=C1C=C2[C@@H]([C@H]3C(=C)C[C@]4(CC)[C@](O)(C#C)CC[C@H]4[C@@H]3CC2)CC1	O=C1C=C2[C@@H]([C@H]3C(=C)C[C@]4(CC)[C@](O)(C#C)CC[C@H]4[C@@H]3CC2)CC1
NCGC00271596-03&NCGC00271596-15	O=C1C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2=C)C=C1	4.8625002	Active	Aromatase Inhibitor	0.125	2	Exemestane	170464628&384568705	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4&-2.2	-31.0927795925&-31.3021962079&-56.3889457547	O=C1C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2=C)C=C1	O=C1C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2=C)C=C1
NCGC00094740-05	O=C1CC2=C(C3C(C4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1	5.0500002	Inactive	Progesterone Receptor Agonist	0.0	1	NORETHYNODREL	405558843	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	47.2859961641	O=C1CC2=C(C3C(C4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1CC2=C(C3C(C4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00164632-02&NCGC00164632-07	O=C1CC2=C([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C#C)CC2)CC3)CC1		Inactive	Androgen Receptor Agonist&Steryl-sulfatase  Inhibitor&Steryl-sulfatase  Inhibitor		2	Tibolone&TIBOLONE	170465874&384568271	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	27.8293200279&0.0&-14.294970728	O=C1CC2=C([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C#C)CC2)CC3)CC1	O=C1CC2=C([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C#C)CC2)CC3)CC1
NCGC00167559-01	O=C1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C=CC4)CC3)CC2)CC1		Inactive			1	Androstenone	144206107	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.2300514519&-20.2654285104	O=C1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C=CC4)CC3)CC2)CC1	O=C1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C=CC4)CC3)CC2)CC1
NCGC00181911-01	O=C1N(C(=O)NC(=O)C1CCCC)C1CCCCC1		Inactive	Cytochrome P450 2c9 Inhibitor&Cytochrome P450 2C9 Inhibitor		1	Bucolome	144206890	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.258418476	O=C1N(C(=O)NC(=O)C1CCCC)C1CCCCC1	O=C1N(C(=O)NC(=O)C1CCCC)C1CCCCC1
NCGC00510355-01	O=C1N(C(C)C)C(=O)C=C(N[C@@H](C)c2ccccc2)N1	4.0500002	Inactive	Drugs Targeting Myosin	0.0	1	Mavacamten	384569430	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-19.6800892559	O=C1N(C(C)C)C(=O)C=C(N[C@@H](C)c2ccccc2)N1	O=C1N(C(C)C)C(=O)C=C(N[C@@H](C)c2ccccc2)N1
NCGC00014873-05	O=C1N(C)C(=O)C2=C(NCCCN(C)C)c3c(N(C)C2=N1)cccc3	4.5	Active	MDM2 (hdm2) Inhibitor	0.0	1	HLI-373989	384567794	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-123.7117560424	O=C1N(C)C(=O)C2=C(NCCCN(C)C)c3c(N(C)C2=N1)cccc3	O=C1N(C)C(=O)C2=C(NCCCN(C)C)c3c(N(C)C2=N1)cccc3
NCGC00189077-01	O=C1N(C)C(=O)CC1(C)c1ccccc1		Inactive	Voltage-gated T-type Calcium Channel Inhibitor&Voltage-gated T-type calcium channel Inhibitor		1	Methsuximide	144207162	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-24.9994953599&-15.6000924999	O=C1N(C)C(=O)CC1(C)c1ccccc1	O=C1N(C)C(=O)CC1(C)c1ccccc1
NCGC00179333-03	O=C1N(C)C(=O)CC1c1ccccc1		Inactive			1	Phensuximide	170465315	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-17.0789176159	O=C1N(C)C(=O)CC1c1ccccc1	O=C1N(C)C(=O)CC1c1ccccc1
NCGC00181148-01	O=C1N(C)C(=O)NC(=O)C1(CC)CC	4.4749999	Active	Gaba-a Receptor; Anion Channel Binding Agent&GABA-A receptor; anion channel Binding Agent	0.0	1	Metharbital	144206305	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-15.222676144&-57.8716557076	O=C1N(C)C(=O)NC(=O)C1(CC)CC	O=C1N(C)C(=O)NC(=O)C1(CC)CC
NCGC00165924-04	O=C1N(C)C(=O)N[C@@]1(CC)c1ccccc1		Inactive	Sodium Channel Protein Type V Alpha Subunit Inhibitor&Sodium channel protein type V alpha subunit Inhibitor		1	(S)-Mephenytoin	170465368	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.155318464&13.555614384	O=C1N(C)C(=O)N[C@@]1(CC)c1ccccc1	O=C1N(C)C(=O)N[C@@]1(CC)c1ccccc1
NCGC00016383-05	O=C1N(C)C(=O)OC1(C)C		Inactive	Voltage-gated T-type Calcium Channel Blocker&Voltage-gated T-type calcium channel Blocker		1	Trimethadione	225144178	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&21.67887272	O=C1N(C)C(=O)OC1(C)C	O=C1N(C)C(=O)OC1(C)C
NCGC00183600-04	O=C1N(C)C(=O)OC1(CC)C	5.1999998	Active	Voltage-gated T-type calcium channel Blocker	0.0	1	PARAMETHADIONE	405558625	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-50.7725417063	O=C1N(C)C(=O)OC1(CC)C	O=C1N(C)C(=O)OC1(CC)C
NCGC00018117-32	O=C1N(C)C(=O)c2[nH]cnc2N1C		Inactive	Adenosine Receptor Antagonist		1	Theophyllamine	384567991	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.973523616	O=C1N(C)C(=O)c2[nH]cnc2N1C	O=C1N(C)C(=O)c2[nH]cnc2N1C
NCGC00015208-19&NCGC00015208-25	O=C1N(C)C(=O)c2n(C)cnc2N1C		Inactive	Chitinase Inhibitor&Chitinase Inhibitors&Chitinase Inhibitor		2	Caffeine	170464929&384567824	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&19.607662996	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C1N(C)C(=O)c2n(C)cnc2N1C	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C1N(C)C(=O)c2n(C)cnc2N1C&O=C1N(C)C(=O)c2n(C)cnc2N1C
NCGC00018121-07	O=C1N(C)C(=O)c2n(CC(O)C)cnc2N1C		Inactive	3',5'-cyclic Phosphodiesterase Inhibitor&3',5'-cyclic phosphodiesterase Inhibitor		1	Proxyphylline	170465953	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.658631264&-16.41535884	O=C1N(C)C(=O)c2n(CC(O)C)cnc2N1C	O=C1N(C)C(=O)c2n(CC(O)C)cnc2N1C
NCGC00018099-09&NCGC00018099-17	O=C1N(C)C(=O)c2n(CC(O)CO)cnc2N1C		Inactive	Xanthine Derivative		2	Dyphylline	170465316&384567989	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	29.9683992759&-14.034824372&0.0	O=C1N(C)C(=O)c2n(CC(O)CO)cnc2N1C	O=C1N(C)C(=O)c2n(CC(O)CO)cnc2N1C
NCGC00159330-04	O=C1N(C)C(=O)c2n(CC3OCCO3)cnc2N1C		Inactive	Adenosine A1 Antagonist		1	Doxofylline	363676585	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N(C)C(=O)c2n(CC3OCCO3)cnc2N1C	O=C1N(C)C(=O)c2n(CC3OCCO3)cnc2N1C
NCGC00018117-17	O=C1N(C)C(=O)c2nc[nH]c2N1C		Inactive	Adenosine Receptor A1 Antagonist&Adenosine Receptor Antagonist		1	Theophyllamine	170466874	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-20.151154708	O=C1N(C)C(=O)c2nc[nH]c2N1C	O=C1N(C)C(=O)c2nc[nH]c2N1C
NCGC00093704-19	O=C1N(C)C(C(O)C(C/C=C/C)C)C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C		Inactive	immunosuppressant		1	Cyclosporine A	384568118	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N(C)C(C(O)C(C/C=C/C)C)C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C	O=C1N(C)C(C(O)C(C/C=C/C)C)C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C
NCGC00370979-01	O=C1N(C)C(NC[C@@H](N)Cc2ccccc2)=NC(c2ccncc2)=C1c1cc2c(cc1)cccc2	4.5500002	Active	p38 MAPK Inhibitor	0.0	1	AMG-548	363677973	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-101.7920489116	O=C1N(C)C(NC[C@@H](N)Cc2ccccc2)=NC(c2ccncc2)=C1c1cc2c(cc1)cccc2	O=C1N(C)C(NC[C@@H](N)Cc2ccccc2)=NC(c2ccncc2)=C1c1cc2c(cc1)cccc2
NCGC00159430-04	O=C1N(C)C(O)=NC(=O)C1(C)C1=CCCCC1	6.1500001	Active	Gaba-a Receptor; Benzodiazepine Site Activator	0.0	1	Hexobarbital	170465860	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-41.1383959289	O=C1N(C)C(O)=NC(=O)C1(C)C1=CCCCC1	O=C1N(C)C(O)=NC(=O)C1(C)C1=CCCCC1
NCGC00510506-01	O=C1N(C)C=C(c2c(CO)c(N3C(=O)c4n(c5c(c4)CC(C)(C)C5)CC3)ncc2)C=C1Nc1ncc(N2[C@@H](C)CN(C3COC3)CC2)cc1		Inactive	BTK Inhibitor		1	RG-7845 (GDC-0853)	384569467	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.936465728	O=C1N(C)C=C(c2c(CO)c(N3C(=O)c4n(c5c(c4)CC(C)(C)C5)CC3)ncc2)C=C1Nc1ncc(N2[C@@H](C)CN(C3COC3)CC2)cc1	O=C1N(C)C=C(c2c(CO)c(N3C(=O)c4n(c5c(c4)CC(C)(C)C5)CC3)ncc2)C=C1Nc1ncc(N2[C@@H](C)CN(C3COC3)CC2)cc1
NCGC00507682-01	O=C1N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@@H]1Cc1ccc(N2CCOCC2)cc1	5.6999998	Active	Synaptic Transmission Modulator&synaptic transmission Modulator	0.0	1	Emodepside	405558968	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-1.4	-44.8252959719&-43.0611387871	O=C1N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@@H]1Cc1ccc(N2CCOCC2)cc1	O=C1N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@@H]1Cc1ccc(N2CCOCC2)cc1
NCGC00507976-02	O=C1N(C)[C@]23[C@H](C(C)(C)[C@@]4(c5c(NC4)c4OC=CC(C)(C)Oc4cc5)C2)C[C@]21[C@@](O)(C)CCN2C3		Inactive			1	Derquantel	405558509	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.7219426799&24.693745628	O=C1N(C)[C@]23[C@H](C(C)(C)[C@@]4(c5c(NC4)c4OC=CC(C)(C)Oc4cc5)C2)C[C@]21[C@@](O)(C)CCN2C3	O=C1N(C)[C@]23[C@H](C(C)(C)[C@@]4(c5c(NC4)c4OC=CC(C)(C)Oc4cc5)C2)C[C@]21[C@@](O)(C)CCN2C3
NCGC00016023-18&NCGC00016023-19	O=C1N(C)c2ncn(C)c2C(=O)N1		Inactive	Phosphodiesterase Inhibitor		2	Theobromine	170465487&384567916	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-12.038424768&0.0	O=C1N(C)c2ncn(C)c2C(=O)N1	O=C1N(C)c2ncn(C)c2C(=O)N1
NCGC00496839-01	O=C1N(C2CCCC2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C=C1C#N	4.75	Active	RET Inhibitor	0.0	1	ON-123300	384569293	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-81.9374107861	O=C1N(C2CCCC2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C=C1C#N	O=C1N(C2CCCC2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C=C1C#N
NCGC00159544-04	O=C1N(C2CCN(CC3(C)OCc4c(-n5c3ccc5)cccc4)CC2)c2c(N1)cccc2		Inactive	Calmodulin Antagonist		1	Zaldaride maleate	384568186	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-31.0717787839	O=C1N(C2CCN(CC3(C)OCc4c(-n5c3ccc5)cccc4)CC2)c2c(N1)cccc2	O=C1N(C2CCN(CC3(C)OCc4c(-n5c3ccc5)cccc4)CC2)c2c(N1)cccc2
NCGC00165727-10	O=C1N(C2CCN(Cc3ccc(-c4c(-c5ccccc5)nc5c(n4)cc4nc[nH]c4c5)cc3)CC2)c2c(N1)cccc2	4.5500002	Active	AKT Inhibitor	0.0	1	AKT Inhibitor VIII	377020224	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-54.6149666395	O=C1N(C2CCN(Cc3ccc(-c4c(-c5ccccc5)nc5c(n4)cc4nc[nH]c4c5)cc3)CC2)c2c(N1)cccc2	O=C1N(C2CCN(Cc3ccc(-c4c(-c5ccccc5)nc5c(n4)cc4nc[nH]c4c5)cc3)CC2)c2c(N1)cccc2
NCGC00179401-03	O=C1N(CC)C(=O)NC1c1ccccc1	4.5	Active	Sodium Channel Protein Type V Alpha Subunit Inhibitor	0.0	1	Ethotoin	225144304	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-32.25677594	O=C1N(CC)C(=O)NC1c1ccccc1	O=C1N(CC)C(=O)NC1c1ccccc1
NCGC00522580-01	O=C1N(CC)C2=NC(c3c(C)nc(-c4[nH]cnn4)cc3)=CNC2=NC1	4.4000001	Active	DNA-PK Inhibitor	0.0	1	CC-115	384569529	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-110.8127095803	O=C1N(CC)C2=NC(c3c(C)nc(-c4[nH]cnn4)cc3)=CNC2=NC1	O=C1N(CC)C2=NC(c3c(C)nc(-c4[nH]cnn4)cc3)=CNC2=NC1
NCGC00167459-02	O=C1N(CC)CC(CCN2CCOCC2)C1(c1ccccc1)c1ccccc1	4.9499998	Active	Potassium Channel Subfamily K Member 9 Inhibitor	0.0	1	Doxapram hydrochloride	170465313	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-46.9137827675	O=C1N(CC)CC(CCN2CCOCC2)C1(c1ccccc1)c1ccccc1.Cl	O=C1N(CC)CC(CCN2CCOCC2)C1(c1ccccc1)c1ccccc1.Cl
NCGC00160611-03	O=C1N(CC)CCC1		Inactive			1	1-Ethyl-2-pyrrolidinone	170465488	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1N(CC)CCC1	O=C1N(CC)CCC1
NCGC00344513-02	O=C1N(CC)c2c(N1[C@H]1[C@H](CO)CN(CC3CCCCCCC3)CC1)cccc2	4.6999998	Active	ORL1 (OP4, NOP) Antagonist	0.0	1	J113397	363677334	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-44.6538667292	O=C1N(CC)c2c(N1[C@H]1[C@H](CO)CN(CC3CCCCCCC3)CC1)cccc2	O=C1N(CC)c2c(N1[C@H]1[C@H](CO)CN(CC3CCCCCCC3)CC1)cccc2
NCGC00387875-03	O=C1N(CC)c2nc(N)nc(C)c2C=C1c1[nH]ncc1	4.6500001	Active	mTORC1/2 Inhibitor	0.0	1	Voxtalisib	363680715	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-47.0720602149	O=C1N(CC)c2nc(N)nc(C)c2C=C1c1[nH]ncc1	O=C1N(CC)c2nc(N)nc(C)c2C=C1c1[nH]ncc1
NCGC00263139-03	O=C1N(CCC)C(=O)c2[nH]c(C34C5C[C@H](C3)CC(C4)C5)nc2N1CCC		Inactive	Adenosine A1 Antagonist		1	Rolofylline	384568617	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.956745588	O=C1N(CCC)C(=O)c2[nH]c(C34C5C[C@H](C3)CC(C4)C5)nc2N1CCC	O=C1N(CCC)C(=O)c2[nH]c(C34C5C[C@H](C3)CC(C4)C5)nc2N1CCC
NCGC00015162-10	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2(C1)CCCC2	4.6999998	Active	Serotonin 1a (5-ht1a) Receptor Partial Agonist	0.0	1	Buspirone	170464909	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.8663652136	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2(C1)CCCC2	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2(C1)CCCC2
NCGC00182990-01	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1		Inactive	Serotonin 1a (5-ht1a) Receptor Partial Agonist&Serotonin 1a (5-HT1a) receptor Partial Agonist		1	Tandospirone	144206869	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.3362014&0.0	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1
NCGC00262941-01	O=C1N(CCCN2CCCCCC2)[C@H](CC(C)C)[C@H](c2ccccc2)O1	4.5500002	Active	Glutamate [nmda] Receptor Antagonist&Glutamate [NMDA] receptor Antagonist	0.0	1	Ipenoxazone hydrochloride	170465754	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-80.0220946644&-56.3183528135	O=C1N(CCCN2CCCCCC2)[C@H](CC(C)C)[C@H](c2ccccc2)O1.Cl	O=C1N(CCCN2CCCCCC2)[C@H](CC(C)C)[C@H](c2ccccc2)O1.Cl
NCGC00346513-02	O=C1N(CCN(C)C)C(=O)c2c3c(cc(N)cc13)ccc2	5.1500001	Active	DNA Topoisomerase II Inhibitor	0.0	1	Amonafide	384568813	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.1368743908	O=C1N(CCN(C)C)C(=O)c2c3c(cc(N)cc13)ccc2	O=C1N(CCN(C)C)C(=O)c2c3c(cc(N)cc13)ccc2
NCGC00160395-04	O=C1N(CCN(C)C)c2c(N(C)c3c1cccc3)cccc2	5.3000002	Active	Monoamine Transporter Inhibitor&Monoamine transporter Inhibitor	0.0	1	Dibenzepin hydrochloride	170466001	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-55.738131962&-35.9968106316	O=C1N(CCN(C)C)c2c(N(C)c3c1cccc3)cccc2.Cl	O=C1N(CCN(C)C)c2c(N(C)c3c1cccc3)cccc2.Cl
NCGC00510704-01	O=C1N(CCN2CCOCC2)C(C)(C)c2sc(-c3nc(Nc4n(C)ncc4)ncc3)cc12	4.5	Active	ERK1/2 Inhibitor	0.0	1	LY-3214996	384569487	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-85.2258600152	O=C1N(CCN2CCOCC2)C(C)(C)c2sc(-c3nc(Nc4n(C)ncc4)ncc3)cc12	O=C1N(CCN2CCOCC2)C(C)(C)c2sc(-c3nc(Nc4n(C)ncc4)ncc3)cc12
NCGC00167480-02	O=C1N(CO)C(=O)CC1	4.6500001	Active		0.0	1	N-Hydroxymethylsuccinimide	225144289	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.2415170508	O=C1N(CO)C(=O)CC1	O=C1N(CO)C(=O)CC1
NCGC00386382-03	O=C1N(C[C@H]2[C@H](CN3CCN(c4nsc5c4cccc5)CC3)CCCC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1	4.5	Active		0.0	1	Lurasidone (Hydrochloride)	405558555	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-82.3140630352&-97.4115117508	O=C1N(C[C@H]2[C@H](CN3CCN(c4nsc5c4cccc5)CC3)CCCC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1	O=C1N(C[C@H]2[C@H](CN3CCN(c4nsc5c4cccc5)CC3)CCCC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1
NCGC00389461-01	O=C1N(Cc2c(C#N)cccc2)C(N2CC(N)CCC2)=CC(=O)N1C		Inactive	Dipeptidyl Peptidase 4 Inhibitor&Dipeptidyl peptidase 4 Inhibitor		1	NCGC00389461-01&ALOGLIPTIN BENZOATE	405558632	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-34.667390016	O=C1N(Cc2c(C#N)cccc2)C(N2CC(N)CCC2)=CC(=O)N1C	O=C1N(Cc2c(C#N)cccc2)C(N2CC(N)CCC2)=CC(=O)N1C
NCGC00386747-06	O=C1N(Cc2c(C)cccc2)C2=NCCN2C2=C1CN(Cc1ccccc1)CC2	5.0	Active	ERK Inhibitor	0.0	1	TIC-10	363680432	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-84.2491146528	O=C1N(Cc2c(C)cccc2)C2=NCCN2C2=C1CN(Cc1ccccc1)CC2	O=C1N(Cc2c(C)cccc2)C2=NCCN2C2=C1CN(Cc1ccccc1)CC2
NCGC00167528-02	O=C1N(Cc2c(C)nc[nH]2)CCc2n(C)c3c(c12)cccc3	4.8249998	Active	Serotonin 3a (5-ht3a) Receptor Antagonist&Serotonin 3a (5-HT3a) receptor Antagonist	0.0	1	Alosetron hydrochloride	170465416	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-35.1600476144&-36.739723196	O=C1N(Cc2c(C)nc[nH]2)CCc2n(C)c3c(c12)cccc3.Cl	O=C1N(Cc2c(C)nc[nH]2)CCc2n(C)c3c(c12)cccc3.Cl
NCGC00095122-05	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)C(CCCC)=NC21CCCC2		Inactive			1	Irbesartan	170464670	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)C(CCCC)=NC21CCCC2	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)C(CCCC)=NC21CCCC2
NCGC00386380-02	O=C1N(Cc2ccccc2)C(=O)SN1c1c2c(ccc1)cccc2		Inactive	GSK-3 Inhibitor		1	Tideglusib	384569130	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	47.9449296588	O=C1N(Cc2ccccc2)C(=O)SN1c1c2c(ccc1)cccc2	O=C1N(Cc2ccccc2)C(=O)SN1c1c2c(ccc1)cccc2
NCGC00346655-02&NCGC00346655-06	O=C1N(Cc2nc(C)c3c(n2)cccc3)C(=O)c2n(CC#CC)c(N3C[C@H](N)CCC3)nc2N1C		Inactive	DPP-IV Inhibitor&Dipeptidyl Peptidase Iv Inhibitor&DPP-IV Inhibitor		2	Linagliptin	405558934&384568886	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.6556835799&-26.9938300799&-21.0574571959	O=C1N(Cc2nc(C)c3c(n2)cccc3)C(=O)c2n(CC#CC)c(N3C[C@H](N)CCC3)nc2N1C	O=C1N(Cc2nc(C)c3c(n2)cccc3)C(=O)c2n(CC#CC)c(N3C[C@H](N)CCC3)nc2N1C
NCGC00164612-02	O=C1N(N(C)C(C)=C1C(C)C)c1ccccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Propyphenazone	170465821	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.3876737839&33.5296980735	O=C1N(N(C)C(C)=C1C(C)C)c1ccccc1	O=C1N(N(C)C(C)=C1C(C)C)c1ccccc1
NCGC00016257-10	O=C1N(N(C)C(C)=C1N(C)C)c1ccccc1		Inactive			1	4-Dimethylaminoantipyrine	170465863	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	27.21766392&-14.487448952	O=C1N(N(C)C(C)=C1N(C)C)c1ccccc1	O=C1N(N(C)C(C)=C1N(C)C)c1ccccc1
NCGC00164582-02	O=C1N(N(c2ccccc2)C(=O)C1C/C=C(\C)/C)c1ccccc1		Inactive			1	Feprazone	170465969	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&32.5519795199	O=C1N(N(c2ccccc2)C(=O)C1C/C=C(\C)/C)c1ccccc1	O=C1N(N(c2ccccc2)C(=O)C1C/C=C(\C)/C)c1ccccc1
NCGC00094748-07	O=C1N(N(c2ccccc2)C(=O)C1CCCC)c1ccc(O)cc1	4.5749998	Active		0.0	1	Oxyphenbutazone	170465310	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-101.1605436139&-109.804471151	O=C1N(N(c2ccccc2)C(=O)C1CCCC)c1ccc(O)cc1	O=C1N(N(c2ccccc2)C(=O)C1CCCC)c1ccc(O)cc1
NCGC00017112-10&NCGC00017112-14	O=C1N(O)C(C2CCCCC2)=CC(C)=C1	4.48749995	Active	Antifungal Agent&Catalase Modulator&Antifungal Agent	0.17499969999999987	2	Ciclopirox	170464708&384567974	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.3&-3.0	-103.9407026924&-119.6694205375&-109.8117885205	O=C1N(O)C(C2CCCCC2)=CC(C)=C1.OCCN	O=C1N(O)C(C2CCCCC2)=CC(C)=C1.OCCN&O=C1N(O)C(C2CCCCC2)=CC(C)=C1
NCGC00167586-03	O=C1N(O)C(CC(CC(C)(C)C)C)=CC(C)=C1	4.5500002	Active		0.0	1	Piroctone Olamine	225144295	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-125.6786195409&-102.729568832	O=C1N(O)C(CC(CC(C)(C)C)C)=CC(C)=C1	O=C1N(O)C(CC(CC(C)(C)C)C)=CC(C)=C1
NCGC00023212-14	O=C1N([C@@H]2O[C@H](CO)C=C2)C=C(C)C(=O)N1		Inactive	Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor&Reverse Transcriptase Inhibitor		1	Stavudine	170464820	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.954790472&0.0	O=C1N([C@@H]2O[C@H](CO)C=C2)C=C(C)C(=O)N1	O=C1N([C@@H]2O[C@H](CO)C=C2)C=C(C)C(=O)N1
NCGC00090705-15	O=C1N([C@@H]2O[C@H](CO)CC2)C=CC(N)=N1	5.0	Active	Reverse Transcriptase Inhibitor	0.0	1	2',3'-Dideoxycytidine	170465128	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-42.6199986951	O=C1N([C@@H]2O[C@H](CO)CC2)C=CC(N)=N1	O=C1N([C@@H]2O[C@H](CO)CC2)C=CC(N)=N1
NCGC00023945-12	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(=O)N1	5.75	Active	Reverse Transcriptase Inhibitor	0.0	1	3'-Azido-3'-deoxythymidine	170464737	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.3	-94.3409740117	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(=O)N1	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(=O)N1
NCGC00166415-03	O=C1N([C@H]2C3CCN(C2)CC3)C[C@@H]2c3c1cccc3CCC2		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist&Serotonin 3a (5-ht3a) Receptor Antagonist		1	Palonosetron hydrochloride	170465300	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.530972952&-26.83537342	O=C1N([C@H]2C3CCN(C2)CC3)C[C@@H]2c3c1cccc3CCC2.Cl	O=C1N([C@H]2C3CCN(C2)CC3)C[C@@H]2c3c1cccc3CCC2.Cl
NCGC00159341-17&NCGC00159341-18	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1		Inactive	Reverse Transcriptase Inhibitor&Dna-directed Dna Polymerase Inhibitor&Reverse Transcriptase Inhibitor		2	Lamivudine	384568170&405558739	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-16.349775092&-16.634056636	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1
NCGC00346560-03&NCGC00346560-06	O=C1N([C@H]2O[C@@H](CO)[C@H](O)C2)C=C(C)C(=O)N1		Inactive	DNA Polymerase Inhibitor&Dna Polymerase Inhibitors&DNA Polymerase Inhibitor		2	Telbivudine	384568840&405558940	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-19.131374204&17.2768768199&-24.600555892	O=C1N([C@H]2O[C@@H](CO)[C@H](O)C2)C=C(C)C(=O)N1	O=C1N([C@H]2O[C@@H](CO)[C@H](O)C2)C=C(C)C(=O)N1
NCGC00093356-10	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1	5.6500001	Active	DNA Polymerase Inhibitor	0.0	1	Cytarabine	384568114	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-100.7665122524	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1
NCGC00017312-04	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(=O)N1		Inactive	Anti-anxiety drug		1	Uridine	363676497	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(=O)N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(=O)N1
NCGC00159549-16	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC=N1		Inactive	Cytidine Deaminase Inhibitor		1	Zebularine	384568187	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	26.111565212	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC=N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC=N1
NCGC00090851-10&NCGC00090851-17	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=NC(N)=N1	4.57500005	Active	Dna Methyltransferase (dnmt) Inhibitor&DNA Methyltransferase (DNMT) Inhibitor&DNA Methyltransferase (DNMT) Inhibitor	0.34999990000000025	2	5-Azacitidine	170465076&384568089	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3&-3.0	-101.306025525&-89.5841253078&-110.5901008912	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=NC(N)=N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=NC(N)=N1
NCGC00345810-01	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1		Inactive	Cytidine Deaminase Inhibitor		1	Tetrahydrouridine	174007307	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.015928288	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1
NCGC00168114-09	O=C1N(c2c(C)cccc2)C(Cn2c3ncnc(N)c3nc2)=Nc2c1c(C)ccc2		Inactive	PI3K Inhibitor		1	IC-87114	363676679	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N(c2c(C)cccc2)C(Cn2c3ncnc(N)c3nc2)=Nc2c1c(C)ccc2	O=C1N(c2c(C)cccc2)C(Cn2c3ncnc(N)c3nc2)=Nc2c1c(C)ccc2
NCGC00346614-07	O=C1N(c2c(C)cccc2)C(Cn2nc(-c3cc(O)ccc3)c3c(N)ncnc23)=Nc2c1c(C)ccc2		Inactive	PI3K Inhibitor		1	PIK-294	363677477	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	34.4706881284	O=C1N(c2c(C)cccc2)C(Cn2nc(-c3cc(O)ccc3)c3c(N)ncnc23)=Nc2c1c(C)ccc2	O=C1N(c2c(C)cccc2)C(Cn2nc(-c3cc(O)ccc3)c3c(N)ncnc23)=Nc2c1c(C)ccc2
NCGC00346579-03	O=C1N(c2c(C)cccc2)C(Cn2ncc3c(N)ncnc23)=Nc2c1c(C)ccc2	4.4000001	Inactive	PI3K Inhibitor	0.0	1	PIK-293	363677461	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	17.92971694	O=C1N(c2c(C)cccc2)C(Cn2ncc3c(N)ncnc23)=Nc2c1c(C)ccc2	O=C1N(c2c(C)cccc2)C(Cn2ncc3c(N)ncnc23)=Nc2c1c(C)ccc2
NCGC00346678-15	O=C1N(c2cc3c(n(C)cc3)cc2)C(c2c(O)cc(O)c(C(C)C)c2)=NN1	4.8000002	Inactive	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	Ganetespib (STA-9090)	384568904	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-9.2905777839	O=C1N(c2cc3c(n(C)cc3)cc2)C(c2c(O)cc(O)c(C(C)C)c2)=NN1	O=C1N(c2cc3c(n(C)cc3)cc2)C(c2c(O)cc(O)c(C(C)C)c2)=NN1
NCGC00345843-02	O=C1N(c2ccc(-c3occn3)cc2)C=CC(C)=C1c1cc2c(nc(N)nc2)cc1		Inactive	KIT Inhibitor		1	AMG-25	363677386	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N(c2ccc(-c3occn3)cc2)C=CC(C)=C1c1cc2c(nc(N)nc2)cc1	O=C1N(c2ccc(-c3occn3)cc2)C=CC(C)=C1c1cc2c(nc(N)nc2)cc1
NCGC00015806-06	O=C1N(c2ccccc2)C=C(C)C=C1		Inactive			1	Pirfenidone	170465606	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-9.372581208	O=C1N(c2ccccc2)C=C(C)C=C1	O=C1N(c2ccccc2)C=C(C)C=C1
NCGC00018218-10&NCGC00018218-13	O=C1N(c2ccccc2)N=C(C)C1		Inactive	Free Radical Scavenger		2	Edaravone	170465935&384567997	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-17.16916308&13.1487041199&-9.1118391199	O=C1N(c2ccccc2)N=C(C)C1	O=C1N(c2ccccc2)N=C(C)C1
NCGC00015590-08	O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2	4.5	Active	K(ATP) Channel Blocker	0.0	1	Linopirdine	384567868	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-51.296641424	O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2	O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2
NCGC00388364-06	O=C1N(c2ncnc(N3CCOCC3)c2)NC=C1n1nncc1	5.1500001	Active	HIF Prolyl Hydroxylase Inhibitor	0.0	1	Molidustat	384569169	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-90.7008857721	O=C1N(c2ncnc(N3CCOCC3)c2)NC=C1n1nncc1	O=C1N(c2ncnc(N3CCOCC3)c2)NC=C1n1nncc1
NCGC00186465-06	O=C1N2C(=NN1)c1c(nc(c(-c3ccccc3)c1)-c1ccc(C3(N)CCC3)cc1)C=C2	5.0500002	Active	AKT Inhibitor	0.0	1	MK-2206	384568442	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-107.8075953814	O=C1N2C(=NN1)c1c(nc(c(-c3ccccc3)c1)-c1ccc(C3(N)CCC3)cc1)C=C2	O=C1N2C(=NN1)c1c(nc(c(-c3ccccc3)c1)-c1ccc(C3(N)CCC3)cc1)C=C2
NCGC00389454-01	O=C1N2C(C(=N)N1)C2		Inactive	Ribonucleoside-diphosphate Reductase Inhibitors&Ribonucleoside-Diphosphate Reductase Inhibitors		1	IMEXON	405558490	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-30.2631276799	O=C1N2C(C(=N)N1)C2	O=C1N2C(C(=N)N1)C2
NCGC00346495-14	O=C1N2C(C(C(Nc3ccccc3)C)=CC(C)=C2)=NC(N2CCOCC2)=C1	4.75	Active	PI3Kbeta Inhibitor	0.0	1	TGX-221	384568801	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-33.1051446959	O=C1N2C(C(C(Nc3ccccc3)C)=CC(C)=C2)=NC(N2CCOCC2)=C1	O=C1N2C(C(C(Nc3ccccc3)C)=CC(C)=C2)=NC(N2CCOCC2)=C1
NCGC00163553-03	O=C1N2C(N(C)c3c1cccc3)c1[nH]c3c(c1CC2)cccc3	5.1999998	Active	Dietary supplement & part of traditional chinese medicines; alkaloid known to have several pharmacological effects including anti-tumor activity; inducer of apoptosis	0.0	1	Evodiamine	363676623	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-59.815179868	O=C1N2C(N(C)c3c1cccc3)c1[nH]c3c(c1CC2)cccc3	O=C1N2C(N(C)c3c1cccc3)c1[nH]c3c(c1CC2)cccc3
NCGC00016463-08	O=C1N2C([C@H]3CNC[C@@H](C2)C3)=CC=C1		Inactive	Nicotinic alpha3beta4 Partial Agonist		1	Cytisine	384567942	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.723224924	O=C1N2C([C@H]3CNC[C@@H](C2)C3)=CC=C1	O=C1N2C([C@H]3CNC[C@@H](C2)C3)=CC=C1
NCGC00160217-03	O=C1N2[C@@H]([C@@H]3[C@H]4N(CCC3)CCC[C@H]4C2)CC=C1		Inactive	HERG Inhibitor		1	Sophocarpine	363676600	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N2[C@@H]([C@@H]3[C@H]4N(CCC3)CCC[C@H]4C2)CC=C1	O=C1N2[C@@H]([C@@H]3[C@H]4N(CCC3)CCC[C@H]4C2)CC=C1
NCGC00346596-02	O=C1N2[C@@H]([C@@H]3[C@H]4[N+]([O-])(CCC3)CCC[C@H]4C2)CCC1		Inactive	mu/kappa-Opioid Agonist		1	Oxymatrine	363677471	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N2[C@@H]([C@@H]3[C@H]4[N+]([O-])(CCC3)CCC[C@H]4C2)CCC1	O=C1N2[C@@H]([C@@H]3[C@H]4[N+]([O-])(CCC3)CCC[C@H]4C2)CCC1
NCGC00186632-01	O=C1N2[C@H]3[C@@H]4[C@@H](OCC=C5[C@@H]4C[C@@H]4[N@@](C5)CC[C@]34c3c2cccc3)C1	4.6500001	Active	Glycine Receptor Subunit Alpha-1 Antagonist&Glycine receptor subunit alpha-1 Antagonist	0.0	1	Strychnine	124897819	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-39.944811576&-43.1044103027	O=C1N2[C@H]3[C@@H]4[C@@H](OCC=C5[C@@H]4C[C@@H]4[N@@](C5)CC[C@]34c3c2cccc3)C1	O=C1N2[C@H]3[C@@H]4[C@@H](OCC=C5[C@@H]4C[C@@H]4[N@@](C5)CC[C@]34c3c2cccc3)C1
NCGC00346440-02	O=C1N2c3c(N1)cccc3C[C@@H](NC)C2		Inactive	Dopamine D2 Agonist		1	Sumanirole maleate	384568778	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	10.706087796	O=C1N2c3c(N1)cccc3C[C@@H](NC)C2	O=C1N2c3c(N1)cccc3C[C@@H](NC)C2
NCGC00346470-02	O=C1N2c3c([C@@H](O)[C@H](NC(C)C)CC2)cccc3N1	4.6999998	Active	Beta1-adrenoceptor Antagonists	0.0	1	ZilpaterolHCl	405558976	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-52.6306506204	O=C1N2c3c([C@@H](O)[C@H](NC(C)C)CC2)cccc3N1	O=C1N2c3c([C@@H](O)[C@H](NC(C)C)CC2)cccc3N1
NCGC00181304-01	O=C1N=C(N)C2N1C2	6.4499998	Inactive	Ribonucleoside-Diphosphate Reductase Inhibitor	0.0	1	Imexon	50125901	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-79.3073520641	O=C1N=C(N)C2N1C2	O=C1N=C(N)C2N1C2
NCGC00263533-01	O=C1N=C(N)Nc2n(CCC(CO)CO)cnc12		Inactive	Human herpesvirus 1 DNA polymerase Inhibitor&Human Herpesvirus 1 Dna Polymerase Inhibitor		1	Penciclovir	170464955	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.467771388&-19.333829876	O=C1N=C(N)Nc2n(CCC(CO)CO)cnc12	O=C1N=C(N)Nc2n(CCC(CO)CO)cnc12
NCGC00016332-04	O=C1N=C2N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3		Inactive	Vitamin		1	Riboflavin	384567932	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1N=C2N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3	O=C1N=C2N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3
NCGC00091288-05	O=C1N=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3	6.4499998	Active	Vitamin	0.0	1	NCGC00091288-05	170465063	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.2606825439	O=C1N=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3	O=C1N=C2N(C[C@H](O)[C@H](O)[C@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3
NCGC00274079-01	O=C1N=C2NC(=O)NC(=O)C2N1	5.125	Active		0.0	1	Sodium urate	170465686	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-33.566719712&-42.1900802	O=C1NC(=O)C=2NC(=O)[N-]C=2N1.[Na+]	O=C1NC(=O)C=2NC(=O)[N-]C=2N1.[Na+]
NCGC00263119-07	O=C1NC(=O)C=2c3c4c(n(c3)CCO[C@H](CN(C)C)CCn3c5c(c(c3)C1=2)cccc5)cccc4	4.4000001	Active	PKC Inhibitor	0.0	1	Ruboxistaurin mesylate	384568603	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-73.5953856593	O=C1NC(=O)C=2c3c4c(n(c3)CCO[C@H](CN(C)C)CCn3c5c(c(c3)C1=2)cccc5)cccc4	O=C1NC(=O)C=2c3c4c(n(c3)CCO[C@H](CN(C)C)CCn3c5c(c(c3)C1=2)cccc5)cccc4
NCGC00181030-02	O=C1NC(=O)C=CN1		Inactive	Dihydropyrimidine Dehydrogenase Substrate&Dihydropyrimidine dehydrogenase Substrate		1	Uracil	170465915	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.529973456&-14.806007796	O=C1NC(=O)C=CN1	O=C1NC(=O)C=CN1
NCGC00016288-06	O=C1NC(=O)CC(CC)(C)C1		Inactive	Gaba-a Receptor; Anion Channel Antagonist&GABA-A receptor; anion channel Antagonist		1	Bemegride	405559005	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.712424848&28.652114292	O=C1NC(=O)CC(CC)(C)C1	O=C1NC(=O)CC(CC)(C)C1
NCGC00346949-01	O=C1NC(=O)CN(C(C(C)N2CC(=O)NC(=O)C2)C)C1		Inactive	DNA Topoisomerase II Inhibitor		1	ICRF-193	174007427	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-33.20048498	O=C1NC(=O)CN(C(C(C)N2CC(=O)NC(=O)C2)C)C1	O=C1NC(=O)CN(C(C(C)N2CC(=O)NC(=O)C2)C)C1
NCGC00263544-01&NCGC00263544-04	O=C1NC(=O)CN([C@H](CN2CC(=O)NC(=O)C2)C)C1		Inactive	Dna Topoisomerase Ii Inhibitor&DNA Topoisomerase II Inhibitor&DNA Topoisomerase II Inhibitor		2	Dexrazoxane hydrochloride	170464709&384568686	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-10.6666126679&0.0&-24.531121184	O=C1NC(=O)CN([C@H](CN2CC(=O)NC(=O)C2)C)C1	O=C1NC(=O)CN([C@H](CN2CC(=O)NC(=O)C2)C)C1
NCGC00485328-01	O=C1NC(N)=NC=2NC[C@H]([C@@H](O)[C@@H](O)C)NC1=2	4.5	Active	Phenylalanine-4-hydroxylase Substrate	0.0	1	(6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride	363681287	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.9857880399	O=C1NC(N)=NC=2NC[C@H]([C@@H](O)[C@@H](O)C)NC1=2	O=C1NC(N)=NC=2NC[C@H]([C@@H](O)[C@@H](O)C)NC1=2
NCGC00164563-04&NCGC00164563-12	O=C1NC(N)=Nc2n([C@@H]3C(=C)[C@H](CO)[C@@H](O)C3)cnc12	4.57500005	Active	Dna Polymerase Inhibitors&DNA Polymerase Inhibitors&DNA Polymerase Inhibitors	0.04999969999999987	2	Entecavir (monohydrate)&Entecavir	405558991&384568253	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4&-2.4	-74.3632117919&-72.7674310406&-39.2888507965	O=C1NC(N)=Nc2n([C@@H]3C(=C)[C@H](CO)[C@@H](O)C3)cnc12	O=C1NC(N)=Nc2n([C@@H]3C(=C)[C@H](CO)[C@@H](O)C3)cnc12
NCGC00521943-01	O=C1NC([C@H]2N3CCC(C2)CC3)=Nc2c1sc(-c1c(C)n[nH]c1)c2	5.9499998	Active	CDK 7 Inhibitor	0.0	1	TAK-931	384569508	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-50.6356939324	O=C1NC([C@H]2N3CCC(C2)CC3)=Nc2c1sc(-c1c(C)n[nH]c1)c2	O=C1NC([C@H]2N3CCC(C2)CC3)=Nc2c1sc(-c1c(C)n[nH]c1)c2
NCGC00263655-01	O=C1NC2=C([C@]3(N)/C(=C\C)/[C@@H](C=C(C)C3)C2)C=C1	4.4000001	Active	Acetylcholinesterase Inhibitors	0.0	1	Huperzine A	170466837	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.8757810679	O=C1NC2=C([C@]3(N)/C(=C\C)/[C@@H](C=C(C)C3)C2)C=C1	O=C1NC2=C([C@]3(N)/C(=C\C)/[C@@H](C=C(C)C3)C2)C=C1
NCGC00094580-10	O=C1NC=Nc2[nH]ncc12	5.4000001	Inactive	Xanthine Oxidase Inhibitor	0.0	1	Allopurinol	384568132	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	79.3976017265	O=C1NC=Nc2[nH]ncc12	O=C1NC=Nc2[nH]ncc12
NCGC00485883-01	O=C1NC=Nc2c([C@H]3[C@H](O)[C@H](O)[C@@H](CO)N3)c[nH]c12	4.4000001	Active	Purine nucleoside phosphorylase Inhibitor	0.0	1	Forodesine (hydrochloride)	363681392	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.520453192	O=C1NC=Nc2c([C@H]3[C@H](O)[C@H](O)[C@@H](CO)N3)c[nH]c12	O=C1NC=Nc2c([C@H]3[C@H](O)[C@H](O)[C@@H](CO)N3)c[nH]c12
NCGC00090691-03	O=C1NC=Nc2n([C@@H]3O[C@H](CO)CC3)cnc12		Inactive	Reverse Transcriptase Inhibitor		1	2',3'-Dideoxyinosine	174006954	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-12.465805016	O=C1NC=Nc2n([C@@H]3O[C@H](CO)CC3)cnc12	O=C1NC=Nc2n([C@@H]3O[C@H](CO)CC3)cnc12
NCGC00095787-05	O=C1NC=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12		Inactive	Reactive Oxygen Species Biosynthetic Process Inhibitor		1	(-)-Inosine	405559132	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.492867612&0.0	O=C1NC=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12	O=C1NC=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00346723-07	O=C1NCCc2[nH]c(-c3ccncc3)cc12	9.0	Inactive	CDC 7 Inhibitor	0.0	1	PHA-767491A	384568934	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-16.7413151079	O=C1NCCc2[nH]c(-c3ccncc3)cc12	O=C1NCCc2[nH]c(-c3ccncc3)cc12
NCGC00163451-04	O=C1NCc2c3c(n(CCC#N)c4c3cccc4)c3n(C)c4c(c3c12)cccc4	4.8499999	Active	PKC Inhibitor	0.0	1	Go-6976	363676620	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-70.3734296596	O=C1NCc2c3c(n(CCC#N)c4c3cccc4)c3n(C)c4c(c3c12)cccc4	O=C1NCc2c3c(n(CCC#N)c4c3cccc4)c3n(C)c4c(c3c12)cccc4
NCGC00244256-04	O=C1NCc2c3c4n([C@@]5(C)[C@@](O)(CO)C[C@H](O5)n5c4c(c4c5cccc4)c12)c1c3cccc1	5.8499999	Active	Jak/Tyk/Flt Inhibitor	0.0	1	Lestaurtinib	377020319	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-100.0928157672	O=C1NCc2c3c4n([C@@]5(C)[C@@](O)(CO)C[C@H](O5)n5c4c(c4c5cccc4)c12)c1c3cccc1	O=C1NCc2c3c4n([C@@]5(C)[C@@](O)(CO)C[C@H](O5)n5c4c(c4c5cccc4)c12)c1c3cccc1
NCGC00263564-04	O=C1NN=C([C@H](C)C1)c1ccc(NN=C(C#N)C#N)cc1	5.4000001	Active	K(ATP) Channel Activator	0.0	1	Levosimendan	384568688	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-38.5892945427	O=C1NN=C([C@H](C)C1)c1ccc(NN=C(C#N)C#N)cc1	O=C1NN=C([C@H](C)C1)c1ccc(NN=C(C#N)C#N)cc1
NCGC00390724-02	O=C1NNc2nc(CN3Cc4c(cccc4)C3)nc3c2c1ccc3	4.6500001	Active	PARP Inhibitor	0.0	1	E-7449	384569209	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-51.3967234204	O=C1NNc2nc(CN3Cc4c(cccc4)C3)nc3c2c1ccc3	O=C1NNc2nc(CN3Cc4c(cccc4)C3)nc3c2c1ccc3
NCGC00351595-02	O=C1N[C@H](C)CNc2c3c(sc12)ccc1nc(-c2cnc(C)cc2)ccc31	4.4000001	Active	MAPKAP-K2 (MK2) Inhibitor	0.0	1	PF-3644022	363677763	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-107.1208686888	O=C1N[C@H](C)CNc2c3c(sc12)ccc1nc(-c2cnc(C)cc2)ccc31	O=C1N[C@H](C)CNc2c3c(sc12)ccc1nc(-c2cnc(C)cc2)ccc31
NCGC00484799-01	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN(C)C)C)cc3)c2-c2c1scc2	5.0	Active	PDZ-binding kinase Inhibitor	0.0	1	OTS964	363681179	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-98.2660859444	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN(C)C)C)cc3)c2-c2c1scc2	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN(C)C)C)cc3)c2-c2c1scc2
NCGC00507851-01	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN)C)cc3)c2-c2c1scc2		Inactive	PBK Inhibitor		1	OTS-514	384569331	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	28.219545741	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN)C)cc3)c2-c2c1scc2	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN)C)cc3)c2-c2c1scc2
NCGC00065890-14	O=C1Nc2c(C)ccnc2N(C2CC2)c2ncccc12	4.4000001	Active	Reverse Transcriptase Inhibitor	0.0	1	Nevirapine	405558819	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.061499368	O=C1Nc2c(C)ccnc2N(C2CC2)c2ncccc12	O=C1Nc2c(C)ccnc2N(C2CC2)c2ncccc12
NCGC00386216-07	O=C1Nc2c(O)ccc([C@@H](O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1	4.5	Active		0.0	1	Indacaterol (maleate)	405559054	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.2238264919	O=C1Nc2c(O)ccc([C@@H](O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1	O=C1Nc2c(O)ccc([C@@H](O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1
NCGC00018291-03&NCGC00024999-04	O=C1Nc2c(O)ccc([C@@H](O)[C@@H](NC(C)C)CC)c2C=C1		Inactive	Beta2-adrenoceptor Agonists&beta2-Adrenoceptor Agonists&beta2-Adrenoceptor Agonist		2	Procaterol&Procaterol hydrochloride	170465820&384568040	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C1Nc2c(O)ccc([C@@H](O)[C@@H](NC(C)C)CC)c2C=C1	O=C1Nc2c(O)ccc([C@@H](O)[C@@H](NC(C)C)CC)c2C=C1
NCGC00507868-01	O=C1Nc2c(c(-c3cc4c(-c5cn(C)nc5)nn(C)c4cc3)ccc2)N[C@H](C)C1	4.3499999	Active	CBP/p300 Inhibitor	0.0	1	CPI-637	384569342	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-38.8869538772	O=C1Nc2c(c(-c3cc4c(-c5cn(C)nc5)nn(C)c4cc3)ccc2)N[C@H](C)C1	O=C1Nc2c(c(-c3cc4c(-c5cn(C)nc5)nn(C)c4cc3)ccc2)N[C@H](C)C1
NCGC00484808-01	O=C1Nc2c(c(-c3cn(C(C)(C)C)nc3)ccc2)N[C@H](C)C1		Inactive	CBP/p300 Inhibitor		1	CPI-703	384569273	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.113483744	O=C1Nc2c(c(-c3cn(C(C)(C)C)nc3)ccc2)N[C@H](C)C1	O=C1Nc2c(c(-c3cn(C(C)(C)C)nc3)ccc2)N[C@H](C)C1
NCGC00015893-06	O=C1Nc2c(c(CCN(CCC)CCC)ccc2)C1		Inactive	Dopamine D3 Receptor Partial Agonist&Dopamine D3 receptor Partial Agonist		1	Ropinirole	170465139	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.0717924279&-38.806464032	O=C1Nc2c(c(CCN(CCC)CCC)ccc2)C1	O=C1Nc2c(c(CCN(CCC)CCC)ccc2)C1
NCGC00184708-02	O=C1OC(C)CCCC(O)CCCCCc2c1c(O)cc(O)c2	4.4749999	Active	Smooth Muscle Contraction Inhibitor&smooth muscle contraction Inhibitor	0.0	1	NCGC00184708-02	124896555	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-74.8240034439&-85.0857815825	O=C1OC(C)CCCC(O)CCCCCc2c1c(O)cc(O)c2	O=C1OC(C)CCCC(O)CCCCCc2c1c(O)cc(O)c2
NCGC00018200-12	O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2	5.0	Active	Store-operated Calcium Entry Blocker	0.0	1	Phenolphthalein	170465559	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-43.4890969781	O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2	O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2
NCGC00161643-05	O=C1OC2(c3c1cccc3)c1c(Oc3c2ccc(O)c3)cc(O)cc1		Inactive			1	Fluorescein sodium	170464991	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.040238996&14.522646448	O=C1OC2(c3c1cccc3)c1c(Oc3c2ccc([O-])c3)cc([O-])cc1.[Na+].[Na+]	O=C1OC2(c3c1cccc3)c1c(Oc3c2ccc([O-])c3)cc([O-])cc1.[Na+].[Na+]
NCGC00163411-06	O=C1OCC=2[C@H]3[C@@](C)([C@]45O[C@H]4[C@H]4[C@@](C(C)C)([C@@H](O)[C@]65O[C@H]6C3)O4)CCC1=2	9.0	Inactive	Inhibition of RNA polymerase II mediated transcription	0.0	1	Triptolide	384568235	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-1.737673468	O=C1OCC=2[C@H]3[C@@](C)([C@]45O[C@H]4[C@H]4[C@@](C(C)C)([C@@H](O)[C@]65O[C@H]6C3)O4)CCC1=2	O=C1OCC=2[C@H]3[C@@](C)([C@]45O[C@H]4[C@H]4[C@@](C(C)C)([C@@H](O)[C@]65O[C@H]6C3)O4)CCC1=2
NCGC00344549-05	O=C1OC[C@]2(C)[C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C)CC4)CC3)CC[C@H]2C1		Inactive	Synthetic Steroid		1	Oxandrolone	384568721	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	30.7288479039	O=C1OC[C@]2(C)[C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C)CC4)CC3)CC[C@H]2C1	O=C1OC[C@]2(C)[C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C)CC4)CC3)CC[C@H]2C1
NCGC00166299-03	O=C1O[Bi](O)Oc2c1cccc2	6.4081006	Active		0.0	1	BISMUTH SUBSALICYLATE	225144280	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-44.989958904&-30.0494270304	O=C1O[Bi](O)Oc2c1cccc2	O=C1O[Bi](O)Oc2c1cccc2
NCGC00263659-01	O=C1O[C@@H](c2cocc2)[C@@]2(C)[C@]3([C@]4(C)C(=O)C[C@H]5C(C)(C)O[C@@H]6[C@@]5([C@H]4CC2)COC(=O)C6)O[C@H]13		Inactive	antiviral&Antiviral		1	Limoni&NCGC00263659-01	170465751	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	12.51310932&0.0	O=C1O[C@@H](c2cocc2)[C@@]2(C)[C@]3([C@]4(C)C(=O)C[C@H]5C(C)(C)O[C@@H]6[C@@]5([C@H]4CC2)COC(=O)C6)O[C@H]13	O=C1O[C@@H](c2cocc2)[C@@]2(C)[C@]3([C@]4(C)C(=O)C[C@H]5C(C)(C)O[C@@H]6[C@@]5([C@H]4CC2)COC(=O)C6)O[C@H]13
NCGC00142523-04	O=C1O[C@@H]2[C@@H](C(O)(C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1	5.1500001	Active	Glycine receptor subunit alpha-1 Antagonist	0.0	1	PICROTIN	405558871	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.5778791287	O=C1O[C@@H]2[C@@H](C(O)(C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1	O=C1O[C@@H]2[C@@H](C(O)(C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1
NCGC00164590-02&NCGC00164590-08	O=C1O[C@@]2([C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C([C@H]6[C@@H]4C6)=CC(=O)CC5)CC3)[C@H]3[C@@H]2C3)CC1		Inactive	Mineralocorticoid Receptor Antagonist&Synthetic progesterone&Synthetic progesterone		2	Drospirenone	170464870&384568260	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-23.6118752799&0.0&0.0	O=C1O[C@@]2([C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C([C@H]6[C@@H]4C6)=CC(=O)CC5)CC3)[C@H]3[C@@H]2C3)CC1	O=C1O[C@@]2([C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C([C@H]6[C@@H]4C6)=CC(=O)CC5)CC3)[C@H]3[C@@H]2C3)CC1
NCGC00390734-01&NCGC00390734-03	O=C1O[Pt+2]O[CH-]1		Inactive	DNA Crosslinking Agent&Dna Alkylating Drugs&DNA Crosslinking Agent		2	Nedaplatin&NCGC00390734-01&Nedaplatin	405558597&384569211	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-27.46246584&-26.3721240879&0.0	O=C1O[Pt+2]O[CH-]1	O=C1O[Pt+2]O[CH-]1
NCGC00016345-08&NCGC00016345-14	O=C1Oc2c(C(C)=C1)ccc(O)c2		Inactive	Amine Oxidase [flavin-containing] A Inhibitor&MAO-A Inhibitor&MAO-A Inhibitor		2	4-Methylumbelliferone	170465819&384567933	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	13.9727661559&0.0&0.0	O=C1Oc2c(C(C)=C1)ccc(O)c2	O=C1Oc2c(C(C)=C1)ccc(O)c2
NCGC00016643-09&NCGC00016643-13	O=C1Oc2c(C)c3oc(C)cc3cc2C(C)=C1		Inactive	phototherapy treatment of skin disorders&Phototherapy Treatment Of Skin Disorders&phototherapy treatment of skin disorders		2	Trioxsalen	170465339&384567955	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C1Oc2c(C)c3oc(C)cc3cc2C(C)=C1	O=C1Oc2c(C)c3oc(C)cc3cc2C(C)=C1
NCGC00522008-01	O=C1Oc2c(c(O)ccc2C2=C1CNCC2)C1OCCCO1		Inactive	IRE1 Inhibitor		1	BI09	384569510	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.894099516	O=C1Oc2c(c(O)ccc2C2=C1CNCC2)C1OCCCO1	O=C1Oc2c(c(O)ccc2C2=C1CNCC2)C1OCCCO1
NCGC00091502-11	O=C1Oc2c(cccc2)C=C1		Inactive	Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor&Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		1	Coumarin	170465665	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&21.3728978543	O=C1Oc2c(cccc2)C=C1	O=C1Oc2c(cccc2)C=C1
NCGC00095003-07	O=C1Sc2c(O1)cc(O)cc2		Inactive	Carbonic Anhydrase Type I Inhibitor		1	Tioxolone	384568140	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.5769490279	O=C1Sc2c(O1)cc(O)cc2	O=C1Sc2c(O1)cc(O)cc2
NCGC00522019-01	O=C1[C@-](Cc2[nH]cnc2)N2C(=O)CCN[Zn+2]2O1	5.6500001	Active		0.0	1	Polaprezinc	405559035	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-43.5957659094	O=C1[C@-](Cc2[nH]cnc2)N2C(=O)CCN[Zn+2]2O1	O=C1[C@-](Cc2[nH]cnc2)N2C(=O)CCN[Zn+2]2O1
NCGC00346666-01	O=C1[C@@H](C)[C@@]2(O)[C@@H](O1)CC13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)C31[C@H](C(C)(C)C)C4		Inactive	GABA(A) Receptor Antagonist		1	Ginkgolide A	174006218	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	5.9767947199	O=C1[C@@H](C)[C@@]2(O)[C@@H](O1)CC13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)C31[C@H](C(C)(C)C)C4	O=C1[C@@H](C)[C@@]2(O)[C@@H](O1)CC13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)C31[C@H](C(C)(C)C)C4
NCGC00263447-01	O=C1[C@@H](C)[C@H]2[C@H](O1)C1=C(C)C(=O)C=C[C@]1(C)CC2		Inactive			1	alpha-Santonin	170465728	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.336104016&-14.8189116	O=C1[C@@H](C)[C@H]2[C@H](O1)C1=C(C)C(=O)C=C[C@]1(C)CC2	O=C1[C@@H](C)[C@H]2[C@H](O1)C1=C(C)C(=O)C=C[C@]1(C)CC2
NCGC00023339-16	O=C1[C@@H](CC)[C@@H](Cc2n(C)cnc2)CO1	5.5	Active	Muscarinic Acetylcholine Receptor M3 Agonist	0.0	1	Pilocarpine	170464845	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.889146388	O=C1[C@@H](CC)[C@@H](Cc2n(C)cnc2)CO1	O=C1[C@@H](CC)[C@@H](Cc2n(C)cnc2)CO1
NCGC00249415-01	O=C1[C@@H](Cc2c(C)nc[nH]2)CCc2c(C)c3c(n12)cccc3	4.4000001	Active	5-hydroxytryptamine Receptor 4 Antagonist	0.0	1	Fabesetron	144206751	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-99.83826594	O=C1[C@@H](Cc2c(C)nc[nH]2)CCc2c(C)c3c(n12)cccc3	O=C1[C@@H](Cc2c(C)nc[nH]2)CCc2c(C)c3c(n12)cccc3
NCGC00167491-14	O=C1[C@@H](N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		1	Lenalidomide	384568318	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.411738972	O=C1[C@@H](N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1	O=C1[C@@H](N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1
NCGC00164524-02	O=C1[C@@H](O)[C@H]2OC(O)[C@H](O)[C@H]2O1		Inactive			1	D-Glucuronolactone	50111689	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.758538288&0.0	O=C1[C@@H](O)[C@H]2OC(O)[C@H](O)[C@H]2O1	O=C1[C@@H](O)[C@H]2OC(O)[C@H](O)[C@H]2O1
NCGC00274058-01	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1		Inactive	Mu Opioid Receptor Inverse Agonist&Mu opioid receptor Inverse Agonist		1	NCGC00274058-01&Naloxone	170465008	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1
NCGC00378877-01	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H]([N+](CC2CC2)(C)CC3)C4)CC1	4.4000001	Active	Mu-type Opioid Receptor Antagonist	0.0	1	Methylnaltrexone Bromide	405558536	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-42.64196624&-42.146843428	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H]([N+](CC2CC2)(C)CC3)C4)CC1	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H]([N+](CC2CC2)(C)CC3)C4)CC1
NCGC00378635-03	O=C1[C@@]2(C(C)C)O[C@H]2[C@@H]2O[C@]32[C@]2(C)[C@H](C4=C(C(=O)OC4)CC2)C[C@@H]2O[C@]132	4.0	Inactive	Immunosuppressants	0.0	1	Triptonide	384569060	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-20.64867396	O=C1[C@@]2(C(C)C)O[C@H]2[C@@H]2O[C@]32[C@]2(C)[C@H](C4=C(C(=O)OC4)CC2)C[C@@H]2O[C@]132	O=C1[C@@]2(C(C)C)O[C@H]2[C@@H]2O[C@]32[C@]2(C)[C@H](C4=C(C(=O)OC4)CC2)C[C@@H]2O[C@]132
NCGC00090730-03	O=C1[C@@]2(C)C(C)(C)[C@@H](C1)CC2		Inactive			1	D-Camphor	170465497	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.718156412&0.0	O=C1[C@@]2(C)C(C)(C)[C@@H](C1)CC2	O=C1[C@@]2(C)C(C)(C)[C@@H](C1)CC2
NCGC00092288-05	O=C1[C@@]2(O)C(N(c3ccccc3)CC2)=Nc2c1cc(C)cc2		Inactive	myosin II ATPase Inhibitor		1	(-)-Blebbistatin	363676556	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1[C@@]2(O)C(N(c3ccccc3)CC2)=Nc2c1cc(C)cc2	O=C1[C@@]2(O)C(N(c3ccccc3)CC2)=Nc2c1cc(C)cc2
NCGC00095606-02	O=C1[C@H](C(C)C)CC[C@@H](C)C1		Inactive	Tnf-alpha Inhibitor&TNF-alpha Inhibitor		1	(2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexanone	170465578	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C1[C@H](C(C)C)CC[C@@H](C)C1	O=C1[C@H](C(C)C)CC[C@@H](C)C1
NCGC00345085-02	O=C1[C@H](C(C)C)N(C)c2c3c([nH]cc3C[C@@H](CO)N1)ccc2		Inactive	lineage-specific differentiation enhancer		1	(-)-Indolactam V	384568733	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1[C@H](C(C)C)N(C)c2c3c([nH]cc3C[C@@H](CO)N1)ccc2	O=C1[C@H](C(C)C)N(C)c2c3c([nH]cc3C[C@@H](CO)N1)ccc2
NCGC00379024-02	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C\C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	4.0	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Epothilone D	384569087	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	62.9842779879	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C\C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C\C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C
NCGC00378665-03	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)NC(=O)C[C@H](O)C1(C)C	5.5500002	Active	Microtubule-Stabilizing Agents	0.0	1	Ixabepilone	384569061	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-70.6537641686	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)NC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)NC(=O)C[C@H](O)C1(C)C
NCGC00346505-02	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	3.8	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Epothilone A	363677432	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	26.500694176	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C
NCGC00346531-02	O=C1[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](O)(C)[C@@H](O)[C@H](C)C/C=C\C=C/[C@H](CC)CC[C@H]2[C@@H](C)[C@H]([C@H](C)[C@]3(O[C@@H](C[C@H](O)C)[C@@H](C)CC3)O2)OC(=O)/C=C/[C@H](C)[C@@H](O)[C@@H]1C	5.0	Active	ATP synthase Inhibitor	0.0	1	Oligomycin A	363677443	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-92.3470081041	O=C1[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](O)(C)[C@@H](O)[C@H](C)C/C=C\C=C/[C@H](CC)CC[C@H]2[C@@H](C)[C@H]([C@H](C)[C@]3(O[C@@H](C[C@H](O)C)[C@@H](C)CC3)O2)OC(=O)/C=C/[C@H](C)[C@@H](O)[C@@H]1C	O=C1[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@](O)(C)[C@@H](O)[C@H](C)C/C=C\C=C/[C@H](CC)CC[C@H]2[C@@H](C)[C@H]([C@H](C)[C@]3(O[C@@H](C[C@H](O)C)[C@@H](C)CC3)O2)OC(=O)/C=C/[C@H](C)[C@@H](O)[C@@H]1C
NCGC00161634-09	O=C1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2		Inactive	antimalarial agents		1	Artemisinin	384568213	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.5751876961	O=C1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2	O=C1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2
NCGC00016306-08&NCGC00016306-09	O=C1[C@H](N)CON1		Inactive	Nmda Partial Agonist&NMDA Glycine-Site Receptor Partial Agonist		2	D-Cycloserine	170465249&384567930	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-17.379729032&-17.137328076&0.0	O=C1[C@H](N)CON1	O=C1[C@H](N)CON1
NCGC00344522-01	O=C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Calcium Chelating Agent		1	Gluconolactone	170465327	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-16.02782186	O=C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O=C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00016024-05	O=C1[C@H](O)[C@@H](c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2		Inactive			1	()-Taxifolin	90341784	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1[C@H](O)[C@@H](c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2	O=C1[C@H](O)[C@@H](c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2
NCGC00025245-05	O=C1[C@H](O)[C@]23[C@H](C(C)(C)C)C[C@H]4OC(=O)[C@@]5([C@@]6(O)[C@H](C)C(=O)OC6[C@H](O)[C@@]245)O[C@@H]3O1		Inactive	GABA(A) Receptor Antagonist		1	Ginkgolide B	384568062	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.046586728	O=C1[C@H](O)[C@]23[C@H](C(C)(C)C)C[C@H]4OC(=O)[C@@]5([C@@]6(O)[C@H](C)C(=O)OC6[C@H](O)[C@@]245)O[C@@H]3O1	O=C1[C@H](O)[C@]23[C@H](C(C)(C)C)C[C@H]4OC(=O)[C@@]5([C@@]6(O)[C@H](C)C(=O)OC6[C@H](O)[C@@]245)O[C@@H]3O1
NCGC00389621-01	O=C1[C@H]([C@@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2	5.1999998	Active	HGFR (MET; c-Met) Inhibitor	0.0	1	Tivantinib (ARQ 197)	384569177	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-102.8946244237	O=C1[C@H]([C@@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2	O=C1[C@H]([C@@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2
NCGC00017363-15	O=C1[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C[C@@H](C)C[C@@H]1C	5.5999999	Active	GSK-3 beta Inhibitor	0.0	1	Cycloheximide	384567988	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-99.6693184334	O=C1[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C[C@@H](C)C[C@@H]1C	O=C1[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C[C@@H](C)C[C@@H]1C
NCGC00346686-10	O=C1[C@H]([C@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2	9.0	Inactive	HGFR Inhibitor	0.0	1	Tivantinib	384568910	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	96.0833965521	O=C1[C@H]([C@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2	O=C1[C@H]([C@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2
NCGC00163547-01	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)(C([C@@H]([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2		Inactive	Steroid prohormone		1	Ecdysone	26756928	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	34.2394837343	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)(C([C@@H]([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)(C([C@@H]([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2
NCGC00346709-02	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2		Inactive	reduces expression of cPEPCK		1	20-hydroxyecdysone	384568926	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.871572932	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2
NCGC00167831-05	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CC)c4C3)cc(O)cc5)=C2)CO1	9.0	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	SN-38	363676672	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-2.799697104	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CC)c4C3)cc(O)cc5)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CC)c4C3)cc(O)cc5)=C2)CO1
NCGC00506803-01	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CCNC(C)C)c4C3)cccc5)=C2)CO1	6.0999999	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	Belotecan	384569319	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-2.1189955201	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CCNC(C)C)c4C3)cccc5)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CCNC(C)C)c4C3)cccc5)=C2)CO1
NCGC00095986-04	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc(O)cc5)cc4C3)=C2)CO1	9.0	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	10-hydroxycamptothecin	363676578	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-16.5638005399	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc(O)cc5)cc4C3)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc(O)cc5)cc4C3)=C2)CO1
NCGC00016994-20	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc4C3)cccc5)=C2)CO1	9.0	Inactive	DNA Topoisomerase I Inhibitor	0.0	1	Camptothecin	384567973	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-21.0234596199	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc4C3)cccc5)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc4C3)cccc5)=C2)CO1
NCGC00018176-05	O=C1[C@]2(C)C(C3C(c4c(cc(O)cc4)CC3)CC2)CC1		Inactive	Steroid hormone		1	Estrone	384567995	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1[C@]2(C)C(C3C(c4c(cc(O)cc4)CC3)CC2)CC1	O=C1[C@]2(C)C(C3C(c4c(cc(O)cc4)CC3)CC2)CC1
NCGC00023902-09	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1		Inactive	Cytochrome P450 19a1 Substrate&Cytochrome P450 19A1 Substrate		1	4-Androstene-3,17-dione	170465907	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.320406808&0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00093802-06&NCGC00093802-09	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1		Inactive	Steroid Hormone&Steroid hormone&Steroid hormone		2	Dehydroepiandrosterone	170465614&363676565	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1
NCGC00023643-15	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1		Inactive	Steroid hormone&Steroid Hormone		1	Estrone	170465020	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-8.10064646	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1
NCGC00025212-08	O=C1[C@]2(C)[C@](C)(C(=O)O1)C1OC2CC1	5.3000002	Active	PP-1 Inhibitors;PP-2A Inhibitors	0.0	1	Cantharidin	170465704	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.3	-90.3656258326	O=C1[C@]2(C)[C@](C)(C(=O)O1)C1OC2CC1	O=C1[C@]2(C)[C@](C)(C(=O)O1)C1OC2CC1
NCGC00025212-26	O=C1[C@]2(C)[C@](C)(C(=O)O1)[C@@H]1O[C@H]2CC1	5.0500002	Active		0.0	1	Cantharidin	384568057	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-102.0635934818	O=C1[C@]2(C)[C@](C)(C(=O)O1)[C@@H]1O[C@H]2CC1	O=C1[C@]2(C)[C@](C)(C(=O)O1)[C@@H]1O[C@H]2CC1
NCGC00017354-07	O=C1[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@H](C)C1		Inactive	Antibiotic		1	Spectinomycin dihydrochloride	170465149	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.934816244&0.0	O=C1[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@H](C)C1.Cl.Cl	O=C1[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@H](C)C1.Cl.Cl
NCGC00263222-02	O=C1c2c(C(=O)C=3OC(C)(C)[C@@H](O)[C@@H](NCc4ccccc4)C1=3)cccc2	5.5	Active	IDO Inhibitor	0.0	1	CAY-10581	384568676	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-98.6631671471	O=C1c2c(C(=O)C=3OC(C)(C)[C@@H](O)[C@@H](NCc4ccccc4)C1=3)cccc2	O=C1c2c(C(=O)C=3OC(C)(C)[C@@H](O)[C@@H](NCc4ccccc4)C1=3)cccc2
NCGC00094960-06	O=C1c2c(C(=O)c3c1cccc3)cccc2		Inactive	Beta Amyloid A4 Protein Binding Agent&Beta amyloid A4 protein Binding Agent		1	Anthraquinone	170466833	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.969590804&0.0	O=C1c2c(C(=O)c3c1cccc3)cccc2	O=C1c2c(C(=O)c3c1cccc3)cccc2
NCGC00510921-01	O=C1c2c(NCCN(CC)CC)ccc(C)c2Sc2c1cccc2	5.0999999	Active	DNA Topoisomerase II Inhibitor	0.0	1	Lucanthone	384569494	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-113.5223794218	O=C1c2c(NCCN(CC)CC)ccc(C)c2Sc2c1cccc2	O=C1c2c(NCCN(CC)CC)ccc(C)c2Sc2c1cccc2
NCGC00274280-01	O=C1c2c(NCCN)ccc(NCCN)c2C(=O)c2c1cncc2	5.0999999	Active	DNA Modulator	0.0	1	Pixantronemaleate	225144373	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.1	-96.8359148171	O=C1c2c(NCCN)ccc(NCCN)c2C(=O)c2c1cncc2	O=C1c2c(NCCN)ccc(NCCN)c2C(=O)c2c1cncc2
NCGC00017236-16	O=C1c2c(O)c(O)c(O)cc2OC(c2ccccc2)=C1		Inactive	Cyp2C9 Inhibitor		1	Baicalein	384567977	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1c2c(O)c(O)c(O)cc2OC(c2ccccc2)=C1	O=C1c2c(O)c(O)c(O)cc2OC(c2ccccc2)=C1
NCGC00095227-06	O=C1c2c(O)c(O)ccc2C(=O)c2c1cccc2		Inactive	Calcium Binding Agent		1	Alizarin	170465641	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.0463415119&0.0	O=C1c2c(O)c(O)ccc2C(=O)c2c1cccc2	O=C1c2c(O)c(O)ccc2C(=O)c2c1cccc2
NCGC00091823-09	O=C1c2c(O)cc(C)cc2C(=O)c2c1c(O)ccc2		Inactive	VEGFR-1/2 Inhibitor		1	Chrysophanol	384568098	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	11.7318707921	O=C1c2c(O)cc(C)cc2C(=O)c2c1c(O)ccc2	O=C1c2c(O)cc(C)cc2C(=O)c2c1c(O)ccc2
NCGC00163510-01	O=C1c2c(O)cc(CO)cc2C(=O)c2c1c(O)ccc2		Inactive	Caspase 3 Activator		1	Aloe-emodin	26756894	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	25.525501648	O=C1c2c(O)cc(CO)cc2C(=O)c2c1c(O)ccc2	O=C1c2c(O)cc(CO)cc2C(=O)c2c1c(O)ccc2
NCGC00389730-01	O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c1c(O)ccc2	4.5999999	Active	Stimulant Laxative	0.0	1	NCGC00389730-01	405558988	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-49.6942800816	O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c1c(O)ccc2	O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c1c(O)ccc2
NCGC00015420-15	O=C1c2c(O)cc(O)cc2C(=O)c2c1c(O)cc(C)c2		Inactive	Casein Kinase 2 Inhibitor		1	Emodin	384567841	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1c2c(O)cc(O)cc2C(=O)c2c1c(O)cc(C)c2	O=C1c2c(O)cc(O)cc2C(=O)c2c1c(O)cc(C)c2
NCGC00016467-10	O=C1c2c(O)cc(O)cc2OC(c2cc(O)c(O)cc2)=C1	4.4000001	Active	alpha-Glucosidase Inhibitor	0.0	1	Digitoflavone	384567943	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-107.2970214248	O=C1c2c(O)cc(O)cc2OC(c2cc(O)c(O)cc2)=C1	O=C1c2c(O)cc(O)cc2OC(c2cc(O)c(O)cc2)=C1
NCGC00015049-24	O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2)=C1	4.4000001	Active	NMDA Receptor Antagonist	0.0	1	Apigenin	384567801	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-106.0741078512	O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2)=C1	O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2)=C1
NCGC00016456-20	O=C1c2c(O)cc(O)cc2OC(c2ccccc2)=C1		Inactive	Antiinflammatory Drug		1	Chrysine	384567941	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.504654488	O=C1c2c(O)cc(O)cc2OC(c2ccccc2)=C1	O=C1c2c(O)cc(O)cc2OC(c2ccccc2)=C1
NCGC00016457-02	O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)C1		Inactive	Estrogen Receptor (ER) beta Agonist		1	Naringenin	124882284	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)C1	O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)C1
NCGC00346890-02	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCC[N+]([O-])(C)C)ccc(NCC[N+]([O-])(C)C)c12	5.1500001	Inactive	DNA Topoisomerase II Inhibitor	0.0	1	Banoxantrone	384568963	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	55.2247621062	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCC[N+]([O-])(C)C)ccc(NCC[N+]([O-])(C)C)c12	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCC[N+]([O-])(C)C)ccc(NCC[N+]([O-])(C)C)c12
NCGC00091367-05	O=C1c2c(O)cccc2C(=O)c2c1c(O)ccc2		Inactive	DNA topoisomerase II alpha Inhibitor&Dna Topoisomerase Ii Alpha Inhibitor		1	Danthron	170465532	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-14.3199008879	O=C1c2c(O)cccc2C(=O)c2c1c(O)ccc2	O=C1c2c(O)cccc2C(=O)c2c1c(O)ccc2
NCGC00091330-07	O=C1c2c(O)cccc2Cc2c1c(O)ccc2		Inactive			1	Anthralin	170466655	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.325763864&-15.156809088	O=C1c2c(O)cccc2Cc2c1c(O)ccc2	O=C1c2c(O)cccc2Cc2c1c(O)ccc2
NCGC00250377-09	O=C1c2c(c(-c3c4sc5c(c4ccc3)cccc5)ccc2)OC(N2CCOCC2)=C1	5.0999999	Active	DNA-PK Inhibitor	0.0	1	NU-7441	384568537	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-97.9376045527	O=C1c2c(c(-c3c4sc5c(c4ccc3)cccc5)ccc2)OC(N2CCOCC2)=C1	O=C1c2c(c(-c3c4sc5c(c4ccc3)cccc5)ccc2)OC(N2CCOCC2)=C1
NCGC00015622-10	O=C1c2c(c(-c3ccccc3)ccc2)OC(N2CCOCC2)=C1		Inactive	PI3K Inhibitor		1	LY-294002	384567876	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.38421802	O=C1c2c(c(-c3ccccc3)ccc2)OC(N2CCOCC2)=C1	O=C1c2c(c(-c3ccccc3)ccc2)OC(N2CCOCC2)=C1
NCGC00015958-18	O=C1c2c3c([nH]nc3-c3c1cccc3)ccc2	4.4499998	Active	SAPK1 (JNK) Inhibitor	0.0	1	SP-600125	384567910	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-47.94719268	O=C1c2c3c([nH]nc3-c3c1cccc3)ccc2	O=C1c2c3c([nH]nc3-c3c1cccc3)ccc2
NCGC00510502-02	O=C1c2scc(-c3cc4OCCOc4cc3)c2OC(N2CCOCC2)=C1		Inactive	PI3K beta Inhibitor		1	SF-2523	384569463	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=C1c2scc(-c3cc4OCCOc4cc3)c2OC(N2CCOCC2)=C1	O=C1c2scc(-c3cc4OCCOc4cc3)c2OC(N2CCOCC2)=C1
NCGC00015580-13	O=C1c2sccc2/C(=C\2/CCN(C)CC/2)/c2c(cccc2)C1	6.0999999	Active	Histamine H1 Receptor Antagonists	0.0	1	Ketotifen	170465378	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-45.0854061199	O=C1c2sccc2/C(=C\2/CCN(C)CC/2)/c2c(cccc2)C1	O=C1c2sccc2/C(=C\2/CCN(C)CC/2)/c2c(cccc2)C1
NCGC00015580-22	O=C1c2sccc2C(=C2CCN(C)CC2)c2c(cccc2)C1	4.5	Active	Histamine H1 Receptor Antagonist	0.0	1	Ketotifen	384567867	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-44.5121986185	O=C1c2sccc2C(=C2CCN(C)CC2)c2c(cccc2)C1	O=C1c2sccc2C(=C2CCN(C)CC2)c2c(cccc2)C1
NCGC00181031-03	O=CCC(CCCC(O)(C)C)C		Inactive	Transient Receptor Potential Cation Channel Subfamily M Member 8 Agonist&Transient receptor potential cation channel subfamily M member 8 Agonist		1	Hydroxycitronellal	225144317	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.9232995685&-11.657708864	O=CCC(CCCC(O)(C)C)C	O=CCC(CCCC(O)(C)C)C
NCGC00091110-01	O=CCCCC=O	4.4000001	Active		0.0	1	Glutaraldehyde	144204634	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-60.085603332	O=CCCCC=O	O=CCCCC=O
NCGC00263872-02	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](OC)[C@H](O)CC(=O)O[C@@H](C)C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](N(C)C)CC2)[C@H](C)C1		Inactive	Bacterial 70s Ribosome Binding Agent&Bacterial 70S ribosome Binding Agent		1	SPIRAMYCIN	405558421	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-22.3594033424	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](OC)[C@H](O)CC(=O)O[C@@H](C)C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](N(C)C)CC2)[C@H](C)C1	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](OC)[C@H](O)CC(=O)O[C@@H](C)C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](N(C)C)CC2)[C@H](C)C1
NCGC00263955-02	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CO[C@H]2[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O2)/C=C(\C)/C=C/C(=O)[C@H](C)C1		Inactive			1	TYLOSIN TARTRATE	405559071	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.449998104&0.0	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CO[C@H]2[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O2)/C=C(\C)/C=C/C(=O)[C@H](C)C1	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CO[C@H]2[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O2)/C=C(\C)/C=C/C(=O)[C@H](C)C1
NCGC00262939-01	O=CN(/C(/C)=C/1\SC(=O)OCC\1)Cc1c(N)nc(C)nc1		Inactive			1	Cycotiamine	170465848	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-30.353338156	O=CN(/C(/C)=C/1\SC(=O)OCC\1)Cc1c(N)nc(C)nc1	O=CN(/C(/C)=C/1\SC(=O)OCC\1)Cc1c(N)nc(C)nc1
NCGC00025167-02	O=CNc1c(O)ccc([C@H](O)CN[C@H](Cc2ccc(OC)cc2)C)c1		Inactive	Beta-2 Adrenergic Receptor Agonist&Voltage-Gated K(V) 7 (KCNQ) Channel Activator		1	Formoterol hemifumarate	405558911	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-29.654363884	O=CNc1c(O)ccc([C@H](O)CN[C@H](Cc2ccc(OC)cc2)C)c1	O=CNc1c(O)ccc([C@H](O)CN[C@H](Cc2ccc(OC)cc2)C)c1
NCGC00386163-02	O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO		Inactive	Glycolysis / Gluconeogenesis Substrate		1	Dextrose&NCGC00386163-02	405559092	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
NCGC00159339-04&NCGC00159339-10	O=C[C@]1(O)[C@@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]2NC(=N)N)O[C@H]1C		Inactive	30S Ribosomal Protein Inhibitors&30s Ribosomal Protein Inhibitors		2	Streptomycin (sulfate)&Streptomycin sulfate	384568169&405558717	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	13.974782936&-20.41168216&-24.29719956	O=C[C@]1(O)[C@@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]2NC(=N)N)O[C@H]1C	O=C[C@]1(O)[C@@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]2NC(=N)N)O[C@H]1C
NCGC00017254-05	O=C\1O[C@@H](C)CCC/C=C/C2[C@H]([C@H](O)/C=C/1)C[C@@H](O)C2	6.0	Active	Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitor	0.0	1	Cyanein	384567981	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-86.525623562	O=C\1O[C@@H](C)CCC/C=C/C2[C@H]([C@H](O)/C=C/1)C[C@@H](O)C2	O=C\1O[C@@H](C)CCC/C=C/C2[C@H]([C@H](O)/C=C/1)C[C@@H](O)C2
NCGC00483033-01	O=C\1[C@H](C)C[C@H](CCN2CCCCC2)[C@H](OC2C(O)C(N(C)C)C(O)C(C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CN2CCCCC2)/C=C(\C)/C=C/1	4.8000002	Active	Bacterial 70S ribosome Inhibitor	0.0	1	Tildipirosin	405559127	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-47.1819419155	O=C\1[C@H](C)C[C@H](CCN2CCCCC2)[C@H](OC2C(O)C(N(C)C)C(O)C(C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CN2CCCCC2)/C=C(\C)/C=C/1	O=C\1[C@H](C)C[C@H](CCN2CCCCC2)[C@H](OC2C(O)C(N(C)C)C(O)C(C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CN2CCCCC2)/C=C(\C)/C=C/1
NCGC00166206-04	O=Cc1c(C=O)cccc1		Inactive			1	1,2-Benzenedicarboxaldehyde	170466016	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.5246731399&-18.8608008039	O=Cc1c(C=O)cccc1	O=Cc1c(C=O)cccc1
NCGC00016423-15	O=Cc1c(O)c(O)c(C(C)C)c2c1c(O)c(-c1c(O)c3c(C=O)c(O)c(O)c(C(C)C)c3cc1C)c(C)c2	4.75	Active	Bcl-xl Inhibitor	0.0	1	(-)-Gossypol	170466800	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-101.6390606699	O=Cc1c(O)c(O)c(C(C)C)c2c1c(O)c(-c1c(O)c3c(C=O)c(O)c(O)c(C(C)C)c3cc1C)c(C)c2	O=Cc1c(O)c(O)c(C(C)C)c2c1c(O)c(-c1c(O)c3c(C=O)c(O)c(O)c(C(C)C)c3cc1C)c(C)c2
NCGC00522012-01	O=N/C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\3/C(=O)N([C@H]4CN(C(=O)OCC5=C(C)OC(=O)O5)CC4)CC/3)CS[C@H]12)=C\1/N=C(N)SN/1		Inactive			1	CEFTOBIPROLE MEDOCARIL SODIUM	405558834	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.447927756&26.6419859799	O=N/C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\3/C(=O)N([C@H]4CN(C(=O)OCC5=C(C)OC(=O)O5)CC4)CC/3)CS[C@H]12)=C\1/N=C(N)SN/1	O=N/C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\3/C(=O)N([C@H]4CN(C(=O)OCC5=C(C)OC(=O)O5)CC4)CC/3)CS[C@H]12)=C\1/N=C(N)SN/1
NCGC00178500-07&NCGC00178500-19	O=NN(C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C		Inactive	Dna Alkylating Agent&DNA Alkylating Agent		2	Streptozotocin&Streptozocin	170464827&384568356	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O=NN(C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C	O=NN(C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C
NCGC00091066-01	O=NOCCC(C)C		Inactive	Vasodilation Activator&vasodilation Activator		1	3-Methylbutyl nitrite	144204625	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=NOCCC(C)C	O=NOCCC(C)C
NCGC00165844-06	O=Nc1c(OCC2CCCCC2)nc(N)nc1N		Inactive			1	NU-6027	384568289	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-23.3173967359	O=Nc1c(OCC2CCCCC2)nc(N)nc1N	O=Nc1c(OCC2CCCCC2)nc(N)nc1N
NCGC00093588-04	O=P1(O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1		Inactive	Camp-dependent Protein Kinase Type Ii-alpha Regulatory Subunit Activator&cAMP-dependent protein kinase type II-alpha regulatory subunit Activator		1	cAMP	170466839	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.948910636&0.0	O=P1(O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1	O=P1(O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1
NCGC00167751-05	O=S1(=O)N(COC=2N=C3C(OCCN4CCCCC4)=CC=CN3C(=O)C=2)C(=O)c2c(C(C)C)cc(OC)cc12		Inactive	Leukocyte Elastase Inhibitor		1	SSR-69071	384568334	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.5083332211	O=S1(=O)N(COC=2N=C3C(OCCN4CCCCC4)=CC=CN3C(=O)C=2)C(=O)c2c(C(C)C)cc(OC)cc12	O=S1(=O)N(COC=2N=C3C(OCCN4CCCCC4)=CC=CN3C(=O)C=2)C(=O)c2c(C(C)C)cc(OC)cc12
NCGC00094918-07	O=S1(=O)NC(=O)c2c1cccc2		Inactive	Taste Receptor Type 1 Member 3 Binding Agent&Taste receptor type 1 member 3 Binding Agent		1	Saccharin	170465766	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.4553265279&-18.6558978119	O=S1(=O)NC(=O)c2c1cccc2	O=S1(=O)NC(=O)c2c1cccc2
NCGC00013109-03	O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2		Inactive	amyloid fibril formation Inhibitor&Amyloid Fibril Formation Inhibitor		1	Phenol red	170465805	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	24.5576364919&0.0	O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2	O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2
NCGC00159388-05	O=[N+](OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])[O-]		Inactive	Soluble guanylate cyclase Activator&Soluble Guanylate Cyclase Activator		1	Pentaerythritol tetranitrate	225144224	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	22.4867046839&26.3906470119	O=[N+](OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])[O-]	O=[N+](OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])[O-]
NCGC00182985-01	O=[N+](OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])[O-]		Inactive	Soluble Guanylate Cyclase Activator&Soluble guanylate cyclase Activator		1	Trolnitrate	144206882	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.516151972&0.0	O=[N+](OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])[O-]	O=[N+](OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])[O-]
NCGC00167981-03	O=[N+](O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1)[O-]		Inactive			1	Isosorbide mononitrate	405559096	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.13509766&-35.0073749039	O=[N+](O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1)[O-]	O=[N+](O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1)[O-]
NCGC00178830-05	O=[N+](O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1)[O-]		Inactive			1	Isosorbide dinitrate	170464980	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-19.4547986515	O=[N+](O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1)[O-]	O=[N+](O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1)[O-]
NCGC00024717-10	O=[N+]([O-])NC(=N)NCCC[C@H](N)C(=O)OC		Inactive	Nitric Oxide Synthase Inhibitor		1	L-NAME	384568032	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.823294412	O=[N+]([O-])NC(=N)NCCC[C@H](N)C(=O)OC	O=[N+]([O-])NC(=N)NCCC[C@H](N)C(=O)OC
NCGC00344620-03	O=[N+]([O-])c1c(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)N=C/3C)cc2)cc(C)c(C)c1		Inactive	Histone N-Acetyltransferase (HAT) Inhibitor		1	C-646	384568724	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=[N+]([O-])c1c(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)N=C/3C)cc2)cc(C)c(C)c1	O=[N+]([O-])c1c(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)N=C/3C)cc2)cc(C)c(C)c1
NCGC00094985-05	O=[N+]([O-])c1c(C)c(C(=O)N)cc([N+](=O)[O-])c1		Inactive			1	Zoalene	170465727	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	O=[N+]([O-])c1c(C)c(C(=O)N)cc([N+](=O)[O-])c1	O=[N+]([O-])c1c(C)c(C(=O)N)cc([N+](=O)[O-])c1
NCGC00347945-09	O=[N+]([O-])c1c(C)n(-c2ccc(OC)cc2)c2c1ccc(O)c2		Inactive	DYRK Inhibitor		1	ID-8	384568993	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=[N+]([O-])c1c(C)n(-c2ccc(OC)cc2)c2c1ccc(O)c2	O=[N+]([O-])c1c(C)n(-c2ccc(OC)cc2)c2c1ccc(O)c2
NCGC00015748-17	O=[N+]([O-])c1c(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)cccc1	4.4000001	Active	Voltage-gated L-type Calcium Channel Alpha-1c Subunit Inhibitor	0.0	1	Nifedipine	170465006	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-74.0952596799	O=[N+]([O-])c1c(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)cccc1	O=[N+]([O-])c1c(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)cccc1
NCGC00182054-03	O=[N+]([O-])c1c(C2C(C(=O)OCC(=O)C)=C(C)NC(C)=C2C(=O)OC)cccc1	4.5500002	Active	Voltage-gated Calcium Channel Antagonist&Voltage-gated calcium channel Antagonist	0.0	1	Aranidipine	170465977	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-45.775445116&-89.9968218556	O=[N+]([O-])c1c(C2C(C(=O)OCC(=O)C)=C(C)NC(C)=C2C(=O)OC)cccc1	O=[N+]([O-])c1c(C2C(C(=O)OCC(=O)C)=C(C)NC(C)=C2C(=O)OC)cccc1
NCGC00164633-02	O=[N+]([O-])c1c(C2C(C(=O)OCC(C)C)=C(C)NC(C)=C2C(=O)OC)cccc1	4.9499998	Inactive	Ca2+ channel blocker (dihydropyridine)	0.0	1	Nisoldipine	170465320	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	58.2915057283	O=[N+]([O-])c1c(C2C(C(=O)OCC(C)C)=C(C)NC(C)=C2C(=O)OC)cccc1	O=[N+]([O-])c1c(C2C(C(=O)OCC(C)C)=C(C)NC(C)=C2C(=O)OC)cccc1
NCGC00164555-03	O=[N+]([O-])c1c(O)c(O)cc(/C=C(/C(=O)N(CC)CC)\C#N)c1	4.5	Active	NCI-H1299 Inhibitor	0.0	1	Entacapone	170464850	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-72.2892255176	O=[N+]([O-])c1c(O)c(O)cc(/C=C(/C(=O)N(CC)CC)\C#N)c1	O=[N+]([O-])c1c(O)c(O)cc(/C=C(/C(=O)N(CC)CC)\C#N)c1
NCGC00165815-06	O=[N+]([O-])c1c(O/N=[N+](\[O-])/N2CCN(C(=O)OCC)CC2)ccc([N+](=O)[O-])c1		Inactive	Nitric Oxide (NO) Donors		1	NSC-724771	384568286	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=[N+]([O-])c1c(O/N=[N+](\[O-])/N2CCN(C(=O)OCC)CC2)ccc([N+](=O)[O-])c1	O=[N+]([O-])c1c(O/N=[N+](\[O-])/N2CCN(C(=O)OCC)CC2)ccc([N+](=O)[O-])c1
NCGC00510691-01	O=[N+]([O-])c1c(OCC2OC(=O)C(Cc3ccccc3)C2)cccc1		Inactive	Inhibitor of autophagy		1	3-BDO	384569481	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	10.304218228	O=[N+]([O-])c1c(OCC2OC(=O)C(Cc3ccccc3)C2)cccc1	O=[N+]([O-])c1c(OCC2OC(=O)C(Cc3ccccc3)C2)cccc1
NCGC00160664-04	O=[N+]([O-])c1c2c(c(O)cc1)nccc2	4.4000001	Active	Methionine Aminopeptidase-2 (MetAP2) Inhibitor	0.0	1	Nitroxoline	384568201	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-113.9354110963	O=[N+]([O-])c1c2c(c(O)cc1)nccc2	O=[N+]([O-])c1c2c(c(O)cc1)nccc2
NCGC00167969-02	O=[N+]([O-])c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1	4.5	Inactive		0.0	1	Rubitecan	124893436	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-5.1582910161&-3.9880521761	O=[N+]([O-])c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1	O=[N+]([O-])c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1
NCGC00246958-03	O=[N+]([O-])c1c2no[n+]([O-])c2c(N2CCN(C)CC2)cc1		Inactive	MDM4 (MDMX) Inhibitor		1	NSC-207895	363677155	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-33.068868276	O=[N+]([O-])c1c2no[n+]([O-])c2c(N2CCN(C)CC2)cc1	O=[N+]([O-])c1c2no[n+]([O-])c2c(N2CCN(C)CC2)cc1
NCGC00346825-02	O=[N+]([O-])c1c2nonc2c(Nc2c(-c3ccccc3)cccc2)cc1	5.0999999	Active	MYC Expression Inhibitor	0.0	1	10074-G5	384568944	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-94.4446623266	O=[N+]([O-])c1c2nonc2c(Nc2c(-c3ccccc3)cccc2)cc1	O=[N+]([O-])c1c2nonc2c(Nc2c(-c3ccccc3)cccc2)cc1
NCGC00241411-01	O=[N+]([O-])c1cc(C(=O)Nc2n(CCCO)c3c(n2)cc(OC(=O)C(C)(C)C)cc3)ccc1		Inactive	IRAK Inhibitor		1	NCGC00241411	137275845	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.579606428	O=[N+]([O-])c1cc(C(=O)Nc2n(CCCO)c3c(n2)cc(OC(=O)C(C)(C)C)cc3)ccc1	O=[N+]([O-])c1cc(C(=O)Nc2n(CCCO)c3c(n2)cc(OC(=O)C(C)(C)C)cc3)ccc1
NCGC00186035-08	O=[N+]([O-])c1cc(C(=O)Nc2n(CCN3CCOCC3)c3c(n2)cccc3)ccc1		Inactive	IRAK Inhibitor		1	IRAK-1-4 Inhibitor I	384568438	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=[N+]([O-])c1cc(C(=O)Nc2n(CCN3CCOCC3)c3c(n2)cccc3)ccc1	O=[N+]([O-])c1cc(C(=O)Nc2n(CCN3CCOCC3)c3c(n2)cccc3)ccc1
NCGC00015714-16	O=[N+]([O-])c1cc(C2C(C(=O)OC(C)C)=C(C)NC(C)=C2C(=O)OCCOC)ccc1		Inactive	Voltage-gated L-type Calcium Channel Antagonist&Voltage-gated L-type calcium channel Antagonist		1	Nimodipine	170466561	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.225024044&-24.53892476	O=[N+]([O-])c1cc(C2C(C(=O)OC(C)C)=C(C)NC(C)=C2C(=O)OCCOC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC(C)C)=C(C)NC(C)=C2C(=O)OCCOC)ccc1
NCGC00167435-07	O=[N+]([O-])c1cc(C2C(C(=O)OC)=C(C#N)NC(C)=C2C(=O)OC(C)C)ccc1	4.8499999	Active	Voltage-gated L-type Calcium Channel Alpha-1c Subunit Blocker&Voltage-gated L-type calcium channel alpha-1C subunit Blocker	0.0	1	Nilvadipine	405558817	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-60.5117410564&-35.114203552	O=[N+]([O-])c1cc(C2C(C(=O)OC)=C(C#N)NC(C)=C2C(=O)OC(C)C)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC)=C(C#N)NC(C)=C2C(=O)OC(C)C)ccc1
NCGC00167436-02	O=[N+]([O-])c1cc(C2C(C(=O)OC3CN(C(c4ccccc4)c4ccccc4)C3)=C(N)NC(C)=C2C(=O)OC(C)C)ccc1	4.4000001	Active	Ca channel blocker - DHP class&Ca Channel Blocker - Dhp Class	0.0	1	Azelnidipine	174006618	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-111.8140564375&-116.5562211079	O=[N+]([O-])c1cc(C2C(C(=O)OC3CN(C(c4ccccc4)c4ccccc4)C3)=C(N)NC(C)=C2C(=O)OC(C)C)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC3CN(C(c4ccccc4)c4ccccc4)C3)=C(N)NC(C)=C2C(=O)OC(C)C)ccc1
NCGC00015713-13	O=[N+]([O-])c1cc(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OC)ccc1		Inactive	Intermediate conductance calcium-activated potassium channel protein 4 Inhibitor&Intermediate Conductance Calcium-activated Potassium Channel Protein 4 Inhibitor		1	Nitrendipine	170465897	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.348472492&-13.1947562559	O=[N+]([O-])c1cc(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00163135-04	O=[N+]([O-])c1cc(C2C(C(=O)OCCCN3CCC(c4ccccc4)(c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1	5.0500002	Active	L-type Ca2+ channel Blocker	0.0	1	Niguldipine	124892401	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-95.8056174132	O=[N+]([O-])c1cc(C2C(C(=O)OCCCN3CCC(c4ccccc4)(c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCCN3CCC(c4ccccc4)(c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00015747-09	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)C)=C(C)NC(C)=C2C(=O)OC)ccc1	4.4000001	Active	Ca Channel Blocker - Dhp Class&Ca channel blocker - DHP class	0.0	1	Nicardipine	170465173	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-62.1712981919&-66.4164734519	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)C)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)C)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00371105-01	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)c3ccccc3)=C(C)NC(C)=C2P2(=O)OCC(C)(C)CO2)ccc1	4.4000001	Active	Voltage-gated T-type calcium channel Blocker	0.0	1	Efonidipine hydrochloride monoethanolate	405558645	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-76.629048196	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)c3ccccc3)=C(C)NC(C)=C2P2(=O)OCC(C)(C)CO2)ccc1.[O-]CC	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)c3ccccc3)=C(C)NC(C)=C2P2(=O)OCC(C)(C)CO2)ccc1.[O-]CC
NCGC00253607-01	O=[N+]([O-])c1cc(C2C(C(=O)OCCc3ccc(N4CCN(C(c5ccccc5)c5ccccc5)CC4)cc3)=C(C)NC(C)=C2C(=O)OC)ccc1		Inactive	Calcium Ion Transmembrane Transport Blocker&calcium ion transmembrane transport Blocker		1	Watanidipine	170465844	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.0339110439	O=[N+]([O-])c1cc(C2C(C(=O)OCCc3ccc(N4CCN(C(c5ccccc5)c5ccccc5)CC4)cc3)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCc3ccc(N4CCN(C(c5ccccc5)c5ccccc5)CC4)cc3)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00167492-03	O=[N+]([O-])c1cc(C2C(C(OC(CN(CCC(c3ccccc3)c3ccccc3)C)(C)C)=O)=C(C)NC(C)=C2C(=O)OC)ccc1	4.4499998	Active	Voltage-gated L-type calcium channel Blocker&Voltage-gated L-type Calcium Channel Blocker	0.0	1	Lercanidipine hydrochloride	170465587	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-97.1179814962&-90.371076962	O=[N+]([O-])c1cc(C2C(C(OC(CN(CCC(c3ccccc3)c3ccccc3)C)(C)C)=O)=C(C)NC(C)=C2C(=O)OC)ccc1.Cl	O=[N+]([O-])c1cc(C2C(C(OC(CN(CCC(c3ccccc3)c3ccccc3)C)(C)C)=O)=C(C)NC(C)=C2C(=O)OC)ccc1.Cl
NCGC00094736-05	O=[N+]([O-])c1cc([N+](=O)[O-])cc(C(=O)N)c1		Inactive	Eimeria Tenella Inhibitor&Eimeria tenella Inhibitor		1	Nitromide	170466818	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.6159149835&12.637276312	O=[N+]([O-])c1cc([N+](=O)[O-])cc(C(=O)N)c1	O=[N+]([O-])c1cc([N+](=O)[O-])cc(C(=O)N)c1
NCGC00091351-01	O=[N+]([O-])c1cc([N+](=O)[O-])ccc1		Inactive			1	m-Dinitrobenzene	17388932	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.8221882119&-15.9745344719	O=[N+]([O-])c1cc([N+](=O)[O-])ccc1	O=[N+]([O-])c1cc([N+](=O)[O-])ccc1
NCGC00381605-01	O=[N+]([O-])c1cc2n(C)cc(C3=C(c4c5c(n(C)c4)cccc5)C(=O)NC3=O)c2cc1	6.0	Active	PKC Inhibitor	0.0	1	MKC-1	384569101	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-85.3761685274	O=[N+]([O-])c1cc2n(C)cc(C3=C(c4c5c(n(C)c4)cccc5)C(=O)NC3=O)c2cc1	O=[N+]([O-])c1cc2n(C)cc(C3=C(c4c5c(n(C)c4)cccc5)C(=O)NC3=O)c2cc1
NCGC00024622-05	O=[N+]([O-])c1ccc(-c2oc(/C=N/N3C(=O)NC(=O)C3)cc2)cc1	4.4000001	Active	Ryanodine Receptor 1 Antagonist	0.0	1	Dantrolene sodium	170464793	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.095611216	O=[N+]([O-])c1ccc(-c2oc(/C=N/N3C(=O)[N-]C(=O)C3)cc2)cc1.[Na+]	O=[N+]([O-])c1ccc(-c2oc(/C=N/N3C(=O)[N-]C(=O)C3)cc2)cc1.[Na+]
NCGC00179658-04	O=[N+]([O-])c1ccc(C(CC(=O)C)C=2C(=O)Oc3c(C=2O)cccc3)cc1	4.9499998	Active	Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor	0.0	1	Acenocoumarol	170465636	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-32.52757592	O=[N+]([O-])c1ccc(C(CC(=O)C)C=2C(=O)Oc3c(C=2O)cccc3)cc1	O=[N+]([O-])c1ccc(C(CC(=O)C)C=2C(=O)Oc3c(C=2O)cccc3)cc1
NCGC00164637-02&NCGC00164637-06	O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1		Inactive	Rapid Delayed Rectifier Potassium Current (ikr) Blockers&K(ATP) Channel Blocker&K(ATP) Channel Blocker		2	Nifekalant	170465960&384568273	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.2453297159&-16.835369588&21.66226668	O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1.Cl	O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1.Cl&O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1
NCGC00166218-02	O=[N+]([O-])c1ccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1	5.1500001	Active		0.0	1	4,4'-Dinitrodiphenylurea	170465744	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.4186753	O=[N+]([O-])c1ccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1	O=[N+]([O-])c1ccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1
NCGC00263237-09	O=[N+]([O-])c1ccc(OC(=O)N2CCC(C(O)(c3cc4OCOc4cc3)c3cc4OCOc4cc3)CC2)cc1		Inactive	Monoacylglycerol lipase (MAGL) Inhibitor		1	JZL-184	384568681	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.271855904	O=[N+]([O-])c1ccc(OC(=O)N2CCC(C(O)(c3cc4OCOc4cc3)c3cc4OCOc4cc3)CC2)cc1	O=[N+]([O-])c1ccc(OC(=O)N2CCC(C(O)(c3cc4OCOc4cc3)c3cc4OCOc4cc3)CC2)cc1
NCGC00346837-02	O=[N+]([O-])c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1	4.4000001	Active	Monoacylglycerol lipase (MAGL) Inhibitor	0.0	1	JZL-195	363677547	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-38.899673188	O=[N+]([O-])c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1	O=[N+]([O-])c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1
NCGC00347955-03	O=[N+]([O-])c1ccc([C@@H](NC(=O)c2cc3c(C)c(C)n(Cc4ccc(-c5c(C(=O)O)cccc5)cc4)c3cc2)C)cc1	4.8000002	Active	PPARgamma Modulator	0.0	1	SR-1664	384568999	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-109.1539168218	O=[N+]([O-])c1ccc([C@@H](NC(=O)c2cc3c(C)c(C)n(Cc4ccc(-c5c(C(=O)O)cccc5)cc4)c3cc2)C)cc1	O=[N+]([O-])c1ccc([C@@H](NC(=O)c2cc3c(C)c(C)n(Cc4ccc(-c5c(C(=O)O)cccc5)cc4)c3cc2)C)cc1
NCGC00263224-03	O=[N+]([O-])c1ccc([C@@H](O)[C@H](NC(=O)CCCCCCCCCCCCC)CO)cc1		Inactive	Ceramidase Inhibitor		1	D-NMAPPD	384568678	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O=[N+]([O-])c1ccc([C@@H](O)[C@H](NC(=O)CCCCCCCCCCCCC)CO)cc1	O=[N+]([O-])c1ccc([C@@H](O)[C@H](NC(=O)CCCCCCCCCCCCC)CO)cc1
NCGC00091398-01	O=[N+]([O-])c1ccccc1		Inactive	Glutathione reductase Inhibitor&Glutathione Reductase Inhibitor		1	Nitrobenzene	17389793	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.246269664&-12.6288640639	O=[N+]([O-])c1ccccc1	O=[N+]([O-])c1ccccc1
NCGC00166238-02	O=[N+]([O-])c1n(CC(=O)NCc2ccccc2)ccn1	4.4000001	Active	Pyruvate:ferredoxin oxidoreductase Substrate	0.0	1	Benznidazole	170466539	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-56.038662384	O=[N+]([O-])c1n(CC(=O)NCc2ccccc2)ccn1	O=[N+]([O-])c1n(CC(=O)NCc2ccccc2)ccn1
NCGC00095158-04&NCGC00095158-08	O=[N+]([O-])c1n(CC(O)C)c(C)nc1		Inactive	antiprotozoal agent&antiprotozoal agent&Antiprotozoal Agent		2	Secnidazole	170466630&405559097	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&33.260987648&23.934873944	O=[N+]([O-])c1n(CC(O)C)c(C)nc1	O=[N+]([O-])c1n(CC(O)C)c(C)nc1
NCGC00261977-03	O=[N+]([O-])c1n(CCN2CCOCC2)cnc1		Inactive	Radiosensitizers		1	Nimorazole	384568569	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.26325336	O=[N+]([O-])c1n(CCN2CCOCC2)cnc1	O=[N+]([O-])c1n(CCN2CCOCC2)cnc1
NCGC00016446-17	O=[N+]([O-])c1n(CCO)c(C)nc1		Inactive	Antibiotic		1	Metronidazole	405558937	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	29.2290898079&-26.788107552	O=[N+]([O-])c1n(CCO)c(C)nc1	O=[N+]([O-])c1n(CCO)c(C)nc1
NCGC00160502-01	O=[N+]([O-])c1n(CCOC(=O)c2ccccc2)c(C)nc1	4.1500001	Active		0.0	1	NCGC00160502-01	29216184	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.830934188	O=[N+]([O-])c1n(CCOC(=O)c2ccccc2)c(C)nc1	O=[N+]([O-])c1n(CCOC(=O)c2ccccc2)c(C)nc1
NCGC00183013-01	O=[N+]([O-])c1n(CO[C@H]([C@H](O)CO)CO)ccn1		Inactive	Apoptosis Modulator		1	Doranidazole	144206845	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	33.3360108744&0.0	O=[N+]([O-])c1n(CO[C@H]([C@H](O)CO)CO)ccn1	O=[N+]([O-])c1n(CO[C@H]([C@H](O)CO)CO)ccn1
NCGC00183106-01	O=[N+]([O-])c1oc(/C=C/c2nc(CO)ccc2)cc1	4.4499998	Active	Aeromonas salmonicida Inhibitor	0.0	1	NCGC00183106-01	124894306	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-53.916398584	O=[N+]([O-])c1oc(/C=C/c2nc(CO)ccc2)cc1	O=[N+]([O-])c1oc(/C=C/c2nc(CO)ccc2)cc1
NCGC00091505-07	O=[N+]([O-])c1oc(/C=N/N2C(=O)NC(=O)C2)cc1	4.4000001	Active	Probable pyruvate-flavodoxin oxidoreductase Substrate	0.0	1	Nitrofurantoin	170464739	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-108.5075141414	O=[N+]([O-])c1oc(/C=N/N2C(=O)NC(=O)C2)cc1	O=[N+]([O-])c1oc(/C=N/N2C(=O)NC(=O)C2)cc1
NCGC00095304-05	O=[N+]([O-])c1oc(/C=N/N2C(=O)OCC2)cc1		Inactive	DNA Crosslinking Agent&Dna Crosslinking Agent		1	Furazolidone	170464641	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.961415996&39.6398358892	O=[N+]([O-])c1oc(/C=N/N2C(=O)OCC2)cc1	O=[N+]([O-])c1oc(/C=N/N2C(=O)OCC2)cc1
NCGC00090686-11	O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1	4.4000001	Active	Antibiotic	0.0	1	Nitrofurazone	170464946	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-76.0048464	O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1	O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1
NCGC00164507-02	O=[N+]([O-])c1oc(CN=O)cc1	4.4749999	Active	Trypanosoma Brucei Rhodesiense Inhibitor	0.0	1	Nifuroxime	124893124	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-32.800280408&-37.302359268	O=[N+]([O-])c1oc(CN=O)cc1	O=[N+]([O-])c1oc(CN=O)cc1
NCGC00390788-02	O=[N+]1N=C(N)N([O-])c2c1cccc2	4.4000001	Active	DNA-Damaging Drugs	0.0	1	Tirapazamine	384569214	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-70.1164185401	[O-][n+]1c(N)n[n+]([O-])c2c1cccc2	[O-][n+]1c(N)n[n+]([O-])c2c1cccc2
NCGC00242511-04	OC(/C=C/C=C/[C@@H](C)[C@@H]1C2(C)[C@H](/C(=C/C=C\3/C(=C)[C@@H](O)C[C@H](O)C/3)/CCC2)CC1)(CC)CC		Inactive	Vitamin D Analog		1	Seocalcitol	384568505	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OC(/C=C/C=C/[C@@H](C)[C@@H]1C2(C)[C@H](/C(=C/C=C\3/C(=C)[C@@H](O)C[C@H](O)C/3)/CCC2)CC1)(CC)CC	OC(/C=C/C=C/[C@@H](C)[C@@H]1C2(C)[C@H](/C(=C/C=C\3/C(=C)[C@@H](O)C[C@H](O)C/3)/CCC2)CC1)(CC)CC
NCGC00378634-01	OC(/C=C/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(CC)CC		Inactive	Vitamin D Analog		1	NCGC00378634-01&Seocalcitol	405559031	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.842674892&0.0	OC(/C=C/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(CC)CC	OC(/C=C/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(CC)CC
NCGC00185769-02	OC(C(C)(C)C)C=Cc1cc2OCOc2cc1	4.4000001	Active	Gaba Synthesis, Release, Reuptake And Degradation Modulator	0.0	1	Stiripentol	405558693	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-57.3439745759	OC(C(C)(C)C)C=Cc1cc2OCOc2cc1	OC(C(C)(C)C)C=Cc1cc2OCOc2cc1
NCGC00024643-10	OC(C(C)N1CCC(Cc2ccccc2)CC1)c1ccc(O)cc1		Inactive	Kir3.1/kir3.4 Inhibitor&Kir3.1/Kir3.4 Inhibitor		1	Ifenprodil	170465791	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.002757208&-27.6582475439	OC(C(C)N1CCC(Cc2ccccc2)CC1)c1ccc(O)cc1	OC(C(C)N1CCC(Cc2ccccc2)CC1)c1ccc(O)cc1
NCGC00091575-03	OC(C(CO)CC)CCC		Inactive			1	2-Ethyl-1,3-hexanediol	170465521	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	7.78811592&0.0	OC(C(CO)CC)CCC	OC(C(CO)CC)CCC
NCGC00249896-01	OC(C(N(C/C=C/c1ccccc1)C)C)c1ccccc1	5.4000001	Active		0.0	1	Cinnamedrine	170465535	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-1.4	-35.3585963855&-31.610482044	OC(C(N(C/C=C/c1ccccc1)C)C)c1ccccc1	OC(C(N(C/C=C/c1ccccc1)C)C)c1ccccc1
NCGC00510907-01	OC(C(N(CC)C)C)c1ccccc1		Inactive	Beta-2 Adrenergic Receptor Agonist&Beta-2 adrenergic receptor Agonist		1	Etafedrine hydrochloride	405558912	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.2525502881&-15.822494052	OC(C(N(CC)C)C)c1ccccc1	OC(C(N(CC)C)C)c1ccccc1
NCGC00018239-11	OC(C(NC(C)C)CC)c1cc(O)c(O)cc1		Inactive			1	ISOETHARINE MESYLATE	405558425	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	55.5973285854&-13.879500872	OC(C(NC(C)C)CC)c1cc(O)c(O)cc1	OC(C(NC(C)C)CC)c1cc(O)c(O)cc1
NCGC00015716-09	OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1	5.4000001	Active	Glutamate NMDA receptor; Grin1/Grin2c Antagonist	0.0	1	Nylidrin	170465637	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-56.4226809436	OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1	OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1
NCGC00015408-05	OC(C(NC)C)c1ccccc1	5.1500001	Active	Norepinephrine Transporter Inhibitor	0.0	1	RACEPHEDRINE HYDROCHLORIDE	405558670	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-39.3822756485	OC(C(NC)C)c1ccccc1	OC(C(NC)C)c1ccccc1
NCGC00015887-06	OC(C(NCCc1ccc(O)cc1)C)c1ccc(O)cc1		Inactive	beta2-Adrenoceptor Agonist		1	Ritodrine hydrochloride	384567901	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.9660764721	OC(C(NCCc1ccc(O)cc1)C)c1ccc(O)cc1	OC(C(NCCc1ccc(O)cc1)C)c1ccc(O)cc1
NCGC00164431-01	OC(C)(C)C1CC=C(C)CC1	4.1999998	Active	Acetylcholinesterase Inhibitor	0.0	1	Terpineol	144205671	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.472185148	OC(C)(C)C1CC=C(C)CC1	OC(C)(C)C1CC=C(C)CC1
NCGC00159414-01	OC(C)(C)C1CCC(O)(C)CC1		Inactive			1	p-Menthane-1,8-diol monohydrate	225144225	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.8230822839&0.0	OC(C)(C)C1CCC(O)(C)CC1	OC(C)(C)C1CCC(O)(C)CC1
NCGC00521941-01	OC(C)(C)c1cc2n([C@H](c3ccccc3)C3CCOCC3)c3c(ncc(-c4n(C)nnc4C)c3)c2cc1	4.9499998	Active	Brd4 Inhibitor	0.0	1	BMS-986158	384569506	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-68.6730001162	OC(C)(C)c1cc2n([C@H](c3ccccc3)C3CCOCC3)c3c(ncc(-c4n(C)nnc4C)c3)c2cc1	OC(C)(C)c1cc2n([C@H](c3ccccc3)C3CCOCC3)c3c(ncc(-c4n(C)nnc4C)c3)c2cc1
NCGC00344509-02	OC(C)(c1sc2c(n1)cccc2)c1c(C)cc(C)cc1	4.4000001	Active	Calcium-Sensing Receptor (CaSR) Agonist	0.0	1	AC-265347	384568719	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-81.521863016	OC(C)(c1sc2c(n1)cccc2)c1c(C)cc(C)cc1	OC(C)(c1sc2c(n1)cccc2)c1c(C)cc(C)cc1
NCGC00160543-01	OC(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)CC1	4.1500001	Active	G-protein Coupled Bile Acid Receptor 1 Agonist	0.0	1	Pregnandiol	144205439	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.0448923036	OC(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)CC1	OC(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)CC1
NCGC00165972-02	OC(CC)c1ccccc1		Inactive	Glycolysis / Gluconeogenesis Activator		1	1-Phenyl-1-propanol	405559080	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.5144646&0.0	OC(CC)c1ccccc1	OC(CC)c1ccccc1
NCGC00344546-01	OC(CCCC)c1ccccc1	4.4000001	Active		0.0	1	Fenipentol	225144389	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-45.2114518319&-39.654860084	OC(CCCC)c1ccccc1	OC(CCCC)c1ccccc1
NCGC00016624-05	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	5.0500002	Active	Muscarinic Acetylcholine Receptor M5 Antagonist	0.0	1	Diphenidol	170465280	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-35.468498188	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
NCGC00249926-01	OC(CCCN1[C@@H](C)CCC[C@H]1C)(c1ncccc1)c1ccccc1	4.4000001	Active		0.0	1	Pirmenol	170466004	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-64.696616224	OC(CCCN1[C@@H](C)CCC[C@H]1C)(c1ncccc1)c1ccccc1	OC(CCCN1[C@@H](C)CCC[C@H]1C)(c1ncccc1)c1ccccc1
NCGC00161326-08	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1)(C)C	4.4000001	Active		0.0	1	Calcifediol (monohydrate)	405559040	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-69.408577688	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1)(C)C	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1)(C)C
NCGC00161327-01&NCGC00161327-10&NCGC00161327-11	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(C)C	4.366666633333334	Active	Vitamin D Analog	0.050000199999999495	3	Calcitriol	26754891&384568203&384568204	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0&-2.3	-81.121107164&-41.0615782039&-76.1000337392	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(C)C	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(C)C
NCGC00018186-07	OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1	4.6999998	Active	Muscarinic acetylcholine receptor M4 Antagonist&Muscarinic Acetylcholine Receptor M4 Antagonist	0.0	1	Procyclidine hydrochloride	170464805	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-62.970786048&-30.4467449361	OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1.Cl	OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1.Cl
NCGC00182965-05&NCGC00182965-11	OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2	5.0250001	Active	Anticholinergic	0.05000020000000038	2	Biperiden	170465324&384568413	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-67.5327274316&-72.6801546928	OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2.Cl	OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2.Cl&OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2
NCGC00521081-01	OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1	4.5250001	Active		0.0	1	Cycrimine Hydrochloride	405558993	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-51.1554130332&-70.439567144	OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1	OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1
NCGC00016003-10	OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1	5.3499999	Active	Muscarinic Acetylcholine Receptor M5 Antagonist&Muscarinic acetylcholine receptor M5 Antagonist	0.0	1	Trihexyphenidyl hydrochloride	170464756	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-1.2	-32.9991073592&-30.7020419872	OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1.Cl	OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1.Cl
NCGC00013289-09	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	4.8249998	Active	Muscarinic Acetylcholine Receptor Antagonist&Muscarinic acetylcholine receptor Antagonist	0.0	1	Pridinol	170465865	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.2	-71.4412577684&-36.9801364679	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1
NCGC00179360-05	OC(CC[N+](CC)(CC)CC)(c1ccccc1)C1CCCCC1	4.6999998	Active	Muscarinic Acetylcholine Receptor M3 Antagonist&Muscarinic acetylcholine receptor M3 Antagonist	0.0	1	Tridihexethyl chloride	405558856	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-45.0709892879&-35.028073268	OC(CC[N+](CC)(CC)CC)(c1ccccc1)C1CCCCC1	OC(CC[N+](CC)(CC)CC)(c1ccccc1)C1CCCCC1
NCGC00167553-02	OC(CN)c1cc(O)ccc1		Inactive	Adrenergic receptor alpha-1 Agonist&Adrenergic Receptor Alpha-1 Agonist		1	Norphenylephrine hydrochloride	225144293	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.1100055039&18.82180902	OC(CN)c1cc(O)ccc1	OC(CN)c1cc(O)ccc1
NCGC00015760-12	OC(CN)c1ccc(O)cc1		Inactive	Dopamine Transporter Binding Agent&Dopamine transporter Binding Agent		1	Octopamine	170465959	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.314566616&12.39452628	OC(CN)c1ccc(O)cc1	OC(CN)c1ccc(O)cc1
NCGC00183838-01	OC(CN1CCCCC1)c1noc(-c2ccccc2)c1		Inactive			1	Perisoxal citrate	144206844	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.807625604&0.0	O=C(O)C(O)(CC(=O)O)CC(=O)O.OC(CN1CCCCC1)c1noc(-c2ccccc2)c1	O=C(O)C(O)(CC(=O)O)CC(=O)O.OC(CN1CCCCC1)c1noc(-c2ccccc2)c1
NCGC00182972-01	OC(CN1CC[N+](C)(C)CC1)(c1ccccc1)C1CCCCC1	4.4000001	Active	Muscarinic acetylcholine receptor M5 Antagonist&Muscarinic Acetylcholine Receptor M5 Antagonist	0.0	1	Hexocyclium	144206775	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-39.821299724&-43.412615776	S(=O)(=O)(OC)[O-].OC(CN1CC[N+](C)(C)CC1)(c1ccccc1)C1CCCCC1	S(=O)(=O)(OC)[O-].OC(CN1CC[N+](C)(C)CC1)(c1ccccc1)C1CCCCC1
NCGC00015955-16&NCGC00015955-22	OC(CNC(C)(C)C)c1cc(CO)c(O)cc1		Inactive	beta2-Adrenoceptor Agonist&Beta2-adrenoceptor Agonists&beta2-Adrenoceptor Agonist		2	Salbutamol sulfate	170465034&384567909	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-15.0464931719	OC(CNC(C)(C)C)c1cc(CO)c(O)cc1	OC(CNC(C)(C)C)c1cc(CO)c(O)cc1
NCGC00016010-09	OC(CNC(C)(C)C)c1cc(O)cc(O)c1	4.9000001	Active	Camp Biosynthetic Process Partial Agonist	0.0	1	Terbutaline hemisulfate	170464990	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-62.5676221536	S(=O)(=O)(O)O.OC(CNC(C)(C)C)c1cc(O)cc(O)c1.OC(CNC(C)(C)C)c1cc(O)cc(O)c1	S(=O)(=O)(O)O.OC(CNC(C)(C)C)c1cc(O)cc(O)c1.OC(CNC(C)(C)C)c1cc(O)cc(O)c1
NCGC00014810-01	OC(CNC(C)(C)C)c1nc(CO)c(O)cc1	4.4000001	Active	Beta-2 Adrenergic Receptor Agonist	0.0	1	Pirbuterol hydrochloride	144203612	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.5654655476	OC(CNC(C)(C)C)c1nc(CO)c(O)cc1.Cl	OC(CNC(C)(C)C)c1nc(CO)c(O)cc1.Cl
NCGC00015558-14&NCGC00015558-16	OC(CNC(C)C)c1cc(O)c(O)cc1		Inactive	Beta-adrenoceptor Agonists&beta-Adrenoceptor Agonist&beta-Adrenoceptor Agonist		2	Isoprenaline hydrochloride	170464679&384567864	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-13.570035592&0.0&0.0	OC(CNC(C)C)c1cc(O)c(O)cc1	OC(CNC(C)C)c1cc(O)c(O)cc1
NCGC00164602-03	OC(CNC(CCc1ccc(O)cc1)C)c1ccc(O)cc1		Inactive	Beta-2 Adrenergic Receptor Agonist&Beta-2 adrenergic receptor Agonist		1	RACTOPAMINE HYDROCHLORIDE	405558703	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	OC(CNC(CCc1ccc(O)cc1)C)c1ccc(O)cc1	OC(CNC(CCc1ccc(O)cc1)C)c1ccc(O)cc1
NCGC00274276-01	OC(CNC(Cc1cc2OCOc2cc1)C)c1cc(O)c(O)cc1	4.8499999	Active	Beta-2 adrenergic receptor Agonist	0.0	1	NCGC00274276-01	225144372	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-38.8171845743	OC(CNC(Cc1cc2OCOc2cc1)C)c1cc(O)c(O)cc1	OC(CNC(Cc1cc2OCOc2cc1)C)c1cc(O)c(O)cc1
NCGC00015430-06	OC(CNC(Cc1ccc(O)cc1)C)c1cc(O)cc(O)c1		Inactive			1	Fenoterol hydrobromide	170465657	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-27.0696824039	OC(CNC(Cc1ccc(O)cc1)C)c1cc(O)cc(O)c1.Br	OC(CNC(Cc1ccc(O)cc1)C)c1cc(O)cc(O)c1.Br
NCGC00015924-24	OC(CNC)c1ccc(O)cc1		Inactive	alpha1-Adrenoceptor Agonist		1	Synephrine	384567908	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-21.92140636	OC(CNC)c1ccc(O)cc1	OC(CNC)c1ccc(O)cc1
NCGC00179276-04	OC(CNCC)c1cc(O)ccc1	4.9000001	Active		0.0	1	Etilefrine hydrochloride	225144301	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-36.9914177531	OC(CNCC)c1cc(O)ccc1	OC(CNCC)c1cc(O)ccc1
NCGC00160423-02	OC(CNCCCC)c1ccc(O)cc1		Inactive			1	Bamethan	225144236	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	OC(CNCCCC)c1ccc(O)cc1	OC(CNCCCC)c1ccc(O)cc1
NCGC00167522-02	OC(CNCCCCCCNCC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1		Inactive	Beta-2 Adrenergic Receptor Agonist&Beta-2 adrenergic receptor Agonist		1	Hexoprenaline sulfate	170465755	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.496450988&14.287652168	S(=O)(=O)(O)O.OC(CNCCCCCCNCC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1	S(=O)(=O)(O)O.OC(CNCCCCCCNCC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1
NCGC00507892-01	OC(CNc1nc(CC2CC2)c(-c2nc(Nc3ccncc3)ncc2)cn1)(C)C	5.0	Active	VPS34 Inhibitor	0.0	1	VPS34 Inhibitor 1 (Compound 19, PIK-III analogue)	384569355	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-116.988435609	OC(CNc1nc(CC2CC2)c(-c2nc(Nc3ccncc3)ncc2)cn1)(C)C	OC(CNc1nc(CC2CC2)c(-c2nc(Nc3ccncc3)ncc2)cn1)(C)C
NCGC00387769-02	OC(Cn1c(CNCC)nc2c(N)nc3c(c12)cccc3)(C)C		Inactive	Toll-Like Receptor 7 (TLR7) Agonist		1	Gardiquimod	363680656	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.4304480887	OC(Cn1c(CNCC)nc2c(N)nc3c(c12)cccc3)(C)C	OC(Cn1c(CNCC)nc2c(N)nc3c(c12)cccc3)(C)C
NCGC00016064-12	OC(c1ccccc1)(c1ccccc1)C1CCN(CCCC(O)c2ccc(C(C)(C)C)cc2)CC1	5.1999998	Active		0.0	1	Terfenadine	170465598	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.5593016792	OC(c1ccccc1)(c1ccccc1)C1CCN(CCCC(O)c2ccc(C(C)(C)C)cc2)CC1	OC(c1ccccc1)(c1ccccc1)C1CCN(CCCC(O)c2ccc(C(C)(C)C)cc2)CC1
NCGC00017343-11	OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	Retinol Dehydrogenase 12 Substrate&Retinol dehydrogenase 12 Substrate		1	RETINOL	405558473	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&27.25495572	OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00013095-10	OC/C=C(/CC/C=C(\C)/C)\C		Inactive	Trichomonas Vaginalis Inhibitor&Trichomonas vaginalis Inhibitor		1	Geraniol	170465692	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	OC/C=C(/CC/C=C(\C)/C)\C	OC/C=C(/CC/C=C(\C)/C)\C
NCGC00166097-02	OC/C=C/c1ccccc1	4.4499998	Active	Prostaglandin Secretion Inhibitor	0.0	1	Cinnamyl alcohol	225144268	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.8549969879	OC/C=C/c1ccccc1	OC/C=C/c1ccccc1
NCGC00179245-04	OC/C=C\1/[C@H]2C3=CN4c5c(cccc5)[C@]56[C@H]7[N@+](CC=C)(C/C(=C\CO)/[C@@H](C(=CN8c9c(cccc9)[C@]9([C@@H]([N@+](CC=C)(C/1)CC9)C2)C38)C45)C7)CC6	5.0500002	Active		0.0	1	Alcuronium chloride	405558585	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-44.137576348	OC/C=C\1/[C@H]2C3=CN4c5c(cccc5)[C@]56[C@H]7[N@+](CC=C)(C/C(=C\CO)/[C@@H](C(=CN8c9c(cccc9)[C@]9([C@@H]([N@+](CC=C)(C/1)CC9)C2)C38)C45)C7)CC6	OC/C=C\1/[C@H]2C3=CN4c5c(cccc5)[C@]56[C@H]7[N@+](CC=C)(C/C(=C\CO)/[C@@H](C(=CN8c9c(cccc9)[C@]9([C@@H]([N@+](CC=C)(C/1)CC9)C2)C38)C45)C7)CC6
NCGC00250375-10	OC1(C)CC(c2n3c(c(-c4cc5nc(-c6ccccc6)ccc5cc4)n2)C(N)=NC=C3)C1		Inactive	IGF-1R Inhibitor		1	Linsitinib	384568536	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.553582492	OC1(C)CC(c2n3c(c(-c4cc5nc(-c6ccccc6)ccc5cc4)n2)C(N)=NC=C3)C1	OC1(C)CC(c2n3c(c(-c4cc5nc(-c6ccccc6)ccc5cc4)n2)C(N)=NC=C3)C1
NCGC00387863-04	OC1=CC=2C(=N/C(=C\3/NN(C(C)C)c4ncnc(N)c/34)/C=2)C=C1	5.1999998	Active	mTOR Inhibitor	0.0	1	Torkinib	363680708	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-100.7135709827	OC1=CC=2C(=N/C(=C\3/NN(C(C)C)c4ncnc(N)c/34)/C=2)C=C1	OC1=CC=2C(=N/C(=C\3/NN(C(C)C)c4ncnc(N)c/34)/C=2)C=C1
NCGC00178580-03	OC1C(O)C(O)C(O)C(O)C1O		Inactive	Serotonin 2 (5-HT2) receptor Activator&Serotonin 2 (5-ht2) Receptor Activator		1	myo-Inositol&NCGC00178580-03	170465541	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.39929582&0.0	OC1C(O)C(O)C(O)C(O)C1O	OC1C(O)C(O)C(O)C(O)C1O
NCGC00263517-03	OC1C2(C)C(C)(C)C(C1)CC2	5.0	Active		0.0	1	BORNEOL	405558915	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-50.7797465321	OC1C2(C)C(C)(C)C(C1)CC2	OC1C2(C)C(C)(C)C(C1)CC2
NCGC00482960-01	OC1C=C(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=2C(C)(C)CC(O)CC=2C)\C)\C)/C)/C)C(C)(C)C1	4.5500002	Active		0.0	1	Xanthophyll	405558848	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.194935434	OC1C=C(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=2C(C)(C)CC(O)CC=2C)\C)\C)/C)/C)C(C)(C)C1	OC1C=C(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=2C(C)(C)CC(O)CC=2C)\C)\C)/C)/C)C(C)(C)C1
NCGC00095486-03	OC1CC=2C(C)(C3C(=CC=2)C2C(C)(C(C(/C=C/C(C(C)C)C)C)CC2)CC3)CC1		Inactive	Sterol (fungal cell wall)		1	Ergosterol	174007452	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OC1CC=2C(C)(C3C(=CC=2)C2C(C)(C(C(/C=C/C(C(C)C)C)C)CC2)CC3)CC1	OC1CC=2C(C)(C3C(=CC=2)C2C(C)(C(C(/C=C/C(C(C)C)C)C)CC2)CC3)CC1
NCGC00160163-01	OC1CC=2C(C)(C3C(C4C(C)(C5[C@H](C)[C@@]6(OC5C4)OC[C@H](C)CC6)CC3)CC=2)CC1		Inactive	Cyclooxygenase up-regulator		1	Diosgenin	50109897	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OC1CC=2C(C)(C3C(C4C(C)(C5[C@H](C)[C@@]6(OC5C4)OC[C@H](C)CC6)CC3)CC=2)CC1	OC1CC=2C(C)(C3C(C4C(C)(C5[C@H](C)[C@@]6(OC5C4)OC[C@H](C)CC6)CC3)CC=2)CC1
NCGC00247785-11	OC1CCC(N2C(=N)c3c(c(n(Cc4ccccc4)c3N=C2)-c2ccccc2)-c2ccccc2)CC1	4.9000001	Active	Perinuclear compartment (PNC) assembly Inhibitor	0.0	1	Metarrestin (KUC109088N)	384568516	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-119.149322652	OC1CCC(N2C(=N)c3c(c(n(Cc4ccccc4)c3N=C2)-c2ccccc2)-c2ccccc2)CC1	OC1CCC(N2C(=N)c3c(c(n(Cc4ccccc4)c3N=C2)-c2ccccc2)-c2ccccc2)CC1
NCGC00386394-01	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)cnc(NCCCC)n2)CC1	5.25	Active	Tyrosine-protein kinase Mer Inhibitor	0.0	1	UNC2250	384569131	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-56.0740578896	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)cnc(NCCCC)n2)CC1	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)cnc(NCCCC)n2)CC1
NCGC00346952-01	OC1CCC(Nc2nc(Nc3cc4c(n(Cc5ccccc5)cc4)cc3)nc(NCC)c2)CC1	4.4000001	Active	CDK4/6 Inhibitor	0.0	1	Cdk4/6 Inhibitor IV	174006970	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-32.5400885362	OC1CCC(Nc2nc(Nc3cc4c(n(Cc5ccccc5)cc4)cc3)nc(NCC)c2)CC1	OC1CCC(Nc2nc(Nc3cc4c(n(Cc5ccccc5)cc4)cc3)nc(NCC)c2)CC1
NCGC00510682-01	OC1CCC(Nc2nc(Nc3sc4c(n3)ccc(CC)c4)cc(Cc3ccccc3)n2)CC1	4.4000001	Active	ITK Inhibitor	0.0	1	GSK-2250665A	384569476	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-96.968441304	OC1CCC(Nc2nc(Nc3sc4c(n3)ccc(CC)c4)cc(Cc3ccccc3)n2)CC1	OC1CCC(Nc2nc(Nc3sc4c(n3)ccc(CC)c4)cc(Cc3ccccc3)n2)CC1
NCGC00390618-03&NCGC00482875-01	OC1CCC(n2c3nc(NCCCC)ncc3c(-c3ccc(CN4CCN(C)CC4)cc3)c2)CC1	4.625	Active	Tyrosine-protein kinase receptor FLT3 Inhibitor&Flt3 Inhibitor	0.4499998000000005	2	UNC2025 (hydrochloride)&UNC-2025	384569201&377020327	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-110.9446549031&-54.2927503239	OC1CCC(n2c3nc(NCCCC)ncc3c(-c3ccc(CN4CCN(C)CC4)cc3)c2)CC1	OC1CCC(n2c3nc(NCCCC)ncc3c(-c3ccc(CN4CCN(C)CC4)cc3)c2)CC1
NCGC00095086-04	OC1CCN(CCCN2c3c(Sc4c2cccc4)ccc(C#N)c3)CC1	4.4000001	Active	Dopamine D2 Receptor Antagonist&Dopamine D2 receptor Antagonist	0.0	1	PERICIAZINE	405558569	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-75.150079388&-88.8726056879	OC1CCN(CCCN2c3c(Sc4c2cccc4)ccc(C#N)c3)CC1	OC1CCN(CCCN2c3c(Sc4c2cccc4)ccc(C#N)c3)CC1
NCGC00346665-01	OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1		Inactive	Metabolite of anisodine. Anisodine is an 1-adrenergic receptor Agonist		1	Scopine	174006292	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1	OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1
NCGC00166213-02	OCC(CCCCCCCCCC)CCCCCCCC	5.1999998	Active		0.0	1	2-Octyl-1-dodecanol	170465533	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.8440322721	OCC(CCCCCCCCCC)CCCCCCCC	OCC(CCCCCCCCCC)CCCCCCCC
NCGC00188399-06	OCC(N)(CO)CCc1ccc(CCCCCCCC)cc1	4.4000001	Active	Sphingosine Kinase 1 (sphk1) Inhibitor&Sphingosine Kinase 1 (SphK1) Inhibitor	0.0	1	Fingolimod hydrochloride	405558994	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-92.4809888048&-116.6013186839	OCC(N)(CO)CCc1ccc(CCCCCCCC)cc1	OCC(N)(CO)CCc1ccc(CCCCCCCC)cc1
NCGC00159412-04	OCC(N)(CO)CO	4.4000001	Active	Calcium Ion Transport Inhibitor	0.0	1	Tromethamine	170464686	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.5603810471	OCC(N)(CO)CO	OCC(N)(CO)CO
NCGC00164595-02	OCC(N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@](O)(CO)C1)CO		Inactive			1	Voglibose	170465993	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.725914804&0.0	OCC(N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@](O)(CO)C1)CO	OCC(N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@](O)(CO)C1)CO
NCGC00476094-01	OCC1=CCC2C(C)(C)Oc3c(c(O)cc(C(CCCCCC)(C)C)c3)[C@H]2C1		Inactive	NMDA Receptor Antagonist		1	Dexanabinol	384569239	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OCC1=CCC2C(C)(C)Oc3c(c(O)cc(C(CCCCCC)(C)C)c3)[C@H]2C1	OCC1=CCC2C(C)(C)Oc3c(c(O)cc(C(CCCCCC)(C)C)c3)[C@H]2C1
NCGC00263603-10	OCC=1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)C=1	5.1500001	Inactive	EZH2 Inhibitor	0.0	1	3-Deazaneplanocin A	384568692	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-14.922981915	OCC=1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)C=1	OCC=1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)C=1
NCGC00159368-05	OCCCCCCCCCCCCCCCC		Inactive	Fatty aldehyde dehydrogenase Substrate&Fatty Aldehyde Dehydrogenase Substrate		1	1-Hexadecanol	170465348	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-34.848686486	OCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCC
NCGC00159369-04	OCCCCCCCCCCCCCCCCCC		Inactive			1	1-Octadecanol	170465526	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-20.951918464	OCCCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCCCC
NCGC00159370-04&NCGC00159370-10	OCCCCCCCCCCCCCCCCCCCCCC		Inactive	Anti-Herpes Simplex Virus Drug&Anti-herpes Simplex Virus Drug&Anti-Herpes Simplex Virus Drug		2	Docosanol	124892111&384568173	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	OCCCCCCCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCCCCCCCC
NCGC00274075-01	OCCCCCCCCCCCCCCCCCCCCCCCCCCCC		Inactive	PI3K-Akt signaling pathway Activator&Pi3k-akt Signaling Pathway Activator		1	1-Octacosanol	405558919	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.824641036&0.0	OCCCCCCCCCCCCCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCCCCCCCCCCCCCC
NCGC00181149-01	OCCCNc1ccccc1	4.4000001	Active		0.0	1	3-Anilinopropan-1-ol	144206306	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.4907662759	OCCCNc1ccccc1	OCCCNc1ccccc1
NCGC00159411-02	OCCN(CCO)CCO	4.4000001	Active		0.0	1	Triethanolamine	144206717	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.415577328	OCCN(CCO)CCO	OCCN(CCO)CCO
NCGC00015385-18&NCGC00015385-22	OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1	4.66250015	Active	Phosphodiesterase PDE3 Inhibitor&Phosphodiesterase Iii/v (pde5) Inhibitor&Phosphodiesterase PDE3 Inhibitor	0.22499989999999936	2	Dipyridamole	170464694&384567839	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4&-3.0	-34.3027358839&-24.022925096&-46.3717264256	OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1	OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
NCGC00162068-06	OCCN1CCN(CCCN2c3c(cccc3)C=Cc3c2cccc3)CC1	4.4000001	Active	Serotonin 2 (5-ht2) Receptor Antagonist	0.0	1	Opipramol dihydrochloride	170465942	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.8557293	OCCN1CCN(CCCN2c3c(cccc3)C=Cc3c2cccc3)CC1.Cl.Cl	OCCN1CCN(CCCN2c3c(cccc3)C=Cc3c2cccc3)CC1.Cl.Cl
NCGC00347941-04	OCCNC1c2[nH]c3c(c2CCC1)cc(-c1ccccc1)cc3	4.4000001	Active	Cdc42 Inhibitor	0.0	1	CASIN	363677723	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-113.3508969856	OCCNC1c2[nH]c3c(c2CCC1)cc(-c1ccccc1)cc3	OCCNC1c2[nH]c3c(c2CCC1)cc(-c1ccccc1)cc3
NCGC00346656-03	OCC[C@H]1N(C2=Nc3c(CC)cnn3C(NCc3c[n+]([O-])ccc3)=C2)CCCC1	4.8499999	Inactive	CDK1/2/5/9 Inhibitor	0.0	1	Dinaciclib (SCH727965)	384568887	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	17.7311366056	OCC[C@H]1N(C2=Nc3c(CC)cnn3C(NCc3c[n+]([O-])ccc3)=C2)CCCC1	OCC[C@H]1N(C2=Nc3c(CC)cnn3C(NCc3c[n+]([O-])ccc3)=C2)CCCC1
NCGC00015219-07	OCC[N+](C)(C)C		Inactive			1	Choline Chloride	405558926	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.009927516&0.0	OCC[N+](C)(C)C	OCC[N+](C)(C)C
NCGC00188957-02	OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1	4.4000001	Active	Thiamin pyrophosphokinase 1 Substrate	0.0	1	Thiamine hydrochloride	225144340	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-60.752496768	OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1	OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1
NCGC00166215-05	OCCc1ccccc1		Inactive			1	2-Phenylethanol	170466787	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.7474164079&0.0	OCCc1ccccc1	OCCc1ccccc1
NCGC00263161-11	OCCn1ncc(-c2nc3n(Cc4cc5c(nccc5)cc4)nnc3nc2)c1		Inactive	HGFR Inhibitor		1	PF-04217903	363677237	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OCCn1ncc(-c2nc3n(Cc4cc5c(nccc5)cc4)nnc3nc2)c1	OCCn1ncc(-c2nc3n(Cc4cc5c(nccc5)cc4)nnc3nc2)c1
NCGC00178864-03	OC[C@@H](NCCN[C@H](CO)CC)CC		Inactive			1	Ethambutol dihydrochloride	174006619	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.1905488079&20.193576052	OC[C@@H](NCCN[C@H](CO)CC)CC.Cl.Cl	OC[C@@H](NCCN[C@H](CO)CC)CC.Cl.Cl
NCGC00164560-05	OC[C@@H]1C=C[C@H](n2c3nc(N)nc(NC4CC4)c3nc2)C1		Inactive			1	ABACAVIR SULFATE	405559145	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	OC[C@@H]1C=C[C@H](n2c3nc(N)nc(NC4CC4)c3nc2)C1	OC[C@@H]1C=C[C@H](n2c3nc(N)nc(NC4CC4)c3nc2)C1
NCGC00182045-03	OC[C@@H]1[C@@H](O)C[C@H](n2c3N=CNC[C@@H](O)c3nc2)O1		Inactive	Adenosine Deaminase Inhibitor		1	Pentostatin	384568404	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-30.15490282	OC[C@@H]1[C@@H](O)C[C@H](n2c3N=CNC[C@@H](O)c3nc2)O1	OC[C@@H]1[C@@H](O)C[C@H](n2c3N=CNC[C@@H](O)c3nc2)O1
NCGC00388420-02	OC[C@@H]1[C@@H](O)C[C@H](n2c3NC=NC[C@@H](O)c3nc2)O1		Inactive	Adenosine Deaminase Inhibitor		1	Pentostatin	363680730	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-17.46423154	OC[C@@H]1[C@@H](O)C[C@H](n2c3NC=NC[C@@H](O)c3nc2)O1	OC[C@@H]1[C@@H](O)C[C@H](n2c3NC=NC[C@@H](O)c3nc2)O1
NCGC00023673-10&NCGC00023673-18	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1		Inactive	Adenosine Receptor Agonist		2	Adenosine	405558447&384568019	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&17.4079433199&34.301735324	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1
NCGC00092314-06	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1		Inactive	AKT Inhibitor		1	Triciribine	363676559	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.099219836	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1
NCGC00346726-01	OC[C@@H]1[C@@H](O)[C@@H]2OC3=NC(=N)C=CN3[C@@H]2O1	5.0	Active	antiviral	0.0	1	Cyclocytidine hydrochloride	174006876	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-72.0443004058	OC[C@@H]1[C@@H](O)[C@@H]2OC3=NC(=N)C=CN3[C@@H]2O1	OC[C@@H]1[C@@H](O)[C@@H]2OC3=NC(=N)C=CN3[C@@H]2O1
NCGC00178826-03	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)C(O)O1		Inactive	Solute Carrier Organic Anion Transporter Family Member 1b3 Inhibitor&Solute carrier organic anion transporter family member 1B3 Inhibitor		1	Glucosamine hydrochloride	170466505	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.1703836839&-25.368392852	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)C(O)O1.Cl	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)C(O)O1.Cl
NCGC00025085-02	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1	5.6750002	Active	Alpha-galactosidase A Chaperone	0.0	1	NCGC00025085-02&deoxynorjrimycin(1)	26752140	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.2	-40.9256529239&-39.6319680084	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1
NCGC00263446-02	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1	4.75	Active		0.0	1	DEXTROSE	405559076	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-54.7538335841	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1
NCGC00485920-01	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@]2(O1)OCc1c2cc(Cc2ccc(CC)cc2)cc1	4.5	Active	Sodium/glucose cotransporter 2 Inhibitor	0.0	1	Tofogliflozin (hydrate)	363681416	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-55.6031859535	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@]2(O1)OCc1c2cc(Cc2ccc(CC)cc2)cc1	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@]2(O1)OCc1c2cc(Cc2ccc(CC)cc2)cc1
NCGC00178869-11	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3nc2)O1	4.5500002	Active	Adenosine Receptor Agonist; Anti-Herpes Simplex Virus Drug	0.0	1	Vidarabine	384568366	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-72.76975902	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3nc2)O1
NCGC00094374-12	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)CC	4.4000001	Active	CDK Inhibitor	0.0	1	Seliciclib	384568129	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-105.0992963979	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)CC	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)CC
NCGC00024452-04	OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O		Inactive	Maltase-glucoamylase Inhibitor		1	Miglustat	170464950	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	31.2731473116&17.7881050641	OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O	OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O
NCGC00092360-02	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)[C@H](O)C1		Inactive	Purine Antagonist		1	Cordycepin	384568106	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-14.1066417119	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)[C@H](O)C1	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)[C@H](O)C1
NCGC00263968-02	OC[C@H]1[C@H](O)[C@H]2OC3=NC(=N)C=CN3[C@H]2O1	5.5999999	Active	antiviral	0.0	1	ANCITABINE HYDROCHLORIDE	405558488	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.1	-98.2620884656	OC[C@H]1[C@H](O)[C@H]2OC3=NC(=N)C=CN3[C@H]2O1	OC[C@H]1[C@H](O)[C@H]2OC3=NC(=N)C=CN3[C@H]2O1
NCGC00016261-08	OCc1c(O)c(C)ncc1CO		Inactive	Oxidative Stress Inhibitor		1	Pyridoxine	170464634	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.6317879719&0.0	OCc1c(O)c(C)ncc1CO	OCc1c(O)c(C)ncc1CO
NCGC00094779-05	OCc1c(O)cccc1	5.4000001	Active		0.0	1	Salicyl alcohol	170465547	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-52.9489361084	OCc1c(O)cccc1	OCc1c(O)cccc1
NCGC00091865-02	OCc1ccccc1	4.4000001	Active		0.0	1	Benzyl alcohol	124891475	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-65.2956212399	OCc1ccccc1	OCc1ccccc1
NCGC00016103-16	OCc1oc(-c2nn(Cc3ccccc3)c3c2cccc3)cc1	4.0	Inactive	HIF-1alpha Inhibitor	0.0	1	Lificiguat	384567922	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	88.2683652001	OCc1oc(-c2nn(Cc3ccccc3)c3c2cccc3)cc1	OCc1oc(-c2nn(Cc3ccccc3)c3c2cccc3)cc1
NCGC00159570-14	OCc1sc(-c2oc(-c3sc(CO)cc3)cc2)cc1		Inactive	MDM2 (hdm2) Inhibitor		1	RITA	384568189	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	OCc1sc(-c2oc(-c3sc(CO)cc3)cc2)cc1	OCc1sc(-c2oc(-c3sc(CO)cc3)cc2)cc1
NCGC00248196-04	ON1C(C)(C)CC(O)CC1(C)C		Inactive	Free Radical Scavenger		1	Tempol	384568523	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.0341363079	ON1C(C)(C)CC(O)CC1(C)C	ON1C(C)(C)CC(O)CC1(C)C
NCGC00378796-01	O[C@@H](C(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	4.4000001	Active	Vitamin D receptor Agonist&Vitamin D Receptor Agonist	0.0	1	Tacalcitol	405558914	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-72.928261868&-54.8659541679	O[C@@H](C(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	O[C@@H](C(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1
NCGC00348363-01	O[C@@H](C(O)[C@H](O)CO)CO		Inactive	Sugar Alcohol&sugar alcohol		1	ARABITOL(D)	405558824	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&15.4218576519	O[C@@H](C(O)[C@H](O)CO)CO	O[C@@H](C(O)[C@H](O)CO)CO
NCGC00159406-12&NCGC00159406-15	O[C@@H](CN)c1cc(O)c(O)cc1		Inactive	alpha/beta-adrenoceptor Agonist&Alpha/beta-adrenoceptor Agonist&alpha/beta-adrenoceptor Agonist		2	Noradrenaline bitartrate monohydrate	170465227&384568174	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-17.8684077079&-18.229716788&-22.2782826439	O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O.O[C@@H](CN)c1cc(O)c(O)cc1	O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O.O[C@@H](CN)c1cc(O)c(O)cc1&O[C@@H](CN)c1cc(O)c(O)cc1
NCGC00142615-08&NCGC00142615-10	O[C@@H](CNC)c1cc(O)c(O)cc1		Inactive	Alpha/beta-adrenoceptor Agonist&alpha/beta-adrenoceptor Agonist&alpha/beta-adrenoceptor Agonist		2	Epinephrine	170464973&384568167	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	O[C@@H](CNC)c1cc(O)c(O)cc1	O[C@@H](CNC)c1cc(O)c(O)cc1
NCGC00178692-04	O[C@@H]([C@@H](N(C)C)C)c1ccccc1		Inactive	Beta-1 adrenergic receptor Agonist&Beta-1 Adrenergic Receptor Agonist		1	N-METHYL (-)EPHEDRINE [1R,2S]	405558430	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	30.4082141359&-23.67813194	O[C@@H]([C@@H](N(C)C)C)c1ccccc1	O[C@@H]([C@@H](N(C)C)C)c1ccccc1
NCGC00016542-06	O[C@@H]([C@@H](N)C)c1cc(O)c(O)cc1		Inactive	Adrenergic Receptor Alpha-2 Agonist&Adrenergic receptor alpha-2 Agonist		1	Levonordefrin	170464794	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.29947516&-29.459645684	O[C@@H]([C@@H](N)C)c1cc(O)c(O)cc1	O[C@@H]([C@@H](N)C)c1cc(O)c(O)cc1
NCGC00178024-05	O[C@@H]([C@@H](N)C)c1cc(O)ccc1		Inactive	Adrenergic Receptor Alpha-1 Agonist&Adrenergic receptor alpha-1 Agonist		1	Metaraminol bitartrate	170465256	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	29.6316611295&-16.709967456	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.O[C@@H]([C@@H](N)C)c1cc(O)ccc1	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.O[C@@H]([C@@H](N)C)c1cc(O)ccc1
NCGC00345852-03	O[C@@H]([C@@H](NC1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1)CO)CO	5.8499999	Inactive	CDK1/2/5/9 Inhibitor	0.0	1	BS-194	384568767	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-21.4290251345	O[C@@H]([C@@H](NC1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1)CO)CO	O[C@@H]([C@@H](NC1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1)CO)CO
NCGC00179566-03	O[C@@H]([C@@H](NCCc1ccc(O)cc1)C)c1ccc(O)cc1	4.4000001	Active	beta2-Adrenoceptor Agonists	0.0	1	Ritodrine hydrochloride	225144308	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.9262548494	O[C@@H]([C@@H](NCCc1ccc(O)cc1)C)c1ccc(O)cc1	O[C@@H]([C@@H](NCCc1ccc(O)cc1)C)c1ccc(O)cc1
NCGC00166072-02	O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](O)CO	4.5500002	Active	osmotic diuretic agent	0.0	1	D-Galactitol	170465564	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.7260070592	O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](O)CO	O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](O)CO
NCGC00166125-02	O[C@@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO		Inactive	Amino Sugar&amino sugar		1	Meglumine	170465359	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	18.3798674239&-28.663134752&23.758565112	O[C@@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO	O[C@@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO
NCGC00164353-11	O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)CO		Inactive	Osmotic diuretic agent		1	Mannitol	384568249	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)CO	O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](O)CO
NCGC00262526-04	O[C@@H]([C@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2	4.4000001	Active	Alkaloid; P-Glycoprotein (MDR-1) Inhibitor	0.0	1	CINCHONIDINE	405558875	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-62.6115190168	O[C@@H]([C@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2	O[C@@H]([C@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2
NCGC00182058-01	O[C@@H]1/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/C(C(C)C)C)C)CC3)CCC/2)/CC(=C)[C@@H](O)C1	4.4000001	Active		0.0	1	Doxercalciferol	405558580	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.3	-94.2095840223	O[C@@H]1/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/C(C(C)C)C)C)CC3)CCC/2)/CC(=C)[C@@H](O)C1	O[C@@H]1/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/C(C(C)C)C)C)CC3)CCC/2)/CC(=C)[C@@H](O)C1
NCGC00182058-03	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/C[C@@H](O)C1		Inactive	Vitamin D Analog		1	Doxercalciferol	124893779	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/C[C@@H](O)C1	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/C[C@@H](O)C1
NCGC00379045-01	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC\2)/C[C@@H](O)C1	4.4000001	Active	Increase blood calcium level via a variety of mechanisms	0.0	1	Alfacalcidol-D6	405558455	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-49.845520036	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC\2)/C[C@@H](O)C1	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC\2)/C[C@@H](O)C1
NCGC00168853-03	O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C)CC4)CC3)CC2)CC1		Inactive	Steroid		1	Lupeol	174006790	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C)CC4)CC3)CC2)CC1	O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C)CC4)CC3)CC2)CC1
NCGC00166307-05	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC/2)/C(=C)CC1	4.4000001	Active	Vitamin D receptor Agonist	0.0	1	ERGOCALCIFEROL	405559070	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-104.737059832	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC/2)/C(=C)CC1	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC/2)/C(=C)CC1
NCGC00159331-07	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC/2)/C(=C)CC1	4.4000001	Active	Vitamin D receptor Binding Agent	0.0	1	CHOLECALCIFEROL	405558699	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-107.3747754046	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC/2)/C(=C)CC1	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC/2)/C(=C)CC1
NCGC00166147-02	O[C@@H]1C/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/[C@@H](C)CC1	4.4000001	Active	Vitamin D receptor Agonist	0.0	1	Dihydrotachysterol	144205894	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.644445704	O[C@@H]1C/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/[C@@H](C)CC1	O[C@@H]1C/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/[C@@H](C)CC1
NCGC00346711-02	O[C@@H]1CC=2[C@@](C)(C3C(C4[C@@](C)(C(n5c6c(nc5)cccc6)=CC4)CC3)CC=2)CC1		Inactive	Selective Androgen Receptor Modulators (SARM)		1	Galeterone	363677531	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@@H]1CC=2[C@@](C)(C3C(C4[C@@](C)(C(n5c6c(nc5)cccc6)=CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)(C3C(C4[C@@](C)(C(n5c6c(nc5)cccc6)=CC4)CC3)CC=2)CC1
NCGC00163474-07	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC=2)CC1	4.75	Active	Smo Receptor Antagonist	0.0	1	Cyclopamine	363676621	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-79.4384302388	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC=2)CC1
NCGC00263148-07	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1		Inactive	Androgen Biosynthesis Inhibitor		1	Abiraterone	384568623	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1
NCGC00142599-02	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1		Inactive	Steroid hormone		1	Stigmasterol	174007475	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	28.8372345919	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1
NCGC00159351-05	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1	6.0500002	Active	Transient Receptor Potential Cation Channel Subfamily V Member 1 Inhibitor	0.0	1	Cholesterol	225144221	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-43.2462634265	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1
NCGC00142598-07	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1		Inactive	Cholesterol lowering drug		1	beta-Sitosterol	384568165	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1
NCGC00344535-01	O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC2)CC1	5.0	Active	Sterol regulatory element-binding protein cleavage-activating protein Binding Agent	0.0	1	5alpha-Cholestan-3beta-ol	225144382	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-43.2118922688	O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC2)CC1	O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC2)CC1
NCGC00248905-02	O[C@@H]1[C@@H](C(C)C)CC[C@H](C)C1	4.5500002	Active	Transient receptor potential cation channel subfamily A member 1 Antagonist	0.0	1	(1S,2R,5S)-(+)-Menthol	225144344	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-31.565865072	O[C@@H]1[C@@H](C(C)C)CC[C@H](C)C1	O[C@@H]1[C@@H](C(C)C)CC[C@H](C)C1
NCGC00262549-02	O[C@@H]1[C@@H](CC)C2C3[C@@H](O)[C@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@@H]3C5)C2	4.9000001	Active	Voltage-gated potassium channel subunit Kv4.3 Inhibitor	0.0	1	Ajmaline	405559078	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-37.6460016316	O[C@@H]1[C@@H](CC)C2C3[C@@H](O)[C@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@@H]3C5)C2	O[C@@H]1[C@@H](CC)C2C3[C@@H](O)[C@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@@H]3C5)C2
NCGC00160355-01	O[C@@H]1[C@@H](O)[C@@H](O)CO[C@@H]1O		Inactive			1	NCGC00160355-01	29216036	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.9656495879&-11.5372527839	O[C@@H]1[C@@H](O)[C@@H](O)CO[C@@H]1O	O[C@@H]1[C@@H](O)[C@@H](O)CO[C@@H]1O
NCGC00179652-04	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CCC2)CC3)C4)CC1	4.5999999	Active	Kappa Opioid Receptor Partial Agonist	0.0	1	Nalbuphine hydrochloride	405558847	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.072904316	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CCC2)CC3)C4)CC1	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CCC2)CC3)C4)CC1
NCGC00274061-01&NCGC00274061-07	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@]5(O[C@@H]5C(O)=C(C#N)C4)CC3)CC2)CC1	4.7750001	Active	Estrogen Receptor (er) Beta Modulators&Estrogen Receptor (ER) beta Modulators	0.4499997999999996	2	Trilostane	174007161&384568709	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-71.6856459998&-32.6218649519	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@]5(O[C@@H]5C(O)=C(C#N)C4)CC3)CC2)CC1	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@]5(O[C@@H]5C(O)=C(C#N)C4)CC3)CC2)CC1
NCGC00344556-01	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H]5S[C@@H]5C4)CC3)CC2)CC1		Inactive			1	Epitiostanol	225144391	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-10.865874652&-24.3042046439	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H]5S[C@@H]5C4)CC3)CC2)CC1	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H]5S[C@@H]5C4)CC3)CC2)CC1
NCGC00091544-18&NCGC00091544-23	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1	4.42499995	Active	Estrogen Receptor (ER) Agonist	0.04999969999999987	2	Estradiol	405558561&384568097	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-36.30212836&-74.7329493038	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1
NCGC00179676-03	O[C@@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	4.4000001	Active		0.0	1	Lynestrenol	170465984	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-52.3464668199	O[C@@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	O[C@@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1
NCGC00167465-02	O[C@H](/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)C1CC1	4.4000001	Active	Vitamin D Receptor Activator&Vitamin D receptor Activator	0.0	1	Calcipotriene	170464710	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-65.591454016&-97.6349723639	O[C@H](/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)C1CC1	O[C@H](/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)C1CC1
NCGC00181006-02	O[C@H](C(NC)C)c1ccc(O)cc1	4.9499998	Active		0.0	1	1-(4-Hydroxyphenyl)-2-methyl-2-methylaminoethanol hydrochloride	225144314	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-63.6128556687	O[C@H](C(NC)C)c1ccc(O)cc1	O[C@H](C(NC)C)c1ccc(O)cc1
NCGC00379027-01	O[C@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1		Inactive	Vitamin D3 Receptor Agonist&Vitamin D3 receptor Agonist		1	(24S)-24,25-Dihydroxyvitamin D3	405558665	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.721428292&0.0	O[C@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1	O[C@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1
NCGC00346735-03	O[C@H]([C@@H]1N2C[C@H](C=C)C(C1)CC2)c1c2c(ncc1)cccc2		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Cinchonine dihydrochloride	384568937	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-27.57823	O[C@H]([C@@H]1N2C[C@H](C=C)C(C1)CC2)c1c2c(ncc1)cccc2	O[C@H]([C@@H]1N2C[C@H](C=C)C(C1)CC2)c1c2c(ncc1)cccc2
NCGC00274057-01	O[C@H]([C@H](N)C)c1ccccc1		Inactive	Adrenergic Receptor Alpha-1 Agonist&Adrenergic receptor alpha-1 Agonist		1	Phenylpropanolamine hydrochloride	170465627	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.528033096&-25.7639541	O[C@H]([C@H](N)C)c1ccccc1.Cl	O[C@H]([C@H](N)C)c1ccccc1.Cl
NCGC00181020-01	O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](O)CC=2C)\C)\C)/C)/C)=C(C)C1	4.75	Active	osteoclast development Inhibitor	0.0	1	Zeaxanthin	144206223	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-65.0626520239	O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](O)CC=2C)\C)\C)/C)/C)=C(C)C1	O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](O)CC=2C)\C)\C)/C)/C)=C(C)C1
NCGC00351597-13	O[C@H]1[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O[C@@H]1CN(C(C)C)C1CC(CCc2[nH]c3c(n2)cc(C(C)(C)C)cc3)C1		Inactive	DOT1L Inhibitor		1	EPZ-5676	384569015	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@H]1[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O[C@@H]1CN(C(C)C)C1CC(CCc2[nH]c3c(n2)cc(C(C)(C)C)cc3)C1	O[C@H]1[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O[C@@H]1CN(C(C)C)C1CC(CCc2[nH]c3c(n2)cc(C(C)(C)C)cc3)C1
NCGC00017331-08	O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1		Inactive	superoxide anion generation Inhibitor&Superoxide Anion Generation Inhibitor		1	(-)-Epicatechin	170465932	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.239413064&-30.4002443599	O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1	O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1
NCGC00166111-06&NCGC00274080-01	O[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(O)c2		Inactive	Estrogen Receptor (ER) Agonist&Estrogen Receptor Alpha Agonist&Estrogen Receptor (ER) Agonist		2	Estriol	384568304&170465807	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-15.516477776&-23.9527719359&-20.952314744	O[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(O)c2	O[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(O)c2
NCGC00345819-01	O[C@H]1[C@H](O)[C@]2(C)[C@@H]([C@H]1O)[C@H]1[C@@H](c3c(cc(O)cc3)CC1)CC2		Inactive	Selective Estrogen Receptor Modulators (SERM)		1	Estetrol	174007301	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@H]1[C@H](O)[C@]2(C)[C@@H]([C@H]1O)[C@H]1[C@@H](c3c(cc(O)cc3)CC1)CC2	O[C@H]1[C@H](O)[C@]2(C)[C@@H]([C@H]1O)[C@H]1[C@@H](c3c(cc(O)cc3)CC1)CC2
NCGC00346606-02	O[C@H]1[C@H]([C@@H](NC)C)[C@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](NC)CC5)CC3)C4)CC2)C1	5.0500002	Active	acute myocardial ischemia drug	0.0	1	Cyclovirobuxin D	363677475	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-52.2244906704	O[C@H]1[C@H]([C@@H](NC)C)[C@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](NC)CC5)CC3)C4)CC2)C1	O[C@H]1[C@H]([C@@H](NC)C)[C@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](NC)CC5)CC3)C4)CC2)C1
NCGC00160508-03	O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1		Inactive			1	Isosorbide	170465187	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.73122072&15.6480480719	O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1	O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1
NCGC00179665-04	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=Cc5oncc5C4)CC3)CC2)CC1	4.4000001	Active	Androgen Receptor Agonist	0.0	1	Danazol	170464884	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-45.1075151879&-69.746171088	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=Cc5oncc5C4)CC3)CC2)CC1	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=Cc5oncc5C4)CC3)CC2)CC1
NCGC00167449-02	O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CCCC2)CC3)CC1		Inactive	Progesterone Receptor Agonist&Progesterone receptor Agonist		1	Desogestrel	225144285	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.047484432&-25.60975284	O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CCCC2)CC3)CC1	O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CCCC2)CC3)CC1
NCGC00344550-03	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5[nH]ncc5C4)CC3)CC2)CC1		Inactive	Synthetic Steroid		1	Stanozolol	384568722	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	14.9713825961	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5[nH]ncc5C4)CC3)CC2)CC1	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5[nH]ncc5C4)CC3)CC2)CC1
NCGC00181290-01	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5nonc5C4)CC3)CC2)CC1	4.4000001	Active		0.0	1	Furazabol	144206325	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-91.6297086759&-91.4842815359	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5nonc5C4)CC3)CC2)CC1	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5nonc5C4)CC3)CC2)CC1
NCGC00167514-02	O[C@]1(CC)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	4.4000001	Active	Androgen Receptor Agonist	0.0	1	Ethylestrenol	170465211	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-81.39063664	O[C@]1(CC)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	O[C@]1(CC)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1
NCGC00159497-02	O[C@]1(CC=C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	5.1500001	Active	Progesterone receptor Agonist	0.0	1	Allylestrenol	144205271	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.2074253679	O[C@]1(CC=C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	O[C@]1(CC=C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1
NCGC00346607-02	O[C@]12[C@H](C(C)C)C[C@@]3([C@@H](C)CC[C@H]3C(=C)C1)O2		Inactive	mitochondrial modulator		1	Curcumol	363677476	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	O[C@]12[C@H](C(C)C)C[C@@]3([C@@H](C)CC[C@H]3C(=C)C1)O2	O[C@]12[C@H](C(C)C)C[C@@]3([C@@H](C)CC[C@H]3C(=C)C1)O2
NCGC00091595-07	Oc1c(-c2ccccc2)cccc1	5.6999998	Active		0.0	1	Sodium 2-phenylphenate tetrahydrate	170465724	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-35.5330144392	[O-]c1c(-c2ccccc2)cccc1.[Na+].O.O.O.O	[O-]c1c(-c2ccccc2)cccc1.[Na+].O.O.O.O
NCGC00166289-02	Oc1c(/C=C/c2ccc(C(=N)N)cc2)ccc(C(=N)N)c1	4.8499999	Active		0.0	1	Hydroxystilbamidine bis(methanesulfonate)	124893257	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-55.0622321804&-33.9702960749	Oc1c(/C=C/c2ccc(C(=N)N)cc2)ccc(C(=N)N)c1	Oc1c(/C=C/c2ccc(C(=N)N)cc2)ccc(C(=N)N)c1
NCGC00166079-02	Oc1c(/N=N/c2c(C)cc(/N=N/c3c(C)cccc3)cc2)c2c(cc1)cccc2	4.4000001	Active		0.0	1	C.I. Solvent Red 24	170465710	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.443220324	Oc1c(/N=N/c2c(C)cc(/N=N/c3c(C)cccc3)cc2)c2c(cc1)cccc2	Oc1c(/N=N/c2c(C)cc(/N=N/c3c(C)cccc3)cc2)c2c(cc1)cccc2
NCGC00159373-04	Oc1c(C(C)C)ccc(C)c1		Inactive	Aldose Reductase Inhibitor&Aldose reductase Inhibitor		1	Thymol	170465504	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	29.204887264&-24.491992392	Oc1c(C(C)C)ccc(C)c1	Oc1c(C(C)C)ccc(C)c1
NCGC00094575-01	Oc1c(C(CCN(C(C)C)C(C)C)c2ccccc2)cc(C)cc1	4.4000001	Active	Muscarinic M3 Antagonist	0.0	1	Tolterodine tartrate	26747834	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-49.521457016	Oc1c(C(CCN(C(C)C)C(C)C)c2ccccc2)cc(C)cc1.Cl	Oc1c(C(CCN(C(C)C)C(C)C)c2ccccc2)cc(C)cc1.Cl
NCGC00015766-13&NCGC00015766-16	Oc1c(C)c(CC2=NCCN2)c(C)cc1C(C)(C)C		Inactive	alpha2A(2D)-Adrenoceptor Agonist&Alpha1a/2a-adrenoceptor Agonists&alpha2A(2D)-Adrenoceptor Agonist		2	Oxymetazoline hydrochloride	170464916&363676461	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-12.216761348&-23.198262396&-23.576290128	Oc1c(C)c(CC2=NCCN2)c(C)cc1C(C)(C)C	Oc1c(C)c(CC2=NCCN2)c(C)cc1C(C)(C)C
NCGC00253592-01	Oc1c(C)cc(O)c2c1cccc2	4.4000001	Active	regulation of blood coagulation Activator&Regulation Of Blood Coagulation Activator	0.0	1	Menadiol	170465455	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-122.0418070319&-116.185947564	Oc1c(C)cc(O)c2c1cccc2	Oc1c(C)cc(O)c2c1cccc2
NCGC00091534-02	Oc1c(C)cccc1	4.1999998	Active		0.0	1	o-Cresol	26753043	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.16767422	Oc1c(C)cccc1	Oc1c(C)cccc1
NCGC00161410-03	Oc1c(CC)cc(-c2c(c(C)[nH]n2)-c2cc3OCCOc3cc2)c(O)c1	4.4499998	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	CCT-018159	384568207	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-84.8590678435	Oc1c(CC)cc(-c2c(c(C)[nH]n2)-c2cc3OCCOc3cc2)c(O)c1	Oc1c(CC)cc(-c2c(c(C)[nH]n2)-c2cc3OCCOc3cc2)c(O)c1
NCGC00180998-01	Oc1c(CCCCC)ccc(C)c1	4.6500001	Active		0.0	1	Amylmetacresol	144206204	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.5886754924	Oc1c(CCCCC)ccc(C)c1	Oc1c(CCCCC)ccc(C)c1
NCGC00091208-09	Oc1c(CCCCCC)ccc(O)c1		Inactive	Tyrosinase Inhibitor		1	4-Hexylresorcinol	170465471	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0	Oc1c(CCCCCC)ccc(O)c1	Oc1c(CCCCCC)ccc(O)c1
NCGC00167544-02	Oc1c(Cc2c(O)c(-n3nc4c(n3)cccc4)cc(C(CC(C)(C)C)(C)C)c2)cc(C(CC(C)(C)C)(C)C)cc1-n1nc2c(n1)cccc2	5.4000001	Active		0.0	1	2,2'-Methylenebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol]	225144291	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-48.298024007	Oc1c(Cc2c(O)c(-n3nc4c(n3)cccc4)cc(C(CC(C)(C)C)(C)C)c2)cc(C(CC(C)(C)C)(C)C)cc1-n1nc2c(n1)cccc2	Oc1c(Cc2c(O)c(-n3nc4c(n3)cccc4)cc(C(CC(C)(C)C)(C)C)c2)cc(C(CC(C)(C)C)(C)C)cc1-n1nc2c(n1)cccc2
NCGC00094226-13	Oc1c(O)ccc(/C=C/c2cc(O)cc(O)c2)c1	7.9499998	Inactive	Syk Kinase Inhibitor	0.0	1	Piceatannol	384568127	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-23.5992930361	Oc1c(O)ccc(/C=C/c2cc(O)cc(O)c2)c1	Oc1c(O)ccc(/C=C/c2cc(O)cc(O)c2)c1
NCGC00347063-02	Oc1c(O)ccc(C2CCN(c3c4c(ncc3)cccc4)CC2)c1	4.4000001	Active	M18 Aspartyl Aminopeptidase Inhibitor	0.0	1	KUC110948N	384568980	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-107.1916997901	Oc1c(O)ccc(C2CCN(c3c4c(ncc3)cccc4)CC2)c1	Oc1c(O)ccc(C2CCN(c3c4c(ncc3)cccc4)CC2)c1
NCGC00015741-13	Oc1c(O)ccc(CC(C(Cc2cc(O)c(O)cc2)C)C)c1	4.4250002	Active	5-lipoxygenase Inhibitor&5-Lipoxygenase Inhibitor	0.0	1	4,4 -(2,3-Dimethyltetramethylene)dipyrocatechol	405558741	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-99.733301568&-106.5819157335	Oc1c(O)ccc(CC(C(Cc2cc(O)c(O)cc2)C)C)c1	Oc1c(O)ccc(CC(C(Cc2cc(O)c(O)cc2)C)C)c1
NCGC00015519-11&NCGC00015519-15	Oc1c(O)ccc(CCN)c1		Inactive	Neurotransmitter&Dopamine Receptor D2 Agonist&Neurotransmitter		2	Dopamine hydrochloride	170464942&384567860	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-22.206913548&17.5401181879&0.0	Oc1c(O)ccc(CCN)c1	Oc1c(O)ccc(CCN)c1
NCGC00015321-11	Oc1c(O)ccc(CCNC(CCc2ccc(O)cc2)C)c1	4.5500002	Active	Beta1-adrenoceptor Antagonists	0.0	1	Dobutamine	170465050	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.0714908494	Oc1c(O)ccc(CCNC(CCc2ccc(O)cc2)C)c1	Oc1c(O)ccc(CCNC(CCc2ccc(O)cc2)C)c1
NCGC00184998-02	Oc1c(O)ccc(CCNCCCCCCNCCc2ccccc2)c1	4.6500001	Active	D(2) dopamine receptor Agonist	0.0	1	Dopexamine	170466408	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-55.1315678511	Oc1c(O)ccc(CCNCCCCCCNCCc2ccccc2)c1	Oc1c(O)ccc(CCNCCCCCCNCCc2ccccc2)c1
NCGC00094201-03	Oc1c(O)ccc(C[C@@H]([C@@H](Cc2cc(O)c(O)cc2)C)C)c1		Inactive	5-Lipoxygenase Inhibitor		1	Masoprocol	124891671	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.1851720999	Oc1c(O)ccc(C[C@@H]([C@@H](Cc2cc(O)c(O)cc2)C)C)c1	Oc1c(O)ccc(C[C@@H]([C@@H](Cc2cc(O)c(O)cc2)C)C)c1
NCGC00183049-01	Oc1c(O)ccc2[C@@H](c3cc(O)c(O)cc3)CNCc12		Inactive			1	Zelandopam	144206852	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	27.992901916&0.0	Oc1c(O)ccc2[C@@H](c3cc(O)c(O)cc3)CNCc12.Cl	Oc1c(O)ccc2[C@@H](c3cc(O)c(O)cc3)CNCc12.Cl
NCGC00025349-05	Oc1c(O)ccc2c1-c1c3[C@H](N(C)CCc3ccc1)C2	5.3499999	Active	D2-like Dopamine Receptor Agonist&D2-like dopamine receptor Agonist	0.0	1	Apomorphine	170465297	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-1.4	-42.8531562832&-32.7244463007	Oc1c(O)ccc2c1-c1c3[C@H](N(C)CCc3ccc1)C2	Oc1c(O)ccc2c1-c1c3[C@H](N(C)CCc3ccc1)C2
NCGC00095460-08	Oc1c(O)ccc2c1OCC1(O)C2c2c(cc(O)c(O)c2)C1		Inactive	Iron Chelator		1	Hematoxylin	384568157	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Oc1c(O)ccc2c1OCC1(O)C2c2c(cc(O)c(O)c2)C1	Oc1c(O)ccc2c1OCC1(O)C2c2c(cc(O)c(O)c2)C1
NCGC00263557-01	Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(C)cc1	5.0250001	Active	Muscarinic M3 Antagonists	0.0	1	NCGC00263557-01&Tolterodine	170465337	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-61.8662444447&-107.3277441647	Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(C)cc1	Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(C)cc1
NCGC00386518-01	Oc1c([C@H]2[C@H](C(=C)C)CCC(C)=C2)c(O)cc(CCCCC)c1	4.6333332	Active	Cannabinoid Receptor Agonist&Dopamine D2 Receptor Partial Agonist	0.0	1	Cannabidiol	377020361	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0&-2.4	-79.5097012734&-55.3805404399&-71.9296873264	Oc1c([C@H]2[C@H](C(=C)C)CCC(C)=C2)c(O)cc(CCCCC)c1	Oc1c([C@H]2[C@H](C(=C)C)CCC(C)=C2)c(O)cc(CCCCC)c1
NCGC00021666-04	Oc1c2O[C@H]3C(=C)CC[C@@]4(O)[C@@H]5N(CC6CC6)CC[C@]34c2c(cc1)C5	6.0500002	Active	Kappa Opioid Receptor Partial Agonist	0.0	1	Nalmefene	170465281	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.622543156	Oc1c2O[C@H]3C(=C)CC[C@@]4(O)[C@@H]5N(CC6CC6)CC[C@]34c2c(cc1)C5	Oc1c2O[C@H]3C(=C)CC[C@@]4(O)[C@@H]5N(CC6CC6)CC[C@]34c2c(cc1)C5
NCGC00181099-01	Oc1c2[C@@H]3OCC45[C@@H]3[C@@](C)(Oc2cc(C)c1)CC[C@H]4C(C)(C)CCC5		Inactive			1	Siccanin	144206268	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.9603503599&0.0	Oc1c2[C@@H]3OCC45[C@@H]3[C@@](C)(Oc2cc(C)c1)CC[C@H]4C(C)(C)CCC5	Oc1c2[C@@H]3OCC45[C@@H]3[C@@](C)(Oc2cc(C)c1)CC[C@H]4C(C)(C)CCC5
NCGC00181774-02	Oc1c2c(O)cc(C)cc2cc2c1c(O)ccc2		Inactive			1	Chrysarobin	170465659	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.513357772&0.0	Oc1c2c(O)cc(C)cc2cc2c1c(O)ccc2	Oc1c2c(O)cc(C)cc2cc2c1c(O)ccc2
NCGC00168748-02	Oc1c2c(ccc1)C[C@@H](N(CCC)CCc1sccc1)CC2	4.6999998	Active	Dopamine D4 Receptor Agonist&Dopamine D4 receptor Agonist	0.0	1	Rotigotine	170465204	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-53.402561164&-71.2579814368	Oc1c2c(ccc1)C[C@@H](N(CCC)CCc1sccc1)CC2	Oc1c2c(ccc1)C[C@@H](N(CCC)CCc1sccc1)CC2
NCGC00159447-07	Oc1c2ncccc2ccc1		Inactive	Trichophyton Interdigitale Inhibitor		1	8-Quinolinol Salicylic acid (1:1)	170465482	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.08016952&-31.086223144	O=C(O)c1c(O)cccc1.Oc1c2ncccc2ccc1	O=C(O)c1c(O)cccc1.Oc1c2ncccc2ccc1
NCGC00346508-12	Oc1cc(-c2c(-c3cc(O)ccc3)nc3nc(N)nc(N)c3n2)ccc1		Inactive	PI3K Inhibitor		1	TG-100115	384568810	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Oc1cc(-c2c(-c3cc(O)ccc3)nc3nc(N)nc(N)c3n2)ccc1	Oc1cc(-c2c(-c3cc(O)ccc3)nc3nc(N)nc(N)c3n2)ccc1
NCGC00187906-15	Oc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1	6.0500002	Active	PI3Kalpha, beta, gamma Inhibitor	0.0	1	PI-103	377020302	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-53.3002675685	Oc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1	Oc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1
NCGC00532496-01	Oc1cc(C)c(C(C)(C)C)cc1	4.4000001	Active		0.0	1	P-T-BUTYL-M-CRESOL	405558633	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-43.3657074612	Oc1cc(C)c(C(C)(C)C)cc1	Oc1cc(C)c(C(C)(C)C)cc1
NCGC00160622-04	Oc1cc(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1	5.25	Active		0.0	1	D-delta-Tocopherol	144206758	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.4808636041	Oc1cc(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1	Oc1cc(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1
NCGC00510073-01	Oc1cc(C)c2[C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)CCC4)CC3)Cc2c1		Inactive	SHIP-1 Activator		1	AQX-MN-100	384569407	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Oc1cc(C)c2[C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)CCC4)CC3)Cc2c1	Oc1cc(C)c2[C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)CCC4)CC3)Cc2c1
NCGC00159366-02	Oc1cc(C)ccc1	4.4000001	Active		0.0	1	m-Cresol	29215286	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.8046775999	Oc1cc(C)ccc1	Oc1cc(C)ccc1
NCGC00179295-03	Oc1cc(C2(CC)CN(C)CCCC2)ccc1		Inactive	Mu Opioid Receptor Partial Agonist&Mu opioid receptor Partial Agonist		1	Meptazinol hydrochloride	170466363	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.517054272&0.0	Oc1cc(C2(CC)CN(C)CCCC2)ccc1.Cl	Oc1cc(C2(CC)CN(C)CCCC2)ccc1.Cl
NCGC00183015-01	Oc1cc(C2=C3N=C(C(c4cc(O)ccc4)=C4N=C(C(c5cc(O)ccc5)=C5N=C(C(c6cc(O)ccc6)=C6N=C2C=C6)C=C5)CC4)C=C3)ccc1	4.5500002	Active	cell proliferation Inhibitor	0.0	1	Temoporfin	144206848	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-73.7143271737	Oc1cc(C2=C3N=C(C(c4cc(O)ccc4)=C4N=C(C(c5cc(O)ccc5)=C5N=C(C(c6cc(O)ccc6)=C6N=C2C=C6)C=C5)CC4)C=C3)ccc1	Oc1cc(C2=C3N=C(C(c4cc(O)ccc4)=C4N=C(C(c5cc(O)ccc5)=C5N=C(C(c6cc(O)ccc6)=C6N=C2C=C6)C=C5)CC4)C=C3)ccc1
NCGC00017352-22	Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1	4.9499998	Active	Cyclooxygenase-2 Inhibitor	0.0	1	Resveratrol	384567987	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-95.6361774163	Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1	Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1
NCGC00166270-02	Oc1cc(O)cc(O)c1	4.4000001	Active	Voltage-gated Calcium Channel Inhibitor	0.0	1	1,3,5-Trihydroxybenzene dihydrate	225144277	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-50.555127909	Oc1cc(O)cc(O)c1	Oc1cc(O)cc(O)c1
NCGC00091501-06	Oc1cc(O)ccc1		Inactive	Leukotriene B4 Biosynthetic Process Inhibitor&leukotriene B4 biosynthetic process Inhibitor		1	Resorcinol	170465462	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&20.0878300879	Oc1cc(O)ccc1	Oc1cc(O)ccc1
NCGC00015409-11	Oc1cc([N+](CC)(C)C)ccc1		Inactive	Butyrylcholinesterase Inhibitor		1	Edrophonium chloride	170464801	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	Oc1cc([N+](CC)(C)C)ccc1.[Cl-]	Oc1cc([N+](CC)(C)C)ccc1.[Cl-]
NCGC00346822-02	Oc1cc2OCC(c3ccc(O)cc3)=Cc2cc1	5.25	Active	Sphingosine Kinase 1 (SphK1) Inhibitor	0.0	1	Idronoxil	377020351	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-99.4733515379	Oc1cc2OCC(c3ccc(O)cc3)=Cc2cc1	Oc1cc2OCC(c3ccc(O)cc3)=Cc2cc1
NCGC00025072-08	Oc1cc2[C@H]3OCCN(CCC)[C@@H]3COc2cc1		Inactive	Dopamine D2/D3 Agonist		1	PD-128907	384568046	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	Oc1cc2[C@H]3OCCN(CCC)[C@@H]3COc2cc1	Oc1cc2[C@H]3OCCN(CCC)[C@@H]3COc2cc1
NCGC00346557-02	Oc1cc2[C@H]3[C@@H]([C@H](c4ccc(O)cc4)Oc2cc1)CCC3	4.75	Active	Estrogen Receptor (ER) beta Agonist	0.0	1	Erteberel	363677454	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-79.6033060987	Oc1cc2[C@H]3[C@@H]([C@H](c4ccc(O)cc4)Oc2cc1)CCC3	Oc1cc2[C@H]3[C@@H]([C@H](c4ccc(O)cc4)Oc2cc1)CCC3
NCGC00274273-01	Oc1cc2[C@]3(C)[C@@H](N)[C@H](Cc2cc1)CCCCC3	4.4000001	Active	Mu opioid receptor Partial Agonist&Mu Opioid Receptor Partial Agonist	0.0	1	NCGC00274273-01	225144371	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-57.4220459279&-53.9487579719	Oc1cc2[C@]3(C)[C@@H](N)[C@H](Cc2cc1)CCCCC3	Oc1cc2[C@]3(C)[C@@H](N)[C@H](Cc2cc1)CCCCC3
NCGC00247716-01	Oc1cc2[C@]3(C)[C@H](C)[C@@H](N(C/C=C(\C)/C)CC3)Cc2cc1	4.1500001	Active		0.0	1	(+)-Pentazocine succinate	144206429	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.769169934	O=C(O)CCC(=O)O.Oc1cc2[C@]3(C)[C@H](C)[C@@H](N(C/C=C(\C)/C)CC3)Cc2cc1	O=C(O)CCC(=O)O.Oc1cc2[C@]3(C)[C@H](C)[C@@H](N(C/C=C(\C)/C)CC3)Cc2cc1
NCGC00091533-10&NCGC00091533-17	Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1	4.4000001	Active	Estrogen Receptor (ER) Agonist	0.0	2	Ethinylestradiol	170464983&384568096	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-74.085165468&-56.218021196	Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1	Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1
NCGC00162247-06	Oc1cc2c(cc1)C[C@H]1N(CC=C)CC[C@@]32[C@H]1CCCC3		Inactive	Mu-type Opioid Receptor Antagonist&Mu-type opioid receptor Antagonist		1	Levallorphan	170465778	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.28207232&-17.1068000559	Oc1cc2c(cc1)C[C@H]1N(CC=C)CC[C@@]32[C@H]1CCCC3	Oc1cc2c(cc1)C[C@H]1N(CC=C)CC[C@@]32[C@H]1CCCC3
NCGC00387215-01	Oc1ccc(-c2[nH]c3ncnc(N[C@H](C)c4ccccc4)c3c2)cc1	4.75	Active	EGFR Inhibitor	0.0	1	PKI-166	384569154	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-76.7666403439	Oc1ccc(-c2[nH]c3ncnc(N[C@H](C)c4ccccc4)c3c2)cc1	Oc1ccc(-c2[nH]c3ncnc(N[C@H](C)c4ccccc4)c3c2)cc1
NCGC00018153-13	Oc1ccc(/C(/C(=C/C)/c2ccc(O)cc2)=C\C)cc1	4.4000001	Active	Estrogen Receptor (ER) Agonist	0.0	1	Dienestrol	384567992	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-117.5314859574	Oc1ccc(/C(/C(=C/C)/c2ccc(O)cc2)=C\C)cc1	Oc1ccc(/C(/C(=C/C)/c2ccc(O)cc2)=C\C)cc1
NCGC00090749-19	Oc1ccc(/C(=C(\CC)/c2ccc(O)cc2)/CC)cc1	4.4000001	Active	Estrogen Receptor (ER) Agonist	0.0	1	Diethylstilbestrol	384568080	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-86.268331208	Oc1ccc(/C(=C(\CC)/c2ccc(O)cc2)/CC)cc1	Oc1ccc(/C(=C(\CC)/c2ccc(O)cc2)/CC)cc1
NCGC00090749-12	Oc1ccc(C(=C(CC)c2ccc(O)cc2)CC)cc1	4.625	Active	Estrogen Receptor Agonist&Estrogen Receptor (ER) Agonist	0.0	1	Diethylstilbestrol	170464803	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.2	-70.03937288&-86.0228513428	Oc1ccc(C(=C(CC)c2ccc(O)cc2)CC)cc1	Oc1ccc(C(=C(CC)c2ccc(O)cc2)CC)cc1
NCGC00094818-13	Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1	6.0500002	Inactive	17-betahydroxysteroid dehydrogenase Inhibitor	0.0	1	Hexestrol	384568137	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	19.3696220041	Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1	Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1
NCGC00159377-04	Oc1ccc(C(C)(C)C)cc1		Inactive	Udp-glucuronosyltransferase 1-6 Substrate&UDP-glucuronosyltransferase 1-6 Substrate		1	4-tert-Butylphenol	170465689	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.102714472&-15.5342705799	Oc1ccc(C(C)(C)C)cc1	Oc1ccc(C(C)(C)C)cc1
NCGC00164127-07	Oc1ccc(C(CC(C)(C)C)(C)C)cc1	4.4499998	Active		0.0	1	4-(1,1,3,3-Tetramethylbutyl)phenol	170465157	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-52.0541135195	Oc1ccc(C(CC(C)(C)C)(C)C)cc1	Oc1ccc(C(CC(C)(C)C)(C)C)cc1
NCGC00345883-07	Oc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1	4.4000001	Active	Serotonin transporter Inhibitor	0.0	1	DESVENLAFAXINE SUCCINATE	405558880	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-54.6139147879	Oc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1	Oc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
NCGC00091519-09	Oc1ccc(C)cc1		Inactive			1	p-Cresol	170465495	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.171345644&16.9457507199	Oc1ccc(C)cc1	Oc1ccc(C)cc1
NCGC00178433-02	Oc1ccc(CC(N)C)cc1	5.0	Active	Adrenergic receptor Agonist	0.0	1	HYDROXYAMPHETAMINE HYDROBROMIDE	405558631	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-34.7533362172	Oc1ccc(CC(N)C)cc1	Oc1ccc(CC(N)C)cc1
NCGC00263553-13	Oc1ccc(CCNc2nc(-c3c4c(sc3)cccc4)nc3n(C(C)C)cnc23)cc1	6.0500002	Inactive	Aryl Hydrocarbon Receptor (AhR) Antagonist	0.0	1	StemRegenin 1	363677284	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-50.6312667331	Oc1ccc(CCNc2nc(-c3c4c(sc3)cccc4)nc3n(C(C)C)cnc23)cc1	Oc1ccc(CCNc2nc(-c3c4c(sc3)cccc4)nc3n(C(C)C)cnc23)cc1
NCGC00015523-13	Oc1ccc(O)cc1	4.4499998	Active		0.0	1	Hydroquinone	170464661	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-101.2029291171	Oc1ccc(O)cc1	Oc1ccc(O)cc1
NCGC00094818-09	Oc1ccc([C@H]([C@@H](CC)c2ccc(O)cc2)CC)cc1	5.0	Active	17-betahydroxysteroid dehydrogenase Inhibitor	0.0	1	Hexestrol	170466031	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-46.7464462956	Oc1ccc([C@H]([C@@H](CC)c2ccc(O)cc2)CC)cc1	Oc1ccc([C@H]([C@@H](CC)c2ccc(O)cc2)CC)cc1
NCGC00091454-07	Oc1ccccc1	5.6500001	Active		0.0	1	Phenol	170465486	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-39.1542541599	Oc1ccccc1	Oc1ccccc1
NCGC00015094-22	Oc1ncnc2[nH]ncc12		Inactive	Xanthine Dehydrogenase/oxidase Inhibitor		1	Allopurinol	405558932	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.795253728	Oc1ncnc2[nH]ncc12	Oc1ncnc2[nH]ncc12
NCGC00165862-02	P(=O)(O)(O)C(P(=O)(O)O)(O)CCN		Inactive	Farnesyl Diphosphate Synthase Inhibitor&Farnesyl diphosphate synthase Inhibitor		1	Pamidronic acid	170464689	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.7251096&-18.004638568	P(=O)(O)(O)C(P(=O)(O)O)(O)CCN	P(=O)(O)(O)C(P(=O)(O)O)(O)CCN
NCGC00183829-01	P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)C=CC=C2		Inactive	Geranylgeranyl pyrophosphate synthetase Inhibitor&Geranylgeranyl Pyrophosphate Synthetase Inhibitor		1	Minodronic acid	144206806	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.645488452&-17.8381860919	P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)C=CC=C2	P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)C=CC=C2
NCGC00024728-02	P(=O)(O)(O)C(P(=O)(O)O)(Oc1ccc(O)cc1)C		Inactive	inositol monophophatase Inhibitor		1	L-690330	384568033	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	P(=O)(O)(O)C(P(=O)(O)O)(Oc1ccc(O)cc1)C	P(=O)(O)(O)C(P(=O)(O)O)(Oc1ccc(O)cc1)C
NCGC00165719-15&NCGC00165719-16	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCCN	5.4499998	Inactive	Protein Tyrosine Phosphatase (ptp) Inhibitor&Geranylgeranyl pyrophosphate synthetase Inhibitor	0.0	2	ALENDRONATE SODIUM&Alendronate (Fosamax)	405559128&384568274	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&1.2	-20.9923853639&23.362738952&34.9880686401	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCCN	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCCN
NCGC00186037-02&NCGC00186037-10	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCN(CCCCC)C		Inactive	Treatment Of Osteoporosis&Treatment of Osteoporosis&Treatment of Osteoporosis		2	Ibandronate sodium hydrate	225144338&384568439	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	17.506335016&-29.7199086559&-15.138037008	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCN(CCCCC)C	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCN(CCCCC)C
NCGC00346521-01	P(=O)(O)(O)C(P(=O)(O)[O-])(O)Cc1cnccc1		Inactive	Farnesyl Pyrophosphate Synthase Inhibitor		1	Risedronate sodium	174006918	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.280586252	P(=O)(O[Na])(O)C(P(=O)(O)O)(O)Cc1cnccc1	P(=O)(O[Na])(O)C(P(=O)(O)O)(O)Cc1cnccc1
NCGC00487176-01	P(=O)(O)(O)CCN1C=2C(=O)C(=O)C=2NCCC1		Inactive			1	EAA-090	405558601	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&16.5773902919	P(=O)(O)(O)CCN1C=2C(=O)C(=O)C=2NCCC1	P(=O)(O)(O)CCN1C=2C(=O)C(=O)C=2NCCC1
NCGC00184994-02&NCGC00184994-11	P(=O)(O)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1		Inactive	Dna Polymerase Inhibitors&DNA Polymerase Inhibitor&DNA Polymerase Inhibitor		2	Cidofovir	225144336&384568422	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&46.7721993059	P(=O)(O)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1	P(=O)(O)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1
NCGC00037856-01	P(=O)(O)(O)CP(=O)(O)O		Inactive			1	Medronic acid	144204525	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.2344185759&-26.401987568	P(=O)(O)(O)CP(=O)(O)O	P(=O)(O)(O)CP(=O)(O)O
NCGC00179380-04	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)C		Inactive	Atp Inhibitor&ATP Inhibitor		1	NCGC00179380-04&Etidronate disodium	170464730	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)C.[Na+].[Na+]	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)C.[Na+].[Na+]
NCGC00274056-01	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)Cc1cnccc1		Inactive	Farnesyl diphosphate synthase Inhibitor&Farnesyl Diphosphate Synthase Inhibitor		1	Risedronate sodium	170464992	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	7.8953923239&-11.02728844	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)Cc1cnccc1.[Na+].[Na+]	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)Cc1cnccc1.[Na+].[Na+]
NCGC00166037-04	P(=O)(OC(CO)CO)([O-])[O-]	4.9000001	Active	Alkaline Phosphatase, Tissue-nonspecific Isozyme Inhibitor	0.0	1	beta-Glycerol phosphate disodium salt pentahydrate	405558431	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.2	-38.0520637024&-58.7888409541	P(=O)(OC(CO)CO)([O-])[O-]	P(=O)(OC(CO)CO)([O-])[O-]
NCGC00182029-01	P(=O)(OC(Cn1ncnc1)(Cn1ncnc1)c1c(F)cc(F)cc1)(O)O		Inactive	Cytochrome P450 51 Inhibitor		1	Fosfluconazole	144206487	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.224343324&0.0	P(=O)(OC(Cn1ncnc1)(Cn1ncnc1)c1c(F)cc(F)cc1)(O)O	P(=O)(OC(Cn1ncnc1)(Cn1ncnc1)c1c(F)cc(F)cc1)(O)O
NCGC00483012-01	P(=O)(OC1C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1OP(=O)(O)O)(O)O	4.6500001	Active	Lipid Oxidation Inhibitor	0.0	1	Phytic acid	405558945	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-40.4555724927	P(=O)(OC1C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1OP(=O)(O)O)(O)O	P(=O)(OC1C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1OP(=O)(O)O)(O)O
NCGC00021226-04	P(=O)(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21)([O-])[O-]		Inactive	Glucocorticoid receptor Agonist&Glucocorticoid Receptor Agonist		1	Dexamethasone 21-phosphate disodium salt	225144188	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	P(=O)(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21)([O-])[O-]	P(=O)(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21)([O-])[O-]
NCGC00388369-01	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)([O-])[O-]	5.1999998	Active	Glucocorticoid Receptor Agonist	0.0	1	Prednisolone Phosphate (sodium salt)	405558865	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.327578472	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)([O-])[O-]	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)([O-])[O-]
NCGC00167464-02	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)([O-])[O-]		Inactive			1	Hydrocortisone Sodium Phosphate	225144288	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.929244108&0.0	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)([O-])[O-]	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)([O-])[O-]
NCGC00181029-01	P(=O)(OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC)(OCC[N+](C)(C)C)[O-]		Inactive	Apolipoprotein A-i Binding Agent&Apolipoprotein A-I Binding Agent		1	1,2-Ditetradecanoyl-rac-glycerol-3-phosphocholine	144206232	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.907862932&-15.218853588	P(=O)(OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC)(OCC[N+](C)(C)C)[O-]	P(=O)(OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC)(OCC[N+](C)(C)C)[O-]
NCGC00183017-01	P(=O)(OCC)(Oc1ccc([N+](=O)[O-])cc1)CC	4.5	Active		0.0	1	Ethyl 4-nitrophenyl ethylphosphonate	144206877	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-80.738100676	P(=O)(OCC)(Oc1ccc([N+](=O)[O-])cc1)CC	P(=O)(OCC)(Oc1ccc([N+](=O)[O-])cc1)CC
NCGC00389328-02	P(=O)(OCC1C(O)C(O)C(n2c3nc(F)nc(N)c3nc2)O1)(O)O		Inactive	Purine Antagonist		1	Fludarabine	384569174	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.52146716	P(=O)(OCC1C(O)C(O)C(n2c3nc(F)nc(N)c3nc2)O1)(O)O	P(=O)(OCC1C(O)C(O)C(n2c3nc(F)nc(N)c3nc2)O1)(O)O
NCGC00346503-01	P(=O)(OCCCCCCCCCCCCCCCCCC)(OC1CC[N+](C)(C)CC1)[O-]		Inactive	PI3K kinase Activator		1	Perifosine	174006514	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.2758849801	P(=O)(OCCCCCCCCCCCCCCCCCC)(OC1CC[N+](C)(C)CC1)[O-]	P(=O)(OCCCCCCCCCCCCCCCCCC)(OC1CC[N+](C)(C)CC1)[O-]
NCGC00379339-01	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)COC(CO)CN1C(=O)N=C(N)C=C1	4.9000001	Active	DNA polymerase Inhibitor	0.0	1	Brincidofovir	377020268	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-109.4036582199	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)COC(CO)CN1C(=O)N=C(N)C=C1	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)COC(CO)CN1C(=O)N=C(N)C=C1
NCGC00378734-08	P(=O)(OCCN(CCCOc1cc2ncnc(Nc3n[nH]c(CC(=O)Nc4cc(F)ccc4)c3)c2cc1)CC)(O)O	4.5	Inactive		0.0	1	AZD1152	384569066	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	67.352725224	P(=O)(OCCN(CCCOc1cc2ncnc(Nc3n[nH]c(CC(=O)Nc4cc(F)ccc4)c3)c2cc1)CC)(O)O	P(=O)(OCCN(CCCOc1cc2ncnc(Nc3n[nH]c(CC(=O)Nc4cc(F)ccc4)c3)c2cc1)CC)(O)O
NCGC00095169-05	P(=O)(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]	4.9000001	Active		0.0	1	Miltefosine	170465622	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.2&-2.2	-56.2286052388&-78.2544313484	P(=O)(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]	P(=O)(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]
NCGC00346622-03	P(=O)(OCN1C(=O)C(C)(C)Oc2c1nc(Nc1c(F)cnc(Nc3cc(OC)c(OC)c(OC)c3)n1)cc2)(O)O		Inactive	Syk Kinase Inhibitor		1	Fostamatinib	384568862	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.408349176	P(=O)(OCN1C(=O)C(C)(C)Oc2c1nc(Nc1c(F)cnc(Nc3cc(OC)c(OC)c(OC)c3)n1)cc2)(O)O	P(=O)(OCN1C(=O)C(C)(C)Oc2c1nc(Nc1c(F)cnc(Nc3cc(OC)c(OC)c(OC)c3)n1)cc2)(O)O
NCGC00249894-01	P(=O)(OCN1C(=O)C(c2ccccc2)(c2ccccc2)NC1=O)(O)O		Inactive	Sodium channel protein type VIII alpha subunit Inhibitor&Sodium Channel Protein Type Viii Alpha Subunit Inhibitor		1	Fosphenytoin	170465016	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.802051268&0.0	P(=O)(OCN1C(=O)C(c2ccccc2)(c2ccccc2)NC1=O)(O)O	P(=O)(OCN1C(=O)C(c2ccccc2)(c2ccccc2)NC1=O)(O)O
NCGC00183876-03	P(=O)(OCOC(=O)OC(C)C)(OCOC(=O)OC(C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C	6.5	Inactive	Reverse Transcriptase Inhibitor	0.0	1	Tenofovir disoproxil fumarate	170465338	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-23.466562532	P(=O)(OCOC(=O)OC(C)C)(OCOC(=O)OC(C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C.O=C(O)C=CC(=O)O	P(=O)(OCOC(=O)OC(C)C)(OCOC(=O)OC(C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C.O=C(O)C=CC(=O)O
NCGC00346450-01	P(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1)(O)O	4.1500001	Inactive	AKT Inhibitor	0.0	1	Triciribine phosphate	174006450	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	80.3839556481	P(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1)(O)O	P(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1)(O)O
NCGC00182047-04	P(=O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3nc(F)nc(N)c3nc2)O1)(O)O		Inactive	Purine Antagonist		1	Fludarabine phosphate	384568405	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	P(=O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3nc(F)nc(N)c3nc2)O1)(O)O	P(=O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3nc(F)nc(N)c3nc2)O1)(O)O
NCGC00389431-01	P(=O)(OC[C@H](O)[C@H](O)[C@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)(O)[O-]		Inactive	Nadh Oxidation Oxidative Enzyme&NADH oxidation Oxidative Enzyme		1	RIBOFLAVIN 5-PHOSPHATE SODIUM	405558646	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.5749797599&17.5438704241	P(=O)(OC[C@H](O)[C@H](O)[C@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)(O)[O-]	P(=O)(OC[C@H](O)[C@H](O)[C@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)(O)[O-]
NCGC00013364-03	P(=O)(OCc1c(C)c(O)c(C)nc1)(O)O		Inactive			1	Vitamin B6	405558556	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-31.260868886&9.48062852	P(=O)(OCc1c(C)c(O)c(C)nc1)(O)O	P(=O)(OCc1c(C)c(O)c(C)nc1)(O)O
NCGC00166300-02	P(=O)(OCc1c(C=O)c(O)c(C)nc1)(O)O	4.75	Active	P2x Purinoceptor 2 Antagonist	0.0	1	Pyridoxal phosphate hydrate	170466028	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.631168892	P(=O)(OCc1c(C=O)c(O)c(C)nc1)(O)O.O	P(=O)(OCc1c(C=O)c(O)c(C)nc1)(O)O.O
NCGC00181045-01	P(=O)(OCc1c(CN)c(O)c(C)nc1)(O)O	4.5500002	Active		0.0	1	Pyridoxamine phosphate	144206246	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-52.88922474&-33.26370116	P(=O)(OCc1c(CN)c(O)c(C)nc1)(O)O	P(=O)(OCc1c(CN)c(O)c(C)nc1)(O)O
NCGC00013687-03	P(=O)(OP(=O)(O)O)(O)O		Inactive			1	Pyrophosphoric acid	405559136	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-24.338524664	P(=O)(OP(=O)(O)O)(O)O	P(=O)(OP(=O)(O)O)(O)O
NCGC00160617-03	P(=O)(OP(=O)(O)O)(OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1)O		Inactive			1	Thiamine pyrophosphate	405559130	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.003592908&21.4014002958	P(=O)(OP(=O)(O)O)(OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1)O	P(=O)(OP(=O)(O)O)(OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1)O
NCGC00178032-03	P(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(=O)N=C(N)C=C2)O1)O	6.4081006	Active		0.0	1	CITICOLINE	405558452	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.8997445439	P(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(=O)N=C(N)C=C2)O1)O	P(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(=O)N=C(N)C=C2)O1)O
NCGC00178839-08	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]([n+]2cc(C(=O)N)ccc2)O1)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O	4.5500002	Active		0.0	1	NAD+	405558451	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.5158355288	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]([n+]2cc(C(=O)N)ccc2)O1)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]([n+]2cc(C(=O)N)ccc2)O1)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O
NCGC00344578-01	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)[O-])(OC[C@@H](O)[C@@H](O)[C@@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)[O-]		Inactive	oxidative phosphorylation Modulator&Oxidative Phosphorylation Modulator		1	Flavin adenine dinucleotide disodium salt hydrate	225144395	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-10.3959084279&-33.0045675	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)[O-])(OC[C@@H](O)[C@@H](O)[C@@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)[O-].[Na+].[Na+].O	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)[O-])(OC[C@@H](O)[C@@H](O)[C@@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)[O-].[Na+].[Na+].O
NCGC00186629-04	P(=O)(OP(=O)(OP(=O)(O)[O-])[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O	6.4081006	Active		0.0	1	ATP (disodium salt)	405558525	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.72242624	P(=O)(OP(=O)(OP(=O)(O)[O-])[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O	P(=O)(OP(=O)(OP(=O)(O)[O-])[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O
NCGC00167432-05	P(=O)(O[C@H](OC(=O)CC)C(C)C)(CC(=O)N1[C@H](C(=O)O)C[C@@H](C2CCCCC2)C1)CCCCc1ccccc1	5.4000001	Active	Angiotensin-converting Enzyme Inhibitor&Angiotensin-converting enzyme Inhibitor	0.0	1	FosinoprilNa	405558492	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-40.3624960783&-39.0598538443	P(=O)(O[C@H](OC(=O)CC)C(C)C)(CC(=O)N1[C@H](C(=O)[O-])C[C@@H](C2CCCCC2)C1)CCCCc1ccccc1	P(=O)(O[C@H](OC(=O)CC)C(C)C)(CC(=O)N1[C@H](C(=O)[O-])C[C@@H](C2CCCCC2)C1)CCCCc1ccccc1
NCGC00346481-02	P(=O)(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)(C)C	4.4000001	Active	mTOR Inhibitor	0.0	1	Ridaforolimus	363677418	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-58.7903545279	P(=O)(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)(C)C	P(=O)(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)(C)C
NCGC00181335-02	P(=O)(Oc1ccc(/C(=C(\CC)/c2ccc(OP(=O)(O)O)cc2)/CC)cc1)(O)O		Inactive	Estrogen-related Receptor Gamma Inverse Agonist&estrogen-related receptor gamma Inverse Agonist		1	Fosfestrol tetrasodium	225144324	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-25.973193892	P(=O)(Oc1ccc(/C(=C(\CC)/c2ccc(OP(=O)(O)O)cc2)/CC)cc1)(O)O	P(=O)(Oc1ccc(/C(=C(\CC)/c2ccc(OP(=O)(O)O)cc2)/CC)cc1)(O)O
NCGC00178317-03	P(=O)([O-])([O-])C(=O)O		Inactive	Human immunodeficiency virus type 1 reverse transcriptase Inhibitor&Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor		1	Foscarnet trisodium	170465060	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	P(=O)([O-])([O-])C(=O)[O-].[Na+].[Na+].[Na+]	P(=O)([O-])([O-])C(=O)[O-].[Na+].[Na+].[Na+]
NCGC00348378-01	P(=O)([O-])([O-])[C@@H]1[C@H](C)O1	5.4000001	Active	Udp-n-acetylglucosamine 1-carboxyvinyltransferase Inhibitor	0.0	1	FOSFOMYCIN	405559146	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-50.9274166019	P(=O)([O-])([O-])[C@@H]1[C@H](C)O1	P(=O)([O-])([O-])[C@@H]1[C@H](C)O1
NCGC00168783-01	P(F)(=O)(OC(C)C)OC(C)C		Inactive	Acetylcholinesterase Inhibitor		1	Diisopropyl fluorophosphate	144206196	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-30.5002567799	P(F)(=O)(OC(C)C)OC(C)C	P(F)(=O)(OC(C)C)OC(C)C
NCGC00092290-11	S(/C(/N)=C(\C#N)/c1c(C(F)(F)F)cccc1)c1ccc(N)cc1		Inactive	Mek 1/2 Inhibitor		1	SL-327	384568103	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-17.632243952	S(/C(/N)=C(\C#N)/c1c(C(F)(F)F)cccc1)c1ccc(N)cc1	S(/C(/N)=C(\C#N)/c1c(C(F)(F)F)cccc1)c1ccc(N)cc1
NCGC00249929-01	S(/C=C(/n1cncc1)\c1c(OCCCCC)cccc1)C	4.7249999	Active	Ergosterol Biosynthetic Process Inhibitor&ergosterol biosynthetic process Inhibitor	0.0	1	Neticonazole	170466035	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-82.2614998412&-92.3482332562	S(/C=C(/n1cncc1)\c1c(OCCCCC)cccc1)C	S(/C=C(/n1cncc1)\c1c(OCCCCC)cccc1)C
NCGC00015148-12	S(=O)(=N)(CCC(N)C(=O)O)CCCC		Inactive	Glutamate-Cysteine Ligase (gamma-Glutamylcysteine Synthetase) Inhibitor		1	Buthionine sulphoximine	384567814	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=N)(CCC(N)C(=O)O)CCCC	S(=O)(=N)(CCC(N)C(=O)O)CCCC
NCGC00372956-01	S(=O)(=N)(c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(C(F)(F)F)cn2)cc1)C1CC1	4.4000001	Active	Jak2/3 Inhibitor	0.0	1	Roniciclib	384569045	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.5340024191	S(=O)(=N)(c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(C(F)(F)F)cn2)cc1)C1CC1	S(=O)(=N)(c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(C(F)(F)F)cn2)cc1)C1CC1
NCGC00386141-07	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(=O)O)c(OC)cc1	6.0999999	Inactive	Tubulin depolymerization Inhibitor	0.0	1	Rigosertib (ON-01910)	384569112	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-10.363707992	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(=O)[O-])c(OC)cc1	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(=O)[O-])c(OC)cc1
NCGC00510493-01	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(OP(=O)(O)O)c(OC)cc1	6.0500002	Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor	0.0	1	Briciclib	384569455	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-15.4813821681	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(OP(=O)(O)O)c(OC)cc1	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(OP(=O)(O)O)c(OC)cc1
NCGC00021202-03	S(=O)(=O)(/N=C(/N)\CCSCc1nc(/N=C(\N)/N)sc1)N		Inactive	Solute Carrier Family 22 Member 3 Inhibitor&Histamine H2 Receptor Antagonists		1	Famotidine	170464877	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-13.519467244	S(=O)(=O)(/N=C(/N)\CCSCc1nc(/N=C(\N)/N)sc1)N	S(=O)(=O)(/N=C(/N)\CCSCc1nc(/N=C(\N)/N)sc1)N
NCGC00507848-01	S(=O)(=O)(C(C)(C)C)c1cc2c(Nc3n[nH]c4c3cc(F)cc4)ccnc2cc1	4.4000001	Active	RIP2 kinase Inhibitor	0.0	1	GSK-583	384569329	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-68.1977234	S(=O)(=O)(C(C)(C)C)c1cc2c(Nc3n[nH]c4c3cc(F)cc4)ccnc2cc1	S(=O)(=O)(C(C)(C)C)c1cc2c(Nc3n[nH]c4c3cc(F)cc4)ccnc2cc1
NCGC00387463-02	S(=O)(=O)(C(C)C)c1c(Nc2c3c([nH]cc3)nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)c2)cccc1		Inactive	MPS1 Inhibitor		1	MPS1-IN-1	384569159	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.5666180559	S(=O)(=O)(C(C)C)c1c(Nc2c3c([nH]cc3)nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)c2)cccc1	S(=O)(=O)(C(C)C)c1c(Nc2c3c([nH]cc3)nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)c2)cccc1
NCGC00345791-06	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(N5CCN(C)CC5)CC4)cc3)ncn2)cccc1	4.4000001	Active	ALK Inhibitor	0.0	1	ASP-3026	384568744	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-52.706027944	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(N5CCN(C)CC5)CC4)cc3)ncn2)cccc1	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(N5CCN(C)CC5)CC4)cc3)ncn2)cccc1
NCGC00390417-03	S(=O)(=O)(C(C)C)c1cc2c(Nc3cc4ncsc4cc3)ccnc2cc1		Inactive	RIP3 kinase Inhibitor		1	GSK-872	363680893	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.769474464	S(=O)(=O)(C(C)C)c1cc2c(Nc3cc4ncsc4cc3)ccnc2cc1	S(=O)(=O)(C(C)C)c1cc2c(Nc3cc4ncsc4cc3)ccnc2cc1
NCGC00386313-08	S(=O)(=O)(C(C)C)c1ccc(-c2nc(c(N)nc2)-c2onc(-c3ccc(CNC)cc3)c2)cc1		Inactive	ATR Kinase Inhibitor		1	Berzosertib	384569124	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.875894796	S(=O)(=O)(C(C)C)c1ccc(-c2nc(c(N)nc2)-c2onc(-c3ccc(CNC)cc3)c2)cc1	S(=O)(=O)(C(C)C)c1ccc(-c2nc(c(N)nc2)-c2onc(-c3ccc(CNC)cc3)c2)cc1
NCGC00182044-02	S(=O)(=O)(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1	4.7249999	Active		0.0	1	Toltrazuril (sulfone)	405558806	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-99.8058547198&-101.7910641921	S(=O)(=O)(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1	S(=O)(=O)(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1
NCGC00167470-05	S(=O)(=O)(C)N1C(=O)N(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)CC1	4.4000001	Active	Bacterial Penicillin-binding Protein Inhibitor	0.0	1	Mezlocillin Sodium	405558684	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.4267756156	S(=O)(=O)(C)N1C(=O)N(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)CC1	S(=O)(=O)(C)N1C(=O)N(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)CC1
NCGC00346632-02	S(=O)(=O)(C)N1CCC(Nc2nc(N)c(C(=O)c3c(F)c(F)ccc3OC)cn2)CC1	3.8499999	Inactive	CDK1/2/4 Inhibitor	0.0	1	R-547	384568868	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	45.86929318	S(=O)(=O)(C)N1CCC(Nc2nc(N)c(C(=O)c3c(F)c(F)ccc3OC)cn2)CC1	S(=O)(=O)(C)N1CCC(Nc2nc(N)c(C(=O)c3c(F)c(F)ccc3OC)cn2)CC1
NCGC00507966-01	S(=O)(=O)(C)N1CCN(C(C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1	5.9499998	Active	PI3K alpha Inhibitor	0.0	1	AMG-511	384569359	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-55.2614543368	S(=O)(=O)(C)N1CCN(C(C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1	S(=O)(=O)(C)N1CCN(C(C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1
NCGC00402368-01	S(=O)(=O)(C)N1CCN([C@@H](C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1		Inactive	PI3Kalpha Inhibitor		1	AMG-511	384569217	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.841099874	S(=O)(=O)(C)N1CCN([C@@H](C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1	S(=O)(=O)(C)N1CCN([C@@H](C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1
NCGC00263115-03	S(=O)(=O)(C)N1c2c(C3(C1)CCN(C(=O)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1)CC3)cccc2	4.5	Active	Growth Hormone Secretagogue	0.0	1	Ibutamoren mesilate	384568599	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-48.4750703704	S(=O)(=O)(C)N1c2c(C3(C1)CCN(C(=O)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1)CC3)cccc2	S(=O)(=O)(C)N1c2c(C3(C1)CCN(C(=O)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1)CC3)cccc2
NCGC00356119-03	S(=O)(=O)(C)c1c(-c2c3n(c(C(=O)C)c2)C=CC(OCCC)=C3)cccc1		Inactive	BAZ2B Inhibitor		1	GSK-2801	384569028	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(C)c1c(-c2c3n(c(C(=O)C)c2)C=CC(OCCC)=C3)cccc1	S(=O)(=O)(C)c1c(-c2c3n(c(C(=O)C)c2)C=CC(OCCC)=C3)cccc1
NCGC00242056-04	S(=O)(=O)(C)c1c(COc2c(C#N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1	4.6500001	Active	IKK-epsilon Inhibitor	0.0	1	IKK-3 Inhibitor IX	384568484	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-61.9638258401	S(=O)(=O)(C)c1c(COc2c(C#N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1	S(=O)(=O)(C)c1c(COc2c(C#N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1
NCGC00351483-01	S(=O)(=O)(C)c1c(F)c(C)c(C(=O)N2Cc3c(OCC2)ccc(-c2cnc(N)cc2)c3)cc1	4.5500002	Active	mTORC1/2 Inhibitor	0.0	1	XL-388	384569010	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-34.548536144	S(=O)(=O)(C)c1c(F)c(C)c(C(=O)N2Cc3c(OCC2)ccc(-c2cnc(N)cc2)c3)cc1	S(=O)(=O)(C)c1c(F)c(C)c(C(=O)N2Cc3c(OCC2)ccc(-c2cnc(N)cc2)c3)cc1
NCGC00387306-01	S(=O)(=O)(C)c1c2[C@H](O)C(F)(F)Cc2c(Oc2cc(F)cc(C#N)c2)cc1		Inactive	HIF-2alpha Inhibitor		1	PT-2385	384569157	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(C)c1c2[C@H](O)C(F)(F)Cc2c(Oc2cc(F)cc(C#N)c2)cc1	S(=O)(=O)(C)c1c2[C@H](O)C(F)(F)Cc2c(Oc2cc(F)cc(C#N)c2)cc1
NCGC00015996-10	S(=O)(=O)(C)c1cc(C(=O)NCCN(CC)CC)c(OC)cc1		Inactive	Dopamine D3 Receptor Antagonist&Dopamine D3 receptor Antagonist		1	Tiapride hydrochloride	170465877	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(C)c1cc(C(=O)NCCN(CC)CC)c(OC)cc1.Cl	S(=O)(=O)(C)c1cc(C(=O)NCCN(CC)CC)c(OC)cc1.Cl
NCGC00263133-09	S(=O)(=O)(C)c1cc(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)CC4)cc3)n2)ccc1	5.0500002	Active	Focal Adhesion Kinase (FAK) Inhibitor	0.0	1	PF-573228	363677220	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-74.3648145208	S(=O)(=O)(C)c1cc(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)CC4)cc3)n2)ccc1	S(=O)(=O)(C)c1cc(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)CC4)cc3)n2)ccc1
NCGC00488781-01	S(=O)(=O)(C)c1cc(OC)c(Nc2nn3c(n2)C=CC(c2ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc2)=C3)cc1	5.0999999	Active	MPS1 Inhibitor	0.0	1	BAY-1161909	363681475	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-65.75056666	S(=O)(=O)(C)c1cc(OC)c(Nc2nn3c(n2)C=CC(c2ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc2)=C3)cc1	S(=O)(=O)(C)c1cc(OC)c(Nc2nn3c(n2)C=CC(c2ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc2)=C3)cc1
NCGC00371131-09	S(=O)(=O)(C)c1ccc(-c2c(C)cc(OCc3n(c(SC4CCCC4)nn3)-c3cnccc3)cc2)cc1		Inactive	p97 ATPase Inhibitor		1	NMS-873	363678047	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.5772247353	S(=O)(=O)(C)c1ccc(-c2c(C)cc(OCc3n(c(SC4CCCC4)nn3)-c3cnccc3)cc2)cc1	S(=O)(=O)(C)c1ccc(-c2c(C)cc(OCc3n(c(SC4CCCC4)nn3)-c3cnccc3)cc2)cc1
NCGC00346637-05	S(=O)(=O)(C)c1ccc(-c2ccc([C@H](N[C@H](C(=O)NC3(C#N)CC3)CC(F)(C)C)C(F)(F)F)cc2)cc1	4.4499998	Active	Cathepsin K Inhibitor	0.0	1	Odanacatib	384568871	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-51.8590109025	S(=O)(=O)(C)c1ccc(-c2ccc([C@H](N[C@H](C(=O)NC3(C#N)CC3)CC(F)(C)C)C(F)(F)F)cc2)cc1	S(=O)(=O)(C)c1ccc(-c2ccc([C@H](N[C@H](C(=O)NC3(C#N)CC3)CC(F)(C)C)C(F)(F)F)cc2)cc1
NCGC00346444-07	S(=O)(=O)(C)c1ccc(-c2nc(C(=O)Nc3ccccc3)c(N)nc2)cc1		Inactive	ATR Kinase Inhibitor		1	VE-821	363677406	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(C)c1ccc(-c2nc(C(=O)Nc3ccccc3)c(N)nc2)cc1	S(=O)(=O)(C)c1ccc(-c2nc(C(=O)Nc3ccccc3)c(N)nc2)cc1
NCGC00346568-05	S(=O)(=O)(C)c1ccc(-c2ncc(OCC3CCN(c4onc(C(C)C)n4)CC3)cc2)cc1	4.4499998	Active	Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonist	0.0	1	GSK-1292263A	363677455	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-79.414579808	S(=O)(=O)(C)c1ccc(-c2ncc(OCC3CCN(c4onc(C(C)C)n4)CC3)cc2)cc1	S(=O)(=O)(C)c1ccc(-c2ncc(OCC3CCN(c4onc(C(C)C)n4)CC3)cc2)cc1
NCGC00389572-01	S(=O)(=O)(C)c1ccc(C2=C(OCC3CC3)C(=O)OC2(C)C)cc1	4.9250002	Active	Cyclooxygenase-2 Inhibitor	0.0	1	FIROCOXIB	405558697	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-45.3955429884&-45.039597937	S(=O)(=O)(C)c1ccc(C2=C(OCC3CC3)C(=O)OC2(C)C)cc1	S(=O)(=O)(C)c1ccc(C2=C(OCC3CC3)C(=O)OC2(C)C)cc1
NCGC00507938-02	S(=O)(=O)(C)c1ccc(C=2c3n(C(NCc4occc4)=NC=2)cnn3)cc1	5.9499998	Inactive	Polycomb protein EED (PRC2/EED-EZH2 non-catalytic subunit) Inhibitor	0.0	1	EED-226	384569357	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-43.6110163237	S(=O)(=O)(C)c1ccc(C=2c3n(C(NCc4occc4)=NC=2)cnn3)cc1	S(=O)(=O)(C)c1ccc(C=2c3n(C(NCc4occc4)=NC=2)cnn3)cc1
NCGC00345854-05	S(=O)(=O)(C)c1ccc(C=2c3n(nc(Nc4cc(N5CCN(C)CC5)ccc4)n3)C=CC=2)cc1	4.4000001	Active	Jak2 Inhibitor	0.0	1	CEP-33779	384568769	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-59.3526255999	S(=O)(=O)(C)c1ccc(C=2c3n(nc(Nc4cc(N5CCN(C)CC5)ccc4)n3)C=CC=2)cc1	S(=O)(=O)(C)c1ccc(C=2c3n(nc(Nc4cc(N5CCN(C)CC5)ccc4)n3)C=CC=2)cc1
NCGC00346617-03	S(=O)(=O)(C)c1ccc(Nc2nc(-c3n(C(C)C)c(C)nc3)ccn2)cc1	6.0999999	Inactive	CDK1/2 Inhibitor	0.0	1	AZD-5438	384568860	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-37.9433980269	S(=O)(=O)(C)c1ccc(Nc2nc(-c3n(C(C)C)c(C)nc3)ccn2)cc1	S(=O)(=O)(C)c1ccc(Nc2nc(-c3n(C(C)C)c(C)nc3)ccn2)cc1
NCGC00378564-01	S(=O)(=O)(C)c1ccc([C@H](C(=O)Nc2sccn2)CC2CCCC2)cc1	4.4000001	Active	Glucokinase Activator	0.0	1	Ro-28-1675	384569049	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-71.4632577479	S(=O)(=O)(C)c1ccc([C@H](C(=O)Nc2sccn2)CC2CCCC2)cc1	S(=O)(=O)(C)c1ccc([C@H](C(=O)Nc2sccn2)CC2CCCC2)cc1
NCGC00378593-02	S(=O)(=O)(C)c1cnc(CNC(=O)C=2C(=O)N(c3cc(C(F)(F)F)ccc3)C(C)=C(c3n(C)ncc3)C=2)cc1		Inactive	Leukocyte elastase Inhibitor		1	AZD9668	384569052	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(C)c1cnc(CNC(=O)C=2C(=O)N(c3cc(C(F)(F)F)ccc3)C(C)=C(c3n(C)ncc3)C=2)cc1	S(=O)(=O)(C)c1cnc(CNC(=O)C=2C(=O)N(c3cc(C(F)(F)F)ccc3)C(C)=C(c3n(C)ncc3)C=2)cc1
NCGC00480770-01	S(=O)(=O)(C)n1nc2c(c1)CN([C@@H]1C[C@H](N)[C@@H](c3c(F)ccc(F)c3)OC1)C2		Inactive	Dipeptidyl Peptidase Iv Inhibitor&Dipeptidyl peptidase IV Inhibitor		1	MK-3102	405558938	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.911546772&-27.41863636	S(=O)(=O)(C)n1nc2c(c1)CN([C@@H]1C[C@H](N)[C@@H](c3c(F)ccc(F)c3)OC1)C2	S(=O)(=O)(C)n1nc2c(c1)CN([C@@H]1C[C@H](N)[C@@H](c3c(F)ccc(F)c3)OC1)C2
NCGC00475744-02	S(=O)(=O)(C1(c2nc(-c3ccc(NC(=S)NCCO)cc3)nc(N3[C@@H](C)COCC3)c2)CC1)C1CC1	4.3000002	Inactive	mTORC1/2 Inhibitor	0.0	1	AZD-3147	377020261	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-25.3083447089	S(=O)(=O)(C1(c2nc(-c3ccc(NC(=S)NCCO)cc3)nc(N3[C@@H](C)COCC3)c2)CC1)C1CC1	S(=O)(=O)(C1(c2nc(-c3ccc(NC(=S)NCCO)cc3)nc(N3[C@@H](C)COCC3)c2)CC1)C1CC1
NCGC00389674-01	S(=O)(=O)(CC(N1C(=O)c2c(NC(=O)C)cccc2C1=O)c1cc(OCC)c(OC)cc1)C	5.0	Active	Phosphodiesterase 4 Inhibitor	0.0	1	Apremilast (CC-10004)	405558478	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-26.685332798	S(=O)(=O)(CC(N1C(=O)c2c(NC(=O)C)cccc2C1=O)c1cc(OCC)c(OC)cc1)C	S(=O)(=O)(CC(N1C(=O)c2c(NC(=O)C)cccc2C1=O)c1cc(OCC)c(OC)cc1)C
NCGC00167977-09	S(=O)(=O)(CC(O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1		Inactive	Androgen Receptor Antagonist		1	Bicalutamide	363676674	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(CC(O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1	S(=O)(=O)(CC(O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1
NCGC00345839-10	S(=O)(=O)(CC)N1CC(CC#N)(n2ncc(-c3ncnc4[nH]ccc34)c2)C1	4.9499998	Active	Jak2 Inhibitor	0.0	1	Baricitinib	384568762	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-36.8386252243	S(=O)(=O)(CC)N1CC(CC#N)(n2ncc(-c3ncnc4[nH]ccc34)c2)C1	S(=O)(=O)(CC)N1CC(CC#N)(n2ncc(-c3ncnc4[nH]ccc34)c2)C1
NCGC00390588-01	S(=O)(=O)(CC)N1CCC(C(C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1		Inactive			1	CPI-169 racemate	384569199	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.3281851279	S(=O)(=O)(CC)N1CCC(C(C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1	S(=O)(=O)(CC)N1CCC(C(C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1
NCGC00481546-01	S(=O)(=O)(CC)N1CCC([C@@H](C)n2c(C)c(/C(/O)=N/Cc3c(O)nc(C)cc3OC)c3c2cccc3)CC1		Inactive	EZH2 Inhibitor		1	CPI-169 racemate	384569255	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(CC)N1CCC([C@@H](C)n2c(C)c(/C(/O)=N/Cc3c(O)nc(C)cc3OC)c3c2cccc3)CC1	S(=O)(=O)(CC)N1CCC([C@@H](C)n2c(C)c(/C(/O)=N/Cc3c(O)nc(C)cc3OC)c3c2cccc3)CC1
NCGC00386415-05	S(=O)(=O)(CC)N1CCN(c2ccc(Nc3nc(NC4CC4)c(C(=O)N)cn3)cc2)CC1	4.5999999	Active	TYK2 Inhibitor	0.0	1	Cerdulatinib	384569133	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-123.0407707367	S(=O)(=O)(CC)N1CCN(c2ccc(Nc3nc(NC4CC4)c(C(=O)N)cn3)cc2)CC1	S(=O)(=O)(CC)N1CCN(c2ccc(Nc3nc(NC4CC4)c(C(=O)N)cn3)cc2)CC1
NCGC00092310-06&NCGC00092310-14	S(=O)(=O)(CC)c1c(N)cc(OC)c(C(=O)NCC2N(CC)CCC2)c1		Inactive	Dopamine D2/d3 Antagonist&Dopamine D2/D3 Antagonist&Dopamine D2/D3 Antagonist		2	Amisulpride	170466480&384568104	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-15.5599244759&0.0	S(=O)(=O)(CC)c1c(N)cc(OC)c(C(=O)NCC2N(CC)CCC2)c1	S(=O)(=O)(CC)c1c(N)cc(OC)c(C(=O)NCC2N(CC)CCC2)c1
NCGC00184999-01	S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CC)CCC2)c(OC)cc1	5.0	Active	Dopamine D3 receptor Antagonist	0.0	1	Sultopride hydrochloride	144207174	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-41.101966888	S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CC)CCC2)c(OC)cc1.Cl	S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CC)CCC2)c(OC)cc1.Cl
NCGC00508865-03	S(=O)(=O)(CC)c1cc2nc(-c3cc4c(cc3)cccc4)oc2cc1		Inactive	enhances expression of utrophin		1	Ezutromid	384569366	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(CC)c1cc2nc(-c3cc4c(cc3)cccc4)oc2cc1	S(=O)(=O)(CC)c1cc2nc(-c3cc4c(cc3)cccc4)oc2cc1
NCGC00346932-04	S(=O)(=O)(CC1SC1)c1ccc(Oc2ccccc2)cc1		Inactive	MMP2/9 Inhibitor		1	SB-3CT	384568968	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(CC1SC1)c1ccc(Oc2ccccc2)cc1	S(=O)(=O)(CC1SC1)c1ccc(Oc2ccccc2)cc1
NCGC00481107-02	S(=O)(=O)(CCC)c1nc(NC2CC2)cc(-c2cc3c(n(C4CC(C)(C)NC(C)(C)C4)cc3)cc2)n1	5.3000002	Active	CECR2 Inhibitor	0.0	1	NVS-CECR2-1	384569252	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-93.0402941861	S(=O)(=O)(CCC)c1nc(NC2CC2)cc(-c2cc3c(n(C4CC(C)(C)NC(C)(C)C4)cc3)cc2)n1	S(=O)(=O)(CCC)c1nc(NC2CC2)cc(-c2cc3c(n(C4CC(C)(C)NC(C)(C)C4)cc3)cc2)n1
NCGC00346669-05	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2cc3OC[C@@H](CC(=O)O)c3cc2)ccc1)C	4.4000001	Active	Insulin Secretagogues	0.0	1	TAK-875	384568895	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-94.9223607439	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2cc3OC[C@@H](CC(=O)O)c3cc2)ccc1)C	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2cc3OC[C@@H](CC(=O)O)c3cc2)ccc1)C
NCGC00508820-02	S(=O)(=O)(CCN(CC)CC)[C@H]1[C@@H]2C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(/C)=C/[C@@H](O)CC(=O)Cc3occ(C(=O)N2CC1)n3	5.8000002	Active	Bacterial 70s Ribosome Inhibitor	0.0	1	Dalfopristin	405559042	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-44.9440121603	S(=O)(=O)(CCN(CC)CC)[C@H]1[C@@H]2C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(/C)=C/[C@@H](O)CC(=O)Cc3occ(C(=O)N2CC1)n3	S(=O)(=O)(CCN(CC)CC)[C@H]1[C@@H]2C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(/C)=C/[C@@H](O)CC(=O)Cc3occ(C(=O)N2CC1)n3
NCGC00346672-02	S(=O)(=O)(CCNCc1oc(-c2cc3c(Nc4cc(C)c(OC5=Cc6n(ncn6)C=C5)cc4)ncnc3cc2)cc1)C		Inactive	HER2 Inhibitor		1	ARRY-380	384568898	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.3260107	S(=O)(=O)(CCNCc1oc(-c2cc3c(Nc4cc(C)c(OC5=Cc6n(ncn6)C=C5)cc4)ncnc3cc2)cc1)C	S(=O)(=O)(CCNCc1oc(-c2cc3c(Nc4cc(C)c(OC5=Cc6n(ncn6)C=C5)cc4)ncnc3cc2)cc1)C
NCGC00016741-09	S(=O)(=O)(CCn1c(C)ncc1[N+](=O)[O-])CC	5.4000001	Active		0.0	1	Tinidazole	170465196	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.6218206532	S(=O)(=O)(CCn1c(C)ncc1[N+](=O)[O-])CC	S(=O)(=O)(CCn1c(C)ncc1[N+](=O)[O-])CC
NCGC00485951-02	S(=O)(=O)(C[C@H](N[C@H](C(F)(F)F)c1ccc(F)cc1)C(=O)N[C@H](C(=O)C(=O)NC1CC1)CC)CC1CC1	5.5500002	Active	Cathepsin S Inhibitor	0.0	1	VBY-825	384569279	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-90.7186276111	S(=O)(=O)(C[C@H](N[C@H](C(F)(F)F)c1ccc(F)cc1)C(=O)N[C@H](C(=O)C(=O)NC1CC1)CC)CC1CC1	S(=O)(=O)(C[C@H](N[C@H](C(F)(F)F)c1ccc(F)cc1)C(=O)N[C@H](C(=O)C(=O)NC1CC1)CC)CC1CC1
NCGC00167487-15	S(=O)(=O)(C[C@](O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1		Inactive	Androgen Receptor Antagonist		1	BICALUTAMIDE	405558511	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	30.988504319&0.0	S(=O)(=O)(C[C@](O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1	S(=O)(=O)(C[C@](O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1
NCGC00351609-09	S(=O)(=O)(Cc1c(C)oc(-c2ccc(C(=O)NCc3cnccc3)cc2)n1)c1ccc(C)cc1	5.4499998	Inactive	Solute Carrier Family 2, Facilitated Glucose Transporter Member 1 (GLUT-1; SLC2A1) Inhibitor	0.0	1	STF-118804	363677780	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-4.2792289321	S(=O)(=O)(Cc1c(C)oc(-c2ccc(C(=O)NCc3cnccc3)cc2)n1)c1ccc(C)cc1	S(=O)(=O)(Cc1c(C)oc(-c2ccc(C(=O)NCc3cnccc3)cc2)n1)c1ccc(C)cc1
NCGC00346972-08	S(=O)(=O)(Cc1cc(OCc2ccc(CN3[C@@H](CO)CCC3)cc2)cc(C)c1)c1ccccc1	4.9000001	Active	Sphingosine Kinase 1 (SphK1) Inhibitor	0.0	1	PF-543	384568978	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-64.9494550397	S(=O)(=O)(Cc1cc(OCc2ccc(CN3[C@@H](CO)CCC3)cc2)cc(C)c1)c1ccccc1	S(=O)(=O)(Cc1cc(OCc2ccc(CN3[C@@H](CO)CCC3)cc2)cc(C)c1)c1ccccc1
NCGC00095135-05&NCGC00095135-12	S(=O)(=O)(Cc1cc2c(CCN(C)C)c[nH]c2cc1)N1CCCC1		Inactive	5-HT1B Agonist&5-ht1b Receptor Agonist&5-HT1B Agonist		2	Almotriptan	170465288&384568150	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-16.613796708&0.0	S(=O)(=O)(Cc1cc2c(CCN(C)C)c[nH]c2cc1)N1CCCC1	S(=O)(=O)(Cc1cc2c(CCN(C)C)c[nH]c2cc1)N1CCCC1
NCGC00249884-01	S(=O)(=O)(N(C(=O)C)c1c(C)c(C)no1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor&Bacterial Dihydropteroate Synthase Inhibitor		1	Sulfisoxazole acetal	170465159	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.8081103999&0.0	S(=O)(=O)(N(C(=O)C)c1c(C)c(C)no1)c1ccc(N)cc1	S(=O)(=O)(N(C(=O)C)c1c(C)c(C)no1)c1ccc(N)cc1
NCGC00387725-02	S(=O)(=O)(N(C)C)N1CCN(c2ccc(OCc3n(C)nc(C)c3-c3c4n(CCN5CCOCC5)c(C(=O)O)c(CCCOc5c6c(ccc5)cccc6)c4ccc3)cc2)CC1		Inactive	Mcl-1 Inhibitor		1	A-1210477	363680650	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(N(C)C)N1CCN(c2ccc(OCc3n(C)nc(C)c3-c3c4n(CCN5CCOCC5)c(C(=O)O)c(CCCOc5c6c(ccc5)cccc6)c4ccc3)cc2)CC1	S(=O)(=O)(N(C)C)N1CCN(c2ccc(OCc3n(C)nc(C)c3-c3c4n(CCN5CCOCC5)c(C(=O)O)c(CCCOc5c6c(ccc5)cccc6)c4ccc3)cc2)CC1
NCGC00015998-06	S(=O)(=O)(N(C)C)c1cc2/C(=C/CCN3CCN(C)CC3)/c3c(Sc2cc1)cccc3	4.9250002	Active	Dopamine Secretion Inhibitor&dopamine secretion Inhibitor	0.0	1	THIOTHIXENE	405558925	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.3&-2.3	-46.7152463705&-100.8089320676	S(=O)(=O)(N(C)C)c1cc2/C(=C/CCN3CCN(C)CC3)/c3c(Sc2cc1)cccc3	S(=O)(=O)(N(C)C)c1cc2/C(=C/CCN3CCN(C)CC3)/c3c(Sc2cc1)cccc3
NCGC00346933-01	S(=O)(=O)(N(C)C)c1cc2C(=Cc3[nH]c4c(c3)CCCC4)C(=O)Nc2cc1	4.5500002	Active	Lyn Kinase Inhibitor	0.0	1	SU-6656	174006696	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-54.4540582952	S(=O)(=O)(N(C)C)c1cc2C(=Cc3[nH]c4c(c3)CCCC4)C(=O)Nc2cc1	S(=O)(=O)(N(C)C)c1cc2C(=Cc3[nH]c4c(c3)CCCC4)C(=O)Nc2cc1
NCGC00249414-01	S(=O)(=O)(N(C)C)c1cc2N(CC(N(C)C)C)c3c(Sc2cc1)cccc3	4.375	Active	Serotonin (5-HT) receptor Antagonist&Serotonin (5-ht) Receptor Antagonist	0.0	1	Fonazine	144206752	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-77.427481276&-89.4533745939	S(=O)(=O)(N(C)C)c1cc2N(CC(N(C)C)C)c3c(Sc2cc1)cccc3	S(=O)(=O)(N(C)C)c1cc2N(CC(N(C)C)C)c3c(Sc2cc1)cccc3
NCGC00182048-01	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCC(CCOC(=O)CCCCCCCCCCCCCCC)CC3)c3c(Sc2cc1)cccc3		Inactive	Dopamine D2 Receptor Antagonist&Dopamine D2 receptor Antagonist		1	Pipothiazine palmitate	144206970	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.088044188&-15.8660429759	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCC(CCOC(=O)CCCCCCCCCCCCCCC)CC3)c3c(Sc2cc1)cccc3	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCC(CCOC(=O)CCCCCCCCCCCCCCC)CC3)c3c(Sc2cc1)cccc3
NCGC00179625-03	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	4.5	Active	Serotonin 2a (5-HT2a) receptor Antagonist&Serotonin 2a (5-ht2a) Receptor Antagonist	0.0	1	Thioproperazine dimethanesulfonate	170465871	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-97.8016226367&-111.9711336081	S(=O)(=O)(O)C.S(=O)(=O)(O)C.S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	S(=O)(=O)(O)C.S(=O)(=O)(O)C.S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3
NCGC00160631-02	S(=O)(=O)(N(C)C)c1ccc(OP(=S)(OC)OC)cc1		Inactive	Trichostrongylus Axei Inhibitor&Trichostrongylus axei Inhibitor		1	Famphur	170466840	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.798257972&0.0	S(=O)(=O)(N(C)C)c1ccc(OP(=S)(OC)OC)cc1	S(=O)(=O)(N(C)C)c1ccc(OP(=S)(OC)OC)cc1
NCGC00263883-04	S(=O)(=O)(N(C)c1nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)n1)C	5.8000002	Active	Hmg-coa Reductase Inhibitor	0.0	1	NCGC00263883-04	405559105	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-74.1790834066	S(=O)(=O)(N(C)c1nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(-c2ccc(F)cc2)n1)C	S(=O)(=O)(N(C)c1nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(-c2ccc(F)cc2)n1)C
NCGC00345808-01	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1cc(O)c(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F		Inactive	STAT-3 Inhibitor		1	BP-1-102	174006728	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.14495136	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1cc(O)c(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1cc(O)c(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F
NCGC00508861-01	S(=O)(=O)(N(CC(C)C)c1ccc(CC)cc1)c1cc(CO)c(OCC2CCOCC2)cc1	4.3000002	Inactive	ROR-gamma Inverse Agonist	0.0	1	GSK-2981278	384569365	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-27.2826664383	S(=O)(=O)(N(CC(C)C)c1ccc(CC)cc1)c1cc(CO)c(OCC2CCOCC2)cc1	S(=O)(=O)(N(CC(C)C)c1ccc(CC)cc1)c1cc(CO)c(OCC2CCOCC2)cc1
NCGC00079434-04	S(=O)(=O)(N(CC(O)Cn1c2c(c3c1cccc3)cccc2)Cc1occc1)C	5.4499998	Inactive	Cryptochrome Activator	0.0	1	KL001	384568075	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	54.6230111902	S(=O)(=O)(N(CC(O)Cn1c2c(c3c1cccc3)cccc2)Cc1occc1)C	S(=O)(=O)(N(CC(O)Cn1c2c(c3c1cccc3)cccc2)Cc1occc1)C
NCGC00507860-01	S(=O)(=O)(N(CC)C)Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1	4.4499998	Active	Raf kinase B Inhibitor	0.0	1	PLX-7904	384569336	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-95.0561681645	S(=O)(=O)(N(CC)C)Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1	S(=O)(=O)(N(CC)C)Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1
NCGC00522534-01	S(=O)(=O)(N(CC)CC)N[C@@H]1CN(CCC)[C@H]2[C@H](C1)Cc1c(O)cccc1C2	4.4000001	Active		0.0	1	Quinagolide (hydrochloride)	405558466	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-47.884329936&-60.9527048999	S(=O)(=O)(N(CC)CC)N[C@@H]1CN(CCC)[C@H]2[C@H](C1)Cc1c(O)cccc1C2	S(=O)(=O)(N(CC)CC)N[C@@H]1CN(CCC)[C@H]2[C@H](C1)Cc1c(O)cccc1C2
NCGC00016251-13	S(=O)(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1		Inactive	Solute Carrier Family 22 Member 8 Inhibitor&Solute carrier family 22 member 8 Inhibitor		1	Probenecid	170464839	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.1698589961&0.0	S(=O)(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1	S(=O)(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1
NCGC00346463-01	S(=O)(=O)(N(CCO)c1c(C2CC2)cc2c(C(=O)NC)c(-c3ccc(F)cc3)oc2c1)C	4.4499998	Inactive	RNA-Directed RNA Polymerase Inhibitor	0.0	1	Nesbuvir	174007343	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	101.3289676609	S(=O)(=O)(N(CCO)c1c(C2CC2)cc2c(C(=O)NC)c(-c3ccc(F)cc3)oc2c1)C	S(=O)(=O)(N(CCO)c1c(C2CC2)cc2c(C(=O)NC)c(-c3ccc(F)cc3)oc2c1)C
NCGC00159461-07	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	4.4000001	Active	HIV Protease Inhibitors	0.0	1	Amprenavir	405558958	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-57.1608927119	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1
NCGC00388284-07	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@H]2[C@@H](OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1		Inactive	Hiv Protease Inhibitors		1	Darunavir (Ethanolate)	405558659	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	17.3949319159&16.872971572	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@H]2[C@@H](OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@H]2[C@@H](OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1
NCGC00378944-02	S(=O)(=O)(N(C[C@@H](OP(=O)([O-])[O-])[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	4.5500002	Active	Human Immunodeficiency Virus Type 1 Protease Inhibitor	0.0	1	NCGC00378944-02	405558979	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-85.5763845884	S(=O)(=O)(N(C[C@@H](OP(=O)([O-])[O-])[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	S(=O)(=O)(N(C[C@@H](OP(=O)([O-])[O-])[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1
NCGC00346695-02	S(=O)(=O)(N(C[C@H]1OCCOC1)C)Nc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1	4.4499998	Active	VEGFR-1 (Flt-1) Inhibitors	0.0	1	MK-2461	363677522	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-59.0134130275	S(=O)(=O)(N(C[C@H]1OCCOC1)C)Nc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1	S(=O)(=O)(N(C[C@H]1OCCOC1)C)Nc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1
NCGC00016508-04	S(=O)(=O)(N)C=1S/C(=N/C(=O)C)/N(C)N=1		Inactive	Carbonic Anhydrase Xii Inhibitor&Carbonic anhydrase XII Inhibitor		1	Methazolamide	405558554	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.7251343559&-23.183384796	S(=O)(=O)(N)C=1S/C(=N/C(=O)C)/N(C)N=1	S(=O)(=O)(N)C=1S/C(=N/C(=O)C)/N(C)N=1
NCGC00159319-04	S(=O)(=O)(N)Cc1noc2c1cccc2		Inactive	Sodium Channel Alpha Subunit Inhibitor&Na channel blocker, T-type Ca channel blocker		1	Zonisamide	174006630	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.284198416&0.0	S(=O)(=O)(N)Cc1noc2c1cccc2	S(=O)(=O)(N)Cc1noc2c1cccc2
NCGC00183012-01	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(CCCCC)NS(=O)(=O)c2c1		Inactive	Thiazide-sensitive Sodium-chloride Cotransporter Inhibitor&Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Penflutizide	144206843	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.414348252&0.0	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(CCCCC)NS(=O)(=O)c2c1	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(CCCCC)NS(=O)(=O)c2c1
NCGC00018194-08	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(Cc3ccccc3)NS(=O)(=O)c2c1		Inactive	Thiazide-sensitive Sodium-chloride Cotransporter Inhibitor&Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Bendroflumethiazide	170465156	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(Cc3ccccc3)NS(=O)(=O)c2c1	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(Cc3ccccc3)NS(=O)(=O)c2c1
NCGC00016401-09	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NCNS(=O)(=O)c2c1	6.1500001	Active	Thiazide-sensitive Sodium-chloride Cotransporter Inhibitor	0.0	1	Hydroflumethiazide	170465082	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-34.5952870269	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NCNS(=O)(=O)c2c1	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NCNS(=O)(=O)c2c1
NCGC00016561-05	S(=O)(=O)(N)c1c(C)cc2c(S(=O)(=O)CCC2)c1		Inactive	Translocator Protein Inhibitor&Translocator protein Inhibitor		1	Meticrane	170465801	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.470015504&0.0	S(=O)(=O)(N)c1c(C)cc2c(S(=O)(=O)CCC2)c1	S(=O)(=O)(N)c1c(C)cc2c(S(=O)(=O)CCC2)c1
NCGC00188865-03&NCGC00188865-05	S(=O)(=O)(N)c1c(C)ccc(Nc2nc(N(C)c3cc4nn(C)c(C)c4cc3)ccn2)c1	4.7125001	Active	Multi-kinase&VEGFR-1/2/3 Inhibitor&VEGFR-1/2/3 Inhibitor	0.5749997999999996	2	Pazopanib	170465625&384568453	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4&-1.2	-73.8270456368&-59.4926268684&-39.3055041903	S(=O)(=O)(N)c1c(C)ccc(Nc2nc(N(C)c3cc4nn(C)c(C)c4cc3)ccn2)c1	S(=O)(=O)(N)c1c(C)ccc(Nc2nc(N(C)c3cc4nn(C)c(C)c4cc3)ccn2)c1
NCGC00249925-01	S(=O)(=O)(N)c1c(F)cc(-c2c(C3CCCCC3)nc(C)o2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Tilmacoxib	170466033	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-13.735946012&0.0	S(=O)(=O)(N)c1c(F)cc(-c2c(C3CCCCC3)nc(C)o2)cc1	S(=O)(=O)(N)c1c(F)cc(-c2c(C3CCCCC3)nc(C)o2)cc1
NCGC00167442-03	S(=O)(=O)(N)c1c(OC)ccc(C[C@H](NCCOc2c(OCC)cccc2)C)c1	5.9000001	Active	Adrenergic Receptor Alpha-1 Antagonist	0.0	1	Tamsulosin hydrochloride	170464826	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-38.8169423259	S(=O)(=O)(N)c1c(OC)ccc(C[C@H](NCCOc2c(OCC)cccc2)C)c1.Cl	S(=O)(=O)(N)c1c(OC)ccc(C[C@H](NCCOc2c(OCC)cccc2)C)c1.Cl
NCGC00016878-04	S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(C(=O)O)c1		Inactive	Cystic Fibrosis Transmembrane Conductance Regulator Antagonist&Cystic fibrosis transmembrane conductance regulator Antagonist		1	Piretanide	170465869	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.948084724&0.0	S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(C(=O)O)c1	S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(C(=O)O)c1
NCGC00015149-16&NCGC00015149-25	S(=O)(=O)(N)c1c(Oc2ccccc2)c(NCCCC)cc(C(=O)O)c1		Inactive	Loop Diuretics		2	Bumetanide	170464735&384567815	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-33.450335864&0.0&-19.1395464159	S(=O)(=O)(N)c1c(Oc2ccccc2)c(NCCCC)cc(C(=O)O)c1	S(=O)(=O)(N)c1c(Oc2ccccc2)c(NCCCC)cc(C(=O)O)c1
NCGC00345811-02	S(=O)(=O)(N)c1c2C(=O)c3c(c(O)ccc3)C(=O)c2ccc1	4.4000001	Active	STAT-3 Inhibitor	0.0	1	LLL-12	384568755	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-113.431544143	S(=O)(=O)(N)c1c2C(=O)c3c(c(O)ccc3)C(=O)c2ccc1	S(=O)(=O)(N)c1c2C(=O)c3c(c(O)ccc3)C(=O)c2ccc1
NCGC00015966-10	S(=O)(=O)(N)c1cc(C(=O)NC[C@H]2N(CC)CCC2)c(OC)cc1		Inactive	Dopamine D2 Antagonist		1	Levosulpiride	170465834	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.4373744039&9.4354990079	S(=O)(=O)(N)c1cc(C(=O)NC[C@H]2N(CC)CCC2)c(OC)cc1	S(=O)(=O)(N)c1cc(C(=O)NC[C@H]2N(CC)CCC2)c(OC)cc1
NCGC00402377-02	S(=O)(=O)(N)c1cc(c(O)cc1)-c1c(O)c(-c2[nH]c3c(n2)cc(C(=N)N)cc3)cc(CC(=O)N[C@H](C(=O)O)CC(=O)O)c1		Inactive	Coagulation Factor VIIa Inhibitor		1	PCI-27483	384569219	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(N)c1cc(c(O)cc1)-c1c(O)c(-c2[nH]c3c(n2)cc(C(=N)N)cc3)cc(CC(=O)N[C@H](C(=O)O)CC(=O)O)c1	S(=O)(=O)(N)c1cc(c(O)cc1)-c1c(O)c(-c2[nH]c3c(n2)cc(C(=N)N)cc3)cc(CC(=O)N[C@H](C(=O)O)CC(=O)O)c1
NCGC00095129-06&NCGC00095129-15	S(=O)(=O)(N)c1ccc(-c2c(C)onc2-c2ccccc2)cc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Cyclooxygenase-2 Inhibitor&Cyclooxygenase-2 Inhibitor		2	Valdecoxib	170465163&384568148	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-24.2969508759&-30.29050834&-16.405735676	S(=O)(=O)(N)c1ccc(-c2c(C)onc2-c2ccccc2)cc1	S(=O)(=O)(N)c1ccc(-c2c(C)onc2-c2ccccc2)cc1
NCGC00095312-04	S(=O)(=O)(N)c1ccc(-n2c(-c3cc(F)c(OC)cc3)cc(C(F)F)n2)cc1		Inactive	Prostaglandin G/h Synthase 2 Inhibitor&Prostaglandin G/H synthase 2 Inhibitor		1	Deracoxib	170465679	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	5.2895611119&0.0	S(=O)(=O)(N)c1ccc(-n2c(-c3cc(F)c(OC)cc3)cc(C(F)F)n2)cc1	S(=O)(=O)(N)c1ccc(-n2c(-c3cc(F)c(OC)cc3)cc(C(F)F)n2)cc1
NCGC00510931-01	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1	4.4000001	Active	Cyclooxygenase-2 Inhibitor	0.0	1	Mavacoxib	405558811	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-44.868917452	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1
NCGC00016403-06	S(=O)(=O)(N)c1ccc(CN)cc1	4.4000001	Active	Carbonic Anhydrase Ii Inhibitor	0.0	1	Mafenide hydrochloride	170465055	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.2848536399	S(=O)(=O)(N)c1ccc(CN)cc1.Cl	S(=O)(=O)(N)c1ccc(CN)cc1.Cl
NCGC00372530-03	S(=O)(=O)(N)c1ccc(Cc2c(CC3CC3)n(-c3scc(C(=O)O)n3)nc2-c2cc(-c3ccccc3)ccc2)cc1	4.9000001	Inactive	LDHA Inhibitor	0.0	1	NCGC00372530	384569044	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	13.34745512	S(=O)(=O)(N)c1ccc(Cc2c(CC3CC3)n(-c3scc(C(=O)O)n3)nc2-c2cc(-c3ccccc3)ccc2)cc1	S(=O)(=O)(N)c1ccc(Cc2c(CC3CC3)n(-c3scc(C(=O)O)n3)nc2-c2cc(-c3ccccc3)ccc2)cc1
NCGC00016285-05&NCGC00016285-09	S(=O)(=O)(N)c1ccc(N)cc1		Inactive	Carbonic Anhydrase Type I/II/IX Inhibitor&Carbonic Anhydrase Type I/ii/ix Inhibitor&Carbonic Anhydrase Type I/II/IX Inhibitor		2	Sulfanilamide	170464653&384567929	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&16.6568701399	S(=O)(=O)(N)c1ccc(N)cc1	S(=O)(=O)(N)c1ccc(N)cc1
NCGC00263209-09	S(=O)(=O)(N)c1ccc(N2C(c3ccc(OC)cc3)CC(c3ccccc3)=N2)cc1		Inactive	Cdc42 GTPase Inhibitor		1	ML-141	363677266	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.224208504	S(=O)(=O)(N)c1ccc(N2C(c3ccc(OC)cc3)CC(c3ccccc3)=N2)cc1	S(=O)(=O)(N)c1ccc(N2C(c3ccc(OC)cc3)CC(c3ccccc3)=N2)cc1
NCGC00249907-01	S(=O)(=O)(N)c1ccc(N2S(=O)(=O)CCCC2)cc1		Inactive	Carbonic Anhydrase Xii Inhibitor&Carbonic anhydrase XII Inhibitor		1	Sulthiame	170465788	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1ccc(N2S(=O)(=O)CCCC2)cc1	S(=O)(=O)(N)c1ccc(N2S(=O)(=O)CCCC2)cc1
NCGC00509913-01	S(=O)(=O)(N)c1ccc(NC(=S)N2CCN(C/C=C/c3ccccc3)CC2)cc1	4.4000001	Active	Antagonist of the beta-Catenin/TCF4 interaction	0.0	1	LF3	384569379	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-84.665420904	S(=O)(=O)(N)c1ccc(NC(=S)N2CCN(C/C=C/c3ccccc3)CC2)cc1	S(=O)(=O)(N)c1ccc(NC(=S)N2CCN(C/C=C/c3ccccc3)CC2)cc1
NCGC00347067-04	S(=O)(=O)(N)c1ccc(NC=2C(=O)c3c(C(=O)C=2)cccc3)cc1		Inactive	microphthalmia-associated transcription factor (MITF) Inhibitor		1	KUC111774N	384568982	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(N)c1ccc(NC=2C(=O)c3c(C(=O)C=2)cccc3)cc1	S(=O)(=O)(N)c1ccc(NC=2C(=O)c3c(C(=O)C=2)cccc3)cc1
NCGC00346950-03	S(=O)(=O)(N)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1	4.4000001	Active	CDK1/2 Inhibitor	0.0	1	NU-6102	363677566	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-105.1059809186	S(=O)(=O)(N)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1	S(=O)(=O)(N)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1
NCGC00499183-01	S(=O)(=O)(N)c1ccc(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)scc4)cc1	4.4000001	Active	MST1/2	0.0	1	XMU-MP-1	363681481	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-70.0946018256	S(=O)(=O)(N)c1ccc(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)scc4)cc1	S(=O)(=O)(N)c1ccc(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)scc4)cc1
NCGC00182551-01	S(=O)(=O)(N)c1ccc(OP(=S)(OC)OC)cc1	5.4499998	Active	Acetylcholinesterase and butyrylcholinesterase (AChE and BChE) Inhibitor	0.0	1	Cythioate	144206631	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.3847073624	S(=O)(=O)(N)c1ccc(OP(=S)(OC)OC)cc1	S(=O)(=O)(N)c1ccc(OP(=S)(OC)OC)cc1
NCGC00015074-14	S(=O)(=O)(N)c1sc(NC(=O)C)nn1		Inactive	Carbonic Anhydrase Xii Inhibitor&Carbonic anhydrase XII Inhibitor		1	Acetazolamide	170464692	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.2195743399&-16.2313754879	S(=O)(=O)(N)c1sc(NC(=O)C)nn1	S(=O)(=O)(N)c1sc(NC(=O)C)nn1
NCGC00179542-03	S(=O)(=O)(N)c1sc2S(=O)(=O)N(CCCOC)C[C@H](NCC)c2c1		Inactive	Carbonic anhydrase II Inhibitor&Carbonic Anhydrase Ii Inhibitor		1	Brinzolamide	170464926	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.92401096&-16.4397518479	S(=O)(=O)(N)c1sc2S(=O)(=O)N(CCCOC)C[C@H](NCC)c2c1	S(=O)(=O)(N)c1sc2S(=O)(=O)N(CCCOC)C[C@H](NCC)c2c1
NCGC00179244-03&NCGC00179244-11	S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1		Inactive	Carbonic Anhydrase Type Ii Inhibitors&Carbonic Anhydrase Type II Inhibitor&Carbonic Anhydrase Type II Inhibitor		2	Dorzolamide hydrochloride	170465119&384568369	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&-22.024352276	S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1.Cl	S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1.Cl&S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1
NCGC00018249-05	S(=O)(=O)(N)c1sc2c(n1)ccc(OCC)c2		Inactive	Carbonic Anhydrase Inhibitor&Carbonic anhydrase Inhibitor		1	Ethoxzolamide	170465083	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1sc2c(n1)ccc(OCC)c2	S(=O)(=O)(N)c1sc2c(n1)ccc(OCC)c2
NCGC00095099-05&NCGC00095099-11	S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1		Inactive	Phosphodiesterase 5a Inhibitor&Phosphodiesterase V (PDE5) Inhibitor&Phosphodiesterase V (PDE5) Inhibitor		2	Sildenafil citrate	170465285&384568144	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-16.044434064&-11.308993624&0.0	S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1.O=C(O)C(O)(CC(=O)O)CC(=O)O	S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1.O=C(O)C(O)(CC(=O)O)CC(=O)O&S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1
NCGC00167533-02&NCGC00167533-04	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1		Inactive	Phosphodiesterase V (pde5) Inhibitor&Phosphodiesterase V (PDE5) Inhibitor&Phosphodiesterase V (PDE5) Inhibitor		2	Vardenafil	170465607&384568328	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-16.5738610439&0.0&-16.328602588	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1.O=C(O)C(O)(CC(=O)O)CC(=O)O	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1.O=C(O)C(O)(CC(=O)O)CC(=O)O&S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1
NCGC00185916-05	S(=O)(=O)(N1CCN(S(=O)(=O)c2cc3OCCOc3cc2)CCC1)c1cc(N)ccc1	4.4000001	Active	PKM2 Activator	0.0	1	DASA-58	384568429	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-42.0870634	S(=O)(=O)(N1CCN(S(=O)(=O)c2cc3OCCOc3cc2)CCC1)c1cc(N)ccc1	S(=O)(=O)(N1CCN(S(=O)(=O)c2cc3OCCOc3cc2)CCC1)c1cc(N)ccc1
NCGC00167805-03	S(=O)(=O)(N1CCOCC1)c1cc2c(nc(C)c3C(=O)N(CCOC(=O)C)C(=O)c23)cc1		Inactive	Caspase 3 Inhibitor		1	Ivachtin	384568340	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.057776208	S(=O)(=O)(N1CCOCC1)c1cc2c(nc(C)c3C(=O)N(CCOC(=O)C)C(=O)c23)cc1	S(=O)(=O)(N1CCOCC1)c1cc2c(nc(C)c3C(=O)N(CCOC(=O)C)C(=O)c23)cc1
NCGC00263092-02	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(OCC#CCO)cc1		Inactive	TNF-alpha-Converting Enzyme Inhibitor		1	Apratastat	384568584	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.476023604	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(OCC#CCO)cc1	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(OCC#CCO)cc1
NCGC00346802-02	S(=O)(=O)(N1[C@@H](C)CN(C(=O)CN)CCC1)c1c2c(C)cncc2ccc1		Inactive	ROCK II Inhibitor		1	Glycyl-H-1152	363677541	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(N1[C@@H](C)CN(C(=O)CN)CCC1)c1c2c(C)cncc2ccc1	S(=O)(=O)(N1[C@@H](C)CN(C(=O)CN)CCC1)c1c2c(C)cncc2ccc1
NCGC00509886-03	S(=O)(=O)(N1[C@H](Cc2ccccc2)CN(Cc2[nH]cnc2)c2c(cc(C#N)cc2)C1)c1sccc1	4.4000001	Active	Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitor	0.0	1	BMS-214662	384569374	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-40.0095356079	S(=O)(=O)(N1[C@H](Cc2ccccc2)CN(Cc2[nH]cnc2)c2c(cc(C#N)cc2)C1)c1sccc1	S(=O)(=O)(N1[C@H](Cc2ccccc2)CN(Cc2[nH]cnc2)c2c(cc(C#N)cc2)C1)c1sccc1
NCGC00249938-01	S(=O)(=O)(N=C1N=CC=CN1)c1cc(OCCOC)ccc1		Inactive			1	Glymidine sodium	170465939	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-32.9836245975&0.0	S(=O)([O-])(=Nc1ncccn1)c1cc(OCCOC)ccc1.[Na+]	S(=O)([O-])(=Nc1ncccn1)c1cc(OCCOC)ccc1.[Na+]
NCGC00183137-01	S(=O)(=O)(N=C1N=CC=CN1)c1ccc(N)cc1	4.9499998	Active		0.0	1	Sulfadiazine silver	144207020	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-48.3649647099	S(=O)([O-])(=Nc1ncccn1)c1ccc(N)cc1.[Ag+]	S(=O)([O-])(=Nc1ncccn1)c1ccc(N)cc1.[Ag+]
NCGC00018234-07	S(=O)(=O)(NC(=N)N)c1ccc(N)cc1	5.8000002	Active		0.0	1	Sulfaguanidine	170465708	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-36.2929649436	S(=O)(=O)(NC(=N)N)c1ccc(N)cc1	S(=O)(=O)(NC(=N)N)c1ccc(N)cc1
NCGC00018242-07	S(=O)(=O)(NC(=O)C)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor&Bacterial Dihydropteroate Synthase Inhibitor		1	Sulfacetamide	170464944	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-10.4902764719	S(=O)(=O)(NC(=O)C)c1ccc(N)cc1	S(=O)(=O)(NC(=O)C)c1ccc(N)cc1
NCGC00181773-05	S(=O)(=O)(NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor&Prostaglandin G/h Synthase 2 Inhibitor		1	Parecoxib	405558622	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.744587916&12.962724568	S(=O)(=O)(NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1	S(=O)(=O)(NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1
NCGC00370833-02	S(=O)(=O)(NC(=O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1)C	4.4000001	Active	Platelet Aggregation Inhibitor&platelet aggregation Inhibitor	0.0	1	NS-304	405558607	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-60.278698036&-51.184397436	S(=O)(=O)(NC(=O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1)C	S(=O)(=O)(NC(=O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1)C
NCGC00016879-06	S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(C)ccc2)ccnc1		Inactive	Loop Diuretics		1	Torsemide	170465279	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-11.715434144	S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(C)ccc2)ccnc1	S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(C)ccc2)ccnc1
NCGC00016960-07	S(=O)(=O)(NC(=O)NC1CCC(C)CC1)c1ccc(CCNC(=O)N2C(=O)C(CC)=C(C)C2)cc1		Inactive	K(ATP) Channel Blocker&K(atp) Channel Blockers		1	Glimepiride	170464966	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-12.8497424719&-29.185380088&-10.666158268	S(=O)(=O)(NC(=O)NC1CCC(C)CC1)c1ccc(CCNC(=O)N2C(=O)C(CC)=C(C)C2)cc1	S(=O)(=O)(NC(=O)NC1CCC(C)CC1)c1ccc(CCNC(=O)N2C(=O)C(CC)=C(C)C2)cc1
NCGC00015014-11	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(C(=O)C)cc1		Inactive	Sulfonylurea Receptor 1, Kir6.2 Inhibitor&Sulfonylurea receptor 1, Kir6.2 Inhibitor		1	Acetohexamide	170465411	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.477772936&10.0636706799	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(C(=O)C)cc1	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(C(=O)C)cc1
NCGC00016819-05	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCN2C(=O)C(C)(C)c3c(C2=O)cc(OC)cc3)cc1	6.1500001	Active	Cytochrome P450 3a4 Substrate	0.0	1	Gliquidone	170465581	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-52.2886593088	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCN2C(=O)C(C)(C)c3c(C2=O)cc(OC)cc3)cc1	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCN2C(=O)C(C)(C)c3c(C2=O)cc(OC)cc3)cc1
NCGC00015999-19	S(=O)(=O)(NC(=O)NCCCC)c1ccc(C)cc1		Inactive	Sulfonylurea Receptor 1, Kir6.2 Inhibitor&Sulfonylurea receptor 1, Kir6.2 Inhibitor		1	Tolbutamide	170465238	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.6274860959&0.0	S(=O)(=O)(NC(=O)NCCCC)c1ccc(C)cc1	S(=O)(=O)(NC(=O)NCCCC)c1ccc(C)cc1
NCGC00095107-09&NCGC00095107-18	S(=O)(=O)(NC(=O)NN1CC2C(C1)CCC2)c1ccc(C)cc1		Inactive	Atp-binding Cassette Sub-family C Member 8 Inhibitor&K(ATP) Channel Blocker&K(ATP) Channel Blocker		2	Gliclazide	170465698&384568145	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(NC(=O)NN1CC2C(C1)CCC2)c1ccc(C)cc1	S(=O)(=O)(NC(=O)NN1CC2C(C1)CCC2)c1ccc(C)cc1
NCGC00016009-19	S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(C)cc1		Inactive	Atp-sensitive Inward Rectifier Potassium Channel 1 Inhibitor&ATP-sensitive inward rectifier potassium channel 1 Inhibitor		1	Tolazamide	170465136	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.5453215399&19.47990862	S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(C)cc1	S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(C)cc1
NCGC00248064-08	S(=O)(=O)(NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1occ(C(O)(C)C)c1		Inactive	IL-1 Production Enhancers		1	CP-456773	384568522	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1occ(C(O)(C)C)c1	S(=O)(=O)(NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1occ(C(O)(C)C)c1
NCGC00386668-01	S(=O)(=O)(NC(=O)OCCCC)c1c(-c2ccc(Cn3cncc3)cc2)cc(CC(C)C)s1		Inactive	Angiotensin AT2 Receptor Agonist		1	M-024	363680384	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(NC(=O)OCCCC)c1c(-c2ccc(Cn3cncc3)cc2)cc(CC(C)C)s1	S(=O)(=O)(NC(=O)OCCCC)c1c(-c2ccc(Cn3cncc3)cc2)cc(CC(C)C)s1
NCGC00378873-04	S(=O)(=O)(NC(=O)[C@H](C)c1ccc(CC(C)C)cc1)C		Inactive	Chemokine CXCR1/CXCR2 (IL-8 Receptor) Receptor Antagonist		1	Reparixin	384569073	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	24.59949206	S(=O)(=O)(NC(=O)[C@H](C)c1ccc(CC(C)C)cc1)C	S(=O)(=O)(NC(=O)[C@H](C)c1ccc(CC(C)C)cc1)C
NCGC00378916-02	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]4[C@@H](C4)CCCCCc4nc5c(nc4O[C@H](C2)C3)cc(OC)cc5)[C@H](C=C)C1)C1CC1	4.6500001	Active		0.0	1	MK-5172	405558457	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.3	-112.5424463493	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]4[C@@H](C4)CCCCCc4nc5c(nc4O[C@H](C2)C3)cc(OC)cc5)[C@H](C=C)C1)C1CC1	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]4[C@@H](C4)CCCCCc4nc5c(nc4O[C@H](C2)C3)cc(OC)cc5)[C@H](C=C)C1)C1CC1
NCGC00378657-01	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3C(C(=O)N(C)CCCC/C=C\[C@@H]1C2)C[C@H](Oc1c2c(c(C)c(OC)cc2)nc(-c2scc(C(C)C)n2)c1)C3)C1CC1	4.5500002	Active		0.0	1	Simeprevir	405558913	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.3349851352	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3C(C(=O)N(C)CCCC/C=C\[C@@H]1C2)C[C@H](Oc1c2c(c(C)c(OC)cc2)nc(-c2scc(C(C)C)n2)c1)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3C(C(=O)N(C)CCCC/C=C\[C@@H]1C2)C[C@H](Oc1c2c(c(C)c(OC)cc2)nc(-c2scc(C(C)C)n2)c1)C3)C1CC1
NCGC00346498-01	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCC/C=C\[C@@H]1C2)C[C@H](OC(=O)N1Cc2c(F)cccc2C1)C3)C1CC1	4.4000001	Active	HCV Protease Inhibitor	0.0	1	Danoprevir	174007476	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-65.9875895999	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCC/C=C\[C@@H]1C2)C[C@H](OC(=O)N1Cc2c(F)cccc2C1)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCC/C=C\[C@@H]1C2)C[C@H](OC(=O)N1Cc2c(F)cccc2C1)C3)C1CC1
NCGC00510188-01	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCC/C=C\[C@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1	4.4749999	Active		0.0	1	NCGC00510188-01&ABT-450	405558893	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-54.9189196639&-88.5315024195	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCC/C=C\[C@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCC/C=C\[C@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1
NCGC00016385-08	S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1		Inactive			1	Sulfabenzamide	170465133	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1	S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1
NCGC00181137-01	S(=O)(=O)(NC(=S)N)c1ccc(N)cc1		Inactive			1	Sulfathiourea	144206297	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.23144274&0.0	S(=O)(=O)(NC(=S)N)c1ccc(N)cc1	S(=O)(=O)(NC(=S)N)c1ccc(N)cc1
NCGC00345845-02	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3cc(CN4CCOCC4)ccc3)n2)ccc1	5.9499998	Active	Jak2 Inhibitor	0.0	1	TG-89	363677388	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.4	-34.6186900736	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3cc(CN4CCOCC4)ccc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3cc(CN4CCOCC4)ccc3)n2)ccc1
NCGC00345846-01	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(CN4CCOCC4)cc3)n2)ccc1	4.9000001	Active	Jak2 Inhibitor	0.0	1	TG-46	174006734	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-94.1453948696	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(CN4CCOCC4)cc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(CN4CCOCC4)cc3)n2)ccc1
NCGC00262608-11	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)ccc1	4.8000002	Active	Jak2 Inhibitor	0.0	1	TG-101209	377020442	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-92.5510172371	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)ccc1
NCGC00244252-03	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(OCCN4CCCC4)cc3)n2)ccc1	4.6500001	Active	Jak2 Inhibitor	0.0	1	TG-101348	384568507	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-99.8072927083	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(OCCN4CCCC4)cc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(OCCN4CCCC4)cc3)n2)ccc1
NCGC00390707-01	S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1	4.4499998	Active	Tyrosine-protein Kinase Jak3 Inhibitor	0.0	1	Oclacitinib	405559019	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-73.693918692	S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1	S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1
NCGC00181786-02	S(=O)(=O)(NC)CCc1cc2c(C3CCN(C)CC3)c[nH]c2cc1	4.7750001	Active	5-ht1b Agonist&5-HT1B Agonist	0.0	1	Naratriptan hydrochloride	170465423	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-1.2	-44.6791320472&-32.469866816	S(=O)(=O)(NC)CCc1cc2c(C3CCN(C)CC3)c[nH]c2cc1.Cl	S(=O)(=O)(NC)CCc1cc2c(C3CCN(C)CC3)c[nH]c2cc1.Cl
NCGC00095838-04	S(=O)(=O)(NC)Cc1cc2c(CCN(C)C)c[nH]c2cc1		Inactive	5-HT1B Agonist&5-ht1b Agonist		1	Sumatriptan	170465377	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(NC)Cc1cc2c(CCN(C)C)c[nH]c2cc1	S(=O)(=O)(NC)Cc1cc2c(CCN(C)C)c[nH]c2cc1
NCGC00509904-02	S(=O)(=O)(NC)Nc1c(F)c(CC=2C(=O)Oc3c(C=2C)ccc(Oc2ncccn2)c3)ccn1	5.0	Active	Raf kinase B/C Inhibitor	0.0	1	RO-5126766	384569375	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-94.4379773518	S(=O)(=O)(NC)Nc1c(F)c(CC=2C(=O)Oc3c(C=2C)ccc(Oc2ncccn2)c3)ccn1	S(=O)(=O)(NC)Nc1c(F)c(CC=2C(=O)Oc3c(C=2C)ccc(Oc2ncccn2)c3)ccn1
NCGC00344481-01	S(=O)(=O)(NC)c1cc2/C(=C/c3c(CCCN4CCN(C)CC4)c4c([nH]3)CCCC4)/C(=O)Nc2cc1	4.5	Active	Yes1 Kinase Inhibitor	0.0	1	PRP01-012	377020180	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-93.9164735494	S(=O)(=O)(NC)c1cc2/C(=C/c3c(CCCN4CCN(C)CC4)c4c([nH]3)CCCC4)/C(=O)Nc2cc1	S(=O)(=O)(NC)c1cc2/C(=C/c3c(CCCN4CCN(C)CC4)c4c([nH]3)CCCC4)/C(=O)Nc2cc1
NCGC00253598-01	S(=O)(=O)(NC1=NC(=O)N(CC)C=C1)c1ccc(N)cc1		Inactive	Dihydropteroate Synthetase Inhibitor&Dihydropteroate synthetase Inhibitor		1	Sulfacytine	170465286	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.190627068&-16.411146668	S(=O)(=O)(NC1=NC(=O)N(CC)C=C1)c1ccc(N)cc1	S(=O)(=O)(NC1=NC(=O)N(CC)C=C1)c1ccc(N)cc1
NCGC00355875-04	S(=O)(=O)(NC1CC1)c1c(Nc2cc(Oc3cc(F)cc(F)c3)cc(C(=O)O)c2)c2c(nc1)cc(-c1c(OC)nc(OC)nc1)cc2		Inactive	LDHA Inhibitor		1	GSK-2837808A	384569024	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-28.947815084	S(=O)(=O)(NC1CC1)c1c(Nc2cc(Oc3cc(F)cc(F)c3)cc(C(=O)O)c2)c2c(nc1)cc(-c1c(OC)nc(OC)nc1)cc2	S(=O)(=O)(NC1CC1)c1c(Nc2cc(Oc3cc(F)cc(F)c3)cc(C(=O)O)c2)c2c(nc1)cc(-c1c(OC)nc(OC)nc1)cc2
NCGC00347935-08	S(=O)(=O)(NC1CC1)c1cc(NC(=O)Nc2cc(C(F)(F)F)ccc2)c(-c2cscc2)cc1	4.4000001	Active	Mutant IDH2 Inhibitor	0.0	1	AGI-6780	363677721	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-99.3861048314	S(=O)(=O)(NC1CC1)c1cc(NC(=O)Nc2cc(C(F)(F)F)ccc2)c(-c2cscc2)cc1	S(=O)(=O)(NC1CC1)c1cc(NC(=O)Nc2cc(C(F)(F)F)ccc2)c(-c2cscc2)cc1
NCGC00510476-01	S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4c([nH]c(C)c4)cc3)ccn2)ccc1	4.4499998	Active	VEGFR-2 Inhibitor	0.0	1	Sulfatinib	384569439	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-109.6797754414	S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4c([nH]c(C)c4)cc3)ccn2)ccc1	S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4c([nH]c(C)c4)cc3)ccn2)ccc1
NCGC00510482-01	S(=O)(=O)(NC[C@@]1(N(C(=O)C(C)(C)C)N=C(NC(=O)C(C)(C)C)S1)c1ccccc1)CCNCC	6.0	Inactive	Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitor	0.0	1	Litronesib	384569445	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	28.3198644841	S(=O)(=O)(NC[C@@]1(N(C(=O)C(C)(C)C)N=C(NC(=O)C(C)(C)C)S1)c1ccccc1)CCNCC	S(=O)(=O)(NC[C@@]1(N(C(=O)C(C)(C)C)N=C(NC(=O)C(C)(C)C)S1)c1ccccc1)CCNCC
NCGC00167485-02	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@@H](C)[C@H]3[C@H]([C@@H](O)C)C(=O)N3C=2C(=O)O)C1)N		Inactive	Carbapenem Antibiotic		1	Doripenem	174006248	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@@H](C)[C@H]3[C@H]([C@@H](O)C)C(=O)N3C=2C(=O)O)C1)N	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@@H](C)[C@H]3[C@H]([C@@H](O)C)C(=O)N3C=2C(=O)O)C1)N
NCGC00167510-02	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@H](C)[C@@H]3[C@@H]([C@H](O)C)C(=O)N3C=2C(=O)O)C1)N		Inactive	Carbapenem Antibiotic		1	Doripenem	170465085	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.056587532&-23.0743824896	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@H](C)[C@@H]3[C@@H]([C@H](O)C)C(=O)N3C=2C(=O)O)C1)N	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@H](C)[C@@H]3[C@@H]([C@H](O)C)C(=O)N3C=2C(=O)O)C1)N
NCGC00378567-02	S(=O)(=O)(NCc1ncccc1)Cc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1		Inactive	HGFR Inhibitor		1	MK-8033	363678092	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-29.8465511553	S(=O)(=O)(NCc1ncccc1)Cc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1	S(=O)(=O)(NCc1ncccc1)Cc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1
NCGC00351479-01	S(=O)(=O)(N[C@@H](C(=O)N1CCCC1)Cc1cc(C(F)(F)F)ccc1)c1cc(F)c2c(c1)CCNC2	4.4000001	Active	Potent and selective SETD7 Inhibitor. Inhibits YAP nuclear translocation and function following activation of the Hippo signaling pathway in MCF7 cells.	0.0	1	(R)-PFI-2	363677753	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-38.8212745799	S(=O)(=O)(N[C@@H](C(=O)N1CCCC1)Cc1cc(C(F)(F)F)ccc1)c1cc(F)c2c(c1)CCNC2	S(=O)(=O)(N[C@@H](C(=O)N1CCCC1)Cc1cc(C(F)(F)F)ccc1)c1cc(F)c2c(c1)CCNC2
NCGC00166413-09	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NCC(C)Cc2ccc1		Inactive	Thrombin Inhibitor		1	Argatroban	384568307	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.2861841481	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NCC(C)Cc2ccc1	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NCC(C)Cc2ccc1
NCGC00166413-02	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NC[C@H](C)Cc2ccc1		Inactive	Thrombin Inhibitor		1	Argatroban	170464871	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-15.4750735519	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NC[C@H](C)Cc2ccc1	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NC[C@H](C)Cc2ccc1
NCGC00509997-02	S(=O)(=O)(N[C@H](C(=O)O)CNc1c(C)c(N2CCC(c3nc4NCCCc4cc3)CC2)nc(C)n1)c1ccc(OC)cc1		Inactive	Integrin Receptor Antagonist		1	GLPG-0187	384569404	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(N[C@H](C(=O)O)CNc1c(C)c(N2CCC(c3nc4NCCCc4cc3)CC2)nc(C)n1)c1ccc(OC)cc1	S(=O)(=O)(N[C@H](C(=O)O)CNc1c(C)c(N2CCC(c3nc4NCCCc4cc3)CC2)nc(C)n1)c1ccc(OC)cc1
NCGC00263584-01	S(=O)(=O)(N[C@H](C(=O)O)Cc1ccc(OCCCCC2CCNCC2)cc1)CCCC	4.4000001	Active	Integrin Alpha-iib/beta-3 Antagonist	0.0	1	Tirofiban hydrochloride monohydrate	170465092	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.373531391	S(=O)(=O)(N[C@H](C(=O)O)Cc1ccc(OCCCCC2CCNCC2)cc1)CCCC.Cl.O	S(=O)(=O)(N[C@H](C(=O)O)Cc1ccc(OCCCCC2CCNCC2)cc1)CCCC.Cl.O
NCGC00346615-02	S(=O)(=O)(N[C@H](C(=O)OC)CCCNC(=N)N)c1ccc(C)cc1		Inactive	Anaphase Promoting Complex (APC) Inhibitor		1	TAME	384568859	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(N[C@H](C(=O)OC)CCCNC(=N)N)c1ccc(C)cc1	S(=O)(=O)(N[C@H](C(=O)OC)CCCNC(=N)N)c1ccc(C)cc1
NCGC00475734-01	S(=O)(=O)(N[C@H]1C[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)C[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC2)CC1)C	4.5999999	Active	Hedgehog Antagonist	0.0	1	Patidegib	384569234	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-99.6738112947	S(=O)(=O)(N[C@H]1C[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)C[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC2)CC1)C	S(=O)(=O)(N[C@H]1C[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)C[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC2)CC1)C
NCGC00167519-02&NCGC00167519-07	S(=O)(=O)(N[C@H]1Cc2c3c(n(CCC(=O)O)c2CC1)cccc3)c1ccc(F)cc1		Inactive	prostaglandin D2 CRTH2 Inhibitor&Thromboxane A2 Receptor Antagonist&prostaglandin D2 CRTH2 Inhibitor		2	Ramatroban	170465980&363676664	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-36.1811306879&-15.094164024&-23.969886284	S(=O)(=O)(N[C@H]1Cc2c3c(n(CCC(=O)O)c2CC1)cccc3)c1ccc(F)cc1	S(=O)(=O)(N[C@H]1Cc2c3c(n(CCC(=O)O)c2CC1)cccc3)c1ccc(F)cc1
NCGC00263570-01&NCGC00346934-02	S(=O)(=O)(Nc1c(C(=O)NCC(=O)O)cccc1)c1ccc(OC(=O)C(C)(C)C)cc1		Inactive	Neutrophil Elastase Inhibitor&Leukocyte Elastase Inhibitor		2	Sivelestat sodium hydrate&Sivelestat	170465996&384568969	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	20.419447756&0.0&20.8399258835	S(=O)(=O)(Nc1c(C(=O)NCC(=O)[O-])cccc1)c1ccc(OC(=O)C(C)(C)C)cc1.[Na+].O.O.O.O	S(=O)(=O)(Nc1c(C(=O)NCC(=O)[O-])cccc1)c1ccc(OC(=O)C(C)(C)C)cc1.[Na+].O.O.O.O&S(=O)(=O)(Nc1c(C(=O)NCC(=O)O)cccc1)c1ccc(OC(=O)C(C)(C)C)cc1
NCGC00016384-15	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfisoxazole	170464636	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.968676788&-20.94986514	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(N)cc1	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(N)cc1
NCGC00522513-01	S(=O)(=O)(Nc1c(C)ccc(-c2cc(C#N)sc2)c1)c1ccc(OC)cc1	4.3000002	Inactive	HIF-1alpha Inhibitor	0.0	1	EL-102	384569522	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-35.8076796384	S(=O)(=O)(Nc1c(C)ccc(-c2cc(C#N)sc2)c1)c1ccc(OC)cc1	S(=O)(=O)(Nc1c(C)ccc(-c2cc(C#N)sc2)c1)c1ccc(OC)cc1
NCGC00390693-06	S(=O)(=O)(Nc1c(C)ccc(-c2sc(C#N)cc2)c1)c1ccc(C)cc1	4.4000001	Inactive	Tubulin polymerization Inhibitor	0.0	1	ELR-510444	384569207	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-17.6739420841	S(=O)(=O)(Nc1c(C)ccc(-c2sc(C#N)cc2)c1)c1ccc(C)cc1	S(=O)(=O)(Nc1c(C)ccc(-c2sc(C#N)cc2)c1)c1ccc(C)cc1
NCGC00346946-02	S(=O)(=O)(Nc1c(C)ccc(Nc2ncnc(-c3cc(N4C(=O)c5c(C4=O)cccc5)ccc3)c2)c1)C	4.4000001	Active	CDK 9 Inhibitor	0.0	1	CDK9 Inhibitor	363677564	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-115.8624110529	S(=O)(=O)(Nc1c(C)ccc(Nc2ncnc(-c3cc(N4C(=O)c5c(C4=O)cccc5)ccc3)c2)c1)C	S(=O)(=O)(Nc1c(C)ccc(Nc2ncnc(-c3cc(N4C(=O)c5c(C4=O)cccc5)ccc3)c2)c1)C
NCGC00346716-02&NCGC00346716-20	S(=O)(=O)(Nc1c(F)c(-c2c(-c3nc(N)ncc3)sc(C(C)(C)C)n2)ccc1)c1c(F)cccc1F	4.47500015	Active	Raf kinase B Inhibitor	0.15000010000000064	2	Dabrafenib	405558586&384568929	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.1	-61.6629837599&-122.6695233816	S(=O)(=O)(Nc1c(F)c(-c2c(-c3nc(N)ncc3)sc(C(C)(C)C)n2)ccc1)c1c(F)cccc1F	S(=O)(=O)(Nc1c(F)c(-c2c(-c3nc(N)ncc3)sc(C(C)(C)C)n2)ccc1)c1c(F)cccc1F
NCGC00483921-01	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1)N1C[C@H](F)CC1		Inactive	Raf kinase B Inhibitor		1	PLX-8394	363681140	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.808054396	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1)N1C[C@H](F)CC1	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1)N1C[C@H](F)CC1
NCGC00346541-04	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(OC)c(C)cc2)cc1		Inactive	mTORC1/2 Inhibitor		1	XL-765	384568827	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(OC)c(C)cc2)cc1	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(OC)c(C)cc2)cc1
NCGC00346492-03	S(=O)(=O)(Nc1c(Nc2cc3nsnc3cc2)nc2c(n1)cccc2)c1ccc(C)cc1		Inactive	PI3K Inhibitor		1	XL-147	384568799	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(Nc1c(Nc2cc3nsnc3cc2)nc2c(n1)cccc2)c1ccc(C)cc1	S(=O)(=O)(Nc1c(Nc2cc3nsnc3cc2)nc2c(n1)cccc2)c1ccc(C)cc1
NCGC00016612-05&NCGC00016612-13	S(=O)(=O)(Nc1c(OC)c(OC)ncn1)c1ccc(N)cc1		Inactive	Dihydropteroate Synthase (DHPS) Inhibitor&Anti-malarial&Dihydropteroate Synthase (DHPS) Inhibitor		2	Sulfadoxine	170464751&384567954	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&12.4861391759&0.0	S(=O)(=O)(Nc1c(OC)c(OC)ncn1)c1ccc(N)cc1	S(=O)(=O)(Nc1c(OC)c(OC)ncn1)c1ccc(N)cc1
NCGC00242479-03	S(=O)(=O)(Nc1c(OC)nc(C)cn1)c1c(-c2ccc(-c3ocnn3)cc2)nccc1		Inactive	Endothelin ETA Receptor Antagonist		1	Zibotentan	363677141	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(Nc1c(OC)nc(C)cn1)c1c(-c2ccc(-c3ocnn3)cc2)nccc1	S(=O)(=O)(Nc1c(OC)nc(C)cn1)c1c(-c2ccc(-c3ocnn3)cc2)nccc1
NCGC00250408-02	S(=O)(=O)(Nc1c(OC)ncc(-c2cc3c(-c4cnncc4)ccnc3cc2)c1)c1c(F)cc(F)cc1	5.5999999	Active	PI3Kalpha/beta/delta/gamma Inhibitor	0.0	1	GSK-2126458	384568556	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-46.2201460919	S(=O)(=O)(Nc1c(OC)ncc(-c2cc3c(-c4cnncc4)ccnc3cc2)c1)c1c(F)cc(F)cc1	S(=O)(=O)(Nc1c(OC)ncc(-c2cc3c(-c4cnncc4)ccnc3cc2)c1)c1c(F)cc(F)cc1
NCGC00160482-02	S(=O)(=O)(Nc1c(OC)nccn1)c1ccc(N)cc1		Inactive	Bacterial Dihydropteroate Synthase Inhibitor&Bacterial dihydropteroate synthase Inhibitor		1	Sulfalene	170465930	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&21.7015344039	S(=O)(=O)(Nc1c(OC)nccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1c(OC)nccn1)c1ccc(N)cc1
NCGC00167440-02	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OCCO)nc(-c2ncccn2)n1)c1ccc(C(C)(C)C)cc1		Inactive	Endothelin Receptor, Et-a/et-b Antagonist&Endothelin receptor, ET-A/ET-B Antagonist		1	Bosentan	170465245	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	46.9090538243&0.0	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OCCO)nc(-c2ncccn2)n1)c1ccc(C(C)(C)C)cc1	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OCCO)nc(-c2ncccn2)n1)c1ccc(C(C)(C)C)cc1
NCGC00475733-01	S(=O)(=O)(Nc1c2[nH]cc(C#N)c2c(C)cc1)c1cc(C#N)ccc1		Inactive	Integrin Receptor Antagonist		1	E-7820	384569233	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.103573876	S(=O)(=O)(Nc1c2[nH]cc(C#N)c2c(C)cc1)c1cc(C#N)ccc1	S(=O)(=O)(Nc1c2[nH]cc(C#N)c2c(C)cc1)c1cc(C#N)ccc1
NCGC00507962-02	S(=O)(=O)(Nc1c2c(-c3cc4N(C)CCc4cc3)cn(C(C)C)c2ncc1)c1nn(C)cc1		Inactive	NADPH Oxidase 2 Inhibitor		1	GSK2795039	384569358	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(Nc1c2c(-c3cc4N(C)CCc4cc3)cn(C(C)C)c2ncc1)c1nn(C)cc1	S(=O)(=O)(Nc1c2c(-c3cc4N(C)CCc4cc3)cn(C(C)C)c2ncc1)c1nn(C)cc1
NCGC00262829-02	S(=O)(=O)(Nc1c2c(c(O)c(-c3c(O)ccc4c3cccc4)c1)cccc2)c1ccc(OC)cc1	4.4000001	Active	STAT3 Expression Inhibitor	0.0	1	C-188-9	174006692	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-74.092203464	S(=O)(=O)(Nc1c2c(c(O)c(-c3c(O)ccc4c3cccc4)c1)cccc2)c1ccc(OC)cc1	S(=O)(=O)(Nc1c2c(c(O)c(-c3c(O)ccc4c3cccc4)c1)cccc2)c1ccc(OC)cc1
NCGC00492474-01	S(=O)(=O)(Nc1c2ncccc2c(-c2cnccc2)cc1)c1cc(C(F)(F)F)ccc1	5.0500002	Active	CKs1-SKp2 protein-protein Inhibitor	0.0	1	Compound 22d	384569289	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-94.5523999491	S(=O)(=O)(Nc1c2ncccc2c(-c2cnccc2)cc1)c1cc(C(F)(F)F)ccc1	S(=O)(=O)(Nc1c2ncccc2c(-c2cnccc2)cc1)c1cc(C(F)(F)F)ccc1
NCGC00165855-05	S(=O)(=O)(Nc1cc(C#C/C=C/C(=O)NO)ccc1)c1ccccc1	4.8000002	Active	Histone Deacetylase (HDAC) Inhibitor	0.0	1	Oxamflatin	384568290	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-71.599368592	S(=O)(=O)(Nc1cc(C#C/C=C/C(=O)NO)ccc1)c1ccccc1	S(=O)(=O)(Nc1cc(C#C/C=C/C(=O)NO)ccc1)c1ccccc1
NCGC00507890-02	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(c3ccc(C(=O)O)cc3)C3C2C=CC3)cc1		Inactive	MDM2 (hdm2) Inhibitor		1	MX-69	384569354	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	18.44121096	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(c3ccc(C(=O)O)cc3)C3C2C=CC3)cc1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(c3ccc(C(=O)O)cc3)C3C2C=CC3)cc1
NCGC00093644-07&NCGC00093644-09	S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4)cccc3)cc1)C	6.0625	Active	Dna Topoisomerase Ii Alpha Inhibitor&DNA Topoisomerase II Inhibitor&DNA Topoisomerase II Inhibitor	0.125	2	Amsacrine	404904675&384568116	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.1&-1.2&-1.2	-92.9299873696&-50.4078205053&-68.9530663455	S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4)cccc3)cc1)C	S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4)cccc3)cc1)C
NCGC00379087-02	S(=O)(=O)(Nc1cc([C@@H](CC)C=2C(=O)O[C@](CCC)(CCc3ccccc3)CC=2O)ccc1)c1ncc(C(F)(F)F)cc1	5.5500002	Inactive		0.0	1	Tipranavir	405558770	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	43.3555596402	S(=O)(=O)(Nc1cc([C@@H](CC)C=2C(=O)O[C@](CCC)(CCc3ccccc3)CC=2O)ccc1)c1ncc(C(F)(F)F)cc1	S(=O)(=O)(Nc1cc([C@@H](CC)C=2C(=O)O[C@](CCC)(CCc3ccccc3)CC=2O)ccc1)c1ncc(C(F)(F)F)cc1
NCGC00507889-01	S(=O)(=O)(Nc1cc(c(Oc2c(F)cc(F)cc2)cc1)C=1c2c(C(=O)N(C)C=1)[nH]cc2)CC	4.4000001	Active	Brd4 Inhibitor	0.0	1	Mivebresib (ABBV-075)	384569353	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-49.5786197262	S(=O)(=O)(Nc1cc(c(Oc2c(F)cc(F)cc2)cc1)C=1c2c(C(=O)N(C)C=1)[nH]cc2)CC	S(=O)(=O)(Nc1cc(c(Oc2c(F)cc(F)cc2)cc1)C=1c2c(C(=O)N(C)C=1)[nH]cc2)CC
NCGC00188863-02&NCGC00188863-06	S(=O)(=O)(Nc1cc2c(C(=O)c3ccc(OCCCN(CCCC)CCCC)cc3)c(CCCC)oc2cc1)C	4.875	Active	Alpha-adrenergic Receptor Antagonist&alpha,beta-Adrenoceptor Antagonist&alpha,beta-Adrenoceptor Antagonist	0.14999959999999923	2	Dronedarone hydrochloride	170465064&384568452	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.1&-1.3	-105.2199501052&-98.3445531152&-84.6746676663	S(=O)(=O)(Nc1cc2c(C(=O)c3ccc(OCCCN(CCCC)CCCC)cc3)c(CCCC)oc2cc1)C	S(=O)(=O)(Nc1cc2c(C(=O)c3ccc(OCCCN(CCCC)CCCC)cc3)c(CCCC)oc2cc1)C
NCGC00168776-03	S(=O)(=O)(Nc1cc2c([nH]c(C(=O)N3CCN(c4c(NC(C)C)cccn4)CC3)c2)cc1)C		Inactive	Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor&Human immunodeficiency virus type 1 reverse transcriptase Inhibitor		1	Delavirdine	170464664	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	20.4216555819&-11.512672236	S(=O)(=O)(Nc1cc2c([nH]c(C(=O)N3CCN(c4c(NC(C)C)cccn4)CC3)c2)cc1)C	S(=O)(=O)(Nc1cc2c([nH]c(C(=O)N3CCN(c4c(NC(C)C)cccn4)CC3)c2)cc1)C
NCGC00378604-01	S(=O)(=O)(Nc1cc2c(cc(-c3c(OC)c(C(C)(C)C)cc(N4C(=O)NC(=O)C=C4)c3)cc2)cc1)C	5.0	Active		0.0	1	ABT-333	405558941	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.2	-32.7649541575&-57.4404524419	S(=O)(=O)(Nc1cc2c(cc(-c3c(OC)c(C(C)(C)C)cc(N4C(=O)NC(=O)C=C4)c3)cc2)cc1)C	S(=O)(=O)(Nc1cc2c(cc(-c3c(OC)c(C(C)(C)C)cc(N4C(=O)NC(=O)C=C4)c3)cc2)cc1)C
NCGC00508859-01	S(=O)(=O)(Nc1cc2c(cc1)CN(C(=O)COc1cnccc1)CC2)CC(O)(C)C	4.0	Inactive	NAMPT Inhibitor	0.0	1	NAMPT-IN-1	384569364	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-7.6827683999	S(=O)(=O)(Nc1cc2c(cc1)CN(C(=O)COc1cnccc1)CC2)CC(O)(C)C	S(=O)(=O)(Nc1cc2c(cc1)CN(C(=O)COc1cnccc1)CC2)CC(O)(C)C
NCGC00386704-01	S(=O)(=O)(Nc1ccc(C(=O)N2CCN(CC3CC3)CC2)cc1)c1c2ncccc2ccc1		Inactive	Phase II PKR Activator, for pyruvate kinase deficiency; however, could be useful for oncology as well.		1	Mitapivat	363680407	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.5333878	S(=O)(=O)(Nc1ccc(C(=O)N2CCN(CC3CC3)CC2)cc1)c1c2ncccc2ccc1	S(=O)(=O)(Nc1ccc(C(=O)N2CCN(CC3CC3)CC2)cc1)c1c2ncccc2ccc1
NCGC00015919-14&NCGC00015919-17	S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C		Inactive	Beta-adrenoceptor Antagonists&beta-Adrenoceptor Antagonist&beta-Adrenoceptor Antagonist		2	Sotalol	405558886&384567907	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-25.0020104921&24.441135168	S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C	S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C
NCGC00263234-01	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(C)cc1	4.1999998	Active	IDH1 Inhibitor	0.0	1	IDH-001	137276078	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-35.800817036	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(C)cc1	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(C)cc1
NCGC00164549-02&NCGC00164549-12	S(=O)(=O)(Nc1ccc(OCCN(CCc2ccc(NS(=O)(=O)C)cc2)C)cc1)C		Inactive	K(v)11.1 (erg1) Channel Blocker&K(V)11.1 (erg1) Channel Blocker&K(V)11.1 (erg1) Channel Blocker		2	Dofetilide	170465418&384568251	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	14.559952824&7.474903252&0.0	S(=O)(=O)(Nc1ccc(OCCN(CCc2ccc(NS(=O)(=O)C)cc2)C)cc1)C	S(=O)(=O)(Nc1ccc(OCCN(CCc2ccc(NS(=O)(=O)C)cc2)C)cc1)C
NCGC00095045-05	S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)C)cc1	5.1500001	Active	Eimeria Tenella Inhibitor	0.0	1	Sulfanitran	170466141	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.5756882336	S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)C)cc1	S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)C)cc1
NCGC00378390-01	S(=O)(=O)(Nc1ccccc1)c1ccc(C(=O)N(Cc2ccccc2)C)cc1	4.9499998	Active	LIMK Inhibitor	0.0	1	Compound 2	384569048	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-47.8310806863	S(=O)(=O)(Nc1ccccc1)c1ccc(C(=O)N(Cc2ccccc2)C)cc1	S(=O)(=O)(Nc1ccccc1)c1ccc(C(=O)N(Cc2ccccc2)C)cc1
NCGC00015925-12	S(=O)(=O)(Nc1n(-c2ccccc2)ncc1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfaphenazole	170465185	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.5753715919&-19.360622212	S(=O)(=O)(Nc1n(-c2ccccc2)ncc1)c1ccc(N)cc1	S(=O)(=O)(Nc1n(-c2ccccc2)ncc1)c1ccc(N)cc1
NCGC00018243-09	S(=O)(=O)(Nc1nc(C)cc(C)n1)c1ccc(N)cc1		Inactive	Bacterial Dihydropteroate Synthase Inhibitor&Bacterial dihydropteroate synthase Inhibitor		1	Sulfamethazine	170464893	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.8910696079&0.0	S(=O)(=O)(Nc1nc(C)cc(C)n1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)cc(C)n1)c1ccc(N)cc1
NCGC00016386-06	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(N)cc1	5.3000002	Active	Bacterial Dihydropteroate Synthase Inhibitor	0.0	1	Sulfamerazine	170464738	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-38.8748607227	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(N)cc1
NCGC00263229-03	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(NC(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)ccn3)cc2)cc1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	GSK-837149A	363677274	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(NC(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)ccn3)cc2)cc1	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(NC(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)ccn3)cc2)cc1
NCGC00164492-02	S(=O)(=O)(Nc1nc(C)nc(C)c1)c1ccc(N)cc1	3.0	Inactive		0.0	1	Sulfisomidine	170465986	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	52.7504397161	S(=O)(=O)(Nc1nc(C)nc(C)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)nc(C)c1)c1ccc(N)cc1
NCGC00183014-01	S(=O)(=O)(Nc1nc(C)nc(OC)c1)c1ccc(N)cc1		Inactive	Bacterial Dihydrofolate Reductase Inhibitor&Bacterial dihydrofolate reductase Inhibitor		1	Sulfamethomidine	144206847	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1nc(C)nc(OC)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)nc(OC)c1)c1ccc(N)cc1
NCGC00016375-09	S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfadimethoxine	170465690	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.5578469239&15.433323884	S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1
NCGC00178376-05	S(=O)(=O)(Nc1nc2c(nc1)cccc2)c1ccc(N)cc1		Inactive			1	Sulfaquinoxaline	170465653	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1nc2c(nc1)cccc2)c1ccc(N)cc1	S(=O)(=O)(Nc1nc2c(nc1)cccc2)c1ccc(N)cc1
NCGC00016530-07	S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfameter	170465428	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.3823413439&0.0	S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1
NCGC00090903-01&NCGC00090903-11	S(=O)(=O)(Nc1ncccc1)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1		Inactive	NFKB Activation Inhibitor&Nfkb Activation Inhibitor&NFKB Activation Inhibitor		2	Sulfasalazine	144204588&170464716	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(Nc1ncccc1)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1	S(=O)(=O)(Nc1ncccc1)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1
NCGC00016408-09	S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1	6.1500001	Active	Antibiotic	0.0	1	Sulfapyridine	170464707	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-32.8870376119	S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1
NCGC00016305-11	S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1		Inactive	Antibiotic		1	Silver sulfadiazine	405559001	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1
NCGC00016572-12	S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1	5.8000002	Active		0.0	1	Sulfamonomethoxine	170465768	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-38.2453265962	S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1
NCGC00016324-09	S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1		Inactive			1	Sulfamethoxypyridazine	170466374	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.424040572&-13.343490204	S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1	S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1
NCGC00181916-01	S(=O)(=O)(Nc1nnc(OCC)cc1)c1ccc(N)cc1	5.0500002	Active		0.0	1	Sulfaethoxypyridazine	144206640	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.4536843412	S(=O)(=O)(Nc1nnc(OCC)cc1)c1ccc(N)cc1	S(=O)(=O)(Nc1nnc(OCC)cc1)c1ccc(N)cc1
NCGC00186654-01	S(=O)(=O)(Nc1noc(C)c1)c1ccc(N)cc1		Inactive	Antibiotic&Bacterial dihydropteroate synthase Inhibitor		1	NCGC00186654-01&Sulfamethoxazole	170464637	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1noc(C)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1noc(C)c1)c1ccc(N)cc1
NCGC00183871-04	S(=O)(=O)(Nc1noc(C)c1)c1ccc(NC(=O)C)cc1	6.0	Active		0.0	1	N-Acetyl sulfamethoxazole	170466005	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-46.597474057	S(=O)(=O)(Nc1noc(C)c1)c1ccc(NC(=O)C)cc1	S(=O)(=O)(Nc1noc(C)c1)c1ccc(NC(=O)C)cc1
NCGC00182991-01	S(=O)(=O)(Nc1sc(C(C)(C)C)nn1)c1ccccc1		Inactive	Insulin Secretion Activator&insulin secretion Activator		1	Glybuzole	144206873	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1sc(C(C)(C)C)nn1)c1ccccc1	S(=O)(=O)(Nc1sc(C(C)(C)C)nn1)c1ccccc1
NCGC00016407-08&NCGC00016407-16	S(=O)(=O)(Nc1sc(C)nn1)c1ccc(N)cc1		Inactive	Antibacterial		2	Sulfamethizole	170465369&384567937	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-17.4722613839&0.0	S(=O)(=O)(Nc1sc(C)nn1)c1ccc(N)cc1	S(=O)(=O)(Nc1sc(C)nn1)c1ccc(N)cc1
NCGC00016309-06	S(=O)(=O)(Nc1sccn1)c1ccc(N)cc1		Inactive	Escherichia coli Inhibitor&Escherichia Coli Inhibitor		1	Sulfathiazole	170465454	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	34.9354911319&-24.463823442	S(=O)(=O)(Nc1sccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1sccn1)c1ccc(N)cc1
NCGC00016367-08	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)CCC(=O)O)cc1		Inactive			1	Succinylsulfathiazole	170465721	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)CCC(=O)O)cc1	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)CCC(=O)O)cc1
NCGC00346547-03	S(=O)(=O)(Nc1scnn1)c1ccc(CCCCCCCCCCCC)cc1		Inactive	Phosphoinositide Dependent Kinase Inhibitor		1	PHT-427	384568833	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(Nc1scnn1)c1ccc(CCCCCCCCCCCC)cc1	S(=O)(=O)(Nc1scnn1)c1ccc(CCCCCCCCCCCC)cc1
NCGC00015997-10&NCGC00015997-12	S(=O)(=O)(O)CCN		Inactive	Antioxidant&Amino Acid Antipsychotic&Antioxidant		2	Taurine	170465726&384567914	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(O)CCN	S(=O)(=O)(O)CCN
NCGC00016936-04	S(=O)(=O)(O)N1[C@@H](C)[C@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2nc(N)sc2)C1=O		Inactive	Beta-lactam Antibiotic&beta-lactam antibiotic		1	Aztreonam	170465110	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.153200592&-13.846242776	S(=O)(=O)(O)N1[C@@H](C)[C@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2nc(N)sc2)C1=O	S(=O)(=O)(O)N1[C@@H](C)[C@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2nc(N)sc2)C1=O
NCGC00181160-01	S(=O)(=O)(O)c1c(C(C)C)cc2c([C@]3(C)[C@H]([C@@](C(=O)O)(C)CCC3)CC2)c1		Inactive	Urease Subunit Alpha Inhibitor&Urease subunit alpha Inhibitor		1	Ecabet	144206316	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.733293332&-35.0244383639	S(=O)(=O)(O)c1c(C(C)C)cc2c([C@]3(C)[C@H]([C@@](C(=O)O)(C)CCC3)CC2)c1	S(=O)(=O)(O)c1c(C(C)C)cc2c([C@]3(C)[C@H]([C@@](C(=O)O)(C)CCC3)CC2)c1
NCGC00159404-04	S(=O)(=O)(O)c1c(OC)cc(O)c(C(=O)c2ccccc2)c1	5.1999998	Active		0.0	1	Sulisobenzone	170465489	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-43.1837495436	S(=O)(=O)(O)c1c(OC)cc(O)c(C(=O)c2ccccc2)c1	S(=O)(=O)(O)c1c(OC)cc(O)c(C(=O)c2ccccc2)c1
NCGC00163318-03	S(=O)(=O)(O)c1c2c(NC(=O)c3cc(NC(=O)c4cc(NC(=O)Nc5cc(C(=O)Nc6c(C)ccc(C(=O)Nc7c8c(S(=O)(=O)O)cc(S(=O)(=O)O)cc8c(S(=O)(=O)O)cc7)c6)ccc5)ccc4)c(C)cc3)ccc(S(=O)(=O)O)c2cc(S(=O)(=O)O)c1		Inactive	Fibroblast Growth Factor (FGF) Inhibitor		1	Suramin sodium	124892422	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	12.585903128	S(=O)(=O)(O)c1c2c(NC(=O)c3cc(NC(=O)c4cc(NC(=O)Nc5cc(C(=O)Nc6c(C)ccc(C(=O)Nc7c8c(S(=O)(=O)O)cc(S(=O)(=O)O)cc8c(S(=O)(=O)O)cc7)c6)ccc5)ccc4)c(C)cc3)ccc(S(=O)(=O)O)c2cc(S(=O)(=O)O)c1	S(=O)(=O)(O)c1c2c(NC(=O)c3cc(NC(=O)c4cc(NC(=O)Nc5cc(C(=O)Nc6c(C)ccc(C(=O)Nc7c8c(S(=O)(=O)O)cc(S(=O)(=O)O)cc8c(S(=O)(=O)O)cc7)c6)ccc5)ccc4)c(C)cc3)ccc(S(=O)(=O)O)c2cc(S(=O)(=O)O)c1
NCGC00013917-09	S(=O)(=O)(O)c1c2c(c(O)c(/N=N/c3cc4c(cc(S(=O)(=O)O)cc4)cc3)c1)nccc2		Inactive	Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor		1	NSC-87877	363676433	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.5215202919	S(=O)(=O)(O)c1c2c(c(O)c(/N=N/c3cc4c(cc(S(=O)(=O)O)cc4)cc3)c1)nccc2	S(=O)(=O)(O)c1c2c(c(O)c(/N=N/c3cc4c(cc(S(=O)(=O)O)cc4)cc3)c1)nccc2
NCGC00166262-03	S(=O)(=O)(O)c1cc2nc(-c3ccccc3)[nH]c2cc1		Inactive			1	Ensulizole	170465490	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.156721632&0.0	S(=O)(=O)(O)c1cc2nc(-c3ccccc3)[nH]c2cc1	S(=O)(=O)(O)c1cc2nc(-c3ccccc3)[nH]c2cc1
NCGC00248146-03	S(=O)(=O)(O)c1ccc(C)cc1	4.6999998	Active		0.0	1	4-Methylbenzenesulfonic acid	405558963	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.967496884	S(=O)(=O)(O)c1ccc(C)cc1	S(=O)(=O)(O)c1ccc(C)cc1
NCGC00164534-02	S(=O)(=O)(O)c1ccc(O)cc1		Inactive			1	4-Phenolsulfonic acid	170465916	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-18.0523630759&-23.484160864	S(=O)(=O)(O)c1ccc(O)cc1	S(=O)(=O)(O)c1ccc(O)cc1
NCGC00091687-01	S(=O)(=O)(O)c1ccccc1	4.4000001	Active		0.0	1	Benzene sulfonic acid	17389167	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.2956623719	S(=O)(=O)(O)c1ccccc1	S(=O)(=O)(O)c1ccccc1
NCGC00166301-04	S(=O)(=O)(OC(CC(C)C)CCC(CCCC)CC)[O-]	4.5	Active	Vitamin K-dependent protein S Inhibitor	0.0	1	SODIUM TETRADECYL SULFATE	405558515	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-81.20278915	S(=O)(=O)(OC(CC(C)C)CCC(CCCC)CC)[O-]	S(=O)(=O)(OC(CC(C)C)CCC(CCCC)CC)[O-]
NCGC00386449-03	S(=O)(=O)(OC)N[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC=2n3nc(-c4cc(SC(F)(F)F)ccc4)cc3N=CC=2)C1	3.6500001	Inactive	Ubiquitin-Activating Enzyme E1 Inhibitor	0.0	1	MLN-7243	384569142	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-15.7138679839	S(=O)(=O)(OC)N[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC=2n3nc(-c4cc(SC(F)(F)F)ccc4)cc3N=CC=2)C1	S(=O)(=O)(OC)N[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC=2n3nc(-c4cc(SC(F)(F)F)ccc4)cc3N=CC=2)C1
NCGC00262641-04	S(=O)(=O)(OCC(=O)Nc1cc(O)c(C(=O)O)cc1)c1ccc(C)cc1		Inactive	STAT-3 Inhibitor		1	S31-201	384568576	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(OCC(=O)Nc1cc(O)c(C(=O)O)cc1)c1ccc(C)cc1	S(=O)(=O)(OCC(=O)Nc1cc(O)c(C(=O)O)cc1)c1ccc(C)cc1
NCGC00181153-01	S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C	4.5	Active	cell growth Inhibitor	0.0	1	Treosulfan	144206310	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-35.9370421485	S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C	S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C
NCGC00274082-01	S(=O)(=O)(OCCCCCCCCCCCC)[O-]	5.1999998	Active		0.0	1	Sodium dodecyl sulfate	170465474	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-55.6541283456	S(=O)(=O)(OCCCCCCCCCCCC)[O-].[Na+]	S(=O)(=O)(OCCCCCCCCCCCC)[O-].[Na+]
NCGC00090905-12&NCGC00090905-16	S(=O)(=O)(OCCCCOS(=O)(=O)C)C		Inactive	Dna Alkylating Agent&DNA Alkylating Agent&DNA Alkylating Agent		2	Busulfan	170465232&384568090	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(OCCCCOS(=O)(=O)C)C	S(=O)(=O)(OCCCCOS(=O)(=O)C)C
NCGC00182974-01	S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C	4.4000001	Active		0.0	1	Improsulfan tosylate	144206762	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-37.679520464	S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C.S(=O)(=O)(O)c1ccc(C)cc1	S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C.S(=O)(=O)(O)c1ccc(C)cc1
NCGC00345794-11	S(=O)(=O)(OC[C@H]1[C@@H](O)C[C@H](n2c3ncnc(N[C@@H]4c5c(cccc5)CC4)c3cc2)C1)N	5.9499998	Inactive	NEDD8-Activating Enzyme (NAE) Inhibitor	0.0	1	MLN-4924	384568745	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	26.8042015681	S(=O)(=O)(OC[C@H]1[C@@H](O)C[C@H](n2c3ncnc(N[C@@H]4c5c(cccc5)CC4)c3cc2)C1)N	S(=O)(=O)(OC[C@H]1[C@@H](O)C[C@H](n2c3ncnc(N[C@@H]4c5c(cccc5)CC4)c3cc2)C1)N
NCGC00178714-04	S(=O)(=O)(OC[C@]12OC(C)(C)O[C@H]1[C@@H]1OC(C)(C)O[C@@H]1CO2)N		Inactive	Gaba-a Receptor; Anion Channel Positive Allosteric Modulator&Na channel blocker		1	Topiramate	170464746	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.9665391959&7.7297479161	S(=O)(=O)(OC[C@]12OC(C)(C)O[C@H]1[C@@H]1OC(C)(C)O[C@@H]1CO2)N	S(=O)(=O)(OC[C@]12OC(C)(C)O[C@H]1[C@@H]1OC(C)(C)O[C@@H]1CO2)N
NCGC00390740-04	S(=O)(=O)(ON1C(=O)N2[C@H](C(=O)N)CC[C@@H]1C2)[O-]	4.4000001	Active		0.0	1	Avibactam sodium	405559079	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-42.31088222	S(=O)(=O)(ON1C(=O)N2[C@H](C(=O)N)CC[C@@H]1C2)[O-]	S(=O)(=O)(ON1C(=O)N2[C@H](C(=O)N)CC[C@@H]1C2)[O-]
NCGC00162137-02	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=2)CC1)[O-]	4.4000001	Active	Estrogen Receptor Alpha Partial Agonist	0.0	1	Dehydroepiandrosterone Sulfate (sodium salt)	405558967	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-57.883260492	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=2)CC1)[O-]	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=2)CC1)[O-]
NCGC00346572-02	S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(C(C)C)cc1C(C)C	4.5999999	Active	Cyp2C9 Inhibitor	0.0	1	Avasimibe	363677457	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-60.139301042	S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(C(C)C)cc1C(C)C	S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(C(C)C)cc1C(C)C
NCGC00378997-07	S(=O)(=O)(Oc1c(O)ccc([C@H](O)[C@@H](O)C2C(=O)NC([C@H](O)CC(=O)N)C(=O)N3C([C@@H](O)[C@@H](C)C3)C(=O)N[C@H](O)[C@H](O)C[C@H](NC(=O)c3ccc(-c4noc(-c5ccc(OCCCCC)cc5)c4)cc3)C(=O)NC([C@H](O)C)C(=O)N3C(C(=O)N2)C[C@@H](O)C3)c1)O	4.75	Active		0.0	1	Micafunginsodium	405558539	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.6632880947	S(=O)(=O)(Oc1c(O)ccc([C@H](O)[C@@H](O)C2C(=O)NC([C@H](O)CC(=O)N)C(=O)N3C([C@@H](O)[C@@H](C)C3)C(=O)N[C@H](O)[C@H](O)C[C@H](NC(=O)c3ccc(-c4noc(-c5ccc(OCCCCC)cc5)c4)cc3)C(=O)NC([C@H](O)C)C(=O)N3C(C(=O)N2)C[C@@H](O)C3)c1)O	S(=O)(=O)(Oc1c(O)ccc([C@H](O)[C@@H](O)C2C(=O)NC([C@H](O)CC(=O)N)C(=O)N3C([C@@H](O)[C@@H](C)C3)C(=O)N[C@H](O)[C@H](O)C[C@H](NC(=O)c3ccc(-c4noc(-c5ccc(OCCCCC)cc5)c4)cc3)C(=O)NC([C@H](O)C)C(=O)N3C(C(=O)N2)C[C@@H](O)C3)c1)O
NCGC00480830-01	S(=O)(=O)(Oc1cc2OC(=O)C3=C(c2cc1)CCCCC3)N		Inactive	Carbonic Anhydrase Type II Inhibitor; Steryl-Sulfatase (STS) Inhibitor		1	Irosustat (STX-64)	384569248	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-26.645964968	S(=O)(=O)(Oc1cc2OC(=O)C3=C(c2cc1)CCCCC3)N	S(=O)(=O)(Oc1cc2OC(=O)C3=C(c2cc1)CCCCC3)N
NCGC00021137-04	S(=O)(=O)(Oc1cc2c(cc1)C1C(C3[C@@](C)(C(=O)CC3)CC1)CC2)O		Inactive			1	ESTROPIPATE&NCGC00021137-04	405558748	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-15.238638172&0.0	S(=O)(=O)(Oc1cc2c(cc1)C1C(C3[C@@](C)(C(=O)CC3)CC1)CC2)O	S(=O)(=O)(Oc1cc2c(cc1)C1C(C3[C@@](C)(C(=O)CC3)CC1)CC2)O
NCGC00182711-02	S(=O)(=O)(Oc1ccc(C(c2[nH+]cccc2)c2ccc(OS(=O)(=O)[O-])cc2)cc1)[O-]		Inactive			1	Picosulfate sodium	225144334	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.5274772599&0.0	S(=O)(=O)(Oc1ccc(C(c2ncccc2)c2ccc(OS(=O)(=O)[O-])cc2)cc1)[O-]	S(=O)(=O)(Oc1ccc(C(c2ncccc2)c2ccc(OS(=O)(=O)[O-])cc2)cc1)[O-]
NCGC00163381-01	S(=O)(=O)(Oc1ccc(CC(N(S(=O)(=O)c2c3c(cncc3)ccc2)C)C(=O)N2CCN(c3ccccc3)CC2)cc1)c1c2c(cncc2)ccc1	4.6999998	Active	CaMK-II Inhibitor	0.0	1	KN-62	26756742	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-46.9658204611	S(=O)(=O)(Oc1ccc(CC(N(S(=O)(=O)c2c3c(cncc3)ccc2)C)C(=O)N2CCN(c3ccccc3)CC2)cc1)c1c2c(cncc2)ccc1	S(=O)(=O)(Oc1ccc(CC(N(S(=O)(=O)c2c3c(cncc3)ccc2)C)C(=O)N2CCN(c3ccccc3)CC2)cc1)c1c2c(cncc2)ccc1
NCGC00182082-03	S(=O)(=O)(Oc1ccc(CCOc2ccc(C[C@@H](OCC)C(=O)O)cc2)cc1)C		Inactive			1	Tesaglitazar	170466025	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.053853304	S(=O)(=O)(Oc1ccc(CCOc2ccc(C[C@@H](OCC)C(=O)O)cc2)cc1)C	S(=O)(=O)(Oc1ccc(CCOc2ccc(C[C@@H](OCC)C(=O)O)cc2)cc1)C
NCGC00183363-01	S(=O)(=O)(Oc1ccc(C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc2ccccc2)CC(=O)O)CCSC)Cc2c3c([nH]c2)cccc3)CCSC)cc1)O	5.0500002	Active	Cholecystokinin A receptor Agonist	0.0	1	Sincalide	144207030	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-36.0744565359	S(=O)(=O)(Oc1ccc(C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc2ccccc2)CC(=O)O)CCSC)Cc2c3c([nH]c2)cccc3)CCSC)cc1)O	S(=O)(=O)(Oc1ccc(C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc2ccccc2)CC(=O)O)CCSC)Cc2c3c([nH]c2)cccc3)CCSC)cc1)O
NCGC00164140-07	S(=O)(=O)([O-])C(C(=O)OCC(CCCC)CC)CC(=O)OCC(CCCC)CC	5.0999999	Active		0.0	1	Dioctyl sulfosuccinate sodium salt	225144252	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-35.6954098202	S(=O)(=O)([O-])C(C(=O)OCC(CCCC)CC)CC(=O)OCC(CCCC)CC	S(=O)(=O)([O-])C(C(=O)OCC(CCCC)CC)CC(=O)OCC(CCCC)CC
NCGC00274268-01	S(=O)(=O)([O-])C(C(=O)[O-])CC(=O)OCCNC(=O)CCCCCCC/C=C/CCCCCCCC	4.4000001	Active		0.0	1	NCGC00274268-01	225144369	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-68.5943442678	S(=O)(=O)([O-])C(C(=O)[O-])CC(=O)OCCNC(=O)CCCCCCC/C=C/CCCCCCCC	S(=O)(=O)([O-])C(C(=O)[O-])CC(=O)OCCNC(=O)CCCCCCC/C=C/CCCCCCCC
NCGC00160478-02	S(=O)(=O)([O-])C1(C)C(=O)c2c(C(=O)C1)cccc2	4.4000001	Active	NQO1 protein Substrate	0.0	1	Menadione sodium bisulfite	225144239	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-107.1917519464	S(=O)(=O)([O-])C1(C)C(=O)c2c(C(=O)C1)cccc2	S(=O)(=O)([O-])C1(C)C(=O)c2c(C(=O)C1)cccc2
NCGC00532506-01	S(=O)(=O)([O-])CC(=O)OCCCCCCCCCCCC	4.8499999	Active		0.0	1	SODIUM LAURYL SULFOACETATE	405559116	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-38.3622163772&-61.8322208099	S(=O)(=O)([O-])CC(=O)OCCCCCCCCCCCC	S(=O)(=O)([O-])CC(=O)OCCCCCCCCCCCC
NCGC00166409-02	S(=O)(=O)([O-])CC(S)CS		Inactive	Reactive Oxygen Species Metabolic Process Modulator		1	Sodium 2,3-dimercaptopropanesulfonate monohydrate	225144282	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.0478834159&-27.7295454599	S(=O)(=O)([O-])CC(S)CS	S(=O)(=O)([O-])CC(S)CS
NCGC00348365-01	S(=O)(=O)([O-])CCCC[N+]1=C(/C=C/C=C/C=C/C=C\2/N(CCCCS(=O)(=O)[O-])c3c(C/2(C)C)c2c(cc3)cccc2)C(C)(C)c2c3c(ccc12)cccc3	5.5	Active		0.0	1	INDOCYANINE GREEN	405558700	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-30.935399976	S(=O)(=O)([O-])CCCC[N+]1=C(/C=C/C=C/C=C/C=C\2/N(CCCCS(=O)(=O)[O-])c3c(C/2(C)C)c2c(cc3)cccc2)C(C)(C)c2c3c(ccc12)cccc3	S(=O)(=O)([O-])CCCC[N+]1=C(/C=C/C=C/C=C/C=C\2/N(CCCCS(=O)(=O)[O-])c3c(C/2(C)C)c2c(cc3)cccc2)C(C)(C)c2c3c(ccc12)cccc3
NCGC00167462-03&NCGC00167462-06	S(=O)(=O)([O-])CCCNC(=O)C		Inactive	Nmda Receptor Antagonist		2	Acamprosate Calcium&ACAMPROSATE CALCIUM	225144287&384568315	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)([O-])CCCNC(=O)C	S(=O)(=O)([O-])CCCNC(=O)C
NCGC00344538-01	S(=O)(=O)([O-])CCCS(=O)(=O)[O-]	5.3000002	Active		0.0	1	1,3-Propanedisulfonic acid disodium salt	225144385	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-18.2537035984	S(=O)(=O)([O-])CCCS(=O)(=O)[O-]	S(=O)(=O)([O-])CCCS(=O)(=O)[O-]
NCGC00178318-04&NCGC00178318-05	S(=O)(=O)([O-])CCS		Inactive	Antineoplastic Enhancing Agents		2	Sodium 2-mercaptoethanesulfonate&Mesna	170464862&384568354	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	11.729372272&0.0&0.0	S(=O)(=O)([O-])CCS.[Na+]	S(=O)(=O)([O-])CCS.[Na+]&S(=O)(=O)([O-])CCS
NCGC00346482-01	S(=O)(=O)([O-])CCSSCCS(=O)(=O)[O-]		Inactive	chemoprotective agent		1	Mesna disulfide	174006230	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.182333248	S(=O)(=O)(O[Na])CCSSCCS(=O)(=O)O[Na]	S(=O)(=O)(O[Na])CCSSCCS(=O)(=O)O[Na]
NCGC00178220-05	S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1	4.4000001	Active	Prostaglandin G/h Synthase 1 Inhibitor	0.0	1	Dipyrone	170465672	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.654175628	S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1.[Na+]	S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1.[Na+]
NCGC00181167-01	S(=O)(=O)([O-])CNNC(=O)c1ccncc1		Inactive			1	Isoniazid sodium methanesulfonate	144206321	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-28.924977992&-28.5628326599	S(=O)(=O)([O-])CNNC(=O)c1ccncc1.[Na+]	S(=O)(=O)([O-])CNNC(=O)c1ccncc1.[Na+]
NCGC00389552-01	S(=O)(=O)([O-])Cn1c(SCC2=C(C(=O)[O-])N3C(=O)[C@H](NC(=O)[C@H](O)c4ccccc4)[C@H]3SC2)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	CEFONICID SODIUM	405558752	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-26.130810508	S(=O)(=O)([O-])Cn1c(SCC2=C(C(=O)[O-])N3C(=O)[C@H](NC(=O)[C@H](O)c4ccccc4)[C@H]3SC2)nnn1	S(=O)(=O)([O-])Cn1c(SCC2=C(C(=O)[O-])N3C(=O)[C@H](NC(=O)[C@H](O)c4ccccc4)[C@H]3SC2)nnn1
NCGC00162106-17	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor&Bacterial Penicillin-binding Protein Inhibitor		1	Cefsulodin Sodium Salt	405559010	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.4532864639&-31.4445064279	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)c1ccccc1	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)c1ccccc1
NCGC00182030-01	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1	4.4000001	Active		0.0	1	Sulbenicillin disodium	144206509	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-30.0729260559&-41.091609888	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]
NCGC00253597-01	S(=O)(=O)([O-])c1c(/C(/c2ccc(N(CC)CC)cc2)=C\2/C=C/C(=[N+](/CC)\CC)/C=C/2)cc(S(=O)(=O)[O-])cc1		Inactive			1	Isosulfan blue	170464639	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.4170087399&-25.193171604	S(=O)(=O)([O-])c1c(/C(/c2ccc(N(CC)CC)cc2)=C\2/C=C/C(=[N+](/CC)\CC)/C=C/2)cc(S(=O)(=O)[O-])cc1.[Na+]	S(=O)(=O)([O-])c1c(/C(/c2ccc(N(CC)CC)cc2)=C\2/C=C/C(=[N+](/CC)\CC)/C=C/2)cc(S(=O)(=O)[O-])cc1.[Na+]
NCGC00181334-04	S(=O)(=O)([O-])c1c(C(C)(C)C)ccc2c1ccc(C(C)(C)C)c2	4.4000001	Active		0.0	1	DIBUNATE SODIUM	225144323	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-30.683809384	S(=O)(=O)([O-])c1c(C(C)(C)C)ccc2c1ccc(C(C)(C)C)c2	S(=O)(=O)([O-])c1c(C(C)(C)C)ccc2c1ccc(C(C)(C)C)c2
NCGC00024822-03	S(=O)(=O)([O-])c1c(N)c2c(O)c(/N=N/c3c(C)cc(-c4cc(C)c(/N=N/c5c(O)c6c(N)c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c6cc5)cc4)cc3)ccc2c(S(=O)(=O)[O-])c1		Inactive	Serum Albumin Binding Agent&Serum albumin Binding Agent		1	EVANS BLUE	405559142	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])c1c(N)c2c(O)c(/N=N/c3c(C)cc(-c4cc(C)c(/N=N/c5c(O)c6c(N)c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c6cc5)cc4)cc3)ccc2c(S(=O)(=O)[O-])c1	S(=O)(=O)([O-])c1c(N)c2c(O)c(/N=N/c3c(C)cc(-c4cc(C)c(/N=N/c5c(O)c6c(N)c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c6cc5)cc4)cc3)ccc2c(S(=O)(=O)[O-])c1
NCGC00344528-01	S(=O)(=O)([O-])c1c(N=Nc2c(C)cc(-c3cc(C)c(N=Nc4c(O)c5c(N)cc(S(=O)(=O)[O-])cc5cc4S(=O)(=O)[O-])cc3)cc2)c(O)c2c(N)cc(S(=O)(=O)[O-])cc2c1		Inactive			1	TRYPAN BLUE	225144379	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-18.742300336	S(=O)(=O)([O-])c1c(N=Nc2c(C)cc(-c3cc(C)c(N=Nc4c(O)c5c(N)cc(S(=O)(=O)[O-])cc5cc4S(=O)(=O)[O-])cc3)cc2)c(O)c2c(N)cc(S(=O)(=O)[O-])cc2c1	S(=O)(=O)([O-])c1c(N=Nc2c(C)cc(-c3cc(C)c(N=Nc4c(O)c5c(N)cc(S(=O)(=O)[O-])cc5cc4S(=O)(=O)[O-])cc3)cc2)c(O)c2c(N)cc(S(=O)(=O)[O-])cc2c1
NCGC00166248-03	S(=O)(=O)([O-])c1c(O)c(C(c2ccc(N(C)C)cc2)=C2C=CC(=[N+](C)C)C=C2)c2c(c1)cc(S(=O)(=O)[O-])cc2		Inactive			1	Green S	405559150	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.611700996&0.0	S(=O)(=O)([O-])c1c(O)c(C(c2ccc(N(C)C)cc2)=C2C=CC(=[N+](C)C)C=C2)c2c(c1)cc(S(=O)(=O)[O-])cc2	S(=O)(=O)([O-])c1c(O)c(C(c2ccc(N(C)C)cc2)=C2C=CC(=[N+](C)C)C=C2)c2c(c1)cc(S(=O)(=O)[O-])cc2
NCGC00187598-03	S(=O)(=O)([O-])c1c(O)c(N=Nc2c3c(c(S(=O)(=O)[O-])cc2)cccc3)c2c(c1)cc(S(=O)(=O)[O-])cc2	4.4000001	Active		0.0	1	Amaranth	405558767	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-88.1354514	S(=O)(=O)([O-])c1c(O)c(N=Nc2c3c(c(S(=O)(=O)[O-])cc2)cccc3)c2c(c1)cc(S(=O)(=O)[O-])cc2	S(=O)(=O)([O-])c1c(O)c(N=Nc2c3c(c(S(=O)(=O)[O-])cc2)cccc3)c2c(c1)cc(S(=O)(=O)[O-])cc2
NCGC00487135-01	S(=O)(=O)([O-])c1c(O)ccc(O)c1		Inactive	Prostaglandin Biosynthetic Process Inhibitor&prostaglandin biosynthetic process Inhibitor		1	NCGC00487135-01&Dobesilate Calcium	405558698	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.406795484&47.4864292448	S(=O)(=O)([O-])c1c(O)ccc(O)c1	S(=O)(=O)([O-])c1c(O)ccc(O)c1
NCGC00167502-01	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)C2(O)C3(C)C(C4C(F)(C5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC2C)ccc1		Inactive			1	NCGC00167502-01	50112755	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)C2(O)C3(C)C(C4C(F)(C5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC2C)ccc1	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)C2(O)C3(C)C(C4C(F)(C5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC2C)ccc1
NCGC00522027-01	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)[C@]2(O)[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)CC2)ccc1		Inactive			1	Predocol	405558881	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)[C@]2(O)[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)CC2)ccc1	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)[C@]2(O)[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)CC2)ccc1
NCGC00090714-01	S(=O)(=O)([O-])c1cc(C)c(C)cc1		Inactive			1	Sodium xylenesulfonate	144204551	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-14.163129312	S(=O)(=O)([O-])c1cc(C)c(C)cc1.[Na+]	S(=O)(=O)([O-])c1cc(C)c(C)cc1.[Na+]
NCGC00344534-01	S(=O)(=O)([O-])c1cc2C(=O)/C(=C\3/C(=O)c4c(N/3)ccc(S(=O)(=O)[O-])c4)/Nc2cc1		Inactive			1	Indigo carmine	225144381	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.224228288&-20.1988018081	S(=O)(=O)([O-])c1cc2C(=O)/C(=C\3/C(=O)c4c(N/3)ccc(S(=O)(=O)[O-])c4)/Nc2cc1	S(=O)(=O)([O-])c1cc2C(=O)/C(=C\3/C(=O)c4c(N/3)ccc(S(=O)(=O)[O-])c4)/Nc2cc1
NCGC00263208-09	S(=O)(=O)(c1c(C(C)(C)C)cccc1)c1ccc(NC(=O)c2c(O)c(O)c(O)c(Cc3c(C(C)C)cccc3)c2)cc1		Inactive	Bcl-xL Inhibitor/Mcl-1 Inhibitor		1	TW-37	384568667	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	23.873681844	S(=O)(=O)(c1c(C(C)(C)C)cccc1)c1ccc(NC(=O)c2c(O)c(O)c(O)c(Cc3c(C(C)C)cccc3)c2)cc1	S(=O)(=O)(c1c(C(C)(C)C)cccc1)c1ccc(NC(=O)c2c(O)c(O)c(O)c(Cc3c(C(C)C)cccc3)c2)cc1
NCGC00356746-04	S(=O)(=O)(c1cc(C(F)(F)F)ccc1)c1ccc(CNC(=O)c2cnc3[nH]ncc3c2)cc1	4.1999998	Inactive	NAMPT Inhibitor	0.0	1	GNE-618	384569031	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-5.682716296	S(=O)(=O)(c1cc(C(F)(F)F)ccc1)c1ccc(CNC(=O)c2cnc3[nH]ncc3c2)cc1	S(=O)(=O)(c1cc(C(F)(F)F)ccc1)c1ccc(CNC(=O)c2cnc3[nH]ncc3c2)cc1
NCGC00346620-06	S(=O)(=O)(c1cc(C)c2ncc(C(=O)N)c(Nc3cc(OC)ccc3)c2c1)c1cc(C(=O)N(C)C)ccc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	GSK-256066	363677481	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(c1cc(C)c2ncc(C(=O)N)c(Nc3cc(OC)ccc3)c2c1)c1cc(C(=O)N(C)C)ccc1	S(=O)(=O)(c1cc(C)c2ncc(C(=O)N)c(Nc3cc(OC)ccc3)c2c1)c1cc(C(=O)N(C)C)ccc1
NCGC00016322-13	S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor&Bacterial Dihydropteroate Synthase Inhibitor		1	Dapsone	170464895	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-20.345472496	S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1	S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1
NCGC00346628-05	S(=O)(=O)(c1ccc([C@]2(C(=O)Nc3sc(SCCN4CCCC4)cn3)[C@H](C3CCCCC3)C2)cc1)C1CC1	4.4499998	Active	Glucokinase Activator	0.0	1	LY-2608204	384568867	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-121.6067667929	S(=O)(=O)(c1ccc([C@]2(C(=O)Nc3sc(SCCN4CCCC4)cn3)[C@H](C3CCCCC3)C2)cc1)C1CC1	S(=O)(=O)(c1ccc([C@]2(C(=O)Nc3sc(SCCN4CCCC4)cn3)[C@H](C3CCCCC3)C2)cc1)C1CC1
NCGC00025379-01	S(=O)(=O)(c1n(C)c2c(c1C(C)C)cccc2)c1ccc(OCCCN(CCc2cc(OC)c(OC)cc2)C)cc1	4.5	Active	Ca2+ channel Antagonist	0.0	1	SR 33805	11114298	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-123.0034836314	S(=O)(=O)(c1n(C)c2c(c1C(C)C)cccc2)c1ccc(OCCCN(CCc2cc(OC)c(OC)cc2)C)cc1	S(=O)(=O)(c1n(C)c2c(c1C(C)C)cccc2)c1ccc(OCCCN(CCc2cc(OC)c(OC)cc2)C)cc1
NCGC00386236-02	S(=O)(=O)(n1c(-c2c(F)cccc2)cc(CNC)c1)c1cnccc1	4.6999998	Active	Potassium-transporting Atpase Blocker&Potassium-transporting ATPase Blocker	0.0	1	TAK 438	405558685	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.2	-43.349294812&-42.5156818751	S(=O)(=O)(n1c(-c2c(F)cccc2)cc(CNC)c1)c1cnccc1	S(=O)(=O)(n1c(-c2c(F)cccc2)cc(CNC)c1)c1cnccc1
NCGC00381559-06	S(=O)(=O)(n1cc(/C=C/C(=O)NO)cc1)c1ccc(CN(C)C)cc1		Inactive	HDAC Inhibitor		1	Resminostat	384569099	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(=O)(=O)(n1cc(/C=C/C(=O)NO)cc1)c1ccc(CN(C)C)cc1	S(=O)(=O)(n1cc(/C=C/C(=O)NO)cc1)c1ccc(CN(C)C)cc1
NCGC00384199-05	S(=O)(=O)(n1cc(/C=C/C(=O)Nc2c(N)cccc2)cc1)c1ccc(-c2cn(C)nc2)cc1	5.0500002	Active	HDAC Inhibitor	0.0	1	4SC-202	384569106	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-38.1606831504	S(=O)(=O)(n1cc(/C=C/C(=O)Nc2c(N)cccc2)cc1)c1ccc(-c2cn(C)nc2)cc1	S(=O)(=O)(n1cc(/C=C/C(=O)Nc2c(N)cccc2)cc1)c1ccc(-c2cn(C)nc2)cc1
NCGC00181773-01	S(=O)([O-])(=NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Parecoxib sodium	144206591	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.610906936	S(=O)([O-])(=NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1.[Na+]	S(=O)([O-])(=NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1.[Na+]
NCGC00249901-01	S(C#N)CC(=O)O	4.6999998	Active		0.0	1	Thiocyanoacetic acid sodium salt	170465517	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-53.1604934	S(C#N)CC(=O)[O-].[Na+]	S(C#N)CC(=O)[O-].[Na+]
NCGC00013037-01	S(C#N)CC(=O)O[C@H]1[C@@]2(C)C(C)(C)[C@@H](C1)CC2	4.4000001	Active		0.0	1	Thanite	144203555	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-53.49540732	S(C#N)CC(=O)O[C@H]1[C@@]2(C)C(C)(C)[C@@H](C1)CC2	S(C#N)CC(=O)O[C@H]1[C@@]2(C)C(C)(C)[C@@H](C1)CC2
NCGC00016764-04	S(C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCOP(=O)(O)O)C(=O)c1ccccc1		Inactive			1	Benfotiamine	170465987	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.593142676&0.0	S(C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCOP(=O)(O)O)C(=O)c1ccccc1	S(C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCOP(=O)(O)O)C(=O)c1ccccc1
NCGC00386198-07	S(C(=O)C(C)C)c1c(NC(=O)C2(CC(CC)CC)CCCCC2)cccc1		Inactive	Cholesteryl ester transfer protein Modulator		1	Dalcetrapib	384569114	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.74764466	S(C(=O)C(C)C)c1c(NC(=O)C2(CC(CC)CC)CCCCC2)cccc1	S(C(=O)C(C)C)c1c(NC(=O)C2(CC(CC)CC)CCCCC2)cccc1
NCGC00179511-08	S(C(=O)C)CC(C(=O)NCC(=O)OCc1ccccc1)Cc1ccccc1		Inactive	Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitor		1	Racecadotril	384568376	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-15.738118344	S(C(=O)C)CC(C(=O)NCC(=O)OCc1ccccc1)Cc1ccccc1	S(C(=O)C)CC(C(=O)NCC(=O)OCc1ccccc1)Cc1ccccc1
NCGC00182987-01	S(C(=O)C)CC(C(=O)O)CC(=O)c1ccc(C)cc1		Inactive	Cytokine Production Involved In Inflammatory Response Inhibitor&cytokine production involved in inflammatory response Inhibitor		1	Esonarimod	144206833	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	19.4801408879&14.278638864	S(C(=O)C)CC(C(=O)O)CC(=O)c1ccc(C)cc1	S(C(=O)C)CC(C(=O)O)CC(=O)c1ccc(C)cc1
NCGC00182037-01	S(C(=O)C)C[C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)O)Cc2ccccc2)CCC1)C	4.0500002	Inactive	Angiotensin-i Converting Enzyme Inhibitor&Angiotensin-I Converting Enzyme Inhibitor	0.0	1	Alacepril	124893756	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	-25.948016404&-20.059859632&-20.474350896	S(C(=O)C)C[C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)O)Cc2ccccc2)CCC1)C	S(C(=O)C)C[C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)O)Cc2ccccc2)CCC1)C
NCGC00183026-01	S(C(=O)OCC)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)OCC	5.0	Active		0.0	1	Dicethiamine hydrochloride	144206821	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.9911269733	S(C(=O)OCC)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)OCC.Cl	S(C(=O)OCC)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)OCC.Cl
NCGC00179308-04	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF		Inactive	Corticosteroid		1	Fluticasone propionate	170464975	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF
NCGC00179308-13	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3)CF		Inactive	Corticosteroid		1	Fluticasone propionate	384568371	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3)CF	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3)CF
NCGC00386509-01	S(C(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF		Inactive	Glucocorticoid Receptor (GR) Agonist&Glucocorticoid Receptor (gr) Agonist		1	Fluticasone furoate	384569143	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	19.4875148799&0.0&0.0	S(C(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF	S(C(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF
NCGC00182993-01	S(C(=O)c1ccccc1)CC(=O)NCC(=O)NCC(=O)NCC(=O)O		Inactive			1	Betiatide	144206816	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.433759056&0.0	S(C(=O)c1ccccc1)CC(=O)NCC(=O)NCC(=O)NCC(=O)O	S(C(=O)c1ccccc1)CC(=O)NCC(=O)NCC(=O)NCC(=O)O
NCGC00167455-02	S(C(=O)c1ccccc1)C[C@@H](C(=O)N1[C@H](C(=O)O)C[C@H](Sc2ccccc2)C1)C	4.9499998	Active		0.0	1	Zofenopril	170465605	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.515550344	S(C(=O)c1ccccc1)C[C@@H](C(=O)N1[C@H](C(=O)O)C[C@H](Sc2ccccc2)C1)C	S(C(=O)c1ccccc1)C[C@@H](C(=O)N1[C@H](C(=O)O)C[C@H](Sc2ccccc2)C1)C
NCGC00167543-05	S(C(=O)c1occc1)CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)[C@H]2SC1	4.4000001	Active	Cephalosporin Antibiotic	0.0	1	CEFTIOFUR HYDROCHLORIDE	405558783	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.474447728	S(C(=O)c1occc1)CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)[C@H]2SC1	S(C(=O)c1occc1)CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)[C@H]2SC1
NCGC00015480-17	S(C(C(=O)O)(C)C)c1ccc(CCN(C(=O)NC2CCCCC2)CCCCC2CCCCC2)cc1		Inactive	PPARalpha Agonist		1	GW-7647	384567856	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(C(C(=O)O)(C)C)c1ccc(CCN(C(=O)NC2CCCCC2)CCCCC2CCCCC2)cc1	S(C(C(=O)O)(C)C)c1ccc(CCN(C(=O)NC2CCCCC2)CCCCC2CCCCC2)cc1
NCGC00344764-12	S(C(CCSCc1ccccc1)CCCCC(=O)O)Cc1ccccc1		Inactive	altered energy metabolism-directed agent		1	CPI-613	384568729	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-25.7557946759	S(C(CCSCc1ccccc1)CCCCC(=O)O)Cc1ccccc1	S(C(CCSCc1ccccc1)CCCCC(=O)O)Cc1ccccc1
NCGC00522551-01	S(C(F)(F)F)c1ccc(C(=O)N[C@@](C#N)(COc2c(C(F)(F)F)ccc(C#N)c2)C)cc1	4.6500001	Active		0.0	1	Monepantel	405558479	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-3.0	-88.708013372&-112.3057945319	S(C(F)(F)F)c1ccc(C(=O)N[C@@](C#N)(COc2c(C(F)(F)F)ccc(C#N)c2)C)cc1	S(C(F)(F)F)c1ccc(C(=O)N[C@@](C#N)(COc2c(C(F)(F)F)ccc(C#N)c2)C)cc1
NCGC00263905-04	S(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1	4.5999999	Active		0.0	1	TOLTRAZURIL	405558935	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-72.427468396&-52.274352256	S(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1	S(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1
NCGC00182999-01	S(C(F)F)CC(=O)N[C@@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(CCO)nnn3)CO[C@@H]12		Inactive	Streptococcus Pneumoniae Inhibitor&Streptococcus pneumoniae Inhibitor		1	Flomoxef	144206879	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-21.2699305399&0.0	S(C(F)F)CC(=O)N[C@@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(CCO)nnn3)CO[C@@H]12	S(C(F)F)CC(=O)N[C@@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(CCO)nnn3)CO[C@@H]12
NCGC00159541-03	S(C(c1ccccc1)(c1ccccc1)c1ccccc1)C[C@@H](N)C(=O)O		Inactive	Mitotic Kinesin Eg5 Inhibitor		1	S-Trityl-L-cysteine	384568185	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.20917516	S(C(c1ccccc1)(c1ccccc1)c1ccccc1)C[C@@H](N)C(=O)O	S(C(c1ccccc1)(c1ccccc1)c1ccccc1)C[C@@H](N)C(=O)O
NCGC00159326-03	S(C)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@H]2N(C)C[C@H](CCC)C2)[C@H](O)C)O1		Inactive	Antibiotic		1	Lincomycin hydrochloride	170465252	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-20.286966248	S(C)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@H]2N(C)C[C@H](CCC)C2)[C@H](O)C)O1.Cl	S(C)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@H]2N(C)C[C@H](CCC)C2)[C@H](O)C)O1.Cl
NCGC00163548-03	S(C)[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c3nc4c(nc3)cccc4)COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc3c(nc1)cccc3)COC(=O)[C@@H](C(C)C)N(C)C2=O	7.75	Inactive	Antineoplastic Antibiotics	0.0	1	Echinomycin	384568246	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-64.18751058	S(C)[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c3nc4c(nc3)cccc4)COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc3c(nc1)cccc3)COC(=O)[C@@H](C(C)C)N(C)C2=O	S(C)[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c3nc4c(nc3)cccc4)COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc3c(nc1)cccc3)COC(=O)[C@@H](C(C)C)N(C)C2=O
NCGC00167816-03	S(C)c1cc(OC)c(C(=O)N2CCC(Cc3ccccc3)CC2)cc1	4.5	Active	p38 MAPK Inhibitor	0.0	1	JX-401	384568341	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-38.224806284	S(C)c1cc(OC)c(C(=O)N2CCC(Cc3ccccc3)CC2)cc1	S(C)c1cc(OC)c(C(=O)N2CCC(Cc3ccccc3)CC2)cc1
NCGC00016059-13	S(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	4.8499999	Active	Serotonin 2c (5-ht2c) Receptor Antagonist&Serotonin 2c (5-HT2c) receptor Antagonist	0.0	1	Thioridazine	170465080	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-117.188878816&-99.3074113767	S(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	S(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3
NCGC00510491-01	S(C)c1ccc(C(=O)/C=C/c2cc(C)c(OC(C(=O)O)(C)C)c(C)c2)cc1	4.0500002	Active	PPARalpha Agonist	0.0	1	Elafibranor	384569453	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-122.0394996164	S(C)c1ccc(C(=O)/C=C/c2cc(C)c(OC(C(=O)O)(C)C)c(C)c2)cc1	S(C)c1ccc(C(=O)/C=C/c2cc(C)c(OC(C(=O)O)(C)C)c(C)c2)cc1
NCGC00015400-05	S(C)c1ccc(C(=O)C2=C(C)NC(=O)N2)cc1		Inactive	Phosphodiesterase 3 Inhibitor		1	Enoximone	170466419	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	30.031323212&0.0	S(C)c1ccc(C(=O)C2=C(C)NC(=O)N2)cc1	S(C)c1ccc(C(=O)C2=C(C)NC(=O)N2)cc1
NCGC00015448-06	S(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c1c(C(=O)O)cccc1		Inactive	mTOR Inhibitor		1	Salirasib	384567849	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-13.868548408	S(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c1c(C(=O)O)cccc1	S(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c1c(C(=O)O)cccc1
NCGC00346570-04	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)OCOC(=O)C(C)(C)C)C1CN(C=2SCCN=2)C1	4.8000002	Active	Carbapenem Antibiotic	0.0	1	Tebipenem pivoxil	405558791	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-47.68639586	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)OCOC(=O)C(C)(C)C)C1CN(C=2SCCN=2)C1	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)OCOC(=O)C(C)(C)C)C1CN(C=2SCCN=2)C1
NCGC00164551-05	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)[O-])C1C[n+]2n(cnc2)C1		Inactive	Carbapenem Antibiotic		1	Biapenem	405558526	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-14.7177315681&0.0	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)[O-])C1C[n+]2n(cnc2)C1	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)[O-])C1C[n+]2n(cnc2)C1
NCGC00023016-07	S(CC#N)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Cefmetazole sodium	170465052	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.088890156&-6.8545490199	S(CC#N)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)[O-])=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]	S(CC#N)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)[O-])=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]
NCGC00162116-04	S(CC(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)c1ccncc1		Inactive	Bacterial penicillin-binding protein Inhibitor&Bacterial Penicillin-binding Protein Inhibitor		1	Cephapirin sodium	170465306	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.677420712&-27.663113048	S(CC(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)c1ccncc1.[Na+]	S(CC(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)c1ccncc1.[Na+]
NCGC00168109-05	S(CC(=O)Nc1ccc(-n2c(-c3cc4OCOc4cc3)nc(OC)n2)cc1)c1ccccc1	4.6500001	Active	GEF Inhibitor	0.0	1	Secin H3	363676677	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.4	-45.0826292724	S(CC(=O)Nc1ccc(-n2c(-c3cc4OCOc4cc3)nc(OC)n2)cc1)c1ccccc1	S(CC(=O)Nc1ccc(-n2c(-c3cc4OCOc4cc3)nc(OC)n2)cc1)c1ccccc1
NCGC00347948-15	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1		Inactive	Wnt Signaling Inhibitor		1	IWP-2	384568995	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-19.73205946	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1
NCGC00185774-02&NCGC00185774-06	S(CC(=O)O)CC(=O)NC1C(=O)SCC1		Inactive	Mucolytic Agent		2	Erdosteine	170465586&384568426	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-19.8507452199&0.0	S(CC(=O)O)CC(=O)NC1C(=O)SCC1	S(CC(=O)O)CC(=O)NC1C(=O)SCC1
NCGC00263559-01	S(CC(=O)O)CC(N)C(=O)O		Inactive	Regulation Of Mucus Secretion Modulator&regulation of mucus secretion Modulator		1	Carbocysteine	170465800	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-9.7057529719&0.0	S(CC(=O)O)CC(N)C(=O)O	S(CC(=O)O)CC(N)C(=O)O
NCGC00379007-02	S(CC(=O)O[C@H]1C2(C)[C@H](C)CCC3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)C1C[C@@H]2N(C)[C@H](C1)CC2	4.75	Active	70s Ribosome Inhibitor&70S ribosome Inhibitor	0.0	1	Retapamulin	405558888	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-66.0497371622&-70.2389872663	S(CC(=O)O[C@H]1C2(C)[C@H](C)CCC3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)C1C[C@@H]2N(C)[C@H](C1)CC2	S(CC(=O)O[C@H]1C2(C)[C@H](C)CCC3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)C1C[C@@H]2N(C)[C@H](C1)CC2
NCGC00167542-01	S(CC(=O)O[C@H]1[C@]2(C)C(C)CC[C@]3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)CCN(CC)CC	4.5500002	Active	Bacterial 70s Ribosome Inhibitor&Bacterial 70S ribosome Inhibitor	0.0	1	Tiamulin	144206092	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-3.0	-96.1570531568&-88.4023103879	S(CC(=O)O[C@H]1[C@]2(C)C(C)CC[C@]3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)CCN(CC)CC	S(CC(=O)O[C@H]1[C@]2(C)C(C)CC[C@]3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)CCN(CC)CC
NCGC00389300-01	S(CC(NC(=O)c1c(C)c(O)ccc1)C(O)CN1C(C(=O)NC(C)(C)C)CC2C(C1)CCCC2)c1ccccc1	4.5	Active	HIV Protease Inhibitor	0.0	1	Nelfinavir	384569173	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-85.2140974505	S(CC(NC(=O)c1c(C)c(O)ccc1)C(O)CN1C(C(=O)NC(C)(C)C)CC2C(C1)CCCC2)c1ccccc1	S(CC(NC(=O)c1c(C)c(O)ccc1)C(O)CN1C(C(=O)NC(C)(C)C)CC2C(C1)CCCC2)c1ccccc1
NCGC00181107-01	S(CC(O)CNC(C)(C)C)c1scc(-c2sc(C(=O)N)cc2)n1		Inactive	Adrenergic Receptor Beta Antagonist&Adrenergic receptor beta Antagonist		1	Arotinolol hydrochloride	144206274	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.877907348&36.1919578314	S(CC(O)CNC(C)(C)C)c1scc(-c2sc(C(=O)N)cc2)n1.Cl	S(CC(O)CNC(C)(C)C)c1scc(-c2sc(C(=O)N)cc2)n1.Cl
NCGC00262537-04	S(CC)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	4.6999998	Active	Dopamine Receptor Antagonist&Dopamine receptor Antagonist	0.0	1	Thiethylperazine dimalate 	405558764	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.3	-75.5059656299&-96.2901410092	S(CC)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	S(CC)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3
NCGC00482867-01	S(CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1)c1n[nH]nc1		Inactive	Serine/threonine-protein Kinase Eef2k Inhibitor&Serine/threonine-protein kinase EEF2K Inhibitor		1	NCGC00482867-01&Cefatrizine	405558532	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	25.4328124199&-24.718977908	S(CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1)c1n[nH]nc1	S(CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)c3ccc(O)cc3)C2SC1)c1n[nH]nc1
NCGC00373220-03	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1n(C)nnn1		Inactive			1	CEFMENOXIME HYDROCHLORIDE	405558647	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.889444928&-29.943087552	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1n(C)nnn1
NCGC00181012-01	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1snnc1		Inactive	Peptidoglycan Biosynthesis Inhibitor&Peptidoglycan biosynthesis Inhibitor		1	Cefuzonam hydrochloride	144206215	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-30.3603074879&0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1snnc1.Cl	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1snnc1.Cl
NCGC00179514-05	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3c(CN)cccc3)[C@H]2SC1)c1n(CC(=O)O)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Ceforanide	405558924	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.83491538&-36.989779052	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3c(CN)cccc3)[C@H]2SC1)c1n(CC(=O)O)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3c(CN)cccc3)[C@H]2SC1)c1n(CC(=O)O)nnn1
NCGC00179594-03	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1	5.0	Active	Escherichia coli Inhibitor	0.0	1	Cefotiam hydrochloride	170465103	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-38.8294712231	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1.Cl	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1.Cl
NCGC00022653-09	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1sc(C)nn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Cefazolin	170465254	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1sc(C)nn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1sc(C)nn1
NCGC00182064-02	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1scnn1		Inactive	Peptidoglycan Biosynthesis Inhibitor&Peptidoglycan biosynthesis Inhibitor		1	Ceftezole sodium	144206691	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-12.852442828	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1scnn1.[Na+]	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1scnn1.[Na+]
NCGC00179599-03&NCGC00179599-13	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Cephalosporin antibiotic&Bacterial penicillin-binding protein Inhibitor		2	Cefoperazone sodium&Cefoperazone (sodium salt)	170465235&384568379	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-11.909925084&22.7310242159&0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1.[Na+]	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1.[Na+]&S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1
NCGC00167444-04	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)c3c(O)cc(C)nc3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Cefpiramide (sodium)	405558753	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-23.8586393	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)c3c(O)cc(C)nc3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)c3c(O)cc(C)nc3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1
NCGC00344529-02	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1)c1n(C)nnn1	4.6750002	Active	Bacterial Penicillin-binding Protein Inhibitor	0.0	1	Cefamandole (nafate)	405558584	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-43.505307891&-45.0575016508	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1)c1n(C)nnn1
NCGC00178851-03	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C(C(=O)O)c3ccc(O)cc3)[C@H]2OC1)c1n(C)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor&Bacterial penicillin-binding protein Inhibitor		1	Moxalactam disodium	170465353	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	10.654872452&0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@](OC)(NC(=O)C(C(=O)[O-])c3ccc(O)cc3)[C@H]2OC1)c1n(C)nnn1.[Na+].[Na+]	S(CC1=C(C(=O)[O-])N2C(=O)[C@@](OC)(NC(=O)C(C(=O)[O-])c3ccc(O)cc3)[C@H]2OC1)c1n(C)nnn1.[Na+].[Na+]
NCGC00016914-06	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C3SC(=C(C(=O)O)C(=O)N)S3)[C@H]2SC1)c1n(C)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor		1	CEFOTETAN	405559123	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	33.201922582&0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C3SC(=C(C(=O)O)C(=O)N)S3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C3SC(=C(C(=O)O)C(=O)N)S3)[C@H]2SC1)c1n(C)nnn1
NCGC00507774-01	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)[C@@H](O)C)[C@H]2SC1)c1n(C)nnn1		Inactive	Peptidoglycan biosynthesis Inhibitor&Peptidoglycan Biosynthesis Inhibitor		1	Cefbuperazone 	405558959	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-17.512844008&-19.813634636	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)[C@@H](O)C)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)[C@@H](O)C)[C@H]2SC1)c1n(C)nnn1
NCGC00263855-02	S(CC1=C(C(=O)O)N2C(=O)[C@H](NC(=O)C(O)c3ccccc3)C2SC1)c1n(C)nnn1	5.4000001	Active		0.0	1	CEFAMANDOLE SODIUM	405558952	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-33.0578511359	S(CC1=C(C(=O)[O-])N2C(=O)[C@H](NC(=O)C(O)c3ccccc3)C2SC1)c1n(C)nnn1	S(CC1=C(C(=O)[O-])N2C(=O)[C@H](NC(=O)C(O)c3ccccc3)C2SC1)c1n(C)nnn1
NCGC00483046-01	S(CC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1		Inactive			1	SCE 2174	405559041	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-19.3213963276	S(CC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1	S(CC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1
NCGC00263961-02	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)C=1N(C)N=C(O)C(=O)N=1		Inactive	Solute Carrier Family 22 Member 8 Inhibitor&Solute carrier family 22 member 8 Inhibitor		1	Ceftriaxone disodium trihydrate	170465387	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-11.58184032&-15.7838484119	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)C=1N(C)N=C([O-])C(=O)N=1.[Na+].[Na+].O.O.O	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)C=1N(C)N=C([O-])C(=O)N=1.[Na+].[Na+].O.O.O
NCGC00506889-01	S(CCC(=O)O)C[C@H]1O[C@H]2[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O2	6.1999998	Active		0.0	1	Sugammadex	405558538	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-32.443251536	S(CCC(=O)[O-])C[C@H]1O[C@H]2[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O2	S(CCC(=O)[O-])C[C@H]1O[C@H]2[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O2
NCGC00379052-01	S(CCC)c1nc(N[C@H]2[C@H](c3cc(F)c(F)cc3)C2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)C3)c2n1	4.9250002	Active	Purinergic Receptor P2y12 Antagonist&Purinergic receptor P2Y12 Antagonist	0.0	1	Ticagrelor	405558613	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-30.544408744&-63.4878265545	S(CCC)c1nc(N[C@H]2[C@H](c3cc(F)c(F)cc3)C2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)C3)c2n1	S(CCC)c1nc(N[C@H]2[C@H](c3cc(F)c(F)cc3)C2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)C3)c2n1
NCGC00188866-01	S(CCCCCOC=1C(=O)C=C(CN2CCOCC2)OC=1)c1c2c(ncc1)cc(C(F)(F)F)cc2	5.0	Active	Rac1 Inhibitor	0.0	1	NCGC00188866	137275837	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-95.8161233692	S(CCCCCOC=1C(=O)C=C(CN2CCOCC2)OC=1)c1c2c(ncc1)cc(C(F)(F)F)cc2	S(CCCCCOC=1C(=O)C=C(CN2CCOCC2)OC=1)c1c2c(ncc1)cc(C(F)(F)F)cc2
NCGC00379214-02	S(CCCN1C(=O)c2c3c(ccc2)cccc3C1=O)c1n(c(-c2ccncc2)nn1)-c1ccc(OC)cc1	4.4000001	Active	Tachykinin NK1 Antagonist	0.0	1	WIKI4	363678422	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-68.348220964	S(CCCN1C(=O)c2c3c(ccc2)cccc3C1=O)c1n(c(-c2ccncc2)nn1)-c1ccc(OC)cc1	S(CCCN1C(=O)c2c3c(ccc2)cccc3C1=O)c1n(c(-c2ccncc2)nn1)-c1ccc(OC)cc1
NCGC00015876-11	S(CCN/C(/NC)=C/[N+](=O)[O-])Cc1oc(CN(C)C)cc1		Inactive	Histamine H2 Receptor Antagonist&Histamine H2 receptor Antagonist		1	Ranitidine	170465134	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(CCN/C(/NC)=C/[N+](=O)[O-])Cc1oc(CN(C)C)cc1	S(CCN/C(/NC)=C/[N+](=O)[O-])Cc1oc(CN(C)C)cc1
NCGC00091439-07	S(CCN/C(=N/C#N)/NC)Cc1c(C)[nH]cn1		Inactive	Multidrug and toxin extrusion protein 1 Inhibitor&Multidrug And Toxin Extrusion Protein 1 Inhibitor		1	Cimetidine	170464651	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.159665888&0.0	S(CCN/C(=N/C#N)/NC)Cc1c(C)[nH]cn1	S(CCN/C(=N/C#N)/NC)Cc1c(C)[nH]cn1
NCGC00016934-06	S(CCNC(NC)=C[N+](=O)[O-])Cc1nc(CN(C)C)sc1		Inactive	Histamine H2 Receptor Antagonist&Histamine H2 receptor Antagonist		1	Nizatidine	170464780	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	22.128442956&18.09065888	S(CCNC(NC)=C[N+](=O)[O-])Cc1nc(CN(C)C)sc1	S(CCNC(NC)=C[N+](=O)[O-])Cc1nc(CN(C)C)sc1
NCGC00167958-05	S(CCNC=N)C1=C(C(=O)O)N2C(=O)[C@H]([C@H](O)C)[C@H]2C1		Inactive	Penicillin-binding protein 2 Inhibitor&Penicillin-binding Protein 2 Inhibitor		1	Imipenem	170464934	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(CCNC=N)C1=C(C(=O)O)N2C(=O)[C@H]([C@H](O)C)[C@H]2C1	S(CCNC=N)C1=C(C(=O)O)N2C(=O)[C@H]([C@H](O)C)[C@H]2C1
NCGC00159387-03	S(CCOCCO)CCCCCCCCCCCC		Inactive			1	Laureth 10s	170465561	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.443565172&0.0	S(CCOCCO)CCCCCCCCCCCC	S(CCOCCO)CCCCCCCCCCCC
NCGC00163683-02	S(CC[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)C(=O)O)C		Inactive	Opioid growth factor		1	Metenkephalin	174006806	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	19.77828674	S(CC[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)C(=O)O)C	S(CC[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)C(=O)O)C
NCGC00160620-02	S(CC[C@H](N)C(=O)O)C		Inactive	S-adenosylmethionine Synthetase (mat 1 And Mat 2) Substrate&S-adenosylmethionine synthetase (MAT 1 and MAT 2) Substrate		1	L-Methionine	225144244	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	9.745910684&0.0	S(CC[C@H](N)C(=O)O)C	S(CC[C@H](N)C(=O)O)C
NCGC00249931-01	S(CC[C@H](NC(=O)C)C(=O)NCCc1cc(OC(=O)OCC)c(OC(=O)OCC)cc1)C		Inactive	Dopamine D1 Receptor Agonist&Dopamine D1 receptor Agonist		1	Docarpamine	170465850	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.94810452	S(CC[C@H](NC(=O)C)C(=O)NCCc1cc(OC(=O)OCC)c(OC(=O)OCC)cc1)C	S(CC[C@H](NC(=O)C)C(=O)NCCc1cc(OC(=O)OCC)c(OC(=O)OCC)cc1)C
NCGC00183362-01	S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C		Inactive	CCK2 receptor Agonist		1	Pentagastrin	124894389	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C	S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C
NCGC00182027-01	S(CC[C@H](NC(=O)[C@@H](NC(=O)OC(CC)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C	5.0	Active	Cholecystokinin Receptor Agonist	0.0	1	Amogastrin	144206458	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-50.5391812928	S(CC[C@H](NC(=O)[C@@H](NC(=O)OC(CC)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C	S(CC[C@H](NC(=O)[C@@H](NC(=O)OC(CC)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C
NCGC00420698-02	S(CCc1sc(NC(=O)Cc2ccccc2)nn1)CCc1sc(NC(=O)Cc2ccccc2)nn1		Inactive	Glutaminase Inhibitor		1	BPTES	384569223	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(CCc1sc(NC(=O)Cc2ccccc2)nn1)CCc1sc(NC(=O)Cc2ccccc2)nn1	S(CCc1sc(NC(=O)Cc2ccccc2)nn1)CCc1sc(NC(=O)Cc2ccccc2)nn1
NCGC00181749-01	S(C[C@@H](N)C(=O)O)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12	4.4000001	Active	Peptidoglycan biosynthesis Inhibitor	0.0	1	Cefminox sodium	144206473	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-35.403367784	S(C[C@@H](N)C(=O)[O-])CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]	S(C[C@@H](N)C(=O)[O-])CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]
NCGC00484844-01	S(C[C@@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@H]1C(C)(C)C1)/C(=O)O	6.1500001	Active	Renal Dipeptidase Inhibitor	0.0	1	Cilastatin	405559021	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-38.4420126437	S(C[C@@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@H]1C(C)(C)C1)/C(=O)O	S(C[C@@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@H]1C(C)(C)C1)/C(=O)O
NCGC00346877-07	S(C[C@@H]([C@H](C(=O)N[C@H](C(=O)NC)Cc1ccccc1)CC(C)C)C(=O)NO)c1sccc1		Inactive	Matrix Metalloproteinase Inhibitor		1	Batimastat	384568955	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	20.6743412559	S(C[C@@H]([C@H](C(=O)N[C@H](C(=O)NC)Cc1ccccc1)CC(C)C)C(=O)NO)c1sccc1	S(C[C@@H]([C@H](C(=O)N[C@H](C(=O)NC)Cc1ccccc1)CC(C)C)C(=O)NO)c1sccc1
NCGC00346840-06	S(C[C@@H]1O[C@H](c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)O[C@H](c2ccc(CO)cc2)C1)c1oc(c(-c2ccccc2)n1)-c1ccccc1		Inactive	HDAC Inhibitor		1	Tubacin	384568949	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(C[C@@H]1O[C@H](c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)O[C@H](c2ccc(CO)cc2)C1)c1oc(c(-c2ccccc2)n1)-c1ccccc1	S(C[C@@H]1O[C@H](c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)O[C@H](c2ccc(CO)cc2)C1)c1oc(c(-c2ccccc2)n1)-c1ccccc1
NCGC00510528-01	S(C[C@@H]1[C@@H](O)CN(Cc2c3ncnc(N)c3[nH]c2)C1)C	6.0500002	Active	Inhibitor of MTAP	0.0	1	MT-DADMe-ImmA	384569475	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.2	-43.8101368385	S(C[C@@H]1[C@@H](O)CN(Cc2c3ncnc(N)c3[nH]c2)C1)C	S(C[C@@H]1[C@@H](O)CN(Cc2c3ncnc(N)c3[nH]c2)C1)C
NCGC00164556-02	S(C[C@H](N)C(=O)O)CCCO		Inactive	Mucin-5AC Inhibitor&Mucin-5ac Inhibitor		1	Fudosteine	170465764	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&17.948451168	S(C[C@H](N)C(=O)O)CCCO	S(C[C@H](N)C(=O)O)CCCO
NCGC00263221-03	S(C[C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)c1ccccc1)Cc1ccccc1		Inactive	Glutathione-s-transferase P1 (GSTP1) Inhibitor		1	Ezatiostat	384568675	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(C[C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)c1ccccc1)Cc1ccccc1	S(C[C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)c1ccccc1)Cc1ccccc1
NCGC00090782-06	S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1	4.4000001	Active	HIV Protease Inhibitors	0.0	1	Nelfinavir mesylate	170465351	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-108.2156177904	S(=O)(=O)(O)C.S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1	S(=O)(=O)(O)C.S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1
NCGC00017366-08	S(C[C@H]1CN(CCC)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)C		Inactive	Dopamine D3 Receptor Agonist&Dopamine D3 receptor Agonist		1	Pergolide methanesulfonate	170465250	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.774391288&-14.8722206721	S(=O)(=O)(O)C.S(C[C@H]1CN(CCC)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)C	S(=O)(=O)(O)C.S(C[C@H]1CN(CCC)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)C
NCGC00092344-05	S(Cc1c(C)nc(-c2cc(F)c(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1		Inactive	PPARgamma Agonist		1	GW-0742	174007302	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(Cc1c(C)nc(-c2cc(F)c(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1	S(Cc1c(C)nc(-c2cc(F)c(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1
NCGC00241455-04	S(Cc1c(C)nc(-c2ccc(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1		Inactive	PPARdelta Agonist		1	GW-501516	384568480	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	21.802027528	S(Cc1c(C)nc(-c2ccc(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1	S(Cc1c(C)nc(-c2ccc(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1
NCGC00263167-10	S(Cc1oc(C(C)(C)C)cn1)c1sc(NC(=O)C2CCNCC2)nc1	5.75	Active	CDK 2/7/9 Inhibitor	0.0	1	SNS-032	384568637	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-88.6574500125	S(Cc1oc(C(C)(C)C)cn1)c1sc(NC(=O)C2CCNCC2)nc1	S(Cc1oc(C(C)(C)C)cn1)c1sc(NC(=O)C2CCNCC2)nc1
NCGC00346705-02	S(F)(=O)(=O)Cc1ccccc1		Inactive	Serine Protease Inhibitor		1	PMSF	384568924	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(F)(=O)(=O)Cc1ccccc1	S(F)(=O)(=O)Cc1ccccc1
NCGC00042523-03	S(N1CCOCC1)c1sc2c(n1)cccc2	5.3499999	Active		0.0	1	N-Oxydiethylenebenzothiazole-2-sulfenamide	170465568	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-32.047744244	S(N1CCOCC1)c1sc2c(n1)cccc2	S(N1CCOCC1)c1sc2c(n1)cccc2
NCGC00159502-03	S(NC1CCCCC1)c1sc2c(n1)cccc2		Inactive	Aryl Hydrocarbon Receptor Agonist&Aryl hydrocarbon receptor Agonist		1	N-Cyclohexyl-2-benzothiazolesulfenamide	29215472	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.0142601479&0.0	S(NC1CCCCC1)c1sc2c(n1)cccc2	S(NC1CCCCC1)c1sc2c(n1)cccc2
NCGC00015073-05	S(P(=O)(O)O)CCNCCCN	5.5999999	Active	Alkaline phosphatase placental-like Substrate&Alkaline Phosphatase Placental-like Substrate	0.0	1	Amifostine	170465179	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-39.5207610299&-33.9239670365	S(P(=O)(O)O)CCNCCCN	S(P(=O)(O)O)CCNCCCN
NCGC00522018-01	S(P(=O)(OCC)OCC)CC[N+](C)(C)C		Inactive	Cholinesterases; Ache & Bche Inhibitor&Cholinesterases; ACHE & BCHE Inhibitor		1	Echothiophate Iodide	405559038	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	23.503007784&-12.669666144	S(P(=O)(OCC)OCC)CC[N+](C)(C)C	S(P(=O)(OCC)OCC)CC[N+](C)(C)C
NCGC00167456-02	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C		Inactive			1	Bisibutiamine	170466019	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C
NCGC00183879-01	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1	4.4000001	Active		0.0	1	Bisbentiamine	144206468	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-76.8750374639&-91.229946696	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1
NCGC00181294-01	S(SC(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO		Inactive	HIV Infection Inhibitor&Hiv Infection Inhibitor		1	Thiamine disulfide	144206326	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.385043388&0.0	S(SC(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO	S(SC(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO
NCGC00016000-21	S(SC(=S)N(CC)CC)C(=S)N(CC)CC	5.0999999	Active	Aldehyde Dehydrogenase (ALDH2) Inhibitor	0.0	1	Disulfiram	384567915	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-94.5481094312	S(SC(=S)N(CC)CC)C(=S)N(CC)CC	S(SC(=S)N(CC)CC)C(=S)N(CC)CC
NCGC00179291-04	S(SCC1OCCC1)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO	4.4000001	Active		0.0	1	Fursultiamine Hydrochloride	405558735	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.767358916	S(SCC1OCCC1)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO	S(SCC1OCCC1)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO
NCGC00319022-01	S(SCCC(SC(=O)C)CCCCC(=O)OC)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO	6.1500001	Active		0.0	1	Octotiamine	170465976	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-34.8327226943	S(SCCC(SC(=O)C)CCCCC(=O)OC)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO	S(SCCC(SC(=O)C)CCCCC(=O)OC)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO
NCGC00167447-02	S(SCCC)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO	6.1999998	Inactive	Apoptosis Activator	0.0	1	Prosultiamine	170465884	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	12.239719128	S(SCCC)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO	S(SCCC)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO
NCGC00181028-02	S(SCCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C		Inactive	Hmg-coa Reductase Inhibitor&HMG-CoA reductase Inhibitor		1	D-Pantethine	225144316	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-23.047574548&0.0	S(SCCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C	S(SCCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C
NCGC00166006-02	S(SC[C@H](N)C(=O)O)C[C@H](N)C(=O)O		Inactive	Cystine/glutamate Transporter Substrate&Cystine/glutamate transporter Substrate		1	L-Cystine	170465457	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	33.931711728&9.77455284	S(SC[C@H](N)C(=O)O)C[C@H](N)C(=O)O	S(SC[C@H](N)C(=O)O)C[C@H](N)C(=O)O
NCGC00344537-01	S(SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O		Inactive	Glutathione Reductase Substrate&Glutathione reductase Substrate		1	L-Glutathione oxidized disodium salt	225144384	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	33.539927988&-18.920251248	S(SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)[O-])C[C@H](NC(=O)CC[C@H](N)C(=O)[O-])C(=O)NCC(=O)O	S(SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)[O-])C[C@H](NC(=O)CC[C@H](N)C(=O)[O-])C(=O)NCC(=O)O
NCGC00166140-02	S(SCc1c(CO)c(O)c(C)nc1)Cc1c(CO)c(O)c(C)nc1	4.4000001	Active	acetylcholine biosynthetic process Activator	0.0	1	Pyrithioxin dihydrochloride	170465839	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-30.8058556279	S(SCc1c(CO)c(O)c(C)nc1)Cc1c(CO)c(O)c(C)nc1.Cl.Cl	S(SCc1c(CO)c(O)c(C)nc1)Cc1c(CO)c(O)c(C)nc1.Cl.Cl
NCGC00164493-02	S(Sc1[n+]([O-])cccc1)c1[n+]([O-])cccc1	9.0	Inactive		0.0	1	Dipyrithione	170465699	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-2.003270388	S(Sc1[n+]([O-])cccc1)c1[n+]([O-])cccc1	S(Sc1[n+]([O-])cccc1)c1[n+]([O-])cccc1
NCGC00346876-03	S(Sc1[nH]ccn1)C(CC)C	4.5	Active	Thioredoxin Reductase Inhibitor	0.0	1	PX-12	384568954	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.3	-108.0763877999	S(Sc1[nH]ccn1)C(CC)C	S(Sc1[nH]ccn1)C(CC)C
NCGC00186047-02	S(Sc1c(O)ccc2c1cccc2)c1c(O)ccc2c1cccc2	4.4000001	Active	p21-Activated Kinase 1 (PAK1) Inhibitor	0.0	1	IPA-3	174006753	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-77.8871066399	S(Sc1c(O)ccc2c1cccc2)c1c(O)ccc2c1cccc2	S(Sc1c(O)ccc2c1cccc2)c1c(O)ccc2c1cccc2
NCGC00091238-03	S(Sc1sc2c(n1)cccc2)c1sc2c(n1)cccc2		Inactive			1	2,2'-Dithiobisbenzothiazole	170465723	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	11.001963052&0.0	S(Sc1sc2c(n1)cccc2)c1sc2c(n1)cccc2	S(Sc1sc2c(n1)cccc2)c1sc2c(n1)cccc2
NCGC00386735-01	S([C@@H](C)c1ccccc1)c1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1	4.4000001	Active	Chemokine CX3CR1 Receptor Antagonist	0.0	1	AZD-8797	363680425	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-106.9109146102	S([C@@H](C)c1ccccc1)c1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1	S([C@@H](C)c1ccccc1)c1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1
NCGC00253670-01	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O		Inactive	Carbapenem Antibiotic		1	Meropenem	170466350	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O
NCGC00179259-06	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)[N@]2C=1C(=O)O		Inactive	Carbapenem Antibiotic		1	Meropenem	405558497	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	26.3694051869&-26.0373279	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)[N@]2C=1C(=O)O	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)[N@]2C=1C(=O)O
NCGC00387409-02	S([C@H]1C[C@@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O		Inactive	Peptidoglycan Synthase Ftsi Inhibitor&Peptidoglycan synthase FtsI Inhibitor		1	Ertapenem	405558624	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S([C@H]1C[C@@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O	S([C@H]1C[C@@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O
NCGC00510504-01	S([C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1)[C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1		Inactive	Galectin 3 Inhibitor		1	TD-139	384569465	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S([C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1)[C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1	S([C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1)[C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1
NCGC00241108-15	S(c1c(C(=O)NC)cccc1)c1cc2[nH]nc(/C=C/c3ncccc3)c2cc1	4.9000001	Active	VEGFR-1/2/3 Inhibitor	0.0	1	Axitinib	384568476	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-85.9575116568	S(c1c(C(=O)NC)cccc1)c1cc2[nH]nc(/C=C/c3ncccc3)c2cc1	S(c1c(C(=O)NC)cccc1)c1cc2[nH]nc(/C=C/c3ncccc3)c2cc1
NCGC00241108-04	S(c1c(C(=O)NC)cccc1)c1cc2n[nH]c(/C=C/c3ncccc3)c2cc1	4.8000002	Active	Vascular Endothelial Growth Factor Receptor 3 Inhibitor&VEGFR-1/2/3 Inhibitor	0.0	1	Axitinib	170466656	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.3	-96.7703063704&-117.4789954325	S(c1c(C(=O)NC)cccc1)c1cc2n[nH]c(/C=C/c3ncccc3)c2cc1	S(c1c(C(=O)NC)cccc1)c1cc2n[nH]c(/C=C/c3ncccc3)c2cc1
NCGC00386237-01&NCGC00386237-08	S(c1c(C)cc(C)cc1)c1c(N2CCNCC2)cccc1	4.5250001	Active	5-HT1D Receptor Antagonist&5-ht1d Receptor Antagonist	0.25	2	Brintellix	384569118&405558626	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.1&-2.4	-111.4154102522&-72.418868888	S(c1c(C)cc(C)cc1)c1c(N2CCNCC2)cccc1	S(c1c(C)cc(C)cc1)c1c(N2CCNCC2)cccc1
NCGC00229512-05	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)(C)C)C)cc2)nc1	4.9000001	Active	ITK Inhibitor	0.0	1	BMS-509744	384568462	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.2	-75.9323765287	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)(C)C)C)cc2)nc1	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)(C)C)C)cc2)nc1
NCGC00346941-01	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)C)C)cc2)nc1	4.6500001	Inactive	ITK Inhibitor	0.0	1	ITK Inhibitor	174006381	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-46.1770940491	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)C)C)cc2)nc1	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)C)C)cc2)nc1
NCGC00181023-03	S(c1c(C)ccc2nc(N)nc(O)c12)c1ccncc1	5.125	Active	Thymidylate Synthase Inhibitor	0.0	1	NOLATREXED HCL	405558825	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-1.4	-30.883054916&-70.6142363688	S(c1c(C)ccc2nc(N)nc(O)c12)c1ccncc1	S(c1c(C)ccc2nc(N)nc(O)c12)c1ccncc1
NCGC00181307-01	S(c1cc(NC(=O)COC)c(/N=C(\NC(=O)OC)/NC(=O)OC)cc1)c1ccccc1	4.4000001	Active		0.0	1	Febantel	144206335	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.3413442799	S(c1cc(NC(=O)COC)c(/N=C(\NC(=O)OC)/NC(=O)OC)cc1)c1ccccc1	S(c1cc(NC(=O)COC)c(/N=C(\NC(=O)OC)/NC(=O)OC)cc1)c1ccccc1
NCGC00015060-18&NCGC00015060-28	S(c1n(C)cnc1[N+](=O)[O-])c1ncnc2nc[nH]c12		Inactive	Purine Antagonist		2	Azathioprine	170464989&384567803	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-21.606196892&0.0&25.2361023217	S(c1n(C)cnc1[N+](=O)[O-])c1ncnc2nc[nH]c12	S(c1n(C)cnc1[N+](=O)[O-])c1ncnc2nc[nH]c12
NCGC00263145-02	S(c1n(c(O)nn1)-c1cc2OCCOc2cc1)c1sc([N+](=O)[O-])cn1	4.4000001	Active	SAPK1 (JNK) Inhibitor	0.0	1	BI-78D3	384568620	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-115.563666646	S(c1n(c(O)nn1)-c1cc2OCCOc2cc1)c1sc([N+](=O)[O-])cn1	S(c1n(c(O)nn1)-c1cc2OCCOc2cc1)c1sc([N+](=O)[O-])cn1
NCGC00263163-11	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1		Inactive	HGFR Inhibitor		1	SGX-523	384568634	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1
NCGC00168110-05	S(c1nc(Nc2[nH]nc(C)c2)cc(N2CCN(C)CC2)n1)c1ccc(NC(=O)C2CC2)cc1	6.0500002	Active	Aurora-A/B/C Kinase Inhibitor	0.0	1	Tozasertib	363676678	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-91.6847941264	S(c1nc(Nc2[nH]nc(C)c2)cc(N2CCN(C)CC2)n1)c1ccc(NC(=O)C2CC2)cc1	S(c1nc(Nc2[nH]nc(C)c2)cc(N2CCN(C)CC2)n1)c1ccc(NC(=O)C2CC2)cc1
NCGC00480922-01	S(c1sc(NC(=O)Nc2ccc(C)cc2)nn1)c1ncnc2c1ccc(OCCCN1CCOCC1)c2		Inactive	Flt3 Inhibitor		1	SKLB4771	377020364	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S(c1sc(NC(=O)Nc2ccc(C)cc2)nn1)c1ncnc2c1ccc(OCCCN1CCOCC1)c2	S(c1sc(NC(=O)Nc2ccc(C)cc2)nn1)c1ncnc2c1ccc(OCCCN1CCOCC1)c2
NCGC00483038-01	S(c1scc(-c2cc[n+](C)cc2)n1)C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC)/c3nc(NP(=O)(O)O)sn3)[C@H]2SC1	5.0	Active		0.0	1	TAK-599	405558609	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-58.1799172316	S(c1scc(-c2cc[n+](C)cc2)n1)C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC)/c3nc(NP(=O)(O)O)sn3)[C@H]2SC1	S(c1scc(-c2cc[n+](C)cc2)n1)C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC)/c3nc(NP(=O)(O)O)sn3)[C@H]2SC1
NCGC00091146-08	S1c2c(Nc3c1cccc3)cccc2	4.5999999	Active	Trichostrongylus Colubriformis Inhibitor	0.0	1	Phenothiazine	170466563	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-48.1450892424	S1c2c(Nc3c1cccc3)cccc2	S1c2c(Nc3c1cccc3)cccc2
NCGC00183862-01	S=C(N(CC(=O)O)C)c1c2c(c(C(F)(F)F)c(OC)cc2)ccc1		Inactive	Aldose Reductase Inhibitor		1	Tolrestat	144206867	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	17.5476633034	S=C(N(CC(=O)O)C)c1c2c(c(C(F)(F)F)c(OC)cc2)ccc1	S=C(N(CC(=O)O)C)c1c2c(c(C(F)(F)F)c(OC)cc2)ccc1
NCGC00183656-11	S=C(N(NC(=O)CC(=O)NN(C(=S)c1ccccc1)C)C)c1ccccc1	3.55	Inactive	Copper Chelator	0.0	1	Elesclomol (STA-4783)	363677096	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-17.4060488519	S=C(N(NC(=O)CC(=O)NN(C(=S)c1ccccc1)C)C)c1ccccc1	S=C(N(NC(=O)CC(=O)NN(C(=S)c1ccccc1)C)C)c1ccccc1
NCGC00016497-09&NCGC00016497-13	S=C(N)c1cc(CC)ncc1		Inactive	Cell Wall Biosynthesis Inhibitor&Cell Wall Biosynthesis Inhibitors&Cell Wall Biosynthesis Inhibitor		2	Ethionamide	170465169&384567946	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&32.4512473319&10.407225608	S=C(N)c1cc(CC)ncc1	S=C(N)c1cc(CC)ncc1
NCGC00095164-04&NCGC00095164-06	S=C(N)c1cc(CCC)ncc1		Inactive	Tuberculosis Treatment&tuberculosis treatment&tuberculosis treatment		2	Protionamide	170465795&384568153	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	24.9463591413&27.1406463599&0.0	S=C(N)c1cc(CCC)ncc1	S=C(N)c1cc(CCC)ncc1
NCGC00347952-11	S=C(N/N=C(\C)/c1ncccc1)N1CCC1	5.0999999	Inactive	Mutant p53 Activator	0.0	1	NSC-319726	384568997	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-5.0831977481	S=C(N/N=C(\C)/c1ncccc1)N1CCC1	S=C(N/N=C(\C)/c1ncccc1)N1CCC1
NCGC00386321-01	S=C(N/N=C/c1c(N)cccn1)N	4.3499999	Active	Ribonucleoside-Diphosphate Reductase Inhibitor	0.0	1	Triapine	384569126	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-39.2757457519	S=C(N/N=C/c1c(N)cccn1)N	S=C(N/N=C/c1c(N)cccn1)N
NCGC00483925-02	S=C(NC(=O)Cc1ccc(F)cc1)Nc1cc(F)c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)cc1	5.5	Active	VEGFR-1/2/3 Inhibitor	0.0	1	Glesatinib	384569266	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.3	-91.8292733605	S=C(NC(=O)Cc1ccc(F)cc1)Nc1cc(F)c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)cc1	S=C(NC(=O)Cc1ccc(F)cc1)Nc1cc(F)c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)cc1
NCGC00346510-06	S=C(NC(=O)Cc1ccccc1)Nc1cc(F)c(Oc2c3sc(-c4ncn(C)c4)cc3ncc2)cc1	5.0500002	Active	HGFR Inhibitor	0.0	1	MGCD-265	384568812	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-97.5726483551	S=C(NC(=O)Cc1ccccc1)Nc1cc(F)c(Oc2c3sc(-c4ncn(C)c4)cc3ncc2)cc1	S=C(NC(=O)Cc1ccccc1)Nc1cc(F)c(Oc2c3sc(-c4ncn(C)c4)cc3ncc2)cc1
NCGC00347068-02	S=C(NC(=O)c1ccccc1)Nc1c(C(=O)O)c2c(s1)COC(C)(C)C2		Inactive	Rab7 GTPase Inhibitor		1	KUC103669N	384568983	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	20.0761449	S=C(NC(=O)c1ccccc1)Nc1c(C(=O)O)c2c(s1)COC(C)(C)C2	S=C(NC(=O)c1ccccc1)Nc1c(C(=O)O)c2c(s1)COC(C)(C)C2
NCGC00091400-02	S=C(NCC=C)N		Inactive			1	Allylthiourea	170465680	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-19.3568550519&-24.038112176	S=C(NCC=C)N	S=C(NCC=C)N
NCGC00538144-01	S=C(Nc1cc(C(F)(F)F)ccc1)N1C(C)CCCC1C	4.7249999	Active	Taenia Pisiformis Inhibitor&Taenia pisiformis Inhibitor	0.0	1	NCGC00538144-01	405558557	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-53.0567984797&-36.76478502	S=C(Nc1cc(C(F)(F)F)ccc1)N1C(C)CCCC1C	S=C(Nc1cc(C(F)(F)F)ccc1)N1C(C)CCCC1C
NCGC00165721-16	S=C(Nc1ccccc1)n1nc(c(-c2c3c(ncc2)cccc3)c1)-c1nc(C)ccc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	A-83-01	377020368	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S=C(Nc1ccccc1)n1nc(c(-c2c3c(ncc2)cccc3)c1)-c1nc(C)ccc1	S=C(Nc1ccccc1)n1nc(c(-c2c3c(ncc2)cccc3)c1)-c1nc(C)ccc1
NCGC00532504-01	S=C(OC)NCCn1c(C)ncc1[N+](=O)[O-]		Inactive	Trichomonas Inhibitor		1	CARNIDAZOLE	405558531	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-26.071314828&-25.471158044	S=C(OC)NCCn1c(C)ncc1[N+](=O)[O-]	S=C(OC)NCCn1c(C)ncc1[N+](=O)[O-]
NCGC00249934-01	S=C(Oc1cc2c(cc1)C1CC2CC1)N(C)c1cc(C)ccc1		Inactive			1	Tolciclate	170465866	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.940406868	S=C(Oc1cc2c(cc1)C1CC2CC1)N(C)c1cc(C)ccc1	S=C(Oc1cc2c(cc1)C1CC2CC1)N(C)c1cc(C)ccc1
NCGC00182984-01	S=C(Oc1cc2c(cc1)CCC2)N(C)c1cc(C)ccc1	4.4000001	Active		0.0	1	Tolindate	144206849	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-91.394076888	S=C(Oc1cc2c(cc1)CCC2)N(C)c1cc(C)ccc1	S=C(Oc1cc2c(cc1)CCC2)N(C)c1cc(C)ccc1
NCGC00164601-02	S=C(Oc1cc2c(cc1)CCCC2)N(C)c1nc(OC)ccc1	4.5500002	Active	Fungal Squalene Monooxygenase Inhibitor	0.0	1	Liranaftate	170466057	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-56.8471960704	S=C(Oc1cc2c(cc1)CCCC2)N(C)c1nc(OC)ccc1	S=C(Oc1cc2c(cc1)CCCC2)N(C)c1nc(OC)ccc1
NCGC00016610-07&NCGC00016610-12	S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(C)ccc1		Inactive	Fungal Squalene Monooxygenase Inhibitor		2	Tolnaftate	170465508&384567952	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-11.42924592&-30.9604082839	S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(C)ccc1	S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(C)ccc1
NCGC00188440-01	S=C(S)N(CCCC)CCCC	4.5500002	Active		0.0	1	Zinc dibutyldithiocarbamate	144206589	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.4	-46.999628632&-57.9312460687	S=C([S-])N(CCCC)CCCC.S=C([S-])N(CCCC)CCCC.[Zn+2]	S=C([S-])N(CCCC)CCCC.S=C([S-])N(CCCC)CCCC.[Zn+2]
NCGC00387263-04	S=C1C(C)=C(c2nccnc2)SS1		Inactive	Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activator		1	Oltipraz	384569156	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	13.2170098159	S=C1C(C)=C(c2nccnc2)SS1	S=C1C(C)=C(c2nccnc2)SS1
NCGC00182983-01	S=C1N(/N=C/c2ccc(C)cc2)C(c2ccccc2)=CS1		Inactive			1	Fezatione	144206829	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.224671412&-12.360407828	S=C1N(/N=C/c2ccc(C)cc2)C(c2ccccc2)=CS1	S=C1N(/N=C/c2ccc(C)cc2)C(c2ccccc2)=CS1
NCGC00016760-08	S=C1N(C(=O)OCC)C=CN1C		Inactive			1	Carbimazole	170465583	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.527393016	S=C1N(C(=O)OCC)C=CN1C	S=C1N(C(=O)OCC)C=CN1C
NCGC00092372-12	S=C1N(C)C(=O)C(Cc2c3c([nH]c2)cccc3)N1		Inactive	RIP1 Kinase Inhibitor		1	Necrostatin-1	384568108	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	S=C1N(C)C(=O)C(Cc2c3c([nH]c2)cccc3)N1	S=C1N(C)C(=O)C(Cc2c3c([nH]c2)cccc3)N1
NCGC00094721-07	S=C1N(C)C=CN1		Inactive	Thyroid peroxidase Inhibitor&Thyroid Peroxidase Inhibitor		1	Methimazole	170464856	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.511473456&0.0	S=C1N(C)C=CN1	S=C1N(C)C=CN1
NCGC00387301-01	S=C1N(C2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c2c(N1)cccc2	4.4749999	Active	Serotonin Receptor Signaling Pathway Modulator&serotonin receptor signaling pathway Modulator	0.0	1	Timiperone	405558737	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-75.3842447399&-99.0678576432	S=C1N(C2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c2c(N1)cccc2	S=C1N(C2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c2c(N1)cccc2
NCGC00164613-04&NCGC00164613-08	S=C1N(CC(=O)O)C(=O)/C(=C/C(=C/c2ccccc2)/C)/S1		Inactive	Aldose Reductase Inhibitor		2	Epalrestat	384568264&405558568	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&50.7292769527&0.0	S=C1N(CC(=O)O)C(=O)/C(=C/C(=C/c2ccccc2)/C)/S1	S=C1N(CC(=O)O)C(=O)/C(=C/C(=C/c2ccccc2)/C)/S1
NCGC00508823-01	S=C1N(Cc2ccc(-c3nn[nH]c3)cc2)C(C)(C)C(=O)N1c1cc(C(F)(F)F)c(C#N)cc1	4.4000001	Active		0.0	1	BG-15a	384569360	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-83.312088192	S=C1N(Cc2ccc(-c3nn[nH]c3)cc2)C(C)(C)C(=O)N1c1cc(C(F)(F)F)c(C#N)cc1	S=C1N(Cc2ccc(-c3nn[nH]c3)cc2)C(C)(C)C(=O)N1c1cc(C(F)(F)F)c(C#N)cc1
NCGC00160606-01	S=C1N(Cc2ccccc2)CN(Cc2ccccc2)CS1	4.625	Active		0.0	1	Sulbentine	144205485	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-1.3	-94.2330643888&-94.5305652983	S=C1N(Cc2ccccc2)CN(Cc2ccccc2)CS1	S=C1N(Cc2ccccc2)CN(Cc2ccccc2)CS1
NCGC00346651-08	S=C1N([C@@H]2Cc3c(c(F)cc(F)c3)CC2)C(CN)=CN1		Inactive	Dopamine beta-monooxygenase Inhibitor		1	Nepicastat hydrochloride	384568882	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-22.1506818479	S=C1N([C@@H]2Cc3c(c(F)cc(F)c3)CC2)C(CN)=CN1	S=C1N([C@@H]2Cc3c(c(F)cc(F)c3)CC2)C(CN)=CN1
NCGC00263137-03	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2		Inactive	Androgen Receptor Antagonist		1	RD-162	384568615	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-20.236703392	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2
NCGC00346725-06	S=C1N(c2cc(C(F)(F)F)c(C#N)nc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2		Inactive	Androgen Receptor Antagonist		1	Apalutamide	363677538	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-18.51356652	S=C1N(c2cc(C(F)(F)F)c(C#N)nc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2	S=C1N(c2cc(C(F)(F)F)c(C#N)nc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2
NCGC00016229-14&NCGC00016229-20	S=C1NC(=O)C=C(CCC)N1	4.9000001	Inactive	Antithyroid Drugs&Thyroperoxidase Inhibitor&Antithyroid Drugs	0.0	2	Propylthiouracil	170464965&384567923	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&5.0	33.448570464&21.080777748&37.5751593172	S=C1NC(=O)C=C(CCC)N1	S=C1NC(=O)C=C(CCC)N1
NCGC00025103-05	S=C1NC(C)=C(C(=O)OCC)C(c2cc(O)ccc2)N1		Inactive	Kinesin-Like Spindle Protein Inhibitor		1	Monastrol	384568050	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0		S=C1NC(C)=C(C(=O)OCC)C(c2cc(O)ccc2)N1	S=C1NC(C)=C(C(=O)OCC)C(c2cc(O)ccc2)N1
NCGC00094717-06&NCGC00094717-10	S=C1NC=Nc2nc[nH]c12	4.60000015	Active	Purine Antagonist	0.09999989999999936	2	6-mercaptopurine	170464985&384568134	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-59.1448864875&-82.978218332	S=C1NC=Nc2nc[nH]c12	S=C1NC=Nc2nc[nH]c12
NCGC00185994-09	S=C1S/C(=C/c2ccc(CC)cc2)/C(=O)N1	4.5	Active	MYC Expression Inhibitor	0.0	1	10058-F4	384568432	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-117.995123929	S=C1S/C(=C/c2ccc(CC)cc2)/C(=O)N1	S=C1S/C(=C/c2ccc(CC)cc2)/C(=O)N1
NCGC00167471-02	S=C1SSC(c2ccc(OC)cc2)=C1	5.1999998	Active		0.0	1	Anethole trithione	170465669	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-3.0	-31.0486215734&-32.0016321601	S=C1SSC(c2ccc(OC)cc2)=C1	S=C1SSC(c2ccc(OC)cc2)=C1
NCGC00182049-02	S=C=Nc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1	4.4499998	Active	ATP biosynthetic process Inhibitor&Atp Biosynthetic Process Inhibitor	0.0	1	Nitroscanate	225144331	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-2.3	-117.5437493159&-118.7616951582	S=C=Nc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1	S=C=Nc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1
NCGC00091635-09	S=P(OC)(OC)Oc1cc(C)c(SC)cc1		Inactive	Acetylcholinesterase Inhibitor		1	Fenthion	170466807	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	S=P(OC)(OC)Oc1cc(C)c(SC)cc1	S=P(OC)(OC)Oc1cc(C)c(SC)cc1
NCGC00091902-11	S=P(SC(C(=O)OCC)CC(=O)OCC)(OC)OC	4.5500002	Active	Acetylcholinesterase Inhibitor	0.0	1	Malathion	170465311	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-47.8809904523	S=P(SC(C(=O)OCC)CC(=O)OCC)(OC)OC	S=P(SC(C(=O)OCC)CC(=O)OCC)(OC)OC
NCGC00080392-05	S=P(SCN1C(=O)c2c(C1=O)cccc2)(OC)OC	4.4000001	Active	Acetylcholinesterase Inhibitor	0.0	1	Phosmet	170466810	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-45.035688564	S=P(SCN1C(=O)c2c(C1=O)cccc2)(OC)OC	S=P(SCN1C(=O)c2c(C1=O)cccc2)(OC)OC
NCGC00159422-04&NCGC00159422-10	SC(C(=O)NCC(=O)O)C		Inactive	Copper Chelator		2	Tiopronin	170465217&384568176	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	16.0678566239&-19.071627724&-11.399956208	SC(C(=O)NCC(=O)O)C	SC(C(=O)NCC(=O)O)C
NCGC00183271-01	SC(C(=O)N[C@H](C(=O)O)CS)(C)C		Inactive			1	Bucillamine	144206469	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-25.8300554239&-28.855242016	SC(C(=O)N[C@H](C(=O)O)CS)(C)C	SC(C(=O)N[C@H](C(=O)O)CS)(C)C
NCGC00024359-10	SC([C@@H](N)C(=O)O)(C)C		Inactive	Copper Chelator		1	Penicillamine	384568025	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	SC([C@@H](N)C(=O)O)(C)C	SC([C@@H](N)C(=O)O)(C)C
NCGC00014602-05	SC([C@H](N)C(=O)O)(C)C	5.4000001	Active	Copper Chelator	0.0	1	L-Penicillamine	405558637	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-51.5621228319	SC([C@H](N)C(=O)O)(C)C	SC([C@H](N)C(=O)O)(C)C
NCGC00248803-03	SCC(N)C(=O)O	4.6999998	Active		0.0	1	DL-Cysteine	170464842	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.4054657283	SCC(N)C(=O)O	SCC(N)C(=O)O
NCGC00015086-06	SCC(NC(=O)C)C(=O)O		Inactive	NF-kappaB Activation Inhibitor		1	Acetylcysteine	384567806	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	SCC(NC(=O)C)C(=O)O	SCC(NC(=O)C)C(=O)O
NCGC00167479-01	SCC(NCCNC(C(=O)OCC)CS)C(=O)OCC		Inactive			1	Bicisate dihydrochloride	144206036	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-22.3581981149&17.3729779439	SCC(NCCNC(C(=O)OCC)CS)C(=O)OCC.Cl.Cl	SCC(NCCNC(C(=O)OCC)CS)C(=O)OCC.Cl.Cl
NCGC00015691-06	SCCN		Inactive	Protein-glutamine Gamma-glutamyltransferase 2 Inhibitor&Protein-glutamine gamma-glutamyltransferase 2 Inhibitor		1	Cysteamine hydrochloride	170466795	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	28.4105572467&0.0	SCCN.Cl	SCCN.Cl
NCGC00023654-13	SC[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C		Inactive	Angiotensin-converting Enzyme Inhibitor&Angiotensin-converting enzyme Inhibitor		1	Captopril	170464644	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-12.3923029919	SC[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C	SC[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C
NCGC00166005-02	SC[C@H](N)C(=O)OC	5.1999998	Active		0.0	1	L-Cysteine methyl ester hydrochloride	225144264	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.4&-2.4	-31.4072654921&-34.3725453453	SC[C@H](N)C(=O)OC	SC[C@H](N)C(=O)OC
NCGC00166061-02	SC[C@H](N)C(=O)OCC	4.4000001	Active		0.0	1	L-Cysteine ethyl ester hydrochloride	225144266	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-76.748455464	SC[C@H](N)C(=O)OCC	SC[C@H](N)C(=O)OCC
NCGC00015086-04	SC[C@H](NC(=O)C)C(=O)O		Inactive	NF-kappaB Activation Inhibitor&Nf-kappab Activation Inhibitor		1	Acetylcysteine&NCGC00015086-04	170464792	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&0.0	SC[C@H](NC(=O)C)C(=O)O	SC[C@H](NC(=O)C)C(=O)O
NCGC00264046-02	SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O	4.6999998	Active	Glutathione reductase, mitochondrial Substrate	0.0	1	Glutathione	170465600	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-33.716445756	SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O	SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O
NCGC00390546-03	SC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)C)CCC1)Cc1nc[nH]c1)CO)C(=O)N[C@H](C(=O)N)CC(=O)N		Inactive	Integrin alphavbeta3 (Vitronectin) Antagonist		1	ATN-161	384569189	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	SC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)C)CCC1)Cc1nc[nH]c1)CO)C(=O)N[C@H](C(=O)N)CC(=O)N	SC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)C)CCC1)Cc1nc[nH]c1)CO)C(=O)N[C@H](C(=O)N)CC(=O)N
NCGC00264003-02	S[C@@H]([C@H](S)C(=O)O)C(=O)O		Inactive	Lead Chelating Agent		1	(2R,3R)-2,3-Dimercaptosuccinic acid	170465255	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-20.711645124	S[C@@H]([C@H](S)C(=O)O)C(=O)O	S[C@@H]([C@H](S)C(=O)O)C(=O)O
NCGC00509984-01	S[C@H](C(=O)N[C@@H]1C(=O)N2[C@H](C(=O)O)CCC[C@@H]2SCC1)Cc1ccccc1	4.4000001	Active	Neprilysin Inhibitor	0.0	1	Omapatrilat	405559059	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.2065688399	S[C@H](C(=O)N[C@@H]1C(=O)N2[C@H](C(=O)O)CCC[C@@H]2SCC1)Cc1ccccc1	S[C@H](C(=O)N[C@@H]1C(=O)N2[C@H](C(=O)O)CCC[C@@H]2SCC1)Cc1ccccc1
NCGC00018107-05	Sc1c(C(=O)O)cccc1		Inactive	Prostaglandin Biosynthetic Process Inhibitor&prostaglandin biosynthetic process Inhibitor		1	2-Thiosalicylic acid	170465571	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.490580596&-15.4015494999	Sc1c(C(=O)O)cccc1	Sc1c(C(=O)O)cccc1
NCGC00263442-05	Sc1nc(N)nc2[nH]cnc12	4.9250002	Active	Purine Antagonist	0.0	1	NCGC00263442-05&6-Thioguanine	405558710	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-92.8314203886&-91.0397498253	Sc1nc(N)nc2[nH]cnc12	Sc1nc(N)nc2[nH]cnc12
NCGC00096122-05	Sc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12	4.6999998	Active	Serine/threonine-protein kinase N1 Inhibitor	0.0	1	Thioinosine	170465903	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-69.3768055976	Sc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12	Sc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00091643-10	Sc1sc2c(n1)cccc2	4.4000001	Active	Thyroid peroxidase Inhibitor	0.0	1	2-Mercaptobenzothiazole	405558936	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.1802655479	Sc1sc2c(n1)cccc2	Sc1sc2c(n1)cccc2
NCGC00166059-02	[Al](OC(=O)C)(OC(=O)C)O		Inactive			1	Aluminum acetate, basic	405558445	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.208303988&17.68296806	[Al](OC(=O)C)(OC(=O)C)O	[Al](OC(=O)C)(OC(=O)C)O
NCGC00160596-03	[Al](OC(=O)CCCCCCCCCCCCCCCCC)(O)O		Inactive			1	Aluminum monostearate	225144243	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	39.0930136719&0.0	[Al](OC(=O)CCCCCCCCCCCCCCCCC)(O)O	[Al](OC(=O)CCCCCCCCCCCCCCCCC)(O)O
NCGC00253586-01	[Al](OC1=NC(NC(=O)N)C(=O)N1)(O)O		Inactive			1	Isalon	170465491	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.5774978999&-14.702075028	[Al](OC1=NC(NC(=O)N)C(=O)N1)(O)O	[Al](OC1=NC(NC(=O)N)C(=O)N1)(O)O
NCGC00094558-09	[As](=O)(O)(C)C		Inactive			1	CACODYLIC ACID	405558943	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	29.1043402199&18.543066128	[As](=O)(O)(C)C	[As](=O)(O)(C)C
NCGC00094812-05	[As](=O)(O)(O)c1cc(NC(=O)C)c(O)cc1		Inactive			1	Acetarsol	170466503	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	16.0682947959&0.0	[As](=O)(O)(O)c1cc(NC(=O)C)c(O)cc1	[As](=O)(O)(O)c1cc(NC(=O)C)c(O)cc1
NCGC00016372-07	[As](=O)(O)(O)c1cc([N+](=O)[O-])c(O)cc1		Inactive			1	4-Hydroxy-3-nitrophenylarsonic acid	170465666	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&-31.397814664	[As](=O)(O)(O)c1cc([N+](=O)[O-])c(O)cc1	[As](=O)(O)(O)c1cc([N+](=O)[O-])c(O)cc1
NCGC00093366-05	[As](=O)(O)(O)c1ccc(N)cc1		Inactive	Apoptosis Activator		1	(4-Aminophenyl)arsonic acid	170465635	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	13.1765135999&-29.9421304959	[As](=O)(O)(O)c1ccc(N)cc1	[As](=O)(O)(O)c1ccc(N)cc1
NCGC00016374-05	[As](=O)(O)(O)c1ccc(NC(=O)N)cc1	5.3000002	Active		0.0	1	Carbarsone	170466507	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-3.0	-31.775765216&-31.902474184	[As](=O)(O)(O)c1ccc(NC(=O)N)cc1	[As](=O)(O)(O)c1ccc(NC(=O)N)cc1
NCGC00181154-03	[As](=O)(O)(O)c1ccc([N+](=O)[O-])cc1		Inactive			1	Nitarsone	170465716	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-16.574497056&0.0	[As](=O)(O)(O)c1ccc([N+](=O)[O-])cc1	[As](=O)(O)(O)c1ccc([N+](=O)[O-])cc1
NCGC00261972-01	[As](SCCN)(SCCN)c1ccc(Nc2nc(N)nc(N)n2)cc1	5.3000002	Active		0.0	1	NCGC00261972-01	225144356	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-30.7741144546	[As](SCCN)(SCCN)c1ccc(Nc2nc(N)nc(N)n2)cc1	[As](SCCN)(SCCN)c1ccc(Nc2nc(N)nc(N)n2)cc1
NCGC00356590-01	[As]12O[As](O1)O2	4.75	Active		0.0	1	Arsenic trioxide 	405558620	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-84.7355878039	[As]12O[As](O1)O2	[As]12O[As](O1)O2
NCGC00506887-01	[Au]SC(C(=O)O)CC(=O)O		Inactive	Prostaglandin E Synthase Inhibitor&Prostaglandin E synthase Inhibitor		1	Sodium aurothiomalate(I)	405558583	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	21.966020064&0.0	[Au]SC(C(=O)[O-])CC(=O)O	[Au]SC(C(=O)[O-])CC(=O)O
NCGC00182975-01	[Bi-]([OH2+])O[As](=O)(O)c1ccc(NC(=O)CO)cc1		Inactive			1	Amoebicon	144206766	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&13.485442476	[Bi-]([OH2+])O[As](=O)(O)c1ccc(NC(=O)CO)cc1	[Bi-]([OH2+])O[As](=O)(O)c1ccc(NC(=O)CO)cc1
NCGC00475727-01	[C@@H](C)(n1nnc2ncc(-c3cn(C)nc3)nc12)C1=Cn2c(ncc2)C=C1	4.4000001	Active	HGFR Inhibitor	0.0	1	Savolitinib	363681098	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-53.653871724	[C@@H](C)(n1nnc2ncc(-c3cn(C)nc3)nc12)C1=Cn2c(ncc2)C=C1	[C@@H](C)(n1nnc2ncc(-c3cn(C)nc3)nc12)C1=Cn2c(ncc2)C=C1
NCGC00162225-11&NCGC00263461-01	[C@@H]1(c2ccccc2)N=C2SCCN2C1		Inactive	Nicotinic Receptor Agonist		2	L-tetramisol&NCGC00263461-01&Levamisole hydrochloride	384568220&170465293	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-17.843954664&-25.733691944&13.450520892	[C@@H]1(c2ccccc2)N=C2SCCN2C1	[C@@H]1(c2ccccc2)N=C2SCCN2C1&Cl.[C@@H]1(c2ccccc2)N=C2SCCN2C1
NCGC00371080-02	[C@H](C)(c1c(C)c(C)ccc1)c1[nH]cnc1		Inactive	Adrenergic Receptor Alpha-2 Agonist&Adrenergic receptor alpha-2 Agonist		1	Dexmedetomidine	405558766	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	35.07465078&-27.42840432	[C@H](C)(c1c(C)c(C)ccc1)c1[nH]cnc1	[C@H](C)(c1c(C)c(C)ccc1)c1[nH]cnc1
NCGC00167578-04	[Ca](OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1		Inactive	Insulin Secretagogues		1	Mitiglinide calcium	384568330	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	[Ca](OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1	[Ca](OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1
NCGC00249888-01	[Co+](C#N)N1[C@]2(C)[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C1=C(C)C=1[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C(N=1)=CC=1C(C)(C)[C@H](CCC(=O)N)C(=C(C)C=3[C@@](CCC(=O)NC[C@H](OP(=O)(O[C@H]4[C@@H](O)[C@@H](n5c6c(nc5)cc(C)c(C)c6)O[C@@H]4CO)[O-])C)(C)[C@@H](CC(=O)N)[C@H]2N=3)N=1	4.4499998	Inactive	Vitamin	0.0	1	Vitamin B12	170464872	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-8.195066876	[Co+](C#N)N1[C@]2(C)[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C1=C(C)C=1[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C(N=1)=CC=1C(C)(C)[C@H](CCC(=O)N)C(=C(C)C=3[C@@](CCC(=O)NC[C@H](OP(=O)(O[C@H]4[C@@H](O)[C@@H](n5c6c(nc5)cc(C)c(C)c6)O[C@@H]4CO)[O-])C)(C)[C@@H](CC(=O)N)[C@H]2N=3)N=1	[Co+](C#N)N1[C@]2(C)[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C1=C(C)C=1[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C(N=1)=CC=1C(C)(C)[C@H](CCC(=O)N)C(=C(C)C=3[C@@](CCC(=O)NC[C@H](OP(=O)(O[C@H]4[C@@H](O)[C@@H](n5c6c(nc5)cc(C)c(C)c6)O[C@@H]4CO)[O-])C)(C)[C@@H](CC(=O)N)[C@H]2N=3)N=1
NCGC00249888-03	[Co](C#N)[n+]1c2c(n(C3C(O)C(OP(=O)(OC(CNC(=O)CCC\4(C)C(CC(=O)N)C=5C6(C)C(CC(=O)N)(C)C(CCC(=O)N)C(/C(/C)=C/7\C(CC(=O)N)(C)C(CCC(=O)N)C(=N\7)/C=C\7/C(C)(C)C(CCC(=O)N)C(/C(/C)=C/4\N=5)=N/7)=N6)C)[O-])C(CO)O3)c1)cc(C)c(C)c2		Inactive			1	Vitamin B12	384568534	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	22.921554728	[Co](C#N)[n+]1c2c(n(C3C(O)C(OP(=O)(OC(CNC(=O)CCC\4(C)C(CC(=O)N)C=5C6(C)C(CC(=O)N)(C)C(CCC(=O)N)C(/C(/C)=C/7\C(CC(=O)N)(C)C(CCC(=O)N)C(=N\7)/C=C\7/C(C)(C)C(CCC(=O)N)C(/C(/C)=C/4\N=5)=N/7)=N6)C)[O-])C(CO)O3)c1)cc(C)c(C)c2	[Co](C#N)[n+]1c2c(n(C3C(O)C(OP(=O)(OC(CNC(=O)CCC\4(C)C(CC(=O)N)C=5C6(C)C(CC(=O)N)(C)C(CCC(=O)N)C(/C(/C)=C/7\C(CC(=O)N)(C)C(CCC(=O)N)C(=N\7)/C=C\7/C(C)(C)C(CCC(=O)N)C(/C(/C)=C/4\N=5)=N/7)=N6)C)[O-])C(CO)O3)c1)cc(C)c(C)c2
NCGC00166055-04	[Fe-2](N=O)(C#N)(C#N)(C#N)(C#N)C#N		Inactive			1	SODIUM NITROPRUSSIDE	405558446	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.519355752&-20.597175904	[Fe-2](N=O)(C#N)(C#N)(C#N)(C#N)C#N	[Fe-2](N=O)(C#N)(C#N)(C#N)(C#N)C#N
NCGC00262588-02	[Hg](O)c1c(O)c(Br)cc2C3(OC(=O)c4c3cccc4)c3c(Oc12)cc(O)c(Br)c3	5.0	Active		0.0	1	Merbromin	225144359	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.1	-89.868443434	[Hg](O)c1c([O-])c(Br)cc2C3(OC(=O)c4c3cccc4)c3c(Oc12)cc([O-])c(Br)c3.[Na+].[Na+].O.O.O	[Hg](O)c1c([O-])c(Br)cc2C3(OC(=O)c4c3cccc4)c3c(Oc12)cc([O-])c(Br)c3.[Na+].[Na+].O.O.O
NCGC00091050-09	[Hg](OC(=O)C)c1ccccc1	5.8000002	Active		0.0	1	Phenylmercuric acetate	170465524	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.1	-97.5060463229	[Hg](OC(=O)C)c1ccccc1	[Hg](OC(=O)C)c1ccccc1
NCGC00166257-03	[Mn](O[Mn-][OH2+])O[Mn-][OH2+]	4.5500002	Active		0.0	1	NCGC00166257-03	50111747	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-3.0&-3.0	-65.0632616176&-33.689302624	[Mn](O[Mn-][OH2+])O[Mn-][OH2+]	[Mn](O[Mn-][OH2+])O[Mn-][OH2+]
NCGC00161827-01	[Mo-2]([OH2+])([OH2+])(O)O		Inactive	Xanthine Dehydrogenase Binding Agent&Xanthine dehydrogenase Binding Agent		1	NCGC00161827-01	26755462	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-10.30583652&-31.867377872	[Mo-2]([OH2+])([OH2+])([O-])[O-]	[Mo-2]([OH2+])([OH2+])([O-])[O-]
NCGC00521082-01	[N+](C)(C)(C)C1CCC(CC2CCC([N+](C)(C)C)CC2)CC1	4.4000001	Active		0.0	1	Mebezonium Iodide	405558841	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-36.21223292	[N+](C)(C)(C)C1CCC(CC2CCC([N+](C)(C)C)CC2)CC1	[N+](C)(C)(C)C1CCC(CC2CCC([N+](C)(C)C)CC2)CC1
NCGC00178214-04	[N+](CCCCCCCCCCCCC)(Cc1ccccc1)(C)C	4.8249998	Active		0.0	1	BENZALKONIUM CHLORIDE	405559118	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-95.9730612023&-106.5307348478	[N+](CCCCCCCCCCCCC)(Cc1ccccc1)(C)C	[N+](CCCCCCCCCCCCC)(Cc1ccccc1)(C)C
NCGC00164283-07	[N+](CCCCCCCCCCCCCCCC)(C)(C)C	4.7249999	Active	Cell Membrane Interacts&Cell membrane Interacts	0.0	1	Hexadecyltrimethylammonium bromide	170465714	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.1	-98.1879568812&-127.7393762859	[N+](CCCCCCCCCCCCCCCC)(C)(C)C.[Br-]	[N+](CCCCCCCCCCCCCCCC)(C)(C)C.[Br-]
NCGC00015323-11	[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C		Inactive	Muscle-type nicotinic acetylcholine receptor Partial Agonist&Muscle-type Nicotinic Acetylcholine Receptor Partial Agonist		1	Decamethonium bromide	170465349	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	18.8317866&-13.70530314	[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C.[Br-].[Br-]	[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C.[Br-].[Br-]
NCGC00015496-08	[N+](CCCCCC[N+](C)(C)C)(C)(C)C	5.3499999	Active		0.0	1	N,N,N,N',N',N'-Hexamethylhexane-1,6-diaminium	170465837	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-39.7065928768	[N+](CCCCCC[N+](C)(C)C)(C)(C)C	[N+](CCCCCC[N+](C)(C)C)(C)(C)C
NCGC00182971-01	[N+](CCCCCC[N+](C)(C)C1c2c(-c3c1cccc3)cccc2)(C)(C)C1c2c(-c3c1cccc3)cccc2		Inactive	Cholinesterase Inhibitor		1	Hexafluorenium dibromide	144206765	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	22.821106484&-20.783399516	[N+](CCCCCC[N+](C)(C)C1c2c(-c3c1cccc3)cccc2)(C)(C)C1c2c(-c3c1cccc3)cccc2.[Br-].[Br-]	[N+](CCCCCC[N+](C)(C)C1c2c(-c3c1cccc3)cccc2)(C)(C)C1c2c(-c3c1cccc3)cccc2.[Br-].[Br-]
NCGC00015831-06	[NH+](CCC(c1ncccc1)c1ccccc1)(C)C	4.4499998	Active	Histamine H1 Receptor Antagonist	0.0	1	Pheniramine maleate	170464902	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-67.9889642912	O=C([O-])/C=C\C(=O)[O-].[NH+](CCC(c1[nH+]cccc1)c1ccccc1)(C)C	O=C([O-])/C=C\C(=O)[O-].[NH+](CCC(c1[nH+]cccc1)c1ccccc1)(C)C
NCGC00015673-13	[O-][n+]1c(N)nc(N2CCCCC2)cc1N		Inactive	K(atp) Channel Activator&K(ATP) Channel Activator		1	Minoxidil	170464704	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	15.8587004719&-12.108591708	[O-][n+]1c(N)nc(N2CCCCC2)cc1N	[O-][n+]1c(N)nc(N2CCCCC2)cc1N
NCGC00346462-07	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C	6.0500002	Inactive	RNA-Directed RNA Polymerase Inhibitor	0.0	1	Sofosbuvir	384568785	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	5.0	-30.747970328	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C
NCGC00390564-03	[P@@](=O)(Oc1ccccc1)(N[C@H](C(=O)OC(C)C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C	4.1999998	Inactive		0.0	1	GS-7340	405558816	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	5.0	-6.031179208	[P@@](=O)(Oc1ccccc1)(N[C@H](C(=O)OC(C)C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C	[P@@](=O)(Oc1ccccc1)(N[C@H](C(=O)OC(C)C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C
NCGC00378598-01	[P@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C	4.4000001	Active	Viral Rna-directed Rna Polymerase (ns5b) (hcv) Inhibitor	0.0	1	PSI-7976	405558839	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.4	-40.7997190679	[P@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C	[P@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C
NCGC00090759-05	[Pt](Cl)(Cl)(N)N		Inactive	DNA Alkylating Agent		1	Cisplatin	384568083	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	[Pt](Cl)(Cl)(N)N	[Pt](Cl)(Cl)(N)N
NCGC00346930-01	[Pt](Cl)(Cl)(N)N1C(C)=CCC=C1		Inactive	DNA Alkylating Agent		1	Picoplatin	174007462	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-30.2306383039	[Pt](Cl)(Cl)(N)[NH+]1C(C)=CC=C[CH-]1	[Pt](Cl)(Cl)(N)[NH+]1C(C)=CC=C[CH-]1
NCGC00181000-02&NCGC00181000-08	[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C		Inactive	Mediator Release Inhibitor		2	Suplatast tosylate	170465881&384568385	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&25.5899245359	[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C.S(=O)(=O)([O-])c1ccc(C)cc1	[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C.S(=O)(=O)([O-])c1ccc(C)cc1&[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C
NCGC00167557-01	[S+](CCC(N)C(=O)O)(C)C	4.4000001	Active	Erk1 And Erk2 Cascade Activator	0.0	1	DL-Methionine methylsulfonium chloride	144206105	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-46.0003549199	[S+](CCC(N)C(=O)O)(C)C.[Cl-]	[S+](CCC(N)C(=O)O)(C)C.[Cl-]
NCGC00167546-03	[S+](CC[C@H](N)C(=O)O)(C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)C		Inactive	S-adenosylmethionine synthase isoform type-2 Binding Agent&S-adenosylmethionine Synthase Isoform Type-2 Binding Agent		1	S-(5 -Adenosyl)-L-methionine p-toluenesulfonate salt	225144292	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	0.0&23.1856807007	[S+](CC[C@H](N)C(=O)O)(C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)C	[S+](CC[C@H](N)C(=O)O)(C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)C
NCGC00386267-03	[S@@H0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2	4.4000001	Active	H+/K+-ATPase Inhibitor	0.0	1	(R)-Lansoprazole	405558696	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-61.9631052519	[S@@H0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2	[S@@H0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2
NCGC00387711-02	[S@](=O)(=N)(C)C1(c2nc(-c3c4c([nH]cc4)ncc3)nc(N3[C@H](C)COCC3)c2)CC1	5.0	Active	ATR Kinase Inhibitor	0.0	1	AZD-6738	363680649	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-1.1	-92.3217479359	[S@](=O)(=N)(C)C1(c2nc(-c3c4c([nH]cc4)ncc3)nc(N3[C@H](C)COCC3)c2)CC1	[S@](=O)(=N)(C)C1(c2nc(-c3c4c([nH]cc4)ncc3)nc(N3[C@H](C)COCC3)c2)CC1
NCGC00163157-05	[SH0](=O)(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	4.8499999	Active	D(2) Dopamine Receptor Antagonist&D(2) dopamine receptor Antagonist	0.0	1	Mesoridazine	170465272	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-2.3&-2.4	-67.1837014771&-70.9634752644	[SH0](=O)(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	[SH0](=O)(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3
NCGC00025035-05	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cc1	4.4000001	Active	p38 MAPK Inhibitor	0.0	1	SB-203580	124886984	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-84.641102792	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cc1	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cc1
NCGC00346554-01	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(cc(OC)cc3)cc2)cc1	4.5	Active	Tie-2 kinase Inhibitor	0.0	1	Tie-2 kinase Inhibitor	174006708	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-2.1	-108.4039471398	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(cc(OC)cc3)cc2)cc1	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(cc(OC)cc3)cc2)cc1
NCGC00015970-10&NCGC00015970-11	[SH0](=O)(C)c1ccc(/C=C\2/C(C)=C(CC(=O)O)c3c/2ccc(F)c3)cc1		Inactive	ABCC1 Expression Enhancer&Abcc1 Expression Enhancer&ABCC1 Expression Enhancer		2	Sulindac	174007228&170464648	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-13.607970208&-36.051565028&0.0	[SH0](=O)(C)c1ccc(/C=C\2/C(C)=C(CC(=O)O)c3c/2ccc(F)c3)cc1	[SH0](=O)(C)c1ccc(/C=C\2/C(C)=C(CC(=O)O)c3c/2ccc(F)c3)cc1
NCGC00186528-19	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(N)ccc4)N=Cc23)c1		Inactive	PKM2 Activator		1	TEPP-46	384568443	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-16.858927108	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(N)ccc4)N=Cc23)c1	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(N)ccc4)N=Cc23)c1
NCGC00263530-01	[SH0](=O)(CC(=O)NC/C=C\COc1nccc(CN2CCCCC2)c1)Cc1occc1		Inactive	Histamine H2 Receptor Antagonists		1	Lafutidine	170465978	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	14.068581788&-17.837543812	[SH0](=O)(CC(=O)NC/C=C\COc1nccc(CN2CCCCC2)c1)Cc1occc1	[SH0](=O)(CC(=O)NC/C=C\COc1nccc(CN2CCCCC2)c1)Cc1occc1
NCGC00025092-02	[SH0](=O)(CC1(OC)CCN(CCc2c3c([nH]c2)ccc(F)c3)CC1)c1ccccc1	4.4000001	Active	Tachykinin NK2 Antagonist	0.0	1	GR-159897	174007484	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-40.982826416	[SH0](=O)(CC1(OC)CCN(CCc2c3c([nH]c2)ccc(F)c3)CC1)c1ccccc1	[SH0](=O)(CC1(OC)CCN(CCc2c3c([nH]c2)ccc(F)c3)CC1)c1ccccc1
NCGC00253760-02	[SH0](=O)(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1	4.4000001	Active	antiparasitic agent	0.0	1	Albendazole oxide	174006227	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	-3.0	-51.882233224	[SH0](=O)(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1	[SH0](=O)(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1
NCGC00016255-10	[SH0](=O)(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)c1ccccc1	5.4000001	Active	Canalicular Multispecific Organic Anion Transporter 1 Modulator	0.0	1	SULFINPYRAZONE	170464677	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.4	-70.232388482	[SH0](=O)(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)c1ccccc1	[SH0](=O)(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)c1ccccc1
NCGC00167521-07	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)nc(OC)cc2		Inactive	Potassium-transporting ATPase Inhibitor		1	Tenatoprazole	384568324	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-11.796116048	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)nc(OC)cc2	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)nc(OC)cc2
NCGC00167521-02	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc-2[nH]c(OC)ccc-2n1	4.6999998	Active	Ido Inhibitor	0.0	1	Tenatoprazole	170465931	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-75.6033020987	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc-2[nH]c(OC)ccc-2n1	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc-2[nH]c(OC)ccc-2n1
NCGC00015615-15	[SH0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2		Inactive	H+/K+-ATPase Inhibitor		1	Lansoprazole	170464649	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	[SH0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2	[SH0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2
NCGC00095188-04&NCGC00095188-05	[SH0](=O)(Cc1c(OC)c(OC)ccn1)c1[nH]c2c(n1)cc(OC(F)F)cc2		Inactive	H+/K+-ATPase Inhibitor&H+/k+-atpase Inhibitor&H+/K+-ATPase Inhibitor		2	Pantoprazole	174007264&170466337	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&-28.7186307759&15.82551354	[SH0](=O)(Cc1c(OC)c(OC)ccn1)c1[nH]c2c(n1)cc(OC(F)F)cc2	[SH0](=O)(Cc1c(OC)c(OC)ccn1)c1[nH]c2c(n1)cc(OC(F)F)cc2
NCGC00185770-01	[SH0](=O)(OC[C@@H]1[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@@H](O[C@@]2(CO[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](CO[SH0](=O)[O-])O2)O1)[O-]		Inactive			1	Sucrose octasulfate, sodium salt	144207173	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-27.412748276&0.0	[SH0](=O)(OC[C@@H]1[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@@H](O[C@@]2(CO[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](CO[SH0](=O)[O-])O2)O1)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]	[SH0](=O)(OC[C@@H]1[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@@H](O[C@@]2(CO[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](CO[SH0](=O)[O-])O2)O1)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
NCGC00183864-01	[SH0](=O)([O-])CNc1ccc(S(=O)(=O)c2ccc(NC[SH0](=O)[O-])cc2)cc1		Inactive	Dihydropteroate Synthase 1 Inhibitor&Dihydropteroate synthase 1 Inhibitor		1	Adesulfone sodium	144206768	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-12.6953296559&-21.814339488	[SH0](=O)([O-])CNc1ccc(S(=O)(=O)c2ccc(NC[SH0](=O)[O-])cc2)cc1.[Na+].[Na+]	[SH0](=O)([O-])CNc1ccc(S(=O)(=O)c2ccc(NC[SH0](=O)[O-])cc2)cc1.[Na+].[Na+]
NCGC00253591-01	[SH0](=O)(c1[nH]c2c(n1)cccc2)C1c2nccc(OC)c2CCCC1	4.4000001	Active		0.0	1	Nepaprazole	170465906	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.74763656	[SH0](=O)(c1[nH]c2c(n1)cccc2)C1c2nccc(OC)c2CCCC1	[SH0](=O)(c1[nH]c2c(n1)cccc2)C1c2nccc(OC)c2CCCC1
NCGC00095157-04&NCGC00095157-05	[SH0](=O)(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1	5.4749999	Active	antiparasitic agent	0.25	2	Oxfendazole	144206994&170466223	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	-1.4&-2.4	-70.6679784947&-48.498185209	[SH0](=O)(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1	[SH0](=O)(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1
NCGC00159438-03	[Se](CCC(N)C(=O)O)C		Inactive	dietary supplement		1	L-selenomethionine	26754506	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	0.0	[Se](CCC(N)C(=O)O)C	[Se](CCC(N)C(=O)O)C
NCGC00181044-04	[Se](CC[C@H](N)C(=O)O)C	4.6999998	Active	dietary supplement	0.0	1	Selenomethionine	405558757	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-34.2994768263	[Se](CC[C@H](N)C(=O)O)C	[Se](CC[C@H](N)C(=O)O)C
NCGC00164100-01	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(C)C		Inactive			1	Trisiloxane, octamethyl-	26757517	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-37.291698348&-16.101131724	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(C)C	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(C)C
NCGC00532508-01	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(CC(Cc1c(O)c(-n2nc3c(n2)cccc3)cc(C)c1)C)C	5.4499998	Active		0.0	1	DROMETRIZOLE TRISILOXANE	405558978	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-40.5181730436	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(CC(Cc1c(O)c(-n2nc3c(n2)cccc3)cc(C)c1)C)C	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(CC(Cc1c(O)c(-n2nc3c(n2)cccc3)cc(C)c1)C)C
NCGC00166115-02	[Sn](OC(=O)CCCCCCCCCCC)(OC(=O)CCCCCCCCCCC)(CCCC)CCCC	4.4000001	Active		0.0	1	Dibutyltin dilaurate	170466843	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-77.593568244	[Sn](OC(=O)CCCCCCCCCCC)(OC(=O)CCCCCCCCCCC)(CCCC)CCCC	[Sn](OC(=O)CCCCCCCCCCC)(OC(=O)CCCCCCCCCCC)(CCCC)CCCC
NCGC00183121-01	[Zn](Sc1[n+]([O-])cccc1)Sc1[n+]([O-])cccc1	3.75	Inactive		0.0	1	Zinc pyrithione	144206950	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	5.0&5.0	-15.2825771919&-11.801141156	[Zn](Sc1[n+]([O-])cccc1)Sc1[n+]([O-])cccc1	[Zn](Sc1[n+]([O-])cccc1)Sc1[n+]([O-])cccc1
NCGC00167539-03	[nH]1c2c(cc1)cccc2		Inactive	Tryptophan Synthase Beta Chain Substrate&Tryptophan synthase beta chain Substrate		1	Indole	170465733	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.7790788999&7.259675308	[nH]1c2c(cc1)cccc2	[nH]1c2c(cc1)cccc2
NCGC00263122-02	c1(-c2n[nH]c3c2CCC3)n[nH]nn1		Inactive	Nicotinic Acid Receptor Partial Agonist		1	MK-0354	363677213	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.3488415719	c1(-c2n[nH]c3c2CCC3)n[nH]nn1	c1(-c2n[nH]c3c2CCC3)n[nH]nn1
NCGC00016410-13&NCGC00016410-25	c1(-c2ncsc2)[nH]c2c(n1)cccc2		Inactive	Methionine Aminopeptidase-1 (MetAP1) Inhibitor&Methionine Aminopeptidase-1 (metap1) Inhibitor&Methionine Aminopeptidase-1 (MetAP1) Inhibitor		2	Thiabendazole	170464939&384567938	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	0.0&0.0&0.0	c1(-c2ncsc2)[nH]c2c(n1)cccc2	c1(-c2ncsc2)[nH]c2c(n1)cccc2
NCGC00162222-04	c1(C2(c3ccccc3)C(C3=NCCN3)C2)ccccc1	5.8000002	Active	Voltage-sensitive Sodium Channel Blocker	0.0	1	Cibenzoline succinate	405558949	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-1.2	-33.3845332599	c1(C2(c3ccccc3)C(C3=NCCN3)C2)ccccc1	c1(C2(c3ccccc3)C(C3=NCCN3)C2)ccccc1
NCGC00063561-03	c1(c(-c2ccccc2)nc[nH]1)-c1ccccc1		Inactive			1	4,5-Diphenylimidazole	170465946	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-20.028855868&-12.258843436	c1(c(-c2ccccc2)nc[nH]1)-c1ccccc1	c1(c(-c2ccccc2)nc[nH]1)-c1ccccc1
NCGC00013822-04	c1(c(c(-c2ccncc2)sc1-c1ccncc1)-c1ccncc1)-c1ccncc1		Inactive	Hedgehog Antagonist		1	NSC-75503	384567789	Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry	4.0	-12.732301848	c1(c(c(-c2ccncc2)sc1-c1ccncc1)-c1ccncc1)-c1ccncc1	c1(c(c(-c2ccncc2)sc1-c1ccncc1)-c1ccncc1)-c1ccncc1
NCGC00090793-05	c12c(cccc1)cccc2	4.9499998	Active	Metabolism Of Xenobiotics By Cytochrome P450 Substrate	0.0	1	NAPHTHALENE, ZONE REFINED	225144198	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-2.2	-32.601339312	c12c(cccc1)cccc2	c12c(cccc1)cccc2
NCGC00247735-02&NCGC00247735-03	n1c2c(ncc1)cc1c(c2)C2CNCC1C2		Inactive	Nicotinic Alpha3beta4 Agonists&Nicotinic alpha3beta4 Agonist&Nicotinic alpha3beta4 Agonist		2	Varenicline tartrate	174007164&363677162	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0&4.0	-23.3706805405&10.406901484&17.367577228	Cl.n1c2c(ncc1)cc1c(c2)C2CNCC1C2	Cl.n1c2c(ncc1)cc1c(c2)C2CNCC1C2&n1c2c(ncc1)cc1c(c2)C2CNCC1C2
NCGC00094646-04	s1c2c(c3c1cccc3)cccc2	5.1999998	Active	Cytochrome P450 2c9 Inhibitor	0.0	1	Dibenzothiophene	170465511	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry	-3.0	-41.2766786195	s1c2c(c3c1cccc3)cccc2	s1c2c(c3c1cccc3)cccc2
NCGC00091399-01	s1c2c(nc1)cccc2		Inactive			1	Benzothiazole	17389158	Approved Drugs Collection (NPC)	SARS-CoV Pseudotyped particle entry&SARS-CoV Pseudotyped particle entry	4.0&4.0	-29.0114748759&-26.2735033519	s1c2c(nc1)cccc2	s1c2c(nc1)cccc2
